,assay_id,doi,year,volume,issue,assay_description,compound_smiles,compound_name,value,unit,relation,log_value,classification_label,scaffold_smiles
0,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,CC(C)Oc1cc2ncnc(Nc3ccc(Cl)c([N+](=O)[O-])c3)c2c2c1OCCO2,"N-(4-Chloro-3-nitrophenyl)-5-isopropoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.1026,uM,=,-0.9888526392242024,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
1,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.2289,uM,=,-0.6403542073254571,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,CCN1CCN(CC#CC(=O)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)CC1,4-(4-Ethyl-piperazin-1-yl)-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.065,uM,=,-1.1870866433571443,0,O=C(C#CCN1CCNCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccc(Cl)cc4)c(Cl)c3)ncnc2cc1OCCCN1CCN(C)CC1,1-(2-chloro-4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)phenyl)-3-(4-chlorophenyl)urea,0.001,uM,=,-3.0,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
4,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCN1CCCCC1,N-(4-(6-methoxy-7-(2-(piperidin-1-yl)ethoxy)quinazolin-4-ylamino)phenyl)benzamide,4.61,uM,=,0.6637009253896482,1,O=C(Nc1ccc(Nc2ncnc3cc(OCCN4CCCCC4)ccc23)cc1)c1ccccc1
5,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(NC(=O)/C=C/CNC(C)C)cc23)c1,"(S,E)-N-(4-(3-Ethynylphenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(isopropylamino)but-2-enamide",0.0064,uM,=,-2.193820026016113,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
6,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)c2cccc([N+](=O)[O-])c2)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"3-methoxy-2-methyl-4-methyl(3-nitrophenyl)carboxamido-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaene",4.8,uM,=,0.6812412373755872,1,O=C(N[C@@H]1CC2O[C@@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O)c1ccccc1
7,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CC(C)N1CCN(C/C=C/C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3s2)CC1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(4-isopropylpiperazin-1-yl)but-2-enamide",0.034,uM,=,-1.4685210829577449,0,O=C(/C=C/CN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
8,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3ccccc3o2)c1O,3-[3-(Benzooxazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,12.5,uM,=,1.0969100130080565,1,c1ccc(CSc2nc3ccccc3o2)cc1
9,1684241,10.1016/j.bmc.2017.04.001,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate measured after 10 mins by mobility shift assay,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.238,uM,=,-0.623423042943488,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
10,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCCCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(3-piperidin-1-yl-propoxy)-quinazolin-4-yl]-amine,0.079,uM,=,-1.1023729087095586,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCCCC4)cc23)cc1
11,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21,"5,6-Bis-phenylamino-isoindole-1,3-dione",0.3,uM,=,-0.5228787452803376,0,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21
12,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",N#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1,"3-[(7,8-Dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)amino]benzonitrile",0.024,uM,=,-1.619788758288394,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
13,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,Cc1cc(Nc2c(C#N)cnc3ccc(NC(=O)/C=C/[C@H]4CCCN4C)cc23)ccc1Oc1cc2nncn2cn1,"(E)-3-[(2S)-1-methylpyrrolidin-2-yl]-N-[4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]prop-2-enamide",0.00313,uM,=,-2.504455662453552,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2nccc(Nc3ccc(Oc4cc5nncn5cn4)cc3)c2c1
14,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Nc3cccc(C(=O)O)c3)c2c1C,"3-(5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-benzoic acid",16.3,uM,=,1.212187604403958,1,c1ccc(Nc2ncnc3[nH]ccc23)cc1
15,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1C(=O)Nc1nccc(-c2cccc(F)c2)n1,N-(4-(3-Fluorophenyl)pyrimidin-2-yl)-2-methyl-5-(4-((4-methylpiperazin-1-yl)methyl)benzamido)benzamide,6.0,uM,=,0.7781512503836436,1,O=C(Nc1cccc(C(=O)Nc2nccc(-c3ccccc3)n2)c1)c1ccc(CN2CCNCC2)cc1
16,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2CC(c3ccc(C)c(C)c3)=NN2c2nc(-c3ccc(Cl)cc3)cs2)cc1,"4-(4-chlorophenyl)-2-(3-(3,4-dimethylphenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)thiazole",1.04,uM,=,0.0170333392987803,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
17,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CCN(C)CC1,4-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-1-methylpiperidine-4-carboxamide,0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccc(CNC4CCNCC4)cc23)cc1
18,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCn1ccnc1[N+](=O)[O-],N-(3-Bromophenyl)-6-methoxy-7-(3-(2-nitro-1H-imidazol-1-yl)propoxy)quinazolin-4-amine,0.00049,uM,=,-3.3098039199714866,0,c1ccc(Nc2ncnc3cc(OCCCn4ccnc4)ccc23)cc1
19,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)acrylamide",0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ncnc3sccc23)cc1
20,1798716,10.1016/j.ejmech.2017.03.083,,,,"Inhibition of wild type N-terminal GST tagged human recombinant EGFR (695 to end amino acids) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) Peptide substrate by ADP-Glo assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCN4CCOCC4)cc3)ncc2Cl)c1,N-[3-[[5-Chloro-2-[4-((1-morpholino)ethoxy)phenylamino]-4-pyrimidinyl]amino]phenyl]acrylamide,0.9613,uM,=,-0.0171410576879248,0,c1ccc(Nc2ccnc(Nc3ccc(OCCN4CCOCC4)cc3)n2)cc1
21,2229998,10.1021/acs.jmedchem.1c00876,,,,Inhibition of wild type EGFR (unknown origin),N#Cc1ccc(O)c(-c2nc(NCc3cccnc3)c3ccccc3n2)c1,4-hydroxy-3-(4-(pyridin-3-ylmethylamino)quinazolin-2-yl)benzonitrile,50.0,uM,=,1.6989700043360187,1,c1ccc(-c2nc(NCc3cccnc3)c3ccccc3n2)cc1
22,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3c(ccn3C(=O)OC(C)(C)C)c2)c2c(N)ncnc21,"tert-butyl 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-1-carboxylate",0.179,uM,=,-0.7471469690201069,0,c1ncc2c(-c3ccc4[nH]ccc4c3)n[nH]c2n1
23,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,C=CC(=O)Nc1ccc2c(c1)CNc1c(Nc3cccc(Br)c3)ncnc1O2,"N-[1-(3-Bromo-phenylamino)-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-8-yl]-acrylamide",5.7,uM,=,0.7558748556724915,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
24,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(S(N)(=O)=O)c2)c2c(N)ncnc21,"3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzenesulfonamide",100.0,uM,=,2.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
25,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3ccc(C#Cc4ccccc4)cc23)cc1Cl,N-(3-chloro-4-fluorophenyl)-6-(2-phenylethynyl)quinazolin-4-amine,0.331,uM,=,-0.4801720062242812,0,C(#Cc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccccc1
26,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2ncnc3c2ccc2[nH]cnc23)c1,"(3-Bromo-phenyl)-(1H-imidazo[4,5-h]quinazolin-6-yl)-amine",0.272,uM,=,-0.5654310959658013,0,c1ccc(Nc2ncnc3c2ccc2[nH]cnc23)cc1
27,425430,10.1021/jm061107l,,,,Inhibition of EGFR,CNc1ncnc(-c2cccnc2Oc2ccc(F)c(C(=O)Nc3cc(C(F)(F)F)ccc3N(C)CCCN(C)C)c2)n1,"N-(2-((3-(dimethylamino)propyl)(methyl)amino)-5-(trifluoromethyl)phenyl)-2-fluoro-5-(3-(4-(methylamino)-1,3,5-triazin-2-yl)pyridin-2-yloxy)benzamide",25.0,uM,=,1.3979400086720375,1,O=C(Nc1ccccc1)c1cccc(Oc2ncccc2-c2ncncn2)c1
28,445904,10.1021/jm070436q,,,,Inhibition of P-EGFR expressed in A431 cells,C[S+]([O-])c1cc(NCc2c[nH]cn2)cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc12,4-[(3-chloro-4-fluorophenyl)amino]-6-[(1H-imidazol-5-ylmethyl)amino]-8-(methylsulfinyl)quinoline-3-carbonitrile,5.0,uM,=,0.6989700043360189,1,c1ccc(Nc2ccnc3ccc(NCc4c[nH]cn4)cc23)cc1
29,622913,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR in human A431 cells by HTRF assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,Erlotinib hydrochloride,0.42,uM,=,-0.3767507096020995,0,c1ccc(Nc2ncnc3ccccc23)cc1
30,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(Nc3ccc(-c4nc5ccccc5s4)c(F)c3)ncnc2cc1OCCCN1CCN(C)CC1,N-(4-(benzo[d]thiazol-2-yl)-3-fluorophenyl)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-amine,0.43,uM,=,-0.3665315444204134,0,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
31,1935778,10.1021/acs.jmedchem.9b00102,,,,Inhibition of wild type EGFR (unknown origin) by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3cn(-c4ccc(C(C)=O)cc4)nn3)c3c(N)ncnc32)C1,"(R)-1-(3-(3-(1-(4-acetylphenyl)-1H-1,2,3-triazol-4-yl)-4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",8.006,uM,=,0.9034155857690864,1,c1ccc(-n2cc(-c3nn([C@@H]4CCCNC4)c4ncncc34)nn2)cc1
32,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCCCCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{10-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-decyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",25.0,uM,=,1.3979400086720375,1,O=C(C=Cc1ccccc1)NCCCCCCCCCCNC(=O)/C=C/c1ccccc1
33,1738745,10.1016/j.ejmech.2018.04.052,,,,"Inhibition of recombinant human GST-tagged wild type EGFR expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(Nc2nccc(Nc3ccccc3-c3ccn(C)n3)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-((2-(1-methyl-1H-pyrazol-3-yl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.3499,uM,=,-0.4560560575170935,0,c1ccc(Nc2nccc(Nc3ccccc3-c3cc[nH]n3)n2)cc1
34,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1,N-(6-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)pyridin-2-yl)acetamide,0.091,uM,=,-1.0409586076789064,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccn1
35,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Nc3cccc(C#N)c3)c2c1C,"3-(5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-benzonitrile",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1
36,306243,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,C=CC(=O)Nc1cc2c(Nc3cc(Cl)c(Cl)cc3F)ncnc2cc1N1CCN(C)CC1,"N-[4-(4,5-Dichloro-2-fluoro-phenylamino)-7-(4-methyl-piperazin-1-yl)-quinazolin-6-yl]-acrylamide",0.25,uM,=,-0.6020599913279624,0,c1ccc(Nc2ncnc3cc(N4CCNCC4)ccc23)cc1
37,67067,10.1016/S0960-894X(01)80792-7,,,,Inhibition of Epidermal growth factor receptor,N#C/C(=C\c1cc(O)ccc1O)C(N)=O,"(E)-2-Cyano-3-(2,5-dihydroxy-phenyl)-acrylamide",10.0,uM,=,1.0,1,c1ccccc1
38,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",COc1cc2ncnc(Nc3cccc(F)c3)c2cc1OC.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-fluoro-phenyl)-amine hydrochloride",0.0319,uM,=,-1.496209316942819,0,c1ccc(Nc2ncnc3ccccc23)cc1
39,1883986,10.1021/acsmedchemlett.8b00461,,,,Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c(C(N)=O)c2N)C1,1-[(3R)-1-Acryloylpiperidin-3-yl]-5-amino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide,0.015,uM,=,-1.8239087409443189,0,c1ccc(Oc2ccc(-c3ccn([C@@H]4CCCNC4)n3)cc2)cc1
40,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,O=C(Nc1ccccn1)Nc1cc(-c2cccnc2)ccc1OC(F)(F)F,1-(Pyridin-2-yl)-3-(5-(pyridin-3-yl)-2-(trifluoromethoxy)phenyl)urea,0.09057,uM,=,-1.04301563225724,0,O=C(Nc1cccc(-c2cccnc2)c1)Nc1ccccn1
41,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC(F)F)ncc2SC)c1,N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-(difluoromethoxy)phenyl)amino)-5-(methylthio)pyrimidin-4-yl)oxy)phenyl)acrylamide,0.0387999999999999,uM,=,-1.4111682744057927,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
42,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,O=C1NCc2ccc(Oc3ccc(Nc4ncnc5ccn(CCO)c45)cc3Cl)cc21,"6-(2-Chloro-4-{[5-(2-hydroxyethyl)-5H-pyrrolo[3,2-d]-pyrimidin-4-yl]amino}phenoxy)-2,3-dihydro-1H-isoindol-1-one",0.0078,uM,=,-2.10790539730952,0,O=C1NCc2ccc(Oc3ccc(Nc4ncnc5cc[nH]c45)cc3)cc21
43,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,CC(C)(C)C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc5sncc45)c(Cl)c3)c21.CS(=O)(=O)O,"N-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]-amino}-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl]-2,2-dimethylpropanamide Methanesulfonate",0.021,uM,=,-1.6777807052660807,0,c1cc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)c2cnsc2c1
44,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N[C@H]1CCN(c2nc(Nc3ccc(N4CCN(C)CC4)cc3)c3ncn(C(C)C)c3n2)C1,(S)-N-(1-(9-isopropyl-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide,0.277,uM,=,-0.5575202309355514,0,c1nc2c(Nc3ccc(N4CCNCC4)cc3)nc(N3CCCC3)nc2[nH]1
45,2285813,10.1016/j.ejmech.2020.112652,,,,Inhibition of EGFR (unknown origin) infected in insect sf9 cells incubated for 1 hrs in presence of ATP,COc1ccc(C(=O)n2nc(-c3cccnc3)nc2N)cc1,"(5-amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl)(4-methoxyphenyl)methanone",3.6,uM,=,0.5563025007672873,1,O=C(c1ccccc1)n1cnc(-c2cccnc2)n1
46,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1ncnc(Oc3cccc(Cl)c3F)c1NC2,"1-(3-chloro-2-fluoro-phenoxy)-7,8-dimethoxy-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cycloheptene",19.3,uM,=,1.285557309007774,1,c1ccc(Oc2ncnc3c2NCc2ccccc2S3)cc1
47,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,Cc1cc(C)cc(COC(=O)c2cc(NCc3cc(O)ccc3O)ccc2O)c1,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3,5-dimethyl-benzyl ester",3.0,uM,=,0.4771212547196624,1,O=C(OCc1ccccc1)c1cccc(NCc2ccccc2)c1
48,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)N1CCc2c(sc3ncnc(Nc4ccc(Br)c(C)c4)c23)C1,"1-(4-((4-bromo-3-methylphenyl)amino)-5,6-dihydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(8H)-yl)prop-2-en-1-one",4.4,uM,=,0.6434526764861874,1,c1ccc(Nc2ncnc3sc4c(c23)CCNC4)cc1
49,1338416,10.1016/j.ejmech.2014.01.018,,,,Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,CCOC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1c(C)nn(-c2ccccc2)c1Cl,"Ethyl 2-amino-4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",2.09,uM,=,0.320146286111054,1,O=C1CCCC2=C1C(c1cnn(-c3ccccc3)c1)C=CN2c1cccnc1
50,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COC6CCNCC6)c45)ccc32)c1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((piperidin-4-yloxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.073,uM,=,-1.136677139879544,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC6CCNCC6)c45)ccc32)cc1
51,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CCCCC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-2-heptynamide",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3cnccc23)cc1
52,1337213,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,COc1ccc(Oc2nc3ccc(C)cc3cc2/C=N/NC(=O)Cn2c([N+](=O)[O-])cnc2C)cc1,(E)-N'-((2-(4-methoxyphenoxy)-6-methylquinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,2.18,uM,=,0.3384564936046048,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
53,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)nc3C)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-((1,3-dimethyl-1H-pyrazol-4-yl)amino)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.0116099999999999,uM,=,-1.9351677802614264,0,c1ccc(Nc2nccc(Nc3cn[nH]c3)n2)cc1
54,1528598,,,,,"In Vitro Kinase Assay: In vitro kinase analysis was performed by using HTScan EGF Receptor Kinase Assay Kit (#7909) and HTScan HER2/ErbB2 Kinase Assay Kit (#7058) from Cell Signaling Technology Company. Operation steps refer to the specification of the used kits, and the method was used to measure the inhibition effects of the compound to be tested on substrate peptide phosphorylation of EGFR or Her2 receptor tyrosine kinase. At room temperature, ATP and substrate peptide as well as the compound to be tested were incubated in kinase reaction buffer, after a period of incubation, a stop buffer was added to terminate the reaction and the sample was transferred to a streptavidin-coated 96-well plate, the plate was washed and the phosphorylation level of substrate peptide was detected by using HRP-marked antibody against substrate phosphorylation, colorated with TMB, terminated the reaction with 2M sulfuric acid. Absorption at 450 nm wavelength was detected, and IC50 value (Î¼M) was calculated.",CSCCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,"US8916574, Compound 3",0.05624,uM,=,-1.2499546879882324,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
55,82323,10.1021/jm9904295,,,,Inhibitory activity against ligand-dependent EGF cell proliferation,Cc1c(CCC(=O)O)c[nH]c1/C=C1\C(=O)Nc2cc(-c3ccccc3)ccc21,"3-{4-Methyl-5-[2-oxo-6-phenyl-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrol-3-yl}-propionic acid",21.8,uM,=,1.3384564936046048,1,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1ccc[nH]1
56,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc(O)cc(Br)c2)c2c(N)ncnc21,"3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-bromophenol",0.249,uM,=,-0.6038006529042637,0,c1ccc(-c2n[nH]c3ncncc23)cc1
57,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,CCOc1ccccc1NC(=O)/C=C/c1ccccc1,(E)-N-(2-ethoxyphenyl)cinnamamide,9.35,uM,=,0.9708116108725178,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
58,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,Clc1cc(Nc2ncnc3[nH]nc(OCCN4CCOCC4)c23)ccc1OCc1ccccn1,"N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-3-(2-morpholinoethoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.001,uM,=,-3.0,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCOCC5)c34)cc2)nc1
59,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",CCN(CC)CCNC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(2-(diethylamino)ethyl)urea,0.365,uM,=,-0.4377071355435253,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
60,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4C)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((2-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",2.5,uM,=,0.3979400086720376,1,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
61,2127056,10.1016/j.bmcl.2021.128118,,,,Inhibition of recombinant wild type EGFR-TK (unknown origin) by ELISA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.13,uM,=,-0.8860566476931633,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
62,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1ccc(F)cc1)NS(=O)(=O)c1ccc(F)cc1,2-(4-Fluorophenyl)-N-(4-fluorophenylsulfonyl)acetamide,5.17,uM,=,0.7134905430939426,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
63,566595,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by SPA assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.05,uM,=,-1.3010299956639813,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5ccccn5)cc4)c3s2)C1)N1CCOCC1
64,1657723,10.1016/j.bmcl.2017.02.018,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells preincubated for 60 mins followed by EGF induction measured after 10 mins by ELISA,COc1ccc(OC)c(Sc2cccc3[nH]c4nc(N)nc(N)c4c23)c1,"5-[(2,5-Dimethoxyphenyl)sulfanyl]-9H-pyrimido[4,5-b]indole-2,4-diamine",4.3,uM,=,0.6334684555795865,1,c1ccc(Sc2cccc3[nH]c4ncncc4c23)cc1
65,78513,10.1016/s0960-894x(02)01047-8,,,,Inhibition of EGFR overexpressing HN5 (Head and neck) tumor cell proliferation,CS(=O)(=O)CCNc1nc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)cs1,(4-Benzyloxy-3-chloro-phenyl)-{6-[2-(2-methanesulfonyl-ethylamino)-thiazol-4-yl]-quinazolin-4-yl}-amine,0.23,uM,=,-0.6382721639824072,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5cscn5)cc34)cc2)cc1
66,305333,10.1021/jm058205b,,,,Inhibition of epidermal growth factor receptor,OCCCNc1cncc(-c2cncc(Nc3cccc(Cl)c3)n2)c1,3-{5-[6-(3-Chloro-phenylamino)-pyrazin-2-yl]-pyridin-3-ylamino}-propan-1-ol,1.36,uM,=,0.1335389083702175,1,c1ccc(Nc2cncc(-c3cccnc3)n2)cc1
67,2213931,10.1016/j.ejmech.2021.113963,,,,Inhibition of GST-tagged EGFR (unknown origin) assessed as phosphorylation level using biotinylated peptide as substrate in presence of ATP by HTScan EGFR kinase assay,CCc1nnc2c(Nc3ccc(C(=O)/C=C/c4cc(OC)c(OC)c(OC)c4)cc3)nc3ccccc3n12,"(E)-1-[4-[(1-ethyl-[1,2,4]triazolo[4,3-a]quinoxalin-4-yl)amino]phenyl]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",0.039,uM,=,-1.408935392973501,0,O=C(/C=C/c1ccccc1)c1ccc(Nc2nc3ccccc3n3cnnc23)cc1
68,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CCn1nc(-c2ccc(OC)c(O)c2)c2c(N)ncnc21,"5-(4-amino-1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol",6.45,uM,=,0.8095597146352678,1,c1ccc(-c2n[nH]c3ncncc23)cc1
69,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OCC,N-(4-(3-Chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl)acrylamide,0.00146,uM,=,-2.835647144215563,0,c1ccc(Nc2ccnc3ccccc23)cc1
70,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,Brc1cccc(Nc2ncnc3cc4[nH]cc(CN5CCOCC5)c4cc23)c1,"(3-Bromo-phenyl)-(6-morpholin-4-ylmethyl-8H-pyrrolo[3,2-g]quinazolin-4-yl)-amine",0.0096,uM,=,-2.017728766960432,0,c1ccc(Nc2ncnc3cc4[nH]cc(CN5CCOCC5)c4cc23)cc1
71,2145645,10.1016/j.bmcl.2021.128406,,,,Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence of ATP by IMAP-FP assay,C=CC(=O)N1CCC2(CC1)CNC(=O)c1cc(-c3ccnc(-c4cccc(OC)c4)n3)[nH]c12,"1-acryloyl-2'-(2-(3-methoxyphenyl)pyrimidin-4-yl)-5',6'-dihydrospiro[piperidine-4,7'-pyrrolo[3,2-c]pyridin]-4'(1'H)-one",0.032,uM,=,-1.494850021680094,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(-c4ccccc4)n3)cc21
72,1675840,10.1016/j.bmc.2017.03.032,,,,"Inhibition of recombinant wild type human EGFR (695 to end residues) using Poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo assay",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0106,uM,=,-1.9746941347352296,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
73,1873904,10.1021/acs.jmedchem.9b00794,,,,Inhibition of N-terminal GST-tagged human EGFR (696 to end aminoacids) expressed in baculovirus infected Sf21 cells,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1,"7-Cyclopentyl-5-(4-phenoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",0.177,uM,=,-0.7520267336381934,0,c1ccc(Oc2ccc(-c3cn(C4CCCC4)c4ncncc34)cc2)cc1
74,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(C(=O)Nc4ccccn4)cc3)c2c1,4-(6-acrylamidoquinazolin-4-ylamino)-N-(pyridin-2-yl)benzamide,0.0038,uM,=,-2.42021640338319,0,O=C(Nc1ccccn1)c1ccc(Nc2ncnc3ccccc23)cc1
75,566595,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by SPA assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5S(=O)(=O)c5ccsc5)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(1-(thiophen-3-ylsulfonyl)-1H-indol-5-ylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.15,uM,=,-0.8239087409443188,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5S(=O)(=O)c5ccsc5)c4)c3s2)C1)N1CCOCC1
76,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,O=C(/C=C/CN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"(2E)-N-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(4-morpholinyl)-2-butenamide",0.012,uM,=,-1.9208187539523751,0,O=C(/C=C/CN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
77,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)cnc23)cc1
78,1769420,10.1016/j.bmc.2018.02.023,,,,Inhibition of EGFR (unknown origin) using peptide substrate after 60 mins by HTRF assay,O=C(N/N=C/c1cccs1)N1CCc2ncnc(Nc3ccc(F)c(Cl)c3)c2C1,"(E)-4-((3-chloro-4-fluorophenyl)amino)-N'-(thiophen-2-ylmethylene)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carbohydrazide",0.0625,uM,=,-1.2041199826559248,0,O=C(N/N=C/c1cccs1)N1CCc2ncnc(Nc3ccccc3)c2C1
79,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc(Cc4ccccn4)cc3)ncnc2cn1,"(2E)-N-{4-[4-(2-Pyridinylmethyl)anilino]pyrido[3,4-d]pyrimidin-6-yl}-4-(1-pyrrolidinyl)-2-butenamide",0.01,uM,=,-2.0,0,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc(Cc4ccccn4)cc3)ncnc2cn1
80,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",CCOc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OCC.Cl,"4-(3'-chloroanilino)-6,7-diethoxyquinazoline hydrochloride",0.00038,uM,=,-3.42021640338319,0,c1ccc(Nc2ncnc3ccccc23)cc1
81,1526584,10.1021/acsmedchemlett.5b00193,,,,Inhibition of wild type EGFR phosphorylation in human A431 cells after 60 mins by mesoscale multiplex assay,C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(OCCN(C)C)cc4OC)nc32)c1,"N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",1.054,uM,=,0.0228406108765278,1,O=c1ccc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
82,2151929,10.1021/acs.jmedchem.0c01949,,,,Inhibition of EGFR (unknown origin),COc1cc2nc(C)nc(N[C@H](C)c3ccccc3)c2cc1OC,"(R)-6,7-Dimethoxy-2-methyl-N-(1-phenylethyl)-quinazolin-4-amine",2.8,uM,=,0.4471580313422192,1,c1ccc(CNc2ncnc3ccccc23)cc1
83,640011,10.1016/j.ejmech.2010.02.056,,,,Inhibition of human EGFR autophosphorylation expressed in Sf9 cells DELFIA assay,Cc1ccc(Br)c2c(C#N)cc(C(=O)C3CC3)n12,8-Bromo-3-cyclopropylcarbonyl-5-methyl-1-indolizinecarbonitrile,0.085,uM,=,-1.0705810742857071,0,O=C(c1ccc2ccccn12)C1CC1
84,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC1CCN(C)CC1,N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(1-methylpiperidin-4-yloxy)quinazolin-4-amine,0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
85,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",N#Cc1ccc(Nc2nncc3ccccc23)cc1,4-(Phthalazin-1-ylamino)benzonitrile,0.0040999999999999,uM,=,-2.3872161432802645,0,c1ccc(Nc2nncc3ccccc23)cc1
86,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)c(O)c1)C(N)=S,"2-Cyano-3-(3,4-dihydroxy-phenyl)-thioacrylamide",3.0,uM,=,0.4771212547196624,1,c1ccccc1
87,1338416,10.1016/j.ejmech.2014.01.018,,,,Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1nn(-c2ccccc2)c(Cl)c1C1C(C#N)=C(N)N(c2cccnc2)C2=C1C(=O)CC(C)(C)C2,"2-Amino-4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-7,7-dimethyl-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile",32.13,uM,=,1.5069107255515182,1,O=C1CCCC2=C1C(c1cnn(-c3ccccc3)c1)C=CN2c1cccnc1
88,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N1CCN(C)CC1,N-(4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide,0.002,uM,=,-2.6989700043360187,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c[nH]c2c1
89,608090,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 1 hr by Western blot,O=C(COc1c(F)c(F)c(F)c(F)c1F)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(perfluorophenoxy)-acetamide,0.084,uM,=,-1.0757207139381184,0,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
90,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",CN(C)C/C=C/C(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@@H](CO)c4ccccc4)c23)c1,"(2E)-4-(Dimethylamino)-N-[3-(4-{[(1R)-2-hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]but-2-enamide",0.562,uM,=,-0.2502636844309389,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
91,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CC(C)N(C)C/C=C/C(=O)N1CCc2sc3ncnc(Nc4ccc(Cl)c(Cl)c4)c3c2C1,"US8524722, 139",0.0092,uM,=,-2.036212172654445,0,c1ccc(Nc2ncnc3sc4c(c23)CNCC4)cc1
92,2220271,10.1016/j.bmcl.2022.128529,,,,Inhibition of EGFR (unknown origin),COc1cc(-c2nc3ccccc3s2)ccc1OCC(=O)NNC(=O)CN[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,"(2S)-2-[(2-{2-[4-(1,3-benzothiazol-2-yl)-2-methoxyphenoxy]acetohydrazido}-2-oxoethyl)amino]-3-(1H-indol-3-yl)propanoic acid",0.209,uM,=,-0.679853713888946,0,O=C(CNCCc1c[nH]c2ccccc12)NNC(=O)COc1ccc(-c2nc3ccccc3s2)cc1
93,1994718,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 40 mins in presence of ATP by caliper mobility shift assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
94,1641517,,,,,"In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CN(C)C/C=C/C(=O)NC1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1,"US9278100, 18",0.02253,uM,=,-1.647238808276169,0,c1ccc(Oc2ccc(-c3nn(C4CCCCC4)c4ncncc34)cc2)cc1
95,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,COCCN1CCC[C@@H]1C#Cc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2s1,"(R)-N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-((1-(2-methoxyethyl)pyrrolidin-2-yl)ethynyl)thieno[3,2-d]pyrimidin-4-amine",0.13,uM,=,-0.8860566476931633,0,C(#C[C@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
96,699068,10.1016/j.bmc.2010.11.007,,,,Inhibition of EGFR by HTRF assay,CN(C)CCCC(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1,N-(1-(3-Bromophenylamino)-4-cyanoisoquinolin-7-yl)-4-(dimethylamino)butanamide,4.1,uM,=,0.6127838567197355,1,c1ccc(Nc2nccc3ccccc23)cc1
97,2233412,10.1016/j.bmcl.2022.128703,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells using kinase substrate 22 incubated for 30 mins in presence of ATP,C=CC(=O)N1C[C@@H]2C[C@H]1CN2C(=O)Oc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC,"4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl(1S,4S)-5-acryloyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate",0.0003,uM,=,-3.522878745280338,0,O=C(Oc1ccc2ncnc(Nc3ccccc3)c2c1)N1C[C@@H]2C[C@H]1CN2
98,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(OCC1CCCCC1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid cyclohexylmethyl ester",1.2,uM,=,0.0791812460476248,1,O=C(OCC1CCCCC1)c1cccc(NCc2ccccc2)c1
99,1642199,,,,,Inhibition Assay: Inhibition of various kinase enzyme.,Nc1nc(N)c2c(n1)[nH]c1cccc(Sc3ccccc3)c12,"5-(phenylthio)-9H-pyrimido[4,5-b]indole-2,4-diamine",15.07,uM,=,1.1781132523146318,1,c1ccc(Sc2cccc3[nH]c4ncncc4c23)cc1
100,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#C/C(=C\c1ccc(O)cc1)C(=O)O,2-Cyano-3-(4-hydroxy-phenyl)-acrylic acid,165.0,uM,=,2.2174839442139063,1,c1ccccc1
101,642516,10.1021/jm1000198,,,,Inhibition of GST-tagged EGFR expressed in Escherichia coli,C=CC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"(S)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)acrylamide",0.007,uM,=,-2.154901959985743,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
102,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Nc1nc(N)c2c(Nc3cccc(Cl)c3)[nH]nc2n1,"N*3*-(3-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4,6-triamine",9.0,uM,=,0.9542425094393248,1,c1ccc(Nc2[nH]nc3ncncc23)cc1
103,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCNC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,N-Octyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetamide,5.33,uM,=,0.7267272090265723,1,O=c1cc(-c2ccccc2)oc2ccccc12
104,2074610,10.1016/j.bmc.2020.115680,,,,Inhibition of wild type EGFR (unknown origin) in presence of ATP preincubated 5 mins measured for 30 mins by detection reagent based HTRF analysis,C=C(Cl)C(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)ncc2Cl)c1,N-(3-((2-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-5-chloropyrimidin-4-yl)oxy)phenyl)-2-chloroacrylamide,0.13,uM,=,-0.8860566476931633,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
105,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,Fc1cccc(COc2ccc(Nc3ncnc4cc(C#C[C@@H]5CCCN5)sc34)cc2Cl)c1,"(S)-N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(pyrrolidin-2-ylethynyl)thieno[3,2-d]pyrimidin-4-amine",0.109,uM,=,-0.9625735020593764,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
106,63595,10.1016/s0960-894x(98)00691-x,,,,Inhibit of epidermal growth factor receptor (EGFR),CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21,"N*2*-((1R,2S)-2-Amino-cyclohexyl)-N*6*-(3-chloro-phenyl)-9-ethyl-9H-purine-2,6-diamine",5.1,uM,=,0.7075701760979364,1,c1ccc(Nc2nc(NC3CCCCC3)nc3[nH]cnc23)cc1
107,1801908,10.1016/j.ejmech.2018.06.061,,,,Inhibition of EGFR in human HepG2 cells,N#CCC(=O)N/N=C1\C(=O)Nc2ccc(S(=O)(=O)N3CCOCC3)cc21,2-Cyano-N'-(5-(morpholino sulfonyl)-2-oxoindolin-3-ylidene)aceto hydrazide,0.023,uM,=,-1.6382721639824072,0,N=C1C(=O)Nc2ccc(S(=O)(=O)N3CCOCC3)cc21
108,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,O=C(/C=C/CN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"(2E)-N-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(4-morpholinyl)-2-butenamide",0.002,uM,=,-2.6989700043360187,0,O=C(/C=C/CN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
109,658253,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR autophosphorylation in human A431 cells,C#CCNC/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OCC,(E)-N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(prop-2-ynylamino)but-2-enamide,0.0602,uM,=,-1.2204035087421754,0,c1ccc(Nc2ccnc3ccccc23)cc1
110,805192,10.1016/j.bmcl.2011.12.027,,,,Inhibition of EGFR,O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1,"trans-4-(9-((S)-tetrahydrofuran-3-yl)-8-(2,4,6-trifluorophenylamino)-9H-purin-2-ylamino)cyclohexanol",0.38,uM,=,-0.4202164033831898,0,c1ccc(Nc2nc3cnc(NC4CCCCC4)nc3n2[C@H]2CCOC2)cc1
111,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CN(C)[C@@H](C)C(N)=O,(S)-2-(((4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)propanamide,0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3ccccc23)cc1
112,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCN(C)CC1,(2E)-N-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}-7-ethoxy-6-quinazolinyl)-4-(4-methyl-1-piperazinyl)-2-butenamide,0.023,uM,=,-1.6382721639824072,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
113,67206,10.1021/jm010496a,,,,Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase,CCOc1cc2ncnc(Nc3cccc(-c4csc(N)n4)c3)c2cc1OCC,"[3-(2-Amino-thiazol-4-yl)-phenyl]-(6,7-diethoxy-quinazolin-4-yl)-amine",0.56,uM,=,-0.2518119729937995,0,c1cc(Nc2ncnc3ccccc23)cc(-c2cscn2)c1
114,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,COc1ccccc1CNc1ncnc2cc(N)ncc12,"N*4*-(2-Methoxy-benzyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",100.0,uM,=,2.0,1,c1ccc(CNc2ncnc3ccncc23)cc1
115,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,COCCn1c(=O)oc2cc3ncnc(Nc4ccc(F)c(F)c4)c3cc21,"8-(3, 4-Difluorophenylamino)-1-(2-methoxyethyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.026,uM,=,-1.585026652029182,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
116,1883874,10.1021/acsmedchemlett.8b00270,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay,C=CC(=O)N(c1ccc(Cl)cc1F)c1ncnc2cc(OC)c(OCCCN3CCOCC3)cc12,4-[N-acryloyl-(4-chloro-2-fluorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline,0.234,uM,=,-0.6307841425898572,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
117,2270884,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) by microplate reader analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.20134,uM,=,-0.6960699357246314,0,c1ccc(Nc2ncnc3ccccc23)cc1
118,727266,10.1016/j.bmc.2011.01.067,,,,Inhibition of EGFR,COc1ccc(Cn2ncc(NC(=O)c3cc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)ccc3C)c2N)cc1,N-(5-Amino-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-5-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-2-methylbenzamide,0.1014,uM,=,-0.9939620450026828,0,O=C(Nc1ccccc1)Nc1cccc(C(=O)Nc2cnn(Cc3ccccc3)c2)c1
119,2107115,10.1016/j.ejmech.2021.113300,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OCCCCC(=O)Nc1ccc(S(N)(=O)=O)cc1,5-((4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-(4-sulfamoylphenyl)pentanamide,0.0348,uM,=,-1.458420756053419,0,O=C(CCCCOc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1ccccc1
120,2119201,10.1021/acs.jmedchem.1c01084,,,,"Inhibition of recombinant human EGFR (696 to end residues) using poly(Glu, Tyr) 4:1 as substrate after 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis",CC(C)Oc1cc(F)ccc1Nc1ncnc2ccc(-c3ccc(C(=O)N4CCNCC4)cc3)nc12,"(4-(4-(4-fluoro-2-isopropoxyphenylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)(piperazin-1-yl)methanone",1.97,uM,=,0.2944662261615929,1,O=C(c1ccc(-c2ccc3ncnc(Nc4ccccc4)c3n2)cc1)N1CCNCC1
121,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(N2C(=O)C(Cc3ccc(OC)cc3)N(C)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-7-(4-methoxybenzyl)-6-methyl-5,8-dioxo-7,8-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-9(6H)-yl)phenyl)acrylamide",0.03395,uM,=,-1.4691602213834796,0,O=C1NC(Cc2ccccc2)C(=O)N(c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc21
122,67051,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor-dependent phosphorylation,COc1cc(O)c2c(O)c(-c3cccc(Cl)c3)cnc2c1,3-(3-Chloro-phenyl)-5-hydroxy-7-methoxy-1H-quinolin-4-one,6.0,uM,=,0.7781512503836436,1,c1ccc(-c2cnc3ccccc3c2)cc1
123,2215119,10.1016/j.ejmech.2022.114255,,,,Inhibition of EGFR (unknown origin) using poly (glu-tyr) as substrate incubated for 1 hr in presence of ATP measured by ADP-Glo kinase assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.02609,uM,=,-1.5835259208997792,0,c1ccc(Nc2ncnc3ccccc23)cc1
124,1472643,10.1016/j.ejmech.2015.03.004,,,,Inhibition of human GST-tagged EGFR expressed in baculovirus-infected insect Sf9 cells using biotinylating polyGluTyr as substrate after 1 hr by scintillation counting analysis in presence of [gamma-33P]-ATP,C#Cc1cccc(N2C(=O)Nc3c(C(=O)Nc4ccc(CN5CCCC5)cc4)sc4ncnc2c34)c1,"5-(3-Ethynyl-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid(4-pyrrolidin-1-ylmethyl-phenyl)-amide",0.026,uM,=,-1.585026652029182,0,O=C(Nc1ccc(CN2CCCC2)cc1)c1sc2ncnc3c2c1NC(=O)N3c1ccccc1
125,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,C[C@H](c1ccccc1)n1ncc2cc(Nc3ncnn4ccc(COC[C@@H]5CNCCO5)c34)ccc21,"5-(((S)-morpholin-2-ylmethoxy)methyl)-N-(1-((R)-1-phenylethyl)-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.12,uM,=,-0.9208187539523752,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)cc1
126,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CCCCCCC(=O)ON[C@H](CS(C)(=O)=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,(S)-hexyl(1-(5-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)furan-2-yl)-2-(methylsulfonyl)ethyl)carbamate,0.1102,uM,=,-0.9578184054842336,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
127,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1cc(O)cc(F)c1)nn2C1CCCC1,"3-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-fluorophenol",0.751,uM,=,-0.1243600629958316,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
128,1500854,10.1016/j.bmc.2015.04.065,,,,Inhibition of recombinant EGFR (unknown origin) assessed as inhibition of autophosphorylation after 1 hr by DELFIA/Time-resolved fluorometry,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)S/C1=C/c1ccc(Cl)cc1,"(S,E)-1-(5-(4-Chlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)-N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)pyrrolidine-2-carboxamide",7.6,uM,=,0.8808135922807914,1,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)S/C1=C/c1ccccc1
129,66567,10.1021/jm950692f,,,,Inhibition of tyrosine kinase activity of Epidermal growth factor receptor from human A431 cells,CN(C)CCn1cnc2cc3ncnc(Nc4cccc(Br)c4)c3cc21,"(3-Bromo-phenyl)-[1-(2-dimethylamino-ethyl)-1H-imidazo[4,5-g]quinazolin-8-yl]-amine",0.00132,uM,=,-2.87942606879415,0,c1ccc(Nc2ncnc3cc4nc[nH]c4cc23)cc1
130,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1cccc2ccccc12)c1ccccc1,(Z)-2-((E)-3-(naphthalen-1-yl)-1-phenylallylidene)hydrazinecarbothioamide,0.41,uM,=,-0.3872161432802645,0,N=C(/C=C/c1cccc2ccccc12)c1ccccc1
131,1291543,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCOCC2)CCO4)c1,"1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-morpholinobut-2-en-1-one",0.64,uM,=,-0.1938200260161128,0,O=C(/C=C/CN1CCOCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
132,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,CCN(CC)CCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1,"6-(2,6-Dichloro-phenyl)-2-(3-diethylamino-propylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",1.4,uM,=,0.1461280356782379,1,O=c1[nH]c2ncncc2cc1-c1ccccc1
133,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)CCN1CCCCC1,N-(4-(3-Chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl)-3-piperidin-1-ylpropanamide,0.00221,uM,=,-2.6556077263148894,0,O=C(CCN1CCCCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
134,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(C=C(C#N)C#N)cc(CSCC(=O)O)c1O,"[5-(2,2-Dicyano-vinyl)-2-hydroxy-3-methoxy-benzylsulfanyl]-acetic acid",96.0,uM,=,1.9822712330395684,1,c1ccccc1
135,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,CN(C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)CCO,4-[(2-Hydroxy-ethyl)-methyl-amino]-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3ccccc23)cc1
136,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(Br)cc3F)c2c1,N-(4-(4-bromo-2-fluorophenylamino)quinazolin-6-yl)acrylamide,0.0021,uM,=,-2.6777807052660805,0,c1ccc(Nc2ncnc3ccccc23)cc1
137,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,8e-05,uM,=,-4.096910013008056,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
138,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCn4ccnc4[N+](=O)[O-])cc23)c1,N-(3-ethynylphenyl)-7-methoxy-6-((5-(2-nitro-1H-imidazol-1-yl)pentyl)oxy)quinazolin-4-amine,0.00049,uM,=,-3.3098039199714866,0,c1ccc(Nc2ncnc3ccc(OCCCCCn4ccnc4)cc23)cc1
139,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,CSc1ccc(CCCCCn2cc(CCN)c3cc(OCCc4ccc(O)cc4)ccc32)cc1.Cl,2-{5-(4-Hydroxyphenethoxy)-1-{5-[4-(methylthio)-phenyl]pentyl}-1H-indole-3-yl}ethanamine hydrochloride,1.92,uM,=,0.2833012287035495,1,c1ccc(CCCCCn2ccc3cc(OCCc4ccccc4)ccc32)cc1
140,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1nc(C)nc(Nc3cccc(Br)c3)c1NC2,"(3-bromo-phenyl)-(7,8-dimethoxy-3-methyl-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",30.7,uM,=,1.4871383754771863,1,c1ccc(Nc2ncnc3c2NCc2ccccc2S3)cc1
141,457884,10.1016/j.bmcl.2007.08.073,,,,Inhibition of EGFR,C[C@H](CN(C)C(=O)CO)Oc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12,(R)-N-(2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)propyl)-2-hydroxy-N-methylacetamide,0.002,uM,=,-2.6989700043360187,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
142,305999,10.1016/j.bmcl.2004.08.007,,,,Inhibitory concentration against Epidermal growth factor receptor tyrosine kinase activity,COc1cc2ncnc(Nc3cc(NC(=O)c4cccc(N(C)C)c4)ccc3Cl)c2cc1OC,"N-[4-Chloro-3-(6,7-dimethoxy-quinazolin-4-ylamino)-phenyl]-3-dimethylamino-benzamide",29.0,uM,=,1.462397997898956,1,O=C(Nc1cccc(Nc2ncnc3ccccc23)c1)c1ccccc1
143,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cnc(NC(C)C)nc1,2-(isopropylamino)-N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-pyrimidine-5-carboxamide,0.043,uM,=,-1.3665315444204136,0,O=C(Nc1cccc(C(=O)Nc2ccc(CN3CCNCC3)cc2)c1)c1cncnc1
144,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc(C)cc3)C2)cc1,"2-(3-(4-Methoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",5.46,uM,=,0.7371926427047373,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
145,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,CNc1ncc(C(=O)Nc2cc(C(=O)Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)ccc2C)cn1,N-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-2-(methylamino)-pyrimidine-5-carboxamide,0.12,uM,=,-0.9208187539523752,0,O=C(Nc1cccc(C(=O)Nc2ccc(CN3CCNCC3)cc2)c1)c1cncnc1
146,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,O=S(=O)(Nc1nccs1)c1ccc(NC(=S)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)cc1,4-(3-(4-((3-bromophenyl)amino)quinazolin-6-yl)thioureido)-N-(thiazol-2-yl)benzene sulfonamide,0.022,uM,=,-1.6575773191777938,0,O=S(=O)(Nc1nccs1)c1ccc(NC(=S)Nc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
147,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,CN(C)C/C=C/C(=O)N1CCCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-8,9-dihydro-7H-pyrimido[5,4-h][1,5]benzoxazepin-6-yl]-4-(dimethylamino)but-2-en-1-one",0.446,uM,=,-0.3506651412878581,0,c1ccc(COc2ccc(Nc3ncnc4cc5c(cc34)NCCCO5)cc2)cc1
148,63780,10.1016/j.bmcl.2004.01.034,,,,Inhibition of epidermal growth factor receptor kinase autophosphorylation,CC#CC(=O)Nc1ccc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2c1,But-2-ynoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-quinolin-6-yl]-amide,1.0278,uM,=,0.0119086133491541,1,c1ccc(Nc2ccnc3ccccc23)cc1
149,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,CN(C)CCNC(=O)c1c(SSc2c(C(=O)NCCN(C)C)c3ccccc3n2C)n(C)c2ccccc12,3N-(2-dimethylaminoethyl)-2-[3-(2-dimethylaminoethylcarbamoyl)-1-methyl-1H-2-indolyldisulfanyl]-1-methyl-1H-3-indolecarboxamide,17.5,uM,=,1.2430380486862944,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
150,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CCOC(=O)CSCc1oc2cc(O)cc(O)c2c(=O)c1-c1ccc(O)cc1,"ethyl 2-((5,7-dihydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-2-yl)methylthio)acetate",9.948335213342348,uM,=,0.9977504105798146,1,O=c1c(-c2ccccc2)coc2ccccc12
151,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)cc3OC)ncc2Br)c1,"US9238629, I-13",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
152,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),O=C(NCc1ccccc1)C(O)Cc1c(SSc2[nH]c3ccccc3c2CC(O)C(=O)NCc2ccccc2)[nH]c2ccccc12,N-Benzyl-3-{2-[3-(2-benzylcarbamoyl-2-hydroxy-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-2-hydroxy-propionamide,14.0,uM,=,1.146128035678238,1,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
153,2067577,10.1016/j.ejmech.2019.111888,,,,"Inhibition of EGFR L858R/T790M/C797S (unknown origin) using Poly (Glu, Tyr) as substrate measured after 40 mins by kinase-glo assay",C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.11,uM,=,-0.958607314841775,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
154,982642,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis,O=C(CCOc1ccccc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-bromoanilino)quinazolin-6-yl)-3-phenoxypropanamide,0.0384,uM,=,-1.4156687756324693,0,O=C(CCOc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
155,2107115,10.1016/j.ejmech.2021.113300,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1OCCCCC(=O)Nc1ccc(S(N)(=O)=O)cc1,5-((4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-(4-sulfamoylphenyl)pentanamide,0.0165,uM,=,-1.7825160557860935,0,O=C(CCCCOc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1)Nc1ccccc1
156,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,OCCOCCNCc1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"2-(2-{4-[7-(1H-Indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-ethoxy)-ethanol",0.004,uM,=,-2.397940008672037,0,c1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
157,86514,10.1021/jm00110a022,,,,Inhibition of HER14 (human EGFR overexpressing) cell proliferation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCc1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-(3-phenyl-propyl)-acrylamide",2.5,uM,=,0.3979400086720376,1,O=C(C=Cc1ccccc1)NCCCc1ccccc1
158,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,Cc1cccc(Nc2ncnc3cc(NCCCN4CCN(C)CC4)ncc23)c1,"N*7*-[3-(4-Methyl-piperazin-1-yl)-propyl]-N*4*-m-tolyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0056,uM,=,-2.2518119729938,0,c1ccc(Nc2ncnc3cc(NCCCN4CCNCC4)ncc23)cc1
159,1914927,10.1016/j.ejmech.2019.111943,,,,Inhibition of N-terminal GST-tagged human EGFR (d746-750AA) expressed in baculovirus using FAM-labelled peptide as substrate pre-incubated for 10 mins followed by substrate addition by mobility shift assay,Cc1cc(F)cc(Nc2cc(NC(=O)Nc3c(Cl)cccc3Cl)ncn2)c1,"1-(2,6-dichlorophenyl)-3-(6-((3-fluoro-5-methylphenyl)amino)pyrimidin-4-yl)urea",0.253,uM,=,-0.5968794788241821,0,O=C(Nc1ccccc1)Nc1cc(Nc2ccccc2)ncn1
160,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,C#Cc1cccc(Nc2ncnc3cc(OCCCCn4ccnc4[N+](=O)[O-])c(OC)cc23)c1,N-(3-Ethynylphenyl)-6-methoxy-7-(4-(2-nitro-1H-imidazol-1-yl)butoxy)quinazolin-4-amine,0.00026,uM,=,-3.585026652029182,0,c1ccc(Nc2ncnc3cc(OCCCCn4ccnc4)ccc23)cc1
161,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.00013,uM,=,-3.886056647693163,0,c1ccc(Nc2ncnc3cnccc23)cc1
162,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3cn[nH]c3c1)nn2C1CCCC1,"1-cyclopentyl-3-(1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.76,uM,=,-0.1191864077192086,0,c1ncc2c(-c3ccc4cn[nH]c4c3)nn(C3CCCC3)c2n1
163,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Cc1cccc(Nc2ncnc3c2sc2ccc([N+](=O)[O-])cc23)c1.Cl,"(8-Nitro-benzo[4,5]thieno[3,2-d]pyrimidin-4-yl)-m-tolyl-amine hydrochloride",0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
164,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),O=C(CCC1C(S)=Nc2ccccc21)NCc1ccccc1,"N-Benzyl-3-(2-thioxo-2,3-dihydro-1H-indol-3-yl)-propionamide",100.0,uM,=,2.0,1,O=C(CCC1C=Nc2ccccc21)NCc1ccccc1
165,1934063,10.1016/j.bmcl.2016.02.003,,,,Inhibition of recombinant human His-tagged EGFR expressed in mammalian expression system by Z'-LYTE assay,Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1,"N-(1RS,2SR)-2-aminocyclohexyl)-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl)thiophene-2-carboxamide",0.34,uM,=,-0.4685210829577448,0,O=C(NC1CCCCC1)c1cc(-c2cnn3cc(-c4cn[nH]c4)cnc23)cs1
166,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1N,"N*4*-(3-Bromo-phenyl)-7-methoxy-quinazoline-4,6-diamine",0.0038,uM,=,-2.42021640338319,0,c1ccc(Nc2ncnc3ccccc23)cc1
167,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,CNC(=O)[C@@H](C)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,(R)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-N-methylpropanamide,0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
168,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(=O)NCc3ccccc3)c3ccccc3n2C)c(C(=O)NCc2ccccc2)c2ccccc21,3N-benzyl-2-(3-benzylcarbamoyl-1-methyl-1H-2-indolyldisulfanyl)-1-methyl-1H-3-indolecarboxamide,1.7,uM,=,0.2304489213782739,1,O=C(NCc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)NCc2ccccc2)[nH]c2ccccc12
169,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(F)c(F)c3)ncnc2cc1OCCOCCOCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-(2-{2-[2-({4-[(3,4-Difluorophenyl)amino]-6-methoxy-quinazolin-7-yl}oxy)ethoxy]ethoxy}ethyl)-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.0199699999999999,uM,=,-1.6996219351292974,0,O=C(Cn1cncn1)NCCOCCOCCOc1ccc2c(Nc3ccccc3)ncnc2c1
170,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cccc(C#Cc4ccccc4)c3)c2cc1OC,"6,7-dimethoxy-N-(3-(2-phenylethynyl)phenyl)quinazolin-4-amine",0.921,uM,=,-0.035740369803151,0,C(#Cc1cccc(Nc2ncnc3ccccc23)c1)c1ccccc1
171,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ncc5c4)c3s2)cc1,"(1H-Indazol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine",1.6,uM,=,0.2041199826559248,1,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ncc5c4)c3s2)cc1
172,2284955,10.1016/j.ejmech.2019.112016,,,,Inhibition of EGFR (unknown origin),CC(C)=NNc1nc(-c2ccc(Cl)cc2)cs1,1-(4-(4-Chlorophenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine,2.0,uM,=,0.3010299956639812,1,c1ccc(-c2cscn2)cc1
173,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",Cc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)nc23)c1,"N*2*-(2-Morpholin-4-yl-ethyl)-N*8*-m-tolyl-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.0023,uM,=,-2.638272163982407,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)nc23)cc1
174,807915,10.1016/j.bmc.2012.01.029,,,,Inhibition of EGFR,Nc1nc(Nc2cccc(Br)c2)c2cc(Cc3ccc(Cl)c(Cl)c3)[nH]c2n1,"N4-(3-bromophenyl)-6-(3,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",19.77,uM,=,1.2960066693136725,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
175,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,C=CCn1ccc2cc(Nc3ncnc4ccc(N)cc34)ccc21,"N4-(1-allyl-1H-indol-5-yl)quinazoline-4,6-diamine",0.3519,uM,=,-0.4535807331648083,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1
176,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Fc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"(3-Bromo-phenyl)-(6-fluoro-pyrido[3,4-d]pyrimidin-4-yl)-amine",0.124,uM,=,-0.906578314837765,0,c1ccc(Nc2ncnc3cnccc23)cc1
177,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5S(=O)(=O)c5cccc(F)c5)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(1-(3-fluorophenylsulfonyl)-1H-indazol-5-ylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.23,uM,=,-0.6382721639824072,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5S(=O)(=O)c5ccccc5)c4)c3s2)C1)N1CCOCC1
178,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(NS(C)(=O)=O)cc2)c2c(N)ncnc21,"N-(4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)methanesulfonamide",12.8,uM,=,1.1072099696478683,1,c1ccc(-c2n[nH]c3ncncc23)cc1
179,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.01,uM,=,-2.0,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
180,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,O=C(NCc1ccccc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-benzyl-3-(4-((3-bromophenyl)amino)quinazolin-6-yl)urea,0.0089,uM,=,-2.050609993355087,0,O=C(NCc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
181,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(NCc1ccccc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-Benzyl-3-(4-((3-bromophenyl)amino)quinazolin-6-yl)thiourea,0.0172,uM,=,-1.764471553092451,0,S=C(NCc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
182,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CCCCC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-2-heptynamide",0.0045,uM,=,-2.3467874862246565,0,c1ccc(Nc2ncnc3cnccc23)cc1
183,974507,10.1016/j.ejmech.2013.05.026,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(CCCOc3no[n+]([O-])c3S(=O)(=O)c3ccccc3)cc2)n1,"4-(3-(4-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide",2.28,uM,=,0.3579348470004537,1,O=S(=O)(c1ccccc1)c1[nH+]onc1OCCCc1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
184,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1,"(2E)-N-{4-[(1-Benzyl-1H-indazol-5-yl)amino]pyrido[3,4-d]-pyrimidin-6-yl}-4-(1-pyrrolidinyl)-2-butenamide",0.003,uM,=,-2.5228787452803374,0,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1
185,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCc1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-(3-phenyl-propyl)-acrylamide",0.7000000000000001,uM,=,-0.1549019599857431,0,O=C(C=Cc1ccccc1)NCCCc1ccccc1
186,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,Fc1ccc(Nc2ncnc3ccc(NC(=S)NCCN4CCOCC4)cc23)cc1Cl,1-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)thiourea,0.00225,uM,=,-2.6478174818886377,0,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
187,2260188,10.1016/j.ejmech.2020.112995,,,,Inhibition of human wild type GST-tagged EGFR expressed in Sf9 cells assessed as substrate phosphorylation using TK-peptide as substrate incubated for 25 mins by HTRF assay,CCC(=O)Nc1cccc(-c2c(-c3ccccc3)[nH]c3ncnc(OC)c23)c1,"N-(3-(4-methoxy-6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl)propionamide",1.203,uM,=,0.0802656273398447,1,c1ccc(-c2[nH]c3ncncc3c2-c2ccccc2)cc1
188,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,Cc1cc2cc(Nc3ccnc4cc(-c5ccc(CN6CCOCC6)cc5)sc34)ccc2[nH]1,"(2-Methyl-1H-indol-5-yl)-[2-(4-morpholin-4-ylmethyl-phenyl)-thieno[3,2-b]pyridin-7-yl]-amine",1.25,uM,=,0.0969100130080564,1,c1cc(Nc2ccc3[nH]ccc3c2)c2sc(-c3ccc(CN4CCOCC4)cc3)cc2n1
189,835647,10.1016/j.bmcl.2012.07.079,,,,Inhibition of EGFR in human A431 cell lysate using tyrosine/glutamic acid polymer as substrate by ELISA,Clc1cccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCCCCO5)cc23)c1,"N4-(3-chlorophenyl)-N6-((2,3,4,5-tetrahydrobenzo[b][1,4]dioxocin-8-yl)methyl)quinazoline-4,6-diamine",0.92,uM,=,-0.0362121726544447,0,c1ccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCCCCO5)cc23)cc1
190,1541392,10.1016/j.ejmech.2015.09.031,,,,Inhibition of wild type recombinant human EGFR preincubated for 10 mins followed by FAM-labeled peptide/ATP addition measured after 1 hr by mobility shift assay,C/C(=N\Nc1ncc(Cl)c(Nc2cccc(NC(=O)/C=C/CN(C)C)c2)n1)c1ccc(F)cc1,(E)-N-(3-(5-Chloro-2-((E)-2-(1-(4-fluorophenyl)ethylidene)hydrazinyl)pyrimidin-4-ylamino)phenyl)-4-(dimethylamino)but-2-enamide,15.32,uM,=,1.1852587652965851,1,C(=NNc1nccc(Nc2ccccc2)n1)c1ccccc1
191,1832355,10.1016/j.bmcl.2018.12.056,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,CCOCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(CC)CC,(E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(2-ethoxyethoxy)quinazolin-6-yl)-4-(diethylamino)but-2-enamide,0.00148,uM,=,-2.8297382846050425,0,c1ccc(Nc2ncnc3ccccc23)cc1
192,2233177,10.1016/j.bmcl.2022.128680,,,,Inhibition of wild type EGFR (unknown origin) incubated for 1 hr in the presence of ATP by FRET based Z'-LYTE assay,C=CC(=O)Nc1cccc(Cn2c(=O)ccc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc32)c1,"N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)methyl)phenyl)acrylamide",0.2612,uM,=,-0.5830268273969638,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1Cc1ccccc1
193,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,NC1CCN(Cc2ccn3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,"5-((4-aminopiperidin-1-yl)methyl)-N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.036,uM,=,-1.4436974992327127,0,c1ccc(COc2ccc(Nc3ncnn4ccc(CN5CCCCC5)c34)cc2)nc1
194,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,Nc1ccccc1NC(=O)/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cc1,(E)-N-(2-aminophenyl)-3-(4-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)phenyl)acrylamide,0.029,uM,=,-1.537602002101044,0,O=C(/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)cc1)Nc1ccccc1
195,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,COc1cc2ncnc(Nc3ccccc3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-phenyl-amine",4.3,uM,=,0.6334684555795865,1,c1ccc(Nc2ncnc3ccccc23)cc1
196,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCOC,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(2-methoxy-ethoxy)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.0009699999999999,uM,=,-3.0132282657337552,0,c1ccc(Nc2ncnc3cccnc23)cc1
197,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(4-methyl-1,4-diazepan-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.209,uM,=,-0.679853713888946,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCCNCC4)cc3)nc2N1[C@H]1CCNC1
198,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1ccc(/C=C/C(=O)O)cc1,"3-[4-(2,2-Dicyano-vinyl)-phenyl]-acrylic acid",450.0,uM,=,2.6532125137753435,1,c1ccccc1
199,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc4c(ccn4Cc4ccccc4)c3)ncnc2cc1OC,N-{4-[(1-Benzyl-1H-indol-5-yl)amino]-7-methoxy-6-quinazol0inyl}propanamide,0.021,uM,=,-1.6777807052660807,0,c1ccc(Cn2ccc3cc(Nc4ncnc5ccccc45)ccc32)cc1
200,2080588,10.1021/acs.jmedchem.0c02005,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu-Tyr) 4:1 as substrate incubated for 1 hr in presence of ATP by ELISA,[2H]C([2H])=CC(=O)Nc1cc(Nc2nccc(-c3cn(C([2H])([2H])[2H])c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(methyl-d3)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide-3,3-d2",0.1138,uM,=,-0.9438577379409476,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
201,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,COc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"(3-Bromo-phenyl)-(7-methoxy-pyrido[4,3-d]pyrimidin-4-yl)-amine",0.039,uM,=,-1.408935392973501,0,c1ccc(Nc2ncnc3ccncc23)cc1
202,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,Cl.NCCNC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,4-(2-nitrovinyl)phenyl 4-(2-aminoethylcarbamoyl)benzenesulfonate hydrochloride,5.0,uM,=,0.6989700043360189,1,O=S(=O)(Oc1ccccc1)c1ccccc1
203,1699473,10.1021/acs.jmedchem.6b01907,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain expressed in baculovirus by Z'-LYTE assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(OCc4ccccn4)c(Cl)c3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.0083,uM,=,-2.0809219076239263,0,c1ccc(COc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)nc1
204,67051,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor-dependent phosphorylation,COc1cc(O)c2c(=O)c(-c3cccc(Cl)c3)cn(C)c2c1,3-(3-Chloro-phenyl)-5-hydroxy-7-methoxy-1-methyl-1H-quinolin-4-one,3.0,uM,=,0.4771212547196624,1,O=c1c(-c2ccccc2)c[nH]c2ccccc12
205,2105982,10.1016/j.ejmech.2020.112994,,,,Inhibition of EGFR in human A-431 cells assessed as antiproliferative activity incubated for 48 hrs by MTS method,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.85,uM,=,-0.0705810742857072,0,c1ccc(/N=c2\nc[nH]c3cc(OCC4CCNCC4)ccc23)cc1
206,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,CC(=O)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccc(F)cc1,"1-(3-(3,4-Dichlorophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone",18.35,uM,=,1.2636360685881085,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
207,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C/c1ccc(O)c(O)c1)C(=O)NC1CCCCC1,"2-cyano-N-cyclohexyl-3-(3,4-dihydroxyphenyl)acrylamide",2.0,uM,=,0.3010299956639812,1,O=C(C=Cc1ccccc1)NC1CCCCC1
208,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1cccc(CNC(=O)/C(C#N)=C/c2ccc(O)c(O)c2)c1,"(E)-2-Cyano-N-(3-{[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-methyl}-benzyl)-3-(3,4-dihydroxy-phenyl)-acrylamide",10.3,uM,=,1.0128372247051722,1,O=C(C=Cc1ccccc1)NCc1cccc(CNC(=O)/C=C/c2ccccc2)c1
209,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,C=CC(=O)Nc1cc(Nc2nc(C)cc(-c3cn(C)c4ccc(F)cc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(5-fluoro-1-methyl-1H-indol-3-yl)-6-methylpyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,1.094,uM,=,0.039017321997412,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
210,600206,10.1016/j.bmcl.2009.05.060,,,,Inhibition of EGFR-mediated poly(L-glutamic acid L-tyrosine) phosphorylation,CC(=O)OCN(C)/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,(3-(4-(3-chlorophenylamino)quinazolin-6-yl)-1-methyltriaz-2-enyl)methyl acetate,0.24,uM,=,-0.619788758288394,0,c1ccc(Nc2ncnc3ccccc23)cc1
211,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,O=S(=O)(c1ccc(/N=C/c2cc(Br)ccc2O)cc1)N1CCCCC1,4-bromo-2-((4-(piperidin-1-ylsulfonyl)phenylimino)methyl)phenol,9.7,uM,=,0.9867717342662448,1,O=S(=O)(c1ccc(/N=C/c2ccccc2)cc1)N1CCCCC1
212,321418,10.1016/j.bmcl.2005.06.068,,,,Inhibitory concentration against EGFR kinase phosphorylation using synthetic peptide as a substrate,CN1CCC(Oc2cccc3ncnc(Nc4ccc(OCc5cnccn5)c(Cl)c4)c23)CC1,[3-Chloro-4-(pyrazin-2-ylmethoxy)-phenyl]-[5-(1-methyl-piperidin-4-yloxy)-quinazolin-4-yl]-amine,0.69,uM,=,-0.1611509092627447,0,c1cc(OC2CCNCC2)c2c(Nc3ccc(OCc4cnccn4)cc3)ncnc2c1
213,2052738,10.1016/j.ejmech.2019.111966,,,,Inhibition of wild type N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus infected Sf21 cells using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km concentration and further incubated for 20 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2cc(-n3c(SC)nnc3-c3ccc(F)cc3)ccn2)c(OC)cc1N1CCCN(C)CC1,"N-(5-((4-(3-(4-Fluorophenyl)-5-(methylthio)-4H-1,2,4-triazol-4-yl)pyridin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide",0.333,uM,=,-0.4775557664936801,0,c1ccc(-c2nncn2-c2ccnc(Nc3ccc(N4CCCNCC4)cc3)c2)cc1
214,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,O=C(Nc1ccc(Cl)cc1)c1ccc(N(CCCl)CCCl)cc1,4-(Bis(2-chloroethyl)amino)-N-(4-chlorophenyl)benzamide,1.49,uM,=,0.173186268412274,1,O=C(Nc1ccccc1)c1ccccc1
215,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1cccc(F)c1,"(R)-4-(4-((1-(3-Fluorophenyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.009,uM,=,-2.0457574905606752,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
216,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(1-benzyl-1H-indazol-5-ylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.08,uM,=,-1.0969100130080565,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1
217,1798716,10.1016/j.ejmech.2017.03.083,,,,"Inhibition of wild type N-terminal GST tagged human recombinant EGFR (695 to end amino acids) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) Peptide substrate by ADP-Glo assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(CN4CCOCC4)cc3)ncc2F)c1,N-[3-[[5-Fluoro-2-[4-((1-morpholino)methyl)phenylamino]-4-pyrimidinyl]amino]phenyl]acrylamide,0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ccnc(Nc3ccc(CN4CCOCC4)cc3)n2)cc1
218,457884,10.1016/j.bmcl.2007.08.073,,,,Inhibition of EGFR,O=C(CO)N1CCC[C@@H]1COc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12,(R)-1-(2-((4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)methyl)pyrrolidin-1-yl)-2-hydroxyethanone,0.097,uM,=,-1.0132282657337552,0,c1ccc(COc2ccc(Nc3ncnc4cccc(OC[C@H]5CCCN5)c34)cc2)nc1
219,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,COC(=O)c1ccc(C(=O)c2c(SSc3c(C(=O)c4ccc(C(=O)OC)cc4)c4ccccc4n3C)n(C)c3ccccc23)cc1,methyl 4-{1-methyl-2-[1-methyl-3-(4-methyloxycarbonylbenzoyl)-1H-2-indolyldisulfanyl]-1H-3-indolylcarbonyl}benzoate,6.1,uM,=,0.785329835010767,1,O=C(c1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)c2ccccc2)[nH]c2ccccc12
220,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),CNC(=O)CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NC)[nH]c2ccccc12,N-Methyl-3-{2-[3-(2-methylcarbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-propionamide,9.4,uM,=,0.9731278535996988,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
221,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,COc1cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c2c1CN1CCCNCC1,"5-((1,4-diazepan-1-yl)methyl)-N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-6-methoxypyrrolo[1,2-f][1,2,4]triazin-4-amine",0.19,uM,=,-0.721246399047171,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)cc1
222,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,O=C(O)/C=C/c1ccc(O)c(O)c1,"(E)-3-(3,4-Dihydroxy-phenyl)-acrylic acid",1200.0,uM,=,3.0791812460476247,1,c1ccccc1
223,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CS(=O)(=O)CCNCc1cc(-c2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)co1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-3-yl)thieno[3,2-d]pyrimidin-4-amine",0.004,uM,=,-2.397940008672037,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5ccoc5)sc34)cc2)cc1
224,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CN(CCO)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"2-{[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-yl]-methyl-amino}-ethanol",0.0026,uM,=,-2.5850266520291822,0,c1ccc(Nc2ncnc3ccncc23)cc1
225,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,COc1ccc2c(c1)CNc1c(Nc3ccc(F)c(Cl)c3)ncnc1O2,"(3-Chloro-4-fluoro-phenyl)-(8-methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",2.4,uM,=,0.380211241711606,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
226,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,COC[C@@H](Nc1ncnc2oc(-c3ccccc3)cc12)c1ccccc1,"(S)-N-(2-Methoxy-1-phenylethyl)-6-phenylfuro[2,3-d]pyrimidin-4-amine",0.028,uM,=,-1.5528419686577808,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
227,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,C=C(CN(C)C)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OCC,N-[4-(3-Chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-2-dimethylaminomethyl-acrylamide,0.56,uM,=,-0.2518119729937995,0,c1ccc(Nc2ccnc3ccccc23)cc1
228,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=[N+]([O-])/C=C/c1ccc(O)c(O)c1,"4-(2-Nitro-vinyl)-benzene-1,2-diol",9.0,uM,=,0.9542425094393248,1,c1ccccc1
229,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCCC1,N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(pyrrolidin-1-ylmethyl)quinazolin-4-amine,0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
230,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1ncnc(Nc3ccc4c[nH]nc4c3)c1NC2,"(7,8-dimethoxy-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(1H-indazol-6-yl)-amine",14.1,uM,=,1.14921911265538,1,c1ccc2c(c1)CNc1c(Nc3ccc4c[nH]nc4c3)ncnc1S2
231,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,O=C1CCN(C/C=C/C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2O[C@H]2CCOC2)CC1,"(S,E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(4-oxopiperidin-1-yl)but-2-enamide",0.5202,uM,=,-0.2838296521401461,0,O=C1CCN(C/C=C/C(=O)Nc2cc3c(Nc4ccccc4)ncnc3cc2O[C@H]2CCOC2)CC1
232,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3ccccc3CC)c2c1,N-(4-(2-ethylphenylamino)quinazolin-6-yl)acrylamide,18.9,uM,=,1.276461804173244,1,c1ccc(Nc2ncnc3ccccc23)cc1
233,519199,10.1016/j.ejmech.2007.09.018,,,,Inhibition of human EGFR tyrosine kinase activity,COc1cc2ncnc(-c3c[nH]c4cc(F)c(Cl)cc34)c2cc1OC,"4-(5-Chloro-6-fluoroindole-3-yl)-6,7-dimethoxyquinazoline",0.209,uM,=,-0.679853713888946,0,c1ccc2c(-c3c[nH]c4ccccc34)ncnc2c1
234,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1ccc(O)c([N+](=O)[O-])c1,2-(4-Hydroxy-3-nitro-benzylidene)-malononitrile,125.0,uM,=,2.096910013008056,1,c1ccccc1
235,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,CC#CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,But-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.94,uM,=,-0.0268721464003013,0,c1ccc(Nc2ccnc3ccccc23)cc1
236,2132157,10.1021/acs.jmedchem.1c01559,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(OC)ccn3)cc2)c(C(N)=O)n1N,(S)-2-(1-acryloylpiperidin-2-yl)-1-amino-4-(4-((4-methoxypyridin-2-yl)carbamoyl)phenyl)-1H-imidazole-5-carboxamide,0.45,uM,=,-0.3467874862246563,0,O=C(Nc1ccccn1)c1ccc(-c2c[nH]c([C@@H]3CCCCN3)n2)cc1
237,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,COc1cc2ncnc(N[C@H](C)c3ccc(Cl)cc3)c2cc1OCCCCCCC(=O)NO,(R)-7-(4-(1-(4-chlorophenyl)ethylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3ccccc23)cc1
238,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)c2cc1NC(=O)/C=C/CN1CCCC1,(2E)-N-(7-Ethoxy-4-{4-[(phenylsulfonyl)amino]anilino}-6-quinazolinyl)-4-(1-pyrrolidinyl)-2-butenamide,0.061,uM,=,-1.214670164989233,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)c2c1
239,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,C[C@@H](Nc1ncnc2sc3c(c12)CCN(C(=O)/C=C/CN(C)C)C3)c1ccccc1,"(E)-4-(Dimethylamino)-1-(4-[(1R)-1-phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-buten-1-one",0.0046,uM,=,-2.337242168318426,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1
240,473816,10.1073/pnas.0708800104,,,,Inhibition of EGFR autophosphorylation,N#CC(C#N)=Cc1ccc(O)c(O)c1,"2-(3,4-Dihydroxy-benzylidene)-malononitrile",40.0,uM,=,1.6020599913279625,1,c1ccccc1
241,1330696,10.1039/C2MD20017A,,,,Inhibition of EGF-induced EGFR-mediated Akt phosphorylation in human A431 cells after 1 hr by immunoblotting method,CCC(=O)Nc1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1,N-(3-(6-(3-bromophenylamino)pyrimidin-4-ylamino)phenyl)propionamide,0.136,uM,=,-0.8664610916297825,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
242,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CCN(CC)CC#CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]-4-(diethylamino)-2-butynamide,0.0031,uM,=,-2.508638306165728,0,c1ccc(Nc2ncnc3ccccc23)cc1
243,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,C[S+]([O-])CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1,6-(5-((2-(Methylsulfinyl)ethylamino)methyl)furan-2-yl)-N-(4-(3-fluorobenzyloxy)3-chlorophenyl)-4-quinazolinamine tosylate,0.013,uM,=,-1.8860566476931635,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1.c1ccccc1
244,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(C(=O)Oc2ccccc2)c(-c2c[nH]c3ccccc23)n1,phenyl-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-4-(1H-indol-3-yl)pyrimidin-5-carboxylate,8e-06,uM,=,-5.096910013008056,0,O=C(Oc1ccccc1)c1cnc(Nc2ccc(N3CCCCC3)cc2)nc1-c1c[nH]c2ccccc12
245,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC[C@H]1CC(N)=O,(S)-2-(1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidin-2-yl)acetamide,0.13,uM,=,-0.8860566476931633,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
246,840626,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR using GST-Crk as substrate assessed as phosphorylated Crk level after 20 mins by SDS-PAGE analysis,Brc1cccc(Nc2ncnc3cc4c(cc23)Oc2ccccc2O4)c1,"(3-Bromo-phenyl)-(6,11-dioxa-1,3-diaza-naphthacen-4-yl)-amine",0.12,uM,=,-0.9208187539523752,0,c1ccc(Nc2ncnc3cc4c(cc23)Oc2ccccc2O4)cc1
247,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,CCN1CCN(C(=O)/C(F)=C/c2c(C)ncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)CC1,3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-methylpyrimidin-5-yl)-1-(4-ethylpiperazin-1-yl)-2-fluoroprop-2-en-1-one,0.156,uM,=,-0.8068754016455384,0,O=C(/C=C/c1cncnc1Nc1ccc(OCc2ccccc2)cc1)N1CCNCC1
248,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)CCN(C)C,N-(4-(3-Chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(dimethylamino)propanamide,0.00068,uM,=,-3.167491087293764,0,c1ccc(Nc2ccnc3ccccc23)cc1
249,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Oc1cc2ncnc(Nc3cccc(Br)c3)c2cc1O,"4-(3-Bromo-phenylamino)-quinazoline-6,7-diol",0.00017,uM,=,-3.769551078621726,0,c1ccc(Nc2ncnc3ccccc23)cc1
250,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,COc1ccc(-c2cn(C3CCCC3)c3ncnc(N)c23)cc1,"7-Cyclopentyl-5-(4-methoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",0.57,uM,=,-0.2441251443275086,0,c1ccc(-c2cn(C3CCCC3)c3ncncc23)cc1
251,608090,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 1 hr by Western blot,O=C(COc1ccc(F)cc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(4-fluorophenoxy)-acetamide,0.031,uM,=,-1.5086383061657274,0,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
252,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C=CC(=O)Nc1cccc(-c2c(-c3ccccc3)sc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-phenylthieno-[2,3-d]pyrimidin-5-yl)phenyl]prop-2-enamide",0.136,uM,=,-0.8664610916297825,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)c(-c4ccccc4)c23)cc1
253,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Nc3ccc(F)cc3Cl)c1NC2,"(2-chloro-4-fluoro-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",3.4,uM,=,0.5314789170422551,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
254,2080997,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCc1cn(CCC(=O)NO)nn1,"N-(4-((3-chloro-4-((2-fluorobenzyl)oxy)phenyl)amino)-7-((1-(3-(hydroxyamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.0022,uM,=,-2.657577319177794,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCc5c[nH]nn5)ccc34)cc2)cc1
255,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,CC(=O)N1CCC[C@@H]1C#Cc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2s1,"(R)-1-(2-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-1-yl)ethanone",0.058,uM,=,-1.2365720064370629,0,C(#C[C@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
256,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0193,uM,=,-1.714442690992226,0,c1ccc(Nc2ncnc3ccccc23)cc1
257,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3cccc(C=O)c3)cc12)c1ccccc1,"(R)-3-(4-(1-phenylethylamino)thieno[2,3-d]pyrimidin-6-yl)benzaldehyde",0.006,uM,=,-2.2218487496163566,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
258,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-9",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
259,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#C/C(=C/c1cc(O)ccc1O)C(=O)O,"2-Cyano-3-(2,5-dihydroxy-phenyl)-acrylic acid",75.0,uM,=,1.8750612633917,1,c1ccccc1
260,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",N#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1F,"3-[(7,8-Dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)amino]-2-fluorobenzonitrile",0.022,uM,=,-1.6575773191777938,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
261,1639950,,,,,Inhibition of recombinant human N-terminal GST His6-tagged thrombin cleavage site-fused EGFR (H672 to A1210 residues) expressed in baculovirus using poly-EY as substrate after 210 mins by luciferase coupled chemiluminescence assay,CCCN1CCCOC(COc2cc3ncnc(Nc4ccc(Cl)c(Cl)c4)c3cc2OC)C1,"N-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(4-propyl-1,4-oxazepan-2-yl)methyl]oxy}quinazolin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3cc(OCC4CNCCCO4)ccc23)cc1
262,1283337,10.1016/j.ejmech.2013.10.058,,,,Inhibition of wild type EGFR (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,COc1cc2nc(Cl)nc(Nc3ccc(S(N)(=O)=O)cc3)c2cc1OC,"4-((2-Chloro-6,7-dimethoxyquinazolin-4-yl)amino)benzenesulfonamide",2.37,uM,=,0.3747483460101038,1,c1ccc(Nc2ncnc3ccccc23)cc1
263,63773,10.1021/jm9508651,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 human epidermoid carcinoma cells,CN(C)c1ccc2c(Nc3cccc(Br)c3)ncnc2n1,"N*4*-(3-Bromo-phenyl)-N*7*,N*7*-dimethyl-pyrido[2,3-d]pyrimidine-4,7-diamine",2.3,uM,=,0.3617278360175928,1,c1ccc(Nc2ncnc3ncccc23)cc1
264,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,Brc1cccc(Nc2ccnc3ccccc23)c1,(3-Bromo-phenyl)-quinolin-4-yl-amine,5.5,uM,=,0.7403626894942439,1,c1ccc(Nc2ccnc3ccccc23)cc1
265,792378,10.1016/j.ejmech.2011.11.015,,,,Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis,Cc1ccc(-c2nnc(SCc3ccccc3)o2)c(O)c1,"2-(5-(Benzylthio)-1,3,4-oxadiazol-2-yl)-5-methylphenol",34.25,uM,=,1.5346605758284444,1,c1ccc(CSc2nnc(-c3ccccc3)o2)cc1
266,1769307,10.1016/j.bmc.2018.02.029,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,C=CC(=O)Nc1cc(Nc2ncc3ncn(-c4ccc(I)cc4)c3n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((9-(4-iodophenyl)-9H-purin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.017,uM,=,-1.769551078621726,0,c1ccc(Nc2ncc3ncn(-c4ccccc4)c3n2)cc1
267,1521034,10.1021/acs.jmedchem.5b01073,,,,Inhibition of EGFR (unknown origin) by HTRF assay in presence of 2 mM of ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C,"4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2R)-2,4-Dimethylpiperazine-1-carboxylate",0.102,uM,=,-0.9913998282380824,0,O=C(Oc1ccc2ncnc(Nc3ccccc3)c2c1)N1CCNCC1
268,982642,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis,CN(C)CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-(dimethylamino)-propanamide,0.0382,uM,=,-1.417936637088291,0,c1ccc(Nc2ncnc3ccccc23)cc1
269,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,CN(C)CCc1ccc(Nc2nc3ncnc(Nc4ccc(F)c(Cl)c4)c3s2)cc1,"N7-(3-chloro-4-fluorophenyl)-N2-(4-(2-(dimethylamino)ethyl)phenyl)thiazolo[4,5-d]pyrimidine-2,7-diamine",0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1
270,2184321,10.1016/j.bmc.2020.115897,,,,Inhibition of EGFR (unknown origin) incubated for 40 mins by intrinsic ATPase activity luminescence assay,O=C(Cc1csc2nc3ccccc3n12)Nc1cccc2ccccc12,"2-(benzo[4,5]imidazo[2,1-b]thiazol-3-yl)-N-(naphthalen-1-yl)acetamide",0.0883,uM,=,-1.0540392964224314,0,O=C(Cc1csc2nc3ccccc3n12)Nc1cccc2ccccc12
271,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,CN(C)CCN(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-(2-dimethylamino-ethyl)-N*6*-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0081,uM,=,-2.0915149811213505,0,c1ccc(Nc2ncnc3cnccc23)cc1
272,612309,10.1021/jm901453q,,,,Inhibition of EGFR,O=C(CCCCCCOc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1)NO,7-(4-(3-Chloro-4-fluorophenylamino)quinazolin-6-yloxy)-N-hydroxyheptanamide,0.0842,uM,=,-1.0746879085003505,0,c1ccc(Nc2ncnc3ccccc23)cc1
273,600206,10.1016/j.bmcl.2009.05.060,,,,Inhibition of EGFR-mediated poly(L-glutamic acid L-tyrosine) phosphorylation,CN(/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)C(=O)OCCl,chloromethyl 3-(4-(3-chlorophenylamino)quinazolin-6-yl)-1-methyltriaz-2-ene-1-carboxylate,0.39,uM,=,-0.4089353929735008,0,c1ccc(Nc2ncnc3ccccc23)cc1
274,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Nc3ccc(F)c(Cl)c3)c1NC2,"(3-Chloro-4-fluoro-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",1.2,uM,=,0.0791812460476248,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
275,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,CN(C)CC(CSCCN)C(=O)c1ccc(OCc2ccccc2)cc1.Cl,2-(2-Amino-ethylsulfanylmethyl)-1-(4-benzyloxy-phenyl)-3-dimethylamino-propan-1-one hydrochloride,8.8,uM,=,0.9444826721501688,1,c1ccc(COc2ccccc2)cc1
276,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,NS(=O)(=O)c1ccc(Nc2nc3ncnc(Nc4ccc(F)c(Cl)c4)c3s2)cc1,"4-(7-(3-chloro-4-fluorophenylamino)thiazolo[4,5-d]pyrimidin-2-ylamino)benzenesulfonamide",0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1
277,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,Fc1c(NC(=S)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)cccc1C(F)(F)F,1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(2-fluoro-3-(trifluoromethyl)phenyl)thiourea,0.1124,uM,=,-0.9492336887669576,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
278,2147415,10.1021/acs.jmedchem.1c01055,,,,Inhibition of Wild type EGFR (unknown origin),COc1cc(N2CCC(N3CCN(C)CC3)CC2)c(-c2cn[nH]c2)cc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)-piperidin-1-yl)-5-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide,0.0013,uM,=,-2.886056647693163,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)c(-c4cn[nH]c4)c3)n2)cc1
279,2205223,10.1016/j.bmc.2022.116907,,,,Inhibition of wild type EGFR (unknown origin) using TK as substrate incubated for 120 mins in the presence of ATP by HTRF assay,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,BRIGATINIB,0.053,uM,=,-1.275724130399211,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
280,1675840,10.1016/j.bmc.2017.03.032,,,,"Inhibition of recombinant wild type human EGFR (695 to end residues) using Poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(/C=C/c4ccc(C)cc4C)cc3)ncc2Cl)c1,"N-[3-[[5-Chloro-2-[(E)-4-(2,4-dimethylstyryl)phenylamino]-4-pyrimidinyl]amino]phenyl]-2-acrylamide",0.9961,uM,=,-0.0016970599014588,0,C(=C/c1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)\c1ccccc1
281,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,CN(C)CC(CNNC(N)=O)C(=O)c1ccc(OCc2ccccc2)cc1.Cl,2-{3-(4-benzyloxy)-2-[(dimethylamino)methyl]-3-oxopropyl}hydrazinecarboxamide hydrochloride,3.9,uM,=,0.5910646070264992,1,c1ccc(COc2ccccc2)cc1
282,2207742,10.1021/acs.jmedchem.2c00893,,,,Inhibition of wild type EGFR expressed in human A-431 cells,Cc1c(C#Cc2ccc(CN3CCC(CO)CC3)cc2)cc(C(F)F)c2cn(C(C(=O)Nc3nccs3)c3ncn4c3CCC43CC3)nc12,"2-[4-(Difluoromethyl)-6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-7-methyl-indazol-2-yl)-2-spiro[6,7-dihydropyrrolo[1,2-c]imidazole-5,1'-cyclopropane)-1-yl-N-thiazol-2-yl-acetamide",0.577,uM,=,-0.2388241868442686,0,O=C(Nc1nccs1)C(c1ncn2c1CCC21CC1)n1cc2ccc(C#Cc3ccc(CN4CCCCC4)cc3)cc2n1
283,1897499,10.1016/j.bmc.2019.07.042,,,,Inhibition of EGFR-TK in human MCF7 cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay,Clc1ccc(COC(c2cccs2)c2cc3ccccc3nc2Cl)cc1,2-Chloro-3-{[(4-chlorobenzyl)oxy](thiophen-2-yl)methyl}quinoline,3.66,uM,=,0.5634810853944107,1,c1ccc(COC(c2cnc3ccccc3c2)c2cccs2)cc1
284,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(C=C(C#N)C#N)cc(CSc2ccccc2C(=O)O)c1O,"2-[5-(2,2-Dicyano-vinyl)-2-hydroxy-3-methoxy-benzylsulfanyl]-benzoic acid",36.0,uM,=,1.5563025007672873,1,c1ccc(CSc2ccccc2)cc1
285,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc(Br)cc3)C2)cc1C,"2-(5-(4-bromophenyl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",1.84,uM,=,0.2648178230095365,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
286,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Cc1c(C)n(C)c2ncnc(Nc3cccc(Cl)c3)c12,"(3-Chloro-phenyl)-(5,6,7-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",450.0,uM,=,2.6532125137753435,1,c1ccc(Nc2ncnc3[nH]ccc23)cc1
287,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Fc1cccc(Nc2ncnc3ccccc23)c1,(3-Fluoro-phenyl)-quinazolin-4-yl-amine,0.056,uM,=,-1.2518119729937995,0,c1ccc(Nc2ncnc3ccccc23)cc1
288,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Fc1c(Nc2ncnc3cc4c(cc23)OCCO4)ccc(Cl)c1Br,"N-(3-Bromo-4-chloro-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0253,uM,=,-1.596879478824182,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
289,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-8",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
290,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(Nc4ccccc4)nc32)c1,"N-(3-(3-Methyl-2-oxo-7-(phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.00695,uM,=,-2.1580151954098863,0,O=C1NCc2cnc(Nc3ccccc3)nc2N1c1ccccc1
291,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),CC(=O)NC(Cc1c(SSc2[nH]c3ccccc3c2CC(NC(C)=O)C(=O)NCc2ccccc2)[nH]c2ccccc12)C(=O)NCc1ccccc1,2-Acetylamino-3-{2-[3-(2-acetylamino-2-benzylcarbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-N-benzyl-propionamide,51.0,uM,=,1.7075701760979365,1,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
292,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,O=C(/C=C/c1ccccc1)Nc1cccc(Cl)c1,(2E)-N-(3-chlorophenyl)-3-phenylprop-2-enamide,14.59,uM,=,1.1640552918934517,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
293,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3cccc(OC)c3OC)ncc2Br)c1,"US9238629, I-14::US9238629, I-6",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
294,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),CO.Nc1cccc2c1sc1c(Nc3cccc(Br)c3)ncnc12,"N*4*-(3-Bromo-phenyl)-benzo[4,5]thieno[3,2-d]pyrimidine-4,6-diamine; compound with methanol",0.0027,uM,=,-2.5686362358410126,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
295,66582,10.1021/jm970634p,,,,Inhibition of human epidermal growth factor receptor,CCN(CC)CCCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(NC(=O)NC(C)(C)C)nc2n1,"1-tert-Butyl-3-[6-(2,6-dichloro-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea",0.39,uM,=,-0.4089353929735008,0,c1ccc(-c2cnc3ncncc3c2)cc1
296,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,NCCCSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,4-(2-((3-Aminopropyl)thio)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-N-phenylpyridin-2-amine,0.055,uM,=,-1.259637310505756,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
297,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),O=C(/C=C/c1ccccc1)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-3-phenyl-acrylamide",0.0091,uM,=,-2.0409586076789066,0,O=C(/C=C/c1ccccc1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
298,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCC2(COC2)C1,6-(3-(2-oxa-6-azaspiro[3.4]octan-6-yl)propoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine,0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCC5(COC5)C4)cc23)cc1
299,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,O=c1oc2cc3ncnc(Nc4ccc(OCc5ccc(Cl)cc5)c(Cl)c4)c3cc2n1CCCN1CCOCC1,"8-(4-(4-Chlorobenzyloxy)-3-chlorophenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.061,uM,=,-1.214670164989233,0,O=c1oc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc2n1CCCN1CCOCC1
300,1891470,10.1016/j.bmc.2019.03.049,,,,Inhibition of c-MET (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins by mobility shift assay,COc1cc2c(Oc3ccc(C4SCC(=O)N4NC(=O)Nc4ccc(F)cc4F)cc3)ccnc2cc1OCCCN1CCOCC1,"1-(2,4-difluorophenyl)-3-(2-(4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)oxy)phenyl)-4-oxothiazolidin-3-yl)urea",3.35,uM,=,0.5250448070368452,1,O=C(Nc1ccccc1)NN1C(=O)CSC1c1ccc(Oc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1
301,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nccc(N)c3c2)c2c(N)ncnc21,"6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)quinolin-4-amine",100.0,uM,=,2.0,1,c1cnc2ccc(-c3n[nH]c4ncncc34)cc2c1
302,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",COc1ccc(N2C(=O)CS/C2=N/Nc2nncc3ccccc23)cc1,3-(4-Methoxyphenyl)-2-(2-(phthalazin-1-yl)hydrazono)thiazolidin-4-one,0.036,uM,=,-1.4436974992327127,0,O=C1CS/C(=N/Nc2nncc3ccccc23)N1c1ccccc1
303,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Fc1c(Br)cc(Cl)cc1Nc1ncnc2cc3c(cc12)OCCO3,"N-(3-Bromo-5-chloro-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",2.186,uM,=,0.339650157613684,1,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
304,305999,10.1016/j.bmcl.2004.08.007,,,,Inhibitory concentration against Epidermal growth factor receptor tyrosine kinase activity,COc1cc2ncnc(Nc3cc(NC(=O)c4ccccc4)c(F)cc3F)c2cc1OC,"N-[5-(6,7-Dimethoxy-quinazolin-4-ylamino)-2,4-difluoro-phenyl]-benzamide",0.49,uM,=,-0.3098039199714864,0,O=C(Nc1cccc(Nc2ncnc3ccccc23)c1)c1ccccc1
305,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,COCC(C)Oc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2c2c1OCCO2,"N-(3-chloro-4-fluorophenyl)-5-(1-methoxypropan-2-yloxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.2471999999999999,uM,=,-0.6069515335832218,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
306,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N1CCSCC1,N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-thiomorpholinophenyl)acrylamide,0.522,uM,=,-0.2823294969977378,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCSCC5)cc4)n3)c[nH]c2c1
307,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,COc1cc2ncnc(Nc3ccccc3F)c2cc1OC.Cl,"4-(2'-fluoroanilino)-6,7-dimethoxyquinazoline hydrochloride",0.0128,uM,=,-1.892790030352132,0,c1ccc(Nc2ncnc3ccccc23)cc1
308,2241040,10.1021/acs.jmedchem.1c00848,,,,Displacement of sapitinib-BODIPY tracer from C-terminal NanoLuc-fused full length wild type EGFR (unknown origin) transfected in HEK293T cells incubated for 2 hrs by NanoBRET assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,1.7,uM,=,0.2304489213782739,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
309,1291543,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN(CC)CC)CCO4)c1,"4-(diethylamino)-1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)but-2-en-1-one",0.042,uM,=,-1.3767507096020994,0,c1ccc(Nc2ncnc3cc4c(cc23)NCCO4)cc1
310,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,CCN1CCN(C(=O)c2cc(C)c(/C=C3\C(=O)Nc4ncnc(Nc5ccc(F)c(Cl)c5)c43)[nH]2)CC1,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[5-(4-ethyl-piperazine-1-carbonyl)-3-methyl-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.013,uM,=,-1.8860566476931635,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCNCC2)[nH]1
311,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1.Cl.Cl,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, hydrochloride (CI-1033)",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
312,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,CCOc1cc2ncnc(Nc3ccc(OCC4CC4)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C,(Z)-N-(4-((3-Chloro-4-(cyclopropylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.0036,uM,=,-2.4436974992327127,0,c1ccc2c(Nc3ccc(OCC4CC4)cc3)ncnc2c1
313,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,CCOC(=O)c1ccc(O)c(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)c1,"Ethyl 4-hydroxy-3-(1-(3-morpholinopropyl)-2-oxo-1,2-dihydrooxazolo[4,5-g]quinazolin-8-ylamino)benzoate",0.23,uM,=,-0.6382721639824072,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
314,64437,10.1016/s0960-894x(00)00131-1,,,,Tested for inhibition of EGF-receptor tyrosine kinase in intact cells,COc1cccc(-c2cn(-c3ccc(CCN(C)CCO)cc3)c3ncnc(N)c23)c1,"2-[(2-{4-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-phenyl}-ethyl)-methyl-amino]-ethanol",10.0,uM,=,1.0,1,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
315,1650711,10.1016/j.bmcl.2017.02.023,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay,O=C(Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)C1CCC2(CC1)OCC1(OO2)C2CC3CC(C2)CC1C3,"N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3,3-adamantane-1,2,5-trioxaspiro[5.5]undecane-9-carboxamide",0.1175,uM,=,-0.929962133392245,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CCC2(CC1)OCC1(OO2)C2CC3CC(C2)CC1C3
316,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,Fc1ccc(Nc2ncnc3ccc(NC(=S)NCCCN4CCOCC4)cc23)cc1Cl,1-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)-3-(3-morpholinopropyl)thiourea,0.39,uM,=,-0.4089353929735008,0,S=C(NCCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
317,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,C=C(F)C(=O)Nc1cc2c(Nc3ccc(Oc4cc5nncn5cn4)c(C)c3)ncnc2cc1OCC,"N-[7-ethoxy-4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-2-fluoro-prop-2-enamide",0.0096,uM,=,-2.017728766960432,0,c1ccc2c(Nc3ccc(Oc4cc5nncn5cn4)cc3)ncnc2c1
318,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,COc1cc2ncnc(C#C[C@@](C)(Cc3ccccc3)N3CCC(C(=O)O)CC3)c2cc1OC,"(R)-1-(4-(6,7-dimethoxyquinazolin-4-yl)-2-methyl-1-phenylbut-3-yn-2-yl)piperidine-4-carboxylic acid",0.033,uM,=,-1.4814860601221125,0,C(#CC(Cc1ccccc1)N1CCCCC1)c1ncnc2ccccc12
319,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,Cc1cc(Nc2ncnc3[nH]nc(OCCN4CCC(O)CC4)c23)ccc1OCc1ccccn1,"1-(2-(4-(3-methyl-4-(pyridin-2-ylmethoxy)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yloxy)ethyl)piperidin-4-ol",0.018,uM,=,-1.744727494896694,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCCC5)c34)cc2)nc1
320,1619030,10.1016/j.bmc.2016.09.001,,,,Inhibition of human recombinant N-terminal GST-tagged wild type EGFR cytoplasmic domain (695 end residues) autophosphorylation expressed in baculovirus infected Sf9 insect cells by ADP-Glo luminescence assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(Cn4ccnc4)cc3)ncc2Cl)c1,N-[3-[[5-Chloro-2-[4-(1H-imidazol-1-ylmethyl)phenylamino]-4-pyrimidinyl]amino]phenyl]-2-propenamide,1.0,uM,=,0.0,0,c1ccc(Nc2ccnc(Nc3ccc(Cn4ccnc4)cc3)n2)cc1
321,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cccc(C#CCCCO)c3)c2cc1OC,"5-(3-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)pent-4-yn-1-ol",1.3625999999999998,uM,=,0.1343683846033787,1,c1ccc(Nc2ncnc3ccccc23)cc1
322,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CO)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-6",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
323,66715,10.1021/jm00046a020,,,,Inhibition of in vitro activity of EGFr enzyme from A431 cells in presence of 5 uM ATP,Nc1cccc(-c2cc(=O)c3c(N)c(O)c(N)cc3o2)c1,"5,7-Diamino-2-(3-amino-phenyl)-6-hydroxy-chromen-4-one",7.8,uM,=,0.8920946026904804,1,O=c1cc(-c2ccccc2)oc2ccccc12
324,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(C)c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-7-((3-Methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3-(m-tolyl)-3,4-dihydropyrimido-[4,5-d]pyrimidin-2(1H)-one",0.365,uM,=,-0.4377071355435253,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
325,67045,10.1021/jm020899q,,,,"In vitro inhibition of Epidermal growth factor receptor (HER-1,ErbB) expressed in baculovirus",O=C(Nc1cccc(C(F)(F)F)c1)c1ccccc1NCc1ccncc1,2-[(Pyridin-4-ylmethyl)-amino]-N-(3-trifluoromethyl-phenyl)-benzamide,10.4,uM,=,1.0170333392987805,1,O=C(Nc1ccccc1)c1ccccc1NCc1ccncc1
326,2227151,10.1016/j.ejmech.2022.114492,,,,Inhibition of wild type EGFR (unknown origin) by mobility shift assay,COc1cc(N(C)CCN(C)C)c(NC(=O)c2ccncn2)cc1Nc1nc(-c2cn(C)c3ccccc23)c2cccnc2n1,"N-(2-((2-(dimethylamino)ethyl)(methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrido[2,3-d]pyrimidin-2-yl)amino)phenyl)pyrimidine-4-carboxamide",0.36,uM,=,-0.4436974992327127,0,O=C(Nc1cccc(Nc2nc(-c3c[nH]c4ccccc34)c3cccnc3n2)c1)c1ccncn1
327,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",C=CC(=O)NCCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,"US9181263, 23::US9278100, 23",0.07049,uM,=,-1.1518724894321253,0,c1ccc(Oc2ccc(-c3n[nH]c4ncncc34)cc2)cc1
328,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,SID17389087,8.65,uM,=,0.9370161074648142,1,O=C(/C=C/c1ccccc1)CC(=O)/C=C/c1ccccc1
329,1798884,10.1016/j.ejmech.2017.07.023,,,,Inhibition of EGFR (unknown origin),CC(C)(O)CC(=O)NCCc1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c2c1,N-(2-(4-(3-chloro-4-(3-(trifluoromethyl)phenoxy)phenylamino)quinazolin-6-yl)ethyl)-3-hydroxy-3-methylbutanamide,0.0098,uM,=,-2.008773924307505,0,c1ccc(Oc2ccc(Nc3ncnc4ccccc34)cc2)cc1
330,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(C#N)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(5-(5-cyano-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,46.0,uM,=,1.662757831681574,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
331,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,O=C(Nc1ccncc1)Nc1cc(-c2cncnc2)cc(C(F)(F)F)c1,1-(Pyridin-4-yl)-3-(3-(pyrimidin-5-yl)-5-(trifluoromethyl)phenyl)urea,0.01483,uM,=,-1.828858848971618,0,O=C(Nc1ccncc1)Nc1cccc(-c2cncnc2)c1
332,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,NNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"(3-Bromo-phenyl)-(7-hydrazino-pyrido[4,3-d]pyrimidin-4-yl)-amine",0.0070999999999999,uM,=,-2.148741651280925,0,c1ccc(Nc2ncnc3ccncc23)cc1
333,1577194,10.1016/j.bmc.2016.05.012,,,,Inhibition of recombinant His6-tagged EGFR (unknown origin) cytoplasmic domain (645 to 1186 residues) autophosphorylation expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometric analysis,Clc1cccc(C2CC(c3ccc4c(c3)OCCO4)=NN2c2ccccc2)c1,"5-(3-Chlorophenyl)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",81.2,uM,=,1.9095560292411755,1,c1ccc(C2CC(c3ccc4c(c3)OCCO4)=NN2c2ccccc2)cc1
334,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccccc1F)c1ccccc1,(Z)-2-((E)-3-(2-fluorophenyl)-1-phenylallylidene)hydrazinecarbothioamide,22.36,uM,=,1.3494717992143856,1,N=C(/C=C/c1ccccc1)c1ccccc1
335,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,COc1cc(Nc2ncnc3ccc(-c4cn(CCCCCC(=O)NO)nn4)cc23)ccc1Oc1ccccc1,"N-Hydroxy-6-(4-(4-((3-methoxy-4-phenoxyphenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)hexanamide",0.0058,uM,=,-2.2365720064370627,0,c1ccc(Oc2ccc(Nc3ncnc4ccc(-c5c[nH]nn5)cc34)cc2)cc1
336,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(NCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(4-benzylamino-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.045,uM,=,-1.3467874862246565,0,c1ccc(CNc2ccc(Nc3ccnc4ccccc34)cc2)cc1
337,1832278,10.1016/j.bmc.2018.12.032,,,,Inhibition of recombinant human His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in autophosphorylation preincubated for 10 mins followed by ATP-MgCl2 addition and measured after 1 hr by DELFIA/time-resolved fluorometric analysis,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.0385,uM,=,-1.4145392704914994,0,c1ccc(Nc2ccnc3ccccc23)cc1
338,2201791,10.1016/j.bmcl.2022.128729,,,,Inhibition of wild type EGFR (unknown origin),COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,BRIGATINIB,0.0747999999999999,uM,=,-1.1260984021355387,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
339,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,COc1ccc(-c2cc3c(NC(CC(N)=O)c4ccccc4)ncnc3o2)cc1,"(+/-)-3-((6-(4-Methoxyphenyl)furo[2,3-d]pyrimidin-4-yl)amino)-3-phenylpropanamide",0.022,uM,=,-1.6575773191777938,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
340,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3ccc(CCCC(=O)O)cc3)nc21,"4-{4-[6-(2,6-Dichloro-phenyl)-8-methyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-phenyl}-butyric acid",0.08,uM,=,-1.0969100130080565,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
341,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,Cc1cccc(Nc2ncnc3cc4c(cc23)N(CCCN2CCCCC2)C(=O)CO4)c1,"6-(3-(piperidin-1-yl)propyl)-4-(m-tolylamino)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.4562,uM,=,-0.3408447190593702,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCCCC1
342,2291456,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR autophosphorylation at Tyr1068 residue in EGFR-amplified human A-431 cells preincubated with compound for 1 hrs followed by stimulation with human recombinant EGF and measured after 10 mins by HTRF-based analysis,C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1,TOLEBRUTINIB,0.074,uM,=,-1.1307682802690238,0,O=c1n(-c2ccc(Oc3ccccc3)cc2)c2cnccc2n1[C@@H]1CCCNC1
343,1299287,10.1039/C3MD00096F,,,,Inhibition of EGFR (unknown origin) after 1 hr by Caliper mobility shift assay,O=C(Nc1cccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)c1)Nc1ccc(F)c(Cl)c1,1-(3-Chloro-4-fluorophenyl)-3-(3-(7-(3-morpholinopropoxy)-quinazolin-4-ylamino)phenyl)urea,3.315,uM,=,0.520483532740792,1,O=C(Nc1ccccc1)Nc1cccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)c1
344,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccccc1Cl)c1ccccc1,(Z)-2-((E)-3-(2-chlorophenyl)-1-phenylallylidene)hydrazinecarbothioamide,23.27,uM,=,1.36679638328673,1,N=C(/C=C/c1ccccc1)c1ccccc1
345,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21,"3-(3,4-dimethylphenyl)-1-isopropyl-4-methyl-1H-indene",0.55,uM,=,-0.2596373105057561,0,c1ccc(-c2n[nH]c3ncncc23)cc1
346,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2=NN(c3nc(-c4ccc(Cl)cc4)cs3)C(c3ccc(Br)cc3)C2)cc1C,"2-(5-(4-bromophenyl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-chlorophenyl)thiazole",0.37,uM,=,-0.431798275933005,0,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
347,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccc(Br)cc3)CC2c2ccc(F)cc2)=N1,"2-(3-(4-Bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",6.48,uM,=,0.8115750058705934,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
348,408552,10.1021/jm0608762,,,,Inhibition of EGFR tyrosine kinase activity,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,0.036,uM,=,-1.4436974992327127,0,c1ccc(Nc2ncnc3ccccc23)cc1
349,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,CN(C)c1ccc(CCCCCn2c3c(c4cc(OCCc5ccc(O)cc5)ccc42)CC(N)CC3)cc1.Cl.Cl,"4-(2-(3-Amino-9-(5-(4-(dimethylamino)phenyl)pentyl)-2,3,4,9-tetrahydro-1H-tetrahydrocarbazole-6-yloxy)ethyl)-phenol dihydrochloride",1.91,uM,=,0.2810333672477275,1,c1ccc(CCCCCn2c3c(c4cc(OCCc5ccccc5)ccc42)CCCC3)cc1
350,1778842,10.1016/j.bmcl.2018.07.039,,,,Inhibition of EGF-induced EGFR activation in human A431 cells pretreated for 60 mins followed by EGF addition and measured after 10 mins by ELISA,CNc1ccc(N(C)c2ncnc3occ(C)c23)cc1,"N1,N4-Dimethyl-N1-(5-methylfuro[2,3-d]pyrimidin-4-yl)benzene-1,4-diamine",0.0064,uM,=,-2.193820026016113,0,c1ccc(Nc2ncnc3occc23)cc1
351,2296337,10.1039/d3md00038a,,,,Inhibition of EGFR (unknown origin),CCc1c(C(=O)NCCc2ccc(N3CCOCC3)cc2)[nH]c2ccc(C(F)(F)F)cc12,3-ethyl-N-(4-morpholinophenethyl)-5-(trifluoromethyl)-1H-indole-2-carboxamide,0.094,uM,=,-1.0268721464003014,0,O=C(NCCc1ccc(N2CCOCC2)cc1)c1cc2ccccc2[nH]1
352,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,O=CN/C=C/c1cc(O)ccc1O,"N-[(E)-2-(2,5-Dihydroxy-phenyl)-vinyl]-formamide",2.0,uM,=,0.3010299956639812,1,c1ccccc1
353,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Brc1ccc2c(c1)CNc1c(NCc3ccccc3)ncnc1O2,"Benzyl-(8-bromo-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",6.0,uM,=,0.7781512503836436,1,c1ccc(CNc2ncnc3c2NCc2ccccc2O3)cc1
354,63758,10.1021/jm00040a003,,,,Concentration required to inhibit phosphorylation of isolated human epidermal growth factor tyrosine kinase receptor by 50%,COc1ccc(/C=C(\C#N)c2cccnc2)cc1OC,"(Z)-3-(3,4-Dimethoxy-phenyl)-2-pyridin-3-yl-acrylonitrile",0.7,uM,=,-0.1549019599857432,0,C(=Cc1cccnc1)c1ccccc1
355,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,CCOC(C)Oc1cc2ncnc(Nc3ccc(F)c([N+](=O)[O-])c3)c2c2c1OCCO2,"5-(1-Ethoxyethoxy)-N-(4-fluoro-3-nitrophenyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.2323,uM,=,-0.6339507901997645,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
356,1662113,10.1016/j.ejmech.2017.02.061,,,,Inhibition of EGFR (unknown origin) measured after 40 mins by Kinase Glo luminescence assay,CC(C)C[C@@H](NC(=O)OC(C)(C)C)C(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,(R)-tert-butyl (1-((4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate,0.14,uM,=,-0.8538719643217619,0,c1ccc(Nc2ncnc3ccccc23)cc1
357,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c(Oc5ccccc5)c(OC)c4)nn32)CC1,"7-(1-acryloylpiperidin-4-yl)-2-(3,5-dimethoxy-4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",4.713,uM,=,0.6732974397596357,1,c1ccc(Oc2ccc(-c3cc4n(n3)C(C3CCNCC3)CCN4)cc2)cc1
358,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OCC)nc32)c1,"N-(3-(2-((2-Ethoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.17,uM,=,-0.7695510786217261,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
359,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(NS(=O)(=O)c1ccc(Br)cc1)c1cccnc1Cl,N-(4-bromophenylsulfonyl)-2-chloronicotinamide,15.68,uM,=,1.1953460583484197,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
360,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",Brc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)nc23)c1,"N*8*-(3-Bromo-phenyl)-N*2*-(2-morpholin-4-yl-ethyl)-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.00081,uM,=,-3.09151498112135,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)nc23)cc1
361,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc(F)cc3)C2)cc1,"2-(5-(4-Fluorophenyl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",2.01,uM,=,0.3031960574204888,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
362,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-2-butynamide",0.0025,uM,=,-2.6020599913279625,0,c1ccc(Nc2ncnc3cnccc23)cc1
363,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,Cc1ccc(S(=O)(=O)NC(=O)Cc2ccc(F)cc2)cc1,2-(4-Fluorophenyl)-N-tosylacetamide,8.28,uM,=,0.91803033678488,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
364,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-propionamide,0.00262,uM,=,-2.5816987086802548,0,c1ccc(Nc2ncnc3ccccc23)cc1
365,612309,10.1021/jm901453q,,,,Inhibition of EGFR,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCC(=O)NO)cc23)c1,5-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxypentanamide,0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3ccccc23)cc1
366,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",COc1ccc(/C=C/C(=N/Nc2nncc3ccccc23)c2ccc(Cl)cc2)cc1,1-(1-(4-Chlorophenyl)-3-(4-methoxyphenyl)allylidene)hydrazinyl)phthalazine,0.0054,uM,=,-2.2676062401770314,0,C(=C/c1ccccc1)\C(=N\Nc1nncc2ccccc12)c1ccccc1
367,5170,10.1021/jm970641d,,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,CN(C)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-(2-dimethylamino-ethyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",43.0,uM,=,1.6334684555795866,1,c1ccc(Nc2ncnc3cnccc23)cc1
368,699068,10.1016/j.bmc.2010.11.007,,,,Inhibition of EGFR by HTRF assay,N#Cc1cnc(Nc2cccc(Br)c2)c2cc(NC(=O)c3ccoc3)ccc12,N-(1-(3-Bromophenylamino)-4-cyanoisoquinolin-7-yl)furan-3-carboxamide,45.2,uM,=,1.6551384348113822,1,O=C(Nc1ccc2ccnc(Nc3ccccc3)c2c1)c1ccoc1
369,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)nc3ccsc23)CC1,"1-(4-((2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.2469,uM,=,-0.6074789100680678,0,c1cc2nc(Nc3ccc(N4CCNCC4)cc3)nc(OC3CCNCC3)c2s1
370,465,10.1016/s0960-894x(02)00364-5,,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Cc1cc(C(=O)NCCN2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc4c(ccn4Cc4ccccc4)c3)c21,"5-[4-(1-Benzyl-1H-indol-5-ylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide",1.95,uM,=,0.290034611362518,1,O=C1Nc2ncnc(Nc3ccc4c(ccn4Cc4ccccc4)c3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1
371,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4nc5c(s4)CN(C)CC5)nc32)c1,"N-(3-(5-Methyl-2-((5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.5496,uM,=,-0.259953275948506,0,O=c1ccc2cnc(Nc3nc4c(s3)CNCC4)nc2n1-c1ccccc1
372,1869715,10.1016/j.bmc.2019.02.012,,,,Inhibition of His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometry,COc1ccc2nc3sc(C(=O)Nc4ccc(C(=O)/C=C/c5ccc(OC)c(OC)c5)cc4)cc3cc2c1,"(E)-N-(4-(3-(3,4-Dimethoxyphenyl)acryloyl)phenyl)-6-methoxythieno[2,3-b]quinoline-2-carboxamide",0.7,uM,=,-0.1549019599857432,0,O=C(/C=C/c1ccccc1)c1ccc(NC(=O)c2cc3cc4ccccc4nc3s2)cc1
373,63773,10.1021/jm9508651,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 human epidermoid carcinoma cells,CNc1ccc2ncnc(Nc3cccc(Br)c3)c2n1,"N*4*-(3-Bromo-phenyl)-N*6*-methyl-pyrido[3,2-d]pyrimidine-4,6-diamine",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3cccnc23)cc1
374,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,O=S(=O)(CCCCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1)c1ccccc1,N-(4-(benzyloxy)-3-chlorophenyl)-6-(5-((4-(phenylsulfonyl)butylamino)methyl)furan-2-yl)quinazolin-4-amine,0.05,uM,=,-1.3010299956639813,0,O=S(=O)(CCCCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1)c1ccccc1
375,1283337,10.1016/j.ejmech.2013.10.058,,,,Inhibition of wild type EGFR (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,COc1cc2nc(Cl)nc(Nc3ccc(C(N)=O)cc3)c2cc1OC,"4-((2-Chloro-6,7-dimethoxyquinazolin-4-yl)amino)benzamide",0.9,uM,=,-0.0457574905606751,0,c1ccc(Nc2ncnc3ccccc23)cc1
376,2070646,10.1016/j.bmcl.2020.127261,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 peptide as substrate preincubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4cc(CC)ccn4)cc3)c2c1,4-(6-acrylamidoquinolin-4-yloxy)-N-(4-ethylpyridin-2-yl)benzamide,0.958,uM,=,-0.0186344909214556,0,O=C(Nc1ccccn1)c1ccc(Oc2ccnc3ccccc23)cc1
377,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)N1CCC(F)CC1,(S)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-fluoropiperidine-1-carboxamide,0.699,uM,=,-0.1555228242543186,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1)N1CCCCC1
378,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,O=C(/C=C/CN1C2CCC1CC2)N1CCc2c(sc3ncnc(Nc4ccc(F)c(Cl)c4)c23)C1,"US8524722, 10",0.0011,uM,=,-2.958607314841775,0,O=C(/C=C/CN1C2CCC1CC2)N1CCc2c(sc3ncnc(Nc4ccccc4)c23)C1
379,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCC4CC4)cc3)nn21,"US9447106, 20",0.0003,uM,=,-3.522878745280338,0,c1ccc(C2CCNc3cc(-c4ccc(OCC5CC5)cc4)nn32)cc1
380,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,Fc1cccc(COc2ccc(Nc3ncnc4sc(Br)cc34)cc2Cl)c1,"6-Bromo-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)thieno[2,3-d]pyrimidin-4-amine",0.257,uM,=,-0.5900668766687055,0,c1ccc(COc2ccc(Nc3ncnc4sccc34)cc2)cc1
381,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)C1=CCCC1,N-{4-(3-Chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl}-1-cyclopentene-1-carboxamide,0.007,uM,=,-2.154901959985743,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)C1=CCCC1
382,1991520,10.1016/j.bmcl.2020.127327,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.3326,uM,=,-0.4780777551164996,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
383,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,Cl.NCCc1cn(Cc2ccc(-c3cccc(C(F)(F)F)c3)cc2)c2ccc(OCCc3ccc(O)cc3)cc12,2-{5-(4-Hydroxyphenethoxy)-1-[4-(3-trifluoromethylphenyl)]benzyl-1H-indole-3-yl}ethanamine hydrochloride,1.11,uM,=,0.0453229787866574,1,c1ccc(CCOc2ccc3c(ccn3Cc3ccc(-c4ccccc4)cc3)c2)cc1
384,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,COc1ccc(C(=O)N(C)[C@H]2C[C@@H]3O[C@](C)([C@H]2OC)n2c4ccccc4c4c5c(c6c7ccccc7n3c6c42)C(=O)NC5)cc1,"3-methoxy-4-[4-methoxyphenyl(methyl)carboxamido]-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaene",3.6,uM,=,0.5563025007672873,1,O=C(N[C@@H]1CC2O[C@@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O)c1ccccc1
385,2153740,10.1021/acsmedchemlett.1c00555,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,CN1CCN(C2CCN(c3ccc(Nc4ncc(Cl)c(Nc5ccccc5P(C)(C)=O)n4)cc3OC(F)(F)F)CC2)CC1,(2-((5-Chloro-2-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-3-(trifluoromethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide,0.157,uM,=,-0.8041003475907662,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
386,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,Nc1ncnc2c1c(-c1ccc(O)cc1)cn2C1CCNC1,"4-(4-Amino-7-pyrrolidin-3-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-phenol",2.67,uM,=,0.4265112613645752,1,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1
387,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,Nc1ccccc1NC(=O)CCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cc1,N-(2-aminophenyl)-3-(4-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)phenyl)propanamide,0.015,uM,=,-1.8239087409443189,0,O=C(CCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)cc1)Nc1ccccc1
388,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC(=O)Cc4c(C)n(C(=O)c5ccc(Cl)cc5)c5ccc(OC)cc45)c(OCCOC(=O)Cc4c(C)n(C(=O)c5ccc(Cl)cc5)c5ccc(OC)cc45)cc23)c1,"((4-((3-Ethynylphenyl)amino)quinazoline-6,7-diyl)bis(oxy))bis(ethane-2,1-diyl)-bis(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate)",0.033,uM,=,-1.4814860601221125,0,O=C(Cc1cn(C(=O)c2ccccc2)c2ccccc12)OCCOc1cc2ncnc(Nc3ccccc3)c2cc1OCCOC(=O)Cc1cn(C(=O)c2ccccc2)c2ccccc12
389,523777,10.1016/j.bmcl.2009.05.009,,,,Inhibition of EGFR,CC(C)N1CCC(n2cc(CNc3cc(Cl)c4ncc(C#N)c(Nc5ccc(F)c(Cl)c5)c4c3)nn2)CC1,"8-chloro-4-(3-chloro-4-fluorophenylamino)-6-((1-(1-isopropylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)methylamino)quinoline-3-carbonitrile",22.0,uM,=,1.3424226808222062,1,c1ccc(Nc2ccnc3ccc(NCc4cn(C5CCNCC5)nn4)cc23)cc1
390,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,Cc1ccc(C2=NN(C(N)=S)C(c3ccccc3F)C2)cc1C,"3-(3,4-Dimethylphenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",5.19,uM,=,0.7151673578484579,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
391,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3cccc(OC)c3OC)ncc2C(F)(F)F)c1,"US9238629, I-16",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
392,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,Oc1ccc(-c2nc(-c3ccco3)c(-c3ccnc4[nH]c(-c5ccccc5)cc34)[nH]2)cc1,"4-(4-(Furan-2-yl)-5-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-imidazol-2-yl)phenol",1.79,uM,=,0.2528530309798932,1,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccco4)ccnc3[nH]2)cc1
393,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cnc(N(C)C)nc1,2-(Dimethylamino)-N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-pyrimidine-5-carboxamide,5.54,uM,=,0.7435097647284298,1,O=C(Nc1cccc(C(=O)Nc2ccc(CN3CCNCC3)cc2)c1)c1cncnc1
394,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,NS(=O)(=O)c1ccc(Nc2nc3ncnc(Nc4cccc(Br)c4)c3s2)cc1,"4-(7-(3-bromophenylamino)thiazolo[4,5-d]pyrimidin-2-ylamino)benzenesulfonamide",0.01,uM,=,-2.0,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1
395,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nccnc3c2)c2c(N)ncnc21,"1-isopropyl-3-(quinoxalin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",18.0,uM,=,1.255272505103306,1,c1cnc2cc(-c3n[nH]c4ncncc34)ccc2n1
396,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,Cc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)c1,"N*6*-(2-Morpholin-4-yl-ethyl)-N*4*-m-tolyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)cc1
397,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)N1CCCC(F)(F)C1,"(S)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3,3-difluoropiperidine-1-carboxamide",0.884,uM,=,-0.0535477349869269,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1)N1CCCCC1
398,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@H]1CCOC1,"(S)-5-(4-amino-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",1.58,uM,=,0.1986570869544226,1,c1ccc(-c2nn([C@H]3CCOC3)c3ncncc23)cc1
399,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Fc1ccc(C2CC(c3ccc(Br)cc3)=NN2c2nc(-c3ccc(Cl)cc3)cs2)cc1,"2-(3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-chlorophenyl)thiazole",24.16,uM,=,1.3830969299490945,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
400,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,"US8476284, 43::US8497277, 15::US9133201, 15::US9181263, 2::US9278100, 2",0.0487999999999999,uM,=,-1.3115801779972895,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
401,834209,10.1021/jm201713h,,,,Inhibition of human EGFR using poly glu-Tyr as substrate after 30 mins,CCOc1ccc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2c1.Cl,"3-(6-ethoxynaphthalen-2-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride",0.7,uM,=,-0.1549019599857432,0,c1ccc2cc(-c3n[nH]c4ncncc34)ccc2c1
402,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)CO)c2)n1,N-(3-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-2-hydroxyacetamide,15.83,uM,=,1.199480914862356,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
403,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3c(F)cc(Cl)cc3F)ncnc2cc1OCC1CCNCC1,"(4-Chloro-2,6-difluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine",0.6,uM,=,-0.2218487496163563,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
404,1566936,10.1021/acs.jmedchem.5b01633,,,,Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3cnn(C)c3)nc3[nH]ccc23)c1,"N-(3-((2-((1-Methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide",0.0016,uM,=,-2.7958800173440754,0,c1ccc(Oc2nc(Nc3cn[nH]c3)nc3[nH]ccc23)cc1
405,66584,10.1016/s0960-894x(02)01047-8,,,,Inhibition of EGFR,CS(=O)(=O)CCNc1nc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)cs1,(4-Benzyloxy-phenyl)-{6-[2-(2-methanesulfonyl-ethylamino)-thiazol-4-yl]-quinazolin-4-yl}-amine,0.082,uM,=,-1.0861861476162833,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5cscn5)cc34)cc2)cc1
406,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(-c3ccccc3)c(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxo-6-phenylpyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.02,uM,=,-1.6989700043360187,0,O=c1c(-c2ccccc2)cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
407,2280915,10.1016/j.ejmech.2019.112025,,,,Inhibition of human EGFR,CN(CCOC(=O)c1ccc(C(=O)Nc2ncnc3c2c(-c2ccc(Cl)cc2)nn3C(C)(C)C)nc1)Cc1ccc(C(=O)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)cc1,"2-((4-((4-((3-chlorophenyl)amino)quinazolin-6-yl)carbamoyl)benzyl)(methyl)amino)ethyl 6-((1-(tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)carbamoyl)nicotinate",0.61,uM,=,-0.2146701649892329,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccc(CNCCOC(=O)c2ccc(C(=O)Nc3ncnc4[nH]nc(-c5ccccc5)c34)nc2)cc1
408,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CN1CCC[C@@H]1C(N)=O,(R)-1-((4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidine-2-carboxamide,0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
409,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N1CC[S+]([O-])CC1,N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(1-oxidothiomorpholino)phenyl)acrylamide,0.421,uM,=,-0.3757179041643317,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CC[SH+]CC5)cc4)n3)c[nH]c2c1
410,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](CO)C(N)=O,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-3-hydroxypropanamide,0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccccc23)cc1
411,1283337,10.1016/j.ejmech.2013.10.058,,,,Inhibition of wild type EGFR (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,COc1cc2nc(Cl)nc(Nc3ccc(S(=O)(=O)Nc4nccs4)cc3)c2cc1OC,"4-(2-Chloro-6,7-dimethoxyquinazolin-4-ylamino)-N-(thiazol-2-yl)benzene-sulfonamide",9.7,uM,=,0.9867717342662448,1,O=S(=O)(Nc1nccs1)c1ccc(Nc2ncnc3ccccc23)cc1
412,66724,10.1021/jm00032a020,,,,Inhibition of EGFR(epidermal growth factor receptor) autophosphorylation in ER22 cell membranes,O=C(OCCCc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3-phenyl-propyl ester",0.7,uM,=,-0.1549019599857432,0,O=C(OCCCc1ccccc1)c1cccc(NCc2ccccc2)c1
413,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O,2-chloro-6-(3-chloro-2-hydroxybenzyl)phenol,0.614,uM,=,-0.2118316288588323,0,c1ccc(Sc2ccccc2)cc1
414,2298900,10.1016/j.bmc.2023.117241,,,,Inhibition of wild type EGFR (unknown origin) pre-incubated for 10 mins followed by substrate addition measured after 60 mins in presence of ATP by mobility shifting assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,8e-05,uM,=,-4.096910013008056,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
415,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(C2CC(c3ccccc3)=NN2C2=NC(=O)CS2)cc1,"2-(5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",4.27,uM,=,0.6304278750250238,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
416,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COc1cc(O)c2c(=O)c(-c3ccc(O)cc3)coc2c1,Prunetin,14.081112032396293,uM,=,1.1486369538446473,1,O=c1c(-c2ccccc2)coc2ccccc12
417,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(OCCCCCCC(=O)NO)cc3)cc12)c1ccc(F)cc1,"(R)-7-(4-(4-(1-(4-fluorophenyl)ethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenoxy)-N-hydroxyheptanamide",0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
418,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N1CCC(N(C)C)CC1,"N-(2-(4-(Dimethylamino)piperidin-1-yl)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)buta-2,3-dienamide",0.0063,uM,=,-2.2006594505464183,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCCCC5)cc4)n3)c[nH]c2c1
419,1528501,,,,,"Time-Resolved Fluorescence Assay: The following assay may be used to determine the activity of the compounds of the invention for inhibiting EGFR kinase activity. The half maximal inhibitory concentration IC50 (the concentration of the tested compound showing 50% inhibition of the enzyme activity) of each compound was determined by incubating several different concentrations of the tested compounds with a specific enzyme and substrate. EGFR kinase used in this assay is a human-derived recombinant protein (Cell signaling technology, #7908), which was reacted with peptide substrate and different concentrations of tested compounds in a buffer solution containing 60 mM HEPES (pH7.5), 5 mM MgCl2, 5 mM MnCl2, 3 Î¼M Na3VO4, 1.25 M DTT (1000Ã) and 20 Î¼M ATP at 25Â° C., for 45 minutes.",CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/[C@@H]1CCCN1C,"US8901140, 7::US9358227, 7",0.002,uM,=,-2.6989700043360187,0,O=C(/C=C/[C@@H]1CCCN1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
420,1798716,10.1016/j.ejmech.2017.03.083,,,,"Inhibition of wild type N-terminal GST tagged human recombinant EGFR (695 to end amino acids) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) Peptide substrate by ADP-Glo assay",C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(OCCCN3CCOCC3)cc2)ncc1Cl,N-[2-[[5-Chloro-2-[4-((1-morpholino)propoxy)phenylamino]-4-pyrimidinyl]amino]phenyl]acrylamide,0.7666000000000001,uM,=,-0.1154311850816666,0,c1ccc(Nc2ccnc(Nc3ccc(OCCCN4CCOCC4)cc3)n2)cc1
421,1338035,10.1016/j.ejmech.2014.02.032,,,,Inhibition of EGFR (unknown origin) after 1.5 hr by FRET-based Z-lyte assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)CCN3CCN(CCOc4no[n+]([O-])c4S(=O)(=O)c4ccccc4)CC3)c2)n1,"4-(2-(4-(3-((3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)amino)-3-oxopropyl)piperazin-1-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole2-oxide",0.201,uM,=,-0.6968039425795112,0,O=C(CCN1CCN(CCOc2no[nH+]c2S(=O)(=O)c2ccccc2)CC1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
422,2014665,10.1021/acsmedchemlett.9b00317,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells preincubated for 24 hrs followed by EGF stimulation and measured after 10 mins by HTRF based immunoassay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.045,uM,=,-1.3467874862246565,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
423,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Br)c(Br)c2)CC1c1ccccc1Br,"5-(2-Bromophenyl)-3-(3,4-dibromophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",10.97,uM,=,1.0402066275747113,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
424,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC[C@@H]1C(N)=O,(R)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidine-2-carboxamide,0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
425,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cc(Cl)ccc3F)c2cc1OCCCN1CCOCC1,N-(5-chloro-2-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine,0.051,uM,=,-1.2924298239020635,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
426,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"(2E)-N-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(1-piperidinyl)-2-butenamide",0.002,uM,=,-2.6989700043360187,0,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
427,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCCN1CCOCC1,(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine,0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
428,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,N#CC(C#N)=CNc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,2-(((4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)amino)methylene)malononitrile,0.445,uM,=,-0.3516399890190684,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
429,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.58,uM,=,-0.2365720064370627,0,c1ccc(/N=c2\nc[nH]c3cc(OCC4CCNCC4)ccc23)cc1
430,1832355,10.1016/j.bmcl.2018.12.056,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,CCCOCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(2-propoxyethoxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0028399999999999,uM,=,-2.5466816599529625,0,c1ccc(Nc2ncnc3ccccc23)cc1
431,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCCN(C(=O)OC(C)(C)C)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-39::US8975249, I-44",0.65,uM,=,-0.1870866433571444,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCCNCC4)cc3)n2)cc1
432,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CCCCC(=O)ON[C@H](CS(C)(=O)=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,(S)-butyl(1-(5-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)furan-2-yl)-2-(methylsulfonyl)ethyl)carbamate,0.0928,uM,=,-1.032452023781138,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
433,66581,10.1016/s0960-894x(02)00598-x,,,,Inhibition of Epidermal Growth Factor Receptor (EGFR) autophosphorylation,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.515,uM,=,-0.2881927709588089,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
434,841363,10.1016/j.bmcl.2012.06.029,,,,Inhibition of EGFR,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccc(Cl)cc2)c2ncc[nH]2)C(=O)N3)CC1,(Z)-3-((4-chlorophenyl)(1H-imidazol-2-yl)methylene)-5-(1-ethylpiperidin-4-ylamino)indolin-2-one,0.137,uM,=,-0.8632794328435932,0,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1ncc[nH]1
435,792073,10.1016/j.bmc.2011.10.085,,,,Inhibition of EGFR expressed in baculovirus infected Sf9 cells assessed as inhibition of autophosphorylation preincubated for 10 mins measured after 1 hr by DELFIA/Time-Resolved Fluorometry,Oc1ccc(CNc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)cc1,4-((4-(3-Chlorophenylamino)quinazolin-6-ylamino)methyl)phenol,1.87,uM,=,0.2718416065364989,1,c1ccc(CNc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
436,2147415,10.1021/acs.jmedchem.1c01055,,,,Inhibition of Wild type EGFR (unknown origin),COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,BRIGATINIB,0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
437,2270862,10.1016/j.ejmech.2020.112640,,,,Inhibition of human EGFR incubated for 1 hrs in presence of ATP by ELISA assay,CCc1cccc(NC(=O)CSc2nc3cc4ccccc4cc3c(=O)n2-c2ccc(S(N)(=O)=O)cc2)c1,"N-(3-ethylphenyl)-2-((4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydrobenzo[g]quinazolin-2-yl)thio)acetamide",0.022,uM,=,-1.6575773191777938,0,O=C(CSc1nc2cc3ccccc3cc2c(=O)n1-c1ccccc1)Nc1ccccc1
438,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,Cc1nc(Nc2cccc(Br)c2)c2cc(NCCN3CCOCC3)ncc2n1,"N*4*-(3-Bromo-phenyl)-2-methyl-N*6*-(2-morpholin-4-yl-ethyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.117,uM,=,-0.9318141382538384,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)cc1
439,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.022,uM,=,-1.6575773191777938,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
440,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCN(C)CC1,(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(4-methylpiperazin-1-yl)but-2-enamide,0.023,uM,=,-1.6382721639824072,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
441,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",145.0,uM,=,2.161368002234975,1,c1ccc(Nc2nccc(-c3cnn4ccccc34)n2)cc1
442,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,O=C(O)c1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1,"3-(6,7,8,9-Tetrahydro-5H-pyrimido[4,5-b]indol-4-ylamino)-benzoic acid",25.7,uM,=,1.4099331233312946,1,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1
443,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",1.0,uM,=,0.0,0,O=c1c(-c2ccccc2)coc2ccccc12
444,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSC2=NCCS2)c1O,"2-Cyano-3-[3-(4,5-dihydro-thiazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-acrylamide",8.8,uM,=,0.9444826721501688,1,c1ccc(CSC2=NCCS2)cc1
445,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,0.3443,uM,=,-0.4630629772953265,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
446,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3nc(Nc4ccc(CN5CCCC5)cc4)sc23)cc1Cl,"N7-(3-chloro-4-fluorophenyl)-N2-(4-(pyrrolidin-1-ylmethyl)phenyl)thiazolo[4,5-d]pyrimidine-2,7-diamine",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3nc(Nc4ccc(CN5CCCC5)cc4)sc23)cc1
447,1869715,10.1016/j.bmc.2019.02.012,,,,Inhibition of His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometry,COc1cc(/C=C/C(=O)c2ccc(NC(=O)c3cc4cc5ccccc5nc4s3)cc2)cc(OC)c1OC,"(E)-N-(4-(3-(3,4,5-Trimethoxyphenyl)acryloyl)phenyl)thieno[2,3-b]quinoline-2-carboxamide",1.2,uM,=,0.0791812460476248,1,O=C(/C=C/c1ccccc1)c1ccc(NC(=O)c2cc3cc4ccccc4nc3s2)cc1
448,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4cccc(O)c4)c3cc21,"Ethyl 4-(8-(3-hydroxyphenylamino)-2-oxooxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",0.0087,uM,=,-2.0604807473813813,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
449,66904,10.1016/S0960-894X(96)00601-4,,,,Inhibition of the epidermal growth factor receptor.,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1,Phenyl-(4-pyridin-3-yl-pyrimidin-2-yl)-amine,100.0,uM,=,2.0,1,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1
450,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCOc1cc2ncnc(C#CC(C)(Cc3ccccc3)N3CCC(C(=O)O)CC3)c2cc1OCC,"1-(4-(6,7-diethoxyquinazolin-4-yl)-2-methyl-1-phenylbut-3-yn-2-yl)piperidine-4-carboxylic acid",0.0116999999999999,uM,=,-1.9318141382538383,0,C(#CC(Cc1ccccc1)N1CCCCC1)c1ncnc2ccccc12
451,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,COc1ccc(-c2cc(NC(=O)Nc3ccncc3)cc(OC)c2OC)cn1,"1-(3,4-Dimethoxy-5-(6-methoxypyridin-3-yl)phenyl)-3-(pyridin-4-yl)urea",0.45517,uM,=,-0.3418263697760108,0,O=C(Nc1ccncc1)Nc1cccc(-c2cccnc2)c1
452,1929287,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide substrate preincubated for 10 mins followed by substrate addition measured after 40 mins by caliper motility shift assay,CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-((3-chloro-4-fluorophenyl)amino)-7,8-dihydro-6H-[1,4]oxazino[3,2 g]quinazolin-6-yl)-4-(dimethylamino)but-2-en-1-one",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3cc4c(cc23)NCCO4)cc1
453,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,"1-[2-(4-Chloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole (Econazole)",32.404,uM,=,1.5105986234999218,1,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1
454,676221,10.1021/jm100607r,,,,Inhibition of EGFR,C=CC(=O)N1CCc2c(sc3ncnc(N[C@H](CC)c4ccccc4)c23)C1,"1-(4-[(1R)-1-Phenylpropyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-propen-1-one",0.046,uM,=,-1.337242168318426,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1
455,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cn1,"(2E)-N-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}pyrido[3,4-d]-pyrimidin-6-yl)-4-(1-pyrrolidinyl)-2-butenamide",0.037,uM,=,-1.431798275933005,0,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc(OCc4ccccc4)cc3)ncnc2cn1
456,1641794,,,,,"Time-Resolved Fluorescence Assay: The following assay may be used to determine the activity of the compounds of the invention for inhibiting EGFR kinase activity. The half maximal inhibitory concentration IC50 (the concentration of the tested compound showing 50% inhibition of the enzyme activity) of each compound was determined by incubating several different concentrations of the tested compounds with a specific enzyme and substrate. EGFR kinase used in this assay is a human-derived recombinant protein (Cell signaling technology, #7908), which was reacted with peptide substrate and different concentrations of tested compounds in a buffer solution containing 60 mM HEPES (pH7.5), 5 mM MgCl2, 5 mM MnCl2, 3 Î¼M Na3VO4, 1.25 M DTT (1000Ã) and 20 Î¼M ATP at 25Â° C., for 45 minutes. The EGFR kinase activity was determined by using a Time-Resolved fluorescence method.",CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@@H]1CCCN1C,"US8901140, 1::US9358227, 1",0.048,uM,=,-1.3187587626244128,0,O=C(/C=C/[C@@H]1CCCN1)Nc1ccc2nccc(Nc3ccc(OCc4ccccn4)cc3)c2c1
457,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(Oc1cccc(O)c1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3-hydroxy-phenyl ester",0.09,uM,=,-1.0457574905606752,0,O=C(Oc1ccccc1)c1cccc(NCc2ccccc2)c1
458,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(NS(=O)(=O)c1ccc(Br)cc1)c1ccc(Cl)nc1,N-(4-bromophenylsulfonyl)-6-chloronicotinamide,29.07,uM,=,1.4634450317704275,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
459,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)NCc1cccc(Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)c1,N-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-pyridin-2-yl)amino)benzyl)acrylamide,0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
460,1461860,10.1016/j.bmcl.2014.12.095,,,,Inhibition of human full length HER1 assessed as phosphorylation state by ELISA assay,O=C(Cc1c[nH]c2ccccc12)NNC(=S)Nc1ncccc1Br,2-(2-(1H-indole-3-yl)acetyl)-N-(3-bromopyridine-2-yl)hydrazinecarbothioamide,8.49,uM,=,0.9289076902439528,1,O=C(Cc1c[nH]c2ccccc12)NNC(=S)Nc1ccccn1
461,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCCc1c(C(=O)OCC)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"4-(1-Benzyl-1H-indazol-5-ylamino)-5-propyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester",0.95,uM,=,-0.0222763947111522,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
462,305999,10.1016/j.bmcl.2004.08.007,,,,Inhibitory concentration against Epidermal growth factor receptor tyrosine kinase activity,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,"(3-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
463,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,Cc1ccccc1NC(=O)/C=C/c1ccccc1,(E)-N-(o-tolyl)cinnamamide,12.29,uM,=,1.089551882886454,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
464,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC,"1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",2.3,uM,=,0.3617278360175928,1,c1ccc(-c2nn(C3CCC3)c3ncncc23)cc1
465,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Oc1ccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"4-[4-(3-Chloro-phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-phenol",0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
466,840626,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR using GST-Crk as substrate assessed as phosphorylated Crk level after 20 mins by SDS-PAGE analysis,Clc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,"N-(3-chlorophenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododeca[2,3-g]quinazolin-4-amine",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)cc1
467,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccc(F)cc1)c1ccc(Br)cc1,(Z)-2-((E)-1-(4-bromophenyl)-3-(4-fluorophenyl)allylidene)hydrazinecarbothioamide,2.17,uM,=,0.3364597338485295,1,N=C(/C=C/c1ccccc1)c1ccccc1
468,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3cc(Cl)ccc3F)c2cc1OC1CCN(S(C)(=O)=O)CC1,N-(5-chloro-2-fluorophenyl)-7-methoxy-6-(1-(methylsulfonyl)piperidin-4-yloxy)quinazolin-4-amine,0.041,uM,=,-1.3872161432802643,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
469,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,COCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-2-methoxy-acetamide,0.174,uM,=,-0.7594507517174003,0,c1ccc(Nc2ncnc3ccccc23)cc1
470,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2cn(C)c3ccccc23)n1,N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine,0.034,uM,=,-1.4685210829577449,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c[nH]c2c1
471,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccc(Cl)c4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-N-[4-({4-[(3-chlorobenzyl)oxy]-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)-7-ethoxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide",0.0121999999999999,uM,=,-1.913640169325252,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
472,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,CCOC(=O)c1ccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)cc1,"Ethyl 4-(1-(3-morpholinopropyl)-2-oxo-1,2-dihydrooxazolo[4,5-g]quinazolin-8-ylamino)benzoate",5.8,uM,=,0.7634279935629373,1,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
473,1891470,10.1016/j.bmc.2019.03.049,,,,Inhibition of c-MET (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins by mobility shift assay,COc1cc2c(Oc3ccc(C4SCC(=O)N4NC(=O)Nc4ccc(F)cc4)cc3)ccnc2cc1OCCCN1CCOCC1,N1-(4-fluorophenyl)-N3-(2-(4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)oxy)phenyl)-4-oxothiazolidin-3-yl)urea,4.3,uM,=,0.6334684555795865,1,O=C(Nc1ccccc1)NN1C(=O)CSC1c1ccc(Oc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1
474,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(Oc4ccccc4)cc3)ncnc2cn1,"(2E)-4-(Dimethylamino)-N-[4-(4-phenoxybenzyl)pyrido[3,4-d]-pyrimidin-6-yl]-2-butenamide",0.014,uM,=,-1.853871964321762,0,c1ccc(Oc2ccc(Nc3ncnc4cnccc34)cc2)cc1
475,2147415,10.1021/acs.jmedchem.1c01055,,,,Inhibition of Wild type EGFR (unknown origin),CCP(=O)(CC)c1ccccc1Nc1nc(Nc2cc(-c3cnn(C)c3)c(N3CCOCC3)cc2OC)ncc1Cl,(2-((5-Chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-morpholinophenyl)amino)pyrimidin-4-yl)amino)phenyl)diethylphosphine Oxide,0.0024,uM,=,-2.619788758288394,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCOCC4)c(-c4cn[nH]c4)c3)n2)cc1
476,63616,10.1016/S0960-894X(97)00034-6,,,,Inhibition of Epidermal growth factor receptor autophosphorylation.,COc1ccc2ncnc(Nc3cc(OC)c(OC)c(OC)c3)c2c1.Cl,"(6-Methoxy-quinazolin-4-yl)-(3,4,5-trimethoxy-phenyl)-amine hydrochloride, 1M H2O",0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
477,2123057,10.1016/j.ejmech.2021.113674,,,,Inhibition of EGFR (unknown origin) incubated for 40 mins in presence of Mg/ATP mix by [gamma p33]-ATP based scintillation counting method,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.0397999999999999,uM,=,-1.400116927926312,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
478,1448250,10.1016/j.bmcl.2014.07.094,,,,Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry,CCOC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2cc(Cl)ccc2n2nnnc12,"Ethyl 2-amino-4-(7-chlorotetrazolo[1,5-a]quinolin-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",16.7,uM,=,1.2227164711475833,1,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1
479,1883986,10.1021/acsmedchemlett.8b00461,,,,Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay,C=C(F)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1,"(R)-5-Amino-3-(4-(2,4-difluorophenoxy)phenyl)-1-(1-(2-fluoroacryloyl)piperidin-3-yl)-1H-pyrazole-4-carboxamide",0.57,uM,=,-0.2441251443275086,0,c1ccc(Oc2ccc(-c3ccn([C@@H]4CCCNC4)n3)cc2)cc1
480,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,CSCCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1,6-(5-((2-(Methylthio)ethylamino)methyl)furan-2-yl)-N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-4-quinazolinamine tosylate,0.0251,uM,=,-1.6003262785189618,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1.c1ccccc1
481,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2C1CCC1,"5-(4-amino-1-cyclobutyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",1.15,uM,=,0.0606978403536116,1,c1ccc(-c2nn(C3CCC3)c3ncncc23)cc1
482,1291542,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGFR (unknown origin) after 10 mins,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCCC2)CCO4)c1,"1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(pyrrolidin-1-yl)but-2-en-1-one",0.003,uM,=,-2.5228787452803374,0,O=C(/C=C/CN1CCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
483,63617,10.1016/S0960-894X(97)00034-6,,,,"Inhibition of Epidermal growth factor receptor autophosphorylation, 0.05-0.10",Cl.Clc1cccc(Nc2ncnc3ccccc23)c1,(3-Chloro-phenyl)-quinazolin-4-yl-amine hydrochloride,0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
484,2270929,10.1016/j.ejmech.2020.112640,,,,Inhibition of human EGFR using 5-FAM-EEPLYWSFPAKKKCONH2 as substrate incubated for 30 mins in presence of ATP,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCN4CCOCC4)cc23)c1,N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine,0.00081,uM,=,-3.09151498112135,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
485,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.00058,uM,=,-3.2365720064370627,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
486,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,CCOC(=O)c1ccc(N2CCOCC2)c(NS(=O)(=O)c2cc(Br)c(Cl)s2)c1,ethyl 3-(4-bromo-5-chlorothiophene-2-sulfonamido)-4-morpholinobenzoate,11.1,uM,=,1.0453229787866574,1,O=S(=O)(Nc1ccccc1N1CCOCC1)c1cccs1
487,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CN1CCN(C/C=C/C(=O)Nc2cc3c(Nc4ccc(Cc5ccccn5)cc4)ncnc3cn2)CC1,"(2E)-4-(4-Methyl-1-piperazinyl)-N-{4-[4-(2-pyridinylmethyl)-anilino]pyrido[3,4-d]pyrimidin-6-yl}-2-butenamide",0.1,uM,=,-1.0,0,O=C(/C=C/CN1CCNCC1)Nc1cc2c(Nc3ccc(Cc4ccccn4)cc3)ncnc2cn1
488,2074610,10.1016/j.bmc.2020.115680,,,,Inhibition of wild type EGFR (unknown origin) in presence of ATP preincubated 5 mins measured for 30 mins by detection reagent based HTRF analysis,C=C(Cl)C(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)ncc2Cl)c1,N-(3-((2-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)-2-chloroacrylamide,0.07,uM,=,-1.154901959985743,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
489,1524114,10.1016/j.bmc.2015.10.035,,,,Inhibition of human EGFR after 1 hr using [gamma-32P]ATP,O=C(Nc1ccc(Nc2ncnc3sc4c(c23)CCCC4)cc1)Nc1cccc(Br)c1,"N-(3-Bromophenyl)-N'-[4-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-ylamino)phenyl]urea",3.95,uM,=,0.5965970956264602,1,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3sc4c(c23)CCCC4)cc1
490,1908531,10.1021/acsmedchemlett.9b00381,,,,Inhibition of EGFR (unknown origin) expressed in mouse Ba/F3 cells assessed as reduction in cell growth incubated for 72 hrs in presence of 1 ug/ml Cetuximab by celltiter-glo luminescent cell viability assay,O=C1c2ccccc2Nc2ccc(F)cc2N1Cc1ccccc1,"10-benzyl-8-fluoro-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one",9.7,uM,=,0.9867717342662448,1,O=C1c2ccccc2Nc2ccccc2N1Cc1ccccc1
491,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,COc1ccc(C(/C=C/c2ccccc2)=N\NC(N)=S)cc1,(Z)-2-((E)-1-(4-methoxyphenyl)-3-phenylallylidene)hydrazinecarbothioamide,8.66,uM,=,0.9375178920173468,1,N=C(/C=C/c1ccccc1)c1ccccc1
492,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1ccc(O)nc1,6-Hydroxy-N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)-methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-nicotinamide,1.33,uM,=,0.1238516409670858,1,O=C(Nc1cccc(C(=O)Nc2ccc(CN3CCNCC3)cc2)c1)c1cccnc1
493,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(5-methyl-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,71.0,uM,=,1.8512583487190752,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
494,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4cnn(C5CCN(C)CC5)c4)nc32)c1,"N-(3-(5-Methyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.1662,uM,=,-0.7793689805519078,0,O=c1ccc2cnc(Nc3cnn(C4CCNCC4)c3)nc2n1-c1ccccc1
495,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1,"2-(4-phenoxyphenyl)-7-(1-propioloylpiperidin-4-yl)-1H-imidazo[1,2-b]pyrazole-3-carboxamide",0.0308,uM,=,-1.5114492834995557,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNCC5)c4[nH]3)cc2)cc1
496,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CC(C)=CC[C@@H](OC(=O)/C=C\C(=O)c1ccc(C)cc1F)C1=CC(=O)c2c(O)ccc(O)c2C1=O,"(R)-1-(5,8-Dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (Z)-4-(2-fluoro-4-methylphenyl)-4-oxobut-2-enoate",0.1202,uM,=,-0.9200955323332792,0,O=C(/C=C\C(=O)c1ccccc1)OCC1=CC(=O)c2ccccc2C1=O
497,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CCN(C(=O)CN(C)C)CC1,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-2-(4-(2-(dimethylamino)acetyl)piperazin-1-yl)-4-methoxyphenyl)acrylamide",10000.0,uM,=,4.0,1,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c2c1
498,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Nc1ccc2c(Nc3cccc(Cl)c3)ncnc2c1,"N*4*-(3-Chloro-phenyl)-quinazoline-4,7-diamine",0.00025,uM,=,-3.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
499,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-22",0.065,uM,=,-1.1870866433571443,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
500,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CCCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCCC,"(3-Bromo-phenyl)-(6,7-dipropoxy-quinazolin-4-yl)-amine",0.00017,uM,=,-3.769551078621726,0,c1ccc(Nc2ncnc3ccccc23)cc1
501,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),O=C(Cc1c(SSc2[nH]c3ccccc3c2CC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1,N-Benzyl-2-{2-[3-(benzylcarbamoyl-methyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-acetamide,38.0,uM,=,1.57978359661681,1,O=C(Cc1c(SSc2[nH]c3ccccc3c2CC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
502,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,COc1cccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)c1OC,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-(2,3-dimethoxyphenyl)-1,3,4-oxadiazole",61.0,uM,=,1.7853298350107671,1,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
503,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C=C=CCCCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O,"4-(3'-Chloro-4'-fluorophenylamino)-6-(hexa-4,5-dienyloxy)-7-methoxyquinazoline",0.00316,uM,=,-2.500312917381596,0,c1ccc(Nc2ncnc3ccccc23)cc1
504,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,O=C(/C=C/Cn1ccnc1)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7,8-dihydropyrimido[5,4-g][1,4]benzoxazin-6-yl]-4-imidazol-1-yl-but-2-en-1-one",0.12,uM,=,-0.9208187539523752,0,O=C(/C=C/Cn1ccnc1)N1CCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
505,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Cl.O=[N+]([O-])c1cccc2c1sc1c(Nc3cccc(Br)c3)ncnc12,"(3-Bromo-phenyl)-(6-nitro-benzo[4,5]thieno[3,2-d]pyrimidin-4-yl)-amine hydrochloride",0.158,uM,=,-0.8013429130455774,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
506,2132157,10.1021/acs.jmedchem.1c01559,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,ACALABRUTINIB,3.513,uM,=,0.5456781497920256,1,O=C(Nc1ccccn1)c1ccc(-c2nc([C@@H]3CCCN3)n3ccncc23)cc1
507,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,C=CC(=O)Nc1cccc(-c2c[nH]c3nccc(Cl)c23)c1,"N-(3-(4-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl)-acrylamide",0.525,uM,=,-0.2798406965940431,0,c1ccc(-c2c[nH]c3ncccc23)cc1
508,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1,(4-benzyloxy-3-chloro-phenyl)-{6-[5-(1-oxo-1lambda*4*-thiomorpholin-4-ylmethyl)-furan-2-yl]-quinazolin-4-yl}-amine,0.012,uM,=,-1.9208187539523751,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CN6CC[SH+]CC6)o5)cc34)cc2)cc1
509,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,COc1cc2ncnc(Nc3ccc(Cc4ccccn4)cc3)c2cc1NC(=O)/C=C/CN1CCCC1,(2E)-N-{7-Methoxy-4-[4-(2-pyridinylmethyl)anilino]-6-quinazolinyl}-4-(1-pyrrolidinyl)-2-butenamide,0.148,uM,=,-0.8297382846050426,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc(Cc4ccccn4)cc3)c2c1
510,1774204,10.1016/j.ejmech.2018.02.080,,,,Inhibition of recombinant human EGFR using peptide as substrate by fluorimetric analysis,CCOc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,7-Ethoxy-5-hydroxy-2-phenyl-chromen-4-one,31.8,uM,=,1.5024271199844328,1,O=c1cc(-c2ccccc2)oc2ccccc12
511,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N1CCS(=O)(=O)CC1,"N-(2-(1,1-dioxidothiomorpholino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide",0.339,uM,=,-0.4698003017969178,0,O=S1(=O)CCN(c2ccc(Nc3nccc(-c4c[nH]c5ccccc45)n3)cc2)CC1
512,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCOC(=O)c1cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1C(C)C,"4-(1-Benzyl-1H-indazol-5-ylamino)-5-isopropyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester",0.2,uM,=,-0.6989700043360187,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
513,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1,"US9447106, 119::US9447106, 29",0.0021,uM,=,-2.6777807052660805,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(C3CNC3)CCN4)cc2)cc1
514,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Sc3cccc(Br)c3)c1NC2,"1-(3-bromo-phenylsulfanyl)-7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene",1.3,uM,=,0.1139433523068367,1,c1ccc(Sc2ncnc3c2NCc2ccccc2O3)cc1
515,2134751,10.1016/j.ejmech.2021.113766,,,,Inhibition of human EGFR using poly(Glu:Tyr)(4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,O=C(Nc1cncnc1Oc1cccc(C(F)(F)F)c1)c1ccc(F)cc1,4-fluoro-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide,2.98,uM,=,0.4742162640762553,1,O=C(Nc1cncnc1Oc1ccccc1)c1ccccc1
516,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,O=C(/C=C/c1ccccc1)Nc1cccc(Oc2cc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncn2)c1,(E)-4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-cinnamamidophenoxy)pyrimidine,1.671,uM,=,0.2229764498933913,1,O=C(/C=C/c1ccccc1)Nc1cccc(Oc2cc(Nc3ccc(OCc4ccccc4)cc3)ncn2)c1
517,2145645,10.1016/j.bmcl.2021.128406,,,,Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence of ATP by IMAP-FP assay,C=CC(=O)N1CCC2(CC1)CNC(=O)c1cc(-c3nc(Nc4ccccc4OC)ncc3Cl)[nH]c12,"1-acryloyl-2'-(5-chloro-2-(2-methoxyphenylamino)pyrimidin-4-yl)-5',6'-dihydrospiro[piperidine-4,7'-pyrrolo[3,2-c]pyridin]-4'(1'H)-one",0.0009,uM,=,-3.0457574905606752,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(Nc4ccccc4)n3)cc21
518,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CC(C)c1ccc(COC(=O)c2cc(NCc3cc(O)ccc3O)ccc2O)cc1,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 4-isopropyl-benzyl ester",1.0,uM,=,0.0,0,O=C(OCc1ccccc1)c1cccc(NCc2ccccc2)c1
519,2132157,10.1021/acs.jmedchem.1c01559,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N,(S)-2-(1-acryloylpiperidin-2-yl)-1-amino-4-(4-((4-(trifluoromethyl)pyridin-2-yl)carbamoyl)phenyl)-1H-imidazole-5-carboxamide,0.433,uM,=,-0.3635121036466345,0,O=C(Nc1ccccn1)c1ccc(-c2c[nH]c([C@@H]3CCCCN3)n2)cc1
520,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.048,uM,=,-1.3187587626244128,0,c1ccc(Nc2ncnc3ccccc23)cc1
521,1338416,10.1016/j.ejmech.2014.01.018,,,,Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,CCOC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1c(C)nn(-c2ccc(C)cc2)c1Cl,"Ethyl 2-amino-4-(5-chloro-3-methyl-1-p-tolyl-1H-pyrazol-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",0.91,uM,=,-0.0409586076789063,0,O=C1CCCC2=C1C(c1cnn(-c3ccccc3)c1)C=CN2c1cccnc1
522,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),COc1cccc2sc3c(Nc4cccc(Br)c4)ncnc3c12.Cl,"(3-Bromo-phenyl)-(9-methoxy-benzo[4,5]thieno[3,2-d]pyrimidin-4-yl)-amine hydrochloride",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
523,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(NC(=O)COCc3ccccc3)cc2)n1,N-(4-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-2-benzyloxyacetamide,4.79,uM,=,0.6803355134145632,1,O=C(COCc1ccccc1)Nc1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
524,2063587,10.1016/j.ejmech.2016.08.068,,,,Inhibition of EGFR (unknown origin) using Tyr 04 peptide as substrate incubated for 1 hr by Z'-LYTE assay,OC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccccc1,"(S)-2-phenyl-2-((6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol",0.0004,uM,=,-3.397940008672037,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
525,1642167,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",0.15,uM,=,-0.8239087409443188,0,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
526,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2ncnc3c2oc2ccccc23)c1,"Benzo[4,5]furo[3,2-d]pyrimidin-4-yl-(3-bromo-phenyl)-amine",0.74,uM,=,-0.1307682802690238,0,c1ccc(Nc2ncnc3c2oc2ccccc23)cc1
527,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,CC(=O)NCCNCc1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"N-(2-{4-[4-(1H-Indol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzylamino}-ethyl)-acetamide",0.005,uM,=,-2.3010299956639813,0,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
528,1739294,10.1016/j.ejmech.2018.05.006,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
529,4991,10.1016/S0960-894X(97)10117-2,,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,COc1ccc(Nc2ccnc3cc(OC)c(OC)cc23)cc1OC,"(3,4-Dimethoxy-phenyl)-(6,7-dimethoxy-quinolin-4-yl)-amine",80.5,uM,=,1.9057958803678683,1,c1ccc(Nc2ccnc3ccccc23)cc1
530,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",COc1cc2ncnc(Nc3cccc(I)c3)c2cc1OC.Cl,"4-(3'-iodoanilino)-6,7-dimethoxyquinazoline hydrochloride",0.00105,uM,=,-2.9788107009300617,0,c1ccc(Nc2ncnc3ccccc23)cc1
531,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),O=C(CCCc1c(SSc2[nH]c3ccccc3c2CCCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1,N-Benzyl-4-{2-[3-(3-benzylcarbamoyl-propyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-butyramide,100.0,uM,=,2.0,1,O=C(CCCc1c(SSc2[nH]c3ccccc3c2CCCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
532,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-(3-Chloro-4-fluoro-phenylamino)-quinazolin-6-yl]-acrylamide,0.0031,uM,=,-2.508638306165728,0,c1ccc(Nc2ncnc3ccccc23)cc1
533,2017706,10.1016/j.bmcl.2020.127557,,,,Inhibition of EGFR in human A549 cells measured after 30 hrs by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC(=O)CCCCC[N+]4=C(/C=C/C=C/C=C/C=C5/N(CCCC)c6ccc(OC)cc6C5(C)C)C(C)(C)c5cc(C(F)(F)F)ccc54)cc23)c1.[Br-],"2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethyl 6-[2-[7-(1-butyl-5-methoxy-3,3-dimethyl-indolin-2-ylidene)hepta-1,3,5-trienyl]-3,3-dimethyl-5-(trifluoromethyl)indol-1-ium-1-yl]hexanoate Bromide",0.124,uM,=,-0.906578314837765,0,O=C(CCCCC[N+]1=C(/C=C/C=C/C=C/C=C2\Cc3ccccc3N2)Cc2ccccc21)OCCOc1ccc2ncnc(Nc3ccccc3)c2c1
534,800208,10.1016/j.bmcl.2011.12.067,,,,Inhibition of wild-type EGFR expressed using baculovirus expression system by ELISA,COc1ccccc1Nc1ccnc(Nc2ccccc2OC)n1,"N2,N4-bis(2-methoxyphenyl)pyrimidine-2,4-diamine",90.4,uM,=,1.956168430475364,1,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
535,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,Fc1ccc(Nc2ncnc3cc(OC4CCOC4)c4c(c23)OCCO4)cc1Cl,"N-(3-chloro-4-fluorophenyl)-5-(tetrahydrofuran-3-yloxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0205,uM,=,-1.6882461389442458,0,c1ccc(Nc2ncnc3cc(OC4CCOC4)c4c(c23)OCCO4)cc1
536,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCCC(=O)NO,5-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxypentanamide,0.0094,uM,=,-2.026872146400301,0,c1ccc(Nc2ncnc3ccccc23)cc1
537,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)C(F)(F)F)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-24",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
538,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,C=CC(=O)Nc1cc(Nc2ncc(Br)c(Nc3ccc4cc[nH]c4c3)n2)ccc1N1CCN(C)CC1,N-(5-((4-((1H-indol-6-yl)amino)-5-bromopyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide,0.2338,uM,=,-0.6311554931741787,0,c1cc(Nc2ccc3cc[nH]c3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
539,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,O=C(CCl)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1,"2-Chloro-N-[4-(4,5-dichloro-2-fluoro-phenylamino)-quinazolin-6-yl]-acetamide",7.000000000000001e-05,uM,=,-4.154901959985743,0,c1ccc(Nc2ncnc3ccccc23)cc1
540,982643,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,0.00394,uM,=,-2.404503778174426,0,c1ccc(Nc2ncnc3ccccc23)cc1
541,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)c2ccc(C(=O)O)cc2)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"4-[3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl(methyl)carbamoyl]benzoic acid",0.11,uM,=,-0.958607314841775,0,O=C(N[C@@H]1CC2O[C@@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O)c1ccccc1
542,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Cc1cc2cc(Nc3ncnc4ccc(N)cc34)ccc2[nH]1,"N4-(2-methyl-1H-indol-5-yl)quinazoline-4,6-diamine",0.255,uM,=,-0.5934598195660449,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1
543,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCC/C(=C\c3cc(OC)cc(OC)c3)C2=O)cc(OC)c1,"(2E,6E)-2,6-Bis(3,5-dimethoxybenzylidene)-cyclohexanone",2.08,uM,=,0.3180633349627615,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
544,612309,10.1021/jm901453q,,,,Inhibition of EGFR,C#Cc1cccc(Nc2ncnc3cc(OCCCCCCC(=O)NO)c(OC)cc23)c1,7-(4-(3-Ethynylphenylamino)-6-methoxyquinazolin-7-yloxy)-N-hydroxyheptanamide,0.0081999999999999,uM,=,-2.086186147616284,0,c1ccc(Nc2ncnc3ccccc23)cc1
545,2120336,10.1016/j.ejmech.2021.113711,,,,Inhibition of wild type EGFR (unknown origin) pretreated with substrate for 10 mins followed by ATP addition measured after 60 mins by mobility shift assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c([N+](=O)[O-])c3)nc3[nH]ccc23)c1,"N-(3-(2-(4-(4-methylpiperazin-1-yl)-3-nitrophenylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl)acrylamide",0.111,uM,=,-0.9546770212133424,0,c1ccc(Oc2nc(Nc3ccc(N4CCNCC4)cc3)nc3[nH]ccc23)cc1
546,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,C#Cc1cccc(Nc2ncnc3ccc(NC(N)=O)cc23)c1,1-(4-((3-Ethynylphenyl)amino)quinazolin-6-yl)urea,0.194,uM,=,-0.712198270069774,0,c1ccc(Nc2ncnc3ccccc23)cc1
547,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)CCN(C)C,N-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)anilino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(dimethylamino)propanamide,0.0125,uM,=,-1.9030899869919435,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
548,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,Cc1ccc(S(=O)(=O)NC(=O)Cc2ccc(Br)cc2)cc1,2-(4-Bromophenyl)-N-tosylacetamide,18.35,uM,=,1.2636360685881085,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
549,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc(NCNc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(phenylaminomethyl-amino)-phenylamino]-3-cyano-7-methoxy-quinolin-6-yl}-amide,0.21,uM,=,-0.6777807052660807,0,c1ccc(NCNc2ccc(Nc3ccnc4ccccc34)cc2)cc1
550,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCOCC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-2",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
551,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1,"(R)-6-(2-Methoxyphenyl)-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine",0.009,uM,=,-2.0457574905606752,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
552,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1c(Cl)cccc1Nc1ncnc2cc3c(cc12)OCCO3,"N-(3-Chloro-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.00391,uM,=,-2.4078232426041333,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
553,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Nc1ncnc(NCc3ccccc3)c1NC2,"benzyl-(7,8-dimethoxy-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cyclohepten-1-yl)-amine",0.2,uM,=,-0.6989700043360187,0,c1ccc(CNc2ncnc3c2NCc2ccccc2N3)cc1
554,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,COCC(=O)NC/C=C/c1ccc2ncc(C#N)c(Nc3ccc(Oc4cc5nncn5cn4)c(C)c3)c2c1,"N-[(E)-3-[3-cyano-4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]-6-quinolyl]allyl]-2-methoxy-acetamide",1.8338,uM,=,0.2633519683935656,1,c1ccc2c(Nc3ccc(Oc4cc5nncn5cn4)cc3)ccnc2c1
555,66884,10.1021/jm970641d,,,,Inhibition of tyrosine/glutamic acid copolymer phosphorylation by epidermal growth factor receptor prepared of human A431,CNc1cc2c(Nc3cccc(C)c3)ncnc2cn1,"N*6*-Methyl-N*4*-m-tolyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.00045,uM,=,-3.3467874862246565,0,c1ccc(Nc2ncnc3cnccc23)cc1
556,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,CCOc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OCC.Cl,"4-(3'-chloroanilino)-6,7-diethoxyquinazoline hydrochloride",0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3ccccc23)cc1
557,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,CCN(CC)CCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,(3-Chloro-4-fluoro-phenyl)-[6-(2-diethylamino-ethoxy)-7-methoxy-quinazolin-4-yl]-amine,0.093,uM,=,-1.031517051446065,0,c1ccc(Nc2ncnc3ccccc23)cc1
558,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(N[C@H](C)c3ccc(F)cc3)ncnc2s1,"(R)-N-(1-(4-fluorophenyl)ethyl)-6-(2-methoxyphenyl)thieno[2,3-d]pyrimidin-4-amine",0.027,uM,=,-1.5686362358410126,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
559,1869224,10.1021/acs.jmedchem.8b01391,,,,Inhibition of wild type EGFR (unknown origin) by bioluminescent ADP-glo kinase assay,COc1cc(Nc2ncnc3cc(-c4ccc(C)cc4)sc23)cc(OC)c1OC,"6-(p-Tolyl)-N-(3,4,5-trimethoxyphenyl)thieno[3,2-d]pyrimidin-4-amine",0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3cc(-c4ccccc4)sc23)cc1
560,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,CN(CC(=O)O)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"{[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-methyl-amino}-acetic acid",0.00044,uM,=,-3.356547323513813,0,c1ccc(Nc2ncnc3cnccc23)cc1
561,2110760,10.1016/j.ejmech.2020.113022,,,,Inhibition of N-terminal GST-tagged human recombinant EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCN/C(=N\C#N)Nc4ccncc4)cc23)c1,2-Cyano-1-(6-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)hexyl)-3-(pyridin-4-yl)guanidine,0.00035,uM,=,-3.4559319556497243,0,N=C(NCCCCCCOc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1ccncc1
562,1650711,10.1016/j.bmcl.2017.02.023,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay,CC1(C)OOC2(CCC(C(=O)Nc3ccc4ncnc(Nc5cccc(Cl)c5)c4c3)CC2)OO1,"N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3,3-dimethyl-1,2,4,5-tetraoxaspiro[5.5]undecane-9-carboxamide",0.01142,uM,=,-1.9423338960901708,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CCC2(CC1)OOCOO2
563,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.Oc1ccc(-c2cc3c(NCc4ccccc4)ncnc3[nH]2)cc1,"4-(4-(Benzylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.0033,uM,=,-2.4814860601221125,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
564,523777,10.1016/j.bmcl.2009.05.009,,,,Inhibition of EGFR,N#Cc1cnc2c(Cl)cc(NCc3c[nH]nn3)cc2c1Nc1ccc(F)c(Cl)c1,"6-((1H-1,2,3-triazol-4-yl)methylamino)-8-chloro-4-(3-chloro-4-fluorophenylamino)quinoline-3-carbonitrile",1.0,uM,=,0.0,0,c1ccc(Nc2ccnc3ccc(NCc4c[nH]nn4)cc23)cc1
565,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,OCCn1ccc2ncnc(Nc3ccc(Oc4cccc5[nH]ccc45)c(Cl)c3)c21,"2-(4-(4-(1H-indol-4-yloxy)-3-chlorophenylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethanol",0.0031,uM,=,-2.508638306165728,0,c1cc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)c2cc[nH]c2c1
566,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(CCCN2CCOCC2)C(=O)CO4)c1,"4-((3-ethynylphenyl)amino)-6-(3-morpholinopropyl)-6H-[1,4]oxazino[3,2-g]quinazoline-7(8H)-one",0.139,uM,=,-0.8569851997459049,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
567,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(N2C(=O)CN(C)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6-methyl-5,8-dioxo-7,8-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-9(6H)-yl)phenyl)acrylamide",0.00914,uM,=,-2.039053804266169,0,O=C1NCC(=O)N(c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc21
568,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3cccnc23)c1,"(3-Bromo-phenyl)-pyrido[3,2-d]pyrimidin-4-yl-amine",0.034,uM,=,-1.4685210829577449,0,c1ccc(Nc2ncnc3cccnc23)cc1
569,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cc(CO)ccc1-c1cc2c(Nc3ccccc3)ncnc2s1,"(3-Methoxy-4-(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)phenyl)methanol",0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3sc(-c4ccccc4)cc23)cc1
570,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,O=C(C#CCN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-4-(4-morpholinyl)-2-butynamide",0.0031,uM,=,-2.508638306165728,0,O=C(C#CCN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
571,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(Cc1cc(NCc2cc(O)ccc2O)ccc1O)NOCc1ccccc1,"N-Benzyloxy-2-[5-(2,5-dihydroxy-benzylamino)-2-hydroxy-phenyl]-acetamide",1.0,uM,=,0.0,0,O=C(Cc1cccc(NCc2ccccc2)c1)NOCc1ccccc1
572,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CN1CC2(CCOCC2)C1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)but-2-enamide",2.159,uM,=,0.3342526423342307,1,O=C(/C=C/CN1CC2(CCOCC2)C1)Nc1cc2c(Nc3ccccc3)ncnc2s1
573,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3[nH]c(=O)ccc3c1)nn2C1CCCC1,"6-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)quinolin-2(1H)-one",1.4,uM,=,0.1461280356782379,1,O=c1ccc2cc(-c3nn(C4CCCC4)c4ncncc34)ccc2[nH]1
574,608091,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 8 hrs by Western blot,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,0.152,uM,=,-0.8181564120552275,0,c1ccc(Nc2ncnc3ccccc23)cc1
575,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,C=C(CN(C)C)C(=O)c1ccc(OCc2ccccc2)cc1.Cl,1-(4-Benzyloxy-phenyl)-2-dimethylaminomethyl-propenone hydrochloride,0.18,uM,=,-0.744727494896694,0,c1ccc(COc2ccccc2)cc1
576,2270906,10.1016/j.ejmech.2020.112640,,,,Inhibition of human EGFR incubated for 2 hrs by ELISA assay,CCCN(c1ccc(F)c(Cl)c1)c1ncnc2cc(OC)c(OCCCN3CCOCC3)cc12,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)-N-propylquinazolin-4-amine,0.0214,uM,=,-1.6695862266508092,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
577,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,CC(=O)c1nn(-c2ccc(Cl)cc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1,"1-(4-(2-Methyl-4,5-diphenyl-1H-pyrrole-3-carbonyl)-1-(p-tolyl)-1H-pyrazol-3-yl)-ethanone",4.48,uM,=,0.651278013998144,1,O=C(c1cnn(-c2ccccc2)c1)c1c[nH]c(-c2ccccc2)c1-c1ccccc1
578,2110760,10.1016/j.ejmech.2020.113022,,,,Inhibition of N-terminal GST-tagged human recombinant EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCN/C(=N\C#N)Nc4cccnc4)cc23)c1,2-Cyano-1-(5-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pentyl)-3-(pyridin-3-yl)guanidine,0.00052,uM,=,-3.283996656365201,0,N=C(NCCCCCOc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1cccnc1
579,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCN1CCOCC1,(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3cc(OCCN4CCOCC4)ccc23)cc1
580,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=C(O)c1cc(N(Cc2ccccc2O)Cc2cc(O)ccc2O)ccc1O,"5-[(2,5-Dihydroxy-benzyl)-(2-hydroxy-benzyl)-amino]-2-hydroxy-benzoic acid",0.0104953479581551,uM,=,-1.979003158434446,0,c1ccc(CN(Cc2ccccc2)c2ccccc2)cc1
581,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc(O)cc4)c3cc21,"Ethyl 4-(8-(4-hydroxyphenylamino)-2-oxooxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",0.02,uM,=,-1.6989700043360187,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
582,952256,10.1016/j.bmc.2013.02.014,,,,Inhibition of human N-terminal DYKDDDD-tagged EGFR cytoplasmic domain (669 to 1210) expressed in baculovirus expression system incubated for 5 mins prior to [gamma-32P]ATP addition measured after 10 mins by scintillation counting analysis,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,"N-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methyl butanamide",0.023,uM,=,-1.6382721639824072,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
583,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,CC(=O)NCCNCc1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"N-(2-{4-[7-(1H-Indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-ethyl)-acetamide",0.002,uM,=,-2.6989700043360187,0,c1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
584,66596,10.1016/j.bmcl.2004.04.080,,,,Concentration required to inhibit autophosphorylation of cytoplasmic domain of epidermal growth factor receptor (EGFR),COCOCC#CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,3-Methoxymethoxy-propynoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.33,uM,=,-0.4814860601221125,0,c1ccc(Nc2ccnc3ccccc23)cc1
585,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)C(C)(C)C)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1,"(S)-3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-pivaloylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0294,uM,=,-1.5316526695878427,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
586,1934063,10.1016/j.bmcl.2016.02.003,,,,Inhibition of recombinant human His-tagged EGFR expressed in mammalian expression system by Z'-LYTE assay,O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1,"4-(6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N-(2,2,2-trifluoroethyl)thiophene-2-carboxamide",1.1,uM,=,0.041392685158225,1,c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1
587,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CSCc1oc2cc(O)cc(O)c2c(=O)c1-c1ccc(O)cc1,"5,7-dihydroxy-3-(4-hydroxyphenyl)-2-(methylthiomethyl)-4H-chromen-4-one",15.148935492173743,uM,=,1.1803821162629018,1,O=c1c(-c2ccccc2)coc2ccccc12
588,1521038,10.1021/acs.jmedchem.5b01073,,,,Inhibition of EGFR (unknown origin) by HTRF assay in presence of Km of ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C,"4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2R)-2,4-Dimethylpiperazine-1-carboxylate",0.0003,uM,=,-3.522878745280338,0,O=C(Oc1ccc2ncnc(Nc3ccccc3)c2c1)N1CCNCC1
589,835647,10.1016/j.bmcl.2012.07.079,,,,Inhibition of EGFR in human A431 cell lysate using tyrosine/glutamic acid polymer as substrate by ELISA,Brc1cccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCCO5)cc23)c1,"N4-(3-bromophenyl)-N6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)quinazoline-4,6-diamine",1.02,uM,=,0.0086001717619175,1,c1ccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCCO5)cc23)cc1
590,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccc(O)cc1,"3-(3,4-Dichlorophenyl)-5-(4-hydroxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",5.27,uM,=,0.7218106152125465,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
591,2059412,10.1016/j.bmc.2021.116061,,,,Inhibition of EGFR in human A431 cells preincubated for 60 mins followed by EGF stimulation and measured after 10 mins by ELISA,COc1cccc2cc(N(C)c3nc(C)nc4ccccc34)ccc12,"N-(5-methoxynaphthalen-2-yl)-N,2-dimethylquinazolin-4-amine",0.0106,uM,=,-1.9746941347352296,0,c1ccc2cc(Nc3ncnc4ccccc34)ccc2c1
592,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(C(=O)NCCN2CCOCC2)[nH]c1/C=C1\C(=O)N(C)c2ncnc(Nc3ccc(F)c(Cl)c3)c21,"5-[4-(3-Chloro-4-fluoro-phenylamino)-7-methyl-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide",5.31,uM,=,0.725094521081469,1,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1
593,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,Cc1cc(Nc2ncnc3cc(O)c(NC(=O)/C=C/[C@H]4CCCN4C)cc23)ccc1Oc1cc2nccn2cn1,"(E)-N-[7-hydroxy-4-(4-imidazo[1,2-c]pyrimidin-7-yloxy-3-methyl-anilino)quinazolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide",0.00111,uM,=,-2.9546770212133424,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4cc5nccn5cn4)cc3)c2c1
594,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{6-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-hexyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",11.0,uM,=,1.0413926851582251,1,O=C(C=Cc1ccccc1)NCCCCCCNC(=O)/C=C/c1ccccc1
595,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,C=CC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-1-(1-acryloylpyrrolidin-3-yl)-3-(2-chlorophenyl)-7-(3-methyl-4-(4-methylpiperazin-1-yl)phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0005,uM,=,-3.3010299956639813,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
596,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(/C=C/c1ccc([N+](=O)[O-])cc1)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,(E)-N-(4-(3-Chlorophenylamino)quinazolin-6-yl)-3-(4-nitrophenyl)acrylamide,3.45,uM,=,0.5378190950732742,1,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
597,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2)c1O,2-Cyano-3-(4-hydroxy-3-methoxy-5-phenylsulfanylmethyl-phenyl)-acrylamide,0.4,uM,=,-0.3979400086720376,0,c1ccc(CSc2ccccc2)cc1
598,489730,10.1021/jm701501x,,,,Inhibition of EGFR by ELISA,Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2,hematoxylin,3.4,uM,=,0.5314789170422551,1,c1ccc2c(c1)CC1COc3ccccc3[C@@H]21
599,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1ccc2c(Nc3cccc(Br)c3)ncnc2c1,(3-Bromo-phenyl)-(7-methoxy-quinazolin-4-yl)-amine,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
600,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,2.753,uM,=,0.4398062113933302,1,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
601,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCc1c(C(N)=O)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide",0.12,uM,=,-0.9208187539523752,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
602,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCc1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-phenethyl-acrylamide",0.9,uM,=,-0.0457574905606751,0,O=C(C=Cc1ccccc1)NCCc1ccccc1
603,63772,10.1021/jm9903949,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cells,Brc1cccc(Nc2ncnc3c2sc2ccccc23)c1,"Benzo[4,5]thieno[3,2-d]pyrimidin-4-yl-(3-bromo-phenyl)-amine",0.17,uM,=,-0.7695510786217261,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
604,2127056,10.1016/j.bmcl.2021.128118,,,,Inhibition of recombinant wild type EGFR-TK (unknown origin) by ELISA,COc1ccc(C(Nc2ccc(Cl)cc2)n2c(=O)ccc3cc(O)ccc32)cc1,1-((4-chlorophenylamino)(4-methoxyphenyl)methyl)-6-hydroxyquinolin-2(1H)-one,1.13,uM,=,0.0530784434834196,1,O=c1ccc2ccccc2n1C(Nc1ccccc1)c1ccccc1
605,506208,10.1021/np50089a001,,,,Inhibition of EGFR,O=CN/C=C/c1cccc(O)c1O,"N-(2,3-dihydroxystyryl)formamide",1.6754325002062935,uM,=,0.22412693567565,1,c1ccccc1
606,2294501,10.1016/j.bmc.2023.117202,,,,Inhibition of wild type EGFR (unknown origin),CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.000641,uM,=,-3.1931419704811828,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
607,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(N)c(O)c2)c2c(N)ncnc21,"2-amino-5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol",2.12,uM,=,0.3263358609287514,1,c1ccc(-c2n[nH]c3ncncc23)cc1
608,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CN1CCN(CCC#CC(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cn2)CC1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-5-(4-methyl-1-piperazinyl)-2-pentynamide",0.0005,uM,=,-3.3010299956639813,0,O=C(C#CCCN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
609,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3nc(NCCN4CCOCC4)sc23)cc1Cl,"N7-(3-chloro-4-fluorophenyl)-N2-(2-morpholinoethyl)thiazolo[4,5-d]pyrimidine-2,7-diamine",0.918,uM,=,-0.0371573187987575,0,c1ccc(Nc2ncnc3nc(NCCN4CCOCC4)sc23)cc1
610,66584,10.1016/s0960-894x(02)01047-8,,,,Inhibition of EGFR,CS(=O)(=O)CCNc1nc(-c2ccc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3c2)cs1,(1-Benzyl-1H-indazol-5-yl)-{6-[2-(2-methanesulfonyl-ethylamino)-thiazol-4-yl]-quinazolin-4-yl}-amine,0.071,uM,=,-1.1487416512809248,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccc(-c6cscn6)cc45)ccc32)cc1
611,63765,10.1021/jm00023a009,,,,In vitro inhibition of intrinsic tyrosine protein kinase activity of the Epidermal growth factor receptor using tripeptide RR-Src,COC(=O)c1ccc(-c2ccc(-c3ccccc3)cc2O)cc1,"2'-Hydroxy-[1,1';4',1'']terphenyl-4-carboxylic acid methyl ester",14.0,uM,=,1.146128035678238,1,c1ccc(-c2ccc(-c3ccccc3)cc2)cc1
612,2088705,10.1016/j.ejmech.2020.112339,,,,Inhibition of EGFR (unknown origin) by ADP-Glo assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.0025,uM,=,-2.6020599913279625,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
613,2270873,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3ccc(OCCn4ccnc4[N+](=O)[O-])c(Cl)c3)c2cc1OCCCN1CCOCC1,N-(3-chloro-4-(2-(2-nitro-1H-imidazol-1-yl)ethoxy)phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine,0.12,uM,=,-0.9208187539523752,0,c1cn(CCOc2ccc(Nc3ncnc4ccc(OCCCN5CCOCC5)cc34)cc2)cn1
614,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,CCCn1ccc2cc(Nc3ncnc4ccc(N)cc34)ccc21,"N4-(1-propyl-1H-indol-5-yl)quinazoline-4,6-diamine",0.3583,uM,=,-0.4457531918338894,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1
615,1662113,10.1016/j.ejmech.2017.02.061,,,,Inhibition of EGFR (unknown origin) measured after 40 mins by Kinase Glo luminescence assay,CC(C)[C@@H](NC(=O)OC(C)(C)C)C(=O)Nc1ccc2ncnc(Nc3cccc(C(F)(F)F)c3)c2c1,(R)-tert-butyl (3-methyl-1-oxo-1-((4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-yl)amino)butan-2-yl)carbamate,1.021,uM,=,0.0090257420869102,1,c1ccc(Nc2ncnc3ccccc23)cc1
616,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.127,uM,=,-0.8961962790440431,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
617,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(Cc4ccccn4)cc3)ncnc2cn1,"(2E)-4-(Dimethylamino)-N-{4-[4-(2-pyridinylmethyl)anilino]-pyrido[3,4-d]pyrimidin-6-yl}-2-butenamide",0.01,uM,=,-2.0,0,c1ccc(Cc2ccc(Nc3ncnc4cnccc34)cc2)nc1
618,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-(2-(2-aminopyrimidin-4-yl)ethynyl)pyrimidin-4-amine,0.032,uM,=,-1.494850021680094,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccncn1
619,2112388,10.1016/j.bmcl.2021.127987,,,,Inhibition of EGFR (unknown origin),O=C(CNc1ccc(Cl)cc1)Nn1c(-c2ccccc2)nc2ccccc2c1=O,SID507577,0.0810699999999999,uM,=,-1.0911398269827235,0,O=C(CNc1ccccc1)Nn1c(-c2ccccc2)nc2ccccc2c1=O
620,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,Clc1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)c(Cl)c1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole",3.7,uM,=,0.568201724066995,1,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
621,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1,"N-Benzyl-2-cyano-3-(3,4-dihydroxy-phenyl)-acrylamide",2.0,uM,=,0.3010299956639812,1,O=C(C=Cc1ccccc1)NCc1ccccc1
622,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCN(CC)CCOc1cc2ncnc(Nc3ccc(C)c(Br)c3)c2cc1OC,N-(3-bromo-4-methylphenyl)-7-(2-(diethylamino)ethoxy)-6-methoxyquinazolin-4-amine,9.45,uM,=,0.9754318085092628,1,c1ccc(Nc2ncnc3ccccc23)cc1
623,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)C(C)(C)C)CC4)cc3OC)ncc2SC)c1,N-(3-((2-((2-Methoxy-4-(4-pivaloylpiperazin-1-yl)phenyl)amino)-5-(methylthio)pyrimidin-4-yl)oxy)phenyl)acrylamide,0.4097,uM,=,-0.3875340360468576,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
624,1528598,,,,,"In Vitro Kinase Assay: In vitro kinase analysis was performed by using HTScan EGF Receptor Kinase Assay Kit (#7909) and HTScan HER2/ErbB2 Kinase Assay Kit (#7058) from Cell Signaling Technology Company. Operation steps refer to the specification of the used kits, and the method was used to measure the inhibition effects of the compound to be tested on substrate peptide phosphorylation of EGFR or Her2 receptor tyrosine kinase. At room temperature, ATP and substrate peptide as well as the compound to be tested were incubated in kinase reaction buffer, after a period of incubation, a stop buffer was added to terminate the reaction and the sample was transferred to a streptavidin-coated 96-well plate, the plate was washed and the phosphorylation level of substrate peptide was detected by using HRP-marked antibody against substrate phosphorylation, colorated with TMB, terminated the reaction with 2M sulfuric acid. Absorption at 450 nm wavelength was detected, and IC50 value (Î¼M) was calculated.",NS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,"US8916574, Compound 1",0.00271,uM,=,-2.567030709125594,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
625,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,OCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"(4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methanol",0.12,uM,=,-0.9208187539523752,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
626,1641794,,,,,"Time-Resolved Fluorescence Assay: The following assay may be used to determine the activity of the compounds of the invention for inhibiting EGFR kinase activity. The half maximal inhibitory concentration IC50 (the concentration of the tested compound showing 50% inhibition of the enzyme activity) of each compound was determined by incubating several different concentrations of the tested compounds with a specific enzyme and substrate. EGFR kinase used in this assay is a human-derived recombinant protein (Cell signaling technology, #7908), which was reacted with peptide substrate and different concentrations of tested compounds in a buffer solution containing 60 mM HEPES (pH7.5), 5 mM MgCl2, 5 mM MnCl2, 3 Î¼M Na3VO4, 1.25 M DTT (1000Ã) and 20 Î¼M ATP at 25Â° C., for 45 minutes. The EGFR kinase activity was determined by using a Time-Resolved fluorescence method.",CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@@H]1C[C@@H](O)CN1C,"US8901140, 3::US9358227, 3",0.059,uM,=,-1.2291479883578558,0,O=C(/C=C/[C@@H]1CCCN1)Nc1ccc2nccc(Nc3ccc(OCc4ccccn4)cc3)c2c1
627,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CC(C)(C)CCOC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3,3-dimethyl-butyl ester",0.7,uM,=,-0.1549019599857432,0,c1ccc(CNc2ccccc2)cc1
628,2224501,10.1016/j.bmc.2021.116534,,,,Inhibition of EGFR in human A-431 cell membrane vesicles using phospholipase C-gamma-1 as substrate incubated for 10 mins by scintillation counter method,c1ccc(CNc2ncnc3c2[nH]c2ccccc23)cc1,"N-benzyl-5H-pyrimido[5,4-b]indol-4-amine",0.46,uM,=,-0.3372421683184259,0,c1ccc(CNc2ncnc3c2[nH]c2ccccc23)cc1
629,1566936,10.1021/acs.jmedchem.5b01633,,,,Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccn(C)n3)nc3[nH]ccc23)c1,"N-(3-((2-((1-Methyl-1H-pyrazol-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide",0.0076,uM,=,-2.1191864077192086,0,c1ccc(Oc2nc(Nc3cc[nH]n3)nc3[nH]ccc23)cc1
630,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccn3)cc2Cl)c1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-(2-(pyridin-2-yl)ethynyl)pyrimidin-4-amine,0.017,uM,=,-1.769551078621726,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccn1
631,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.1124,uM,=,-0.9492336887669576,0,c1ccc(/N=c2\nc[nH]c3cc(OCC4CCNCC4)ccc23)cc1
632,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,"5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2n[nH]c3ncncc23)cc1
633,2283470,10.1016/j.bmcl.2022.129102,,,,Inhibition of EGFR (unknown origin),N=C1N=C(NCCS(=O)(=O)O)/C(=C/C(O)CNC(=O)c2cc(Br)c(Br)[nH]2)N1,tauroacidin A,44.64,uM,=,1.6497241859295224,1,N=C1N=C/C(=C/CCNC(=O)c2ccc[nH]2)N1
634,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(C)c3)c2c1,N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide,0.0004199999999999,uM,=,-3.3767507096021,0,c1ccc(Nc2ncnc3ccccc23)cc1
635,1642159,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",1.78,uM,=,0.250420002308894,1,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
636,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,Cn1ncc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-(1-methyl-1H-pyrazolo[4,3-g]quinazolin-5-yl)-amine",0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2ncnc3cc4[nH]ncc4cc23)cc1
637,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,CN(C)C/C=C/C(=O)NCCSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,(E)-4-(Dimethylamino)-N-(2-((4-(4-fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)ethyl)but-2-enamide,0.0027,uM,=,-2.5686362358410126,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
638,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1cc(O)c(O)c(O)c1)C(=O)NCCCCNC(=O)/C(C#N)=C/c1cc(O)c(O)c(O)c1,"(E)-2-Cyano-N-{4-[(E)-2-cyano-3-(3,4,5-trihydroxy-phenyl)-acryloylamino]-butyl}-3-(3,4,5-trihydroxy-phenyl)-acrylamide",5.0,uM,=,0.6989700043360189,1,O=C(C=Cc1ccccc1)NCCCCNC(=O)/C=C/c1ccccc1
639,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCCCCCCn1ccnc1[N+](=O)[O-],N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-methoxy-7-((6-(2-nitro-1H-imidazol-1-yl)hexyl)oxy)quinazolin-4-amine,0.0355,uM,=,-1.449771646944906,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCCCCCCn5ccnc5)ccc34)cc2)cc1
640,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)CC)CC4)cc3OC)ncc2SC)c1,N-(3-((2-((2-Methoxy-4-(4-propionylpiperazin-1-yl)phenyl)amino)-5-(methylthio)pyrimidin-4-yl)oxy)phenyl)acrylamide,0.1536999999999999,uM,=,-0.813326132500255,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
641,2236990,10.1016/j.ejmech.2021.113334,,,,Inhibition of EGFR (unknown origin) by colorimetric assay,N#CC1=C(c2ccccc2)Nc2c(c(-c3cccs3)nn2-c2ccccc2)C12C(=O)Nc1ccc(Br)cc12,"5'-bromo-2'-oxo-1,6-diphenyl-3-(2-thienyl)spiro[7H-pyrazolo[3,4-b]pyridine-4,3'-indoline]-5-carbonitrile",0.15,uM,=,-0.8239087409443188,0,O=C1Nc2ccccc2C12C=C(c1ccccc1)Nc1c2c(-c2cccs2)nn1-c1ccccc1
642,63769,10.1016/S0960-894X(97)00014-0,,,,Displacement of [gamma-32P]-ATP from Epidermal growth factor receptor in A431 cell-free extracts,CNC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-N-methyl-benzamide",9.7,uM,=,0.9867717342662448,1,c1ccc(CNc2ccccc2)cc1
643,2107115,10.1016/j.ejmech.2021.113300,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0171,uM,=,-1.7670038896078462,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
644,1526584,10.1021/acsmedchemlett.5b00193,,,,Inhibition of wild type EGFR phosphorylation in human A431 cells after 60 mins by mesoscale multiplex assay,C=CC(=O)Nc1cccc(-n2c(=O)ccc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.05,uM,=,-1.3010299956639813,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
645,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CC(C)=CC[C@@H](OC(=O)/C=C\C(=O)c1ccc(C)cc1Cl)C1=CC(=O)c2c(O)ccc(O)c2C1=O,"(R)-1-(5,8-Dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (Z)-4-(2-chloro-4-methylphenyl)-4-oxobut-2-enoate",0.1052999999999999,uM,=,-0.9775716288145136,0,O=C(/C=C\C(=O)c1ccccc1)OCC1=CC(=O)c2ccccc2C1=O
646,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc(C=O)co2)c2c(N)ncnc21,"5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)furan-3-carbaldehyde",5.96,uM,=,0.7752462597402364,1,c1coc(-c2n[nH]c3ncncc23)c1
647,840627,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR-mediated intracellular tyrosine phosphorylation in EGF-stimulated human A431 cells after 2.5 hrs by SDS-PAGE analysis,Brc1cccc(Nc2ncnc3cc4c(cc23)OCCOCOCOCCO4)c1,"N-(3-bromophenyl)-7,8,14,15-tetrahydro-[1,3,5,8,11]pentaoxacyclotrideca[9,10-g]quinazolin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCOCOCCO4)cc1
648,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,COCCN(CCOC)S(=O)(=O)c1ccc(Nc2nc3ncnc(Nc4ccc(F)c(Cl)c4)c3s2)cc1,"4-(7-(3-chloro-4-fluorophenylamino)thiazolo[4,5-d]pyrimidin-2-ylamino)-N,N-bis(2-methoxyethyl)benzenesulfonamide",0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1
649,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCc2ccc(Cl)cc2)c1O,3-[3-(4-Chloro-benzylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,14.8,uM,=,1.1702617153949575,1,c1ccc(CSCc2ccccc2)cc1
650,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCCNC1,"5-(4-amino-1-(piperidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",2.72,uM,=,0.4345689040341987,1,c1ccc(-c2nn(CC3CCCNC3)c3ncncc23)cc1
651,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,Cl.NCCc1cn(CCCCCc2ccccc2)c2ccc(OCCc3ccc(O)cc3)cc12,2-[5-(4-Hydroxyphenethoxy)-1-(5-phenylpentyl)-1Hindole-3-yl]ethanamine hydrochloride,1.63,uM,=,0.2121876044039577,1,c1ccc(CCCCCn2ccc3cc(OCCc4ccccc4)ccc32)cc1
652,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCOCc1cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1CC,"(1-Benzyl-1H-indazol-5-yl)-(6-ethoxymethyl-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-4-yl)-amine",0.95,uM,=,-0.0222763947111522,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
653,791584,10.1016/j.bmc.2011.11.023,,,,"Inhibition of EGFR using poly(Glu,Tyr)4:1 as substrate and [gamma33P]ATP after 60 mins by scintillation counting",O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3ccc(F)cc3)ncnc2s1,"(4-(4-Fluorophenylamino)thieno[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanone",0.0437,uM,=,-1.359518563029578,0,O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3ccccc3)ncnc2s1
654,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NO)n3)cc2)CC1,2-((5-chloro-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-N-hydroxybenzamide,0.006564,uM,=,-2.1828314276189444,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
655,63764,10.1021/jm960689b,,,,Inhibition of epidermal growth factor receptor (EGFr),CCN(CC)CCn1c([Se][Se]c2c(C(=O)NC)c3ccccc3n2CCN(CC)CC)c(C(=O)NC)c2ccccc21,"2,2'-Diselenobis[1-[2-(diethylamino)ethyl]-N-methyl-1H-indole-3-carboxamide]",6.9,uM,=,0.8388490907372553,1,c1ccc2[nH]c([Se][Se]c3cc4ccccc4[nH]3)cc2c1
656,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,COC(=O)CN1CCC(n2cc(-c3cccc(OC)c3)c3c(N)ncnc32)C1,"{3-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-pyrrolidin-1-yl}-acetic acid methyl ester",0.83,uM,=,-0.0809219076239261,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1
657,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.002,uM,=,-2.6989700043360187,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
658,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(Nc3nccc4ccccc34)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-isoquinolin-1-yl-amine",0.2,uM,=,-0.6989700043360187,0,c1ccc2c(Nc3ncnc4ccccc34)nccc2c1
659,2102324,10.1016/j.bmcl.2021.128308,,,,Inhibition of EGFR (unknown origin),CCS(=O)(=O)NNC(=O)CSc1nc2ccccc2c(=O)n1Cc1ccc2c(c1)OCO2,"N'-(2-(3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-oxo-3,4-dihydroquinazolin-2-ylthio)acetyl)ethanesulfonohydrazide",0.1469,uM,=,-0.8329782042097436,0,O=c1c2ccccc2ncn1Cc1ccc2c(c1)OCO2
660,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=NNc1ccc(O)cc1,2-[(4-Hydroxy-phenyl)-hydrazono]-malononitrile,225.0,uM,=,2.3521825181113627,1,c1ccccc1
661,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccccc3)C2)cc1,"2-(5-Phenyl-3-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",1.08,uM,=,0.0334237554869497,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
662,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,CN1CCN(CCCCCNc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)CC1,"6-(2,6-Dichloro-phenyl)-8-methyl-2-[5-(4-methyl-piperazin-1-yl)-pentylamino]-8H-pyrido[2,3-d]pyrimidin-7-one",4.5,uM,=,0.6532125137753437,1,O=c1[nH]c2nc(NCCCCCN3CCNCC3)ncc2cc1-c1ccccc1
663,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(NCc3ccccc3)c2c1C,"Benzyl-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",1.08,uM,=,0.0334237554869497,1,c1ccc(CNc2ncnc3[nH]ccc23)cc1
664,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(O)c2F)c2c(N)ncnc21,"3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",3.72,uM,=,0.5705429398818975,1,c1ccc(-c2n[nH]c3ncncc23)cc1
665,2147299,10.1021/acs.jmedchem.1c01013,,,,Inhibition of exogenous EGFR (unknown origin),CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.01342,uM,=,-1.872247484167027,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
666,2132157,10.1021/acs.jmedchem.1c01559,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(Cl)ccn3)cc2)c(C(N)=O)n1N,(S)-2-(1-acryloylpiperidin-2-yl)-1-amino-4-(4-((4-chloropyridin-2-yl)carbamoyl)phenyl)-1H-imidazole-5-carboxamide,0.176,uM,=,-0.7544873321858502,0,O=C(Nc1ccccn1)c1ccc(-c2c[nH]c([C@@H]3CCCCN3)n2)cc1
667,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(F)cc3)cc12)c1ccc(F)cc1,"(R)-6-(4-Fluorophenyl)-N-(1-(4-fluorophenyl)ethyl)-7Hpyrrolo[2,3-d]pyrimidin-4-amine",0.027,uM,=,-1.5686362358410126,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
668,591074,10.1021/jm9010065,,,,Inhibition of human recombinant HER1 expressed in Sf9 cells by liquid scintillation counting,CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)OCCN1CCCCC1,"{4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl}-carbamic acid 2-(piperidin-1-yl)ethyl ester",0.038,uM,=,-1.42021640338319,0,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OCCN1CCCCC1
669,82323,10.1021/jm9904295,,,,Inhibitory activity against ligand-dependent EGF cell proliferation,Cc1[nH]c(/C=C2\C(=O)Nc3cc(-c4ccccc4)ccc32)c(C)c1CCC(=O)O,"3-{2,4-Dimethyl-5-[2-oxo-6-phenyl-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrol-3-yl}-propionic acid",21.9,uM,=,1.3404441148401185,1,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1ccc[nH]1
670,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C=CC(=O)Nc1cccc(-c2coc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}furo[2,3-d]-pyrimidin-5-yl)phenyl]prop-2-enamide",0.159,uM,=,-0.7986028756795485,0,c1ccc(CNc2ncnc3occ(-c4ccccc4)c23)cc1
671,2203131,10.1016/j.ejmech.2022.114455,,,,Inhibition of wild type EGFR (unknown origin) incubated for 10 mins by HTRF KinEASE-TK assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(CC(=O)NCCNc5cccc6c5CN(C5CCC(=O)NC5=O)C6=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"N-(3-((2-((4-(4-(2-((2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethyl)amino)-2-oxoethyl)piperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide",2.397,uM,=,0.3796680340336538,1,O=C(CN1CCN(c2ccc(Nc3nccc(Nc4ccccc4)n3)cc2)CC1)NCCNc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O
672,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Fc1c(Nc2ncnc3cc4c(cc23)OCCO4)ccc(Cl)c1Cl,"N-(3,4-Dichloro-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0367,uM,=,-1.435333935747911,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
673,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(C)c(=O)c3cnc(Nc4ccc(N5CCN(C(C)=O)CC5)cc4OC)nc32)c1,"N-(3-(7-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-3-methyl-2,4-dioxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)-phenyl)acrylamide",0.18,uM,=,-0.744727494896694,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12
674,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,Fc1ccc(-c2nc(-c3ccccc3)[nH]c2-c2ccnc3[nH]c(-c4ccccc4)cc23)cc1,"4-[4-(4-Fluorophenyl)-2-phenyl-1H-imidazol-5-yl]-2-phenyl-1H-pyrrolo[2,3-b]pyridine",0.215,uM,=,-0.6675615400843947,0,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccccc4)ccnc3[nH]2)cc1
675,1639950,,,,,Inhibition of recombinant human N-terminal GST His6-tagged thrombin cleavage site-fused EGFR (H672 to A1210 residues) expressed in baculovirus using poly-EY as substrate after 210 mins by luciferase coupled chemiluminescence assay,COc1cc2c(Nc3ccc(Cl)c(Cl)c3)ncnc2cc1OCc1csc2ccc(Cl)cc12,"7-{[(5-chloro-1-benzothien-3-yl)methyl]oxy}-N-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3cc(OCc4csc5ccccc45)ccc23)cc1
676,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.Cc1cccc(C(C)Nc2ncnc3[nH]c(-c4ccc(O)cc4)cc23)c1,"rac-4-(4-((1-(m-Tolyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.095,uM,=,-1.0222763947111522,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
677,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(/C=C/c1ccccc1Br)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,(E)-N-(4-(3-Bromophenylamino)quinazolin-6-yl)-3-(2-bromophenyl)acrylamide,4.28,uM,=,0.631443769013172,1,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
678,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,COc1ccc(NC(=O)c2ccc(N(CCCl)CCCl)cc2)cc1,4-(Bis(2-chloroethyl)amino)-N-(4-methoxyphenyl)benzamide,0.08,uM,=,-1.0969100130080565,0,O=C(Nc1ccccc1)c1ccccc1
679,1556348,10.1016/j.bmc.2016.02.017,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by addition of substrate by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
680,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Oc1c(Br)cccc1CN(Cc1ccc(F)cc1)C(=S)Nc1ccccc1,1-(5-Bromo-2-hydroxybenzyl)-1-(4-fluorobenzyl)-3-phenylthiourea,0.98,uM,=,-0.0087739243075051,0,S=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
681,591074,10.1021/jm9010065,,,,Inhibition of human recombinant HER1 expressed in Sf9 cells by liquid scintillation counting,CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)OCCN1CCOCC1,"{4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl}-carbamic acid 2-(morpholine-1-yl)ethyl ester",0.111,uM,=,-0.9546770212133424,0,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OCCN1CCOCC1
682,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1ccc(CO)cc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1,"(R)-(4-Methoxy-3-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)phenyl)methanol",0.005,uM,=,-2.3010299956639813,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
683,63616,10.1016/S0960-894X(97)00034-6,,,,Inhibition of Epidermal growth factor receptor autophosphorylation.,COc1cc(Nc2ncnc3cc(OC)c(OC)cc23)cc(OC)c1.Cl,"(3,5-Dimethoxy-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine hydrochloride",3.0,uM,=,0.4771212547196624,1,c1ccc(Nc2ncnc3ccccc23)cc1
684,1668743,10.1021/acs.jmedchem.7b00076,,,,"Inhibition of recombinant EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",Cc1n[nH]c2ccc(-c3cc(N[C@@H](CO)c4ccccc4)cnc3-c3cc(Cl)ccc3O)cc12,(R)-4-Chloro-2-(5-(2-hydroxy-1-phenylethylamino)-3-(3-methyl-1H-indazol-5-yl)pyridin-2-yl)phenol,0.0031,uM,=,-2.508638306165728,0,c1ccc(CNc2cnc(-c3ccccc3)c(-c3ccc4[nH]ncc4c3)c2)cc1
685,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,CCOC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl ethyl carbonate",0.141,uM,=,-0.8507808873446201,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
686,2270910,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) incubated for 1 hrs in presence of ATP by ELISA assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",6.21,uM,=,0.7930916001765802,1,c1ccc(Nc2ncnc3ccccc23)cc1
687,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nc(Cl)ccc3c2)c2c(N)ncnc21,"3-(2-chloroquinolin-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",100.0,uM,=,2.0,1,c1cnc2ccc(-c3n[nH]c4ncncc34)cc2c1
688,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,COC(=O)c1ccc(C(=O)N(C)[C@H]2C[C@@H]3O[C@](C)([C@H]2OC)n2c4ccccc4c4c5c(c6c7ccccc7n3c6c42)C(=O)NC5)cc1,Staurosporine derivative,7.4,uM,=,0.8692317197309762,1,O=C(N[C@@H]1CC2O[C@@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O)c1ccccc1
689,67041,10.1016/s0960-894x(01)00080-4,,,,Inhibition of epidermal growth factor receptor (EGF-R),COCCNCCN1CCC(n2cc(-c3cccc(OC)c3)c3c(N)ncnc32)CC1,"7-{1-[2-(2-Methoxy-ethylamino)-ethyl]-piperidin-4-yl}-5-(3-methoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",0.31,uM,=,-0.5086383061657274,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1
690,306382,10.1016/j.bmcl.2004.12.015,,,,Inhibition of poly(L-glutamic acid-L-tyrosine) phosphorylation by EGFR tyrosine kinase of A431 carcinoma cells,ClCCNc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,"N*6*-(2-Chloro-ethyl)-N*4*-(3-chloro-phenyl)-quinazoline-4,6-diamine",0.026,uM,=,-1.585026652029182,0,c1ccc(Nc2ncnc3ccccc23)cc1
691,66904,10.1016/S0960-894X(96)00601-4,,,,Inhibition of the epidermal growth factor receptor.,COc1ccccc1C(=O)Nc1cccc(Nc2nccc(-c3cccnc3)n2)c1,2-Methoxy-N-[3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide,100.0,uM,=,2.0,1,O=C(Nc1cccc(Nc2nccc(-c3cccnc3)n2)c1)c1ccccc1
692,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,O=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,1-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)urea,0.00292,uM,=,-2.5346171485515816,0,O=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
693,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1ccc(Nc2ncnc3cc4c(cc23)OCCO4)c(F)c1Br,"N-(3-Bromo-2,4-difluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0156,uM,=,-1.8068754016455384,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
694,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(=O)c2ccc(O)c(O)c2)cc(CSCc2ccccc2)c1O,"3-(3-Benzylsulfanylmethyl-4-hydroxy-5-methoxy-phenyl)-2-(3,4-dihydroxy-benzoyl)-acrylonitrile",0.75,uM,=,-0.1249387366082999,0,O=C(C=Cc1cccc(CSCc2ccccc2)c1)c1ccccc1
695,66904,10.1016/S0960-894X(96)00601-4,,,,Inhibition of the epidermal growth factor receptor.,Nc1cccc(Nc2nccc(-c3cccnc3)n2)c1,"N-(4-Pyridin-3-yl-pyrimidin-2-yl)-benzene-1,3-diamine",50.0,uM,=,1.6989700043360187,1,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1
696,591074,10.1021/jm9010065,,,,Inhibition of human recombinant HER1 expressed in Sf9 cells by liquid scintillation counting,CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)O[C@H]1CC[C@@](C)(N)CC1,"{4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl}-carbamic acid cis-4-amino-4-methylcyclohexyl ester",0.019,uM,=,-1.7212463990471711,0,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OC1CCCCC1
697,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,O=C(C#CCN1CCOCC1)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1,4-(6-(4-morpholinobut-2-ynamido)quinolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.013,uM,=,-1.8860566476931635,0,O=C(C#CCN1CCOCC1)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1
698,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,CN(C)c1ccc(Nc2ncnc3cc(N)ncc23)cc1,"N*4*-(4-Dimethylamino-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",4.86,uM,=,0.6866362692622934,1,c1ccc(Nc2ncnc3ccncc23)cc1
699,321418,10.1016/j.bmcl.2005.06.068,,,,Inhibitory concentration against EGFR kinase phosphorylation using synthetic peptide as a substrate,COc1cc2ncnc(Nc3ccc(OCc4ccccn4)c(C)c3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-[3-methyl-4-(pyridin-2-ylmethoxy)-phenyl]-amine",0.059,uM,=,-1.2291479883578558,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
700,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,COC(=O)Nc1cc(Nc2ncnc3cc(OC)c(OC)cc23)ccc1C,"methyl 5-(6,7-dimethoxyquinazolin-4-ylamino)-2-methylphenylcarbamate",7.2,uM,=,0.8573324964312685,1,c1ccc(Nc2ncnc3ccccc23)cc1
701,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3[nH]c(=O)[nH]c3c2)c2c(N)ncnc21,"5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-benzo[d]imidazol-2(3H)-one",0.937,uM,=,-0.0282604091122217,0,O=c1[nH]c2ccc(-c3n[nH]c4ncncc34)cc2[nH]1
702,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Nc1ccc2sc3c(Nc4cccc(C(F)(F)F)c4)ncnc3c2c1,"N*4*-(3-Trifluoromethyl-phenyl)-benzo[4,5]thieno[3,2-d]pyrimidine-4,8-diamine",0.047,uM,=,-1.3279021420642825,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
703,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,CCOc1cc2ncnc(NCc3ccc(F)cc3)c2cc1OCC.Cl,"4-[(4'-fluorobenzyl)amino]-6,7-diethoxyquinazoline hydrochloride",0.188,uM,=,-0.7258421507363202,0,c1ccc(CNc2ncnc3ccccc23)cc1
704,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3cccc(O)c3)nc21,"6-(2,6-Dichloro-phenyl)-2-(3-hydroxy-phenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",0.15,uM,=,-0.8239087409443188,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
705,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,"3,5,7-Trihydroxy-2-(4-hydroxy-phenyl)-chromen-4-one",10.487759912230068,uM,=,1.020682736844965,1,O=c1cc(-c2ccccc2)oc2ccccc12
706,2224994,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin),O=C(/C=C\c1ccc(OC(F)(F)F)cc1)c1ccc(Br)c2cc(-c3ccc(F)cc3)oc12,(Z)-1-[4-bromo-2-(4-fluorophenyl)benzofuran-7-yl]-3-[4-(trifluoromethoxy)phenyl]prop-2-en-1-one,0.12,uM,=,-0.9208187539523752,0,O=C(/C=C\c1ccccc1)c1cccc2cc(-c3ccccc3)oc12
707,1891470,10.1016/j.bmc.2019.03.049,,,,Inhibition of c-MET (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins by mobility shift assay,COc1cc2c(Oc3ccc(C4SCC(=O)N4NC(=O)Nc4cc(F)cc(F)c4)cc3)ccnc2cc1OCCCN1CCOCC1,"N1-(3,5-difluorophenyl)-N3-(2-(4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)oxy)phenyl)-4-oxothiazolidin-3-yl)urea",4.75,uM,=,0.6766936096248666,1,O=C(Nc1ccccc1)NN1C(=O)CSC1c1ccc(Oc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1
708,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CN(C)C/C=C/C(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1,"US9181263, 7::US9278100, 7",0.2687,uM,=,-0.5707323335668315,0,c1ccc(Oc2ccc(-c3nn(C4CCNCC4)c4ncncc34)cc2)cc1
709,1991314,10.1016/j.bmcl.2020.127288,,,,Inhibition of wild type EGFR (unknown origin) in presence of radiolabelled gammaATP by radioisotope filter binding assay,N#Cc1cnc2cc(OC[C@@H](O)CO)c(NC(=O)C3CSSC3)cc2c1Nc1ccc(OCc2cccc(F)c2)c(Cl)c1,"(S)-N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-3-cyano-7-(2,3-dihydroxypropoxy)quinolin-6-yl)-1,2-dithiolane-4-carboxamide",0.0015,uM,=,-2.8239087409443187,0,O=C(Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1)C1CSSC1
710,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccccc4)c(Cl)c3)ncnc2cc1OCCN1CCCCC1,1-(2-chloro-4-((6-methoxy-7-(2-(piperidin-1-yl)ethoxy)quinazolin-4-yl)amino)phenyl)-3-phenylurea,0.212,uM,=,-0.6736641390712486,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCN4CCCCC4)ccc23)cc1
711,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,C[C@@H](Nc1ncnc2sc(Br)cc12)c1ccccc1,"(R)-6-Bromo-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine",0.038,uM,=,-1.42021640338319,0,c1ccc(CNc2ncnc3sccc23)cc1
712,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccccc1Cl,"2-(2-Chloro-benzoyl)-3-(3,4-dihydroxy-phenyl)-acrylonitrile",6.6,uM,=,0.8195439355418687,1,O=C(C=Cc1ccccc1)c1ccccc1
713,940299,10.1021/ml300327z,,,,Inhibition of human wild type EGFR expressed in Sf9 cells using [gamma32P]-ATP after 10 mins by scintillation counting,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,"N-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methyl butanamide",0.004,uM,=,-2.397940008672037,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
714,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Br)c3)c2c1,N-[4-(3-Bromo-4-fluoro-phenylamino)-quinazolin-6-yl]-acrylamide,0.0027,uM,=,-2.5686362358410126,0,c1ccc(Nc2ncnc3ccccc23)cc1
715,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,CS(=O)(=O)CCN(CCCCOc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1)C(=O)C(F)(F)F,"N-{4-[4-(4-Benzyloxy-phenylamino)-quinazolin-6-yloxy]-butyl}-2,2,2-trifluoro-N-(2-methanesulfonyl-ethyl)-acetamide",0.263,uM,=,-0.5800442515102421,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
716,1642164,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",0.091,uM,=,-1.0409586076789064,0,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
717,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(3-Isopropyl-7-((2-methoxy-4-(4-methylpiperazin-1-yl)-phenyl)amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.079,uM,=,-1.1023729087095586,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12
718,63773,10.1021/jm9508651,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 human epidermoid carcinoma cells,Nc1ccc2ncnc(Nc3cccc(Br)c3)c2n1,"N*4*-(3-Bromo-phenyl)-pyrido[3,2-d]pyrimidine-4,6-diamine",0.053,uM,=,-1.275724130399211,0,c1ccc(Nc2ncnc3cccnc23)cc1
719,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,Cc1ccc(C2=NN(C(N)=S)C(c3ccc(F)cc3)C2)cc1C,"3-(3,4-Dimethylphenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",0.83,uM,=,-0.0809219076239261,0,c1ccc(C2=NNC(c3ccccc3)C2)cc1
720,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.12,uM,=,-0.9208187539523752,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
721,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@@H]1CCOC1,"(R)-5-(4-amino-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2nn([C@@H]3CCOC3)c3ncncc23)cc1
722,1553877,10.1016/j.ejmech.2016.01.045,,,,Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay,COCCOc1cc2ncnc(Nc3ccc(NC(=O)C45CC6CC(CC(C6)C4)C5)cc3C)c2cc1OCCOC,"N-(4-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)amino)-3-methylphenyl)adamantane-1-carboxamide",0.00452,uM,=,-2.344861565188618,0,O=C(Nc1ccc(Nc2ncnc3ccccc23)cc1)C12CC3CC(CC(C3)C1)C2
723,2229998,10.1021/acs.jmedchem.1c00876,,,,Inhibition of wild type EGFR (unknown origin),Oc1ccccc1-c1nc(NCc2cccnc2)c2ccccc2n1,SID26667099,24.3,uM,=,1.385606273598312,1,c1ccc(-c2nc(NCc3cccnc3)c3ccccc3n2)cc1
724,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(NCc3cccc(C)c3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-methyl-benzyl)-amine",0.17,uM,=,-0.7695510786217261,0,c1ccc(CNc2ncnc3ccccc23)cc1
725,1914926,10.1016/j.ejmech.2019.111943,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669-1210 AA) expressed in baculovirus using FAM-labelled peptide as substrate pre-incubated for 10 mins followed by substrate addition by mobility shift assay,COc1ccc(OC)c(Nc2cc(NC(=O)Nc3c(Cl)cccc3Cl)ncn2)c1,"1-(2,6-dichlorophenyl)-3-(6-((2,5-dimethoxyphenyl)amino)pyrimidin-4-yl)urea",0.202,uM,=,-0.6946486305533762,0,O=C(Nc1ccccc1)Nc1cc(Nc2ccccc2)ncn1
726,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C=CC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@@H](CO)c4ccccc4)c23)c1,"N-[3-(4-{[(1R)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro-[2,3-d]pyrimidin-5-yl)phenyl]prop-2-enamide",0.238,uM,=,-0.623423042943488,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
727,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4cccc(Cl)c4)cc3)ncnc2cc1OCCN1CCCCC1,N-(4-(6-methoxy-7-(2-(piperidin-1-yl)ethoxy)quinazolin-4-ylamino)phenyl)-3-chlorobenzamide,0.3,uM,=,-0.5228787452803376,0,O=C(Nc1ccc(Nc2ncnc3cc(OCCN4CCCCC4)ccc23)cc1)c1ccccc1
728,792073,10.1016/j.bmc.2011.10.085,,,,Inhibition of EGFR expressed in baculovirus infected Sf9 cells assessed as inhibition of autophosphorylation preincubated for 10 mins measured after 1 hr by DELFIA/Time-Resolved Fluorometry,COc1ccccc1CNc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N6-(2-Methoxybenzyl)-N4-(3-bromophenyl)quinazoline-4,6-diamine",11.22,uM,=,1.0499928569201429,1,c1ccc(CNc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
729,946709,10.1016/j.bmc.2012.12.045,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,C#Cc1cccc(Nc2nc(N)nc3[nH]c(CCc4ccccn4)cc23)c1,"N4-(3-Ethynylphenyl)-6-(2-pyridin-2-yl-ethyl)-7Hpyrrolo[2,3-d]pyrimidine-2,4-diamine",19.9,uM,=,1.2988530764097066,1,c1ccc(Nc2ncnc3[nH]c(CCc4ccccn4)cc23)cc1
730,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C\CN1CCCCC1,(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide,0.00067,uM,=,-3.1739251972991736,0,O=C(/C=C\CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
731,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O)NOCc1ccccc1,"N-Benzyloxy-2-(5-{[1-(2,5-dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-phenyl)-acetamide",50.0,uM,=,1.6989700043360187,1,O=C(Cc1cccc(/N=C/c2ccccc2)c1)NOCc1ccccc1
732,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CNc1ncc(C(C)C)c2cc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)ncc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-(methylamino)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",23.605,uM,=,1.3730040047672738,1,c1cc2cc(Nc3ccnc(N4CCCCC4)n3)ncc2cn1
733,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6COCCN6)c45)ccc32)c1,"(R)-N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((morpholin-3-ylmethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.64,uM,=,-0.1938200260161128,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6COCCN6)c45)ccc32)cc1
734,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"N-(3-Chloro-4-fluorophenyl)-6-(2-methoxyphenyl)thieno[2,3-d]pyrimidin-4-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3sc(-c4ccccc4)cc23)cc1
735,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5C[C@@H](C)N(C)[C@@H](C)C5)c(C)c4)nc32)C1,"3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-((3R,5S)-3,4,5-trimethylpiperazin-1-yl)phenyl)amino)-1-((S)-1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.8882000000000001,uM,=,-0.0514892311623428,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
736,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(OC)c(NC(=O)/C=C/CNC4CC4)cc23)c1,(E)-4-(Cyclopropylamino)-N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)but-2-enamide,0.0079,uM,=,-2.1023729087095586,0,O=C(/C=C/CNC1CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
737,78513,10.1016/s0960-894x(02)01047-8,,,,Inhibition of EGFR overexpressing HN5 (Head and neck) tumor cell proliferation,CS(=O)(=O)CCNc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1,(3-Chloro-4-fluoro-phenyl)-{6-[2-(2-methanesulfonyl-ethylamino)-thiazol-4-yl]-quinazolin-4-yl}-amine,0.57,uM,=,-0.2441251443275086,0,c1ccc(Nc2ncnc3ccc(-c4cscn4)cc23)cc1
738,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccccc3OC)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(2-methoxybenzylidene)cyclohexanone",20.8,uM,=,1.3180633349627615,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
739,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1cc2c(Nc3cccc(C)c3)ncnc2cc1OCCCN1CCN(C)CC1,N-{7-[3-(4-Methyl-piperazin-1-yl)-propoxy]-4-m-tolylamino-quinazolin-6-yl}-acrylamide,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
740,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,CCOC(=O)/C=C/C(=O)Nc1cccc(Oc2cc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncn2)c1,(E)-ethyl 4-(3-(6-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)pyrimidin-4-yloxy)phenylamino)-4-oxobut-2-enoate,0.129,uM,=,-0.889410289700751,0,c1ccc(COc2ccc(Nc3cc(Oc4ccccc4)ncn3)cc2)cc1
741,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(CC)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(ethyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)buta2,3-dienamide",0.0254,uM,=,-1.595166283380062,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
742,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21,"5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",0.158,uM,=,-0.8013429130455774,0,c1ccc(-c2n[nH]c3ncncc23)cc1
743,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(NC3CCc4ccccc43)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-indan-1-yl-amine",0.91,uM,=,-0.0409586076789063,0,c1ccc2c(c1)CCC2Nc1ncnc2ccccc12
744,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(C(=O)O)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"5-[4-(3-Chloro-4-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid",0.029,uM,=,-1.537602002101044,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
745,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3cccc(F)c3)c2cn1,"N*4*-(3-Fluoro-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.84,uM,=,-0.0757207139381183,0,c1ccc(Nc2ncnc3ccncc23)cc1
746,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,OCCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"2-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-ylamino]-ethanol",0.0002399999999999,uM,=,-3.619788758288394,0,c1ccc(Nc2ncnc3ccncc23)cc1
747,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,COc1cccc2ncnc(NCc3ccccc3)c12,Benzyl-(5-methoxy-quinazolin-4-yl)-amine,4.9,uM,=,0.6901960800285137,1,c1ccc(CNc2ncnc3ccccc23)cc1
748,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc3cc(C=O)ccc3s2)c2c(N)ncnc21,"2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[b]thiophene-5-carbaldehyde",100.0,uM,=,2.0,1,c1ccc2sc(-c3n[nH]c4ncncc34)cc2c1
749,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,COC(=O)CN1CCC(n2cc(-c3cccc(OC)c3)c3c(N)ncnc32)CC1,"{4-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-piperidin-1-yl}-acetic acid methyl ester",1.47,uM,=,0.1673173347481761,1,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1
750,1774290,10.1016/j.ejmech.2018.03.001,,,,Inhibition of His-6 tagged recombinant EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in Baculovirus infected Sf9 cells by dissociation-enhanced lanthanide fluorescence immunoassay/time-resolved fluorometric analysis,NCCCCCCC(=S)N/N=C1\CC2(CCCCC2)Oc2c1ccc1ccccc21,"(N-hexyl-2-(spiro[benzo[h]chromene-2,1'-cyclohexan]-4(3H)-ylidene)hydrazinecarbothioamide",1.4,uM,=,0.1461280356782379,1,N=C1CC2(CCCCC2)Oc2c1ccc1ccccc21
751,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,O=C(CCCCCn1cc(-c2ccc3ncnc(Nc4cccc(Cl)c4F)c3c2)nn1)NO,"6-(4-(4-((3-Chloro-2-fluorophenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)-N-hydroxyhexanamide",0.00027,uM,=,-3.5686362358410126,0,c1ccc(Nc2ncnc3ccc(-c4c[nH]nn4)cc23)cc1
752,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,C#Cc1cccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)c1,"8-(3-Ethynylphenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.38,uM,=,-0.4202164033831898,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
753,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(C)cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-6-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.016,uM,=,-1.7958800173440752,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
754,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1O,"5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol",2.19,uM,=,0.3404441148401183,1,c1ccc(-c2n[nH]c3ncncc23)cc1
755,2272590,10.1016/j.ejmech.2021.113865,,,,Inhibition of human EGFR,COc1ccc2nc(Cl)c(/C=C/C(=O)c3ccc(C)cc3)cc2c1,3-(2-chloro-6-methoxyquinolin-3-yl)-1-(p-tolyl)prop-2-en-1-one,0.03707,uM,=,-1.4309774139704363,0,O=C(/C=C/c1cnc2ccccc2c1)c1ccccc1
756,980989,10.1021/jm400822z,,,,Inhibition of wild type human EGFR after 50 mins by HTRF assay,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(-c2c[nH]c3ccccc23)n1,1-[4-[4-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-3-methoxyphenyl]piperazin-1-yl]ethanone,0.79,uM,=,-0.1023729087095585,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c[nH]c2c1
757,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(CC)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1,"N-(3-(7-((4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-3-ethyl-2,4-dioxo-3,4-dihydropyrimido-[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.111,uM,=,-0.9546770212133424,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCCCC4)cc3)ncc12
758,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Nc3ccc(F)cc3)c1NC2,"(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(4-fluoro-phenyl)-amine",7.1,uM,=,0.8512583487190752,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
759,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)c(O)c1,"3-Amino-2,4-dicyano-5-(3,4-dihydroxy-phenyl)-penta-2,4-dienenitrile",3.0,uM,=,0.4771212547196624,1,c1ccccc1
760,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3C)c3ncn(C(C)C)c3n2)C[C@H]1F,"N-((3R,4R)-1-(6-(1,3-dimethyl-1H-pyrazol-4-ylamino)-9-isopropyl-9H-purin-2-yl)-4-fluoropyrrolidin-3-yl)acrylamide",1.45,uM,=,0.1613680022349748,1,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1
761,676221,10.1021/jm100607r,,,,Inhibition of EGFR,C=CC(=O)N1CCc2c(sc3ncnc(N[C@H](C)c4ccccc4)c23)C1,"1-(4-[(1R)-1-Phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-propen-1-one",0.02,uM,=,-1.6989700043360187,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1
762,2270920,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
763,1883986,10.1021/acsmedchemlett.8b00461,,,,Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay,N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c(C(N)=O)c2N)C1,(R)-5-amino-3-(4-(4-chlorophenoxy)phenyl)-1-(1-cyanopiperidin-3-yl)-1H-pyrazole-4-carboxamide,3.89,uM,=,0.5899496013257077,1,c1ccc(Oc2ccc(-c3ccn([C@@H]4CCCNC4)n3)cc2)cc1
764,554997,10.1021/jm8001185,,,,Inhibition of human recombinant EGFR,COc1cc(C2=C(c3cn(COCc4ccccc4)c4ccccc34)CNC2=O)cc(OC)c1OC,"4-{1-[(Benzyloxy)methyl]-1H-indol-3-yl}-3-(3,4,5-trimethoxyphenyl)-1,5-dihydro-2H-pyrrole-2-one",14.0,uM,=,1.146128035678238,1,O=C1NCC(c2cn(COCc3ccccc3)c3ccccc23)=C1c1ccccc1
765,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)N1CCN(c2ccccc2)CC1,"3-(3,4-Dihydroxy-phenyl)-2-(4-phenyl-piperazine-1-carbonyl)-acrylonitrile",55.0,uM,=,1.740362689494244,1,O=C(C=Cc1ccccc1)N1CCN(c2ccccc2)CC1
766,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1ccc2ncnc(Nc3cccc(Br)c3)c2c1OC,"(3-Bromo-phenyl)-(5,6-dimethoxy-quinazolin-4-yl)-amine",1.367,uM,=,0.1357685145678222,1,c1ccc(Nc2ncnc3ccccc23)cc1
767,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,c1ccc(CNc2ncnc3cnccc23)cc1,"Benzyl-pyrido[3,4-d]pyrimidin-4-yl-amine",2.03,uM,=,0.3074960379132129,1,c1ccc(CNc2ncnc3cnccc23)cc1
768,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCn4ccnc4[N+](=O)[O-])cc23)c1,N-(3-ethynylphenyl)-7-methoxy-6-(3-(2-nitro-1H-imidazol-1-yl)propoxy)quinazolin-4-amine,0.00108,uM,=,-2.96657624451305,0,c1ccc(Nc2ncnc3ccc(OCCCn4ccnc4)cc23)cc1
769,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,COc1cc2ncnc(C#CCCc3ccccc3)c2cc1OC,"6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline",0.014,uM,=,-1.853871964321762,0,C(#Cc1ncnc2ccccc12)CCc1ccccc1
770,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,O=C1CN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CCN1,"4-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)piperazin-2-one",0.35,uM,=,-0.4559319556497244,0,O=C1CN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c23)CCN1
771,2112388,10.1016/j.bmcl.2021.127987,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.166,uM,=,-0.7798919119599449,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
772,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,"1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole",29.256,uM,=,1.466214947329988,1,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1
773,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,Clc1ccc(CNc2ncnc3ccccc23)cc1,(4-Chloro-benzyl)-quinazolin-4-yl-amine,7.0,uM,=,0.8450980400142568,1,c1ccc(CNc2ncnc3ccccc23)cc1
774,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1,"1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.26,uM,=,-0.585026652029182,0,c1ncc2c(-c3cnc4[nH]ccc4c3)nn(C3CCCC3)c2n1
775,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,CC(C)c1ccc(NC(=O)c2ccc(N(CCCl)CCCl)cc2)cc1,4-(Bis(2-chloroethyl)amino)-N-(4-isopropylphenyl)benzamide,0.75,uM,=,-0.1249387366082999,0,O=C(Nc1ccccc1)c1ccccc1
776,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,COCOCC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Methoxymethoxy-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.059,uM,=,-1.2291479883578558,0,c1ccc(Nc2ncnc3ccccc23)cc1
777,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CS(=O)(=O)CCNCc1ccc(-c2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)[nH]1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)-1H-pyrrol-2-yl)thieno[3,2-d]pyrimidin-4-amine",0.007,uM,=,-2.154901959985743,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2)cc1
778,1642311,,,,,Inhibition Assay: Inhibition of recombinant EGFR tyrosine kinase using exogenous substrate.,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1,"1-(3-(4-bromo-2,6-difluorobenzyloxy)-4-carbamoylisothiazol-5-yl)-3-(4-(pyrrolidin-1-yl)butyl)urea",5.8534,uM,=,0.7674082032286527,1,O=C(NCCCCN1CCCC1)Nc1cc(OCc2ccccc2)ns1
779,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Oc1ncnc(Nc3cccc(Cl)c3F)c1NC2,"(3-chloro-2-fluoro-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",4.6,uM,=,0.6627578316815741,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
780,2270922,10.1016/j.ejmech.2020.112640,,,,Inhibition of recombinant EGFR (unknown origin) using by ELISA assay,CCN(CC)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,"4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-((N,N-diethyl(aminoethyl))aminomethyl)furan-2-yl)quinazolines",0.0156,uM,=,-1.8068754016455384,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
781,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"2-Cyano-N-{3-[2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-propyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",3.0,uM,=,0.4771212547196624,1,O=C(C=Cc1ccccc1)NCCCNC(=O)/C=C/c1ccccc1
782,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1cnc(N2C[C@H](CS(C)(=O)=O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",0.27,uM,=,-0.5686362358410126,0,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
783,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,C[C@@H](CN)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,"(S)-5-(4-amino-1-(1-aminopropan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",26.0,uM,=,1.414973347970818,1,c1ccc(-c2n[nH]c3ncncc23)cc1
784,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",[Cl-].[Cl-].[Zn+2],ZINC CHLORIDE,2.1884,uM,=,0.3401267061054316,1,
785,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,CCOC(=O)C(Cc1ccccc1)NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"2-[2-Cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-3-phenyl-propionic acid ethyl ester",49.0,uM,=,1.6901960800285136,1,O=C(/C=C/c1ccccc1)NCCc1ccccc1
786,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Nc3ccc4c[nH]nc4c3)c1NC2,"(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(1H-indazol-6-yl)-amine",1.2,uM,=,0.0791812460476248,1,c1ccc2c(c1)CNc1c(Nc3ccc4c[nH]nc4c3)ncnc1O2
787,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(Nc3cncc4ccccc34)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-isoquinolin-4-yl-amine",0.36,uM,=,-0.4436974992327127,0,c1ccc2c(Nc3ncnc4ccccc34)cncc2c1
788,1842432,10.1016/j.ejmech.2019.03.004,,,,Inhibition of EGFR (unknown origin),C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
789,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC(=O)c4ccccc4OC(C)=O)c(OCCOC)cc23)c1,2-((4-((3-Ethynylphenyl)amino)-6-(2-methoxyethoxy)quinazolin-7-yl)oxy)ethyl-2-acetoxybenzoate,0.005,uM,=,-2.3010299956639813,0,O=C(OCCOc1ccc2c(Nc3ccccc3)ncnc2c1)c1ccccc1
790,1757697,10.1016/j.ejmech.2017.06.023,,,,Inhibition of recombinant human C-terminal His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells by ELISA,C/C=C/c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(OCCCN4CCOCC4)cc23)cc1,"(E)-6,7-bis(3-morpholinopropoxy)-N-(4-(prop-1-enyl)phenyl)quinazolin-4-amine",0.02072,uM,=,-1.6836102489268046,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(OCCCN4CCOCC4)cc23)cc1
791,574946,10.1021/np8004997,,,,Inhibition of recombinant EGFR,COc1cc(O)c2c(c1)C(=O)c1cc(C)c(O)c(O)c1C2=O,6-O-methylalaternin,13.33051667940784,uM,=,1.1248469826221923,1,O=C1c2ccccc2C(=O)c2ccccc21
792,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3OC)n2)c1,N-(3-(3-(2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.08,uM,=,-1.0969100130080565,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCC(N4CCNCC4)CC3)cc2)n1
793,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,COc1ccc(-c2ccc(OC(F)(F)F)c(NC(=O)Nc3nccs3)c2)cn1,1-(5-(6-Methoxypyridin-3-yl)-2-(trifluoromethoxy)phenyl)-3-(thiazol-2-yl)urea,0.4953,uM,=,-0.3051316720175439,0,O=C(Nc1cccc(-c2cccnc2)c1)Nc1nccs1
794,942125,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin) using biotinylated-PTP1B (Tyr66) as substrate incubated for 5 mins prior to substrate addition measured after 1 hr by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCO,2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)ethanol,0.0634,uM,=,-1.197910742118267,0,c1ccc(Nc2ncnc3ccccc23)cc1
795,63615,10.1021/jm980123i,,,,Concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Epidermal growth factor receptor (EGF RTK).,CC(C)(C)c1cc(/C=C2\C(=O)Nc3ccccc32)cc(C(C)(C)C)c1O,"3-[1-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one",7.9,uM,=,0.8976270912904415,1,O=C1Nc2ccccc2/C1=C/c1ccccc1
796,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-phenylthiourea,0.0158,uM,=,-1.8013429130455774,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
797,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,COc1cccc2c(C(=O)Nc3ccccc3)c(SSc3c(C(=O)Nc4ccccc4)c4cccc(OC)c4n3C)n(C)c12,"2,2'-Dithiobis(1-methyl-7-methoxy-N-phenyl-1H-indole-3-carboxamide)",6.5,uM,=,0.8129133566428556,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
798,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CN(C)C(=O)O[C@@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3S,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl dimethylcarbamate",0.079,uM,=,-1.1023729087095586,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
799,66577,10.1016/j.bmcl.2004.03.106,,,,"Inhibition of human Epidermal growth factor receptor, HER-1",C[C@H](Nc1cc(-c2sc(C3CCN(C)CC3)nc2-c2ccc(F)cc2)ccn1)c1ccccc1,4-{4-(4-Fluoro-phenyl)-5-[2-((S)-1-phenyl-ethylamino)-pyridin-4-yl]-thiazol-2-yl}-1-methyl-piperidin-4-ol,1.1,uM,=,0.041392685158225,1,c1ccc(CNc2cc(-c3sc(C4CCNCC4)nc3-c3ccccc3)ccn2)cc1
800,2147415,10.1021/acs.jmedchem.1c01055,,,,Inhibition of Wild type EGFR (unknown origin),COc1cc(N2CCC(N3CCN(C)CC3)CC2)c(-c2cnn(C)c2)cc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,(2-((5-Chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide,0.0009199999999999,uM,=,-3.036212172654445,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)c(-c4cn[nH]c4)c3)n2)cc1
801,1527997,,,,,"ELISA-Based Kinase Assay: Inhibition of erbB tyrosine kinase activity was assessed using an ELISA-based receptor tyrosine kinase assay. Kinase reactions (50 mM HEPES, pH 7.4, 125 mM NaCl, 10 mM MgCl2, 100 Î¼M sodium orthovanadate, 2 mM dithiothreitol, 20 uM ATP, test compound or vehicle control and 1-5 nM GST-erbB per 50 uL reaction) were run in 96-well plates coated with 0.25 mg/ml poly-Glu-Tyr (Sigma). The reactions were incubated for 6 minutes at room temperature while shaking. Kinase reactions were stopped by removal of reaction mixture, then wells were washed with wash buffer comprising 3% Bovine Serum Albumin and 0.1% Tween 20 in Phosphate Buffered Saline (PBS). Phosphorylated tyrosine residues were detected by adding 0.2 Î¼g/ml anti-phosphotyrosine antibody (Oncogene Ab-4; 50 Î¼L/well) coupled to Horse Radish Peroxidase (HRP) for 25 minutes while shaking at room temperature.",O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCC(F)F,"US8623883, No. 6",0.0098699999999999,uM,=,-2.0056828473303634,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
802,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Nc1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"N*3*-(4-Amino-phenyl)-N*4*-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
803,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CN1CCN(CCC#CC(=O)Nc2cc3c(Nc4ccc(F)c(Br)c4)ncnc3cn2)CC1,"N-[4-[(3-bromo-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-5-(4-methyl-1-piperazinyl)-2-pentynamide",0.0027,uM,=,-2.5686362358410126,0,O=C(C#CCCN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
804,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,COc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3o2)cc1,"(S)-2-((6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0027,uM,=,-2.5686362358410126,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
805,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,C[C@@H](Nc1ncnc2oc(-c3ccc(O)cc3)cc12)c1ccccc1,"(R)-4-(4-((1-Phenylethyl)amino)furo[2,3-d]pyrimidin-6-yl)phenol",0.0015,uM,=,-2.8239087409443187,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
806,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"Ethyl 4-(8-(3-Chloro-4-fluorophenylamino)-2-oxooxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",7.8,uM,=,0.8920946026904804,1,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
807,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OCC)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,ethyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.019,uM,=,-1.7212463990471711,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
808,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc(OC(C)C)cc4)c3cc21,"Ethyl 4-(8-(4-isopropoxyphenylamino)-2-oxooxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",0.16,uM,=,-0.7958800173440752,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
809,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,CS(=O)(=O)CCNCCCCOc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1,(4-Benzyloxy-phenyl)-{6-[4-(2-methanesulfonyl-ethylamino)-butoxy]-quinazolin-4-yl}-amine,0.074,uM,=,-1.1307682802690238,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
810,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,CCC/C=C\C(=O)Nc1cc(Nc2nc(C)cc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,(Z)-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-methyl-6-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)hex-2-enamide,1.531,uM,=,0.184975190698261,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
811,2092920,10.1016/j.ejmech.2020.112691,,,,Inhibition of EGFR (unknown origin),CC(C)(C)c1cc(NC(=O)Cc2ccc(Nc3ncnc4[nH]c(-c5ccc(S(C)(=O)=O)cc5)cc34)cc2)no1,"N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-((6-(4-(methylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)acetamide",56.78,uM,=,1.7541953881898384,1,O=C(Cc1ccc(Nc2ncnc3[nH]c(-c4ccccc4)cc23)cc1)Nc1ccon1
812,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)N1CC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)C1,"US9447106, 119::US9447106, 29",0.027,uM,=,-1.5686362358410126,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(C3CNC3)CCN4)cc2)cc1
813,1283337,10.1016/j.ejmech.2013.10.058,,,,Inhibition of wild type EGFR (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,COc1cc2nc(Cl)nc(Nc3ccc(O)cc3)c2cc1OC,"4-((2-Chloro-6,7-dimethoxyquinazolin-4-yl)amino)phenol",4.3,uM,=,0.6334684555795865,1,c1ccc(Nc2ncnc3ccccc23)cc1
814,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,Clc1cc(Nc2ncnc3[nH]nc(OCCN4CCNCC4)c23)ccc1OCc1ccccn1,"N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-3-(2-(piperazin-1-yl)ethoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.008,uM,=,-2.096910013008056,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCNCC5)c34)cc2)nc1
815,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,OCc1ccc(-c2cc3c(Nc4ccccc4)ncnc3s2)cc1,"(4-(4-(Phenylamino)thieno[2,3-d]pyrimidin-6-yl)phenyl)methanol",0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3sc(-c4ccccc4)cc23)cc1
816,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Nc1ncnc(Nc3cccc(Br)c3)c1NC2,"(3-bromo-phenyl)-(7,8-dimethoxy-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cyclohepten-1-yl)-amine",1.5,uM,=,0.1760912590556812,1,c1ccc(Nc2ncnc3c2NCc2ccccc2N3)cc1
817,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"(2E)-N-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(dimethylamino)-2-butenamide",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3cnccc23)cc1
818,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,Cc1ccc(NC(=O)/C=C/c2ccccc2)cc1,(E)-N-(p-tolyl)cinnamamide,12.69,uM,=,1.1034616220947049,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
819,1929287,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide substrate preincubated for 10 mins followed by substrate addition measured after 40 mins by caliper motility shift assay,CC1CCCCN1C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(2-methylpiperidin-1-yl)but-2-en-1-one",0.003,uM,=,-2.5228787452803374,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
820,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,CC(=O)Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1,N-(4-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)phenyl)acetamide,25.1,uM,=,1.3996737214810382,1,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
821,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc(Cl)cc3)C2)cc1,"2-(5-(4-Chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",5.35,uM,=,0.7283537820212285,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
822,1526584,10.1021/acsmedchemlett.5b00193,,,,Inhibition of wild type EGFR phosphorylation in human A431 cells after 60 mins by mesoscale multiplex assay,C=CC(=O)Nc1cc(Nc2cncc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(6-(1-methyl-1H-indol-3-yl)pyrazin-2-ylamino)phenyl)acrylamide,0.348,uM,=,-0.4584207560534191,0,c1ccc(Nc2cncc(-c3c[nH]c4ccccc34)n2)cc1
823,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1[C@H](C)CCC[C@@H]1C,"(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-((2R,6S)-2,6-dimethylpiperidin-1-yl)but-2-enamide",0.079,uM,=,-1.1023729087095586,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
824,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CC(C)NC(CS(C)(=O)=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,Rac-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(1-(isopropylamino)-2-(methylsulfonyl)ethyl)furan-2-yl)quinazolin-4-amine,0.0392,uM,=,-1.4067139329795426,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
825,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,CCN(CC)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Diethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.073,uM,=,-1.136677139879544,0,c1ccc(Nc2ncnc3ccccc23)cc1
826,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1/C=C(\F)C(=O)NCCN1CCOCC1,3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-methylpyrimidin-5-yl)-2-fluoro-N-(2-morpholinoethyl)acrylamide,0.018,uM,=,-1.744727494896694,0,O=C(C=Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)NCCN1CCOCC1
827,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1ccc(Br)cc1Nc1ncnc2cc3c(cc12)OCCO3,"N-(5-Bromo-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.00763,uM,=,-2.11747546204512,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
828,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CC(C)(C)ONC(=O)Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O,"N-tert-Butoxy-2-(5-{[1-(2,5-dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-phenyl)-acetamide",31.0,uM,=,1.4913616938342726,1,C(=N/c1ccccc1)\c1ccccc1
829,2018691,10.1016/j.bmc.2020.115674,,,,Inhibition of EGFR-TK (unknown origin) relative to control,Cc1cc(NC2=NC(=O)/C(=C\c3c4ccccc4cc4ccccc34)S2)no1,5-((Anthracen-9-yl)methylidene)-2-((5-methylisoxazol-3-yl)amino)thiazol-4(5H)-one,0.054,uM,=,-1.2676062401770314,0,O=C1N=C(Nc2ccon2)S/C1=C/c1c2ccccc2cc2ccccc12
830,78513,10.1016/s0960-894x(02)01047-8,,,,Inhibition of EGFR overexpressing HN5 (Head and neck) tumor cell proliferation,CS(=O)(=O)CCNc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cs1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-{6-[2-(2-methanesulfonyl-ethylamino)-thiazol-4-yl]-quinazolin-4-yl}-amine,0.08,uM,=,-1.0969100130080565,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5cscn5)cc34)cc2)cc1
831,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)/C=C/CN(C)C)c2)n1,"N-(3-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-4-N,N-dimethylaminobut-2-enamide",10.02,uM,=,1.000867721531227,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
832,792378,10.1016/j.ejmech.2011.11.015,,,,Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis,COc1ccccc1-c1nnc(SCc2ccccc2)o1,"2-(Benzylthio)-5-(2-methoxyphenyl)-1,3,4-oxadiazole",12.32,uM,=,1.0906107078284066,1,c1ccc(CSc2nnc(-c3ccccc3)o2)cc1
833,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,Cl.NC1CCc2[nH]c3ccc(OCCc4ccc(O)cc4)cc3c2C1,"4-(2-(3-Amino-2,3,4,9-tetrahydro-1H-tetrahydrocarbazole-6-yloxy)ethyl)phenol hydrochloride",15.12,uM,=,1.1795517911651878,1,c1ccc(CCOc2ccc3[nH]c4c(c3c2)CCCC4)cc1
834,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,COc1cc(Nc2ncnc3ccc(-c4ccc(CNCCS(C)(=O)=O)o4)cc23)ccc1OCc1cccc(F)c1,N-(4-(3-fluorobenzyloxy)-3-methoxyphenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.1,uM,=,-1.0,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
835,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1ccc(OC)c(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c1,"N-(3-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide",12.8,uM,=,1.1072099696478683,1,c1ccc(Nc2nccc(-c3cnn4ccccc34)n2)cc1
836,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C(Nc1ccccc1)N(Cc1ccc(O)cc1)Cc1cc(Cl)cc(Cl)c1O,"1-(3,5-Dichloro-2-hydroxybenzyl)-1-(4-hydroxybenzyl)-3-phenylurea",1.86,uM,=,0.2695129442179163,1,O=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
837,608091,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 8 hrs by Western blot,O=C(Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)[C@@H]1O[C@H]1CN1CCCCC1,"(2R,3S)-N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-(piperidin-1-ylmethyl)oxirane-2-carboxamide",0.044,uM,=,-1.3565473235138126,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)[C@@H]1O[C@H]1CN1CCCCC1
838,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",Cc1cc(NS(=O)(=O)c2ccc(Nc3nncc4ccccc34)cc2)no1,N-(5-Methylisoxazol-3-yl)-4-(phthalazin-1-ylamino)benzenesulfonamide,0.13,uM,=,-0.8860566476931633,0,O=S(=O)(Nc1ccon1)c1ccc(Nc2nncc3ccccc23)cc1
839,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.114,uM,=,-0.9430951486635274,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
840,305999,10.1016/j.bmcl.2004.08.007,,,,Inhibitory concentration against Epidermal growth factor receptor tyrosine kinase activity,COc1cc2ncnc(Nc3ccc(C)c(NC(=O)c4ccccc4)c3)c2cc1OC,"N-[5-(6,7-Dimethoxy-quinazolin-4-ylamino)-2-methyl-phenyl]-benzamide",3.2,uM,=,0.505149978319906,1,O=C(Nc1cccc(Nc2ncnc3ccccc23)c1)c1ccccc1
841,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,N-(3-(2-(2-Methoxy-4-(4-methylpiperazin-1-yl)-phenylamino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.00382,uM,=,-2.417936637088291,0,O=c1cnc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
842,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,CCOc1cc2ncnc(Nc3cccc([N+](=O)[O-])c3)c2c2c1OCCO2,"5-Ethoxy-N-(3-nitrophenyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0096999999999999,uM,=,-2.0132282657337552,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
843,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(=O)c1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1,"1-(3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)ethanone",2.8,uM,=,0.4471580313422192,1,c1ccc(-c2n[nH]c3ncncc23)cc1
844,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Cc1cc(C)c(O)c(CN(Cc2ccc(O)cc2)C(=O)Nc2ccccc2)c1,"1-(2-Hydroxy-3,5-dimethylbenzyl)-1-(4-hydroxybenzyl)-3-phenylurea",9.26,uM,=,0.9666109866819343,1,O=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
845,946792,10.1016/j.bmc.2013.01.040,,,,Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA,Nc1nc(Nc2ccc(Cl)cc2F)c2c(n1)[nH]c1cccc(Cl)c12,"5-chloro-N4-(4-chloro-2-fluorophenyl)-9H-pyrimido[4,5-b]indole-2,4-diamine",38.9,uM,=,1.5899496013257075,1,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
846,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,COc1cc(NC(=O)Nc2nccs2)cc(-c2cccnc2)c1OC,"1-(3,4-Dimethoxy-5-(pyridin-3-yl)phenyl)-3-(thiazol-2-yl)urea",0.31712,uM,=,-0.4987763671948186,0,O=C(Nc1cccc(-c2cccnc2)c1)Nc1nccs1
847,2017706,10.1016/j.bmcl.2020.127557,,,,Inhibition of EGFR in human A549 cells measured after 30 hrs by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",5.182,uM,=,0.714497408649806,1,c1ccc(Nc2ncnc3ccccc23)cc1
848,800208,10.1016/j.bmcl.2011.12.067,,,,Inhibition of wild-type EGFR expressed using baculovirus expression system by ELISA,CN(C)c1nc(N/N=C/c2cc(Br)c(O)c(Br)c2O)nc(Nc2ccc(F)cc2)n1,"2,4-dibromo-6-((2-(4-(dimethylamino)-6-(4-fluorophenylamino)-1,3,5-triazin-2-yl)hydrazono)methyl)benzene-1,3-diol",25.9,uM,=,1.413299764081252,1,C(=N/Nc1ncnc(Nc2ccccc2)n1)\c1ccccc1
849,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,COCCOc1cc2ncnc(Nc3ccc(Cl)c([N+](=O)[O-])c3)c2c2c1OCCO2,"N-(4-Chloro-3-nitrophenyl)-5-(2-methoxyethoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0362,uM,=,-1.4412914294668342,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
850,1769420,10.1016/j.bmc.2018.02.023,,,,Inhibition of EGFR (unknown origin) using peptide substrate after 60 mins by HTRF assay,Cc1ccc(/C=N/NC(=O)N2CCc3ncnc(Nc4cccc(C(F)(F)F)c4)c3C2)cc1,"(E)-N'-(4-methylbenzylidene)-4-((3-(trifluoromethyl)phenyl)amino)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carbohydrazide",0.0242,uM,=,-1.616184634019569,0,O=C(N/N=C/c1ccccc1)N1CCc2ncnc(Nc3ccccc3)c2C1
851,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3cccc(C(=O)NCCN(C)C)c3)cc12)c1ccccc1,"(R)-N-(2-(Dimethylamino)ethyl)-3-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzamide",0.0009,uM,=,-3.0457574905606752,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
852,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CN1CCN(CC(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3s2)CC1,"N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-2-(4-methylpiperazin-1-yl)acetamide",3.399,uM,=,0.5313511645830598,1,O=C(CN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
853,2270910,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) incubated for 1 hrs in presence of ATP by ELISA assay,Cc1ccc(NC(=O)CSc2nc3cc4ccccc4cc3c(=O)n2-c2ccc(S(N)(=O)=O)cc2)cc1C,"N-(3,4-dimethylphenyl)-2-((4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydrobenzo[g]quinazolin-2-yl)thio)acetamide",3.9,uM,=,0.5910646070264992,1,O=C(CSc1nc2cc3ccccc3cc2c(=O)n1-c1ccccc1)Nc1ccccc1
854,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.217,uM,=,-0.6635402661514705,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
855,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CS(=O)(=O)CCNCc1cc(-c2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)cs1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)thiophen-3-yl)thieno[3,2-d]pyrimidin-4-amine",0.003,uM,=,-2.5228787452803374,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5ccsc5)sc34)cc2)cc1
856,66899,10.1016/s0960-894x(99)00188-2,,,,In vitro activity against Epidermal growth factor receptor (using poly(Glu4Tyr1) as a substrate),CNN1C(=O)c2c(c3c4cccc(O)c4n(C4OC(CO)C(O)C(O)C4O)c3c3[nH]c4c(O)cccc4c23)C1=O,"1,11-dihydroxy-6-methylamino-12-(3,4,5-trihydroxy-6-hydroxymethyltetrahydro-2H-2-pyranyl)-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione",100.0,uM,=,2.0,1,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1c2c2ccccc2n1C1CCCCO1
857,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)N1CCC(N2CCCC2)CC1,(S)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(pyrrolidin-1-yl)piperidine-1-carboxamide,0.265,uM,=,-0.5767541260631921,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1)N1CCC(N2CCCC2)CC1
858,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1ccc([N+](=O)[O-])c(O)c1,2-(3-Hydroxy-4-nitro-benzylidene)-malononitrile,450.0,uM,=,2.6532125137753435,1,c1ccccc1
859,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,CCc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cnc2[nH]ccc2c1,"N-(2-Ethyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-pyrrolo[2,3-b]-pyridine-5-carboxamide",0.099,uM,=,-1.00436480540245,0,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(NC(=O)c2cnc3[nH]ccc3c2)c1
860,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2n1,"1-isopropyl-3-(2-methylquinolin-7-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",18.0,uM,=,1.255272505103306,1,c1cnc2cc(-c3n[nH]c4ncncc34)ccc2c1
861,982643,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0399,uM,=,-1.3990271043132518,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
862,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Brc1ccc2c(c1)CNc1c(Nc3ccccc3)ncnc1O2,"(8-Bromo-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-phenyl-amine",10.0,uM,=,1.0,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
863,1891470,10.1016/j.bmc.2019.03.049,,,,Inhibition of c-MET (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins by mobility shift assay,COc1cc2c(Oc3ccc(C4SCC(=O)N4NC(=O)Nc4ccccc4F)cc3)ccnc2cc1OCCCN1CCOCC1,1-(2-fluorophenyl)-3-(2-(4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)oxy)phenyl)-4-oxothiazolidin-3-yl)urea,4.1,uM,=,0.6127838567197355,1,O=C(Nc1ccccc1)NN1C(=O)CSC1c1ccc(Oc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1
864,1553877,10.1016/j.ejmech.2016.01.045,,,,Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay,COCCOc1cc2ncnc(Nc3ccc(NC(=O)C45CC6CC(CC(C6)C4)C5)c(C)c3)c2cc1OCCOC,"N-(4-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)amino)-2-methylphenyl)adamantane-1-carboxamide",0.00292,uM,=,-2.5346171485515816,0,O=C(Nc1ccc(Nc2ncnc3ccccc23)cc1)C12CC3CC(CC(C3)C1)C2
865,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Cc1cc(C)c(O)c(CN(Cc2ccc(F)cc2)C(=S)Nc2ccccc2)c1,"1-(4-Fluorobenzyl)-1-(2-hydroxy-3,5-dimethylbenzyl)-3-phenylthiourea",19.41,uM,=,1.2880255353883627,1,S=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
866,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,O=C(O)c1ccccc1Nc1nc(Nc2ccc(OCC(=O)N3CCOCC3)cc2)ncc1Cl,2-(5-chloro-2-(4-(2-morpholino-2-oxoethoxy)phenylamino)pyrimidin-4-ylamino)benzoic acid,0.0814,uM,=,-1.0893755951107988,0,O=C(COc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)N1CCOCC1
867,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,CNc1cc2c(Nc3cccc(Cl)c3)ncnc2cn1,"N*4*-(3-Chloro-phenyl)-N*6*-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.00019,uM,=,-3.721246399047171,0,c1ccc(Nc2ncnc3cnccc23)cc1
868,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1ccc(Br)cc1)NS(=O)(=O)c1ccc(F)cc1,2-(4-Bromophenyl)-N-(4-fluorophenylsulfonyl)acetamide,14.53,uM,=,1.1622656142980214,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
869,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCC(=O)NO,4-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxybutanamide,0.0078,uM,=,-2.10790539730952,0,c1ccc(Nc2ncnc3ccccc23)cc1
870,554997,10.1021/jm8001185,,,,Inhibition of human recombinant EGFR,COc1cc(C2=C(c3cn(COC(C)(C)C)c4ccccc34)CNC2=O)cc(OC)c1OC,"4-[1-(tert-Butoxymethyl)-1H-indol-3-yl]-3-(3,4,5-trimethoxyphenyl)-1,5-dihydro-2H-pyrrole-2-one",9.0,uM,=,0.9542425094393248,1,O=C1NCC(c2c[nH]c3ccccc23)=C1c1ccccc1
871,1500854,10.1016/j.bmc.2015.04.065,,,,Inhibition of recombinant EGFR (unknown origin) assessed as inhibition of autophosphorylation after 1 hr by DELFIA/Time-resolved fluorometry,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)S/C1=C/c1cccc(Br)n1,"(S,E)-1-(5-((6-Bromopyridin-2-yl)methylene)-4-oxo-4,5-dihydrothiazol-2-yl)-N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)pyrrolidine-2-carboxamide",3.1,uM,=,0.4913616938342727,1,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)S/C1=C/c1ccccn1
872,1642166,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",2.6,uM,=,0.414973347970818,1,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
873,1368552,10.1021/jm500034j,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of [32P] gamma-ATP in to myelin basic protein after 30 mins by autoradiographic analysis,c1ccc(-c2cccc(Nc3ncnc4cc5c(cc34)OCCO5)c2)cc1,"N-(biphenyl-3-yl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine",0.042,uM,=,-1.3767507096020994,0,c1ccc(-c2cccc(Nc3ncnc4cc5c(cc34)OCCO5)c2)cc1
874,1641793,,,,,"Cell Proliferation Inhibition Assay: The following in vitro assay is to determine the activity of the tested compounds for inhibiting the proliferation of cancer cells, which has high expression of EGFR. The activity is represented by the IC50 value. The general procedures of the assay are given as follows: The cancer cells A431 that highly expressing EGFR (Institute of biochemistry and cell biology) were chosen and seeded to 96-well cell culture plate at a suitable concentration (e.g., 5000 cells/mL medium). The cells then were incubated in carbon dioxide (CO2) incubator until they reached 85% confluency. Then, the cell culture medium was replaced by fresh one with tested compounds added in it at serial concentrations (general 6 to 7 concentrations). Then the cells were put back to the incubator and cultured continuously. 72 hours later, the activity of the tested compounds for inhibiting the cell proliferation was determined by using Sulforhodamine B (SRB) method.",CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,PYROTINIB,0.045,uM,=,-1.3467874862246565,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2nccc(Nc3ccc(OCc4ccccn4)cc3)c2c1
875,305333,10.1021/jm058205b,,,,Inhibition of epidermal growth factor receptor,OCCCCNc1cncc(-c2cncc(Nc3cccc(Cl)c3)n2)c1,4-{5-[6-(3-Chloro-phenylamino)-pyrazin-2-yl]-pyridin-3-ylamino}-butan-1-ol,7.4,uM,=,0.8692317197309762,1,c1ccc(Nc2cncc(-c3cccnc3)n2)cc1
876,1338416,10.1016/j.ejmech.2014.01.018,,,,Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,CCOC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CC(C)(C)C2)C1c1c(C)nn(-c2ccc(C)cc2)c1Cl,"Ethyl 2-amino-4-(5-chloro-3-methyl-1-p-tolyl-1H-pyrazol-4-yl)-7,7-dimethyl-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",0.51,uM,=,-0.2924298239020636,0,O=C1CCCC2=C1C(c1cnn(-c3ccccc3)c1)C=CN2c1cccnc1
877,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1OC,"1-cyclopentyl-3-(4-ethoxy-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
878,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc(Sc4ncc(-c5ccccc5)s4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(5-phenyl-thiazol-2-ylsulfanyl)-phenylamino]-3-cyano-7-methoxy-quinolin-6-yl}-amide,0.032,uM,=,-1.494850021680094,0,c1ccc(-c2cnc(Sc3ccc(Nc4ccnc5ccccc45)cc3)s2)cc1
879,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCOc1cc2ncnc(C#Cc3nccn3-c3ccccc3)c2cc1OCC,"6,7-diethoxy-4-(2-(1-phenyl-1H-imidazol-2-yl)ethynyl)quinazoline",0.012,uM,=,-1.9208187539523751,0,C(#Cc1nccn1-c1ccccc1)c1ncnc2ccccc12
880,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cccc(C#CCCO)c3)c2cc1OC,"4-(3-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)but-3-yn-1-ol",0.4021,uM,=,-0.3956659268970889,0,c1ccc(Nc2ncnc3ccccc23)cc1
881,1541778,10.1016/j.bmc.2015.12.001,,,,Inhibition of wild-type EGFR tyrosine kinase (unknown origin) assessed as ATP level by luminescence analysis,CN1CCN(Cc2ccc(NC(=O)Nc3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)cc2)CC1,1-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)phenyl)urea,0.0084,uM,=,-2.0757207139381184,0,O=C(Nc1ccc(CN2CCNCC2)cc1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
882,665430,10.1016/j.bmcl.2010.08.079,,,,Inhibition of EGFR,Nc1ccc2c(c1)C(c1ccccc1Cl)=Nc1c[nH]nc1N2,"5-(2-chlorophenyl)-2,10-dihydrobenzo[e]pyrazolo[4,3-b][1,4]diazepin-7-amine",0.989,uM,=,-0.0048037084028205,0,c1ccc(C2=Nc3c[nH]nc3Nc3ccccc32)cc1
883,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(C=C(C#N)C#N)cc(CSc2ccccc2)c1O,2-(4-Hydroxy-3-methoxy-5-phenylsulfanylmethyl-benzylidene)-malononitrile,370.0,uM,=,2.568201724066995,1,c1ccc(CSc2ccccc2)cc1
884,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CS(=O)(=O)CCNCc1ccc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)o1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)thieno[2,3-d]pyrimidin-4-amine",0.012,uM,=,-1.9208187539523751,0,c1ccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2)cc1
885,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,CCOc1cc2ncc(C#N)c(Nc3cccc(Br)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,1.6,uM,=,0.2041199826559248,1,c1ccc(Nc2ccnc3ccccc23)cc1
886,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,COc1ccc(Nc2ncc3ncc(=O)n(-c4cccc(NC(=O)/C=C/CN(C)C)c4)c3n2)cc1,(E)-4-(Dimethylamino)-N-(3-(2-(4-methoxyphenylamino)-7-oxopteridin-8(7H)-yl)phenyl)but-2-enamide,26.283,uM,=,1.4196749350538724,1,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
887,67206,10.1021/jm010496a,,,,Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase,CCOc1cc2nc(CC)nc(Nc3cccc(-c4csc(C)n4)c3)c2cc1OCC,"(6,7-Diethoxy-2-ethyl-quinazolin-4-yl)-[3-(2-methyl-thiazol-4-yl)-phenyl]-amine",9.3,uM,=,0.9684829485539352,1,c1cc(Nc2ncnc3ccccc23)cc(-c2cscn2)c1
888,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,COc1cc2ncnc(C#Cc3ccccc3-c3ccccc3)c2cc1OC,"4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline",0.026,uM,=,-1.585026652029182,0,C(#Cc1ncnc2ccccc12)c1ccccc1-c1ccccc1
889,2260086,10.1016/j.ejmech.2020.112904,,,,Inhibition of EGFR wildtype (unknown origin) incubated for 40 mins in presence of ATP,COc1cc(NC(=O)CCCCCCC(=O)NO)ccc1Nc1nccc(-c2cn(C)c3ccccc23)n1,8-(hydroxyamino)-N-[3-methoxy-4-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]-8-oxo-octanamide,5.9,uM,=,0.7708520116421442,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
890,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,CN(C)C/C=C/C(=O)Nc1cccc(Oc2nc(Nc3n[nH]c4ccccc34)cc(N3CCN(C)CC3)n2)c1,N-(3-(4-(1H-indazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-yloxy)phenyl)-4-(dimethylamino)but-2-enamide,6.7,uM,=,0.8260748027008264,1,c1ccc(Oc2nc(Nc3n[nH]c4ccccc34)cc(N3CCNCC3)n2)cc1
891,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,COc1cc(/C=C(\C#N)C(=O)O)ccc1O,2-Cyano-3-(4-hydroxy-3-methoxy-phenyl)-acrylic acid,325.0,uM,=,2.5118833609788744,1,c1ccccc1
892,1566936,10.1021/acs.jmedchem.5b01633,,,,Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA,C#CCCn1cc(Nc2nc(OC[C@H]3CN(C(=O)C=C)C[C@@H]3OC)c3c(Cl)c[nH]c3n2)cn1,"1-((3R,4R)-3-(((2-((1-(But-3-yn-1-yl)-1H-pyrazol-4-yl)amino)-5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)-4-methoxypyrrolidin-1-yl)prop-2-en-1-one",4.2,uM,=,0.6232492903979004,1,c1cc2c(OC[C@@H]3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1
893,2052738,10.1016/j.ejmech.2019.111966,,,,Inhibition of wild type N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus infected Sf21 cells using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km concentration and further incubated for 20 mins by HTRF assay,C=CC(=O)Nc1ccc(OC)c(Nc2cc(-n3c(SC)nnc3-c3ccc(F)cc3)ccn2)c1,"N-[3-[[4-[3-(4-fluorophenyl)-5-methylsulfanyl-1,2,4-triazol-4-yl]-2-pyridyl]amino]-4-methoxy-phenyl]prop-2-enamide",0.1788,uM,=,-0.7476324855401011,0,c1ccc(Nc2cc(-n3cnnc3-c3ccccc3)ccn2)cc1
894,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Nc1ccc2cncnc2c1,Quinazolin-7-ylamine,0.0001,uM,=,-4.0,0,c1ccc2ncncc2c1
895,1798716,10.1016/j.ejmech.2017.03.083,,,,"Inhibition of wild type N-terminal GST tagged human recombinant EGFR (695 to end amino acids) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) Peptide substrate by ADP-Glo assay",C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(OCC(=O)N3CCOCC3)cc2)ncc1Cl,N-(2-(5-chloro-2-(4-(2-morpholino-2-oxoethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide,0.1429,uM,=,-0.8449677712090298,0,O=C(COc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)N1CCOCC1
896,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(S(=O)(=O)Nc4ccccn4)cc3)c2c1,N-(4-(4-(N-pyridin-2-ylsulfamoyl)phenylamino)quinazolin-6-yl)acrylamide,9.8,uM,=,0.9912260756924948,1,O=S(=O)(Nc1ccccn1)c1ccc(Nc2ncnc3ccccc23)cc1
897,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,COc1cccc2ncnc(Nc3cccc(Br)c3)c12,(3-Bromo-phenyl)-(5-methoxy-quinazolin-4-yl)-amine,0.139,uM,=,-0.8569851997459049,0,c1ccc(Nc2ncnc3ccccc23)cc1
898,2074610,10.1016/j.bmc.2020.115680,,,,Inhibition of wild type EGFR (unknown origin) in presence of ATP preincubated 5 mins measured for 30 mins by detection reagent based HTRF analysis,C=C(Cl)C(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)-2-chloroacrylamide,0.257,uM,=,-0.5900668766687055,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
899,1714364,10.1016/j.bmc.2018.05.039,,,,"Inhibition of wild type EGFR (unknown origin) using Poly(Glu,Tyr) as substrate after 40 mins by Kinase-Glo luminescence assay",C=CC(=O)N[C@@H]1CCN(c2nc(Nc3ccccc3)nc3cnc(Nc4ccc(N5CCN(C)CC5)cn4)cc23)C1,"(R)-N-(1-(6-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-2-(phenylamino)pyrido[3,4-d]pyrimidin-4-yl)pyrrolidin-3-yl)acrylamide",0.0027,uM,=,-2.5686362358410126,0,c1ccc(Nc2nc(N3CCCC3)c3cc(Nc4ccc(N5CCNCC5)cn4)ncc3n2)cc1
900,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,Cc1cc(Nc2ncnc3cc(O)c(NC(=O)/C=C/[C@H]4CCCN4C)cc23)ccc1Oc1cnc2ccnn2c1,"(E)-N-[7-hydroxy-4-(3-methyl-4-pyrazolo[1,5-a]pyrimidin-6-yloxy-anilino)quinazolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide",0.00103,uM,=,-2.987162775294828,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4cnc5ccnn5c4)cc3)c2c1
901,1842432,10.1016/j.ejmech.2019.03.004,,,,Inhibition of EGFR (unknown origin),C=CC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OCCN4CCOCC4)cc23)cc1,N-(4-(7-methoxy-6-(2-morpholinoethoxy)quinazolin-4-ylamino)phenyl)acrylamide,0.105,uM,=,-0.978810700930062,0,c1ccc(Nc2ncnc3ccc(OCCN4CCOCC4)cc23)cc1
902,1979311,10.1021/acsmedchemlett.9b00561,,,,Inhibition of EGFR (unknown origin),C#Cc1cccc(Nc2cccc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1,7-(8-(3-ethynylphenylamino)-3-methoxynaphthalen-2-yloxy)-N-hydroxyheptanamide,0.0024,uM,=,-2.619788758288394,0,c1ccc(Nc2cccc3ccccc23)cc1
903,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccccc3F)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(2-fluorobenzylidene)cyclohexanone",2.1,uM,=,0.3222192947339193,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
904,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCc1c(NC(=O)OCCn2ccnc2)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"[4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid 2-imidazol-1-yl-ethyl ester",0.04,uM,=,-1.3979400086720375,0,O=C(Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnn2c1)OCCn1ccnc1
905,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Oc1c(Cl)cccc1CN(Cc1ccc(F)cc1)C(=S)Nc1ccccc1,1-(5-Chloro-2-hydroxybenzyl)-1-(4-fluorobenzyl)-3-phenylthiourea,0.67,uM,=,-0.1739251972991735,0,S=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
906,2074183,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.01292,uM,=,-1.8887374863409347,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
907,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1cc(O)ccc1O)C(=O)O,"trans-2-cyano-3-(2,5-dihydroxyphenyl)acrylic acid",20.0,uM,=,1.3010299956639813,1,c1ccccc1
908,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc(Br)cc3)C2)cc1,"2-(5-(4-bromophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",5.56,uM,=,0.7450747915820575,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
909,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#Cc1ccc(CN2CCOCC2)cc1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-((4-(morpholinomethyl)phenyl)ethynyl)pyrimidin-4-amine,0.24,uM,=,-0.619788758288394,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccc(CN2CCOCC2)cc1
910,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(C)c(Br)c3)ncnc2cc1OCCOCCOCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-(2-{2-[2-({4-[(3-Bromo-4-methylphenyl)amino]-6-methoxy-quinazolin-7-yl}oxy)ethoxy]ethoxy}ethyl)-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.00624,uM,=,-2.204815410317576,0,O=C(Cn1cncn1)NCCOCCOCCOc1ccc2c(Nc3ccccc3)ncnc2c1
911,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,COc1cc(N(C)CCN(C)C)c(NC(=O)/C=C\C(C)C)cc1Nc1ncc(C#N)c(-c2cn(C)c3ccc(F)cc23)n1,(Z)-N-(5-((5-cyano-4-(5-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)-4-methylpent-2-enamide,0.415,uM,=,-0.3819519032879073,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
912,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,Fc1ccc(NC(=S)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)cc1Cl,1-(4-((3-Bromophenyl)amino)quinazolin-6-yl)-3-(3-chloro-4-fluorophenyl)thiourea,0.0253,uM,=,-1.596879478824182,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
913,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,c1cc(Nc2ccc3[nH]ccc3c2)c2sc(-c3ccc(CN4CCOCC4)cc3)cc2n1,"(1H-Indol-5-yl)-[2-(4-morpholin-4-ylmethyl-phenyl)-thieno[3,2-b]pyridin-7-yl]-amine",0.03,uM,=,-1.5228787452803376,0,c1cc(Nc2ccc3[nH]ccc3c2)c2sc(-c3ccc(CN4CCOCC4)cc3)cc2n1
914,566595,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by SPA assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Oc5ccccn5)c(Cl)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(3-chloro-4-(pyridin-2-yloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.19,uM,=,-0.721246399047171,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Oc5ccccn5)cc4)c3s2)C1)N1CCOCC1
915,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),C[C@H](Nc1ncnc2c1sc1ccccc12)c1ccccc1,"(S)-Benzo[4,5]thieno[3,2-d]pyrimidin-4-yl-(1-phenyl-ethyl)-amine",0.538,uM,=,-0.2692177243336108,0,c1ccc(CNc2ncnc3c2sc2ccccc23)cc1
916,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CC(COC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O)Cc1ccccc1,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 2-methyl-3-phenyl-propyl ester",3.5,uM,=,0.5440680443502757,1,O=C(OCCCc1ccccc1)c1cccc(NCc2ccccc2)c1
917,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1.O,Tykerb,0.01,uM,=,-2.0,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1.c1ccccc1.c1ccccc1
918,1774204,10.1016/j.ejmech.2018.02.080,,,,Inhibition of recombinant human EGFR using peptide as substrate by fluorimetric analysis,O=C1Nc2ccccc2/C1=C/c1ccc(-c2cccs2)s1,"3-[2,2']Bithiophenyl-5-ylmethylene-1,3-dihydro-indol-2-one",10.1,uM,=,1.0043213737826426,1,O=C1Nc2ccccc2/C1=C/c1ccc(-c2cccs2)s1
919,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Oc3ccc(NC(=O)/C=C/CN(C)C)cc3)n2)n[nH]1,4-(dimethylamino)-N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-yloxy)phenyl)but-2-enamide,1.7,uM,=,0.2304489213782739,1,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1
920,63616,10.1016/S0960-894X(97)00034-6,,,,Inhibition of Epidermal growth factor receptor autophosphorylation.,COc1cc2ncnc(Nc3ccc4c(c3)CCC4)c2cc1OC.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-indan-5-yl-amine hydrochloride, 1.4 M H2O",0.6,uM,=,-0.2218487496163563,0,c1ccc2c(Nc3ccc4c(c3)CCC4)ncnc2c1
921,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4cnn(CCN(C)C)c4)nc32)c1,"N-(3-(2-((1-(2-(Dimethylamino)ethyl)-1H-pyrazol-4-yl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.4447,uM,=,-0.3519328705510653,0,O=c1ccc2cnc(Nc3cn[nH]c3)nc2n1-c1ccccc1
922,792073,10.1016/j.bmc.2011.10.085,,,,Inhibition of EGFR expressed in baculovirus infected Sf9 cells assessed as inhibition of autophosphorylation preincubated for 10 mins measured after 1 hr by DELFIA/Time-Resolved Fluorometry,Oc1ccccc1CNc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,2-((4-(3-Chlorophenylamino)quinazolin-6-ylamino)methyl)phenol,3.54,uM,=,0.5490032620257879,1,c1ccc(CNc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
923,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(C#CCC3CCCC3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(3-cyclopentylprop-1-yn-1-yl)-1H-pyrazolo-[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.75,uM,=,-0.1249387366082999,0,C(#Cc1nn([C@@H]2CCCNC2)c2ncncc12)CC1CCCC1
924,1769420,10.1016/j.bmc.2018.02.023,,,,Inhibition of EGFR (unknown origin) using peptide substrate after 60 mins by HTRF assay,O=C(N/N=C/c1cc(F)c(F)cc1Cl)N1CCc2ncnc(Nc3ccc(F)c(Cl)c3)c2C1,"(E)-N'-(2-chloro-4,5-difluorobenzylidene)-4-((3-chloro-4-fluorophenyl)amino)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carbohydrazide",0.0423,uM,=,-1.3736596326249575,0,O=C(N/N=C/c1ccccc1)N1CCc2ncnc(Nc3ccccc3)c2C1
925,676221,10.1021/jm100607r,,,,Inhibition of EGFR,CN(C)C/C=C/C(=O)N1CCc2c(sc3ncnc(NCCO)c23)C1,"(E)-4-(Dimethylamino)-1-4-[(2-hydroxyethyl)amino]-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl-2-buten-1-one",4.884,uM,=,0.6887756552728449,1,c1ncc2c3c(sc2n1)CNCC3
926,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CC[C@H](C(N)=O)C1,(S)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidine-3-carboxamide,0.15,uM,=,-0.8239087409443188,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
927,982642,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis,O=C(COc1c(F)c(F)c(F)c(F)c1F)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(perfluorophenoxy)-acetamide,0.118,uM,=,-0.9281179926938746,0,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
928,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,COc1ccc(-c2cc3c(NCc4ccccc4)ncnc3o2)cc1,"N-Benzyl-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-amine",0.074,uM,=,-1.1307682802690238,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
929,66897,10.1021/jm970367n,,,,Inhibition of Epidermal growth factor receptor (EGFr) tyrosine kinase,Cc1cc(C)c(C)c(-c2cc3cnc(NCCCN4CCN(C)CC4)nc3nc2NC(=O)NC(C)(C)C)c1C,"1-tert-Butyl-3-[2-[3-(4-methyl-piperazin-1-yl)-propylamino]-6-(2,3,5,6-tetramethyl-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-urea",7.0,uM,=,0.8450980400142568,1,c1ccc(-c2cnc3nc(NCCCN4CCNCC4)ncc3c2)cc1
930,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,O[C@@H]1CNCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,"(R)-1-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)-1,4-diazepan-6-ol",0.2,uM,=,-0.6989700043360187,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)cc1
931,331141,10.1016/j.bmcl.2005.08.115,,,,Inhibitory activity against EGFR kinase,COC(=O)c1c(OCCN(C)C)c2ccccc2c2oc3c(c12)C(=O)c1ccccc1C3=O,"5-(2-dimethylamino-ethoxy)-7,12-dioxo-7,12-dihydro-dinaphtho[1,2-b;2',3'-d]furan-6-carboxylic acid methylester",31.0,uM,=,1.4913616938342726,1,O=C1c2ccccc2C(=O)c2c1oc1c2ccc2ccccc21
932,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,Cc1ccc(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)cc1,"3-(3,4-Dihydroxy-phenyl)-2-(4-methyl-benzoyl)-acrylonitrile",0.9,uM,=,-0.0457574905606751,0,O=C(/C=C/c1ccccc1)c1ccccc1
933,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,O=C(NO)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)-N-hydroxyfuran-2-carboxamide,0.0039,uM,=,-2.408935392973501,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
934,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3cc(Cl)c(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,"4-Dimethylamino-but-2-enoic acid {3-cyano-4-[3,5-dichloro-4-(3-fluoro-benzyloxy)-phenylamino]-7-ethoxy-quinolin-6-yl}-amide",0.362,uM,=,-0.4412914294668343,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
935,792073,10.1016/j.bmc.2011.10.085,,,,Inhibition of EGFR expressed in baculovirus infected Sf9 cells assessed as inhibition of autophosphorylation preincubated for 10 mins measured after 1 hr by DELFIA/Time-Resolved Fluorometry,Oc1ccccc1CNc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,2-((4-(3-Bromophenylamino)quinazolin-6-ylamino)methyl)phenol,3.22,uM,=,0.5078558716958309,1,c1ccc(CNc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
936,661840,10.1016/j.bmc.2010.05.049,,,,Inhibition of EGFR expressed in human A431 cells,CN(c1cccc(Br)c1)c1nc(N)nc2c1cc(Cc1ccccc1)n2C,"2-Amino-4-(N-methyl-m-bromoanilino)-6-benzyl-7-methyl-pyrrolo[2,3-d]pyrimidine",253.6,uM,=,2.404149249209695,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
937,2296008,10.1021/acsmedchemlett.3c00006,,,,Inhibition of recombinant human EGFR del19/T790M using biotinEEPLYWSFPAKKK-NH2 as substrate incubated for 120 mins by TR-FRET assay,C=CC(=O)N1CC[C@H](n2nc(-c3cnc4ccccc4c3)c3c(N)ncnc32)C1,"(S)-1-(3-(4-amino-3-(quinolin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one",0.741,uM,=,-0.1301817920206718,0,c1ccc2ncc(-c3nn([C@H]4CCNC4)c4ncncc34)cc2c1
938,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,NC(=O)CN1CCC(n2cc(-c3cccc(O)c3)c3c(N)ncnc32)C1,"2-{3-[4-Amino-5-(3-hydroxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-pyrrolidin-1-yl}-acetamide",0.4,uM,=,-0.3979400086720376,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1
939,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21,"US9447106, 33",0.0007199999999999,uM,=,-3.1426675035687315,0,c1ccc(Oc2ccc(-c3cc4n(n3)CCCN4)cc2)cc1
940,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4ccccn4)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)acrylamide,0.1349,uM,=,-0.8699880503280958,0,c1ccc(COc2ccc(Nc3ncnc4cc(O[C@H]5CCOC5)ccc34)cc2)nc1
941,933957,10.1016/j.bmcl.2012.12.028,,,,Inhibition of EGFR (unknown origin) in presence of ATP,COc1ccccc1CNc1ncc(C(=O)NC2CCN(C)CC2)c(NC2CCCC2)n1,4-(cyclopentylamino)-2-(2-methoxybenzylamino)-N-(1-methylpiperidin-4-yl)pyrimidine-5-carboxamide,30.0,uM,=,1.4771212547196624,1,O=C(NC1CCNCC1)c1cnc(NCc2ccccc2)nc1NC1CCCC1
942,1515019,10.1016/j.ejmech.2015.07.030,,,,Inhibition of epidermal growth factor receptor kinase (unknown origin) using [33P]-ATP after 20 to 30 mins by radiometric assay,N#Cc1cnc2ccc(NCc3c[nH]cn3)cc2c1Nc1ccc(F)c(Cl)c1,6-((1H-imidazol-4-yl)methylamino)-4-(3-chloro-4-fluorophenylamino)quinoline-3-carbonitrile,0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ccnc3ccc(NCc4c[nH]cn4)cc23)cc1
943,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COc1cc(/C=C(\C#N)C(N)=C(C#N)C#N)cc(O)c1O,"3-Amino-2,4-dicyano-5-(3,4-dihydroxy-5-methoxy-phenyl)-penta-2,4-dienenitrile",1.0,uM,=,0.0,0,c1ccccc1
944,2127056,10.1016/j.bmcl.2021.128118,,,,Inhibition of recombinant wild type EGFR-TK (unknown origin) by ELISA,COc1cc2cccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,Cabozantinib,3.11,uM,=,0.4927603890268375,1,O=C(Nc1ccccc1)C1(C(=O)Nc2ccc(Oc3cccc4ccccc34)cc2)CC1
945,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc(F)c(F)c4)c3cc21,"Ethyl 4-(8-(3,4-difluorophenylamino)-2-oxooxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",0.14,uM,=,-0.8538719643217619,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
946,1298902,10.1039/C3MD00301A,,,,Inhibition of EGFR (unknown origin),COc1cc(Nc2nccc(-c3ccc(Cl)cc3)n2)cc(OC)c1OC,"4-(4-chlorophenyl)-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine",2.145,uM,=,0.331427296520743,1,c1ccc(Nc2nccc(-c3ccccc3)n2)cc1
947,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,CCN(c1ccc(OC)cc1)c1nc(C)nc2oc(C)cc12,"N-Ethyl-N-(4-methoxyphenyl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine",0.0707,uM,=,-1.1505805862031009,0,c1ccc(Nc2ncnc3occc23)cc1
948,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(F)cc3)ncnc2cc1OCCOCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-{2-[2-({4-[(4-Fluorophenyl)amino]-6-methoxyquinazolin-7-yl}oxy)ethoxy]ethyl}-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.01643,uM,=,-1.7843624365649382,0,O=C(Cn1cncn1)NCCOCCOc1ccc2c(Nc3ccccc3)ncnc2c1
949,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(CCCc3ccccc3)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1,"N-(3-(7-((4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-2,4-dioxo-3-(3-phenylpropyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.0038,uM,=,-2.42021640338319,0,O=c1c2cnc(Nc3ccc(N4CCCCC4)cc3)nc2n(-c2ccccc2)c(=O)n1CCCc1ccccc1
950,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"(E)-1-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7, 8-dihydro-6H-[1, 4]oxazino[3,2-g]quinazolin-6-yl)-4-(dimethylamino)but-2-en-1-one",0.126,uM,=,-0.8996294548824371,0,c1ccc(COc2ccc(Nc3ncnc4cc5c(cc34)NCCO5)cc2)cc1
951,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(OCc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid benzyl ester",2.5,uM,=,0.3979400086720376,1,O=C(OCc1ccccc1)c1cccc(NCc2ccccc2)c1
952,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,Brc1cccc(Nc2ncnc3cnc(NCc4cccnc4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-pyridin-3-ylmethyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2ncnc3cnc(NCc4cccnc4)cc23)cc1
953,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,Nc1cc(Br)ccc1NC(=O)COc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-(2-amino-4-bromophenyl)-2-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yloxy)acetamide,0.1,uM,=,-1.0,0,O=C(COc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1ccccc1
954,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc([N+](=O)[O-])c2)n1,5-Chloro-N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)-4-(3-nitrophenoxy)pyrimidin-2-amine,23.57,uM,=,1.3723595825243238,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
955,1829742,10.1021/acs.jmedchem.8b01612,,,,Inhibition of wild type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system after 1 hr in presence of ULight-labeled peptide substrate and ATP by LANCE ultra kinase assay,COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1OCCCN1CCNCCNCCNCC1,"6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-methoxyquinazolin-4-amine",0.0014,uM,=,-2.853871964321762,0,c1ccc(COc2ccc(Nc3ncnc4ccc(OCCCN5CCNCCNCCNCC5)cc34)cc2)cc1
956,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,O=c1oc2cc3ncnc(Nc4ccc(F)c(F)c4)c3cc2n1CCCN1CCOCC1,"8-(3,4-Difluorophenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.57,uM,=,-0.2441251443275086,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
957,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)cc3O)c2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)-2-hydroxyphenyl]-7'-methoxy-6'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,0.23,uM,=,-0.6382721639824072,0,c1ccc2sc(-c3ccc(Nc4ncnc5ccc(OCCCN6CCNCC6)cc45)cc3)nc2c1
958,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",Brc1cccc(Nc2ncnc3cnc(NCCCn4ccnc4)nc23)c1,"N*8*-(3-Bromo-phenyl)-N*2*-(3-imidazol-1-yl-propyl)-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.0023,uM,=,-2.638272163982407,0,c1ccc(Nc2ncnc3cnc(NCCCn4ccnc4)nc23)cc1
959,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,CCNC(=O)Nc1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c2c1,1-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)quinazolin-6-yl)-3-ethylurea,0.029,uM,=,-1.537602002101044,0,c1ccc(Oc2ccc(Nc3ncnc4ccccc34)cc2)cc1
960,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,OCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,"2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethanol",0.034,uM,=,-1.4685210829577449,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
961,512831,10.1016/j.bmcl.2008.07.057,,,,Inhibition of EGFR,Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)Nc1ccccc1,4-amino-6-(4-(benzyloxy)-3-chlorophenylamino)-N-phenylpyrimidine-5-carboxamide,0.076,uM,=,-1.1191864077192086,0,O=C(Nc1ccccc1)c1cncnc1Nc1ccc(OCc2ccccc2)cc1
962,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CN1CCN(Cc2ccc(C(=O)Nc3ccc(-c4cncc(C#N)c4Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)cc3)cc2)CC1,N-(4-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-5-cyanopyridin-3-yl)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide,2.5,uM,=,0.3979400086720376,1,O=C(Nc1ccc(-c2cnccc2Nc2ccc(OCc3ccccc3)cc2)cc1)c1ccc(CN2CCNCC2)cc1
963,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CCOc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc(C)cc2)c1O,2-cyano-3-(3-ethoxy-4-hydroxy-5-(p-tolylthiomethyl)phenyl)acrylamide,20.0,uM,=,1.3010299956639813,1,c1ccc(CSc2ccccc2)cc1
964,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N(C)CCN(C)C)cc3OC)nc3[nH]ccc23)CC1,"1-(4-((2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.0593,uM,=,-1.2269453066357374,0,c1ccc(Nc2nc(OC3CCNCC3)c3cc[nH]c3n2)cc1
965,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,O=C(CCCCl)Nc1ccc2ncnc(Nc3ccc4[nH]ccc4c3)c2c1,N-(4-((1H-indol-5-yl)amino)quinazolin-6-yl)-4-chlorobutanamide,0.0058,uM,=,-2.2365720064370627,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1
966,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@H]6CCCNC6)c45)ccc32)c1,"(S)-N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((piperidin-3-ylmethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.19,uM,=,-0.721246399047171,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@H]6CCCNC6)c45)ccc32)cc1
967,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,O=C(C#CCCN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-5-(4-morpholinyl)-2-pentynamide",0.0013,uM,=,-2.886056647693163,0,O=C(C#CCCN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
968,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COCCN(Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC)[C@@H](C)C(N)=O,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(2-methoxyethyl)amino)propanamide,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
969,2246488,10.1016/j.ejmech.2022.114231,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.00843,uM,=,-2.0741724253752576,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
970,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)c(Cl)c4)nn32)CC1,"US9447106, 173",0.0017,uM,=,-2.7695510786217263,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(C3CCNCC3)CCN4)cc2)cc1
971,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1ncnc(Nc3ccc(F)c(Cl)c3)c1NC2,"(3-chloro-4-fluoro-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",8.2,uM,=,0.9138138523837168,1,c1ccc(Nc2ncnc3c2NCc2ccccc2S3)cc1
972,1337213,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,COc1ccc(Oc2nc3ccccc3cc2/C=N/NC(=O)Cn2c([N+](=O)[O-])cnc2C)cc1,(E)-N'-((2-(4-methoxyphenoxy)quinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,12.02,uM,=,1.0799044676667209,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
973,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN(C(C)C)C(C)C,(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(diisopropylamino)but-2-enamide,0.015,uM,=,-1.8239087409443189,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccccc45)ccc32)cc1
974,2153740,10.1021/acsmedchemlett.1c00555,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,CN1CCN(C2CCN(c3ccc(Nc4ncc(Cl)c(Nc5ccccc5P(C)(C)=O)n4)cc3Cl)CC2)CC1,(2-((5-Chloro-2-((3-chloro-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide,0.0382999999999999,uM,=,-1.4168012260313774,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
975,665430,10.1016/j.bmcl.2010.08.079,,,,Inhibition of EGFR,CC(=O)Nc1ccc2c(c1)C(c1ccccc1Cl)=Nc1c[nH]nc1N2,"N-(5-(2-chlorophenyl)-2,10-dihydrobenzo[e]pyrazolo[4,3-b][1,4]diazepin-7-yl)acetamide",0.726,uM,=,-0.1390633792999063,0,c1ccc(C2=Nc3c[nH]nc3Nc3ccccc32)cc1
976,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(Nc3ccc(-c4nc5ccccc5s4)cc3O)ncnc2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)-2-methylphenyl]-6'-methoxy-7'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,0.35,uM,=,-0.4559319556497244,0,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
977,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1ccccn1,N-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)picolinamide,0.575,uM,=,-0.2403321553103695,0,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(NC(=O)c2ccccn2)c1
978,65107,10.1021/jm00032a020,,,,Inhibition of EGF-stimulated DNA synthesis in ER 22 (EGF-receptor expressing) cells,CC(COC(=O)c1cc(/N=C/c2cc(O)ccc2O)ccc1O)CC(C)(C)C,"5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-benzoic acid 2,4,4-trimethyl-pentyl ester",10.0,uM,=,1.0,1,C(=N/c1ccccc1)\c1ccccc1
979,2185663,10.1016/j.ejmech.2021.113523,,,,"Inhibition of recombinant C-terminal His-tagged/N-terminal GST-tagged human EGFR expressed in sf9 insect cells using poly(Glu, Tyr) sodium salt (4:1, Glu:Tyr) as a substrate measured after 40 mins by Kinase-Glo reagent based luminescence analysis",Fc1cccc(COc2ccc(Nc3ncnc4sc5c(c34)CCCC5)cc2Cl)c1,"N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine",0.2,uM,=,-0.6989700043360187,0,c1ccc(COc2ccc(Nc3ncnc4sc5c(c34)CCCC5)cc2)cc1
980,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,COC(=O)CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)OC)[nH]c2ccccc12,3-{2-[3-(2-Methoxycarbonyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-propionic acid methyl ester,21.0,uM,=,1.3222192947339193,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
981,306642,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate; Range = 1000-10000 nM,COCC(=O)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1,"N-[4-(4,5-Dichloro-2-fluoro-phenylamino)-quinazolin-6-yl]-2-methoxy-acetamide",10.0,uM,=,1.0,1,c1ccc(Nc2ncnc3ccccc23)cc1
982,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc(C)cc2)c1O,2-Cyano-3-(4-hydroxy-3-methoxy-5-p-tolylsulfanylmethyl-phenyl)-acrylamide,12.0,uM,=,1.0791812460476249,1,c1ccc(CSc2ccccc2)cc1
983,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCN(C(=O)/C=C/CN2CCOCC2)CC1,"US9181263, 20::US9278100, 20",0.3036,uM,=,-0.5176982327765572,0,O=C(/C=C/CN1CCOCC1)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3cncnc32)CC1
984,63773,10.1021/jm9508651,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 human epidermoid carcinoma cells,Nc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.11,uM,=,-0.958607314841775,0,c1ccc(Nc2ncnc3ccncc23)cc1
985,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CCN(CC)CC#CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]-4-(diethylamino)-2-butynamide,0.0068,uM,=,-2.167491087293764,0,c1ccc(Nc2ncnc3ccccc23)cc1
986,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3cccc(OC)c3OC)ncc2C(F)(F)F)c1,"US9238629, I-23",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
987,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2C(=O)O)c1O,2-[5-(2-Carbamoyl-2-cyano-vinyl)-2-hydroxy-3-methoxy-benzylsulfanyl]-benzoic acid,0.71,uM,=,-0.1487416512809247,0,c1ccc(CSc2ccccc2)cc1
988,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)N1CCC(F)(F)C1,"(S)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3,3-difluoropyrrolidine-1-carboxamide",1.581,uM,=,0.198931869932209,1,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1)N1CCCC1
989,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CCN(CC)CCC#CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]-5-(4-diethylamino)-2-pentynamide,0.0045,uM,=,-2.3467874862246565,0,c1ccc(Nc2ncnc3ccccc23)cc1
990,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CCC(Oc2cc3c(Nc4cccc(Cl)c4)ncnc3cc2OC)CC1,1-(4-(4-(3-chlorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one,0.0042,uM,=,-2.3767507096021,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
991,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(C)=O)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"1N-[3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl]-1N-methylacetamide",2.6,uM,=,0.414973347970818,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
992,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)c2ccccc2)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"3-methoxy-2-methyl-4-methyl(phenyl)carboxamido-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaene",1.9,uM,=,0.2787536009528289,1,O=C(N[C@@H]1CC2O[C@@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O)c1ccccc1
993,1461860,10.1016/j.bmcl.2014.12.095,,,,Inhibition of human full length HER1 assessed as phosphorylation state by ELISA assay,Cc1ccc2c(C)nc(Nc3nc(O)cc(CSc4nnnn4-c4ccccc4)n3)nc2c1,SID863003,3.92,uM,=,0.5932860670204573,1,c1ccc(-n2nnnc2SCc2ccnc(Nc3ncc4ccccc4n3)n2)cc1
994,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c5c(c4)OCC5(C)C)nn32)CC1,"NA7-(1-acryloylpiperidin-4-yl)-2-(4-methoxy-3,3-dimethyl-2,3-dihydrobenzofuran-6-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",0.129,uM,=,-0.889410289700751,0,c1cc2c(cc1-c1cc3n(n1)C(C1CCNCC1)CCN3)OCC2
995,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccccc3P(C)(C)=O)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.149,uM,=,-0.826813731587726,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
996,1782454,10.1016/j.ejmech.2017.12.022,,,,Inhibition of recombinant human C-terminal His/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using biotin-labeled poly[Glu:Tyr] (4:1) as substrate after 30 mins by Kinase-Glo plus luminescence assay,Cc1oc2ncnc(Nc3cccc(Cl)c3)c2c1C(=O)NCCO,"4-((3-Chlorophenyl)amino)-N-(2-hydroxyethyl)-6-methylfuro[2,3-d]pyrimidine-5-carboxamide",2.7,uM,=,0.4313637641589873,1,c1ccc(Nc2ncnc3occc23)cc1
997,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CC(C)=CC[C@@H](OC(=O)/C=C\C(=O)c1cc(F)ccc1C)C1=CC(=O)c2c(O)ccc(O)c2C1=O,"(R)-1-(5,8-Dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (Z)-4-(5-fluoro-2-methylphenyl)-4-oxobut-2-enoate",0.0233999999999999,uM,=,-1.6307841425898573,0,O=C(/C=C\C(=O)c1ccccc1)OCC1=CC(=O)c2ccccc2C1=O
998,971466,10.1021/jm400402q,,,,Inhibition of EGFR (unknown origin) after 60 mins,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine",0.9,uM,=,-0.0457574905606751,0,c1ccc(Nc2ccnc(Nc3ccc(C4CCNCC4)cc3)n2)cc1
999,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)OC)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-29",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1000,1586270,10.1016/j.bmc.2016.04.046,,,,Inhibition of wild type human EGFR preincubated for 5 mins followed by ATP addition for 30 mins by HTRF assay,CCOc1cc2ncnc(Nc3ccc(OCC4CC4)c(Cl)c3)c2cc1NC(=O)[C@@H]1COC(=O)N1,(S)-N-(4-((3-Chloro-4-(cyclopropylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-2-oxooxazolidine-4-carboxamide,0.03781,uM,=,-1.4223933226374643,0,O=C1N[C@H](C(=O)Nc2ccc3ncnc(Nc4ccc(OCC5CC5)cc4)c3c2)CO1
1001,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)CCO,4-[(2-Hydroxy-ethyl)-methyl-amino]-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.02,uM,=,-1.6989700043360187,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
1002,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,CC/C=C\C(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,(Z)-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)pent-2-enamide,1.277,uM,=,0.1061908972634152,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1003,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CC(=O)N1CCc2ccc(Nc3nc(Nc4ccc(N5CCN(C)CC5)cc4)ncc3Br)cc21,1-(6-((5-bromo-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)indolin-1-yl)ethan-1-one,5.7,uM,=,0.7558748556724915,1,c1cc(Nc2ccc3c(c2)NCC3)nc(Nc2ccc(N3CCNCC3)cc2)n1
1004,786720,10.1016/j.bmc.2011.09.042,,,,Inhibition EGFR,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.1883,uM,=,-0.7251496799833351,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
1005,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1c(Nc2ncnc3cc4c(cc23)OCCO4)ccc(Br)c1Br,"N-(3,4-Dibromo-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
1006,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc(F)cc3)C2)cc1,"2-(5-(4-Fluorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",5.95,uM,=,0.7745169657285496,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
1007,5002,10.1021/jm00033a019,,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,COc1ccc(Nc2cc3c(cc2Nc2ccccc2)C(=O)NC3=O)cc1,"5-(4-Methoxy-phenylamino)-6-phenylamino-isoindole-1,3-dione",18.0,uM,=,1.255272505103306,1,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21
1008,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OC)c(OC)c3OC)ncc2Cl)c1,"US9238629, I-4",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
1009,1329770,10.1039/C2MD00317A,,,,Inhibition of recombinant EGFR (unknown origin) using poly-Glu-Tyr peptide as substrate,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
1010,66582,10.1021/jm970634p,,,,Inhibition of human epidermal growth factor receptor,CN1CCN(CCCNc2ncc3cc(-c4c(Cl)cccc4Cl)c(NC(=O)NC4CCCCC4)nc3n2)CC1,"1-Cyclohexyl-3-{6-(2,6-dichloro-phenyl)-2-[3-(4-methyl-piperazin-1-yl)-propylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea",0.88,uM,=,-0.0555173278498313,0,O=C(Nc1nc2nc(NCCCN3CCNCC3)ncc2cc1-c1ccccc1)NC1CCCCC1
1011,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(=O)c3ccc(C(=O)O)cc3)c3ccccc3n2C)c(C(=O)c2ccc(C(=O)O)cc2)c2ccccc21,4-{2-[3-(4-carboxybenzoyl)-1-methyl-1H-2-indolyldisulfanyl]-1-methyl-1H-3-indolylcarbonyl}benzoic acid2 H2O,5.5,uM,=,0.7403626894942439,1,O=C(c1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)c2ccccc2)[nH]c2ccccc12
1012,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,COCCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCCC1,(2E)-N-[4-[(1-Benzyl-1H-indazol-5-yl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]-4-(1-pyrrolidinyl)-2-butenamide,0.01,uM,=,-2.0,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
1013,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Clc1cccc(CNc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"N*3*-(3-Chloro-benzyl)-N*4*-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.026,uM,=,-1.585026652029182,0,c1ccc(CNc2[nH]nc3ncnc(Nc4ccccc4)c23)cc1
1014,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Cc1ccn2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c12,"N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-methylpyrrolo[1,2-f][1,2,4]triazin-4-amine",0.25,uM,=,-0.6020599913279624,0,c1ccc(COc2ccc(Nc3ncnn4cccc34)cc2)cc1
1015,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccccc3)C2)cc1,"2-(3-(4-Methoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",2.37,uM,=,0.3747483460101038,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
1016,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(NCc3ccccc3)c2cc1OCCCCCCC(=O)NO,7-(4-(Benzylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.0994,uM,=,-1.0026136156026868,0,c1ccc(CNc2ncnc3ccccc23)cc1
1017,2080995,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R/T790M (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.00043,uM,=,-3.3665315444204134,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1018,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCC/C(=C\c3ccccc3)C2=O)cc(OC)c1,"(2E,6E)-2-Benzylidene-6-(3,5-dimethoxybenzylidene)-cyclohexanone",1.68,uM,=,0.2253092817258628,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
1019,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,COc1cccc(Nc2ncnc3ccccc23)c1,(3-Methoxy-phenyl)-quinazolin-4-yl-amine,0.842,uM,=,-0.0746879085003505,0,c1ccc(Nc2ncnc3ccccc23)cc1
1020,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,O=C1NN(c2ccc(F)c(Cl)c2)C(=O)/C1=C\c1cccc(OC(=O)c2cccs2)c1,SID14731890,3.5,uM,=,0.5440680443502757,1,O=C1NN(c2ccccc2)C(=O)/C1=C\c1cccc(OC(=O)c2cccs2)c1
1021,1476364,10.1021/acs.jmedchem.5b00270,,,,Inhibition of human EGFR,CCn1nc(C#Cc2cc(C(=O)Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)ccc2C)c2c(N)ncnc21,"3-((4-Amino-1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide",3.518,uM,=,0.5462958351214424,1,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(C#Cc2n[nH]c3ncncc23)c1
1022,1986369,10.1016/j.bmc.2020.115373,,,,Inhibition of human EGFR-TK using PTK substrate after 40 mins in presence of ATP by Kinase-Glo luminescent assay,COc1ccc(/C=N/c2nnc3c4ccccc4nc(Nc4ccc(C)cc4N)n23)cc1O,"5-[({5[(2-amino-4-methylphenyl)amino]-[1,2,4]triazolo[4,3-c]quinazolin-3-yl}imino)methyl]-2-methoxyphenol",4.28,uM,=,0.631443769013172,1,C(=N/c1nnc2c3ccccc3nc(Nc3ccccc3)n12)\c1ccccc1
1023,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-bromoanilino)-quinazolin-6-yl)acetamide,0.00101,uM,=,-2.9956786262173574,0,c1ccc(Nc2ncnc3ccccc23)cc1
1024,1589608,10.1016/j.ejmech.2016.04.026,,,,Inhibition of cytoplasmic GST-tagged human recombinant EGFR expressed in baculovirus system by z-lyte assay,c1cnc2ccc(Nc3ncnc4ccc(-c5cnn(C6CCNCC6)c5)cc34)cc2c1,6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-N-(quinolin-6-yl)quinazolin-4-amine,0.0282,uM,=,-1.5497508916806388,0,c1cnc2ccc(Nc3ncnc4ccc(-c5cnn(C6CCNCC6)c5)cc34)cc2c1
1025,608076,10.1021/jm9016043,,,,Inhibition of EGFR,CN(C)c1cccc2c(S(=O)(=O)NCCN/N=N/c3ccc4ncnc(Nc5cccc(Cl)c5)c4c3)cccc12,N-(2-(3-(4-(3-chlorophenylamino)quinazolin-6-yl)triaz-2-enyl)ethyl)-5-(dimethylamino)naphthalene-1-sulfonamide,1.4,uM,=,0.1461280356782379,1,O=S(=O)(NCCN/N=N/c1ccc2ncnc(Nc3ccccc3)c2c1)c1cccc2ccccc12
1026,1541778,10.1016/j.bmc.2015.12.001,,,,Inhibition of wild-type EGFR tyrosine kinase (unknown origin) assessed as ATP level by luminescence analysis,O=C(Nc1ccc(CN2CCCCC2)cc1)Nc1ccc2ncnc(Nc3cccc(C(F)(F)F)c3)c2c1,1-(4-((Piperidin-1-yl)methyl)phenyl)-3-(4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-yl)urea,0.005,uM,=,-2.3010299956639813,0,O=C(Nc1ccc(CN2CCCCC2)cc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1027,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Sc5ccccn5)cc4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(4-(pyridin-2-ylthio)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",1.65,uM,=,0.2174839442139062,1,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Sc5ccccn5)cc4)c3s2)C1)N1CCOCC1
1028,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1,3-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)-N-methylbenzamide,0.079,uM,=,-1.1023729087095586,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
1029,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",O=S(=O)(Nc1nccs1)c1ccc(Nc2nncc3ccccc23)cc1,4-(Phthalazin-1-ylamino)-N-(thiazol-2-yl)benzenesulfonamide,0.088,uM,=,-1.055517327849831,0,O=S(=O)(Nc1nccs1)c1ccc(Nc2nncc3ccccc23)cc1
1030,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N(C)CCN(C)C)c(C)c4)nc32)C1,"(S)-7-((4-((2-(Dimethylamino)ethyl)(methyl)amino)-3-methylphenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",1.3,uM,=,0.1139433523068367,1,O=C1N(c2ccccc2)Cc2cnc(Nc3ccccc3)nc2N1[C@H]1CCNC1
1031,1353177,10.1021/ml4003309,,,,Inhibition of recombinant EGFR (unknown origin) using poly-GT peptide as substrate by Transcreener assay,COc1cc2c(Oc3ccc(NS(=O)(=O)c4cccc(-c5ccoc5)c4)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,N-[3-fluoro-4-({6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yl}oxy)phenyl]-3-(3-furyl)benzenesulfonamide,0.168,uM,=,-0.7746907182741372,0,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1cccc(-c2ccoc2)c1
1032,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,O=C(/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)NO,3-{5-[4-(3-Chloro-4-(3-fluorobenzyloxy)phenylamino]quinazolin-6-yl}furan-2-yl)-N-hydroxy-acrylamide Hydrochloride Monohydrate,0.0025,uM,=,-2.6020599913279625,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
1033,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Nc1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"N*3*-(4-Amino-phenyl)-N*4*-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
1034,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,O=C(C#CCCN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-5-(4-morpholinyl)-2-pentynamide",0.0018,uM,=,-2.744727494896694,0,O=C(C#CCCN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
1035,1883986,10.1021/acsmedchemlett.8b00461,,,,Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay,NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/CO)C2)c1N,"(R)-5-Amino-3-(4-(2,4-difluorophenoxy)phenyl)-1-(1-((2E)-4-hydroxybut-2-enoyl)piperidin-3-yl)-1H-pyrazole-4-carboxamide",2.91,uM,=,0.4638929889859073,1,c1ccc(Oc2ccc(-c3ccn([C@@H]4CCCNC4)n3)cc2)cc1
1036,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2ncnc3ccc4cc[nH]c4c23)c1,"(3-Bromo-phenyl)-(1H-1,6,8-triaza-cyclopenta[a]naphthalen-9-yl)-amine",0.00124,uM,=,-2.906578314837765,0,c1ccc(Nc2ncnc3ccc4cc[nH]c4c23)cc1
1037,2067577,10.1016/j.ejmech.2019.111888,,,,"Inhibition of EGFR L858R/T790M/C797S (unknown origin) using Poly (Glu, Tyr) as substrate measured after 40 mins by kinase-glo assay",CNC(=O)CN1CC[C@H](n2c(Nc3ccc(F)cc3)nc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc32)C1,(S)-N-methyl-2-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(4-fluorophenylamino)-9H-purin-9-yl)pyrrolidin-1-yl)acetamide,0.561,uM,=,-0.2510371387438385,0,c1ccc(Nc2nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc3n2[C@H]2CCNC2)cc1
1038,658253,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR autophosphorylation in human A431 cells,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CNC,(E)-4-(Methylamino)-but-2-enoic acid [4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxy-quinoline-6-yl]amide,0.00535,uM,=,-2.2716462179787715,0,c1ccc(Nc2ccnc3ccccc23)cc1
1039,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC[C@H](O)CN1CCOCC1,1-[4-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-3-morpholin-4-yl-propan-2-ol,0.067,uM,=,-1.1739251972991736,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1040,1770089,10.1016/j.bmcl.2017.12.009,,,,Inhibition of wild-type EGFR phosphorylation in human A431 cells preincubated for 1 hr followed by EGF stimulation measured after 45 mins by ELISA,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N(C)CCN(C)C)cc3OC)n2)c1,N-(3-(3-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,1.703,uM,=,0.231214647962601,1,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccccc2)n1
1041,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,O=C(NCCN1CCCCC1)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,1-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)-3-(2-(piperidin-1-yl)ethyl)urea,0.00106,uM,=,-2.9746941347352296,0,O=C(NCCN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1042,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4Cl)cc3)ncnc2cc1OCc1ccccc1,N-(4-(7-benzyloxy-6-methoxyquinazolin-4-ylamino)phenyl)-2-chlorobenzamide,0.73,uM,=,-0.1366771398795441,0,O=C(Nc1ccc(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1)c1ccccc1
1043,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CN(C)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-phenyl)-N*7*,N*7*-dimethyl-pyrido[4,3-d]pyrimidine-4,7-diamine",8.999999999999999e-05,uM,=,-4.045757490560675,0,c1ccc(Nc2ncnc3ccncc23)cc1
1044,2224503,10.1016/j.bmc.2021.116534,,,,Inhibition of EGFR derived from human A-431 cell membrane vesicles using copolymer of Glu/Ala/Tyr as substrate by scintillation counting method,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)Nc2ccccc2)[nH]c2ccccc12)Nc1ccccc1,N-Phenyl-3-{2-[3-(2-phenylcarbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-propionamide,0.85,uM,=,-0.0705810742857072,0,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)Nc2ccccc2)[nH]c2ccccc12)Nc1ccccc1
1045,2074610,10.1016/j.bmc.2020.115680,,,,Inhibition of wild type EGFR (unknown origin) in presence of ATP preincubated 5 mins measured for 30 mins by detection reagent based HTRF analysis,C=C(Cl)C(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3Cl)ncc2Cl)c1,N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-chlorophenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)-2-chloroacrylamide,0.301,uM,=,-0.5214335044061567,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1046,67049,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor,COc1cc(O)c2c(O)c(-c3cccc(Cl)c3)cnc2c1,3-(3-Chloro-phenyl)-5-hydroxy-7-methoxy-1H-quinolin-4-one,0.038,uM,=,-1.42021640338319,0,c1ccc(-c2cnc3ccccc3c2)cc1
1047,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccc(C)cc4)cc3)ncnc2cc1OCCCN1CCN(C)CC1,N-(4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-ylamino)phenyl)-4-methylbenzamide,0.69,uM,=,-0.1611509092627447,0,O=C(Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1ccccc1
1048,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Cc1[nH]c2ncnc(Nc3cccc(Cl)c3)c2c1C,"(3-Chloro-phenyl)-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",27.0,uM,=,1.4313637641589874,1,c1ccc(Nc2ncnc3[nH]ccc23)cc1
1049,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCC/C(=C\c3ccccc3Br)C2=O)cc(OC)c1,"(2E,6E)-2-(2-Bromobenzylidene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",8.08,uM,=,0.9074113607745862,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
1050,2233412,10.1016/j.bmcl.2022.128703,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells using kinase substrate 22 incubated for 30 mins in presence of ATP,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.00033,uM,=,-3.4814860601221125,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1051,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(N[C@H](C)c3ccccc3)ncnc2cc1OC,N-(7-Methoxy-4-{[(1R)-1-phenylethyl]amino}-6-quinazolinyl)-propanamide,0.086,uM,=,-1.0655015487564323,0,c1ccc(CNc2ncnc3ccccc23)cc1
1052,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc(-c2nc3ccccc3s2)ccc1Nc1ncnc2cc(OC)c(OC)cc12,"N-(4-(benzo[d]thiazol-2-yl)-2-methoxyphenyl)-6,7-dimethoxyquinazolin-4-amine",0.063,uM,=,-1.2006594505464183,0,c1ccc2sc(-c3ccc(Nc4ncnc5ccccc45)cc3)nc2c1
1053,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CC(C)(C)CCOC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3,3-dimethyl-butyl ester",7.0,uM,=,0.8450980400142568,1,c1ccc(CNc2ccccc2)cc1
1054,624979,10.1016/j.bmcl.2010.03.015,,,,Inhibition of EGFR intracellular phosphorylation in human A431 cells by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.034,uM,=,-1.4685210829577449,0,c1ccc(Nc2ncnc3ccccc23)cc1
1055,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,COc1ccc(-c2cc3c(N[C@H](C)c4cccc(F)c4)ncnc3o2)cc1,"(R)-N-(1-(3-Fluorophenyl)ethyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-amine",0.024,uM,=,-1.619788758288394,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
1056,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2C(=O)O)c1O,2-[5-(2-Carbamoyl-2-cyano-vinyl)-2-hydroxy-3-methoxy-benzylsulfanyl]-benzoic acid,37.0,uM,=,1.568201724066995,1,c1ccc(CSc2ccccc2)cc1
1057,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1,N-(3-(3-(2-(4-morpholinophenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.644,uM,=,-0.1911141326401879,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
1058,2227151,10.1016/j.ejmech.2022.114492,,,,Inhibition of wild type EGFR (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1059,593141,10.1021/jm901146p,,,,Inhibition of Her1 by fluorescence polarization assay,C=CC(=O)N1CCC[C@H]1C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3F)ncnc2cc1OCCOC,"(S)-1-Acryloyl-N-[4-(3-chloro-2,4-difluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl]pyrrolidine-2-carboxamide",0.009,uM,=,-2.0457574905606752,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)[C@@H]1CCCN1
1060,591074,10.1021/jm9010065,,,,Inhibition of human recombinant HER1 expressed in Sf9 cells by liquid scintillation counting,CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)OCCC1CCNCC1,"{4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl}-carbamic acid trans-2-piperidin-4-ylethyl ester",0.044,uM,=,-1.3565473235138126,0,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OCCC1CCNCC1
1061,1657723,10.1016/j.bmcl.2017.02.018,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells preincubated for 60 mins followed by EGF induction measured after 10 mins by ELISA,COc1ccc(Sc2cccc3[nH]c4nc(N)nc(N)c4c23)cc1,"5-[(4-methoxyphenyl)sulfanyl]-9H-pyrimido[4,5-b]indole-2,4-diamine",20.8,uM,=,1.3180633349627615,1,c1ccc(Sc2cccc3[nH]c4ncncc4c23)cc1
1062,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,Cl.NCCc1c[nH]c2ccc(OCCc3ccc(O)cc3)cc12,2-[5-(4-Hydroxyphenethoxy)-1H-indole-3-yl]ethanamine hydrochloride,2.07,uM,=,0.3159703454569177,1,c1ccc(CCOc2ccc3[nH]ccc3c2)cc1
1063,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,CC(=O)N1N=C(c2ccc(C)c(C)c2)CC1c1ccc(Cl)cc1,"1-(5-(4-Chlorophenyl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone",19.73,uM,=,1.2951270852521912,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
1064,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1,"(3S,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.079,uM,=,-1.1023729087095586,0,O=C(O[C@@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3s2)C1)N1CCOCC1
1065,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3ccc(C)cc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-7-((3-Methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3-(p-tolyl)-3,4-dihydropyrimido-[4,5-d]pyrimidin-2(1H)-one",0.377,uM,=,-0.4236586497942071,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
1066,835647,10.1016/j.bmcl.2012.07.079,,,,Inhibition of EGFR in human A431 cell lysate using tyrosine/glutamic acid polymer as substrate by ELISA,O=C(Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)c1cccc2c1OCCO2,"N-(4-((3-bromophenyl)amino)quinazolin-6-yl)-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide",1.63,uM,=,0.2121876044039577,1,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1cccc2c1OCCO2
1067,942122,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3ccccc3C(F)(F)F)c2cc1OC,"6,7-dimethoxy-N-(2-(trifluoromethyl)phenyl)quinazolin-4-amine",10.0,uM,=,1.0,1,c1ccc(Nc2ncnc3ccccc23)cc1
1068,952256,10.1016/j.bmc.2013.02.014,,,,Inhibition of human N-terminal DYKDDDD-tagged EGFR cytoplasmic domain (669 to 1210) expressed in baculovirus expression system incubated for 5 mins prior to [gamma-32P]ATP addition measured after 10 mins by scintillation counting analysis,CS(=O)(=O)CCNC(=O)C1=Cc2c(ncnc2Nc2ccc(Oc3cccc(C(F)(F)F)c3)c(Cl)c2)NCC1,"4-((3-Chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-N-(2-(methylsulfonyl)ethyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxamide",0.075,uM,=,-1.1249387366083,0,C1=Cc2c(ncnc2Nc2ccc(Oc3ccccc3)cc2)NCC1
1069,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccc(F)cc1,"3-(3,4-Dichlorophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",6.27,uM,=,0.7972675408307164,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
1070,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21,"1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",15.0,uM,=,1.1760912590556811,1,c1ncc2c(-c3cnc4[nH]ccc4c3)n[nH]c2n1
1071,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(Nc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1,N-(4-(benzo[d]thiazol-2-yl)phenyl)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-amine,0.046,uM,=,-1.337242168318426,0,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
1072,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,C=C(Cl)C(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,2-chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,0.257,uM,=,-0.5900668766687055,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1073,1467840,10.1016/j.ejmech.2015.03.029,,,,Inhibition of EGFR intracellular domain (unknown origin) purified from a baculovirus expression system using Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2 as substrate after 10 mins by scintillation counting in presence of [gamma-33P]ATP,CS(=O)(=O)CCNCc1ccc(-c2cc3c(Nc4ccc(OCc5ccccc5)cc4)ncnc3cn2)o1,"(4-Benzyloxy-phenyl)-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-pyrido[3,4-d]pyrimidin-4-yl)-amine",0.025,uM,=,-1.6020599913279625,0,c1ccc(COc2ccc(Nc3ncnc4cnc(-c5ccco5)cc34)cc2)cc1
1074,1770089,10.1016/j.bmcl.2017.12.009,,,,Inhibition of wild-type EGFR phosphorylation in human A431 cells preincubated for 1 hr followed by EGF stimulation measured after 45 mins by ELISA,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cc3OC)n2)c1,N-(3-(3-(2-(2-methoxy-4-(4-morpholinopiperidin-1-yl)phenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,6.463,uM,=,0.8104341559226728,1,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCC(N4CCOCC4)CC3)cc2)n1
1075,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Nc1cccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"[3-(3-Amino-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-chloro-phenyl)-amine",0.8,uM,=,-0.0969100130080563,0,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
1076,1882261,10.1016/j.bmc.2018.10.018,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (696-end residues) expressed in baculovirus expression system using Srctide as substrate by fluorescence assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4cccnc34)n2)c(OC)cc1N(C)CCNC,"N-(2-((2-(Methylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide",277.0,uM,=,2.4424797690644486,1,c1ccc(Nc2nccc(-c3c[nH]c4cccnc34)n2)cc1
1077,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C/C=C/C(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"(2E)-N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]but-2-enamide",0.239,uM,=,-0.6216020990518624,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
1078,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,Fc1cccc(COc2ccc(Nc3ncnn4ccc(CN5CCCNCC5)c34)cc2Cl)c1,"5-((1,4-diazepan-1-yl)methyl)-N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.048,uM,=,-1.3187587626244128,0,c1ccc(COc2ccc(Nc3ncnn4ccc(CN5CCCNCC5)c34)cc2)cc1
1079,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,Cn1c(SSc2c(C(=O)Nc3ccccc3)c3cccnc3n2C)c(C(=O)Nc2ccccc2)c2cccnc21,"2,2'-Dithiobis(1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid phenylamide)",22.3,uM,=,1.3483048630481609,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ncccc3c2C(=O)Nc2ccccc2)[nH]c2ncccc12
1080,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc(N)c(C(=O)Nc2ccc(F)c(Cl)c2)cc1NC(=O)/C=C/CN(C)C,2-amino-N-(3-chloro-4-fluorophenyl)-5-(4-(dimethylamino)but-2-enamido)-4-ethoxybenzamide,4.5,uM,=,0.6532125137753437,1,O=C(Nc1ccccc1)c1ccccc1
1081,1973895,10.1021/acs.jmedchem.9b02008,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (668 to end residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 2 hrs followed by EGF stimulation and measured after 30 mins by TMB peroxidase substrate based assay,CN(CCOS(=O)(=O)CCc1cn(CCCC(=O)N2CCN(C(=O)c3cc(Cc4n[nH]c(=O)c5ccccc45)ccc3F)CC2)nn1)c1ccc2ncnc(Nc3cccc(Br)c3)c2c1,2-[[4-(3-bromoanilino)quinazolin-6-yl]-methylamino]ethyl 2-[1-[4-[4-[2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]benzoyl]piperazin-1-yl]-4-oxobutyl]triazol-4-yl]ethanesulfonate,0.3262,uM,=,-0.486516043295743,0,O=C(CCCn1cc(CCS(=O)(=O)OCCNc2ccc3ncnc(Nc4ccccc4)c3c2)nn1)N1CCN(C(=O)c2cccc(Cc3n[nH]c(=O)c4ccccc34)c2)CC1
1082,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(NC(CO)c3ccccc3)ncnc2s1,"(Rac)-2-((6-(2-Methoxyphenyl)thieno[2,3-d]pyrimidin-4-yl)amino)-2-phenylethanol",0.008,uM,=,-2.096910013008056,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
1083,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,COc1ccccc1/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,(E)-N-(4-(3-Bromophenylamino)quinazolin-6-yl)-3-(2-methoxyphenyl)acrylamide,7.71,uM,=,0.887054378050957,1,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1084,1769420,10.1016/j.bmc.2018.02.023,,,,Inhibition of EGFR (unknown origin) using peptide substrate after 60 mins by HTRF assay,O=C(N/N=C/c1ccc(F)cc1Cl)N1CCc2ncnc(Nc3cccc(Br)c3)c2C1,"(E)-4-((3-bromophenyl)amino)-N'-(2-chloro-4-fluorobenzylidene)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carbohydrazide",0.018,uM,=,-1.744727494896694,0,O=C(N/N=C/c1ccccc1)N1CCc2ncnc(Nc3ccccc3)c2C1
1085,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,O=C(C#CCO)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-[(3-Chloro-4-fluorophenyl)amino]-6-quinazolinyl]-4-hydroxy-2-butynamide,0.0014,uM,=,-2.853871964321762,0,c1ccc(Nc2ncnc3ccccc23)cc1
1086,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)C(C)C)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1,"(S)-3-(2-Chlorophenyl)-1-(1-isobutyrylpyrrolidin-3-yl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0085,uM,=,-2.070581074285707,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
1087,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)c(O)c1,"3-Amino-2,4-dicyano-5-(3,4-dihydroxy-phenyl)-penta-2,4-dienenitrile",2.5,uM,=,0.3979400086720376,1,c1ccccc1
1088,800208,10.1016/j.bmcl.2011.12.067,,,,Inhibition of wild-type EGFR expressed using baculovirus expression system by ELISA,CCOC(=O)c1ccc(NC(=O)CSc2nnc(CNc3ccc(OC)cc3)n2-c2ccccc2)cc1,"ethyl 4-(2-(5-((4-methoxyphenylamino)methyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)acetamido)benzoate",92.4,uM,=,1.9656719712201067,1,O=C(CSc1nnc(CNc2ccccc2)n1-c1ccccc1)Nc1ccccc1
1089,2270884,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) by microplate reader analysis,CCCCCCCCCNc1nc2ccccc2c2c(C(=O)c3ccc(F)cc3)c(N)cn12,"2-amino-5-((2,4,4-trimethylpentan-2-yl)amino)pyrazolo[1,5-c]quinazolin-1-yl)(4-fluorophenyl)methanone",0.15763,uM,=,-0.8023611244444305,0,O=C(c1ccccc1)c1ccn2cnc3ccccc3c12
1090,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-8",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1091,608090,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 1 hr by Western blot,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3ccccc23)cc1
1092,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C(=O)OC,methyl (2-((2-acrylamido-5-methoxy-4-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)(methyl)carbamate,0.2127,uM,=,-0.672232510097271,0,c1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1
1093,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Oc1ccc(CN(Cc2cc(Cl)cc(Cl)c2O)C(=S)Nc2ccccc2)cc1,"1-(3,5-Dichloro-2-hydroxybenzyl)-1-(4-hydroxybenzyl)-3-phenylthiourea",0.56,uM,=,-0.2518119729937995,0,S=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
1094,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,OCCN(CCO)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"2-[[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-yl]-(2-hydroxy-ethyl)-amino]-ethanol",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3ccncc23)cc1
1095,1714364,10.1016/j.bmc.2018.05.039,,,,"Inhibition of wild type EGFR (unknown origin) using Poly(Glu,Tyr) as substrate after 40 mins by Kinase-Glo luminescence assay",CN1CCN(c2ccc(Nc3cc4c(N[C@@H]5CCCN(C)C5)nc(Nc5ccccc5)nc4cn3)nc2)CC1,"(R)-1-(3-((6-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-2-(phenyl amino)pyrido[3,4-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one",0.0047,uM,=,-2.3279021420642825,0,c1ccc(Nc2nc(N[C@@H]3CCCNC3)c3cc(Nc4ccc(N5CCNCC5)cn4)ncc3n2)cc1
1096,982643,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis,O=C(CCCN1CCCCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-bromoanilino)quinazolin-6-yl)-4-(piperidin-1-yl)butanamide,0.0057,uM,=,-2.2441251443275085,0,O=C(CCCN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1097,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3occc3c1)nn2C1CCCC1,"3-(benzofuran-5-yl)-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.575,uM,=,-0.2403321553103695,0,c1ncc2c(-c3ccc4occc4c3)nn(C3CCCC3)c2n1
1098,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,Cc1ccc(S(=O)(=O)O)cc1.NS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,6-(5-((2-(Sulfamoyl)ethylamino)methyl)furan-2-yl)-N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)quinazolin-4-amine tosylate,0.0108,uM,=,-1.9665762445130504,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1.c1ccccc1
1099,2270899,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR L858R/T790M (unknown origin) incubated for 60 mins in presence of ATP by ADP-Glo kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.8322999999999999,uM,=,-0.0797201053670516,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1100,1618202,10.1021/acs.jmedchem.5b01985,,,,Inhibition of wild type EGFR phosphorylation in human HaCaT cells incubated for 3 hrs by ELISA method,C=CC(=O)N1CCCC[C@@H](n2c(NC(=O)c3cccc(C(F)(F)F)c3)nc3cccc(C)c32)C1,(R)-N-(1-(1-Acryloylazepan-3-yl)-7-methyl-1H-benzo[d]-imidazol-2-yl)-3-(trifluoromethyl)benzamide,0.2496,uM,=,-0.6027554189896136,0,O=C(Nc1nc2ccccc2n1[C@@H]1CCCCNC1)c1ccccc1
1101,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(NC3CCc4ccccc43)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-indan-1-yl-amine",1.73,uM,=,0.2380461031287954,1,c1ccc2c(c1)CCC2Nc1ncnc2ccccc12
1102,305999,10.1016/j.bmcl.2004.08.007,,,,Inhibitory concentration against Epidermal growth factor receptor tyrosine kinase activity,COc1cc2ncnc(Nc3cccc(NC(=O)c4ccccc4)c3)c2cc1OC,"N-[3-(6,7-Dimethoxy-quinazolin-4-ylamino)-phenyl]-benzamide",5.6,uM,=,0.7481880270062004,1,O=C(Nc1cccc(Nc2ncnc3ccccc23)c1)c1ccccc1
1103,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc([N+](=O)[O-])c(C(=O)Nc2ccc(F)c(Cl)c2)cc1NC(=O)/C=C/CN(C)C,N-(3-Chloro-4-fluorophenyl)-5-(4-(dimethylamino)but-2-enamido)-4-ethoxy-2-nitrobenzamide,6.0,uM,=,0.7781512503836436,1,O=C(Nc1ccccc1)c1ccccc1
1104,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,CC(C)Oc1cccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)c1,"8-(3-Isopropoxyphenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",3.0,uM,=,0.4771212547196624,1,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
1105,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1ccc(-c2nn(C3CCCCC3)c3ncnc(N)c23)cc1OC,"1-cyclohexyl-3-(4-ethoxy-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",1.16,uM,=,0.0644579892269184,1,c1ccc(-c2nn(C3CCCCC3)c3ncncc23)cc1
1106,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,C=CC(=O)NCc1cccc(-c2nc(-c3ccc(F)cc3)c(-c3ccnc4[nH]c(-c5ccccc5)cc34)[nH]2)c1,"N-(3-(4-(4-Fluorophenyl)-5-(2-phenyl-1H-pyrrolo[2,3-b]-pyridin-4-yl)-1H-imidazol-2-yl)benzyl)acrylamide",0.0176,uM,=,-1.75448733218585,0,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccccc4)ccnc3[nH]2)cc1
1107,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)N(C)c1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21,"US9447106, 14",0.0031,uM,=,-2.508638306165728,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(c3ccccc3)CCN4)cc2)cc1
1108,67214,10.1016/s0960-894x(03)00644-9,,,,Inhibition of Epidermal growth factor receptor,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.049,uM,=,-1.3098039199714864,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
1109,66715,10.1021/jm00046a020,,,,Inhibition of in vitro activity of EGFr enzyme from A431 cells in presence of 5 uM ATP,Nc1ccc(-c2cc(=O)c3cc(N)ccc3o2)cc1,6-Amino-2-(4-amino-phenyl)-chromen-4-one,8.7,uM,=,0.9395192526186184,1,O=c1cc(-c2ccccc2)oc2ccccc12
1110,2201791,10.1016/j.bmcl.2022.128729,,,,Inhibition of wild type EGFR (unknown origin),CCc1cc(Nc2ncc(Br)c(Nc3ccc4nccnc4c3P(C)(C)=O)n2)c(OC)cc1N1CCC(N2CCN(CCS(C)(=O)=O)CC2)CC1,"5-bromo-N4-(5-(dimethylphosphoryl)quinoxalin-6-yl)-N2-(5-ethyl-2-methoxy-4-(4-(4-(2-(methylsulfonyl)ethyl)piperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine",0.0104,uM,=,-1.98296666070122,0,c1cc(Nc2ccc3nccnc3c2)nc(Nc2ccc(N3CCC(N4CCNCC4)CC3)cc2)n1
1111,793571,10.1016/j.bmc.2011.11.058,,,,Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA,Nc1nc(Nc2ccc(Cl)cc2F)c2cc(Cc3cccc4ccccc34)[nH]c2n1,"N4-(4-Chloro-2-fluorophenyl)-6-(1-naphthylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",112.1,uM,=,2.049605612594973,1,c1ccc(Nc2ncnc3[nH]c(Cc4cccc5ccccc45)cc23)cc1
1112,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,CN(C)/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,gilotrif,0.0024,uM,=,-2.619788758288394,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1113,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C(C)C)c4)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-isopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.365,uM,=,-0.4377071355435253,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
1114,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,COc1cc(C=C(C#N)C#N)cc(Br)c1O,2-(3-Bromo-4-hydroxy-5-methoxy-benzylidene)-malononitrile,153.0,uM,=,2.184691430817599,1,c1ccccc1
1115,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C(Nc1ccccc1)N(Cc1ccc(F)cc1)Cc1cccc(Br)c1O,1-(5-Bromo-2-hydroxybenzyl)-1-(4-fluorobenzyl)-3-phenylurea,2.24,uM,=,0.3502480183341628,1,O=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
1116,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCN(C)CC1,4-(4-Methyl-piperazin-1-yl)-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.36,uM,=,-0.4436974992327127,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
1117,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1,"7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-1H-imidazo[1,2-b]pyrazole-3-carboxamide",14.01,uM,=,1.1464381352857749,1,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNCC5)c4[nH]3)cc2)cc1
1118,1873759,10.1021/acs.jmedchem.9b00576,,,,"Inhibition of wild-type EGFR (unknown origin) using Poly(Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",CCC(=O)N[C@H]1CC[C@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)CC1,"N-((trans)-4-(3-(2-chlorophenyl)-7-(3-methyl-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)cyclohexyl)propionamide",0.0068,uM,=,-2.167491087293764,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1C1CCCCC1
1119,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methylamide,0.08,uM,=,-1.0969100130080565,0,O=C(Nc1ccccc1)Nc1ccc(Oc2ccncc2)cc1
1120,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,O=S(=O)(O)CCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"2-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-ylamino]-ethanesulfonic acid",0.0014,uM,=,-2.853871964321762,0,c1ccc(Nc2ncnc3ccncc23)cc1
1121,1801908,10.1016/j.ejmech.2018.06.061,,,,Inhibition of EGFR in human HepG2 cells,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0125,uM,=,-1.9030899869919435,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1122,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1cnc(N2CC[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-((R)-2-methylazetidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",7.289,uM,=,0.8626679502285879,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
1123,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccc(C)c4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-[7-ethoxy-4-({4-[(3-methylbenzyl)oxy]-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)quinazolin-6-yl]but-2-enamide",0.1731,uM,=,-0.7617029321246062,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
1124,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
1125,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1[nH]c(/C=C2\C(=O)Nc3ncnc(Nc4ccc(F)c(Cl)c4)c32)c(C)c1CCC(=O)O,"3-{5-[4-(3-Chloro-4-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propionic acid",0.18,uM,=,-0.744727494896694,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
1126,66576,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1,N-[4-(4-Benzyloxy-phenylamino)-quinazolin-6-yl]-acrylamide,0.0036,uM,=,-2.4436974992327127,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
1127,1935778,10.1021/acs.jmedchem.9b00102,,,,Inhibition of wild type EGFR (unknown origin) by HTRF assay,CCC(=O)N1CCC[C@@H](n2nc(-c3cn(-c4ccc(C(C)=O)cc4)nn3)c3c(N)ncnc32)C1,"(R)-1-(3-(3-(1-(4-acetylphenyl)-1H-1,2,3-triazol-4-yl)-4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)propan-1-one",0.649,uM,=,-0.1877553031996307,0,c1ccc(-n2cc(-c3nn([C@@H]4CCCNC4)c4ncncc34)nn2)cc1
1128,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,O=C(C#CCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]-5-(4-morpholinyl)-2-pentynamide,0.0017,uM,=,-2.7695510786217263,0,O=C(C#CCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1129,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,Brc1cc2c(NCc3ccncc3)ncnc2s1,"6-Bromo-N-(pyridin-4-ylmethyl)thieno[2,3-d]pyrimidin-4-amine",3.883,uM,=,0.5891673905460476,1,c1cc(CNc2ncnc3sccc23)ccn1
1130,1798716,10.1016/j.ejmech.2017.03.083,,,,"Inhibition of wild type N-terminal GST tagged human recombinant EGFR (695 to end amino acids) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) Peptide substrate by ADP-Glo assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1131,2270929,10.1016/j.ejmech.2020.112640,,,,Inhibition of human EGFR using 5-FAM-EEPLYWSFPAKKKCONH2 as substrate incubated for 30 mins in presence of ATP,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0009599999999999,uM,=,-3.017728766960432,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1132,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,COc1cc2ncnc(Nc3ccc(NC(=O)OC(C)C)cc3)c2cc1OC,"isopropyl 4-(6,7-dimethoxyquinazolin-4-ylamino)phenylcarbamate",4.8,uM,=,0.6812412373755872,1,c1ccc(Nc2ncnc3ccccc23)cc1
1133,1695880,10.1016/j.bmcl.2017.08.035,,,,Inhibition of wild type recombinant EGFR (unknown origin) by ELISA,COc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,"4-(3-chloro-4-fluorophenylamino)-6-methoxy-7-(3-((2R,3R,4R,5S)-2-hydroxymethyl-3,4,5-trihydroxy-1-piperidyl)propoxy)quinazoline",0.00179,uM,=,-2.7471469690201067,0,c1ccc(Nc2ncnc3cc(OCCCN4CCCCC4)ccc23)cc1
1134,306418,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate; Range = 1-10 nM,CN(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
1135,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(N)=O,"(E)-2-Cyano-3-(3,4-dihydroxy-phenyl)-acrylamide",4.5,uM,=,0.6532125137753437,1,c1ccccc1
1136,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,O=C(/C=C/CN1CCCCC1)N1CCCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-8,9-dihydro-7H-pyrimido[5,4-h][1,5]benzoxazepin-6-yl]-4-(1-piperidyl)but-2-en-1-one",0.844,uM,=,-0.0736575533743449,0,O=C(/C=C/CN1CCCCC1)N1CCCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
1137,1832277,10.1016/j.bmc.2018.12.032,,,,Inhibition of human A431 cell-derived EGFR using polyglutamic acid/tyrosine as substrate incubated for 10 mins followed by [32P]ATP addition and measured after 10 mins by beta counting method,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
1138,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CNC(=O)C1CN(c2ncc(C(C)C)c3cc(Nc4ccnc(N5CC[C@@H](O)[C@@](C)(F)C5)n4)ncc23)C1,"1-(6-((2-((3S,4R)-3-fluoro-4-hydroxy-3-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-4-isopropyl-2,7-naphthyridin-1-yl)-N-methylazetidine-3-carboxamide",10.0,uM,=,1.0,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
1139,512831,10.1016/j.bmcl.2008.07.057,,,,Inhibition of EGFR,N#Cc1c(N)ncnc1Nc1ccc(OCc2ccccc2)c(Cl)c1,4-amino-6-(4-(benzyloxy)-3-chlorophenylamino)pyrimidine-5-carbonitrile,0.027,uM,=,-1.5686362358410126,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
1140,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,Fc1ccc2c(c1)CNc1c(Nc3ccc(F)c(Cl)c3)ncnc1O2,"(3-Chloro-4-fluoro-phenyl)-(8-fluoro-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",7.2,uM,=,0.8573324964312685,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
1141,1641794,,,,,"Time-Resolved Fluorescence Assay: The following assay may be used to determine the activity of the compounds of the invention for inhibiting EGFR kinase activity. The half maximal inhibitory concentration IC50 (the concentration of the tested compound showing 50% inhibition of the enzyme activity) of each compound was determined by incubating several different concentrations of the tested compounds with a specific enzyme and substrate. EGFR kinase used in this assay is a human-derived recombinant protein (Cell signaling technology, #7908), which was reacted with peptide substrate and different concentrations of tested compounds in a buffer solution containing 60 mM HEPES (pH7.5), 5 mM MgCl2, 5 mM MnCl2, 3 Î¼M Na3VO4, 1.25 M DTT (1000Ã) and 20 Î¼M ATP at 25Â° C., for 45 minutes. The EGFR kinase activity was determined by using a Time-Resolved fluorescence method.",COCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,"US8901140, 8::US9358227, 8",0.002,uM,=,-2.6989700043360187,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1142,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",C=CC(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1,"US8476284, 40::US9133201, 10::US9181263, 9::US9278100, 9",0.0206,uM,=,-1.6861327796308467,0,c1ccc(Oc2ccc(-c3nn(C4CCCCC4)c4ncncc34)cc2)cc1
1143,608091,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 8 hrs by Western blot,O=C(COc1c(F)c(F)c(F)c(F)c1F)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(perfluorophenoxy)-acetamide,0.078,uM,=,-1.1079053973095196,0,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1144,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)O,"2-Cyano-3-(3,4-dihydroxy-phenyl)-acrylic acid",30.0,uM,=,1.4771212547196624,1,c1ccccc1
1145,2260087,10.1016/j.ejmech.2020.112904,,,,Inhibition of EGFR T790M (unknown origin) incubated for 40 mins in presence of ATP,Cn1cc(-c2ccnc(Nc3ccc(NC(=O)CCCCCCC(=O)NO)cc3)n2)c2ccccc21,,1.2,uM,=,0.0791812460476248,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1146,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C(C)=O)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,isopropyl 4-(1-acetyl-1H-indol-3-yl)-2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)pyrimidine-5-carboxylate,0.079,uM,=,-1.1023729087095586,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1147,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,CCCCN(Cc1cccc(Cl)c1O)C(=O)Nc1ccccc1,1-Butyl-1-(5-chloro-2-hydroxybenzyl)-3-phenylurea,32.12,uM,=,1.506775536606643,1,O=C(NCc1ccccc1)Nc1ccccc1
1148,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,COCC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Methoxy-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
1149,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C=CC(=O)Nc1cc2c(Nc3ccc(Cl)c(C(F)(F)F)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(4-Chloro-3-(trifluoromethyl)phenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)acrylamide,0.1047,uM,=,-0.9800533183211576,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1150,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1cc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)ncn1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methylpyrimidin-4-amine,1.1,uM,=,0.041392685158225,1,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
1151,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc(Br)cc3)C2)cc1,"2-(5-(4-Bromophenyl)-3-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",0.24,uM,=,-0.619788758288394,0,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
1152,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,C=CCN(C)CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-(Allyl-methyl-amino)-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.071,uM,=,-1.1487416512809248,0,c1ccc(Nc2ncnc3ccccc23)cc1
1153,632809,10.1016/j.bmc.2010.04.001,,,,Noncompetitive inhibition of EGFR after 30 mins by chemiluminescence ELISA in presence of 50 uM ATP,Cl.NC1CCc2c(c3cc(OCCc4ccc(O)cc4)ccc3n2CCCCCc2ccccc2)C1,"4-(2-(3-amino-9-(5-phenylpentyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-6-yloxy)ethyl)phenol hydrochloride",0.98,uM,=,-0.0087739243075051,0,c1ccc(CCCCCn2c3c(c4cc(OCCc5ccccc5)ccc42)CCCC3)cc1
1154,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,C[C@H](CN)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21,"(R)-5-(4-amino-1-(1-aminopropan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",4.8,uM,=,0.6812412373755872,1,c1ccc(-c2n[nH]c3ncncc23)cc1
1155,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(N(CC)CC)cc4)nc32)c1,N-(3-(2-(4-(Diethylamino)phenylamino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.0145,uM,=,-1.8386319977650247,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
1156,958682,10.1021/jm400463q,,,,Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC(=O)NCCOc5no[n+]([O-])c5S(=O)(=O)c5ccccc5)CC4)cc3OC)ncc2Cl)c1,"4-(2-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetamido)-ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide",0.051,uM,=,-1.2924298239020635,0,O=C(CN1CCN(c2ccc(Nc3nccc(Oc4ccccc4)n3)cc2)CC1)NCCOc1no[nH+]c1S(=O)(=O)c1ccccc1
1157,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC(F)(F)F)ncc2C(F)(F)F)c1,"US8975249, I-33",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1158,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,Cc1ccc(S(=O)(=O)O)cc1.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)CC(F)(F)F,"6-(5-((2-(2,2,2-Trifluoroethylsulfonyl)ethylamino)methyl)furan-2-yl)-N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)quinazolin-4-amine tosylate",0.0211,uM,=,-1.6757175447023074,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1.c1ccccc1
1159,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OCC,(E)-But-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,7.5,uM,=,0.8750612633917001,1,c1ccc(Nc2ccnc3ccccc23)cc1
1160,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,COc1ccc(/C=C/C(=O)Nc2cccc(Oc3cc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncn3)c2)cc1OC,"(E)-4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-6-[3-(3,4-dimethoxycinnamamido)phenoxy]pyrimidine",0.523,uM,=,-0.2814983111327257,0,O=C(/C=C/c1ccccc1)Nc1cccc(Oc2cc(Nc3ccc(OCc4ccccc4)cc3)ncn2)c1
1161,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1c(I)cccc1Nc1ncnc2cc3c(cc12)OCCO3,"N-(2-Fluoro-3-iodophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0104,uM,=,-1.98296666070122,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
1162,1829742,10.1021/acs.jmedchem.8b01612,,,,Inhibition of wild type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system after 1 hr in presence of ULight-labeled peptide substrate and ATP by LANCE ultra kinase assay,COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1OCCCN1CCNCCNCC1,"6-(3-(1,4,7-Triazonan-1-yl)propoxy)-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-methoxyquinazolin-4-amine",0.0003,uM,=,-3.522878745280338,0,c1ccc(COc2ccc(Nc3ncnc4ccc(OCCCN5CCNCCNCC5)cc34)cc2)cc1
1163,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,MOBOCERTINIB,0.031,uM,=,-1.5086383061657274,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1164,2132157,10.1021/acs.jmedchem.1c01559,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(-c4ccccc4)ccn3)cc2)c(C(N)=O)n1N,(S)-2-(1-acryloylpiperidin-2-yl)-1-amino-4-(4-((4-phenylpyridin-2-yl)carbamoyl)phenyl)-1H-imidazole-5-carboxamide,0.0794,uM,=,-1.1001794975729036,0,O=C(Nc1cc(-c2ccccc2)ccn1)c1ccc(-c2c[nH]c([C@@H]3CCCCN3)n2)cc1
1165,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCC(O)CC1,4-(4-Methoxy-piperidin-1-yl)-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.221,uM,=,-0.6556077263148893,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
1166,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,CN1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((4-methylpiperazin-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.17,uM,=,-0.7695510786217261,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCNCC6)c45)ccc32)cc1
1167,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,O=C(/C=C/CNC1CC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,"(S,E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(cyclopropylamino)but-2-enamide",0.0065,uM,=,-2.1870866433571443,0,O=C(/C=C/CNC1CC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
1168,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CCOC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid ethyl ester",6.1,uM,=,0.785329835010767,1,c1ccc(CNc2ccccc2)cc1
1169,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)CC(C)(C)C)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-23",0.2,uM,=,-0.6989700043360187,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1170,2205223,10.1016/j.bmc.2022.116907,,,,Inhibition of wild type EGFR (unknown origin) using TK as substrate incubated for 120 mins in the presence of ATP by HTRF assay,CCOC1CN(C2CCN(c3cc(OC)c(Nc4ncc(Br)c(Nc5ccc6nccnc6c5P(C)(C)=O)n4)cc3C)CC2)C1,(6-((5-Bromo-2-((4-(4-(3-ethoxyazetidin-1-yl)piperidin-1-yl)-2-methoxy-5-methylphenyl)amino)pyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide,0.652,uM,=,-0.1857524042680797,0,c1cc(Nc2ccc3nccnc3c2)nc(Nc2ccc(N3CCC(N4CCC4)CC3)cc2)n1
1171,1869715,10.1016/j.bmc.2019.02.012,,,,Inhibition of His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometry,COc1ccc(/C=C/C(=O)c2ccc(NC(=O)c3cc4cc5ccccc5nc4s3)cc2)cc1OC,"(E)-N-(4-(3-(3,4-Dimethoxyphenyl)acryloyl)phenyl)thieno[2,3-b]quinoline-2-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(/C=C/c1ccccc1)c1ccc(NC(=O)c2cc3cc4ccccc4nc3s2)cc1
1172,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1,"3-Amino-2,4-dicyano-5-(4-hydroxy-phenyl)-penta-2,4-dienenitrile",0.125,uM,=,-0.9030899869919436,0,c1ccccc1
1173,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1,"(2E)-N-{4-[(1-Benzyl-1H-indazol-5-yl)amino]pyrido[3,4-d]-pyrimidin-6-yl}-4-(dimethylamino)-2-butenamide",0.041,uM,=,-1.3872161432802643,0,c1ccc(Cn2ncc3cc(Nc4ncnc5cnccc45)ccc32)cc1
1174,2291456,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR autophosphorylation at Tyr1068 residue in EGFR-amplified human A-431 cells preincubated with compound for 1 hrs followed by stimulation with human recombinant EGF and measured after 10 mins by HTRF-based analysis,C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1,ORELABRUTINIB,5.9,uM,=,0.7708520116421442,1,c1ccc(Oc2ccc(-c3cccc(C4CCNCC4)n3)cc2)cc1
1175,624184,10.1021/jm901877j,,,,Inhibition of wild type EGFR by HTRF assay,CCC(=O)Nc1ccc2nccc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromophenylamino)quinolin-6-yl)propionamide,0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ccnc3ccccc23)cc1
1176,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CN1CCC(F)CC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(4-fluoropiperidin-1-yl)but-2-enamide",0.004,uM,=,-2.397940008672037,0,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
1177,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4ccc(Br)cc4)c3cc2N1CCCN1CCOCC1,"4-((4-bromophenyl)amino)-6-(3-morpholinopropyl)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.8239,uM,=,-0.0841254971423085,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
1178,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,Cl.NC1CCc2c(c3cc(OCCc4ccc(O)cc4)ccc3n2CCCc2ccccc2)C1,"4-(2-(3-Amino-9-(3-phenylpropyl)-2,3,4,9-tetrahydro-1H-tetrahydrocarbazole-6-yloxy)ethyl)phenol hydrochloride",2.5,uM,=,0.3979400086720376,1,c1ccc(CCCn2c3c(c4cc(OCCc5ccccc5)ccc42)CCCC3)cc1
1179,1337213,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ccc2nc(Oc3ccc(Cl)cc3)c(/C=N/NC(=O)Cn3c([N+](=O)[O-])cnc3C)cc2c1,(E)-N'-((2-(4-chlorophenoxy)-6-methylquinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,19.0,uM,=,1.2787536009528289,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
1180,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccccc3OC)ncc2Br)c1,"US9238629, I-22",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
1181,63615,10.1021/jm980123i,,,,Concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Epidermal growth factor receptor (EGF RTK).,CC(C)c1cc(/C=C2\C(=O)Nc3ccccc32)cc(C(C)C)c1O,"3-[1-(4-Hydroxy-3,5-diisopropyl-phenyl)-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one",15.3,uM,=,1.1846914308175989,1,O=C1Nc2ccccc2/C1=C/c1ccccc1
1182,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,CN1CCN(CCCNc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)CC1,"6-(2,6-Dichloro-phenyl)-8-methyl-2-[3-(4-methyl-piperazin-1-yl)-propylamino]-8H-pyrido[2,3-d]pyrimidin-7-one",8.7,uM,=,0.9395192526186184,1,O=c1[nH]c2nc(NCCCN3CCNCC3)ncc2cc1-c1ccccc1
1183,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,CCOc1cc2ncnc(Nc3cccc(F)c3)c2cc1OCC.Cl,"4-(3'-fluoroanilino)-6,7-diethoxyquinazoline hydrochloride",0.0065,uM,=,-2.1870866433571443,0,c1ccc(Nc2ncnc3ccccc23)cc1
1184,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",4.8,uM,=,0.6812412373755872,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
1185,554997,10.1021/jm8001185,,,,Inhibition of human recombinant EGFR,COc1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,"3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione",16.0,uM,=,1.2041199826559248,1,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1ccccc1
1186,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,O=C(NC1CCCC1)c1ccc(N(CCCl)CCCl)cc1,4-(Bis(2-chloroethyl)amino)-N-cyclopentylbenzamide,35.29,uM,=,1.547651658359969,1,O=C(NC1CCCC1)c1ccccc1
1187,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(CN(C)C)c(Br)c3)c2c1,N-[4-(3-Bromo-4-dimethylaminomethyl-phenylamino)-quinazolin-6-yl]-acrylamide,0.416,uM,=,-0.3809066693732573,0,c1ccc(Nc2ncnc3ccccc23)cc1
1188,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,Cc1ccc(Oc2ccc(Nc3ncnc4[nH]nc(OCCN5CCC(O)CC5)c34)cc2C)cn1,"1-(2-(4-(3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yloxy)ethyl)piperidin-4-ol",0.216,uM,=,-0.6655462488490691,0,c1cncc(Oc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCCC5)c34)cc2)c1
1189,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2c2c1OCCO2,"N-(3-Chloro-4-fluorophenyl)-5-methoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0225,uM,=,-1.6478174818886375,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
1190,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(N2C(=O)C(C(C)C)N(C)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(7-isopropyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6-methyl-5,8-dioxo-7,8-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-9(6H)-yl)phenyl)acrylamide",0.0248299999999999,uM,=,-1.605023280445436,0,O=C1NCC(=O)N(c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc21
1191,1739299,10.1016/j.ejmech.2018.05.006,,,,Inhibition of wild type EGFR (unknown origin) using FAM-labeled peptide substrate after 10 mins by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2c(N3CCc4ccccc43)ncnc2cc1O[C@@H]1CCOC1,"(R,E)-4-(dimethylamino)-N-(4-(indolin-1-yl)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)but-2-enamide",0.005,uM,=,-2.3010299956639813,0,c1ccc2c(c1)CCN2c1ncnc2cc(O[C@@H]3CCOC3)ccc12
1192,465,10.1016/s0960-894x(02)00364-5,,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Cc1cc(C(=O)N2CC(C)NC(C)C2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[5-(3,5-dimethyl-piperazine-1-carbonyl)-3-methyl-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",2.58,uM,=,0.4116197059632301,1,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCNCC2)[nH]1
1193,658253,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR autophosphorylation in human A431 cells,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)CCF,(E)-4-[(2-Fluoroethyl)methylamino]-but-2-enoic acid[4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinoline-6-yl]amide,0.02302,uM,=,-1.6378946807062271,0,c1ccc(Nc2ccnc3ccccc23)cc1
1194,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Fc1cc(Br)c(F)c(Nc2ncnc3cc4c(cc23)OCCO4)c1,"N-(3-Bromo-2,5-difluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0068,uM,=,-2.167491087293764,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
1195,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC.Cl,"(3-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine hydrochloride",0.0008,uM,=,-3.096910013008056,0,c1ccc(Nc2ncnc3ccccc23)cc1
1196,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,CN(C)/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,(2E)-N-{4-[(3-Bromophenyl)amino]-6-quinazolinyl}-3-(dimethylamino)-2-propenamide,0.25,uM,=,-0.6020599913279624,0,c1ccc(Nc2ncnc3ccccc23)cc1
1197,1348544,10.1016/j.bmcl.2014.03.072,,,,Inhibition of autophosphorylation of recombinant his-tagged EGFR (amino acid 645-1186) (unknown origin) expressed in Sf-9 cells after 10 mins by time-resolved fluorometry,COc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc4ccccc4c3)C2)cc1,"2-(3-(4-methoxyphenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",2.8,uM,=,0.4471580313422192,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccc3ccccc3c2)=N1
1198,1523969,10.1016/j.ejmech.2015.08.027,,,,Inhibition of EGFR (unknown origin) using omnia tyr peptide 7 substrate by fluorescence assay,COc1ccc2c(c1)SCc1cnc(-c3ccccc3)nc1-2,"8-methoxy-2-phenyl-5H-thiochromeno[4,3-d]pyrimidine",4.72,uM,=,0.6739419986340878,1,c1ccc(-c2ncc3c(n2)-c2ccccc2SC3)cc1
1199,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Brc1cccc(Nc2ncnc3cc4c(cc23)OCO4)c1,"(3-Bromo-phenyl)-[1,3]dioxolo[4,5-g]quinazolin-8-yl-amine",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3cc4c(cc23)OCO4)cc1
1200,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,CC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)acetamide,0.41,uM,=,-0.3872161432802645,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
1201,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(Br)c5)cc4)c3c2)o1,N-(4-(3-bromobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.043,uM,=,-1.3665315444204136,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
1202,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(CNCCCCCCCC(=O)NO)cc3)cc12)c1ccccc1,"(R)-N-hydroxy-8-(4-(4-(1-phenylethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzylamino)octanamide",0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
1203,1641517,,,,,"In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",C=CC(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,"US9181263, 14::US9278100, 14",0.01875,uM,=,-1.7269987279362624,0,c1ccc(Oc2ccc(-c3nn(C[C@@H]4CCCN4)c4ncncc34)cc2)cc1
1204,1515019,10.1016/j.ejmech.2015.07.030,,,,Inhibition of epidermal growth factor receptor kinase (unknown origin) using [33P]-ATP after 20 to 30 mins by radiometric assay,C=CC(=O)Nc1ccc2ncnc(Nc3cc(F)c(Cl)c(Cl)c3)c2c1,"N-(4-(3,4-dichloro-5-fluorophenylamino)quinazolin-6-yl)acrylamide",3.7e-05,uM,=,-4.431798275933005,0,c1ccc(Nc2ncnc3ccccc23)cc1
1205,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Nc1ncnc(N[C@H](C)c3ccccc3)c1NC2,"(7,8-dimethoxy-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cyclohepten-1-yl)-((R)-1-phenyl-ethyl)-amine",0.5,uM,=,-0.3010299956639812,0,c1ccc(CNc2ncnc3c2NCc2ccccc2N3)cc1
1206,409130,10.1021/jm060727j,,,,Inhibition of Her1,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,"N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide",0.18,uM,=,-0.744727494896694,0,O=C(Nc1ccccc1)c1cnc(Nc2cc(N3CCNCC3)ncn2)s1
1207,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C1CC1,(E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-ethoxyquinazolin-6-yl)-4-(cyclopropyl(methyl)amino)but-2-enamide,0.0055,uM,=,-2.2596373105057563,0,O=C(/C=C/CNC1CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1208,2213946,10.1016/j.ejmech.2021.113963,,,,Inhibition of EGFR (unknown origin),C=CC(=O)Nc1cc2c(cc1OCCNC(=O)CN(C)C)NCN=C2Nc1ccc(Br)cc1F,"N-[4-(4-bromo-2-fluoro-anilino)-7-[2-[[2-(dimethylamino)acetyl]amino]ethoxy]-1,2-dihydroquinazolin-6-yl]prop-2-enamide",0.002,uM,=,-2.6989700043360187,0,c1ccc(NC2=NCNc3ccccc32)cc1
1209,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC(=O)CC4=C(C)/C(=C/c5ccc([S+](C)[O-])cc5)c5ccc(F)cc54)c(OCCOC(=O)CC4=C(C)/C(=C/c5ccc([S+](C)[O-])cc5)c5ccc(F)cc54)cc23)c1,"(Z)-((4-((3-Ethynylphenyl)amino)quinazoline-6,7-diyl)bis(oxy))bis(ethane-2,1-diyl)bis(2-((Z)-5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetate)",0.027,uM,=,-1.5686362358410126,0,O=C(CC1=C/C(=C/c2ccccc2)c2ccccc21)OCCOc1cc2ncnc(Nc3ccccc3)c2cc1OCCOC(=O)CC1=C/C(=C/c2ccccc2)c2ccccc21
1210,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,CN(CCO)Cc1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"2-({4-[7-(1H-Indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-methyl-amino)-ethanol",0.003,uM,=,-2.5228787452803374,0,c1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
1211,1778842,10.1016/j.bmcl.2018.07.039,,,,Inhibition of EGF-induced EGFR activation in human A431 cells pretreated for 60 mins followed by EGF addition and measured after 10 mins by ELISA,Cc1coc2ncnc(N(C)c3ccc(N(C)C)cc3)c12,"N1,N1,N4-Trimethyl-N4-(5-methylfuro[2,3-d]pyrimidin-4-yl)benzene-1,4-diamine",0.0031,uM,=,-2.508638306165728,0,c1ccc(Nc2ncnc3occc23)cc1
1212,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,Nc1cccc2ncnc(Nc3cccc(Br)c3)c12,"N*4*-(3-Bromo-phenyl)-quinazoline-4,5-diamine",0.439,uM,=,-0.3575354797578786,0,c1ccc(Nc2ncnc3ccccc23)cc1
1213,609779,10.1016/j.bmc.2009.12.004,,,,Inhibition of EGFR after 80 mins by radiometric protein kinase assay,COc1cc(C2=C(c3c[nH]c4ccc(I)cc34)C(=O)NC2=O)cc(OC)c1OC,"3-(5-Iodo-1H-indol-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione",1.688,uM,=,0.2273724422896362,1,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1ccccc1
1214,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,C=CC(=O)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1,4-(6-acrylamidoquinolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.159,uM,=,-0.7986028756795485,0,O=C(Nc1ccccn1)c1ccc(Oc2ccnc3ccccc23)cc1
1215,942125,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin) using biotinylated-PTP1B (Tyr66) as substrate incubated for 5 mins prior to substrate addition measured after 1 hr by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCBr,6-(2-Bromoethoxy)-4-(3'-chloro-4'-fluoroanilino)-7-methoxy-quinazoline,0.0181,uM,=,-1.7423214251308154,0,c1ccc(Nc2ncnc3ccccc23)cc1
1216,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COC(=O)CNC(=O)c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(OC)cc23)cc1,Methyl 2-(4-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)benzamido)acetate,0.763,uM,=,-0.1174754620451195,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
1217,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,CNC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1,1-((6-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)pyridin-2-yl)methyl)-3-methylurea,0.023,uM,=,-1.6382721639824072,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccn1
1218,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,C#Cc1cccc(Nc2ncnc3c2NCc2cc(OC)c(OC)cc2O3)c1,"(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(3-ethynyl-phenyl)-amine",3.2,uM,=,0.505149978319906,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
1219,66907,10.1016/S0960-894X(00)80473-4,,,,Inhibition of epidermal growth factor receptor (EGFR),N#C/C(=C\c1ccc(O)c(O)c1)C(N)=O,"(E)-2-Cyano-3-(3,4-dihydroxy-phenyl)-acrylamide",20.0,uM,=,1.3010299956639813,1,c1ccccc1
1220,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.009,uM,=,-2.0457574905606752,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
1221,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,CS(=O)(=O)N1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1.Cc1ccc(S(=O)(=O)O)cc1,N-(3-Chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((4-(methylsulfonyl)piperazin-1-yl)methyl)furan-2-yl)quinazolin-4-amine tosylate,0.0599,uM,=,-1.2225731776106885,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CN6CCNCC6)o5)cc34)cc2)cc1.c1ccccc1
1222,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,O=C(NCc1ccccc1)c1ccc(N(CCCl)CCCl)cc1,N-Benzyl-4-(bis(2-chloroethyl)amino)benzamide,17.51,uM,=,1.243286146083446,1,O=C(NCc1ccccc1)c1ccccc1
1223,2260087,10.1016/j.ejmech.2020.112904,,,,Inhibition of EGFR T790M (unknown origin) incubated for 40 mins in presence of ATP,COc1cc(NC(=O)CCCCCCC(=O)NO)ccc1Nc1nccc(-c2cn(C)c3ccccc23)n1,8-(hydroxyamino)-N-[3-methoxy-4-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]-8-oxo-octanamide,5.0,uM,=,0.6989700043360189,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1224,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)CC1,"2-(4-(4-methoxyphenoxy)phenyl)-7-(1-propioloylpiperidin-4-yl)-1H-imidazo[1,2-b]pyrazole-3-carboxamide",0.0508,uM,=,-1.2941362877160807,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNCC5)c4[nH]3)cc2)cc1
1225,793571,10.1016/j.bmc.2011.11.058,,,,Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",1.2,uM,=,0.0791812460476248,1,c1ccc(Nc2ncnc3ccccc23)cc1
1226,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2nc(OC)cc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-methoxy-6-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,0.685,uM,=,-0.1643094285075744,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1227,1924071,10.1021/acs.jmedchem.6b00403,,,,"Inhibition of wild type EGFR kinase domain (unknown origin) expressed using baculovirus expression system incubated for 1 hr using Poly(Glu,Tyr) 4:1 by ELISA method",C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N(C)CCN(C)C)cc4OC)nc32)c1,"N-(3-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-5-isopropyl-6,7-dioxo-6,7-dihydropteridin-8(5H)-yl)phenyl)acrylamide",0.223,uM,=,-0.6516951369518393,0,O=c1[nH]c2cnc(Nc3ccccc3)nc2n(-c2ccccc2)c1=O
1228,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,COc1cccc(-c2cc3c(N[C@H](C)c4ccccc4)ncnc3o2)c1,"(R)-6-(3-Methoxyphenyl)-N-(1-phenylethyl)furo[2,3-d]pyrimidin-4-amine",0.007,uM,=,-2.154901959985743,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
1229,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CC(=O)Nc1cc2ncnc(NCc3ccccc3)c2cn1,"N-(4-Benzylamino-pyrido[4,3-d]pyrimidin-7-yl)-acetamide",0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3ccncc23)cc1
1230,1986369,10.1016/j.bmc.2020.115373,,,,Inhibition of human EGFR-TK using PTK substrate after 40 mins in presence of ATP by Kinase-Glo luminescent assay,O=C1CSCC(=O)N1c1nnc2c3ccccc3nc(Sc3ccc(Br)cc3)n12,"4-{5-[(4-Bromophenyl)sulfanyl]-[1,2,4]-triazolo[4,3-c]quinazolin-3-yl}thiomorpholine-3,5-dione",4.1,uM,=,0.6127838567197355,1,O=C1CSCC(=O)N1c1nnc2c3ccccc3nc(Sc3ccccc3)n12
1231,622913,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR in human A431 cells by HTRF assay,CCOC(=O)c1[nH]c(C)c2cnnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c12,"ethyl 4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methyl-6H-pyrrolo[3,4-d]pyridazine-5-carboxylate",1.21,uM,=,0.08278537031645,1,c1ccc(COc2ccc(Nc3nncc4c[nH]cc34)cc2)cc1
1232,1896899,10.1016/j.ejmech.2019.06.054,,,,"Inhibition of EGFR (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methylamide,0.0578,uM,=,-1.238072161579471,0,O=C(Nc1ccccc1)Nc1ccc(Oc2ccncc2)cc1
1233,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.06,uM,=,-1.2218487496163564,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1234,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccccc1)c1ccc(Br)cc1,(Z)-2-((E)-1-(4-bromophenyl)-3-phenylallylidene)hydrazinecarbothioamide,12.24,uM,=,1.0877814178095424,1,N=C(/C=C/c1ccccc1)c1ccccc1
1235,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(OCCCCc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 4-phenyl-butyl ester",1.25,uM,=,0.0969100130080564,1,O=C(OCCCCc1ccccc1)c1cccc(NCc2ccccc2)c1
1236,1577194,10.1016/j.bmc.2016.05.012,,,,Inhibition of recombinant His6-tagged EGFR (unknown origin) cytoplasmic domain (645 to 1186 residues) autophosphorylation expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometric analysis,c1ccc(COc2cccc(C3CC(c4ccc5c(c4)OCCO5)=NN3c3ccccc3)c2)cc1,"5-(3-(Benzyloxy)phenyl)-3-(2,3-dihydrobenzo[b][1,4]-dioxin-6-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",7.92,uM,=,0.8987251815894935,1,c1ccc(COc2cccc(C3CC(c4ccc5c(c4)OCCO5)=NN3c3ccccc3)c2)cc1
1237,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=CC(=O)N(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-N-methyl-acrylamide",0.00017,uM,=,-3.769551078621726,0,c1ccc(Nc2ncnc3cnccc23)cc1
1238,2153740,10.1021/acsmedchemlett.1c00555,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,CN1CCN(C2CCN(c3ccc(Nc4ncc(Cl)c(Nc5ccccc5P(C)(C)=O)n4)cc3C(F)(F)F)CC2)CC1,(2-((5-Chloro-2-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-3-(trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide,0.5381,uM,=,-0.2691370079535061,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
1239,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,COc1cc2ncnc(NCc3ccccc3)c2cc1OC,"Benzyl-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.01,uM,=,-2.0,0,c1ccc(CNc2ncnc3ccccc23)cc1
1240,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1,"N-Benzyl-2-cyano-3-(3,4-dihydroxy-phenyl)-acrylamide",0.1,uM,=,-1.0,0,O=C(C=Cc1ccccc1)NCc1ccccc1
1241,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,Cc1ccc(-n2cc(NC(=O)c3cccc(NS(=O)(=O)c4ccccc4)c3)cn2)cc1,3-(Phenylsulfonamido)-N-(1-(p-tolyl)-1H-pyrazol-4-yl)benzamide,9.57,uM,=,0.9809119377768436,1,O=C(Nc1cnn(-c2ccccc2)c1)c1cccc(NS(=O)(=O)c2ccccc2)c1
1242,2241031,10.1021/acs.jmedchem.1c00848,,,,Inhibition of wild type human EGFR expressed in Sf9 insect cells in presence of ATP measured by HTRF assay,CSc1nc(-c2cccc(NC(=O)c3cc(O)ccc3F)c2)c(-c2ccnc(NC(C)=O)c2)[nH]1,N-(3-(5-(2-Acetamidopyridin-4-yl)-2-(methylthio)-1H-imidazol-4-yl)phenyl)-2-fluoro-5-hydroxybenzamide,0.0062,uM,=,-2.207608310501746,0,O=C(Nc1cccc(-c2nc[nH]c2-c2ccncc2)c1)c1ccccc1
1243,946709,10.1016/j.bmc.2012.12.045,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,Nc1nc(Nc2cccc(C(F)(F)F)c2)c2cc(CCc3ccccn3)[nH]c2n1,"N4-(3-Trifluoromethylphenyl)-6-(2-pyridin-2-yl-ethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",19.3,uM,=,1.285557309007774,1,c1ccc(Nc2ncnc3[nH]c(CCc4ccccn4)cc23)cc1
1244,800208,10.1016/j.bmcl.2011.12.067,,,,Inhibition of wild-type EGFR expressed using baculovirus expression system by ELISA,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.008,uM,=,-2.096910013008056,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
1245,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,O=C(CCCCCCn1cc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)nn1)NO,"7-(4-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)-N-hydroxyheptanamide",0.0042,uM,=,-2.3767507096021,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5c[nH]nn5)cc34)cc2)cc1
1246,982642,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis,O=C(CCCN1CCCCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-bromoanilino)quinazolin-6-yl)-4-(piperidin-1-yl)butanamide,0.0135,uM,=,-1.869666231504994,0,O=C(CCCN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1247,676221,10.1021/jm100607r,,,,Inhibition of EGFR,C=CC(=O)N1CCc2c(sc3ncnc(N[C@@H](CO)c4ccccc4)c23)C1,"1-(4-[(1R)-2-Hydroxy-1-phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-propen-1-one",3.057,uM,=,0.4852954387260888,1,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1
1248,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,CC(=O)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccc(C)cc1,"1-(3-(3,4-Dichlorophenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)ethanone",19.32,uM,=,1.2860071220794749,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
1249,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,C=CC(=O)NCc1cccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccc(F)cc4)ccnc3[nH]2)c1,"N-(3-(4-(4-(4-Fluorophenyl)-2-phenyl-1H-imidazol-5-yl)-1Hpyrrolo[2,3-b]pyridin-2-yl)benzyl)acrylamide",0.0332,uM,=,-1.4788619162959638,0,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccccc4)ccnc3[nH]2)cc1
1250,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,Nc1ncnc2c1c(-c1ccccc1)cn2C1CCCC1,"7-Cyclopentyl-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",0.5,uM,=,-0.3010299956639812,0,c1ccc(-c2cn(C3CCCC3)c3ncncc23)cc1
1251,465,10.1016/s0960-894x(02)00364-5,,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Cc1cc(C(=O)NCCN2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"5-[4-(3-Chloro-4-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide",2.05,uM,=,0.3117538610557542,1,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1
1252,66579,10.1016/j.bmcl.2004.03.106,,,,Inhibition of human epidermal growth factor receptor,OC1(c2nc(-c3ccc(F)cc3)c(-c3ccnc(NC4CCCCC4)c3)o2)CCNCC1,4-[5-(2-Cyclohexylamino-pyridin-4-yl)-4-(4-fluoro-phenyl)-oxazol-2-yl]-piperidin-4-ol,1.1,uM,=,0.041392685158225,1,c1ccc(-c2nc(C3CCNCC3)oc2-c2ccnc(NC3CCCCC3)c2)cc1
1253,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCCCCNC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,N-Dodecyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetamide,1.27,uM,=,0.1038037209559568,1,O=c1cc(-c2ccccc2)oc2ccccc12
1254,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CCOC(=O)c1oc2cc(O)cc(O)c2c(=O)c1-c1ccc(O)cc1,"ethyl 5,7-dihydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromene-2-carboxylate",5.846688950443117,uM,=,0.7669099895616773,1,O=c1c(-c2ccccc2)coc2ccccc12
1255,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,(1-{(R)-1-{3-[(E)-2-(7-Chloro-quinolin-2-yl)-vinyl]-phenyl}-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propylsulfanylmethyl}-cyclopropyl)-acetic acid,3.197,uM,=,0.504742636271688,1,C(=C/c1ccc2ccccc2n1)\c1cccc([C@@H](CCc2ccccc2)SCC2CC2)c1
1256,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,O=[N+]([O-])c1ccc(C2CC(c3ccc(Br)cc3)=NN2c2nc(-c3ccccc3)cs2)cc1,"2-(3-(4-bromophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",15.72,uM,=,1.196452541703389,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
1257,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,C#Cc1cccc(Nc2ncnc3nc(Nc4ccc(CN5CCOCC5)cc4)sc23)c1,"N7-(3-ethynylphenyl)-N2-(4-(morpholinomethyl)phenyl)thiazolo[4,5-d]pyrimidine-2,7-diamine",0.043,uM,=,-1.3665315444204136,0,c1ccc(Nc2ncnc3nc(Nc4ccc(CN5CCOCC5)cc4)sc23)cc1
1258,2230042,10.1021/acs.jmedchem.1c00963,,,,Inhibition of N-terminal GST fused EGFR (668 to 1091 residues) (unknown origin) using poly (Glu-Tyr) E4Y1 peptide as substrate incubated for 2 hrs by ADP-Glo reagent method,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,TUCATINIB,0.449,uM,=,-0.3477536589966768,0,c1nc(Nc2ccc(Oc3ccn4ncnc4c3)cc2)c2cc(NC3=NCCO3)ccc2n1
1259,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1c(Br)cccc1Nc1ncnc2cc3c(cc12)OCCO3,"N-(3-Bromo-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.00249,uM,=,-2.603800652904264,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
1260,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,"5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide",18.0,uM,=,1.255272505103306,1,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1
1261,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CC(C)=CC[C@@H](OC(=O)/C=C\C(=O)c1cc(Cl)ccc1C)C1=CC(=O)c2c(O)ccc(O)c2C1=O,"(R)-1-(5,8-Dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (Z)-4-(5-chloro-2-methylphenyl)-4-oxobut-2-enoate",0.1462,uM,=,-0.8350526273781583,0,O=C(/C=C\C(=O)c1ccccc1)OCC1=CC(=O)c2ccccc2C1=O
1262,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,O=C(O)CC1C(S)=Nc2ccccc21,"(2-Thioxo-2,3-dihydro-1H-indol-3-yl)-acetic acid",14.9,uM,=,1.173186268412274,1,C1=Nc2ccccc2C1
1263,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,Nc1ccc2c(c1)CNc1c(Nc3ccc(F)c(Cl)c3)ncnc1O2,"N*1*-(3-Chloro-4-fluoro-phenyl)-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene-1,8-diamine",9.1,uM,=,0.9590413923210936,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
1264,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,COC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1Cl,"methyl 2-chloro-4-(6,7-dimethoxyquinazolin-4-ylamino)phenylcarbamate",6.15,uM,=,0.7888751157754168,1,c1ccc(Nc2ncnc3ccccc23)cc1
1265,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,O=C(NO)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2)ncc1Cl,2-(5-chloro-2-(4-morpholinophenylamino)pyrimidin-4-ylamino)-N-hydroxybenzamide,0.1687,uM,=,-0.7728849174108748,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
1266,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,Oc1cccc(-c2nc(-c3ccc(F)cc3)c(-c3ccnc4[nH]c(-c5ccccc5)cc34)[nH]2)c1,"3-(4-(4-Fluorophenyl)-5-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-imidazol-2-yl)phenol",0.0304,uM,=,-1.5171264163912463,0,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccccc4)ccnc3[nH]2)cc1
1267,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CN1CCC[C@H]1C(N)=O,(S)-1-((4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidine-2-carboxamide,0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
1268,1674599,10.1021/acs.jmedchem.8b00125,,,,Inhibition of EGFR (unknown origin),CNS(=O)(=O)c1cccc(Nc2cc(Nc3cccc(C(C)(C)C)c3)ncn2)c1,"3-[(6-{[3-(1,1-Dimethylethyl)phenyl]amino}-4-pyrimidinyl)-amino]-N-methylbenzenesulfonamide",0.4,uM,=,-0.3979400086720376,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
1269,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",O=C(/C=C/c1ccccc1)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"(2E)-N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]-3-phenylprop-2-enamide",5.004,uM,=,0.6993173010213823,1,O=C(/C=C/c1ccccc1)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(NCc4ccccc4)c23)c1
1270,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,CCCCN(CCCC)C(=O)c1ccc(N(CCCl)CCCl)cc1,"4-(Bis(2-chloroethyl)amino)-N,N-dibutylbenzamide",31.18,uM,=,1.493876110852823,1,c1ccccc1
1271,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1cc(O)c(O)c(Br)c1)C(=O)NCCCNC(=O)/C(C#N)=C/c1cc(O)c(O)c(Br)c1,"(E)-3-(3-Bromo-4,5-dihydroxy-phenyl)-N-{3-[(E)-3-(3-bromo-4,5-dihydroxy-phenyl)-2-cyano-acryloylamino]-propyl}-2-cyano-acrylamide",7.3,uM,=,0.8633228601204559,1,O=C(C=Cc1ccccc1)NCCCNC(=O)/C=C/c1ccccc1
1272,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(C4CCN(C)CC4)cc3OC)n2)c1,N-(3-(3-(2-(2-methoxy-4-(1-methylpiperidin-4-yl)phenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.273,uM,=,-0.563837352959244,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(C3CCNCC3)cc2)n1
1273,1883986,10.1021/acsmedchemlett.8b00461,,,,Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay,CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1,"(R)-5-Amino-3-(4-(2,4-difluorophenoxy)phenyl)-1-(1-((2E)-4-(dimethylamino)but-2-enoyl)piperidin-3-yl)-1H-pyrazole-4-carboxamide",0.149,uM,=,-0.826813731587726,0,c1ccc(Oc2ccc(-c3ccn([C@@H]4CCCNC4)n3)cc2)cc1
1274,66719,10.1021/jm00050a005,,,,Inhibition of EGF-R Tyrosine kinase (TK),O=C(O)c1cc(CCc2cc(O)ccc2O)ccc1O,"5-[2-(2,5-Dihydroxy-phenyl)-ethyl]-2-hydroxy-benzoic acid",3.3,uM,=,0.5185139398778875,1,c1ccc(CCc2ccccc2)cc1
1275,1973895,10.1021/acs.jmedchem.9b02008,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (668 to end residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 2 hrs followed by EGF stimulation and measured after 30 mins by TMB peroxidase substrate based assay,CN(CCO)c1ccc2ncnc(Nc3cccc(Br)c3)c2c1,2-[[4-(3-bromoanilino)quinazolin-6-yl]-methyl-amino]ethanol,0.145,uM,=,-0.8386319977650252,0,c1ccc(Nc2ncnc3ccccc23)cc1
1276,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cccc(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)c1,N-(3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,3.5,uM,=,0.5440680443502757,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1277,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid",92.0,uM,=,1.963787827345556,1,c1ccc(CNc2ccccc2)cc1
1278,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,CCOc1cc2ncnc(Nc3ccc(F)cc3)c2cc1OCC.Cl,"4-(4'-fluoroanilino)-6,7-diethoxyquinazoline hydrochloride",0.0231,uM,=,-1.6363880201078556,0,c1ccc(Nc2ncnc3ccccc23)cc1
1279,66569,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of Epidermal growth factor receptor in A431 cells,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2c1,N-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-acrylamide,0.0048,uM,=,-2.318758762624413,0,c1ccc(Oc2ccc(Nc3ncnc4ccccc34)cc2)cc1
1280,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Nc3ccc4ncsc4c3)c1NC2,"benzothiazol-6-yl-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",5.6,uM,=,0.7481880270062004,1,c1ccc2c(c1)CNc1c(Nc3ccc4ncsc4c3)ncnc1O2
1281,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(4-Bromo-2-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)acrylamide,0.1211,uM,=,-0.9168558568569478,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1282,1500854,10.1016/j.bmc.2015.04.065,,,,Inhibition of recombinant EGFR (unknown origin) assessed as inhibition of autophosphorylation after 1 hr by DELFIA/Time-resolved fluorometry,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)S/C1=C/c1cccnc1Cl,"(S,E)-N-(4-((3-Chlorophenyl)amino)quinazolin-6-yl)-1-(5-((2-chloropyridin-3-yl)methylene)-4-oxo-4,5-dihydrothiazol-2-yl)pyrrolidine-2-carboxamide",7.4,uM,=,0.8692317197309762,1,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)S/C1=C/c1cccnc1
1283,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc3ccccc3c2)c1O,2-Cyano-3-[4-hydroxy-3-methoxy-5-(naphthalen-2-ylsulfanylmethyl)-phenyl]-acrylamide,1.7,uM,=,0.2304489213782739,1,c1ccc(CSc2ccc3ccccc3c2)cc1
1284,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@H](C)C(N)=O,(R)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)propanamide,0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
1285,2260086,10.1016/j.ejmech.2020.112904,,,,Inhibition of EGFR wildtype (unknown origin) incubated for 40 mins in presence of ATP,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0022,uM,=,-2.657577319177794,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1286,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,OCC(O)Cn1ccc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"3-[4-(3-Bromo-phenylamino)-pyrrolo[3,2-g]quinazolin-8-yl]-propane-1,2-diol",0.049,uM,=,-1.3098039199714864,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
1287,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)N1CCC2(CC1)OCCO2,"(S)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-1,4-dioxa-8-azaspiro[4.5]decane-8-carboxamide",1.715,uM,=,0.2342641243787893,1,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1)N1CCC2(CC1)OCCO2
1288,792378,10.1016/j.ejmech.2011.11.015,,,,Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis,CCOc1ccccc1-c1nnc(SCc2ccccc2)o1,"2-(Benzylthio)-5-(2-ethoxyphenyl)-1,3,4-oxadiazole",38.43,uM,=,1.5846703844643488,1,c1ccc(CSc2nnc(-c3ccccc3)o2)cc1
1289,958682,10.1021/jm400463q,,,,Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC(=O)OCC#CCOc5no[n+]([O-])c5S(=O)(=O)c5ccccc5)CC4)cc3OC)ncc2Cl)c1,"4-((4-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetoxy)but-2-yn-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide",0.052,uM,=,-1.2839966563652008,0,O=C(CN1CCN(c2ccc(Nc3nccc(Oc4ccccc4)n3)cc2)CC1)OCC#CCOc1no[nH+]c1S(=O)(=O)c1ccccc1
1290,835647,10.1016/j.bmcl.2012.07.079,,,,Inhibition of EGFR in human A431 cell lysate using tyrosine/glutamic acid polymer as substrate by ELISA,Clc1cccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCCCO5)cc23)c1,"N4-(3-chlorophenyl)-N6-((3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)methyl)quinazoline-4,6-diamine",0.216,uM,=,-0.6655462488490691,0,c1ccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCCCO5)cc23)cc1
1291,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2cc(-c3cn(C)c4ccccc34)nc(OC)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((2-methoxy-6-(1-methyl-1H-indol-3-yl)pyrimidin-4-yl)amino)phenyl)acrylamide,0.636,uM,=,-0.1965428843515861,0,c1ccc(Nc2cc(-c3c[nH]c4ccccc34)ncn2)cc1
1292,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,0.272,uM,=,-0.5654310959658013,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1293,99801,10.1021/jm990947f,,,,Inhibition of EGF-stimulated MCF-7 human breast tumor cell proliferation,COc1cc(/C=C(\C#N)c2ccccn2)ccc1O,3-(4-Hydroxy-3-methoxy-phenyl)-2-pyridin-2-yl-acrylonitrile,2.1,uM,=,0.3222192947339193,1,C(=Cc1ccccn1)c1ccccc1
1294,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),N#CCCc1c(SSc2[nH]c3ccccc3c2CCC#N)[nH]c2ccccc12,3-{2-[3-(2-Cyano-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-propionitrile,47.0,uM,=,1.6720978579357175,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
1295,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(NCCO)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(2-hydroxyethyl)urea,0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1296,887629,10.1021/jm3003203,,,,Inhibition of EGF-induced autophosphorylation of EGFR in human A431 cells,CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,But-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
1297,665191,10.1016/j.bmcl.2010.08.052,,,,Inhibition of EGFR phosphorylation in human MIAPaCa cells by ELISA,CN1CCN([C@H]2CC[C@H](n3nc(-c4ccc(Nc5nc6cccc(Cl)c6o5)c(F)c4)c4c(N)ncnc43)CC2)CC1,"trans-N-(4-(4-amino-1-(4-(4-methylpiperazin-1-yl)cyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenyl)-7-chlorobenzo[d]oxazol-2-amine",2.88,uM,=,0.4593924877592308,1,c1ccc2oc(Nc3ccc(-c4nn([C@H]5CC[C@H](N6CCNCC6)CC5)c5ncncc45)cc3)nc2c1
1298,63772,10.1021/jm9903949,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cells,CCNc1cc2sc3c(Nc4cccc(Br)c4)ncnc3c2cc1F.CCO,"N*4*-(3-Bromo-phenyl)-N*7*-ethyl-8-fluoro-benzo[4,5]thieno[3,2-d]pyrimidine-4,7-diamine; compound with ethanol",0.085,uM,=,-1.0705810742857071,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
1299,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COCCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)cc3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-(Dimethylamino)-N-(7-(2-methoxyethoxy)-4-(4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl)but-2-enamide,0.01,uM,=,-2.0,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
1300,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(NS(=O)(=O)c1ccc(Br)cc1)c1cncc(Br)c1,5-bromo-N-(4-bromophenylsulfonyl)nicotinamide,2.08,uM,=,0.3180633349627615,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
1301,989154,10.1016/j.bmc.2013.09.027,,,,Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA,COc1cc(O)c2c(c1)CCN(c1cccc(C(=O)N3CCCCC3)c1)C2=O,"3,4-dihydro-8-hydroxy-6-methoxy-2-(3-(piperidin-1-ylcarbonyl)phenyl)-isoquinolin-1-(2H)-one",1.18,uM,=,0.0718820073061253,1,O=C(c1cccc(N2CCc3ccccc3C2=O)c1)N1CCCCC1
1302,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)cc1)C(=O)O,2-Cyano-3-(4-hydroxy-phenyl)-acrylic acid,200.0,uM,=,2.3010299956639813,1,c1ccccc1
1303,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C=CC(=O)Nc1cccc(-c2c(C)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-methylfuro-[2,3-d]pyrimidin-5-yl)phenyl]prop-2-enamide",0.062,uM,=,-1.207608310501746,0,c1ccc(CNc2ncnc3occ(-c4ccccc4)c23)cc1
1304,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(NC3CC3c3ccccc3)c2cc1OC(C)=O,Acetic acid 7-methoxy-4-(2-phenyl-cyclopropylamino)-quinazolin-6-yl ester,11.4,uM,=,1.0569048513364727,1,c1ccc(C2CC2Nc2ncnc3ccccc23)cc1
1305,305378,10.1021/jm049892u,,,,In vitro inhibition of Epidermal growth factor receptor,Cc1cc2c(Nc3ccc(F)c(Cl)c3)ncnn2c1,"(3-Chloro-4-fluoro-phenyl)-(6-methyl-pyrrolo[2,1-f][1,2,4]triazin-4-yl)-amine",0.15,uM,=,-0.8239087409443188,0,c1ccc(Nc2ncnn3cccc23)cc1
1306,2203131,10.1016/j.ejmech.2022.114455,,,,Inhibition of wild type EGFR (unknown origin) incubated for 10 mins by HTRF KinEASE-TK assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(CCOCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"N-(3-((2-((4-(4-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)piperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide",0.3641999999999999,uM,=,-0.4386600585410988,0,O=C1CCC(N2C(=O)c3cccc(NCCOCCN4CCN(c5ccc(Nc6nccc(Nc7ccccc7)n6)cc5)CC4)c3C2=O)C(=O)N1
1307,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,Brc1cccc(Nc2ncnc3cc4c(cnn4CCCN4CCOCC4)cc23)c1,"(3-Bromo-phenyl)-[1-(3-morpholin-4-yl-propyl)-1H-pyrazolo[4,3-g]quinazolin-5-yl]-amine",0.077,uM,=,-1.1135092748275182,0,c1ccc(Nc2ncnc3cc4c(cnn4CCCN4CCOCC4)cc23)cc1
1308,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C#CCN(C)CCN(C)c1cc(OC)c(Nc2nccc(Nc3ccn(C)n3)n2)cc1NC(=O)C=C,N-(4-methoxy-2-(methyl(2-(methyl(prop-2-yn-1-yl)amino)ethyl)amino)-5-((4-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.02234,uM,=,-1.65091683122041,0,c1ccc(Nc2nccc(Nc3cc[nH]n3)n2)cc1
1309,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,CN(C)c1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"N*4*-(3-Chloro-phenyl)-N*3*-(4-dimethylamino-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.029,uM,=,-1.537602002101044,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
1310,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,COC(=O)Cc1c(SSSc2[nH]c3ccccc3c2CC(=O)OC)[nH]c2ccccc12,"Dimethyl 2,2'-Trithiobis (1H-indole-3-acetate)",35.0,uM,=,1.5440680443502757,1,c1ccc2[nH]c(SSSc3cc4ccccc4[nH]3)cc2c1
1311,66726,10.1021/jm970641d,,,,Inhibition of tyrosine/glutamic acid copolymer phosphorylation by epidermal growth factor receptor prepared of human A431,CN(C)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-(2-dimethylamino-ethyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2ncnc3cnccc23)cc1
1312,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nc(NN)ccc3c2)c2c(N)ncnc21,"3-(2-hydrazinylquinolin-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",7.0,uM,=,0.8450980400142568,1,c1cnc2ccc(-c3n[nH]c4ncncc34)cc2c1
1313,1642157,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",2.0,uM,=,0.3010299956639812,1,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
1314,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OCC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-ethoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)buta2,3-dienamide",0.0147,uM,=,-1.832682665251824,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1315,2088808,10.1016/j.ejmech.2020.112388,,,,Inhibition of N-terminal GST-fused human wild type EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate incubated for 20 mins by Mobility shift assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1,"N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide",0.039,uM,=,-1.408935392973501,0,c1ccc(Oc2nc(Nc3ccc(N4CCNCC4)cc3)nc3ccsc23)cc1
1316,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1cccc(O)c1F)nn2C1CCCC1,"3-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",1.77,uM,=,0.2479732663618066,1,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
1317,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,Cc1ccc(NC(=O)/C=C/CN(C)C)cc1C(=O)Nc1nccc(-c2cccnc2)n1,5-(4-(Dimethylamino)but-2-enamido)-2-methyl-N-(4-(pyridin-3-yl)pyrimidin-2-yl)benzamide,5.0,uM,=,0.6989700043360189,1,O=C(Nc1nccc(-c2cccnc2)n1)c1ccccc1
1318,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,O=C(Cn1c(-c2ccccc2)cc(=O)n2ncnc12)NNC(=S)Nc1ccccc1,"2-(2-(7-oxo-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-4(7H)-yl)acetyl)-N-phenylhydrazinecarbothioamide",6.8,uM,=,0.8325089127062363,1,O=C(Cn1c(-c2ccccc2)cc(=O)n2ncnc12)NNC(=S)Nc1ccccc1
1319,327362,10.1016/j.bmcl.2005.10.015,,,,Inhibitory activity against HER1,COc1ccc(C#CC(C)(C)N)cc1-c1[nH]nc2nc(Nc3ccc(F)cc3F)ncc12,"3-(5-(3-amino-3-methylbut-1-ynyl)-2-methoxyphenyl)-N-(2,4-difluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine",5.2,uM,=,0.7160033436347992,1,c1ccc(Nc2ncc3c(-c4ccccc4)[nH]nc3n2)cc1
1320,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,CN1CCN(Cc2ccc(Nc3nc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)cc2)CC1,"N7-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-N2-(4-((4-methylpiperazin-1-yl)methyl)phenyl)thiazolo[4,5-d]pyrimidine-2,7-diamine",0.009,uM,=,-2.0457574905606752,0,c1ccc(COc2ccc(Nc3ncnc4nc(Nc5ccc(CN6CCNCC6)cc5)sc34)cc2)cc1
1321,1627833,10.1016/j.ejmech.2016.06.056,,,,Inhibition of EGFR (unknown origin) using peptide as substrate after 60 mins by HTRF assay,CC(C)S(=O)(=O)c1ccccc1Nc1nc(N/N=C/c2ccc(OC(F)(F)F)cc2)ncc1Cl,(E)-5-chloro-N-(2-(isopropylsulfonyl)phenyl)-2-(2-(4-(trifluoromethoxy)benzylidene)hydrazinyl)pyrimidin-4-amine,0.898,uM,=,-0.0467236633326956,0,C(=N/Nc1nccc(Nc2ccccc2)n1)\c1ccccc1
1322,850422,10.1016/j.bmc.2012.08.002,,,,Inhibition of human N-terminal DYKDDDD tagged EGFR cytoplasmic domain amino acid 669 to 1210 expressed in baculovirus after 5 mins by scintillation counter,CCS(=O)(=O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,"N-(2-(4-(3-chloro-4-(3-(trifluoromethyl)phenoxy)phenylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-2-(ethylsulfonyl)acetamide",0.031,uM,=,-1.5086383061657274,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
1323,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)cc3OC)ncc2Cl)c1,"US9238629, I-15",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
1324,66719,10.1021/jm00050a005,,,,Inhibition of EGF-R Tyrosine kinase (TK),O=C(O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid",2.9,uM,=,0.4623979978989561,1,c1ccc(CNc2ccccc2)cc1
1325,2203131,10.1016/j.ejmech.2022.114455,,,,Inhibition of wild type EGFR (unknown origin) incubated for 10 mins by HTRF KinEASE-TK assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CCCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"N-(3-((2-((4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoyl)piperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide",0.6144,uM,=,-0.2115487929765444,0,O=C1CCC(N2C(=O)c3cccc(NCCCCC(=O)N4CCN(c5ccc(Nc6nccc(Nc7ccccc7)n6)cc5)CC4)c3C2=O)C(=O)N1
1326,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COC[C@@H](Nc1ncnc2sc(Br)cc12)c1ccccc1,"(S)-6-bromo-N-(2-methoxy-1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine",0.262,uM,=,-0.5816987086802545,0,c1ccc(CNc2ncnc3sccc23)cc1
1327,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CN1CCN(CCC#CC(=O)Nc2cc3c(Nc4ccc(F)c(Br)c4)ncnc3cn2)CC1,"N-[4-[(3-bromo-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-5-(4-methyl-1-piperazinyl)-2-pentynamide",0.0011,uM,=,-2.958607314841775,0,O=C(C#CCCN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
1328,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)c1,"5-((1,4-diazepan-1-yl)methyl)-N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.033,uM,=,-1.4814860601221125,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)cc1
1329,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CN1CC2CCC1C(=O)C2)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(6-oxo-2-azabicyclo[2.2.2]octan-2-yl)but-2-enamide",0.0009,uM,=,-3.0457574905606752,0,O=C(/C=C/CN1CC2CCC1C(=O)C2)Nc1cc2c(Nc3ccccc3)ncnc2s1
1330,591074,10.1021/jm9010065,,,,Inhibition of human recombinant HER1 expressed in Sf9 cells by liquid scintillation counting,CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)OC[C@@H]1COCCN1,"{4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl}-carbamic acid,(3S)-3-morpholinylmethyl ester",0.033,uM,=,-1.4814860601221125,0,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OC[C@@H]1COCCN1
1331,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Oc1c(Br)cc(Br)cc1CN(Cc1ccc(F)cc1)C(=S)Nc1ccccc1,"1-(3,5-Dibromo-2-hydroxybenzyl)-1-(4-fluorobenzyl)-3-phenylthiourea",1.76,uM,=,0.2455126678141498,1,S=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
1332,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)ncnc2cc1OC,N-(7-Methoxy-4-{4-[(phenylsulfonyl)amino]anilino}-6-quinazolinyl)propanamide,0.065,uM,=,-1.1870866433571443,0,O=S(=O)(Nc1ccc(Nc2ncnc3ccccc23)cc1)c1ccccc1
1333,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#CCN1CCOCC1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-(3-morpholinoprop-1-ynyl)pyrimidin-4-amine,4.13,uM,=,0.615950051656401,1,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)CN1CCOCC1
1334,1291542,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGFR (unknown origin) after 10 mins,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN(C)C)CCO4)c1,"4-(dimethylamino)-1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)but-2-en-1-one",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3cc4c(cc23)NCCO4)cc1
1335,800208,10.1016/j.bmcl.2011.12.067,,,,Inhibition of wild-type EGFR expressed using baculovirus expression system by ELISA,COc1ccc2c3oc(=O)cc(O)c3c(=O)n(C)c2c1,"4-hydroxy-8-methoxy-6-methyl-2H-pyrano[3,2-c]quinoline-2,5(6H)-dione",76.4,uM,=,1.88309335857569,1,O=c1ccc2c(=O)[nH]c3ccccc3c2o1
1336,1674791,10.1016/j.ejmech.2017.03.001,,,,"Inhibition of recombinant human N-terminal GST-tagged wild-type EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay",C=CC(=O)N1CCc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21,"1-(1-acryloylindolin-6-yl)-9-(1-methyl-1H-pyrazol-4-yl)benzo[h][1,6]naphthyridin-2(1H)-one",0.874,uM,=,-0.0584885673655969,0,O=c1ccc2cnc3ccc(-c4cn[nH]c4)cc3c2n1-c1ccc2c(c1)NCC2
1337,2013776,10.1016/j.bmc.2019.04.024,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins followed by substrate addition and measured after 1 hr by mobility shift assay,COc1ncc(-c2ccc3ncnc(Nc4cnn(CCO)c4)c3c2)cc1NS(C)(=O)=O,N-(5-(4-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)quinazolin-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide,2.52,uM,=,0.4014005407815441,1,c1cncc(-c2ccc3ncnc(Nc4cn[nH]c4)c3c2)c1
1338,947940,10.1021/np300764u,,,,Inhibition of EGFR (unknown origin),O=C1NCCc2ccc(O)c(c2)Oc2c(Br)cc(cc2Br)CCNC(=O)/C(=N/O)Cc2cc(Br)c(O)c(c2)Oc2c(Br)cc(cc2Br)C/C1=N\O,Bastadin 16,2.9,uM,=,0.4623979978989561,1,N=C1Cc2ccc(cc2)Oc2cccc(c2)CC(=N)C(=O)NCCc2ccc(cc2)Oc2cccc(c2)CCNC1=O
1339,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",CCOc1cc2ncnc(Nc3ccccc3F)c2cc1OCC.Cl,"4-(2'-fluoroanilino)-6,7-diethoxyquinazoline hydrochloride",0.00931,uM,=,-2.0310503190186573,0,c1ccc(Nc2ncnc3ccccc23)cc1
1340,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(Cc1cc(NCc2cc(O)ccc2O)ccc1O)NOCc1ccccc1,"N-Benzyloxy-2-[5-(2,5-dihydroxy-benzylamino)-2-hydroxy-phenyl]-acetamide",16.0,uM,=,1.2041199826559248,1,O=C(Cc1cccc(NCc2ccccc2)c1)NOCc1ccccc1
1341,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,CC(=O)N1N=C(c2ccc(C)c(C)c2)CC1c1ccc(Br)cc1,"1-(5-(4-Bromophenyl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone",20.61,uM,=,1.314077991779213,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
1342,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCC(N(C)C)CC4)cc3OC)n2)c1,N-(3-(3-(2-(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.045,uM,=,-1.3467874862246565,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCCCC3)cc2)n1
1343,2059412,10.1016/j.bmc.2021.116061,,,,Inhibition of EGFR in human A431 cells preincubated for 60 mins followed by EGF stimulation and measured after 10 mins by ELISA,COc1ccc2c(c1)CCCN2c1nc(C)nc2ccccc12,"6-Methoxy-N-(2'-methylquinazol-4'-yl)-1,2,3,4-tetrahydroquinoline",0.005,uM,=,-2.3010299956639813,0,c1ccc2c(c1)CCCN2c1ncnc2ccccc12
1344,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,NC(=O)C1CCN(Cc2ccc(-c3cc4nccc(Nc5ccc6[nH]ccc6c5)c4s3)cc2)CC1,"1-{4-[7-(1H-Indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-isonicotinamide",0.001,uM,=,-3.0,0,c1cc(Nc2ccc3[nH]ccc3c2)c2sc(-c3ccc(CN4CCCCC4)cc3)cc2n1
1345,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(CCN(C)C)[C@@H](C)C(N)=O,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(2-(dimethylamino)ethyl)amino)propanamide,0.12,uM,=,-0.9208187539523752,0,c1ccc(Nc2ncnc3ccccc23)cc1
1346,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CN(C)CCN(C)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-phenyl)-N*7*-(2-dimethylamino-ethyl)-N*7*-methyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3ccncc23)cc1
1347,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3ccc(Br)cc3)c2cc1OC,"(4-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.0009599999999999,uM,=,-3.017728766960432,0,c1ccc(Nc2ncnc3ccccc23)cc1
1348,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,COc1ccc(-c2cc3c(N[C@H](C)c4ccccc4F)ncnc3o2)cc1,"(R)-N-(1-(2-Fluorophenyl)ethyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-amine",0.024,uM,=,-1.619788758288394,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
1349,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccccc3OC)ncc2Cl)c1,"US9238629, I-18",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
1350,1500854,10.1016/j.bmc.2015.04.065,,,,Inhibition of recombinant EGFR (unknown origin) assessed as inhibition of autophosphorylation after 1 hr by DELFIA/Time-resolved fluorometry,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)S/C1=C/c1cccnc1,"(S,E)-N-(4-((3-Chlorophenyl)amino)quinazolin-6-yl)-1-(4-oxo-5-(pyridin-3-ylmethylene)-4,5-dihydrothiazol-2-yl)-pyrrolidine-2-carboxamide",9.8,uM,=,0.9912260756924948,1,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)S/C1=C/c1cccnc1
1351,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1cc(O)ccc1-c1nn(C(C)C)c2ncnc(N)c12,"4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-methylphenol",0.954,uM,=,-0.0204516252959049,0,c1ccc(-c2n[nH]c3ncncc23)cc1
1352,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,C/C(=C\c1c(C)ncnc1Nc1ccc(OCc2cccc(F)c2)c(Cl)c1)C(=O)NCCN1CCOCC1,3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-methylpyrimidin-5-yl)-2-methyl-N-(2-morpholinoethyl)acrylamide,0.028,uM,=,-1.5528419686577808,0,O=C(C=Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)NCCN1CCOCC1
1353,974507,10.1016/j.ejmech.2013.05.026,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.0032,uM,=,-2.494850021680094,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1354,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),NC(=O)CCC1C(S)=Nc2ccccc21,"3-(2-Thioxo-2,3-dihydro-1H-indol-3-yl)-propionamide",22.0,uM,=,1.3424226808222062,1,C1=Nc2ccccc2C1
1355,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(CC#N)c2)c2c(N)ncnc21,"2-(3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)acetonitrile",17.0,uM,=,1.230448921378274,1,c1ccc(-c2n[nH]c3ncncc23)cc1
1356,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc4c(ccn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(1-benzyl-1H-indol-5-ylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.1,uM,=,-1.0,0,c1ccc(Cn2ccc3cc(Nc4ccnc5ccccc45)ccc32)cc1
1357,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc(O)cc3)C2)cc1C,"4-(3-(3,4-dimethylphenyl)-1-(4-phenylthiazol-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)phenol",1.92,uM,=,0.2833012287035495,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
1358,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,CC(C)(C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc5sncc45)c(Cl)c3)c21)S(C)(=O)=O,"N-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]-amino}-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl]-2-methyl-2-(methylsulfonyl)propanamide",0.0055,uM,=,-2.2596373105057563,0,c1cc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)c2cnsc2c1
1359,457884,10.1016/j.bmcl.2007.08.073,,,,Inhibition of EGFR,C[C@H](COc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12)N(C)C(=O)CO,(R)-N-(1-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)propan-2-yl)-2-hydroxy-N-methylacetamide,0.003,uM,=,-2.5228787452803374,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
1360,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,Cc1ncc([N+](=O)[O-])n1CC(=O)NS(=O)(=O)c1ccccc1,2-(2-Methyl-5-nitro-1H-imidazol-1-yl)-N-(phenylsulfonyl)acetamide,2.94,uM,=,0.4683473304121572,1,O=C(Cn1ccnc1)NS(=O)(=O)c1ccccc1
1361,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(c3ccc(OCc4ccccc4)cc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(3-(4-(Benzyloxy)phenyl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.0016699999999999,uM,=,-2.7772835288524167,0,O=C1N(c2ccc(OCc3ccccc3)cc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
1362,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C#N)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((5-cyano-4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.035,uM,=,-1.4559319556497243,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)cc1
1363,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)NC1(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"US9447106, 108",0.0032,uM,=,-2.494850021680094,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(C3CC3)CCN4)cc2)cc1
1364,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(OCc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid benzyl ester",0.08,uM,=,-1.0969100130080565,0,O=C(OCc1ccccc1)c1cccc(NCc2ccccc2)c1
1365,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Fc1ccc2c(c1)CNc1c(Nc3cccc(Br)c3)ncnc1O2,"(3-Bromo-phenyl)-(8-fluoro-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",1.5,uM,=,0.1760912590556812,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
1366,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#C/C(=C\c1ccc(C=O)cc1)C(=O)O,2-Cyano-3-(4-formyl-phenyl)-acrylic acid,47.0,uM,=,1.6720978579357175,1,c1ccccc1
1367,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1ccc(-n2c(=O)c(C)nc3cnc(Nc4ccc(OC)cc4)nc32)cc1,N-(4-(2-(4-Methoxyphenylamino)-6-methyl-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,16.338,uM,=,1.2131988917236085,1,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
1368,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3cc[nH]c3c2)c2c(N)ncnc21,"3-(1H-indol-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.22,uM,=,-0.6575773191777937,0,c1ncc2c(-c3ccc4cc[nH]c4c3)n[nH]c2n1
1369,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,COc1ccc(NC(=O)/C=C/CN(C)C)cc1Nc1ncc(C)c(-c2cnn3ccccc23)n1,"(E)-4-(dimethylamino)-N-(4-methoxy-3-(5-methyl-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)phenyl)but-2-enamide",24.0,uM,=,1.380211241711606,1,c1ccc(Nc2nccc(-c3cnn4ccccc34)n2)cc1
1370,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(Nc4ccc(N5CCCN(C)CC5)cc4OC)nc32)c1,"N-(3-(7-(2-Methoxy-4-(4-methyl-1,4-diazepan-1-yl)-phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]-pyrimidin-1(2H)-yl)phenyl)acrylamide",0.00147,uM,=,-2.832682665251824,0,O=C1NCc2cnc(Nc3ccc(N4CCCNCC4)cc3)nc2N1c1ccccc1
1371,78511,10.1016/j.bmcl.2003.10.010,,,,Inhibition of EGFR overexpressing HN5 (head/neck carcinoma) cell line proliferation,CS(=O)(=O)CCNCCCCOc1ccc2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c2c1,[1-(3-Fluoro-benzyl)-1H-indazol-5-yl]-{6-[4-(methanesulfonylmethyl-amino)-butoxy]-quinazolin-4-yl}-amine,0.63,uM,=,-0.2006594505464183,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccccc45)ccc32)cc1
1372,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,COc1cc(/C=C(\C#N)C(N)=C(C#N)C#N)cc(O)c1O,"3-Amino-2,4-dicyano-5-(3,4-dihydroxy-5-methoxy-phenyl)-penta-2,4-dienenitrile",1.2,uM,=,0.0791812460476248,1,c1ccccc1
1373,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)[C@H](C(=O)OC)C4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-48",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1374,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),O=C(CC1C(S)=Nc2ccccc21)NCc1ccccc1,"N-Benzyl-2-(2-thioxo-2,3-dihydro-1H-indol-3-yl)-acetamide",100.0,uM,=,2.0,1,O=C(CC1C=Nc2ccccc21)NCc1ccccc1
1375,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,FC(F)(F)c1csc(NC(=S)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)n1,1-(4-((3-Chlorophenyl)amino)quinazolin-6-yl)-3-(4-(trifluoromethyl)thiazol-2-yl)thiourea,0.137,uM,=,-0.8632794328435932,0,S=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1nccs1
1376,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)CCN(C)C,N-(4-(3-Chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl)-3-(dimethylamino)propanamide,0.00027,uM,=,-3.5686362358410126,0,c1ccc(Nc2ncnc3ccccc23)cc1
1377,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,OCc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)o1,(5-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)furan-2-yl)methanol,0.033,uM,=,-1.4814860601221125,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccco1
1378,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,O=C(C#CCCN1CCCCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-5-(1-piperidinyl)-2-pentynamide",0.0043,uM,=,-2.3665315444204134,0,O=C(C#CCCN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
1379,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc(NCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(4-benzylamino-3-chloro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,0.4,uM,=,-0.3979400086720376,0,c1ccc(CNc2ccc(Nc3ccnc4ccccc34)cc2)cc1
1380,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(Nc3cncc4ccccc34)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-isoquinolin-4-yl-amine",0.0064,uM,=,-2.193820026016113,0,c1ccc2c(Nc3ncnc4ccccc34)cncc2c1
1381,2203131,10.1016/j.ejmech.2022.114455,,,,Inhibition of wild type EGFR (unknown origin) incubated for 10 mins by HTRF KinEASE-TK assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(CC(=O)NCCNc5cccc6c5C(=O)N(C5CCC(=O)N(C)C5=O)C6=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"N-(3-((2-((2-methoxy-4-(4-(2-((2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)amino)-2-oxoethyl)piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide",1.404,uM,=,0.1473671077937864,1,O=C(CN1CCN(c2ccc(Nc3nccc(Nc4ccccc4)n3)cc2)CC1)NCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O
1382,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)S(=O)(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-[(E)-2-Cyano-1-(3,4-dihydroxy-phenyl)-ethenesulfonyl]-3-(3,4-dihydroxy-phenyl)-acrylonitrile",2.0,uM,=,0.3010299956639812,1,O=S(=O)(C=Cc1ccccc1)/C=C/c1ccccc1
1383,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,C[C@@H](Nc1ncnc2oc(-c3ccc(NCCN4CCCCC4)cc3)cc12)c1ccccc1,"(R)-N-(1-Phenylethyl)-6-(4-((2-(piperidin-1-yl)ethyl)amino)phenyl)furo[2,3-d]pyrimidin-4-amine",0.0006,uM,=,-3.2218487496163566,0,c1ccc(CNc2ncnc3oc(-c4ccc(NCCN5CCCCC5)cc4)cc23)cc1
1384,66724,10.1021/jm00032a020,,,,Inhibition of EGFR(epidermal growth factor receptor) autophosphorylation in ER22 cell membranes,CC(COC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O)CC(C)(C)C,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 2,4,4-trimethyl-pentyl ester",8.0,uM,=,0.9030899869919436,1,c1ccc(CNc2ccccc2)cc1
1385,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,"(3S,4aS,8aS)-2-[(2R,3R)-2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylsulfanyl-butyl]-decahydro-isoquinoline-3-carboxylic acid tert-butylamide",55.629,uM,=,1.7453012530311502,1,O=C(N[C@H](CCN1CC[C@@H]2CCCC[C@@H]2C1)CSc1ccccc1)c1ccccc1
1386,65106,10.1021/jm00032a020,,,,Inhibition of EGF-stimulated DNA synthesis in ER 22 (EGF-receptor expressing) cells,COC(=O)Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O,"(5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-phenyl)-acetic acid methyl ester",20.0,uM,=,1.3010299956639813,1,C(=N/c1ccccc1)\c1ccccc1
1387,1770089,10.1016/j.bmcl.2017.12.009,,,,Inhibition of wild-type EGFR phosphorylation in human A431 cells preincubated for 1 hr followed by EGF stimulation measured after 45 mins by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.71,uM,=,-0.1487416512809247,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1388,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,COC(=O)c1ccccc1SCC(CN(C)C)C(=O)c1ccc(OCc2ccccc2)cc1.Cl,2-[3-(4-Benzyloxy-phenyl)-2-dimethylaminomethyl-3-oxo-propylsulfanyl]-benzoic acid methyl ester hydrochloride,8.8,uM,=,0.9444826721501688,1,O=C(CCSc1ccccc1)c1ccc(OCc2ccccc2)cc1
1389,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCOC(=O)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnn2c1,"4-(1-Benzyl-1H-indazol-5-ylamino)-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester",0.12,uM,=,-0.9208187539523752,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
1390,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCCOC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,Decyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetate,3.11,uM,=,0.4927603890268375,1,O=c1cc(-c2ccccc2)oc2ccccc12
1391,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1ccc(-c2cc3c(N[C@H](C)c4ccccc4)ncnc3s2)c(OC)c1,"(R)-6-(2,4-Dimethoxyphenyl)-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
1392,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cnc3nccnc3c2)c2c(N)ncnc21,"1-isopropyl-3-(pyrido[3,2-b]pyrazin-7-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",70.0,uM,=,1.845098040014257,1,c1cnc2ncc(-c3n[nH]c4ncncc34)cc2n1
1393,1738745,10.1016/j.ejmech.2018.04.052,,,,"Inhibition of recombinant human GST-tagged wild type EGFR expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(Nc2nccc(Nc3ccccc3-n3cccn3)n2)c(OC)cc1N(C)CCN(C)C,N-(5-((4-((2-(1H-pyrazol-1-yl)phenyl)amino)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,0.6482,uM,=,-0.1882909733038088,0,c1ccc(Nc2nccc(Nc3ccccc3-n3cccn3)n2)cc1
1394,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1SCCN(C)C,N-(2-((2-(dimethylamino)ethyl)thio)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,0.329,uM,=,-0.4828041020500256,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1395,66576,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1ccc2c(Nc3cccc(C)c3)ncnc2c1,N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide,0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2ncnc3ccccc23)cc1
1396,66578,10.1016/j.bmcl.2004.03.111,,,,Inhibition of human Epidermal growth factor receptor,COc1ccc(C#CC(C)(C)N)cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1,"[5-(3-Amino-3-methyl-but-1-ynyl)-2-methoxy-phenyl]-[4-(2,4-difluoro-phenylamino)-phenyl]-methanone",4.4,uM,=,0.6434526764861874,1,O=C(c1ccccc1)c1ccc(Nc2ccccc2)cc1
1397,1338035,10.1016/j.ejmech.2014.02.032,,,,Inhibition of EGFR (unknown origin) after 1.5 hr by FRET-based Z-lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.0044,uM,=,-2.356547323513813,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1398,1541778,10.1016/j.bmc.2015.12.001,,,,Inhibition of wild-type EGFR tyrosine kinase (unknown origin) assessed as ATP level by luminescence analysis,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0013,uM,=,-2.886056647693163,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1399,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,C=CC(=O)Nc1ccc2c(c1)CNc1c(Nc3ccc(F)c(Cl)c3)ncnc1O2,"N-[1-(3-Chloro-4-fluoro-phenylamino)-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-8-yl]-acrylamide",4.9,uM,=,0.6901960800285137,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
1400,550161,10.1021/np9605293,,,,Displacement of [125I]-TGFalpha from human EGFR in human A431 cell membrane by SPA,CCC(C)/C=C/C(=O)C(=O)/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H]1C[C@@H](O)[C@H](C(=O)O)O1,cochliobolic acid,1.6,uM,=,0.2041199826559248,1,C1CCOC1
1401,1467840,10.1016/j.ejmech.2015.03.029,,,,Inhibition of EGFR intracellular domain (unknown origin) purified from a baculovirus expression system using Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2 as substrate after 10 mins by scintillation counting in presence of [gamma-33P]ATP,CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1,"N*4*-(1-Benzyl-1H-indazol-5-yl)-N*6*,N*6*-dimethyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.007,uM,=,-2.154901959985743,0,c1ccc(Cn2ncc3cc(Nc4ncnc5cnccc45)ccc32)cc1
1402,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCOC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,Octyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetate,5.84,uM,=,0.7664128471123994,1,O=c1cc(-c2ccccc2)oc2ccccc12
1403,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,Cc1cc2cc(Nc3ccnc4cc(-c5ccc(CNCCOCCO)cc5)sc34)ccc2[nH]1,"2-(2-{4-[7-(2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-ethoxy)-ethanol",0.657,uM,=,-0.1824346304402192,0,c1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
1404,1528598,,,,,"In Vitro Kinase Assay: In vitro kinase analysis was performed by using HTScan EGF Receptor Kinase Assay Kit (#7909) and HTScan HER2/ErbB2 Kinase Assay Kit (#7058) from Cell Signaling Technology Company. Operation steps refer to the specification of the used kits, and the method was used to measure the inhibition effects of the compound to be tested on substrate peptide phosphorylation of EGFR or Her2 receptor tyrosine kinase. At room temperature, ATP and substrate peptide as well as the compound to be tested were incubated in kinase reaction buffer, after a period of incubation, a stop buffer was added to terminate the reaction and the sample was transferred to a streptavidin-coated 96-well plate, the plate was washed and the phosphorylation level of substrate peptide was detected by using HRP-marked antibody against substrate phosphorylation, colorated with TMB, terminated the reaction with 2M sulfuric acid. Absorption at 450 nm wavelength was detected, and IC50 value (Î¼M) was calculated.",O=S(=O)(NCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)C(F)(F)F,"US8916574, Compound 6",0.0324,uM,=,-1.489454989793388,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
1405,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1ccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc32)cc1,N-(4-(2-(4-(4-Methylpiperazin-1-yl)phenylamino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,1.1,uM,=,0.041392685158225,1,O=c1cnc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
1406,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#C/C=N/OCCN1CCOCC1,3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-methylpyrimidin-5-yl)propiolaldehyde O-2-morpholinoethyl oxime,0.038,uM,=,-1.42021640338319,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)/C=N/OCCN1CCOCC1
1407,64442,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor (EGFR) in A431 cells,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-4-fluoro-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-acrylamide",0.0021,uM,=,-2.6777807052660805,0,c1ccc(Nc2ncnc3cnccc23)cc1
1408,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Oc3cccc(Cl)c3)c2c1C,"4-(3-Chloro-phenoxy)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine",2.5,uM,=,0.3979400086720376,1,c1ccc(Oc2ncnc3[nH]ccc23)cc1
1409,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Nc1ccc2ncnc(Nc3ccc4c(ccn4Cc4cccc(F)c4)c3)c2c1,"N4-(1-(3-fluorobenzyl)-1H-indol-5-yl)quinazoline-4,6-diamine",0.0030099999999999,uM,=,-2.521433504406157,0,c1ccc(Cn2ccc3cc(Nc4ncnc5ccccc45)ccc32)cc1
1410,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Cc1cccc(Nc2cc(NCCO)ncn2)c1,2-(6-m-Tolylamino-pyrimidin-4-ylamino)-ethanol,0.001,uM,=,-3.0,0,c1ccc(Nc2ccncn2)cc1
1411,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,COc1cc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc(OC)c1,"6-(2,6-Dichloro-phenyl)-2-(3,5-dimethoxy-phenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",0.33,uM,=,-0.4814860601221125,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
1412,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CCCCN(CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1)CCCC,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-4-(dibutylamino)-2-butynamide",0.017,uM,=,-1.769551078621726,0,c1ccc(Nc2ncnc3cnccc23)cc1
1413,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC1CCN(S(C)(=O)=O)CC1,N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(1-(methylsulfonyl)piperidin-4-yloxy)quinazolin-4-amine,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
1414,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,C=CC(=O)Nc1cccc(-c2c[nH]c3nccc(-c4[nH]c(-c5ccccc5)nc4-c4ccc(F)cc4)c23)c1,"N-(3-(4-(4-(4-Fluorophenyl)-2-phenyl-1H-imidazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl)acrylamide",0.0105,uM,=,-1.978810700930062,0,c1ccc(-c2nc(-c3ccccc3)c(-c3ccnc4[nH]cc(-c5ccccc5)c34)[nH]2)cc1
1415,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Cc1ccc(-n2cc(C(=O)c3c(C)[nH]c(-c4ccccc4)c3-c3ccccc3)c(C(=O)Nc3ccccc3)n2)cc1,"1-(4-Chlorophenyl)-4-(2-methyl-4,5-diphenyl-1H-pyrrole-3-carbonyl)-N-phenyl-1H-pyrazole-3-carboxamide",4.49,uM,=,0.6522463410033232,1,O=C(c1cn(-c2ccccc2)nc1C(=O)Nc1ccccc1)c1c[nH]c(-c2ccccc2)c1-c1ccccc1
1416,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1Cl,"N*4*-(3-Bromo-phenyl)-7-chloro-quinazoline-4,6-diamine",0.0065,uM,=,-2.1870866433571443,0,c1ccc(Nc2ncnc3ccccc23)cc1
1417,1842435,10.1016/j.ejmech.2019.03.004,,,,Inhibition of EGFR in human DU145 cells assessed as reduction in cell proliferation incubated for 72 hrs by Coulter counter method,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.4,uM,=,-0.3979400086720376,0,c1ccc(Nc2ncnc3ccccc23)cc1
1418,2017350,10.1021/acs.jmedchem.0c00870,,,,Inhibiton of EGFR (unknown origin) expressed in human A431 cells assessed as reduction in EGFR induced cell viability after 96 hrs by CellTiter-Glo assay,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,10.117,uM,=,1.005051749993996,1,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
1419,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4cccc(C(F)(F)F)c4)c3cc2N1CCCN1CCOCC1,"6-(3-morpholinopropyl)-4-((3-(trifluoromethyl)phenyl)amino)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.8292,uM,=,-0.0813407065781767,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
1420,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,CN(c1ccccc1)c1ncnc2ccccc12,Methyl-phenyl-quinazolin-4-yl-amine,100.0,uM,=,2.0,1,c1ccc(Nc2ncnc3ccccc23)cc1
1421,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CN1CCN(C/C=C/C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cn2)CC1,"(2E)-N-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(4-methyl-1-piperazinyl)-2-butenamide",0.019,uM,=,-1.7212463990471711,0,O=C(/C=C/CN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
1422,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,"2-(2,2-Dicyclohexyl-ethyl)-piperidine",1.4852,uM,=,0.1717849405541213,1,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1
1423,2192552,10.1021/acs.jmedchem.1c01170,,,,Inhibition of EGFR (unknown origin) using peptide substrate in presence of ATP by caliper electrophoresis method,CC(C)(C)/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1,"US9090621, 125A",0.368,uM,=,-0.4341521813264823,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
1424,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5OC)cc4)[nH]c23)C1,"2-(4-(2-methoxyphenoxy)phenyl)-7-(1-propioloylpyrrolidin-3-yl)-1H-imidazo[1,2-b]pyrazole-3-carboxamide",0.104,uM,=,-0.9829666607012196,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNC5)c4[nH]3)cc2)cc1
1425,942125,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin) using biotinylated-PTP1B (Tyr66) as substrate incubated for 5 mins prior to substrate addition measured after 1 hr by ELISA,COc1cc2ncnc(Nc3cccc(SC)c3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-methylsulfanyl-phenyl)-amine",0.1267,uM,=,-0.8972233851165586,0,c1ccc(Nc2ncnc3ccccc23)cc1
1426,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1,N-(3-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)benzyl)acetamide,0.06,uM,=,-1.2218487496163564,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
1427,2147415,10.1021/acs.jmedchem.1c01055,,,,Inhibition of Wild type EGFR (unknown origin),COc1cc(N2CCOCC2)c(-c2cnn(C)c2)cc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,(2-((5-Chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-morpholinophenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide,0.0044,uM,=,-2.356547323513813,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCOCC4)c(-c4cn[nH]c4)c3)n2)cc1
1428,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.08,uM,=,-1.0969100130080565,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1429,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,COc1cc2ncnc(Nc3ccc(N4Cc5ccccc5C4)cc3)c2cc1OC,"N-[4-(isoindolin-2-yl)phenyl]-6',7'-dimethoxyquinazolin-4'-amine",1.6,uM,=,0.2041199826559248,1,c1ccc2c(c1)CN(c1ccc(Nc3ncnc4ccccc34)cc1)C2
1430,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(Br)c(C)c3)c2c1,N-(4-(4-bromo-3-methylphenylamino)quinazolin-6-yl)acrylamide,2.3,uM,=,0.3617278360175928,1,c1ccc(Nc2ncnc3ccccc23)cc1
1431,340860,10.1016/j.bmcl.2005.12.028,,,,Inhibitory activity against EGFR,COc1cc(OC2CCOCC2)c2c(Nc3ccc(F)c(Cl)c3)ncnc2c1,N-(3-chloro-4-fluorophenyl)-7-methoxy-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine,1.384,uM,=,0.1411360901207389,1,c1ccc(Nc2ncnc3cccc(OC4CCOCC4)c23)cc1
1432,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,OCCCNCc1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"3-{4-[7-(1H-Indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-propan-1-ol",0.009,uM,=,-2.0457574905606752,0,c1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
1433,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1cc2c(cc1[N+](=O)[O-])OCO2,"2-(6-Nitro-benzo[1,3]dioxol-5-ylmethylene)-malononitrile",560.0,uM,=,2.7481880270062,1,c1ccc2c(c1)OCO2
1434,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-{4-(3-Chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl}propanamide,0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
1435,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)cc3O)c2cc1OC,"5-(benzo[d]thiazol-2-yl)-2-(6,7-dimethoxyquinazolin-4-ylamino)phenol",2.2,uM,=,0.3424226808222063,1,c1ccc2sc(-c3ccc(Nc4ncnc5ccccc45)cc3)nc2c1
1436,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CS(=O)(=O)CCNCc1ccc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)s1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)thiophen-2-yl)thieno[2,3-d]pyrimidin-4-amine",0.096,uM,=,-1.0177287669604316,0,c1ccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2)cc1
1437,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4ccccn4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-(4-{[3,6-dioxo-4-(pyridin-2-ylmethoxy)cyclohexa-1,4-dien-1-yl]amino}-7-ethoxyquinazolin-6-yl)but-2-enamide",0.0907999999999999,uM,=,-1.041914151478915,0,O=C1C=C(OCc2ccccn2)C(=O)C=C1Nc1ncnc2ccccc12
1438,76720,10.1021/jm0000214,,,,Inhibition of EGF-dependent proliferation of human and guinea pig keratinocytes; range 7-15 uM,N#C/C(=C\c1ccc(O)c(O)c1)C(N)=S,"2-Cyano-3-(3,4-dihydroxy-phenyl)-thioacrylamide",7.0,uM,=,0.8450980400142568,1,c1ccccc1
1439,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Fc1c(Br)cccc1Nc1ncnc2cc3c(cc12)OCCO3,"N-(3-Bromo-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.00395,uM,=,-2.40340290437354,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
1440,63772,10.1021/jm9903949,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cells,CCO.CNc1ccc2sc3c(Nc4cccc(Br)c4)ncnc3c2c1,"N*4*-(3-Bromo-phenyl)-N*8*-methyl-benzo[4,5]thieno[3,2-d]pyrimidine-4,8-diamine; compound with ethanol",0.033,uM,=,-1.4814860601221125,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
1441,553933,10.1021/np070447m,,,,Inhibition of recombinant EGFR,COc1cc(O)c(C(=O)O)c(C2=C(C)C[C@@H](O)C2=O)c1,Alternarienonic acid,0.02337464931849,uM,=,-1.6312548959714717,0,O=C1CCC=C1c1ccccc1
1442,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,O=[N+]([O-])c1ccc2c(Nc3cccc(Br)c3)ncnc2c1,(3-Bromo-phenyl)-(7-nitro-quinazolin-4-yl)-amine,1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
1443,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,Oc1cccc(Nc2ncnc3ccc(NC(=S)NCc4ccccc4)cc23)c1,1-benzyl-3-(4-((3-hydroxyphenyl)amino)quinazolin-6-yl)thiourea,0.0636,uM,=,-1.1965428843515862,0,S=C(NCc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1444,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3ccccc3)c3c(N)ncnc32)C1,"(R,E)-1-(3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-4-(dimethylamino)but-2-en-1-one",3.0,uM,=,0.4771212547196624,1,c1ccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)cc1
1445,1639950,,,,,Inhibition of recombinant human N-terminal GST His6-tagged thrombin cleavage site-fused EGFR (H672 to A1210 residues) expressed in baculovirus using poly-EY as substrate after 210 mins by luciferase coupled chemiluminescence assay,COc1cc(Nc2ncnc3cc(OCC4CN(C)CCO4)c(OC)cc23)c(OC)cc1Cl,"N-[4-chloro-2,5-bis(methyloxy)phenyl]-7-{[(4-methylmorpholin-2-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3cc(OCC4CNCCO4)ccc23)cc1
1446,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.0216,uM,=,-1.665546248849069,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)cc1
1447,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(C#N)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-Cyano-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)acrylamide,0.1673,uM,=,-0.7765040590376056,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1448,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cccc(/C=C2\CCC/C(=C\c3cc(OC)cc(OC)c3)C2=O)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(3-methoxybenzylidene)cyclohexanone",6.1,uM,=,0.785329835010767,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
1449,2074183,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin),C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
1450,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Oc3cccc(Br)c3)c1NC2,"1-(3-bromo-phenoxy)-7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene",0.7,uM,=,-0.1549019599857432,0,c1ccc(Oc2ncnc3c2NCc2ccccc2O3)cc1
1451,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=CS(=O)(=O)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"(3-Bromo-phenyl)-(6-ethenesulfonyl-pyrido[3,4-d]pyrimidin-4-yl)-amine",0.00043,uM,=,-3.3665315444204134,0,c1ccc(Nc2ncnc3cnccc23)cc1
1452,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,Cc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)cc2)c(Cl)n1,N-(4-bromophenylsulfonyl)-2-chloro-6-methylnicotinamide,2.64,uM,=,0.421603926869831,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
1453,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cscn5)c(Cl)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(3-chloro-4-(thiazol-4-ylmethoxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.12,uM,=,-0.9208187539523752,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cscn5)cc4)c3s2)C1)N1CCOCC1
1454,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,Cn1c(SSc2c(C(=O)Nc3ccccc3)c3c(Cl)cccc3n2C)c(C(=O)Nc2ccccc2)c2c(Cl)cccc21,"2,2'-Dithiobis(1-methyl-4-chloro-N-phenyl-1H-indole-3-carboxamide)",100.0,uM,=,2.0,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
1455,2229998,10.1021/acs.jmedchem.1c00876,,,,Inhibition of wild type EGFR (unknown origin),COc1cc(N2CCC(N3CCN(C)CC3)CC2)c(C)cc1Nc1ncc(Br)c(Nc2ccc3nccnc3c2P(C)(C)=O)n1,(6-((5-bromo-2-((2-methoxy-5-methyl-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide,0.00792,uM,=,-2.1012748184105066,0,c1cc(Nc2ccc3nccnc3c2)nc(Nc2ccc(N3CCC(N4CCNCC4)CC3)cc2)n1
1456,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COCCN1CCC(Oc2cc3c(Nc4cc(Cl)ccc4F)ncnc3cc2OC)CC1,N-(5-chloro-2-fluorophenyl)-7-methoxy-6-(1-(2-methoxyethyl)piperidin-4-yloxy)quinazolin-4-amine,0.166,uM,=,-0.7798919119599449,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
1457,5004,10.1016/s0960-894x(02)00364-5,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Cc1cc(C)c(/C=C2\C(=O)Nc3ncnc(Nc4ccc(F)c(Cl)c4)c32)[nH]1,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-(3,5-dimethyl-1H-pyrrol-2-yl)-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.3,uM,=,-0.5228787452803376,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
1458,2105982,10.1016/j.ejmech.2020.112994,,,,Inhibition of EGFR in human A-431 cells assessed as antiproliferative activity incubated for 48 hrs by MTS method,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C(=O)Cn2cncc2[N+](=O)[O-])CC1,1-(4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidin-1-yl)-2-(5-nitro-1H-imidazol-1-yl)ethanone,1.64,uM,=,0.2148438480476978,1,O=C(Cn1ccnc1)N1CCC(COc2ccc3c(Nc4ccccc4)ncnc3c2)CC1
1459,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCN(C)CC1,(2E)-N-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}-7-ethoxy-6-quinazolinyl)-4-(4-methyl-1-piperazinyl)-2-butenamide,0.01,uM,=,-2.0,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
1460,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),COc1cccc2c1sc1c(Nc3cccc(Br)c3)ncnc12.Cl,"(3-Bromo-phenyl)-(6-methoxy-benzo[4,5]thieno[3,2-d]pyrimidin-4-yl)-amine hydrochloride",0.0126,uM,=,-1.899629454882437,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
1461,850422,10.1016/j.bmc.2012.08.002,,,,Inhibition of human N-terminal DYKDDDD tagged EGFR cytoplasmic domain amino acid 669 to 1210 expressed in baculovirus after 5 mins by scintillation counter,CS(=O)(=O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(Cl)c4)c(Cl)c3)c21,"N-[2-(4-{[3-Chloro-4-(3-chlorophenoxy)phenyl]amino}-5Hpyrrolo[3,2-d]pyrimidin-5-yl)ethyl]-2-(methylsulfonyl)acetamide",0.0067,uM,=,-2.1739251972991736,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
1462,1353177,10.1021/ml4003309,,,,Inhibition of recombinant EGFR (unknown origin) using poly-GT peptide as substrate by Transcreener assay,COc1cc2c(Oc3ccc(NS(=O)(=O)c4cccc(-c5cnn(C)c5)c4)cc3F)ccnc2cc1OCCCN1CCOCC1,N-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-3-(1-methyl-1H-pyrazol-4-yl)benzenesulfonamide,1.37,uM,=,0.1367205671564068,1,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1)c1cccc(-c2cn[nH]c2)c1
1463,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(=O)NCC(O)CO)c3ccccc3n2C)c(C(=O)NCC(O)CO)c2ccccc21,"3N-(2,3-dihydroxypropyl)-2-[3-(2,3-dihydroxypropylcarbamoyl)-1-methyl-1H-2-indolyldisulfanyl]-1-methyl-1H-3-indolecarboxamide",43.0,uM,=,1.6334684555795866,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
1464,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,COc1ccc(-c2cc3c(N[C@H](C)c4ccccc4)ncnc3o2)cc1,"(R)-6-(4-Methoxyphenyl)-N-(1-phenylethyl)furo[2,3-d]pyrimidin-4-amine",0.0053,uM,=,-2.275724130399211,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
1465,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,CCOC(=O)C(=CNC(=O)Nc1ccc(C(=O)Nc2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cc1)C(=O)OCC,diethyl 2-(((4-((4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)carbamoyl)phenyl)amino)methylene)malonate,1.46,uM,=,0.1643528557844371,1,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccccc1
1466,946709,10.1016/j.bmc.2012.12.045,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,Nc1nc(Nc2ccc(F)c(C(F)(F)F)c2)c2cc(CCc3ccccn3)[nH]c2n1,"N4-(3-Trifluoromethl,4-fluorophenyl)-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",15.6,uM,=,1.1931245983544616,1,c1ccc(Nc2ncnc3[nH]c(CCc4ccccn4)cc23)cc1
1467,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3cccnc3)cc2Cl)c1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-(2-(pyridin-3-yl)ethynyl)pyrimidin-4-amine,0.074,uM,=,-1.1307682802690238,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1cccnc1
1468,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1,N-(4-(benzyloxy)-3-bromophenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.025,uM,=,-1.6020599913279625,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
1469,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.002,uM,=,-2.6989700043360187,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccccc45)ccc32)cc1
1470,1883986,10.1021/acsmedchemlett.8b00461,,,,Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1,"(R)-1-(1-Acryloylpiperidin-3-yl)-5-amino-3-(4-(2,4-difluorophenoxy)phenyl)-1H-pyrazole-4-carboxamide",0.026,uM,=,-1.585026652029182,0,c1ccc(Oc2ccc(-c3ccn([C@@H]4CCCNC4)n3)cc2)cc1
1471,445904,10.1021/jm070436q,,,,Inhibition of P-EGFR expressed in A431 cells,COc1cc(NCc2c[nH]cn2)cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc12,4-(3-chloro-4-fluorophenylamino)-6-[(3H-imidazol-4-ylmethyl)-amino]-8-methoxyquinoline-3-carbonitrile,2.08,uM,=,0.3180633349627615,1,c1ccc(Nc2ccnc3ccc(NCc4c[nH]cn4)cc23)cc1
1472,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cnn(C)c3)c3ncn(C(C)C)c3n2)C[C@H]1F,"N-((3R,4R)-4-fluoro-1-(9-isopropyl-6-(1-methyl-1H-pyrazol-4-ylamino)-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide",0.178,uM,=,-0.7495799976911061,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1
1473,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1,"(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(2-[1,2,3]triazol-1-yl-ethoxy)-quinazolin-4-yl]-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3cc(OCCn4ccnn4)ccc23)cc1
1474,331141,10.1016/j.bmcl.2005.08.115,,,,Inhibitory activity against EGFR kinase,CCN(CC)CCOc1c(C(=O)OC)c2c3c(oc2c2ccccc12)C(=O)c1ccccc1C3=O,"5-(2-diethylamino-ethoxy)-7,12-dioxo-7,12-dihydro-dinaphtho[1,2-b;2',3'-d]furan-6-carboxylic acid methyl ester",5.1,uM,=,0.7075701760979364,1,O=C1c2ccccc2C(=O)c2c1oc1c2ccc2ccccc21
1475,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,Cc1cccc(Nc2ncnc3cc4c(cc23)N(CCCN2CCOCC2)C(=O)CO4)c1,"6-(3-morpholinopropyl)-4-(m-tolylamino)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.1869,uM,=,-0.7283906986211679,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
1476,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CN1CCN(c2ccc(Nc3ncc(Br)c(Nc4ccc5cc[nH]c5c4)n3)cc2)CC1,"5-bromo-N4-(1H-indol-6-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,4-diamine",1.4,uM,=,0.1461280356782379,1,c1cc(Nc2ccc3cc[nH]c3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
1477,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CNc1ccc2c(Nc3cccc(Br)c3)ncnc2n1,"N*4*-(3-Bromo-phenyl)-N*7*-methyl-pyrido[2,3-d]pyrimidine-4,7-diamine",0.052,uM,=,-1.2839966563652008,0,c1ccc(Nc2ncnc3ncccc23)cc1
1478,1730164,10.1016/j.ejmech.2017.08.035,,,,Inhibition of recombinant human wild-type His-tagged EGFR expressed in mammalian expression system using Tyr 4 peptide as substrate after 1 hr in presence of ATP by Z-LYTE kinase assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N1CCCN(C)CC1,"N-(5-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide",0.108,uM,=,-0.9665762445130504,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCCNCC4)cc3)n2)cc1
1479,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Cc1ccc(-n2cc3c(-c4c(C)[nH]c(-c5ccccc5)c4-c4ccccc4)nnc(C)c3n2)cc1,"2-(4-Chlorophenyl)-7-methyl-4-(2-methyl-4,5-diphenyl-1H-pyrrol-3-yl)-2H-pyrazolo-[3,4-d]pyridazine",5.43,uM,=,0.7347998295888469,1,c1ccc(-c2[nH]cc(-c3nncc4nn(-c5ccccc5)cc34)c2-c2ccccc2)cc1
1480,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4cc(C)cc(C)c4)c3cc21,"Ethyl 4-(8-(3,5-dimethylphenylamino)-2-oxooxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",1.5,uM,=,0.1760912590556812,1,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
1481,1283337,10.1016/j.ejmech.2013.10.058,,,,Inhibition of wild type EGFR (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,NS(=O)(=O)c1ccc(Nc2nc(Cl)nc3cc4c(cc23)OCO4)cc1,"4-((2-Chloro-6,7-methylenedioxy-quinazolin-4-yl)amino)benzenesulfonamide",34.6,uM,=,1.5390760987927767,1,c1ccc(Nc2ncnc3cc4c(cc23)OCO4)cc1
1482,1353177,10.1021/ml4003309,,,,Inhibition of recombinant EGFR (unknown origin) using poly-GT peptide as substrate by Transcreener assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ncnc3ccccc23)cc1
1483,1994718,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 40 mins in presence of ATP by caliper mobility shift assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1484,1842432,10.1016/j.ejmech.2019.03.004,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",2.9e-05,uM,=,-4.537602002101044,0,c1ccc(Nc2ncnc3ccccc23)cc1
1485,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3ccccc3[nH]2)c1O,3-[3-(1H-Benzoimidazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,14.5,uM,=,1.1613680022349748,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
1486,331141,10.1016/j.bmcl.2005.08.115,,,,Inhibitory activity against EGFR kinase,COC(=O)c1c(OC)c2ccccc2c2oc3c(c12)C(=O)c1ccccc1C3=O,"5-methoxy-7,12-dioxo-7,12-dihydro-dinaphtho[1,2-b;2',3'-d]furan-6-carboxylic acid methyl ester",12.6,uM,=,1.100370545117563,1,O=C1c2ccccc2C(=O)c2c1oc1c2ccc2ccccc21
1487,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)CC1,"1-(4-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.11904,uM,=,-0.9243070817981964,0,c1cc2c(OC3CCNCC3)nc(Nc3ccc(N4CCNCC4)cc3)nc2[nH]1
1488,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCCn1c([N+](=O)[O-])cnc1C,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(4-(2-methyl-5-nitro-1H-imidazol-1-yl)-butoxy)-quinazolin-4-amine,0.00053,uM,=,-3.275724130399211,0,c1ccc(Nc2ncnc3ccc(OCCCCn4ccnc4)cc23)cc1
1489,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Fc1ccc(Nc2ncnc3cc4c(cc23)OCCO4)c(F)c1Br,"N-(3-Bromo-2,4-difluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0219,uM,=,-1.6595558851598815,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
1490,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CNc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-N*6*-methyl-quinazoline-4,6-diamine",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccccc23)cc1
1491,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC4CCCC4)cc3)nn21,"US9447106, 18",0.00079,uM,=,-3.1023729087095586,0,c1ccc(C2CCNc3cc(-c4ccc(OC5CCCC5)cc4)nn32)cc1
1492,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(NC3CCCCC3)c2c1,N-(4-(cyclohexylamino)quinazolin-6-yl)acrylamide,3.4,uM,=,0.5314789170422551,1,c1ccc2c(NC3CCCCC3)ncnc2c1
1493,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCOCCn1ccnc1[N+](=O)[O-],N-(3-Chloro-4-fluorophenyl)-6-methoxy-7-(2-(2-(2-nitro-1H-imidazol-1-yl)ethoxy)ethoxy)quinazolin-4-amine,0.00032,uM,=,-3.494850021680094,0,c1ccc(Nc2ncnc3cc(OCCOCCn4ccnc4)ccc23)cc1
1494,1553877,10.1016/j.ejmech.2016.01.045,,,,Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay,COCCOc1cc2ncnc(Nc3ccc(NC(=O)C45CC6CC(CC(C6)C4)C5)c(OC)c3)c2cc1OCCOC,"N-(4-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)amino)-2-methoxyphenyl)adamantane-1-carboxamide",0.00594,uM,=,-2.2262135550188065,0,O=C(Nc1ccc(Nc2ncnc3ccccc23)cc1)C12CC3CC(CC(C3)C1)C2
1495,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,CCCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1,"2-Butylamino-6-(2,6-dichloro-phenyl)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",4.4,uM,=,0.6434526764861874,1,O=c1[nH]c2ncncc2cc1-c1ccccc1
1496,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CN1CCN(CCCNc2cc3ncnc(Nc4cccc(Br)c4)c3cn2)CC1,"N*4*-(3-Bromo-phenyl)-N*7*-[3-(4-methyl-piperazin-1-yl)-propyl]-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0049,uM,=,-2.309803919971486,0,c1ccc(Nc2ncnc3cc(NCCCN4CCNCC4)ncc23)cc1
1497,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCCN(C)C,N-[4-(3-Bromo-phenylamino)-7-(4-dimethylamino-butoxy)-quinazolin-6-yl]-acrylamide,0.0079,uM,=,-2.1023729087095586,0,c1ccc(Nc2ncnc3ccccc23)cc1
1498,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(NC3CC3c3ccccc3)c2cc1O,7-Methoxy-4-(2-phenyl-cyclopropylamino)-quinazolin-6-ol,0.39,uM,=,-0.4089353929735008,0,c1ccc(C2CC2Nc2ncnc3ccccc23)cc1
1499,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1OCCN1CCN(C)CC1,"N-(4-Methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)buta-2,3-dienamide",0.0139,uM,=,-1.8569851997459048,0,c1ccc2c(-c3ccnc(Nc4ccc(OCCN5CCNCC5)cc4)n3)c[nH]c2c1
1500,2270920,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins by mobility shift assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.00325,uM,=,-2.4881166390211256,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1501,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c5ccsc5c4)nn32)CC1,"7-(1-acryloylpiperidin-4-yl)-2-(4-methoxybenzo[b]thiophen-6-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",0.1,uM,=,-1.0,0,c1cc2ccc(-c3cc4n(n3)C(C3CCNCC3)CCN4)cc2s1
1502,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1cccc(Br)c1)NS(=O)(=O)c1ccccc1,2-(3-Bromophenyl)-N-(phenylsulfonyl)acetamide,24.68,uM,=,1.392345155361204,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
1503,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,O=C(/C=C/c1ccccc1)Nc1ccc(Cl)cc1Cl,"(E)-N-(2,4-dichlorophenyl)cinnamamide",16.17,uM,=,1.2087100199064011,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
1504,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1ccc(Cl)cc1)NS(=O)(=O)c1ccc(Cl)cc1,2-(4-chlorophenyl)-N-(4-chlorophenylsulfonyl)acetamide,10.34,uM,=,1.0145205387579237,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
1505,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1OC,"3-(2,3-dimethoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",3.66,uM,=,0.5634810853944107,1,c1ccc(-c2n[nH]c3ncncc23)cc1
1506,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCCCCC(=O)NO,7-(4-(3-chloro-4-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)-N-hydroxyheptanamide,0.007,uM,=,-2.154901959985743,0,c1ccc(Nc2ncnc3ccccc23)cc1
1507,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,{3-[2-Methoxy-4-(toluene-2-sulfonylaminocarbonyl)-benzyl]-1-methyl-1H-indol-5-yl}-carbamic acid cyclopentyl ester,5.751,uM,=,0.7597433675977251,1,O=C(Nc1ccc2[nH]cc(Cc3ccc(C(=O)NS(=O)(=O)c4ccccc4)cc3)c2c1)OC1CCCC1
1508,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,Cc1ccc(S(=O)(=O)O)cc1.Fc1cccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CN6CCOCC6)o5)cc34)cc2Cl)c1,N-(3-Chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-(morpholinomethyl)furan-2-yl)quinazolin-4-amine tosylate,0.026,uM,=,-1.585026652029182,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CN6CCOCC6)o5)cc34)cc2)cc1.c1ccccc1
1509,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",COCCNC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(2-methoxyethyl)urea,0.479,uM,=,-0.3196644865854368,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1510,2298900,10.1016/j.bmc.2023.117241,,,,Inhibition of wild type EGFR (unknown origin) pre-incubated for 10 mins followed by substrate addition measured after 60 mins in presence of ATP by mobility shifting assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.01467,uM,=,-1.833569886156717,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1511,1527997,,,,,"ELISA-Based Kinase Assay: Inhibition of erbB tyrosine kinase activity was assessed using an ELISA-based receptor tyrosine kinase assay. Kinase reactions (50 mM HEPES, pH 7.4, 125 mM NaCl, 10 mM MgCl2, 100 Î¼M sodium orthovanadate, 2 mM dithiothreitol, 20 uM ATP, test compound or vehicle control and 1-5 nM GST-erbB per 50 uL reaction) were run in 96-well plates coated with 0.25 mg/ml poly-Glu-Tyr (Sigma). The reactions were incubated for 6 minutes at room temperature while shaking. Kinase reactions were stopped by removal of reaction mixture, then wells were washed with wash buffer comprising 3% Bovine Serum Albumin and 0.1% Tween 20 in Phosphate Buffered Saline (PBS). Phosphorylated tyrosine residues were detected by adding 0.2 Î¼g/ml anti-phosphotyrosine antibody (Oncogene Ab-4; 50 Î¼L/well) coupled to Horse Radish Peroxidase (HRP) for 25 minutes while shaking at room temperature.",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCC(F)C1,"US8623883, No. 8",0.04534,uM,=,-1.3435184842095014,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1512,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,Brc1cccc(Nc2ncnc3cc(NCCN4CCOCC4)ncc23)c1,"N*4*-(3-Bromo-phenyl)-N*7*-(2-morpholin-4-yl-ethyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0032,uM,=,-2.494850021680094,0,c1ccc(Nc2ncnc3cc(NCCN4CCOCC4)ncc23)cc1
1513,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,CC(C)Oc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2c2c1OCCO2,"N-(3-Chloro-4-fluorophenyl)-5-isopropoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0291,uM,=,-1.5361070110140926,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
1514,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,Cn1cc(NC(=O)c2ccc(NS(=O)(=O)c3ccccc3)cc2)cn1,N-(1-Methyl-1H-pyrazol-4-yl)-4-(phenylsulfonamido)benzamide,36.84,uM,=,1.5663196215248114,1,O=C(Nc1cn[nH]c1)c1ccc(NS(=O)(=O)c2ccccc2)cc1
1515,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,OCC(O)CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"3-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-propane-1,2-diol",0.0001799999999999,uM,=,-3.744727494896694,0,c1ccc(Nc2ncnc3cnccc23)cc1
1516,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,CCOc1cc2ncnc(Nc3ccc(Oc4cc5nncn5cn4)c(C)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,"(E)-N-[7-ethoxy-4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide",0.00136,uM,=,-2.8664610916297826,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4cc5nncn5cn4)cc3)c2c1
1517,695091,10.1021/jm100665z,,,,Inhibition of EGF-induced EGFR phosphorylation in human CAL27 cells overexpressing EGFR after 16 hrs by Western blot,O=C(/C=C/c1cccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)c1)NO,(E)-3-{3-[4-(3-Chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]phenyl}-N-hydroxyacrylamide,0.5,uM,=,-0.3010299956639812,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccccc5)cc34)cc2)cc1
1518,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)NCCCSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,N-(3-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)propyl)acrylamide,0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
1519,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,CCOc1ccc(-c2cc(C(F)(F)F)c(C#N)c(SCC(=O)NCC(=O)O)n2)cc1,2-(2-(3-cyano-6-(4-ethoxyphenyl)-4-(trifluoromethyl)pyridin-2-ylthio)acetamido)acetic acid,8.4,uM,=,0.9242792860618816,1,c1ccc(-c2ccccn2)cc1
1520,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1.[Cl-],"{4-[Bis-(4-dimethylamino-phenyl)-methylene]-cyclohexa-2,5-dienylidene}-dimethyl-ammonium chloride",0.473,uM,=,-0.3251388592621884,0,[N+]=C1C=CC(=C(c2ccccc2)c2ccccc2)C=C1
1521,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,Nc1nn2c(=O)cc(-c3ccccc3)[nH]c2c1/N=N/c1ccc2c(c1)OCO2,"2-amino-3-(benzo[d][1,3]dioxol-5-yldiazenyl)-5-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one",5.3,uM,=,0.724275869600789,1,O=c1cc(-c2ccccc2)[nH]c2c(/N=N/c3ccc4c(c3)OCO4)cnn12
1522,835647,10.1016/j.bmcl.2012.07.079,,,,Inhibition of EGFR in human A431 cell lysate using tyrosine/glutamic acid polymer as substrate by ELISA,O=C(Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)C1COc2ccccc2O1,"N-(4-((3-bromophenyl)amino)quinazolin-6-yl)-2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamide",3.68,uM,=,0.5658478186735176,1,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1COc2ccccc2O1
1523,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C,N-(5-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,0.151,uM,=,-0.8210230527068306,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
1524,1642159,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,3.1,uM,=,0.4913616938342727,1,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1525,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(/C=C2\C(=O)Nc3ncnc(Nc4ccc(F)c(Cl)c4)c32)[nH]c1C(=O)N1CCN(C)CC1,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[4-methyl-5-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.21,uM,=,-0.6777807052660807,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCNCC2)[nH]1
1526,1567355,10.1016/j.bmcl.2016.02.067,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells preincubated for 2 hrs followed by EGF stimulation measured after 30 mins by ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCNC,N-(4-methoxy-2-(methyl(2-(methylamino)ethyl)amino)-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.786,uM,=,-0.104577453960592,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1527,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,"1,4-Dihydroxy-5,8-bis-[2-(2-hydroxy-ethylamino)-ethylamino]-anthraquinone",5.3859,uM,=,0.7312582856051305,1,O=C1c2ccccc2C(=O)c2ccccc21
1528,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC[C@@H](Oc2cc3c(Nc4ccc(F)c(Cl)c4F)ncnc3cc2OC)C[C@@H]1C(N)=O,"(2R,4R)-1-acryloyl-4-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-2-carboxamide",0.0040999999999999,uM,=,-2.3872161432802645,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
1529,935919,10.1016/j.bmcl.2012.11.001,,,,Inhibition of EGFR (unknown origin) by Z-LYTE assay,CC1=CCC[C@](C)(CC/C(C)=C/CC2=C(O)C(=O)C=C(N[C@@H](C(=O)O)C(C)C)C2=O)[C@@H]1C,"(R)-2-(4-hydroxy-5-((E)-3-methyl-5-((1R,2S)-1,2,3-trimethylcyclohex-3-enyl)pent-2-enyl)-3,6-dioxocyclohexa-1,4-dienylamino)-3-methylbutanoic acid",333.88441310355466,uM,=,2.5235961451366675,1,O=C1C=CC(=O)C(C/C=C/CCC2CC=CCC2)=C1
1530,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0039,uM,=,-2.408935392973501,0,c1ccc(Nc2ncnc3ccccc23)cc1
1531,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1cc(O)cc(O)c1,"2-(3,5-Dihydroxy-benzylidene)-malononitrile",37.0,uM,=,1.568201724066995,1,c1ccccc1
1532,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21,"5-(4-amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-bromophenol",100.0,uM,=,2.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
1533,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(C(=O)NCCN2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"5-[4-(3-Chloro-4-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide",0.0065,uM,=,-2.1870866433571443,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1
1534,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COc1cc(/C=C/[N+](=O)[O-])ccc1OS(=O)(=O)c1ccc(C(=O)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)[C@H](O)[C@@H]2O)cc1,"4-[2-Methoxy-4-(2-nitro-vinyl)-phenoxysulfonyl]-benzoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester",0.5,uM,=,-0.3010299956639812,0,O=C(OC[C@@H]1CC[C@H](n2cnc3cncnc32)O1)c1ccc(S(=O)(=O)Oc2ccccc2)cc1
1535,1618202,10.1021/acs.jmedchem.5b01985,,,,Inhibition of wild type EGFR phosphorylation in human HaCaT cells incubated for 3 hrs by ELISA method,Cc1cc(C(=O)Nc2nc3cccc(C)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1,"(R,E)-N-(1-(1-(4-(Dimethylamino)but-2-enoyl)-azepan-3-yl)-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide",0.068,uM,=,-1.1674910872937636,0,O=C(Nc1nc2ccccc2n1[C@@H]1CCCCNC1)c1ccncc1
1536,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,C#Cc1cccc(Nc2ncnc3ccc(NC(C)=O)cc23)c1,N-(4-((3-Ethynylphenyl)amino)quinazolin-6-yl)acetamide,0.039,uM,=,-1.408935392973501,0,c1ccc(Nc2ncnc3ccccc23)cc1
1537,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,CN(C)C/C=C(/F)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(E)-(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.00031,uM,=,-3.508638306165728,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1538,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccccc4)cc3)ncnc2cc1OCc1ccccc1,1-(4-((7-(benzyloxy)-6-methoxyquinazolin-4-yl)amino)phenyl)-3-phenylurea,2.933,uM,=,0.4673120629805521,1,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1
1539,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,C=C(CN1CCOCC1)C(=O)c1ccc(OCc2ccccc2)cc1.Cl,1-(4-Benzyloxy-phenyl)-2-morpholin-4-ylmethyl-propenone hydrochloride,1.1,uM,=,0.041392685158225,1,C=C(CN1CCOCC1)C(=O)c1ccc(OCc2ccccc2)cc1
1540,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,COc1cc2ncnc(N[C@@H](C)c3ccccc3)c2cc1OCCCCCCC(=O)NO,(S)-N-hydroxy-7-(7-methoxy-4-(1-phenylethylamino)quinazolin-6-yloxy)heptanamide,1.0,uM,=,0.0,0,c1ccc(CNc2ncnc3ccccc23)cc1
1541,990875,10.1021/ml4002437,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins prior to ATP addition measured after 30 mins by HTRF method,Fc1ccc(Nc2ncnc3cc4c(cc23)NCCO4)cc1Cl,"N-(3-chloro-4-fluorophenyl)-7, 8-dihydro-6H-[1, 4]oxazino[3,2-g]quinazolin-4-amine",0.00129,uM,=,-2.889410289700751,0,c1ccc(Nc2ncnc3cc4c(cc23)NCCO4)cc1
1542,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N1CCC(N(C)C)C1,"N-(2-(3-(Dimethylamino)pyrrolidin-1-yl)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)buta-2,3-dienamide",0.0189,uM,=,-1.723538195826756,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCCC5)cc4)n3)c[nH]c2c1
1543,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#C/C(=C\c1ccc(O)c(O)c1)C(N)=S,"2-Cyano-3-(3,4-dihydroxy-phenyl)-thioacrylamide",2.4,uM,=,0.380211241711606,1,c1ccccc1
1544,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,O=C(Nc1ccccc1F)c1ccc(N(CCCl)CCCl)cc1,4-(Bis(2-chloroethyl)amino)-N-(2-fluorophenyl)benzamide,11.57,uM,=,1.0633333589517495,1,O=C(Nc1ccccc1)c1ccccc1
1545,2132157,10.1021/acs.jmedchem.1c01559,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.0017,uM,=,-2.7695510786217263,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
1546,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COc1cc(/C=C(\C)[N+](=O)[O-])ccc1OS(=O)(=O)c1ccc(C(=O)O)cc1,4-[2-Methoxy-4-(2-nitro-propenyl)-phenoxysulfonyl]-benzoic acid,3.0,uM,=,0.4771212547196624,1,O=S(=O)(Oc1ccccc1)c1ccccc1
1547,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC[C@@H]1C(N)=O,(R)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidine-2-carboxamide,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
1548,591074,10.1021/jm9010065,,,,Inhibition of human recombinant HER1 expressed in Sf9 cells by liquid scintillation counting,CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)O[C@H]1CC[C@H](N)CC1,"{4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl}-carbamic acid trans-4-aminocyclohexyl ester",0.023,uM,=,-1.6382721639824072,0,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OC1CCCCC1
1549,1744972,10.1016/j.bmcl.2017.09.048,,,,Inhibition of wild-type EGFR (unknown origin),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.49388,uM,=,-0.3063785605270651,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1550,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,Cc1nnc(NC(=S)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)s1,"1-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3-(5-methyl-1,3,4-thiadiazol-2-yl)thiourea",0.12,uM,=,-0.9208187539523752,0,S=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1nncs1
1551,591074,10.1021/jm9010065,,,,Inhibition of human recombinant HER1 expressed in Sf9 cells by liquid scintillation counting,CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)OCC1CCNCC1,"{4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl}-carbamic acid piperidin-4-ylmethyl ester",0.03,uM,=,-1.5228787452803376,0,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OCC1CCNCC1
1552,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Nc3ccc(F)cc3)c2c1C,"(5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(4-fluoro-phenyl)-amine",0.56,uM,=,-0.2518119729937995,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1
1553,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](C)C(N)=O,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)propanamide,0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
1554,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(/C=C/c1cccc2ccccc12)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,(E)-N-(4-(3-Chlorophenylamino)quinazolin-6-yl)-3-(naphthalen-4-yl)acrylamide,2.81,uM,=,0.4487063199050799,1,O=C(/C=C/c1cccc2ccccc12)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1555,2121823,10.1016/j.ejmech.2021.113786,,,,Inhibition of wild type EGFR (unknown origin) using fluoresceine-labelled poly-GT peptide as substrate incubated for 1 hr by TR-FRET assay,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccc(NCc3ccc(S(=O)(=O)F)cc3)cc2)n1,4-(((4-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)amino)methyl)benzenesulfonyl fluoride,0.21,uM,=,-0.6777807052660807,0,c1ccc(CNc2ccc(Nc3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cc2)cc1
1556,792378,10.1016/j.ejmech.2011.11.015,,,,Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis,Cc1ccccc1-c1nnc(SCc2ccccc2)o1,SID4256355,5.72,uM,=,0.7573960287930241,1,c1ccc(CSc2nnc(-c3ccccc3)o2)cc1
1557,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,COc1ccc2ncnc(NCc3ccccc3)c2c1,Benzyl-(6-methoxy-quinazolin-4-yl)-amine,0.2,uM,=,-0.6989700043360187,0,c1ccc(CNc2ncnc3ccccc23)cc1
1558,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)acetamide,0.264,uM,=,-0.5783960731301689,0,c1ccc(Nc2ncnc3ccccc23)cc1
1559,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#Cc1ccc(CNCCS(C)(=O)=O)o1,N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-methyl-5-((5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)ethynyl)pyrimidin-4-amine,0.045,uM,=,-1.3467874862246565,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccco1
1560,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Nc1cccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"[3-(3-Amino-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-chloro-phenyl)-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
1561,1589608,10.1016/j.ejmech.2016.04.026,,,,Inhibition of cytoplasmic GST-tagged human recombinant EGFR expressed in baculovirus system by z-lyte assay,C#Cc1cccc(Nc2ncnc3ccc(-c4cnn(C)c4)cc23)c1,N-(3-ethynylphenyl)-6-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-amine,0.00358,uM,=,-2.446116973356125,0,c1ccc(Nc2ncnc3ccc(-c4cn[nH]c4)cc23)cc1
1562,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,Cc1nc(Nc2ccc(Cl)cc2)c2cc(C)oc2n1,"N-(4-Chlorophenyl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine",0.1023,uM,=,-0.9901243662878398,0,c1ccc(Nc2ncnc3occc23)cc1
1563,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Cl.c1ccc(Nc2[nH]cnc3c4ccccc4nc2-3)cc1,"Phenyl-(5H-pyrimido[5,4-b]indol-4-yl)-amine hydrochloride",2.11,uM,=,0.3242824552976926,1,c1ccc(Nc2[nH]cnc3c4ccccc4nc2-3)cc1
1564,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1c(-c2ccccc2)[nH]c2ncnc(Nc3cccc(Cl)c3)c12,"(3-Chloro-phenyl)-(5-methyl-6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
1565,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3ccsc23)CC1,"1-(4-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.14431,uM,=,-0.8407035733116146,0,c1cc2nc(Nc3ccc(N4CCNCC4)cc3)nc(OC3CCNCC3)c2s1
1566,1675840,10.1016/j.bmc.2017.03.032,,,,"Inhibition of recombinant wild type human EGFR (695 to end residues) using Poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(/C=C/c4cc(Cl)cc(Cl)c4)cc3)ncc2F)c1,"N-[3-[[5-Fluoro-2-[(E)-4-(3,5-dichlorostyryl)phenylamino]-4-pyrimidinyl]amino]phenyl]-2-acrylamide",0.3881,uM,=,-0.4110563572599851,0,C(=C/c1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)\c1ccccc1
1567,1674599,10.1021/acs.jmedchem.8b00125,,,,Inhibition of EGFR (unknown origin),CNS(=O)(=O)c1cccc(Nc2cc(Nc3cccc(S(=O)(=O)NC)c3)ncn2)c1,"3,3'-(4,6-Pyrimidinediyldiimino)bis(N-methylbenzenesulfonamide)",1.6,uM,=,0.2041199826559248,1,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
1568,1657723,10.1016/j.bmcl.2017.02.018,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells preincubated for 60 mins followed by EGF induction measured after 10 mins by ELISA,COc1cc2cnnc(Nc3ccc(Cl)cc3F)c2cc1OC,"N-(4-chloro-2-fluorophenyl)-6,7-dimethoxyphthalazin-1-amine",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2nncc3ccccc23)cc1
1569,5004,10.1016/s0960-894x(02)00364-5,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Cc1cc(C(=O)N2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[3-methyl-5-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.04,uM,=,-1.3979400086720375,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCOCC2)[nH]1
1570,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,O=C(/C=C/c1ccccc1)Nc1cc(F)c(F)c(F)c1,"(E)-N-(3,4,5-trifluorophenyl)cinnamamide",12.88,uM,=,1.1099158630237933,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
1571,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(NC(=O)CO)cc2)n1,N-(4-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-2-hydroxyacetamide,3.87,uM,=,0.5877109650189114,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1572,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.0006,uM,=,-3.2218487496163566,0,c1ccc(Nc2ccnc3ccccc23)cc1
1573,497088,10.1016/j.bmcl.2008.08.051,,,,Inhibition of EGFR,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1-c1ccc2ccncc2c1,N-(3-(isoquinolin-7-yl)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide,0.7,uM,=,-0.1549019599857432,0,O=C(Nc1cccc(-c2ccc3ccncc3c2)c1)c1ccc(CN2CCNCC2)cc1
1574,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(Nc1ccc(Cl)c(Cl)c1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(3,4-dichlorophenyl)thiourea",0.1331,uM,=,-0.8758219445253249,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1575,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CC(C)C(C)C/C=C/C(=O)N1CCc2c(sc3ncnc(Nc4cc(O)cc(Cl)c4)c23)C1,"US8524722, 123",0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3sc4c(c23)CCNC4)cc1
1576,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,C=CC(=O)Nc1cc(Nc2ncc(Br)c(Nc3ccc4c(c3)CCC4)n2)ccc1N(C)CCN(C)C,"N-(5-((5-bromo-4-((2,3-dihydro-1H-inden-5-yl)amino)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide",0.0261999999999999,uM,=,-1.5816987086802543,0,c1ccc(Nc2nccc(Nc3ccc4c(c3)CCC4)n2)cc1
1577,2153185,10.1016/j.ejmech.2021.113845,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,CCC(=O)Nc1cc(Nc2ncc(Cl)c(N3CCc4sccc4C3)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((5-chloro-4-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)propionamide",0.17,uM,=,-0.7695510786217261,0,c1ccc(Nc2nccc(N3CCc4sccc4C3)n2)cc1
1578,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,NC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,1-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)urea,0.099,uM,=,-1.00436480540245,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
1579,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(C2CC(c3ccc(Br)cc3)=NN2C2=NC(=O)CS2)cc1,"2-(3-(4-Bromophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",7.96,uM,=,0.900913067737669,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
1580,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,Fc1ccc(Nc2ncnc3sc(Br)cc23)cc1Cl,"6-Bromo-N-(3-chloro-4-fluorophenyl)thieno[2,3-d]pyrimidin-4-amine",0.053,uM,=,-1.275724130399211,0,c1ccc(Nc2ncnc3sccc23)cc1
1581,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)C(F)(F)F)CC4)cc3OC)ncc2SC)c1,"N-(3-((2-((2-Methoxy-4-(4-(2,2,2-trifluoroacetyl)piperazin-1-yl)phenyl)amino)-5-(methylthio)pyrimidin-4-yl)oxy)phenyl)acrylamide",0.2478,uM,=,-0.6058986979599553,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1582,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc(O)cc2)c1O,2-Cyano-3-[4-hydroxy-3-(4-hydroxy-phenylsulfanylmethyl)-5-methoxy-phenyl]-acrylamide,2.5,uM,=,0.3979400086720376,1,c1ccc(CSc2ccccc2)cc1
1583,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CN1CCN(c2ccc(Nc3ncc(Br)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1,"5-bromo-N4-(1H-indazol-5-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,4-diamine",0.393,uM,=,-0.4056074496245733,0,c1cc(Nc2ccc3[nH]ncc3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
1584,2224994,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin),COc1ccc(N(C)c2nc(N)nc3c(Cc4ccccc4)c[nH]c23)cc1,"7-Benzyl-N4-(4-methoxyphenyl)-N4-methyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine",0.0011,uM,=,-2.958607314841775,0,c1ccc(Cc2c[nH]c3c(Nc4ccccc4)ncnc23)cc1
1585,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,COc1ccc(-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)cc1,"(R)-6-(4-methoxyphenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.0047,uM,=,-2.3279021420642825,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
1586,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(OCc4ccccc4)cc3)ncnc2cc1OC,N-{4-[4-(Benzyloxy)anilino]-7-methoxy-6-quinazolinyl}-propanamide,0.036,uM,=,-1.4436974992327127,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
1587,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc32)c1,N-(3-(2-(4-(4-Methylpiperazin-1-yl)phenylamino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.00121,uM,=,-2.91721462968355,0,O=c1cnc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
1588,1799769,10.1016/j.ejmech.2018.06.011,,,,"Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay",Nc1ccc(-c2cc3c(Nc4ccc(Oc5cccc(C(F)(F)F)c5)c(Cl)c4)ncnc3s2)cc1,"6-(4-aminophenyl)-N-(3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)thieno[2,3-d]pyrimidin-4-amine",0.0214,uM,=,-1.6695862266508092,0,c1ccc(Oc2ccc(Nc3ncnc4sc(-c5ccccc5)cc34)cc2)cc1
1589,63616,10.1016/S0960-894X(97)00034-6,,,,Inhibition of Epidermal growth factor receptor autophosphorylation.,COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC.Cl,"4-(6,7-Dimethoxy-quinazolin-4-ylamino)-phenol hydrochloride, 0.9 M H2O",0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
1590,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,C[C@@H](Nc1ncnc2sc(Br)cc12)c1ccc(F)cc1,"(R)-6-bromo-N-(1-(4-fluorophenyl)ethyl)thieno[2,3-d]pyrimidin-4-amine",0.15,uM,=,-0.8239087409443188,0,c1ccc(CNc2ncnc3sccc23)cc1
1591,63615,10.1021/jm980123i,,,,Concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Epidermal growth factor receptor (EGF RTK).,COc1c(Br)cc(/C=C2\C(=O)Nc3ccccc32)cc1C(C)(C)C,"3-[1-(3-Bromo-5-tert-butyl-4-methoxy-phenyl)-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one",19.0,uM,=,1.2787536009528289,1,O=C1Nc2ccccc2/C1=C/c1ccccc1
1592,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(c3ccc4ccccc4c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(7-(2-Methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-(naphthalen-2-yl)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.0008,uM,=,-3.096910013008056,0,O=C1N(c2ccc3ccccc3c2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
1593,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CC(C)(C)ONC(=O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,"N-tert-Butoxy-2-[5-(2,5-dihydroxy-benzylamino)-2-hydroxy-phenyl]-acetamide",46.0,uM,=,1.662757831681574,1,c1ccc(CNc2ccccc2)cc1
1594,1467840,10.1016/j.ejmech.2015.03.029,,,,Inhibition of EGFR intracellular domain (unknown origin) purified from a baculovirus expression system using Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2 as substrate after 10 mins by scintillation counting in presence of [gamma-33P]ATP,[O-][S+]1CCN(Cc2ccc(-c3cc4c(Nc5ccc(OCc6cccc(F)c6)cc5)ncnc4cn3)o2)CC1,"[4-(3-Fluoro-benzyloxy)-phenyl]-{6-[5-(1-oxo-1lambda*4*-thiomorpholin-4-ylmethyl)-furan-2-yl]-pyrido[3,4-d]pyrimidin-4-yl}-amine",0.023,uM,=,-1.6382721639824072,0,c1ccc(COc2ccc(Nc3ncnc4cnc(-c5ccc(CN6CC[SH+]CC6)o5)cc34)cc2)cc1
1595,1577194,10.1016/j.bmc.2016.05.012,,,,Inhibition of recombinant His6-tagged EGFR (unknown origin) cytoplasmic domain (645 to 1186 residues) autophosphorylation expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometric analysis,c1ccc(COc2ccc(C3CC(c4ccc5c(c4)OCCO5)=NN3c3ccccc3)cc2)cc1,"5-(4-(Benzyloxy)phenyl)-3-(2,3-dihydrobenzo[b][1,4]-dioxin-6-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",9.04,uM,=,0.9561684304753632,1,c1ccc(COc2ccc(C3CC(c4ccc5c(c4)OCCO5)=NN3c3ccccc3)cc2)cc1
1596,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,N#CCCSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,3-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)propanenitrile,0.109,uM,=,-0.9625735020593764,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
1597,2220271,10.1016/j.bmcl.2022.128529,,,,Inhibition of EGFR (unknown origin),C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.18,uM,=,-0.744727494896694,0,c1ccc(Nc2ncnc3ccccc23)cc1
1598,63782,10.1021/jm970366v,,,,Inhibition of epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Cc1cccc(Nc2ncnc3cc(NCCc4c[nH]cn4)ncc23)c1,"N*7*-[2-(1H-Imidazol-4-yl)-ethyl]-N*4*-m-tolyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0072,uM,=,-2.1426675035687315,0,c1ccc(Nc2ncnc3cc(NCCc4c[nH]cn4)ncc23)cc1
1599,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(N(C)c3cccc(Cl)c3)c2c1C,"(3-Chloro-phenyl)-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-methyl-amine",0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1
1600,5170,10.1021/jm970641d,,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,CCN(CC)CC(O)CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"1-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-3-diethylamino-propan-2-ol",28.0,uM,=,1.4471580313422192,1,c1ccc(Nc2ncnc3cnccc23)cc1
1601,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cn1,"(2E)-N-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}pyrido[3,4-d]-pyrimidin-6-yl)-4-(1-pyrrolidinyl)-2-butenamide",0.016,uM,=,-1.7958800173440752,0,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc(OCc4ccccc4)cc3)ncnc2cn1
1602,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1cc(O)c(O)c(Br)c1)S(=O)(=O)/C(C#N)=C/c1cc(O)c(O)c(Br)c1,"(E)-3-(3-Bromo-4,5-dihydroxy-phenyl)-2-[(E)-1-(3-bromo-4,5-dihydroxy-phenyl)-2-cyano-ethenesulfonyl]-acrylonitrile",1.4,uM,=,0.1461280356782379,1,O=S(=O)(C=Cc1ccccc1)/C=C/c1ccccc1
1603,2074183,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin),CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1604,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,CN(C)C/C=C(\F)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(Z)-(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.00016,uM,=,-3.795880017344075,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1605,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,CCN(CC)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OC,(E)-4-Diethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,1.91,uM,=,0.2810333672477275,1,c1ccc(Nc2ccnc3ccccc23)cc1
1606,86514,10.1021/jm00110a022,,,,Inhibition of HER14 (human EGFR overexpressing) cell proliferation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccc(F)cc1,"3-(3,4-Dihydroxy-phenyl)-2-(4-fluoro-benzoyl)-acrylonitrile",20.0,uM,=,1.3010299956639813,1,O=C(C=Cc1ccccc1)c1ccccc1
1607,1914433,10.1021/acs.jnatprod.9b00659,,,,Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,BRIGATINIB,0.13,uM,=,-0.8860566476931633,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
1608,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc(Br)cc3)C2)cc1,"2-(5-(4-Bromophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",1.26,uM,=,0.1003705451175629,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
1609,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,O=C1NCc2c(Oc3ccc(Nc4ncnc5ccn(CCO)c45)cc3Cl)cccc21,"4-(2-Chloro-4-{[5-(2-hydroxyethyl)-5H-pyrrolo[3,2-d]-pyrimidin-4-yl]amino}phenoxy)-2,3-dihydro-1H-isoindol-1-one",0.89,uM,=,-0.0506099933550872,0,O=C1NCc2c(Oc3ccc(Nc4ncnc5cc[nH]c45)cc3)cccc21
1610,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CC(N(C)C)C1,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-2-(3-(dimethylamino)azetidin-1-yl)-4-methoxyphenyl)acrylamide",938.0,uM,=,2.9722028383790646,1,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCC5)cc4)n3)c2c1
1611,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,CC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2c1,N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)quinazolin-6-yl)acetamide,0.003,uM,=,-2.5228787452803374,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
1612,63764,10.1021/jm960689b,,,,Inhibition of epidermal growth factor receptor (EGFr),NC(Cc1c(SSc2[nH]c3ccccc3c2CC(N)C(=O)NCc2ccccc2)[nH]c2ccccc12)C(=O)NCc1ccccc1,2-Amino-3-{2-[3-(2-amino-2-benzylcarbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-N-benzyl-propionamide,7.4,uM,=,0.8692317197309762,1,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
1613,946792,10.1016/j.bmc.2013.01.040,,,,Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA,CC(C)c1ccc(Nc2nc(N)nc3[nH]c4cccc(Cl)c4c23)cc1,"5-chloro-N4-(4-isopropylphenyl)-9H-pyrimido[4,5-b]indole-2,4-diamine",42.0,uM,=,1.6232492903979006,1,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
1614,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,C#Cc1cccc(Nc2ncnc3cc(OCCOCCn4ccnc4[N+](=O)[O-])c(OC)cc23)c1,N-(3-Ethynylphenyl)-6-methoxy-7-(2-(2-(2-nitro-1H-imidazol-1-yl)ethoxy)ethoxy)quinazolin-4-amine,0.00054,uM,=,-3.2676062401770314,0,c1ccc(Nc2ncnc3cc(OCCOCCn4ccnc4)ccc23)cc1
1615,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,N[C@H]1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,"(S)-N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((3-aminopyrrolidin-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCC6)c45)ccc32)cc1
1616,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(Cl)cc3)c2c1,1-(4-((4-Chlorophenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)thiourea,0.066,uM,=,-1.1804560644581312,0,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1617,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-17",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1618,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CCCCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-piperidin-1-yl-ethoxy)-quinazolin-4-yl]-amine,0.098,uM,=,-1.0087739243075051,0,c1ccc(Nc2ncnc3ccc(OCCN4CCCCC4)cc23)cc1
1619,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCc1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-(4-phenyl-butyl)-acrylamide",5.0,uM,=,0.6989700043360189,1,O=C(C=Cc1ccccc1)NCCCCc1ccccc1
1620,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CC(CCOC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O)c1ccccc1,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3-phenyl-butyl ester",0.4,uM,=,-0.3979400086720376,0,O=C(OCCCc1ccccc1)c1cccc(NCc2ccccc2)c1
1621,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,CN(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccccc23)cc1
1622,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.03,uM,=,-1.5228787452803376,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1
1623,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCCCCCCCCOC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,Hexadecyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetate,0.048,uM,=,-1.3187587626244128,0,O=c1cc(-c2ccccc2)oc2ccccc12
1624,67067,10.1016/S0960-894X(01)80792-7,,,,Inhibition of Epidermal growth factor receptor,O=CN/C=C/c1cc(O)ccc1O,"N-[(E)-2-(2,5-Dihydroxy-phenyl)-vinyl]-formamide",3.0,uM,=,0.4771212547196624,1,c1ccccc1
1625,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,CC1(N)CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((4-amino-4-methylpiperidin-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
1626,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,COc1ccc2c(c1)CNc1c(Nc3ccccc3)ncnc1O2,"(8-Methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-phenyl-amine",7.5,uM,=,0.8750612633917001,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
1627,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Oc1ncnc(Nc3ccc(F)c(Cl)c3)c1NC2,"(3-Chloro-4-fluoro-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",0.7,uM,=,-0.1549019599857432,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
1628,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCC1,(2E)-N-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}-7-ethoxy-6-quinazolinyl)-4-(1-pyrrolidinyl)-2-butenamide,0.06,uM,=,-1.2218487496163564,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
1629,1348544,10.1016/j.bmcl.2014.03.072,,,,Inhibition of autophosphorylation of recombinant his-tagged EGFR (amino acid 645-1186) (unknown origin) expressed in Sf-9 cells after 10 mins by time-resolved fluorometry,Cc1ccc(C2=NN(C3=NC(c4ccccc4)CS3)C(c3cccc4ccccc34)C2)cc1C,"2-(3-(3,4-dimethylphenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",3.96,uM,=,0.5976951859255123,1,c1ccc(C2=NN(C3=NC(c4ccccc4)CS3)C(c3cccc4ccccc34)C2)cc1
1630,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CSc1nc2ccccc2n1C,N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-2-((1-methyl-1H-benzo[d]imidazol-2-yl)thio)acetamide,0.012,uM,=,-1.9208187539523751,0,O=C(CSc1nc2ccccc2[nH]1)Oc1ccc2ncnc(Nc3ccccc3)c2c1
1631,940299,10.1021/ml300327z,,,,Inhibition of human wild type EGFR expressed in Sf9 cells using [gamma32P]-ATP after 10 mins by scintillation counting,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.0025,uM,=,-2.6020599913279625,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
1632,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COc1cc2ncc(C#N)c(Nc3cccc(Br)c3)c2cc1NC(=O)C#CCN(C)C,4-Dimethylamino-but-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ccnc3ccccc23)cc1
1633,1798716,10.1016/j.ejmech.2017.03.083,,,,"Inhibition of wild type N-terminal GST tagged human recombinant EGFR (695 to end amino acids) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) Peptide substrate by ADP-Glo assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(CN4CCOCC4)cc3)ncc2Cl)c1,N-[3-[[5-Chloro-2-[4-((1-morpholino)methyl)phenylamino]-4-pyrimidinyl]amino]phenyl]acrylamide,0.4487,uM,=,-0.3480439304669258,0,c1ccc(Nc2ccnc(Nc3ccc(CN4CCOCC4)cc3)n2)cc1
1634,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,CN(C)CCNC(=O)c1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3s2)cc1,"(S)-N-(2-(Dimethylamino)ethyl)-4-(4-((2-hydroxy-1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzamide",0.002,uM,=,-2.6989700043360187,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
1635,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,CC(=O)Oc1cccc2c1c(C(=O)Nc1ccccc1)c(SSc1c(C(=O)Nc3ccccc3)c3c(OC(C)=O)cccc3n1C)n2C,Acetic acid 2-(4-acetoxy-1-methyl-3-phenylcarbamoyl-1H-indol-2-yldisulfanyl)-1-methyl-3-phenylcarbamoyl-1H-indol-4-yl ester,20.0,uM,=,1.3010299956639813,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
1636,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(NCc3ccccn3)ncnc2s1,"6-(2-Methoxyphenyl)-N-(pyridin-2-ylmethyl)thieno[2,3-d]pyrimidin-4-amine",0.183,uM,=,-0.7375489102695706,0,c1ccc(-c2cc3c(NCc4ccccn4)ncnc3s2)cc1
1637,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C#Cc1nn([C@@H]2CCCN(C(=O)C=C)C2)c2ncnc(N)c12,"(R)-1-(3-(4-Amino-3-ethynyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",1.5,uM,=,0.1760912590556812,1,c1ncc2cnn([C@@H]3CCCNC3)c2n1
1638,1870312,10.1021/acs.jmedchem.8b00672,,,,Inhibition of wild type EGFR (unknown origin),COc1cc2c(Oc3ccc(NS(=O)(=O)c4ccccc4C(F)(F)F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,N-(3-fluoro-4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinolin-4-yloxy)phenyl)-2-(trifluoromethyl)benzenesulfonamide,0.281,uM,=,-0.5512936800949201,0,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1ccccc1
1639,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3cc(OC)c(C4CC4)c(OC)c3)nn21,"7-(2-acrylamidophenyl)-2-(4-cyclopropyl-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",0.064,uM,=,-1.193820026016113,0,c1ccc(C2CCNc3cc(-c4ccc(C5CC5)cc4)nn32)cc1
1640,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1CCCCN1CCOCC1,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(4-morpholin-4-yl-butyl)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.0027,uM,=,-2.5686362358410126,0,c1ccc(Nc2ncnc3cc(CCCCN4CCOCC4)cnc23)cc1
1641,519199,10.1016/j.ejmech.2007.09.018,,,,Inhibition of human EGFR tyrosine kinase activity,COCCOc1cc2ncnc(-c3c[nH]c4cc(F)c(Cl)cc34)c2cc1OCCOC,"4-(5-Chloro-6-fluoro-indole-3-yl)-6,7-di-(2-methoxyethoxy)quinazoline",0.472,uM,=,-0.3260580013659122,0,c1ccc2c(-c3c[nH]c4ccccc34)ncnc2c1
1642,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3n[nH]c4ccccc34)cc(N3CCN(C(C)=O)CC3)n2)c1,N-(3-(4-(1H-indazol-3-ylamino)-6-(4-acetylpiperazin-1-yl)pyrimidin-2-yloxy)phenyl)acrylamide,3.6,uM,=,0.5563025007672873,1,c1ccc(Oc2nc(Nc3n[nH]c4ccccc34)cc(N3CCNCC3)n2)cc1
1643,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCC1CCN(C)CC1,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine,0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3ccc(OCC4CCNCC4)cc23)cc1
1644,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,Cc1ccc(S(=O)(=O)NC(=O)Cc2cccc(Br)c2)cc1,2-(3-Bromophenyl)-N-tosylacetamide,26.17,uM,=,1.417803722639881,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
1645,1618202,10.1021/acs.jmedchem.5b01985,,,,Inhibition of wild type EGFR phosphorylation in human HaCaT cells incubated for 3 hrs by ELISA method,Cc1cccc2nc(NC(=O)c3cccc(C(F)(F)F)c3)n([C@@H]3CCCCN(C(=O)/C=C/CN(C)C)C3)c12,"(R,E)-N-(1-(1-(4-(Dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-1H-benzo[d]imidazol-2-yl)-3-(trifluoromethyl)-benzamide",0.351,uM,=,-0.4546928835341759,0,O=C(Nc1nc2ccccc2n1[C@@H]1CCCCNC1)c1ccccc1
1646,2102324,10.1016/j.bmcl.2021.128308,,,,Inhibition of EGFR (unknown origin),O=C(CSc1nc2ccccc2c(=O)n1Cc1ccc2c(c1)OCO2)Nc1ccc(I)cc1,"2-(3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-oxo-3,4-dihydroquinazolin-2-ylthio)-N-(4-iodophenyl)acetamide",0.7543,uM,=,-0.1224558922840559,0,O=C(CSc1nc2ccccc2c(=O)n1Cc1ccc2c(c1)OCO2)Nc1ccccc1
1647,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1,Suloctidil,0.7944,uM,=,-0.0999607645126752,0,c1ccccc1
1648,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CN(CC(=O)O)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"{[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-yl]-methyl-amino}-acetic acid",0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ncnc3ccncc23)cc1
1649,2294501,10.1016/j.bmc.2023.117202,,,,Inhibition of wild type EGFR (unknown origin),C=CC(=O)N1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2O[C@H]2CCOC2)CC1,(S)-1-(4-((4-((3-Chloro-2-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one,0.000406,uM,=,-3.3914739664228057,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(OC4CCNCC4)cc23)cc1
1650,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1651,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CCC1CCCNC1,"5-(4-amino-1-(2-(piperidin-3-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",20.5,uM,=,1.3117538610557542,1,c1ccc(-c2nn(CCC3CCCNC3)c3ncncc23)cc1
1652,2268693,10.1016/j.ejmech.2021.113768,,,,Inhibition of EGFR (unknown origin) phosphorylation by ELISA,O=C(/C=C/c1ccc(F)cc1)c1cc(Br)cc2cc(-c3ccccc3)oc12,1-(5-bromo-2-phenylbenzofuran-7-yl)-3-(4-fluorophenyl)prop-2-en-1-one,0.09,uM,=,-1.0457574905606752,0,O=C(/C=C/c1ccccc1)c1cccc2cc(-c3ccccc3)oc12
1653,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1[C@H](C)CCC[C@@H]1C,"(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-((2R,6S)-2,6-dimethylpiperidin-1-yl)but-2-enamide",0.026,uM,=,-1.585026652029182,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
1654,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,OCCC#Cc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,4-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)but-3-yn-1-ol,0.1858,uM,=,-0.730954290342377,0,c1ccc(Nc2ncnc3ccccc23)cc1
1655,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Nc1cc2ncnc(Nc3cccc(Br)c3)c2cc1[N+](=O)[O-],"N*4*-(3-Bromo-phenyl)-6-nitro-quinazoline-4,7-diamine",0.053,uM,=,-1.275724130399211,0,c1ccc(Nc2ncnc3ccccc23)cc1
1656,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(C(=O)N2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc4c(c3)CCC4)c21,"4-(Indan-5-ylamino)-5-[1-[3-methyl-5-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",1.41,uM,=,0.1492191126553798,1,O=C1Nc2ncnc(Nc3ccc4c(c3)CCC4)c2/C1=C/c1ccc(C(=O)N2CCOCC2)[nH]1
1657,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Clc1cccc(Nc2[nH]cnc3nnc(-c4ccccc4)c2-3)c1,"(3-Chloro-phenyl)-(3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine",0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2[nH]cnc3nnc(-c4ccccc4)c2-3)cc1
1658,2080997,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCc1cn(CCCC(=O)NO)nn1,"4-(4-(((6-Acrylamido-4-((3-chloro-2-fluorophenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutanamide",0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
1659,1674599,10.1021/acs.jmedchem.8b00125,,,,Inhibition of EGFR (unknown origin),CNS(=O)(=O)c1cccc(Nc2cc(Nc3cccc(C(C)C)c3)ncn2)c1,N-Methyl-3-[(6-{[3-(1-methylethyl)phenyl]amino}-4-pyrimidinyl)-amino]benzenesulfonamide,0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
1660,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1C(=O)Nc1ccc(OCc2cccc(F)c2)c(Cl)c1,N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-2-methyl-5-(4-((4-methylpiperazin-1-yl)methyl)benzamido)benzamide,0.6,uM,=,-0.2218487496163563,0,O=C(Nc1cccc(C(=O)Nc2ccc(OCc3ccccc3)cc2)c1)c1ccc(CN2CCNCC2)cc1
1661,63769,10.1016/S0960-894X(97)00014-0,,,,Displacement of [gamma-32P]-ATP from Epidermal growth factor receptor in A431 cell-free extracts,O=C(O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid",4.0,uM,=,0.6020599913279624,1,c1ccc(CNc2ccccc2)cc1
1662,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=CC(=O)N(CCCN1CCOCC1)c1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-N-(3-morpholin-4-yl-propyl)-acrylamide,0.0033,uM,=,-2.4814860601221125,0,c1ccc(Nc2ncnc3ccc(NCCCN4CCOCC4)cc23)cc1
1663,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Nc1cc2ncnc(NCc3ccccc3)c2cn1,"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.578,uM,=,-0.2380721615794709,0,c1ccc(CNc2ncnc3ccncc23)cc1
1664,1642199,,,,,Inhibition Assay: Inhibition of various kinase enzyme.,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,0.13,uM,=,-0.8860566476931633,0,c1ccc(Nc2ncnc3ccccc23)cc1
1665,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc4[nH]ncc4c3)ncnc2cc1OC,N-[4-(1H-Indazol-5-ylamino)-7-methoxy-6-quinazolinyl]-propanamide,0.079,uM,=,-1.1023729087095586,0,c1ccc2c(Nc3ccc4[nH]ncc4c3)ncnc2c1
1666,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,CS(=O)(=O)CCNCCCOc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1,(4-Benzyloxy-phenyl)-{6-[3-(2-methanesulfonyl-ethylamino)-propoxy]-quinazolin-4-yl}-amine,0.104,uM,=,-0.9829666607012196,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
1667,2296337,10.1039/d3md00038a,,,,Inhibition of EGFR (unknown origin),CCc1c(C(=O)NCCc2ccccc2)[nH]c2ccc(C)cc12,3-ethyl-5-methyl-N-phenethyl-1H-indole-2-carboxamide,0.134,uM,=,-0.8728952016351924,0,O=C(NCCc1ccccc1)c1cc2ccccc2[nH]1
1668,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,Fc1ccc(Nc2ncnc3ccc(NC(=S)NCCN4CCCCC4)cc23)cc1Cl,1-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)-3-(2-(piperidin-1-yl)ethyl)thiourea,0.08,uM,=,-1.0969100130080565,0,S=C(NCCN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1669,1739299,10.1016/j.ejmech.2018.05.006,,,,Inhibition of wild type EGFR (unknown origin) using FAM-labeled peptide substrate after 10 mins by mobility shift assay,C/C=C/C(=O)Nc1cc2c(N3CCc4ccccc43)ncnc2cc1O[C@@H]1CCOC1,"(R,E)-N-(4-(indolin-1-yl)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)but-2-enamide",0.029,uM,=,-1.537602002101044,0,c1ccc2c(c1)CCN2c1ncnc2cc(O[C@@H]3CCOC3)ccc12
1670,1674599,10.1021/acs.jmedchem.8b00125,,,,Inhibition of EGFR (unknown origin),CNS(=O)(=O)c1cccc(Nc2cc(Nc3ccc(Cl)cc3)ncn2)c1,3-((6-((4-Chlorophenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzenesulfonamide,0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
1671,1801908,10.1016/j.ejmech.2018.06.061,,,,Inhibition of EGFR in human HepG2 cells,COc1ccc(C2=C(C#N)C3=NC4=Nc5ccc(S(=O)(=O)N6CCOCC6)cc5C4=NC3C(O)=C2C#N)cc1,"1-Hydroxy-3-(4-methoxy phenyl)-9-(morpholinosulfonyl)-11aH-indolo[2,3-b]quinoxaline-2,4-dicarbonitrile",0.108,uM,=,-0.9665762445130504,0,O=S(=O)(c1ccc2c(c1)C1=NC3C=CC(c4ccccc4)=CC3=NC1=N2)N1CCOCC1
1672,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccccc2N)n1,4-(2-Aminophenoxy)-5-chloro-N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)pyrimidin-2-amine,9.78,uM,=,0.9903388547876014,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1673,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Oc1ncnc(Nc3cccc(Br)c3)c1NC2,"(3-Bromo-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
1674,2241040,10.1021/acs.jmedchem.1c00848,,,,Displacement of sapitinib-BODIPY tracer from C-terminal NanoLuc-fused full length wild type EGFR (unknown origin) transfected in HEK293T cells incubated for 2 hrs by NanoBRET assay,O=C(Nc1nccs1)C(c1cc(F)ccc1O)N1Cc2ccccc2C1=O,2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxoisoindolin-2-yl)-N-(thiazol-2-yl)acetamide,15.0,uM,=,1.1760912590556811,1,O=C(Nc1nccs1)C(c1ccccc1)N1Cc2ccccc2C1=O
1675,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1676,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,N#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1,"3-[(7,8-Dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)amino]benzonitrile",0.0453,uM,=,-1.343901797987168,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
1677,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CN(C)[C@H](CS(C)(=O)=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,(S)-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(1-(dimethylamino)-2-(methylsulfonyl)ethyl)furan-2-yl)quinazolin-4-amine,0.0040999999999999,uM,=,-2.3872161432802645,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
1678,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,Cn1c(SSc2c(C(=O)Nc3ccccc3)c3cc(C#N)ccc3n2C)c(C(=O)Nc2ccccc2)c2cc(C#N)ccc21,"2,2'-Dithiobis(1-methyl-5-cyano-N-phenyl-1H-indole-3-carboxamide)",54.1,uM,=,1.7331972651065697,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
1679,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1cnc(N2CC(CS(C)(=O)=O)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-(3-((methylsulfonyl)methyl)azetidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",1.05,uM,=,0.021189299069938,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
1680,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1ccc(C2CC(c3ccccc3)=NN2C2=NC(=O)CS2)cc1,"2-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",3.03,uM,=,0.481442628502305,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
1681,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc(NCc4cccnc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,"4-Dimethylamino-but-2-enoic acid (4-{3-chloro-4-[(1,6-dihydro-pyridin-3-ylmethyl)-amino]-phenylamino}-3-cyano-7-methoxy-quinolin-6-yl)-amide",0.072,uM,=,-1.1426675035687317,0,c1cncc(CNc2ccc(Nc3ccnc4ccccc34)cc2)c1
1682,63772,10.1021/jm9903949,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cells,Nc1ccc2sc3c(Nc4cccc(Br)c4)ncnc3c2c1,"N*4*-(3-Bromo-phenyl)-benzo[4,5]thieno[3,2-d]pyrimidine-4,8-diamine",0.086,uM,=,-1.0655015487564323,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
1683,1642159,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",2.8,uM,=,0.4471580313422192,1,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
1684,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCn1ccnc1,(3-Chloro-4-fluoro-phenyl)-[6-(2-imidazol-1-yl-ethoxy)-7-methoxy-quinazolin-4-yl]-amine,0.066,uM,=,-1.1804560644581312,0,c1ccc(Nc2ncnc3ccc(OCCn4ccnc4)cc23)cc1
1685,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCC/C(=C\c3ccccc3F)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(2-fluorobenzylidene)cyclohexanone",2.17,uM,=,0.3364597338485295,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
1686,2076853,10.1039/d0md00436g,,,,Inhibition of human EGFR TK domain expressed in Escherichia coli BL21 (DE3) pLysS using poly-Glu-Tyr (51 to 68 residues) as substrate incubated for 1 hr by ADP-Glo assay,CNc1nc(C)c(C(=O)/C=C/c2ccc(O)cc2)s1,(E)-1-(4-methyl-2-(methylamino)thiazol-5-yl)-3-(4-hydroxyphenyl)prop-2-en-1-one,0.0336599999999999,uM,=,-1.472885888360195,0,O=C(/C=C/c1ccccc1)c1cncs1
1687,935919,10.1016/j.bmcl.2012.11.001,,,,Inhibition of EGFR (unknown origin) by Z-LYTE assay,C=C1[C@H](C)CCC[C@]1(C)CC/C(C)=C/CC1=C(O)C(=O)C=C(N[C@@H](C(=O)O)[C@@H](C)O)C1=O,"(2R,3R)-2-(5-((E)-5-((1R,3R)-1,3-dimethyl-2-methylenecyclohexyl)-3-methylpent-2-enyl)-4-hydroxy-3,6-dioxocyclohexa-1,4-dienylamino)-3-hydroxybutanoic acid",211.1190388316572,uM,=,2.3245273999902345,1,C=C1CCCCC1CC/C=C/CC1=CC(=O)C=CC1=O
1688,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,Oc1ccc(-c2nc(-c3ccccc3)c(-c3ccnc4[nH]c(-c5ccccc5)cc34)[nH]2)cc1,"4-(4-Phenyl-5-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1Himidazol-2-yl)phenol",0.0136,uM,=,-1.8664610916297824,0,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccccc4)ccnc3[nH]2)cc1
1689,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.1,uM,=,-1.0,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
1690,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2cc(-c3cn(C)c4ccccc34)ncn2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((6-(1-methyl-1H-indol-3-yl)pyrimidin-4-yl)amino)phenyl)acrylamide,0.0023,uM,=,-2.638272163982407,0,c1ccc(Nc2cc(-c3c[nH]c4ccccc34)ncn2)cc1
1691,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,Cc1cc(C=C(C#N)C#N)cc(O)c1O,"2-(3,4-Dihydroxy-5-methyl-benzylidene)-malononitrile",62.0,uM,=,1.792391689498254,1,c1ccccc1
1692,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCc1c(C(=O)NC)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methylamide",0.07,uM,=,-1.154901959985743,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
1693,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Oc5ccnc6ccc(F)cc56)c(Cl)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(3-chloro-4-(6-fluoroquinolin-4-yloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.28,uM,=,-0.5528419686577808,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Oc5ccnc6ccccc56)cc4)c3s2)C1)N1CCOCC1
1694,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCc1c(NC(=O)OCc2ccccc2)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"[4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid benzyl ester",0.21,uM,=,-0.6777807052660807,0,O=C(Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnn2c1)OCc1ccccc1
1695,661840,10.1016/j.bmc.2010.05.049,,,,Inhibition of EGFR expressed in human A431 cells,COc1ccc(OC)c(Cc2cc3c(N(C)c4cccc(Br)c4)nc(N)nc3[nH]2)c1,"2-Amino-4-(N-methyl-m-bromoanilino)-6-(2,5-dimethoxybenzyl)-pyrrolo[2,3-d]pyrimidine",143.5,uM,=,2.156851901070011,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
1696,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)Nc1cc(Nc2ccnc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(2-(1-methyl-1H-indol-3-yl)pyrimidin-4-ylamino)phenyl)acrylamide,0.152,uM,=,-0.8181564120552275,0,c1ccc(Nc2ccnc(-c3c[nH]c4ccccc34)n2)cc1
1697,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4cc(OC)c(Br)c(OC)c4)nn32)CC1,"(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-bromo-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",1.092,uM,=,0.0382226383687184,1,c1ccc(-c2cc3n(n2)[C@H](C2CCNCC2)CCN3)cc1
1698,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,N#C/C(=C\c1cc(O)c(O)c(CSCc2ccccc2)c1)C(N)=O,"3-(3-Benzylsulfanylmethyl-4,5-dihydroxy-phenyl)-2-cyano-acrylamide",0.64,uM,=,-0.1938200260161128,0,c1ccc(CSCc2ccccc2)cc1
1699,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,COc1ccc2c(C(=O)Nc3ccccc3)c(SSc3c(C(=O)Nc4ccccc4)c4ccc(OC)cc4n3C)n(C)c2c1,"2,2'-Dithiobis(1-methyl-6-methoxy-N-phenyl-1H-indole-3-carboxamide)",3.6,uM,=,0.5563025007672873,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
1700,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCOC(=O)c1cn2ncnc(Nc3ccc4[nH]ncc4c3)c2c1CC,"5-Ethyl-4-(1H-indazol-5-ylamino)-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester",0.05,uM,=,-1.3010299956639813,0,c1cc2c(Nc3ccc4[nH]ncc4c3)ncnn2c1
1701,520709,10.1016/j.ejmech.2008.04.012,,,,Inhibition of EGFR,Nc1ncnc2ncn(CC(=O)c3c[nH]c4ccccc34)c12,2-(6-Amino-7H-purine-7-yl)-1-(1H-indole-3-yl)ethanone,82.0,uM,=,1.9138138523837167,1,O=C(Cn1cnc2ncncc21)c1c[nH]c2ccccc12
1702,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,CC(=O)N1CCN(CCOc2n[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,"1-(4-(2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yloxy)ethyl)piperazin-1-yl)ethanone",0.003,uM,=,-2.5228787452803374,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCNCC5)c34)cc2)nc1
1703,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,Cc1ccc(/C=C/C(=N/NC(N)=S)c2ccccc2)cc1,(Z)-2-((E)-1-phenyl-3-p-tolylallylidene)hydrazinecarbothioamide,17.39,uM,=,1.2402995820027125,1,N=C(/C=C/c1ccccc1)c1ccccc1
1704,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)cc3)c2cc1NC(=O)/C=C/CN1CCCC1,(2E)-N-{7-Ethoxy-4-[4-(2-pyridinylmethoxy)anilino]-6-quinazolinyl}-4-(1-pyrrolidinyl)-2-butenamide,0.012,uM,=,-1.9208187539523751,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccn4)cc3)c2c1
1705,1472643,10.1016/j.ejmech.2015.03.004,,,,Inhibition of human GST-tagged EGFR expressed in baculovirus-infected insect Sf9 cells using biotinylating polyGluTyr as substrate after 1 hr by scintillation counting analysis in presence of [gamma-33P]-ATP,O=C(Nc1ccc(CN2CCCC2)cc1)c1sc2ncnc3c2c1NC(=O)N3c1ccc(F)c(Cl)c1,"5-(3-Chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid(4-pyrrolidin-1-ylmethyl-phenyl)-amide",0.007,uM,=,-2.154901959985743,0,O=C(Nc1ccc(CN2CCCC2)cc1)c1sc2ncnc3c2c1NC(=O)N3c1ccccc1
1706,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,CCC(=O)N1CCC[C@@H](n2nc(-c3ccc(C(F)(F)F)cc3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(4-(trifluoromethyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)propan-1-one",6.5,uM,=,0.8129133566428556,1,c1ccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)cc1
1707,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COCCOCC#CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,3-(2-Methoxy-ethoxy)-propynoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.93,uM,=,-0.0315170514460648,0,c1ccc(Nc2ccnc3ccccc23)cc1
1708,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,CCn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3ccccc3)nc21,"6-(2,6-Dichloro-phenyl)-8-ethyl-2-phenylamino-8H-pyrido[2,3-d]pyrimidin-7-one",0.2,uM,=,-0.6989700043360187,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
1709,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,CC#CC(=O)Nc1cc2c(Oc3ccc(C(=O)Nc4ccccn4)cc3)ccnc2cc1OCCCN1CCN(C)CC1,4-(6-but-2-ynamido-7-(3-(4-methylpiperazin-1-yl)propoxy)quinolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.233,uM,=,-0.632644078973981,0,O=C(Nc1ccccn1)c1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1
1710,933476,10.1016/j.bmcl.2012.12.013,,,,Inhibition of EGFR (unknown origin),O=C(NCCCN1CCOC1=O)c1cnc(NCc2cc(Cl)ccc2Cl)nc1NC1CCCC1,"4-(cyclopentylamino)-2-(2,5-dichlorobenzylamino)-N-(3-(2-oxooxazolidin-3-yl)propyl)pyrimidine-5-carboxamide",4.09,uM,=,0.6117233080073418,1,O=C(NCCCN1CCOC1=O)c1cnc(NCc2ccccc2)nc1NC1CCCC1
1711,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),O=C(/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1)NCCCN1CCOCC1,"But-2-enedioic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide (3-morpholin-4-yl-propyl)-amide",0.00081,uM,=,-3.09151498112135,0,O=C(/C=C/C(=O)Nc1cc2c(Nc3ccccc3)ncnc2cn1)NCCCN1CCOCC1
1712,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-bromoanilino)-quinazolin-6-yl)acetamide,0.041,uM,=,-1.3872161432802643,0,c1ccc(Nc2ncnc3ccccc23)cc1
1713,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccc(O)c(O)c1,"2-(3,4-Dihydroxy-benzoyl)-3-(3,4-dihydroxy-phenyl)-acrylonitrile",5.0,uM,=,0.6989700043360189,1,O=C(C=Cc1ccccc1)c1ccccc1
1714,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",C=CC(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,"US9181263, 14::US9278100, 14",0.002298,uM,=,-2.6386499756477337,0,c1ccc(Oc2ccc(-c3nn(C[C@@H]4CCCN4)c4ncncc34)cc2)cc1
1715,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(Cl)cc3)c2c1,1-(4-((4-Chlorophenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)thiourea,0.0050599999999999,uM,=,-2.2958494831602008,0,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1716,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,FC(F)(F)c1cccc(NC(=S)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)c1,1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(3-(trifluoromethyl)phenyl)thiourea,0.0607,uM,=,-1.2168113089247423,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1717,946792,10.1016/j.bmc.2013.01.040,,,,Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA,COc1cccc(Nc2nc(NC(=O)C(C)(C)C)nc3[nH]c4cccc(Cl)c4c23)c1,"N-(5-chloro-4-(3-methoxyphenylamino)-9H-pyrimido[4,5-b]indol-2-yl)pivalamide",130.5,uM,=,2.1156105116743,1,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
1718,63761,10.1021/jm9906116,,,,Evaluated for inhibitory activity towards tyrosine kinase Epidermal growth factor receptor,NS(=O)(=O)c1ccc2c(c1)/C(=C/c1[nH]c3c(c1CCC(=O)O)CCCC3)C(=O)N2,"3-[2-(2-Oxo-5-sulfamoyl-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-1H-indol-3-yl]-propionic acid",29.1,uM,=,1.4638929889859074,1,O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCCC2
1719,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,COC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid methyl ester",0.6,uM,=,-0.2218487496163563,0,c1ccc(CNc2ccccc2)cc1
1720,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-(2-(6-(aminomethyl)pyridin-2-yl)ethynyl)pyrimidin-4-amine,0.021,uM,=,-1.6777807052660807,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccn1
1721,803381,10.1016/j.bmc.2005.05.012,,,,Inhibition of human recombinant His-tagged intracellular domain of EGFR using biotin-EEEEYFELV as substrate by HTRF assay,COc1ccc(N2Cc3cnc(Nc4ccccc4)nc3N([C@@H]3CC[C@@H](O)C3)C2=O)cc1,"(+/-)-1-(anti-3-Hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one",0.239,uM,=,-0.6216020990518624,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccccc3)nc2N1C1CCCC1
1722,574946,10.1021/np8004997,,,,Inhibition of recombinant EGFR,COc1cc2c(c(O)c1-c1c(OC)cc(O)c3c1C(=O)C1=C(C3=O)[C@H](O)[C@@H](O)[C@@](C)(O)[C@@H]1O)C(=O)c1cc(O)c(C)cc1C2=O,alterporriol G/H,4.367961327338321,uM,=,0.6402787845964248,1,O=C1c2ccccc2C(=O)c2cc(-c3cccc4c3C(=O)C3=C(CCCC3)C4=O)ccc21
1723,1526584,10.1021/acsmedchemlett.5b00193,,,,Inhibition of wild type EGFR phosphorylation in human A431 cells after 60 mins by mesoscale multiplex assay,C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.386,uM,=,-0.413412695328245,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
1724,554997,10.1021/jm8001185,,,,Inhibition of human recombinant EGFR,COc1cc(C2=C(c3cn(COCC[Si](C)(C)C)c4ccccc34)CNC2=O)cc(OC)c1OC,"3-(3,4,5-Trimethoxyphenyl)-4-(1-{[2-(trimethylsilyl)ethoxy]-methyl}-1H-indol-3-yl)-1,5-dihydro-2H-pyrrole-2-one",22.0,uM,=,1.3424226808222062,1,O=C1NCC(c2c[nH]c3ccccc23)=C1c1ccccc1
1725,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)c2cccc(Cl)c2)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"4-[3-chlorophenyl(methyl)carboxamido]-3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaene",4.6,uM,=,0.6627578316815741,1,O=C(N[C@@H]1CC2O[C@@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O)c1ccccc1
1726,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cc(Cl)ccc3F)c2cc1OC1CCN(S(C)(=O)=O)CC1,N-(5-chloro-2-fluorophenyl)-7-methoxy-6-(1-(methylsulfonyl)piperidin-4-yloxy)quinazolin-4-amine,0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
1727,1553877,10.1016/j.ejmech.2016.01.045,,,,Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay,COCCOc1cc2ncnc(Nc3ccc(NC(=O)C45CC6CC(CC(C6)C4)C5)c(C#N)c3)c2cc1OCCOC,"N-(4-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)amino)-2-cyanophenyl)adamantane-1-carboxamide",0.00501,uM,=,-2.3001622741327545,0,O=C(Nc1ccc(Nc2ncnc3ccccc23)cc1)C12CC3CC(CC(C3)C1)C2
1728,1701500,10.1021/acs.jmedchem.7b00178,,,,Inhibition of wild-type EGFR (unknown origin),C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.0014,uM,=,-2.853871964321762,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1729,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CCN(C)CC1,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide",12.0,uM,=,1.0791812460476249,1,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c2c1
1730,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCC6)c45)ccc32)c1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-(pyrrolidin-1-ylmethyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.5,uM,=,-0.3010299956639812,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCC6)c45)ccc32)cc1
1731,2110760,10.1016/j.ejmech.2020.113022,,,,Inhibition of N-terminal GST-tagged human recombinant EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCCN/C(=N\C#N)Nc4ccncc4)cc23)c1,2-Cyano-1-(7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)heptyl)-3-(pyridin-4-yl)guanidine,0.0004729999999999,uM,=,-3.3251388592621884,0,N=C(NCCCCCCCOc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1ccncc1
1732,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OCCCN1CCOCC1,N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine,0.018,uM,=,-1.744727494896694,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1733,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,COCC#CC(=O)Nc1cc2c(Oc3ccc(C(=O)Nc4ccccn4)cc3)ccnc2cc1OC,4-(7-methoxy-6-(4-methoxybut-2-ynamido)quinolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.012,uM,=,-1.9208187539523751,0,O=C(Nc1ccccn1)c1ccc(Oc2ccnc3ccccc23)cc1
1734,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)ccc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)buta-2,3-dienamide",0.0228,uM,=,-1.6420651529995465,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1735,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Clc1cccc(Nc2ncnc3ccccc23)c1,(3-Chloro-phenyl)-quinazolin-4-yl-amine,0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2ncnc3ccccc23)cc1
1736,1434846,10.1021/jm5011012,,,,Inhibition of EGFR (unknown origin),C[C@@H]1CN(c2nc(C(F)(F)F)no2)CCN1c1ncc(OCc2ccc(CS(C)(=O)=O)cc2F)cn1,"5-({2-Fluoro-4-[(methylsulfonyl)methyl]benzyl}oxy)-2-{(2R)-2-methyl-4-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]piperazin-1-yl}-pyrimidine",2.1,uM,=,0.3222192947339193,1,c1ccc(COc2cnc(N3CCN(c4ncno4)CC3)nc2)cc1
1737,1737123,10.1016/j.ejmech.2018.03.062,,,,Inhibition of wild type EGFR phosphorylation in human H358 cells,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1,"N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide",2.0,uM,=,0.3010299956639812,1,c1ccc(Oc2nc(Nc3ccc(N4CCNCC4)cc3)nc3ccsc23)cc1
1738,2270859,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) using TK as substrate incubated for 30 min in presence of ATP by TR-FRET assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.001,uM,=,-3.0,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1739,66581,10.1016/s0960-894x(02)00598-x,,,,Inhibition of Epidermal Growth Factor Receptor (EGFR) autophosphorylation,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OCCCN1CCOCC1,N-[4-(3-Chloro-4-fluoro-phenylamino)-3-cyano-7-(3-morpholin-4-yl-propoxy)-quinolin-6-yl]-acrylamide,0.08,uM,=,-1.0969100130080565,0,c1ccc(Nc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1
1740,66719,10.1021/jm00050a005,,,,Inhibition of EGF-R Tyrosine kinase (TK),COC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid methyl ester",24.4,uM,=,1.3873898263387294,1,c1ccc(CNc2ccccc2)cc1
1741,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1,"(2E)-N-{4-[(1-Benzyl-1H-indazol-5-yl)amino]pyrido[3,4-d]-pyrimidin-6-yl}-4-(dimethylamino)-2-butenamide",0.003,uM,=,-2.5228787452803374,0,c1ccc(Cn2ncc3cc(Nc4ncnc5cnccc45)ccc32)cc1
1742,2294501,10.1016/j.bmc.2023.117202,,,,Inhibition of wild type EGFR (unknown origin),C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,POZIOTINIB,0.000137,uM,=,-3.863279432843593,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
1743,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Oc1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1,"3-(6,7,8,9-Tetrahydro-5H-pyrimido[4,5-b]indol-4-ylamino)-phenol",0.42,uM,=,-0.3767507096020995,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1
1744,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3cc[nH]c3c1)nn2C1CCCC1,"1-cyclopentyl-3-(1H-indol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.085,uM,=,-1.0705810742857071,0,c1ncc2c(-c3ccc4cc[nH]c4c3)nn(C3CCCC3)c2n1
1745,67067,10.1016/S0960-894X(01)80792-7,,,,Inhibition of Epidermal growth factor receptor,O=CN/C=C/c1ccc(O)c(O)c1,"N-[(E)-2-(3,4-Dihydroxy-phenyl)-vinyl]-formamide",7.0,uM,=,0.8450980400142568,1,c1ccccc1
1746,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1ccc(C(=O)Nc2ccc(OCc3ccccn3)c(Cl)c2)cc1NC(=O)/C=C/CN(C)C,N-(3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)-3-(4-(dimethylamino)but-2-enamido)-4-ethoxybenzamide,1.2,uM,=,0.0791812460476248,1,O=C(Nc1ccc(OCc2ccccn2)cc1)c1ccccc1
1747,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CC(CCOC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O)CC(C)(C)C,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3,5,5-trimethyl-hexyl ester",0.8,uM,=,-0.0969100130080563,0,c1ccc(CNc2ccccc2)cc1
1748,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,COCCOCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((2-methoxyethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.49,uM,=,-0.3098039199714864,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
1749,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1,[3-chloro-4-(3-fluoro-benzyloxy)-phenyl]-{6-[5-(1-oxo-1lambda*4*-thiomorpholin-4-ylmethyl)-furan-2-yl]-quinazolin-4-yl}-amine,0.028,uM,=,-1.5528419686577808,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CN6CC[SH+]CC6)o5)cc34)cc2)cc1
1750,2231861,10.1021/acs.jnatprod.1c01085,,,,Inhibition of EGFR (unknown origin) by lanthascreen Tb kinase activity assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.0112,uM,=,-1.9507819773298185,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
1751,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCCN(C(=O)C(F)(F)F)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-19",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCCNCC4)cc3)n2)cc1
1752,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC[C@@H]1CCCN(C)C1,(R)-(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-3-ylmethoxy)-quinazolin-4-yl]-amine,0.15,uM,=,-0.8239087409443188,0,c1ccc(Nc2ncnc3cc(OC[C@@H]4CCCNC4)ccc23)cc1
1753,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,Clc1ccc2c(Nc3ccc(-c4nc5ccccc5s4)c(Cl)c3)ncnc2c1,N-(4-(benzo[d]thiazol-2-yl)-3-chlorophenyl)-7-chloroquinazolin-4-amine,0.8,uM,=,-0.0969100130080563,0,c1ccc2sc(-c3ccc(Nc4ncnc5ccccc45)cc3)nc2c1
1754,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CCCC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-2-hexynamide",0.0017,uM,=,-2.7695510786217263,0,c1ccc(Nc2ncnc3cnccc23)cc1
1755,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.0026,uM,=,-2.5850266520291822,0,c1ccc(Nc2ncnc3ccccc23)cc1
1756,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COCCN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1,N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(1-(2-methoxyethyl)piperidin-4-yloxy)quinazolin-4-amine,0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
1757,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{8-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-octyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",24.0,uM,=,1.380211241711606,1,O=C(C=Cc1ccccc1)NCCCCCCCCNC(=O)/C=C/c1ccccc1
1758,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Nc1ccc2c(Nc3cccc(C(F)(F)F)c3)ncnc2c1,"N*4*-(3-Trifluoromethyl-phenyl)-quinazoline-4,7-diamine",0.0033,uM,=,-2.4814860601221125,0,c1ccc(Nc2ncnc3ccccc23)cc1
1759,642329,10.1016/j.bmc.2010.05.032,,,,Inhibition EGFR,NS(=O)(=O)c1ccc(Nc2nc(N3CCOCC3)nc3[nH]cnc23)cc1,N-(4-Aminosulfonylphenyl)-2-morpholino-9H-purin-6-amine,10.0,uM,=,1.0,1,c1ccc(Nc2nc(N3CCOCC3)nc3[nH]cnc23)cc1
1760,1991314,10.1016/j.bmcl.2020.127288,,,,Inhibition of wild type EGFR (unknown origin) in presence of radiolabelled gammaATP by radioisotope filter binding assay,N#Cc1cnc2cc(OC[C@H](O)CO)c(NC(=O)CC3CSSC3)cc2c1Nc1ccc(OCc2cccc(F)c2)c(Cl)c1,"(R)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-3-cyano-7-(2,3-dihydroxypropoxy)quinolin-6-yl)-2-(1,2-dithiolan-4-yl)acetamide",0.002,uM,=,-2.6989700043360187,0,O=C(CC1CSSC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
1761,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,C=CC(=O)Nc1ccc(Oc2nc(Nc3cc(C)[nH]n3)cc(N3CCN(C)CC3)n2)cc1,N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-yloxy)phenyl)acrylamide,3.1,uM,=,0.4913616938342727,1,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1
1762,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)cc(OC)c1OC,"1-isopropyl-3-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",5.14,uM,=,0.7109631189952758,1,c1ccc(-c2n[nH]c3ncncc23)cc1
1763,2017350,10.1021/acs.jmedchem.0c00870,,,,Inhibiton of EGFR (unknown origin) expressed in human A431 cells assessed as reduction in EGFR induced cell viability after 96 hrs by CellTiter-Glo assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.911,uM,=,-0.0404816230270017,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1764,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)CCN1CCCCC1,N-(4-(3-Chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl)-3-piperidin-1-ylpropanamide,0.00051,uM,=,-3.292429823902064,0,O=C(CCN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1765,2207742,10.1021/acs.jmedchem.2c00893,,,,Inhibition of wild type EGFR expressed in human A-431 cells,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.092,uM,=,-1.0362121726544449,0,c1ccc(Nc2ncnc3ccccc23)cc1
1766,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0118,uM,=,-1.9281179926938743,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1767,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NC1CCCC[C@@H]1NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{(S)-2-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-cyclohexyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",4.0,uM,=,0.6020599913279624,1,O=C(C=Cc1ccccc1)NC1CCCC[C@@H]1NC(=O)/C=C/c1ccccc1
1768,632393,10.1016/j.bmcl.2010.03.064,,,,Inhibition of EGFR,Nc1nc(Nc2ccc(F)c(Br)c2)c2cc(CCc3ccccc3)[nH]c2n1,"N4-(3-bromo-4-fluorophenyl)-6-(2-phenylethyl)-7Hpyrrolo[2,3-d]pyrimidine-2,4-diamine",22.8,uM,=,1.3579348470004535,1,c1ccc(CCc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
1769,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C6COC6)CC5)c(C)c4)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.302,uM,=,-0.5199930570428494,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCN(C5COC5)CC4)cc3)nc2N1[C@H]1CCNC1
1770,506208,10.1021/np50089a001,,,,Inhibition of EGFR,O=C(O)/C=C/c1cc(O)ccc1O,"2,5-dihydroxystyrylcarbamic acid",44.43401263772512,uM,=,1.6477155342116858,1,c1ccccc1
1771,63772,10.1021/jm9903949,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cells,Cc1cccc(Nc2ncnc3c2sc2ccc(N)cc23)c1,"N*4*-m-Tolyl-benzo[4,5]thieno[3,2-d]pyrimidine-4,8-diamine",0.098,uM,=,-1.0087739243075051,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
1772,2201427,10.1016/j.ejmech.2021.114085,,,,Inhibition of wild-type EGFR (unknown origin),COC(=O)CCc1nc2ccc(Br)cc2[nH]c1=O,"methyl 3-(6-bromo-3-oxo-3,4-dihydroquinoxalin-2-yl)propanoate",0.957,uM,=,-0.0190880622231564,0,O=c1cnc2ccccc2[nH]1
1773,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0157,uM,=,-1.8041003475907664,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
1774,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,NC(=O)Nc1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c2c1,1-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)quinazolin-6-yl)urea,0.004,uM,=,-2.397940008672037,0,c1ccc(Oc2ccc(Nc3ncnc4ccccc34)cc2)cc1
1775,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cc(F)cc(F)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,"4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(3,5-difluoro-benzyloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide",0.14,uM,=,-0.8538719643217619,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
1776,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCOCCOCCOCC1,"4-(1,4,7-Trioxa-10-aza-cyclododec-10-yl)-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide",0.321,uM,=,-0.4934949675951279,0,O=C(/C=C/CN1CCOCCOCCOCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
1777,2260083,10.1016/j.ejmech.2020.112904,,,,Inhibition of EGFR (unknown origin),C#Cc1cccc(Nc2ncnc3ccc(S(=O)(=O)n4ccc(/C=C/C(=O)NO)c4)cc23)c1,(E)-3-{1-[4-(3-ethynylphenylamino)quinazoline-6-ylsulfonyl]-1H-pyrrol-3-yl}-N-hydroxyacrylamide,1.2,uM,=,0.0791812460476248,1,O=S(=O)(c1ccc2ncnc(Nc3ccccc3)c2c1)n1cccc1
1778,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,CN(C)CCc1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"{6-[4-(2-Dimethylamino-ethyl)-phenyl]-thieno[3,2-d]pyrimidin-4-yl}-(1H-indol-5-yl)-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
1779,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,COc1ccc(CC(CO)n2cc(-c3ccccc3)c3c(N)ncnc32)cc1,"2-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-3-(4-methoxy-phenyl)-propan-1-ol",14.4,uM,=,1.1583624920952498,1,c1ccc(CCn2cc(-c3ccccc3)c3cncnc32)cc1
1780,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-(5-((2-(phenylsulfonyl)ethoxy)methyl)furan-2-yl)quinazolin-4-amine,0.025,uM,=,-1.6020599913279625,0,O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1)c1ccccc1
1781,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,Cc1ccc(C2CC(c3ccc(Cl)c(Cl)c3)=NN2C(N)=S)cc1,"3-(3,4-Dichlorophenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazole-1-carbothioamide",7.38,uM,=,0.8680563618230416,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
1782,952256,10.1016/j.bmc.2013.02.014,,,,Inhibition of human N-terminal DYKDDDD-tagged EGFR cytoplasmic domain (669 to 1210) expressed in baculovirus expression system incubated for 5 mins prior to [gamma-32P]ATP addition measured after 10 mins by scintillation counting analysis,CS(=O)(=O)CCNC(=O)C1=Cc2c(ncnc2Nc2ccc(Oc3cccc4sccc34)c(Cl)c2)NCC1,"4-((4-(1-Benzothiophen-4-yloxy)-3-chlorophenyl)amino)-N-(2-(methylsulfonyl)ethyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxamide",0.047,uM,=,-1.3279021420642825,0,C1=Cc2c(ncnc2Nc2ccc(Oc3cccc4sccc34)cc2)NCC1
1783,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(C=C(C#N)C#N)cc(C)c1O,2-(4-Hydroxy-3-methoxy-5-methyl-benzylidene)-malononitrile,2600.0,uM,=,3.414973347970818,1,c1ccccc1
1784,2260087,10.1016/j.ejmech.2020.112904,,,,Inhibition of EGFR T790M (unknown origin) incubated for 40 mins in presence of ATP,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0014,uM,=,-2.853871964321762,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1785,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)cc(CCC)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-5-propylpyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.97,uM,=,-0.0132282657337551,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
1786,2241040,10.1021/acs.jmedchem.1c00848,,,,Displacement of sapitinib-BODIPY tracer from C-terminal NanoLuc-fused full length wild type EGFR (unknown origin) transfected in HEK293T cells incubated for 2 hrs by NanoBRET assay,C=CC(=O)Nc1ccc(OC)c(Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)c1,N-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.33,uM,=,-0.4814860601221125,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
1787,2198131,10.1016/j.ejmech.2022.114661,,,,Inhibition of recombinant human EGFR incubated for 40 to 45 mins and measured after 15 mins by Kinase-Glo Max assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.062,uM,=,-1.207608310501746,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1788,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",CS(=O)(=O)CCNC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(2-(methylsulfonyl)ethyl)urea,0.041,uM,=,-1.3872161432802643,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1789,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,Cc1ccc(S(=O)(=O)NC(=O)Cc2ccc(Cl)cc2)cc1,2-(4-Chlorophenyl)-N-tosylacetamide,13.73,uM,=,1.137670537236755,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
1790,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc(Sc4nccn4C)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,2-{2-Chloro-4-[3-cyano-6-(4-dimethylamino-but-2-enoylamino)-7-methoxy-quinolin-4-ylamino]-phenylsulfanyl}-1-methyl-3H-imidazol-1-ium,0.041,uM,=,-1.3872161432802643,0,c1ccc2c(Nc3ccc(Sc4ncc[nH]4)cc3)ccnc2c1
1791,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)cc3)c2cc1NC(=O)/C=C/CN1CCN(C)CC1,(2E)-N-{7-Ethoxy-4-[4-(2-pyridinylmethoxy)anilino]-6-quinazolinyl}-4-(4-methyl-1-piperazinyl)-2-butenamide,0.164,uM,=,-0.7851561519523022,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccn4)cc3)c2c1
1792,2268700,10.1016/j.ejmech.2021.113768,,,,Inhibition of EGFR (unknown origin),O=[N+]([O-])OCCCOc1ccc(Nc2ncnc3c2cnn3-c2ccc(Br)cc2)cc1,"3-(4-((1-(4-Bromophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenoxy)propyl nitrate",3.0,uM,=,0.4771212547196624,1,c1ccc(Nc2ncnc3c2cnn3-c2ccccc2)cc1
1793,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,Cc1nn(C)cc1C(=O)Nc1ccn(Cc2c(F)cccc2Cl)n1,"N-(1-(2-chloro-6-fluorobenzyl)-1H-pyrazol-3-yl)-1,3-dimethyl-1H-pyrazole-4-carboxamide",72.4,uM,=,1.859738566197147,1,O=C(Nc1ccn(Cc2ccccc2)n1)c1cn[nH]c1
1794,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,COCCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCN(C)CC1,(2E)-N-[4-[(1-Benzyl-1H-indazol-5-yl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]-4-(4-methyl-1-piperazinyl)-2-butenamide,0.026,uM,=,-1.585026652029182,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
1795,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CC[C@@H](N(C)C)C1,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-2-((R)-3-(dimethylamino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamide",357.0,uM,=,2.552668216112193,1,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCCC5)cc4)n3)c2c1
1796,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccc(Br)cc2)=N1,"2-(5-(4-Bromophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",1.35,uM,=,0.1303337684950061,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
1797,661840,10.1016/j.bmc.2010.05.049,,,,Inhibition of EGFR expressed in human A431 cells,Cc1ccccc1Cc1cc2c(N(C)c3cccc(Br)c3)nc(N)nc2[nH]1,"2-Amino-4-(N-methyl-m-bromoanilino)-6-(2-methylbenzyl)-pyrrolo[2,3-d]pyrimidine",31.2,uM,=,1.4941545940184429,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
1798,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),CC(=O)/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Oxo-pent-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3ccccc23)cc1
1799,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Oc1cccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"3-[4-(3-Chloro-phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-ylamino]-phenol",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
1800,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccc(Cl)cc2)=N1,"2-(5-(4-Chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",3.49,uM,=,0.5428254269591799,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
1801,2229998,10.1021/acs.jmedchem.1c00876,,,,Inhibition of wild type EGFR (unknown origin),COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(N)(=O)=O)n1,5-chloro-2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)-1-piperidyl]anilino]-4-[2-(sulfamoylamino)anilino]pyrimidine,0.0028,uM,=,-2.552841968657781,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
1802,66579,10.1016/j.bmcl.2004.03.106,,,,Inhibition of human epidermal growth factor receptor,C[C@H](Nc1cc(-c2sc(C3CCN(C)CC3)nc2-c2ccc(F)cc2)ccn1)c1ccccc1,4-{4-(4-Fluoro-phenyl)-5-[2-((S)-1-phenyl-ethylamino)-pyridin-4-yl]-thiazol-2-yl}-1-methyl-piperidin-4-ol,0.7,uM,=,-0.1549019599857432,0,c1ccc(CNc2cc(-c3sc(C4CCNCC4)nc3-c3ccccc3)ccn2)cc1
1803,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,O=C(Nc1cnn(-c2ccccc2)c1)c1ccc(NS(=O)(=O)c2ccc(Cl)cc2)cc1,4-((4-Chlorophenyl)sulfonamido)-N-(1-phenyl-1H-pyrazol-4-yl)benzamide,18.69,uM,=,1.271609301378832,1,O=C(Nc1cnn(-c2ccccc2)c1)c1ccc(NS(=O)(=O)c2ccccc2)cc1
1804,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccccc23)cc1
1805,1567355,10.1016/j.bmcl.2016.02.067,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells preincubated for 2 hrs followed by EGF stimulation measured after 30 mins by ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(5-(4-(1H-indol-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,0.033,uM,=,-1.4814860601221125,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1806,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CO[C@@H]1CCN(c2nccc(Nc3cc4c(C(C)C)ccc(N5C[C@H](CS(C)(=O)=O)[C@H]5C)c4cn3)n2)C[C@@H]1F,BLU-945,0.544,uM,=,-0.26440110030182,0,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
1807,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)N1CCc2ccccc21,"2-(2,3-Dihydro-indole-1-carbonyl)-3-(3,4-dihydroxy-phenyl)-acrylonitrile",12.0,uM,=,1.0791812460476249,1,O=C(C=Cc1ccccc1)N1CCc2ccccc21
1808,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCC6(CCN(C)CC6)CC5)c(C)c4)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(9-methyl-3,9-diazaspiro[5.5]undecan-3-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]-pyrimidin-2(1H)-one",0.2245,uM,=,-0.648783654660658,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCC5(CCNCC5)CC4)cc3)nc2N1[C@H]1CCNC1
1809,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(F)c4)nc32)C1,"(S)-7-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",1.3,uM,=,0.1139433523068367,1,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
1810,63764,10.1021/jm960689b,,,,Inhibition of epidermal growth factor receptor (EGFr),CNC(=O)c1c([Se][Se]c2[nH]c3ccccc3c2C(=O)NC)[nH]c2ccccc12,"2,2'-Diselenobis[N-methyl-1H-indole-3-carboxamide]",13.0,uM,=,1.1139433523068367,1,c1ccc2[nH]c([Se][Se]c3cc4ccccc4[nH]3)cc2c1
1811,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C#CCCCCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,4-(3'-Chloro-4'-fluoroanilino)-6-(hex-5-ynyloxy)-7-methoxyquinazoline,0.0871,uM,=,-1.0599818449923368,0,c1ccc(Nc2ncnc3ccccc23)cc1
1812,807915,10.1016/j.bmc.2012.01.029,,,,Inhibition of EGFR,Nc1nc(Nc2cccc(Br)c2)c2cc(Cc3ccc(-c4ccccc4)cc3)[nH]c2n1,"6-(biphenyl-4-ylmethyl)-N4-(3-bromophenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",6.16,uM,=,0.7895807121644255,1,c1ccc(Nc2ncnc3[nH]c(Cc4ccc(-c5ccccc5)cc4)cc23)cc1
1813,1642199,,,,,Inhibition Assay: Inhibition of various kinase enzyme.,Nc1nc2c(c(Nc3ccc(Cl)cc3)n1)-c1ccccc1C2,"N4-(4-Chlorophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine",26.0,uM,=,1.414973347970818,1,c1ccc(Nc2ncnc3c2-c2ccccc2C3)cc1
1814,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCN(C)CC4)cc3)n2)c1,N-(3-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.143,uM,=,-0.8446639625349383,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1
1815,67206,10.1021/jm010496a,,,,Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase,CCOc1cc2nc(C)nc(Nc3cccc(-c4csc(C)n4)c3)c2cc1OCC,"(6,7-Diethoxy-2-methyl-quinazolin-4-yl)-[3-(2-methyl-thiazol-4-yl)-phenyl]-amine",9.0,uM,=,0.9542425094393248,1,c1cc(Nc2ncnc3ccccc23)cc(-c2cscn2)c1
1816,1778842,10.1016/j.bmcl.2018.07.039,,,,Inhibition of EGF-induced EGFR activation in human A431 cells pretreated for 60 mins followed by EGF addition and measured after 10 mins by ELISA,CCN(c1ccc(OC)cc1)c1ncnc2occ(C)c12,"N-ethyl-N-(4-methoxyphenyl)-5-methylfuro[2,3-d]pyrimidin-4-amine",0.0925,uM,=,-1.0338582672609675,0,c1ccc(Nc2ncnc3occc23)cc1
1817,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CC(C)N(CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1)C(C)C,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-4-(bis(1-methylethyl)amino)-2-butynamide",0.044,uM,=,-1.3565473235138126,0,c1ccc(Nc2ncnc3cnccc23)cc1
1818,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1,N-(3-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)phenyl)acetamide,0.012,uM,=,-1.9208187539523751,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
1819,2080997,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R (unknown origin) by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1O[C@@H]1CCOC1,Afatinib,0.00088,uM,=,-3.055517327849832,0,c1ccc(Nc2ncnc3ccc(O[C@@H]4CCOC4)cc23)cc1
1820,2203131,10.1016/j.ejmech.2022.114455,,,,Inhibition of wild type EGFR (unknown origin) incubated for 10 mins by HTRF KinEASE-TK assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CCCCCC(=O)Nc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"7-(4-(4-((4-((3-acrylamidophenyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-7-oxoheptanamide",0.6479,uM,=,-0.1884920200546733,0,O=C1CCC(N2C(=O)c3cccc(NC(=O)CCCCCC(=O)N4CCN(c5ccc(Nc6nccc(Nc7ccccc7)n6)cc5)CC4)c3C2=O)C(=O)N1
1821,624979,10.1016/j.bmcl.2010.03.015,,,,Inhibition of EGFR intracellular phosphorylation in human A431 cells by ELISA,CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(NC(=O)c6c(F)cccc6F)c5)nc5sccn45)n3)cc2)CC1,"N-(3-(5-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2,6-difluorobenzamide",0.05,uM,=,-1.3010299956639813,0,O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1)c1ccccc1
1822,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Nc1ccc2c(c1)CNc1c(Nc3ccc(F)c(Cl)c3)ncnc1O2,"N*1*-(3-Chloro-4-fluoro-phenyl)-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene-1,8-diamine",3.7,uM,=,0.568201724066995,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
1823,66582,10.1021/jm970634p,,,,Inhibition of human epidermal growth factor receptor,COc1cc(OC)cc(-c2cc3cnc(N)nc3nc2NC(=O)NC(C)(C)C)c1,"1-[2-Amino-6-(3,5-dimethoxy-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl-urea",50.0,uM,=,1.6989700043360187,1,c1ccc(-c2cnc3ncncc3c2)cc1
1824,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,CN(C)C/C=C/C(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.31,uM,=,-0.5086383061657274,0,c1ccc(Nc2ccnc3ccccc23)cc1
1825,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4C)nc32)c1,"N-(3-(3-Methyl-7-(2-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.00195,uM,=,-2.709965388637482,0,O=C1NCc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
1826,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,N#Cc1cnc2sc3c(c2c1Nc1ccc(Cl)c(Cl)c1)CCN(C(=O)/C=C/CN1CCCOCC1)C3,"US8524722, 148",0.0043,uM,=,-2.3665315444204134,0,O=C(/C=C/CN1CCCOCC1)N1CCc2c(sc3nccc(Nc4ccccc4)c23)C1
1827,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,But-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3ccccc23)cc1
1828,1873904,10.1021/acs.jmedchem.9b00794,,,,Inhibition of N-terminal GST-tagged human EGFR (696 to end aminoacids) expressed in baculovirus infected Sf21 cells,C=CC(=O)Nc1cccc(-c2c(N)ncnc2Nc2ccc(Oc3ccccc3)cc2)c1,N-(3-(4-amino-6-((4-phenoxyphenyl)amino)pyrimidin-5-yl)phenyl)acrylamide,0.001,uM,=,-3.0,0,c1ccc(Oc2ccc(Nc3ncncc3-c3ccccc3)cc2)cc1
1829,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CC2(COC2)C1,6-(3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)propoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine,0.056,uM,=,-1.2518119729937995,0,c1ccc(Nc2ncnc3ccc(OCCCN4CC5(COC5)C4)cc23)cc1
1830,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)CCCCCCC(=O)NO,N1-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-N8-hydroxyoctanediamide,0.0021,uM,=,-2.6777807052660805,0,c1ccc(Nc2ncnc3ccccc23)cc1
1831,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCNC(C)(CO)CO,"2-{2-[4-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-ethylamino}-2-methyl-propane-1,3-diol",0.069,uM,=,-1.1611509092627446,0,c1ccc(Nc2ncnc3ccccc23)cc1
1832,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1cnc(N2CC(CS(C)(=O)=O)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-(3-((methylsulfonyl)methyl)azetidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",1.608,uM,=,0.2062860444124324,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
1833,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#CC(C#N)=C(C#N)c1cccc(O)c1,"2-(3,5-dihydroxyphenyl)ethene-1,1,2-tricarbonitrile",400.0,uM,=,2.6020599913279625,1,c1ccccc1
1834,2123057,10.1016/j.ejmech.2021.113674,,,,Inhibition of EGFR (unknown origin) incubated for 40 mins in presence of Mg/ATP mix by [gamma p33]-ATP based scintillation counting method,CS(=O)(=O)c1nccc(-c2c(-c3cccc(OCc4ccccc4)c3)nc3sccn23)n1,"6-(3-(Benzyloxy)phenyl)-5-(2-(methylsulfonyl)pyrimidin-4-yl)imidazo[2,1-b]thiazole",9.92,uM,=,0.9965116721541788,1,c1ccc(COc2cccc(-c3nc4sccn4c3-c3ccncn3)c2)cc1
1835,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(F)c(Cl)c4F)ncnc3cc2OCCC)CC1,"1-(4-(4-(3-chloro-2,4-difluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one",0.0007,uM,=,-3.154901959985743,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
1836,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1,"(2E)-N-{4-[(1-Benzyl-1H-indazol-5-yl)amino]pyrido[3,4-d]-pyrimidin-6-yl}-4-(1-pyrrolidinyl)-2-butenamide",0.057,uM,=,-1.2441251443275083,0,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1
1837,1739294,10.1016/j.ejmech.2018.05.006,,,,Inhibition of EGFR (unknown origin),C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.0074,uM,=,-2.130768280269024,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
1838,5167,10.1021/jm010888h,,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,C[C@@H](Nc1ncnc2c1sc1ccccc12)c1ccccc1,"Benzo[4,5]thieno[3,2-d]pyrimidin-4-yl-(1-phenyl-ethyl)-amine",0.538,uM,=,-0.2692177243336108,0,c1ccc(CNc2ncnc3c2sc2ccccc23)cc1
1839,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1-c1cccc(CN2CCOCC2)c1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-(3-(morpholinomethyl)phenyl)pyrimidin-4-amine,0.59,uM,=,-0.2291479883578558,0,c1ccc(COc2ccc(Nc3ncncc3-c3cccc(CN4CCOCC4)c3)cc2)cc1
1840,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cc1ccc(S(=O)(=O)c2c(SSc3[nH]c4ccccc4c3S(=O)(=O)c3ccc(C)cc3)[nH]c3ccccc23)cc1,di[3-(4-methylphenylsulfonyl)-1H-2-indolyl] disulfide0.2 C6H6,28.7,uM,=,1.4578818967339924,1,O=S(=O)(c1ccccc1)c1c(SSc2[nH]c3ccccc3c2S(=O)(=O)c2ccccc2)[nH]c2ccccc12
1841,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,Cc1cccc(Nc2ncnc3nc(Nc4ccc(S(N)(=O)=O)cc4)sc23)c1,"4-(7-(m-tolylamino)thiazolo[4,5-d]pyrimidin-2-ylamino)benzenesulfonamide",0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1
1842,340860,10.1016/j.bmcl.2005.12.028,,,,Inhibitory activity against EGFR,CN1CCC(Oc2cccc3ncnc(Nc4ccc(F)c(Cl)c4)c23)CC1,N-(3-chloro-4-fluorophenyl)-5-(1-methylpiperidin-4-yloxy)quinazolin-4-amine,0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3cccc(OC4CCNCC4)c23)cc1
1843,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,CCOc1cc2ncnc(Nc3ccc(Oc4cc5nncn5cn4)c(C)c3)c2cc1NC(=O)/C(F)=C/[C@@H]1CCCN1C,"(Z)-N-[7-ethoxy-4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-2-fluoro-3-[(2S)-1-methylpyrrolidin-2-yl]prop-2-enamide",0.03214,uM,=,-1.4929541275726743,0,O=C(/C=C/[C@@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4cc5nncn5cn4)cc3)c2c1
1844,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,O=C(C#CCN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Morpholin-4-yl-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.02,uM,=,-1.6989700043360187,0,O=C(C#CCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1845,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1c(C(=O)N2CCN(C)CC2)c[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[3-methyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.41,uM,=,-0.3872161432802645,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1cc(C(=O)N2CCNCC2)c[nH]1
1846,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3ccccc23)cc1
1847,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Nc1ncnc(NCc3ccc(F)c(Cl)c3)c1NC2,"(3-chloro-4-fluoro-benzyl)-(7,8-dimethoxy-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cyclohepten-1-yl)-amine",0.3,uM,=,-0.5228787452803376,0,c1ccc(CNc2ncnc3c2NCc2ccccc2N3)cc1
1848,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCSCC1,4-Thiomorpholin-4-yl-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.016,uM,=,-1.7958800173440752,0,O=C(/C=C/CN1CCSCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
1849,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.0079,uM,=,-2.1023729087095586,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
1850,2255258,10.6019/CHEMBL5209897,,,,Affinity Phenotypic Cellular interaction (Alamar Blueâ¢ assay (growth inhibition of H3255 cells expressing both EGFR and HER2)) EUB0000596aBDA EGFR,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,AFATINIB DIMALEATE,1.437,uM,=,0.1574567681342256,1,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1851,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,C#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-propynamide,0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2ncnc3ccccc23)cc1
1852,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,Nc1ncnc2c1c(-c1ccccc1)cn2C(CO)Cc1ccc(O)cc1,"4-[2-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-3-hydroxy-propyl]-phenol",13.2,uM,=,1.1205739312058498,1,c1ccc(CCn2cc(-c3ccccc3)c3cncnc32)cc1
1853,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,COc1ccc(NC(=O)/C=C/CN(C)C)cc1Nc1nccc(-c2cnn3ccccc23)n1,"(E)-4-(dimethylamino)-N-(4-methoxy-3-(4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)phenyl)but-2-enamide",20.0,uM,=,1.3010299956639813,1,c1ccc(Nc2nccc(-c3cnn4ccccc34)n2)cc1
1854,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccn2)c1O,2-Cyano-3-[4-hydroxy-3-methoxy-5-(pyridin-2-ylsulfanylmethyl)-phenyl]-acrylamide,25.0,uM,=,1.3979400086720375,1,c1ccc(CSc2ccccn2)cc1
1855,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(Nc3ccc(-c4nc5ccccc5s4)c(OC)c3)ncnc2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)-3-hydroxyphenyl]-6'-methoxy-7'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,0.002,uM,=,-2.6989700043360187,0,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
1856,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,"(S,E)-N-(4-(3-Chloro-4-(3-fluorobenzyloxy)phenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide",0.5102,uM,=,-0.2922595457262288,0,c1ccc(COc2ccc(Nc3ncnc4cc(O[C@H]5CCOC5)ccc34)cc2)cc1
1857,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,"{2-[4-(1,2-Diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine",3.553,uM,=,0.5505952074893279,1,C(=C(c1ccccc1)c1ccccc1)c1ccccc1
1858,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,Cc1ccc2c(CCC(=O)O)c(SSc3[nH]c4cc(C)ccc4c3CCC(=O)O)[nH]c2c1,3-{2-[3-(2-Carboxy-ethyl)-6-methyl-1H-indol-2-yldisulfanyl]-6-methyl-1H-indol-3-yl}-propionic acid,2.9,uM,=,0.4623979978989561,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
1859,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,COCCn1c(=O)oc2cc3ncnc(Nc4cccc(C(C)=O)c4)c3cc21,"8-(3-Acetylphenylamino)-1-(2-methoxyethyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.56,uM,=,-0.2518119729937995,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
1860,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,6.057,uM,=,0.7822575736633017,1,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
1861,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,C[C@H](CN)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,"(R)-5-(4-amino-1-(1-aminopropan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",100.0,uM,=,2.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
1862,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,C=CCOC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"Allyl(4-((3-chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)carbamate",1.792,uM,=,0.2533380053261064,1,c1ccc(Nc2ncnc3sccc23)cc1
1863,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(NC(=O)/C=C/CN4CCCCC4)cc23)c1,"(S,E)-N-(4-(3-Ethynylphenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide",0.0053,uM,=,-2.275724130399211,0,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
1864,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Cc1c(C(=O)c2coc3ccc(O)cc23)[nH]c(-c2ccccc2)c1-c1ccccc1,"(5-Hydroxybenzofuran-3-yl)(2-methyl-4,5-diphenyl-1H-pyrrol-3-yl)methanone",3.67,uM,=,0.5646660642520893,1,O=C(c1cc(-c2ccccc2)c(-c2ccccc2)[nH]1)c1coc2ccccc12
1865,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",Cc1cccc(Nc2ncnc3cnc(Cl)nc23)c1,"(6-Chloro-pyrimido[5,4-d]pyrimidin-4-yl)-m-tolyl-amine",0.38,uM,=,-0.4202164033831898,0,c1ccc(Nc2ncnc3cncnc23)cc1
1866,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1nc(C)nc(Nc3ccc4c[nH]nc4c3)c1NC2,"(7,8-dimethoxy-3-methyl-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(1H-indazol-6-yl)-amine",24.6,uM,=,1.390935107103379,1,c1ccc2c(c1)CNc1c(Nc3ccc4c[nH]nc4c3)ncnc1S2
1867,958682,10.1021/jm400463q,,,,Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC(=O)OCCOCCOc5no[n+]([O-])c5S(=O)(=O)c5ccccc5)CC4)cc3OC)ncc2Cl)c1,"4-(2-(2-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetoxy)-ethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide",0.101,uM,=,-0.9956786262173574,0,O=C(CN1CCN(c2ccc(Nc3nccc(Oc4ccccc4)n3)cc2)CC1)OCCOCCOc1no[nH+]c1S(=O)(=O)c1ccccc1
1868,1524114,10.1016/j.bmc.2015.10.035,,,,Inhibition of human EGFR after 1 hr using [gamma-32P]ATP,O=C(Nc1cccc(Br)c1)Nc1ccc(Oc2ncnc3sc4c(c23)CCCC4)cc1Cl,"N-(3-Bromophenyl)-N'-{3-chloro-4-[(5,6,7,8-tetrahydrobenzo[4,5]-thieno[2,3-d]pyrimidin-4-yl)oxy]phenyl}urea",1.26,uM,=,0.1003705451175629,1,O=C(Nc1ccccc1)Nc1ccc(Oc2ncnc3sc4c(c23)CCCC4)cc1
1869,2017353,10.1021/acs.jmedchem.0c00870,,,,Inhibition of human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using TK as substrate preincubated for 30 mins followed by substrate addition and measured after 25 mins by HTRF assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,6e-05,uM,=,-4.221848749616356,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
1870,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)C(F)(F)F)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-24",0.065,uM,=,-1.1870866433571443,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
1871,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(C)cc3F)ncnc2cc1OCC1CCN(C)CC1,(2-Fluoro-4-methyl-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.4,uM,=,-0.3979400086720376,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
1872,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,Cc1ccc(C2=NN(C(N)=S)C(c3ccc(Cl)cc3)C2)cc1C,"5-(4-Chlorophenyl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",1.36,uM,=,0.1335389083702175,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
1873,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(Nc4ccc(N5CCCCC5)cc4OC)nc32)c1,"N-(3-(7-(2-Methoxy-4-(piperidin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)-acrylamide",0.0295,uM,=,-1.530177984021837,0,O=C1NCc2cnc(Nc3ccc(N4CCCCC4)cc3)nc2N1c1ccccc1
1874,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,COC(=O)CN(C)[C@H]1C[C@@H]2O[C@](C)([C@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"methyl 2-[3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl(methyl)amino]acetate",1.3,uM,=,0.1139433523068367,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
1875,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCCCCOc1ccc(Nc2c(C#N)cnc3cc(OCC)c(NC(=O)/C=C/CN(C)C)cc23)cc1Cl,4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-pentyloxy-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.894,uM,=,-0.0486624812040823,0,c1ccc(Nc2ccnc3ccccc23)cc1
1876,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3cc(N4CCN(C)CC4)cc([N+](=O)[O-])c3)c2)[nH]1,4-(4-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-N-(3-(4-methylpiperazin-1-yl)-5-nitrophenyl)pyridin-2-amine,0.0021,uM,=,-2.6777807052660805,0,c1ccc(-c2nc[nH]c2-c2ccnc(Nc3cccc(N4CCNCC4)c3)c2)cc1
1877,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,C=CC(=O)Nc1cc(Nc2cc[nH]n2)nc(-c2ccccc2)n1,N-(6-(1H-pyrazol-3-ylamino)-2-phenylpyrimidin-4-yl)acrylamide,0.9,uM,=,-0.0457574905606751,0,c1ccc(-c2nccc(Nc3cc[nH]n3)n2)cc1
1878,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,O=C(CCCCCn1cc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)nn1)NO,"6-(4-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)-N-hydroxyhexanamide",0.0019,uM,=,-2.721246399047171,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5c[nH]nn5)cc34)cc2)cc1
1879,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCn1ccnc1[N+](=O)[O-],N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(2-nitro-1Himidazol-1-yl)propoxy)quinazolin-4-amine,0.00089,uM,=,-3.050609993355087,0,c1ccc(Nc2ncnc3ccc(OCCCn4ccnc4)cc23)cc1
1880,5004,10.1016/s0960-894x(02)00364-5,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Cc1cc(C(=O)N2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c21,"4-(1-Benzyl-1H-indazol-5-ylamino)-5-[1-[3-methyl-5-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.1,uM,=,-1.0,0,O=C1Nc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2/C1=C/c1ccc(C(=O)N2CCOCC2)[nH]1
1881,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1cc(O)c(O)c(O)c1)C(=O)NCCCCNC(=O)/C(C#N)=C/c1cc(O)c(O)c(O)c1,"(E)-2-Cyano-N-{4-[(E)-2-cyano-3-(3,4,5-trihydroxy-phenyl)-acryloylamino]-butyl}-3-(3,4,5-trihydroxy-phenyl)-acrylamide",21.0,uM,=,1.3222192947339193,1,O=C(C=Cc1ccccc1)NCCCCNC(=O)/C=C/c1ccccc1
1882,1832355,10.1016/j.bmcl.2018.12.056,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,CCOCCOc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-N-(4-(4-(3-fluorobenzyloxy)3-chlorophenylamino)-7-(2-ethoxyethoxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.1535,uM,=,-0.8138916201867947,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
1883,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,COc1ccc(/C=C/C(=N/NC(N)=S)c2ccccc2)cc1,(Z)-2-((E)-3-(4-methoxyphenyl)-1-phenylallylidene)hydrazinecarbothioamide,14.83,uM,=,1.171141151028382,1,N=C(/C=C/c1ccccc1)c1ccccc1
1884,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,OCCCC#Cc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,5-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)pent-4-yn-1-ol,0.1142,uM,=,-0.9423338960901708,0,c1ccc(Nc2ncnc3ccccc23)cc1
1885,2069123,10.1016/j.bmcl.2020.127757,,,,Inhibition of EGFR (unknown origin),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.096,uM,=,-1.0177287669604316,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
1886,1674791,10.1016/j.ejmech.2017.03.001,,,,"Inhibition of recombinant human N-terminal GST-tagged wild-type EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay",C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(N(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1,"N-(3-(5-(3-acrylamido-4-(morpholine-4-carbonyl)phenylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(dimethylamino)benzamide",5.882,uM,=,0.7695250201710505,1,O=C(Nc1cccc(-c2c[nH]c(=O)c(Nc3ccc(C(=O)N4CCOCC4)cc3)c2)c1)c1ccccc1
1887,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CCc1ccc(C(=O)/C=C\C(=O)O[C@H](CC=C(C)C)C2=CC(=O)c3c(O)ccc(O)c3C2=O)cc1,"(R)-1-(5,8-Dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (Z)-4-(4-ethylphenyl)-4-oxobut-2-enoate",0.0508,uM,=,-1.2941362877160807,0,O=C(/C=C\C(=O)c1ccccc1)OCC1=CC(=O)c2ccccc2C1=O
1888,554997,10.1021/jm8001185,,,,Inhibition of human recombinant EGFR,COc1cc(C2=C(c3c[nH]c4ccccc34)CNC2=O)cc(OC)c1OC,"4-(1H-Indol-3-yl)-3-(3,4,5-trimethoxyphenyl)-1,5-dihydro-2H-pyrrole-2-one",23.0,uM,=,1.3617278360175928,1,O=C1NCC(c2c[nH]c3ccccc23)=C1c1ccccc1
1889,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,CN1CCN(c2cc3c(Nc4cccc(Br)c4)ncnc3cn2)CC1,"(3-Bromo-phenyl)-[6-(4-methyl-piperazin-1-yl)-pyrido[3,4-d]pyrimidin-4-yl]-amine",0.0064,uM,=,-2.193820026016113,0,c1ccc(Nc2ncnc3cnc(N4CCNCC4)cc23)cc1
1890,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(NCc3ccccc3)ncnc2cc1OC,N-[4-(Benzylamino)-7-methoxy-6-quinazolinyl]propanamide,0.136,uM,=,-0.8664610916297825,0,c1ccc(CNc2ncnc3ccccc23)cc1
1891,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.639,uM,=,-0.1944991418415998,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1892,1639950,,,,,Inhibition of recombinant human N-terminal GST His6-tagged thrombin cleavage site-fused EGFR (H672 to A1210 residues) expressed in baculovirus using poly-EY as substrate after 210 mins by luciferase coupled chemiluminescence assay,COc1cc2c(Nc3ccc(Cl)c(Cl)c3)ncnc2cc1OCc1c(-c2c(Cl)cccc2Cl)noc1C,"N-(3,4-dichlorophenyl)-7-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3cc(OCc4conc4-c4ccccc4)ccc23)cc1
1893,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,O=C1Cc2cc(Oc3ccc(Nc4ncnc5ccn(CCO)c45)cc3Cl)ccc2N1,"5-(2-Chloro-4-{[5-(2-hydroxyethyl)-5H-pyrrolo[3,2-d]-pyrimidin-4-yl]amino}phenoxy)-1,3-dihydro-2H-indol-2-one",0.96,uM,=,-0.0177287669604316,0,O=C1Cc2cc(Oc3ccc(Nc4ncnc5cc[nH]c45)cc3)ccc2N1
1894,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,O=C(Nc1ccc(Cl)cc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(4-chlorophenyl)urea,0.0193,uM,=,-1.714442690992226,0,O=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
1895,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c4c(c23)OCCO4)c1,"N-(3-ethynylphenyl)-5-(2-methoxyethoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
1896,63620,10.1021/jm970366v,,,,Inhibition of epidermal growth factor receptor (EGFR) autophosphorylation in A431 cells,O=C(O)CCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"3-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-ylamino]-propionic acid",11.4,uM,=,1.0569048513364727,1,c1ccc(Nc2ncnc3ccncc23)cc1
1897,1883986,10.1021/acsmedchemlett.8b00461,,,,Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay,NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/CF)C2)c1N,"(R)-5-Amino-3-(4-(2,4-difluorophenoxy)phenyl)-1-(1-((2E)-4-fluorobut-2-enoyl)piperidin-3-yl)-1H-pyrazole-4-carboxamide",2.18,uM,=,0.3384564936046048,1,c1ccc(Oc2ccc(-c3ccn([C@@H]4CCCNC4)n3)cc2)cc1
1898,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc5[nH]ncc5c4)c3cc21,"Ethyl 4-(8-(1H-indazol-5-ylamino)-2-oxooxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",0.13,uM,=,-0.8860566476931633,0,O=c1[nH]c2cc3c(Nc4ccc5[nH]ncc5c4)ncnc3cc2o1
1899,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CC2(COC2)C1,6-(2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine,0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ncnc3ccc(OCCN4CC5(COC5)C4)cc23)cc1
1900,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCCC[C@@H]1C(N)=O,(R)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)piperidine-2-carboxamide,0.075,uM,=,-1.1249387366083,0,c1ccc(Nc2ncnc3ccc(CN4CCCCC4)cc23)cc1
1901,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCCC1,"5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",0.318,uM,=,-0.4975728800155673,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
1902,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,Nc1ccc(O)c(-c2nnc(Cc3nc4ccccc4[nH]3)o2)c1,"2-(5-((1H-benzo[d]imidazol-2-yl)methyl)-1,3,4-oxadiazol-2-yl)-4-aminophenol",70.0,uM,=,1.845098040014257,1,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
1903,1739299,10.1016/j.ejmech.2018.05.006,,,,Inhibition of wild type EGFR (unknown origin) using FAM-labeled peptide substrate after 10 mins by mobility shift assay,COc1cc2ncnc(N3CCCc4ccccc43)c2cc1NC(=O)/C=C/CN(C)C,"(E)-N-(4-(3,4-dihydroquinolin-1(2H)-yl)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)but-2-enamide",0.072,uM,=,-1.1426675035687317,0,c1ccc2c(c1)CCCN2c1ncnc2ccccc12
1904,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1C[C@H](OC)C[C@@H]1C(N)=O,"(2R,4R)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)-4-methoxypyrrolidine-2-carboxamide",0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
1905,2233412,10.1016/j.bmcl.2022.128703,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells using kinase substrate 22 incubated for 30 mins in presence of ATP,C#CC(=O)N1CCN(C(=O)Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)[C@H](C)C1,"4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl(R)-2-methyl-4-propioloylpiperazine-1-carboxylate",0.00032,uM,=,-3.494850021680094,0,O=C(Oc1ccc2ncnc(Nc3ccccc3)c2c1)N1CCNCC1
1906,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.405,uM,=,-0.3925449767853314,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)cc1
1907,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OC(F)(F)F,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-trifluoromethoxy-quinolin-6-yl]-amide,2.64,uM,=,0.421603926869831,1,c1ccc(Nc2ccnc3ccccc23)cc1
1908,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CC(C)=CC[C@@H](OC(=O)/C=C\C(=O)c1ccc(C)cc1)C1=CC(=O)c2c(O)ccc(O)c2C1=O,"(R)-1-(5,8-Dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (Z)-4-oxo-4-(p-tolyl)but-2-enoate",0.0452,uM,=,-1.3448615651886178,0,O=C(/C=C\C(=O)c1ccccc1)OCC1=CC(=O)c2ccccc2C1=O
1909,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",CN(C)CCN(C)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-3-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-1-(2-(dimethylamino)ethyl)-1-methylurea,0.281,uM,=,-0.5512936800949201,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1910,66726,10.1021/jm970641d,,,,Inhibition of tyrosine/glutamic acid copolymer phosphorylation by epidermal growth factor receptor prepared of human A431,Brc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-(2-morpholin-4-yl-ethyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0007,uM,=,-3.154901959985743,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)cc1
1911,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-(2-{4-[(4-Bromo-2-fluorophenyl)amino]-6-methoxy-quinazolin-7-yl}oxy)ethyl-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.04356,uM,=,-1.360912128916263,0,O=C(Cn1cncn1)NCCOc1ccc2c(Nc3ccccc3)ncnc2c1
1912,1759197,10.1016/j.ejmech.2017.08.060,,,,Inhibition of EGFR (unknown origin),COc1cc2c(cc1OC)Nc1ncnc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)c1NC2,"N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide",0.2676,uM,=,-0.5725138909042145,0,O=C(Nc1ccccc1)C1(C(=O)Nc2ccc(Oc3ncnc4c3NCc3ccccc3N4)cc2)CC1
1913,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3n[nH]c4ccccc34)cc(N3CCN(C)CC3)n2)c1,N-(3-(4-(1H-indazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-yloxy)phenyl)acrylamide,1.7,uM,=,0.2304489213782739,1,c1ccc(Oc2nc(Nc3n[nH]c4ccccc34)cc(N3CCNCC3)n2)cc1
1914,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(NC3CC3c3ccccc3)c2cc1OC(C)=O,Acetic acid 7-methoxy-4-(2-phenyl-cyclopropylamino)-quinazolin-6-yl ester,0.084,uM,=,-1.0757207139381184,0,c1ccc(C2CC2Nc2ncnc3ccccc23)cc1
1915,676221,10.1021/jm100607r,,,,Inhibition of EGFR,OC[C@@H](Nc1ncnc2sc3c(c12)CCCC3)c1ccccc1,"(2S)-2-Phenyl-2-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]-pyrimidin-4-ylamino)ethan-1-ol",0.72,uM,=,-0.1426675035687315,0,c1ccc(CNc2ncnc3sc4c(c23)CCCC4)cc1
1916,67051,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor-dependent phosphorylation,COC(=O)Cn1cc(-c2cccc(Cl)c2)c(=O)c2c(O)cc(OC)cc21,[3-(3-Chloro-phenyl)-5-hydroxy-7-methoxy-4-oxo-4H-quinolin-1-yl]-acetic acid methyl ester,12.5,uM,=,1.0969100130080565,1,O=c1c(-c2ccccc2)c[nH]c2ccccc12
1917,989154,10.1016/j.bmc.2013.09.027,,,,Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA,COc1cc2c(c(OC)c1)C(=O)N(c1cccc(C(=O)N3CCCCC3)c1)CC2,"3,4-dihydro-6,8-dimethoxy-2-(3-(piperidin-1-ylcarbonyl)phenyl)-isoquinolin-1-(2H)-one",1.23,uM,=,0.0899051114393979,1,O=C(c1cccc(N2CCc3ccccc3C2=O)c1)N1CCCCC1
1918,1674791,10.1016/j.ejmech.2017.03.001,,,,"Inhibition of recombinant human N-terminal GST-tagged wild-type EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1,SPEBRUTINIB,0.442,uM,=,-0.3545777306509081,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
1919,1798892,10.1016/j.ejmech.2017.07.023,,,,Inhibition of GST-tagged human EGFR catalytic domain expressed in insect cells,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1,SID137276039,0.0014,uM,=,-2.853871964321762,0,C(#Cc1ccc2c(Nc3ccccc3)ncnc2c1)CN1CCNCC1
1920,445904,10.1021/jm070436q,,,,Inhibition of P-EGFR expressed in A431 cells,N#Cc1cnc2c(Cl)cc(NCc3cccc[n+]3[O-])cc2c1Nc1ccc(F)c(Cl)c1,8-chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-{[(1-oxidopyridin-2-yl)methyl]amino}quinoline-3-carbonitrile,2.9,uM,=,0.4623979978989561,1,c1ccc(Nc2ccnc3ccc(NCc4cccc[nH+]4)cc23)cc1
1921,2074610,10.1016/j.bmc.2020.115680,,,,Inhibition of wild type EGFR (unknown origin) in presence of ATP preincubated 5 mins measured for 30 mins by detection reagent based HTRF analysis,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
1922,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),CCOC(=O)/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,3-[4-(3-Bromo-phenylamino)-quinazolin-6-ylcarbamoyl]-acrylic acid ethyl ester,0.0027,uM,=,-2.5686362358410126,0,c1ccc(Nc2ncnc3ccccc23)cc1
1923,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCOCC1,(2E)-N-(7-Ethoxy-4-{[1-(phenylsulfonyl)-1H-indol-5-yl]amino}-6-quinazolinyl)-4-(4-morpholinyl)-2-butenamide,0.03,uM,=,-1.5228787452803376,0,O=C(/C=C/CN1CCOCC1)Nc1ccc2ncnc(Nc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c3)c2c1
1924,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2ncnc3ccc4[nH]cnc4c23)c1,"(3-Bromo-phenyl)-(1H-imidazo[4,5-f]quinazolin-9-yl)-amine",0.029,uM,=,-1.537602002101044,0,c1ccc(Nc2ncnc3ccc4[nH]cnc4c23)cc1
1925,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1cc(O)c(O)c(Br)c1)S(=O)(=O)/C(C#N)=C/c1cc(O)c(O)c(Br)c1,"(E)-3-(3-Bromo-4,5-dihydroxy-phenyl)-2-[(E)-1-(3-bromo-4,5-dihydroxy-phenyl)-2-cyano-ethenesulfonyl]-acrylonitrile",11.0,uM,=,1.0413926851582251,1,O=S(=O)(C=Cc1ccccc1)/C=C/c1ccccc1
1926,321418,10.1016/j.bmcl.2005.06.068,,,,Inhibitory concentration against EGFR kinase phosphorylation using synthetic peptide as a substrate,CN1CCC(Oc2cccc3ncnc(Nc4ccc(OCc5ccccn5)cc4)c23)CC1,[5-(1-Methyl-piperidin-4-yloxy)-quinazolin-4-yl]-[4-(pyridin-2-ylmethoxy)-phenyl]-amine,2.1,uM,=,0.3222192947339193,1,c1ccc(COc2ccc(Nc3ncnc4cccc(OC5CCNCC5)c34)cc2)nc1
1927,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC(C)C)nc32)c1,"N-(3-(7-(2-Isopropoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)-phenyl)acrylamide",0.00881,uM,=,-2.0550240915879523,0,O=C1NCc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
1928,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,COc1ccc(Nc2ncnc3cc(N)ncc23)cc1,"N*4*-(4-Methoxy-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.67,uM,=,-0.1739251972991735,0,c1ccc(Nc2ncnc3ccncc23)cc1
1929,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCN(CC)[C@@](C)(C#Cc1ncnc2cc(OC)c(OC)cc12)CC1CCCCC1,"(R)-1-cyclohexyl-4-(6,7-dimethoxyquinazolin-4-yl)-N,N-diethyl-2-methylbut-3-yn-2-amine",1.1,uM,=,0.041392685158225,1,C(#Cc1ncnc2ccccc12)CCC1CCCCC1
1930,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,COc1cc2ncnc(C#C[C@](C)(O)Cc3ccccc3)c2cc1OC,"(R)-4-(6,7-dimethoxyquinazolin-4-yl)-2-methyl-1-phenylbut-3-yn-2-ol",0.009,uM,=,-2.0457574905606752,0,C(#Cc1ncnc2ccccc12)CCc1ccccc1
1931,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Nc3cccc(Cl)c3)c2c1C,"(3-Chloro-phenyl)-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1
1932,2019883,10.1039/d0md00227e,,,,Inhibition of EGFR (unknown origin),Cc1nn(-c2ccc(F)cc2)c2ncnc(Nc3ccc(F)c(Cl)c3)c12,"N-(3-chloro-4-fluorophenyl)-1-(4-fluorophenyl)-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.186,uM,=,-0.7304870557820837,0,c1ccc(Nc2ncnc3c2cnn3-c2ccccc2)cc1
1933,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Cc1c(C(=O)c2coc3c2cc(O)c2ccccc23)[nH]c(-c2ccccc2)c1-c1ccccc1,"(5-Hydroxynaphtho[1,2-b]furan-3-yl)(2-methyl-4,5-diphenyl-1H-pyrrol-3-yl)-methanone",5.1,uM,=,0.7075701760979364,1,O=C(c1cc(-c2ccccc2)c(-c2ccccc2)[nH]1)c1coc2c1ccc1ccccc12
1934,1714364,10.1016/j.bmc.2018.05.039,,,,"Inhibition of wild type EGFR (unknown origin) using Poly(Glu,Tyr) as substrate after 40 mins by Kinase-Glo luminescence assay",C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0009,uM,=,-3.0457574905606752,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1935,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(Cl)cc4)nc32)c1,N-(3-(2-(4-Chlorophenylamino)-7-oxopteridin-8(7H)-yl)-phenyl)acrylamide,0.0471,uM,=,-1.3269790928711038,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
1936,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,Cc1ccc(S(=O)(=O)NC(=O)c2cccnc2Cl)cc1,2-Chloro-N-tosylnicotinamide,27.05,uM,=,1.4321672694425882,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
1937,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,C=CC(=O)NCc1cccc(-c2nc(C3CC3)c(-c3ccnc4[nH]c(-c5ccccc5)cc34)[nH]2)c1,"N-(3-(4-Cyclopropyl-5-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-imidazol-2-yl)benzyl)acrylamide",4.05,uM,=,0.6074550232146685,1,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4C4CC4)ccnc3[nH]2)cc1
1938,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1ccncc1,2-Pyridin-4-ylmethylene-malononitrile,250.0,uM,=,2.397940008672037,1,c1ccncc1
1939,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,Nc1ncnc2c1c(-c1ccc(O)cc1)cn2C1CCCC1,"4-(4-Amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-phenol",0.25,uM,=,-0.6020599913279624,0,c1ccc(-c2cn(C3CCCC3)c3ncncc23)cc1
1940,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COCOc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1Br,"3-(4-bromo-3-(methoxymethoxy)phenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",4.32,uM,=,0.6354837468149122,1,c1ccc(-c2n[nH]c3ncncc23)cc1
1941,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,COC1CCN(CCOc2n[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,"N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-3-(2-(4-methoxypiperidin-1-yl)ethoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.028,uM,=,-1.5528419686577808,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCCC5)c34)cc2)nc1
1942,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1OCCCCn1ccnc1[N+](=O)[O-],N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-methoxy-6-(4-(2-nitro-1H-imidazol-1-yl)butoxy)quinazolin-4-amine,0.0285,uM,=,-1.5451551399914898,0,c1ccc(COc2ccc(Nc3ncnc4ccc(OCCCCn5ccnc5)cc34)cc2)cc1
1943,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,Cc1ccccc1-c1nnc(Cc2nc3ccccc3[nH]2)o1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-o-tolyl-1,3,4-oxadiazole",39.7,uM,=,1.5987905067631152,1,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
1944,2270862,10.1016/j.ejmech.2020.112640,,,,Inhibition of human EGFR incubated for 1 hrs in presence of ATP by ELISA assay,Cc1ccc(NC(=O)CSc2nc3cc4ccccc4cc3c(=O)n2-c2ccc(S(N)(=O)=O)cc2)cc1,"2-((4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydrobenzo[g]quinazolin-2-yl)thio)-N-(p-tolyl)acetamide",0.009,uM,=,-2.0457574905606752,0,O=C(CSc1nc2cc3ccccc3cc2c(=O)n1-c1ccccc1)Nc1ccccc1
1945,2239138,10.1021/acs.jmedchem.2c01041,,,,Inhibition of wild type EGFR (unknown origin) preincubated with compound 30 mins followed ATP addition incubated for 30 mins by HTRF KinEASE TK assay,COc1cc2ncnc(Nc3cc(Cl)c(F)cc3O)c2cc1O,4-((5-chloro-4-fluoro-2-hydroxyphenyl)amino)-7-methoxyquinazolin-6-ol,1.7953,uM,=,0.254137030885468,1,c1ccc(Nc2ncnc3ccccc23)cc1
1946,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[S+]([O-])CCN(C)C,(+)-N-(2-((2-(dimethylamino)ethyl)sulfinyl)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,0.239,uM,=,-0.6216020990518624,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1947,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(NCc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-benzyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",1.0,uM,=,0.0,0,c1ccc(CNc2ncnc3ccncc23)cc1
1948,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCCCC(=O)O)c1O,4-[5-(2-Carbamoyl-2-cyano-vinyl)-2-hydroxy-3-methoxy-benzylsulfanyl]-butyric acid,48.0,uM,=,1.6812412373755872,1,c1ccccc1
1949,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,CN(C)CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-(dimethylamino)-propanamide,0.00028,uM,=,-3.552841968657781,0,c1ccc(Nc2ncnc3ccccc23)cc1
1950,2107115,10.1016/j.ejmech.2021.113300,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0582,uM,=,-1.2350770153501116,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1951,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2ncnc3c2sc2ncccc23)c1,"(3-Bromo-phenyl)-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-yl-amine",0.732,uM,=,-0.1354889189416081,0,c1ccc(Nc2ncnc3c2sc2ncccc23)cc1
1952,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(NS(=O)(=O)c1ccc(Cl)cc1)c1ccc(Cl)nc1,6-Chloro-N-(4-chlorophenylsulfonyl)nicotinamide,18.15,uM,=,1.2588766293721314,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
1953,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(-c3cnn(C)c3)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-5-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncc(-c3cn[nH]c3)c(-c3cn4c5c(cccc35)CCC4)n2)cc1
1954,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,C=CC(=O)Nc1ccc2ncnc(Nc3ccc4[nH]cc(Br)c4c3)c2c1,N-(4-(3-bromo-1H-indol-5-ylamino)quinazolin-6-yl)acrylamide,0.00038,uM,=,-3.42021640338319,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1
1955,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(OC)c3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(2-Fluoro-3-methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.421,uM,=,-0.3757179041643317,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
1956,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1Cl,"ethyl 2-chloro-4-(6,7-dimethoxyquinazolin-4-ylamino)phenylcarbamate",1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
1957,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,CN1CCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((4-methyl-1,4-diazepan-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.13,uM,=,-0.8860566476931633,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)cc1
1958,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CC(=O)Nc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-yl]-acetamide",0.029,uM,=,-1.537602002101044,0,c1ccc(Nc2ncnc3ccncc23)cc1
1959,741313,10.1016/j.bmcl.2011.02.075,,,,Inhibition of EGFR,c1ccc2ncc(Nc3ccnc(Nc4ccc(OCCCN5CCCCC5)cc4)n3)cc2c1,"N2-(4-(3-(piperidin-1-yl)propoxy)phenyl)-N4-(quinolin-3-yl)pyrimidine-2,4-diamine",2.29,uM,=,0.359835482339888,1,c1ccc2ncc(Nc3ccnc(Nc4ccc(OCCCN5CCCCC5)cc4)n3)cc2c1
1960,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,COc1ccc(CC(CO)n2cc(-c3cccc(OC)c3)c3c(N)ncnc32)cc1,"2-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-3-(4-methoxy-phenyl)-propan-1-ol",9.7,uM,=,0.9867717342662448,1,c1ccc(CCn2cc(-c3ccccc3)c3cncnc32)cc1
1961,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCOc1cc2ncnc(C#Cc3[nH]ccc3-c3ccccc3)c2cc1OCC,"6,7-diethoxy-4-(2-(3-phenyl-1H-pyrrol-2-yl)ethynyl)quinazoline",0.01,uM,=,-2.0,0,C(#Cc1ncnc2ccccc12)c1[nH]ccc1-c1ccccc1
1962,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,COc1ccccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2o1,"(R)-6-(2-Methoxyphenyl)-N-(1-phenylethyl)furo[2,3-d]pyrimidin-4-amine",0.004,uM,=,-2.397940008672037,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
1963,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,C#Cc1cccc(Nc2ncnc3c2NCc2cc(OC)c(OC)cc2O3)c1,"(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(3-ethynyl-phenyl)-amine",0.9,uM,=,-0.0457574905606751,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
1964,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCCCCCCNC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,N-Tetradecyl 2-(5-hydroxy-4-oxo-2-phenyl-4Hchromen-7-yloxy)acetamide,0.316,uM,=,-0.5003129173815962,0,O=c1cc(-c2ccccc2)oc2ccccc12
1965,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc(C)cc3)C2)cc1,"2-(3,5-Dip-tolyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",1.16,uM,=,0.0644579892269184,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
1966,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,C[C@@H](Nc1ncnc2oc(-c3ccccc3)cc12)c1ccccc1,"(R)-6-Phenyl-N-(1-phenylethyl)furo[2,3-d]pyrimidin-4-amine",0.011,uM,=,-1.958607314841775,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
1967,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,C[C@H](c1cccc(F)c1)n1ncc2cc(Nc3ncnn4ccc(COC[C@@H]5CNCCO5)c34)ccc21,"N-(1-((R)-1-(3-fluorophenyl)ethyl)-1H-indazol-5-yl)-5-(((S)-morpholin-2-ylmethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.068,uM,=,-1.1674910872937636,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)cc1
1968,465,10.1016/s0960-894x(02)00364-5,,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,C#Cc1cccc(Nc2ncnc3c2/C(=C/c2[nH]c(C(=O)NCCN4CCOCC4)cc2C)C(=O)N3)c1,"5-[4-(3-Ethynyl-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide",0.62,uM,=,-0.2076083105017461,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1
1969,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Nc1ncnc(NCc3ccc(F)c(Cl)c3)c1NC2,"(3-chloro-4-fluoro-benzyl)-(7,8-dimethoxy-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cyclohepten-1-yl)-amine",1.6,uM,=,0.2041199826559248,1,c1ccc(CNc2ncnc3c2NCc2ccccc2N3)cc1
1970,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,Fc1ccc(Nc2ncnc3cc(OCC4CCCO4)c4c(c23)OCCO4)cc1Cl,"N-(3-Chloro-4-fluorophenyl)-5-((tetrahydrofuran-2-yl)-methoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0241,uM,=,-1.6179829574251317,0,c1ccc(Nc2ncnc3cc(OCC4CCCO4)c4c(c23)OCCO4)cc1
1971,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2CC(c3ccc(Br)cc3)=NN2c2nc(-c3ccc(Cl)cc3)cs2)cc1,"2-(3-(4-bromophenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-chlorophenyl)thiazole",28.17,uM,=,1.449786846985773,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
1972,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,CN(C)C(=O)c1c(SSc2c(C(=O)N(C)C)c3ccccc3n2C)n(C)c2ccccc12,"1,3N,3N-trimethyl-2-(3-dimethylcarbamoyl-1-methyl-1H-2-indolyldisulfanyl)-1H-3-indolecarboxamide0.5 H2O",21.2,uM,=,1.3263358609287514,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
1973,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3S,5R)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl dimethylcarbamate",0.04,uM,=,-1.3979400086720375,0,C(#C[C@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
1974,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,4-Piperidin-1-yl-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.031,uM,=,-1.5086383061657274,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
1975,1642156,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0014,uM,=,-2.853871964321762,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
1976,1801908,10.1016/j.ejmech.2018.06.061,,,,Inhibition of EGFR in human HepG2 cells,N=c1oc2ccccc2cc1C(=O)N/N=C1\C(=O)Nc2ccc(S(=O)(=O)N3CCOCC3)cc21,2-Imino-N'-(5-(morpholino sulfonyl)-2-oxoindolin-3-ylidene)-2H-chromene-3-carbo hydrazide,0.205,uM,=,-0.6882461389442457,0,N=c1oc2ccccc2cc1C(=O)N/N=C1\C(=O)Nc2ccc(S(=O)(=O)N3CCOCC3)cc21
1977,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccc(Cl)cc4)cs3)C(c3ccc(Cl)cc3)C2)cc1,"4-(4-chlorophenyl)-2-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazole",7.78,uM,=,0.890979596989689,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
1978,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,COc1cc2ncnc(Nc3cccc(I)c3)c2cc1OC.Cl,"4-(3'-iodoanilino)-6,7-dimethoxyquinazoline hydrochloride",0.585,uM,=,-0.2328441339178195,0,c1ccc(Nc2ncnc3ccccc23)cc1
1979,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Oc1nnc(-c2c[nH]c(-c3ccccc3)c2-c2ccccc2)c2cn(-c3ccccc3)nc12,"4-(4,5-Diphenyl-1H-pyrrol-3-yl)-2-phenyl-2H-pyrazolo[3,4-d]pyridazin-7-ol",3.6,uM,=,0.5563025007672873,1,c1ccc(-c2[nH]cc(-c3nncc4nn(-c5ccccc5)cc34)c2-c2ccccc2)cc1
1980,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,Cc1cc(Nc2ncnc3cc(O)c(NC(=O)/C=C/[C@H]4CCCN4C)cc23)ccc1Oc1ccc2nccn2c1,"(E)-N-[7-hydroxy-4-(4-imidazo[1,2-a]pyridin-6-yloxy-3-methyl-anilino)quinazolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide",0.00232,uM,=,-2.6345120151091,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4ccc5nccn5c4)cc3)c2c1
1981,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,O=C1NN(c2ccc(F)cc2)C(=O)/C1=C\c1cccc(OCc2ccccc2F)c1,"4-(3-(2-fluorobenzyloxy)benzylidene)-1-(4-fluorophenyl)pyrazolidine-3,5-dione",5.6,uM,=,0.7481880270062004,1,O=C1NN(c2ccccc2)C(=O)/C1=C\c1cccc(OCc2ccccc2)c1
1982,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4cc5nncn5cn4)c(C)c3)c2c1,"2-methoxy-N-[(E)-3-[4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]allyl]acetamide",0.1103199999999999,uM,=,-0.9573457468322067,0,c1ccc2c(Nc3ccc(Oc4cc5nncn5cn4)cc3)ncnc2c1
1983,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,CC1CCN(C/C=C/C(=O)N2CCCOc3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4cc32)CC1,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-8,9-dihydro-7H-pyrimido[5,4-h][1,5]benzoxazepin-6-yl]-4-(4-methyl-1-piperidyl)but-2-en-1-one",4.87,uM,=,0.6875289612146344,1,O=C(/C=C/CN1CCCCC1)N1CCCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
1984,989154,10.1016/j.bmc.2013.09.027,,,,Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA,COc1cc(OC)c2c(=O)n(-c3cccc(C(=O)N4CCCCC4)c3)ccc2c1,"6,8-dimethoxy-2-(3-(piperidin-1-ylcarbonyl)phenyl)isoquinoline-1(2H)-one",2.12,uM,=,0.3263358609287514,1,O=C(c1cccc(-n2ccc3ccccc3c2=O)c1)N1CCCCC1
1985,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,COC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1C,"methyl 4-(6,7-dimethoxyquinazolin-4-ylamino)-2-methylphenylcarbamate",4.0,uM,=,0.6020599913279624,1,c1ccc(Nc2ncnc3ccccc23)cc1
1986,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.CC[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1,"(R)-4-(4-((1-Phenylpropyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.004,uM,=,-2.397940008672037,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
1987,1338416,10.1016/j.ejmech.2014.01.018,,,,Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,CCOC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CC(C)(C)C2)C1c1c(C)nn(-c2ccccc2)c1Cl,"Ethyl 2-amino-4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-7,7-dimethyl-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",11.18,uM,=,1.0484418035504044,1,O=C1CCCC2=C1C(c1cnn(-c3ccccc3)c1)C=CN2c1cccnc1
1988,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(C)cc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)-5-methylphenyl)acrylamide",0.2084,uM,=,-0.6811022853725132,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
1989,65106,10.1021/jm00032a020,,,,Inhibition of EGF-stimulated DNA synthesis in ER 22 (EGF-receptor expressing) cells,O=C(O)Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O,"(5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-phenyl)-acetic acid",60.0,uM,=,1.7781512503836436,1,C(=N/c1ccccc1)\c1ccccc1
1990,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,CCOC(=O)C(=CNc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1)C(=O)OCC,Diethyl 2-(((4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)amino)methylene)malonate,0.812,uM,=,-0.0904439707588246,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
1991,2153740,10.1021/acsmedchemlett.1c00555,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,CN1CCN(C2CCN(c3ccc(Nc4ncc(Cl)c(Nc5ccccc5P(C)(C)=O)n4)cc3C(F)F)CC2)CC1,(2-((5-Chloro-2-((3-(difluoromethyl)-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide,0.1987,uM,=,-0.7018021328901849,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
1992,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc(F)cc3)C2)cc1,"2-(5-(4-fluorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",5.71,uM,=,0.756636108245848,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
1993,600206,10.1016/j.bmcl.2009.05.060,,,,Inhibition of EGFR-mediated poly(L-glutamic acid L-tyrosine) phosphorylation,C=COC(=O)N(C)/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,vinyl 3-(4-(3-chlorophenylamino)quinazolin-6-yl)-1-methyltriaz-2-ene-1-carboxylate,0.72,uM,=,-0.1426675035687315,0,c1ccc(Nc2ncnc3ccccc23)cc1
1994,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2ncnc3c2sc2ncsc23)c1.CO,"(3-Bromo-phenyl)-thiazolo[5',4':4,5]thieno[3,2-d]pyrimidin-5-yl-amine; compound with methanol",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3c2sc2ncsc23)cc1
1995,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C#CCCCCCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,4-(3'-Chloro-4'-fluoroanilino)-6-(hept-6-ynyloxy)-7-methoxyquinazoline,0.0327,uM,=,-1.485452247339714,0,c1ccc(Nc2ncnc3ccccc23)cc1
1996,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3cccc(Br)c3)c2c(OC)c1OC,"(3-Bromo-phenyl)-(5,6,7-trimethoxy-quinazolin-4-yl)-amine",0.00067,uM,=,-3.1739251972991736,0,c1ccc(Nc2ncnc3ccccc23)cc1
1997,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1ccc(Nc2ncnc3[nH]c(C)c(C)c23)cc1,"(5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-p-tolyl-amine",2.1,uM,=,0.3222192947339193,1,c1ccc(Nc2ncnc3[nH]ccc23)cc1
1998,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OCC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,isobutyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.142,uM,=,-0.8477116556169436,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1999,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,COC/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Methoxy-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,1.132,uM,=,0.0538464268522525,1,c1ccc(Nc2ncnc3ccccc23)cc1
2000,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,C#Cc1cccc(Nc2ncnc3cc(OCCCn4ccnc4[N+](=O)[O-])c(OC)cc23)c1,N-(3-Ethynylphenyl)-6-methoxy-7-(3-(2-nitro-1H-imidazol-1-yl)propoxy)quinazolin-4-amine,0.00065,uM,=,-3.1870866433571443,0,c1ccc(Nc2ncnc3cc(OCCCn4ccnc4)ccc23)cc1
2001,622913,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR in human A431 cells by HTRF assay,Cc1c(C(=O)NCCN2CCOCC2)[nH]c2cnnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12,"4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-methyl-N-(2-morpholinoethyl)-1H-pyrrolo[3,2-d]pyridazine-2-carboxamide",0.867,uM,=,-0.0619809025237897,0,O=C(NCCN1CCOCC1)c1cc2c(Nc3ccc(OCc4ccccn4)cc3)nncc2[nH]1
2002,65107,10.1021/jm00032a020,,,,Inhibition of EGF-stimulated DNA synthesis in ER 22 (EGF-receptor expressing) cells,O=C(Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O)NOCc1ccccc1,"N-Benzyloxy-2-(5-{[1-(2,5-dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-phenyl)-acetamide",61.0,uM,=,1.7853298350107671,1,O=C(Cc1cccc(/N=C/c2ccccc2)c1)NOCc1ccccc1
2003,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cncnc1,N-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrimidine-5-carboxamide,1.92,uM,=,0.2833012287035495,1,O=C(Nc1cccc(C(=O)Nc2ccc(CN3CCNCC3)cc2)c1)c1cncnc1
2004,63772,10.1021/jm9903949,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cells,Nc1nc(Nc2cccc(Br)c2)c2c(n1)[nH]c1ccccc12,"N*4*-(3-Bromo-phenyl)-9H-pyrimido[4,5-b]indole-2,4-diamine",0.493,uM,=,-0.30715308072277,0,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
2005,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3cc(Cl)ccc3F)c2cc1OC1CCN(C)CC1,N-(5-chloro-2-fluorophenyl)-7-methoxy-6-(1-methylpiperidin-4-yloxy)quinazolin-4-amine,0.115,uM,=,-0.9393021596463884,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
2006,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1c(CO)cccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1,"(R)-(2-Methoxy-3-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)phenyl)methanol",0.0015,uM,=,-2.8239087409443187,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
2007,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCC,N-(4-(3-Chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl)-acrylamide,0.0001799999999999,uM,=,-3.744727494896694,0,c1ccc(Nc2ncnc3ccccc23)cc1
2008,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(C#N)c3)ncnc2cc1O[C@H]1CCOC1,"(S,E)-N-(4-(3-Cyano-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide",0.1474,uM,=,-0.8315025164769674,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
2009,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)c(C#N)cnc2cc1OC,N-[4-(3-Bromo-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-acrylamide,0.81,uM,=,-0.0915149811213502,0,c1ccc(Nc2ccnc3ccccc23)cc1
2010,699068,10.1016/j.bmc.2010.11.007,,,,Inhibition of EGFR by HTRF assay,CN(C)C/C=C/C(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1,(E)-N-(1-(3-Bromophenylamino)-4-cyanoisoquinolin-7-yl)-4-(dimethylamino)but-2-enamide,0.15,uM,=,-0.8239087409443188,0,c1ccc(Nc2nccc3ccccc23)cc1
2011,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C(Nc1ccccc1)N(Cc1ccc(O)cc1)Cc1cccc(Cl)c1O,1-(5-Chloro-2-hydroxybenzyl)-1-(4-hydroxybenzyl)-3-phenylurea,0.96,uM,=,-0.0177287669604316,0,O=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
2012,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Clc1ccc2c(c1)CNc1c(Nc3cccc(Br)c3)ncnc1O2,"(3-Bromo-phenyl)-(8-chloro-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",3.4,uM,=,0.5314789170422551,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
2013,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2s1,"(S)-2-((6-(2-Methoxyphenyl)thieno[2,3-d]pyrimidin-4-yl)amino)-2-phenylethanol",0.001,uM,=,-3.0,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
2014,217009,10.1021/jm990947f,,,,Inhibition of c-erbB2 receptor,COc1cc(/C=C(\C#N)C(N)=O)cc(Sc2nc3ccccc3s2)c1O,3-[3-(Benzothiazol-2-ylsulfanyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,0.35,uM,=,-0.4559319556497244,0,c1ccc(Sc2nc3ccccc3s2)cc1
2015,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(C#N)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(4-benzyloxy-3-cyano-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.768,uM,=,-0.114638779968488,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
2016,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccc(O)c(O)c1,"2-(3,4-Dihydroxy-benzoyl)-3-(3,4-dihydroxy-phenyl)-acrylonitrile",0.4,uM,=,-0.3979400086720376,0,O=C(C=Cc1ccccc1)c1ccccc1
2017,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,C[C@@H](Nc1ncnc2ccc(OCCCCCC(=O)NO)cc12)c1ccccc1,(R)-N-hydroxy-6-(4-(1-phenylethylamino)quinazolin-6-yloxy)hexanamide,0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3ccccc23)cc1
2018,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Fc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"(3-Bromo-phenyl)-(7-fluoro-pyrido[4,3-d]pyrimidin-4-yl)-amine",0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2ncnc3ccncc23)cc1
2019,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCCCn1ccnc1[N+](=O)[O-],N-(3-bromophenyl)-7-methoxy-6-(3-(2-nitro-1H-imidazol-1-yl)propoxy)quinazolin-4-amine,0.00066,uM,=,-3.1804560644581312,0,c1ccc(Nc2ncnc3ccc(OCCCn4ccnc4)cc23)cc1
2020,305378,10.1021/jm049892u,,,,In vitro inhibition of Epidermal growth factor receptor,Cc1cc2c(Nc3ccc(C)c(O)c3)ncnn2c1,"2-Methyl-5-(6-methyl-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-phenol",0.65,uM,=,-0.1870866433571444,0,c1ccc(Nc2ncnn3cccc23)cc1
2021,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)Nc1ccc(OC)c(Nc2cc(-c3cnc(SC)[nH]3)ccn2)c1,N-(4-Methoxy-3-((4-(2-(methylthio)-1H-imidazol-5-yl)pyridin-2-yl)amino)phenyl)acrylamide,0.017,uM,=,-1.769551078621726,0,c1ccc(Nc2cc(-c3cnc[nH]3)ccn2)cc1
2022,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,Nc1ccccc1NC(=O)/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,N-(2-aminophenyl)-3-(5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-yl)acrylamide,0.026,uM,=,-1.585026652029182,0,O=C(/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1)Nc1ccccc1
2023,2017353,10.1021/acs.jmedchem.0c00870,,,,Inhibition of human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using TK as substrate preincubated for 30 mins followed by substrate addition and measured after 25 mins by HTRF assay,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,2e-05,uM,=,-4.698970004336019,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
2024,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,CN(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(I)c3)c2c1,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-iodo-phenylamino)-quinazolin-6-yl]-amide,0.00094,uM,=,-3.026872146400301,0,c1ccc(Nc2ncnc3ccccc23)cc1
2025,1798892,10.1016/j.ejmech.2017.07.023,,,,Inhibition of GST-tagged human EGFR catalytic domain expressed in insect cells,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.0003,uM,=,-3.522878745280338,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
2026,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,CCOc1cc2ncnc(Nc3ccc(Oc4cc5nncn5cn4)c(C)c3)c2cc1NC(=O)/C(F)=C/[C@H]1CCCN1C,"(Z)-N-[7-ethoxy-4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-2-fluoro-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide",0.00813,uM,=,-2.089909454405932,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4cc5nncn5cn4)cc3)c2c1
2027,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Fc1ccc2c(c1)CNc1c(NCc3ccccc3)ncnc1O2,"Benzyl-(8-fluoro-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",8.9,uM,=,0.9493900066449128,1,c1ccc(CNc2ncnc3c2NCc2ccccc2O3)cc1
2028,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",CCN=C(S)NNc1nncc2ccccc12,SID24826017,0.076,uM,=,-1.1191864077192086,0,c1ccc2cnncc2c1
2029,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)N1CCOCC1,N-(4-((3-bromophenyl)amino)quinazolin-6-yl)morpholine-4-carbothioamide,0.0269,uM,=,-1.570247719997592,0,S=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)N1CCOCC1
2030,1869224,10.1021/acs.jmedchem.8b01391,,,,Inhibition of wild type EGFR (unknown origin) by bioluminescent ADP-glo kinase assay,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,"5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide",0.14,uM,=,-0.8538719643217619,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1
2031,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C,(Z)-N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.00156,uM,=,-2.8068754016455384,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
2032,1500854,10.1016/j.bmc.2015.04.065,,,,Inhibition of recombinant EGFR (unknown origin) assessed as inhibition of autophosphorylation after 1 hr by DELFIA/Time-resolved fluorometry,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)S/C1=C/c1ccc(-c2ccccc2)cc1,"(S,E)-1-(5-([1,10-Biphenyl]-4-ylmethylene)-4-oxo-4,5-dihydrothiazol-2-yl)-N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)pyrrolidine-2-carboxamide",13.2,uM,=,1.1205739312058498,1,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)S/C1=C/c1ccc(-c2ccccc2)cc1
2033,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)c(OC)c3)c2cc1OC,"N-(4-(benzo[d]thiazol-2-yl)-3-methoxyphenyl)-6,7-dimethoxyquinazolin-4-amine",0.063,uM,=,-1.2006594505464183,0,c1ccc2sc(-c3ccc(Nc4ncnc5ccccc45)cc3)nc2c1
2034,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc3ccccc3c2)c1O,2-Cyano-3-[4-hydroxy-3-methoxy-5-(naphthalen-2-ylsulfanylmethyl)-phenyl]-acrylamide,10.0,uM,=,1.0,1,c1ccc(CSc2ccc3ccccc3c2)cc1
2035,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,NC(=O)C1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"1-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)piperidine-4-carboxamide",0.14,uM,=,-0.8538719643217619,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
2036,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,COc1cc2ncnc(Nc3ccccc3F)c2cc1OC.Cl,"4-(2'-fluoroanilino)-6,7-dimethoxyquinazoline hydrochloride",0.179,uM,=,-0.7471469690201069,0,c1ccc(Nc2ncnc3ccccc23)cc1
2037,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,Bacitracin,5.377,uM,=,0.7305400364771192,1,O=C1CNC(=O)CNC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]2CSC=N2)CCCCN1
2038,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CCN(C(=O)N2CCNCC2)CC1,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-(piperazine-1-carbonyl)piperazin-1-yl)phenyl)acrylamide",10300.0,uM,=,4.012837224705172,1,O=C(N1CCNCC1)N1CCN(c2ccc(Nc3nccc(-c4cnn5ccccc45)n3)cc2)CC1
2039,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3ccccc23)cc1
2040,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,C=CC(=O)Nc1cccc(-c2c[nH]c3nccc(-c4[nH]c(CCCO)nc4C4CC4)c23)c1,"N-(3-(4-(4-Cyclopropyl-2-(3-hydroxypropyl)-1H-imidazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl)acrylamide",0.673,uM,=,-0.1719849357760231,0,c1ccc(-c2c[nH]c3nccc(-c4[nH]cnc4C4CC4)c23)cc1
2041,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,O=C(CN1CCOCC1)Nc1ccc(Nc2ncc(Cl)c(Nc3ccccc3C(=O)NO)n2)cc1,2-(5-chloro-2-(4-(2-morpholinoacetamido)phenylamino)pyrimidin-4-ylamino)-N-hydroxybenzamide,0.126,uM,=,-0.8996294548824371,0,O=C(CN1CCOCC1)Nc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1
2042,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Fc1cccc(COc2ccc(Nc3ccncn3)cc2Cl)c1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)pyrimidin-4-amine,0.92,uM,=,-0.0362121726544447,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
2043,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCC1,"5-(4-amino-1-cyclobutyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",2.9,uM,=,0.4623979978989561,1,c1ccc(-c2nn(C3CCC3)c3ncncc23)cc1
2044,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1,N-Benzyl-3-{2-[3-(2-benzylcarbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-propionamide,0.85,uM,=,-0.0705810742857072,0,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
2045,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,COc1ccc(CCCCCn2cc(CCN)c3cc(OCCc4ccc(O)cc4)ccc32)cc1.Cl,2-{5-(4-Hydroxyphenethoxy)-1-[5-(4-methoxyphenyl)-pentyl]-1H-indole-3-yl}ethanamine hydrochloride,4.4,uM,=,0.6434526764861874,1,c1ccc(CCCCCn2ccc3cc(OCCc4ccccc4)ccc32)cc1
2046,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1ncnc(N(C)c3cccc(Cl)c3)c1NC2,"(3-chloro-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-methyl-amine",27.0,uM,=,1.4313637641589874,1,c1ccc(Nc2ncnc3c2NCc2ccccc2S3)cc1
2047,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(Oc1cccc2ccccc12)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid naphthalen-1-yl ester",4.4,uM,=,0.6434526764861874,1,O=C(Oc1cccc2ccccc12)c1cccc(NCc2ccccc2)c1
2048,66899,10.1016/s0960-894x(99)00188-2,,,,In vitro activity against Epidermal growth factor receptor (using poly(Glu4Tyr1) as a substrate),CCCNN1C(=O)c2c(c3c4cccc(O)c4n(C4OC(CO)C(O)C(O)C4O)c3c3[nH]c4c(O)cccc4c23)C1=O,"1,11-dihydroxy-6-propylamino-12-(3,4,5-trihydroxy-6-hydroxymethyltetrahydro-2H-2-pyranyl)-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione",59.0,uM,=,1.7708520116421442,1,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1c2c2ccccc2n1C1CCCCO1
2049,1842432,10.1016/j.ejmech.2019.03.004,,,,Inhibition of EGFR (unknown origin),C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCC(=O)CN(C)C,N-(4-(4-bromo-2-fluorophenylamino)-7-(5-(dimethylamino)-4-oxopentyloxy)quinazolin-6-yl)acrylamide,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
2050,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccc(C)cc4)cc3)ncnc2cc1OCCCN1CCOCC1,N-(4-(6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-ylamino)phenyl)-4-methylbenzamide,0.76,uM,=,-0.1191864077192086,0,O=C(Nc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1)c1ccccc1
2051,64442,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor (EGFR) in A431 cells,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2n1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.0056,uM,=,-2.2518119729938,0,c1ccc(Nc2ncnc3cccnc23)cc1
2052,65107,10.1021/jm00032a020,,,,Inhibition of EGF-stimulated DNA synthesis in ER 22 (EGF-receptor expressing) cells,CC(C)(C)ONC(=O)Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O,"N-tert-Butoxy-2-(5-{[1-(2,5-dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-phenyl)-acetamide",30.0,uM,=,1.4771212547196624,1,C(=N/c1ccccc1)\c1ccccc1
2053,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N1CCN(C)CC1,"N-(4-Methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)buta-2,3-dienamide",0.0063,uM,=,-2.2006594505464183,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c[nH]c2c1
2054,66904,10.1016/S0960-894X(96)00601-4,,,,Inhibition of the epidermal growth factor receptor.,FC(F)C(F)(F)Oc1cccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c1,"[4-(1H-Indol-3-yl)-pyrimidin-2-yl]-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-amine",1.8,uM,=,0.255272505103306,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2055,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,NC(=O)Nc1ccc2ncnc(Nc3ccc(Br)cc3)c2c1,1-(4-((4-Bromophenyl)amino)quinazolin-6-yl)urea,0.273,uM,=,-0.563837352959244,0,c1ccc(Nc2ncnc3ccccc23)cc1
2056,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,Cc1ccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)cc1,"8-(p-Toluidino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.067,uM,=,-1.1739251972991736,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
2057,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,O=C1Cc2c(cccc2Oc2ccc(Nc3ncnc4ccn(CCO)c34)cc2Cl)N1,"4-(2-Chloro-4-{[5-(2-hydroxyethyl)-5H-pyrrolo[3,2-d]-pyrimidin-4-yl]amino}phenoxy)-1,3-dihydro-2H-indol-2-one",0.003,uM,=,-2.5228787452803374,0,O=C1Cc2c(cccc2Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)N1
2058,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#C/C(=C\c1ccc([N+](=O)[O-])cc1)C(=O)O,2-Cyano-3-(4-nitro-phenyl)-acrylic acid,1300.0,uM,=,3.113943352306837,1,c1ccccc1
2059,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,C#Cc1cccc(Nc2ncnc3cc(OCC4CCCO4)c4c(c23)OCCO4)c1,"N-(3-Ethynylphenyl)-5-((tetrahydrofuran-2-yl)-methoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0273,uM,=,-1.563837352959244,0,c1ccc(Nc2ncnc3cc(OCC4CCCO4)c4c(c23)OCCO4)cc1
2060,1337213,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ncc([N+](=O)[O-])n1CC(=O)N/N=C/c1cc2ccccc2nc1Oc1ccccc1,(E)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)-N'-((2-phenoxyquinolin-3-yl)methylene)acetohydrazide,15.3,uM,=,1.1846914308175989,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
2061,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cscn5)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(1-(thiazol-4-ylmethyl)-1H-indol-5-ylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.68,uM,=,-0.1674910872937636,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cscn5)c4)c3s2)C1)N1CCOCC1
2062,67051,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor-dependent phosphorylation,O=c1c(-c2cccc(Cl)c2)coc2cc(O)cc(O)c12,"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one",12.0,uM,=,1.0791812460476249,1,O=c1c(-c2ccccc2)coc2ccccc12
2063,5000,10.1021/jm960118j,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Clc1cccc(Nc2ncnc3[nH]c4ccccc4c23)c1,"(3-Chloro-phenyl)-(9H-pyrimido[4,5-b]indol-4-yl)-amine",0.12,uM,=,-0.9208187539523752,0,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
2064,66581,10.1016/s0960-894x(02)00598-x,,,,Inhibition of Epidermal Growth Factor Receptor (EGFR) autophosphorylation,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",1.45,uM,=,0.1613680022349748,1,c1ccc(Nc2ncnc3ccccc23)cc1
2065,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CN(C)CCCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-phenyl)-N*7*-(3-dimethylamino-propyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0088,uM,=,-2.055517327849832,0,c1ccc(Nc2ncnc3ccncc23)cc1
2066,1586270,10.1016/j.bmc.2016.04.046,,,,Inhibition of wild type human EGFR preincubated for 5 mins followed by ATP addition for 30 mins by HTRF assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)[C@H]1NC(=O)O[C@@H]1C,"(4S,5R)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-5-methyl-2-oxooxazolidine-4-carboxamide",0.00198,uM,=,-2.703334809738469,0,O=C1N[C@H](C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)CO1
2067,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,COc1cc2ncnc(Nc3ccc(Br)cc3)c2cc1OC,"(4-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",3.6,uM,=,0.5563025007672873,1,c1ccc(Nc2ncnc3ccccc23)cc1
2068,2201427,10.1016/j.ejmech.2021.114085,,,,Inhibition of wild-type EGFR (unknown origin),COC(=O)CCc1nc2ccc(Cl)cc2[nH]c1=O,"methyl 3-(6-chloro-3-oxo-3,4-dihydroquinoxalin-2-yl)propanoate",1.34,uM,=,0.1271047983648076,1,O=c1cnc2ccccc2[nH]1
2069,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2CC(c3ccc(C)c(C)c3)=NN2c2nc(-c3ccccc3)cs2)cc1,"2-(3-(3,4-dimethylphenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",2.67,uM,=,0.4265112613645752,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
2070,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(Oc1cccc2ccccc12)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid naphthalen-1-yl ester",0.11,uM,=,-0.958607314841775,0,O=C(Oc1cccc2ccccc12)c1cccc(NCc2ccccc2)c1
2071,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccc(F)cc2)=N1,"2-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",4.86,uM,=,0.6866362692622934,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
2072,622913,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR in human A431 cells by HTRF assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1.O,Tykerb,0.14,uM,=,-0.8538719643217619,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1.c1ccccc1.c1ccccc1
2073,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(NC3CC3c3ccccc3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-(2-phenyl-cyclopropyl)-amine",0.01,uM,=,-2.0,0,c1ccc(C2CC2Nc2ncnc3ccccc23)cc1
2074,1924071,10.1021/acs.jmedchem.6b00403,,,,"Inhibition of wild type EGFR kinase domain (unknown origin) expressed using baculovirus expression system incubated for 1 hr using Poly(Glu,Tyr) 4:1 by ELISA method",C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(CC)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(5-ethyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6,7-dioxo-6,7-dihydropteridin-8(5H)-yl)phenyl)acrylamide",0.081,uM,=,-1.0915149811213505,0,O=c1[nH]c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n(-c2ccccc2)c1=O
2075,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC[C@H]1CC(N)=O,(S)-2-(1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidin-2-yl)acetamide,0.17,uM,=,-0.7695510786217261,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
2076,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CC(C)(C)ONC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"N-tert-Butoxy-5-(2,5-dihydroxy-benzylamino)-2-hydroxy-benzamide",0.1,uM,=,-1.0,0,c1ccc(CNc2ccccc2)cc1
2077,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(Oc1ccc2ccccc2c1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid naphthalen-2-yl ester",0.09,uM,=,-1.0457574905606752,0,O=C(Oc1ccc2ccccc2c1)c1cccc(NCc2ccccc2)c1
2078,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((5-chloro-4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.071,uM,=,-1.1487416512809248,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)cc1
2079,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(Nc3ccc(-c4nc5ccc(Cl)cc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1,N-(4-(6-chlorobenzo[d]thiazol-2-yl)-2-fluorophenyl)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-amine,6.2,uM,=,0.7923916894982539,1,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
2080,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(C(=O)OC(C)C)c(-c2cn(C(C)=O)c3ccccc23)n1,Isopropyl-4-(1-acetyl-1H-indol-3-yl)-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-5-carboxylate,0.00086,uM,=,-3.065501548756432,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCCCC5)cc4)n3)c[nH]c2c1
2081,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3OC)ncc2SC)c1,N-(3-((2-((2-Methoxy-4-(4-(methylsulfonyl)piperazin-1-yl)-phenyl)amino)-5-(methylthio)pyrimidin-4-yl)oxy)phenyl)acrylamide,0.7305,uM,=,-0.1363797797296844,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2082,1991314,10.1016/j.bmcl.2020.127288,,,,Inhibition of wild type EGFR (unknown origin) in presence of radiolabelled gammaATP by radioisotope filter binding assay,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.125,uM,=,-0.9030899869919436,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
2083,2145645,10.1016/j.bmcl.2021.128406,,,,Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence of ATP by IMAP-FP assay,C=CC(=O)N1CCC2(CC1)CNC(=O)c1cc(-c3ccnc(Nc4ccccc4OC)n3)[nH]c12,"1-acryloyl-2'-(2-(2-methoxyphenylamino)pyrimidin-4-yl)-5',6'-dihydrospiro[piperidine-4,7'-pyrrolo[3,2-c]pyridin]-4'(1'H)-one",0.0004,uM,=,-3.397940008672037,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(Nc4ccccc4)n3)cc21
2084,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,0.024,uM,=,-1.619788758288394,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
2085,306382,10.1016/j.bmcl.2004.12.015,,,,Inhibition of poly(L-glutamic acid-L-tyrosine) phosphorylation by EGFR tyrosine kinase of A431 carcinoma cells,ClCCNc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-N*6*-(2-chloro-ethyl)-quinazoline-4,6-diamine",0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
2086,2218631,10.1021/acs.jmedchem.1c00302,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,"(3-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3ccccc23)cc1
2087,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(NCc3ccccc3[N+](=O)[O-])c2cn1,"N*4*-(2-Nitro-benzyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",4.25,uM,=,0.6283889300503115,1,c1ccc(CNc2ncnc3ccncc23)cc1
2088,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCc1c(C(=O)NCCCn2ccnc2)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid (3-imidazol-1-yl-propyl)-amide",0.04,uM,=,-1.3979400086720375,0,O=C(NCCCn1ccnc1)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnn2c1
2089,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(N[C@@H](C)c3ccc(Cl)cc3)c2cc1OCCCCCCC(=O)NO,(R)-7-(4-(1-(4-Chlorophenyl)ethylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.614,uM,=,-0.2118316288588323,0,c1ccc(CNc2ncnc3ccccc23)cc1
2090,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3cccc(Cl)c3)C2=O)cc(OC)c1,"(2E,6E)-2-(3-Chlorobenzylidene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",2.2,uM,=,0.3424226808222063,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
2091,2121823,10.1016/j.ejmech.2021.113786,,,,Inhibition of wild type EGFR (unknown origin) using fluoresceine-labelled poly-GT peptide as substrate incubated for 1 hr by TR-FRET assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.00032,uM,=,-3.494850021680094,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2092,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CN(C/C=C/C(=O)N1CCc2c(sc3ncnc(Nc4cc(O)c(Cl)c(Cl)c4)c23)C1)C(C)(C)C,"US8524722, 134",0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3sc4c(c23)CCNC4)cc1
2093,1348544,10.1016/j.bmcl.2014.03.072,,,,Inhibition of autophosphorylation of recombinant his-tagged EGFR (amino acid 645-1186) (unknown origin) expressed in Sf-9 cells after 10 mins by time-resolved fluorometry,Cc1ccc(C2=NN(C3=NC(c4ccccc4)CS3)C(c3ccc4ccccc4c3)C2)cc1,"2-(5-(naphthalen-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",5.26,uM,=,0.7209857441537391,1,c1ccc(C2=NN(C3=NC(c4ccccc4)CS3)C(c3ccc4ccccc4c3)C2)cc1
2094,2110760,10.1016/j.ejmech.2020.113022,,,,Inhibition of N-terminal GST-tagged human recombinant EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCN/C(=N\C#N)Nc4ccncc4)cc23)c1,2-Cyano-1-(5-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pentyl)-3-(pyridin-4-yl)guanidine,0.00023,uM,=,-3.638272163982407,0,N=C(NCCCCCOc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1ccncc1
2095,445904,10.1021/jm070436q,,,,Inhibition of P-EGFR expressed in A431 cells,N#Cc1cnc2c(Cl)cc(NCc3cnc[nH]3)cc2c1Nc1ccc(F)c(Cl)c1,8-chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[(1H-imidazol-5-ymethyl)amino]quinoline-3-carbonitrile,1.8,uM,=,0.255272505103306,1,c1ccc(Nc2ccnc3ccc(NCc4cnc[nH]4)cc23)cc1
2096,1896899,10.1016/j.ejmech.2019.06.054,,,,"Inhibition of EGFR (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,"5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide",0.0318,uM,=,-1.4975728800155672,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1
2097,1448250,10.1016/j.bmcl.2014.07.094,,,,Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry,CCOC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2cc(OC)ccc2n2nnnc12,"Ethyl 2-amino-4-(7-methoxytetrazolo[1,5-a]quinolin-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",0.2,uM,=,-0.6989700043360187,0,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1
2098,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccc(Cl)cc4)cc3)ncnc2cc1OCCCN1CCOCC1,N-(4-(6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-ylamino)phenyl)-4-chlorobenzamide,1.35,uM,=,0.1303337684950061,1,O=C(Nc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1)c1ccccc1
2099,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1,"N-(3-ethynylphenyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0487,uM,=,-1.3124710387853658,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
2100,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,COc1ccc2c(c1)CNc1c(NCc3ccccc3)ncnc1O2,"Benzyl-(8-methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",2.0,uM,=,0.3010299956639812,1,c1ccc(CNc2ncnc3c2NCc2ccccc2O3)cc1
2101,835647,10.1016/j.bmcl.2012.07.079,,,,Inhibition of EGFR in human A431 cell lysate using tyrosine/glutamic acid polymer as substrate by ELISA,Clc1cccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCCO5)cc23)c1,"N4-(3-chlorophenyl)-N6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)quinazoline-4,6-diamine",0.79,uM,=,-0.1023729087095585,0,c1ccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCCO5)cc23)cc1
2102,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(4-benzylphenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylatef",0.24,uM,=,-0.619788758288394,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1
2103,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COCC[C@@H](C(N)=O)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-4-methoxybutanamide,0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
2104,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),COc1ccc2[nH]c3ncnc(Nc4cccc(Br)c4)c3c2c1,"(3-Bromo-phenyl)-(6-methoxy-9H-pyrimido[4,5-b]indol-4-yl)-amine",0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
2105,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Br)c(Br)c2)CC1c1ccc(Br)cc1,"5-(4-Bromophenyl)-3-(3,4-dibromophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",10.06,uM,=,1.0025979807199086,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
2106,2229998,10.1021/acs.jmedchem.1c00876,,,,Inhibition of wild type EGFR (unknown origin),CC(C)(C)n1cc(-c2cncc3ccccc23)c2c(N)ncnc21,"7-(tert-butyl)-5-(isoquinolin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",1.623,uM,=,0.2103185198262318,1,c1ccc2c(-c3c[nH]c4ncncc34)cncc2c1
2107,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,c1ccc2ncncc2c1,Quinazoline,0.027,uM,=,-1.5686362358410126,0,c1ccc2ncncc2c1
2108,1528598,,,,,"In Vitro Kinase Assay: In vitro kinase analysis was performed by using HTScan EGF Receptor Kinase Assay Kit (#7909) and HTScan HER2/ErbB2 Kinase Assay Kit (#7058) from Cell Signaling Technology Company. Operation steps refer to the specification of the used kits, and the method was used to measure the inhibition effects of the compound to be tested on substrate peptide phosphorylation of EGFR or Her2 receptor tyrosine kinase. At room temperature, ATP and substrate peptide as well as the compound to be tested were incubated in kinase reaction buffer, after a period of incubation, a stop buffer was added to terminate the reaction and the sample was transferred to a streptavidin-coated 96-well plate, the plate was washed and the phosphorylation level of substrate peptide was detected by using HRP-marked antibody against substrate phosphorylation, colorated with TMB, terminated the reaction with 2M sulfuric acid. Absorption at 450 nm wavelength was detected, and IC50 value (Î¼M) was calculated.",O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)CC(F)(F)F,"US8916574, Compound 5",0.01461,uM,=,-1.8353497840657031,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
2109,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,CCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C,(Z)-N-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.0001799999999999,uM,=,-3.744727494896694,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
2110,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,O=c1oc2cc3ncnc(Nc4ccc5[nH]ncc5c4)c3cc2n1CCCN1CCOCC1,"8-(1H-indazol-5-ylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.12,uM,=,-0.9208187539523752,0,O=c1oc2cc3ncnc(Nc4ccc5[nH]ncc5c4)c3cc2n1CCCN1CCOCC1
2111,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3cc(Cl)ccc3F)c2cc1OC1CCN(CC(N)=O)CC1,2-(4-(4-(5-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)acetamide,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
2112,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/Cc1c[nH]cn1,4-(1H-Imidazol-4-yl)-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.024,uM,=,-1.619788758288394,0,O=C(/C=C/Cc1c[nH]cn1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
2113,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,Cc1cc(Nc2ncnc3cc(O)c(NC(=O)/C=C/[C@H]4CCCN4C)cc23)ccc1Oc1ccn2cnnc2c1,"(E)-N-[7-hydroxy-4-[3-methyl-4-([1,2,4]triazolo[4,3-a]pyridin-7-yloxy)anilino]quinazolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide",0.02275,uM,=,-1.6430185990068689,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4ccn5cnnc5c4)cc3)c2c1
2114,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(thiophen-2-yl)thieno[2,3-d]pyrimidin-4-amine",0.009,uM,=,-2.0457574905606752,0,c1ccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2)cc1
2115,624979,10.1016/j.bmcl.2010.03.015,,,,Inhibition of EGFR intracellular phosphorylation in human A431 cells by ELISA,CN(C)CCc1ccc(Nc2nccc(-c3c(-c4cccc(NC(=O)c5c(F)cccc5F)c4)nc4sccn34)n2)cc1,"N-(3-(5-(2-(4-(2-(dimethylamino)ethyl)phenylamino)pyrimidin-4-yl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2,6-difluorobenzamide",0.22,uM,=,-0.6575773191777937,0,O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccccc3)n2)c1)c1ccccc1
2116,593141,10.1021/jm901146p,,,,Inhibition of Her1 by fluorescence polarization assay,C=CC(=O)N1CCC[C@H]1C(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCCOC,(S)-1-Acryloyl-N-[4-(3-chloro-2-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl]pyrrolidine-2-carboxamide,0.013,uM,=,-1.8860566476931635,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)[C@@H]1CCCN1
2117,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.00618,uM,=,-2.209011524911184,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2118,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,COc1cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c2c1COC[C@@H]1CNCCO1,"(S)-N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-6-methoxy-5-((morpholin-2-ylmethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.43,uM,=,-0.3665315444204134,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)cc1
2119,2127056,10.1016/j.bmcl.2021.128118,,,,Inhibition of recombinant wild type EGFR-TK (unknown origin) by ELISA,COc1ccc(C(Nc2ccc([N+](=O)[O-])cc2)n2c(=O)ccc3cc(O)ccc32)cc1,6-hydroxy-1-((4-methoxyphenyl)(4-nitrophenylamino)methyl)quinolin-2(1H)-one,1.35,uM,=,0.1303337684950061,1,O=c1ccc2ccccc2n1C(Nc1ccccc1)c1ccccc1
2120,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccnc4[nH]c(-c5ccccc5)cc34)[nH]2)cc1,"4-[4-(4-Fluorophenyl)-5-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-imidazol-2-yl]phenol",0.0492,uM,=,-1.3080348972326397,0,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccccc4)ccnc3[nH]2)cc1
2121,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(C(=O)Oc2ccccc2)c(-c2cn(C)c3ccccc23)n1,Phenyl 2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate,5.3e-05,uM,=,-4.275724130399211,0,O=C(Oc1ccccc1)c1cnc(Nc2ccc(N3CCNCC3)cc2)nc1-c1c[nH]c2ccccc12
2122,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(=O)NCC(=O)O)c3ccccc3n2C)c(C(=O)NCC(=O)O)c2ccccc21,({2-[3-(Carboxymethyl-carbamoyl)-1-methyl-1H-indol-2-yldisulfanyl]-1-methyl-1H-indole-3-carbonyl}-amino)-acetic acid,10.0,uM,=,1.0,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
2123,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-41",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2124,2074610,10.1016/j.bmc.2020.115680,,,,Inhibition of wild type EGFR (unknown origin) in presence of ATP preincubated 5 mins measured for 30 mins by detection reagent based HTRF analysis,C=C(Cl)C(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)nc3)ncc2Cl)c1,N-(3-((2-((6-(4-acetylpiperazin-1-yl)pyridin-3-yl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)-2-chloroacrylamide,0.13,uM,=,-0.8860566476931633,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)nc3)n2)cc1
2125,1618202,10.1021/acs.jmedchem.5b01985,,,,Inhibition of wild type EGFR phosphorylation in human HaCaT cells incubated for 3 hrs by ELISA method,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,0.2623,uM,=,-0.5812017094096464,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2126,1553877,10.1016/j.ejmech.2016.01.045,,,,Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay,COc1cc2ncnc(Nc3cccc(C(=O)NC45CC6CC(CC(C6)C4)C5)c3)c2cc1OCCCN1CCOCC1,N-(Adamantan-1-yl)-3-((7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl)amino)benzamide,0.00112,uM,=,-2.9507819773298185,0,O=C(NC12CC3CC(CC(C3)C1)C2)c1cccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)c1
2127,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,O=C(O)c1ccc2c(c1)CNc1c(Nc3ccc(F)c(Cl)c3)ncnc1O2,"1-(3-Chloro-4-fluoro-phenylamino)-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene-8-carboxylic acid",4.4,uM,=,0.6434526764861874,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
2128,2241031,10.1021/acs.jmedchem.1c00848,,,,Inhibition of wild type human EGFR expressed in Sf9 insect cells in presence of ATP measured by HTRF assay,C=CC(=O)Nc1ccc(OC)c(Nc2cc(-c3[nH]c(SC)nc3-c3cccc(NC(=O)c4c(F)ccc(O)c4CN4C(=O)c5ccccc5C4=O)c3)ccn2)c1,"N-(3-(5-(2-((5-Acrylamido-2-methoxyphenyl)amino)pyridin-4-yl)-2-(methylthio)-1H-imidazol-4-yl)phenyl)-2-((1,3-dioxoisoindolin-2-yl)methyl)-6-fluoro-3-hydroxybenzamide",0.047,uM,=,-1.3279021420642825,0,O=C(Nc1cccc(-c2nc[nH]c2-c2ccnc(Nc3ccccc3)c2)c1)c1ccccc1CN1C(=O)c2ccccc2C1=O
2129,1934063,10.1016/j.bmcl.2016.02.003,,,,Inhibition of recombinant human His-tagged EGFR expressed in mammalian expression system by Z'-LYTE assay,Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1,"4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-N-(2,2,2-trifluoroethyl)thiophene-2-carboxamide",28.0,uM,=,1.4471580313422192,1,c1cc(-c2cnn3cc(-c4cn[nH]c4)cnc23)cs1
2130,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccc(F)cc3)CC2c2ccc(Br)cc2)=N1,"2-(5-(4-Bromophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",4.79,uM,=,0.6803355134145632,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
2131,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)cc3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(4-benzyloxy-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,0.185,uM,=,-0.7328282715969863,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
2132,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Oc1ccc(CN(Cc2cccc(Cl)c2O)C(=S)Nc2ccccc2)cc1,1-(5-Chloro-2-hydroxybenzyl)-1-(4-hydroxybenzyl)-3-phenylthiourea,0.08,uM,=,-1.0969100130080565,0,S=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
2133,1897498,10.1016/j.bmc.2019.07.042,,,,Inhibition of EGFR-TK in human HeLa cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay,OC(c1cccs1)c1cc2ccccc2nc1Cl,(2-chloroquinolin-3-yl))thiophen-2-yl)methanol,6.3,uM,=,0.7993405494535817,1,c1csc(Cc2cnc3ccccc3c2)c1
2134,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(CCC(=O)O)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"3-{5-[4-(3-Chloro-4-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrol-2-yl}-propionic acid",0.0047,uM,=,-2.3279021420642825,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
2135,66576,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,N-[4-(3-Chloro-phenylamino)-quinazolin-6-yl]-acrylamide,0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2ncnc3ccccc23)cc1
2136,1870312,10.1021/acs.jmedchem.8b00672,,,,Inhibition of wild type EGFR (unknown origin),COc1cc2c(Oc3ccc(NS(=O)(=O)c4cc(F)ccc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,"2,5-difluoro-N-(3-fluoro-4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinolin-4-yloxy)phenyl)benzenesulfonamide",0.149,uM,=,-0.826813731587726,0,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1ccccc1
2137,63773,10.1021/jm9508651,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 human epidermoid carcinoma cells,COc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"(3-Bromo-phenyl)-(6-methoxy-pyrido[3,4-d]pyrimidin-4-yl)-amine",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3cnccc23)cc1
2138,305999,10.1016/j.bmcl.2004.08.007,,,,Inhibitory concentration against Epidermal growth factor receptor tyrosine kinase activity,COc1cc2ncnc(Nc3ccc(Cl)c(NC(=O)c4ccccc4)c3)c2cc1OC,"N-[2-Chloro-5-(6,7-dimethoxy-quinazolin-4-ylamino)-phenyl]-benzamide",2.2,uM,=,0.3424226808222063,1,O=C(Nc1cccc(Nc2ncnc3ccccc23)c1)c1ccccc1
2139,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,C=CCOc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1,(6-Allyloxy-quinazolin-4-yl)-(4-benzyloxy-phenyl)-amine,0.079,uM,=,-1.1023729087095586,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
2140,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(CC#N)cc2)c2c(N)ncnc21,"2-(4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)acetonitrile",13.0,uM,=,1.1139433523068367,1,c1ccc(-c2n[nH]c3ncncc23)cc1
2141,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,C/C(=C\c1ccc(O)c(O)c1)[N+](=O)[O-],"4-(2-Nitro-propenyl)-benzene-1,2-diol",9.0,uM,=,0.9542425094393248,1,c1ccccc1
2142,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CN1CCN(C/C=C/C(=O)Nc2cc3c(Nc4ccc(Cc5ccccn5)cc4)ncnc3cn2)CC1,"(2E)-4-(4-Methyl-1-piperazinyl)-N-{4-[4-(2-pyridinylmethyl)-anilino]pyrido[3,4-d]pyrimidin-6-yl}-2-butenamide",0.857,uM,=,-0.0670191780768018,0,O=C(/C=C/CN1CCNCC1)Nc1cc2c(Nc3ccc(Cc4ccccn4)cc3)ncnc2cn1
2143,1528501,,,,,"Time-Resolved Fluorescence Assay: The following assay may be used to determine the activity of the compounds of the invention for inhibiting EGFR kinase activity. The half maximal inhibitory concentration IC50 (the concentration of the tested compound showing 50% inhibition of the enzyme activity) of each compound was determined by incubating several different concentrations of the tested compounds with a specific enzyme and substrate. EGFR kinase used in this assay is a human-derived recombinant protein (Cell signaling technology, #7908), which was reacted with peptide substrate and different concentrations of tested compounds in a buffer solution containing 60 mM HEPES (pH7.5), 5 mM MgCl2, 5 mM MnCl2, 3 Î¼M Na3VO4, 1.25 M DTT (1000Ã) and 20 Î¼M ATP at 25Â° C., for 45 minutes.",COCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/[C@@H]1CCCN1C,"US8901140, 8::US9358227, 8",0.002,uM,=,-2.6989700043360187,0,O=C(/C=C/[C@@H]1CCCN1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2144,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.434,uM,=,-0.3625102704874893,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)cnc23)cc1
2145,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CCOC(=O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,"[5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-phenyl]-acetic acid ethyl ester",7.0,uM,=,0.8450980400142568,1,c1ccc(CNc2ccccc2)cc1
2146,65120,10.1021/jm00023a009,,,,In vitro inhibition of EGF-stimulated DNA synthesis of ER 22 cells by following the incorporation of methyl-[3H]thymidine.,O=C(O)c1ccc(-c2cc(O)cc(-c3ccccc3)c2)cc1,"5'-Hydroxy-[1,1',3',1'']terphenyl-4-carboxylic acid",10.0,uM,=,1.0,1,c1ccc(-c2cccc(-c3ccccc3)c2)cc1
2147,1348544,10.1016/j.bmcl.2014.03.072,,,,Inhibition of autophosphorylation of recombinant his-tagged EGFR (amino acid 645-1186) (unknown origin) expressed in Sf-9 cells after 10 mins by time-resolved fluorometry,Cc1ccc(C2=NN(C3=NC(c4ccccc4)CS3)C(c3ccc4ccccc4c3)C2)cc1C,"2-(3-(3,4-dimethylphenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",0.65,uM,=,-0.1870866433571444,0,c1ccc(C2=NN(C3=NC(c4ccccc4)CS3)C(c3ccc4ccccc4c3)C2)cc1
2148,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CN1CCN(Cc2ccc(C(=O)Nc3ccc(-c4cncc(C#N)c4Nc4ccc(OCc5ccccn5)c(Cl)c4)cc3)cc2)CC1,N-(4-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-5-cyanopyridin-3-yl)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide,2.3,uM,=,0.3617278360175928,1,O=C(Nc1ccc(-c2cnccc2Nc2ccc(OCc3ccccn3)cc2)cc1)c1ccc(CN2CCNCC2)cc1
2149,66570,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor in A431 cells,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(C(F)(F)F)c3)c2c1,N-[4-(3-Trifluoromethyl-phenylamino)-quinazolin-6-yl]-acrylamide,0.0045,uM,=,-2.3467874862246565,0,c1ccc(Nc2ncnc3ccccc23)cc1
2150,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),CCOC(=O)/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"3-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylcarbamoyl]-acrylic acid ethyl ester",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2ncnc3cnccc23)cc1
2151,946792,10.1016/j.bmc.2013.01.040,,,,Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA,Nc1nc(Nc2ccc(Cl)cc2)c2c(n1)[nH]c1cccc(Cl)c12,"5-chloro-N4-(4-chlorophenyl)-9H-pyrimido[4,5-b]indole-2,4-diamine",63.6,uM,=,1.8034571156484136,1,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
2152,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cccc(CNc2ncnc3c2NCc2cc(OC)c(OC)cc2N3)c1,"(7,8-dimethoxy-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cyclohepten-1-yl)-(3-methoxy-benzyl)-amine",11.7,uM,=,1.0681858617461617,1,c1ccc(CNc2ncnc3c2NCc2ccccc2N3)cc1
2153,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"(2E)-N-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(1-piperidinyl)-2-butenamide",0.014,uM,=,-1.853871964321762,0,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
2154,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",COC(=O)/C=C/CNC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,"(S,E)-Methyl-4-(3-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)ureido)but-2-enoate",0.404,uM,=,-0.393618634889395,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
2155,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,COc1cc2ncnc(NCc3ccc(F)cc3)c2cc1OC.Cl,"4-[(4'-fluorobenzyl)amino]-6,7-dimethoxyquinazoline hydrochloride",0.489,uM,=,-0.3106911408763798,0,c1ccc(CNc2ncnc3ccccc23)cc1
2156,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3cnn(C)c3)nc3ccsc23)CC1,"1-(4-((2-((1-methyl-1H-pyrazol-4-yl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.19602,uM,=,-0.707699615140919,0,c1cc2nc(Nc3cn[nH]c3)nc(OC3CCNCC3)c2s1
2157,2088168,10.1016/j.ejmech.2020.112363,,,,Inhibition of EGFR (unknown origin) by FRET assay,S=C(Nc1ccc2c(c1)OCO2)Nc1c2ccccc2nc2ccccc12,"1-(acridin-9-yl)-3-(benzo[d][1,3]dioxol-5-yl)thiourea",0.493,uM,=,-0.30715308072277,0,S=C(Nc1ccc2c(c1)OCO2)Nc1c2ccccc2nc2ccccc12
2158,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,CCOc1cc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(Cl)c3)c2cc1NC(=O)/C(F)=C\CN1CCCCC1,(E)-N-(4-((3-Chloro-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide,0.0392,uM,=,-1.4067139329795426,0,O=C(/C=C\CN1CCCCC1)Nc1ccc2ncnc(Nc3ccc(Oc4cccnc4)cc3)c2c1
2159,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,COc1ccc(-n2cc(NC(=O)c3cccc(NS(=O)(=O)c4ccccc4)c3)cn2)cc1,N-(1-(4-Methoxyphenyl)-1H-pyrazol-4-yl)-3-(phenylsulfonamido)benzamide,26.97,uM,=,1.430880946452891,1,O=C(Nc1cnn(-c2ccccc2)c1)c1cccc(NS(=O)(=O)c2ccccc2)c1
2160,63769,10.1016/S0960-894X(97)00014-0,,,,Displacement of [gamma-32P]-ATP from Epidermal growth factor receptor in A431 cell-free extracts,CCCCCCCCCCCCCCNC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-N-tetradecyl-benzamide",27.2,uM,=,1.434568904034199,1,c1ccc(CNc2ccccc2)cc1
2161,1873759,10.1021/acs.jmedchem.9b00576,,,,"Inhibition of wild-type EGFR (unknown origin) using Poly(Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",CCC(=O)N[C@H]1CC[C@@H](n2c(=O)c(-c3ccccc3Cl)c(C)c3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)CC1,"N-((1s,4s)-4-(6-(2-chlorophenyl)-5-methyl-2-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)propionamide",0.1688,uM,=,-0.7726275577103637,0,O=c1c(-c2ccccc2)cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1C1CCCCC1
2162,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.01976,uM,=,-1.7042130597483909,0,c1ccc(/N=c2\nc[nH]c3cc(OCC4CCNCC4)ccc23)cc1
2163,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=S)NCCN5CCOCC5)cc34)cc2Cl)c1,1-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)thiourea,0.332,uM,=,-0.4788619162959637,0,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
2164,1695880,10.1016/j.bmcl.2017.08.035,,,,Inhibition of wild type recombinant EGFR (unknown origin) by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,"4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-((2R,3R,4R,5S)-2-hydroxymethyl-3,4,5-trihydroxy-1-piperidyl)propoxy)quinazoline",0.01071,uM,=,-1.9702105291681444,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCCCC4)cc23)cc1
2165,1770732,10.1016/j.bmc.2018.03.025,,,,"Inhibition of wild type EGFR (unknown origin) using poly (Glu, Tyr) as substrate after 40 mins by kinase-glo plus luminescence assay",CN(C)CCOc1ccc(Nc2ncc3nc(Sc4ccc(F)cc4)n(C4CCOCC4)c3n2)cc1,N-(4-(2-(Dimethylamino)ethoxy)phenyl)-8-((4-fluorophenyl)thio)-9-(tetrahy-dro-2H-pyran-4-yl)-9H-purin-2-amine,0.0025,uM,=,-2.6020599913279625,0,c1ccc(Nc2ncc3nc(Sc4ccccc4)n(C4CCOCC4)c3n2)cc1
2166,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCc1c(C(=O)OCCCn2ccnc2)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid 3-imidazol-1-yl-propyl ester",0.17,uM,=,-0.7695510786217261,0,O=C(OCCCn1ccnc1)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnn2c1
2167,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,Cc1ccc(N2NC(=O)/C(=C\c3ccc(-c4cc([N+](=O)[O-])ccc4O)o3)C2=O)cc1C,"1-(3,4-dimethylphenyl)-4-((5-(2-hydroxy-5-nitrophenyl)furan-2-yl)methylene)pyrazolidine-3,5-dione",74.3,uM,=,1.8709888137605752,1,O=C1NN(c2ccccc2)C(=O)/C1=C/c1ccc(-c2ccccc2)o1
2168,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc([N+](=O)[O-])cc3)C2)cc1,"2-(3-(4-methoxyphenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",8.63,uM,=,0.9360107957152096,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
2169,1761187,10.1016/j.ejmech.2018.01.081,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr by mobility shift assay,CCS(=O)(=O)Nc1cc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cnc1OC,N-(5-(4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide,0.0024,uM,=,-2.619788758288394,0,c1ccc(Nc2ncnc3ccc(-c4cccnc4)cc23)cc1
2170,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCC/C(=C\c3ccc(O)cc3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(4-hydroxybenzylidene)cyclohexanone",4.66,uM,=,0.6683859166900001,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
2171,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"2-Cyano-N-{3-[2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-propyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",3.3,uM,=,0.5185139398778875,1,O=C(C=Cc1ccccc1)NCCCNC(=O)/C=C/c1ccccc1
2172,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(N[C@@H](C)c3ccccc3)ncnc2s1,"(S)-6-(2-Methoxyphenyl)-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine",1.86,uM,=,0.2695129442179163,1,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
2173,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)c(O)c4)nn32)CC1,"7-(1-acryloylpiperidin-4-yl)-2-(3-hydroxy-4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",0.061,uM,=,-1.214670164989233,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(C3CCNCC3)CCN4)cc2)cc1
2174,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(F)cc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-Fluoro-5-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.026,uM,=,-1.585026652029182,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
2175,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CCOC(=O)C(=O)Oc1ccc(-c2c(C(=O)OCC)oc3cc(O)cc(O)c3c2=O)cc1.O=C(O)C(=O)O,"4-(2-(ethoxycarbonyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)phenyl ethyl oxalate",1.0,uM,=,0.0,0,O=c1c(-c2ccccc2)coc2ccccc12
2176,1869224,10.1021/acs.jmedchem.8b01391,,,,Inhibition of wild type EGFR (unknown origin) by bioluminescent ADP-glo kinase assay,COc1cc(Nc2ncnc3cc(-c4cccs4)sc23)cc(OC)c1OC,"6-(Thiophen-2-yl)-N-(3,4,5-trimethoxyphenyl)thieno[3,2-d]-pyrimidin-4-amine",0.0025,uM,=,-2.6020599913279625,0,c1ccc(Nc2ncnc3cc(-c4cccs4)sc23)cc1
2177,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CC(C)(C)ONC(=O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,"N-tert-Butoxy-2-[5-(2,5-dihydroxy-benzylamino)-2-hydroxy-phenyl]-acetamide",5.0,uM,=,0.6989700043360189,1,c1ccc(CNc2ccccc2)cc1
2178,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)Nc1ccc(OC)c(Nc2cc(-c3[nH]c(SC)nc3C(C)(C)C)ccn2)c1,N-(3-((4-(4-(tert-Butyl)-2-(methylthio)-1H-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.057,uM,=,-1.2441251443275083,0,c1ccc(Nc2cc(-c3cnc[nH]3)ccn2)cc1
2179,305584,10.1021/jm0580196,,,,Inhibition of HER1 kinase in intact DHER14 cells; Range = 5-15 nM,O=C(CCl)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1,"2-Chloro-N-[4-(4,5-dichloro-2-fluoro-phenylamino)-quinazolin-6-yl]-acetamide",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3ccccc23)cc1
2180,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Cc1cccc(CN(Cc2ccc(O)cc2)C(=S)Nc2ccccc2)c1O,1-(2-Hydroxy-5-methylbenzyl)-1-(4-hydroxybenzyl)-3-phenylthiourea,3.46,uM,=,0.5390760987927766,1,S=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
2181,2088808,10.1016/j.ejmech.2020.112388,,,,Inhibition of N-terminal GST-fused human wild type EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate incubated for 20 mins by Mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0002399999999999,uM,=,-3.619788758288394,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
2182,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(OCC)c(NC(=O)/C=C/CN(C)C4CC4)cc23)c1,(E)-4-(Cyclopropyl(methyl)amino)-N-(7-ethoxy-4-(3-ethynylphenylamino)quinazolin-6-yl)but-2-enamide,0.0024,uM,=,-2.619788758288394,0,O=C(/C=C/CNC1CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2183,676221,10.1021/jm100607r,,,,Inhibition of EGFR,CCN(CC)C/C=C/C(=O)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,"(E)-4-(Diethylamino)-1-(4-(((1R)-2-hydroxy-1-phenylethyl)-amino)-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-buten-1-one",0.009,uM,=,-2.0457574905606752,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1
2184,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CCNC(=O)O[C@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5R)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl ethylcarbamate",0.032,uM,=,-1.494850021680094,0,C(#C[C@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
2185,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(CCO)CC4)cc3)ncc2Cl)CC1,1-(4-((5-chloro-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one,0.1237,uM,=,-0.9076303003708792,0,c1cc(OC2CCNCC2)nc(Nc2ccc(N3CCNCC3)cc2)n1
2186,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,O=C(/C=C/c1ccccc1)Nc1ccc(Cl)cc1,(E)-N-(4-chlorophenyl)cinnamamide,13.71,uM,=,1.1370374547895128,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
2187,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(NC3CC3c3ccccc3)c2cc1OCCCN(C)C,[6-(3-Dimethylamino-propoxy)-7-methoxy-quinazolin-4-yl]-(2-phenyl-cyclopropyl)-amine,0.027,uM,=,-1.5686362358410126,0,c1ccc(C2CC2Nc2ncnc3ccccc23)cc1
2188,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3occc3c2)c2c(N)ncnc21,"3-(benzofuran-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.964,uM,=,-0.0159229660971692,0,c1ncc2c(-c3ccc4occc4c3)n[nH]c2n1
2189,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,CS(=O)(=O)CCNCCCCOc1ccc2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c2c1,[1-(3-Fluoro-benzyl)-1H-indazol-5-yl]-{6-[4-(methanesulfonylmethyl-amino)-butoxy]-quinazolin-4-yl}-amine,0.024,uM,=,-1.619788758288394,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccccc45)ccc32)cc1
2190,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCC/C(=C\c3ccc(S(C)(=O)=O)cc3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(4-(methylsulfonyl)benzylidene)cyclohexanone",1.96,uM,=,0.292256071356476,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
2191,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=S)NCCCN5CCOCC5)cc34)cc2Cl)c1,1-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)-3-(3-morpholinopropyl)thiourea,0.271,uM,=,-0.5670307091255943,0,S=C(NCCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
2192,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(C#N)cc3)cc12)c1ccccc1,"(R)-4-(4-(1-phenylethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzonitrile",0.012,uM,=,-1.9208187539523751,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
2193,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C)c3n2)C[C@H]1F,MAVELERTINIB,0.307,uM,=,-0.5128616245228135,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1
2194,1580544,10.1016/j.ejmech.2016.04.002,,,,Inhibition of EGFR-TK in human A431 cell lysate assessed as reduction in EGF stimulated kinase activity after 60 mins using biotinylated peptide substrate by ELISA,C[S+]([O-])CCCCN=C=S,1-Isothiocyanato-4-methanesulfinyl-butane,9.0,uM,=,0.9542425094393248,1,
2195,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,O=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-Bromophenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)urea,0.0014299999999999,uM,=,-2.844663962534938,0,O=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2196,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3c(c2)CCO3)c2c(N)ncnc21,"3-(2,3-dihydrobenzofuran-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",5.0,uM,=,0.6989700043360189,1,c1ncc2c(-c3ccc4c(c3)CCO4)n[nH]c2n1
2197,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,Cc1ccc(-n2cc(NC(=O)c3cccc(NS(=O)(=O)c4ccc(Cl)cc4)c3)cn2)cc1,3-((4-Chlorophenyl)sulfonamido)-N-(1-(p-tolyl)-1H-pyrazol-4-yl)benzamide,8.77,uM,=,0.9429995933660406,1,O=C(Nc1cnn(-c2ccccc2)c1)c1cccc(NS(=O)(=O)c2ccccc2)c1
2198,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,Nc1ncnc2c1c(-c1ccccc1)cn2C1CCNC1,"5-Phenyl-7-pyrrolidin-3-yl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",13.4,uM,=,1.1271047983648077,1,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1
2199,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1NC(=O)/C=C/CN1CCCCC1,(2E)-N-[7-Methoxy-4-(4-phenoxyanilino)-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide,0.132,uM,=,-0.8794260687941501,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2c1
2200,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,223.9,uM,=,2.3500540935790304,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2201,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Oc1c(Br)cccc1Nc1ncnc2cc3c(cc12)OCCO3,"2-Bromo-6-[(7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)amino]phenol",0.5051,uM,=,-0.2966226314876504,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
2202,1741055,10.1016/j.ejmech.2018.06.024,,,,Inhibition of EGFR in human MCF7 cell lysates after 24 to 48 hrs by ELISA,O=C(CN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-((3-bromophenyl)amino)quinazolin-6-yl)-4-morpholinylacetamide,0.098,uM,=,-1.0087739243075051,0,O=C(CN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2203,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Nc1ccc2c(Nc3cccc(I)c3)ncnc2c1,"N*4*-(3-Iodo-phenyl)-quinazoline-4,7-diamine",0.00035,uM,=,-3.4559319556497243,0,c1ccc(Nc2ncnc3ccccc23)cc1
2204,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,CCc1ccc(Nc2ncnc3[nH]c(C)c(C)c23)cc1,"(5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(4-ethyl-phenyl)-amine",77.5,uM,=,1.8893017025063104,1,c1ccc(Nc2ncnc3[nH]ccc23)cc1
2205,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(CNCC(=O)NO)cc3)cc12)c1ccccc1,"(R)-N-hydroxy-2-(4-(4-(1-phenylethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzylamino)acetamide",1.0,uM,=,0.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
2206,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CO[C@@H]1[C@H](O)CN(c2nccc(Nc3cc4c(C(C)C)ccc(N5C[C@H](CS(C)(=O)=O)[C@H]5C)c4cn3)n2)CC1(F)F,"N-(2-((4R,5R)-3,3-difluoro-4-methoxy-5-methylpiperidin-1-yl)pyrimidin-5-yl)-5-isopropyl-8-((2R)-2-methyl-3-(methylsulfonyl)azetidin-1-yl)isoquinolin-3-amine",0.81,uM,=,-0.0915149811213502,0,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
2207,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(/C=C/c1cccc([N+](=O)[O-])c1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,(E)-N-(4-(3-Bromophenylamino)quinazolin-6-yl)-3-(3-nitrophenyl)acrylamide,0.12,uM,=,-0.9208187539523752,0,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2208,5000,10.1021/jm960118j,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Cc1c(-c2ccccc2)[nH]c2ncnc(Nc3cccc(Cl)c3)c12,"(3-Chloro-phenyl)-(5-methyl-6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",6.0,uM,=,0.7781512503836436,1,c1ccc(Nc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
2209,1657589,10.1016/j.bmcl.2017.02.027,,,,"Inhibition of wild type recombinant EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",C#Cc1cccc(Nc2ncnc3ccc(-c4ccc(CO)o4)cc23)c1,4-(3-ethynylphenylamino)-6-(5-hydroxymethylfuran-2-yl)quinazoline,0.01569,uM,=,-1.804377056413064,0,c1ccc(Nc2ncnc3ccc(-c4ccco4)cc23)cc1
2210,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1ccc[nH]1,2-(1H-Pyrrol-2-ylmethylene)-malononitrile,260.0,uM,=,2.414973347970818,1,c1cc[nH]c1
2211,2297695,10.1021/acsmedchemlett.2c00523,,,,Inhibition of EGFR (unknown origin) by Z'LYTE assay,C=CC(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3C)c3c(N)ncnc32)C1,"1-[(3S)-3-[4-amino-3-(2-methyl-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one",0.197,uM,=,-0.7055337738384071,0,c1ccc(Oc2ccc(-c3nn([C@H]4CCCNC4)c4ncncc34)cc2)cc1
2212,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,O=C(/C=C/CNC12CC3CC(CC(C3)C1)C2)N1CCc2c(sc3ncnc(Nc4ccc(Cl)c(Cl)c4)c23)C1,"US8524722, 119",0.001,uM,=,-3.0,0,O=C(/C=C/CNC12CC3CC(CC(C3)C1)C2)N1CCc2c(sc3ncnc(Nc4ccccc4)c23)C1
2213,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,CC(C)(N)C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc5sncc45)c(Cl)c3)c21,"N-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]-amino}-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl]-2-methylalaninamide",0.0026,uM,=,-2.5850266520291822,0,c1cc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)c2cnsc2c1
2214,340860,10.1016/j.bmcl.2005.12.028,,,,Inhibitory activity against EGFR,COc1cc(OC2CCN(C(C)=O)CC2)c2c(Nc3ccc(F)c(Cl)c3)ncnc2c1,1-(4-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-5-yloxy)piperidin-1-yl)ethanone,0.873,uM,=,-0.0589857562944302,0,c1ccc(Nc2ncnc3cccc(OC4CCNCC4)c23)cc1
2215,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(Nc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)-2-(trifluoromethoxy)phenyl]-6'-methoxy-7'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,0.805,uM,=,-0.0942041196321314,0,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
2216,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,Dacomitinib,0.011,uM,=,-1.958607314841775,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2217,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,Clc1cc(Nc2ncnc3[nH]nc(OCCN4CCCC4)c23)ccc1OCc1ccccn1,"N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-3-(2-(pyrrolidin-1-yl)ethoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.008,uM,=,-2.096910013008056,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCC5)c34)cc2)nc1
2218,1741055,10.1016/j.ejmech.2018.06.024,,,,Inhibition of EGFR in human MCF7 cell lysates after 24 to 48 hrs by ELISA,O=C(CN1CCCC1)Nc1ccc2ncnc(Nc3ccc(Cl)cc3)c2c1,N-(4-((4-chlorophenyl)amino)quinazolin-6-yl)-2-(pyrrolidin-1-yl)acetamide,0.032,uM,=,-1.494850021680094,0,O=C(CN1CCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2219,2112388,10.1016/j.bmcl.2021.127987,,,,Inhibition of EGFR (unknown origin),CCc1ccc(NCC(=O)Nn2c(-c3ccccc3)nc3ccccc3c2=O)cc1,2-(4-ethylphenylamino)-N-(4-oxo-2-phenylquinazolin-3(4H)-yl)acetamide,0.1434,uM,=,-0.8434508486682187,0,O=C(CNc1ccccc1)Nn1c(-c2ccccc2)nc2ccccc2c1=O
2220,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(N=[N+]=[N-])c2)n1,N-(3-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)azide,6.02,uM,=,0.7795964912578245,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2221,63764,10.1021/jm960689b,,,,Inhibition of epidermal growth factor receptor (EGFr),CCN(CC)CCNC(=O)c1c([Se][Se]c2c(C(=O)NCCN(CC)CC)c3ccccc3n2C)n(C)c2ccccc12,"2,2'-Diselenobis[N-[2-(diethylamino)ethyl]-1-methyl-1H-indole-3-carboxamide]",4.7,uM,=,0.6720978579357175,1,c1ccc2[nH]c([Se][Se]c3cc4ccccc4[nH]3)cc2c1
2222,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCNC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,N-Heptyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetamide,6.28,uM,=,0.7979596437371962,1,O=c1cc(-c2ccccc2)oc2ccccc12
2223,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),NC(=O)CCc1c(SSc2[nH]c3ccccc3c2CCC(N)=O)[nH]c2ccccc12,3-{2-[3-(2-Carbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-propionamide,16.0,uM,=,1.2041199826559248,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
2224,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CNc1ccc2ncncc2c1,Methyl-quinazolin-6-yl-amine,0.007,uM,=,-2.154901959985743,0,c1ccc2ncncc2c1
2225,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,CCOC(C)Oc1cc2ncnc(Nc3ccc(F)c(C#N)c3)c2c2c1OCCO2,"5-(5-(1-Ethoxyethoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-ylamino)-2-fluorobenzonitrile",0.3518,uM,=,-0.4537041648785576,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
2226,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3ccccc3Br)c2cc1OC,"(2-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.128,uM,=,-0.8927900303521317,0,c1ccc(Nc2ncnc3ccccc23)cc1
2227,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccc(-c2nn(C)c3ncnc(N)c23)cc1O,"5-(4-amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methylphenol",19.0,uM,=,1.2787536009528289,1,c1ccc(-c2n[nH]c3ncncc23)cc1
2228,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,CCN(CC)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7,8-dihydropyrimido[5,4-g][1,4]benzoxazin-6-yl]-4-(diethylamino)but-2-en-1-one",0.163,uM,=,-0.7878123955960422,0,c1ccc(COc2ccc(Nc3ncnc4cc5c(cc34)NCCO5)cc2)cc1
2229,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,O=C(c1ccccc1)c1cc2ncnc(Nc3ccc4[nH]ccc4c3)c2s1,"[4-(1H-Indol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-phenyl-methanone",0.009,uM,=,-2.0457574905606752,0,O=C(c1ccccc1)c1cc2ncnc(Nc3ccc4[nH]ccc4c3)c2s1
2230,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),O=C(O)/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,3-[4-(3-Bromo-phenylamino)-quinazolin-6-ylcarbamoyl]-acrylic acid,0.00037,uM,=,-3.431798275933005,0,c1ccc(Nc2ncnc3ccccc23)cc1
2231,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid methyl ester,2.0,uM,=,0.3010299956639812,1,O=S(=O)(Oc1ccccc1)c1ccccc1
2232,1330697,10.1039/C2MD20017A,,,,Inhibition of EGF-induced EGFR-mediated ERK phosphorylation in human A431 cells after 1 hr by immunoblotting method,CCC(=O)Nc1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1,N-(3-(6-(3-bromophenylamino)pyrimidin-4-ylamino)phenyl)propionamide,1.158,uM,=,0.0637085593914173,1,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
2233,1353177,10.1021/ml4003309,,,,Inhibition of recombinant EGFR (unknown origin) using poly-GT peptide as substrate by Transcreener assay,COc1cc2c(Oc3ccc(NS(=O)(=O)c4cccc(-c5ccoc5)c4)cc3F)ccnc2cc1OCCCN1CCOCC1,N-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-3-(3-furyl)benzenesulfonamide,3.86,uM,=,0.5865873046717549,1,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1)c1cccc(-c2ccoc2)c1
2234,1741055,10.1016/j.ejmech.2018.06.024,,,,Inhibition of EGFR in human MCF7 cell lysates after 24 to 48 hrs by ELISA,O=C(CN1CCCC1)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)cc3)c2c1,N-(4-((4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)-2-(pyrrolidin-1-yl)acetamide,0.071,uM,=,-1.1487416512809248,0,O=C(CN1CCCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
2235,67066,10.1016/s0960-894x(02)00577-2,,,,Inhibition of Epidermal growth factor receptor,COc1cc(Nc2c(C#N)cnc3cc(-c4ccc(CN5CCOCC5)cc4)ccc23)c(Cl)cc1Cl,"4-(2,4-Dichloro-5-methoxy-phenylamino)-7-(4-morpholin-4-ylmethyl-phenyl)-quinoline-3-carbonitrile",3.0,uM,=,0.4771212547196624,1,c1ccc(Nc2ccnc3cc(-c4ccc(CN5CCOCC5)cc4)ccc23)cc1
2236,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1cnc(N2C[C@H](O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((8-((2R,3S)-3-hydroxy-2-methylazetidin-1-yl)-5-isopropyl-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",5.29,uM,=,0.7234556720351858,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
2237,1337213,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ccc2nc(Oc3ccccc3)c(/C=N/NC(=O)Cn3c([N+](=O)[O-])cnc3C)cc2c1,(E)-N'-((6-methyl-2-phenoxyquinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,1.58,uM,=,0.1986570869544226,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
2238,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)CC(=O)OC,methyl 2-((2-((2-acrylamido-5-methoxy-4-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)(methyl)amino)acetate,0.04636,uM,=,-1.3338565727084415,0,c1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1
2239,1738745,10.1016/j.ejmech.2018.04.052,,,,"Inhibition of recombinant human GST-tagged wild type EGFR expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(Nc2nccc(Nc3ccccc3-c3ccn(C)n3)n2)c(OC)cc1OCCN(C)C,N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-((2-(1-methyl-1H-pyrazol-3-yl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.3168,uM,=,-0.499214827082544,0,c1ccc(Nc2nccc(Nc3ccccc3-c3cc[nH]n3)n2)cc1
2240,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(Nc3ccccc3)ncnc2s1,"6-(2-Methoxyphenyl)-N-phenylthieno[2,3-d]pyrimidin-4-amine",0.173,uM,=,-0.7619538968712046,0,c1ccc(Nc2ncnc3sc(-c4ccccc4)cc23)cc1
2241,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21,"1-isopropyl-3-(quinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.61,uM,=,-0.2146701649892329,0,c1cnc2ccc(-c3n[nH]c4ncncc34)cc2c1
2242,2293062,10.1021/acs.jmedchem.6b00995,,,,Inhibition of EGFR autophosphorylation in human NCI-H292 cells harboring harboring wild type EGFR preincubated for 60 mins followed by EGF stimulation and measured after 8 mins by SULFO-TAG based electrochemiluminescent assay,CC(C)n1nc(N2CC(CO)C2)c2cnc(Nc3ccnc(-c4cnn(S(=O)(=O)C5CC5)c4)n3)cc21,"(1-(6-((2-(1-(Cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-yl)amino)-1-isopropyl-1H-pyrazolo[4,3-c]pyridin-3-yl)azetidin-3-yl)methanol",0.096,uM,=,-1.0177287669604316,0,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3cc4[nH]nc(N5CCC5)c4cn3)n2)cn1
2243,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC[C@@H](O)CN1CCOCC1,1-[4-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-3-morpholin-4-yl-propan-2-ol,0.095,uM,=,-1.0222763947111522,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2244,2296337,10.1039/d3md00038a,,,,Inhibition of EGFR (unknown origin),Cc1c(C(=O)NCCc2ccc(N3CCCC3C)cc2)[nH]c2ccc(Cl)cc12,5-chloro-3-methyl-N-(4-(2-methylpyrrolidin-1-yl)phenethyl)-1H-indole-2-carboxamide,0.093,uM,=,-1.031517051446065,0,O=C(NCCc1ccc(N2CCCC2)cc1)c1cc2ccccc2[nH]1
2245,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(Oc4ccccc4)cc3)ncnc2cn1,"(2E)-4-(Dimethylamino)-N-[4-(4-phenoxybenzyl)pyrido[3,4-d]-pyrimidin-6-yl]-2-butenamide",0.201,uM,=,-0.6968039425795112,0,c1ccc(Oc2ccc(Nc3ncnc4cnccc34)cc2)cc1
2246,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,Cc1nc(Nc2ccc(F)c(Cl)c2)c2cc(C)oc2n1,"N-(3-Chloro-4-fluorophenyl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine",0.0301999999999999,uM,=,-1.5199930570428497,0,c1ccc(Nc2ncnc3occc23)cc1
2247,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,O=C(C#CCN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-4-(4-morpholinyl)-2-butynamide",0.014,uM,=,-1.853871964321762,0,O=C(C#CCN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
2248,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4OC)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(2-methoxy-benzyloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.031,uM,=,-1.5086383061657274,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
2249,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(NC(=O)/C=C/CN(C)C)cc23)c1,(E)-4-(Dimethylamino)-N-(4-(3-ethynylphenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)but-2-enamide,0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3ccccc23)cc1
2250,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,Cc1ccc(Nc2ncnc3cc(OC(C)C)c4c(c23)OCCO4)cc1[N+](=O)[O-],"5-Isopropoxy-N-(4-methyl-3-nitrophenyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.1845,uM,=,-0.7340036295049208,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
2251,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccc(F)cc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(4-fluoro-benzyloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.064,uM,=,-1.193820026016113,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
2252,63607,10.1016/0960-894X(96)00197-7,,,,Inhibition of tyrosine kinase Epidermal growth factor receptor,Cc1ccc(N(C(=O)c2ccccc2)C(=O)c2ccccc2)cc1Nc1nccc(-c2cccnc2)n1,N-Benzoyl-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide,75.0,uM,=,1.8750612633917,1,O=C(c1ccccc1)N(C(=O)c1ccccc1)c1cccc(Nc2nccc(-c3cccnc3)n2)c1
2253,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(NO)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2,N-dihydroxy-benzamide",0.4,uM,=,-0.3979400086720376,0,c1ccc(CNc2ccccc2)cc1
2254,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1ccc2c(c1)OCO2,"2-Benzo[1,3]dioxol-5-ylmethylene-malononitrile",350.0,uM,=,2.544068044350276,1,c1ccc2c(c1)OCO2
2255,1642156,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",0.21,uM,=,-0.6777807052660807,0,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
2256,2220271,10.1016/j.bmcl.2022.128529,,,,Inhibition of EGFR (unknown origin),CCOC(=O)[C@H](Cc1c[nH]c2ccccc12)NCC(=O)NNC(=O)COc1ccc(-c2nc3ccccc3s2)cc1OC,"ethyl (2S)-2-[(2-{2-[4-(1,3-benzothiazol-2-yl)-2-methoxyphenoxy]acetohydrazido}-2-oxoethyl)amino]-3-(1H-indol-3-yl)propanoate",0.114,uM,=,-0.9430951486635274,0,O=C(CNCCc1c[nH]c2ccccc12)NNC(=O)COc1ccc(-c2nc3ccccc3s2)cc1
2257,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCN(CC)[C@@](C)(C#Cc1ncnc2cc(OC)c(OC)cc12)Cc1ccncc1,"(R)-4-(6,7-dimethoxyquinazolin-4-yl)-N,N-diethyl-2-methyl-1-(pyridin-4-yl)but-3-yn-2-amine",0.2,uM,=,-0.6989700043360187,0,C(#Cc1ncnc2ccccc12)CCc1ccncc1
2258,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CN(C)c1cc2ncnc(Nc3cccc(Br)c3)c2cc1N,"N*4*-(3-Bromo-phenyl)-N*7*,N*7*-dimethyl-quinazoline-4,6,7-triamine",0.159,uM,=,-0.7986028756795485,0,c1ccc(Nc2ncnc3ccccc23)cc1
2259,1695880,10.1016/j.bmcl.2017.08.035,,,,Inhibition of wild type recombinant EGFR (unknown origin) by ELISA,COc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,"4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-methoxy-7-(3-((2R,3R,4R,5S)-2-hydroxymethyl-3,4,5-trihydroxy-1-piperidyl)propoxy)quinazoline",0.00453,uM,=,-2.343901797987168,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCCCN5CCCCC5)ccc34)cc2)cc1
2260,2284955,10.1016/j.ejmech.2019.112016,,,,Inhibition of EGFR (unknown origin),O=C(Nn1c(-c2ccc(Br)cc2)cs/c1=N\c1ccc([N+](=O)[O-])cc1)c1ccc(Cl)cc1,N-(4-(4-bromophenyl)-2-((4-nitrophenyl)imino)thiazol-3(2H)-yl)-4-chlorobenzamide,8.28,uM,=,0.91803033678488,1,O=C(Nn1c(-c2ccccc2)cs/c1=N\c1ccccc1)c1ccccc1
2261,1806458,10.1016/j.ejmech.2019.06.005,,,,Inhibition of EGFR (unknown origin),Cc1nc2c(F)cc(-c3nc(Nc4ccc5c(n4)CCN(CCN(C)C)C5)ncc3F)cc2n1C(C)C,"6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine",1.97,uM,=,0.2944662261615929,1,c1cc(-c2ccc3nc[nH]c3c2)nc(Nc2ccc3c(n2)CCNC3)n1
2262,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,Cc1cc(Nc2ncnc3cc(O)c(NC(=O)/C=C/[C@H]4CCCN4C)cc23)ccc1Oc1cnn2cnnc2c1,"(E)-N-[7-hydroxy-4-[3-methyl-4-([1,2,4]triazolo[4,3-b]pyridazin-7-yloxy)anilino]quinazolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide",0.01182,uM,=,-1.927382523454764,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4cnn5cnnc5c4)cc3)c2c1
2263,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(-c3nc(C)no3)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.049,uM,=,-1.3098039199714864,0,c1ccc(Nc2ncc(-c3ncno3)c(-c3cn4c5c(cccc35)CCC4)n2)cc1
2264,558980,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by scintillation proximity assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCCC1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl pyrrolidine-1-carboxylate",0.099,uM,=,-1.00436480540245,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3s2)C1)N1CCCC1
2265,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,COc1ccc(CNc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"N*4*-(3-Chloro-phenyl)-N*3*-(4-methoxy-benzyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.007,uM,=,-2.154901959985743,0,c1ccc(CNc2[nH]nc3ncnc(Nc4ccccc4)c23)cc1
2266,2088168,10.1016/j.ejmech.2020.112363,,,,Inhibition of EGFR (unknown origin) by FRET assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.046,uM,=,-1.337242168318426,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
2267,1641517,,,,,"In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@H]1CCCN(C(=O)/C=C/CN2CCOCC2)C1,"US9181263, 24::US9278100, 24",0.3837,uM,=,-0.4160082008016836,0,O=C(/C=C/CN1CCOCC1)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3cncnc32)C1
2268,2147415,10.1021/acs.jmedchem.1c01055,,,,Inhibition of Wild type EGFR (unknown origin),COc1cc(N2CCOCC2)c(-c2cn[nH]c2)cc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,(2-((5-Chloro-2-((2-methoxy-4-morpholino-5-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide,0.0056,uM,=,-2.2518119729938,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCOCC4)c(-c4cn[nH]c4)c3)n2)cc1
2269,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COc1cc(/C=C/[N+](=O)[O-])ccc1O,2-Methoxy-4-(2-nitro-vinyl)-phenol,8.0,uM,=,0.9030899869919436,1,c1ccccc1
2270,2119947,10.1021/acsmedchemlett.1c00156,,,,Inhibition of EGFR (unknown origin),Oc1cc(Nc2ccnc3cc(-c4ccccc4)ccc23)ccc1Cl,2-chloro-5-(7-phenylquinolin-4-ylamino)phenol,0.1,uM,=,-1.0,0,c1ccc(Nc2ccnc3cc(-c4ccccc4)ccc23)cc1
2271,2291456,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR autophosphorylation at Tyr1068 residue in EGFR-amplified human A-431 cells preincubated with compound for 1 hrs followed by stimulation with human recombinant EGF and measured after 10 mins by HTRF-based analysis,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"US9447106, 27",0.37,uM,=,-0.431798275933005,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(C3CCNCC3)CCN4)cc2)cc1
2272,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,C#Cc1cccc(Nc2ncnc3cc(OC(C)COC)c4c(c23)OCCO4)c1,"N-(3-Ethynylphenyl)-5-((tetrahydrofuran-3-yl)oxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.4736,uM,=,-0.3245883062851366,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
2273,1527997,,,,,"ELISA-Based Kinase Assay: Inhibition of erbB tyrosine kinase activity was assessed using an ELISA-based receptor tyrosine kinase assay. Kinase reactions (50 mM HEPES, pH 7.4, 125 mM NaCl, 10 mM MgCl2, 100 Î¼M sodium orthovanadate, 2 mM dithiothreitol, 20 uM ATP, test compound or vehicle control and 1-5 nM GST-erbB per 50 uL reaction) were run in 96-well plates coated with 0.25 mg/ml poly-Glu-Tyr (Sigma). The reactions were incubated for 6 minutes at room temperature while shaking. Kinase reactions were stopped by removal of reaction mixture, then wells were washed with wash buffer comprising 3% Bovine Serum Albumin and 0.1% Tween 20 in Phosphate Buffered Saline (PBS). Phosphorylated tyrosine residues were detected by adding 0.2 Î¼g/ml anti-phosphotyrosine antibody (Oncogene Ab-4; 50 Î¼L/well) coupled to Horse Radish Peroxidase (HRP) for 25 minutes while shaking at room temperature.",O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCF,"US8623883, No. 1",0.00644,uM,=,-2.191114132640188,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2274,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1cccc(-c2c[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn23)c1,"US9447106, 50",0.208,uM,=,-0.6819366650372385,0,c1ccc(Oc2ccc(-c3cc4[nH]cc(-c5ccccc5)n4n3)cc2)cc1
2275,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CNc1cc2ncnc(Nc3cccc(C)c3)c2cn1,"N*7*-Methyl-N*4*-m-tolyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0014,uM,=,-2.853871964321762,0,c1ccc(Nc2ncnc3ccncc23)cc1
2276,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(CCl)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"2-chloro-N-(4-((3-chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)acetamide",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3sccc23)cc1
2277,850915,10.1021/jm300403a,,,,Inhibition of EGFR,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3C)c2)cnc1N,3-Amino-6-(4-chloro-3-(N-(3-fluoro-2-methylphenyl)-sulfamoyl)phenyl)-N-methylpyrazine-2-carboxamide,0.41,uM,=,-0.3872161432802645,0,O=S(=O)(Nc1ccccc1)c1cccc(-c2cnccn2)c1
2278,2052738,10.1016/j.ejmech.2019.111966,,,,Inhibition of wild type N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus infected Sf21 cells using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km concentration and further incubated for 20 mins by HTRF assay,C=CC(=O)Nc1cccc(Nc2cc(-n3c(CCCO)nnc3-c3ccc(F)cc3)ccn2)c1,"N-(3-((4-(3-(4-Fluorophenyl)-5-(3-hydroxypropyl)-4H-1,2,4-triazol-4-yl)pyridin-2-yl)amino)phenyl)acrylamide",0.1958,uM,=,-0.708187312532881,0,c1ccc(Nc2cc(-n3cnnc3-c3ccccc3)ccn2)cc1
2279,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,Cn1c(SSc2c(C(=O)Nc3ccccc3)c3cc([N+](=O)[O-])ccc3n2C)c(C(=O)Nc2ccccc2)c2cc([N+](=O)[O-])ccc21,"2,2'-Dithiobis(1-methyl-5-nitro-N-phenyl-1H-indole-3-carboxamide)",5.0,uM,=,0.6989700043360189,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
2280,1566936,10.1021/acs.jmedchem.5b01633,,,,Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA,C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](C(F)(F)F)C1,"1-((3R,4R)-3-(((5-Chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)-4-(trifluoromethyl)pyrrolidin-1-yl)prop-2-en-1-one",3.5,uM,=,0.5440680443502757,1,c1cc2c(OC[C@@H]3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1
2281,64442,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor (EGFR) in A431 cells,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Br)c3)c2n1,"N-[4-(3-Bromo-4-fluoro-phenylamino)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.018,uM,=,-1.744727494896694,0,c1ccc(Nc2ncnc3cccnc23)cc1
2282,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CN1CCC2(CC1)OCCO2)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)but-2-enamide",0.002,uM,=,-2.6989700043360187,0,O=C(/C=C/CN1CCC2(CC1)OCCO2)Nc1cc2c(Nc3ccccc3)ncnc2s1
2283,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,c1ccc(OCc2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-(phenoxymethyl)-1,3,4-oxadiazole",46.3,uM,=,1.665580991017953,1,c1ccc(OCc2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
2284,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCN(C)c1ccncc1,(4-Chloro-2-fluoro-phenyl)-{6-methoxy-7-[2-(methyl-pyridin-4-yl-amino)-ethoxy]-quinazolin-4-yl}-amine,0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3cc(OCCNc4ccncc4)ccc23)cc1
2285,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CNC(=S)N(C)[C@H]1C[C@@H]2O[C@](C)([C@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"3-methoxy-2-methyl-4-methyl[methylamino(thioxo)methyl]amino-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-16-one",12.5,uM,=,1.0969100130080565,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
2286,2145645,10.1016/j.bmcl.2021.128406,,,,Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence of ATP by IMAP-FP assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2287,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,CN(C)C/C=C/C(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccccc4)nc32)c1,(E)-4-(Dimethylamino)-N-(3-(7-oxo-2-(phenylamino)-pteridin-8(7H)-yl)phenyl)but-2-enamide,0.115,uM,=,-0.9393021596463884,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
2288,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Fc1ccc2c(c1)CNc1c(Nc3ccccc3)ncnc1O2,"(8-Fluoro-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-phenyl-amine",7.0,uM,=,0.8450980400142568,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
2289,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CC(C)N(C)C(C)C5)cc4OC)nc32)cc(C(F)(F)F)c1,"N-(3-(2-((2-Methoxy-4-(3,4,5-trimethylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)-5-(trifluoromethyl)phenyl)acrylamide",0.097,uM,=,-1.0132282657337552,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
2290,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc([N+](=O)[O-])cc2)n1,5-Chloro-N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)-4-(4-nitrophenoxy)pyrimidin-2-amine,12.03,uM,=,1.0802656273398448,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2291,850422,10.1016/j.bmc.2012.08.002,,,,Inhibition of human N-terminal DYKDDDD tagged EGFR cytoplasmic domain amino acid 669 to 1210 expressed in baculovirus after 5 mins by scintillation counter,CC(C)(C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(Cl)c4)c(Cl)c3)c21)S(C)(=O)=O,"N-[2-(4-{[3-Chloro-4-(3-chlorophenoxy)phenyl]amino}-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl]-2-methyl-2-(methylsulfonyl)propanamide",0.011,uM,=,-1.958607314841775,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
2292,66570,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor in A431 cells,C=CC(=O)Nc1ccc2c(Nc3cccc(C)c3)ncnc2c1,N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide,0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
2293,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(OC4CCN(C)CC4)c(NC(=O)/C=C/CN(C)C)cc23)c1,(E)-4-(Dimethylamino)-N-(4-(3-ethynylphenylamino)-7-(1-methylpiperidin-4-yloxy)quinazolin-6-yl)but-2-enamide,0.0081,uM,=,-2.0915149811213505,0,c1ccc(Nc2ncnc3cc(OC4CCNCC4)ccc23)cc1
2294,1986369,10.1016/j.bmc.2020.115373,,,,Inhibition of human EGFR-TK using PTK substrate after 40 mins in presence of ATP by Kinase-Glo luminescent assay,CCN1CCN(CCCNc2ccc(Oc3nc4ccccc4c4nncn34)cc2)CC1,"4-[([1,2,4]Triazolo[4,3-c]quinazolin-5-yl)oxy]-N-[3-(4-ethylpiperazinyl)propyl]aniline",9.51,uM,=,0.978180516937414,1,c1ccc2c(c1)nc(Oc1ccc(NCCCN3CCNCC3)cc1)n1cnnc21
2295,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCN(C(=O)/C=C/CN2CCOCC2)C1,"US9181263, 5::US9278100, 5",0.326,uM,=,-0.4867823999320609,0,O=C(/C=C/CN1CCOCC1)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3cncnc32)C1
2296,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,CCOc1cc2ncnc(Nc3ccc(Oc4cc5nncn5cn4)c(C)c3)c2cc1NC(=O)/C(F)=C\[C@@H]1CCCN1C,"(E)-N-[7-ethoxy-4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-2-fluoro-3-[(2S)-1-methylpyrrolidin-2-yl]prop-2-enamide",0.02592,uM,=,-1.5863650028014442,0,O=C(/C=C\[C@@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4cc5nncn5cn4)cc3)c2c1
2297,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2nccc(-c3c4n(c5ccccc35)CCOC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-10-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.288,uM,=,-0.5406075122407692,0,c1ccc(Nc2nccc(-c3c4n(c5ccccc35)CCOC4)n2)cc1
2298,2215119,10.1016/j.ejmech.2022.114255,,,,Inhibition of EGFR (unknown origin) using poly (glu-tyr) as substrate incubated for 1 hr in presence of ATP measured by ADP-Glo kinase assay,COc1cc(/C=C/S(=O)(=O)c2ccccc2)cc(OC)c1OC,"1,2,3-trimethoxy-5-(2-(phenylsulfonyl)vinyl)benzene",0.00785,uM,=,-2.105130343254748,0,O=S(=O)(/C=C/c1ccccc1)c1ccccc1
2299,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1OC,"3-(3,4-dimethoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",3.02,uM,=,0.4800069429571506,1,c1ccc(-c2n[nH]c3ncncc23)cc1
2300,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,Cc1cccc(Nc2ncnc3cnc(N(C)C)cc23)c1,"N*6*,N*6*-Dimethyl-N*4*-m-tolyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0028,uM,=,-2.552841968657781,0,c1ccc(Nc2ncnc3cnccc23)cc1
2301,5167,10.1021/jm010888h,,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,C[C@H](Nc1[nH]cnc2c3ccccc3nc1-2)c1ccccc1,"(1-Phenyl-ethyl)-(9H-2,4,9-triaza-fluoren-1-yl)-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(CNc2[nH]cnc3c4ccccc4nc2-3)cc1
2302,676221,10.1021/jm100607r,,,,Inhibition of EGFR,C[C@@H](Nc1ncnc2sc3c(c12)CCN(C(=O)/C=C/CN(C)C)C3)c1ccccc1,"(E)-4-(Dimethylamino)-1-(4-[(1R)-1-phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-buten-1-one",0.012,uM,=,-1.9208187539523751,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1
2303,506208,10.1021/np50089a001,,,,Inhibition of EGFR,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2)c1O,2-Cyano-3-(4-hydroxy-3-methoxy-5-phenylsulfanylmethyl-phenyl)-acrylamide,0.5,uM,=,-0.3010299956639812,0,c1ccc(CSc2ccccc2)cc1
2304,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,CC(=O)N1N=C(c2ccc(C)c(C)c2)CC1c1ccc(C)cc1,"1-(3-(3,4-Dimethylphenyl)-5-p-tolyl-4,5-dihydro-1Hpyrazol-1-yl)ethanone",17.49,uM,=,1.2427898094786765,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
2305,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cncnc2)c2c(N)ncnc21,"1-isopropyl-3-(pyrimidin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",100.0,uM,=,2.0,1,c1ncc(-c2n[nH]c3ncncc23)cn1
2306,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C(=O)c1ccc(Br)cc1,N-(2-((2-acrylamido-5-methoxy-4-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)-4-bromo-N-methylbenzamide,0.3005,uM,=,-0.5221555236612417,0,O=C(NCCNc1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1)c1ccccc1
2307,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,Nc1ccccc1NC(=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)s1,N-(2-aminophenyl)-5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)thiophene-2-carboxamide,0.0028,uM,=,-2.552841968657781,0,O=C(Nc1ccccc1)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)s1
2308,807915,10.1016/j.bmc.2012.01.029,,,,Inhibition of EGFR,Nc1nc(Nc2cccc(Br)c2)c2cc(Cc3ccc(Cl)cc3Cl)[nH]c2n1,"N4-(3-bromophenyl)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",0.23,uM,=,-0.6382721639824072,0,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
2309,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,COCCOc1cc2ncnc(Nc3ccc(F)c(C#N)c3)c2c2c1OCCO2,"2-Fluoro-5-((5-(2-methoxyethoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-yl)amino)benzonitrile",0.3878,uM,=,-0.4113921952573134,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
2310,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,CCCCN(Cc1cccc(C)c1O)C(=S)Nc1ccccc1,1-Butyl-1-(2-hydroxy-5-methylbenzyl)-3-phenylthiourea,43.21,uM,=,1.63558426631123,1,S=C(NCc1ccccc1)Nc1ccccc1
2311,2017353,10.1021/acs.jmedchem.0c00870,,,,Inhibition of human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using TK as substrate preincubated for 30 mins followed by substrate addition and measured after 25 mins by HTRF assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,1e-05,uM,=,-5.0,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
2312,946709,10.1016/j.bmc.2012.12.045,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,CC(C)(C)C(=O)Nc1nc(Nc2ccc(F)c(C(F)(F)F)c2)c2cc(CCc3ccccn3)[nH]c2n1,"N-{4-[(3-Trifluoromethyl,4-fluorophenyl)amino]-6-(2-pyridin-2-yl-ethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl}-2,2-dimethylpropanamide",26.9,uM,=,1.429752280002408,1,c1ccc(Nc2ncnc3[nH]c(CCc4ccccn4)cc23)cc1
2313,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Clc1cccc(Nc2[nH]cnc3nnc(NCc4ccccc4)c2-3)c1,"N*3*-Benzyl-N*4*-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.007,uM,=,-2.154901959985743,0,c1ccc(CNc2nnc3nc[nH]c(Nc4ccccc4)c2-3)cc1
2314,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COc1cc(/C=C/[N+](=O)[O-])ccc1OS(=O)(=O)c1ccc(C(=O)O)cc1,4-[2-Methoxy-4-(2-nitro-vinyl)-phenoxysulfonyl]-benzoic acid,3.0,uM,=,0.4771212547196624,1,O=S(=O)(Oc1ccccc1)c1ccccc1
2315,1908071,10.1016/j.bmcl.2019.126711,,,,"Inhibition of EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 1 hr in presence of ATP by spectrophotometric analysis",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methylamide,0.0435,uM,=,-1.3615107430453628,0,O=C(Nc1ccccc1)Nc1ccc(Oc2ccncc2)cc1
2316,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(F)c4ccccc34)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(4-fluoronaphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.07,uM,=,-1.154901959985743,0,c1ccc2c(-c3nn([C@@H]4CCCNC4)c4ncncc34)cccc2c1
2317,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C(F)(F)F)c4)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",3.4,uM,=,0.5314789170422551,1,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
2318,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CN1CCC(F)(F)C1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(3,3-difluoropyrrolidin-1-yl)but-2-enamide",0.028,uM,=,-1.5528419686577808,0,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
2319,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,NCCCOCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((3-aminopropoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.064,uM,=,-1.193820026016113,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
2320,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCCC1,(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(pyrrolidin-1-yl)but-2-enamide,0.007,uM,=,-2.154901959985743,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
2321,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.095,uM,=,-1.0222763947111522,0,c1ccc(Nc2nccc(-c3cnn4ccccc34)n2)cc1
2322,1628134,10.1016/j.bmc.2016.10.006,,,,"Inhibition of recombinant human GST-fused EGFR (668 to 1211 residues) assessed as phosphotyrosine formation using poly(Glu:Tyr, 4:1) as substrate and ATP measured after 6 mins",COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,2-methoxy-N-(3-(4-(3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino)quinazolin-6-yl)allyl)acetamide,6.4,uM,=,0.8061799739838872,1,c1cncc(Oc2ccc(Nc3ncnc4ccccc34)cc2)c1
2323,1657589,10.1016/j.bmcl.2017.02.027,,,,"Inhibition of wild type recombinant EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",OCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,(5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-yl)methanol,0.0050599999999999,uM,=,-2.2958494831602008,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
2324,1906489,10.1016/j.ejmech.2019.111648,,,,"Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay",Fc1ccc(-c2csc(N3N=C(c4ccc(N5CCOCC5)cc4)CC3c3ccc(Cl)cc3)n2)cc1,1-(4-(4-Fluorophenyl)thiazol-2-yl)-3-(4-morpholinophenyl)-5-(4-chlorophenyl)-2-pyrazoline,23.34,uM,=,1.3681008517093514,1,c1ccc(-c2csc(N3N=C(c4ccc(N5CCOCC5)cc4)CC3c3ccccc3)n2)cc1
2325,1524114,10.1016/j.bmc.2015.10.035,,,,Inhibition of human EGFR after 1 hr using [gamma-32P]ATP,COc1cc2ncnc(Nc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c2cc1OC,"1-(3-bromophenyl)-3-(4-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)urea",7.71,uM,=,0.887054378050957,1,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3ccccc23)cc1
2326,1291542,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGFR (unknown origin) after 10 mins,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCC(C)CC2)CCO4)c1,"1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(4-methylpiperidin-1-yl)but-2-en-1-one",0.005,uM,=,-2.3010299956639813,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
2327,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,CCNC(=O)Nc1ccc(C(=O)Nc2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cc1,N-(4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)-4-(3-ethylureido)benzamide,0.031,uM,=,-1.5086383061657274,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccccc1
2328,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1ccc(F)cc1)NS(=O)(=O)c1ccc(Cl)cc1,N-(4-Chlorophenylsulfonyl)-2-(4-fluorophenyl)acetamide,5.93,uM,=,0.7730546933642626,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
2329,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.077,uM,=,-1.1135092748275182,0,c1ccc(Nc2ncnc3ccccc23)cc1
2330,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cnc(NC2CC2)nc1,2-(Cyclopropylamino)-N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)-phenyl)pyrimidine-5-carboxamide,0.044,uM,=,-1.3565473235138126,0,O=C(Nc1cccc(C(=O)Nc2ccc(CN3CCNCC3)cc2)c1)c1cnc(NC2CC2)nc1
2331,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,CCC/C=C\C(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccc(F)cc34)n2)c(OC)cc1N(C)CCN(C)C,(Z)-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(5-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)hex-2-enamide,0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2332,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)ccc1C,"N-(5-(2-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)-2-methylphenyl)acrylamide",0.0368999999999999,uM,=,-1.4329736338409398,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
2333,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,Clc1cccc(Nc2ncnc3nc(Nc4ccccc4)sc23)c1,"N7-(3-chlorophenyl)-N2-phenylthiazolo[4,5-d]pyrimidine-2,7-diamine",0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1
2334,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(NS(=O)(=O)c1ccc(F)cc1)c1cncc(Br)c1,5-bromo-N-(4-fluorophenylsulfonyl)nicotinamide,3.27,uM,=,0.5145477526602861,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
2335,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",Clc1ncc2ncnc(Nc3cccc(Br)c3)c2n1,"(3-Bromo-phenyl)-(6-chloro-pyrimido[5,4-d]pyrimidin-4-yl)-amine",0.082,uM,=,-1.0861861476162833,0,c1ccc(Nc2ncnc3cncnc23)cc1
2336,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3ccc(Cl)cc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(4-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.383,uM,=,-0.4168012260313772,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
2337,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1nc(C)nc(Nc3ccc4c(c3)CN=N4)c1NC2,"(7,8-dimethoxy-3-methyl-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(3H-indazol-5-yl)-amine",16.2,uM,=,1.209515014542631,1,c1ccc2c(c1)CNc1c(Nc3ccc4c(c3)CN=N4)ncnc1S2
2338,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1OC,"3-(4-ethoxy-3-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",5.95,uM,=,0.7745169657285496,1,c1ccc(-c2n[nH]c3ncncc23)cc1
2339,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCC(O)CN,1-Amino-3-[4-(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-propan-2-ol,0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccccc23)cc1
2340,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,NC(=O)Nc1ccc(C(=O)Nc2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cc1,N-(4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)-4-ureidobenzamide,0.009,uM,=,-2.0457574905606752,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccccc1
2341,63778,10.1021/jm0004291,,,,Inhibition of epidermal growth factor receptor,CCNC(=O)Nc1nc2nc(NCCCCN(CC)CC)ncc2cc1-c1c(Cl)cccc1Cl,"1-[6-(2,6-Dichloro-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-ethyl-urea",1.3,uM,=,0.1139433523068367,1,c1ccc(-c2cnc3ncncc3c2)cc1
2342,67206,10.1021/jm010496a,,,,Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase,CCOc1cc2ncnc(Nc3cccc(-c4ccco4)c3)c2cc1OCC,"(6,7-Diethoxy-quinazolin-4-yl)-(3-furan-2-yl-phenyl)-amine",0.003,uM,=,-2.5228787452803374,0,c1cc(Nc2ncnc3ccccc23)cc(-c2ccco2)c1
2343,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc4[nH]ccc4c3)ncnc2cc1OC,N-[4-(1H-Indol-5-ylamino)-7-methoxy-6-quinazolinyl]-propanamide,0.006,uM,=,-2.2218487496163566,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1
2344,2153740,10.1021/acsmedchemlett.1c00555,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,COc1cc(Nc2ncc(Cl)c(Nc3ccccc3P(C)(C)=O)n2)ccc1N1CCC(N2CCN(C)CC2)CC1,(2-((5-Chloro-2-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide,0.0512,uM,=,-1.2907300390241692,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
2345,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,COc1cccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"N*4*-(3-Chloro-phenyl)-N*3*-(3-methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.8,uM,=,-0.0969100130080563,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
2346,67050,10.1021/jm0201520,,,,Inhibition of Epidermal growth factor receptor (Her1/ErbB1),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,"2-(2-Chloro-phenyl)-5,7-dihydroxy-8-((3R,4S)-3-hydroxy-1-methyl-piperidin-4-yl)-chromen-4-one",7.6,uM,=,0.8808135922807914,1,O=c1cc(-c2ccccc2)oc2c(C3CCNCC3)cccc12
2347,1799769,10.1016/j.ejmech.2018.06.011,,,,"Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay",O=C(NCCN1CCOCC1)Nc1ccc(-c2cc3c(Nc4ccc(Oc5cccc(C(F)(F)F)c5)c(Cl)c4)ncnc3s2)cc1,"1-(4-(4-(3-chloro-4-(3-(trifluoromethyl)phenoxy)phenylamino)thieno[2,3-d]pyrimidin-6-yl)phenyl)-3-(2-morpholinoethyl)urea",0.0917,uM,=,-1.0376306643299789,0,O=C(NCCN1CCOCC1)Nc1ccc(-c2cc3c(Nc4ccc(Oc5ccccc5)cc4)ncnc3s2)cc1
2348,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,COc1cc2ncnc(Nc3ccc(F)cc3)c2cc1OC.Cl,"4-(4'-fluoroanilino)-6,7-dimethoxyquinazoline hydrochloride",0.612,uM,=,-0.2132485778544388,0,c1ccc(Nc2ncnc3ccccc23)cc1
2349,1472644,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) using Poly(Glu:Tyr) 4:1 as substrate after 12 to 16 hrs,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.38,uM,=,-0.4202164033831898,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2350,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)cc(CC)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(5-ethyl-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.114,uM,=,-0.9430951486635274,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
2351,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(c4)c(F)cn5Cc4ccccc4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(1-benzyl-3-fluoro-1H-indol-5-ylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.24,uM,=,-0.619788758288394,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1
2352,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,COc1cc2ncnc(NCCc3ccccc3)c2cc1OCCCCCCC(=O)NO,N-hydroxy-7-(7-methoxy-4-(phenethylamino)quinazolin-6-yloxy)heptanamide,0.1,uM,=,-1.0,0,c1ccc(CCNc2ncnc3ccccc23)cc1
2353,2229998,10.1021/acs.jmedchem.1c00876,,,,Inhibition of wild type EGFR (unknown origin),COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1,N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide,0.43,uM,=,-0.3665315444204134,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
2354,1983835,10.1016/j.bmc.2019.115281,,,,Inhibition of wild type EGFR (unknown origin),C=C1CC(CI)(c2ccccc2)OC1=O,rac-5-(iodomethyl)-3-methylene-5-phenyldihydrofuran-2(3H)-one,47.0,uM,=,1.6720978579357175,1,C=C1CC(c2ccccc2)OC1=O
2355,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CCl,2-chloro-N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)acetamide,0.007,uM,=,-2.154901959985743,0,c1ccc(Nc2ncnc3ccccc23)cc1
2356,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C#CCOc1cc2c(Nc3cccc(Cl)c3)ncnc2cc1OC,4-(3'-Chloroanilino)-7-methoxy-6-(prop-2-ynyloxy)quinazoline,0.0259,uM,=,-1.586700235918748,0,c1ccc(Nc2ncnc3ccccc23)cc1
2357,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,Cc1cc(Nc2ccnc(Nc3cccc(-c4nc5ccccc5s4)c3)n2)n[nH]1,"N2-(3-(benzo[d]thiazol-2-yl)phenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine",1.9,uM,=,0.2787536009528289,1,c1cc(Nc2nccc(Nc3cc[nH]n3)n2)cc(-c2nc3ccccc3s2)c1
2358,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.2603999999999999,uM,=,-0.5843590201038458,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2359,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,CN(C)CCCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-(3-dimethylamino-propyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3cnccc23)cc1
2360,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCCc2ccccc2)[nH]c2ccccc12)NCCc1ccccc1,N-Phenethyl-3-{2-[3-(2-phenethylcarbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-propionamide,24.0,uM,=,1.380211241711606,1,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCCc2ccccc2)[nH]c2ccccc12)NCCc1ccccc1
2361,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCCCC(=O)O)c1O,4-[5-(2-Carbamoyl-2-cyano-vinyl)-2-hydroxy-3-methoxy-benzylsulfanyl]-butyric acid,6.5,uM,=,0.8129133566428556,1,c1ccccc1
2362,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,COc1nc(Nc2ccc(-c3nc4ccccc4s3)c(OC)c2)c2cc[nH]c2n1,N-(4-(benzo[d]thiazol-2-yl)-3-methoxyphenyl)-2-methoxy-9H-purin-6-amine,5.1,uM,=,0.7075701760979364,1,c1ccc2sc(-c3ccc(Nc4ncnc5[nH]ccc45)cc3)nc2c1
2363,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc([N+](=O)[O-])c(C(=O)Nc2ccc(OCc3ccccn3)c(Cl)c2)cc1NC(=O)/C=C/CN(C)C,N-(3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)-5-(4-(dimethylamino)but-2-enamido)-4-ethoxy-2-nitrobenzamide,0.85,uM,=,-0.0705810742857072,0,O=C(Nc1ccc(OCc2ccccn2)cc1)c1ccccc1
2364,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccccc4)cc3)ncnc2cc1OCCCN1CCN(C)CC1,1-(4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)phenyl)-3-phenylurea,0.194,uM,=,-0.712198270069774,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
2365,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,O=[N+]([O-])c1ccc2c(Nc3ccccc3)ncnc2c1,(7-Nitro-quinazolin-4-yl)-phenyl-amine,12.0,uM,=,1.0791812460476249,1,c1ccc(Nc2ncnc3ccccc23)cc1
2366,457884,10.1016/j.bmcl.2007.08.073,,,,Inhibition of EGFR,C[C@@H](COc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12)N(C)C(=O)CO,(S)-N-(1-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)propan-2-yl)-2-hydroxy-N-methylacetamide,2.58,uM,=,0.4116197059632301,1,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
2367,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCCN(C(=O)/C=C/c2c[nH]cn2)C1,"US9181263, 4::US9278100, 4",0.4876,uM,=,-0.3119363030536556,0,O=C(/C=C/c1c[nH]cn1)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3cncnc32)C1
2368,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,O=C(Nc1ccc(Br)cc1)c1ccc(N(CCCl)CCCl)cc1,4-(Bis(2-chloroethyl)amino)-N-(4-bromophenyl)benzamide,0.94,uM,=,-0.0268721464003013,0,O=C(Nc1ccccc1)c1ccccc1
2369,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#CC(C#N)=C(C#N)c1ccc(C=O)cc1,"2-(4-formylphenyl)ethene-1,1,2-tricarbonitrile",600.0,uM,=,2.778151250383644,1,c1ccccc1
2370,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3cccc(Br)c3)C2=O)cc(OC)c1,"(2E,6E)-2-(3-Bromobenzylidene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",6.8,uM,=,0.8325089127062363,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
2371,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,COCCOc1cc2ncnc(Nc3cccc(OC)c3)c2c2c1OCCO2,"5-(2-Methoxyethoxy)-N-(3-methoxyphenyl)-2,3-dihydro[1,4]dioxino[2,3-f]quinazolin-10-amine",0.1599,uM,=,-0.7961515362537652,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
2372,1476964,10.1016/j.bmc.2015.04.038,,,,Inhibition of wild type N-terminal His6-tagged human EGFR kinase domain (702 to 1016 residues) expressed in Sf9 cells pre-incubated for 30 mins before ATP and substrate addition by homogeneous time-resolved FRET assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.016,uM,=,-1.7958800173440752,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2373,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4cccc(Br)c4)c3cc2N1CCCN1CCOCC1,"4-((3-bromophenyl)amino)-6-(3-morpholinopropyl)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.0896,uM,=,-1.0476919903378747,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
2374,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/C(C)N(C)C,(E)-4-Dimethylamino-pent-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,5.22,uM,=,0.7176705030022621,1,c1ccc(Nc2ccnc3ccccc23)cc1
2375,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,CN(C)CCC(=O)N(C)c1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromophenylamino)quinazolin-6-yl)-3-(dimethylamino)-N-methylpropanamide,0.0174,uM,=,-1.7594507517174005,0,c1ccc(Nc2ncnc3ccccc23)cc1
2376,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),CCO.CNc1ccc2sc3c(Nc4cccc(Br)c4)ncnc3c2c1,"N*4*-(3-Bromo-phenyl)-N*8*-methyl-benzo[4,5]thieno[3,2-d]pyrimidine-4,8-diamine; compound with ethanol",0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
2377,66899,10.1016/s0960-894x(99)00188-2,,,,In vitro activity against Epidermal growth factor receptor (using poly(Glu4Tyr1) as a substrate),O=C1NC(=O)c2c1c1c3cccc(O)c3[nH]c1c1[nH]c3c(O)cccc3c21,"1,11-dihydroxy-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione",29.0,uM,=,1.462397997898956,1,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21
2378,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,CNc1cc2c(Nc3cccc(C(F)(F)F)c3)ncnc2cn1,"N*6*-Methyl-N*4*-(3-trifluoromethyl-phenyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2ncnc3cnccc23)cc1
2379,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.00647,uM,=,-2.1890957193312994,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2380,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1S(=O)(=O)CCCCCCC(=O)NO,7-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ylsulfonyl)-N-hydroxyheptanamide,0.0154,uM,=,-1.812479279163537,0,c1ccc(Nc2ncnc3ccccc23)cc1
2381,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,Cl.O=C(CCN1CCCCC1)c1ccc(OCc2ccccc2)cc1,1-(4-Benzyloxy-phenyl)-3-piperidin-1-yl-propan-1-one hydrochloride,1.8,uM,=,0.255272505103306,1,O=C(CCN1CCCCC1)c1ccc(OCc2ccccc2)cc1
2382,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",CCN(CC)CCCNC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(3-(diethylamino)propyl)urea,0.032,uM,=,-1.494850021680094,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
2383,1348544,10.1016/j.bmcl.2014.03.072,,,,Inhibition of autophosphorylation of recombinant his-tagged EGFR (amino acid 645-1186) (unknown origin) expressed in Sf-9 cells after 10 mins by time-resolved fluorometry,Cc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc4ccccc4c3)C2)cc1C,"2-(3-(3,4-dimethylphenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",0.12,uM,=,-0.9208187539523752,0,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccc3ccccc3c2)=N1
2384,1675840,10.1016/j.bmc.2017.03.032,,,,"Inhibition of recombinant wild type human EGFR (695 to end residues) using Poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,0.4602,uM,=,-0.3370533856673754,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2385,1657589,10.1016/j.bmcl.2017.02.027,,,,"Inhibition of wild type recombinant EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)o1,4-(3-chloro-4-fluorophenylamino)-6-(5-((2-(methylsulfonyl)ethyl)aminomethyl)furan-2-yl)quinazoline,0.0239899999999999,uM,=,-1.6199697520321694,0,c1ccc(Nc2ncnc3ccc(-c4ccco4)cc23)cc1
2386,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COc1cc(C(C#N)=C(C#N)C#N)cc(O)c1O,"2-(3,4-dihydroxy-5-methoxyphenyl)ethene-1,1,2-tricarbonitrile",6.0,uM,=,0.7781512503836436,1,c1ccccc1
2387,63616,10.1016/S0960-894X(97)00034-6,,,,Inhibition of Epidermal growth factor receptor autophosphorylation.,COc1cc2ncnc(Nc3cccc(F)c3)c2cc1OC.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-fluoro-phenyl)-amine hydrochloride",0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
2388,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCCCCCCCCCCCCNC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,N-Icosyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetamide,1.35,uM,=,0.1303337684950061,1,O=c1cc(-c2ccccc2)oc2ccccc12
2389,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,Cn1c(SSc2c(C(=O)Nc3ccccc3)c3ccccc3n2C)c(C(=O)Nc2ccccc2)c2ccccc21,"2,2'-Dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide)",10.0,uM,=,1.0,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
2390,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,Cc1ccc(S(=O)(=O)O)cc1.Fc1cccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CN6CCNCC6)o5)cc34)cc2Cl)c1,N-(3-Chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-(piperazin-1-ylmethyl)furan-2-yl)quinazolin-4-amine tosylate,0.0108,uM,=,-1.9665762445130504,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CN6CCNCC6)o5)cc34)cc2)cc1.c1ccccc1
2391,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4nccn4C)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,2-{2-Chloro-4-[3-cyano-6-(4-dimethylamino-but-2-enoylamino)-7-ethoxy-quinolin-4-ylamino]-phenoxymethyl}-1-methyl-3H-imidazol-1-ium,0.5,uM,=,-0.3010299956639812,0,c1ccc2c(Nc3ccc(OCc4ncc[nH]4)cc3)ccnc2c1
2392,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CC(COC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O)CC(C)(C)C,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 2,4,4-trimethyl-pentyl ester",0.8,uM,=,-0.0969100130080563,0,c1ccc(CNc2ccccc2)cc1
2393,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCCOCC4)cc3OC)ncc2Cl)c1,"US8975249, I-37",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCCOCC4)cc3)n2)cc1
2394,63769,10.1016/S0960-894X(97)00014-0,,,,Displacement of [gamma-32P]-ATP from Epidermal growth factor receptor in A431 cell-free extracts,O=S(=O)(O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzenesulfonic acid",10.3,uM,=,1.0128372247051722,1,c1ccc(CNc2ccccc2)cc1
2395,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,Cc1cccc(C)c1NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-(2,6-dimethyl-phenyl)-acrylamide",10.3,uM,=,1.0128372247051722,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
2396,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C(Nc1ccccc1)N(Cc1ccc(F)cc1)Cc1cc(Br)cc(Br)c1O,"1-(3,5-Dibromo-2-hydroxybenzyl)-1-(4-fluorobenzyl)-3-phenylurea",4.68,uM,=,0.670245853074124,1,O=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
2397,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3ccccc23)cc1
2398,850422,10.1016/j.bmc.2012.08.002,,,,Inhibition of human N-terminal DYKDDDD tagged EGFR cytoplasmic domain amino acid 669 to 1210 expressed in baculovirus after 5 mins by scintillation counter,CS(=O)(=O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,"N-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-2-(methylsulfonyl)acetamide",0.015,uM,=,-1.8239087409443189,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
2399,2052738,10.1016/j.ejmech.2019.111966,,,,Inhibition of wild type N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus infected Sf21 cells using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km concentration and further incubated for 20 mins by HTRF assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0141999999999999,uM,=,-1.8477116556169435,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2400,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),CCNc1cc2sc3c(Nc4cccc(Br)c4)ncnc3c2cc1F.CCO,"N*4*-(3-Bromo-phenyl)-N*7*-ethyl-8-fluoro-benzo[4,5]thieno[3,2-d]pyrimidine-4,7-diamine; compound with ethanol",0.0079,uM,=,-2.1023729087095586,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
2401,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4cc(OC)c(C5CC5)c(OC)c4)nn32)CC1,"(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-cyclopropyl-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",0.45,uM,=,-0.3467874862246563,0,c1cc(C2CC2)ccc1-c1cc2n(n1)[C@H](C1CCNCC1)CCN2
2402,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3cccc(C(N)=O)c3)cc12)c1ccccc1,"(R)-3-(4-((1-Phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzamide",0.005,uM,=,-2.3010299956639813,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
2403,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CC2(C1)CS(=O)(=O)C2,"(3-Chloro-4-fluoro-phenyl)-{6-[2-(2,2-dioxo-2lambda*6*-thia-6-aza-spiro[3.3]hept-6-yl)-ethoxy]-7-methoxy-quinazolin-4-yl}-amine",0.158,uM,=,-0.8013429130455774,0,O=S1(=O)CC2(CN(CCOc3ccc4ncnc(Nc5ccccc5)c4c3)C2)C1
2404,63615,10.1021/jm980123i,,,,Concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Epidermal growth factor receptor (EGF RTK).,CCc1ccc(/C=C2\C(=O)Nc3ccccc32)s1,"3-[1-(5-Ethyl-thiophen-2-yl)-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one",44.0,uM,=,1.6434526764861874,1,O=C1Nc2ccccc2/C1=C/c1cccs1
2405,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Oc3cccc([N+](=O)[O-])c3)n2)n[nH]1,N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-(3-nitrophenoxy)pyrimidin-4-amine,3.9,uM,=,0.5910646070264992,1,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1
2406,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(/N=N/c3ccc(F)c(Cl)c3)c2cc1OC,"(3-Chloro-4-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-diazene",0.73,uM,=,-0.1366771398795441,0,c1ccc(/N=N/c2ncnc3ccccc23)cc1
2407,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C(Nc1ccccc1)N(Cc1ccc(F)cc1)Cc1cc(Cl)cc(Cl)c1O,"1-(3,5-Dichloro-2-hydroxybenzyl)-1-(4-fluorobenzyl)-3-phenylurea",4.15,uM,=,0.6180480967120927,1,O=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
2408,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccc(F)cc1)c1ccccc1,(Z)-2-((E)-3-(4-fluorophenyl)-1-phenylallylidene)hydrazinecarbothioamide,19.12,uM,=,1.2814878879400813,1,N=C(/C=C/c1ccccc1)c1ccccc1
2409,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1ccc(-c2n[nH]c3ncnc(N)c23)cc1OC,"3-(4-ethoxy-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",100.0,uM,=,2.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
2410,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC1CCN(CC(N)=O)CC1,2-(4-(4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)acetamide,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
2411,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,CNC(=O)c1c(SSc2[nH]c3ccccc3c2C(=O)NC)[nH]c2ccccc12,3N-methyl-2-(3-methylcarbamoyl-1H-2-indolyldisulfanyl)-1H-3-indolecarboxamide,6.1,uM,=,0.785329835010767,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
2412,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(-n2c(=O)c(C)nc3cnc(Nc4ccc(OC)cc4)nc32)c1,N-(3-(2-(4-Methoxyphenylamino)-6-methyl-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.00529,uM,=,-2.2765443279648143,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
2413,1642199,,,,,Inhibition Assay: Inhibition of various kinase enzyme.,CC(C)c1ccc(Nc2nc(N)nc3c2-c2ccccc2C3)cc1,"N4-(4-Isopropylphenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine",42.6,uM,=,1.6294095991027189,1,c1ccc(Nc2ncnc3c2-c2ccccc2C3)cc1
2414,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,Cc1cccc(Nc2ncnc3cnc(NCCCN4CCOCC4)cc23)c1,"N*6*-(3-Morpholin-4-yl-propyl)-N*4*-m-tolyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0018,uM,=,-2.744727494896694,0,c1ccc(Nc2ncnc3cnc(NCCCN4CCOCC4)cc23)cc1
2415,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc4c(ccn4CC(C)C)c3)ncnc2cc1OC,N-{4-[(1-Isobutyl-1H-indol-5-yl)amino]-7-methoxy-6-quinazolinyl}propanamide,0.421,uM,=,-0.3757179041643317,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1
2416,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,c1cc(Nc2ccc3[nH]ccc3c2)c2sc(-c3ccc(CNCCN4CCNCC4)cc3)cc2n1,"(1H-Indol-5-yl)-(2-{4-[(2-pyridin-1-yl-ethylamino)-methyl]-phenyl}-thieno[3,2-b]pyridin-7-yl)-amine",0.003,uM,=,-2.5228787452803374,0,c1cc(Nc2ccc3[nH]ccc3c2)c2sc(-c3ccc(CNCCN4CCNCC4)cc3)cc2n1
2417,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,COC(=O)CC1C(S)=Nc2ccccc21,"(2-Thioxo-2,3-dihydro-1H-indol-3-yl)-acetic acid methyl ester",100.0,uM,=,2.0,1,C1=Nc2ccccc2C1
2418,66897,10.1021/jm970367n,,,,Inhibition of Epidermal growth factor receptor (EGFr) tyrosine kinase,CCN(CC)CCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(NC(=O)NC(C)(C)C)nc2n1,"1-tert-Butyl-3-[6-(2,6-dichloro-phenyl)-2-(3-diethylamino-propylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea",6.2,uM,=,0.7923916894982539,1,c1ccc(-c2cnc3ncncc3c2)cc1
2419,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-1-(1-Acetylpyrrolidin-3-yl)-3-(2-chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0121,uM,=,-1.91721462968355,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
2420,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CN1CC(O)C1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(3-hydroxyazetidin-1-yl)but-2-enamide",0.038,uM,=,-1.42021640338319,0,O=C(/C=C/CN1CCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
2421,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1,"5-[4-(1-Methyl-cyclohexylmethoxy)-benzyl]-thiazolidine-2,4-dione (ciglitazone)",4.655,uM,=,0.6679196853173615,1,O=C1NC(=O)C(Cc2ccc(OCC3CCCCC3)cc2)S1
2422,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CCN(C(C)C)CC1,4-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-1-isopropylpiperidine-4-carboxamide,0.095,uM,=,-1.0222763947111522,0,c1ccc(Nc2ncnc3ccc(CNC4CCNCC4)cc23)cc1
2423,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@@H]1CCOC1,(E)-N-(7-((R)-tetrahydrofuran-3-yloxy)-4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,3.7,uM,=,0.568201724066995,1,c1ccc(Nc2ncnc3cc(O[C@@H]4CCOC4)ccc23)cc1
2424,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,O=C(/C=C/CN1CC[S+]([O-])CC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(E)-4-(1-Oxo-1lambda(4)-thiomorpholin-4-yl)-but-2-enoicacid{4-(3-chloro-4-fluoro-phenylamino)-7-[(S)-(tetrahydro-furan-3-yl)oxy]-quinazolin-6-yl}-amide,0.1094,uM,=,-0.960982678002588,0,O=C(/C=C/CN1CC[SH+]CC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
2425,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Fc1cccc(COc2ccc(Nc3cc(-c4cccnc4)ncn3)cc2Cl)c1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(pyridin-3-yl)pyrimidin-4-amine,47.0,uM,=,1.6720978579357175,1,c1ccc(COc2ccc(Nc3cc(-c4cccnc4)ncn3)cc2)cc1
2426,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,0.0027,uM,=,-2.5686362358410126,0,c1ccc(Nc2ncnc3ccccc23)cc1
2427,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,COc1cccc(CNc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"N*4*-(3-Chloro-phenyl)-N*3*-(3-methoxy-benzyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.008,uM,=,-2.096910013008056,0,c1ccc(CNc2[nH]nc3ncnc(Nc4ccccc4)c23)cc1
2428,1720134,10.1016/j.ejmech.2017.09.061,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus virus expression system after 1 hr by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.17,uM,=,-0.7695510786217261,0,c1ccc(Nc2ncnc3ccccc23)cc1
2429,840627,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR-mediated intracellular tyrosine phosphorylation in EGF-stimulated human A431 cells after 2.5 hrs by SDS-PAGE analysis,Clc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,"N-(3-chlorophenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododeca[2,3-g]quinazolin-4-amine",0.055,uM,=,-1.259637310505756,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)cc1
2430,803850,10.1021/jm201387s,,,,Inhibition of EGFR,Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCCCC2)n1,4-(1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyrimidin-2-amine,0.15,uM,=,-0.8239087409443188,0,c1ccc(-c2ncn(C3CCCCC3)c2-c2ccncn2)cc1
2431,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,COCC(=O)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1,"N-[4-(4,5-Dichloro-2-fluoro-phenylamino)-quinazolin-6-yl]-2-methoxy-acetamide",0.252,uM,=,-0.5985994592184559,0,c1ccc(Nc2ncnc3ccccc23)cc1
2432,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1cccc(Br)c1)NS(=O)(=O)c1ccc(Br)cc1,2-(3-Bromophenyl)-N-(4-bromophenylsulfonyl)acetamide,24.33,uM,=,1.3861421089308186,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
2433,2198131,10.1016/j.ejmech.2022.114661,,,,Inhibition of recombinant human EGFR incubated for 40 to 45 mins and measured after 15 mins by Kinase-Glo Max assay,COc1ccc(-c2c(CN3CCOCC3)nc3scc(C(=O)NN)n23)cc1,"5-(4-Methoxyphenyl)-6-(morpholinomethyl)imidazo[2,1-b]thiazole-3-carbohydrazide",0.122,uM,=,-0.9136401693252518,0,c1ccc(-c2c(CN3CCOCC3)nc3sccn23)cc1
2434,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C3CNC3)c3ncnc(N)c23)cc1O,"5-(4-amino-1-(azetidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol",17.0,uM,=,1.230448921378274,1,c1ccc(-c2nn(C3CNC3)c3ncncc23)cc1
2435,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,Clc1ccc(-c2nnc(Cc3nc4ccc(Cl)cc4[nH]3)o2)cc1,"2-((6-chloro-1H-benzo[d]imidazol-2-yl)methyl)-5-(4-chlorophenyl)-1,3,4-oxadiazole",0.98,uM,=,-0.0087739243075051,0,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
2436,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,O=C(Nc1nccs1)Nc1cc(-c2cccnc2)ccc1OC(F)(F)F,1-(5-(Pyridin-3-yl)-2-(trifluoromethoxy)phenyl)-3-(thiazol-2-yl)urea,0.12109,uM,=,-0.9168917208052652,0,O=C(Nc1cccc(-c2cccnc2)c1)Nc1nccs1
2437,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC)cc3)nn21,"US9447106, 94",0.0004799999999999,uM,=,-3.318758762624413,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1
2438,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccc(Cl)cc3)C2=O)cc(OC)c1,"(2E,6E)-2-(4-Chlorobenzylidene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",15.3,uM,=,1.1846914308175989,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
2439,1642199,,,,,Inhibition Assay: Inhibition of various kinase enzyme.,Nc1nc2c(c(Nc3cccc(Cl)c3)n1)-c1ccccc1C2,"N4-(3-Chlorophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine",19.6,uM,=,1.292256071356476,1,c1ccc(Nc2ncnc3c2-c2ccccc2C3)cc1
2440,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccccc2NC(=O)CCO)n1,N-(2-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-3-hydroxypropanamide,2.15,uM,=,0.3324384599156053,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2441,1638920,,,,,Inhibition of EGFR phosphorylation at Tyr1068 in human MDA-MB-468 cells,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1,7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.0176,uM,=,-1.75448733218585,0,c1ccc(Nc2ncnc3ccccc23)cc1
2442,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Oc1cccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"3-[4-(3-Chloro-phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-ylamino]-phenol",0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
2443,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NC1CCCCC1,"2-Cyano-N-cyclohexyl-3-(3,4-dihydroxy-phenyl)-acrylamide",5.9,uM,=,0.7708520116421442,1,O=C(C=Cc1ccccc1)NC1CCCCC1
2444,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OC,N-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}-7-methoxy-6-quinazolinyl)propanamide,0.067,uM,=,-1.1739251972991736,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
2445,2080995,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R/T790M (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(CCCC(=O)NO)nn1,"4-(4-(((6-Acrylamido-4-((3-chloro-4-fluorophenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutanamide",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
2446,1781376,10.1016/j.ejmech.2017.11.034,,,,"Inhibition of EGFR (unknown origin) using poly(Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",O=C(Nc1ccc(Oc2ccnc3[nH]ccc23)c(F)c1)c1cc2cccnc2n(-c2ccc(F)cc2)c1=O,"N-(4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-3-fluorophenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide",0.6327999999999999,uM,=,-0.1987335295103799,0,O=C(Nc1ccc(Oc2ccnc3[nH]ccc23)cc1)c1cc2cccnc2n(-c2ccccc2)c1=O
2447,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Nc3ccccc3)c2c1C,"(5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-phenyl-amine",1.9,uM,=,0.2787536009528289,1,c1ccc(Nc2ncnc3[nH]ccc23)cc1
2448,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccccc1)c1ccc(Cl)cc1,(Z)-2-((E)-1-(4-chlorophenyl)-3-phenylallylidene)hydrazinecarbothioamide,0.59,uM,=,-0.2291479883578558,0,N=C(/C=C/c1ccccc1)c1ccccc1
2449,2213959,10.1016/j.ejmech.2021.113963,,,,Inhibition of EGFR (unknown origin) by ADP-Glo kinase assay,COc1ccc(CCOc2ccc(C(=O)/C=C/c3ccc(O)c(O)c3)cc2OC)cc1OC,"(E)-3-(3,4-dihydroxyphenyl)-1-[4-[2-(3,4-dimethoxyphenyl)ethoxy]-3-methoxy-phenyl]prop-2-en-1-one",11.12,uM,=,1.0461047872460387,1,O=C(/C=C/c1ccccc1)c1ccc(OCCc2ccccc2)cc1
2450,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,Clc1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-(4-chlorophenyl)-1,3,4-oxadiazole",0.081,uM,=,-1.0915149811213505,0,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
2451,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",CCCCN1C(=O)CS/C1=N/Nc1nncc2ccccc12,3-Butyl-2-(2-(phthalazin-1-yl)hydrazono)thiazolidin-4-one,0.023,uM,=,-1.6382721639824072,0,O=C1CS/C(=N/Nc2nncc3ccccc23)N1
2452,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1cnc(N2CCC2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-1-(4-((8-(azetidin-1-yl)-5-isopropyl-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-fluoro-3-methylpiperidin-4-ol",10.0,uM,=,1.0,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
2453,2069689,10.1016/j.bmc.2021.116039,,,,Inhibition of recombinant wild type EGFR (696 to C terminal end) (unknown origin) using poly (Glu-Tyr) as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by ELISA,COc1ccc(-c2c3c4cc(OC)c(OCCCN(C)C)cc4[nH]c(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O.O=C(O)C(F)(F)F,"3-[3-(dimethylamino)propoxy]-11-hydroxy-14-(3-hydroxy-4-methoxyphenyl)-2,12-dimethoxybenzo[7,8]indolizino[3,2-c]quinolin-6(5H)-one 2,2,2-trifluoroacetate",0.0155,uM,=,-1.8096683018297088,0,O=c1[nH]c2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
2454,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,CC1CCN(C/C=C/C(=O)N2CCOc3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4cc32)CC1,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7,8-dihydropyrimido[5,4-g][1,4]benzoxazin-6-yl]-4-(4-methyl-1-piperidyl)but-2-en-1-one",0.569,uM,=,-0.2448877336049288,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
2455,1906489,10.1016/j.ejmech.2019.111648,,,,"Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay",C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
2456,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=P(O)(O)C(O)c1ccc2ccccc2c1,(Hydroxy-naphthalen-2-yl-methyl)-phosphonic acid,200.0,uM,=,2.3010299956639813,1,c1ccc2ccccc2c1
2457,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,C/C=C\C(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,(Z)-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)but-2-enamide,0.395,uM,=,-0.4034029043735397,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2458,2227151,10.1016/j.ejmech.2022.114492,,,,Inhibition of wild type EGFR (unknown origin) by mobility shift assay,COc1cc(N(C)CCN(C)C)c(NC(=O)c2ncccn2)cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)pyrimidine-2-carboxamide,0.146,uM,=,-0.835647144215563,0,O=C(Nc1cccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c1)c1ncccn1
2459,2238034,10.1021/acs.jmedchem.0c02167,,,,Inhibition of EGFR (unknown origin),COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.0005,uM,=,-3.3010299956639813,0,c1ccc(/N=c2\nc[nH]c3cc(OCC4CCNCC4)ccc23)cc1
2460,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CC(C)N(CC#CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1)C(C)C,N-[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]-4-(bis-(1-methylethyl)amino)-2-butynamide,0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccccc23)cc1
2461,63761,10.1021/jm9906116,,,,Evaluated for inhibitory activity towards tyrosine kinase Epidermal growth factor receptor,COc1cccc(-c2ccc3c(c2)NC(=O)/C3=C\c2[nH]c3c(c2CCC(=O)O)CCCC3)c1,"3-{2-[6-(3-Methoxy-phenyl)-2-oxo-1,2-dihydro-indol-3-ylidenemethyl]-4,5,6,7-tetrahydro-1H-indol-3-yl}-propionic acid",8.88,uM,=,0.9484129657786012,1,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1cc2c([nH]1)CCCC2
2462,63620,10.1021/jm970366v,,,,Inhibition of epidermal growth factor receptor (EGFR) autophosphorylation in A431 cells,Brc1cccc(Nc2ncnc3cc(NCCN4CCOCC4)ncc23)c1,"N*4*-(3-Bromo-phenyl)-N*7*-(2-morpholin-4-yl-ethyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.036,uM,=,-1.4436974992327127,0,c1ccc(Nc2ncnc3cc(NCCN4CCOCC4)ncc23)cc1
2463,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(N2C(=O)C(Cc3ccc(F)cc3)N(C)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(7-(4-fluorobenzyl)-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6-methyl-5,8-dioxo-7,8-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-9(6H)-yl)phenyl)acrylamide",0.00578,uM,=,-2.238072161579471,0,O=C1NC(Cc2ccccc2)C(=O)N(c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc21
2464,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,COc1ccc(-c2cc(NC(=O)Nc3ccccn3)cc(OC)c2OC)cn1,"1-(3,4-Dimethoxy-5-(6-methoxypyridin-3-yl)phenyl)-3-(pyridin-2-yl)urea",0.06659,uM,=,-1.1765909851074554,0,O=C(Nc1cccc(-c2cccnc2)c1)Nc1ccccn1
2465,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Nc1[nH]cnc2nnc(Nc3cccc(Cl)c3)c1-2,"N*3*-(3-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",35.0,uM,=,1.5440680443502757,1,c1ccc(Nc2nnc3nc[nH]cc2-3)cc1
2466,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1.Cl.Cl,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, hydrochloride (CI-1033)",0.0017,uM,=,-2.7695510786217263,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
2467,2227151,10.1016/j.ejmech.2022.114492,,,,Inhibition of wild type EGFR (unknown origin) by mobility shift assay,COc1cc(N(C)CCN(C)C)c(NC(=O)c2ccnc(Cl)c2)cc1Nc1nccc(-c2cn(CCCO)c3ccccc23)n1,2-Chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-(3-hydroxypropyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)isonicotinamide,0.743,uM,=,-0.1290111862394247,0,O=C(Nc1cccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c1)c1ccncc1
2468,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,Brc1cccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-[2-(3H-imidazol-4-yl)-ethyl]-pyrido[3,4-d]pyrimidine-4,6-diamine",0.00078,uM,=,-3.10790539730952,0,c1ccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)cc23)cc1
2469,1914927,10.1016/j.ejmech.2019.111943,,,,Inhibition of N-terminal GST-tagged human EGFR (d746-750AA) expressed in baculovirus using FAM-labelled peptide as substrate pre-incubated for 10 mins followed by substrate addition by mobility shift assay,COc1ccc(OC)c(Nc2cc(NC(=O)Nc3c(Cl)cccc3Cl)ncn2)c1,"1-(2,6-dichlorophenyl)-3-(6-((2,5-dimethoxyphenyl)amino)pyrimidin-4-yl)urea",0.073,uM,=,-1.136677139879544,0,O=C(Nc1ccccc1)Nc1cc(Nc2ccccc2)ncn1
2470,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,Brc1ccc2c(c1)CNc1c(NCc3ccccc3)ncnc1O2,"Benzyl-(8-bromo-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",30.0,uM,=,1.4771212547196624,1,c1ccc(CNc2ncnc3c2NCc2ccccc2O3)cc1
2471,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",2.5e-05,uM,=,-4.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
2472,1618202,10.1021/acs.jmedchem.5b01985,,,,Inhibition of wild type EGFR phosphorylation in human HaCaT cells incubated for 3 hrs by ELISA method,Cc1cc(C(=O)Nc2nc3cccc(Cl)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1,NAZARTINIB,0.1606,uM,=,-0.7942544590573379,0,O=C(Nc1nc2ccccc2n1[C@@H]1CCCCNC1)c1ccncc1
2473,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCN(C)CC4)cc3OC)n2)c1,N-(3-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.017,uM,=,-1.769551078621726,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1
2474,1524114,10.1016/j.bmc.2015.10.035,,,,Inhibition of human EGFR after 1 hr using [gamma-32P]ATP,Fc1ccc(Nc2ncnc3ccccc23)cc1Cl,N-(3-chloro-4-fluorophenyl)quinazolin-4-amine,0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccccc23)cc1
2475,471543,10.1016/j.bmc.2007.10.068,,,,Inhibition of EGFR,COc1cc(Nc2nn3c(N[C@H](CO)Cc4ccccc4)cc(C4CC4)nc3c2C(N)=O)cc(OC)c1,"7-((S)-1-benzyl-2-hydroxyethylamino)-5-cyclopropyl-2-(3,5-dimethoxyphenylaminopyrazolo[1,5-a]pyrimidine-3-carboxamide",2.4,uM,=,0.380211241711606,1,c1ccc(CCNc2cc(C3CC3)nc3cc(Nc4ccccc4)nn23)cc1
2476,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,CC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)acetamide,0.00396,uM,=,-2.402304814074488,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
2477,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,CCN(CC)CCNC(=O)c1cc(C)c(/C=C2\C(=O)Nc3ncnc(Nc4ccc(F)c(Cl)c4)c32)[nH]1,"5-[4-(3-Chloro-4-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)-amide",0.0012,uM,=,-2.920818753952376,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
2478,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,NC(Cc1c(SSc2[nH]c3ccccc3c2CC(N)C(=O)NCc2ccccc2)[nH]c2ccccc12)C(=O)NCc1ccccc1,2-Amino-3-{2-[3-(2-amino-2-benzylcarbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-N-benzyl-propionamide,3.3,uM,=,0.5185139398778875,1,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
2479,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc(C)cc2)c1O,2-Cyano-3-(4-hydroxy-3-methoxy-5-p-tolylsulfanylmethyl-phenyl)-acrylamide,8.7,uM,=,0.9395192526186184,1,c1ccc(CSc2ccccc2)cc1
2480,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Oc1cccc(O)c1O,"Benzene-1,2,3-triol",1.23,uM,=,0.0899051114393979,1,c1ccccc1
2481,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,Cc1c[nH]c2ccc(Nc3ncnc4cc(-c5ccccc5)sc34)cc12,"(3-Methyl-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
2482,465,10.1016/s0960-894x(02)00364-5,,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,CCN1CCN(C(=O)c2cc(C)c(/C=C3\C(=O)Nc4ncnc(Nc5ccc(F)c(Cl)c5)c43)[nH]2)CC1,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[5-(4-ethyl-piperazine-1-carbonyl)-3-methyl-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",7.5,uM,=,0.8750612633917001,1,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCNCC2)[nH]1
2483,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(=O)Nc3ccccc3)c3cc(Cl)ccc3n2C)c(C(=O)Nc2ccccc2)c2cc(Cl)ccc21,"2,2'-Dithiobis(1-methyl-5-chloro-N-phenyl-1H-indole-3-carboxamide)",4.3,uM,=,0.6334684555795865,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
2484,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccc(-c2n[nH]c3ncnc(N)c23)cc1O,"5-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methylphenol",12.4,uM,=,1.0934216851622351,1,c1ccc(-c2n[nH]c3ncncc23)cc1
2485,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccc(Cl)cc1,"5-(4-Chlorophenyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",7.32,uM,=,0.8645110810583919,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
2486,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,Cl.NCCc1cn(Cc2ccc(-c3ccccc3)cc2)c2ccc(OCCc3ccc(O)cc3)cc12,2-[5-(4-Hydroxyphenethoxy)-1-(4-phenyl)benzyl-1Hindole-3-yl]ethanamine hydrochloride,1.3,uM,=,0.1139433523068367,1,c1ccc(CCOc2ccc3c(ccn3Cc3ccc(-c4ccccc4)cc3)c2)cc1
2487,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)CCOC,4-[(2-Methoxy-ethyl)-methyl-amino]-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.068,uM,=,-1.1674910872937636,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
2488,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(C#N)c2)c2c(N)ncnc21,"3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzonitrile",100.0,uM,=,2.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
2489,1338035,10.1016/j.ejmech.2014.02.032,,,,Inhibition of EGFR (unknown origin) after 1.5 hr by FRET-based Z-lyte assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)CCN3CCN(C)CC3)c2)n1,N-(3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)-3-(4-methylpiperazin-1-yl)propanamide,7.442,uM,=,0.8716896656855153,1,O=C(CCN1CCNCC1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
2490,2052738,10.1016/j.ejmech.2019.111966,,,,Inhibition of wild type N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus infected Sf21 cells using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km concentration and further incubated for 20 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2cc(-n3c(SC)nnc3-c3ccc(F)cc3)ccn2)ccc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-(3-(4-fluorophenyl)-5-(methylthio)-4H-1,2,4-triazol-4-yl)pyridin-2-yl)amino)phenyl)acrylamide",0.1564,uM,=,-0.8057632512761708,0,c1ccc(Nc2cc(-n3cnnc3-c3ccccc3)ccn2)cc1
2491,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,Cc1ccc(Nc2ncnc3cc(OC(C)C)c4c(c23)OCCO4)cc1C#N,"5-((5-Isopropoxy-2,3-dihydro-[1,4]dioxino[2,3-f]-quinazolin-10-yl)amino)-2-methylbenzonitrile",0.4161,uM,=,-0.3808022842070526,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
2492,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1cc(O)c(O)c(Br)c1)C(=O)NCCCNC(=O)/C(C#N)=C/c1cc(O)c(O)c(Br)c1,"(E)-3-(3-Bromo-4,5-dihydroxy-phenyl)-N-{3-[(E)-3-(3-bromo-4,5-dihydroxy-phenyl)-2-cyano-acryloylamino]-propyl}-2-cyano-acrylamide",3.9,uM,=,0.5910646070264992,1,O=C(C=Cc1ccccc1)NCCCNC(=O)/C=C/c1ccccc1
2493,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=C(O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)c(O)c1,3-Hydroxy-4-[4-(2-nitro-vinyl)-phenoxysulfonyl]-benzoic acid,0.3,uM,=,-0.5228787452803375,0,O=S(=O)(Oc1ccccc1)c1ccccc1
2494,553933,10.1021/np070447m,,,,Inhibition of recombinant EGFR,O=C1C[C@H](O)[C@@H]2c3c(ccc(O)c31)-c1ccc(O)c3c1[C@@]2(O)CCC3=O,altertoxin I,0.0099405078150278,uM,=,-2.002591428919476,0,O=C1CCC2c3c1cccc3-c1cccc3c1[C@H]2CCC3=O
2495,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COc1cc2ncc(C#N)c(Nc3cccc(Br)c3)c2cc1OC,"4-(3-Bromo-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile",0.19,uM,=,-0.721246399047171,0,c1ccc(Nc2ccnc3ccccc23)cc1
2496,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(C)c(=O)c3cnc(Nc4ccc(N5CCSCC5)cc4OC)nc32)c1,"N-(3-(7-((2-Methoxy-4-thiomorpholinophenyl)amino)-3-methyl-2,4-dioxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)-acrylamide",0.314,uM,=,-0.5030703519267851,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCSCC4)cc3)ncc12
2497,2090102,10.1016/j.ejmech.2020.112445,,,,Inhibition of human EGFR L858R using poly[Glu:Tyr] (4:1) as substrate measured after 40 mins in presence of [gamma-33P]ATP by radiometric assay,O=C1Nc2ccccc2N/C1=C\C(=O)c1cccc2ccccc12,"(Z)-3-(2-(Naphthalen-1-yl)-2-oxoethylidene)-3,4-dihydroquinoxalin-2(1H)-one",4.5,uM,=,0.6532125137753437,1,O=C1Nc2ccccc2N/C1=C\C(=O)c1cccc2ccccc12
2498,942125,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin) using biotinylated-PTP1B (Tyr66) as substrate incubated for 5 mins prior to substrate addition measured after 1 hr by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCNCCN,"N1-(3-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)propyl)ethane-1,2-diamine",0.0136,uM,=,-1.8664610916297824,0,c1ccc(Nc2ncnc3ccccc23)cc1
2499,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,O=C(O)Cn1ccc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"[4-(3-Bromo-phenylamino)-pyrrolo[3,2-g]quinazolin-8-yl]-acetic acid",1.78,uM,=,0.250420002308894,1,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
2500,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Cc1c(C)n(-c2ccccc2)c2ncnc(N)c12,"5,6-Dimethyl-7-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",2.71,uM,=,0.4329692908744057,1,c1ccc(-n2ccc3cncnc32)cc1
2501,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC[C@H](Oc2cc3c(Nc4ccc(OCc5ccccn5)c(Cl)c4)ncnc3cc2OC)C1,1-((3S)-3-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1-yl)prop-2-en-1-one,0.005,uM,=,-2.3010299956639813,0,c1ccc(COc2ccc(Nc3ncnc4ccc(O[C@H]5CCNC5)cc34)cc2)nc1
2502,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,COc1cc(NC(=O)Nc2ccccn2)cc(-c2c[nH]cn2)c1OC,"1-(3-(1H-imidazol-4-yl)-4,5-dimethoxyphenyl)-3-(pyridin-2-yl)urea",0.02481,uM,=,-1.605373235727791,0,O=C(Nc1cccc(-c2c[nH]cn2)c1)Nc1ccccn1
2503,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccc(Cl)cc4)cc3)ncnc2cc1OCCCN1CCN(C)CC1,1-(4-chlorophenyl)-3-(4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)phenyl)urea,0.235,uM,=,-0.6289321377282637,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
2504,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,C/C=C/C(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,(E)-But-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,1.62,uM,=,0.2095150145426309,1,c1ccc(Nc2ccnc3ccccc23)cc1
2505,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)OC)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-20",0.02,uM,=,-1.6989700043360187,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2506,63616,10.1016/S0960-894X(97)00034-6,,,,Inhibition of Epidermal growth factor receptor autophosphorylation.,COc1cc2ncnc(Sc3cccc(Cl)c3)c2cc1OC,"4-(3-Chloro-phenylsulfanyl)-6,7-dimethoxy-quinazoline",0.01,uM,=,-2.0,0,c1ccc(Sc2ncnc3ccccc23)cc1
2507,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CCCN(C)CCN(C)c1cc(OC)c(Nc2nccc(Nc3cn(C)c4ccccc34)n2)cc1NC(=O)C=C,N-(2-((2-(but-3-en-1-yl(methyl)amino)ethyl)(methyl)amino)-4-methoxy-5-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.01311,uM,=,-1.882397308309916,0,c1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1
2508,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CN(C)Cc1ccc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)[nH]1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((dimethylamino)methyl)-1H-pyrrol-2-yl)thieno[2,3-d]pyrimidin-4-amine",0.068,uM,=,-1.1674910872937636,0,c1ccc(COc2ccc(Nc3ncnc4sc(-c5ccc[nH]5)cc34)cc2)cc1
2509,67049,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor,COc1cc(O)c2c(=O)c(-c3cccc(Cl)c3)cn(CCc3ccccc3)c2c1,3-(3-Chloro-phenyl)-5-hydroxy-7-methoxy-1-phenethyl-1H-quinolin-4-one,4.0,uM,=,0.6020599913279624,1,O=c1c(-c2ccccc2)cn(CCc2ccccc2)c2ccccc12
2510,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3CC)c3ncn(C(C)C)c3n2)C[C@H]1F,"N-((3R,4R)-4-Fluoro-1-(9-isopropyl-6-((3-ethyl-1-methyl-1H-pyrazol-4-yl)amino)-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide",0.649,uM,=,-0.1877553031996307,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1
2511,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(NS(=O)(=O)c1ccc(Cl)cc1)c1cccnc1Cl,2-Chloro-N-(4-chlorophenylsulfonyl)nicotinamide,19.83,uM,=,1.2973227142053028,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
2512,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,COc1cccc(-c2cn(C3CCN(CCN(C)CCO)CC3)c3ncnc(N)c23)c1,"2-[(2-{4-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-piperidin-1-yl}-ethyl)-methyl-amino]-ethanol",0.295,uM,=,-0.530177984021837,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1
2513,2236990,10.1016/j.ejmech.2021.113334,,,,Inhibition of EGFR (unknown origin) by colorimetric assay,N#CC1=C(c2ccccc2)Nc2c(c(-c3cccs3)nn2-c2ccccc2)C12C(=O)Nc1ccc(Cl)cc12,"5'-chloro-2'-oxo-1,6-diphenyl-3-(2-thienyl)spiro[7H-pyrazolo[3,4-b]pyridine-4,3'-indoline]-5-carbonitrile",0.12,uM,=,-0.9208187539523752,0,O=C1Nc2ccccc2C12C=C(c1ccccc1)Nc1c2c(-c2cccs2)nn1-c1ccccc1
2514,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,CC(=O)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccc(Cl)cc1,"1-(5-(4-Chlorophenyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone",16.14,uM,=,1.2079035303860517,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
2515,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@@H]1CCOC1,"(R)-5-(4-amino-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",2.6,uM,=,0.414973347970818,1,c1ccc(-c2nn([C@@H]3CCOC3)c3ncncc23)cc1
2516,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C[C@@H](C)CO)c3ncnc(N)c23)cc1OC,"(R)-3-(4-amino-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methylpropan-1-ol",18.0,uM,=,1.255272505103306,1,c1ccc(-c2n[nH]c3ncncc23)cc1
2517,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CN(C)c1ccc2c(Nc3cccc(Br)c3)ncnc2c1,"N*4*-(3-Bromo-phenyl)-N*7*,N*7*-dimethyl-quinazoline-4,7-diamine",0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccccc23)cc1
2518,531091,10.1073/pnas.0707498104,,,,Inhibition of EGFR,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,"(R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one",3.8,uM,=,0.5797835966168101,1,O=C1Nc2ccc(S(=O)(=O)Cc3ccccc3)cc2/C1=C/c1cc(C(=O)N2CCC[C@@H]2CN2CCCC2)c[nH]1
2519,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,CC(=O)c1nn(-c2ccc(C)cc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1,"1-(1-(4-Chlorophenyl)-4-(2-methyl-4,5-diphenyl-1H-pyrrole-3-carbonyl)-1H-pyrazol-3-yl)ethanone",9.19,uM,=,0.9633155113861112,1,O=C(c1cnn(-c2ccccc2)c1)c1c[nH]c(-c2ccccc2)c1-c1ccccc1
2520,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,O=C1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CCN1,"1-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)-1,4-diazepan-5-one",0.24,uM,=,-0.619788758288394,0,O=C1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c23)CCN1
2521,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(S(N)(=O)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-27",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2522,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-carbamic acid methyl ester,0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3ccccc23)cc1
2523,1782454,10.1016/j.ejmech.2017.12.022,,,,Inhibition of recombinant human C-terminal His/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using biotin-labeled poly[Glu:Tyr] (4:1) as substrate after 30 mins by Kinase-Glo plus luminescence assay,Cc1oc2ncnc(Nc3cccc(Br)c3)c2c1C(=O)O,"4-((3-Bromophenyl)amino)-6-methylfuro[2,3-d]pyrimidine-5-carboxylic acid",0.752,uM,=,-0.1237821594083577,0,c1ccc(Nc2ncnc3occc23)cc1
2524,65120,10.1021/jm00023a009,,,,In vitro inhibition of EGF-stimulated DNA synthesis of ER 22 cells by following the incorporation of methyl-[3H]thymidine.,O=C(NCc1ccccc1)c1ccc(-c2ccc(-c3ccccc3)cc2O)cc1,"2'-Hydroxy-[1,1';4',1'']terphenyl-4-carboxylic acid benzylamide",1.4,uM,=,0.1461280356782379,1,O=C(NCc1ccccc1)c1ccc(-c2ccc(-c3ccccc3)cc2)cc1
2525,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CN(C)Cc1ccc(-c2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)[nH]1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((dimethylamino)methyl)-1H-pyrrol-2-yl)thieno[3,2-d]pyrimidin-4-amine",0.004,uM,=,-2.397940008672037,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2)cc1
2526,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3c(C=O)c[nH]c3c2)c2c(N)ncnc21,"6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-3-carbaldehyde",0.638,uM,=,-0.1951793212788376,0,c1ncc2c(-c3ccc4cc[nH]c4c3)n[nH]c2n1
2527,1801908,10.1016/j.ejmech.2018.06.061,,,,Inhibition of EGFR in human HepG2 cells,O=C1Nc2ccc(S(=O)(=O)N3CCOCC3)cc2/C1=N/Nc1ccccc1,5-(Morpholinosulfonyl)-3-(2-phenylhydrazono)indolin-2-one,0.046,uM,=,-1.337242168318426,0,O=C1Nc2ccc(S(=O)(=O)N3CCOCC3)cc2/C1=N/Nc1ccccc1
2528,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,CCOC(=O)CNc1cccc(Oc2cc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncn2)c1,4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-6-[3-(2-ethoxycarbonylethylamino)phenoxy]pyrimidine,0.37,uM,=,-0.431798275933005,0,c1ccc(COc2ccc(Nc3cc(Oc4ccccc4)ncn3)cc2)cc1
2529,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(C#N)nc2)c2c(N)ncnc21,"5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)picolinonitrile",100.0,uM,=,2.0,1,c1cncc(-c2n[nH]c3ncncc23)c1
2530,739835,10.1016/j.bmcl.2011.01.139,,,,Inhibition of EGFR,CC(=O)NC[C@H]1CC[C@H](c2nc(-c3cc4ccccc4[nH]3)c3c(N)nccn32)CC1,"Trans-N-((-4-(8-amino-1-(1H-indol-2-yl)imidazo[1,5-a]pyrazin-3-yl)cyclohexyl)methyl)acetamide",3.58,uM,=,0.5538830266438743,1,c1ccc2[nH]c(-c3nc(C4CCCCC4)n4ccncc34)cc2c1
2531,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,But-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.0002,uM,=,-3.6989700043360174,0,c1ccc(Nc2ncnc3ccccc23)cc1
2532,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(NCc3cccc(C(F)(F)F)c3)c2cn1,"N*4*-(3-Trifluoromethyl-benzyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",1.95,uM,=,0.290034611362518,1,c1ccc(CNc2ncnc3ccncc23)cc1
2533,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",O=C1CS/C(=N/Nc2nncc3ccccc23)N1,2-(2-(Phthalazin-1-yl)hydrazono)thiazolidin-4-one,0.051,uM,=,-1.2924298239020635,0,O=C1CS/C(=N/Nc2nncc3ccccc23)N1
2534,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN1CCOCC1,"N-(4-Methoxy-2-(methyl(2-morpholinoethyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)buta-2,3-dienamide",0.042,uM,=,-1.3767507096020994,0,c1ccc2c(-c3ccnc(Nc4ccc(NCCN5CCOCC5)cc4)n3)c[nH]c2c1
2535,1580544,10.1016/j.ejmech.2016.04.002,,,,Inhibition of EGFR-TK in human A431 cell lysate assessed as reduction in EGF stimulated kinase activity after 60 mins using biotinylated peptide substrate by ELISA,Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine",6.1,uM,=,0.785329835010767,1,c1ccc(Nc2ncnc3ccccc23)cc1
2536,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Clc1cccc(Nc2ncnc3[nH]c(-c4ccccc4)c(-c4ccccc4)c23)c1,"(3-Chloro-phenyl)-(5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",0.096,uM,=,-1.0177287669604316,0,c1ccc(Nc2ncnc3[nH]c(-c4ccccc4)c(-c4ccccc4)c23)cc1
2537,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(CN1CCN(CCO)CC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-2-(4-(2-hydroxyethyl)piperazin-1-yl)acetamide",0.77,uM,=,-0.1135092748275181,0,O=C(CN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
2538,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,COCCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCCC1,(2E)-N-[4-[(1-Benzyl-1H-indazol-5-yl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]-4-(1-pyrrolidinyl)-2-butenamide,0.008,uM,=,-2.096910013008056,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
2539,990874,10.1021/ml4002437,,,,Inhibition of wild type EGFR in human A431 cells assessed as growth inhibition after 48 hrs by MTT assay,CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-((3-chloro-4-fluorophenyl)amino)-7,8-dihydro-6H-[1,4]oxazino[3,2 g]quinazolin-6-yl)-4-(dimethylamino)but-2-en-1-one",2.2,uM,=,0.3424226808222063,1,c1ccc(Nc2ncnc3cc4c(cc23)NCCO4)cc1
2540,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,c1nc(Nc2ccc3[nH]ccc3c2)c2sccc2n1,"(1H-Indol-5-yl)-thieno[3,2-d]pyrimidin-4-yl-amine",0.6,uM,=,-0.2218487496163563,0,c1nc(Nc2ccc3[nH]ccc3c2)c2sccc2n1
2541,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CC2(C1)CS(=O)(=O)C2,"(3-Chloro-4-fluoro-phenyl)-{6-[3-(2,2-dioxo-2lambda*6*-thia-6-aza-spiro[3.3]hept-6-yl)-propoxy]-7-methoxy-quinazolin-4-yl}-amine",0.024,uM,=,-1.619788758288394,0,O=S1(=O)CC2(CN(CCCOc3ccc4ncnc(Nc5ccccc5)c4c3)C2)C1
2542,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(=O)c1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1,"1-(4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)ethanone",12.0,uM,=,1.0791812460476249,1,c1ccc(-c2n[nH]c3ncncc23)cc1
2543,1924071,10.1021/acs.jmedchem.6b00403,,,,"Inhibition of wild type EGFR kinase domain (unknown origin) expressed using baculovirus expression system incubated for 1 hr using Poly(Glu,Tyr) 4:1 by ELISA method",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)c(OC)c3)ncc2C(F)(F)F)c1,Rociletinib,0.272,uM,=,-0.5654310959658013,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2544,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3cccc(C(F)(F)F)c3)c2cn1,"N*4*-(3-Trifluoromethyl-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3ccncc23)cc1
2545,63615,10.1021/jm980123i,,,,Concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Epidermal growth factor receptor (EGF RTK).,COc1ccc(/C=C2\C(=O)Nc3ccc(Cl)cc32)cc1C(C)(C)C,"3-[1-(3-tert-Butyl-4-methoxy-phenyl)-meth-(Z)-ylidene]-5-chloro-1,3-dihydro-indol-2-one",19.3,uM,=,1.285557309007774,1,O=C1Nc2ccccc2/C1=C/c1ccccc1
2546,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCCCn1ccnc1[N+](=O)[O-],N-(3-chloro-4-fluorophenyl)-7-methoxy-6-((5-(2-nitro-1Himidazol-1-yl)pentyl)oxy)quinazolin-4-amine,0.00051,uM,=,-3.292429823902064,0,c1ccc(Nc2ncnc3ccc(OCCCCCn4ccnc4)cc23)cc1
2547,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,OCc1cccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3s2)c1,"(S)-2-((6-(3-(Hydroxymethyl)phenyl)thieno[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.003,uM,=,-2.5228787452803374,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
2548,1524114,10.1016/j.bmc.2015.10.035,,,,Inhibition of human EGFR after 1 hr using [gamma-32P]ATP,Fc1ccc(Oc2ncnc3ccccc23)cc1Cl,4-(3-chloro-4-fluorophenoxy)quinazoline,0.59,uM,=,-0.2291479883578558,0,c1ccc(Oc2ncnc3ccccc23)cc1
2549,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,COc1ccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)cc1,"8-(4-Methoxyphenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.38,uM,=,-0.4202164033831898,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
2550,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)C(F)(F)F)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"1N-[3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl]-1N-methyl-2,2,2-trifluoroacetamide",6.4,uM,=,0.8061799739838872,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
2551,305999,10.1016/j.bmcl.2004.08.007,,,,Inhibitory concentration against Epidermal growth factor receptor tyrosine kinase activity,COc1cc2ncnc(Nc3cccc(NC(=O)c4ccccc4)c3F)c2cc1OC,"N-[3-(6,7-Dimethoxy-quinazolin-4-ylamino)-2-fluoro-phenyl]-benzamide",2.8,uM,=,0.4471580313422192,1,O=C(Nc1cccc(Nc2ncnc3ccccc23)c1)c1ccccc1
2552,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CONC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-N-methoxy-benzamide",0.3,uM,=,-0.5228787452803376,0,c1ccc(CNc2ccccc2)cc1
2553,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,OC[C@@H]1CCCN1Cc1ccc(Nc2nc3ncnc(Nc4ccc(F)c(Cl)c4)c3s2)cc1,"(S)-(1-(4-(7-(3-chloro-4-fluorophenylamino)thiazolo[4,5-d]pyrimidin-2-ylamino)benzyl)pyrrolidin-2-yl)methanol",0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3nc(Nc4ccc(CN5CCCC5)cc4)sc23)cc1
2554,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COC[C@@H](C(N)=O)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-3-methoxypropanamide,0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccccc23)cc1
2555,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)c(Cl)c3)c2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)-3-chlorophenyl]-7'-methoxy-6'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,0.044,uM,=,-1.3565473235138126,0,c1ccc2sc(-c3ccc(Nc4ncnc5ccc(OCCCN6CCNCC6)cc45)cc3)nc2c1
2556,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(Nc3ccc(-c4nc5ccc(Cl)cc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1,N-[4-(6''-Fluorobenzo[d]thiazol-2''-yl)phenyl]-6'-methoxy-7'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,0.26,uM,=,-0.585026652029182,0,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
2557,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC3CCC3)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,cyclobutyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.084,uM,=,-1.0757207139381184,0,O=C(OC1CCC1)c1cnc(Nc2ccccc2)nc1-c1c[nH]c2ccccc12
2558,1283337,10.1016/j.ejmech.2013.10.058,,,,Inhibition of wild type EGFR (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,CNS(=O)(=O)c1ccc(Nc2nc(Cl)nc3cc(OC)c(OC)cc23)cc1,"4-((2-Chloro-6,7-dimethoxyquinazolin-4-yl)amino)-Nmethylbenzenesulfonamide",1.63,uM,=,0.2121876044039577,1,c1ccc(Nc2ncnc3ccccc23)cc1
2559,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)CC(=O)O)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"2-[3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl(methyl)amino]acetic acid",0.031,uM,=,-1.5086383061657274,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
2560,2233412,10.1016/j.bmcl.2022.128703,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells using kinase substrate 22 incubated for 30 mins in presence of ATP,C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,POZIOTINIB,0.00027,uM,=,-3.5686362358410126,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
2561,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,CC(C)(C)OC(=O)N1CCC(n2cc(-c3ccccc3)c3c(N)ncnc32)C1,"3-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester",8.3,uM,=,0.919078092376074,1,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1
2562,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,CNCC(O)COc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,1-[4-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-3-methylamino-propan-2-ol,0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
2563,2160722,10.1021/acs.jmedchem.1c02208,,,,Inhibition of EGFR phosphorylation in human A549 cells incubated for 4 hrs by Western blot assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.0166,uM,=,-1.779891911959945,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
2564,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),COC(=O)c1ccc(CNC(=O)CCc2c(SSc3[nH]c4ccccc4c3CCC(=O)NCc3ccc(C(=O)OC)cc3)[nH]c3ccccc23)cc1,methyl 4-[2-(2-{3-[2-(4-methyloxycarbonylbenzylcarbamoyl)ethyl]-1H-2-indolyldisulfanyl}-1H-3-indolyl)ethylcarboxamidomethyl]benzoate,44.0,uM,=,1.6434526764861874,1,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
2565,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C#Cc1cnc(Nc2cc(NC(=O)C=C)c(N(C)CCN(C)C)cc2OC)nc1-c1cn2c3c(cccc13)CCC2,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-5-ethynylpyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.042,uM,=,-1.3767507096020994,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)cc1
2566,840626,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR using GST-Crk as substrate assessed as phosphorylated Crk level after 20 mins by SDS-PAGE analysis,Brc1cccc(Nc2ncnc3cc4c(cc23)OCCCSCCCO4)c1,"N-(3-bromophenyl)-7,8,9,11,12,13-hexahydro-[1,4,8]dioxathiacycloundeca[2,3-g]quinazolin-4-amine",0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCCSCCCO4)cc1
2567,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Nc1[nH]cnc2nnc(Nc3cccc(Cl)c3)c1-2,"N*3*-(3-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.16,uM,=,-0.7958800173440752,0,c1ccc(Nc2nnc3nc[nH]cc2-3)cc1
2568,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,COc1cccc(-c2cn(C3CC(C(=O)NCCO)C3)c3ncnc(N)c23)c1,"3-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-cyclobutanecarboxylic acid (2-hydroxy-ethyl)-amide",0.33,uM,=,-0.4814860601221125,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1
2569,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ncccn3)cc2Cl)c1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-(2-(pyrimidin-2-yl)ethynyl)pyrimidin-4-amine,0.077,uM,=,-1.1135092748275182,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ncccn1
2570,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1/C=C/CCN1CCOCC1,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(4-morpholin-4-yl-but-1-enyl)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.119,uM,=,-0.9244530386074692,0,C(=C/c1cnc2c(Nc3ccccc3)ncnc2c1)\CCN1CCOCC1
2571,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(N[C@H](C)c3cccs3)ncnc2s1,"(R)-6-(2-Methoxyphenyl)-N-(1-(thiophen-2-yl)ethyl)thieno[2,3-d]pyrimidin-4-amine",0.055,uM,=,-1.259637310505756,0,c1ccc(-c2cc3c(NCc4cccs4)ncnc3s2)cc1
2572,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,MOBOCERTINIB,2.5e-05,uM,=,-4.6020599913279625,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2573,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,CS(=O)(=O)CCC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1,N-(3-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)phenyl)-3-(methylsulfonyl)propanamide,0.05,uM,=,-1.3010299956639813,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
2574,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CCCC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-2-hexynamide",0.0096,uM,=,-2.017728766960432,0,c1ccc(Nc2ncnc3cnccc23)cc1
2575,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CNC1CC1,(E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-4-(cyclopropylamino)but-2-enamide,0.0021,uM,=,-2.6777807052660805,0,O=C(/C=C/CNC1CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2576,1675840,10.1016/j.bmc.2017.03.032,,,,"Inhibition of recombinant wild type human EGFR (695 to end residues) using Poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(/C=C/c4cc(Cl)cc(Cl)c4)cc3)ncc2Cl)c1,"N-[3-[[5-Chloro-2-[(E)-4-(3,5-dichlorostyryl)phenylamino]-4-pyrimidinyl]amino]phenyl]-2-acrylamide",1.037,uM,=,0.0157787563890409,1,C(=C/c1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)\c1ccccc1
2577,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O,"2-amino-5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol",0.033,uM,=,-1.4814860601221125,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
2578,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1OCCN1CCOCC1,"N-(4-Methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-morpholinoethoxy)phenyl)buta-2,3-dienamide",0.0304,uM,=,-1.5171264163912463,0,c1ccc2c(-c3ccnc(Nc4ccc(OCCN5CCOCC5)cc4)n3)c[nH]c2c1
2579,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,COc1ccc(/C=C/C(=O)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)cc1,(E)-N-(4-(3-Bromophenylamino)quinazolin-6-yl)-3-(4-methoxyphenyl)acrylamide,7.22,uM,=,0.8585371975696391,1,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2580,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Br)c(Br)c2)CC1c1ccccc1F,"3-(3,4-Dibromophenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",13.37,uM,=,1.1261314072619844,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
2581,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)N1CCN(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)CC1,"(E)-2-{4-[(E)-2-Cyano-3-(3,4-dihydroxy-phenyl)-acryloyl]-piperazine-1-carbonyl}-3-(3,4-dihydroxy-phenyl)-acrylonitrile",25.0,uM,=,1.3979400086720375,1,O=C(C=Cc1ccccc1)N1CCN(C(=O)/C=C/c2ccccc2)CC1
2582,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,CCOC(=O)c1ccccc1Nc1nc(Nc2ccc(OCC(=O)N3CCOCC3)cc2)ncc1Cl,ethyl 2-(5-chloro-2-(4-(2-morpholino-2-oxoethoxy)phenylamino)pyrimidin-4-ylamino)benzoate,0.032,uM,=,-1.494850021680094,0,O=C(COc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)N1CCOCC1
2583,1883874,10.1021/acsmedchemlett.8b00270,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay,C=CC(=O)N(c1cc(F)c(F)cc1F)c1ncnc2cc(OC)c(OCCCN3CCOCC3)cc12,"4-[N-acryloyl-(2,4,5-trifluorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline",0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2584,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)CC1,"1-(4-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.35933,uM,=,-0.4445065225933977,0,c1cc2nc(Nc3ccc(N4CCNCC4)cc3)nc(OC3CCNCC3)c2s1
2585,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCCCCn1ccnc1[N+](=O)[O-],N-(3-chloro-4-fluorophenyl)-7-methoxy-6-((6-(2-nitro-1Himidazol-1-yl)hexyl)oxy)quinazolin-4-amine,0.00032,uM,=,-3.494850021680094,0,c1ccc(Nc2ncnc3ccc(OCCCCCCn4ccnc4)cc23)cc1
2586,340860,10.1016/j.bmcl.2005.12.028,,,,Inhibitory activity against EGFR,CN1CCN(CCCOc2cc(OC3CCOCC3)c3c(Nc4ccc(F)c(Cl)c4)ncnc3c2)CC1,N-(3-chloro-4-fluorophenyl)-7-(3-(4-methylpiperazin-1-yl)propoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine,0.066,uM,=,-1.1804560644581312,0,c1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)cc(OC4CCOCC4)c23)cc1
2587,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,COC(=O)N(C)[C@H]1C[C@@H]2O[C@](C)([C@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Staurosporine derivative,2.4,uM,=,0.380211241711606,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
2588,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,CN(C)CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Dimethylamino-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccccc23)cc1
2589,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3cc[nH]n3)cc2Cl)c1,5-(2-(1H-pyrazol-3-yl)ethynyl)-N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)pyrimidin-4-amine,0.042,uM,=,-1.3767507096020994,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1cc[nH]n1
2590,953503,10.1016/j.ejmech.2012.10.017,,,,"Inhibition of EGFR tyrosine kinase (unknown origin) using poly (Glu,Tyr) as substrate after 30 mins by ADP-GloTM assay",NC(=O)Nc1ccc2ncnc(Nc3ccc(Cl)cc3)c2c1,4-(4-Chlorophenylamino)-6-ureidoquinazoline,0.061,uM,=,-1.214670164989233,0,c1ccc(Nc2ncnc3ccccc23)cc1
2591,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1cnc(N2CCC2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-1-(4-((8-(azetidin-1-yl)-5-isopropyl-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-fluoro-3-methylpiperidin-4-ol",8.668,uM,=,0.9379189026477804,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
2592,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Br)c(Br)c2)CC1c1ccc(F)cc1,"3-(3,4-Dibromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",8.92,uM,=,0.9503648543761232,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
2593,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCC(O)CN(CCO)CCO,1-[Bis-(2-hydroxy-ethyl)-amino]-3-[4-(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-propan-2-ol,0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
2594,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,COC1CNCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((6-methoxy-1,4-diazepan-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.19,uM,=,-0.721246399047171,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)cc1
2595,1642167,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0022,uM,=,-2.657577319177794,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2596,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1,N-(4-(benzyloxy)-3-(trifluoromethyl)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.16,uM,=,-0.7958800173440752,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
2597,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN(C(C)C)C(C)C,(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(diisopropylamino)but-2-enamide,0.007,uM,=,-2.154901959985743,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccccc45)ccc32)cc1
2598,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0203,uM,=,-1.692503962086787,0,c1ccc(Nc2ncnc3ccccc23)cc1
2599,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,O=C(CCCCCCOc1ccc(-c2cc3c(NCc4ccccc4)ncnc3[nH]2)cc1)NO,"7-(4-(4-(benzylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenoxy)-N-hydroxyheptanamide",0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
2600,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),C[C@H](Nc1[nH]cnc2c3ccccc3nc1-2)c1ccccc1.Cl,"(S)-(1-Phenyl-ethyl)-(5H-pyrimido[5,4-b]indol-4-yl)-amine hydrochloride",0.419,uM,=,-0.3777859770337047,0,c1ccc(CNc2[nH]cnc3c4ccccc4nc2-3)cc1
2601,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,C#Cc1cccc(Nc2ncnc3sc(Br)cc23)c1,"6-Bromo-N-(3-ethynylphenyl)thieno[2,3-d]pyrimidin-4-amine",0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2ncnc3sccc23)cc1
2602,5000,10.1021/jm960118j,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1,"Phenyl-(6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]indol-4-yl)-amine",3.0,uM,=,0.4771212547196624,1,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1
2603,2018691,10.1016/j.bmc.2020.115674,,,,Inhibition of EGFR-TK (unknown origin) relative to control,CC(C)(C)c1cc(NC(=O)CCl)no1,N-(5-(t-Butyl)isoxazol-3-yl)-2-chloroacetamide,0.124,uM,=,-0.906578314837765,0,c1cnoc1
2604,2238039,10.1021/acs.jmedchem.0c02167,,,,Inhibition of EGFR (unknown origin) by ELISA method,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)NC5CC5)CC4)c(Cl)c3)c2cc1C(N)=O,"N1-[4-[(6-carbamoyl-7-methoxy-4-quinolyl)oxy]-2-chloro-phenyl]-N1'-cyclopropyl-cyclopropane-1,1-dicarboxamide",6.5,uM,=,0.8129133566428556,1,O=C(Nc1ccc(Oc2ccnc3ccccc23)cc1)C1(C(=O)NC2CC2)CC1
2605,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccc(Cl)cc4)cc3)ncnc2cc1OCCCN1CCN(C)CC1,N-(4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-ylamino)phenyl)-4-chlorobenzamide,1.33,uM,=,0.1238516409670858,1,O=C(Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1ccccc1
2606,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"US9447106, 27b (peak 2)",0.0026,uM,=,-2.5850266520291822,0,c1ccc(Oc2ccc(-c3cc4n(n3)[C@H](C3CCNCC3)CCN4)cc2)cc1
2607,1472644,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) using Poly(Glu:Tyr) 4:1 as substrate after 12 to 16 hrs,OCCN1CCN(Cc2ccc(-c3cc4c(N[C@H](CO)c5ccccc5)ncnc4s3)cc2)CC1,"(S)-2-(6-(4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)phenyl)thieno[2,3-d]pyrimidin-4-ylamino)-2-phenylethanol",0.6,uM,=,-0.2218487496163563,0,c1ccc(CNc2ncnc3sc(-c4ccc(CN5CCNCC5)cc4)cc23)cc1
2608,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCNC(C)(C)C,[6-(2-tert-Butylamino-ethoxy)-7-methoxy-quinazolin-4-yl]-(3-chloro-4-fluoro-phenyl)-amine,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
2609,1778842,10.1016/j.bmcl.2018.07.039,,,,Inhibition of EGF-induced EGFR activation in human A431 cells pretreated for 60 mins followed by EGF addition and measured after 10 mins by ELISA,COc1ccc(N(c2ncnc3occ(C)c23)C(C)C)cc1,"N-isopropyl-N-(4-methoxyphenyl)-5-methylfuro[2,3-d]pyrimidin-4-amine",0.0101,uM,=,-1.9956786262173567,0,c1ccc(Nc2ncnc3occc23)cc1
2610,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,NC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5ccncc5)c4)c23)CC1,"5-((4-aminopiperidin-1-yl)methyl)-N-(1-(pyridin-4-ylmethyl)-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.53,uM,=,-0.2757241303992109,0,c1cc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)ccn1
2611,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,O=C(/C=C/CN1CCCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7,8-dihydropyrimido[5,4-g][1,4]benzoxazin-6-yl]-4-pyrrolidin-1-yl-but-2-en-1-one",0.121,uM,=,-0.91721462968355,0,O=C(/C=C/CN1CCCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
2612,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.08,uM,=,-1.0969100130080565,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3s2)C1)N1CCOCC1
2613,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS,(S)-2-{(S)-2-[(S)-2-((R)-2-Amino-3-mercapto-propylamino)-3-methyl-pentyloxy]-3-phenyl-propionylamino}-4-methanesulfonyl-butyric acid isopropyl ester,3.216,uM,=,0.5073160400764136,1,c1ccccc1
2614,2067577,10.1016/j.ejmech.2019.111888,,,,"Inhibition of EGFR L858R/T790M/C797S (unknown origin) using Poly (Glu, Tyr) as substrate measured after 40 mins by kinase-glo assay",CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccccc5)n([C@H]5CCN(S(=O)(=O)C6CC6)C5)c4n3)cc2)CC1,"(S)-9-(1-cyclopropylsulfonylpyrrolidine-3-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine",0.04,uM,=,-1.3979400086720375,0,O=S(=O)(C1CC1)N1CC[C@H](n2c(Nc3ccccc3)nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc32)C1
2615,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",O=C1CS/C(=N/Nc2nncc3ccccc23)N1c1ccccc1,3-Phenyl-2-(2-(phthalazin-1-yl)hydrazono)thiazolidin-4-one,0.045,uM,=,-1.3467874862246565,0,O=C1CS/C(=N/Nc2nncc3ccccc23)N1c1ccccc1
2616,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,OCCNCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"2-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methylamino)ethanol",0.045,uM,=,-1.3467874862246565,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
2617,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CC#CC(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,"US9181263, 16::US9278100, 16",2.807,uM,=,0.4482424126344391,1,c1ccc(Oc2ccc(-c3nn(C[C@@H]4CCCN4)c4ncncc34)cc2)cc1
2618,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",CCOC(=O)c1ccc(Nc2nncc3ccccc23)cc1,Ethyl 4-(phthalazin-1-ylamino)benzoate,0.0044,uM,=,-2.356547323513813,0,c1ccc(Nc2nncc3ccccc23)cc1
2619,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(Br)cc3)cc12)c1ccccc1,"(R)-6-(4-Bromophenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.063,uM,=,-1.2006594505464183,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
2620,840626,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR using GST-Crk as substrate assessed as phosphorylated Crk level after 20 mins by SDS-PAGE analysis,Brc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,"N-(3-bromophenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododeca[2,3-g]quinazolin-4-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)cc1
2621,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCC/C(=C\c3ccc(N(C)C)cc3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(4-(dimethylamino)benzylidene)cyclohexanone",3.98,uM,=,0.5998830720736879,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
2622,553933,10.1021/np070447m,,,,Inhibition of recombinant EGFR,COc1cc(O)c2c(=O)oc3cc(O)cc(C)c3c2c1,alternariol 5-O-methyl ether,0.0062484270162965,uM,=,-2.204229298515469,0,O=c1oc2ccccc2c2ccccc12
2623,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,O=C(O)/C=C/c1ccc(O)cc1,(E)-3-(4-Hydroxy-phenyl)-acrylic acid,3000.0,uM,=,3.4771212547196626,1,c1ccccc1
2624,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COCCOc1cc2ncnc(Nc3ccc(Br)cc3F)c2cc1NC(=O)/C=C/CN(C)C,(E)-N-(4-(4-Bromo-2-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3ccccc23)cc1
2625,1807705,10.1016/j.ejmech.2019.06.070,,,,Inhibition of human EGFR by ELISA,Cc1ccc(C2=NN(c3ccccc3)C(c3ccc(OC4CCCC4)cc3)C2)cc1,"5-(4-(cyclopentyloxy)phenyl)-1-phenyl-3-p-tolyl-4,5-dihydro-1H-pyrazole",2.16,uM,=,0.3344537511509309,1,c1ccc(C2=NN(c3ccccc3)C(c3ccc(OC4CCCC4)cc3)C2)cc1
2626,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3cc(Cl)ccc3F)c2cc1OCC1CCN(C)CC1,N-(5-chloro-2-fluorophenyl)-7-methoxy-6-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine,0.058,uM,=,-1.2365720064370629,0,c1ccc(Nc2ncnc3ccc(OCC4CCNCC4)cc23)cc1
2627,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,NC1CCN(Cc2ccn3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c23)CC1,"N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-((4-aminopiperidin-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.038,uM,=,-1.42021640338319,0,c1ccc(COc2ccc(Nc3ncnn4ccc(CN5CCCCC5)c34)cc2)cc1
2628,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-1",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
2629,1883874,10.1021/acsmedchemlett.8b00270,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay,C=CC(=O)N(c1ccc(F)c(C)c1)c1ncnc2cc(OC)c(OCCCN3CCOCC3)cc12,4-[N-acryloyl-(4-fluoro-3-methylphenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline,0.499,uM,=,-0.3018994543766101,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2630,1908531,10.1021/acsmedchemlett.9b00381,,,,Inhibition of EGFR (unknown origin) expressed in mouse Ba/F3 cells assessed as reduction in cell growth incubated for 72 hrs in presence of 1 ug/ml Cetuximab by celltiter-glo luminescent cell viability assay,CN1CCN(c2ccc(Oc3ccc4c(c3)C(=O)N(Cc3ccccc3)c3cc(F)ccc3N4)cc2)CC1,"10-Benzyl-8-fluoro-2-(4-(4-methylpiperazin-1-yl)phenoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one",3.2,uM,=,0.505149978319906,1,O=C1c2cc(Oc3ccc(N4CCNCC4)cc3)ccc2Nc2ccccc2N1Cc1ccccc1
2631,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(N(C)Cc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[4-(benzyl-methyl-amino)-3-chloro-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.25,uM,=,-0.6020599913279624,0,c1ccc(CNc2ccc(Nc3ccnc4ccccc34)cc2)cc1
2632,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0054,uM,=,-2.2676062401770314,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2633,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1C(=O)c1cn(-c2ccccc2)nc1-c1ccccc1,"(1,3-Diphenyl-1H-pyrazol-4-yl)(2-methyl-4,5-diphenyl-1H-pyrrol-3-yl)methanone",2.56,uM,=,0.4082399653118496,1,O=C(c1cn(-c2ccccc2)nc1-c1ccccc1)c1c[nH]c(-c2ccccc2)c1-c1ccccc1
2634,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C,(Z)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.0002,uM,=,-3.6989700043360174,0,c1ccc(Nc2ncnc3ccccc23)cc1
2635,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,COc1cc2nccc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCOCC1,N-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinolin-6-yl)-4-morpholinobut-2-enamide,13.57,uM,=,1.132579847659737,1,O=C(/C=C/CN1CCOCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
2636,2270899,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR L858R/T790M (unknown origin) incubated for 60 mins in presence of ATP by ADP-Glo kinase assay,C=CC(=O)Nc1ccccc1Nc1ncnc2cc(OC)c(OCCN3CCOCC3)cc12,N-(2-Propenamide)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine,0.0043,uM,=,-2.3665315444204134,0,c1ccc(Nc2ncnc3ccc(OCCN4CCOCC4)cc23)cc1
2637,1472645,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) after 40 mins by scintillation proximity assay,Nc1cnc(C#Cc2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cn1,"6-((5-aminopyrazin-2-yl)ethynyl)-N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)thieno[2,3-d]pyrimidin-4-amine",0.372,uM,=,-0.4294570601181025,0,C(#Cc1cc2c(Nc3ccc(OCc4ccccc4)cc3)ncnc2s1)c1cnccn1
2638,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3cc(Br)cc(Br)c3)c2cc1OC,"(3,5-Dibromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.113,uM,=,-0.9469215565165804,0,c1ccc(Nc2ncnc3ccccc23)cc1
2639,1769420,10.1016/j.bmc.2018.02.023,,,,Inhibition of EGFR (unknown origin) using peptide substrate after 60 mins by HTRF assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0296,uM,=,-1.5287082889410617,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2640,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,"3,4,6-trichloro-2-(2,3,5-trichloro-6-hydroxybenzyl)phenol (hexachlorophene)",0.7486,uM,=,-0.1257501772215969,0,c1ccc(Cc2ccccc2)cc1
2641,1914433,10.1021/acs.jnatprod.9b00659,,,,Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,1.23,uM,=,0.0899051114393979,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2642,2284955,10.1016/j.ejmech.2019.112016,,,,Inhibition of EGFR (unknown origin),O=C(NC1=NC2C(=O)NN=C(c3ccc(Br)cc3)C2S1)Nc1ccc(Cl)cc1,"1-(7-(4-bromophenyl)-4-oxo-3a,4,5,7a-tetrahydrothiazolo[4,5-d]pyridazin-2-yl)-3-(4-chlorophenyl)urea",0.08,uM,=,-1.0969100130080565,0,O=C(NC1=NC2C(=O)NN=C(c3ccccc3)C2S1)Nc1ccccc1
2643,1929287,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide substrate preincubated for 10 mins followed by substrate addition measured after 40 mins by caliper motility shift assay,O=C(/C=C/CN1CCCC1)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(pyrrolidin-1-yl)but-2-en-1-one",0.003,uM,=,-2.5228787452803374,0,O=C(/C=C/CN1CCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
2644,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,Oc1ccc(NC(=S)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)cc1,1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(4-hydroxyphenyl)thiourea,0.0089,uM,=,-2.050609993355087,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2645,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC1CCN(C)CC1,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(1-methylpiperidin-4-yloxy)quinazolin-4-amine,0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
2646,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC(Oc2cc3c(Nc4ccc(F)c(Cl)c4F)ncnc3cc2OC)C1,"1-(3-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1-yl)prop-2-en-1-one",0.0007,uM,=,-3.154901959985743,0,c1ccc(Nc2ncnc3ccc(OC4CNC4)cc23)cc1
2647,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Oc1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"4-[4-(3-Chloro-phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-ylamino]-phenol",0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
2648,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(O)c(F)c2)c2c(N)ncnc21,"4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",1.04,uM,=,0.0170333392987803,1,c1ccc(-c2n[nH]c3ncncc23)cc1
2649,2184321,10.1016/j.bmc.2020.115897,,,,Inhibition of EGFR (unknown origin) incubated for 40 mins by intrinsic ATPase activity luminescence assay,O=C(Cc1csc2nc3ccccc3n12)Nc1ccccc1O,"2-(benzo[4,5]imidazo[2,1-b]thiazol-3-yl)-N-(2-hydroxyphenyl)acetamide",0.055,uM,=,-1.259637310505756,0,O=C(Cc1csc2nc3ccccc3n12)Nc1ccccc1
2650,2270866,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) incubated for 1 hrs by ELISA assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.52,uM,=,-0.2839966563652008,0,c1ccc(Nc2ncnc3ccccc23)cc1
2651,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CCNCc1ccc(-c2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)[nH]1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((ethylamino)methyl)-1H-pyrrol-2-yl)thieno[3,2-d]pyrimidin-4-amine",0.006,uM,=,-2.2218487496163566,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2)cc1
2652,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(NC(=O)/C=C/CN(C)C)cc2)n1,"N-(4-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-4-N,N-dimethylaminobut-2-enamide",5.02,uM,=,0.7007037171450193,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2653,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1OCCCCCn1ccnc1[N+](=O)[O-],N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-methoxy-6-((5-(2-nitro-1H-imidazol-1-yl)pentyl)oxy)quinazolin-4-amine,0.0512,uM,=,-1.2907300390241692,0,c1ccc(COc2ccc(Nc3ncnc4ccc(OCCCCCn5ccnc5)cc34)cc2)cc1
2654,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CNC1=CC2N=CN(C)/C(=N\c3cccc(Br)c3)C2C=N1,"{4-[(Z)-3-Bromo-phenylimino]-3-methyl-3,4,4a,8a-tetrahydro-pyrido[4,3-d]pyrimidin-7-yl}-methyl-amine",0.0031,uM,=,-2.508638306165728,0,C1=CC2N=CN/C(=N\c3ccccc3)C2C=N1
2655,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(C)c(/C=C2\C(=O)Nc3ncnc(Nc4ccc(F)c(Cl)c4)c32)[nH]1,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-(3,5-dimethyl-1H-pyrrol-2-yl)-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.041,uM,=,-1.3872161432802643,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
2656,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CN(C)C/C=C/C(=O)Nc1ccc(-c2cncc(C#N)c2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1,N-(4-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-5-cyanopyridin-3-yl)phenyl)-4-(dimethylamino)but-2-enamide,0.66,uM,=,-0.1804560644581313,0,c1ccc(COc2ccc(Nc3ccncc3-c3ccccc3)cc2)cc1
2657,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc4ccccc4c3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.02,uM,=,-1.6989700043360187,0,c1ccc2cc(-c3nn([C@@H]4CCCNC4)c4ncncc34)ccc2c1
2658,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,CC(C)(C)NC(=O)c1ccc(N(CCCl)CCCl)cc1,4-(Bis(2-chloroethyl)amino)-N-tert-butylbenzamide,31.43,uM,=,1.49734438101758,1,c1ccccc1
2659,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O,"5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-ethoxyphenol",0.768,uM,=,-0.114638779968488,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
2660,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=C(O)c1ccc(O)c(N(Cc2ccccc2O)Cc2cc(O)ccc2O)c1,"3-((2,5-dihydroxybenzyl)(2-hydroxybenzyl)amino)-4-hydroxybenzoic acid",0.524767397907759,uM,=,-0.2800331540984273,0,c1ccc(CN(Cc2ccccc2)c2ccccc2)cc1
2661,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nc(N)ccc3c2)c2c(N)ncnc21,"6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)quinolin-2-amine",12.0,uM,=,1.0791812460476249,1,c1cnc2ccc(-c3n[nH]c4ncncc34)cc2c1
2662,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,COc1cc2c(NCc3ccccc3)ncnc2cc1O,4-Benzylamino-6-methoxy-quinazolin-7-ol,0.588,uM,=,-0.2306226739238615,0,c1ccc(CNc2ncnc3ccccc23)cc1
2663,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,O=C1Nc2ncnc(Nc3ccc(F)c(Cl)c3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1,"5-[4-(3-Chloro-4-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide",0.022,uM,=,-1.6575773191777938,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1
2664,1524114,10.1016/j.bmc.2015.10.035,,,,Inhibition of human EGFR after 1 hr using [gamma-32P]ATP,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC,"(3-Chloro-4-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.4,uM,=,-0.3979400086720376,0,c1ccc(Nc2ncnc3ccccc23)cc1
2665,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C#Cc1cccc(Nc2ncnc3sc(-c4ccc(CO)cc4OC)cc23)c1,"(4-(4-((3-Ethynylphenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-3-methoxyphenyl)methanol",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3sc(-c4ccccc4)cc23)cc1
2666,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Sc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorophenylthio)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.63,uM,=,-0.2006594505464183,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Sc5ccccc5)cc4)c3s2)C1)N1CCOCC1
2667,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#CC(C#N)=C(C#N)c1cc(O)cc(O)c1,"2-(3,5-dihydroxyphenyl)ethene-1,1,2-tricarbonitrile",10.0,uM,=,1.0,1,c1ccccc1
2668,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CC(C)=CC[C@@H](OC(=O)/C=C\C(=O)c1ccc(F)cc1)C1=CC(=O)c2c(O)ccc(O)c2C1=O,"(R)-1-(5,8-Dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (Z)-4-(4-fluorophenyl)-4-oxobut-2-enoate",0.0226999999999999,uM,=,-1.6439741428068773,0,O=C(/C=C\C(=O)c1ccccc1)OCC1=CC(=O)c2ccccc2C1=O
2669,67206,10.1021/jm010496a,,,,Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase,C#Cc1cc(Nc2ncnc3cc(OC)c(OC)cc23)ccc1F,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-ethynyl-4-fluoro-phenyl)-amine",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccccc23)cc1
2670,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,Brc1cc2c(NCc3ccccc3)ncnc2s1,"N-benzyl-6-bromothieno[2,3-d]pyrimidin-4-amine",0.241,uM,=,-0.6179829574251317,0,c1ccc(CNc2ncnc3sccc23)cc1
2671,658253,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR autophosphorylation in human A431 cells,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CNCc1cn(CCF)nn1,"(E)-4-{[1-(2-Fluoroethyl)-1H-[1,2,3]triazol-4-ylmethyl]-amino}-but-2-enoic acid[4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide",0.02197,uM,=,-1.6581699430794896,0,O=C(/C=C/CNCc1c[nH]nn1)Nc1ccc2nccc(Nc3ccccc3)c2c1
2672,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,CC(C)Oc1cc2ncnc(Nc3ccc(F)c([N+](=O)[O-])c3)c2c2c1OCCO2,"N-(4-Fluoro-3-nitrophenyl)-5-isopropoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0825,uM,=,-1.083546051450075,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
2673,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CSc1ccc(/C=C2/C(C)=C(CC(=O)O)c3cc(F)ccc32)cc1,[6-Fluoro-2-methyl-3-(4-methylsulfanyl-benzylidene)-3H-inden-1-yl]-acetic acid,23.981,uM,=,1.3798672890808783,1,C1=Cc2ccccc2/C1=C\c1ccccc1
2674,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,COc1ccc(C(/C=C/c2ccccc2Cl)=N\NC(N)=S)cc1,(Z)-2-((E)-3-(2-chlorophenyl)-1-(4-methoxyphenyl)allylidene)hydrazinecarbothioamide,7.83,uM,=,0.8937617620579434,1,N=C(/C=C/c1ccccc1)c1ccccc1
2675,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1,"N-[4-(3-Chloro-4-fluoro-phenylamino)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.00075,uM,=,-3.1249387366083,0,c1ccc(Nc2ncnc3cccnc23)cc1
2676,739728,10.1016/j.bmcl.2011.01.137,,,,Inhibition of human EGFR-mediated poly(Glu4Tyr) phosphorylation after 1 hr,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.07,uM,=,-1.154901959985743,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2677,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CN1CCN(c2ccc(Nc3ncc(Br)c(Nc4ccc5nccnc5c4)n3)cc2)CC1,"5-bromo-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N4-(quinoxalin-6-yl)pyrimidine-2,4-diamine",0.408,uM,=,-0.3893398369101201,0,c1cc(Nc2ccc3nccnc3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
2678,63595,10.1016/s0960-894x(98)00691-x,,,,Inhibit of epidermal growth factor receptor (EGFR),CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21,"N*2*-((1R,2S)-2-Amino-cyclohexyl)-N*6*-(3-chloro-phenyl)-9-ethyl-9H-purine-2,6-diamine",2.0,uM,=,0.3010299956639812,1,c1ccc(Nc2nc(NC3CCCCC3)nc3[nH]cnc23)cc1
2679,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=S)NCCCN5CCOCC5)cc34)cc2Cl)c1,1-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)-3-(3-morpholinopropyl)thiourea,0.0015,uM,=,-2.8239087409443187,0,S=C(NCCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
2680,2198131,10.1016/j.ejmech.2022.114661,,,,Inhibition of recombinant human EGFR incubated for 40 to 45 mins and measured after 15 mins by Kinase-Glo Max assay,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methylamide,0.11,uM,=,-0.958607314841775,0,O=C(Nc1ccccc1)Nc1ccc(Oc2ccncc2)cc1
2681,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CN(C)CCCN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-((3-(dimethylamino)propyl)(methyl)amino)but-2-enamide",0.093,uM,=,-1.031517051446065,0,c1ccc(Nc2ncnc3sccc23)cc1
2682,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,Cc1cccc(N2NC(=O)/C(=C/c3ccc(-c4ccccc4F)o3)C2=O)c1,"4-((5-(2-fluorophenyl)furan-2-yl)methylene)-1-m-tolylpyrazolidine-3,5-dione",23.1,uM,=,1.3636119798921444,1,O=C1NN(c2ccccc2)C(=O)/C1=C\c1ccc(-c2ccccc2)o1
2683,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.053,uM,=,-1.275724130399211,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
2684,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3ccccc3)nc21,"6-(2,6-Dichloro-phenyl)-8-methyl-2-phenylamino-8H-pyrido[2,3-d]pyrimidin-7-one",0.26,uM,=,-0.585026652029182,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
2685,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1ccc(Cl)cc1)NS(=O)(=O)c1ccc(F)cc1,2-(4-Chlorophenyl)-N-(4-fluorophenylsulfonyl)acetamide,9.59,uM,=,0.9818186071706636,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
2686,1368552,10.1021/jm500034j,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of [32P] gamma-ATP in to myelin basic protein after 30 mins by autoradiographic analysis,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.19,uM,=,-0.721246399047171,0,c1ccc(/N=c2\nc[nH]c3cc(OCC4CCNCC4)ccc23)cc1
2687,676221,10.1021/jm100607r,,,,Inhibition of EGFR,CN1CCN(C/C=C/C(=O)N2CCc3c(sc4ncnc(N[C@H](CO)c5ccccc5)c34)C2)CC1,"(E)-1-(4-[(1S)-2-Hydroxy-1-phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-4-(4-methylpiperazino)-2-buten-1-one",0.089,uM,=,-1.0506099933550872,0,O=C(/C=C/CN1CCNCC1)N1CCc2c(sc3ncnc(NCc4ccccc4)c23)C1
2688,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(F)c(-c2nn(C(C)C)c3ncnc(N)c23)cc1F,"3-(2,5-difluoro-4-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",10.2,uM,=,1.0086001717619175,1,c1ccc(-c2n[nH]c3ncncc23)cc1
2689,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1,"(6,7,8,9-Tetrahydro-5H-pyrimido[4,5-b]indol-4-yl)-p-tolyl-amine",0.11,uM,=,-0.958607314841775,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1
2690,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-(5-(((2-(methylsulfonyl)ethyl)(propyl)amino)methyl)furan-2-yl)quinazolin-4-amine,0.085,uM,=,-1.0705810742857071,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
2691,63615,10.1021/jm980123i,,,,Concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Epidermal growth factor receptor (EGF RTK).,CC(C)c1cc(/C=C2\C(=O)Nc3ccc(Cl)cc32)cc(C(C)C)c1O,"5-Chloro-3-[1-(4-hydroxy-3,5-diisopropyl-phenyl)-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one",9.5,uM,=,0.9777236052888478,1,O=C1Nc2ccccc2/C1=C/c1ccccc1
2692,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CC(=O)N1CCc2cc(Nc3nc(Nc4ccc(N5CCN(C)CC5)cc4)ncc3Br)ccc21,1-(5-((5-bromo-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)indolin-1-yl)ethan-1-one,14.3,uM,=,1.155336037465062,1,c1cc(Nc2ccc3c(c2)CCN3)nc(Nc2ccc(N3CCNCC3)cc2)n1
2693,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(CO)c2)c2c(N)ncnc21,"(3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)methanol",100.0,uM,=,2.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
2694,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C3CCCC3)c3ncnc(N)c23)ccc1N,"3-(4-amino-3-methoxyphenyl)-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.084,uM,=,-1.0757207139381184,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
2695,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,Cc1ccc(Oc2ccc(Nc3ncnc4ccc(-c5cn(CCCCCC(=O)NO)nn5)cc34)cc2C)cn1,"N-Hydroxy-6-(4-(4-((3-methyl-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)hexanamide",0.0064,uM,=,-2.193820026016113,0,c1cncc(Oc2ccc(Nc3ncnc4ccc(-c5c[nH]nn5)cc34)cc2)c1
2696,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1ccc(F)cc1)NS(=O)(=O)c1ccccc1,2-(4-Fluorophenyl)-N-(phenylsulfonyl)acetamide,6.74,uM,=,0.8286598965353198,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
2697,1500854,10.1016/j.bmc.2015.04.065,,,,Inhibition of recombinant EGFR (unknown origin) assessed as inhibition of autophosphorylation after 1 hr by DELFIA/Time-resolved fluorometry,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)S/C1=C/c1ccc(Br)s1,"(S,E)-1-(5-((5-Bromothiophen-2-yl)methylene)-4-oxo-4,5-dihydrothiazol-2-yl)-N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)pyrrolidine-2-carboxamide",31.4,uM,=,1.4969296480732148,1,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)S/C1=C/c1cccs1
2698,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,OCCN(CCO)Cc1c[nH]c2cc3ncnc(Nc4cccc(Br)c4)c3cc12,"2-[[4-(3-Bromo-phenylamino)-8H-pyrrolo[3,2-g]quinazolin-6-ylmethyl]-(2-hydroxy-ethyl)-amino]-ethanol",0.135,uM,=,-0.8696662315049939,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
2699,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,C[C@H](NC(=O)[C@H](C)NC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1)C(=O)O,(S)-2-((S)-2-(4-(4-(2-nitrovinyl)phenoxysulfonyl)benzamido)propanamido)propanoic acid,7.0,uM,=,0.8450980400142568,1,O=S(=O)(Oc1ccccc1)c1ccccc1
2700,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,CN(C)c1ccc(Nc2ncnc3cc(-c4ccccc4)sc23)cc1,"N,N-Dimethyl-N'-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine",0.094,uM,=,-1.0268721464003014,0,c1ccc(Nc2ncnc3cc(-c4ccccc4)sc23)cc1
2701,1329770,10.1039/C2MD00317A,,,,Inhibition of recombinant EGFR (unknown origin) using poly-Glu-Tyr peptide as substrate,Nc1ccccc1NC(=O)c1ccc(COc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)cc1,N-(2-aminophenyl)-4-{[4-(3-bromophenylamino)quinazoline-6-yloxy]-methyl}benzamide,0.033,uM,=,-1.4814860601221125,0,O=C(Nc1ccccc1)c1ccc(COc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
2702,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(O[C@H](C)c4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-((R)-1-phenyl-ethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.1,uM,=,-1.0,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
2703,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC,"(3-Chloro-4-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
2704,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(Cc3ccccc3)cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(6-benzyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.001,uM,=,-3.0,0,O=c1c(Cc2ccccc2)cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
2705,2203131,10.1016/j.ejmech.2022.114455,,,,Inhibition of wild type EGFR (unknown origin) incubated for 10 mins by HTRF KinEASE-TK assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CCCC(=O)Nc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"5-(4-(4-((4-((3-acrylamidophenyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-5-oxopentanamide",3.23,uM,=,0.5092025223311029,1,O=C1CCC(N2C(=O)c3cccc(NC(=O)CCCC(=O)N4CCN(c5ccc(Nc6nccc(Nc7ccccc7)n6)cc5)CC4)c3C2=O)C(=O)N1
2706,982646,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type human EGFR tyrosine kinase assessed as Ulight-CAGAGAIETDKEYYTVKD phosphorylation after 15 mins by time-resolved fluorometry,Brc1cccc(Nc2ncnc3ccc(NCCCN4CCCCC4)cc23)c1,"N4-(3-bromophenyl)-N6-(3-(piperidin-1-yl)propyl)quinazoline-4,6-diamine",0.00041,uM,=,-3.3872161432802645,0,c1ccc(Nc2ncnc3ccc(NCCCN4CCCCC4)cc23)cc1
2707,2270920,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins by mobility shift assay,O=C(N/N=C/c1cnc(N2CCCC2)nc1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,"(S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-((2-(pyrrolidin-1-yl)pyrimidin-5-yl)methylene)hydrazine-1-carboxamide",0.0063,uM,=,-2.2006594505464183,0,O=C(N/N=C/c1cnc(N2CCCC2)nc1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
2708,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,O[C@H]1CNCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,"(S)-1-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)-1,4-diazepan-6-ol",0.026,uM,=,-1.585026652029182,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)cc1
2709,1633048,10.1016/j.ejmech.2016.08.055,,,,Inhibition of human EGFR using poly (Glu:Tyr) as substrate measured for 1.5 hrs by oregon green 488 dye-based fluorescence assay,Cc1cccc(Nc2ccnc(Nc3ccc(N4CCN(C)CC4)cc3)n2)c1,"4-N-(3-Methylphenyl)-2-N-[4-(4-methylpiperazin-1-yl)phenyl]pyrimidine-2,4-diamine",11.0,uM,=,1.0413926851582251,1,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2710,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1cccc(Br)c1)NS(=O)(=O)c1ccc(Cl)cc1,2-(3-Bromophenyl)-N-(4-chlorophenylsulfonyl)acetamide,21.28,uM,=,1.3279716236230106,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
2711,471124,10.1016/j.bmc.2007.10.061,,,,Inhibition of EGFR,Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](CN2CCC2)C1,"cis-3-(3-azetidin-1-ylmethylcyclobutyl)-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine",9.6,uM,=,0.9822712330395684,1,c1ccc(-c2ccc3ccc(-c4nc([C@H]5C[C@@H](CN6CCC6)C5)n5ccncc45)cc3n2)cc1
2712,529998,10.1016/j.bmc.2008.02.053,,,,Inhibition of EGFR,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0036,uM,=,-2.4436974992327127,0,c1ccc(Nc2ncnc3ccccc23)cc1
2713,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4cccc(F)c4)c3cc2N1CCCN1CCCCC1,"4-((3-fluorophenyl)amino)-6-(3-(piperidin-1-yl)propyl)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.46,uM,=,-0.3372421683184259,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCCCC1
2714,1523969,10.1016/j.ejmech.2015.08.027,,,,Inhibition of EGFR (unknown origin) using omnia tyr peptide 7 substrate by fluorescence assay,Clc1ccc2c(c1)SCc1cnc(Nc3ccccc3)nc1-2,"8-Chloro-2-Anilino-5H-benzothiopyrane[4,3-d]pyrimidine",21.18,uM,=,1.3259259557714662,1,c1ccc(Nc2ncc3c(n2)-c2ccccc2SC3)cc1
2715,982643,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis,Brc1cccc(Nc2ncnc3ccc(NCCCN4CCCCC4)cc23)c1,"N4-(3-bromophenyl)-N6-(3-(piperidin-1-yl)propyl)quinazoline-4,6-diamine",0.0017,uM,=,-2.7695510786217263,0,c1ccc(Nc2ncnc3ccc(NCCCN4CCCCC4)cc23)cc1
2716,512416,10.1016/j.bmcl.2008.07.103,,,,Inhibition of EGFR,Cc1c(C(=O)c2ccc(Cl)cc2)c2ccc(OC(F)(F)F)cc2n1Cc1cccc(O[C@H](C)C(=O)O)c1,(R)-2-(3-((3-(4-chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl)methyl)phenoxy)propanoic acid,2.24,uM,=,0.3502480183341628,1,O=C(c1ccccc1)c1cn(Cc2ccccc2)c2ccccc12
2717,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,COc1cc(/C=C(\C#N)C(=O)NCCCCNC(=O)/C(C#N)=C/c2cc(Br)c(O)c(OC)c2)cc(Br)c1O,(E)-3-(3-Bromo-4-hydroxy-5-methoxy-phenyl)-N-{4-[(E)-3-(3-bromo-4-hydroxy-5-methoxy-phenyl)-2-cyano-acryloylamino]-butyl}-2-cyano-acrylamide,3.0,uM,=,0.4771212547196624,1,O=C(C=Cc1ccccc1)NCCCCNC(=O)/C=C/c1ccccc1
2718,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,"N-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}-amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methyl butanamide",0.001,uM,=,-3.0,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
2719,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,COc1cccc(/C=C/C(=O)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)c1,(E)-N-(4-(3-Bromophenylamino)quinazolin-6-yl)-3-(3-methoxyphenyl)acrylamide,6.02,uM,=,0.7795964912578245,1,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2720,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.072,uM,=,-1.1426675035687317,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2721,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccc(OC)c4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-[7-ethoxy-4-({4-[(3-methoxybenzyl)oxy]-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)-quinazolin-6-yl]but-2-enamide",0.1072999999999999,uM,=,-0.9694002780340488,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
2722,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(NS(=O)(=O)c4ccccc4)nc3)ncnc2cc1OC,N-[7-Methoxy-4-({6-[(phenylsulfonyl)amino]-3-pyridinyl}amino)-6-quinazolinyl]propanamide,0.522,uM,=,-0.2823294969977378,0,O=S(=O)(Nc1ccc(Nc2ncnc3ccccc23)cn1)c1ccccc1
2723,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,CCOC(C)Oc1cc2ncnc(Nc3ccc(C)c([N+](=O)[O-])c3)c2c2c1OCCO2,"5-(1-Ethoxyethoxy)-N-(4-methyl-3-nitrophenyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.3633,uM,=,-0.4397346021372853,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
2724,2270893,10.1016/j.ejmech.2020.112640,,,,Inhibition of human EGFR incubated for 10 mins in presence of ATP by mobility shift assay,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methylamide,0.056,uM,=,-1.2518119729937995,0,O=C(Nc1ccccc1)Nc1ccc(Oc2ccncc2)cc1
2725,1741055,10.1016/j.ejmech.2018.06.024,,,,Inhibition of EGFR in human MCF7 cell lysates after 24 to 48 hrs by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.073,uM,=,-1.136677139879544,0,c1ccc(Nc2ncnc3ccccc23)cc1
2726,1650711,10.1016/j.bmcl.2017.02.023,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay,O=C(Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)C1CCC2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3,"N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3,3-adamantane-1,2,4-trioxaspiro[4.5]decane-8-carboxamide",0.03235,uM,=,-1.490125714995281,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CCC2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3
2727,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,COc1ccccc1Nc1ncnc2cc(N)ncc12,"N*4*-(2-Methoxy-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",3.71,uM,=,0.5693739096150459,1,c1ccc(Nc2ncnc3ccncc23)cc1
2728,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,Brc1cc2c(Nc3ccccc3)ncnc2s1,"6-Bromo-N-phenylthieno[2,3-d]pyrimidin-4-amine",0.08,uM,=,-1.0969100130080565,0,c1ccc(Nc2ncnc3sccc23)cc1
2729,1642199,,,,,Inhibition Assay: Inhibition of various kinase enzyme.,Nc1nc2c(c(Nc3cccc(Br)c3)n1)-c1ccccc1C2,"N4-(3-Bromophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine",24.1,uM,=,1.3820170425748683,1,c1ccc(Nc2ncnc3c2-c2ccccc2C3)cc1
2730,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(NC(=O)C=C)cc23)c1,(S)-N-(4-(3-Ethynylphenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)acrylamide,0.0322,uM,=,-1.4921441283041692,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
2731,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CSc1nc2cc(OC)ccc2s1,N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-2-((5-methoxybenzo[d]thiazol-2-yl)thio)acetamide,0.197,uM,=,-0.7055337738384071,0,O=C(CSc1nc2ccccc2s1)Oc1ccc2ncnc(Nc3ccccc3)c2c1
2732,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(S(=O)(=O)Nc4nccs4)cc3)c2c1,N-(4-(4-(N-thiazol-2-ylsulfamoyl)phenylamino)quinazolin-6-yl)acrylamide,43.7,uM,=,1.640481436970422,1,O=S(=O)(Nc1nccs1)c1ccc(Nc2ncnc3ccccc23)cc1
2733,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,Clc1ccc2nc(Cc3nnc(-c4ccccc4Cl)o3)[nH]c2c1,"2-((6-chloro-1H-benzo[d]imidazol-2-yl)methyl)-5-(2-chlorophenyl)-1,3,4-oxadiazole",33.2,uM,=,1.5211380837040362,1,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
2734,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(Cl)c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(3-C hlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.144,uM,=,-0.8416375079047503,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
2735,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),O=C(O)CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)O)[nH]c2ccccc12,3-{2-[3-(2-Carboxy-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-propionic acid,4.8,uM,=,0.6812412373755872,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
2736,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)N1CCN(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)CC1,"(E)-2-{4-[(E)-2-Cyano-3-(3,4-dihydroxy-phenyl)-acryloyl]-piperazine-1-carbonyl}-3-(3,4-dihydroxy-phenyl)-acrylonitrile",10.0,uM,=,1.0,1,O=C(C=Cc1ccccc1)N1CCN(C(=O)/C=C/c2ccccc2)CC1
2737,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COC(=O)c1ccc(OC)c(-c2cc3c(N[C@H](C)c4ccccc4)ncnc3s2)c1,"Methyl (R)-4-methoxy-3-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzoate",0.007,uM,=,-2.154901959985743,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
2738,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccccc4C)c(Cl)c3)ncnc2cc1OCCCN1CCN(C)CC1,1-(2-chloro-4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)phenyl)-3-(o-tolyl)urea,0.015,uM,=,-1.8239087409443189,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
2739,66899,10.1016/s0960-894x(99)00188-2,,,,In vitro activity against Epidermal growth factor receptor (using poly(Glu4Tyr1) as a substrate),O=C1c2c(c3c4cccc(O)c4n(C4OC(CO)C(O)C(O)C4O)c3c3[nH]c4c(O)cccc4c23)C(=O)N1NCC(O)CO,"6-(2,3-dihydroxypropylamino)-1,11-dihydroxy-12-(3,4,5-trihydroxy-6-hydroxymethyltetrahydro-2H-2-pyranyl)-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione",180.0,uM,=,2.255272505103306,1,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1c2c2ccccc2n1C1CCCCO1
2740,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,CN(C)Cc1ccc(Nc2nc3ncnc(Nc4ccc(F)c(Cl)c4)c3s2)cc1,"N7-(3-chloro-4-fluorophenyl)-N2-(4-((dimethylamino)methyl)phenyl)thiazolo[4,5-d]pyrimidine-2,7-diamine",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1
2741,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Nc1ccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"[3-(4-Amino-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-chloro-phenyl)-amine",0.8,uM,=,-0.0969100130080563,0,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
2742,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COCCOc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)cc3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-(Dimethylamino)-N-(4-(4-(3-fluorobenzyloxy)phenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)but-2-enamide,0.091,uM,=,-1.0409586076789064,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
2743,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccc(F)cc4F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,"4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(2,4-difluoro-benzyloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide",0.11,uM,=,-0.958607314841775,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
2744,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc(F)c3cn[nH]c3c2)c2c(N)ncnc21,"3-(4-fluoro-1H-indazol-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",1.2,uM,=,0.0791812460476248,1,c1ncc2c(-c3ccc4cn[nH]c4c3)n[nH]c2n1
2745,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,CNC(=S)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-methylthiourea,0.0091,uM,=,-2.0409586076789066,0,c1ccc(Nc2ncnc3ccccc23)cc1
2746,2207742,10.1021/acs.jmedchem.2c00893,,,,Inhibition of wild type EGFR expressed in human A-431 cells,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.322,uM,=,-0.4921441283041691,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2747,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1NC(=O)OC(C)(C)C,"tert-butyl 4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenylcarbamate",0.17,uM,=,-0.7695510786217261,0,c1ccc(-c2n[nH]c3ncncc23)cc1
2748,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,N[C@@H]1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,"(R)-N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((3-aminopyrrolidin-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.06,uM,=,-1.2218487496163564,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCC6)c45)ccc32)cc1
2749,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Nc1cc2ncnc(Nc3cccc(Br)c3)c2cc1N,"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine",0.0001199999999999,uM,=,-3.9208187539523753,0,c1ccc(Nc2ncnc3ccccc23)cc1
2750,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Brc1cccc(Nc2ncnc3ccccc23)c1,(3-Bromo-phenyl)-quinazolin-4-yl-amine,0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ncnc3ccccc23)cc1
2751,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,COc1ccc2c(c1)CNc1c(NCc3ccccc3)ncnc1O2,"Benzyl-(8-methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",8.5,uM,=,0.9294189257142929,1,c1ccc(CNc2ncnc3c2NCc2ccccc2O3)cc1
2752,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccc(Br)cc3)C2=O)cc(OC)c1,"(2E,6E)-2-(4-Bromobenzylidene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",7.1,uM,=,0.8512583487190752,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
2753,1721451,10.1016/j.ejmech.2017.11.008,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using peptide substrate after 1 hr by mobility shift assay,COc1cc(-n2cc(CN3CCNCC3)nn2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,"5-Chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(piperazin-1-ylmethyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine",0.89,uM,=,-0.0506099933550872,0,c1ccc(Nc2ccnc(Nc3ccc(-n4cc(CN5CCNCC5)nn4)cc3)n2)cc1
2754,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,OCCNC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"2-(1-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)piperidin-4-ylamino)ethanol",0.048,uM,=,-1.3187587626244128,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
2755,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2CC(c3ccc(C)c(C)c3)=NN2c2nc(-c3ccccc3)cs2)cc1,"2-(3-(3,4-dimethylphenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",3.08,uM,=,0.4885507165004443,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
2756,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1ccc(N2C[C@H](CS(C)(=O)=O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinolin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",1.78,uM,=,0.250420002308894,1,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
2757,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,Cc1cccc2c(CCC(=O)O)c(SSc3[nH]c4c(C)cccc4c3CCC(=O)O)[nH]c12,3-{2-[3-(2-Carboxy-ethyl)-7-methyl-1H-indol-2-yldisulfanyl]-7-methyl-1H-indol-3-yl}-propionic acid,1.5,uM,=,0.1760912590556812,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
2758,2270906,10.1016/j.ejmech.2020.112640,,,,Inhibition of human EGFR incubated for 2 hrs by ELISA assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.045,uM,=,-1.3467874862246565,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2759,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccc(CNCc6ccccc6)o5)cc34)cc2Cl)c1,"6-(5-((benzylamino)methyl)furan-2-yl)-N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)thieno[2,3-d]pyrimidin-4-amine",0.054,uM,=,-1.2676062401770316,0,c1ccc(CNCc2ccc(-c3cc4c(Nc5ccc(OCc6ccccc6)cc5)ncnc4s3)o2)cc1
2760,306181,10.1016/j.bmcl.2005.01.079,,,,Inhibition of Epidermal growth factor receptor,CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,"6-(2,6-Dichloro-phenyl)-2-[4-(2-diethylamino-ethoxy)-phenylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",44.0,uM,=,1.6434526764861874,1,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
2761,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCCCn1ccnc1[N+](=O)[O-],N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-methoxy-7-(3-(2-nitro-1H-imidazol-1-yl)propoxy)quinazolin-4-amine,0.0305,uM,=,-1.515700160653214,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCCCn5ccnc5)ccc34)cc2)cc1
2762,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Oc1c(I)cc(I)c2cccnc12,"5,7-Diiodo-quinolin-8-ol",1.889,uM,=,0.2762319579218336,1,c1ccc2ncccc2c1
2763,2047186,10.1021/acs.jmedchem.0c01170,,,,Inhibition of EGFR in human KYSE-520 cells assessed as reduction in p-ERK levels,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3ccccc23)cc1
2764,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3ccccc3o2)c1O,3-[3-(Benzooxazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,6.0,uM,=,0.7781512503836436,1,c1ccc(CSc2nc3ccccc3o2)cc1
2765,86514,10.1021/jm00110a022,,,,Inhibition of HER14 (human EGFR overexpressing) cell proliferation.,Cc1ccc(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)cc1,"3-(3,4-Dihydroxy-phenyl)-2-(4-methyl-benzoyl)-acrylonitrile",7.0,uM,=,0.8450980400142568,1,O=C(/C=C/c1ccccc1)c1ccccc1
2766,2213928,10.1016/j.ejmech.2021.113963,,,,Inhibition of human EGFR expressed in baculovirus expression system using CAGAGAIETDKEYYTVKD as substrate preincubated for 10 mins followed by substrate and ATP addition measured after 1 hr by TR-FRET assay,O=C(Cc1ccccc1)Nc1cccc(-c2nc3n(c2-c2ccnc(Nc4ccc(N5CCOCC5)cc4)n2)CCS3)c1,"N-[3-[5-[2-(4-morpholinoanilino)pyrimidin-4-yl]-2,3-dihydroimidazo[2,1-b]thiazol-6-yl]phenyl]-2-phenyl-acetamide",0.0355,uM,=,-1.449771646944906,0,O=C(Cc1ccccc1)Nc1cccc(-c2nc3n(c2-c2ccnc(Nc4ccc(N5CCOCC5)cc4)n2)CCS3)c1
2767,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,O=C1CNCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,"1-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)-1,4-diazepan-6-one",0.78,uM,=,-0.1079053973095195,0,O=C1CNCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c23)C1
2768,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,POZIOTINIB,0.0013,uM,=,-2.886056647693163,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
2769,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2Cl)CC1,1-(4-((5-chloro-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one,0.03026,uM,=,-1.519131076312832,0,c1cc(OC2CCNCC2)nc(Nc2ccc(N3CCNCC3)cc2)n1
2770,591074,10.1021/jm9010065,,,,Inhibition of human recombinant HER1 expressed in Sf9 cells by liquid scintillation counting,CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)OCCn1ccnc1,"{4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl}-carbamic acid 2-(1H-imidazol-1-yl)ethyl ester",0.04,uM,=,-1.3979400086720375,0,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OCCn1ccnc1
2771,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Nc1ccc2c(c1)CNc1c(Nc3cccc(Br)c3)ncnc1O2,"N*1*-(3-Bromo-phenyl)-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene-1,8-diamine",1.7,uM,=,0.2304489213782739,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
2772,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,NC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,1-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)urea,0.0020299999999999,uM,=,-2.692503962086787,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
2773,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cc(CO)ccc1-c1cc2c(NCc3ccccc3)ncnc2s1,"(4-(4-(Benzylamino)thieno[2,3-d]pyrimidin-6-yl)-3-methoxyphenyl)methanol",0.005,uM,=,-2.3010299956639813,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
2774,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc([N+](=O)[O-])c(C(=O)Nc2ccc(F)c(Cl)c2)cc1NC(=O)c1ccc(CN2CCN(C)CC2)cc1,N-(3-Chloro-4-fluorophenyl)-4-ethoxy-5-(4-((4-methylpiperazin-1-yl)methyl)benzamido)-2-nitrobenzamide,5.0,uM,=,0.6989700043360189,1,O=C(Nc1cccc(C(=O)Nc2ccccc2)c1)c1ccc(CN2CCNCC2)cc1
2775,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN[C@H](C)C(N)=O,(R)-2-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methylamino)propanamide,0.12,uM,=,-0.9208187539523752,0,c1ccc(Nc2ncnc3ccccc23)cc1
2776,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCCN1CCN(C)CC1.Cl,(4-Chloro-2-fluoro-phenyl)-{6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinazolin-4-yl}-amine hydrochloride,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
2777,2080995,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R/T790M (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCc1cn(CCC(=O)NO)nn1,"N-(4-((3-chloro-4-((2-fluorobenzyl)oxy)phenyl)amino)-7-((1-(3-(hydroxyamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.016,uM,=,-1.7958800173440752,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCc5c[nH]nn5)ccc34)cc2)cc1
2778,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(Nc1cncc(Cl)c1)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,1-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3-(5-chloropyridin-3-yl)thiourea,0.0555,uM,=,-1.2557070168773237,0,S=C(Nc1cccnc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2779,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,CN(CCO)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"2-{[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-methyl-amino}-ethanol",0.00022,uM,=,-3.657577319177794,0,c1ccc(Nc2ncnc3cnccc23)cc1
2780,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cc(Cl)ccc3F)c2cc1OC1CCN(C)CC1,N-(5-chloro-2-fluorophenyl)-7-methoxy-6-(1-methylpiperidin-4-yloxy)quinazolin-4-amine,0.106,uM,=,-0.9746941347352298,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
2781,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)thiophen-3-yl)thieno[2,3-d]pyrimidin-4-amine",0.304,uM,=,-0.5171264163912462,0,c1ccc(COc2ccc(Nc3ncnc4sc(-c5ccsc5)cc34)cc2)cc1
2782,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccc(O)c(O)c3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,4-Dihydroxybenzylidene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",0.4,uM,=,-0.3979400086720376,0,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
2783,1556348,10.1016/j.bmc.2016.02.017,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by addition of substrate by mobility shift assay,COc1ccc(/C=C/C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2O[C@H]2CCOC2)cc1,(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-3-(4-methoxyphenyl)-acrylamide,0.0091,uM,=,-2.0409586076789066,0,O=C(/C=C/c1ccccc1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
2784,66599,10.1021/jm960879m,,,,Tested for inhibition of PLC gamma-derived substrate in Epidermal growth factor receptor stimulated A431 cells,CNc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-N*6*-methyl-quinazoline-4,6-diamine",0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccccc23)cc1
2785,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=S)NCCN5CCCCC5)cc34)cc2Cl)c1,1-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)-3-(2-(piperidin-1-yl)ethyl)thiourea,0.296,uM,=,-0.5287082889410615,0,S=C(NCCN1CCCCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
2786,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCCCn1c([N+](=O)[O-])cnc1C,N-(3-bromophenyl)-7-methoxy-6-(3-(2-methyl-5-nitro-1Himidazol-1-yl)propoxy)quinazolin-4-amine,0.0011799999999999,uM,=,-2.9281179926938745,0,c1ccc(Nc2ncnc3ccc(OCCCn4ccnc4)cc23)cc1
2787,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N(C)CCN(C)C)cc4OC)nc32)c1,"N-(3-(7-((4-((2-(Dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-3-isopropyl-2,4-dioxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.121,uM,=,-0.91721462968355,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccccc3)ncc12
2788,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,O=C(/C=C/CN1CCC(N2CCCCC2)CC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"4-[1,4']Bipiperidinyl-1'-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide",0.068,uM,=,-1.1674910872937636,0,O=C(/C=C/CN1CCC(N2CCCCC2)CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2789,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.0022,uM,=,-2.657577319177794,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
2790,1628134,10.1016/j.bmc.2016.10.006,,,,"Inhibition of recombinant human GST-fused EGFR (668 to 1211 residues) assessed as phosphotyrosine formation using poly(Glu:Tyr, 4:1) as substrate and ATP measured after 6 mins",COc1cc(Nc2ncnc3ccc(-c4ccc(CN5C[C@@H]6[C@@H](CO)[C@@H]6C5)cc4)cc23)ccc1Oc1ccccc1,"((1R,5S,6r)-3-(4-(4-(3-methoxy-4-phenoxyphenylamino)quinazolin-6-yl)benzyl)-3-azabicyclo[3.1.0]hexan-6-yl)methanol",0.67,uM,=,-0.1739251972991735,0,c1ccc(Oc2ccc(Nc3ncnc4ccc(-c5ccc(CN6C[C@H]7C[C@H]7C6)cc5)cc34)cc2)cc1
2791,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0002399999999999,uM,=,-3.619788758288394,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2792,1674599,10.1021/acs.jmedchem.8b00125,,,,Inhibition of EGFR (unknown origin),CNS(=O)(=O)c1cccc(Nc2cc(Nc3cccc(C)c3)ncn2)c1,N-Methyl-3-({6-[(3-methylphenyl)amino]-4-pyrimidinyl}amino)-benzenesulfonamide,0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
2793,1693612,10.1016/j.bmc.2017.06.004,,,,Inhibition of wild-type EGFR (unknown origin) using Tyr 4 peptide as substrate in presence of ATP by Z-LYTE kinase assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccc(F)cc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-(5-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.1663,uM,=,-0.7791077507804808,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2794,1448250,10.1016/j.bmcl.2014.07.094,,,,Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry,CCOC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2ccccc2n2nnnc12,"Ethyl 2-amino-5-oxo-1-(pyridin-3-yl)-4-(tetrazolo[1,5-a]quinolin-4-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",0.09,uM,=,-1.0457574905606752,0,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1
2795,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,O=C(Nc1ccncc1)Nc1cc(-c2cncnc2)ccc1OC(F)(F)F,1-(Pyridin-4-yl)-3-(5-(pyrimidin-5-yl)-2-(trifluoromethoxy)phenyl)urea,0.01804,uM,=,-1.7437634667940771,0,O=C(Nc1ccncc1)Nc1cccc(-c2cncnc2)c1
2796,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,Nc1cccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccc(F)cc4)ccnc3[nH]2)c1,"3-(4-(4-(4-Fluorophenyl)-2-phenyl-1H-imidazol-5-yl)-1Hpyrrolo[2,3-b]pyridin-2-yl)aniline",0.0241,uM,=,-1.6179829574251317,0,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccccc4)ccnc3[nH]2)cc1
2797,2270927,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR T790M (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2c(N3CCc4ccccc43)ncnc2cc1O[C@@H]1CCOC1,"(R,E)-4-(dimethylamino)-N-(4-(indolin-1-yl)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)but-2-enamide",0.026,uM,=,-1.585026652029182,0,c1ccc2c(c1)CCN2c1ncnc2cc(O[C@@H]3CCOC3)ccc12
2798,1882933,10.1016/j.ejmech.2018.11.029,,,,Inhibition of recombinant human wild type GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system after 1 hr by kinase tracer 199 based TR-FRET assay,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CSc1nnnn1C,N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-2-((1-methyl-1H-tetrazol-5-yl)thio)acetamide,0.00053,uM,=,-3.275724130399211,0,O=C(CSc1nnn[nH]1)Oc1ccc2ncnc(Nc3ccccc3)c2c1
2799,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3nc(Nc4ccccc4)sc23)cc1Cl,"N7-(3-chloro-4-fluorophenyl)-N2-phenylthiazolo[4,5-d]pyrimidine-2,7-diamine",0.059,uM,=,-1.2291479883578558,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1
2800,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc(OCc5ccc(Cl)cc5)c(Cl)c4)c3cc21,"Ethyl 4-(8-(4-(4-chlorobenzyloxy)-3-chlorophenylamino)-2-oxooxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",0.053,uM,=,-1.275724130399211,0,O=c1[nH]c2cc3c(Nc4ccc(OCc5ccccc5)cc4)ncnc3cc2o1
2801,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)c(O)c1)C(N)=O,"(E)-2-Cyano-3-(3,4-dihydroxy-phenyl)-acrylamide",10.0,uM,=,1.0,1,c1ccccc1
2802,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",NS(=O)(=O)c1ccc(Nc2nncc3ccccc23)cc1,4-(Phthalazin-1-ylamino)benzenesulfonamide,0.14,uM,=,-0.8538719643217619,0,c1ccc(Nc2nncc3ccccc23)cc1
2803,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Oc1c(Br)cccc1Nc1ncnc2cc3c(cc12)OCCO3,"2-Bromo-6-[(7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)amino]phenol",0.7291,uM,=,-0.1372129017646556,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
2804,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,Cn1cc(NC(=O)c2cccc(NS(=O)(=O)c3ccccc3)c2)cn1,N-(1-Methyl-1H-pyrazol-4-yl)-3-(phenylsulfonamido)benzamide,34.28,uM,=,1.5350408132511606,1,O=C(Nc1cn[nH]c1)c1cccc(NS(=O)(=O)c2ccccc2)c1
2805,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CCN(C)CC1,4-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-1-methylpiperidine-4-carboxamide,0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3ccc(CNC4CCNCC4)cc23)cc1
2806,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)cc3)ncnc2cc1O[C@H]1CCOC1,"(S,E)-4-(Dimethylamino)-N-(4-(4-(3-fluorobenzyloxy)phenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)but-2-enamide",0.1339,uM,=,-0.8732194229879909,0,c1ccc(COc2ccc(Nc3ncnc4cc(O[C@H]5CCOC5)ccc34)cc2)cc1
2807,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,CN(C)C/C=C/C(=O)N1CCC[C@@H](n2nc(-c3cccc(C(F)(F)F)c3)c3c(N)ncnc32)C1,"(R,E)-1-(3-(4-Amino-3-(3-(trifluoromethyl)phenyl)-1H-pyrazolo-[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-4-(dimethylamino)but-2-en-1-one",7.3,uM,=,0.8633228601204559,1,c1ccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)cc1
2808,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccn(C)n3)n2)c(OC)cc1N(C)CCN(C)C(=O)OC,methyl (2-((2-acrylamido-5-methoxy-4-((4-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)(methyl)carbamate,0.2877,uM,=,-0.5410601381096739,0,c1ccc(Nc2nccc(Nc3cc[nH]n3)n2)cc1
2809,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CC[C@H](C(N)=O)C1,(S)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidine-3-carboxamide,0.08,uM,=,-1.0969100130080565,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
2810,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(=O)c3ccco3)c3ccccc3n2C)c(C(=O)c2ccco2)c2ccccc21,{2-[3-(Furan-2-carbonyl)-1-methyl-1H-indol-2-yldisulfanyl]-1-methyl-1H-indol-3-yl}-furan-2-yl-methanone,7.7,uM,=,0.8864907251724818,1,O=C(c1ccco1)c1c(SSc2[nH]c3ccccc3c2C(=O)c2ccco2)[nH]c2ccccc12
2811,1619030,10.1016/j.bmc.2016.09.001,,,,Inhibition of human recombinant N-terminal GST-tagged wild type EGFR cytoplasmic domain (695 end residues) autophosphorylation expressed in baculovirus infected Sf9 insect cells by ADP-Glo luminescence assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(Cn4ccnc4)cc3)ncc2F)c1,N-[3-[[5-Fluoro-2-[4-(1H-imidazol-1-ylmethyl)phenylamino]-4-pyrimidinyl]amino]phenyl]-2-propenamide,0.987,uM,=,-0.0056828473303632,0,c1ccc(Nc2ccnc(Nc3ccc(Cn4ccnc4)cc3)n2)cc1
2812,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1c(C(=O)NCCN(C)C)cccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1,"(R)-N-(2-(Dimethylamino)ethyl)-2-methoxy-3-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzamide",0.003,uM,=,-2.5228787452803374,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
2813,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCOC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,Nonyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetate,4.96,uM,=,0.6954816764901974,1,O=c1cc(-c2ccccc2)oc2ccccc12
2814,1924071,10.1021/acs.jmedchem.6b00403,,,,"Inhibition of wild type EGFR kinase domain (unknown origin) expressed using baculovirus expression system incubated for 1 hr using Poly(Glu,Tyr) 4:1 by ELISA method",C=CC(=O)Nc1cccc(-n2c(=O)c(=O)[nH]c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6,7-dioxo-6,7-dihydropteridin-8(5H)-yl)phenyl)acrylamide",0.0028,uM,=,-2.552841968657781,0,O=c1[nH]c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n(-c2ccccc2)c1=O
2815,454469,10.1016/j.bmcl.2007.01.057,,,,Inhibition of EGFR,CC(C)Nc1ncnc2oc(-c3ccc(OCCN4CCCC4)cc3)c(-c3ccccc3)c12,"N-isopropyl-5-phenyl-6-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)furo[2,3-d]pyrimidin-4-amine",1.029,uM,=,0.0124153747624328,1,c1ccc(-c2c(-c3ccc(OCCN4CCCC4)cc3)oc3ncncc23)cc1
2816,1908531,10.1021/acsmedchemlett.9b00381,,,,Inhibition of EGFR (unknown origin) expressed in mouse Ba/F3 cells assessed as reduction in cell growth incubated for 72 hrs in presence of 1 ug/ml Cetuximab by celltiter-glo luminescent cell viability assay,O=C1c2cc(-c3ccc(N4CCNCC4)cc3)ccc2Nc2ccc(F)cc2N1Cc1ccccc1,"10-Benzyl-8-fluoro-2-(4-(piperazin-1-yl)phenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one",4.1,uM,=,0.6127838567197355,1,O=C1c2cc(-c3ccc(N4CCNCC4)cc3)ccc2Nc2ccccc2N1Cc1ccccc1
2817,661840,10.1016/j.bmc.2010.05.049,,,,Inhibition of EGFR expressed in human A431 cells,Cc1ccccc1Cc1cc2c(Nc3cccc(Br)c3)nc(N)nc2n1C,"2-Amino-4-(m-bromoanilino)-6-(2-methylbenzyl)-7-methyl-pyrrolo[2,3-d]pyrimidine",12.8,uM,=,1.1072099696478683,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
2818,66906,10.1016/s0960-894x(01)00776-4,,,,Inhibition of epidermal growth factor receptor (EGFR),COc1cc2cc3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3cc2cc1OC,"4-(3-Chloro-4-fluoro-phenylamino)-7,8-dimethoxy-benzo[g]quinoline-3-carbonitrile",18.0,uM,=,1.255272505103306,1,c1ccc(Nc2ccnc3cc4ccccc4cc23)cc1
2819,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,O=C(Nc1ccccc1Br)c1ccc(N(CCCl)CCCl)cc1,4-(Bis(2-chloroethyl)amino)-N-(2-bromophenyl)benzamide,7.82,uM,=,0.893206753059848,1,O=C(Nc1ccccc1)c1ccccc1
2820,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OCC)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"ethyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidine-5-carboxylate",0.032,uM,=,-1.494850021680094,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)cc1
2821,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,O=C(Nc1cnn(-c2ccccc2)c1)c1ccc(NS(=O)(=O)c2ccccc2)cc1,N-(1-Phenyl-1H-pyrazol-4-yl)-4-(phenylsulfonamido)benzamide,25.41,uM,=,1.4050046650503694,1,O=C(Nc1cnn(-c2ccccc2)c1)c1ccc(NS(=O)(=O)c2ccccc2)cc1
2822,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CC1C(=O)OC,1-{(E)-3-[4-(4-Benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-ylcarbamoyl]-allyl}-aziridine-2-carboxylic acid methyl ester,0.343,uM,=,-0.4647058799572294,0,O=C(/C=C/CN1CC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
2823,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Nc1ccc2ncncc2c1,Quinazolin-6-ylamine,0.00079,uM,=,-3.1023729087095586,0,c1ccc2ncncc2c1
2824,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Nc3ccc4ccccc4c3)c1NC2,"(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-naphthalen-2-yl-amine",0.5,uM,=,-0.3010299956639812,0,c1ccc2c(c1)CNc1c(Nc3ccc4ccccc4c3)ncnc1O2
2825,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCn1ccnc1[N+](=O)[O-],N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-(2-nitro-1Himidazol-1-yl)ethoxy)quinazolin-4-amine,0.0030499999999999,uM,=,-2.515700160653214,0,c1ccc(Nc2ncnc3ccc(OCCn4ccnc4)cc23)cc1
2826,65107,10.1021/jm00032a020,,,,Inhibition of EGF-stimulated DNA synthesis in ER 22 (EGF-receptor expressing) cells,O=C(O)c1cc(/N=C/c2cc(O)ccc2O)ccc1O,"5-[(2,5-Dihydroxy-benzylidene)-amino]-2-hydroxy-benzoic acid",100.0,uM,=,2.0,1,C(=N/c1ccccc1)\c1ccccc1
2827,1897499,10.1016/j.bmc.2019.07.042,,,,Inhibition of EGFR-TK in human MCF7 cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay,Fc1ccc(COC(c2cccs2)c2cc3ccccc3nc2Cl)cc1,2-Chloro-3-{[(4-fluorobenzyl)oxy](thiophen-2-yl)methyl}quinoline,2.75,uM,=,0.4393326938302626,1,c1ccc(COC(c2cnc3ccccc3c2)c2cccs2)cc1
2828,1524114,10.1016/j.bmc.2015.10.035,,,,Inhibition of human EGFR after 1 hr using [gamma-32P]ATP,Cc1cc(Oc2ncnc3sc4c(c23)CCCC4)ccc1NC(=O)Nc1cccc(Br)c1,"N-(3-Bromophenyl)-N'-{3-methyl-4-[(5,6,7,8-tetrahydrobenzo[4,5]-thieno[2,3-d]pyrimidin-4-yl)oxy]phenyl}urea",3.29,uM,=,0.5171958979499743,1,O=C(Nc1ccccc1)Nc1ccc(Oc2ncnc3sc4c(c23)CCCC4)cc1
2829,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,O=C(O)CCC1C(S)=Nc2ccccc21,"3-(2-Thioxo-2,3-dihydro-1H-indol-3-yl)-propionic acid",1.62,uM,=,0.2095150145426309,1,C1=Nc2ccccc2C1
2830,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,C=C(CN(C)C)C(=O)c1ccc(OS(=O)(=O)c2ccc(C(=O)O)cc2)cc1,4-[4-(2-Dimethylaminomethyl-acryloyl)-phenoxysulfonyl]-benzoic acid,0.23,uM,=,-0.6382721639824072,0,O=S(=O)(Oc1ccccc1)c1ccccc1
2831,2088168,10.1016/j.ejmech.2020.112363,,,,Inhibition of EGFR (unknown origin) by FRET assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.095,uM,=,-1.0222763947111522,0,c1ccc(Nc2ncnc3ccccc23)cc1
2832,1891470,10.1016/j.bmc.2019.03.049,,,,Inhibition of c-MET (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins by mobility shift assay,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,CABOZANTINIB,0.019,uM,=,-1.7212463990471711,0,O=C(Nc1ccccc1)C1(C(=O)Nc2ccc(Oc3ccnc4ccccc34)cc2)CC1
2833,1721451,10.1016/j.ejmech.2017.11.008,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using peptide substrate after 1 hr by mobility shift assay,COc1cc(-n2cc(CN3C[C@@H](C)N[C@@H](C)C3)nn2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,"5-Chloro-N2-(4-(4-((3,5-dimethylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-2-methoxyphenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine",0.865,uM,=,-0.0629838925351857,0,c1ccc(Nc2ccnc(Nc3ccc(-n4cc(CN5CCNCC5)nn4)cc3)n2)cc1
2834,1642158,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",0.067,uM,=,-1.1739251972991736,0,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
2835,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(C=C(C#N)C#N)cc(CSc2ccccc2)c1O,2-(4-Hydroxy-3-methoxy-5-phenylsulfanylmethyl-benzylidene)-malononitrile,6.7,uM,=,0.8260748027008264,1,c1ccc(CSc2ccccc2)cc1
2836,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(C(=O)N2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[3-methyl-5-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.17,uM,=,-0.7695510786217261,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCOCC2)[nH]1
2837,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COCOC#CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,3-Methoxymethoxy-propynoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.33,uM,=,-0.4814860601221125,0,c1ccc(Nc2ccnc3ccccc23)cc1
2838,506208,10.1021/np50089a001,,,,Inhibition of EGFR,N#C/C(=C\c1cc(-c2ccccc2)c(O)c(-c2ccccc2)c1)C(N)=O,"2-Cyano-3-(2'-hydroxy-[1,1',3',1'']terphenyl-5'-yl)-acrylamide",0.4,uM,=,-0.3979400086720376,0,c1ccc(-c2cccc(-c3ccccc3)c2)cc1
2839,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,Cc1cccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)cc23)c1,"N*6*-[2-(3H-Imidazol-4-yl)-ethyl]-N*4*-m-tolyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0013,uM,=,-2.886056647693163,0,c1ccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)cc23)cc1
2840,2145645,10.1016/j.bmcl.2021.128406,,,,Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence of ATP by IMAP-FP assay,C=CC(=O)N1CCC2(CC1)CNC(=O)c1cc(-c3nc(Nc4ccccc4OC)ncc3C)[nH]c12,"1-acryloyl-2'-(2-(2-methoxyphenylamino)-5-methylpyrimidin-4-yl)-5',6'-dihydrospiro[piperidine-4,7'-pyrrolo[3,2-c]pyridin]-4'(1'H)-one",0.0014,uM,=,-2.853871964321762,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(Nc4ccccc4)n3)cc21
2841,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC[C@H](Oc2ccc3ncnc(Nc4ccc(F)c(Cl)c4F)c3c2)C1,"1-((3S)-3-(4-(3-chloro-2,4-difluorophenylamino)quinazolin-6-yloxy)pyrrolidin-1-yl)prop-2-en-1-one",0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccc(O[C@H]4CCNC4)cc23)cc1
2842,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,CCO[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(((2S,4R)-4-ethoxypyrrolidin-2-yl)ethynyl)thieno[3,2-d]pyrimidin-4-amine",0.115,uM,=,-0.9393021596463884,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
2843,1675840,10.1016/j.bmc.2017.03.032,,,,"Inhibition of recombinant wild type human EGFR (695 to end residues) using Poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(/C=C/c4cc(C)cc(C)c4)cc3)ncc2F)c1,"N-[3-[[5-Fluoro-2-[(E)-4-(3,5-dimethylstyryl)phenylamino]-4-pyrimidinyl]amino]phenyl]-2-acrylamide",0.5392,uM,=,-0.2682501164727366,0,C(=C/c1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)\c1ccccc1
2844,1641793,,,,,"Cell Proliferation Inhibition Assay: The following in vitro assay is to determine the activity of the tested compounds for inhibiting the proliferation of cancer cells, which has high expression of EGFR. The activity is represented by the IC50 value. The general procedures of the assay are given as follows: The cancer cells A431 that highly expressing EGFR (Institute of biochemistry and cell biology) were chosen and seeded to 96-well cell culture plate at a suitable concentration (e.g., 5000 cells/mL medium). The cells then were incubated in carbon dioxide (CO2) incubator until they reached 85% confluency. Then, the cell culture medium was replaced by fresh one with tested compounds added in it at serial concentrations (general 6 to 7 concentrations). Then the cells were put back to the incubator and cultured continuously. 72 hours later, the activity of the tested compounds for inhibiting the cell proliferation was determined by using Sulforhodamine B (SRB) method.",CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@@H]1C[C@@H](O)CN1C,"US8901140, 3::US9358227, 3",0.036,uM,=,-1.4436974992327127,0,O=C(/C=C/[C@@H]1CCCN1)Nc1ccc2nccc(Nc3ccc(OCc4ccccn4)cc3)c2c1
2845,828211,10.1016/j.bmc.2012.05.068,,,,Inhibition of EGFR in human A431 cells pretreated for 60 mins measured after 1 hr by ELISA,Nc1nc2c(c(Nc3ccc(F)cc3)n1)-c1ccccc1C2,"N4-(4-Fluorophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine",276.1,uM,=,2.441066406639264,1,c1ccc(Nc2ncnc3c2-c2ccccc2C3)cc1
2846,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CN(C)C/C=C/C(=O)N1Cc2sc3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c3c2C1,"US8524722, 87",0.019,uM,=,-1.7212463990471711,0,c1ccc(COc2ccc(Nc3ncnc4sc5c(c34)CNC5)cc2)nc1
2847,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,C[C@@H](Nc1ncnc2sc(Br)cc12)c1cccs1,"(R)-6-Bromo-N-(1-(thiophen-2-yl)ethyl)thieno[2,3-d]pyrimidin-4-amine",0.415,uM,=,-0.3819519032879073,0,c1csc(CNc2ncnc3sccc23)c1
2848,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,c1ccc(Cc2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-benzyl-1,3,4-oxadiazole",25.0,uM,=,1.3979400086720375,1,c1ccc(Cc2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
2849,457884,10.1016/j.bmcl.2007.08.073,,,,Inhibition of EGFR,CN(CCOc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12)C(=O)CO,N-(2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)ethyl)-2-hydroxy-N-methylacetamide,0.035,uM,=,-1.4559319556497243,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
2850,1883874,10.1021/acsmedchemlett.8b00270,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay,C=CC(=O)N(c1ccc(F)cc1F)c1ncnc2cc(OC)c(OCCCN3CCOCC3)cc12,"4-[N-acryloyl-(2,4-difluorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline",0.302,uM,=,-0.5199930570428494,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
2851,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CC(C)CCCC(C)CCOC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3,7-dimethyl-octyl ester",7.0,uM,=,0.8450980400142568,1,c1ccc(CNc2ccccc2)cc1
2852,608091,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 8 hrs by Western blot,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-phenoxyacetamide,0.292,uM,=,-0.5346171485515817,0,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2853,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(C=C(C#N)C#N)cc(C)c1O,2-(4-Hydroxy-3-methoxy-5-methyl-benzylidene)-malononitrile,87.0,uM,=,1.9395192526186185,1,c1ccccc1
2854,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,N#CCNCc1ccc(-c2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)o1,"2-((5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)furan-2-yl)methylamino)acetonitrile",0.003,uM,=,-2.5228787452803374,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5ccco5)sc34)cc2)cc1
2855,66904,10.1016/S0960-894X(96)00601-4,,,,Inhibition of the epidermal growth factor receptor.,c1cc(Nc2nccc(-c3cccnc3)n2)cc(OCCn2ccnc2)c1,[3-(2-Imidazol-1-yl-ethoxy)-phenyl]-(4-pyridin-3-yl-pyrimidin-2-yl)-amine,7.1,uM,=,0.8512583487190752,1,c1cc(Nc2nccc(-c3cccnc3)n2)cc(OCCn2ccnc2)c1
2856,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1,"5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one",140.8111203239629,uM,=,2.148636953844647,1,O=c1cc(-c2ccccc2)oc2ccccc12
2857,800208,10.1016/j.bmcl.2011.12.067,,,,Inhibition of wild-type EGFR expressed using baculovirus expression system by ELISA,O=c1c2c(-c3ccccc3)c3c(nc2nc2[nH]nc(S)n12)-c1ccccc1CC3,"9-Mercapto-7-phenyl-5,6-dihydro-11H-8a,10,11,12,13-pentaaza-benzo[a]cyclopenta[i]anthracen-8-one",85.6,uM,=,1.9324737646771533,1,O=c1c2c(-c3ccccc3)c3c(nc2nc2[nH]ncn12)-c1ccccc1CC3
2858,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC1C(N)=O,1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)azetidine-2-carboxamide,0.07,uM,=,-1.154901959985743,0,c1ccc(Nc2ncnc3ccc(CN4CCC4)cc23)cc1
2859,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.362,uM,=,-0.4412914294668343,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
2860,2147299,10.1021/acs.jmedchem.1c01013,,,,Inhibition of exogenous EGFR (unknown origin),CC(OC(=O)CCCC(=O)N(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1cc2c(o1)C(=O)c1ccccc1C2=O,"1-(4,9-Dioxo-4,9-dihydronaphtho[2,3-b]furan-2-yl)ethyl-5-(((5-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)furan-2-yl)methyl)(2-(methylsulfonyl)ethyl)amino)-5-oxopentanoate",0.00736,uM,=,-2.133122185662501,0,O=C(CCCC(=O)OCc1cc2c(o1)C(=O)c1ccccc1C2=O)NCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1
2861,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,NS(=O)(=O)c1ccc(Nc2nc3ncnc(Nc4c(F)cccc4F)c3s2)cc1,"4-(7-(2,6-difluorophenylamino)thiazolo[4,5-d]pyrimidin-2-ylamino)benzenesulfonamide",0.187,uM,=,-0.728158393463501,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1
2862,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,O=C(NO)c1ccccc1Nc1nc(Nc2ccc(OCCN3CCOCC3)cc2)ncc1Cl,2-(5-chloro-2-(4-(2-morpholinoethoxy)phenylamino)pyrimidin-4-ylamino)-N-hydroxybenzamide,0.0476599999999999,uM,=,-1.3218459619895628,0,c1ccc(Nc2ccnc(Nc3ccc(OCCN4CCOCC4)cc3)n2)cc1
2863,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,COc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"(3-Bromo-phenyl)-(6-methoxy-pyrido[3,4-d]pyrimidin-4-yl)-amine",0.0026,uM,=,-2.5850266520291822,0,c1ccc(Nc2ncnc3cnccc23)cc1
2864,63773,10.1021/jm9508651,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 human epidermoid carcinoma cells,Nc1cc2ncnc(NCc3ccccc3)c2cn1,"N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine",2.085,uM,=,0.3191060593097763,1,c1ccc(CNc2ncnc3ccncc23)cc1
2865,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3nc(Nc4ccc(CN5CCCCC5)cc4)sc23)cc1Cl,"N7-(3-chloro-4-fluorophenyl)-N2-(4-(piperidin-1-ylmethyl)phenyl)thiazolo[4,5-d]pyrimidine-2,7-diamine",0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3nc(Nc4ccc(CN5CCCCC5)cc4)sc23)cc1
2866,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,c1ccc(NCCN(c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)n2cccc2)cc1,"N*4*-(1H-Indol-5-yl)-N*6*-(2-phenylamino-ethyl)-N*6*-pyrrol-1-yl-thieno[3,2-d]pyrimidine-4,6-diamine",0.001,uM,=,-3.0,0,c1ccc(NCCN(c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)n2cccc2)cc1
2867,879290,10.1021/jm1013693,,,,Inhibition of HER1,O=S1(=O)N=S(c2ccc(Br)cc2)c2ccncc21,"1-(4-Bromo-phenyl)-1lambda(4),3-dithia-2,5-diaza-indene 3,3-dioxide",5.4,uM,=,0.7323937598229685,1,O=S1(=O)N=S(c2ccccc2)c2ccncc21
2868,1761038,10.1016/j.ejmech.2018.01.042,,,,Inhibition of His6-tagged EGFR (unknown origin) cytoplasmic domain expressed in baculovirus infected Sf9 insect cells after 10 mins followed by addition of ATP-MgCl2 and measured after 1 hr by time-resolved fluorometric analysis,CCc1c2cc(C(F)(F)F)ccc2n2cc(Cc3ccccc3)[nH]c(=O)c12,"3-Benzyl-10-ethyl-8-(trifluoromethyl)pyrazino[1,2-a]indol-1(2H)-one",3.9,uM,=,0.5910646070264992,1,O=c1[nH]c(Cc2ccccc2)cn2c1cc1ccccc12
2869,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CC(=O)Nc1cc2ncnc(Nc3cccc(Br)c3)c2cc1[N+](=O)[O-],N-[4-(3-Bromo-phenylamino)-6-nitro-quinazolin-7-yl]-acetamide,0.028,uM,=,-1.5528419686577808,0,c1ccc(Nc2ncnc3ccccc23)cc1
2870,2241040,10.1021/acs.jmedchem.1c00848,,,,Displacement of sapitinib-BODIPY tracer from C-terminal NanoLuc-fused full length wild type EGFR (unknown origin) transfected in HEK293T cells incubated for 2 hrs by NanoBRET assay,CSc1nc(-c2cccc(NC(=O)c3cc(O)ccc3F)c2)c(-c2ccnc(NC(C)=O)c2)[nH]1,N-(3-(5-(2-Acetamidopyridin-4-yl)-2-(methylthio)-1H-imidazol-4-yl)phenyl)-2-fluoro-5-hydroxybenzamide,0.33,uM,=,-0.4814860601221125,0,O=C(Nc1cccc(-c2nc[nH]c2-c2ccncc2)c1)c1ccccc1
2871,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C#N)c3ccccc3n2C)c(C#N)c2ccccc21,2-(3-cyano-1-methyl-1H-2-indolyldisulfanyl)-1-methyl-1H-3-indolecarbonitrile,6.9,uM,=,0.8388490907372553,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
2872,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1ccc(N2CC(CS(C)(=O)=O)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-(3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinolin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",0.385,uM,=,-0.4145392704914993,0,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
2873,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CNc1cc2ncnc(Nc3cccc(Br)c3)c2cc1[N+](=O)[O-],"N*4*-(3-Bromo-phenyl)-N*7*-methyl-6-nitro-quinazoline-4,7-diamine",0.068,uM,=,-1.1674910872937636,0,c1ccc(Nc2ncnc3ccccc23)cc1
2874,2145645,10.1016/j.bmcl.2021.128406,,,,Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence of ATP by IMAP-FP assay,COc1ccccc1Nc1nccc(-c2cc3c([nH]2)C2(CCN(C(=O)C#CN(C)C)CC2)CNC3=O)n1,"1-(3-(dimethylamino)propioloyl)-2'-(2-(2-methoxyphenylamino)pyrimidin-4-yl)-5',6'-dihydrospiro[piperidine-4,7'-pyrrolo[3,2-c]pyridin]-4'(1'H)-one",0.0053,uM,=,-2.275724130399211,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(Nc4ccccc4)n3)cc21
2875,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,C=CC(=O)Nc1ccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)cc1,N-(4-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,2.48,uM,=,0.3944516808262163,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
2876,67049,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor,COc1cc(OC)c2c(=O)c(-c3cccc(Cl)c3)coc2c1,"3-(3-Chloro-phenyl)-5,7-dimethoxy-chromen-4-one",500.0,uM,=,2.6989700043360187,1,O=c1c(-c2ccccc2)coc2ccccc12
2877,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CSc1nnnn1C,N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-2-((1-methyl-1H-tetrazol-5-yl)thio)acetamide,0.005,uM,=,-2.3010299956639813,0,O=C(CSc1nnn[nH]1)Oc1ccc2ncnc(Nc3ccccc3)c2c1
2878,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)Nc1ccc(OC)c(Nc2cc(-c3[nH]c(SC)nc3C)ccn2)c1,N-(4-Methoxy-3-((4-(4-methyl-2-(methylthio)-1H-imidazol-5-yl)-pyridin-2-yl)amino)phenyl)acrylamide,0.032,uM,=,-1.494850021680094,0,c1ccc(Nc2cc(-c3cnc[nH]3)ccn2)cc1
2879,408552,10.1021/jm0608762,,,,Inhibition of EGFR tyrosine kinase activity,O=C(Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)C1CCSS1,"N-(4-(3-bromophenylamino)quinazolin-6-yl)-1,2-dithiolane-3-carboxamide",0.06,uM,=,-1.2218487496163564,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CCSS1
2880,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,CCOc1cc2nccc(Nc3cccc(Br)c3)c2cc1NC(=O)/C=C/CN1CCOCC1,N-(4-(3-bromophenylamino)-7-ethoxyquinolin-6-yl)-4-morpholinobut-2-enamide,10.32,uM,=,1.0136796972911926,1,O=C(/C=C/CN1CCOCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
2881,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COCCN1CC(C(N)=O)(N(C)Cc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)C1,3-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-1-(2-methoxyethyl)azetidine-3-carboxamide,0.045,uM,=,-1.3467874862246565,0,c1ccc(Nc2ncnc3ccc(CNC4CNC4)cc23)cc1
2882,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)N1CCc2c(sc3ncnc(Nc4cccc(C)c4F)c23)C1,"1-(4-((2-fluoro-3-methylphenyl)amino)-5,6-dihydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(8H)-yl)prop-2-en-1-one",3.95,uM,=,0.5965970956264602,1,c1ccc(Nc2ncnc3sc4c(c23)CCNC4)cc1
2883,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,Nc1ncnc2c1c(-c1ccccc1)cn2C1CCC(O)C1,"3-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-cyclopentanol",0.79,uM,=,-0.1023729087095585,0,c1ccc(-c2cn(C3CCCC3)c3ncncc23)cc1
2884,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3ccc(S(C)(=O)=O)cc3)cc12)c1ccccc1,"(R)-6-(4-(Methylsulfonyl)phenyl)-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine",0.041,uM,=,-1.3872161432802643,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
2885,739728,10.1016/j.bmcl.2011.01.137,,,,Inhibition of human EGFR-mediated poly(Glu4Tyr) phosphorylation after 1 hr,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.8,uM,=,-0.0969100130080563,0,c1ccc(/N=c2\nc[nH]c3cc(OCC4CCNCC4)ccc23)cc1
2886,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3P(C)(C)=O)n2)c(OC)cc1N(C)CCN(C)C,N-(5-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
2887,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,CC(=O)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccc(Br)cc1,"1-(5-(4-Bromophenyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone",18.45,uM,=,1.2659963704950792,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
2888,1566936,10.1021/acs.jmedchem.5b01633,,,,Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA,C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](F)C1,"1-((3R,4R)-3-(((5-Chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)-4-fluoropyrrolidin-1-yl)prop-2-en-1-one",4.2,uM,=,0.6232492903979004,1,c1cc2c(OC[C@@H]3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1
2889,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4cccc(Cl)c4)c3cc2N1CCCN1CCOCC1,"4-((3-chlorophenyl)amino)-6-(3-morpholinopropyl)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.0631,uM,=,-1.1999706407558657,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
2890,1361207,10.1021/jm4017762,,,,Inhibition of EGFR (unknown origin) after 1 hr by HTRF assay,C=CC(=O)NCC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1,N-(2-(3-(2-Acrylamidoacetamido)phenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide,0.007,uM,=,-2.154901959985743,0,O=C(Nc1cccc(C(=O)Nc2cnc(Nc3ccccc3)nc2)c1)c1ccccc1
2891,63607,10.1016/0960-894X(96)00197-7,,,,Inhibition of tyrosine kinase Epidermal growth factor receptor,Cc1ccc(N(C)C(=O)c2ccccc2)cc1Nc1nccc(-c2cccnc2)n1,N-Methyl-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide,49.0,uM,=,1.6901960800285136,1,O=C(Nc1cccc(Nc2nccc(-c3cccnc3)n2)c1)c1ccccc1
2892,436426,10.1021/jm070144p,,,,Inhibition of EGFR tyrosine kinase expressed in A431 cells,COc1ccc(N(CCN/N=N/c2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)CC(C)Cl)cc1,1-{4-[(3-chlorophenyl)amino-6-quinazolinyl}-3-{2-[N-(2-chloropropyl)-N-4-methoxyphenylethylenamine]} triazene,0.97,uM,=,-0.0132282657337551,0,c1ccc(NCCN/N=N/c2ccc3ncnc(Nc4ccccc4)c3c2)cc1
2893,935919,10.1016/j.bmcl.2012.11.001,,,,Inhibition of EGFR (unknown origin) by Z-LYTE assay,C=C1[C@H](C)CCC[C@]1(C)CC/C(C)=C/CC1=C(O)C(=O)C=C(N[C@@H](C(=O)O)C(C)C)C1=O,"(R)-2-(5-((E)-5-((1R,3R)-1,3-dimethyl-2-methylenecyclohexyl)-3-methylpent-2-enyl)-4-hydroxy-3,6-dioxocyclohexa-1,4-dienylamino)-3-methylbutanoic acid",293.27684934771696,uM,=,2.467277782048547,1,C=C1CCCCC1CC/C=C/CC1=CC(=O)C=CC1=O
2894,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.00075,uM,=,-3.1249387366083,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
2895,2203131,10.1016/j.ejmech.2022.114455,,,,Inhibition of wild type EGFR (unknown origin) incubated for 10 mins by HTRF KinEASE-TK assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(CC(=O)NCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"N-(3-((2-((4-(4-(2-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)amino)-2-oxoethyl)piperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide",0.8386,uM,=,-0.0764451419324505,0,O=C(CN1CCN(c2ccc(Nc3nccc(Nc4ccccc4)n3)cc2)CC1)NCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O
2896,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(OCc4ccccn4)cc3)ncnc2cc1O[C@H]1CCOC1,"(S,E)-4-(Dimethylamino)-N-(4-(4-(pyridin-2-ylmethoxy)phenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)but-2-enamide",0.009,uM,=,-2.0457574905606752,0,c1ccc(COc2ccc(Nc3ncnc4cc(O[C@H]5CCOC5)ccc34)cc2)nc1
2897,1873904,10.1021/acs.jmedchem.9b00794,,,,Inhibition of N-terminal GST-tagged human EGFR (696 to end aminoacids) expressed in baculovirus infected Sf21 cells,C=CC(=O)N1CCC[C@H](Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)C1,1-[(3R)-3-{[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino}piperidin-1-yl]prop-2-en-1-one,0.55,uM,=,-0.2596373105057561,0,c1ccc(Oc2ccc(-c3cncnc3N[C@H]3CCCNC3)cc2)cc1
2898,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,O=C(C#CCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]-4-(4-morpholinyl)-2-butynamide,0.031,uM,=,-1.5086383061657274,0,O=C(C#CCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2899,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,OCC(CO)Nc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"2-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-ylamino]-propane-1,3-diol",0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3ccncc23)cc1
2900,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(Cl)c(Br)c(OC)c4)nn32)CC1,"7-(1-acryloylpiperidin-4-yl)-2-(4-bromo-3-chloro-5-methoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",0.656,uM,=,-0.1830961606243397,0,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1
2901,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,COCCN(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-[(2-Methoxy-ethyl)-methyl-amino]-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.062,uM,=,-1.207608310501746,0,c1ccc(Nc2ncnc3ccccc23)cc1
2902,2018691,10.1016/j.bmc.2020.115674,,,,Inhibition of EGFR-TK (unknown origin) relative to control,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.067,uM,=,-1.1739251972991736,0,c1ccc(Nc2ncnc3ccccc23)cc1
2903,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-phenyl-1,3,4-oxadiazole",31.8,uM,=,1.5024271199844328,1,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
2904,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(Nc1cccc(Cl)c1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(3-chlorophenyl)thiourea,0.0206,uM,=,-1.6861327796308467,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2905,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(OCC)c(NC(=O)/C=C/CNC4CC4)cc23)c1,(E)-4-(Cyclopropylamino)-N-(7-ethoxy-4-(3-ethynylphenylamino)quinazolin-6-yl)but-2-enamide,0.0042,uM,=,-2.3767507096021,0,O=C(/C=C/CNC1CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2906,67207,10.1021/jm000231g,,,,Inhibition of Epidermal growth factor receptor,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,"2-(2-Chloro-phenyl)-5,7-dihydroxy-8-((3R,4S)-3-hydroxy-1-methyl-piperidin-4-yl)-chromen-4-one",22.0,uM,=,1.3424226808222062,1,O=c1cc(-c2ccccc2)oc2c(C3CCNCC3)cccc12
2907,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,c1ccc2sc(-c3ccc(Nc4ncnc5[nH]cnc45)cc3)nc2c1,N-(4-(benzo[d]thiazol-2-yl)phenyl)-9H-purin-6-amine,7.8,uM,=,0.8920946026904804,1,c1ccc2sc(-c3ccc(Nc4ncnc5[nH]cnc45)cc3)nc2c1
2908,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccc(F)cc1,"3-(3,4-Dihydroxy-phenyl)-2-(4-fluoro-benzoyl)-acrylonitrile",0.6000000000000001,uM,=,-0.2218487496163563,0,O=C(C=Cc1ccccc1)c1ccccc1
2909,2080997,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCc1cn(CCCCC(=O)NO)nn1,"5-(4-(((6-Acrylamido-4-((3-chloro-2-fluorophenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypentanamide",0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
2910,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,COC(=O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,"[5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-phenyl]-acetic acid methyl ester",3.0,uM,=,0.4771212547196624,1,c1ccc(CNc2ccccc2)cc1
2911,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",O=S(=O)(Nc1ncccn1)c1ccc(Nc2nncc3ccccc23)cc1,4-(Phthalazin-1-ylamino)-N-(pyrimidin-2-yl)benzenesulfonamide,0.086,uM,=,-1.0655015487564323,0,O=S(=O)(Nc1ncccn1)c1ccc(Nc2nncc3ccccc23)cc1
2912,608090,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 1 hr by Western blot,Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine",0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccccc23)cc1
2913,67206,10.1021/jm010496a,,,,Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase,CCOc1cc2ncnc(Nc3cccc(-c4cncs4)c3)c2cc1OCC,"(6,7-Diethoxy-quinazolin-4-yl)-(3-thiazol-5-yl-phenyl)-amine",0.011,uM,=,-1.958607314841775,0,c1cc(Nc2ncnc3ccccc23)cc(-c2cncs2)c1
2914,699068,10.1016/j.bmc.2010.11.007,,,,Inhibition of EGFR by HTRF assay,N#Cc1cnc(Nc2cccc(Br)c2)c2cc(NC(=O)CCc3cc4ccccc4[nH]3)ccc12,N-(1-(3-Bromophenylamino)-4-cyanoisoquinolin-7-yl)-3-(1H-indol-3-yl)propanamide,28.0,uM,=,1.4471580313422192,1,O=C(CCc1cc2ccccc2[nH]1)Nc1ccc2ccnc(Nc3ccccc3)c2c1
2915,1873904,10.1021/acs.jmedchem.9b00794,,,,Inhibition of N-terminal GST-tagged human EGFR (696 to end aminoacids) expressed in baculovirus infected Sf21 cells,C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,Evobrutinib,5.8,uM,=,0.7634279935629373,1,c1ccc(Oc2ccc(-c3cncnc3NCC3CCNCC3)cc2)cc1
2916,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCOCC4)cc3OC)n2)c1,N-(3-(3-(2-(2-methoxy-4-morpholinophenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.225,uM,=,-0.6478174818886375,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
2917,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O,"2-Amino-3-(3,4-dihydroxy-phenyl)-2-methyl-propionic acid",5.228,uM,=,0.7183355789085066,1,c1ccccc1
2918,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,O=C(COc1cc(F)c(F)c(F)c1)Nc1cccc(Oc2cc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncn2)c1,"4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-6-[3-(3,4,5-trifluorophenoxyacetamido)phenoxy]pyrimidine",0.721,uM,=,-0.1420647352805709,0,O=C(COc1ccccc1)Nc1cccc(Oc2cc(Nc3ccc(OCc4ccccc4)cc3)ncn2)c1
2919,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),CCN(CC)CCn1c2ccc(OC)cc2c2c(Nc3cccc(Br)c3)ncnc21,"(3-Bromo-phenyl)-[9-(2-diethylamino-ethyl)-6-methoxy-9H-pyrimido[4,5-b]indol-4-yl]-amine",4.27,uM,=,0.6304278750250238,1,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
2920,321418,10.1016/j.bmcl.2005.06.068,,,,Inhibitory concentration against EGFR kinase phosphorylation using synthetic peptide as a substrate,COc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12,[3-Chloro-4-(pyridin-2-ylmethoxy)-phenyl]-(5-methoxy-quinazolin-4-yl)-amine,0.44,uM,=,-0.3565473235138126,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
2921,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,CCCCN(Cc1cc(Br)cc(Br)c1O)C(=S)Nc1ccccc1,"1-Butyl-1-(3,5-dibromo-2-hydroxybenzyl)-3-phenylthiourea",31.94,uM,=,1.5043349118024645,1,S=C(NCc1ccccc1)Nc1ccccc1
2922,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Clc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1,"N-(3-Chlorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0088,uM,=,-2.055517327849832,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
2923,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\C3CCCCC3)C2=O)cc(OC)c1,"(2E,6E)-2-(Cyclohexylmethylene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",7.5,uM,=,0.8750612633917001,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\C1CCCCC1
2924,1641794,,,,,"Time-Resolved Fluorescence Assay: The following assay may be used to determine the activity of the compounds of the invention for inhibiting EGFR kinase activity. The half maximal inhibitory concentration IC50 (the concentration of the tested compound showing 50% inhibition of the enzyme activity) of each compound was determined by incubating several different concentrations of the tested compounds with a specific enzyme and substrate. EGFR kinase used in this assay is a human-derived recombinant protein (Cell signaling technology, #7908), which was reacted with peptide substrate and different concentrations of tested compounds in a buffer solution containing 60 mM HEPES (pH7.5), 5 mM MgCl2, 5 mM MnCl2, 3 Î¼M Na3VO4, 1.25 M DTT (1000Ã) and 20 Î¼M ATP at 25Â° C., for 45 minutes. The EGFR kinase activity was determined by using a Time-Resolved fluorescence method.",CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,PYROTINIB,0.013,uM,=,-1.8860566476931635,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2nccc(Nc3ccc(OCc4ccccn4)cc3)c2c1
2925,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1N1CCN(C)CC1,N-[4-(3-Bromo-phenylamino)-7-(4-methyl-piperazin-1-yl)-quinazolin-6-yl]-acrylamide,13.0,uM,=,1.1139433523068367,1,c1ccc(Nc2ncnc3cc(N4CCNCC4)ccc23)cc1
2926,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CN(C)[C@@H](CS(C)(=O)=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,(R)-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(1-(dimethylamino)-2-(methylsulfonyl)ethyl)furan-2-yl)quinazolin-4-amine,0.0304,uM,=,-1.5171264163912463,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
2927,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O,"N-{5-Chloro-4-[(4-chloro-phenyl)-cyano-methyl]-2-methyl-phenyl}-2-hydroxy-3,5-diiodo-benzamide",0.564,uM,=,-0.2487208960166577,0,O=C(Nc1ccc(Cc2ccccc2)cc1)c1ccccc1
2928,958682,10.1021/jm400463q,,,,Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC(=O)OCCCCOc5no[n+]([O-])c5S(=O)(=O)c5ccccc5)CC4)cc3OC)ncc2Cl)c1,"4-(4-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetoxy)butoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide",0.174,uM,=,-0.7594507517174003,0,O=C(CN1CCN(c2ccc(Nc3nccc(Oc4ccccc4)n3)cc2)CC1)OCCCCOc1no[nH+]c1S(=O)(=O)c1ccccc1
2929,982642,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis,Brc1cccc(Nc2ncnc3ccc(NCCCN4CCCCC4)cc23)c1,"N4-(3-bromophenyl)-N6-(3-(piperidin-1-yl)propyl)quinazoline-4,6-diamine",0.0141,uM,=,-1.85078088734462,0,c1ccc(Nc2ncnc3ccc(NCCCN4CCCCC4)cc23)cc1
2930,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,NCCSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,4-(2-((2-Aminoethyl)thio)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-N-phenylpyridin-2-amine,0.0048,uM,=,-2.318758762624413,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
2931,2270927,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR T790M (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.007,uM,=,-2.154901959985743,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
2932,1778842,10.1016/j.bmcl.2018.07.039,,,,Inhibition of EGF-induced EGFR activation in human A431 cells pretreated for 60 mins followed by EGF addition and measured after 10 mins by ELISA,CSc1ccc(N(C)c2ncnc3occ(C)c23)cc1,"N,5-dimethyl-N-(4-(methylthio)phenyl)furo[2,3-d]pyrimidin-4-amine",0.0072,uM,=,-2.1426675035687315,0,c1ccc(Nc2ncnc3occc23)cc1
2933,1291543,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCC(C)CC2)CCO4)c1,"1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(4-methylpiperidin-1-yl)but-2-en-1-one",0.082,uM,=,-1.0861861476162833,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
2934,1627833,10.1016/j.ejmech.2016.06.056,,,,Inhibition of EGFR (unknown origin) using peptide as substrate after 60 mins by HTRF assay,CC(C)S(=O)(=O)c1ccccc1Nc1nc(N/N=C/c2ccc(C(F)(F)F)cc2)ncc1Cl,(E)-5-chloro-N-(2-(isopropylsulfonyl)phenyl)-2-(2-(4-(trifluoromethyl)benzylidene)hydrazinyl)pyrimidin-4-amine,0.593,uM,=,-0.2269453066357374,0,C(=N/Nc1nccc(Nc2ccccc2)n1)\c1ccccc1
2935,624184,10.1021/jm901877j,,,,Inhibition of wild type EGFR by HTRF assay,CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-propionamide,0.0001,uM,=,-4.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
2936,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCN(CCF)CC4)cc3OC)n2)c1,N-(3-(3-(2-(4-(4-(2-fluoroethyl)piperazin-1-yl)-2-methoxyphenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.158,uM,=,-0.8013429130455774,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1
2937,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CBr)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(NC(=O)N5CCCCC5)cc4)c3cc21,"1-(2-(2-bromoacetoxy)ethyl)-8-((4-(piperidine-1-carboxamido)phenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",9.3,uM,=,0.9684829485539352,1,O=C(Nc1ccc(Nc2ncnc3cc4oc(=O)[nH]c4cc23)cc1)N1CCCCC1
2938,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",CN1CCN(C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2O[C@H]2CCOC2)CC1,(S)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-methylpiperazine-1-carboxamide,0.464,uM,=,-0.3334820194451191,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1)N1CCNCC1
2939,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(5-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,11.0,uM,=,1.0413926851582251,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2940,63764,10.1021/jm960689b,,,,Inhibition of epidermal growth factor receptor (EGFr),CCN(CC)CCNC(=O)c1c([Se][Se]c2[nH]c3ccccc3c2C(=O)NCCN(CC)CC)[nH]c2ccccc12,"2,2'-Diselenobis[N-[2-(diethylamino)ethyl]-1H-indole-3-carboxamide]",4.6,uM,=,0.6627578316815741,1,c1ccc2[nH]c([Se][Se]c3cc4ccccc4[nH]3)cc2c1
2941,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccc(Cl)c4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-N-[4-({4-[(3-chlorobenzyl)oxy]-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)-7-ethoxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide",0.0356,uM,=,-1.448550002027125,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
2942,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,CC[C@@H](Nc1ncnc2sc(Br)cc12)c1ccccc1,"(R)-6-bromo-N-(1-phenylpropyl)thieno[2,3-d]pyrimidin-4-amine",0.183,uM,=,-0.7375489102695706,0,c1ccc(CNc2ncnc3sccc23)cc1
2943,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,CC(C)(CO)NCc1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"2-{4-[4-(1H-Indol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzylamino}-2-methyl-propan-1-ol",0.001,uM,=,-3.0,0,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
2944,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCC/C(=C\c3ccc(OC)c(O)c3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(3-hydroxy-4-methoxybenzylidene)cyclohexanone",5.37,uM,=,0.7299742856995556,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
2945,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(c3ccccc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(7-(2-Methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3-phenyl-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)-phenyl)acrylamide",0.0003,uM,=,-3.522878745280338,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
2946,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)OC(C)(C)C)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Staurosporine derivative,13.5,uM,=,1.130333768495006,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
2947,76720,10.1021/jm0000214,,,,Inhibition of EGF-dependent proliferation of human and guinea pig keratinocytes; range 7-15 uM,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1,"N-Benzyl-2-cyano-3-(3,4-dihydroxy-phenyl)-acrylamide",7.0,uM,=,0.8450980400142568,1,O=C(C=Cc1ccccc1)NCc1ccccc1
2948,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,COc1ccc(C2CC(c3ccc(Br)c(Br)c3)=NN2C(N)=S)cc1,"3-(3,4-Dibromophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",8.09,uM,=,0.9079485216122724,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
2949,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4cc(OC)c(C)c(OC)c4)nn32)CC1,"(S)-7-(1-acryloylpiperidin-4-yl)-2-(3,5-dimethoxy-4-methylphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",0.621,uM,=,-0.2069083998234198,0,c1ccc(-c2cc3n(n2)[C@H](C2CCNCC2)CCN3)cc1
2950,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#CC(C#N)=C(O)c1ccc(O)cc1,2-[Hydroxy-(4-hydroxy-phenyl)-methylene]-malononitrile,500.0,uM,=,2.6989700043360187,1,c1ccccc1
2951,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(N2C(=O)C(c3ccccc3)N(C)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6-methyl-5,8-dioxo-7-phenyl-7,8-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-9(6H)-yl)phenyl)acrylamide",0.07719,uM,=,-1.112438959069991,0,O=C1NC(c2ccccc2)C(=O)N(c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc21
2952,2298648,10.1016/j.bmcl.2023.129285,,,,Inhibition of EGFR (unknown origin) by fluorimetric assay,CC(=O)Nc1nc(C(=O)NNC(=O)CCN2CCCCC2)cs1,N-(4-(2-(3-(piperidin-1-yl)propanoyl)hydrazine-1-carbonyl)thiazol-2-yl)acetamide,9.202,uM,=,0.9638822289287774,1,O=C(CCN1CCCCC1)NNC(=O)c1cscn1
2953,5000,10.1021/jm960118j,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Cc1[nH]c2ncnc(Nc3cccc(Cl)c3)c2c1C,"(3-Chloro-phenyl)-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1
2954,2293062,10.1021/acs.jmedchem.6b00995,,,,Inhibition of EGFR autophosphorylation in human NCI-H292 cells harboring harboring wild type EGFR preincubated for 60 mins followed by EGF stimulation and measured after 8 mins by SULFO-TAG based electrochemiluminescent assay,CC[C@@H](C)n1nc(N2CC(C(C)(C)O)C2)c2cnc(Nc3ccnc(-c4cnn(S(=O)(=O)C5CC5)c4)n3)cc21,"(R)-2-(1-(1-(sec-Butyl)-6-((2-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-yl)amino)-1Hpyrazolo[4,3-c]pyridin-3-yl)azetidin-3-yl)propan-2-ol",0.58,uM,=,-0.2365720064370627,0,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3cc4[nH]nc(N5CCC5)c4cn3)n2)cn1
2955,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCC6(CCN(C)C6)C5)c(C)c4)nc32)C1,"3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)phenyl)amino)-1-((S)-1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.2956999999999999,uM,=,-0.5291486754738824,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCC5(CCNC5)C4)cc3)nc2N1[C@H]1CCNC1
2956,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(N2C(=O)C(C(C)CC)N(C)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(7-sec-butyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6-methyl-5,8-dioxo-7,8-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-9(6H)-yl)phenyl)acrylamide",0.01018,uM,=,-1.99225222199926,0,O=C1NCC(=O)N(c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc21
2957,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CC(C(N)=O)C1,1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)azetidine-3-carboxamide,0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3ccc(CN4CCC4)cc23)cc1
2958,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.0349,uM,=,-1.45717457304082,0,c1ccc(Nc2ccnc3ccccc23)cc1
2959,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccc(Br)cc1)c1ccccc1,(Z)-2-((E)-3-(4-bromophenyl)-1-phenylallylidene)hydrazinecarbothioamide,26.56,uM,=,1.4242280706959798,1,N=C(/C=C/c1ccccc1)c1ccccc1
2960,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,C#Cc1cccc(Nc2ncnc3cc(OC)c(OC)cc23)c1,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-ethynyl-phenyl)-amine",0.0288,uM,=,-1.5406075122407692,0,c1ccc(Nc2ncnc3ccccc23)cc1
2961,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCc1c(CC(N)=O)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"2-[4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-acetamide",1.1,uM,=,0.041392685158225,1,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
2962,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)cc3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(4-(3-Fluorobenzyloxy)phenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)acrylamide,0.0722,uM,=,-1.1414628024303608,0,c1ccc(COc2ccc(Nc3ncnc4cc(O[C@H]5CCOC5)ccc34)cc2)cc1
2963,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccn3ccnc3c1)nn2C1CCCC1,"1-cyclopentyl-3-(imidazo[1,2-a]pyridin-7-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",12.0,uM,=,1.0791812460476249,1,c1ncc2c(-c3ccn4ccnc4c3)nn(C3CCCC3)c2n1
2964,67051,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor-dependent phosphorylation,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,"(3-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.12,uM,=,-0.9208187539523752,0,c1ccc(Nc2ncnc3ccccc23)cc1
2965,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,CC(C)c1ccc(NC(=O)/C=C/c2ccccc2)cc1,(E)-N-(4-isopropylphenyl)cinnamamide,14.58,uM,=,1.1637575239819558,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
2966,2267874,10.1021/acs.jmedchem.1c00100,,,,Inhibition of EGFR (unknown origin),COc1ccc(-c2cc(=O)oc3c(O)c(O)ccc23)cc1O,"7,8-dihydroxy-4-(3-hydroxy-4-methoxyphenyl)-2H-chromen-2-one",4.9,uM,=,0.6901960800285137,1,O=c1cc(-c2ccccc2)c2ccccc2o1
2967,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccn2)c1O,2-Cyano-3-[4-hydroxy-3-methoxy-5-(pyridin-2-ylsulfanylmethyl)-phenyl]-acrylamide,3.4,uM,=,0.5314789170422551,1,c1ccc(CSc2ccccn2)cc1
2968,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,COc1ccc(CNc2ncnc3ccccc23)cc1,(4-Methoxy-benzyl)-quinazolin-4-yl-amine,10.0,uM,=,1.0,1,c1ccc(CNc2ncnc3ccccc23)cc1
2969,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,C[C@@H](Nc1ncnc2cc3oc(=O)n(CCCN4CCOCC4)c3cc12)c1ccccc1,"(R)-1-(3-morpholinopropyl)-8-(1-phenylethylamino)oxazolo[4,5-g]quinazolin-2(1H)-one",4.5,uM,=,0.6532125137753437,1,O=c1oc2cc3ncnc(NCc4ccccc4)c3cc2n1CCCN1CCOCC1
2970,1906489,10.1016/j.ejmech.2019.111648,,,,"Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay",N#Cc1ccc(-c2csc(N3N=C(c4ccc(N5CCCCC5)cc4)CC3c3ccc(Cl)cc3)n2)cc1,1-(4-(4-Cyanophenyl)thiazol-2-yl)-3-(4-piperidinophenyl)-5-(4-chlorophenyl)-2-pyrazoline,4.71,uM,=,0.6730209071288962,1,c1ccc(-c2csc(N3N=C(c4ccc(N5CCCCC5)cc4)CC3c3ccccc3)n2)cc1
2971,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,O=C1NCc2cc(Oc3ccc(Nc4ncnc5ccn(CCO)c45)cc3Cl)ccc21,"5-(2-Chloro-4-{[5-(2-hydroxyethyl)-5H-pyrrolo[3,2-d]-pyrimidin-4-yl]amino}phenoxy)-2,3-dihydro-1H-isoindol-1-one",0.51,uM,=,-0.2924298239020636,0,O=C1NCc2cc(Oc3ccc(Nc4ncnc5cc[nH]c45)cc3)ccc21
2972,1693612,10.1016/j.bmc.2017.06.004,,,,Inhibition of wild-type EGFR (unknown origin) using Tyr 4 peptide as substrate in presence of ATP by Z-LYTE kinase assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[N+](C)(C)[O-],"2-((2-Acrylamido-5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)(methyl)amino)-N,N-dimethylethan-1-amine oxide",0.3176,uM,=,-0.4981195062449413,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2973,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,S=C(NCCCN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-Bromophenyl)amino)quinazolin-6-yl)-3-(3-morpholinopropyl)thiourea,0.247,uM,=,-0.6073030467403343,0,S=C(NCCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2974,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(Oc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-phenoxy-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.445,uM,=,-0.3516399890190684,0,c1ccc(Oc2ccc(Nc3ccnc4ccccc34)cc2)cc1
2975,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1nc(C)nc(Nc3ccc4ncsc4c3)c1NC2,"benzothiazol-6-yl-(7,8-dimethoxy-3-methyl-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",15.2,uM,=,1.1818435879447726,1,c1ccc2c(c1)CNc1c(Nc3ccc4ncsc4c3)ncnc1S2
2976,2014672,10.1021/acsmedchemlett.9b00317,,,,Inhibition of EGFR (unknown origin),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.016,uM,=,-1.7958800173440752,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
2977,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.Oc1ccc(-c2cc3c(NCc4cccc(F)c4)ncnc3[nH]2)cc1,"4-(4-(3-fluorobenzylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.052,uM,=,-1.2839966563652008,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
2978,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(C)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methyl-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)buta2,3-dienamide",0.0299,uM,=,-1.5243288116755704,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
2979,1870312,10.1021/acs.jmedchem.8b00672,,,,Inhibition of wild type EGFR (unknown origin),COc1cc2c(Oc3ccc(NS(=O)(=O)c4cc(F)ccc4F)cc3F)ccnc2cc1OCCCN1CCCC(C)C1,"2,5-difluoro-N-(3-fluoro-4-(6-methoxy-7-(3-(3-methylpiperidin-1-yl)propoxy)quinolin-4-yloxy)phenyl)benzenesulfonamide",1.128,uM,=,0.0523090996473234,1,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCCCC4)ccc23)cc1)c1ccccc1
2980,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,O=C(/C=C/c1ccccc1)Nc1ccc(F)cc1F,"(E)-N-(2,4-difluorophenyl)cinnamamide",11.69,uM,=,1.06781451116184,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
2981,1714364,10.1016/j.bmc.2018.05.039,,,,"Inhibition of wild type EGFR (unknown origin) using Poly(Glu,Tyr) as substrate after 40 mins by Kinase-Glo luminescence assay",C=CC(=O)N[C@H]1CCN(c2nc(Nc3ccccc3)nc3cnc(Nc4ccc(N5CCN(C)CC5)cn4)cc23)C1,"(S)-N-(1-(6-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-2-(phenylamino)pyrido[3,4-d]pyrimidin-4-yl)pyrrolidin-3-yl)acrylamide",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2nc(N3CCCC3)c3cc(Nc4ccc(N5CCNCC5)cn4)ncc3n2)cc1
2982,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)COC(=O)c1ccccc1,2-((4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)amino)-2-oxoethyl benzoate,0.025,uM,=,-1.6020599913279625,0,O=C(COC(=O)c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
2983,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(NC3CC3c3ccccc3)c2cc1OCCCN(C)C,[6-(3-Dimethylamino-propoxy)-7-methoxy-quinazolin-4-yl]-(2-phenyl-cyclopropyl)-amine,0.31,uM,=,-0.5086383061657274,0,c1ccc(C2CC2Nc2ncnc3ccccc23)cc1
2984,946792,10.1016/j.bmc.2013.01.040,,,,Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA,CC(C)(C)C(=O)Nc1nc(Nc2ccccc2)c2c(n1)[nH]c1cccc(Cl)c12,"N-(5-chloro-4-(phenylamino)-9H-pyrimido[4,5-b]indol-2-yl)pivalamide",114.7,uM,=,2.059563417901268,1,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
2985,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(OC)c3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(2-Chloro-3-methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.413,uM,=,-0.384049948343599,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
2986,1283337,10.1016/j.ejmech.2013.10.058,,,,Inhibition of wild type EGFR (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,COc1cc2nc(Cl)nc(Nc3ccc(S(=O)(=O)N(C)C)cc3)c2cc1OC,"4-((2-Chloro-6,7-dimethoxyquinazolin-4-yl)amino)-N,N-dimethylbenzenesulfonamide",67.2,uM,=,1.827369273053825,1,c1ccc(Nc2ncnc3ccccc23)cc1
2987,1882933,10.1016/j.ejmech.2018.11.029,,,,Inhibition of recombinant human wild type GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system after 1 hr by kinase tracer 199 based TR-FRET assay,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)COC(C)=O,2-((4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)amino)-2-oxoethyl acetate,0.00052,uM,=,-3.283996656365201,0,c1ccc(Nc2ncnc3ccccc23)cc1
2988,306070,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,O=C(CCl)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-2-chloro-acetamide,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
2989,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3c(F)cccc3Br)c2c1,N-(4-(2-bromo-6-fluorophenylamino)quinazolin-6-yl)acrylamide,2.2,uM,=,0.3424226808222063,1,c1ccc(Nc2ncnc3ccccc23)cc1
2990,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cc(C(N)=O)ccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1,"(R)-3-Methoxy-4-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzamide",0.002,uM,=,-2.6989700043360187,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
2991,2088705,10.1016/j.ejmech.2020.112339,,,,Inhibition of EGFR (unknown origin) by ADP-Glo assay,C=CC(=O)Nc1cccc(Nc2ncnc(Nc3ccc(C(=O)N4CCCCC4)cc3)n2)c1,"N-(3-((4-((4-(piperidine-1-carbonyl)phenyl)amino)-1,3,5-triazin-2-yl)amino)phenyl)acrylamide",0.031,uM,=,-1.5086383061657274,0,O=C(c1ccc(Nc2ncnc(Nc3ccccc3)n2)cc1)N1CCCCC1
2992,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)cc(C(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(5-Isopropyl-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.098,uM,=,-1.0087739243075051,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
2993,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(Nc3ccc(-c4nc5ccc(F)cc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1,N-[4-(6''-Methoxybenzo[d]thiazol-2''-yl)phenyl]-6'-methoxy-7'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,0.73,uM,=,-0.1366771398795441,0,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
2994,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(C(=O)N2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c21,"4-(1-Benzyl-1H-indazol-5-ylamino)-5-[1-[3-methyl-5-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.0018,uM,=,-2.744727494896694,0,O=C1Nc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2/C1=C/c1ccc(C(=O)N2CCOCC2)[nH]1
2995,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,c1cncc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)c1,"(S)-5-((morpholin-2-ylmethoxy)methyl)-N-(1-(pyridin-3-ylmethyl)-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.81,uM,=,-0.0915149811213502,0,c1cncc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)c1
2996,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C=CC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](C)c4ccccc4)c23)c1,"N-[3-(6-Phenyl-4-{[(1R)-1-phenylethyl]amino}furo[2,3-d]-pyrimidin-5-yl)phenyl]prop-2-enamide",0.117,uM,=,-0.9318141382538384,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
2997,2063587,10.1016/j.ejmech.2016.08.068,,,,Inhibition of EGFR (unknown origin) using Tyr 04 peptide as substrate incubated for 1 hr by Z'-LYTE assay,OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1,"(S)-2-(6-(4-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-2-phenylethanol",0.0002,uM,=,-3.6989700043360174,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
2998,1847939,10.1016/j.ejmech.2019.03.038,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in Baculovirus expression system using srctide as substrate incubated for 1 hr by mobility shift assay,COc1cc(N2CCNC2=O)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)imidazolidin-2-one,0.765,uM,=,-0.1163385648463823,0,O=C1NCCN1c1ccc(Nc2nccc(Nc3ccccc3)n2)cc1
2999,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(C(=O)N2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc4c(ccn4Cc4ccccc4)c3)c21,"4-(1-Benzyl-1H-indol-5-ylamino)-5-[1-[3-methyl-5-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.0045,uM,=,-2.3467874862246565,0,O=C1Nc2ncnc(Nc3ccc4c(ccn4Cc4ccccc4)c3)c2/C1=C/c1ccc(C(=O)N2CCOCC2)[nH]1
3000,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)CO)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1,"(S)-3-(2-Chlorophenyl)-1-(1-(2-hydroxyacetyl)pyrrolidin-3-yl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.007,uM,=,-2.154901959985743,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
3001,1641517,,,,,"In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",Cc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C[C@H]1CCCN1C(=O)/C=C/CN(C)C,"US9278100, 11",0.01885,uM,=,-1.7246886454581882,0,c1ccc(Oc2ccc(-c3nn(C[C@H]4CCCN4)c4ncncc34)cc2)cc1
3002,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,CN(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3ccc(Br)cc3F)c2c1,(2E)-N-{4-[(4-bromo-2-fluorophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide,0.704,uM,=,-0.1524273408578878,0,c1ccc(Nc2ncnc3ccccc23)cc1
3003,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",2.592085471038842,uM,=,0.413649317795985,1,O=c1c(-c2ccccc2)coc2ccccc12
3004,699068,10.1016/j.bmc.2010.11.007,,,,Inhibition of EGFR by HTRF assay,N#Cc1cnc(Nc2cccc(Br)c2)c2cc(NC(=O)[C@@H]3CCC(=O)N3)ccc12,(S)-N-(1-(3-Bromophenylamino)-4-cyanoisoquinolin-7-yl)-5-oxopyrrolidine-2-carboxamide,2.2,uM,=,0.3424226808222063,1,O=C1CC[C@@H](C(=O)Nc2ccc3ccnc(Nc4ccccc4)c3c2)N1
3005,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3ccsc23)CC1,"1-(4-((2-((4-morpholinophenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.19703,uM,=,-0.7054676426581301,0,c1cc2nc(Nc3ccc(N4CCOCC4)cc3)nc(OC3CCNCC3)c2s1
3006,4991,10.1016/S0960-894X(97)10117-2,,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccccc23)cc1
3007,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCOCC4)cc3OC(F)F)ncc2C(F)(F)F)c1,"US8975249, I-14",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
3008,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",COC(=O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,"[5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-phenyl]-acetic acid methyl ester",12.0,uM,=,1.0791812460476249,1,c1ccc(CNc2ccccc2)cc1
3009,2224994,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin),O=C(Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)c1ccc(C(F)(F)F)cc1O,N-(4-(3-bromophenylamino)quinazolin-6-yl)-2-hydroxy-4-(trifluoromethyl)benzamide,0.12,uM,=,-0.9208187539523752,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccccc1
3010,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.34,uM,=,-0.4685210829577448,0,c1ccc(Nc2ncnc3ccccc23)cc1
3011,82323,10.1021/jm9904295,,,,Inhibitory activity against ligand-dependent EGF cell proliferation,COc1ccccc1-c1ccc2c(c1)NC(=O)/C2=C\c1[nH]c(C)c(CCC(=O)O)c1C,"3-{5-[6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propionic acid",31.3,uM,=,1.4955443375464486,1,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1ccc[nH]1
3012,792378,10.1016/j.ejmech.2011.11.015,,,,Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis,CC(C)(C)c1ccc(-c2nnc(SCc3ccccc3)o2)cc1,"2-(Benzylthio)-5-(4-tert-butylphenyl)-1,3,4-oxadiazole",7.44,uM,=,0.8715729355458788,1,c1ccc(CSc2nnc(-c3ccccc3)o2)cc1
3013,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",Clc1ccc(C(/C=C/c2ccccc2)=N\Nc2nncc3ccccc23)cc1,1-(2-(1-(4-Chlorophenyl)-3-phenylallylidene)hydrazinyl)phthalazine,0.0063,uM,=,-2.2006594505464183,0,C(=C/c1ccccc1)\C(=N\Nc1nncc2ccccc12)c1ccccc1
3014,840627,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR-mediated intracellular tyrosine phosphorylation in EGF-stimulated human A431 cells after 2.5 hrs by SDS-PAGE analysis,C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,"N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododeca[2,3-g]quinazolin-4-amine",0.045,uM,=,-1.3467874862246565,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)cc1
3015,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CNC(CS(C)(=O)=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,Rac-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(1-(methylamino)-2-(methylsulfonyl)ethyl)furan-2-yl)quinazolin-4-amine,0.0348,uM,=,-1.458420756053419,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
3016,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CCN(CC)CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-4-(diethylamino)-2-butynamide",0.048,uM,=,-1.3187587626244128,0,c1ccc(Nc2ncnc3cnccc23)cc1
3017,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(Cc4ccncc4)cc3)ncnc2cc1OC,N-{7-Methoxy-4-[4-(4-pyridinylmethyl)anilino]-6-quinazolinyl}-propanamide,0.388,uM,=,-0.4111682744057927,0,c1ccc2c(Nc3ccc(Cc4ccncc4)cc3)ncnc2c1
3018,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Nc1ncnc2c1cnn2-c1ccccc1,"1-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine",2.7,uM,=,0.4313637641589873,1,c1ccc(-n2ncc3cncnc32)cc1
3019,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Oc3ccc(F)c(Cl)c3)c1N(C)C2,"1-(3-chloro-4-fluoro-phenoxy)-7,8-dimethoxy-11-methyl-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene",10.8,uM,=,1.0334237554869496,1,c1ccc(Oc2ncnc3c2NCc2ccccc2O3)cc1
3020,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Cc1ccn2ncnc(Nc3ccc4[nH]ncc4c3)c12,"N-(1H-indazol-5-yl)-5-methylpyrrolo[1,2-f][1,2,4]triazin-4-amine",0.21,uM,=,-0.6777807052660807,0,c1cc2c(Nc3ccc4[nH]ncc4c3)ncnn2c1
3021,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3ccccc3N)c2cn1,"N*4*-(2-Amino-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",5.25,uM,=,0.7201593034059569,1,c1ccc(Nc2ncnc3ccncc23)cc1
3022,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(O[C@H]4CCc5ccccc54)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-((S)-indan-1-yloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.4,uM,=,-0.3979400086720376,0,c1ccc2c(c1)CC[C@@H]2Oc1ccc(Nc2ccnc3ccccc23)cc1
3023,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCOCC1C(N)=O,4-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)morpholine-3-carboxamide,0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ncnc3ccc(CN4CCOCC4)cc23)cc1
3024,1761187,10.1016/j.ejmech.2018.01.081,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr by mobility shift assay,CCS(=O)(=O)Nc1cc(-c2ccc3ncnc(Nc4cccc(C(=O)OC)c4)c3c2)cnc1OC,methyl 3-((6-(6-methoxy-5-(methylsulfonamido)pyridin-3-yl)quinazolin-4-yl)amino)benzoate,0.409,uM,=,-0.3882766919926582,0,c1ccc(Nc2ncnc3ccc(-c4cccnc4)cc23)cc1
3025,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,But-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.236,uM,=,-0.6270879970298935,0,c1ccc(Nc2ncnc3ccccc23)cc1
3026,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,Cc1cc(Nc2ncnc3ccc(NC(=O)/C=C/CN(C)C)cc23)ccc1Oc1cc2nncn2cn1,"(E)-4-(dimethylamino)-N-[4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]but-2-enamide",0.00213,uM,=,-2.6716203965612624,0,c1ccc2c(Nc3ccc(Oc4cc5nncn5cn4)cc3)ncnc2c1
3027,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CCN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl ethyl(methyl)carbamate",0.05,uM,=,-1.3010299956639813,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
3028,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCCCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1C,"butyl 4-(6,7-dimethoxyquinazolin-4-ylamino)-2-methylphenylcarbamate",7.6,uM,=,0.8808135922807914,1,c1ccc(Nc2ncnc3ccccc23)cc1
3029,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C=C=CCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O,"6-(Buta-2,3-dienyloxy)-4-(3'-chloro-4'-fluoroanilino)-7-methoxyquinazoline",0.0238,uM,=,-1.623423042943488,0,c1ccc(Nc2ncnc3ccccc23)cc1
3030,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)c(F)c3)c2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)-3-fluorophenyl]-7'-methoxy-6'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,2.3,uM,=,0.3617278360175928,1,c1ccc2sc(-c3ccc(Nc4ncnc5ccc(OCCCN6CCNCC6)cc45)cc3)nc2c1
3031,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,O=C(Nc1ccc([N+](=O)[O-])cc1)c1ccc(N(CCCl)CCCl)cc1,4-(Bis(2-chloroethyl)amino)-N-(4-nitrophenyl)benzamide,19.26,uM,=,1.2846562827885155,1,O=C(Nc1ccccc1)c1ccccc1
3032,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,COC(=O)CN1CCC(n2cc(-c3cccc(O)c3)c3c(N)ncnc32)C1,"{3-[4-Amino-5-(3-hydroxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-pyrrolidin-1-yl}-acetic acid methyl ester",0.74,uM,=,-0.1307682802690238,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1
3033,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)cc3)c2cc1NC(=O)/C=C/CN1CCCC1,(2E)-N-{7-Ethoxy-4-[4-(2-pyridinylmethoxy)anilino]-6-quinazolinyl}-4-(1-pyrrolidinyl)-2-butenamide,0.098,uM,=,-1.0087739243075051,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccn4)cc3)c2c1
3034,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(C(=O)NCCN2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc4c(ccn4Cc4ccccc4)c3)c21,"5-[4-(1-Benzyl-1H-indol-5-ylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide",0.0011,uM,=,-2.958607314841775,0,O=C1Nc2ncnc(Nc3ccc4c(ccn4Cc4ccccc4)c3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1
3035,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C(C)=O)CC5)c(C)c4)nc32)C1,"(S)-7-((4-(4-Acetylpiperazin-1-yl)-3-methylphenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.148,uM,=,-0.8297382846050426,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
3036,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,COc1ccc(CC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1,2-(4-methoxyphenyl)-N-tosylacetamide,38.52,uM,=,1.585686278452497,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
3037,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)CCO)c2)n1,N-(3-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-3-hydroxypropanamide,18.3,uM,=,1.2624510897304295,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3038,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CNCc1ncccn1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-((pyrimidin-2-ylmethyl)amino)but-2-enamide",0.008,uM,=,-2.096910013008056,0,O=C(/C=C/CNCc1ncccn1)Nc1cc2c(Nc3ccccc3)ncnc2s1
3039,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,C=CC(=O)Nc1ccc2ncnc(Nc3ccc4c(ccn4Cc4cccc(F)c4)c3)c2c1,N-(4-(1-(3-fluorobenzyl)-1H-indol-5-ylamino)quinazolin-6-yl)acrylamide,0.0011,uM,=,-2.958607314841775,0,c1ccc(Cn2ccc3cc(Nc4ncnc5ccccc45)ccc32)cc1
3040,958682,10.1021/jm400463q,,,,Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC(=O)OCCCOc5no[n+]([O-])c5S(=O)(=O)c5ccccc5)CC4)cc3OC)ncc2Cl)c1,"4-(3-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetoxy)-propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide",0.099,uM,=,-1.00436480540245,0,O=C(CN1CCN(c2ccc(Nc3nccc(Oc4ccccc4)n3)cc2)CC1)OCCCOc1no[nH+]c1S(=O)(=O)c1ccccc1
3041,1565876,10.1016/j.bmcl.2016.02.075,,,,Inhibition of EGFR (unknown origin) in presence of [gamma33P]ATP,Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,"7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",5.2,uM,=,0.7160033436347992,1,c1ccc(COc2cccc(-c3cn([C@H]4C[C@@H](CN5CCC5)C4)c4ncncc34)c2)cc1
3042,676221,10.1021/jm100607r,,,,Inhibition of EGFR,O=C(/C=C/CN1CCOCC1)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,"(E)-1-(4-[(1R)-2-Hydroxy-1-phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-4-morpholino-2-buten-1-one",0.021,uM,=,-1.6777807052660807,0,O=C(/C=C/CN1CCOCC1)N1CCc2c(sc3ncnc(NCc4ccccc4)c23)C1
3043,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,COc1ccc(-n2cc(NC(=O)c3ccc(NS(=O)(=O)c4ccc(Cl)cc4)cc3)cn2)cc1,4-((4-Chlorophenyl)sulfonamido)-N-(1-(4-methoxyphenyl)-1Hpyrazol-4-yl)benzamide,16.18,uM,=,1.2089785172762535,1,O=C(Nc1cnn(-c2ccccc2)c1)c1ccc(NS(=O)(=O)c2ccccc2)cc1
3044,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(OCc4ccccn4)cc3)ncnc2cc1OC,N-{7-Methoxy-4-[4-(2-pyridinylmethoxy)anilino]-6-quinazolinyl}-propanamide,0.116,uM,=,-0.9355420107730816,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
3045,66897,10.1021/jm970367n,,,,Inhibition of Epidermal growth factor receptor (EGFr) tyrosine kinase,CCNC(=O)Nc1nc2nc(N)ncc2cc1-c1c(Cl)cccc1Cl,"1-[2-Amino-6-(2,6-dichloro-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-ethyl-urea",1.36,uM,=,0.1335389083702175,1,c1ccc(-c2cnc3ncncc3c2)cc1
3046,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCCN(C(=O)OC(C)(C)C)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-39::US8975249, I-44",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCCNCC4)cc3)n2)cc1
3047,1642156,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",0.11,uM,=,-0.958607314841775,0,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
3048,2112388,10.1016/j.bmcl.2021.127987,,,,Inhibition of EGFR (unknown origin),O=C(Cn1sccc1=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(3-oxoisothiazolin-2-yl)acetamide,0.0003599999999999,uM,=,-3.4436974992327127,0,O=C(Cn1sccc1=O)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3049,1586270,10.1016/j.bmc.2016.04.046,,,,Inhibition of wild type human EGFR preincubated for 5 mins followed by ATP addition for 30 mins by HTRF assay,CCOc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)[C@H]1COC(=O)N1,(R)-N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-2-oxooxazolidine-4-carboxamide,0.0011899999999999,uM,=,-2.9244530386074694,0,O=C1N[C@@H](C(=O)Nc2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)CO1
3050,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,COc1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"N*4*-(3-Chloro-phenyl)-N*3*-(4-methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
3051,1761038,10.1016/j.ejmech.2018.01.042,,,,Inhibition of His6-tagged EGFR (unknown origin) cytoplasmic domain expressed in baculovirus infected Sf9 insect cells after 10 mins followed by addition of ATP-MgCl2 and measured after 1 hr by time-resolved fluorometric analysis,Cc1c(C(=O)NC(CO)Cc2ccccc2)[nH]c2ccc(Cl)cc12,5-Chloro-N-(1-hydroxy-3-phenylpropan-2-yl)-3-methyl-1H-indole-2-carboxamide,0.5,uM,=,-0.3010299956639812,0,O=C(NCCc1ccccc1)c1cc2ccccc2[nH]1
3052,2018691,10.1016/j.bmc.2020.115674,,,,Inhibition of EGFR-TK (unknown origin) relative to control,CC(C)(C)c1cc(NC(=O)CN2CCOCC2)no1,N-(5-(t-Butyl)isoxazol-3-yl)-2-morpholinoacetamide,0.144,uM,=,-0.8416375079047503,0,O=C(CN1CCOCC1)Nc1ccon1
3053,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,O=C(CCCCCCn1cc(-c2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)nn1)NO,"7-(4-(4-((3-Chloro-4-(thiazol-2-ylmethoxy)phenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)-N-hydroxyheptanamide",0.0036,uM,=,-2.4436974992327127,0,c1csc(COc2ccc(Nc3ncnc4ccc(-c5c[nH]nn5)cc34)cc2)n1
3054,574946,10.1021/np8004997,,,,Inhibition of recombinant EGFR,COc1cc(O)c2c(c1)C(=O)C1=C(C2=O)[C@H](O)[C@@H](O)[C@@](C)(O)[C@@H]1O,altersolanol A,17.85265219930839,uM,=,1.251702744255588,1,O=C1C2=C(CCCC2)C(=O)c2ccccc21
3055,1538410,10.1021/acs.jmedchem.5b01412,,,,Inhibition of EGFR phosphorylation in human NCI-H292 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0063,uM,=,-2.2006594505464183,0,c1ccc(Nc2ncnc3ccccc23)cc1
3056,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CCOc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2)c1O,alpha-cyano-3-ethoxy-4-hydroxy-5-phenylthiomethylcinnamamide,0.4,uM,=,-0.3979400086720376,0,c1ccc(CSc2ccccc2)cc1
3057,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc2N1CCCN1CCCCC1,"4-((3-chloro-4-fluorophenyl)amino)-6-(3-(piperidin-1-yl)propyl)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.1379,uM,=,-0.8604357338241503,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCCCC1
3058,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,O=C(CCCOc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1)NO,4-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yloxy)-N-hydroxybutanamide,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
3059,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,COc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,(3-Bromo-phenyl)-(6-methoxy-quinazolin-4-yl)-amine,0.348,uM,=,-0.4584207560534191,0,c1ccc(Nc2ncnc3ccccc23)cc1
3060,2268712,10.1016/j.ejmech.2021.113768,,,,Inhibition of EGFR (unknown origin) by ELISA,Cc1ccc2c(=O)n(Cc3ccccc3)c(SCc3cn(-c4ccc(C(=O)O)cc4)nn3)nc2c1,"4-(4-(((3-benzyl-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)methyl)-1H-1,2,3-triazol-1-yl)benzoic acid",0.0388,uM,=,-1.4111682744057927,0,O=c1c2ccccc2nc(SCc2cn(-c3ccccc3)nn2)n1Cc1ccccc1
3061,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,Cc1c(OCC(F)(F)F)ccnc1COc1cccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)c1,"8-(3-((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methoxy)phenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.099,uM,=,-1.00436480540245,0,O=c1oc2cc3ncnc(Nc4cccc(OCc5ccccn5)c4)c3cc2n1CCCN1CCOCC1
3062,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1ccc(-n2c(=O)cnc3cnc(Nc4ccc(OC)cc4)nc32)cc1,N-(4-(2-(4-Methoxyphenylamino)-7-oxopteridin-8(7H)-yl)-phenyl)acrylamide,5.129,uM,=,0.7100326990657535,1,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
3063,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1,"1-isopropyl-3-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",4.3,uM,=,0.6334684555795865,1,c1ccc(-c2n[nH]c3ncncc23)cc1
3064,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COCCN1CCC(Oc2cc3c(Nc4cc(Cl)ccc4F)ncnc3cc2OC)CC1,N-(5-chloro-2-fluorophenyl)-7-methoxy-6-(1-(2-methoxyethyl)piperidin-4-yloxy)quinazolin-4-amine,0.114,uM,=,-0.9430951486635274,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
3065,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC[C@@H]1C(=O)N(C)C,"(R)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)-N,N-dimethylpyrrolidine-2-carboxamide",0.45,uM,=,-0.3467874862246563,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
3066,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(=O)Nc3ccccn3)c3ccccc3n2C)c(C(=O)Nc2ccccn2)c2ccccc21,3N-(2-pyridyl)-1-methyl-2-[1-methyl-3-(2-pyridylcarbamoyl)-1H-2-indolyldisulfanyl]-1H-3-indolecarboxamide0.25 H2O,47.0,uM,=,1.6720978579357175,1,O=C(Nc1ccccn1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccn2)[nH]c2ccccc12
3067,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,COc1ccc(NC(=O)/C=C/CN(C)C)cc1Nc1ncc(F)c(-c2cnn3ccccc23)n1,"(E)-4-(dimethylamino)-N-(3-(5-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)but-2-enamide",19.0,uM,=,1.2787536009528289,1,c1ccc(Nc2nccc(-c3cnn4ccccc34)n2)cc1
3068,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,COc1ccc(CC(CO)n2cc(-c3cccc(O)c3)c3c(N)ncnc32)cc1,"3-{4-Amino-7-[1-hydroxymethyl-2-(4-methoxy-phenyl)-ethyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-phenol",3.4,uM,=,0.5314789170422551,1,c1ccc(CCn2cc(-c3ccccc3)c3cncnc32)cc1
3069,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),O=S(=O)(CCO)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"2-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidine-6-sulfonyl]-ethanol",0.0935,uM,=,-1.0291883891274822,0,c1ccc(Nc2ncnc3cnccc23)cc1
3070,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,CS(=O)(=O)CCNC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1,1-((6-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)pyridin-2-yl)methyl)-3-(2-(methylsulfonyl)ethyl)urea,0.015,uM,=,-1.8239087409443189,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccn1
3071,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)CC(C)(C)C)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-42",0.65,uM,=,-0.1870866433571444,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3072,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CCOC(=O)c1cc(/N=C/c2cc(O)ccc2O)ccc1O,"5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-benzoic acid ethyl ester",50.0,uM,=,1.6989700043360187,1,C(=N/c1ccccc1)\c1ccccc1
3073,5000,10.1021/jm960118j,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Brc1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1,"(3-Bromo-phenyl)-(6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]indol-4-yl)-amine",0.4,uM,=,-0.3979400086720376,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1
3074,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,Cc1cc2cc(Nc3ncnc4cc(-c5ccccc5)sc34)ccc2[nH]1,"(2-Methyl-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine",0.1,uM,=,-1.0,0,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
3075,66582,10.1021/jm970634p,,,,Inhibition of human epidermal growth factor receptor,COc1ccc(NC(=O)Nc2nc3nc(NCCCN4CCN(C)CC4)ncc3cc2-c2c(Cl)cccc2Cl)cc1,"1-{6-(2,6-Dichloro-phenyl)-2-[3-(4-methyl-piperazin-1-yl)-propylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-(4-methoxy-phenyl)-urea",0.72,uM,=,-0.1426675035687315,0,O=C(Nc1ccccc1)Nc1nc2nc(NCCCN3CCNCC3)ncc2cc1-c1ccccc1
3076,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCN1CCN(C)CC1,N-{4-(3-Bromo-phenylamino)-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinazolin-6-yl}-acrylamide,0.0017,uM,=,-2.7695510786217263,0,c1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
3077,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1cnc(N2CC(C(=O)N(C)C)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"1-(6-((2-((3S,4R)-3-fluoro-4-hydroxy-3-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-4-isopropyl-2,7-naphthyridin-1-yl)-N,N-dimethylazetidine-3-carboxamide",4.126,uM,=,0.6155292236371328,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
3078,2112388,10.1016/j.bmcl.2021.127987,,,,Inhibition of EGFR (unknown origin),C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.05434,uM,=,-1.264880365918128,0,c1ccc(Nc2ncnc3ccccc23)cc1
3079,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc([N+](=O)[O-])cc3)C2)cc1C,"2-(3-(3,4-dimethylphenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",3.85,uM,=,0.5854607295085007,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
3080,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,C=CC(=O)Nc1cc(Nc2nc(C)cc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-methyl-6-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,1.336,uM,=,0.1258064581395268,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3081,64443,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,0.0007,uM,=,-3.154901959985743,0,c1ccc(Nc2ncnc3ccccc23)cc1
3082,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(N2C(=O)C(Cc3ccc(Cl)cc3)N(C)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(7-(4-chlorobenzyl)-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6-methyl-5,8-dioxo-7,8-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-9(6H)-yl)phenyl)acrylamide",0.03737,uM,=,-1.4274769021503624,0,O=C1NC(Cc2ccccc2)C(=O)N(c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc21
3083,2198131,10.1016/j.ejmech.2022.114661,,,,Inhibition of recombinant human EGFR incubated for 40 to 45 mins and measured after 15 mins by Kinase-Glo Max assay,CCC(=O)NNC(=O)c1csc2ncc(-c3ccc(C)cc3)n12,"N'-Propionyl-5-(p-tolyl)imidazo[2,1-b]thiazole-3-carbohydrazide",0.45,uM,=,-0.3467874862246563,0,c1ccc(-c2cnc3sccn23)cc1
3084,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,10-[2-(1-Methyl-piperidin-2-yl)-ethyl]-2-methylsulfanyl-10H-phenothiazine,2.947,uM,=,0.4693801358499251,1,c1ccc2c(c1)Sc1ccccc1N2CCC1CCCCN1
3085,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(-c3nnco3)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-5-(1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncc(-c3nnco3)c(-c3cn4c5c(cccc35)CCC4)n2)cc1
3086,436426,10.1021/jm070144p,,,,Inhibition of EGFR tyrosine kinase expressed in A431 cells,ClCCN(CCN/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)c1ccc(Cl)cc1,1-{4-[(3-chlorophenyl)amino-6-quinazolinyl}-3-{2-[N-(2-chloroethyl)-N-4-chlorophenylethylenamine]} triazene,2.2,uM,=,0.3424226808222063,1,c1ccc(NCCN/N=N/c2ccc3ncnc(Nc4ccccc4)c3c2)cc1
3087,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),O=C(/C=C/Cl)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-3-chloro-acrylamide",0.00069,uM,=,-3.161150909262745,0,c1ccc(Nc2ncnc3cnccc23)cc1
3088,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCCCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1Cl,"butyl 2-chloro-4-(6,7-dimethoxyquinazolin-4-ylamino)phenylcarbamate",6.4,uM,=,0.8061799739838872,1,c1ccc(Nc2ncnc3ccccc23)cc1
3089,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,COc1ccc(-c2ccc(OC(F)(F)F)c(NC(=O)Nc3ccncc3)c2)cn1,1-(5-(6-Methoxypyridin-3-yl)-2-(trifluoromethoxy)phenyl)-3-(pyridin-4-yl)urea,0.10293,uM,=,-0.9874580272241642,0,O=C(Nc1ccncc1)Nc1cccc(-c2cccnc2)c1
3090,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.Oc1ccc(-c2cc3c(NCc4ccccc4F)ncnc3[nH]2)cc1,"4-(4-(2-fluorobenzylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.045,uM,=,-1.3467874862246565,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
3091,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,COCC1CN(c2ncc(C(C)C)c3cc(Nc4ccnc(N5CC[C@@H](O)[C@@](C)(F)C5)n4)ncc23)C1,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-(3-(methoxymethyl)azetidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",10.0,uM,=,1.0,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
3092,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,c1cc(Nc2ncnc3[nH]cnc23)cc(-c2nc3ccccc3s2)c1,N-(3-(benzo[d]thiazol-2-yl)phenyl)-9H-purin-6-amine,1.7,uM,=,0.2304489213782739,1,c1cc(Nc2ncnc3[nH]cnc23)cc(-c2nc3ccccc3s2)c1
3093,1870312,10.1021/acs.jmedchem.8b00672,,,,Inhibition of wild type EGFR (unknown origin),COc1cc2c(Oc3ccc(NS(=O)(=O)c4ccccc4C(F)(F)F)cc3F)ccnc2cc1OCCCN1CCC(C)CC1,N-(3-fluoro-4-(6-methoxy-7-(3-(4-methylpiperidin-1-yl)propoxy)quinolin-4-yloxy)phenyl)-2-(trifluoromethyl)benzenesulfonamide,0.592,uM,=,-0.2276782932770802,0,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCCCC4)ccc23)cc1)c1ccccc1
3094,2293062,10.1021/acs.jmedchem.6b00995,,,,Inhibition of EGFR autophosphorylation in human NCI-H292 cells harboring harboring wild type EGFR preincubated for 60 mins followed by EGF stimulation and measured after 8 mins by SULFO-TAG based electrochemiluminescent assay,CC(C)n1nc(N2CCC(O)CC2)c2cnc(Nc3ccnc(-c4cnn(S(=O)(=O)C5CC5)c4)n3)cc21,"1-(6-(2-(1-(Cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-ylamino)-1-isopropyl-1H-pyrazolo[4,3-c]pyridin-3-yl)piperidin-4-ol",1.5,uM,=,0.1760912590556812,1,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3cc4[nH]nc(N5CCCCC5)c4cn3)n2)cn1
3095,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCN(C)CC1C(N)=O,1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)-4-methylpiperazine-2-carboxamide,0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccc(CN4CCNCC4)cc23)cc1
3096,66595,10.1021/jm960879m,,,,Tested for ability to inhibit autophosphorylation of the Epidermal growth factor receptor in human epidermoid carcinoma cells,Brc1cccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)nc23)c1,"N*8*-(3-Bromo-phenyl)-N*2*-[2-(3H-imidazol-4-yl)-ethyl]-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.0050999999999999,uM,=,-2.292429823902064,0,c1ccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)nc23)cc1
3097,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Clc1ccc(-c2csc(N3N=C(c4ccc(Br)cc4)CC3c3ccc(Cl)cc3)n2)cc1,"2-(3-(4-bromophenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-chlorophenyl)thiazole",17.84,uM,=,1.2513948500401042,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
3098,1883986,10.1021/acsmedchemlett.8b00461,,,,Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.018,uM,=,-1.744727494896694,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
3099,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,O=C(C#CCCN1CCCCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-5-(1-piperidinyl)-2-pentynamide",0.0009,uM,=,-3.0457574905606752,0,O=C(C#CCCN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
3100,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,Cc1cc(C)c(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)c(C)c1,"3-(3,4-Dihydroxy-phenyl)-2-(2,4,6-trimethyl-benzoyl)-acrylonitrile",24.0,uM,=,1.380211241711606,1,O=C(/C=C/c1ccccc1)c1ccccc1
3101,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1.O,Tykerb,0.0163,uM,=,-1.787812395596042,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1.c1ccccc1.c1ccccc1
3102,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Nc3cccc(F)c3)c2c1C,"(5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(3-fluoro-phenyl)-amine",0.55,uM,=,-0.2596373105057561,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1
3103,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,NC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,1-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)urea,0.0008539999999999,uM,=,-3.068542129310995,0,c1ccc(Nc2ncnc3ccccc23)cc1
3104,1432409,10.1016/j.ejmech.2014.09.095,,,,Inhibition of EGFR (unknown origin),COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,EXEL-2880/GSK-1363089,2.99,uM,=,0.4756711883244297,1,O=C(Nc1ccccc1)C1(C(=O)Nc2ccc(Oc3ccnc4cc(OCCCN5CCOCC5)ccc34)cc2)CC1
3105,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(F)cc3Cl)ncnc2cc1OCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-(2-{4-[(2-Chloro-4-fluorophenyl)amino]-6-methoxy-quinazolin-7-yl}oxy)ethyl-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.04807,uM,=,-1.3181258778713532,0,O=C(Cn1cncn1)NCCOc1ccc2c(Nc3ccccc3)ncnc2c1
3106,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(Cc3ccccc3)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1,"N-(3-(3-Benzyl-7-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-d]-pyrimidin-1(2H)-yl)phenyl)acrylamide",0.0012,uM,=,-2.920818753952376,0,O=c1c2cnc(Nc3ccc(N4CCCCC4)cc3)nc2n(-c2ccccc2)c(=O)n1Cc1ccccc1
3107,2283192,10.1039/d2md00139j,,,,Inhibition of EGFR (unknown origin),C=CC(=O)N1CCC[C@H](n2nc(C(=O)c3ccc(CC(=O)N(C)C)c(C)c3C)c3c(N)ncnc32)C1,"(S)-2-(4-(1-(1-Acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo[3,4-d]pyrimidine-3-carbonyl)-2,3-dimethylphenyl)-N,N-dimethylacetamide",0.065,uM,=,-1.1870866433571443,0,O=C(c1ccccc1)c1nn([C@H]2CCCNC2)c2ncncc12
3108,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide",0.024,uM,=,-1.619788758288394,0,c1ccc(Nc2ncnc3sccc23)cc1
3109,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,NS(=O)(=O)c1ccc(NC(=S)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)cc1,4-(3-(4-((3-bromophenyl)amino)quinazolin-6-yl)thioureido)benzenesulfonamide,0.0095,uM,=,-2.0222763947111524,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3110,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,COc1cc(N(C)CCN(C)C)c(NC(=O)/C=C\C(C)C)cc1Nc1ncc(C#N)c(-c2cn(C)c3ccccc23)n1,(Z)-N-(5-((5-cyano-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)-4-methylpent-2-enamide,0.985,uM,=,-0.0065637695023882,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3111,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,O=C(NO)c1ccccc1Nc1nc(Nc2ccc(OCC(=O)N3CCOCC3)cc2)ncc1Cl,2-(5-chloro-2-(4-(2-morpholino-2-oxoethoxy)phenylamino)pyrimidin-4-ylamino)-N-hydroxybenzamide,0.05731,uM,=,-1.2417695915422504,0,O=C(COc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)N1CCOCC1
3112,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(C)cc3)nn21,"US9447106, 164",0.00034,uM,=,-3.468521082957745,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1
3113,305378,10.1021/jm049892u,,,,In vitro inhibition of Epidermal growth factor receptor,Cc1ccc2c(Nc3ccc(F)c(Cl)c3)ncnn12,"(3-Chloro-4-fluoro-phenyl)-(7-methyl-pyrrolo[2,1-f][1,2,4]triazin-4-yl)-amine",3.25,uM,=,0.5118833609788744,1,c1ccc(Nc2ncnn3cccc23)cc1
3114,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccc(Cl)cc3)CC2c2ccc(F)cc2)=N1,"2-(3-(4-Chlorophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",14.21,uM,=,1.1525940779274697,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
3115,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,CCOC(=O)CCCc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,"4-{4-[6-(2,6-Dichloro-phenyl)-8-methyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-phenyl}-butyric acid ethyl ester",0.7,uM,=,-0.1549019599857432,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
3116,1448250,10.1016/j.bmcl.2014.07.094,,,,Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry,COC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2ccccc2n2nnnc12,"Methyl 2-amino-5-oxo-1-(pyridin-3-yl)-4-(tetrazolo[1,5-a]quinolin-4-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",1.1,uM,=,0.041392685158225,1,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1
3117,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCOCCn1ccnc1[N+](=O)[O-],N-(3-Bromophenyl)-6-methoxy-7-(2-(2-(2-nitro-1H-imidazol-1-yl)ethoxy)ethoxy)quinazolin-4-amine,0.00082,uM,=,-3.086186147616284,0,c1ccc(Nc2ncnc3cc(OCCOCCn4ccnc4)ccc23)cc1
3118,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(Nc4ccc(N(C)C)cc4OC)nc32)c1,"N-(3-(7-(4-(Dimethylamino)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)-acrylamide",0.00499,uM,=,-2.3018994543766103,0,O=C1NCc2cnc(Nc3ccccc3)nc2N1c1ccccc1
3119,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CC(C)(C)C)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-45",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3120,1627833,10.1016/j.ejmech.2016.06.056,,,,Inhibition of EGFR (unknown origin) using peptide as substrate after 60 mins by HTRF assay,COc1ccc(/C=N/Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)cc1,(E)-5-chloro-N-(2-(isopropylsulfonyl)phenyl)-2-(2-(4-methoxybenzylidene)hydrazinyl)pyrimidin-4-amine,0.587,uM,=,-0.2313618987523855,0,C(=N/Nc1nccc(Nc2ccccc2)n1)\c1ccccc1
3121,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,Cc1ccc(Oc2ccc(Nc3ncnc4[nH]nc(OCCN5CCC(O)CC5)c34)cc2Cl)cn1,"1-(2-(4-(3-chloro-4-(6-methylpyridin-3-yloxy)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yloxy)ethyl)piperidin-4-ol",0.007,uM,=,-2.154901959985743,0,c1cncc(Oc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCCC5)c34)cc2)c1
3122,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,COc1cccc(-c2cn(C3CCN(CC(N)=O)CC3)c3ncnc(N)c23)c1,"2-{4-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-piperidin-1-yl}-acetamide",0.35,uM,=,-0.4559319556497244,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1
3123,2160973,10.1021/acs.jmedchem.1c01792,,,,Inhibition of human recombinant EGFR incubated for 1 hrs by HTRF KinEASE TK assay,CN(C)C(=O)c1ccc(Nc2ncc(C(F)(F)F)c(N[C@H]3CC[C@@H](N)CC3)n2)cc1,"4-(4-((1s,4s)-4-aminocyclohexylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-N,N-dimethylbenzamide",7.137,uM,=,0.8535156967569286,1,c1ccc(Nc2nccc(NC3CCCCC3)n2)cc1
3124,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3c(F)cc(Br)cc3F)ncnc2cc1OCC1CCNCC1,"(4-Bromo-2,6-difluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine",0.4,uM,=,-0.3979400086720376,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
3125,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Ic1cccc(Nc2ncnc3ccccc23)c1,(3-Iodo-phenyl)-quinazolin-4-yl-amine,0.08,uM,=,-1.0969100130080565,0,c1ccc(Nc2ncnc3ccccc23)cc1
3126,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,CC1CCCCN1C/C=C/C(=O)N1CCCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-8,9-dihydro-7H-pyrimido[5,4-h][1,5]benzoxazepin-6-yl]-4-(2-methyl-1-piperidyl)but-2-en-1-one",5.83,uM,=,0.7656685547590141,1,O=C(/C=C/CN1CCCCC1)N1CCCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
3127,1657723,10.1016/j.bmcl.2017.02.018,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells preincubated for 60 mins followed by EGF induction measured after 10 mins by ELISA,Nc1nc(N)c2c(n1)[nH]c1cccc(Sc3cccc4ccccc34)c12,"5-(1-Naphthylsulfanyl)-9H-pyrimido[4,5-b]indole-2,4-diamine",167.3,uM,=,2.2234959409623944,1,c1ccc2c(Sc3cccc4[nH]c5ncncc5c34)cccc2c1
3128,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(OC/C=C/c1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid (E)-3-phenyl-allyl ester",1.3,uM,=,0.1139433523068367,1,O=C(OC/C=C/c1ccccc1)c1cccc(NCc2ccccc2)c1
3129,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.00216,uM,=,-2.6655462488490693,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3130,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.24,uM,=,-0.619788758288394,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
3131,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CC(C)(C)OC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid tert-butyl ester",1.0,uM,=,0.0,0,c1ccc(CNc2ccccc2)cc1
3132,1438922,10.1016/j.bmcl.2014.08.036,,,,Inhibition of EGFR (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",25.12,uM,=,1.4000196350651586,1,O=c1c(-c2ccccc2)coc2ccccc12
3133,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,CN1CCN(c2ccc(Nc3ncnc4cc5oc(=O)n(CCOC(=O)CCl)c5cc34)cc2Cl)CC1,"1-(2-(2-chloroacetoxy)ethyl)-8-((3-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.02,uM,=,-1.6989700043360187,0,O=c1[nH]c2cc3c(Nc4ccc(N5CCNCC5)cc4)ncnc3cc2o1
3134,67207,10.1021/jm000231g,,,,Inhibition of Epidermal growth factor receptor,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21,2-(6-Benzylamino-9-methyl-9H-purin-2-ylamino)-ethanol,440.0,uM,=,2.6434526764861874,1,c1ccc(CNc2ncnc3[nH]cnc23)cc1
3135,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC[C@@H](Oc2cc3c(Nc4ccc(F)c(Cl)c4F)ncnc3cc2OC)C[C@@H]1C(=O)OC,"(2R,4R)-methyl-1-acryloyl-4-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-2-carboxamide",0.0044,uM,=,-2.356547323513813,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
3136,2293062,10.1021/acs.jmedchem.6b00995,,,,Inhibition of EGFR autophosphorylation in human NCI-H292 cells harboring harboring wild type EGFR preincubated for 60 mins followed by EGF stimulation and measured after 8 mins by SULFO-TAG based electrochemiluminescent assay,CC(C)n1nc(N2CCOCC2)c2cnc(Nc3ccnc(-c4cnn(S(=O)(=O)C5CC5)c4)n3)cc21,"N-(2-(1-(Cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-yl)-1-isopropyl-3-morpholino-1H-pyrazolo[4,3-c]pyridin-6-amine",0.85,uM,=,-0.0705810742857072,0,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3cc4[nH]nc(N5CCOCC5)c4cn3)n2)cn1
3137,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1CCNC1=O,3-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)pyrrolidin-2-one,0.02,uM,=,-1.6989700043360187,0,O=C1NCCC1NCc1ccc2ncnc(Nc3ccccc3)c2c1
3138,66563,10.1021/jm9904295,,,,Inhibitory activity against Epidermal growth factor receptor,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c(C)c1CCC(=O)O,"3-{2,4-Dimethyl-5-[2-oxo-5-sulfamoyl-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrol-3-yl}-propionic acid",84.8,uM,=,1.9283958522567133,1,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1
3139,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(=O)c2ccc(O)c(O)c2)cc(CSCc2ccccc2)c1O,"3-(3-Benzylsulfanylmethyl-4-hydroxy-5-methoxy-phenyl)-2-(3,4-dihydroxy-benzoyl)-acrylonitrile",2.0,uM,=,0.3010299956639812,1,O=C(C=Cc1cccc(CSCc2ccccc2)c1)c1ccccc1
3140,66600,10.1021/jm960879m,,,,Tested for inhibition of autophosphorylation in Epidermal growth factor receptor stimulated A431 cells,CN(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*,N*6*-dimethyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3cnccc23)cc1
3141,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(N3CCc4ccccc43)c2cc1OC,"4-(2,3-Dihydro-indol-1-yl)-6,7-dimethoxy-quinazoline",4.1,uM,=,0.6127838567197355,1,c1ccc2c(c1)CCN2c1ncnc2ccccc12
3142,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,O=C(Nc1cc(-c2cncnc2)cc(C(F)(F)F)c1)Nc1nccs1,1-(3-(Pyrimidin-5-yl)-5-(trifluoromethyl)phenyl)-3-(thiazol-2-yl)urea,0.07182,uM,=,-1.1437545992099458,0,O=C(Nc1cccc(-c2cncnc2)c1)Nc1nccs1
3143,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,O=C(/C=C/c1ccccc1)Nc1ccccc1F,SID448890,7.37,uM,=,0.8674674878590515,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
3144,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Br)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Bromo-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.0018,uM,=,-2.744727494896694,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
3145,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc(Cc4ccccn4)cc3)ncnc2cn1,"(2E)-N-{4-[4-(2-Pyridinylmethyl)anilino]pyrido[3,4-d]pyrimidin-6-yl}-4-(1-pyrrolidinyl)-2-butenamide",0.405,uM,=,-0.3925449767853314,0,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc(Cc4ccccn4)cc3)ncnc2cn1
3146,1829742,10.1021/acs.jmedchem.8b01612,,,,Inhibition of wild type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system after 1 hr in presence of ULight-labeled peptide substrate and ATP by LANCE ultra kinase assay,COc1cc2ncnc(Nc3ccc(Br)cc3F)c2cc1OCCCN1CCNCCNCC1,"6-(3-(1,4,7-Triazonan-1-yl)propoxy)-N-(4-bromo-2-fluorophenyl)-7-methoxyquinazolin-4-amine",0.0282,uM,=,-1.5497508916806388,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCNCCNCC4)cc23)cc1
3147,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OCCOC)cc3)nn21,"US9447106, 22",0.00063,uM,=,-3.2006594505464183,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1
3148,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)CCN1CCOCC1,N-(4-(3-Chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl)-3-morpholinopropanamide,0.00202,uM,=,-2.694648630553376,0,O=C(CCN1CCOCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
3149,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OC)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-{7-ethoxy-4-[(4-methoxy-3,6-dioxocyclohexa-1,4-dien-1-yl)amino]quinazolin-6-yl}but-2-enamide",0.7992999999999999,uM,=,-0.0972901870301229,0,O=C1C=CC(=O)C(Nc2ncnc3ccccc23)=C1
3150,2224994,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin),COc1ccc2c(c1)CCCN2c1nc(C)nc2c(Cc3ccccc3)cn(C)c12,"1-(7-benzyl-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline",0.0049,uM,=,-2.309803919971486,0,c1ccc(Cc2c[nH]c3c(N4CCCc5ccccc54)ncnc23)cc1
3151,608091,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 8 hrs by Western blot,O=C(COc1ccc(F)cc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(4-fluorophenoxy)-acetamide,0.291,uM,=,-0.5361070110140927,0,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3152,2032236,10.1016/j.ejmech.2020.112241,,,,Inhibition of EGFR (unknown origin),COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,EXEL-2880/GSK-1363089,3.02,uM,=,0.4800069429571506,1,O=C(Nc1ccccc1)C1(C(=O)Nc2ccc(Oc3ccnc4cc(OCCCN5CCOCC5)ccc34)cc2)CC1
3153,600206,10.1016/j.bmcl.2009.05.060,,,,Inhibition of EGFR-mediated poly(L-glutamic acid L-tyrosine) phosphorylation,CN(/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)C(=O)OCCCl,2-chloroethyl 3-(4-(3-chlorophenylamino)quinazolin-6-yl)-1-methyltriaz-2-ene-1-carboxylate,0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ncnc3ccccc23)cc1
3154,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,CS(=O)(=O)N1CCC[C@@H]1C#Cc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2s1,"(R)-N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-((1-(methylsulfonyl)pyrrolidin-2-yl)ethynyl)thieno[3,2-d]pyrimidin-4-amine",0.12,uM,=,-0.9208187539523752,0,C(#C[C@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
3155,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C#CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)C1,"2-(4-phenoxyphenyl)-7-(1-propioloylazetidin-3-yl)-1H-imidazo[1,2-b]pyrazole-3-carboxamide",0.0338,uM,=,-1.4710832997223453,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CNC5)c4[nH]3)cc2)cc1
3156,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)ncc2Cl)CC1,1-(4-((5-chloro-2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one,0.03712,uM,=,-1.4303920324531756,0,c1cc(OC2CCNCC2)nc(Nc2ccc(N3CCNCC3)cc2)n1
3157,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,CN1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1.Cc1ccc(S(=O)(=O)O)cc1,N-(3-Chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((4-methylpiperazin-1-yl)methyl)furan-2-yl)quinazolin-4-amine tosylate,0.0125,uM,=,-1.9030899869919435,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CN6CCNCC6)o5)cc34)cc2)cc1.c1ccccc1
3158,2017706,10.1016/j.bmcl.2020.127557,,,,Inhibition of EGFR in human A549 cells measured after 30 hrs by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC(=O)CCCCC[N+]4=C(/C=C/C=C/C=C/C=C5/N(CCCC)c6ccccc6C5(C)C)C(C)(C)c5cc(C(F)(F)F)ccc54)cc23)c1.[Br-],"2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethyl 6-[2-[7-(1-butyl-3,3-dimethyl-indolin-2-ylidene)hepta-1,3,5-trienyl]-3,3-dimethyl-5-(trifluoromethyl)indol-1-ium-1-yl]hexanoate Bromide",0.205,uM,=,-0.6882461389442457,0,O=C(CCCCC[N+]1=C(/C=C/C=C/C=C/C=C2\Cc3ccccc3N2)Cc2ccccc21)OCCOc1ccc2ncnc(Nc3ccccc3)c2c1
3159,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Cc1cccc(Nc2ncnc3c2sc2ccc(N)cc23)c1,"N*4*-m-Tolyl-benzo[4,5]thieno[3,2-d]pyrimidine-4,8-diamine",0.0021,uM,=,-2.6777807052660805,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
3160,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,Cc1cc2cc(Nc3ccnc4cc(-c5ccc(CNCCCO)cc5)sc34)ccc2[nH]1,"3-{4-[7-(2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-propan-1-ol",0.5,uM,=,-0.3010299956639812,0,c1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
3161,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,COCCN(C/C=C/C(=O)N1CCc2c(sc3ncnc(Nc4ccc(F)c(Cl)c4)c23)C1)CCOC,"US8524722, 31",0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3sc4c(c23)CCNC4)cc1
3162,624184,10.1021/jm901877j,,,,Inhibition of wild type EGFR by HTRF assay,C#Cc1cccc(Nc2ccnc3cc(OCCOC)c(OCCOC)cc23)c1,"N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinolin-4-amine",0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ccnc3ccccc23)cc1
3163,99801,10.1021/jm990947f,,,,Inhibition of EGF-stimulated MCF-7 human breast tumor cell proliferation,N#C/C(=C\c1ccc(Oc2ccccc2)c(I)c1)c1ccccn1,3-(3-Iodo-4-phenoxy-phenyl)-2-pyridin-2-yl-acrylonitrile,45.8,uM,=,1.6608654780038692,1,C(=Cc1ccccn1)c1ccc(Oc2ccccc2)cc1
3164,2220271,10.1016/j.bmcl.2022.128529,,,,Inhibition of EGFR (unknown origin),CCOC(=O)[C@H](Cc1c[nH]cn1)NCC(=O)NNC(=O)COc1ccc(-c2nc3ccccc3s2)cc1OC,"ethyl (2S)-2-[(2-{2-[4-(1,3-benzothiazol-2-yl)-2-methoxyphenoxy]acetohydrazido}-2-oxoethyl)amino]-3-(1H-imidazol-4-yl)propanoate",0.157,uM,=,-0.8041003475907662,0,O=C(CNCCc1c[nH]cn1)NNC(=O)COc1ccc(-c2nc3ccccc3s2)cc1
3165,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCCCCCn1ccnc1[N+](=O)[O-],N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-methoxy-7-((5-(2-nitro-1H-imidazol-1-yl)pentyl)oxy)quinazolin-4-amine,0.0166,uM,=,-1.779891911959945,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCCCCCn5ccnc5)ccc34)cc2)cc1
3166,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,4-(4-Benzhydryloxy-piperidin-1-yl)-1-(4-tert-butyl-phenyl)-butan-1-one,0.5591,uM,=,-0.2525105077413271,0,O=C(CCCN1CCC(OC(c2ccccc2)c2ccccc2)CC1)c1ccccc1
3167,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2ncnc3sccc23)c1,"(3-Bromo-phenyl)-thieno[2,3-d]pyrimidin-4-yl-amine",0.035,uM,=,-1.4559319556497243,0,c1ccc(Nc2ncnc3sccc23)cc1
3168,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccc(Cl)cc3)CC2c2ccc(Br)cc2)=N1,"2-(5-(4-Bromophenyl)-3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",2.28,uM,=,0.3579348470004537,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
3169,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,COc1cccc(-c2cn(C3CCN(CCO)CC3)c3ncnc(N)c23)c1,"2-{4-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-piperidin-1-yl}-ethanol",0.9,uM,=,-0.0457574905606751,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1
3170,658253,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR autophosphorylation in human A431 cells,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)Cc1ccc(F)cc1,(E)-4-[(4-Fluorobenzyl)methylamino]-but-2-enoic acid[4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinoline-6-yl]amide,0.01652,uM,=,-1.7819899570156366,0,O=C(/C=C/CNCc1ccccc1)Nc1ccc2nccc(Nc3ccccc3)c2c1
3171,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,C=CC(=O)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4cc(CC)ccn4)cc3)c2c1,4-(6-acrylamidoquinolin-4-yloxy)-N-(4-ethylpyridin-2-yl)benzamide,0.2,uM,=,-0.6989700043360187,0,O=C(Nc1ccccn1)c1ccc(Oc2ccnc3ccccc23)cc1
3172,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CSc1cccnc1,N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-2-(pyridin-3-ylthio)acetamide,0.0006,uM,=,-3.2218487496163566,0,O=C(CSc1cccnc1)Oc1ccc2ncnc(Nc3ccccc3)c2c1
3173,2147299,10.1021/acs.jmedchem.1c01013,,,,Inhibition of exogenous EGFR (unknown origin),CS(=O)(=O)CCN(Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)C(=O)CCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,2-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethyl 4-(((5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-yl)methyl)(2-(methylsulfonyl)ethyl)amino)-4-oxobutanoate,0.01052,uM,=,-1.97798426018228,0,O=C(CCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccccc32)CC1)NCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1
3174,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc([N+](=O)[O-])c(C(=O)Nc2ccc(OCc3ccccn3)c(Cl)c2)cc1NC(=O)c1ccc(CN2CCN(C)CC2)cc1,N-(3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)-4-ethoxy-5-(4-((4-methylpiperazin-1-yl)methyl)benzamido)-2-nitrobenzamide,0.9,uM,=,-0.0457574905606751,0,O=C(Nc1cccc(C(=O)Nc2ccc(OCc3ccccn3)cc2)c1)c1ccc(CN2CCNCC2)cc1
3175,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,CC(=O)c1cccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)c1,"8-(3-Acetylphenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",6.8,uM,=,0.8325089127062363,1,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
3176,2074183,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.037,uM,=,-1.431798275933005,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
3177,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCC1COC,4-(2-Methoxymethyl-pyrrolidin-1-yl)-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.151,uM,=,-0.8210230527068306,0,O=C(/C=C/CN1CCCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
3178,63758,10.1021/jm00040a003,,,,Concentration required to inhibit phosphorylation of isolated human epidermal growth factor tyrosine kinase receptor by 50%,COc1ccc(/C=C/c2cnc3cc(OC)c(OC)cc3c2)cc1,"6,7-Dimethoxy-3-[(E)-2-(4-methoxy-phenyl)-vinyl]-quinoline",20.0,uM,=,1.3010299956639813,1,C(=C/c1cnc2ccccc2c1)\c1ccccc1
3179,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)C[C@@H]1CCCN1C,isopropyl (S)-2-((5-acrylamido-2-methoxy-4-(methyl((1-methylpyrrolidin-2-yl)methyl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.057,uM,=,-1.2441251443275083,0,c1ccc2c(-c3ccnc(Nc4ccc(NC[C@@H]5CCCN5)cc4)n3)c[nH]c2c1
3180,2088168,10.1016/j.ejmech.2020.112363,,,,Inhibition of EGFR (unknown origin) by FRET assay,S=C(NN=C(c1ccccc1)c1ccccc1)Nc1ccc2c(c1)OCO2,"N-(benzo[d][1,3]dioxol-5-yl)-2-(diphenylmethylene)hydrazinecarbothioamide",0.993,uM,=,-0.0030507515046188,0,S=C(NN=C(c1ccccc1)c1ccccc1)Nc1ccc2c(c1)OCO2
3181,465,10.1016/s0960-894x(02)00364-5,,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,CCN(CC)CCNC(=O)c1cc(C)c(/C=C2\C(=O)Nc3ncnc(Nc4ccc(F)c(Cl)c4)c32)[nH]1,"5-[4-(3-Chloro-4-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)-amide",1.29,uM,=,0.1105897102992489,1,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
3182,1869224,10.1021/acs.jmedchem.8b01391,,,,Inhibition of wild type EGFR (unknown origin) by bioluminescent ADP-glo kinase assay,COc1cc(Nc2ncnc3cc(-c4ccc(Br)cc4)sc23)cc(OC)c1OC,"6-(4-Bromophenyl)-N-(3,4,5-trimethoxyphenyl)thieno[3,2-d]-pyrimidin-4-amine",0.326,uM,=,-0.4867823999320609,0,c1ccc(Nc2ncnc3cc(-c4ccccc4)sc23)cc1
3183,2146989,10.1021/acs.jmedchem.1c00607,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 4 hr followed by EGF stimulation by Western blot analysis,COc1cc(CC(=O)N2CC(=O)N[C@@H](Cc3ccccc3)C(=O)N(CC(N)=O)C(=O)CCSCc3ccc(cc3)C(=O)N[C@@H](CCCCN)CN(C(=O)CCC3CCCCC3)CC(=O)N[C@@H](Cc3ccccc3)CN(C(=O)CCc3ccccc3)CC(=O)N[C@@H](Cc3ccccc3)C2)cc(OC)c1,,17.7,uM,=,1.2479732663618066,1,O=C1CCSCc2ccc(cc2)C(=O)NCCN(C(=O)CCC2CCCCC2)CC(=O)N[C@@H](Cc2ccccc2)CN(C(=O)CCc2ccccc2)CC(=O)N[C@@H](Cc2ccccc2)CN(C(=O)Cc2ccccc2)CC(=O)N[C@@H](Cc2ccccc2)C(=O)N1
3184,2260083,10.1016/j.ejmech.2020.112904,,,,Inhibition of EGFR (unknown origin),C#Cc1cccc(Nc2ncnc3ccc(S(=O)(=O)n4ccc(/C=C/C(=O)Nc5ccccc5N)c4)cc23)c1,(E)-N-(2-aminophenyl)-3-{1-[4-(3-ethynylphenylamino)quinazoline-6-ylsulfonyl]-1H-pyrrol-3-yl}acrylamide,0.078,uM,=,-1.1079053973095196,0,O=C(/C=C/c1ccn(S(=O)(=O)c2ccc3ncnc(Nc4ccccc4)c3c2)c1)Nc1ccccc1
3185,840627,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR-mediated intracellular tyrosine phosphorylation in EGF-stimulated human A431 cells after 2.5 hrs by SDS-PAGE analysis,Brc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,"N-(3-bromophenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododeca[2,3-g]quinazolin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)cc1
3186,850422,10.1016/j.bmc.2012.08.002,,,,Inhibition of human N-terminal DYKDDDD tagged EGFR cytoplasmic domain amino acid 669 to 1210 expressed in baculovirus after 5 mins by scintillation counter,CC(C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21)S(C)(=O)=O,"N-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-2-(methylsulfonyl)propanamide",0.018,uM,=,-1.744727494896694,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
3187,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)c1,"N-(3-(3-Isopropyl-7-((3-methyl-4-(4-methylpiperazin-1-yl)-phenyl)amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.034,uM,=,-1.4685210829577449,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12
3188,2268682,10.1016/j.ejmech.2021.113781,,,,Inhibition of EGFR (unknown origin) by EGFR Kinase Assay Kit method,COc1nc2ccccc2cc1-c1nc2c(cnn2-c2ccc(Br)cc2)c(=O)[nH]1,"1-(4-bromophenyl)-6-(2-methoxyquinolin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one",5.827,uM,=,0.7654450180901501,1,O=c1[nH]c(-c2cnc3ccccc3c2)nc2c1cnn2-c1ccccc1
3189,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.00067,uM,=,-3.1739251972991736,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
3190,305912,10.1016/j.bmcl.2005.05.100,,,,Inhibitory concentration against EGFR by using [gamma-33P]-ATP as radioligand in pH 7.5,Clc1cc(Nc2ncnc3nn4ccccc4c23)ccc1OCc1ccccc1,"(4-Benzyloxy-3-chloro-phenyl)-(1,3,8a,9-tetraaza-fluoren-4-yl)-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(COc2ccc(Nc3ncnc4nn5ccccc5c34)cc2)cc1
3191,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCN(CC)[C@@](C)(C#Cc1ncnc2cc(OC)c(OC)cc12)CCc1ccccc1,"(R)-1-(6,7-dimethoxyquinazolin-4-yl)-N,N-diethyl-3-methyl-5-phenylpent-1-yn-3-amine",1.2,uM,=,0.0791812460476248,1,C(#Cc1ncnc2ccccc12)CCCc1ccccc1
3192,1642199,,,,,Inhibition Assay: Inhibition of various kinase enzyme.,Nc1nc2c(c(Nc3ccc(Cl)cc3F)n1)-c1ccccc1C2,"N4-(4-Chloro-2-fluorophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine",11.7,uM,=,1.0681858617461617,1,c1ccc(Nc2ncnc3c2-c2ccccc2C3)cc1
3193,821720,10.1021/jm201758g,,,,Inhibition of wild-type EGFR preincubated for 10 mins followed by incubation for 30 mins by fluorescence polarization assay,C=CC(=O)NCc1coc(-c2c(N)ncnc2Nc2ccc(OCc3ccccn3)c(Cl)c2)n1,N-((2-(4-Amino-6-(3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide,0.0033,uM,=,-2.4814860601221125,0,c1ccc(COc2ccc(Nc3ncncc3-c3ncco3)cc2)nc1
3194,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1ccc(NC(=O)CCC(=O)O)cc1,"N-[4-(2,2-Dicyano-vinyl)-phenyl]-succinamic acid",640.0,uM,=,2.806179973983887,1,c1ccccc1
3195,2259421,10.6019/CHEMBL5212743,,,,Selectivity interaction (MSD Pharma/Taiwan screen (enzymes and receptors) ) EUB0000296b EGFR,CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12,"N-(3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl)acetamide",3.26,uM,=,0.5132176000679389,1,O=c1ccc2cc(-c3ccccc3)c(-c3ccccc3)nc2[nH]1
3196,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2ncnc(-c3cn(C)c4ccccc34)c2OC)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((5-methoxy-6-(1-methyl-1H-indol-3-yl)pyrimidin-4-yl)amino)phenyl)acrylamide,0.2225,uM,=,-0.6526699846830496,0,c1ccc(Nc2cc(-c3c[nH]c4ccccc34)ncn2)cc1
3197,2224994,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin),COc1cc(Nc2ncnc3cc(-c4ccc(C)cc4)sc23)cc(OC)c1OC,"6-(p-Tolyl)-N-(3,4,5-trimethoxyphenyl)thieno[3,2-d]pyrimidin-4-amine",30.0,uM,=,1.4771212547196624,1,c1ccc(Nc2ncnc3cc(-c4ccccc4)sc23)cc1
3198,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,CCC(=O)Nc1cccc(Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)c1,N-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-pyridin-2-yl)amino)phenyl)propionamide,0.022,uM,=,-1.6575773191777938,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
3199,803381,10.1016/j.bmc.2005.05.012,,,,Inhibition of human recombinant His-tagged intracellular domain of EGFR using biotin-EEEEYFELV as substrate by HTRF assay,COc1ccc(N2Cc3cnc(Nc4ccccc4)nc3N([C@@H]3CC[C@@H](O)C3)C2=O)cc1,"(+/-)-1-(anti-3-Hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one",0.31,uM,=,-0.5086383061657274,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccccc3)nc2N1C1CCCC1
3200,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3ccc(C(N)=O)cc3)cc12)c1ccccc1,"(R)-4-(4-((1-Phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzamide",0.007,uM,=,-2.154901959985743,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
3201,5004,10.1016/s0960-894x(02)00364-5,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,C#Cc1cccc(Nc2ncnc3c2/C(=C/c2[nH]c(C(=O)NCCN4CCOCC4)cc2C)C(=O)N3)c1,"5-[4-(3-Ethynyl-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide",0.04,uM,=,-1.3979400086720375,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1
3202,1832355,10.1016/j.bmcl.2018.12.056,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,COCCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(3-methoxypropoxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.00076,uM,=,-3.1191864077192086,0,c1ccc(Nc2ncnc3ccccc23)cc1
3203,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,C=C(CN(C)C)C(=O)Nc1cc2c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c(C#N)cnc2cc1OCC,N-[4-(4-Benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-2-dimethylaminomethyl-acrylamide,0.223,uM,=,-0.6516951369518393,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
3204,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(Cc3ccccc3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-benzyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.02,uM,=,-1.6989700043360187,0,c1ccc(Cc2nn([C@@H]3CCCNC3)c3ncncc23)cc1
3205,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(S(N)(=O)=O)cc2)c2c(N)ncnc21,"4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzenesulfonamide",100.0,uM,=,2.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
3206,63758,10.1021/jm00040a003,,,,Concentration required to inhibit phosphorylation of isolated human epidermal growth factor tyrosine kinase receptor by 50%,Oc1cc2cc(-c3cccnc3)cnc2cc1O,"3-Pyridin-3-yl-quinoline-6,7-diol",0.5,uM,=,-0.3010299956639812,0,c1cncc(-c2cnc3ccccc3c2)c1
3207,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1cc(-c2nn(C(C)C)c3ncnc(N)c23)sc1C=O,"5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-methylthiophene-2-carbaldehyde",9.9,uM,=,0.99563519459755,1,c1csc(-c2n[nH]c3ncncc23)c1
3208,506208,10.1021/np50089a001,,,,Inhibition of EGFR,O=C(O)c1oc2cc(O)cc(O)c2c(=O)c1-c1ccc(O)cc1,"5,7-dihydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromene-2-carboxylic acid",6.368561668485558,uM,=,0.8040413585560996,1,O=c1c(-c2ccccc2)coc2ccccc12
3209,1390771,10.1039/C0MD00119H,,,,Inhibition of EGFR kinase (unknown origin) using poly(Glu:Tyr) as substrate,OB(O)/C=C/COc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,3-(4-(3-chlorophenylamino)quinazolin-6-yloxy)prop-1-enylboronic acid,0.27,uM,=,-0.5686362358410126,0,c1ccc(Nc2ncnc3ccccc23)cc1
3210,2080995,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R/T790M (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCc1cn(CCC(=O)NO)nn1,"N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1-(3-(hydroxyamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.0083,uM,=,-2.0809219076239263,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
3211,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccccc2NC(=O)CCOCc2ccccc2)n1,N-(2-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-3-benzyloxypropanamide,3.06,uM,=,0.48572142648158,1,O=C(CCOCc1ccccc1)Nc1ccccc1Oc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1
3212,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Nc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccncc23)cc1
3213,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,CC(C)(C)c1cc(C=C(C#N)C#N)cc(C(C)(C)C)c1O,"2-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-malononitrile",460.0,uM,=,2.6627578316815743,1,c1ccccc1
3214,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Cl.Cn1c2ccccc2c2ncnc(Nc3cccc(Br)c3)c21,"(3-Bromo-phenyl)-(5-methyl-5H-pyrimido[5,4-b]indol-4-yl)-amine hydrochloride",0.132,uM,=,-0.8794260687941501,0,c1ccc(Nc2ncnc3c2[nH]c2ccccc23)cc1
3215,1914926,10.1016/j.ejmech.2019.111943,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669-1210 AA) expressed in baculovirus using FAM-labelled peptide as substrate pre-incubated for 10 mins followed by substrate addition by mobility shift assay,COc1cc(Nc2cc(NC(=O)Nc3c(Cl)cccc3Cl)ncn2)cc(OC)c1,"1-(2,6-dichlorophenyl)-3-(6-((3,5-dimethoxyphenyl)amino)pyrimidin-4-yl)urea",0.315,uM,=,-0.5016894462103995,0,O=C(Nc1ccccc1)Nc1cc(Nc2ccccc2)ncn1
3216,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCOCCOCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-(2-{2-[2-({4-[(4-Bromo-2-fluorophenyl)amino]-6-methoxy-quinazolin-7-yl}oxy)ethoxy]ethoxy}ethyl)-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.00495,uM,=,-2.305394801066431,0,O=C(Cn1cncn1)NCCOCCOCCOc1ccc2c(Nc3ccccc3)ncnc2c1
3217,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3cccc(OC)c3OC)ncc2Cl)c1,"US9238629, I-17",0.055,uM,=,-1.259637310505756,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
3218,1586270,10.1016/j.bmc.2016.04.046,,,,Inhibition of wild type human EGFR preincubated for 5 mins followed by ATP addition for 30 mins by HTRF assay,CCOc1cc2ncnc(N[C@@H](C)c3ccccc3)c2cc1NC(=O)[C@@H]1COC(=O)N1,(S)-N-(7-Ethoxy-4-(((S)-1-phenylethyl)amino)quinazolin-6-yl)-2-oxooxazolidine-4-carboxamide,0.00552,uM,=,-2.258060922270801,0,O=C1N[C@H](C(=O)Nc2ccc3ncnc(NCc4ccccc4)c3c2)CO1
3219,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,colistin,1.5,uM,=,0.1760912590556812,1,O=C1CCCNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CN1.O=C1CCCNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CN1
3220,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,CCOc1cc2ncnc(Nc3cccc(F)c3)c2cc1OCC.Cl,"4-(3'-fluoroanilino)-6,7-diethoxyquinazoline hydrochloride",0.099,uM,=,-1.00436480540245,0,c1ccc(Nc2ncnc3ccccc23)cc1
3221,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",COc1ncc2ncnc(Nc3cccc(Br)c3)c2n1,"(3-Bromo-phenyl)-(6-methoxy-pyrimido[5,4-d]pyrimidin-4-yl)-amine",0.0038,uM,=,-2.42021640338319,0,c1ccc(Nc2ncnc3cncnc23)cc1
3222,66904,10.1016/S0960-894X(96)00601-4,,,,Inhibition of the epidermal growth factor receptor.,NCCCNC(=O)c1cccc(Nc2nccc(-c3cccnc3)n2)c1,N-(3-Amino-propyl)-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide,45.0,uM,=,1.6532125137753435,1,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1
3223,1361207,10.1021/jm4017762,,,,Inhibition of EGFR (unknown origin) after 1 hr by HTRF assay,C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1,N-(2-(3-Acrylamidophenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide,0.011,uM,=,-1.958607314841775,0,O=C(Nc1cccc(C(=O)Nc2cnc(Nc3ccccc3)nc2)c1)c1ccccc1
3224,2185676,10.1016/j.ejmech.2021.113523,,,,Inhibition of recombinant EGFR (unknown origin) using TMB as substrate incubated for 3 hrs in presence of ATP by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)cc3)nc3c2CSCC3)c1,"N-(3-((2-((4-methoxyphenyl)amino)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide",0.0279999999999999,uM,=,-1.5528419686577808,0,c1ccc(Nc2nc3c(c(Oc4ccccc4)n2)CSCC3)cc1
3225,593141,10.1021/jm901146p,,,,Inhibition of Her1 by fluorescence polarization assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.052,uM,=,-1.2839966563652008,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
3226,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccccc3Br)C2=O)cc(OC)c1,"(2E,6E)-2-(2-Bromobenzylidene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",8.0,uM,=,0.9030899869919436,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
3227,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CN(C)c1ccc2ncncc2c1,Dimethyl-quinazolin-6-yl-amine,0.12,uM,=,-0.9208187539523752,0,c1ccc2ncncc2c1
3228,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc(Cl)cc3)C2)cc1,"2-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",4.94,uM,=,0.693726948923647,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
3229,1770089,10.1016/j.bmcl.2017.12.009,,,,Inhibition of wild-type EGFR phosphorylation in human A431 cells preincubated for 1 hr followed by EGF stimulation measured after 45 mins by ELISA,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(C4CCN(C)CC4)cc3OC)n2)c1,N-(3-(3-(2-(2-methoxy-4-(1-methylpiperidin-4-yl)phenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,4.999,uM,=,0.6988831367525902,1,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(C3CCNCC3)cc2)n1
3230,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CS(=O)(=O)CCN(Cc1ccccc1)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-(5-((benzyl(2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine,0.09,uM,=,-1.0457574905606752,0,c1ccc(CNCc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)cc5)c4c3)o2)cc1
3231,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",S=C(NNc1nncc2ccccc12)Nc1ccc(Cl)cc1,N-(4-Chlorophenyl)-2-(phthalazin-1-yl)hydrazine-1-carbothioamide,0.064,uM,=,-1.193820026016113,0,S=C(NNc1nncc2ccccc12)Nc1ccccc1
3232,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc(C)cc2)c1O,2-Cyano-3-(4-hydroxy-3-methoxy-5-p-tolylsulfanylmethyl-phenyl)-acrylamide,1.75,uM,=,0.2430380486862944,1,c1ccc(CSc2ccccc2)cc1
3233,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2ncc(C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((5-methyl-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)buta-2,3-dienamide",0.0052,uM,=,-2.283996656365201,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3234,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,CNc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1,"6-(2,6-Dichloro-phenyl)-8-methyl-2-methylamino-8H-pyrido[2,3-d]pyrimidin-7-one",7.5,uM,=,0.8750612633917001,1,O=c1[nH]c2ncncc2cc1-c1ccccc1
3235,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)CC(C)C)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1,"(S)-3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-(3-methylbutanoyl)pyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0222,uM,=,-1.6536470255493614,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
3236,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(N(C)C)c4ccccc34)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(4-(dimethylamino)naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.81,uM,=,-0.0915149811213502,0,c1ccc2c(-c3nn([C@@H]4CCCNC4)c4ncncc34)cccc2c1
3237,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",O=S(=O)(Nc1ccccn1)c1ccc(Nc2nncc3ccccc23)cc1,4-(Phthalazin-1-ylamino)-N-(pyridin-2-yl)benzenesulfonamide,0.084,uM,=,-1.0757207139381184,0,O=S(=O)(Nc1ccccn1)c1ccc(Nc2nncc3ccccc23)cc1
3238,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CN1CCN(c2ccc(Nc3ncc(Br)c(Nc4ccc5[nH]c(Cc6cccc(F)c6)cc5c4)n3)cc2)CC1,"5-bromo-N4-(2-(3-fluorobenzyl)-1H-indol-5-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,4-diamine",0.325,uM,=,-0.4881166390211256,0,c1ccc(Cc2cc3cc(Nc4ccnc(Nc5ccc(N6CCNCC6)cc5)n4)ccc3[nH]2)cc1
3239,2058361,10.1016/j.ejmech.2020.113019,,,,Inhibition of recombinant human GST-tagged EGFR expressed in baculovirus expression system using tyr-04 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C4CC4)c4ccccc34)n2)c(OC)cc1[S+]([O-])CCN(C)C,N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2((2-(dimethylamino)ethyl)sulfinyl)-4-methoxyphenyl)acrylamide,0.0040999999999999,uM,=,-2.3872161432802645,0,c1ccc(Nc2nccc(-c3cn(C4CC4)c4ccccc34)n2)cc1
3240,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#CC(C#N)=C(O)c1cc(O)c(O)c(O)c1,"2-[Hydroxy-(3,4,5-trihydroxy-phenyl)-methylene]-malononitrile",10.0,uM,=,1.0,1,c1ccccc1
3241,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,CC(=O)Nc1cccc(Oc2cc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncn2)c1,4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-acetamidophenoxy)pyrimidine,0.108,uM,=,-0.9665762445130504,0,c1ccc(COc2ccc(Nc3cc(Oc4ccccc4)ncn3)cc2)cc1
3242,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(NCc3ccncc3)ncnc2s1,"6-(2-Methoxyphenyl)-N-(pyridin-4-ylmethyl)thieno[2,3-d]pyrimidin-4-amine",0.108,uM,=,-0.9665762445130504,0,c1ccc(-c2cc3c(NCc4ccncc4)ncnc3s2)cc1
3243,1991321,10.1016/j.bmcl.2020.127288,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system by competitive binding assay,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.0505,uM,=,-1.2967086218813386,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
3244,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(NS(C)(=O)=O)c2)c2c(N)ncnc21,"N-(3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)methanesulfonamide",100.0,uM,=,2.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
3245,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Oc1cccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"3-[4-(3-Chloro-phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-phenol",1.5,uM,=,0.1760912590556812,1,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
3246,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Br)c3)c2c1,N-[4-(3-Bromo-4-fluoro-phenylamino)-quinazolin-6-yl]-acrylamide,0.00069,uM,=,-3.161150909262745,0,c1ccc(Nc2ncnc3ccccc23)cc1
3247,793868,10.1016/j.bmcl.2011.09.078,,,,Inhibition of EGFR,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea,3.8,uM,=,0.5797835966168101,1,O=C(Nc1ccc(OCCN2CCOCC2)c2ccccc12)Nc1ccnn1-c1ccccc1
3248,835647,10.1016/j.bmcl.2012.07.079,,,,Inhibition of EGFR in human A431 cell lysate using tyrosine/glutamic acid polymer as substrate by ELISA,O=C(Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)c1cccc2c1OCCO2,"N-(4-(3-chlorophenylamino)quinazolin-6-yl)-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide",1.29,uM,=,0.1105897102992489,1,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1cccc2c1OCCO2
3249,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3cc(OC)cc(OC)c3)C2=O)cc(OC)c1,"(2E,6E)-2,6-Bis(3,5-dimethoxybenzylidene)-cyclohexanone",2.0,uM,=,0.3010299956639812,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
3250,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)S(=O)(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-[(E)-2-Cyano-1-(3,4-dihydroxy-phenyl)-ethenesulfonyl]-3-(3,4-dihydroxy-phenyl)-acrylonitrile",12.0,uM,=,1.0791812460476249,1,O=S(=O)(C=Cc1ccccc1)/C=C/c1ccccc1
3251,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-46",0.2,uM,=,-0.6989700043360187,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3252,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CC(OC)C1,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(3-methoxyazetidin-1-yl)propoxy)quinazolin-4-amine,0.034,uM,=,-1.4685210829577449,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCC4)cc23)cc1
3253,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCOCC1C(N)=O,4-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)morpholine-3-carboxamide,0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3ccc(CN4CCOCC4)cc23)cc1
3254,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,O=[N+]([O-])c1cccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"(3-Chloro-phenyl)-[3-(3-nitro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine",0.27,uM,=,-0.5686362358410126,0,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
3255,2282820,10.1039/d1md00280e,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr in presence of ATP by ADP-Glo kinase assay,CCOc1ccc2nc(NC(=O)CSc3nnc(Cc4c[nH]c5ccccc45)o3)sc2c1,"N-(6-ethoxy-1,3-benzothiazol-2-yl)-2-[[5-(1H-indol-3-ylmethyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetamide",2.8,uM,=,0.4471580313422192,1,O=C(CSc1nnc(Cc2c[nH]c3ccccc23)o1)Nc1nc2ccccc2s1
3256,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CNC1CC(F)(F)C1,"(E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-4-(3,3-difluorocyclobutylamino)but-2-enamide",0.141,uM,=,-0.8507808873446201,0,O=C(/C=C/CNC1CCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3257,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Clc1ccc(-c2csc(N3N=C(c4ccc(Br)cc4)CC3c3ccc(Br)cc3)n2)cc1,"2-(3,5-bis(4-bromophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-chlorophenyl)thiazole",25.74,uM,=,1.410608542568368,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
3258,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-acrylamide",0.00091,uM,=,-3.0409586076789066,0,c1ccc(Nc2ncnc3cnccc23)cc1
3259,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,"4-[N-Methyl-N''-((2R,3R,4R,5S)-2,3,4,5,6-pentahydroxy-hexyl)-hydrazino]-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide",0.719,uM,=,-0.1432711096171174,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
3260,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(N(C)c3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-methyl-amine",0.152,uM,=,-0.8181564120552275,0,c1ccc(Nc2ncnc3ccccc23)cc1
3261,811225,10.1021/jm201391u,,,,"Inhibition of wild type EGFR using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",0.113,uM,=,-0.9469215565165804,0,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
3262,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,COC1CN(c2ncc(C(C)C)c3cc(Nc4ccnc(N5CC[C@@H](O)[C@@](C)(F)C5)n4)ncc23)C1,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-(3-methoxyazetidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",10.0,uM,=,1.0,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
3263,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc(O)cc(F)c2)c2c(N)ncnc21,"3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-fluorophenol",0.576,uM,=,-0.239577516576788,0,c1ccc(-c2n[nH]c3ncncc23)cc1
3264,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1cc(O)c(O)c(O)c1,"2-(3,4,5-Trihydroxy-benzylidene)-malononitrile",3.0,uM,=,0.4771212547196624,1,c1ccccc1
3265,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(F)c(Cl)c4F)ncnc3cc2OC)CC1,"1-(4-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one",0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
3266,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C=C=CCCCCCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O,"4-(3-Chloro-4-fluorophenylamino)-6-(octa-6,7-dienyloxy)-7-methoxyquinazoline",0.00445,uM,=,-2.3516399890190685,0,c1ccc(Nc2ncnc3ccccc23)cc1
3267,1330696,10.1039/C2MD20017A,,,,Inhibition of EGF-induced EGFR-mediated Akt phosphorylation in human A431 cells after 1 hr by immunoblotting method,C=CC(=O)Nc1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1,N-(3-(6-(3-bromophenylamino)pyrimidin-4-ylamino)phenyl)acrylamide,0.104,uM,=,-0.9829666607012196,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
3268,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(CNC6CCNCC6)c45)ccc32)c1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((piperidin-4-ylamino)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.11,uM,=,-0.958607314841775,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CNC6CCNCC6)c45)ccc32)cc1
3269,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,COC[C@@H](Nc1ncnc2oc(-c3ccc(OC)cc3)cc12)c1ccccc1,"(S)-N-(2-Methoxy-1-phenylethyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-amine",0.014,uM,=,-1.853871964321762,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
3270,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1C,"propyl 4-(6,7-dimethoxyquinazolin-4-ylamino)-2-methylphenylcarbamate",0.9,uM,=,-0.0457574905606751,0,c1ccc(Nc2ncnc3ccccc23)cc1
3271,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3cc(OC)c(C)c(OC)c3)nn21,"7-(2-acrylamidophenyl)-2-(3,5-dimethoxy-4-methylphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",0.018,uM,=,-1.744727494896694,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1
3272,1337213,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ncc([N+](=O)[O-])n1CC(=O)N/N=C/c1cc2ccccc2nc1Oc1ccc(F)cc1,(E)-N'-((2-(4-fluorophenoxy)quinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,0.37,uM,=,-0.431798275933005,0,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
3273,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OCC1CCN(C)CC1,N-(3-chloro-2-fluorophenyl)-7-methoxy-6-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine,0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3ccc(OCC4CCNCC4)cc23)cc1
3274,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,CNC(=O)[C@H]1CCCN1Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,(R)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)-N-methylpyrrolidine-2-carboxamide,0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
3275,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,OC[C@@H](Nc1ncnc2sc(Br)cc12)c1ccccc1,"(S)-2-((6-Bromothieno[2,3-d]pyrimidin-4-yl)amino)-2-phenylethanol",0.036,uM,=,-1.4436974992327127,0,c1ccc(CNc2ncnc3sccc23)cc1
3276,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)Nc2ccccc2)[nH]c2ccccc12)Nc1ccccc1,N-Phenyl-3-{2-[3-(2-phenylcarbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-propionamide,25.0,uM,=,1.3979400086720375,1,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)Nc2ccccc2)[nH]c2ccccc12)Nc1ccccc1
3277,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,COc1cccc(/C=C/C(=N/NC(N)=S)c2ccccc2)c1,(Z)-2-((E)-3-(3-methoxyphenyl)-1-phenylallylidene)hydrazinecarbothioamide,10.95,uM,=,1.0394141191761372,1,N=C(/C=C/c1ccccc1)c1ccccc1
3278,840626,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR using GST-Crk as substrate assessed as phosphorylated Crk level after 20 mins by SDS-PAGE analysis,C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,"N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododeca[2,3-g]quinazolin-4-amine",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)cc1
3279,2260188,10.1016/j.ejmech.2020.112995,,,,Inhibition of human wild type GST-tagged EGFR expressed in Sf9 cells assessed as substrate phosphorylation using TK-peptide as substrate incubated for 25 mins by HTRF assay,CCC(=O)Nc1cccc(-c2c(-c3ccc(N4CCN(C)CC4)cc3)[nH]c3ncn(C4CCCCC4)c(=O)c23)c1,"N-(3-(3-cyclohexyl-6-(4-(4-methylpiperazin-1-yl)phenyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl)propionamide",0.0004,uM,=,-3.397940008672037,0,O=c1c2c(-c3ccccc3)c(-c3ccc(N4CCNCC4)cc3)[nH]c2ncn1C1CCCCC1
3280,2080995,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R/T790M (unknown origin) by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1O[C@@H]1CCOC1,Afatinib,0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3ccc(O[C@@H]4CCOC4)cc23)cc1
3281,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",CCCCNC(=S)NNc1nncc2ccccc12,N-Butyl-2-(phthalazin-1-yl)hydrazine-1-carbothioamide,0.052,uM,=,-1.2839966563652008,0,c1ccc2cnncc2c1
3282,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3ccccc3)c2cn1,"N*4*-Phenyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.25,uM,=,-0.6020599913279624,0,c1ccc(Nc2ncnc3ccncc23)cc1
3283,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4Cl)cc3)ncnc2cc1OCCCN1CCN(C)CC1,N-(4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-ylamino)phenyl)-2-chlorobenzamide,0.02,uM,=,-1.6989700043360187,0,O=C(Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1ccccc1
3284,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2ncc(F)c(Nc3ccccc3P(C)(C)=O)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(dimethylphosphoryl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.106,uM,=,-0.9746941347352298,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
3285,66899,10.1016/s0960-894x(99)00188-2,,,,In vitro activity against Epidermal growth factor receptor (using poly(Glu4Tyr1) as a substrate),O=C1NC(=O)c2c1c1c3cccc(O)c3[nH]c1c1c2c2cccc(O)c2n1C1OC(CO)C(O)C(O)C1O,"1,11-dihydroxy-12-(3,4,5-trihydroxy-6-hydroxymethyltetrahydro-2H-2-pyranyl)-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione",90.0,uM,=,1.954242509439325,1,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1c2c2ccccc2n1C1CCCCO1
3286,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C=CC(=O)Nc1cccc(-c2csc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}thieno[2,3-d]-pyrimidin-5-yl)phenyl]prop-2-enamide",0.082,uM,=,-1.0861861476162833,0,c1ccc(CNc2ncnc3scc(-c4ccccc4)c23)cc1
3287,64443,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-4-fluoro-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-acrylamide",0.0007199999999999,uM,=,-3.1426675035687315,0,c1ccc(Nc2ncnc3cnccc23)cc1
3288,2198131,10.1016/j.ejmech.2022.114661,,,,Inhibition of recombinant human EGFR incubated for 40 to 45 mins and measured after 15 mins by Kinase-Glo Max assay,NNC(=O)c1csc2nc(CN3CCOCC3)c(-c3ccc(Br)cc3)n12,"5-(4-Bromophenyl)-6-(morpholinomethyl)imidazo[2,1-b]thiazole-3-carbohydrazide",0.419,uM,=,-0.3777859770337047,0,c1ccc(-c2c(CN3CCOCC3)nc3sccn23)cc1
3289,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCc2ccccc2)c1O,3-(3-Benzylsulfanylmethyl-4-hydroxy-5-methoxy-phenyl)-2-cyano-acrylamide,1.95,uM,=,0.290034611362518,1,c1ccc(CSCc2ccccc2)cc1
3290,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
3291,1983835,10.1016/j.bmc.2019.115281,,,,Inhibition of wild type EGFR (unknown origin),C=C1CC(c2ccccc2)(C(Br)c2ccccc2)OC1=O,rac-5-(bromo(phenyl)methyl)-3-methylene-5-phenyldihydrofuran-2(3H)-one,29.0,uM,=,1.462397997898956,1,C=C1CC(Cc2ccccc2)(c2ccccc2)OC1=O
3292,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,1.18,uM,=,0.0718820073061253,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3293,1883986,10.1021/acsmedchemlett.8b00461,,,,Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay,N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(Cl)cn4)cc3)c(C(N)=O)c2N)C1,(R)-5-Amino-3-(4-((5-chloropyridin-2-yl)oxy)phenyl)-1-(1-cyanopiperidin-3-yl)-1H-pyrazole-4-carboxamide,15.4,uM,=,1.187520720836463,1,c1ccc(Oc2ccc(-c3ccn([C@@H]4CCCNC4)n3)cc2)nc1
3294,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{8-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-octyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",21.0,uM,=,1.3222192947339193,1,O=C(C=Cc1ccccc1)NCCCCCCCCNC(=O)/C=C/c1ccccc1
3295,2018691,10.1016/j.bmc.2020.115674,,,,Inhibition of EGFR-TK (unknown origin) relative to control,Cc1cc(NC(=O)CCl)no1,SID24804165,0.106,uM,=,-0.9746941347352298,0,c1cnoc1
3296,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CCCCCCCCCCCCCCCC[n+]1ccccc1.[Br-],1-Hexadecyl-pyridinium bromide,3.472,uM,=,0.5405797165044542,1,c1cc[nH+]cc1
3297,512831,10.1016/j.bmcl.2008.07.057,,,,Inhibition of EGFR,NNC(=O)c1c(N)ncnc1Nc1ccc(OCc2ccccc2)c(Cl)c1,4-amino-6-(4-(benzyloxy)-3-chlorophenylamino)pyrimidine-5-carbohydrazide,0.458,uM,=,-0.3391345219961308,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
3298,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3cn[nH]c3c2)c2c(N)ncnc21,"3-(1H-indazol-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",2.5,uM,=,0.3979400086720376,1,c1ncc2c(-c3ccc4cn[nH]c4c3)n[nH]c2n1
3299,1929287,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide substrate preincubated for 10 mins followed by substrate addition measured after 40 mins by caliper motility shift assay,O=C(/C=C/CN1CCOCC1)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-((3-chloro-4-fluorophenyl)amino)-7,8-dihydro-6H-[1, 4]oxazino[3, 2-g]quinazolin-6-yl)-4-morpholinobut-2-en-1-one",0.007,uM,=,-2.154901959985743,0,O=C(/C=C/CN1CCOCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
3300,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,C#Cc1cccc(Nc2ncnc3cc(OC4CCOCC4)c4c(c23)OCCO4)c1,"N-(3-Ethynylphenyl)-5-((1-methoxypropan-2-yl)oxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0578,uM,=,-1.238072161579471,0,c1ccc(Nc2ncnc3cc(OC4CCOCC4)c4c(c23)OCCO4)cc1
3301,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,COc1ccc(N(c2nc(C)nc3oc(C)cc23)C(C)C)cc1,"N-(4-Methoxyphenyl)-2,6-dimethyl-N-(propan-2-yl)furo[2,3-d]pyrimidin-4-amine",0.0844,uM,=,-1.0736575533743449,0,c1ccc(Nc2ncnc3occc23)cc1
3302,1714364,10.1016/j.bmc.2018.05.039,,,,"Inhibition of wild type EGFR (unknown origin) using Poly(Glu,Tyr) as substrate after 40 mins by Kinase-Glo luminescence assay",C=CC(=O)N[C@H]1CCCN(c2nc(Nc3ccccc3)nc3cnc(Nc4ccc(N5CCN(C)CC5)cn4)cc23)C1,"(S)-N-(1-(6-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-2-(phenylamino)pyrido[3,4-d]pyrimidin-4-yl)piperidin-3-yl)acrylamide",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2nc(N3CCCCC3)c3cc(Nc4ccc(N5CCNCC5)cn4)ncc3n2)cc1
3303,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ncnc(Nc4ccc(F)c(Cl)c4)c32)c1C,"5-[4-(3-Chloro-4-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide",0.2,uM,=,-0.6989700043360187,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
3304,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,CC/C=C\C(=O)Nc1cc(Nc2nc(C)cc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,(Z)-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-methyl-6-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)pent-2-enamide,1.255,uM,=,0.0986437258170569,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3305,66897,10.1021/jm970367n,,,,Inhibition of Epidermal growth factor receptor (EGFr) tyrosine kinase,Cc1cccc(C)c1-c1cc2cnc(N)nc2nc1NC(=O)NC(C)(C)C,"1-[2-Amino-6-(2,6-dimethyl-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl-urea",0.61,uM,=,-0.2146701649892329,0,c1ccc(-c2cnc3ncncc3c2)cc1
3306,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",Cc1cccc(Nc2ncnc3cnc(N(C)C)nc23)c1,"N*2*,N*2*-Dimethyl-N*8*-m-tolyl-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3cncnc23)cc1
3307,1641794,,,,,"Time-Resolved Fluorescence Assay: The following assay may be used to determine the activity of the compounds of the invention for inhibiting EGFR kinase activity. The half maximal inhibitory concentration IC50 (the concentration of the tested compound showing 50% inhibition of the enzyme activity) of each compound was determined by incubating several different concentrations of the tested compounds with a specific enzyme and substrate. EGFR kinase used in this assay is a human-derived recombinant protein (Cell signaling technology, #7908), which was reacted with peptide substrate and different concentrations of tested compounds in a buffer solution containing 60 mM HEPES (pH7.5), 5 mM MgCl2, 5 mM MnCl2, 3 Î¼M Na3VO4, 1.25 M DTT (1000Ã) and 20 Î¼M ATP at 25Â° C., for 45 minutes. The EGFR kinase activity was determined by using a Time-Resolved fluorescence method.",CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@@H]1CCCN1,"US8901140, 2::US9358227, 2",0.006,uM,=,-2.2218487496163566,0,O=C(/C=C/[C@@H]1CCCN1)Nc1ccc2nccc(Nc3ccc(OCc4ccccn4)cc3)c2c1
3308,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,O=C(/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)s1)NO,(E)-3-(5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)thiophen-2-yl)-N-hydroxyacrylamide,0.0048,uM,=,-2.318758762624413,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5cccs5)cc34)cc2)cc1
3309,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(C=C(C#N)C#N)cc(CSc2ccccc2)c1O,2-(4-Hydroxy-3-methoxy-5-phenylsulfanylmethyl-benzylidene)-malononitrile,6.0,uM,=,0.7781512503836436,1,c1ccc(CSc2ccccc2)cc1
3310,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(-c3ccccc3)cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-6-phenylpyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.0078,uM,=,-2.10790539730952,0,O=c1c(-c2ccccc2)cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
3311,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cccc(Nc2ncnc3cc(N)ncc23)c1,"N*4*-(3-Amino-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",1.55,uM,=,0.1903316981702915,1,c1ccc(Nc2ncnc3ccncc23)cc1
3312,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,Cn1c(SSc2c(C(=O)Nc3ccccc3)c3cc(O)ccc3n2C)c(C(=O)Nc2ccccc2)c2cc(O)ccc21,"2,2'-Dithiobis(1-methyl-5-hydroxy-N-phenyl-1H-indole-3-carboxamide)",40.5,uM,=,1.6074550232146685,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
3313,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](CN(C)C)C(N)=O,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-3-(dimethylamino)propanamide,0.075,uM,=,-1.1249387366083,0,c1ccc(Nc2ncnc3ccccc23)cc1
3314,958682,10.1021/jm400463q,,,,Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC(=O)N5CCC(Oc6no[n+]([O-])c6S(=O)(=O)c6ccccc6)CC5)CC4)cc3OC)ncc2Cl)c1,"4-((1-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetyl)piperidin-4-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide",0.042,uM,=,-1.3767507096020994,0,O=C(CN1CCN(c2ccc(Nc3nccc(Oc4ccccc4)n3)cc2)CC1)N1CCC(Oc2no[nH+]c2S(=O)(=O)c2ccccc2)CC1
3315,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.065,uM,=,-1.1870866433571443,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3s2)C1)N1CCOCC1
3316,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)NCCSc1nc(-c2ccc(F)c(C(F)(F)F)c2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,N-(2-((4-(4-Fluoro-3-(trifluoromethyl)phenyl)-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)ethyl)acrylamide,0.045,uM,=,-1.3467874862246565,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
3317,632393,10.1016/j.bmcl.2010.03.064,,,,Inhibition of EGFR,c1ccc(CCc2cc3c(Nc4ccc5[nH]ccc5c4)ncnc3[nH]2)cc1,"N-1H-indol-5-yl-6-(2-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",56.1,uM,=,1.7489628612561614,1,c1ccc(CCc2cc3c(Nc4ccc5[nH]ccc5c4)ncnc3[nH]2)cc1
3318,1509378,10.1021/acs.jmedchem.5b00710,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte assay,C=CC(=O)Nc1cccc(CNc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)methyl)phenyl)acrylamide,0.409,uM,=,-0.3882766919926582,0,c1ccc(CNc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3319,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,N#C/C(=C\c1cc(O)c(O)c(CSc2nc3ccccc3s2)c1)C(N)=O,"3-[3-(Benzothiazol-2-ylsulfanylmethyl)-4,5-dihydroxy-phenyl]-2-cyano-acrylamide",3.2,uM,=,0.505149978319906,1,c1ccc(CSc2nc3ccccc3s2)cc1
3320,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,O=C(NCCN1CCCCC1)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,1-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)-3-(2-(piperidin-1-yl)ethyl)urea,0.062,uM,=,-1.207608310501746,0,O=C(NCCN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3321,436426,10.1021/jm070144p,,,,Inhibition of EGFR tyrosine kinase expressed in A431 cells,ClCCN(CCN/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)Cc1ccccc1,1-{4-[(3-chlorophenyl)amino-6-quinazolinyl}-3-{2-[N-(2-chloroethyl)-N-benzylethylenamine]}triazene,0.071,uM,=,-1.1487416512809248,0,c1ccc(CNCCN/N=N/c2ccc3ncnc(Nc4ccccc4)c3c2)cc1
3322,1641793,,,,,"Cell Proliferation Inhibition Assay: The following in vitro assay is to determine the activity of the tested compounds for inhibiting the proliferation of cancer cells, which has high expression of EGFR. The activity is represented by the IC50 value. The general procedures of the assay are given as follows: The cancer cells A431 that highly expressing EGFR (Institute of biochemistry and cell biology) were chosen and seeded to 96-well cell culture plate at a suitable concentration (e.g., 5000 cells/mL medium). The cells then were incubated in carbon dioxide (CO2) incubator until they reached 85% confluency. Then, the cell culture medium was replaced by fresh one with tested compounds added in it at serial concentrations (general 6 to 7 concentrations). Then the cells were put back to the incubator and cultured continuously. 72 hours later, the activity of the tested compounds for inhibiting the cell proliferation was determined by using Sulforhodamine B (SRB) method.",CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,"US8901140, 9::US9358227, 9",0.008,uM,=,-2.096910013008056,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3323,1984105,10.1021/acs.jmedchem.9b01617,,,,Inhibition of EGFR1 (unknown origin),COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0031,uM,=,-2.508638306165728,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
3324,66570,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor in A431 cells,C=CC(=O)Nc1ccc2c(Nc3cccc(Cl)c3)ncnc2c1,N-[4-(3-Chloro-phenylamino)-quinazolin-7-yl]-acrylamide,0.053,uM,=,-1.275724130399211,0,c1ccc(Nc2ncnc3ccccc23)cc1
3325,1769307,10.1016/j.bmc.2018.02.029,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,C=CC(=O)Nc1cc(Nc2ncc3ncn(-c4ccc(F)cc4)c3n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((9-(4-fluorophenyl)-9H-purin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.0182,uM,=,-1.739928612014925,0,c1ccc(Nc2ncc3ncn(-c4ccccc4)c3n2)cc1
3326,624979,10.1016/j.bmcl.2010.03.015,,,,Inhibition of EGFR intracellular phosphorylation in human A431 cells by ELISA,O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc4c(c3)CCNC4)n2)c1,"2-phenyl-N-(3-(5-(2-(1,2,3,4-tetrahydroisoquinolin-6-ylamino)pyrimidin-4-yl)imidazo[2,1-b]thiazol-6-yl)phenyl)acetamide",1.0,uM,=,0.0,0,O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc4c(c3)CCNC4)n2)c1
3327,2145645,10.1016/j.bmcl.2021.128406,,,,Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence of ATP by IMAP-FP assay,C=CC(=O)N1CCC2(CC1)CNC(=O)c1cc(-c3ccnc(Nc4ccccc4OC(C)C)n3)[nH]c12,"1-acryloyl-2'-(2-(2-isopropoxyphenylamino)pyrimidin-4-yl)-5',6'-dihydrospiro[piperidine-4,7'-pyrrolo[3,2-c]pyridin]-4'(1'H)-one",0.0012,uM,=,-2.920818753952376,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(Nc4ccccc4)n3)cc21
3328,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.039,uM,=,-1.408935392973501,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
3329,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C(Nc1ccccc1)N(Cc1ccc(O)cc1)Cc1cccc(Br)c1O,1-(5-Bromo-2-hydroxybenzyl)-1-(4-hydroxybenzyl)-3-phenylurea,1.07,uM,=,0.0293837776852096,1,O=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
3330,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)N1CCc2c(sc3ncnc(Nc4cccc(CC)c4)c23)C1,"1-(4-((3-ethylphenyl)amino)-5,6-dihydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(8H)-yl)prop-2-en-1-one",8.73,uM,=,0.9410142437055696,1,c1ccc(Nc2ncnc3sc4c(c23)CCNC4)cc1
3331,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,CCCN(C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)CCC,4-Dipropylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
3332,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc(Oc4ccccc4)cc3)ncnc2cn1,"(2E)-N-[4-(4-Phenoxybenzyl)pyrido[3,4-d]pyrimidin-6-yl]-4-(1-pyrrolidinyl)-2-butenamide",0.18,uM,=,-0.744727494896694,0,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc(Oc4ccccc4)cc3)ncnc2cn1
3333,2069689,10.1016/j.bmc.2021.116039,,,,Inhibition of recombinant wild type EGFR (696 to C terminal end) (unknown origin) using poly (Glu-Tyr) as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by ELISA,COc1ccc(-c2c3c4cc(OC)c(O)cc4[nH]c(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O,Azalamellarin N,0.3077,uM,=,-0.5118725037525416,0,O=c1[nH]c2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
3334,1906489,10.1016/j.ejmech.2019.111648,,,,"Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay",N#Cc1ccc(-c2csc(N3N=C(c4ccc(N5CCOCC5)cc4)CC3c3ccc(Cl)cc3)n2)cc1,1-(4-(4-Cyanophenyl)thiazol-2-yl)-3-(4-morpholinophenyl)-5-(4-chlorophenyl)-2-pyrazoline,4.34,uM,=,0.6374897295125107,1,c1ccc(-c2csc(N3N=C(c4ccc(N5CCOCC5)cc4)CC3c3ccccc3)n2)cc1
3335,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,O=[N+]([O-])c1cc2c(Nc3cccc(Br)c3)ncnc2cc1Cl,(3-Bromo-phenyl)-(7-chloro-6-nitro-quinazolin-4-yl)-amine,0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
3336,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CCNCc1ccc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)[nH]1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((ethylamino)methyl)-1H-pyrrol-2-yl)thieno[2,3-d]pyrimidin-4-amine",0.121,uM,=,-0.91721462968355,0,c1ccc(COc2ccc(Nc3ncnc4sc(-c5ccc[nH]5)cc34)cc2)cc1
3337,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(C(O)c4ccccc4)cc3)ncnc2cc1OC,N-(4-{4-[Hydroxy(phenyl)methyl]anilino}-7-methoxy-6-quinazolinyl)propanamide,0.343,uM,=,-0.4647058799572294,0,c1ccc(Cc2ccc(Nc3ncnc4ccccc34)cc2)cc1
3338,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,O=C(NO)c1ccccc1Nc1nc(Nc2ccc(CN3CCOCC3)cc2)ncc1Cl,2-(5-chloro-2-(4-(morpholinomethyl)phenylamino)pyrimidin-4-ylamino)-N-hydroxybenzamide,0.004495,uM,=,-2.3472703039307525,0,c1ccc(Nc2ccnc(Nc3ccc(CN4CCOCC4)cc3)n2)cc1
3339,2268700,10.1016/j.ejmech.2021.113768,,,,Inhibition of EGFR (unknown origin),CSc1nn(-c2ccc(Br)cc2)c2nc(C)nc(Nc3ccc(OCCCC[N+](=O)[O-])cc3)c12,"1-(4-bromophenyl)-6-methyl-3-(methylthio)-N-(4-(4-nitrobutoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",3.0,uM,=,0.4771212547196624,1,c1ccc(Nc2ncnc3c2cnn3-c2ccccc2)cc1
3340,1649110,10.1016/j.bmc.2016.11.026,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF induced phosphorylation preincubated for 60 mins followed by EGF addition measured after 10 mins by ELISA method,COc1ccc2c(c1)CCCN2c1nc(C)nc2c(Cc3ccccc3)cn(C)c12.Cl,"1-(7-Benzyl-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline hydrochloride",0.0049,uM,=,-2.309803919971486,0,c1ccc(Cc2c[nH]c3c(N4CCCc5ccccc54)ncnc23)cc1
3341,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,But-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.00055,uM,=,-3.2596373105057563,0,c1ccc(Nc2ncnc3ccccc23)cc1
3342,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2NC(C)=O)c1O,3-[3-(2-Acetylamino-phenylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,5.6,uM,=,0.7481880270062004,1,c1ccc(CSc2ccccc2)cc1
3343,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccccc1,"2-Benzoyl-3-(3,4-dihydroxy-phenyl)-acrylonitrile",1.0,uM,=,0.0,0,O=C(C=Cc1ccccc1)c1ccccc1
3344,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,Cc1cncc(COc2ccc(Nc3ncnn4ccc(CN5CCC(N)CC5)c34)cc2Cl)c1,"5-((4-aminopiperidin-1-yl)methyl)-N-(3-chloro-4-((5-methylpyridin-3-yl)methoxy)phenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.085,uM,=,-1.0705810742857071,0,c1cncc(COc2ccc(Nc3ncnn4ccc(CN5CCCCC5)c34)cc2)c1
3345,2233412,10.1016/j.bmcl.2022.128703,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells using kinase substrate 22 incubated for 30 mins in presence of ATP,C=C(C(=O)N1CCN(C(=O)Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)[C@H](C)C1)C(F)(F)F,"4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl(R)-2-methyl-4-(2-(trifluoromethyl)acryloyl)piperazine-1-carboxylate",0.00038,uM,=,-3.42021640338319,0,O=C(Oc1ccc2ncnc(Nc3ccccc3)c2c1)N1CCNCC1
3346,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(NC(=O)/C=C/CNC4CC4)cc23)c1,"(S,E)-4-(Cyclopropylamino)-N-(4-(3-ethynylphenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)but-2-enamide",0.0056,uM,=,-2.2518119729938,0,O=C(/C=C/CNC1CC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
3347,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(NS(=O)(=O)c4ccccc4)c(F)c3)ncnc2cc1OC,N-(4-{3-Fluoro-4-[(phenylsulfonyl)amino]anilino}-7-methoxy-6-quinazolinyl)propanamide,0.593,uM,=,-0.2269453066357374,0,O=S(=O)(Nc1ccc(Nc2ncnc3ccccc23)cc1)c1ccccc1
3348,2088168,10.1016/j.ejmech.2020.112363,,,,Inhibition of EGFR (unknown origin) by FRET assay,O=S(=O)(Nc1ccccn1)c1ccc(NC(=S)Nc2ccc3c(c2)OCO3)cc1,"4-(3-Benzo[d][1,3]dioxol-5-ylthioureido)-N-(pyridin-2-yl)benzenesulfonamide",1.885,uM,=,0.2753113545418116,1,O=S(=O)(Nc1ccccn1)c1ccc(NC(=S)Nc2ccc3c(c2)OCO3)cc1
3349,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CC(O)C1,1-(3-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)propyl)azetidin-3-ol,0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCC4)cc23)cc1
3350,2132157,10.1021/acs.jmedchem.1c01559,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(-c4ccc(Cl)cc4)ccn3)cc2)c(C(N)=O)n1N,(S)-2-(1-acryloylpiperidin-2-yl)-1-amino-4-(4-((4-(4-chlorophenyl)pyridin-2-yl)carbamoyl)phenyl)-1H-imidazole-5-carboxamide,0.0126,uM,=,-1.899629454882437,0,O=C(Nc1cc(-c2ccccc2)ccn1)c1ccc(-c2c[nH]c([C@@H]3CCCCN3)n2)cc1
3351,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c(OC)cc1N1CCN(C)CC1,N-(5-(4-(1H-indol-3-yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide,1.3,uM,=,0.1139433523068367,1,c1ccc2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c[nH]c2c1
3352,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CN(C)C/C=C/C(=O)Nc1ccc(-c2cncc(C#N)c2Nc2ccc(F)c(Cl)c2)cc1,N-(4-(4-((3-Chloro-4-fluorophenyl)amino)-5-cyanopyridin-3-yl)phenyl)-4-(dimethylamino)but-2-enamide,3.5,uM,=,0.5440680443502757,1,c1ccc(Nc2ccncc2-c2ccccc2)cc1
3353,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(/C=C/c1ccc([N+](=O)[O-])cc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,(E)-N-(4-(3-Bromophenylamino)quinazolin-6-yl)-3-(4-nitrophenyl)acrylamide,5.16,uM,=,0.7126497016272114,1,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3354,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC(=O)c4ccccc4OC(C)=O)c(OCCOC(=O)c4ccccc4OC(C)=O)cc23)c1,"((4-((3-Ethynylphenyl)amino)quinazoline-6,7-diyl)bis(oxy))bis(ethane-2,1-diyl)-bis(2-acetoxybenzoate)",0.034,uM,=,-1.4685210829577449,0,O=C(OCCOc1cc2ncnc(Nc3ccccc3)c2cc1OCCOC(=O)c1ccccc1)c1ccccc1
3355,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,C=CS(=O)(=O)Nc1cc2c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c(C#N)cnc2cc1OCC,Ethenesulfonic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.045,uM,=,-1.3467874862246565,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
3356,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,NCCCCOCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((4-aminobutoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.16,uM,=,-0.7958800173440752,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
3357,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc(Cl)cc3)C2)cc1C,"2-(5-(4-chlorophenyl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",2.36,uM,=,0.3729120029701065,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
3358,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCN(C)CC1,"N-{4-(3-Chloro-4-fluoro-phenylamino)-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-pyrido[3,2-d]pyrimidin-6-yl}-acrylamide",0.0066,uM,=,-2.1804560644581312,0,c1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)cnc23)cc1
3359,1639950,,,,,Inhibition of recombinant human N-terminal GST His6-tagged thrombin cleavage site-fused EGFR (H672 to A1210 residues) expressed in baculovirus using poly-EY as substrate after 210 mins by luciferase coupled chemiluminescence assay,COc1cc2c(Nc3ccc(Cl)c(Cl)c3)ncnc2cc1OCc1nc(-c2ccc(C(C)(C)C)cc2)no1,"N-(3,4-dichlorophenyl)-7-[({3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)oxy]-6-(methyloxy)quinazolin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3cc(OCc4nc(-c5ccccc5)no4)ccc23)cc1
3360,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCC1CCNCC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(2-piperidin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.08,uM,=,-1.0969100130080565,0,c1ccc(Nc2ncnc3cc(OCCC4CCNCC4)ccc23)cc1
3361,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,C[C@H](Nc1ncnc2cc3oc(=O)n(CCCN4CCOCC4)c3cc12)c1ccccc1,"(S)-1-(3-morpholinopropyl)-8-(1-phenylethylamino)oxazolo[4,5-g]quinazolin-2(1H)-one",3.7,uM,=,0.568201724066995,1,O=c1oc2cc3ncnc(NCc4ccccc4)c3cc2n1CCCN1CCOCC1
3362,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=C(O)c1cc(O)c(O)c(O)c1,"2-[Hydroxy-(3,4,5-trihydroxy-phenyl)-methylene]-malononitrile",13.5,uM,=,1.130333768495006,1,c1ccccc1
3363,807903,10.1016/j.bmc.2012.01.029,,,,Inhibition of EGF-induced EGFR autophosphorylation in human A431 cells incubated for 60 mins prior to EGF-induction measured after 10 mins by phosphotyrosine ELISA,COc1ccc(OC)c(Cn2ccc3c(Nc4cccc(Br)c4)nc(N)nc32)c1,"N4-(3-bromophenyl)-7-(2,5-dimethoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",69.2,uM,=,1.840106094456757,1,c1ccc(Cn2ccc3c(Nc4ccccc4)ncnc32)cc1
3364,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-(3-Chloro-4-fluoro-phenylamino)-quinazolin-6-yl]-acrylamide,0.00075,uM,=,-3.1249387366083,0,c1ccc(Nc2ncnc3ccccc23)cc1
3365,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C4CC4)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-cyclopropyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.224,uM,=,-0.6497519816658371,0,c1ccc(Nc2nccc(-c3cn(C4CC4)c4ccccc34)n2)cc1
3366,465,10.1016/s0960-894x(02)00364-5,,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Cc1cc(C(=O)N2CCN(C)CC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[3-methyl-5-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.75,uM,=,-0.1249387366082999,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCNCC2)[nH]1
3367,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OC[C@@H]1CCCN(C)C1,(R)-(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-3-ylmethoxy)-quinazolin-4-yl]-amine,0.15,uM,=,-0.8239087409443188,0,c1ccc(Nc2ncnc3cc(OC[C@@H]4CCCNC4)ccc23)cc1
3368,2110760,10.1016/j.ejmech.2020.113022,,,,Inhibition of N-terminal GST-tagged human recombinant EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.0045899999999999,uM,=,-2.338187314462739,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3369,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",CCOC(=O)/C=C/C(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"Ethyl (2E)-4-{[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]amino}-4-oxobut-2-enoate",0.079,uM,=,-1.1023729087095586,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
3370,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCC/C(=C\c3ccc(F)cc3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(4-fluorobenzylidene)cyclohexanone",5.69,uM,=,0.7551122663950712,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
3371,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,COC[C@H]1Oc2cc3ncnc(Nc4cccc(Cl)c4)c3cc2O[C@@H]1COC,"(7R,8R)-N-(3-chlorophenyl)-7,8-bis(methoxymethyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine",0.01008,uM,=,-1.9965394678904933,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
3372,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,CN(C)Cc1c[nH]c2cc3ncnc(Nc4cccc(Br)c4)c3cc12,"(3-Bromo-phenyl)-(6-dimethylaminomethyl-8H-pyrrolo[3,2-g]quinazolin-4-yl)-amine",0.0096999999999999,uM,=,-2.0132282657337552,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
3373,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C3CC3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(3-Cyclopropyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)-phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.00058,uM,=,-3.2365720064370627,0,O=C1N(c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc2CN1C1CC1
3374,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.21,uM,=,-0.6777807052660807,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3375,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(CC)c3)c2c1,N-(4-(3-ethylphenylamino)quinazolin-6-yl)acrylamide,2.7,uM,=,0.4313637641589873,1,c1ccc(Nc2ncnc3ccccc23)cc1
3376,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(Br)cc3C)c2c1,N-(4-(4-bromo-2-methylphenylamino)quinazolin-6-yl)acrylamide,2.2,uM,=,0.3424226808222063,1,c1ccc(Nc2ncnc3ccccc23)cc1
3377,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,COCC1CN(c2ncc(C(C)C)c3cc(Nc4ccnc(N5CC[C@@H](O)[C@@](C)(F)C5)n4)ncc23)C1,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-(3-(methoxymethyl)azetidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",25.0,uM,=,1.3979400086720375,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
3378,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine",8e-06,uM,=,-5.096910013008056,0,c1ccc(Nc2ncnc3cnccc23)cc1
3379,642516,10.1021/jm1000198,,,,Inhibition of GST-tagged EGFR expressed in Escherichia coli,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
3380,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c4c(c23)OCCO4)cc1Cl,"N-(3-Chloro-4-fluorophenyl)-5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.02586,uM,=,-1.5873714794556248,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c4c(c23)OCCO4)cc1
3381,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(C2CC(c3ccc(Cl)cc3)=NN2C2=NC(=O)CS2)cc1,"2-(3-(4-Chlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",8.58,uM,=,0.9334872878487056,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
3382,2127056,10.1016/j.bmcl.2021.128118,,,,Inhibition of recombinant wild type EGFR-TK (unknown origin) by ELISA,COc1ccc(NC(c2ccc(OC)cc2)n2c(=O)ccc3cc(O)ccc32)cc1,6-hydroxy-1-((4-methoxyphenyl)(4-methoxyphenylamino)methyl)quinolin-2(1H)-one,5.29,uM,=,0.7234556720351858,1,O=c1ccc2ccccc2n1C(Nc1ccccc1)c1ccccc1
3383,520709,10.1016/j.ejmech.2008.04.012,,,,Inhibition of EGFR,Nc1ncnc2c1ncn2CC(=O)c1cccnc1,2-(6-Amino-9H-purine-9-yl)-1-(pyridine-3-yl)ethanone,93.0,uM,=,1.9684829485539352,1,O=C(Cn1cnc2cncnc21)c1cccnc1
3384,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,CS(=O)(=O)CCNC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((4-(2-(methylsulfonyl)ethylamino)piperidin-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.2,uM,=,-0.6989700043360187,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
3385,66724,10.1021/jm00032a020,,,,Inhibition of EGFR(epidermal growth factor receptor) autophosphorylation in ER22 cell membranes,O=C(OCCc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid phenethyl ester",0.2,uM,=,-0.6989700043360187,0,O=C(OCCc1ccccc1)c1cccc(NCc2ccccc2)c1
3386,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1OCCCCCCC(=O)NO,7-(4-(3-Chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.00908,uM,=,-2.041914151478915,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
3387,1739299,10.1016/j.ejmech.2018.05.006,,,,Inhibition of wild type EGFR (unknown origin) using FAM-labeled peptide substrate after 10 mins by mobility shift assay,COc1cc2ncnc(N3CCc4ccccc43)c2cc1NC(=O)/C=C/CN1CCCC1,(E)-N-(4-(indolin-1-yl)-7-methoxyquinazolin-6-yl)-4-(pyrrolidin-1-yl)but-2-enamide,0.003,uM,=,-2.5228787452803374,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(N3CCc4ccccc43)c2c1
3388,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,CS(=O)(=O)CCNCCCCOc1ccc2ncnc(Nc3ccc(S(=O)(=O)c4ccccc4)cc3)c2c1,(4-Benzenesulfonyl-phenyl)-{6-[4-(methanesulfonylmethyl-amino)-butoxy]-quinazolin-4-yl}-amine,0.093,uM,=,-1.031517051446065,0,O=S(=O)(c1ccccc1)c1ccc(Nc2ncnc3ccccc23)cc1
3389,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Oc1ncnc(Sc3cccc(Cl)c3)c1NC2,"1-(3-chloro-phenylsulfanyl)-7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene",2.4,uM,=,0.380211241711606,1,c1ccc(Sc2ncnc3c2NCc2ccccc2O3)cc1
3390,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Nc1ccc2ncnc(Nc3cccc4cc[nH]c34)c2c1,"N4-(1H-indol-7-yl)quinazoline-4,6-diamine",0.02517,uM,=,-1.5991167844516372,0,c1cc(Nc2ncnc3ccccc23)c2[nH]ccc2c1
3391,2080997,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(CCC(=O)NO)nn1,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-((1-(3-(hydroxyamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
3392,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2n1,"1-isopropyl-3-(2-methylquinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",100.0,uM,=,2.0,1,c1cnc2ccc(-c3n[nH]c4ncncc34)cc2c1
3393,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,Brc1cccc(Nc2ncnc3c2NCc2ccccc2O3)c1,"(3-Bromo-phenyl)-(10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",8.1,uM,=,0.9084850188786496,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
3394,800208,10.1016/j.bmcl.2011.12.067,,,,Inhibition of wild-type EGFR expressed using baculovirus expression system by ELISA,Cc1ccc(-n2c(SCC(=O)Nc3ccccc3Cl)nc3sc(C)c(C)c3c2=O)cc1,"N-(2-chlorophenyl)-2-(5,6-dimethyl-4-oxo-3-p-tolyl-3,4-dihydrothieno[2,3-d]pyrimidin-2-ylthio)acetamide",81.6,uM,=,1.911690158753861,1,O=C(CSc1nc2sccc2c(=O)n1-c1ccccc1)Nc1ccccc1
3395,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,COC(=O)C1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"methyl 1-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)piperidine-4-carboxylate",1.0,uM,=,0.0,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
3396,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC,"(3-Chloro-4-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.38,uM,=,-0.4202164033831898,0,c1ccc(Nc2ncnc3ccccc23)cc1
3397,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Cc1cc(C)c(O)c(CN(Cc2ccc(F)cc2)C(=O)Nc2ccccc2)c1,"1-(4-fluorobenzyl)-1-(2-hydroxy-3,5-dimethylbenzyl)-3-phenylurea",27.35,uM,=,1.4369573306694496,1,O=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
3398,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Fc1ccc2c(c1)CNc1c(Nc3ccc(F)c(Cl)c3)ncnc1O2,"(3-Chloro-4-fluoro-phenyl)-(8-fluoro-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
3399,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,Cc1nc(Nc2ccc(C(F)(F)F)cc2)c2cc(C)oc2n1,"2,6-Dimethyl-N-[4-(trifluoromethyl)phenyl]furo[2,3-d]pyrimidin-4-amine",0.1221,uM,=,-0.9132843360551176,0,c1ccc(Nc2ncnc3occc23)cc1
3400,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,CC(C)(O)C#Cc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,4-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)-2-methylbut-3-yn-2-ol,0.1515,uM,=,-0.8195873671616762,0,c1ccc(Nc2ncnc3ccccc23)cc1
3401,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1,"3-Amino-2,4-dicyano-5-(4-hydroxy-phenyl)-penta-2,4-dienenitrile",0.1,uM,=,-1.0,0,c1ccccc1
3402,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Clc1cccc(CNc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"N*3*-(3-Chloro-benzyl)-N*4*-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",1.5,uM,=,0.1760912590556812,1,c1ccc(CNc2[nH]nc3ncnc(Nc4ccccc4)c23)cc1
3403,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(Nc1ccc(Br)cc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-bromophenyl)-3-(4-((3-bromophenyl)amino)quinazolin-6-yl)thiourea,0.0354,uM,=,-1.450996737974212,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3404,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3cccc(F)c3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-fluoro-phenyl)-amine",0.0038,uM,=,-2.42021640338319,0,c1ccc(Nc2ncnc3ccccc23)cc1
3405,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",CN(C)C/C=C/C(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"(2E)-4-(Dimethylamino)-N-[3-(4-{[(1S)-2-hydroxy-1-phenylethyl]-amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]but-2-enamide",0.015,uM,=,-1.8239087409443189,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
3406,614501,10.1021/jm901132v,,,,Inhibition of EGFR,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.01,uM,=,-2.0,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
3407,1991314,10.1016/j.bmcl.2020.127288,,,,Inhibition of wild type EGFR (unknown origin) in presence of radiolabelled gammaATP by radioisotope filter binding assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.003,uM,=,-2.5228787452803374,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
3408,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,COCCOCC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-(2-Methoxy-ethoxy)-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2ncnc3ccccc23)cc1
3409,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COc1cc2ncc(C#N)c(Nc3cccc(Br)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,0.79,uM,=,-0.1023729087095585,0,c1ccc(Nc2ccnc3ccccc23)cc1
3410,1641868,,,,,"Luminescence Kinase Assay: The assay was performed using Kinase-Glo Plus luminescence kinase assay kit (Promega). The compounds were diluted in 10% DMSO and 5 Î¼l of the dilution was added to a 50 Î¼l reaction so that the final concentration of DMSO is 1% in all of reactions. All of the enzymatic reactions were conducted at 30Â° C. for 25 minutes. The 50 Î¼l reaction mixture contains 40 mM Tris, pH 7.4, 10 mM MgCl2, 0.1 mg/ml BSA, 1 mM DTT, 0.2 mg/ml Poly (Glu, Tyr) substrate, 10 Î¼M ATP and EGFR (Table 2.3.1). After the enzymatic reaction, 50 Î¼l of Kinase-Glo Plus Luminescence kinase assay solution (Promega) was added to each reaction and incubate the plate for 5 minutes at room temperature. Luminescence signal was measured using a BioTek Synergy 2 microplate reader. EGFR activity assays were performed in duplicate at each concentration.",C#Cc1cccc(Nc2ncnc3cc(OC)c(NC(=O)/C=C/CN4CCCCC4)cc23)c1,(E)-N-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide,0.022,uM,=,-1.6575773191777938,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3411,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,O=C(/C=C/[C@@H]1CCCN1)N1CCc2c(sc3ncnc(Nc4ccc(F)c(Cl)c4)c23)C1,"US8524722, 13",0.002,uM,=,-2.6989700043360187,0,O=C(/C=C/[C@@H]1CCCN1)N1CCc2c(sc3ncnc(Nc4ccccc4)c23)C1
3412,850422,10.1016/j.bmc.2012.08.002,,,,Inhibition of human N-terminal DYKDDDD tagged EGFR cytoplasmic domain amino acid 669 to 1210 expressed in baculovirus after 5 mins by scintillation counter,CC(C)(C)S(=O)(=O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,"2-(tert-Butylsulfonyl)-N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}acetamide",0.056,uM,=,-1.2518119729937995,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
3413,1527997,,,,,"ELISA-Based Kinase Assay: Inhibition of erbB tyrosine kinase activity was assessed using an ELISA-based receptor tyrosine kinase assay. Kinase reactions (50 mM HEPES, pH 7.4, 125 mM NaCl, 10 mM MgCl2, 100 Î¼M sodium orthovanadate, 2 mM dithiothreitol, 20 uM ATP, test compound or vehicle control and 1-5 nM GST-erbB per 50 uL reaction) were run in 96-well plates coated with 0.25 mg/ml poly-Glu-Tyr (Sigma). The reactions were incubated for 6 minutes at room temperature while shaking. Kinase reactions were stopped by removal of reaction mixture, then wells were washed with wash buffer comprising 3% Bovine Serum Albumin and 0.1% Tween 20 in Phosphate Buffered Saline (PBS). Phosphorylated tyrosine residues were detected by adding 0.2 Î¼g/ml anti-phosphotyrosine antibody (Oncogene Ab-4; 50 Î¼L/well) coupled to Horse Radish Peroxidase (HRP) for 25 minutes while shaking at room temperature.",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,Dacomitinib,0.0069,uM,=,-2.161150909262745,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3414,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc(F)c3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(3-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.13,uM,=,-0.8860566476931633,0,c1ccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)cc1
3415,63780,10.1016/j.bmcl.2004.01.034,,,,Inhibition of epidermal growth factor receptor kinase autophosphorylation,CN(C)C/C=C/C(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.1229,uM,=,-0.910448117113546,0,c1ccc(Nc2ccnc3ccccc23)cc1
3416,1299287,10.1039/C3MD00096F,,,,Inhibition of EGFR (unknown origin) after 1 hr by Caliper mobility shift assay,COc1cc2ncnc(Nc3cccc(NC(=O)Nc4cccc(C)c4)c3)c2cc1OCCCN1CCOCC1,1-(3-(7-Methoxy-6-(3-morpholinopropoxy)quinazolin-4-ylamino)phenyl)-3-m-tolylurea,2.35,uM,=,0.3710678622717362,1,O=C(Nc1ccccc1)Nc1cccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)c1
3417,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
3418,2107115,10.1016/j.ejmech.2021.113300,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,COc1cc2ncnc(Nc3ccc(Cl)c(C(F)(F)F)c3)c2cc1OCCCCC(=O)Nc1ccc(S(N)(=O)=O)cc1,5-((4-((4-chloro-3-(trifluoromethyl)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-(4-sulfamoylphenyl)pentanamide,0.0136999999999999,uM,=,-1.863279432843593,0,O=C(CCCCOc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1ccccc1
3419,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(NCc4cccc5ccccc45)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid (4-{3-chloro-4-[(naphthalen-1-ylmethyl)-amino]-phenylamino}-3-cyano-7-ethoxy-quinolin-6-yl)-amide,0.034,uM,=,-1.4685210829577449,0,c1ccc2c(CNc3ccc(Nc4ccnc5ccccc45)cc3)cccc2c1
3420,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CC(C(N)=O)C1,1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)azetidine-3-carboxamide,0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3ccc(CN4CCC4)cc23)cc1
3421,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,N#CC(Cc1ccc(O)c(O)c1)C(=N)S,"2-Cyano-2-(3,4-dihydroxy-benzyl)-thioacetamide",70.0,uM,=,1.845098040014257,1,c1ccccc1
3422,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,C#Cc1cccc(Nc2ncnc3cc4oc(=O)n(CCCC(=O)OCC)c4cc23)c1,"Ethyl 4-(8-(3-ethynylphenylamino)-2-oxooxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",5.7,uM,=,0.7558748556724915,1,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
3423,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.00045,uM,=,-3.3467874862246565,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
3424,1983835,10.1016/j.bmc.2019.115281,,,,Inhibition of wild type EGFR (unknown origin),C=C1CC(CBr)(c2ccc(F)cc2)OC1=O,rac-5-(bromomethyl)-5-(4-fluorophenyl)-3-methylenedihydrofuran-2(3H)-one,64.0,uM,=,1.806179973983887,1,C=C1CC(c2ccccc2)OC1=O
3425,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OC(CF)CF)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-[7-ethoxy-4-({4-[2-fluoro-1-(fluoromethyl)ethoxy]-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)quinazolin-6-yl]but-2-enamide",0.2833,uM,=,-0.5477534254795628,0,O=C1C=CC(=O)C(Nc2ncnc3ccccc23)=C1
3426,2293047,10.1021/acs.jmedchem.6b00438,,,,Inhibition of EGFR (unknown origin) using flurogenic substrate in presence of ATP,COc1cc2ncnc(NCCOc3ccccc3F)c2cc1OC,"N-(2-(2-fluorophenoxy)ethyl)-6,7-dimethoxyquinazolin-4-amine",0.044,uM,=,-1.3565473235138126,0,c1ccc(OCCNc2ncnc3ccccc23)cc1
3427,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,C=CC(=O)Nc1cc(Nc2ncc(Br)c(Nc3ccc4c(c3)CCC4)n2)ccc1N1CCN(C)CC1,"N-(5-((5-bromo-4-((2,3-dihydro-1H-inden-5-yl)amino)pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide",0.4657,uM,=,-0.3318937620672686,0,c1cc(Nc2ccc3c(c2)CCC3)nc(Nc2ccc(N3CCNCC3)cc2)n1
3428,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(O)c1cc(/N=C/c2cc(O)ccc2O)ccc1O,"5-[(2,5-Dihydroxy-benzylidene)-amino]-2-hydroxy-benzoic acid",5.0,uM,=,0.6989700043360189,1,C(=N/c1ccccc1)\c1ccccc1
3429,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CCOP(=O)(Cc1cc(NCc2cc(O)ccc2O)ccc1O)OCC,"[5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzyl]-phosphonic acid diethyl ester",4.0,uM,=,0.6020599913279624,1,c1ccc(CNc2ccccc2)cc1
3430,1566936,10.1021/acs.jmedchem.5b01633,,,,Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA,C=CC(=O)N1C[C@H](COC)[C@@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)C1,"1-((3R,4R)-3-(((5-Chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)-4-(methoxymethyl)pyrrolidin-1-yl)prop-2-en-1-one",9.1,uM,=,0.9590413923210936,1,c1cc2c(OC[C@@H]3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1
3431,1668743,10.1021/acs.jmedchem.7b00076,,,,"Inhibition of recombinant EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",Cc1n[nH]c2ccc(-c3cc(N[C@@H](CO)c4ccccc4)cnc3-c3ccc(F)cc3O)cc12,(R)-5-Fluoro-2-(5-(2-hydroxy-1-phenylethylamino)-3-(3-methyl-1H-indazol-5-yl)pyridin-2-yl)phenol,0.0081,uM,=,-2.0915149811213505,0,c1ccc(CNc2cnc(-c3ccccc3)c(-c3ccc4[nH]ncc4c3)c2)cc1
3432,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCNC,N-(4-methoxy-2-(methyl(2-(methylamino)ethyl)amino)-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,786.0,uM,=,2.895422546039408,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3433,67206,10.1021/jm010496a,,,,Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase,CCOc1cc2ncnc(Nc3cccc(-c4cscn4)c3)c2cc1OCC,"(6,7-Diethoxy-quinazolin-4-yl)-(3-thiazol-4-yl-phenyl)-amine",0.018,uM,=,-1.744727494896694,0,c1cc(Nc2ncnc3ccccc23)cc(-c2cscn2)c1
3434,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,CCOC(=O)c1nn(-c2ccc(Cl)cc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1,"Ethyl 4-(2-methyl-4,5-diphenyl-1H-pyrrole-3-carbonyl)-1-(p-tolyl)-1H-pyrazole-3-carboxylate",3.2,uM,=,0.505149978319906,1,O=C(c1cnn(-c2ccccc2)c1)c1c[nH]c(-c2ccccc2)c1-c1ccccc1
3435,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CN1CCN(C/C=C/C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3s2)CC1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(4-methylpiperazin-1-yl)but-2-enamide",0.124,uM,=,-0.906578314837765,0,O=C(/C=C/CN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
3436,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](OC)C1,"1-{(3R,4R)-3-[({5-chloro-2-[(1-methyl-1H-pyrazol-4-yl)-amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one",5.1,uM,=,0.7075701760979364,1,c1cc2c(OC[C@@H]3CCNC3)nc(Nc3cn[nH]c3)nc2[nH]1
3437,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ncc(-c2nn(C(C)C)c3ncnc(N)c23)c(OC)n1,"3-(2,4-dimethoxypyrimidin-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",100.0,uM,=,2.0,1,c1ncc(-c2n[nH]c3ncncc23)cn1
3438,642516,10.1021/jm1000198,,,,Inhibition of GST-tagged EGFR expressed in Escherichia coli,C=CC(=O)Nc1ccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)cc1,"(S)-N-(4-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)acrylamide",0.082,uM,=,-1.0861861476162833,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
3439,2153185,10.1016/j.ejmech.2021.113845,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,C/C=C/C(=O)Nc1cc(Nc2ncc(Cl)c(N3CCc4sccc4C3)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((5-chloro-4-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)but-2-enamide",0.3528,uM,=,-0.4524714235402178,0,c1ccc(Nc2nccc(N3CCc4sccc4C3)n2)cc1
3440,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccc(Br)cc3)CC2c2ccccc2)=N1,"2-(3-(4-Bromophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",3.2,uM,=,0.505149978319906,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
3441,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Clc1ccc(C2CC(c3ccc(Br)cc3)=NN2c2nc(-c3ccccc3)cs2)cc1,"2-(3-(4-bromophenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",9.37,uM,=,0.9717395908877784,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
3442,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(NCc3cccnc3)ncnc2s1,"6-(2-Methoxyphenyl)-N-(pyridin-3-ylmethyl)thieno[2,3-d]pyrimidin-4-amine",0.275,uM,=,-0.5606673061697374,0,c1ccc(-c2cc3c(NCc4cccnc4)ncnc3s2)cc1
3443,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1-c1nnc(C)c2nn(-c3ccc(Cl)cc3)cc12,"7-Methyl-4-(2-methyl-4,5-diphenyl-1H-pyrrol-3-yl)-2-(p-tolyl)-2H-pyrazolo[3,4-d]-pyridazine",2.55,uM,=,0.4065401804339551,1,c1ccc(-c2[nH]cc(-c3nncc4nn(-c5ccccc5)cc34)c2-c2ccccc2)cc1
3444,946792,10.1016/j.bmc.2013.01.040,,,,Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA,CC(C)(C)C(=O)Nc1nc(Nc2ccc(Cl)cc2)c2c(n1)[nH]c1cccc(Cl)c12,"N-(5-chloro-4-(4-chlorophenylamino)-9H-pyrimido[4,5-b]indol-2-yl)pivalamide",58.7,uM,=,1.7686381012476144,1,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
3445,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Oc3ccc(NC(=O)/C=C/C(F)(F)F)cc3)n2)n[nH]1,"4,4,4-trifluoro-N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-yloxy)phenyl)but-2-enamide",2.0,uM,=,0.3010299956639812,1,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1
3446,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)C(C)C5)cc4OC)nc32)cc(C(F)(F)F)c1,"N-(3-(2-((4-(3,4-Dimethylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)-5-(trifluoromethyl)phenyl)acrylamide",0.066,uM,=,-1.1804560644581312,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
3447,661840,10.1016/j.bmc.2010.05.049,,,,Inhibition of EGFR expressed in human A431 cells,COc1ccc(OC)c(Cc2cc3c(N(C)c4cccc(Br)c4)nc(N)nc3n2C)c1,"2-Amino-4-(N-methyl-m-bromoanilino)-6-(2,5-dimethoxybenzyl)-7-methyl-pyrrolo[2,3-d]pyrimidine",0.5,uM,=,-0.3010299956639812,0,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
3448,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1,"{2-[4-(2-Chloro-1,2-diphenyl-vinyl)-phenoxy]-ethyl}-diethyl-amine",1.05,uM,=,0.021189299069938,1,C(=C(c1ccccc1)c1ccccc1)c1ccccc1
3449,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,CCCCCCCCCCCCNC(=O)/C=C/c1ccccc1,(E)-N-dodecylcinnamamide,38.46,uM,=,1.585009279902461,1,c1ccccc1
3450,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1ccc(N2C[C@H](O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((8-((2R,3S)-3-hydroxy-2-methylazetidin-1-yl)-5-isopropylisoquinolin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",2.222,uM,=,0.3467440546048488,1,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
3451,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,NC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((4-aminopiperidin-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.035,uM,=,-1.4559319556497243,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
3452,2080997,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCc1cn(CCC(=O)NO)nn1,"N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1-(3-(hydroxyamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
3453,1832274,10.1016/j.bmc.2018.12.032,,,,Inhibition of human A431 cell-derived EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0037,uM,=,-2.431798275933005,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
3454,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(F)c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(3-Fluorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0358,uM,=,-1.4461169733561257,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
3455,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,COc1ccc(-n2cc(NC(=O)c3ccc(NS(=O)(=O)c4ccccc4)cc3)cn2)cc1,N-(1-(4-Methoxyphenyl)-1H-pyrazol-4-yl)-4-(phenylsulfonamido)benzamide,26.15,uM,=,1.417471693203293,1,O=C(Nc1cnn(-c2ccccc2)c1)c1ccc(NS(=O)(=O)c2ccccc2)cc1
3456,2237044,10.1016/j.ejmech.2021.113329,,,,Inhibition EGFR (unknown origin) expressed in baculovirus expression system by ELISA,C=CC(=O)Nc1cccc(N2C(=O)OCc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazin-1-yl)phenyl)acrylamide",0.0288,uM,=,-1.5406075122407692,0,O=C1OCc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
3457,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2=NN(c3nc(-c4ccc(Cl)cc4)cs3)C(c3ccc(Cl)cc3)C2)cc1C,"4-(4-chlorophenyl)-2-(5-(4-chlorophenyl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazole",0.19,uM,=,-0.721246399047171,0,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
3458,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCN(CC)CCOc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC,N-(4-bromo-2-fluorophenyl)-6-(2-(diethylamino)ethoxy)-7-methoxyquinazolin-4-amine,9.1,uM,=,0.9590413923210936,1,c1ccc(Nc2ncnc3ccccc23)cc1
3459,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",Clc1ccc(/C=C/C(=N/Nc2nncc3ccccc23)c2ccccc2)cc1,1-(2-(3-(4-Chlorophenyl)-1-phenylallylidene)hydrazinyl)phthalazine,0.0046,uM,=,-2.337242168318426,0,C(=C/c1ccccc1)\C(=N\Nc1nncc2ccccc12)c1ccccc1
3460,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-phenethyloxy-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.165,uM,=,-0.7825160557860937,0,c1ccc(CCOc2ccc(Nc3ccnc4ccccc34)cc2)cc1
3461,1641517,,,,,"In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CC#CC(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,"US9181263, 17::US9278100, 17",0.4353,uM,=,-0.3612113328426016,0,c1ccc(Oc2ccc(-c3nn([C@H]4CCCNC4)c4ncncc34)cc2)cc1
3462,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)cc3C)c2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)-2-methylphenyl]-7'-methoxy-6'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,1.4,uM,=,0.1461280356782379,1,c1ccc2sc(-c3ccc(Nc4ncnc5ccc(OCCCN6CCNCC6)cc45)cc3)nc2c1
3463,585220,10.1016/j.ejmech.2009.01.035,,,,Inhibition of EGFR autophosphorylation in human A549 cells,O=C1NC(=O)N(CCc2ccccc2)/C1=C/c1ccc(O)cc1,"(E)-5-(4-hydroxybenzylidene)-1-phenethylimidazolidine-2,4-dione",19.0,uM,=,1.2787536009528289,1,O=C1NC(=O)N(CCc2ccccc2)/C1=C/c1ccccc1
3464,506208,10.1021/np50089a001,,,,Inhibition of EGFR,O=c1c(-c2ccc(O)cc2)c(CSC2=NCCS2)oc2cc(O)cc(O)c12,"2-((4,5-dihydrothiazol-2-ylthio)methyl)-5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one",12.467610252570712,uM,=,1.0957832174255009,1,O=c1c(-c2ccccc2)c(CSC2=NCCS2)oc2ccccc12
3465,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(CC)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-ethyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.024,uM,=,-1.619788758288394,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3466,2284955,10.1016/j.ejmech.2019.112016,,,,Inhibition of EGFR (unknown origin),COc1cc(C(=O)c2csc(-c3ccc4[nH]ccc4c3)n2)cc(OC)c1OC,"(2-(1H-Indol-5-yl)thiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone",0.008,uM,=,-2.096910013008056,0,O=C(c1ccccc1)c1csc(-c2ccc3[nH]ccc3c2)n1
3467,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,Cc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,"6-(2,6-Dichloro-phenyl)-8-methyl-2-p-tolylamino-8H-pyrido[2,3-d]pyrimidin-7-one",0.48,uM,=,-0.3187587626244128,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
3468,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCn1ccnc1,N-[4-(3-Bromo-phenylamino)-7-(3-imidazol-1-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3cc(OCCCn4ccnc4)ccc23)cc1
3469,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cnn(CC)c3)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.0186999999999999,uM,=,-1.728158393463501,0,c1ccc(Nc2nccc(Nc3cn[nH]c3)n2)cc1
3470,1368552,10.1021/jm500034j,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of [32P] gamma-ATP in to myelin basic protein after 30 mins by autoradiographic analysis,c1ccc(-c2cccc(Nc3ncnc4cc5c(cc34)OCO5)c2)cc1,"N-(biphenyl-3-yl)-[1,3]dioxolo[4,5-g]quinazolin-8-amine",0.002,uM,=,-2.6989700043360187,0,c1ccc(-c2cccc(Nc3ncnc4cc5c(cc34)OCO5)c2)cc1
3471,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,CCOC(=O)N1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1.Cc1ccc(S(=O)(=O)O)cc1,Ethyl 4-((5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-yl)methyl)piperazine-1-carboxylate tosylate,0.028,uM,=,-1.5528419686577808,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CN6CCNCC6)o5)cc34)cc2)cc1.c1ccccc1
3472,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)/C=C/CN2CCOCC2)C1,"US9181263, 24::US9278100, 24",0.3837,uM,=,-0.4160082008016836,0,O=C(/C=C/CN1CCOCC1)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3cncnc32)C1
3473,64437,10.1016/s0960-894x(00)00131-1,,,,Tested for inhibition of EGF-receptor tyrosine kinase in intact cells,COc1cccc(-c2cn(-c3ccc(CNCCO)cc3)c3ncnc(N)c23)c1,"2-{4-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-benzylamino}-ethanol",6.4,uM,=,0.8061799739838872,1,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
3474,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,O=C(CCCCCn1cc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)nn1)NO,"6-(4-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)-N-hydroxyhexanamide",0.00065,uM,=,-3.1870866433571443,0,c1ccc(Nc2ncnc3ccc(-c4c[nH]nn4)cc23)cc1
3475,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,COc1cc(C=C(C#N)C#N)cc(O)c1O,"2-(3,4-Dihydroxy-5-methoxy-benzylidene)-malononitrile",6.0,uM,=,0.7781512503836436,1,c1ccccc1
3476,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,COCCOc1cc2ncnc(Nc3ccc(F)cc3)c2c2c1OCCO2,"N-(4-Fluorophenyl)-5-(2-methoxyethoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.2003,uM,=,-0.6983190507064237,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
3477,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,O=[N+]([O-])c1ccc2c(Nc3cccc(F)c3)ncnc2c1,(3-Fluoro-phenyl)-(7-nitro-quinazolin-4-yl)-amine,6.1,uM,=,0.785329835010767,1,c1ccc(Nc2ncnc3ccccc23)cc1
3478,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-{6-methoxy-7-[2-(1-methyl-piperidin-4-yl)-ethoxy]-quinazolin-4-yl}-amine,0.15,uM,=,-0.8239087409443188,0,c1ccc(Nc2ncnc3cc(OCCC4CCNCC4)ccc23)cc1
3479,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,COc1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1,"(3-Methoxy-phenyl)-(6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]indol-4-yl)-amine",0.86,uM,=,-0.0655015487564322,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1
3480,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(NCc3ccc(C(F)(F)F)cc3)c2cn1,"N*4*-(4-Trifluoromethyl-benzyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",8.0,uM,=,0.9030899869919436,1,c1ccc(CNc2ncnc3ccncc23)cc1
3481,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(OC)c(NC(=O)/C=C/CN4CCCCC4)cc23)c1,(E)-N-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide,0.0027,uM,=,-2.5686362358410126,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3482,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,C#Cc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-(3-chloro-4-fluorophenyl)-6-ethynylquinazolin-4-amine,0.1269,uM,=,-0.8965383779052952,0,c1ccc(Nc2ncnc3ccccc23)cc1
3483,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COC(=O)CNC(=O)c1ccc(Nc2ncnc3cc(OCCN4CCCCC4)c(OC)cc23)cc1,Methyl 2-(4-((6-methoxy-7-(2-(piperidin-1-yl)ethoxy)quinazolin-4-yl)amino)benzamido)acetate,9.941,uM,=,0.9974300737974712,1,c1ccc(Nc2ncnc3cc(OCCN4CCCCC4)ccc23)cc1
3484,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)NCCSc1nc(-c2ccccc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,N-(2-((4-Phenyl-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)ethyl)acrylamide,0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
3485,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=C1C(=O)NC(=O)NC1=O,"2-(2,4,6-Trioxo-tetrahydro-pyrimidin-5-ylidene)-malononitrile",1400.0,uM,=,3.146128035678238,1,C=C1C(=O)NC(=O)NC1=O
3486,1783409,10.1016/j.ejmech.2017.12.078,,,,Inhibition of EGFR (unknown origin),O=C(N/N=C/c1cccn1CCCN1CCCC1)Nc1ccc(Oc2ccnc3[nH]ccc23)cc1,"(E)-N-(4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-((1-(3-(pyrrolidin-1-yl)propyl)-1H-pyrrol-2-yl)methylene)hydrazinecarboxamide",45.0,uM,=,1.6532125137753435,1,O=C(N/N=C/c1cccn1CCCN1CCCC1)Nc1ccc(Oc2ccnc3[nH]ccc23)cc1
3487,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,COC(=O)Cc1c(SSc2c(CC(=O)OC)c3ccccc3n2C)n(C)c2ccccc12,[2-(3-Methoxycarbonylmethyl-1-methyl-1H-indol-2-yldisulfanyl)-1-methyl-1H-indol-3-yl]-acetic acid methyl ester,33.0,uM,=,1.5185139398778875,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
3488,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),CN(C)C(=O)CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)N(C)C)[nH]c2ccccc12,"3-{2-[3-(2-Dimethylcarbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-N,N-dimethyl-propionamide",12.0,uM,=,1.0791812460476249,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
3489,2214127,10.1016/j.ejmech.2021.114009,,,,Inhibition of EGFR (unknown origin),C=CC(=O)N1CCC([C@@H]2CCNC3C(C(N)=O)C(c4ccc(Oc5ccccc5)cc4)=NN32)CC1,Zanubrutinib,0.021,uM,=,-1.6777807052660807,0,c1ccc(Oc2ccc(C3=NN4C(C3)NCC[C@H]4C3CCNCC3)cc2)cc1
3490,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COCC1CCCN1CC#CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,(2S)4-(2-Methoxymethyl-pyrrolidin-1-yl)-but-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.15,uM,=,-0.8239087409443188,0,O=C(C#CCN1CCCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
3491,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1cnc(N2CCCC2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-(pyrrolidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",10.0,uM,=,1.0,1,c1cc(Nc2cc3ccnc(N4CCCC4)c3cn2)nc(N2CCCCC2)n1
3492,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,c1ccc(CCNc2ncnc3ccccc23)cc1,Phenethyl-quinazolin-4-yl-amine,4.1,uM,=,0.6127838567197355,1,c1ccc(CCNc2ncnc3ccccc23)cc1
3493,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn([C@@H]3CCNC3)c3ncnc(N)c23)cc1O,"(R)-5-(4-amino-1-(pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol",12.6,uM,=,1.100370545117563,1,c1ccc(-c2nn([C@@H]3CCNC3)c3ncncc23)cc1
3494,506208,10.1021/np50089a001,,,,Inhibition of EGFR,O=CN/C=C/c1ccc(O)c(O)c1O,"N-(2,3,4-trihydroxystyryl)formamide",4.6141267862501225,uM,=,0.6640895238244986,1,c1ccccc1
3495,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,OC[C@@H](Nc1ncnc2oc(-c3ccccc3)cc12)c1ccccc1,"(S)-2-Phenyl-2-((6-phenylfuro[2,3-d]pyrimidin-4-yl)amino)ethanol",0.0039,uM,=,-2.408935392973501,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
3496,66576,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1ccc2ncnc(Nc3cccc(C(F)(F)F)c3)c2c1,N-[4-(3-Trifluoromethyl-phenylamino)-quinazolin-6-yl]-acrylamide,0.00091,uM,=,-3.0409586076789066,0,c1ccc(Nc2ncnc3ccccc23)cc1
3497,807903,10.1016/j.bmc.2012.01.029,,,,Inhibition of EGF-induced EGFR autophosphorylation in human A431 cells incubated for 60 mins prior to EGF-induction measured after 10 mins by phosphotyrosine ELISA,Nc1nc(Nc2cccc(Br)c2)c2ccn(Cc3ccccc3)c2n1,"7-Benzyl-N4-(3-bromophenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",166.4,uM,=,2.2211533219547053,1,c1ccc(Cn2ccc3c(Nc4ccccc4)ncnc32)cc1
3498,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)/C(F)=C\CN1CCOCC1,(E)-(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-4-morpholinobut-2-enamide,0.001,uM,=,-3.0,0,O=C(/C=C\CN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
3499,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
3500,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.006,uM,=,-2.2218487496163566,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccccc45)ccc32)cc1
3501,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)cc3)c2cc1OC,"N-(4-(benzo[d]thiazol-2-yl)phenyl)-6,7-dimethoxyquinazolin-4-amine",1.5,uM,=,0.1760912590556812,1,c1ccc2sc(-c3ccc(Nc4ncnc5ccccc45)cc3)nc2c1
3502,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(Cc4ccccn4)cc3)ncnc2cn1,"(2E)-4-(Dimethylamino)-N-{4-[4-(2-pyridinylmethyl)anilino]-pyrido[3,4-d]pyrimidin-6-yl}-2-butenamide",0.304,uM,=,-0.5171264163912462,0,c1ccc(Cc2ccc(Nc3ncnc4cnccc34)cc2)nc1
3503,2112388,10.1016/j.bmcl.2021.127987,,,,Inhibition of EGFR (unknown origin),O=C1N=C(NN2Cc3ccccc3N=C2c2ccccc2)S/C1=C/c1ccc(O)cc1O,"3-(5-(2,4-dihydroxybenzylidene)-4-oxo-4,5-dihydrothiazol-2-ylamino)-2-phenylquinazolin-4(H)-one",0.1780999999999999,uM,=,-0.7493360805367565,0,O=C1N=C(NN2Cc3ccccc3N=C2c2ccccc2)S/C1=C/c1ccccc1
3504,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCOCCCCO,N-{4-(3-Chloro-4-fluoro-phenylamino)-7-[2-(4-hydroxy-butoxy)-ethoxy]-quinazolin-6-yl}-acrylamide,0.0017,uM,=,-2.7695510786217263,0,c1ccc(Nc2ncnc3ccccc23)cc1
3505,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,"(3-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.00031,uM,=,-3.508638306165728,0,c1ccc(Nc2ncnc3ccccc23)cc1
3506,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,COc1cccc(CNc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"N*4*-(3-Chloro-phenyl)-N*3*-(3-methoxy-benzyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.2,uM,=,-0.6989700043360187,0,c1ccc(CNc2[nH]nc3ncnc(Nc4ccccc4)c23)cc1
3507,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(NS(=O)(=O)c1ccccc1)c1cncc(Br)c1,5-bromo-N-(phenylsulfonyl)nicotinamide,20.19,uM,=,1.3051363189436394,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
3508,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,CC(=O)N1N=C(c2ccc(C)c(C)c2)CC1c1ccccc1Cl,"1-(5-(2-Chlorophenyl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone",21.48,uM,=,1.332034277027518,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
3509,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,CN(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1,"(E)-4-Dimethylamino-but-2-enoic acid [4-(4,5-dichloro-2-fluoro-phenylamino)-quinazolin-6-yl]-amide",0.00011,uM,=,-3.958607314841775,0,c1ccc(Nc2ncnc3ccccc23)cc1
3510,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2CC(c3ccc(C)c(C)c3)=NN2c2nc(-c3ccc(Cl)cc3)cs2)cc1,"4-(4-chlorophenyl)-2-(3-(3,4-dimethylphenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazole",0.82,uM,=,-0.0861861476162833,0,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
3511,2268542,10.1021/acs.jmedchem.1c00683,,,,Inhibition of EGFR (unknown origin),CN(CCN(C)Cc1ccc(C(=O)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)cc1)CCn1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21,"4-(((2-((2-(4-amino-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)(methyl)amino)ethyl)(methyl)amino)methyl)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)benzamide",0.32,uM,=,-0.494850021680094,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccc(CNCCNCCn2nc(-c3ccccc3)c3cncnc32)cc1
3512,5002,10.1021/jm00033a019,,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21,"5,6-Bis-(4-fluoro-phenylamino)-isoindole-1,3-dione",2.2,uM,=,0.3424226808222063,1,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21
3513,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCn1c([N+](=O)[O-])cnc1C,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy)quinazolin-4-amine,0.0049,uM,=,-2.309803919971486,0,c1ccc(Nc2ncnc3ccc(OCCn4ccnc4)cc23)cc1
3514,2224994,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin),COc1ccc(N(C)c2nc(C)nc3c(Cc4ccccc4)cn(C)c23)cc1,"7-benzyl-N-(4-methoxyphenyl)-N,2,5-trimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine",0.0023,uM,=,-2.638272163982407,0,c1ccc(Cc2c[nH]c3c(Nc4ccccc4)ncnc23)cc1
3515,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1,"N-(3-ethynylphenyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0598,uM,=,-1.2232988160115892,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
3516,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,Clc1ccc(-c2nnc(Cc3nc4ccc(Cl)cc4[nH]3)o2)c(Cl)c1,"2-((6-chloro-1H-benzo[d]imidazol-2-yl)methyl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole",45.1,uM,=,1.6541765418779606,1,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
3517,1799769,10.1016/j.ejmech.2018.06.011,,,,"Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay",CC(=O)Nc1ccc(-c2cc3c(Nc4ccc(Oc5cccc(C(F)(F)F)c5)c(Cl)c4)ncnc3s2)cc1,"N-(4-(4-(3-chloro-4-(3-(trifluoromethyl)phenoxy)phenylamino)thieno[2,3-d]pyrimidin-6-yl)phenyl)acetamide",0.0477,uM,=,-1.321481620959886,0,c1ccc(Oc2ccc(Nc3ncnc4sc(-c5ccccc5)cc34)cc2)cc1
3518,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,CN1C(=S)C(CCC(=O)O)c2ccccc21,"3-(1-Methyl-2-thioxo-2,3-dihydro-1H-indol-3-yl)-propionic acid",6.7,uM,=,0.8260748027008264,1,S=C1Cc2ccccc2N1
3519,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C(C)C)c3n2)C[C@H]1F,"N-((3R,4R)-4-Fluoro-1-(9-isopropyl-6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide",0.16,uM,=,-0.7958800173440752,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1
3520,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1ccc(Br)cc1)NS(=O)(=O)c1ccccc1,2-(4-Bromophenyl)-N-(phenylsulfonyl)acetamide,17.81,uM,=,1.2506639194632436,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
3521,306459,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate; Range = 6.7-20 nM,C=CC(=O)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1,"N-[4-(4,5-Dichloro-2-fluoro-phenylamino)-quinazolin-6-yl]-acrylamide",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
3522,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,Fc1ccc(-c2nc(-c3ccccc3)[nH]c2-c2ccnc3[nH]ccc23)cc1,"4-[4-(4-Fluorophenyl)-2-phenyl-1H-imidazol-5-yl]-1H-pyrrolo[2,3-b]pyridine",0.712,uM,=,-0.1475200063631436,0,c1ccc(-c2nc(-c3ccccc3)c(-c3ccnc4[nH]ccc34)[nH]2)cc1
3523,1618202,10.1021/acs.jmedchem.5b01985,,,,Inhibition of wild type EGFR phosphorylation in human HaCaT cells incubated for 3 hrs by ELISA method,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0737,uM,=,-1.1325325121409486,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3524,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,OCCN(CCO)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"2-[{2-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-ethyl}-(2-hydroxy-ethyl)-amino]-ethanol",0.00093,uM,=,-3.0315170514460648,0,c1ccc(Nc2ncnc3cnccc23)cc1
3525,66724,10.1021/jm00032a020,,,,Inhibition of EGFR(epidermal growth factor receptor) autophosphorylation in ER22 cell membranes,CC(C)CCCC(C)CCOC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3,7-dimethyl-octyl ester",25.0,uM,=,1.3979400086720375,1,c1ccc(CNc2ccccc2)cc1
3526,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,OCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1,(6-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)pyridin-2-yl)methanol,0.04,uM,=,-1.3979400086720375,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccn1
3527,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CN(C/C=C/C(=O)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1)CCO,"US9181263, 3::US9278100, 3",0.0745,uM,=,-1.1278437272517072,0,c1ccc(Oc2ccc(-c3nn(C4CCCNC4)c4ncncc34)cc2)cc1
3528,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CN1CCN(c2ccc(Nc3ncc(Br)c(Nc4ccc5c(c4)CCC5)n3)cc2)CC1,"5-bromo-N4-(2,3-dihydro-1H-inden-5-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,4-diamine",6.8,uM,=,0.8325089127062363,1,c1cc(Nc2ccc3c(c2)CCC3)nc(Nc2ccc(N3CCNCC3)cc2)n1
3529,1908531,10.1021/acsmedchemlett.9b00381,,,,Inhibition of EGFR (unknown origin) expressed in mouse Ba/F3 cells assessed as reduction in cell growth incubated for 72 hrs in presence of 1 ug/ml Cetuximab by celltiter-glo luminescent cell viability assay,O=C1c2cc(Oc3ccc(N4CCNCC4)cc3)ccc2Nc2ccc(F)cc2N1Cc1ccccc1,"10-Benzyl-8-fluoro-2-(4-(piperazin-1-yl)phenoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one",4.0,uM,=,0.6020599913279624,1,O=C1c2cc(Oc3ccc(N4CCNCC4)cc3)ccc2Nc2ccccc2N1Cc1ccccc1
3530,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,C=CC(=O)Nc1cccc(-c2nc(Nc3cc[nH]n3)c3ccccc3n2)c1,N-(3-(4-(1H-pyrazol-3-ylamino)quinazolin-2-yl)phenyl)acrylamide,1.1,uM,=,0.041392685158225,1,c1ccc(-c2nc(Nc3cc[nH]n3)c3ccccc3n2)cc1
3531,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1ccc(C(=O)O)cc1,"4-(2,2-Dicyano-vinyl)-benzoic acid",430.0,uM,=,2.633468455579586,1,c1ccccc1
3532,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#C/C(=C\c1ccccc1)C(=O)O,2-Cyano-3-phenyl-acrylic acid,850.0,uM,=,2.929418925714293,1,c1ccccc1
3533,840626,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR using GST-Crk as substrate assessed as phosphorylated Crk level after 20 mins by SDS-PAGE analysis,Fc1ccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)cc1Cl,"N-(3-chloro-4-fluorophenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododeca[2,3-g]quinazolin-4-amine",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)cc1
3534,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[S+]([O-])CCN(C)C,(+)-N-(2-((2-(dimethylamino)ethyl)sulfinyl)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,0.229,uM,=,-0.640164517660112,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3535,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),CN(C)CCCOC(=O)/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,3-[4-(3-Bromo-phenylamino)-quinazolin-6-ylcarbamoyl]-acrylic acid 3-dimethylamino-propyl ester,0.0024,uM,=,-2.619788758288394,0,c1ccc(Nc2ncnc3ccccc23)cc1
3536,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCC/C(=C\c3ccc(O)c(O)c3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,4-Dihydroxybenzylidene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",0.43,uM,=,-0.3665315444204134,0,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
3537,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ccc5c4)n3)cc2)CC1,"5-chloro-N4-(1H-indol-5-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,4-diamine",0.557,uM,=,-0.254144804826271,0,c1cc(Nc2ccc3[nH]ccc3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
3538,2268691,10.1016/j.ejmech.2021.113768,,,,Inhibition of GST-fused EGFR (unknown origin) in presence of ATP by microplate reader analysis,CCCOCCSc1nc(-c2ccccc2Cl)nn1CCOCCC,"3-(2-chlorophenyl)-1-(2-propoxyethyl)-5-((2-propoxyethyl)thio)-1H-1,2,4-triazole",0.867,uM,=,-0.0619809025237897,0,c1ccc(-c2nc[nH]n2)cc1
3539,67065,10.1016/s0960-894x(03)00655-3,,,,Inhibition of Epidermal growth factor receptor,COc1cc2ncc(N[C@H]3CC[C@H](O)CC3)nc2cc1OC,"4-((R)-6,7-Dimethoxy-quinoxalin-2-ylamino)-cyclohexanol",3.7,uM,=,0.568201724066995,1,c1ccc2nc(NC3CCCCC3)cnc2c1
3540,2132157,10.1021/acs.jmedchem.1c01559,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(-c4ccccc4)ccn3)cc2)c(C(N)=O)n1N,(S)-1-amino-2-(1-(but-2-ynoyl)piperidin-2-yl)-4-(4-((4-phenylpyridin-2-yl)carbamoyl)phenyl)-1H-imidazole-5-carboxamide,16.807,uM,=,1.2254902000712842,1,O=C(Nc1cc(-c2ccccc2)ccn1)c1ccc(-c2c[nH]c([C@@H]3CCCCN3)n2)cc1
3541,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Br)c(Br)c2)CC1c1ccc([N+](=O)[O-])cc1,"3-(3,4-Dibromophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",10.64,uM,=,1.026941627959029,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
3542,574946,10.1021/np8004997,,,,Inhibition of recombinant EGFR,COc1cc(O)c2c(c1)C(=O)c1cc(C)c(O)cc1C2=O,macrosporin,9.5047506218675,uM,=,0.9779407266756722,1,O=C1c2ccccc2C(=O)c2ccccc21
3543,64437,10.1016/s0960-894x(00)00131-1,,,,Tested for inhibition of EGF-receptor tyrosine kinase in intact cells,Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccccc1,"5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",3.0,uM,=,0.4771212547196624,1,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
3544,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(N[C@@H](C)c3ccc(F)cc3)c2cc1OCCCCCCC(=O)NO,(R)-7-(4-(1-(4-Fluorophenyl)ethylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.1256,uM,=,-0.9010103605988228,0,c1ccc(CNc2ncnc3ccccc23)cc1
3545,1991321,10.1016/j.bmcl.2020.127288,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system by competitive binding assay,N#Cc1cnc2cc(OC[C@@H](O)CO)c(NC(=O)CC3CSSC3)cc2c1Nc1ccc(OCc2cccc(F)c2)c(Cl)c1,"(S)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-3-cyano-7-(2,3-dihydroxypropoxy)quinolin-6-yl)-2-(1,2-dithiolan-4-yl)acetamide",0.0123,uM,=,-1.9100948885606024,0,O=C(CC1CSSC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
3546,457884,10.1016/j.bmcl.2007.08.073,,,,Inhibition of EGFR,C[C@@H](CN(C)C(=O)CO)Oc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12,(S)-N-(2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)propyl)-2-hydroxy-N-methylacetamide,0.191,uM,=,-0.7189666327522725,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
3547,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(1-benzyl-1H-indazol-5-ylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,0.13,uM,=,-0.8860566476931633,0,c1ccc(Cn2ncc3cc(Nc4ccnc5ccccc45)ccc32)cc1
3548,791584,10.1016/j.bmc.2011.11.023,,,,"Inhibition of EGFR using poly(Glu,Tyr)4:1 as substrate and [gamma33P]ATP after 60 mins by scintillation counting",O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3ccc(OCc4cccc(F)c4)cc3Cl)ncnc2s1,"(4-(2-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanone",0.0185,uM,=,-1.7328282715969865,0,O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3ccc(OCc4ccccc4)cc3)ncnc2s1
3549,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,Cc1cc(Nc2ncnc3ccc(NC(=O)/C=C/[C@H]4CCCN4C)cc23)ccc1Oc1cc2nncn2cn1,"(E)-3-[(2R)-1-methylpyrrolidin-2-yl]-N-[4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]prop-2-enamide",0.0011899999999999,uM,=,-2.9244530386074694,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4cc5nncn5cn4)cc3)c2c1
3550,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.012,uM,=,-1.9208187539523751,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
3551,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,Fc1ccc2c(c1)CNc1c(Nc3cccc(Br)c3)ncnc1O2,"(3-Bromo-phenyl)-(8-fluoro-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",6.9,uM,=,0.8388490907372553,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
3552,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CC2(CCO2)C1,6-(3-(1-oxa-6-azaspiro[3.3]heptan-6-yl)propoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine,0.036,uM,=,-1.4436974992327127,0,c1ccc(Nc2ncnc3ccc(OCCCN4CC5(CCO5)C4)cc23)cc1
3553,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCOC(=O)c1cn2ncnc(NCc3ccccc3)c2c1CC,"4-Benzylamino-5-ethyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester",0.2,uM,=,-0.6989700043360187,0,c1ccc(CNc2ncnn3cccc23)cc1
3554,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCCOCCn1ccnc1[N+](=O)[O-],N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-methoxy-7-(2-(2-(2-nitro-1H-imidazol-1-yl)ethoxy)ethoxy)quinazolin-4-amine,0.0201,uM,=,-1.6968039425795112,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCCOCCn5ccnc5)ccc34)cc2)cc1
3555,1674599,10.1021/acs.jmedchem.8b00125,,,,Inhibition of EGFR (unknown origin),CNS(=O)(=O)c1cccc(Nc2cc(Nc3ccc(Cl)cn3)ncn2)c1,3-({6-[(5-Chloro-2-pyridinyl)amino]-4-pyrimidinyl}amino)-N-methylbenzenesulfonamide,0.63,uM,=,-0.2006594505464183,0,c1ccc(Nc2cc(Nc3ccccn3)ncn2)cc1
3556,1566936,10.1021/acs.jmedchem.5b01633,,,,Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3[nH]ccc23)c1,"N-(3-((2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide",0.00079,uM,=,-3.1023729087095586,0,c1ccc(Oc2nc(Nc3ccc(N4CCNCC4)cc3)nc3[nH]ccc23)cc1
3557,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2ncnc3c2sc2ccccc23)c1,"Benzo[4,5]thieno[3,2-d]pyrimidin-4-yl-(3-bromo-phenyl)-amine",0.0018,uM,=,-2.744727494896694,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
3558,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccc(F)c4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-[7-ethoxy-4-({4-[(3-fluorobenzyl)oxy]-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)quinazolin-6-yl]but-2-enamide",0.0040999999999999,uM,=,-2.3872161432802645,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
3559,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",Cc1ccc(C(/C=C/c2ccc(F)cc2)=N\Nc2nncc3ccccc23)cc1,1-(2-(3-(4-Fluorophenyl)-1-(p-tolyl)allylidene)hydrazinyl)phthalazine,0.0065,uM,=,-2.1870866433571443,0,C(=C/c1ccccc1)\C(=N\Nc1nncc2ccccc12)c1ccccc1
3560,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCC(=O)NO,3-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxypropanamide,0.0070999999999999,uM,=,-2.148741651280925,0,c1ccc(Nc2ncnc3ccccc23)cc1
3561,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,COc1ccc(Nc2ncc3ncc(=O)n(-c4ccc(NC(=O)/C=C/CN(C)C)cc4)c3n2)cc1,(E)-4-(Dimethylamino)-N-(4-(2-(4-methoxyphenylamino)-7-oxopteridin-8(7H)-yl)phenyl)but-2-enamide,0.0591,uM,=,-1.2284125191187447,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
3562,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccccc3S(=O)(=O)N(C)C)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(N,N-dimethylsulfamoyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide",0.307,uM,=,-0.5128616245228135,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
3563,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1ccc(C=O)cc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1,"(R)-4-Methoxy-3-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzaldehyde",0.003,uM,=,-2.5228787452803374,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
3564,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3occc(=O)c3c2)c2c(N)ncnc21,"6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4H-chromen-4-one",29.0,uM,=,1.462397997898956,1,O=c1ccoc2ccc(-c3n[nH]c4ncncc34)cc12
3565,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",NC(=S)NNc1nncc2ccccc12,2-(Phthalazin-1-yl)hydrazine-1-carbothioamide,0.077,uM,=,-1.1135092748275182,0,c1ccc2cnncc2c1
3566,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC.Cl,"(3-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine hydrochloride",0.00126,uM,=,-2.899629454882437,0,c1ccc(Nc2ncnc3ccccc23)cc1
3567,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#C/C(=C/c1ccc[nH]1)C(=O)O,2-Cyano-3-(1H-pyrrol-2-yl)-acrylic acid,1360.0,uM,=,3.133538908370217,1,c1cc[nH]c1
3568,5167,10.1021/jm010888h,,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,C[C@@H](Nc1[nH]cnc2c3ccccc3nc1-2)c1ccccc1,"(1-Phenyl-ethyl)-(9H-2,4,9-triaza-fluoren-1-yl)-amine",0.419,uM,=,-0.3777859770337047,0,c1ccc(CNc2[nH]cnc3c4ccccc4nc2-3)cc1
3569,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(C)c4ccccc43)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-1H-indol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,0.7145,uM,=,-0.1459977668730109,0,c1ccc(Nc2nccc(-n3ccc4ccccc43)n2)cc1
3570,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,Cn1c(SSc2c(C(=O)Nc3ccccc3)c3cccc(O)c3n2C)c(C(=O)Nc2ccccc2)c2cccc(O)c21,"2,2'-Dithiobis(1-methyl-7-hydroxy-N-phenyl-1H-indole-3-carboxamide)",100.0,uM,=,2.0,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
3571,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2)c1O,2-Cyano-3-(4-hydroxy-3-methoxy-5-phenylsulfanylmethyl-phenyl)-acrylamide,2.9,uM,=,0.4623979978989561,1,c1ccc(CSc2ccccc2)cc1
3572,473572,10.1073/pnas.0708800104,,,,Inhibition of wild type EGFR,O=C(O)/C=C/c1cc(CO)ccc1CO,"2,5-Dihydroxymethylcinnamate",0.78,uM,=,-0.1079053973095195,0,c1ccccc1
3573,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc5ccccc45)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(naphthalen-1-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.01,uM,=,-2.0,0,c1ccc2c(COc3ccc(Nc4ccnc5ccccc45)cc3)cccc2c1
3574,1772659,10.1016/j.ejmech.2017.06.003,,,,Inhibition of EGFR (unknown origin),Oc1cccc(Nc2nnnc3sc4c(c23)CCC4)c1,"3-(2,3-Dihydro-1H-8-thia-5,6,7-triaza-cyclopenta[a]inden-4-ylamino)-phenol",52.11,uM,=,1.716921073166761,1,c1ccc(Nc2nnnc3sc4c(c23)CCC4)cc1
3575,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC.Cl,"4-(3'-bromoanilino)-6,7-dimethoxyquinazoline hydrochloride",0.0026,uM,=,-2.5850266520291822,0,c1ccc(Nc2ncnc3ccccc23)cc1
3576,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,COc1cccc(-c2cn(C3CCCC3)c3ncnc(N)c23)c1,"7-Cyclopentyl-5-(3-methoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",0.46,uM,=,-0.3372421683184259,0,c1ccc(-c2cn(C3CCCC3)c3ncncc23)cc1
3577,1842433,10.1016/j.ejmech.2019.03.004,,,,Inhibition of EGFR in human A431 cells assessed as reduction in cell proliferation incubated for 72 hrs by Coulter counter method,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.22,uM,=,-0.6575773191777937,0,c1ccc(Nc2ncnc3ccccc23)cc1
3578,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,CC(C)(C)NC(=O)/C=C/c1ccccc1,(E)-N-(tert-butyl)cinnamamide,29.85,uM,=,1.474944335465388,1,c1ccccc1
3579,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(C(C)C)cc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-Isopropyl-5-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxo-pyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.024,uM,=,-1.619788758288394,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
3580,512831,10.1016/j.bmcl.2008.07.057,,,,Inhibition of EGFR,Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C=O,4-amino-6-(4-(benzyloxy)-3-chlorophenylamino)pyrimidine-5-carbaldehyde,0.076,uM,=,-1.1191864077192086,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
3581,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(NCCN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(2-morpholinoethyl)urea,0.082,uM,=,-1.0861861476162833,0,O=C(NCCN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
3582,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c3)c2cc1NC(=O)/C=C/CN(C)C,(2E)-4-(Dimethylamino)-N-(7-ethoxy-4-{[1-(phenylsulfonyl)-1Hindol-5-yl]amino}-6-quinazolinyl)-2-butenamide,0.016,uM,=,-1.7958800173440752,0,O=S(=O)(c1ccccc1)n1ccc2cc(Nc3ncnc4ccccc34)ccc21
3583,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Oc1ccc(CN(Cc2cc(Br)cc(Br)c2O)C(=S)Nc2ccccc2)cc1,"1-(3,5-Dibromo-2-hydroxybenzyl)-1-(4-hydroxybenzyl)-3-phenylthiourea",0.87,uM,=,-0.0604807473813814,0,S=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
3584,739728,10.1016/j.bmcl.2011.01.137,,,,Inhibition of human EGFR-mediated poly(Glu4Tyr) phosphorylation after 1 hr,COc1cc2ncnc(Oc3cccc(Br)c3)c2cc1OC,"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline",7.6,uM,=,0.8808135922807914,1,c1ccc(Oc2ncnc3ccccc23)cc1
3585,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCOCC5)cc4)nc32)c1,N-(3-(2-(4-Morpholinophenylamino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.00695,uM,=,-2.1580151954098863,0,O=c1cnc2cnc(Nc3ccc(N4CCOCC4)cc3)nc2n1-c1ccccc1
3586,2222500,10.1021/acs.jmedchem.1c02134,,,,Inhibition of EGFR (unknown origin),C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"US9447106, 27b (peak 2)",0.0024,uM,=,-2.619788758288394,0,c1ccc(Oc2ccc(-c3cc4n(n3)[C@H](C3CCNCC3)CCN4)cc2)cc1
3587,63782,10.1021/jm970366v,,,,Inhibition of epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3cc(NCCc4c[nH]cn4)ncc23)c1,"N*4*-(3-Bromo-phenyl)-N*7*-[2-(1H-imidazol-4-yl)-ethyl]-pyrido[4,3-d]pyrimidine-4,7-diamine",0.00091,uM,=,-3.0409586076789066,0,c1ccc(Nc2ncnc3cc(NCCc4c[nH]cn4)ncc23)cc1
3588,1338035,10.1016/j.ejmech.2014.02.032,,,,Inhibition of EGFR (unknown origin) after 1.5 hr by FRET-based Z-lyte assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)CCN3CCN(CCO)CC3)c2)n1,N-(3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)-3-(4-(2-hydroxyethyl)piperazin-1-yl)propanamide,2.388,uM,=,0.3780343224573315,1,O=C(CCN1CCNCC1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
3589,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1cccc(F)c1)c1ccccc1,(Z)-2-((E)-3-(3-fluorophenyl)-1-phenylallylidene)hydrazinecarbothioamide,2.08,uM,=,0.3180633349627615,1,N=C(/C=C/c1ccccc1)c1ccccc1
3590,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",C=CC(=O)N1CCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1,"US8476284, 9::US8497277, 10::US8497277, 9::US9133201, 9::US9181263, 6::US9278100, 6",0.0608999999999999,uM,=,-1.2153827073671246,0,c1ccc(Oc2ccc(-c3nn(C4CCNCC4)c4ncncc34)cc2)cc1
3591,2260190,10.1016/j.ejmech.2020.112995,,,,Inhibition of human wild type EGFR expressed in Sf9 insect cells using ATP as substrate by HTRF assay,O=C(Nc1nccs1)C(c1cc(F)ccc1O)N1Cc2ccccc2C1=O,2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxoisoindolin-2-yl)-N-(thiazol-2-yl)acetamide,4.3,uM,=,0.6334684555795865,1,O=C(Nc1nccs1)C(c1ccccc1)N1Cc2ccccc2C1=O
3592,1929287,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide substrate preincubated for 10 mins followed by substrate addition measured after 40 mins by caliper motility shift assay,CN1CCN(C/C=C/C(=O)N2CCOc3cc4ncnc(Nc5ccc(F)c(Cl)c5)c4cc32)CC1,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(4-methylpiperazin-1-yl)but-2-en-1-one",0.009,uM,=,-2.0457574905606752,0,O=C(/C=C/CN1CCNCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
3593,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Nc3cc(Cl)ccc3F)c1NC2,"(5-chloro-2-fluoro-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",1.1,uM,=,0.041392685158225,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
3594,1627833,10.1016/j.ejmech.2016.06.056,,,,Inhibition of EGFR (unknown origin) using peptide as substrate after 60 mins by HTRF assay,COc1cccc(/C=N/Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c1,(E)-5-chloro-N-(2-(isopropylsulfonyl)phenyl)-2-(2-(3-methoxybenzylidene)hydrazinyl)pyrimidin-4-amine,0.601,uM,=,-0.2211255279972604,0,C(=N/Nc1nccc(Nc2ccccc2)n1)\c1ccccc1
3595,420174,10.1021/jm0609871,,,,Inhibition of human EGFR,COc1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,"3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione",32.0,uM,=,1.505149978319906,1,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1ccccc1
3596,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N1CCOCC1,"N-(4-Methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-morpholinophenyl)buta-2,3-dienamide",0.0135,uM,=,-1.869666231504994,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCOCC5)cc4)n3)c[nH]c2c1
3597,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3ccncc3)nc21,"6-(2,6-Dichloro-phenyl)-8-methyl-2-(pyridin-4-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one",0.91,uM,=,-0.0409586076789063,0,O=c1[nH]c2nc(Nc3ccncc3)ncc2cc1-c1ccccc1
3598,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc(Cl)cc3)C2)cc1,"2-(5-(4-Chlorophenyl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",1.66,uM,=,0.220108088040055,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
3599,457884,10.1016/j.bmcl.2007.08.073,,,,Inhibition of EGFR,O=C(CO)N1CCC[C@H]1COc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12,(S)-1-(2-((4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)methyl)pyrrolidin-1-yl)-2-hydroxyethanone,0.327,uM,=,-0.4854522473397139,0,c1ccc(COc2ccc(Nc3ncnc4cccc(OC[C@@H]5CCCN5)c34)cc2)nc1
3600,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)Nc1ncc(Cl)s1,1-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3-(5-chlorothiazol-2-yl)thiourea,0.12,uM,=,-0.9208187539523752,0,S=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1nccs1
3601,1642199,,,,,Inhibition Assay: Inhibition of various kinase enzyme.,Nc1nc(Nc2cccc(Br)c2)c2c(n1)-c1ccccc1C2,"US9422297, AAG155-336",98.8,uM,=,1.994756944587628,1,c1ccc(Nc2ncnc3c2Cc2ccccc2-3)cc1
3602,1769307,10.1016/j.bmc.2018.02.029,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,C=CC(=O)Nc1cc(Nc2ncc3nc(Nc4ccccc4)n(C(C)C)c3n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((9-isopropyl-8-(phenylamino)-9H-purin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.041,uM,=,-1.3872161432802643,0,c1ccc(Nc2ncc3nc(Nc4ccccc4)[nH]c3n2)cc1
3603,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(N(C)c3ccc(-c4nc5ccccc5s4)c(OC)c3)ncnc2cc1OCCCN1CCN(C)CC1,N-[4-(6''-Chlorobenzo[d]thiazol-2''-yl)-2-fluorophenyl]-6'-methoxy-7'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,1.4,uM,=,0.1461280356782379,1,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
3604,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CN(C)CCCCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-phenyl)-N*7*-(4-dimethylamino-butyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0074,uM,=,-2.130768280269024,0,c1ccc(Nc2ncnc3ccncc23)cc1
3605,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),CONC(=O)CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NOC)[nH]c2ccccc12,N-Methoxy-3-{2-[3-(2-methoxycarbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-propionamide,68.0,uM,=,1.8325089127062364,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
3606,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.062,uM,=,-1.207608310501746,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
3607,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,C=C(F)C(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-2-fluoroacrylamide,0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3608,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1ccc(Br)c(F)c1Nc1ncnc2cc3c(cc12)OCCO3,"N-(3-Bromo-2,6-difluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
3609,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(Cl)cc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-Chloro-5-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.0331,uM,=,-1.4801720062242811,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
3610,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COCCNCCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,(3-Chloro-4-fluoro-phenyl)-{7-methoxy-6-[2-(2-methoxy-ethylamino)-ethoxy]-quinazolin-4-yl}-amine,0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3ccccc23)cc1
3611,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1cc[n+]([O-])cc1,2-(1-Oxy-pyridin-4-ylmethylene)-malononitrile,1300.0,uM,=,3.113943352306837,1,c1cc[nH+]cc1
3612,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(O[C@@H]4CCc5ccccc54)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-((R)-indan-1-yloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.38,uM,=,-0.4202164033831898,0,c1ccc2c(c1)CC[C@H]2Oc1ccc(Nc2ccnc3ccccc23)cc1
3613,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(NC)nc32)c1,"N-(3-(3-Methyl-7-(methylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.929,uM,=,-0.0319842860063582,0,O=C1NCc2cncnc2N1c1ccccc1
3614,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,O=[N+]([O-])c1ccc2ncnc(Nc3cccc(Br)c3)c2c1,(3-Bromo-phenyl)-(6-nitro-quinazolin-4-yl)-amine,0.9,uM,=,-0.0457574905606751,0,c1ccc(Nc2ncnc3ccccc23)cc1
3615,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccccc1Br,"5-(2-Bromophenyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",6.43,uM,=,0.8082109729242221,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
3616,586303,10.1016/s0006-2952(00)00405-6,,,,Inhibition of EGFR,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3ccc(F)cc3)nc21,"6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one",0.38,uM,=,-0.4202164033831898,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
3617,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Nc1ccc2ncnc(Nc3ccc4[nH]ncc4c3)c2c1,"N4-(1H-indazol-5-yl)quinazoline-4,6-diamine",0.00298,uM,=,-2.5257837359237447,0,c1ccc2c(Nc3ccc4[nH]ncc4c3)ncnc2c1
3618,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(N=C=S)cc2)n1,N-(4-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)isothiocyanate,15.27,uM,=,1.1838390370564211,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3619,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCCCC2=O)cc(OC)c1,"US9409845, Table 1, Compound 17: (2E,6E)-2-di-(3,5-dimethoxybenzylidene)cyclohexanone",18.67,uM,=,1.2711443179490785,1,O=C1CCCC/C1=C\c1ccccc1
3620,1720134,10.1016/j.ejmech.2017.09.061,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus virus expression system after 1 hr by ELISA,NS(=O)(=O)c1ccc(-n2c(SCC(=O)Nc3cnc4ccccc4c3)nc3cc4ccccc4cc3c2=O)cc1,"2-(4-Oxo-3-(4-sulfamoylphenyl)-3,4-dihydrobenzo[g]quinazolin-2-ylthio)-N-(quinolin-3-yl)acetamide",0.11,uM,=,-0.958607314841775,0,O=C(CSc1nc2cc3ccccc3cc2c(=O)n1-c1ccccc1)Nc1cnc2ccccc2c1
3621,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,"4-(2-Amino-ethyl)-benzene-1,2-diol",2.88,uM,=,0.4593924877592308,1,c1ccccc1
3622,1348544,10.1016/j.bmcl.2014.03.072,,,,Inhibition of autophosphorylation of recombinant his-tagged EGFR (amino acid 645-1186) (unknown origin) expressed in Sf-9 cells after 10 mins by time-resolved fluorometry,COc1ccc(C2=NN(C3=NC(=O)CS3)C(c3cccc4ccccc34)C2)cc1,"2-(3-(4-methoxyphenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",5.53,uM,=,0.7427251313046983,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2cccc3ccccc23)=N1
3623,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2ncnc3ccsc23)c1,"(3-Bromo-phenyl)-thieno[3,2-d]pyrimidin-4-yl-amine",0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccsc23)cc1
3624,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(NNc3ccc(F)c(Cl)c3)c2cc1OC,"N-(3-Chloro-4-fluoro-phenyl)-N'-(6,7-dimethoxy-quinazolin-4-yl)-hydrazine",0.78,uM,=,-0.1079053973095195,0,c1ccc(NNc2ncnc3ccccc23)cc1
3625,807915,10.1016/j.bmc.2012.01.029,,,,Inhibition of EGFR,Nc1nc(Nc2cccc(Br)c2)c2cc(Cc3ccc(Cl)cc3)[nH]c2n1,"N4-(3-bromophenyl)-6-(4-chlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",17.42,uM,=,1.2410481506716444,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
3626,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,NC(=O)Nc1ccc2ncnc(Nc3ccc(Br)cc3)c2c1,1-(4-((4-Bromophenyl)amino)quinazolin-6-yl)urea,0.000803,uM,=,-3.095284454721319,0,c1ccc(Nc2ncnc3ccccc23)cc1
3627,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CONC(=O)c1cc(/N=C/c2cc(O)ccc2O)ccc1O,"5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-N-methoxy-benzamide",27.0,uM,=,1.4313637641589874,1,C(=N/c1ccccc1)\c1ccccc1
3628,1580544,10.1016/j.ejmech.2016.04.002,,,,Inhibition of EGFR-TK in human A431 cell lysate assessed as reduction in EGF stimulated kinase activity after 60 mins using biotinylated peptide substrate by ELISA,S=C=Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(3-bromophenyl)-6-isothiocyanatoquinazolin-4-amine,0.88,uM,=,-0.0555173278498313,0,c1ccc(Nc2ncnc3ccccc23)cc1
3629,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3ccc(OC)cc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(4-Methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.153,uM,=,-0.8153085691824012,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
3630,63763,10.1021/jm00018a008,,,,Inhibition of Epidermal growth factor receptor from A431 cells,O=[N+]([O-])c1cccc2ncnc(Nc3cccc(Br)c3)c12,(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine,0.355,uM,=,-0.4497716469449059,0,c1ccc(Nc2ncnc3ccccc23)cc1
3631,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccc(Cl)cc4)cs3)C(c3ccc(C)cc3)C2)cc1,"4-(4-chlorophenyl)-2-(3-(4-methoxyphenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)thiazole",4.68,uM,=,0.670245853074124,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
3632,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(N)nc21,"2-Amino-6-(2,6-dichloro-phenyl)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",5.6,uM,=,0.7481880270062004,1,O=c1[nH]c2ncncc2cc1-c1ccccc1
3633,64442,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor (EGFR) in A431 cells,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-(3-Chloro-4-fluoro-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-acrylamide",0.0033,uM,=,-2.4814860601221125,0,c1ccc(Nc2ncnc3cnccc23)cc1
3634,840626,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR using GST-Crk as substrate assessed as phosphorylated Crk level after 20 mins by SDS-PAGE analysis,Brc1cccc(Nc2ncnc3cc4c(cc23)OCCSCCO4)c1,"N-(3-bromophenyl)-7,8,10,11-tetrahydro-[1,4,7]dioxathionino[2,3-g]quinazolin-4-amine",0.007,uM,=,-2.154901959985743,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCSCCO4)cc1
3635,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-41",0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3636,5004,10.1016/s0960-894x(02)00364-5,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Cc1cc(C(=O)N2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc4c(ccn4Cc4ccccc4)c3)c21,"4-(1-Benzyl-1H-indol-5-ylamino)-5-[1-[3-methyl-5-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.1,uM,=,-1.0,0,O=C1Nc2ncnc(Nc3ccc4c(ccn4Cc4ccccc4)c3)c2/C1=C/c1ccc(C(=O)N2CCOCC2)[nH]1
3637,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,NC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,1-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)urea,0.315,uM,=,-0.5016894462103995,0,c1ccc(Nc2ncnc3ccccc23)cc1
3638,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c(C5CCCC5)c(OC)c4)nn32)CC1,"7-(1-acryloylpiperidin-4-yl)-2-(4-cyclopentyl-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",4.496,uM,=,0.6528263025610047,1,c1cc(C2CCCC2)ccc1-c1cc2n(n1)C(C1CCNCC1)CCN2
3639,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCc2ccccc2Cl)c1O,3-[3-(2-Chloro-benzylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,10.0,uM,=,1.0,1,c1ccc(CSCc2ccccc2)cc1
3640,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1OCCCCCCn1ccnc1[N+](=O)[O-],N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-methoxy-6-((6-(2-nitro-1H-imidazol-1-yl)hexyl)oxy)quinazolin-4-amine,0.0150999999999999,uM,=,-1.8210230527068303,0,c1ccc(COc2ccc(Nc3ncnc4ccc(OCCCCCCn5ccnc5)cc34)cc2)cc1
3641,1641794,,,,,"Time-Resolved Fluorescence Assay: The following assay may be used to determine the activity of the compounds of the invention for inhibiting EGFR kinase activity. The half maximal inhibitory concentration IC50 (the concentration of the tested compound showing 50% inhibition of the enzyme activity) of each compound was determined by incubating several different concentrations of the tested compounds with a specific enzyme and substrate. EGFR kinase used in this assay is a human-derived recombinant protein (Cell signaling technology, #7908), which was reacted with peptide substrate and different concentrations of tested compounds in a buffer solution containing 60 mM HEPES (pH7.5), 5 mM MgCl2, 5 mM MnCl2, 3 Î¼M Na3VO4, 1.25 M DTT (1000Ã) and 20 Î¼M ATP at 25Â° C., for 45 minutes. The EGFR kinase activity was determined by using a Time-Resolved fluorescence method.",CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/[C@@H]1CCCN1C,"US8901140, 7::US9358227, 7",0.004,uM,=,-2.397940008672037,0,O=C(/C=C/[C@@H]1CCCN1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3642,2017353,10.1021/acs.jmedchem.0c00870,,,,Inhibition of human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using TK as substrate preincubated for 30 mins followed by substrate addition and measured after 25 mins by HTRF assay,C=CC(=O)Nc1cccc(-c2c[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)c1,"N-{3-{4-{[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl}acrylamide",8e-05,uM,=,-4.096910013008056,0,c1ccc(-c2c[nH]c3ncnc(Nc4ccc(OCc5ccccn5)cc4)c23)cc1
3643,512831,10.1016/j.bmcl.2008.07.057,,,,Inhibition of EGFR,Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)O,4-amino-6-(4-(benzyloxy)-3-chlorophenylamino)pyrimidine-5-carboxylic acid,0.041,uM,=,-1.3872161432802643,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
3644,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCCCC5)c(C)c4)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(piperidin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.467,uM,=,-0.3306831194338878,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCCCC4)cc3)nc2N1[C@H]1CCNC1
3645,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(/C=C/c1ccc(Cl)cc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,(E)-N-(4-(3-Bromophenylamino)quinazolin-6-yl)-3-(4-chlorophenyl)acrylamide,1.21,uM,=,0.08278537031645,1,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3646,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,COc1ccc2c(c1)Oc1ncnc(Nc3ccc(F)c(Cl)c3)c1NC2,"(3-Chloro-4-fluoro-phenyl)-(7-methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
3647,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CC(C)c1cc(/C=C2\C(=O)Nc3ccccc32)cc(C(C)C)c1O,"3-[1-(4-Hydroxy-3,5-diisopropyl-phenyl)-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one",0.4,uM,=,-0.3979400086720376,0,O=C1Nc2ccccc2/C1=C/c1ccccc1
3648,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COCC6CCNCC6)c45)ccc32)c1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((piperidin-4-ylmethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.13,uM,=,-0.8860566476931633,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COCC6CCNCC6)c45)ccc32)cc1
3649,622913,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR in human A431 cells by HTRF assay,Cc1c(C(=O)NCCN2CCN(C)CC2)[nH]c2cnnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c12,"4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-3-methyl-N-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrrolo[3,2-d]pyridazine-2-carboxamide",0.257,uM,=,-0.5900668766687055,0,O=C(NCCN1CCNCC1)c1cc2c(Nc3ccc(OCc4ccccc4)cc3)nncc2[nH]1
3650,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,O=C(Nc1ccccc1Cl)c1ccc(N(CCCl)CCCl)cc1,4-(Bis(2-chloroethyl)amino)-N-(2-chlorophenyl)benzamide,9.46,uM,=,0.9758911364017928,1,O=C(Nc1ccccc1)c1ccccc1
3651,608090,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 1 hr by Western blot,O=C(O)[C@@H]1O[C@H]1C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"(2R,3R)-ethyl 3-(4-(3-bromoanilino)quinazolin-6-ylcarbamoyl)oxirane-2-carboxylate",0.011,uM,=,-1.958607314841775,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)[C@H]1CO1
3652,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,Cc1ccc(C(=O)NS(=O)(=O)c2ccccc2)c(Cl)n1,2-Chloro-6-methyl-N-(phenylsulfonyl)nicotinamide,21.56,uM,=,1.333648756514701,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
3653,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1cnc(N2CC(O)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((8-(3-hydroxyazetidin-1-yl)-5-isopropyl-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",5.521,uM,=,0.7420177471401382,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
3654,1891470,10.1016/j.bmc.2019.03.049,,,,Inhibition of c-MET (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins by mobility shift assay,COc1cc2c(Oc3ccc(C4SCC(=O)N4NC(=O)Nc4ccc(F)c(F)c4F)cc3)ccnc2cc1OCCCN1CCOCC1,"N1-(2,3,4-trifluorophenyl)-N3-(2-(4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)oxy)phenyl)-4-oxothiazolidin-3-yl)urea",4.24,uM,=,0.6273658565927327,1,O=C(Nc1ccccc1)NN1C(=O)CSC1c1ccc(Oc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1
3655,946792,10.1016/j.bmc.2013.01.040,,,,Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA,Nc1nc(Nc2ccccc2)c2c(n1)[nH]c1ccccc12,"N4-phenyl-9H-pyrimido[4,5-b]indole-2,4-diamine",0.147,uM,=,-0.8326826652518239,0,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
3656,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(NCCCCCC(=O)O)nc21,"6-[6-(2,6-Dichloro-phenyl)-8-methyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-hexanoic acid",1.0,uM,=,0.0,0,O=c1[nH]c2ncncc2cc1-c1ccccc1
3657,1725307,10.1016/j.ejmech.2017.10.008,,,,Inhibition of EGFR (unknown origin),Nc1n[nH]c2cccc(-c3ccc(NC(=S)Nc4cc(Br)ccc4OC(F)(F)F)cc3)c12,N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N'-[5-bromo-2-(trifluoromethoxy)phenyl]thiourea,5.4,uM,=,0.7323937598229685,1,S=C(Nc1ccccc1)Nc1ccc(-c2cccc3[nH]ncc23)cc1
3658,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CCN(CC)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(diethylamino)but-2-enamide",0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3sccc23)cc1
3659,739728,10.1016/j.bmcl.2011.01.137,,,,Inhibition of human EGFR-mediated poly(Glu4Tyr) phosphorylation after 1 hr,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.063,uM,=,-1.2006594505464183,0,c1ccc(Nc2ncnc3ccccc23)cc1
3660,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.0001799999999999,uM,=,-3.744727494896694,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
3661,340860,10.1016/j.bmcl.2005.12.028,,,,Inhibitory activity against EGFR,COCCOc1cc(OC2CCOCC2)c2c(Nc3ccc(F)c(Cl)c3)ncnc2c1,N-(3-chloro-4-fluorophenyl)-7-(2-methoxyethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine,0.671,uM,=,-0.1732774798310079,0,c1ccc(Nc2ncnc3cccc(OC4CCOCC4)c23)cc1
3662,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4Cl)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(2-chloro-benzyloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.011,uM,=,-1.958607314841775,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
3663,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)cc(C3CC3)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(5-Cyclopropyl-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido [2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.12,uM,=,-0.9208187539523752,0,O=c1cc(C2CC2)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
3664,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,Nc1ccccc1NC(=O)/C=C/c1cccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)c1,(E)-N-(2-aminophenyl)-3-(3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)phenyl)acrylamide,0.049,uM,=,-1.3098039199714864,0,O=C(/C=C/c1cccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1)Nc1ccccc1
3665,65120,10.1021/jm00023a009,,,,In vitro inhibition of EGF-stimulated DNA synthesis of ER 22 cells by following the incorporation of methyl-[3H]thymidine.,COCOc1cc(C(C)(C)C)ccc1-c1ccc(C(=O)OC)cc1,4'-tert-Butyl-2'-methoxymethoxy-biphenyl-4-carboxylic acid methyl ester,10.0,uM,=,1.0,1,c1ccc(-c2ccccc2)cc1
3666,66567,10.1021/jm950692f,,,,Inhibition of tyrosine kinase activity of Epidermal growth factor receptor from human A431 cells,CN(C)CCn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-[3-(2-dimethylamino-ethyl)-3H-imidazo[4,5-g]quinazolin-8-yl]-amine",0.022,uM,=,-1.6575773191777938,0,c1ccc(Nc2ncnc3cc4[nH]cnc4cc23)cc1
3667,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4ccccn4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-(4-{[3,6-dioxo-4-(pyridin-2-ylmethoxy)cyclohexa-1,4-dien-1-yl]amino}-7-ethoxyquinazolin-6-yl)but-2-enamide",0.7918999999999999,uM,=,-0.1013296570344702,0,O=C1C=C(OCc2ccccn2)C(=O)C=C1Nc1ncnc2ccccc12
3668,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CC(C)OC(=O)c1oc2cc(O)cc(O)c2c(=O)c1-c1ccc(O)cc1,"isopropyl 5,7-dihydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromene-2-carboxylate",28.08281938003188,uM,=,1.448440706724298,1,O=c1c(-c2ccccc2)coc2ccccc12
3669,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3ccncc23)c1,"(3-Bromo-phenyl)-pyrido[4,3-d]pyrimidin-4-yl-amine",0.035,uM,=,-1.4559319556497243,0,c1ccc(Nc2ncnc3ccncc23)cc1
3670,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCN1CCN(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)CC1,"(E)-2-Cyano-N-(2-{4-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloyl]-piperazin-1-yl}-ethyl)-3-(3,4-dihydroxy-phenyl)-acrylamide",10.0,uM,=,1.0,1,O=C(C=Cc1ccccc1)NCCN1CCN(C(=O)/C=C/c2ccccc2)CC1
3671,1338035,10.1016/j.ejmech.2014.02.032,,,,Inhibition of EGFR (unknown origin) after 1.5 hr by FRET-based Z-lyte assay,CCN(CC)CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)-3-(diethylamino)propanamide,0.877,uM,=,-0.0570004066339594,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3672,1891470,10.1016/j.bmc.2019.03.049,,,,Inhibition of c-MET (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins by mobility shift assay,COc1cc2c(Oc3ccc(C4SCC(=O)N4NC(=O)Nc4ccccc4)cc3)ccnc2cc1OCCCN1CCOCC1,N1-(2-(4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)oxy)phenyl)-4-oxothiazolidin-3-yl)-N3-phenylurea,4.52,uM,=,0.6551384348113821,1,O=C(Nc1ccccc1)NN1C(=O)CSC1c1ccc(Oc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1
3673,840626,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR using GST-Crk as substrate assessed as phosphorylated Crk level after 20 mins by SDS-PAGE analysis,Brc1cccc(Nc2ncnc3cc4c(cc23)OCCOCOCOCCO4)c1,"N-(3-bromophenyl)-7,8,14,15-tetrahydro-[1,3,5,8,11]pentaoxacyclotrideca[9,10-g]quinazolin-4-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCOCOCCO4)cc1
3674,2127056,10.1016/j.bmcl.2021.128118,,,,Inhibition of recombinant wild type EGFR-TK (unknown origin) by ELISA,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methylamide,1.15,uM,=,0.0606978403536116,1,O=C(Nc1ccccc1)Nc1ccc(Oc2ccncc2)cc1
3675,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCNCC1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl piperazine-1-carboxylate",0.063,uM,=,-1.2006594505464183,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3s2)C1)N1CCNCC1
3676,600206,10.1016/j.bmcl.2009.05.060,,,,Inhibition of EGFR-mediated poly(L-glutamic acid L-tyrosine) phosphorylation,CC(=O)OCOC(=O)N(C)/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,acetoxymethyl 3-(4-(3-chlorophenylamino)quinazolin-6-yl)-1-methyltriaz-2-ene-1-carboxylate,0.63,uM,=,-0.2006594505464183,0,c1ccc(Nc2ncnc3ccccc23)cc1
3677,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc4ccccc34)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.06,uM,=,-1.2218487496163564,0,c1ccc2c(-c3nn([C@@H]4CCCNC4)c4ncncc34)cccc2c1
3678,63772,10.1021/jm9903949,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cells,Cn1c2ccccc2c2c(Nc3cccc(Br)c3)ncnc21,"(3-Bromo-phenyl)-(9-methyl-9H-pyrimido[4,5-b]indol-4-yl)-amine",0.769,uM,=,-0.1140736601985689,0,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
3679,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CC(C)N(C)C/C=C/C(=O)N1Cc2sc3ncnc(Nc4ccc(Cl)c(Cl)c4)c3c2C1,"US8524722, 84",0.0014,uM,=,-2.853871964321762,0,c1ccc(Nc2ncnc3sc4c(c23)CNC4)cc1
3680,1924071,10.1021/acs.jmedchem.6b00403,,,,"Inhibition of wild type EGFR kinase domain (unknown origin) expressed using baculovirus expression system incubated for 1 hr using Poly(Glu,Tyr) 4:1 by ELISA method",C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-6,7-dioxo-6,7-dihydropteridin-8(5H)-yl)phenyl)acrylamide",0.474,uM,=,-0.324221658325915,0,O=c1[nH]c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n(-c2ccccc2)c1=O
3681,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,22.8,uM,=,1.3579348470004535,1,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
3682,1798892,10.1016/j.ejmech.2017.07.023,,,,Inhibition of GST-tagged human EGFR catalytic domain expressed in insect cells,C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,POZIOTINIB,0.0032,uM,=,-2.494850021680094,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
3683,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,NC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl carbamate",0.04,uM,=,-1.3979400086720375,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
3684,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1,N-(4-(3-(trifluoromethyl)benzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.091,uM,=,-1.0409586076789064,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
3685,1754932,10.1021/acs.jmedchem.8b00441,,,,"Inhibition of recombinant human EGFR using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.0012,uM,=,-2.920818753952376,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
3686,1801908,10.1016/j.ejmech.2018.06.061,,,,Inhibition of EGFR in human HepG2 cells,O=C1Nc2ccc(S(=O)(=O)N3CCOCC3)cc2/C1=N/c1ccc(/N=C2\C(=O)Nc3ccc(S(=O)(=O)N4CCOCC4)cc32)cc1,"3,3'-((1,4-phenylene bis(azanylylidene))bis(5-(morpholinosulfonyl)-indolin-2-one)",1.182,uM,=,0.0726174765452365,1,O=C1Nc2ccc(S(=O)(=O)N3CCOCC3)cc2/C1=N/c1ccc(/N=C2\C(=O)Nc3ccc(S(=O)(=O)N4CCOCC4)cc32)cc1
3687,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,COc1cc2ncnc(NCc3cccc(Br)c3)c2cc1OCCCCCCC(=O)NO,7-(4-(3-bromobenzylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3ccccc23)cc1
3688,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CCCCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCCCC,"(3-Bromo-phenyl)-(6,7-dibutoxy-quinazolin-4-yl)-amine",0.105,uM,=,-0.978810700930062,0,c1ccc(Nc2ncnc3ccccc23)cc1
3689,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1OC,"1-tert-butyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",6.34,uM,=,0.8020892578817327,1,c1ccc(-c2n[nH]c3ncncc23)cc1
3690,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,Cc1ccc(NC(=O)c2ccc(N(CCCl)CCCl)cc2)cc1,4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide,0.58,uM,=,-0.2365720064370627,0,O=C(Nc1ccccc1)c1ccccc1
3691,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Cl.Nc1ccc2c(c1)sc1c(Nc3cccc(Br)c3)ncnc12,"N*4*-(3-Bromo-phenyl)-benzo[4,5]thieno[3,2-d]pyrimidine-4,7-diamine hydrochloride",0.00047,uM,=,-3.3279021420642825,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
3692,1842437,10.1016/j.ejmech.2019.03.004,,,,Inhibition of EGFR in human ME180 cells assessed as reduction in cell proliferation incubated for 72 hrs by Coulter counter method,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.95,uM,=,-0.0222763947111522,0,c1ccc(Nc2ncnc3ccccc23)cc1
3693,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{6-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-hexyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",5.0,uM,=,0.6989700043360189,1,O=C(C=Cc1ccccc1)NCCCCCCNC(=O)/C=C/c1ccccc1
3694,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CCN(C(=O)[C@H](C)N)CC1,"N-(2-(4-((S)-2-aminopropanoyl)piperazin-1-yl)-5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide",1600.0,uM,=,3.204119982655925,1,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c2c1
3695,64443,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-(3-Chloro-4-fluoro-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-acrylamide",0.00077,uM,=,-3.113509274827518,0,c1ccc(Nc2ncnc3cnccc23)cc1
3696,2107115,10.1016/j.ejmech.2021.113300,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCC(=O)Nc4ccc(S(N)(=O)=O)cc4)cc23)c1,5-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-(4-sulfamoylphenyl)pentanamide,0.0492,uM,=,-1.3080348972326397,0,O=C(CCCCOc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1ccccc1
3697,2296337,10.1039/d3md00038a,,,,Inhibition of EGFR (unknown origin),Cc1c(C(=O)NCCc2ccc(N3CCOCC3)cc2)[nH]c2ccc(Cl)cc12,5-chloro-3-methyl-N-(4-morpholinophenethyl)-1H-indole-2-carboxamide,0.089,uM,=,-1.0506099933550872,0,O=C(NCCc1ccc(N2CCOCC2)cc1)c1cc2ccccc2[nH]1
3698,67046,10.1016/s0960-894x(01)00080-4,,,,Inhibition of autophosphorylation of epidermal growth factor receptor (EGF-R) in a cellular assay,COc1cccc(-c2cn(C3CCN(CCN(C)CCO)CC3)c3ncnc(N)c23)c1,"2-[(2-{4-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-piperidin-1-yl}-ethyl)-methyl-amino]-ethanol",7.8,uM,=,0.8920946026904804,1,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1
3699,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(N2C(=O)CN(Cc3ccccc3)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(6-benzyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5,8-dioxo-7,8-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-9(6H)-yl)phenyl)acrylamide",0.00626,uM,=,-2.2034256667895704,0,O=C1c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N(c2ccccc2)C(=O)CN1Cc1ccccc1
3700,2227151,10.1016/j.ejmech.2022.114492,,,,Inhibition of wild type EGFR (unknown origin) by mobility shift assay,COc1cc(N(C)CCN(C)C)c(NC(=O)c2ccncn2)cc1Nc1nccc(-c2cn(CCCO)c3ccccc23)n1,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-(3-hydroxypropyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)pyrimidine-4-carboxamide,0.59,uM,=,-0.2291479883578558,0,O=C(Nc1cccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c1)c1ccncn1
3701,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,C=C(CN1CCCCC1)C(=O)c1ccc(OCc2ccccc2)cc1.Cl,1-(4-Benzyloxy-phenyl)-2-piperidin-1-ylmethyl-propenone hydrochloride,1.1,uM,=,0.041392685158225,1,C=C(CN1CCCCC1)C(=O)c1ccc(OCc2ccccc2)cc1
3702,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,N-[4-(3-Chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-propanamide,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
3703,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3c4n(c5ccccc35)CCOC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((5-chloro-4-(3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-10-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",2.969,uM,=,0.4726101975960446,1,c1ccc(Nc2nccc(-c3c4n(c5ccccc35)CCOC4)n2)cc1
3704,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(Cl)c(Cl)c3)c2c1,"1-(4-((3,4-Dichlorophenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)thiourea",0.00905,uM,=,-2.0433514207947967,0,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3705,321418,10.1016/j.bmcl.2005.06.068,,,,Inhibitory concentration against EGFR kinase phosphorylation using synthetic peptide as a substrate,CN1CCC(Oc2cccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c23)CC1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-[5-(1-methyl-piperidin-4-yloxy)-quinazolin-4-yl]-amine,0.005,uM,=,-2.3010299956639813,0,c1ccc(COc2ccc(Nc3ncnc4cccc(OC5CCNCC5)c34)cc2)cc1
3706,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCCC1,N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(pyrrolidin-1-ylmethyl)quinazolin-4-amine,0.36,uM,=,-0.4436974992327127,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
3707,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccc(Cl)cc4)cs3)C(c3ccc(O)cc3)C2)cc1,"4-(1-(4-(4-chlorophenyl)thiazol-2-yl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol",7.66,uM,=,0.884228769632604,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
3708,1924071,10.1021/acs.jmedchem.6b00403,,,,"Inhibition of wild type EGFR kinase domain (unknown origin) expressed using baculovirus expression system incubated for 1 hr using Poly(Glu,Tyr) 4:1 by ELISA method",C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(OCCN(C)C)cc4OC)nc32)c1,"N-(3-(2-(4-(2-(dimethylamino)ethoxy)-2-methoxyphenylamino)-5-isopropyl-6,7-dioxo-6,7-dihydropteridin-8(5H)-yl)phenyl)acrylamide",0.068,uM,=,-1.1674910872937636,0,O=c1[nH]c2cnc(Nc3ccccc3)nc2n(-c2ccccc2)c1=O
3709,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCCCCOC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,Dodecyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetate,1.72,uM,=,0.2355284469075489,1,O=c1cc(-c2ccccc2)oc2ccccc12
3710,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Clc1cccc(Nc2[nH]nc3ncnc(Nc4cccc(Br)c4)c23)c1,"N*4*-(3-Bromo-phenyl)-N*3*-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.13,uM,=,-0.8860566476931633,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
3711,1642157,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",3.3,uM,=,0.5185139398778875,1,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
3712,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)N1CCN(CCO)CC1,(S)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(2-hydroxyethyl)piperazine-1-carboxamide,0.331,uM,=,-0.4801720062242812,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1)N1CCNCC1
3713,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Oc1ncnc(Sc3cccc(Br)c3)c1NC2,"1-(3-bromo-phenylsulfanyl)-7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene",1.2,uM,=,0.0791812460476248,1,c1ccc(Sc2ncnc3c2NCc2ccccc2O3)cc1
3714,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccccc2NC(=O)/C=C/CN(C)C)n1,"N-(2-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-4-N,N-dimethylaminobut-2-enamide",12.02,uM,=,1.0799044676667209,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3715,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NC1CCC(CC2CCC(NC(=O)/C(C#N)=C/c3ccc(O)c(O)c3)CC2)CC1,"(E)-2-Cyano-N-(4-{4-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-cyclohexylmethyl}-cyclohexyl)-3-(3,4-dihydroxy-phenyl)-acrylamide",20.3,uM,=,1.307496037913213,1,O=C(C=Cc1ccccc1)NC1CCC(CC2CCC(NC(=O)/C=C/c3ccccc3)CC2)CC1
3716,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC(=O)c4ccc(C(=O)Nc5ccc6c(c5)C(C)(C)CCC6(C)C)cc4)c(OCCOC)cc23)c1,"2-((4-((3-Ethynylphenyl)amino)-6-(2-methoxyethoxy)quinazolin-7-yl)oxy)ethyl-4-((5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbamoyl)benzoate",0.032,uM,=,-1.494850021680094,0,O=C(Nc1ccc2c(c1)CCCC2)c1ccc(C(=O)OCCOc2ccc3c(Nc4ccccc4)ncnc3c2)cc1
3717,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,Cn1cnc(-c2cc(NC(=O)Nc3ccncc3)cc(C(F)(F)F)c2)c1,1-(3-(1-methyl-1H-imidazol-4-yl)-5-(trifluoromethyl)phenyl)-3-(pyridin-4-yl)urea,0.1656,uM,=,-0.7809396675511386,0,O=C(Nc1ccncc1)Nc1cccc(-c2c[nH]cn2)c1
3718,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Cc1ccn2ncnc(Nc3ccc(F)c(Cl)c3)c12,"(3-Chloro-4-fluoro-phenyl)-(5-methyl-pyrrolo[2,1-f][1,2,4]triazin-4-yl)-amine",0.1,uM,=,-1.0,0,c1ccc(Nc2ncnn3cccc23)cc1
3719,2112388,10.1016/j.bmcl.2021.127987,,,,Inhibition of EGFR (unknown origin),O=C1N=C(NN2Cc3ccccc3N=C2c2ccccc2)S/C1=C/c1ccccc1,"3-(5-benzylidene-4-oxo-4,5-dihydrothiazol-2-ylamino)-2-phenylquinazolin-4(H)-one",0.06563,uM,=,-1.182897595743077,0,O=C1N=C(NN2Cc3ccccc3N=C2c2ccccc2)S/C1=C/c1ccccc1
3720,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCCC1,(2E)-N-(7-Ethoxy-4-{[1-(phenylsulfonyl)-1H-indol-5-yl]amino}-6-quinazolinyl)-4-(1-pyrrolidinyl)-2-butenamide,0.036,uM,=,-1.4436974992327127,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c3)c2c1
3721,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2C1CCCC1,"5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",0.067,uM,=,-1.1739251972991736,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
3722,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COC(=O)c1cccc(-c2cc3c(N[C@H](C)c4ccccc4)ncnc3s2)c1OC,"(R)-methyl 2-methoxy-3-(4-(1-phenylethylamino)thieno[2,3-d]pyrimidin-6-yl)benzoate",0.009,uM,=,-2.0457574905606752,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
3723,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Oc3cccc(Cl)c3F)c1NC2,"1-(3-chloro-2-fluoro-phenoxy)-7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene",4.6,uM,=,0.6627578316815741,1,c1ccc(Oc2ncnc3c2NCc2ccccc2O3)cc1
3724,2030549,10.1016/j.ejmech.2020.112062,,,,Inhibition of EGFR in human RPMI-8226 cells incubated for 2 hrs by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.018,uM,=,-1.744727494896694,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
3725,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Clc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1,"N-(3-Chlorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.00641,uM,=,-2.1931419704811828,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
3726,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC(=O)c4ccc(C(=O)Nc5ccc6c(c5)C(C)(C)CCC6(C)C)cc4)c(OCCOC(=O)c4ccc(C(=O)Nc5ccc6c(c5)C(C)(C)CCC6(C)C)cc4)cc23)c1,"((4-((3-Ethynylphenyl)amino)quinazoline-6,7-diyl)bis(oxy))bis(ethane-2,1-diyl)-bis(4-((5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbamoyl)benzoate)",0.88,uM,=,-0.0555173278498313,0,O=C(Nc1ccc2c(c1)CCCC2)c1ccc(C(=O)OCCOc2cc3ncnc(Nc4ccccc4)c3cc2OCCOC(=O)c2ccc(C(=O)Nc3ccc4c(c3)CCCC4)cc2)cc1
3727,465,10.1016/s0960-894x(02)00364-5,,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Cc1cc(C(=O)N2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[3-methyl-5-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.44,uM,=,-0.3565473235138126,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCOCC2)[nH]1
3728,63770,10.1021/jm0204183,,,,Inhibition of epidermal growth factor receptor (EGF-R),CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Br)cc32)c1C,"5-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide",10.0,uM,=,1.0,1,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1
3729,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccnc2)c2c(N)ncnc21,"1-isopropyl-3-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",100.0,uM,=,2.0,1,c1cncc(-c2n[nH]c3ncncc23)c1
3730,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,COCCOc1cc2ncnc(Nc3ccc(C)c([N+](=O)[O-])c3)c2c2c1OCCO2,"5-(2-Methoxyethoxy)-N-(4-methyl-3-nitrophenyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0746,uM,=,-1.1272611725273312,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
3731,305007,10.1021/jm050267e,,,,Inhibition of Epidermal growth factor receptor,Cc1ccc(F)c(C(=O)n2nc(Nc3ccc(S(N)(=O)=O)cc3)nc2C)c1F,"4-[1-(2,6-Difluoro-3-methyl-benzoyl)-5-methyl-1H-[1,2,4]triazol-3-ylamino]-benzenesulfonamide",45.8,uM,=,1.6608654780038692,1,O=C(c1ccccc1)n1cnc(Nc2ccccc2)n1
3732,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COCC[C@@H](C(N)=O)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-4-methoxybutanamide,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
3733,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,COc1cc2ncnc(Nc3ccc(Cc4ccccn4)cc3)c2cc1NC(=O)/C=C/CN1CCCC1,(2E)-N-{7-Methoxy-4-[4-(2-pyridinylmethyl)anilino]-6-quinazolinyl}-4-(1-pyrrolidinyl)-2-butenamide,0.029,uM,=,-1.537602002101044,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc(Cc4ccccn4)cc3)c2c1
3734,840626,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR using GST-Crk as substrate assessed as phosphorylated Crk level after 20 mins by SDS-PAGE analysis,Brc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCO4)c1,"N-(3-bromophenyl)-7,8,10,11-tetrahydro-[1,4,7]trioxonino[2,3-g]quinazolin-4-amine",0.055,uM,=,-1.259637310505756,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCCO4)cc1
3735,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,COc1ccc(C2CC(c3ccc(Cl)c(Cl)c3)=NN2C(N)=S)cc1,"3-(3,4-Dichlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",5.74,uM,=,0.7589118923979735,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
3736,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.0029,uM,=,-2.537602002101044,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
3737,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(C)c(Br)c3)ncnc2cc1OCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-(2-{4-[(3-Bromo-4-methylphenyl)amino]-6-methoxy-quinazolin-7-yl}oxy)ethyl-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.0185399999999999,uM,=,-1.7318902701915218,0,O=C(Cn1cncn1)NCCOc1ccc2c(Nc3ccccc3)ncnc2c1
3738,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)acrylamide,0.0058,uM,=,-2.2365720064370627,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
3739,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,Fc1ccc(-c2nc(SCCN3CCOCC3)[nH]c2-c2ccnc(Nc3ccccc3)c2)cc1,4-(4-(4-Fluorophenyl)-2-((2-morpholinoethyl)thio)-1H-imidazol-5-yl)-N-phenylpyridin-2-amine,0.183,uM,=,-0.7375489102695706,0,c1ccc(Nc2cc(-c3[nH]c(SCCN4CCOCC4)nc3-c3ccccc3)ccn2)cc1
3740,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3cn(C)c4ccccc34)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(1-methyl-1H-indol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.04,uM,=,-1.3979400086720375,0,c1ccc2c(-c3nn([C@@H]4CCCNC4)c4ncncc34)c[nH]c2c1
3741,2110760,10.1016/j.ejmech.2020.113022,,,,Inhibition of N-terminal GST-tagged human recombinant EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCCN/C(=N\C#N)Nc4cccnc4)cc23)c1,2-Cyano-1-(7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)heptyl)-3-(pyridin-3-yl)guanidine,0.000538,uM,=,-3.2692177243336107,0,N=C(NCCCCCCCOc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1cccnc1
3742,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,Cl.Cl.NC1CCc2c(c3cc(OCCc4ccc(O)cc4)ccc3n2CCCCCc2ccccn2)C1,"4-(2-(3-Amino-9-(5-(pyridine-2-yl)pentyl)-2,3,4,9-tetrahydro-1H-tetrahydrocarbazole-6-yloxy)ethyl)phenol dihydrochloride",2.28,uM,=,0.3579348470004537,1,c1ccc(CCOc2ccc3c(c2)c2c(n3CCCCCc3ccccn3)CCCC2)cc1
3743,5004,10.1016/s0960-894x(02)00364-5,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Cc1cc(C(=O)N2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc4c(c3)CCC4)c21,"4-(Indan-5-ylamino)-5-[1-[3-methyl-5-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",5.0,uM,=,0.6989700043360189,1,O=C1Nc2ncnc(Nc3ccc4c(c3)CCC4)c2/C1=C/c1ccc(C(=O)N2CCOCC2)[nH]1
3744,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,CCOc1cc2ncnc(Nc3ccccc3F)c2cc1OCC.Cl,"4-(2'-fluoroanilino)-6,7-diethoxyquinazoline hydrochloride",0.141,uM,=,-0.8507808873446201,0,c1ccc(Nc2ncnc3ccccc23)cc1
3745,1798892,10.1016/j.ejmech.2017.07.023,,,,Inhibition of GST-tagged human EGFR catalytic domain expressed in insect cells,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@@H]1CCOC1,(E)-N-(7-((R)-tetrahydrofuran-3-yloxy)-4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0005,uM,=,-3.3010299956639813,0,c1ccc(Nc2ncnc3cc(O[C@@H]4CCOC4)ccc23)cc1
3746,612309,10.1021/jm901453q,,,,Inhibition of EGFR,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCC(=O)NO)cc23)c1,6-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyhexanamide,0.0046,uM,=,-2.337242168318426,0,c1ccc(Nc2ncnc3ccccc23)cc1
3747,5170,10.1021/jm970641d,,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,Brc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-(2-morpholin-4-yl-ethyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",7.9,uM,=,0.8976270912904415,1,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)cc1
3748,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1NC(=O)/C=C/CN1CCCCC1,(2E)-N-[7-Methoxy-4-(4-phenoxyanilino)-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide,0.016,uM,=,-1.7958800173440752,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2c1
3749,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1ccc(C2CC(c3ccc(Cl)cc3)=NN2C2=NC(=O)CS2)cc1,"2-(3-(4-Chlorophenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",6.67,uM,=,0.8241258339165489,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
3750,66581,10.1016/s0960-894x(02)00598-x,,,,Inhibition of Epidermal Growth Factor Receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.083,uM,=,-1.080921907623926,0,c1ccc(Nc2ccnc3ccccc23)cc1
3751,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(C(F)(F)F)c5)c4c3)o2)CC1,[4-(3-fluoro-benzyloxy)-3-trifluoromethyl-phenyl]-{6-[5-(1-oxo-1lambda*4*-thiomorpholin-4-ylmethyl)-furan-2-yl]-quinazolin-4-yl}-amine,0.089,uM,=,-1.0506099933550872,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CN6CC[SH+]CC6)o5)cc34)cc2)cc1
3752,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccn(C)n3)nc3ccsc23)CC1,"1-(4-((2-((1-methyl-1H-pyrazol-3-yl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.224,uM,=,-0.6497519816658371,0,c1cc(Nc2nc(OC3CCNCC3)c3sccc3n2)n[nH]1
3753,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,2-(((5-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)quinazolin-6-yl)furan-2-yl)methyl)(2-(methylsulfonyl)ethyl)amino)acetonitrile,0.027,uM,=,-1.5686362358410126,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
3754,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)c(OC)cc1N1CCN(C)CC1,N-[5-[[5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide,0.77,uM,=,-0.1135092748275181,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c[nH]c2c1
3755,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](CO)C(N)=O,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-3-hydroxypropanamide,0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
3756,1924071,10.1021/acs.jmedchem.6b00403,,,,"Inhibition of wild type EGFR kinase domain (unknown origin) expressed using baculovirus expression system incubated for 1 hr using Poly(Glu,Tyr) 4:1 by ELISA method",C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(CCC)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6,7-dioxo-5-propyl-6,7-dihydropteridin-8(5H)-yl)phenyl)acrylamide",0.0022,uM,=,-2.657577319177794,0,O=c1[nH]c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n(-c2ccccc2)c1=O
3757,935919,10.1016/j.bmcl.2012.11.001,,,,Inhibition of EGFR (unknown origin) by Z-LYTE assay,C=C1[C@H](C)CCC[C@]1(C)CC/C(C)=C/CC1=C(O)C(=O)C=C(NCC(=O)O)C1=O,Metachromin L,491.0021695362744,uM,=,2.6910834110955766,1,C=C1CCCCC1CC/C=C/CC1=CC(=O)C=CC1=O
3758,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cn1,"(2E)-N-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}pyrido[3,4-d]-pyrimidin-6-yl)-4-(dimethylamino)-2-butenamide",0.025,uM,=,-1.6020599913279625,0,c1ccc(COc2ccc(Nc3ncnc4cnccc34)cc2)cc1
3759,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N(CC)CC)cc3OC)n2)c1,N-(3-(3-(2-(4-(diethylamino)-2-methoxyphenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.183,uM,=,-0.7375489102695706,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccccc2)n1
3760,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,COc1cc2ncnc(Nc3cccc(F)c3)c2cc1OC.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-fluoro-phenyl)-amine hydrochloride",0.059,uM,=,-1.2291479883578558,0,c1ccc(Nc2ncnc3ccccc23)cc1
3761,67207,10.1021/jm000231g,,,,Inhibition of Epidermal growth factor receptor,COC(=O)[C@@]1(Cc2ccc(O)c(CC=C(C)C)c2)OC(=O)C(O)=C1c1ccc(O)cc1,Dihydro-furan-2-one,590.0,uM,=,2.770852011642144,1,O=C1C=C(c2ccccc2)C(Cc2ccccc2)O1
3762,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(/C=C/c1ccccc1[N+](=O)[O-])Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,(E)-N-(4-(3-Chlorophenylamino)quinazolin-6-yl)-3-(2-nitrophenyl)acrylamide,0.94,uM,=,-0.0268721464003013,0,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3763,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(Oc1ccc(-c2ccccc2)cc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid biphenyl-4-yl ester",5.0,uM,=,0.6989700043360189,1,O=C(Oc1ccc(-c2ccccc2)cc1)c1cccc(NCc2ccccc2)c1
3764,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(Cc4ccccn4)cc3)ncnc2cc1OC,N-{7-Methoxy-4-[4-(2-pyridinylmethyl)anilino]-6-quinazolinyl}-propanamide,0.205,uM,=,-0.6882461389442457,0,c1ccc(Cc2ccc(Nc3ncnc4ccccc34)cc2)nc1
3765,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCCOC,N-(4-(3-Chloro-4-(3-fluorobenzyloxy)phenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)acrylamide,0.1022,uM,=,-0.9905491042013062,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
3766,1869224,10.1021/acs.jmedchem.8b01391,,,,Inhibition of wild type EGFR (unknown origin) by bioluminescent ADP-glo kinase assay,COc1cc(Nc2ncnc3cc(-c4ccc(I)cc4)sc23)cc(OC)c1OC,"6-(4-Iodophenyl)-N-(3,4,5-trimethoxyphenyl)thieno[3,2-d]-pyrimidin-4-amine",0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3cc(-c4ccccc4)sc23)cc1
3767,63773,10.1021/jm9508651,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 human epidermoid carcinoma cells,CNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-phenyl)-N*7*-methyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ncnc3ccncc23)cc1
3768,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CN1CCN(c2ccc(Nc3nc(Nc4ccc5[nH]ccc5c4)c4cn[nH]c4n3)cc2)CC1,"N4-(1H-indol-5-yl)-N6-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine",0.127,uM,=,-0.8961962790440431,0,c1cc2cc(Nc3nc(Nc4ccc(N5CCNCC5)cc4)nc4[nH]ncc34)ccc2[nH]1
3769,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,COC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1,"methyl 4-(6,7-dimethoxyquinazolin-4-ylamino)phenylcarbamate",6.9,uM,=,0.8388490907372553,1,c1ccc(Nc2ncnc3ccccc23)cc1
3770,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CN1CCC[C@@H]1C(N)=O,(R)-1-((4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidine-2-carboxamide,0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
3771,1515019,10.1016/j.ejmech.2015.07.030,,,,Inhibition of epidermal growth factor receptor kinase (unknown origin) using [33P]-ATP after 20 to 30 mins by radiometric assay,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.0008,uM,=,-3.096910013008056,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
3772,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3cccnc3)nc21,"6-(2,6-Dichloro-phenyl)-8-methyl-2-(pyridin-3-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one",0.51,uM,=,-0.2924298239020636,0,O=c1[nH]c2nc(Nc3cccnc3)ncc2cc1-c1ccccc1
3773,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cc(C(=O)NCCN(C)C)cc(OC)c1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1,"(R)-N-(2-(Dimethylamino)ethyl)-3,5-dimethoxy-4-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzamide",0.0004,uM,=,-3.397940008672037,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
3774,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCOC(=O)c1cn2ncnc(Nc3ccc(F)c(Cl)c3)c2c1CC,"4-(3-Chloro-4-fluoro-phenylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester",0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ncnn3cccc23)cc1
3775,1476964,10.1016/j.bmc.2015.04.038,,,,Inhibition of wild type N-terminal His6-tagged human EGFR kinase domain (702 to 1016 residues) expressed in Sf9 cells pre-incubated for 30 mins before ATP and substrate addition by homogeneous time-resolved FRET assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)/C(C#N)=C/c3ccncc3)c2)n1,(E)-N-(3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)-2-cyano-3-(pyridin-4-yl)acrylamide,8.7,uM,=,0.9395192526186184,1,O=C(/C=C/c1ccncc1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
3776,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,COc1cccc(CNc2ncnc3cc(N)ncc23)c1,"N*4*-(3-Methoxy-benzyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",2.87,uM,=,0.4578818967339924,1,c1ccc(CNc2ncnc3ccncc23)cc1
3777,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),COC(=O)c1ccc(CNC(=O)CCc2c(SSc3[nH]c4ccccc4c3CCC(=O)NCc3ccc(C(=O)OC)c(O)c3)[nH]c3ccccc23)cc1O,methyl 2-hydroxy-4-[2-(2-{3-[2-(3-hydroxy-4-methyloxycarbonylbenzylcarbamoyl)ethyl]-1H-2-indolyldisulfanyl}-1H-3-indolyl)ethylcarboxamidomethyl]benzoate,100.0,uM,=,2.0,1,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
3778,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2CC(c3ccc(Br)cc3)=NN2c2nc(-c3ccccc3)cs2)cc1,"2-(3-(4-bromophenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",19.64,uM,=,1.293141483450931,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
3779,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",Brc1cccc(Nc2ncnc3cnc(NCCCN4CCOCC4)nc23)c1,"N*8*-(3-Bromo-phenyl)-N*2*-(3-morpholin-4-yl-propyl)-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.0029,uM,=,-2.537602002101044,0,c1ccc(Nc2ncnc3cnc(NCCCN4CCOCC4)nc23)cc1
3780,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,CNC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((4-(methylamino)piperidin-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.063,uM,=,-1.2006594505464183,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
3781,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1ccc(C(=O)NCCN(C)C)cc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1,"(R)-N-(2-(Dimethylamino)ethyl)-4-methoxy-3-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzamide",0.0005,uM,=,-3.3010299956639813,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
3782,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCc2ccccc2)c1O,3-(3-Benzylsulfanylmethyl-4-hydroxy-5-methoxy-phenyl)-2-cyano-acrylamide,0.9,uM,=,-0.0457574905606751,0,c1ccc(CSCc2ccccc2)cc1
3783,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
3784,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,COc1cc2ncnc(C#CCOc3ccccc3)c2cc1OC,"6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline",0.015,uM,=,-1.8239087409443189,0,C(#Cc1ncnc2ccccc12)COc1ccccc1
3785,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,O=C(/C=C/CN1CCCOCC1)N1CCc2c(sc3ncnc(Nc4ccc(F)c(Cl)c4)c23)C1,"US8524722, 5",0.001,uM,=,-3.0,0,O=C(/C=C/CN1CCCOCC1)N1CCc2c(sc3ncnc(Nc4ccccc4)c23)C1
3786,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CNc1ncc(C(C)C)c2cc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)ncc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-(methylamino)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",10.0,uM,=,1.0,1,c1cc2cc(Nc3ccnc(N4CCCCC4)n3)ncc2cn1
3787,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1,"(3S,5R)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.04,uM,=,-1.3979400086720375,0,O=C(O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3s2)C1)N1CCOCC1
3788,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,CN(C)CC(CSc1ccccc1)C(=O)c1ccc(OCc2ccccc2)cc1.Cl,1-(4-Benzyloxy-phenyl)-3-dimethylamino-2-phenylsulfanylmethyl-propan-1-one hydrochloride,7.3,uM,=,0.8633228601204559,1,O=C(CCSc1ccccc1)c1ccc(OCc2ccccc2)cc1
3789,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@H](C)C(N)=O,(R)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)propanamide,0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccccc23)cc1
3790,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CN(C)C/C=C/C(=O)N1Cc2sc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2C1,"US8524722, 81",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3sc4c(c23)CNC4)cc1
3791,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,COCCn1c(=O)oc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"8-(3-Chloro-4-fluorophenylamino)-1-(2-methoxyethyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.47,uM,=,-0.3279021420642826,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
3792,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,Cc1ccc(Nc2ncnc3cc4c(cc23)N(CCCN2CCOCC2)C(=O)CO4)cc1Cl,"4-((3-chloro-4-methylphenyl)amino)-6-(3-morpholinopropyl)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.1626999999999999,uM,=,-0.7886124470631413,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
3793,2107115,10.1016/j.ejmech.2021.113300,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,NS(=O)(=O)c1ccc(CCNC(=S)Nc2ccc3ncnc(Nc4cccc(C(F)(F)F)c4)c3c2)cc1,4-(2-(3-(4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-yl)thioureido)ethyl)benzenesulfonamide,0.0426,uM,=,-1.3705904008972811,0,S=C(NCCc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3794,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(CC)cc3)c2c1,N-(4-(4-ethylphenylamino)quinazolin-6-yl)acrylamide,3.2,uM,=,0.505149978319906,1,c1ccc(Nc2ncnc3ccccc23)cc1
3795,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine",0.00079,uM,=,-3.1023729087095586,0,c1ccc(Nc2ncnc3ccccc23)cc1
3796,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,CN1CCN(C(=O)c2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1.Cc1ccc(S(=O)(=O)O)cc1,(5-(4-(3-Chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-yl)(4-methylpiperazin-1-yl)methanone tosylate,0.2324,uM,=,-0.6337638762817069,0,O=C(c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1)N1CCNCC1.c1ccccc1
3797,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,C#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-propynamide,0.0027,uM,=,-2.5686362358410126,0,c1ccc(Nc2ncnc3ccccc23)cc1
3798,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,CCOc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OCC.Cl,"4-(3'-chloroanilino)-6,7-diethoxyquinazoline hydrochloride",0.108,uM,=,-0.9665762445130504,0,c1ccc(Nc2ncnc3ccccc23)cc1
3799,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,COc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cn1,"6-(2,6-Dichloro-phenyl)-2-(6-methoxy-pyridin-3-ylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",1.3,uM,=,0.1139433523068367,1,O=c1[nH]c2nc(Nc3cccnc3)ncc2cc1-c1ccccc1
3800,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCCn1ccnc1[N+](=O)[O-],N-(3-Chloro-4-fluorophenyl)-6-methoxy-7-(4-(2-nitro-1H-imidazol-1-yl)butoxy)quinazolin-4-amine,0.00031,uM,=,-3.508638306165728,0,c1ccc(Nc2ncnc3cc(OCCCCn4ccnc4)ccc23)cc1
3801,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(1-(2,5-difluorobenzyl)-1H-indazol-5-ylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.033,uM,=,-1.4814860601221125,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1
3802,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,Brc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-(2-morpholin-4-yl-ethyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.00065,uM,=,-3.1870866433571443,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)cc1
3803,1353177,10.1021/ml4003309,,,,Inhibition of recombinant EGFR (unknown origin) using poly-GT peptide as substrate by Transcreener assay,COc1cc2c(Oc3ccc(NS(=O)(=O)c4cccc(-c5cnn(C)c5)c4)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,N-[3-fluoro-4-({6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yl}oxy)phenyl]-3-(1-methyl-1H-pyrazol-4-yl)benzenesulfonamide,0.084,uM,=,-1.0757207139381184,0,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1cccc(-c2cn[nH]c2)c1
3804,2080995,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R/T790M (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCc1cn(CCCCC(=O)NO)nn1,"5-(4-(((6-Acrylamido-4-((3-chloro-2-fluorophenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypentanamide",0.017,uM,=,-1.769551078621726,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
3805,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,Cc1cc2cc(Nc3ccnc4cc(-c5ccc(CN(C)CCO)cc5)sc34)ccc2[nH]1,"2-(Methyl-{4-[7-(2-methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-amino)-ethanol",0.14,uM,=,-0.8538719643217619,0,c1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
3806,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,Cc1cc(Nc2ncnc3cc(O)c(NC(=O)/C=C/[C@H]4CCCN4C)cc23)ccc1Oc1ccn2ccnc2c1,"(E)-N-[7-hydroxy-4-(4-imidazo[1,2-a]pyridin-7-yloxy-3-methyl-anilino)quinazolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide",0.00231,uM,=,-2.636388020107856,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4ccn5ccnc5c4)cc3)c2c1
3807,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccc(O)cc3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(4-hydroxybenzylidene)cyclohexanone",4.6,uM,=,0.6627578316815741,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
3808,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccc(Cl)cc3)CC2c2ccc(Cl)cc2)=N1,"2-(3,5-Bis(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",8.16,uM,=,0.9116901587538612,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
3809,1618202,10.1021/acs.jmedchem.5b01985,,,,Inhibition of wild type EGFR phosphorylation in human HaCaT cells incubated for 3 hrs by ELISA method,C=CC(=O)N1CCCCC(n2c(NC(=O)c3cccc(C(F)(F)F)c3)nc3cc(C)ccc32)C1,N-(1-(1-Acryloylazepan-3-yl)-5-methyl-1H-benzo[d]-imidazol-2-yl)-3-(trifluoromethyl)benzamide,4.33,uM,=,0.6364878963533654,1,O=C(Nc1nc2ccccc2n1C1CCCCNC1)c1ccccc1
3810,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(Nc1ccc(Nc2ncnc3cc4oc(=O)n(CCOC(=O)CBr)c4cc23)cc1)NC1CCCCC1,"1-(2-(2-bromoacetoxy)ethyl)-8-((4-(3-cyclohexylureido)phenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",8.5,uM,=,0.9294189257142929,1,O=C(Nc1ccc(Nc2ncnc3cc4oc(=O)[nH]c4cc23)cc1)NC1CCCCC1
3811,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,CNC(=O)[C@@H](C)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,(R)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-N-methylpropanamide,0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccccc23)cc1
3812,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,O=C(/C=C/CN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Morpholin-4-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.074,uM,=,-1.1307682802690238,0,O=C(/C=C/CN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
3813,66897,10.1021/jm970367n,,,,Inhibition of Epidermal growth factor receptor (EGFr) tyrosine kinase,CC(C)(C)NC(=O)Nc1nc2nc(N)ncc2cc1-c1c(Cl)cccc1Cl,"1-[2-Amino-6-(2,6-dichloro-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl-urea",0.45,uM,=,-0.3467874862246563,0,c1ccc(-c2cnc3ncncc3c2)cc1
3814,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CC[S+](C)[O-],N-(4-methoxy-2-(methyl(2-(methylsulfinyl)ethyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,1.741,uM,=,0.2407987711173312,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3815,2233745,10.1016/j.bmcl.2022.128730,,,,Inhibition of wild type EGFR (unknown origin),COc1cc(N2CCC3(CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,IRUPLINALKIB,0.035,uM,=,-1.4559319556497243,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC5(CCNCC5)CC4)cc3)n2)cc1
3816,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3c(ccn3C)c2)c2c(N)ncnc21,"1-isopropyl-3-(1-methyl-1H-indol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.955,uM,=,-0.0199966284162536,0,c1ncc2c(-c3ccc4[nH]ccc4c3)n[nH]c2n1
3817,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-phenyl-acrylamide",1.25,uM,=,0.0969100130080564,1,O=C(C=Cc1ccccc1)Nc1ccccc1
3818,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1,N-(4-(benzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.027,uM,=,-1.5686362358410126,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
3819,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,Cc1cc(C)cc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)c1,"8-(3,5-Dimethylphenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",75.0,uM,=,1.8750612633917,1,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
3820,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide,0.002,uM,=,-2.6989700043360187,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
3821,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,COc1cc2c(cc1OC)Oc1ncnc(Nc3cccc(Br)c3)c1NC2,"(3-Bromo-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",0.34,uM,=,-0.4685210829577448,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
3822,66595,10.1021/jm960879m,,,,Tested for ability to inhibit autophosphorylation of the Epidermal growth factor receptor in human epidermoid carcinoma cells,CNc1ncc2ncnc(Nc3cccc(Br)c3)c2n1,"N*8*-(3-Bromo-phenyl)-N*2*-methyl-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3cncnc23)cc1
3823,658253,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR autophosphorylation in human A431 cells,CNC/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OCCF,(E)-4-Methylamino-but-2-enoic acid[4-(3-chloro-4-fluorophenylamino)-3-cyano-7-(2-fluoroethoxy)-quinolin-6-yl]-amide,0.0081199999999999,uM,=,-2.090443970758825,0,c1ccc(Nc2ccnc3ccccc23)cc1
3824,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)c2cnccn2)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"3-methoxy-2-methyl-4-methyl(2-pyrazinyl)carboxamido-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaene",8.18,uM,=,0.912753303671323,1,O=C(N[C@@H]1CC2O[C@@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O)c1cnccn1
3825,66907,10.1016/S0960-894X(00)80473-4,,,,Inhibition of epidermal growth factor receptor (EGFR),O=C(NCc1ccccc1)c1cc2cc(O)c(O)cc2cn1,"6,7-Dihydroxy-isoquinoline-3-carboxylic acid benzylamide",3.1,uM,=,0.4913616938342727,1,O=C(NCc1ccccc1)c1cc2ccccc2cn1
3826,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1cnc(N2CC(C(=O)N(C)C)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"1-(6-((2-((3S,4R)-3-fluoro-4-hydroxy-3-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-4-isopropyl-2,7-naphthyridin-1-yl)-N,N-dimethylazetidine-3-carboxamide",10.0,uM,=,1.0,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
3827,2280919,10.1016/j.ejmech.2019.112025,,,,Inhibition of human EGFR phosphorylation by invitro enzyme assay,COc1cccc(-c2cc(=O)c3ccccc3o2)c1NC(=O)OCCOC(=O)NCCN(C)CCN/N=N/c1ccc2c(Nc3cccc(Cl)c3)ncnc2c1,(E)-2-(((2-((2-(3-(4-((3-chlorophenyl)amino)quinazolin-7-yl)triaz-2-en-1-yl)ethyl)(methyl)amino)ethyl)carbamoyl)oxy)ethyl-(2-methoxy-6-(4-oxo-4H-chromen-2-yl)phenyl)carbamate,0.102,uM,=,-0.9913998282380824,0,O=C(NCCNCCN/N=N/c1ccc2c(Nc3ccccc3)ncnc2c1)OCCOC(=O)Nc1ccccc1-c1cc(=O)c2ccccc2o1
3828,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCCNC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,N-Decyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetamide,2.14,uM,=,0.3304137733491908,1,O=c1cc(-c2ccccc2)oc2ccccc12
3829,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",CCOc1cc2ncnc(Nc3ccc(F)cc3)c2cc1OCC.Cl,"4-(4'-fluoroanilino)-6,7-diethoxyquinazoline hydrochloride",0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ncnc3ccccc23)cc1
3830,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,COc1ccc(NN=C(C#N)C#N)cc1,2-[(4-Methoxy-phenyl)-hydrazono]-malononitrile,600.0,uM,=,2.778151250383644,1,c1ccccc1
3831,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3C)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-7-((3-Methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3-(o-tolyl)-3,4-dihydropyrimido-[4,5-d]pyrimidin-2(1H)-one",0.0076,uM,=,-2.1191864077192086,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
3832,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),N#CCc1c(SSc2[nH]c3ccccc3c2CC#N)[nH]c2ccccc12,[2-(3-Cyanomethyl-1H-indol-2-yldisulfanyl)-1H-indol-3-yl]-acetonitrile,32.0,uM,=,1.505149978319906,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
3833,2088808,10.1016/j.ejmech.2020.112388,,,,Inhibition of N-terminal GST-fused human wild type EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate incubated for 20 mins by Mobility shift assay,O=c1ccc2ccc(Oc3nc(Nc4ccc(N5CCC(N6CCCCC6)CC5)c(F)c4)nc4ccsc34)cc2[nH]1,"7-(2-(4-(1,4'-bipiperidin-1'-yl)-3-fluorophenylamino)thieno[3,2-d]pyrimidin-4-yloxy)quinolin-2(1H)-one",12.43,uM,=,1.0944711286416449,1,O=c1ccc2ccc(Oc3nc(Nc4ccc(N5CCC(N6CCCCC6)CC5)cc4)nc4ccsc34)cc2[nH]1
3834,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(OCCN(C)C)c(Br)c3)c2c1,N-{4-[3-Bromo-4-(2-dimethylamino-ethoxy)-phenylamino]-quinazolin-6-yl}-acrylamide,0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ncnc3ccccc23)cc1
3835,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,Cn1c(SSc2c(C(=O)Nc3ccccc3)c3ccc(O)cc3n2C)c(C(=O)Nc2ccccc2)c2ccc(O)cc21,"2,2'-Dithiobis(1-methyl-6-hydroxy-N-phenyl-1H-indole-3-carboxamide)",44.0,uM,=,1.6434526764861874,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
3836,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(C(F)(F)F)cc3)nn21,"US9447106, 161",0.00066,uM,=,-3.1804560644581312,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1
3837,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,O=C(/C=C/c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cc1)NO,(E)-3-(4-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)phenyl)-N-hydroxyacrylamide,0.018,uM,=,-1.744727494896694,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccccc5)cc34)cc2)cc1
3838,64443,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1cc2c(Nc3cccc(C)c3)ncnc2cn1,"N-(4-m-Tolylamino-pyrido[3,4-d]pyrimidin-6-yl)-acrylamide",0.0004799999999999,uM,=,-3.318758762624413,0,c1ccc(Nc2ncnc3cnccc23)cc1
3839,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COc1cc(C(C#N)=C(C#N)C#N)cc(OC)c1O,"2-(4-hydroxy-3,5-dimethoxyphenyl)ethene-1,1,2-tricarbonitrile",900.0,uM,=,2.9542425094393248,1,c1ccccc1
3840,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,O=C(O)Cc1c(SSSc2[nH]c3ccccc3c2CC(=O)O)[nH]c2ccccc12,"2,2'-Trithiobis (1H-indole-3-acetic acid)",9.3,uM,=,0.9684829485539352,1,c1ccc2[nH]c(SSSc3cc4ccccc4[nH]3)cc2c1
3841,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CN(C)C(=O)O[C@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5R)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl dimethylcarbamate",0.079,uM,=,-1.1023729087095586,0,C(#C[C@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
3842,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2SC)c1,N-(3-((2-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(methylthio)pyrimidin-4-yl)oxy)phenyl)acrylamide,0.2716,uM,=,-0.5660702343915359,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3843,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",Fc1ccc(/C=C/C(=N/Nc2nncc3ccccc23)c2ccccc2)cc1,1-(2-(3-(4-Fluorophenyl)-1-phenylallylidene)hydrazinyl)phthalazine,0.0069,uM,=,-2.161150909262745,0,C(=C/c1ccccc1)\C(=N\Nc1nncc2ccccc12)c1ccccc1
3844,958682,10.1021/jm400463q,,,,Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC(=O)NCC(C)Oc5no[n+]([O-])c5S(=O)(=O)c5ccccc5)CC4)cc3OC)ncc2Cl)c1,"4-((1-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetamido)-propan-2-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide",0.073,uM,=,-1.136677139879544,0,O=C(CN1CCN(c2ccc(Nc3nccc(Oc4ccccc4)n3)cc2)CC1)NCCOc1no[nH+]c1S(=O)(=O)c1ccccc1
3845,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCC(C(=O)NO)CC3)cc2)ncc1Cl,1-(4-(5-chloro-4-(2-(methylcarbamoyl)phenylamino)pyrimidin-2-ylamino)benzyl)-N-hydroxypiperidine-4-carboxamide,0.001095,uM,=,-2.9605858808238628,0,c1ccc(Nc2ccnc(Nc3ccc(CN4CCCCC4)cc3)n2)cc1
3846,63620,10.1021/jm970366v,,,,Inhibition of epidermal growth factor receptor (EGFR) autophosphorylation in A431 cells,Brc1cccc(Nc2ncnc3cc(NCCCN4CCOCC4)ncc23)c1,"N*4*-(3-Bromo-phenyl)-N*7*-(3-morpholin-4-yl-propyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0081,uM,=,-2.0915149811213505,0,c1ccc(Nc2ncnc3cc(NCCCN4CCOCC4)ncc23)cc1
3847,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CNc1cc2ncnc(Nc3cccc(Br)c3)c2cc1N,"N*4*-(3-Bromo-phenyl)-N*7*-methyl-quinazoline-4,6,7-triamine",0.00069,uM,=,-3.161150909262745,0,c1ccc(Nc2ncnc3ccccc23)cc1
3848,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccc(OC)c(O)c3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(3-hydroxy-4-methoxybenzylidene)cyclohexanone",5.3,uM,=,0.724275869600789,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
3849,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Nc1ccc2ncnc(Nc3ccc4cc[nH]c4c3)c2c1,"N4-(1H-indol-6-yl)quinazoline-4,6-diamine",0.1837,uM,=,-0.7358908436941917,0,c1ccc2c(Nc3ccc4cc[nH]c4c3)ncnc2c1
3850,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,Nc1cccc(Oc2cc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncn2)c1,4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-aminophenoxy)pyrimidine,0.473,uM,=,-0.3251388592621884,0,c1ccc(COc2ccc(Nc3cc(Oc4ccccc4)ncn3)cc2)cc1
3851,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,C#Cc1cccc(Nc2nc(C)nc3oc(C)cc23)c1,"N-(3-Ethynylphenyl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine",0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3occc23)cc1
3852,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2ncc(I)c(Nc3ccccc3P(C)(C)=O)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(dimethylphosphoryl)phenyl)amino)-5-iodopyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.054,uM,=,-1.2676062401770316,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
3853,2283232,10.1039/d2md00139j,,,,Inhibition of human recombinant His-tagged EGFR expressed in baculovirus using poly-Gluo-Tyr as a substrate measured after 24 hrs by western blot analysis,COc1cccc(-c2cn(-c3ccc(CCN4CCC(O)CC4)cc3)c3ncnc(N)c23)c1,"1-(4-(4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenethyl)piperidin-4-ol",0.15,uM,=,-0.8239087409443188,0,c1ccc(-c2cn(-c3ccc(CCN4CCCCC4)cc3)c3ncncc23)cc1
3854,1338416,10.1016/j.ejmech.2014.01.018,,,,Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1nn(-c2ccc(Cl)cc2)c(Cl)c1C1C(C#N)=C(N)N(c2cccnc2)C2=C1C(=O)CCC2,"2-Amino-4-(5-chloro-1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile",4.15,uM,=,0.6180480967120927,1,O=C1CCCC2=C1C(c1cnn(-c3ccccc3)c1)C=CN2c1cccnc1
3855,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,COc1ccc(CNc2cc3c(Nc4cccc(Br)c4)ncnc3cn2)cc1,"N*4*-(3-Bromo-phenyl)-N*6*-(4-methoxy-benzyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0023,uM,=,-2.638272163982407,0,c1ccc(CNc2cc3c(Nc4ccccc4)ncnc3cn2)cc1
3856,63780,10.1016/j.bmcl.2004.01.034,,,,Inhibition of epidermal growth factor receptor kinase autophosphorylation,CN(C)C/C=C/C(=O)Nc1cnc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,"(E)-4-Dimethylamino-but-2-enoic acid [5-(3-bromo-phenylamino)-6-cyano-[1,8]naphthyridin-3-yl]-amide",4.1286000000000005,uM,=,0.6158028082300362,1,c1ccc(Nc2ccnc3ncccc23)cc1
3857,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"US9447106, 27b (peak 2)",0.006,uM,=,-2.2218487496163566,0,c1ccc(Oc2ccc(-c3cc4n(n3)[C@H](C3CCNCC3)CCN4)cc2)cc1
3858,2068935,10.1021/acs.jmedchem.0c01647,,,,Inhibition of EGFR (unknown origin),CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.09,uM,=,-1.0457574905606752,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
3859,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCN(C)CC1C(N)=O,1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)-4-methylpiperazine-2-carboxamide,0.08,uM,=,-1.0969100130080565,0,c1ccc(Nc2ncnc3ccc(CN4CCNCC4)cc23)cc1
3860,63780,10.1016/j.bmcl.2004.01.034,,,,Inhibition of epidermal growth factor receptor kinase autophosphorylation,C=CC(=O)Nc1cnc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,"N-[5-(3-Bromo-phenylamino)-6-cyano-[1,8]naphthyridin-3-yl]-acrylamide",0.9757,uM,=,-0.0106836950100485,0,c1ccc(Nc2ccnc3ncccc23)cc1
3861,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O,"5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol",0.437,uM,=,-0.3595185630295782,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
3862,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CNc1ccc2c(Nc3cccc(Br)c3)ncnc2c1,"N*4*-(3-Bromo-phenyl)-N*7*-methyl-quinazoline-4,7-diamine",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccccc23)cc1
3863,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Nc1ccc2ncnc(Nc3ccc4[nH]cc(Br)c4c3)c2c1,"N4-(3-bromo-1H-indol-5-yl)quinazoline-4,6-diamine",0.00074,uM,=,-3.130768280269024,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1
3864,2076853,10.1039/d0md00436g,,,,Inhibition of human EGFR TK domain expressed in Escherichia coli BL21 (DE3) pLysS using poly-Glu-Tyr (51 to 68 residues) as substrate incubated for 1 hr by ADP-Glo assay,CNc1nc(C)c(C(=O)/C=C/c2nccs2)s1,(E)-1-(4-methyl-2-(methylamino)thiazol-5-yl)-3-(thiazol-2-yl)prop-2-en-1-one,0.2556,uM,=,-0.5924391505136375,0,O=C(/C=C/c1nccs1)c1cncs1
3865,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21,"2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol",4.4,uM,=,0.6434526764861874,1,c1ccc2[nH]c(-c3n[nH]c4ncncc34)cc2c1
3866,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21,"1-methyl-3-(quinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",34.0,uM,=,1.5314789170422551,1,c1cnc2ccc(-c3n[nH]c4ncncc34)cc2c1
3867,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Nc1ccc2ncnc(Nc3ccc4c(ccn4Cc4cccc(Cl)c4)c3)c2c1,"N4-(1-(3-chlorobenzyl)-1H-indol-5-yl)quinazoline-4,6-diamine",0.00838,uM,=,-2.076755981369724,0,c1ccc(Cn2ccc3cc(Nc4ncnc5ccccc45)ccc32)cc1
3868,2018691,10.1016/j.bmc.2020.115674,,,,Inhibition of EGFR-TK (unknown origin) relative to control,CC(C)(C)c1cc(NC2=NC(=O)CS2)no1,2-((5-(t-Butyl)isoxazol-3-yl)amino)thiazol-4(5H)-one,0.15,uM,=,-0.8239087409443188,0,O=C1CSC(Nc2ccon2)=N1
3869,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,c1ccc(Nc2nc[nH]c3nnc(Nc4ccccc4)c2-3)cc1,"N*3*,N*4*-Diphenyl-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.058,uM,=,-1.2365720064370629,0,c1ccc(Nc2nc[nH]c3nnc(Nc4ccccc4)c2-3)cc1
3870,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C=C=CCCCOc1cc2c(Nc3cccc(Cl)c3)ncnc2cc1O,"4-(3'-Chlorophenylamino)-6-(hexa-4,5-dienyloxy)-7-methoxyquinazoline",0.0285,uM,=,-1.5451551399914898,0,c1ccc(Nc2ncnc3ccccc23)cc1
3871,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)C(C)C5)c(C)c4)nc32)C1,"7-((4-((S)-3,4-Dimethylpiperazin-1-yl)-3-methylphenyl)-amino)-3-(2-fluoro-5-methoxyphenyl)-1-((S)-1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.715,uM,=,-0.1456939581989194,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
3872,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccccc3OC)ncc2C(F)(F)F)c1,"US9238629, I-1",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
3873,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCOC(=O)c1cn2ncnc(Nc3cccc(Br)c3)c2c1CC,"4-(3-Bromo-phenylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester",0.06,uM,=,-1.2218487496163564,0,c1ccc(Nc2ncnn3cccc23)cc1
3874,2080995,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R/T790M (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(CCC(=O)NO)nn1,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-((1-(3-(hydroxyamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.0023,uM,=,-2.638272163982407,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
3875,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4cccc(Cl)c4)c3cc2N1CCCN1CCCCC1,"4-((3-chlorophenyl)amino)-6-(3-(piperidin-1-yl)propyl)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.1159,uM,=,-0.935916564036404,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCCCC1
3876,683876,10.1021/jm1007566,,,,Inhibition of EGFR,CN1C[C@@H]2C[C@H]1CN2c1cc(F)c(-c2ccnc3c(-c4cccc5[nH]ncc45)c(-c4ccncc4)nn23)c(F)c1,"7-(2,6-difluoro-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)-3-(1H-indazol-4-yl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine",0.173,uM,=,-0.7619538968712046,0,c1cc(-c2c(-c3ccncc3)nn3c(-c4ccc(N5C[C@@H]6C[C@H]5CN6)cc4)ccnc23)c2cn[nH]c2c1
3877,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2ncc(I)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(N,N-dimethylsulfamoyl)phenyl)amino)-5-iodopyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide",0.244,uM,=,-0.6126101736612706,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
3878,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCn1ccnc1[N+](=O)[O-],N-(3-Chloro-4-fluorophenyl)-6-methoxy-7-(3-(2-nitro-1H-imidazol-1-yl)propoxy)quinazolin-4-amine,0.00077,uM,=,-3.113509274827518,0,c1ccc(Nc2ncnc3cc(OCCCn4ccnc4)ccc23)cc1
3879,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3ncccc23)c1,"(3-Bromo-phenyl)-pyrido[2,3-d]pyrimidin-4-yl-amine",0.688,uM,=,-0.1624115617644887,0,c1ccc(Nc2ncnc3ncccc23)cc1
3880,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Cc1cccc(Nc2[nH]cnc3nnc(Nc4cccc(Cl)c4)c2-3)c1,"N*3*-(3-Chloro-phenyl)-N*4*-m-tolyl-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.13,uM,=,-0.8860566476931633,0,c1ccc(Nc2nnc3nc[nH]c(Nc4ccccc4)c2-3)cc1
3881,989154,10.1016/j.bmc.2013.09.027,,,,Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,1.1,uM,=,0.041392685158225,1,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
3882,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,O=C(C#CCCN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Br)c3)ncnc2cn1,"N-[4-[(3-bromo-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-5-(4-morpholinyl)-2-pentynamide",0.0015,uM,=,-2.8239087409443187,0,O=C(C#CCCN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
3883,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,CS(=O)(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1,N-(3-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)phenyl)methanesulfonamide,0.11,uM,=,-0.958607314841775,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
3884,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)buta-2,3-dienamide",0.0278999999999999,uM,=,-1.5543957967264026,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3885,2270862,10.1016/j.ejmech.2020.112640,,,,Inhibition of human EGFR incubated for 1 hrs in presence of ATP by ELISA assay,Cc1ccccc1NC(=O)CSc1nc2cc3ccccc3cc2c(=O)n1-c1ccc(S(N)(=O)=O)cc1,"2-((4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydrobenzo[g]quinazolin-2-yl)thio)-N-(o-tolyl)acetamide",0.012,uM,=,-1.9208187539523751,0,O=C(CSc1nc2cc3ccccc3cc2c(=O)n1-c1ccccc1)Nc1ccccc1
3886,67206,10.1021/jm010496a,,,,Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase,CCOc1cc2ncnc(Nc3cccc(-c4cncnc4)c3)c2cc1OCC,"(6,7-Diethoxy-quinazolin-4-yl)-(3-pyrimidin-5-yl-phenyl)-amine",1.1,uM,=,0.041392685158225,1,c1cc(Nc2ncnc3ccccc23)cc(-c2cncnc2)c1
3887,1662113,10.1016/j.ejmech.2017.02.061,,,,Inhibition of EGFR (unknown origin) measured after 40 mins by Kinase Glo luminescence assay,CC(C)(C)OC(=O)NCC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,Tert-butyl (2-((4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)amino)-2-oxoethyl)carbamate,0.017,uM,=,-1.769551078621726,0,c1ccc(Nc2ncnc3ccccc23)cc1
3888,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,NS(=O)(=O)c1ccc(Nc2nc3ncnc(Nc4ccc(N5CCOCC5)cc4)c3s2)cc1,"4-(7-(4-morpholinophenylamino)thiazolo[4,5-d]pyrimidin-2-ylamino)benzenesulfonamide",17.9,uM,=,1.252853030979893,1,c1ccc(Nc2nc3ncnc(Nc4ccc(N5CCOCC5)cc4)c3s2)cc1
3889,2213946,10.1016/j.ejmech.2021.113963,,,,Inhibition of EGFR (unknown origin),CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)cc3)c2cc1NC(=O)/C=C/c1cccnc1,(E)-N-[4-(4-benzyloxyanilino)-3-cyano-7-ethoxy-6-quinolyl]-3-(3-pyridyl)prop-2-enamide,0.597,uM,=,-0.2240256688706309,0,O=C(/C=C/c1cccnc1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
3890,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1ccccc1Cl,"N-(2-Chloro-phenyl)-2-cyano-3-(3,4-dihydroxy-phenyl)-acrylamide",2.1,uM,=,0.3222192947339193,1,O=C(C=Cc1ccccc1)Nc1ccccc1
3891,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,C=C(Cl)C(=O)Nc1cc(Nc2nc(C)cc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,2-chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-methyl-6-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,0.083,uM,=,-1.080921907623926,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3892,763211,10.1021/np200196j,,,,Inhibition of EGFR-induced HIF1alpha activation in human HeLa cells preincubated for 1 hr prior to EGF stimulation by luciferase reporter gene assay,C/C=C(\C)[C@H](O)[C@H](C)/C=C(C)/C=C/CC(C)/C=C/c1oc(OC)c(C)c(=O)c1C,"2-((1E,5E,7E,9R,10R,11E)-10-hydroxy-3,7,9,11-tetramethyltrideca-1,5,7,11-tetraenyl)-6-methoxy-3,5-dimethyl-4H-pyran-4-one",0.47,uM,=,-0.3279021420642826,0,O=c1ccocc1
3893,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3ccc(CO)cc3F)cc12)c1ccccc1,"(R)-(3-Fluoro-4-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)phenyl)methanol",0.013,uM,=,-1.8860566476931635,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
3894,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(S(N)(=O)=O)cc3)c2c1,N-(4-(4-sulfamoylphenylamino)quinazolin-6-yl)acrylamide,76.5,uM,=,1.8836614351536176,1,c1ccc(Nc2ncnc3ccccc23)cc1
3895,1515019,10.1016/j.ejmech.2015.07.030,,,,Inhibition of epidermal growth factor receptor kinase (unknown origin) using [33P]-ATP after 20 to 30 mins by radiometric assay,NC(=O)c1cnc2ccc(C(=O)/C=C/c3ccc(Cl)cc3)cc2c1Nc1ccc(Br)cc1,4-(4-Bromophenylamino)-6-(3-(4-chlorophenyl)acryloyl)quinoline-3-carboxamide,4.824,uM,=,0.6834072991320949,1,O=C(/C=C/c1ccccc1)c1ccc2nccc(Nc3ccccc3)c2c1
3896,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,COc1cccc(-c2cn(C3CCC3)c3ncnc(N)c23)c1,"7-Cyclobutyl-5-(3-methoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",0.45,uM,=,-0.3467874862246563,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1
3897,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3OC(F)F)ncc2Cl)c1,"US8975249, I-36",0.02,uM,=,-1.6989700043360187,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
3898,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,CCC/C=C\C(=O)Nc1cc(Nc2ncc(C#N)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,(Z)-N-(5-((5-cyano-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)hex-2-enamide,0.377,uM,=,-0.4236586497942071,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3899,2268716,10.1016/j.ejmech.2021.113768,,,,Inhibition of EGFR (unknown origin) phosphorylation using kit-tyr4 peptide as substrate incubated for 1 hr in presence of ATP by UV-Vis spectrophotometer,COc1ccc(CNc2nc3ccccc3c(NCc3ccc(OC)cc3)c2[N+](=O)[O-])cc1,"N2,N4-bis(4-methoxybenzyl)-3-nitroquinoline-2,4-diamine",0.22,uM,=,-0.6575773191777937,0,c1ccc(CNc2cc(NCc3ccccc3)c3ccccc3n2)cc1
3900,64443,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Br)c3)c2n1,"N-[4-(3-Bromo-4-fluoro-phenylamino)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3cccnc23)cc1
3901,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",O=C(O)c1ccc(Nc2nncc3ccccc23)cc1,4-(Phthalazin-1-ylamino)benzoic acid,0.0062,uM,=,-2.207608310501746,0,c1ccc(Nc2nncc3ccccc23)cc1
3902,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,"4-(2-Amino-ethyl)-benzene-1,2-diol",900.0,uM,=,2.9542425094393248,1,c1ccccc1
3903,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1,GNF-Pf-5343,0.002,uM,=,-2.6989700043360187,0,c1ccc(CNc2ncnc3[nH]c(-c4ccc(CN5CCNCC5)cc4)cc23)cc1
3904,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,COc1cc(NC(=O)/C=C/CN2CCOCC2)cc2c(Nc3cccc(Br)c3)ccnc12,N-(4-(3-bromophenylamino)-8-methoxyquinolin-6-yl)-4-morpholinobut-2-enamide,5.39,uM,=,0.7315887651867387,1,O=C(/C=C/CN1CCOCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
3905,1935778,10.1021/acs.jmedchem.9b00102,,,,Inhibition of wild type EGFR (unknown origin) by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3cn(C)c4ccccc34)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(1-methyl-1H-indol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.035,uM,=,-1.4559319556497243,0,c1ccc2c(-c3nn([C@@H]4CCCNC4)c4ncncc34)c[nH]c2c1
3906,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OCC1CCN(C)CC1,N-(3-chloro-2-fluorophenyl)-7-methoxy-6-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccc(OCC4CCNCC4)cc23)cc1
3907,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,OCc1nc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cs1,(4-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)thiazol-2-yl)methanol,0.076,uM,=,-1.1191864077192086,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1cscn1
3908,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc(OC)cc4)c3cc21,"Ethyl 4-(8-(4-methoxyphenylamino)-2-oxooxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",7.5,uM,=,0.8750612633917001,1,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
3909,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0144,uM,=,-1.8416375079047504,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
3910,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc5sncc45)c(Cl)c3)c21,"N-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]-amino}-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl]acetamide",0.0029,uM,=,-2.537602002101044,0,c1cc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)c2cnsc2c1
3911,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,C[C@@H](c1cccc(F)c1)n1ncc2cc(Nc3ncnn4ccc(COC[C@@H]5CNCCO5)c34)ccc21,"N-(1-((S)-1-(3-fluorophenyl)ethyl)-1H-indazol-5-yl)-5-(((S)-morpholin-2-ylmethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.4,uM,=,-0.3979400086720376,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)cc1
3912,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{4-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-butyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",4.3,uM,=,0.6334684555795865,1,O=C(C=Cc1ccccc1)NCCCCNC(=O)/C=C/c1ccccc1
3913,1641865,,,,,"Enzyme Assay: BT474 Cell Line: 1. 5Ã103 cells per well in 100 Î¼l of medium were seeded in 96-well plate, here the medium contained 5% FBS2. 24 hours later, 100 Î¼l fresh medium was added with various concentrations of compounds into each well, while the medium here was free of FBS.3. After the cells were treated with compounds for 72 hours, 20 Î¼l MTT (5 mg/ml) was added into each well, and then the assay plate was incubated at 37Â° C. for 4 more hours.4. The assay plate was centrifuged at 800 g for 10 min. The medium was aspirated, 150 Î¼l DMSO was added into each well. The plate was gently shaken for 10 min.5. The absorbance at 570 nm was measured on the plate reader.6. IR %=(WCâWT)/WCÃ100%.",C#Cc1cccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(NC(=O)/C=C/CN(C)C)cc23)c1,"(S,E)-4-(Dimethylamino)-N-(4-(3-ethynylphenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)but-2-enamide",0.057,uM,=,-1.2441251443275083,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
3914,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCCN1CC[C@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0528,uM,=,-1.2773660774661877,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
3915,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,BRIGATINIB,0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
3916,676221,10.1021/jm100607r,,,,Inhibition of EGFR,C=CS(=O)(=O)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,"(2S)-2-Phenyl-2-[7-(vinylsulfonyl)-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4-yl]aminoethan-1-ol",0.091,uM,=,-1.0409586076789064,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1
3917,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,480.0,uM,=,2.681241237375587,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3918,2218631,10.1021/acs.jmedchem.1c00302,,,,Inhibition of EGFR (unknown origin),O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",0.6,uM,=,-0.2218487496163563,0,O=c1c(-c2ccccc2)coc2ccccc12
3919,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,NC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccnc5)c4)c23)CC1,"5-((4-aminopiperidin-1-yl)methyl)-N-(1-(pyridin-3-ylmethyl)-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.19,uM,=,-0.721246399047171,0,c1cncc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)c1
3920,66596,10.1016/j.bmcl.2004.04.080,,,,Concentration required to inhibit autophosphorylation of cytoplasmic domain of epidermal growth factor receptor (EGFR),COC[C@@H]1CCCN1CC#CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,4-(2-Methoxymethyl-pyrrolidin-1-yl)-but-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.15,uM,=,-0.8239087409443188,0,O=C(C#CCN1CCCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
3921,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,2.48,uM,=,0.3944516808262163,1,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
3922,520709,10.1016/j.ejmech.2008.04.012,,,,Inhibition of EGFR,Nc1ncnc2c1ncn2CC(=O)c1ccccn1,2-(6-Amino-9H-purine-9-yl)-1-(pyridine-2-yl)ethanone,89.0,uM,=,1.9493900066449128,1,O=C(Cn1cnc2cncnc21)c1ccccn1
3923,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCCCCCCCCNC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,N-Hexadecyl 2-(5-hydroxy-4-oxo-2-phenyl-4Hchromen-7-yloxy)acetamide,0.035,uM,=,-1.4559319556497243,0,O=c1cc(-c2ccccc2)oc2ccccc12
3924,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,{4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-phenyl-amine,0.024,uM,=,-1.619788758288394,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
3925,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1ccc(C(=O)Nc2ccc(OCc3ccccn3)c(Cl)c2)cc1NC(=O)c1ccc(CN2CCN(C)CC2)cc1,N-(3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)-4-ethoxy-3-(4-((4-methylpiperazin-1-yl)methyl)benzamido)benzamide,3.5,uM,=,0.5440680443502757,1,O=C(Nc1cccc(C(=O)Nc2ccc(OCc3ccccn3)cc2)c1)c1ccc(CN2CCNCC2)cc1
3926,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(F)cc3Cl)ncnc2cc1OCCOCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-{2-[2-({4-[(2-Chloro-4-fluorophenyl)amino]-6-methoxyquinazolin-7-yl}oxy)ethoxy]ethyl}-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.0208299999999999,uM,=,-1.6813107300522545,0,O=C(Cn1cncn1)NCCOCCOc1ccc2c(Nc3ccccc3)ncnc2c1
3927,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,COc1cccc(-n2cc(NC(=O)c3ccc(NS(=O)(=O)c4ccccc4)cc3)cn2)c1,N-(1-(3-Methoxyphenyl)-1H-pyrazol-4-yl)-4-(phenylsulfonamido)benzamide,24.13,uM,=,1.382557321908786,1,O=C(Nc1cnn(-c2ccccc2)c1)c1ccc(NS(=O)(=O)c2ccccc2)cc1
3928,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1OC,"1-cyclopentyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",3.3,uM,=,0.5185139398778875,1,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
3929,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccc(Cl)cc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(4-chloro-benzyloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.051,uM,=,-1.2924298239020635,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
3930,1924071,10.1021/acs.jmedchem.6b00403,,,,"Inhibition of wild type EGFR kinase domain (unknown origin) expressed using baculovirus expression system incubated for 1 hr using Poly(Glu,Tyr) 4:1 by ELISA method",C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N5CCC(N6CCN(C)CC6)CC5)cc4OC)nc32)c1,"N-(3-(5-isopropyl-2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenylamino)-6,7-dioxo-6,7-dihydropteridin-8(5H)-yl)phenyl)acrylamide",0.028,uM,=,-1.5528419686577808,0,O=c1[nH]c2cnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)nc2n(-c2ccccc2)c1=O
3931,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CNC(=O)C1CN(c2ncc(C(C)C)c3cc(Nc4ccnc(N5CC[C@@H](O)[C@@](C)(F)C5)n4)ncc23)C1,"1-(6-((2-((3S,4R)-3-fluoro-4-hydroxy-3-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-4-isopropyl-2,7-naphthyridin-1-yl)-N-methylazetidine-3-carboxamide",25.0,uM,=,1.3979400086720375,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
3932,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)cc1)C(N)=O,2-Cyano-3-(4-hydroxy-phenyl)-acrylamide,800.0,uM,=,2.903089986991944,1,c1ccccc1
3933,2153740,10.1021/acsmedchemlett.1c00555,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3P(C)(C)=O)n2)cnc1N1CCC(N2CCN(C)CC2)CC1,(2-((5-Chloro-2-((5-methyl-6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)pyridin-3-yl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide,0.3376,uM,=,-0.4715975620463826,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)nc3)n2)cc1
3934,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)CO,N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-2-hydroxyacetamide,0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ncnc3ccccc23)cc1
3935,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccc(OCCN4CCOCC4)cc23)cc1
3936,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccc(F)cc3)CC2c2ccc(Cl)cc2)=N1,"2-(5-(4-Chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",10.92,uM,=,1.0382226383687183,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
3937,63773,10.1021/jm9508651,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 human epidermoid carcinoma cells,CNc1ccc2c(Nc3cccc(Br)c3)ncnc2n1,"N*4*-(3-Bromo-phenyl)-N*7*-methyl-pyrido[2,3-d]pyrimidine-4,7-diamine",0.552,uM,=,-0.2580609222708011,0,c1ccc(Nc2ncnc3ncccc23)cc1
3938,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc3[nH]ccc23)c2c(N)ncnc21,"3-(1H-indol-4-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",4.6,uM,=,0.6627578316815741,1,c1cc(-c2n[nH]c3ncncc23)c2cc[nH]c2c1
3939,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCCl,N-(2-((2-chloroethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,1.982,uM,=,0.2971036501492565,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3940,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{5-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-pentyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",9.0,uM,=,0.9542425094393248,1,O=C(C=Cc1ccccc1)NCCCCCNC(=O)/C=C/c1ccccc1
3941,1706661,10.1016/j.bmc.2017.06.037,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",COc1cc2c(Oc3ccc(NC(=O)c4nc5ccccc5n(-c5ccc(F)cc5)c4=O)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,"N-(3-fluoro-4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-4-(4-fluorophenyl)-3-oxo-3,4-dihydroquinoxaline-2-carboxamide",0.98083,uM,=,-0.0084062591437648,0,O=C(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1nc2ccccc2n(-c2ccccc2)c1=O
3942,86514,10.1021/jm00110a022,,,,Inhibition of HER14 (human EGFR overexpressing) cell proliferation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)N1CCc2ccccc21,"2-(2,3-Dihydro-indole-1-carbonyl)-3-(3,4-dihydroxy-phenyl)-acrylonitrile",25.0,uM,=,1.3979400086720375,1,O=C(C=Cc1ccccc1)N1CCc2ccccc21
3943,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCOC(=O)Nc1cc(Nc2ncnc3cc(OC)c(OC)cc23)ccc1C,"ethyl 5-(6,7-dimethoxyquinazolin-4-ylamino)-2-methylphenylcarbamate",5.0,uM,=,0.6989700043360189,1,c1ccc(Nc2ncnc3ccccc23)cc1
3944,624184,10.1021/jm901877j,,,,Inhibition of wild type EGFR by HTRF assay,CN(C)CCCC(=O)Nc1ccc2nccc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromophenylamino)quinolin-6-yl)-4-(dimethylamino)-butanamide,0.0017,uM,=,-2.7695510786217263,0,c1ccc(Nc2ccnc3ccccc23)cc1
3945,86514,10.1021/jm00110a022,,,,Inhibition of HER14 (human EGFR overexpressing) cell proliferation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1ccccc1Cl,"N-(2-Chloro-phenyl)-2-cyano-3-(3,4-dihydroxy-phenyl)-acrylamide",35.0,uM,=,1.5440680443502757,1,O=C(C=Cc1ccccc1)Nc1ccccc1
3946,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1cccs1,"3-(3,4-Dihydroxy-phenyl)-2-(thiophene-2-carbonyl)-acrylonitrile",31.0,uM,=,1.4913616938342726,1,O=C(C=Cc1ccccc1)c1cccs1
3947,66577,10.1016/j.bmcl.2004.03.106,,,,"Inhibition of human Epidermal growth factor receptor, HER-1",OC1(c2nc(-c3ccc(F)cc3)c(-c3ccnc(NC4CCCCC4)c3)o2)CCNCC1,4-[5-(2-Cyclohexylamino-pyridin-4-yl)-4-(4-fluoro-phenyl)-oxazol-2-yl]-piperidin-4-ol,2.0,uM,=,0.3010299956639812,1,c1ccc(-c2nc(C3CCNCC3)oc2-c2ccnc(NC3CCCCC3)c2)cc1
3948,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1cnc(N2CC[C@@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-((S)-2-methylazetidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",10.0,uM,=,1.0,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
3949,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(=O)Nc3ccc(C(=O)O)cc3)c3ccccc3n2C)c(C(=O)Nc2ccc(C(=O)O)cc2)c2ccccc21,4-{2-[3-(4-carboxyphenylcarbamoyl)-1-methyl-1H-2-indolyldisulfanyl]-1-methyl-1H-3-indolylcarboxamido}benzoic acid H2O,16.9,uM,=,1.2278867046136734,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
3950,86512,10.1021/jm00110a022,,,,Inhibition of HER14 (human EGFR overexpressing) cell proliferation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCc1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-(4-phenyl-butyl)-acrylamide",3.0,uM,=,0.4771212547196624,1,O=C(C=Cc1ccccc1)NCCCCc1ccccc1
3951,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,NC1CCN(Cc2ccn3ncnc(Nc4ccc(OCc5cccc[n+]5[O-])c(Cl)c4)c23)CC1,"[5-(4-amino-piperidin-1-ylmethyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-[3-chloro-4-(1-oxy-pyridin-2-ylmethoxy)-phenyl]-amine",0.07,uM,=,-1.154901959985743,0,c1ccc(COc2ccc(Nc3ncnn4ccc(CN5CCCCC5)c34)cc2)[nH+]c1
3952,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,O=C(NO)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)s1,5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)-N-hydroxythiophene-2-carboxamide,0.0022,uM,=,-2.657577319177794,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5cccs5)cc34)cc2)cc1
3953,1798921,10.1016/j.ejmech.2017.07.033,,,,Inhibition of 6x-His-tagged human EGFR cytoplasmic domain (645 to 1186 amino acids) assessed as reduction in autophosphorylation pre-incubated for 10 mins and measured after 1 hr by DELFIA/time-resolved fluorometry,O=C1CSC(N2N=C(c3ccncc3)CC2c2ccc(Br)cc2)=N1,"2-(5-(4-bromophenyl)-3-(pyridin-4-yl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",0.009,uM,=,-2.0457574905606752,0,O=C1CSC(N2N=C(c3ccncc3)CC2c2ccccc2)=N1
3954,1869715,10.1016/j.bmc.2019.02.012,,,,Inhibition of His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometry,COc1cccc(/C=C/C(=O)c2ccc(NC(=O)c3cc4cc5cc(OC)ccc5nc4s3)cc2)c1,"(E)-6-Methoxy-N-(4-(3-(3-methoxyphenyl)acryloyl)phenyl)thieno[2,3-b]quinoline-2-carboxamide",2.8,uM,=,0.4471580313422192,1,O=C(/C=C/c1ccccc1)c1ccc(NC(=O)c2cc3cc4ccccc4nc3s2)cc1
3955,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,C#Cc1cncnc1Nc1ccc(OCc2cccc(F)c2)c(Cl)c1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-ethynylpyrimidin-4-amine,0.085,uM,=,-1.0705810742857071,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
3956,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,COC(=O)c1ccc(CNC(=O)c2c(SSc3c(C(=O)NCc4ccc(C(=O)OC)cc4)c4ccccc4n3C)n(C)c3ccccc23)cc1,methyl 4-{1-methyl-2-[1-methyl-3-(4-methyloxycarbonylbenzylcarbamoyl)-1H-2-indolyldisulfanyl]-1H-3-indolylcarboxamidomethyl}benzoate0.5 H2O,13.0,uM,=,1.1139433523068367,1,O=C(NCc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)NCc2ccccc2)[nH]c2ccccc12
3957,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCC/C(=C\c3cccc(Cl)c3)C2=O)cc(OC)c1,"(2E,6E)-2-(3-Chlorobenzylidene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",2.27,uM,=,0.3560258571931227,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
3958,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCOc1cc2ncnc(/C=C/c3ccccc3)c2cc1OCC,"6,7-diethoxy-4-styrylquinazoline",0.015,uM,=,-1.8239087409443189,0,C(=C/c1ncnc2ccccc12)\c1ccccc1
3959,2069689,10.1016/j.bmc.2021.116039,,,,Inhibition of recombinant wild type EGFR (696 to C terminal end) (unknown origin) using poly (Glu-Tyr) as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by ELISA,COc1ccc(-c2c3c4cc(OC)c(OC)cc4[nH]c(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O,"11-Hydroxy-14-(3-hydroxy-4-methoxyphenyl)-2,3,12-trimethoxybenzo[7,8]indolizino[3,2-c]quinolin-6(5H)-one",0.259,uM,=,-0.5867002359187482,0,O=c1[nH]c2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
3960,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cc1OC,N-{4-[(1-Benzyl-1H-indazol-5-yl)amino]-7-methoxy-6-quinazolinyl}propanamide,0.017,uM,=,-1.769551078621726,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccccc45)ccc32)cc1
3961,78511,10.1016/j.bmcl.2003.10.010,,,,Inhibition of EGFR overexpressing HN5 (head/neck carcinoma) cell line proliferation,C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1,(3-Ethynyl-phenyl)-{6-[4-(methanesulfonylmethyl-amino)-butoxy]-quinazolin-4-yl}-amine,0.045,uM,=,-1.3467874862246565,0,c1ccc(Nc2ncnc3ccccc23)cc1
3962,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(N)c2)n1,4-(3-Aminophenoxy)-5-chloro-N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)pyrimidin-2-amine,6.68,uM,=,0.8247764624755457,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3963,2192552,10.1021/acs.jmedchem.1c01170,,,,Inhibition of EGFR (unknown origin) using peptide substrate in presence of ATP by caliper electrophoresis method,CN1CCN(C(C)(C)/C=C(\C#N)C(=O)N2CCC[C@@H](n3nc(-c4ccc(Oc5ccccc5)cc4F)c4c(N)ncnc43)C2)CC1,"(R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-methylpiperazin-1-yl)pent-2-enenitrile",0.98,uM,=,-0.0087739243075051,0,O=C(C=CCN1CCNCC1)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3cncnc32)C1
3964,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CC[N+](C)(C)[C@H]1C[C@@H]2O[C@](C)([C@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"ethyl[3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl]dimethylammonium",0.043,uM,=,-1.3665315444204136,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
3965,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1,(4-benzyloxy-3-fluoro-phenyl)-{6-[5-(1-oxo-1lambda*4*-thiomorpholin-4-ylmethyl)-furan-2-yl]-quinazolin-4-yl}-amine,0.016,uM,=,-1.7958800173440752,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CN6CC[SH+]CC6)o5)cc34)cc2)cc1
3966,1869224,10.1021/acs.jmedchem.8b01391,,,,Inhibition of wild type EGFR (unknown origin) by bioluminescent ADP-glo kinase assay,COc1cc(Nc2ncnc3cc(-c4ccc(Cl)cc4)sc23)cc(OC)c1OC,"6-(4-Chlorophenyl)-N-(3,4,5-trimethoxyphenyl)thieno[3,2-d]-pyrimidin-4-amine",0.273,uM,=,-0.563837352959244,0,c1ccc(Nc2ncnc3cc(-c4ccccc4)sc23)cc1
3967,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN[C@H](C)C(N)=O,(R)-2-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methylamino)propanamide,0.15,uM,=,-0.8239087409443188,0,c1ccc(Nc2ncnc3ccccc23)cc1
3968,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4cccc(F)c4)c3cc2N1CCCN1CCOCC1,"(4-(3-fluorophenyl)amino)-6-(3-morpholinopropyl)-6H-[1,4]oxazino[3,2-g]quinazoline-7(8H)-one",0.2450999999999999,uM,=,-0.6106566887479221,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
3969,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C(C)C)cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-3-methylbut-2-enamide,1.282,uM,=,0.1078880251827986,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3970,2241031,10.1021/acs.jmedchem.1c00848,,,,Inhibition of wild type human EGFR expressed in Sf9 insect cells in presence of ATP measured by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.017,uM,=,-1.769551078621726,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
3971,676221,10.1021/jm100607r,,,,Inhibition of EGFR,CC#CC(=O)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,"1-(4-[(1S)-2-Hydroxy-1-phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-butyn-1-one",1.27,uM,=,0.1038037209559568,1,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1
3972,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,CC(C)(O)C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc5sncc45)c(Cl)c3)c21.CS(=O)(=O)O,"N-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]-amino}-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl]-2-hydroxy-2-methylpropanamide Methanesulfonate",0.007,uM,=,-2.154901959985743,0,c1cc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)c2cnsc2c1
3973,305999,10.1016/j.bmcl.2004.08.007,,,,Inhibitory concentration against Epidermal growth factor receptor tyrosine kinase activity,COc1cc2ncnc(Nc3ccc(Cl)c(NC(=O)c4cccc(N(C)C)c4)c3)c2cc1OC,"N-[2-Chloro-5-(6,7-dimethoxy-quinazolin-4-ylamino)-phenyl]-3-dimethylamino-benzamide",1.0,uM,=,0.0,0,O=C(Nc1cccc(Nc2ncnc3ccccc23)c1)c1ccccc1
3974,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Clc1cccc(Nc2[nH]cnc3nnc(-c4ccccc4)c2-3)c1,"(3-Chloro-phenyl)-(3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine",0.019,uM,=,-1.7212463990471711,0,c1ccc(Nc2[nH]cnc3nnc(-c4ccccc4)c2-3)cc1
3975,305378,10.1021/jm049892u,,,,In vitro inhibition of Epidermal growth factor receptor,Cc1ccc(Nc2ncnn3c(C)ccc23)cc1O,"2-Methyl-5-(7-methyl-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-phenol",29.4,uM,=,1.4683473304121573,1,c1ccc(Nc2ncnn3cccc23)cc1
3976,519199,10.1016/j.ejmech.2007.09.018,,,,Inhibition of human EGFR tyrosine kinase activity,COc1cc2ncnc(-c3c[nH]c4ccc(Br)cc34)c2cc1OC,"4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline",0.131,uM,=,-0.8827287043442358,0,c1ccc2c(-c3c[nH]c4ccccc34)ncnc2c1
3977,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"US9447106, 27",0.0012,uM,=,-2.920818753952376,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(C3CCNCC3)CCN4)cc2)cc1
3978,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1F,"N-(2,3-difluorophenyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0189,uM,=,-1.723538195826756,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
3979,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(NCc3ccccc3C(F)(F)F)c2cn1,"N*4*-(2-Trifluoromethyl-benzyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",10.0,uM,=,1.0,1,c1ccc(CNc2ncnc3ccncc23)cc1
3980,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(OCCCN3CCC(C(=O)NO)CC3)cc2)ncc1Cl,1-(3-(4-(5-chloro-4-(2-(methylcarbamoyl)phenylamino)pyrimidin-2-ylamino)phenoxy)propyl)-N-hydroxypiperidine-4-carboxamide,0.0466899999999999,uM,=,-1.3307761260691944,0,c1ccc(Nc2ccnc(Nc3ccc(OCCCN4CCCCC4)cc3)n2)cc1
3981,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,Nc1ncnc2c1c(-c1ccccc1)cn2C1CC(O)C1,"3-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-cyclobutanol",2.82,uM,=,0.450249108319361,1,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1
3982,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,CCCN(c1ccc(OC)cc1)c1nc(C)nc2oc(C)cc12,"N-(4-Methoxyphenyl)-2,6-dimethyl-N-propylfuro[2,3-d]pyrimidin-4-amine",0.0733,uM,=,-1.134896025358872,0,c1ccc(Nc2ncnc3occc23)cc1
3983,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,N#Cc1cnc2ccc(NC(=O)/C=C/CN3CCOCC3)cc2c1Nc1ccc(F)c(Cl)c1,(E)-4-Morpholin-4-yl-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-quinolin-6-yl]-amide,2.29,uM,=,0.359835482339888,1,O=C(/C=C/CN1CCOCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
3984,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)cc3)c2cc1NC(=O)/C=C/CN1CCN(C)CC1,(2E)-N-{7-Ethoxy-4-[4-(2-pyridinylmethoxy)anilino]-6-quinazolinyl}-4-(4-methyl-1-piperazinyl)-2-butenamide,0.061,uM,=,-1.214670164989233,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccn4)cc3)c2c1
3985,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3ccccc3C(F)(F)F)c2cn1,"N*4*-(2-Trifluoromethyl-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",10.0,uM,=,1.0,1,c1ccc(Nc2ncnc3ccncc23)cc1
3986,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,OCc1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"{4-[4-(1H-Indol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-phenyl}-methanol",0.001,uM,=,-3.0,0,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
3987,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC(Oc2cc3c(Nc4cccc(Cl)c4)ncnc3cc2OC)C1,1-(3-(4-(3-chlorophenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1-yl)prop-2-en-1-one,0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2ncnc3ccc(OC4CNC4)cc23)cc1
3988,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,C#Cc1cccc(Nc2ncnc3ccc(OCCCC(=O)NO)cc23)c1,4-(4-(3-ethynylphenylamino)quinazolin-6-yloxy)-N-hydroxybutanamide,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
3989,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,CN1CCN(CCCCNc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)CC1,"6-(2,6-Dichloro-phenyl)-8-methyl-2-[4-(4-methyl-piperazin-1-yl)-butylamino]-8H-pyrido[2,3-d]pyrimidin-7-one",0.21,uM,=,-0.6777807052660807,0,O=c1[nH]c2nc(NCCCCN3CCNCC3)ncc2cc1-c1ccccc1
3990,1338035,10.1016/j.ejmech.2014.02.032,,,,Inhibition of EGFR (unknown origin) after 1.5 hr by FRET-based Z-lyte assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)CCN(C)C)c2)n1,N-(3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)-3-(dimethylamino)propanamide,0.638,uM,=,-0.1951793212788376,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
3991,65120,10.1021/jm00023a009,,,,In vitro inhibition of EGF-stimulated DNA synthesis of ER 22 cells by following the incorporation of methyl-[3H]thymidine.,COCOc1cc(-c2ccccc2)ccc1-c1ccc(C(=O)O)cc1,"2'-Methoxymethoxy-[1,1';4',1'']terphenyl-4-carboxylic acid",10.0,uM,=,1.0,1,c1ccc(-c2ccc(-c3ccccc3)cc2)cc1
3992,63778,10.1021/jm0004291,,,,Inhibition of epidermal growth factor receptor,CCN(CC)CCCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(NC(=O)Nc3ccccc3)nc2n1,"1-[6-(2,6-Dichloro-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-phenyl-urea",1.0,uM,=,0.0,0,O=C(Nc1ccccc1)Nc1nc2ncncc2cc1-c1ccccc1
3993,800208,10.1016/j.bmcl.2011.12.067,,,,Inhibition of wild-type EGFR expressed using baculovirus expression system by ELISA,COc1cccc(Nc2ccnc(Nc3cccc(OC)c3)n2)c1,"N2,N4-bis(3-methoxyphenyl)pyrimidine-2,4-diamine",7.7,uM,=,0.8864907251724818,1,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
3994,63779,10.1021/jm960689b,,,,Inhibition of epidermal growth factor receptor (EGFr) autophosphorylation,N[C@H](Cc1c([Se][Se]c2[nH]c3ccccc3c2C[C@H](N)C(=O)NCc2ccccc2)[nH]c2ccccc12)C(=O)NCc1ccccc1,"[S-(R*,R*)]-2,2'-Diselenobis [alpha-amino-N-(phenylmethyl)-1H-indole-3-propanamide]",4.2,uM,=,0.6232492903979004,1,O=C(CCc1c([Se][Se]c2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
3995,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CN1CCN(c2ccc(Nc3nccc(Nc4ccc5[nH]ccc5c4)n3)cc2)CC1,"N4-(1H-indol-5-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,4-diamine",0.049,uM,=,-1.3098039199714864,0,c1cc(Nc2ccc3[nH]ccc3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
3996,1674599,10.1021/acs.jmedchem.8b00125,,,,Inhibition of EGFR (unknown origin),CNS(=O)(=O)c1cccc(Nc2cc(N(C)c3cccc(C)c3)ncn2)c1,N-Methyl-3-({6-[methyl(3-methylphenyl)amino]-4-pyrimidinyl}-amino)benzenesulfonamide,0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
3997,1832273,10.1016/j.bmc.2018.12.032,,,,Inhibition of human A431 cell-derived EGFR using Lys-His-Lys-LysLeu-Ala-Glu-Gly-Ser-Ala-Tyr472-Glu-Glu-Val as substrate measured after 10 mins in presence of [32P]ATP by scintillation counting method,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
3998,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,COc1cc2ncnc(NCc3ccccc3)c2cc1O,4-Benzylamino-7-methoxy-quinazolin-6-ol,0.056,uM,=,-1.2518119729937995,0,c1ccc(CNc2ncnc3ccccc23)cc1
3999,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(C)c(Br)c3)ncnc2cc1OCCOCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-{2-[2-({4-[(3-Bromo-4-methylphenyl)amino]-6-methoxyquinazolin-7-yl}oxy)ethoxy]ethyl}-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.00037,uM,=,-3.431798275933005,0,O=C(Cn1cncn1)NCCOCCOc1ccc2c(Nc3ccccc3)ncnc2c1
4000,2058361,10.1016/j.ejmech.2020.113019,,,,Inhibition of recombinant human GST-tagged EGFR expressed in baculovirus expression system using tyr-04 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.02201,uM,=,-1.657379957446652,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4001,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,COc1cc2ncnc(Nc3ccc(NC(=O)OC(C)C)c(C)c3)c2cc1OC,"isopropyl 4-(6,7-dimethoxyquinazolin-4-ylamino)-2-methylphenylcarbamate",5.8,uM,=,0.7634279935629373,1,c1ccc(Nc2ncnc3ccccc23)cc1
4002,2112388,10.1016/j.bmcl.2021.127987,,,,Inhibition of EGFR (unknown origin),COc1ccc(/C=C2/SC(NN3Cc4ccccc4N=C3c3ccccc3)=NC2=O)cc1,"3-(5-(4-methoxybenzylidene)-4-oxo-4,5-dihydrothiazol-2-ylamino)-2-phenylquinazolin-4(H)-one",0.136,uM,=,-0.8664610916297825,0,O=C1N=C(NN2Cc3ccccc3N=C2c2ccccc2)S/C1=C/c1ccccc1
4003,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3cc(O)c(C)cc3F)ncnc2cc1OCC1CCN(C)CC1.Cl,4-Fluoro-5-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-ylamino]-2-methyl-phenol hydrochloride,0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
4004,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1C[C@@H](C)N[C@@H](C)C1,"(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-((3S,5R)-3,5-dimethylpiperazin-1-yl)but-2-enamide",0.019,uM,=,-1.7212463990471711,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
4005,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1SCCCN(CC)CC,N-[4-(3-Bromo-phenylamino)-7-(3-diethylamino-propylsulfanyl)-quinazolin-6-yl]-acrylamide,0.00078,uM,=,-3.10790539730952,0,c1ccc(Nc2ncnc3ccccc23)cc1
4006,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCCC1,"3-(4-Amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-phenol",0.08,uM,=,-1.0969100130080565,0,c1ccc(-c2cn(C3CCCC3)c3ncncc23)cc1
4007,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCCCn1ccnc1[N+](=O)[O-],N-(3-Bromophenyl)-6-methoxy-7-((5-(2-nitro-1H-imidazol-1-yl)pentyl)oxy)quinazolin-4-amine,0.00033,uM,=,-3.4814860601221125,0,c1ccc(Nc2ncnc3cc(OCCCCCn4ccnc4)ccc23)cc1
4008,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,CC(C)(CO)NCc1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"2-{4-[4-(1H-Indol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzylamino}-2-methyl-propan-1-ol",0.008,uM,=,-2.096910013008056,0,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
4009,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,O=C(/C=C/c1ccccc1)Nc1ccc(F)cc1,(E)-N-(4-fluorophenyl)cinnamamide,10.02,uM,=,1.000867721531227,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
4010,2115571,10.1016/j.ejmech.2021.113609,,,,Inhibition of autophosphorylation of EGFR (unknown origin) by Cell free assay,Cc1nc2c(Br)cc(Br)cc2c(=O)n1N,"3-Amino-6,8-dibromo-2-methylquinazolin-4(3H)-one",0.072,uM,=,-1.1426675035687317,0,O=c1[nH]cnc2ccccc12
4011,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC1CCC(n2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)C1,"5-(4-amino-1-(3-methylcyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",0.366,uM,=,-0.4365189146055893,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
4012,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Cc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-methylpyrrolo[1,2-f][1,2,4]triazin-4-amine",0.081,uM,=,-1.0915149811213505,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
4013,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(OC(F)(F)F)c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-7-((3-Methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.889,uM,=,-0.0510982390297863,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
4014,2260083,10.1016/j.ejmech.2020.112904,,,,Inhibition of EGFR (unknown origin),O=C(CCCCCCC(=O)Nc1ccccc1)NO,Octanedioic acid hydroxyamide phenylamide,0.012,uM,=,-1.9208187539523751,0,c1ccccc1
4015,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,c1ccc(CNc2ncnc3ccncc23)cc1,"Benzyl-pyrido[4,3-d]pyrimidin-4-yl-amine",1.46,uM,=,0.1643528557844371,1,c1ccc(CNc2ncnc3ccncc23)cc1
4016,1662113,10.1016/j.ejmech.2017.02.061,,,,Inhibition of EGFR (unknown origin) measured after 40 mins by Kinase Glo luminescence assay,CC(C)(C)OC(=O)NCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,Tert-butyl (2-((4-((3-bromophenyl)amino)quinazolin-6-yl)amino)-2-oxoethyl)carbamate,0.0032,uM,=,-2.494850021680094,0,c1ccc(Nc2ncnc3ccccc23)cc1
4017,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,OCC(O)C(O)C(O)C(O)CNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"6-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-ylamino]-hexane-1,2,3,4,5-pentaol",0.0048,uM,=,-2.318758762624413,0,c1ccc(Nc2ncnc3ccncc23)cc1
4018,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccccc1Cl,"5-(2-Chlorophenyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",7.28,uM,=,0.8621313793130372,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
4019,66570,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor in A431 cells,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,N-[4-(3-Chloro-phenylamino)-quinazolin-6-yl]-acrylamide,0.0023,uM,=,-2.638272163982407,0,c1ccc(Nc2ncnc3ccccc23)cc1
4020,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CC#CC(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1,"US9181263, 22::US9278100, 22",0.1563,uM,=,-0.8060410219808131,0,c1ccc(Oc2ccc(-c3nn(C4CCCCC4)c4ncncc34)cc2)cc1
4021,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COc1c(O)cc(O)c2c(=O)c(-c3ccc(O)cc3)coc12,psi-tectorigenin,0.333262916985196,uM,=,-0.4772130087057701,0,O=c1c(-c2ccccc2)coc2ccccc12
4022,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,COc1cccc(-c2cn(C3CCN(CC(=O)N(C)C)CC3)c3ncnc(N)c23)c1,"2-{4-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-piperidin-1-yl}-N,N-dimethyl-acetamide",0.75,uM,=,-0.1249387366082999,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1
4023,66724,10.1021/jm00032a020,,,,Inhibition of EGFR(epidermal growth factor receptor) autophosphorylation in ER22 cell membranes,O=C(O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid",0.15,uM,=,-0.8239087409443188,0,c1ccc(CNc2ccccc2)cc1
4024,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cnc2[nH]ncc2c1,"N-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide",0.03,uM,=,-1.5228787452803376,0,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(NC(=O)c2cnc3[nH]ncc3c2)c1
4025,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,O=c1oc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc2n1CCCN1CCOCC1,"8-(3-Chloro-4-fluorophenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.078,uM,=,-1.1079053973095196,0,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
4026,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Nc1ccc2c(Nc3cccc(F)c3)ncnc2c1,"N*4*-(3-Fluoro-phenyl)-quinazoline-4,7-diamine",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
4027,933957,10.1016/j.bmcl.2012.12.028,,,,Inhibition of EGFR (unknown origin) in presence of ATP,CN1CCC(NC(=O)c2cnc(NCc3cc(Cl)ccc3Cl)nc2NC2CCCC2)CC1,"4-(cyclopentylamino)-2-(2,5-dichlorobenzylamino)-N-(1-methylpiperidin-4-yl)pyrimidine-5-carboxamide",30.0,uM,=,1.4771212547196624,1,O=C(NC1CCNCC1)c1cnc(NCc2ccccc2)nc1NC1CCCC1
4028,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,[O-][N+]1(CCCNc2cc3ncnc(Nc4cccc(Br)c4)c3cn2)CCOCC1,"N*4*-(3-Bromo-phenyl)-N*7*-[3-(4-oxy-morpholin-4-yl)-propyl]-pyrido[4,3-d]pyrimidine-4,7-diamine",0.00074,uM,=,-3.130768280269024,0,c1ccc(Nc2ncnc3cc(NCCC[NH+]4CCOCC4)ncc23)cc1
4029,2145645,10.1016/j.bmcl.2021.128406,,,,Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence of ATP by IMAP-FP assay,C=CC(=O)N1CCC2(CC1)CNC(=O)c1cc(-c3ccnc(Nc4ccccc4OC)c3)[nH]c12,"1-acryloyl-2'-(2-(2-methoxyphenylamino)pyridin-4-yl)-5',6'-dihydrospiro[piperidine-4,7'-pyrrolo[3,2-c]pyridin]-4'(1'H)-one",0.192,uM,=,-0.7166987712964504,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(Nc4ccccc4)c3)cc21
4030,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,C=CC(=O)Oc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCC,4-(3-chloro-4-fluorophenylamino)-7-ethoxyquinazolin-6-yl acrylate,0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3ccccc23)cc1
4031,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,C=CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-3-cyano-quinolin-6-yl]-acrylamide,0.59,uM,=,-0.2291479883578558,0,c1ccc(Nc2ccnc3ccccc23)cc1
4032,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,CCC(=O)N1CCC[C@@H](n2nc(-c3ccccc3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)propan-1-one",7.3,uM,=,0.8633228601204559,1,c1ccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)cc1
4033,793571,10.1016/j.bmc.2011.11.058,,,,Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA,COc1ccc(OC)c(Cc2cc3c(Nc4ccc(Cl)cc4F)nc(N)nc3[nH]2)c1,"N4-(4-chloro-2-fluorophenyl)-6-(2,5-dimethoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",112.7,uM,=,2.0519239160461065,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
4034,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,c1ccc2sc(-c3ccc(Nc4ncnc5[nH]ccc45)cc3)nc2c1,"N-(4-(benzo[d]thiazol-2-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",1.3,uM,=,0.1139433523068367,1,c1ccc2sc(-c3ccc(Nc4ncnc5[nH]ccc45)cc3)nc2c1
4035,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C#CCN(C)CCN(C)c1cc(OC)c(Nc2nccc(Nc3cn(C)c4ccccc34)n2)cc1NC(=O)C=C,N-(4-methoxy-2-(methyl(2-(methyl(prop-2-yn-1-yl)amino)ethyl)amino)-5-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.009574,uM,=,-2.01890657685407,0,c1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1
4036,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,Cc1ncc([N+](=O)[O-])n1CC(=O)NS(=O)(=O)c1ccc(Cl)cc1,N-(4-Chlorophenylsulfonyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetamide,1.51,uM,=,0.1789769472931694,1,O=C(Cn1ccnc1)NS(=O)(=O)c1ccccc1
4037,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,CCOC(=O)c1nn(-c2ccc(C)cc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1,"Ethyl 1-(4-chlorophenyl)-4-(2-methyl-4,5-diphenyl-1H-pyrrole-3-carbonyl)-1H-pyrazole-3-carboxylate",7.88,uM,=,0.8965262174895553,1,O=C(c1cnn(-c2ccccc2)c1)c1c[nH]c(-c2ccccc2)c1-c1ccccc1
4038,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3cccc(C)c3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
4039,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7,8-dihydropyrimido[5,4-g][1,4]benzoxazin-6-yl]-4-(1-piperidyl)but-2-en-1-one",0.116,uM,=,-0.9355420107730816,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
4040,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,FC(F)(F)c1ccc(-n2cnnc2SCc2nc(COc3c(Cl)cccc3Cl)no2)cc1,"3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole",6.3,uM,=,0.7993405494535817,1,c1ccc(OCc2noc(CSc3nncn3-c3ccccc3)n2)cc1
4041,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(CCc4ccccc4)cc3)ncnc2cc1OC,N-{7-Methoxy-4-[4-(2-phenylethyl)anilino]-6-quinazolinyl}-propanamide,0.747,uM,=,-0.1266793981846012,0,c1ccc(CCc2ccc(Nc3ncnc4ccccc34)cc2)cc1
4042,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,C#Cc1cccc(Nc2ncnc3cc(OCCCCCn4ccnc4[N+](=O)[O-])c(OC)cc23)c1,N-(3-Ethynylphenyl)-6-methoxy-7-((5-(2-nitro-1H-imidazol-1-yl)pentyl)oxy)quinazolin-4-amine,0.00047,uM,=,-3.3279021420642825,0,c1ccc(Nc2ncnc3cc(OCCCCCn4ccnc4)ccc23)cc1
4043,340860,10.1016/j.bmcl.2005.12.028,,,,Inhibitory activity against EGFR,COc1cc(OC2CCN(C)CC2)c2c(Nc3ccc(F)c(Cl)c3)ncnc2c1,N-(3-chloro-4-fluorophenyl)-7-methoxy-5-(1-methylpiperidin-4-yloxy)quinazolin-4-amine,0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3cccc(OC4CCNCC4)c23)cc1
4044,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Oc1ncnc(Nc3ccc4ccccc4c3)c1NC2,"(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-naphthalen-2-yl-amine",2.3,uM,=,0.3617278360175928,1,c1ccc2c(c1)CNc1c(Nc3ccc4ccccc4c3)ncnc1O2
4045,306070,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,O=C(CCl)Nc1ccc2ncnc(Nc3cccc(I)c3)c2c1,2-Chloro-N-[4-(3-iodo-phenylamino)-quinazolin-6-yl]-acetamide,0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccccc23)cc1
4046,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CC(C)c1cc(/C=C(\C#N)C(N)=O)cc(C(C)C)c1O,"2-cyano-3-(4-hydroxy-3,5-diisopropylphenyl)acrylamide",1.0,uM,=,0.0,0,c1ccccc1
4047,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1/C=C/C(=O)NCCN1CCOCC1,3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-methylpyrimidin-5-yl)-N-(2-morpholinoethyl)acrylamide,0.114,uM,=,-0.9430951486635274,0,O=C(/C=C/c1cncnc1Nc1ccc(OCc2ccccc2)cc1)NCCN1CCOCC1
4048,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCn1ccnc1,N-[4-(3-Bromo-phenylamino)-7-(3-imidazol-1-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3cc(OCCCn4ccnc4)ccc23)cc1
4049,465,10.1016/s0960-894x(02)00364-5,,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Cc1cc(C(=O)N2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc4c(c3)CCC4)c21,"4-(Indan-5-ylamino)-5-[1-[3-methyl-5-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",4.32,uM,=,0.6354837468149122,1,O=C1Nc2ncnc(Nc3ccc4c(c3)CCC4)c2/C1=C/c1ccc(C(=O)N2CCOCC2)[nH]1
4050,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,COC(=O)CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"Methyl 3-((4-((3-chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)amino)-3-oxopropanoate",4.997,uM,=,0.6987093494425869,1,c1ccc(Nc2ncnc3sccc23)cc1
4051,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,OC[C@@H](Nc1ncnc2oc(-c3ccc(O)cc3)cc12)c1ccccc1,"(S)-4-(4-((2-Hydroxy-1-phenylethyl)amino)furo[2,3-d]pyrimidin-6-yl)phenol",0.002,uM,=,-2.6989700043360187,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
4052,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",O=C(/C=C/c1ccc(O)c(O)c1)OCCc1ccccc1,"(E)-3-(3,4-Dihydroxy-phenyl)-acrylic acid phenethyl ester",1.005,uM,=,0.0021660617565076,1,O=C(/C=C/c1ccccc1)OCCc1ccccc1
4053,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1C,"ethyl 4-(6,7-dimethoxyquinazolin-4-ylamino)-2-methylphenylcarbamate",0.9,uM,=,-0.0457574905606751,0,c1ccc(Nc2ncnc3ccccc23)cc1
4054,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1,"N-(3-(7-((4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-3-isopropyl-2,4-dioxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.02,uM,=,-1.6989700043360187,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCCCC4)cc3)ncc12
4055,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,COc1ccc2c(c1)CNc1c(Nc3ccc(F)c(Cl)c3)ncnc1O2,"(3-Chloro-4-fluoro-phenyl)-(8-methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",0.9,uM,=,-0.0457574905606751,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
4056,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,COc1ccc2ncnc(Nc3cccc(Br)c3)c2n1,"(3-Bromo-phenyl)-(6-methoxy-pyrido[3,2-d]pyrimidin-4-yl)-amine",0.0043,uM,=,-2.3665315444204134,0,c1ccc(Nc2ncnc3cccnc23)cc1
4057,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,O=C(Nc1ccc(F)cc1)c1ccc(N(CCCl)CCCl)cc1,4-(Bis(2-chloroethyl)amino)-N-(4-fluorophenyl)benzamide,1.72,uM,=,0.2355284469075489,1,O=C(Nc1ccccc1)c1ccccc1
4058,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,O=C(O)C(=Cc1ccc(O)cc1)C(=O)O,2-(4-Hydroxy-benzylidene)-malonic acid,1500.0,uM,=,3.1760912590556813,1,c1ccccc1
4059,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCCC5)cc4)nc32)c1,N-(3-(7-Oxo-2-(4-(pyrrolidin-1-yl)phenylamino)pteridin-8(7H)-yl)phenyl)acrylamide,0.0153,uM,=,-1.815308569182401,0,O=c1cnc2cnc(Nc3ccc(N4CCCC4)cc3)nc2n1-c1ccccc1
4060,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(NCc3ccc(Cl)c(F)c3)c2cc1OCCCCCCC(=O)NO,7-(4-(3-Chloro-4-fluorobenzylamino)-7-methoxyquinazolin-6-yloxy)-hydroxyheptanamide,0.072,uM,=,-1.1426675035687317,0,c1ccc(CNc2ncnc3ccccc23)cc1
4061,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CC(C)S(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-(5-((2-(isopropylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.018,uM,=,-1.744727494896694,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
4062,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C=CC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"(S)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)acrylamide",0.02,uM,=,-1.6989700043360187,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
4063,1299287,10.1039/C3MD00096F,,,,Inhibition of EGFR (unknown origin) after 1 hr by Caliper mobility shift assay,CCN(CCO)CCCOc1ccc2c(Nc3cccc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)c3)ncnc2c1,1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(3-(7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-ylamino)phenyl)urea,0.188,uM,=,-0.7258421507363202,0,O=C(Nc1ccccc1)Nc1cccc(Nc2ncnc3ccccc23)c1
4064,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,CC(=O)N1N=C(c2ccc(C)c(C)c2)CC1c1ccccc1,"1-(3-(3,4-Dimethylphenyl)-5-phenyl-4,5-dihydro-1Hpyrazol-1-yl)ethanone",20.04,uM,=,1.3018977171952082,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
4065,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC.Cl,"4-(3'-bromoanilino)-6,7-dimethoxyquinazoline hydrochloride",0.211,uM,=,-0.6757175447023074,0,c1ccc(Nc2ncnc3ccccc23)cc1
4066,622914,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR by HTRF assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1.O,Tykerb,0.019,uM,=,-1.7212463990471711,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1.c1ccccc1.c1ccccc1
4067,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,NC1CCN(Cc2ccn3ncnc(Nc4ccc(OCc5cnccn5)c(Cl)c4)c23)CC1,"5-((4-aminopiperidin-1-yl)methyl)-N-(3-chloro-4-(pyrazin-2-ylmethoxy)phenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.032,uM,=,-1.494850021680094,0,c1cnc(COc2ccc(Nc3ncnn4ccc(CN5CCCCC5)c34)cc2)cn1
4068,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,O=C(/C=C/CN1CCOCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"(E)-1-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7, 8-dihydro-6H-[1, 4]oxazino[3,2-g]quinazolin-6-yl)-4-morpholinobut-2-en-1-one",0.012,uM,=,-1.9208187539523751,0,O=C(/C=C/CN1CCOCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
4069,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,CNCCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-methylamino-ethoxy)-quinazolin-4-yl]-amine,0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3ccccc23)cc1
4070,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,NS(=O)(=O)c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1,"4-(7-(phenylamino)thiazolo[4,5-d]pyrimidin-2-ylamino)benzenesulfonamide",0.082,uM,=,-1.0861861476162833,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1
4071,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,1-[(2-Chloro-phenyl)-diphenyl-methyl]-1H-imidazole,69.421,uM,=,1.8414908653330009,1,c1ccc(C(c2ccccc2)(c2ccccc2)n2ccnc2)cc1
4072,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCO,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-2-((2-hydroxyethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.8385,uM,=,-0.0764969330578954,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)cc1
4073,1641865,,,,,"Enzyme Assay: BT474 Cell Line: 1. 5Ã103 cells per well in 100 Î¼l of medium were seeded in 96-well plate, here the medium contained 5% FBS2. 24 hours later, 100 Î¼l fresh medium was added with various concentrations of compounds into each well, while the medium here was free of FBS.3. After the cells were treated with compounds for 72 hours, 20 Î¼l MTT (5 mg/ml) was added into each well, and then the assay plate was incubated at 37Â° C. for 4 more hours.4. The assay plate was centrifuged at 800 g for 10 min. The medium was aspirated, 150 Î¼l DMSO was added into each well. The plate was gently shaken for 10 min.5. The absorbance at 570 nm was measured on the plate reader.6. IR %=(WCâWT)/WCÃ100%.",CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.047,uM,=,-1.3279021420642825,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
4074,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(O[C@@H](C)c4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-((S)-1-phenyl-ethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.77,uM,=,-0.1135092748275181,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
4075,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccc(Cl)cc3)CC2c2ccccc2)=N1,"2-(3-(4-Chlorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",5.34,uM,=,0.7275412570285564,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
4076,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCN1CCN(C)CC1,N-{4-(3-Bromo-phenylamino)-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinazolin-6-yl}-acrylamide,0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
4077,1770732,10.1016/j.bmc.2018.03.025,,,,"Inhibition of wild type EGFR (unknown origin) using poly (Glu, Tyr) as substrate after 40 mins by kinase-glo plus luminescence assay",CN(C)C1CCN(c2ccc(Nc3ncc4nc(Sc5ccccc5)n(C5CCOCC5)c4n3)cc2)CC1,N-(4-(4-(Dimethylamino)piperidin-1-yl)phenyl)-8-(phenylthio)-9-(tetrahydro-2H-pyran-4-yl)-9H-purin-2-amine,0.0016,uM,=,-2.7958800173440754,0,c1ccc(Sc2nc3cnc(Nc4ccc(N5CCCCC5)cc4)nc3n2C2CCOCC2)cc1
4078,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,CN(C)CCCOCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((3-(dimethylamino)propoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.62,uM,=,-0.2076083105017461,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
4079,529998,10.1016/j.bmc.2008.02.053,,,,Inhibition of EGFR,CN(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.00022,uM,=,-3.657577319177794,0,c1ccc(Nc2ncnc3ccccc23)cc1
4080,947940,10.1021/np300764u,,,,Inhibition of EGFR (unknown origin),O=C(NCCc1ccc(O)c(Br)c1)/C(Cc1cc(Br)c(O)c(-c2cc(C/C(=N/O)C(=O)NCCc3ccc(O)c(Br)c3)cc(Br)c2O)c1)=N\O,Bastadin 3,1.3,uM,=,0.1139433523068367,1,N=C(Cc1cccc(-c2cccc(CC(=N)C(=O)NCCc3ccccc3)c2)c1)C(=O)NCCc1ccccc1
4081,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CCN(C)CC1,(3-Chloro-4-fluoro-phenyl)-{7-methoxy-6-[2-(4-methyl-piperazin-1-yl)-ethoxy]-quinazolin-4-yl}-amine,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccc(OCCN4CCNCC4)cc23)cc1
4082,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,O=C(/C=C/c1ccccc1)Nc1cc(Cl)cc(Cl)c1,"(E)-N-(3,5-dichlorophenyl)cinnamamide",13.93,uM,=,1.1439511164239635,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
4083,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,CC(C)N(CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)C(C)C,4-Diisopropylamino-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.097,uM,=,-1.0132282657337552,0,c1ccc(Nc2ncnc3ccccc23)cc1
4084,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(furan-2-yl)thieno[2,3-d]pyrimidin-4-amine",0.015,uM,=,-1.8239087409443189,0,c1ccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2)cc1
4085,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc32)c1,"N-(3-(3-Methyl-7-(4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)-acrylamide",0.00043,uM,=,-3.3665315444204134,0,O=C1NCc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
4086,78745,10.1016/j.bmcl.2004.03.111,,,,Inhibition of human Epidermal growth factor receptor,COc1ccc(C#CC(C)(C)N)cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1,"[5-(3-Amino-3-methyl-but-1-ynyl)-2-methoxy-phenyl]-[4-(2,4-difluoro-phenylamino)-phenyl]-methanone",8.8,uM,=,0.9444826721501688,1,O=C(c1ccccc1)c1ccc(Nc2ccccc2)cc1
4087,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3cccc(OC)c3OC)ncc2Br)c1,"US9238629, I-14::US9238629, I-6",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
4088,1883874,10.1021/acsmedchemlett.8b00270,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay,C=CC(=O)N(c1ccc(F)c(F)c1)c1ncnc2cc(OC)c(OCCCN3CCOCC3)cc12,"4-[N-acryloyl-(3,4-difluorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline",0.368,uM,=,-0.4341521813264823,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
4089,2220179,10.1016/j.bmcl.2021.128524,,,,Inhibition of EGFR tyrosine kinase (unknown origin) preincubated for 5 mins followed by substrate addition and further incubated for 10 mins in presence of ATP by fluorescence based microplate reader analysis,O=c1c2cccc(O)c2oc2cccc(O)c12,"1,5-Dihydroxy-xanthen-9-one",0.9,uM,=,-0.0457574905606751,0,O=c1c2ccccc2oc2ccccc12
4090,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC(=O)Cc4c(C)n(C(=O)c5ccc(Cl)cc5)c5ccc(OC)cc45)c(OCCOC)cc23)c1,2-((4-((3-Ethynylphenyl)amino)-6-(2-methoxyethoxy)quinazolin-7-yl)oxy)ethyl-2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate,0.027,uM,=,-1.5686362358410126,0,O=C(Cc1cn(C(=O)c2ccccc2)c2ccccc12)OCCOc1ccc2c(Nc3ccccc3)ncnc2c1
4091,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)ccc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.015,uM,=,-1.8239087409443189,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
4092,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,CC(=O)Oc1ccc2c(c1)c(C(=O)Nc1ccccc1)c(SSc1c(C(=O)Nc3ccccc3)c3cc(OC(C)=O)ccc3n1C)n2C,Acetic acid 2-(5-acetoxy-1-methyl-3-phenylcarbamoyl-1H-indol-2-yldisulfanyl)-1-methyl-3-phenylcarbamoyl-1H-indol-5-yl ester,5.3,uM,=,0.724275869600789,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
4093,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",C=CC(=O)N[C@H]1CC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1,"US9181263, 10::US9278100, 10",0.0445,uM,=,-1.3516399890190685,0,c1ccc(Oc2ccc(-c3nn(C4CCCCC4)c4ncncc34)cc2)cc1
4094,1353177,10.1021/ml4003309,,,,Inhibition of recombinant EGFR (unknown origin) using poly-GT peptide as substrate by Transcreener assay,COc1cc2c(Oc3ccc(NS(=O)(=O)c4ccc(-c5ccsc5)cc4)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,N-[3-fluoro-4-({6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yl}oxy)phenyl]-4-(3-thienyl)benzenesulfonamide,1.201,uM,=,0.079543007402906,1,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1ccc(-c2ccsc2)cc1
4095,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1.Cl.Cl,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, hydrochloride (CI-1033)",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
4096,2260188,10.1016/j.ejmech.2020.112995,,,,Inhibition of human wild type GST-tagged EGFR expressed in Sf9 cells assessed as substrate phosphorylation using TK-peptide as substrate incubated for 25 mins by HTRF assay,CCC(=O)Nc1cccc(-c2c(-c3ccc(N4CCN(C)CC4)cc3)[nH]c3ncnc(OCC(C)C)c23)c1,"N-(3-(4-isobutoxy-6-(4-(4-methylpiperazin-1-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl)propionamide",0.0002,uM,=,-3.6989700043360174,0,c1ccc(-c2c(-c3ccc(N4CCNCC4)cc3)[nH]c3ncncc23)cc1
4097,340860,10.1016/j.bmcl.2005.12.028,,,,Inhibitory activity against EGFR,COc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1OC1CCN(C)CC1,N-(3-chloro-4-fluorophenyl)-6-methoxy-5-(1-methylpiperidin-4-yloxy)quinazolin-4-amine,0.225,uM,=,-0.6478174818886375,0,c1ccc(Nc2ncnc3cccc(OC4CCNCC4)c23)cc1
4098,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,COCC#CC(=O)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1,4-(6-(4-methoxybut-2-ynamido)quinolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.016,uM,=,-1.7958800173440752,0,O=C(Nc1ccccn1)c1ccc(Oc2ccnc3ccccc23)cc1
4099,935919,10.1016/j.bmcl.2012.11.001,,,,Inhibition of EGFR (unknown origin) by Z-LYTE assay,C=C1[C@H](C)CCC[C@]1(C)CC/C(C)=C/CC1=C(O)C(=O)C=C(N[C@H](C(=O)O)C(C)C)C1=O,"(S)-2-(5-((E)-5-((1R,3R)-1,3-dimethyl-2-methylenecyclohexyl)-3-methylpent-2-enyl)-4-hydroxy-3,6-dioxocyclohexa-1,4-dienylamino)-3-methylbutanoic acid",435.403322493149,uM,=,2.638891738749484,1,C=C1CCCCC1CC/C=C/CC1=CC(=O)C=CC1=O
4100,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccc(C)c(C)c4)cc3)ncnc2cc1OCCCN1CCN(C)CC1,"1-(3,4-dimethylphenyl)-3-(4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)phenyl)urea",0.668,uM,=,-0.1752235375244543,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
4101,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)C[C@H]1CCCN1C,isopropyl (R)-2-((5-acrylamido-2-methoxy-4-(methyl((1-methylpyrrolidin-2-yl)methyl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.043,uM,=,-1.3665315444204136,0,c1ccc2c(-c3ccnc(Nc4ccc(NC[C@H]5CCCN5)cc4)n3)c[nH]c2c1
4102,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CN(C)C/C=C/C(=O)N1CCc2c(sc3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c23)C1,"US8524722, 95",0.01,uM,=,-2.0,0,c1ccc(Nc2ccnc3sc4c(c23)CCNC4)cc1
4103,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(C(=O)NO)CC3)cc2)ncc1Cl,1-(4-(5-chloro-4-(2-(methylcarbamoyl)phenylamino)pyrimidin-2-ylamino)phenyl)-N-hydroxypiperidine-4-carboxamide,0.1187,uM,=,-0.9255492810454088,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCCCC4)cc3)n2)cc1
4104,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,CCN(CC)CC(O)CNC(=O)c1cc(C)c(/C=C2\C(=O)Nc3ncnc(Nc4ccc(F)c(Cl)c4)c32)[nH]1,"5-[4-(3-Chloro-4-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (3-diethylamino-2-hydroxy-propyl)-amide",0.00045,uM,=,-3.3467874862246565,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
4105,423049,10.1021/jm061031t,,,,Inhibitory activity against EGFR,COc1cc(Nc2c(C#N)cnc3cc(-c4coc(CN5CCN(C)CC5)c4)c(OC)cc23)c(Cl)cc1Cl,"4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile",0.23,uM,=,-0.6382721639824072,0,c1ccc(Nc2ccnc3cc(-c4coc(CN5CCNCC5)c4)ccc23)cc1
4106,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,O=[N+]([O-])c1ccc2c(NCc3ccccc3)ncnc2c1,Benzyl-(7-nitro-quinazolin-4-yl)-amine,5.9,uM,=,0.7708520116421442,1,c1ccc(CNc2ncnc3ccccc23)cc1
4107,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(C(N)=O)c(Cl)c2)c2c(N)ncnc21,"4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorobenzamide",100.0,uM,=,2.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
4108,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Nc1ccc2ncnc(Nc3ccc4ncccc4c3)c2c1,"N4-(quinolin-6-yl)quinazoline-4,6-diamine",0.2150999999999999,uM,=,-0.6673595896125375,0,c1cnc2ccc(Nc3ncnc4ccccc34)cc2c1
4109,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)(C)OC(=O)n1ccc2cc(-c3nn(C4CCCC4)c4ncnc(N)c34)ccc21,"tert-butyl 5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-1-carboxylate",0.391,uM,=,-0.4078232426041331,0,c1ncc2c(-c3ccc4[nH]ccc4c3)nn(C3CCCC3)c2n1
4110,2270862,10.1016/j.ejmech.2020.112640,,,,Inhibition of human EGFR incubated for 1 hrs in presence of ATP by ELISA assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.047,uM,=,-1.3279021420642825,0,c1ccc(Nc2ncnc3ccccc23)cc1
4111,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc4c(c3)CCN4Cc3ccccn3)ncnc2cc1OC,"N-(7-Methoxy-4-{[1-(2-pyridinylmethyl)-2,3-dihydro-1H-indol-5-yl]amino}-6-quinazolinyl)propanamide",0.519,uM,=,-0.2848326421515421,0,c1ccc(CN2CCc3cc(Nc4ncnc5ccccc45)ccc32)nc1
4112,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,CC(=O)N1N=C(c2ccc(C)c(C)c2)CC1c1ccc(F)cc1,"1-(3-(3,4-Dimethylphenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone",15.56,uM,=,1.1920095926536702,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
4113,1528501,,,,,"Time-Resolved Fluorescence Assay: The following assay may be used to determine the activity of the compounds of the invention for inhibiting EGFR kinase activity. The half maximal inhibitory concentration IC50 (the concentration of the tested compound showing 50% inhibition of the enzyme activity) of each compound was determined by incubating several different concentrations of the tested compounds with a specific enzyme and substrate. EGFR kinase used in this assay is a human-derived recombinant protein (Cell signaling technology, #7908), which was reacted with peptide substrate and different concentrations of tested compounds in a buffer solution containing 60 mM HEPES (pH7.5), 5 mM MgCl2, 5 mM MnCl2, 3 Î¼M Na3VO4, 1.25 M DTT (1000Ã) and 20 Î¼M ATP at 25Â° C., for 45 minutes.",CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@@H]1CCCN1C,"US8901140, 1::US9358227, 1",0.013,uM,=,-1.8860566476931635,0,O=C(/C=C/[C@@H]1CCCN1)Nc1ccc2nccc(Nc3ccc(OCc4ccccn4)cc3)c2c1
4114,1438922,10.1016/j.bmcl.2014.08.036,,,,Inhibition of EGFR (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay,COc1cc(Br)c(Br)c(/C=N/c2ccc3[nH]c(=O)[nH]c3c2)c1O,"(E)-5-((2,3-dibromo-6-hydroxy-5-methoxybenzylidene)amino)-1H-benzo[d]imidazol-2(3H)-one",88.67,uM,=,1.9477767084647384,1,O=c1[nH]c2ccc(/N=C/c3ccccc3)cc2[nH]1
4115,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,COc1cc(C=C(C#N)C#N)cc(OC)c1O,"2-(4-Hydroxy-3,5-dimethoxy-benzylidene)-malononitrile",850.0,uM,=,2.929418925714293,1,c1ccccc1
4116,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,COc1cc(/C=C(\C#N)C(=O)O)cc(OC)c1O,"2-Cyano-3-(4-hydroxy-3,5-dimethoxy-phenyl)-acrylic acid",264.0,uM,=,2.421603926869832,1,c1ccccc1
4117,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)O,"2-Cyano-3-(3,4-dihydroxy-phenyl)-acrylic acid",25.0,uM,=,1.3979400086720375,1,c1ccccc1
4118,1741055,10.1016/j.ejmech.2018.06.024,,,,Inhibition of EGFR in human MCF7 cell lysates after 24 to 48 hrs by ELISA,O=C(CN1CCCCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-((3-bromophenyl)amino)quinazolin-6-yl)-2-(piperidin-1-yl)acetamide,0.037,uM,=,-1.431798275933005,0,O=C(CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4119,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
4120,66897,10.1021/jm970367n,,,,Inhibition of Epidermal growth factor receptor (EGFr) tyrosine kinase,CCN(CC)CCCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(NC(=O)NC(C)(C)C)nc2n1,"1-tert-Butyl-3-[6-(2,6-dichloro-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea",0.24,uM,=,-0.619788758288394,0,c1ccc(-c2cnc3ncncc3c2)cc1
4121,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Nc1ccc2c(Nc3cccc(Br)c3)ncnc2n1,"N*4*-(3-Bromo-phenyl)-pyrido[2,3-d]pyrimidine-4,7-diamine",0.94,uM,=,-0.0268721464003013,0,c1ccc(Nc2ncnc3ncccc23)cc1
4122,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)c(O)c3)c2cc1OC,"2-(benzo[d]thiazol-2-yl)-5-(6,7-dimethoxyquinazolin-4-ylamino)phenol",2.2,uM,=,0.3424226808222063,1,c1ccc2sc(-c3ccc(Nc4ncnc5ccccc45)cc3)nc2c1
4123,1770089,10.1016/j.bmcl.2017.12.009,,,,Inhibition of wild-type EGFR phosphorylation in human A431 cells preincubated for 1 hr followed by EGF stimulation measured after 45 mins by ELISA,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3OC)n2)c1,N-(3-(3-(2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,2.338,uM,=,0.3688445068258213,1,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCC(N4CCNCC4)CC3)cc2)n1
4124,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC.Cl,"4-(3'-bromoanilino)-6,7-diethoxyquinazoline hydrochloride",0.00041,uM,=,-3.3872161432802645,0,c1ccc(Nc2ncnc3ccccc23)cc1
4125,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,(E)-N-(4-(3-Chlorophenylamino)quinazolin-6-yl)cinnamamide,3.61,uM,=,0.557507201905658,1,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4126,665191,10.1016/j.bmcl.2010.08.052,,,,Inhibition of EGFR phosphorylation in human MIAPaCa cells by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.051,uM,=,-1.2924298239020635,0,c1ccc(Nc2ncnc3ccccc23)cc1
4127,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#CCCCN1CCCC1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-(5-(pyrrolidin-1-yl)pent-1-ynyl)pyrimidin-4-amine,0.011,uM,=,-1.958607314841775,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)CCCN1CCCC1
4128,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,OCCNCc1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"2-{4-[7-(1H-Indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-ethanol",0.002,uM,=,-2.6989700043360187,0,c1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
4129,2115571,10.1016/j.ejmech.2021.113609,,,,Inhibition of autophosphorylation of EGFR (unknown origin) by Cell free assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.087,uM,=,-1.0604807473813815,0,c1ccc(Nc2ncnc3ccccc23)cc1
4130,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,CCC(=O)Nc1cccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccc(F)cc4)ccnc3[nH]2)c1,"N-(3-(4-(4-(4-Fluorophenyl)-2-phenyl-1H-imidazol-5-yl)-1Hpyrrolo[2,3-b]pyridin-2-yl)phenyl)propionamide",0.0272,uM,=,-1.565431095965801,0,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccccc4)ccnc3[nH]2)cc1
4131,2070249,10.1021/acs.jmedchem.0c00491,,,,Inhibition of EGFR (unknown origin),Cn1cc(-c2ccnc(Nc3ccc(C(=O)NCCCCCCC(=O)NO)cc3)n2)c2ccccc21,N-(7-(hydroxyamino)-7-oxoheptyl)-4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)benzamide,5.7,uM,=,0.7558748556724915,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4132,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COCCN(Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC)[C@@H](C)C(N)=O,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(2-methoxyethyl)amino)propanamide,0.055,uM,=,-1.259637310505756,0,c1ccc(Nc2ncnc3ccccc23)cc1
4133,2220271,10.1016/j.bmcl.2022.128529,,,,Inhibition of EGFR (unknown origin),CCOC(=O)[C@@H]1CCCN1CC(=O)NNC(=O)COc1ccc(-c2nc3ccccc3s2)cc1OC,"ethyl (2S)-1-(2-{2-[4-(1,3-benzothiazol-2-yl)-2-methoxyphenoxy]acetohydrazido}-2-oxoethyl)pyrrolidine-2-carboxylate",0.109,uM,=,-0.9625735020593764,0,O=C(COc1ccc(-c2nc3ccccc3s2)cc1)NNC(=O)CN1CCCC1
4134,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccccc1Cl,"2-(2-Chloro-benzoyl)-3-(3,4-dihydroxy-phenyl)-acrylonitrile",2.0,uM,=,0.3010299956639812,1,O=C(C=Cc1ccccc1)c1ccccc1
4135,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cnn4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)buta-2,3-dienamide",0.0224,uM,=,-1.6497519816658373,0,c1ccc(Nc2nccc(-c3cnn4ccccc34)n2)cc1
4136,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CBr)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(Oc5cccc(C(F)(F)F)c5)c(Cl)c4)c3cc21,"1-(2-(2-bromoacetoxy)ethyl)-8-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.16,uM,=,-0.7958800173440752,0,O=c1[nH]c2cc3c(Nc4ccc(Oc5ccccc5)cc4)ncnc3cc2o1
4137,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(OC4CCOCC4)c(NC(=O)/C=C/CN(C)C)cc23)c1,(E)-4-(Dimethylamino)-N-(4-(3-ethynylphenylamino)-7-(tetrahydro-2H-pyran-4-yloxy)quinazolin-6-yl)but-2-enamide,0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3cc(OC4CCOCC4)ccc23)cc1
4138,1714364,10.1016/j.bmc.2018.05.039,,,,"Inhibition of wild type EGFR (unknown origin) using Poly(Glu,Tyr) as substrate after 40 mins by Kinase-Glo luminescence assay",CN1CCN(c2ccc(Nc3cc4c(N[C@H]5CCCN(C)C5)nc(Nc5ccccc5)nc4cn3)nc2)CC1,"(S)-1-(3-((6-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-2-(phenyl amino)pyrido[3,4-d]pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one",0.0019,uM,=,-2.721246399047171,0,c1ccc(Nc2nc(N[C@H]3CCCNC3)c3cc(Nc4ccc(N5CCNCC5)cn4)ncc3n2)cc1
4139,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,CCCCNC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,4-Butylcarbamoyl-benzenesulfonic acid 4-(2-nitro-vinyl)-phenyl ester,5.0,uM,=,0.6989700043360189,1,O=S(=O)(Oc1ccccc1)c1ccccc1
4140,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,C=C(C)C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-{4-[(3-Bromophenyl)amino]-6-quinazolinyl}-2-methylacrylamide,0.339,uM,=,-0.4698003017969178,0,c1ccc(Nc2ncnc3ccccc23)cc1
4141,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,CS(=O)(=O)CCNCCCCOc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-{6-[4-(methanesulfonylmethyl-amino)-butoxy]-quinazolin-4-yl}-amine,0.027,uM,=,-1.5686362358410126,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
4142,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=CS(=O)(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"Ethenesulfonic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide",0.00076,uM,=,-3.1191864077192086,0,c1ccc(Nc2ncnc3cnccc23)cc1
4143,1283337,10.1016/j.ejmech.2013.10.058,,,,Inhibition of wild type EGFR (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,CN(C)S(=O)(=O)c1ccc(Nc2nc(Cl)nc3cc4c(cc23)OCO4)cc1,"4-((2-Chloro-6,7-methylenedioxy-quinazolin-4-yl)amino)-N,N-dimethylbenzenesulfonamide",18.3,uM,=,1.2624510897304295,1,c1ccc(Nc2ncnc3cc4c(cc23)OCO4)cc1
4144,2107115,10.1016/j.ejmech.2021.113300,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,COc1cc2ncnc(Nc3cccc(C(F)(F)F)c3)c2cc1OCCCCC(=O)Nc1ccc(S(N)(=O)=O)cc1,5-((7-methoxy-4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-yl)oxy)-N-(4-sulfamoylphenyl)pentanamide,0.027,uM,=,-1.5686362358410126,0,O=C(CCCCOc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1ccccc1
4145,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,OCCn1ccc2ncnc(Nc3ccc(Oc4cccc5[nH]ncc45)c(Cl)c3)c21,"2-(4-{[3-Chloro-4-(1H-indazol-4-yloxy)phenyl]amino}-5Hpyrrolo[3,2-d]pyrimidin-5-yl)ethanol",0.0019,uM,=,-2.721246399047171,0,c1cc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)c2cn[nH]c2c1
4146,850422,10.1016/j.bmc.2012.08.002,,,,Inhibition of human N-terminal DYKDDDD tagged EGFR cytoplasmic domain amino acid 669 to 1210 expressed in baculovirus after 5 mins by scintillation counter,CC(C)S(=O)(=O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,"N-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-2-(isopropylsulfonyl)acetamide",0.053,uM,=,-1.275724130399211,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
4147,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CS(=O)(=O)CCNCc1ccc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)[nH]1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)-1H-pyrrol-2-yl)thieno[2,3-d]pyrimidin-4-amine",0.138,uM,=,-0.8601209135987634,0,c1ccc(COc2ccc(Nc3ncnc4sc(-c5ccc[nH]5)cc34)cc2)cc1
4148,1337213,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.16,uM,=,-0.7958800173440752,0,c1ccc(Nc2ncnc3ccccc23)cc1
4149,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(NCc1ccccc1)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,1-benzyl-3-(4-((3-chlorophenyl)amino)quinazolin-6-yl)thiourea,0.0114,uM,=,-1.9430951486635275,0,S=C(NCc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4150,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CN(C)C(CS(C)(=O)=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,Rac-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(1-(dimethylamino)-2-(methylsulfonyl)ethyl)furan-2-yl)quinazolin-4-amine,0.0068,uM,=,-2.167491087293764,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
4151,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1ccc2cc(-c3nn(C)c4ncnc(N)c34)ccc2c1,"3-(6-ethoxynaphthalen-2-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",21.0,uM,=,1.3222192947339193,1,c1ccc2cc(-c3n[nH]c4ncncc34)ccc2c1
4152,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,COCCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccc(OC)c4)=CC3=O)c2cc1OC,"2-(3-methoxybenzyloxy)-5-(6-methoxy-7-(2-methoxyethoxy)quinazolin-4-ylamino)cyclohexa-2,5-diene-1,4-dione",7.71,uM,=,0.887054378050957,1,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
4153,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CCOP(=O)(Cc1cc(NCc2cc(O)ccc2O)ccc1O)OCC,"[5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzyl]-phosphonic acid diethyl ester",70.0,uM,=,1.845098040014257,1,c1ccc(CNc2ccccc2)cc1
4154,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Oc1cccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"3-[4-(3-Chloro-phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-phenol",0.026,uM,=,-1.585026652029182,0,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
4155,1448250,10.1016/j.bmcl.2014.07.094,,,,Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry,N#CC1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2ccccc2n2nnnc12,"2-Amino-5-oxo-1-(pyridin-3-yl)-4-(tetrazolo[1,5-a]quinolin-4-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile",4.8,uM,=,0.6812412373755872,1,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1
4156,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,O=C(/C=C/c1cccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)c1)NO,(E)-3-{3-[4-(3-Chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]phenyl}-N-hydroxyacrylamide,0.018,uM,=,-1.744727494896694,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccccc5)cc34)cc2)cc1
4157,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,Brc1cccc(Nc2ncnc3cnc(NCCCn4ccnc4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-(3-imidazol-1-yl-propyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0017,uM,=,-2.7695510786217263,0,c1ccc(Nc2ncnc3cnc(NCCCn4ccnc4)cc23)cc1
4158,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,C[C@@H](Nc1[nH]cnc2nc(-c3ccccc3)cc1-2)c1ccccc1,"(1-Phenyl-ethyl)-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",0.0033,uM,=,-2.4814860601221125,0,c1ccc(CNc2[nH]cnc3nc(-c4ccccc4)cc2-3)cc1
4159,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(C(=O)OC(C)C)c(-c2cn(C)c3ccccc23)n1,Isopropyl 2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.001,uM,=,-3.0,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c[nH]c2c1
4160,2298648,10.1016/j.bmcl.2023.129285,,,,Inhibition of EGFR (unknown origin) by fluorimetric assay,CC(=O)Nc1nc(C(=O)NNC(=O)CCN2CCN(C)CC2)cs1,N-(4-(2-(3-(4-methylpiperazin-1-yl)propanoyl)hydrazine-1-carbonyl)thiazol-2-yl)acetamide,0.131,uM,=,-0.8827287043442358,0,O=C(CCN1CCNCC1)NNC(=O)c1cscn1
4161,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Fc1c(Cl)cccc1Nc1ncnc2cc3c(cc12)OCCO3,"N-(3-Chloro-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0047,uM,=,-2.3279021420642825,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
4162,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,CCCCNC(=O)c1ccc(N(CCCl)CCCl)cc1,4-(Bis(2-chloroethyl)amino)-N-butylbenzamide,22.81,uM,=,1.3581252852766486,1,c1ccccc1
4163,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCC1,"3-(4-Amino-7-cyclobutyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-phenol",0.3,uM,=,-0.5228787452803376,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1
4164,974507,10.1016/j.ejmech.2013.05.026,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay,COc1cc(N2CCC(O)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(COc3no[n+]([O-])c3S(=O)(=O)c3ccccc3)cc2)n1,"4-(4-(5-chloro-2-(4-(4-hydroxypiperidin-1-yl)-2-methoxyphenylamino)pyrimidin-4-yloxy)benzyloxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide",3.15,uM,=,0.4983105537896005,1,O=S(=O)(c1ccccc1)c1[nH+]onc1OCc1ccc(Oc2ccnc(Nc3ccc(N4CCCCC4)cc3)n2)cc1
4165,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Oc1ccc(C2CC(c3ccc(Br)cc3)=NN2c2nc(-c3ccc(Cl)cc3)cs2)cc1,"4-(3-(4-bromophenyl)-1-(4-(4-chlorophenyl)thiazol-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)phenol",21.52,uM,=,1.3328422669943516,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
4166,1675840,10.1016/j.bmc.2017.03.032,,,,"Inhibition of recombinant wild type human EGFR (695 to end residues) using Poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(/C=C/c4cc(OC)cc(OC)c4)cc3)ncc2Cl)c1,"N-[3-[[5-Chloro-2-[(E)-4-(3,5-dimethoxystyryl)phenylamino]-4-pyrimidinyl]amino]phenyl]-2-acrylamide",0.2161,uM,=,-0.6653452331167587,0,C(=C/c1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)\c1ccccc1
4167,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,COc1cc(OC)cc(C2CC(c3ccc(C)c(C)c3)=NN2C(C)=O)c1,"1-(5-(3,5-Dimethoxyphenyl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone",17.31,uM,=,1.238297067875394,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
4168,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(I)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-piperidin-1-yl)prop-2-en-1-one",0.28,uM,=,-0.5528419686577808,0,c1ncc2cnn([C@@H]3CCCNC3)c2n1
4169,834209,10.1021/jm201713h,,,,Inhibition of human EGFR using poly glu-Tyr as substrate after 30 mins,COc1ccc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2c1.Cl,"1-isopropyl-3-(6-methoxynaphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride",0.51,uM,=,-0.2924298239020636,0,c1ccc2cc(-c3n[nH]c4ncncc34)ccc2c1
4170,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,O=C(CCCCCN1CCN(Cc2ccc(-c3cc4c(NCc5ccccc5)ncnc4[nH]3)cc2)CC1)NO,"6-(4-(4-(4-(benzylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzyl)piperazin-1-yl)-N-hydroxyhexanamide",0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccc(CN5CCNCC5)cc4)cc23)cc1
4171,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)NC)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-N-methylpyrimidine-5-carboxamide",0.147,uM,=,-0.8326826652518239,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)cc1
4172,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"But-2-enoic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide",0.0005,uM,=,-3.3010299956639813,0,c1ccc(Nc2ncnc3cnccc23)cc1
4173,2110760,10.1016/j.ejmech.2020.113022,,,,Inhibition of N-terminal GST-tagged human recombinant EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCN/C(=N\C#N)Nc4cccnc4)cc23)c1,2-Cyano-1-(6-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)hexyl)-3-(pyridin-3-yl)guanidine,0.00032,uM,=,-3.494850021680094,0,N=C(NCCCCCCOc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1cccnc1
4174,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,COc1ccc(CNc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"N*4*-(3-Chloro-phenyl)-N*3*-(4-methoxy-benzyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.02,uM,=,-1.6989700043360187,0,c1ccc(CNc2[nH]nc3ncnc(Nc4ccccc4)c23)cc1
4175,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,CC(=C(C#N)C#N)c1ccc(NC(=O)CCC(=O)O)cc1,"N-[4-(2,2-Dicyano-1-methyl-vinyl)-phenyl]-succinamic acid",500.0,uM,=,2.6989700043360187,1,c1ccccc1
4176,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(N)cc2)n1,4-(4-Aminophenoxy)-5-chloro-N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)pyrimidin-2-amine,14.01,uM,=,1.1464381352857749,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4177,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,Cc1ccc(C(=O)NS(=O)(=O)c2ccc(Cl)cc2)c(Cl)n1,2-Chloro-N-(4-chlorophenylsulfonyl)-6-methylnicotinamide,1.19,uM,=,0.0755469613925307,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
4178,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CONC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-N-methoxy-benzamide",20.0,uM,=,1.3010299956639813,1,c1ccc(CNc2ccccc2)cc1
4179,1330697,10.1039/C2MD20017A,,,,Inhibition of EGF-induced EGFR-mediated ERK phosphorylation in human A431 cells after 1 hr by immunoblotting method,C=CC(=O)Nc1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1,N-(3-(6-(3-bromophenylamino)pyrimidin-4-ylamino)phenyl)acrylamide,0.509,uM,=,-0.2932822176632412,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
4180,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine",0.00078,uM,=,-3.10790539730952,0,c1ccc(Nc2ncnc3ccccc23)cc1
4181,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1ccc(C2CC(c3ccc(Br)cc3)=NN2C2=NC(=O)CS2)cc1,"2-(3-(4-bromophenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",5.58,uM,=,0.7466341989375788,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
4182,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,NC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5ccccn5)c4)c23)CC1,"5-((4-aminopiperidin-1-yl)methyl)-N-(1-(pyridin-2-ylmethyl)-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.047,uM,=,-1.3279021420642825,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)nc1
4183,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CN1CC2(COC2)C1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)but-2-enamide",0.007,uM,=,-2.154901959985743,0,O=C(/C=C/CN1CC2(COC2)C1)Nc1cc2c(Nc3ccccc3)ncnc2s1
4184,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(OCC1CCCCC1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid cyclohexylmethyl ester",2.5,uM,=,0.3979400086720376,1,O=C(OCC1CCCCC1)c1cccc(NCc2ccccc2)c1
4185,63620,10.1021/jm970366v,,,,Inhibition of epidermal growth factor receptor (EGFR) autophosphorylation in A431 cells,OCC(O)CNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"3-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-ylamino]-propane-1,2-diol",0.227,uM,=,-0.6439741428068773,0,c1ccc(Nc2ncnc3ccncc23)cc1
4186,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(=O)Nc3cccc(C(=O)O)c3)c3ccccc3n2C)c(C(=O)Nc2cccc(C(=O)O)c2)c2ccccc21,3-{2-[3-(3-carboxyphenylcarbamoyl)-1-methyl-1H-2-indolyldisulfanyl]-1-methyl-1H-3-indolylcarboxamido}benzoic acid0.5 H2O,12.0,uM,=,1.0791812460476249,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
4187,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,Fc1cccc(COc2ccc(Nc3ncnn4ccc(COC[C@@H]5CNCCO5)c34)cc2Cl)c1,"(S)-N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-((morpholin-2-ylmethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.56,uM,=,-0.2518119729937995,0,c1ccc(COc2ccc(Nc3ncnn4ccc(COC[C@@H]5CNCCO5)c34)cc2)cc1
4188,66897,10.1021/jm970367n,,,,Inhibition of Epidermal growth factor receptor (EGFr) tyrosine kinase,CCNC(=O)Nc1nc2nc(NCCCCN(CC)CC)ncc2cc1-c1c(Cl)cccc1Cl,"1-[6-(2,6-Dichloro-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-ethyl-urea",1.26,uM,=,0.1003705451175629,1,c1ccc(-c2cnc3ncncc3c2)cc1
4189,66584,10.1016/s0960-894x(02)01047-8,,,,Inhibition of EGFR,CS(=O)(=O)CCNc1nc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)cs1,(4-Benzyloxy-3-chloro-phenyl)-{6-[2-(2-methanesulfonyl-ethylamino)-thiazol-4-yl]-quinazolin-4-yl}-amine,0.008,uM,=,-2.096910013008056,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5cscn5)cc34)cc2)cc1
4190,2192017,10.1016/j.ejmech.2020.112946,,,,Inhibition of EGFR (unknown origin),CN(C)c1ccc(/C=N/NC(=O)Cn2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)cc1,2-(4-(4-chlorobenzyl)-1-oxophthalazin-2(1H)-yl)-N'-(4-(dimethylamino)benzylidene)acetohydrazide,0.00045,uM,=,-3.3467874862246565,0,O=C(Cn1nc(Cc2ccccc2)c2ccccc2c1=O)N/N=C/c1ccccc1
4191,1739299,10.1016/j.ejmech.2018.05.006,,,,Inhibition of wild type EGFR (unknown origin) using FAM-labeled peptide substrate after 10 mins by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@@H]1CCOC1,(E)-N-(7-((R)-tetrahydrofuran-3-yloxy)-4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3cc(O[C@@H]4CCOC4)ccc23)cc1
4192,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,COc1cc2ncnc(C#CC(C)(C)N(C)c3ccccc3)c2cc1OC,"N-(4-(6,7-dimethoxyquinazolin-4-yl)-2-methylbut-3-yn-2-yl)-N-methylbenzenamine",0.08,uM,=,-1.0969100130080565,0,C(#Cc1ncnc2ccccc12)CNc1ccccc1
4193,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCCN1,"5-(4-amino-1-(pyrrolidin-2-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",9.38,uM,=,0.9722028383790644,1,c1ccc(-c2nn(CC3CCCN3)c3ncncc23)cc1
4194,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(NOCc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"N-Benzyloxy-5-(2,5-dihydroxy-benzylamino)-2-hydroxy-benzamide",0.05,uM,=,-1.3010299956639813,0,O=C(NOCc1ccccc1)c1cccc(NCc2ccccc2)c1
4195,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(C=C(C#N)C#N)cc(CS(=O)(=O)c2ccc(C)cc2)c1O,2-[4-Hydroxy-3-methoxy-5-(toluene-4-sulfonylmethyl)-benzylidene]-malononitrile,23.0,uM,=,1.3617278360175928,1,O=S(=O)(Cc1ccccc1)c1ccccc1
4196,63764,10.1021/jm960689b,,,,Inhibition of epidermal growth factor receptor (EGFr),Cn1c([Se][Se]c2c(C(=O)O)c3ccccc3n2C)c(C(=O)O)c2ccccc21,"2,2'-Diselenobis[1-methyl-1H-indole-3-carboxylic acid]",3.5,uM,=,0.5440680443502757,1,c1ccc2[nH]c([Se][Se]c3cc4ccccc4[nH]3)cc2c1
4197,2145645,10.1016/j.bmcl.2021.128406,,,,Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence of ATP by IMAP-FP assay,C=CC(=O)N1CCC2(CC1)CNC(=O)c1cc(-c3ccnc(-c4ccc5c(c4)OCO5)n3)[nH]c12,"1-acryloyl-2'-(2-(benzo[d][1,3]dioxol-5-yl)pyrimidin-4-yl)-5',6'-dihydrospiro[piperidine-4,7'-pyrrolo[3,2-c]pyridin]-4'(1'H)-one",0.043,uM,=,-1.3665315444204136,0,O=C1NCC2(CCNCC2)c2[nH]c(-c3ccnc(-c4ccc5c(c4)OCO5)n3)cc21
4198,66582,10.1021/jm970634p,,,,Inhibition of human epidermal growth factor receptor,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3ccccc3)nc21,"6-(2,6-Dichloro-phenyl)-8-methyl-2-phenylamino-8H-pyrido[2,3-d]pyrimidin-7-one",0.078,uM,=,-1.1079053973095196,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
4199,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1c(Nc2ncnc3cc4c(cc23)OCCO4)ccc(Cl)c1Br,"N-(3-Bromo-4-chloro-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0162,uM,=,-1.790484985457369,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
4200,445904,10.1021/jm070436q,,,,Inhibition of P-EGFR expressed in A431 cells,N#Cc1cnc2c(Br)cc(NCc3c[nH]cn3)cc2c1Nc1ccc(F)c(Cl)c1,8-bromo-4-[(3-chloro-4-fluorophenyl)amino]-6-[(1H-imidazol-5-ylmethyl)amino]quinoline-3-carbonitrile,3.3,uM,=,0.5185139398778875,1,c1ccc(Nc2ccnc3ccc(NCc4c[nH]cn4)cc23)cc1
4201,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,Cc1ccc(C2=NN(C(N)=S)C(c3ccc(Br)cc3)C2)cc1C,"5-(4-Bromophenyl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",2.17,uM,=,0.3364597338485295,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
4202,67045,10.1021/jm020899q,,,,"In vitro inhibition of Epidermal growth factor receptor (HER-1,ErbB) expressed in baculovirus",COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.016,uM,=,-1.7958800173440752,0,c1ccc(/N=c2\nc[nH]c3cc(OCC4CCNCC4)ccc23)cc1
4203,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,CC(CN(C)C)C(=O)c1ccc(OS(=O)(=O)c2ccc(C(=O)O)cc2)cc1.Cl,4-[4-(3-Dimethylamino-2-methyl-propionyl)-phenoxysulfonyl]-benzoic acid hydrochloride,100.0,uM,=,2.0,1,O=S(=O)(Oc1ccccc1)c1ccccc1
4204,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1F,"N-(3-Ethynyl-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0205,uM,=,-1.6882461389442458,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
4205,1448250,10.1016/j.bmcl.2014.07.094,,,,Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry,COC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2cc(OC)ccc2n2nnnc12,"Methyl 2-amino-4-(7-methoxytetrazolo[1,5-a]quinolin-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",1.3,uM,=,0.1139433523068367,1,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1
4206,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OC)cc3OC)ncc2Cl)c1,"US9238629, I-21",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
4207,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccc(OCc5ccccc5)cc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[4-(4-benzyloxy-benzyloxy)-3-chloro-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.574,uM,=,-0.2410881076020265,0,c1ccc(COc2ccc(COc3ccc(Nc4ccnc5ccccc45)cc3)cc2)cc1
4208,1589608,10.1016/j.ejmech.2016.04.026,,,,Inhibition of cytoplasmic GST-tagged human recombinant EGFR expressed in baculovirus system by z-lyte assay,Cn1cc(-c2ccc3ncnc(Nc4ccc5ncccc5c4)c3c2)cn1,6-(1-methyl-1H-pyrazol-4-yl)-N-(quinolin-6-yl)quinazolin-4-amine,0.0441,uM,=,-1.3555614105321614,0,c1cnc2ccc(Nc3ncnc4ccc(-c5cn[nH]c5)cc34)cc2c1
4209,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C(=O)Cn2cncc2[N+](=O)[O-])CC1,1-(4-((4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)methyl)piperidin-1-yl)-2-(5-nitro-1H-imidazol-1-yl)ethanone,0.00323,uM,=,-2.490797477668897,0,O=C(Cn1ccnc1)N1CCC(COc2ccc3c(Nc4ccccc4)ncnc3c2)CC1
4210,1883874,10.1021/acsmedchemlett.8b00270,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay,COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3)c2cc1OCCCN1CCOCC1,"4-[(3,4-dichlorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline",0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
4211,676221,10.1021/jm100607r,,,,Inhibition of EGFR,CN(C)C/C=C/C(=O)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,"(E)-4-(Dimethylamino)-1-(4-[(1S)-2-hydroxy-1-phenylethyl]-amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-buten-1-one",0.07,uM,=,-1.154901959985743,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1
4212,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCNC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,N-Hexyl-2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetamide,8.71,uM,=,0.9400181550076632,1,O=c1cc(-c2ccccc2)oc2ccccc12
4213,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Fc1ccc2c(Nc3cccc(Br)c3)ncnc2n1,"(3-Bromo-phenyl)-(7-fluoro-pyrido[2,3-d]pyrimidin-4-yl)-amine",0.684,uM,=,-0.1649438982798837,0,c1ccc(Nc2ncnc3ncccc23)cc1
4214,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,CCOc1ccc(NC(=O)/C=C/c2ccccc2)cc1,(E)-N-(4-ethoxyphenyl)cinnamamide,10.23,uM,=,1.0098756337121602,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
4215,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC.Cl,"4-(3'-bromoanilino)-6,7-diethoxyquinazoline hydrochloride",0.078,uM,=,-1.1079053973095196,0,c1ccc(Nc2ncnc3ccccc23)cc1
4216,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Nc1ccc2c(Nc3cccc(Br)c3)ncnc2c1,"N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine",0.0001,uM,=,-4.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
4217,787516,10.1016/j.bmcl.2011.09.008,,,,Inhibition of EGFR relative to control,Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12,"(E)-4-(Dimethylamino)-N-(7-fluoro-4-(o-tolylamino)imidazo[1,5-a]quinoxalin-8-yl)-N-methylbut-2-enamide",0.0756,uM,=,-1.1214782044987934,0,c1ccc(Nc2nc3ccccc3n3cncc23)cc1
4218,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CC(=O)N/C=C/c1cc(O)ccc1O,"N-(2,5-dihydroxystyryl)acetamide",15.538092437520408,uM,=,1.191397700777031,1,c1ccccc1
4219,64437,10.1016/s0960-894x(00)00131-1,,,,Tested for inhibition of EGF-receptor tyrosine kinase in intact cells,Nc1ncnc2c1c(-c1ccccc1)cn2-c1cccc(CO)c1,"[3-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-phenyl]-methanol",12.0,uM,=,1.0791812460476249,1,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
4220,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O,3-[3-(Benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,19.0,uM,=,1.2787536009528289,1,c1ccc(CSc2nc3ccccc3s2)cc1
4221,942122,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3cccc(C(F)(F)F)c3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-trifluoromethyl-phenyl)-amine",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3ccccc23)cc1
4222,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc3ccccc3c2)c1O,2-Cyano-3-[4-hydroxy-3-methoxy-5-(naphthalen-2-ylsulfanylmethyl)-phenyl]-acrylamide,6.6,uM,=,0.8195439355418687,1,c1ccc(CSc2ccc3ccccc3c2)cc1
4223,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,OCCn1ccc2ncnc(Nc3ccc(Oc4cccc5sccc45)c(Cl)c3)c21,"2-(4-{[4-(1-Benzothiophen-4-yloxy)-3-chlorophenyl]amino}-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethanol",0.0088,uM,=,-2.055517327849832,0,c1cc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)c2ccsc2c1
4224,1553877,10.1016/j.ejmech.2016.01.045,,,,Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay,COc1cc2ncnc(Nc3ccc(C(=O)NC45CC6CC(CC(C6)C4)C5)cc3)c2cc1OCCCN1CCOCC1,N-(Adamantan-1-yl)-4-((7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl)amino)benzamide,0.0020099999999999,uM,=,-2.6968039425795114,0,O=C(NC12CC3CC(CC(C3)C1)C2)c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
4225,306626,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate; Range = 1000-5000 nM,COCC(=O)Nc1ccc2ncnc(Nc3cccc(I)c3)c2c1,N-[4-(3-Iodo-phenylamino)-quinazolin-6-yl]-2-methoxy-acetamide,5.0,uM,=,0.6989700043360189,1,c1ccc(Nc2ncnc3ccccc23)cc1
4226,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccc(Br)cc1,"5-(4-Bromophenyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",6.85,uM,=,0.8356905714924255,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
4227,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=CS(=O)(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,Ethenesulfonic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.0014,uM,=,-2.853871964321762,0,c1ccc(Nc2ncnc3ccccc23)cc1
4228,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1OCCCn1ccnc1[N+](=O)[O-],N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-methoxy-6-(3-(2-nitro-1H-imidazol-1-yl)propoxy)quinazolin-4-amine,0.0382999999999999,uM,=,-1.4168012260313774,0,c1ccc(COc2ccc(Nc3ncnc4ccc(OCCCn5ccnc5)cc34)cc2)cc1
4229,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,Brc1cc2c(NCc3cccs3)ncnc2s1,"6-Bromo-N-(thiophen-2-ylmethyl)thieno[2,3-d]pyrimidin-4-amine",1.374,uM,=,0.1379867327235316,1,c1csc(CNc2ncnc3sccc23)c1
4230,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,COc1cc(NC(=O)Nc2nccs2)cc(-c2cn(C)cn2)c1OC,"1-(3,4-dimethoxy-5-(1-methyl-1H-imidazol-4-yl)phenyl)-3-(thiazol-2-yl)urea",0.362,uM,=,-0.4412914294668343,0,O=C(Nc1cccc(-c2c[nH]cn2)c1)Nc1nccs1
4231,1970998,10.1016/j.ejmech.2019.111918,,,,Inhibition of EGFR (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay,C=CC(=O)NCCOc1cc(Cc2ccccc2)cc2[nH]c(-c3n[nH]c4cc(C(F)F)ccc34)cc12,N-(2-((6-benzyl-2-(6-(difluoromethyl)-1H-indazol-3-yl)-1H-indol-4-yl)oxy)ethyl)acrylamide,2.36,uM,=,0.3729120029701065,1,c1ccc(Cc2ccc3cc(-c4n[nH]c5ccccc45)[nH]c3c2)cc1
4232,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,COc1cccc(-c2cn(C3CCN(CC(N)=O)C3)c3ncnc(N)c23)c1,"2-{3-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-pyrrolidin-1-yl}-acetamide",0.44,uM,=,-0.3565473235138126,0,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1
4233,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(c3ccc(-c4ccccc4)cc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(3-(Biphenyl-4-yl)-7-(2-methoxy-4-(4-methylpiperazin-1-yl)-phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.00141,uM,=,-2.8507808873446203,0,O=C1N(c2ccc(-c3ccccc3)cc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
4234,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1/C=C/CCN1CCOCC1,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(4-morpholin-4-yl-but-1-enyl)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.00016,uM,=,-3.795880017344075,0,C(=C/c1cnc2c(Nc3ccccc3)ncnc2c1)\CCN1CCOCC1
4235,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.092,uM,=,-1.0362121726544449,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
4236,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,COCCn1c(=O)oc2cc3ncnc(Nc4ccc(OCc5ccc(Cl)cc5)c(Cl)c4)c3cc21,"8-(4-(4-Chlorobenzyloxy)-3-chlorophenylamino)-1-(2-methoxyethyl)oxazolo[4,5-g]quinazolin-2(1H)-one",1.3,uM,=,0.1139433523068367,1,O=c1[nH]c2cc3c(Nc4ccc(OCc5ccccc5)cc4)ncnc3cc2o1
4237,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2)c1O,2-Cyano-3-(4-hydroxy-3-methoxy-5-phenylsulfanylmethyl-phenyl)-acrylamide,12.5,uM,=,1.0969100130080565,1,c1ccc(CSc2ccccc2)cc1
4238,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,Cc1ccc(S(=O)(=O)NC(=O)c2cncc(Br)c2)cc1,5-bromo-N-tosylnicotinamide,12.11,uM,=,1.0831441431430522,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
4239,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,N#C/C(=C\c1cc(O)c(O)c(CSc2nc3ccccc3s2)c1)C(N)=O,"3-[3-(Benzothiazol-2-ylsulfanylmethyl)-4,5-dihydroxy-phenyl]-2-cyano-acrylamide",6.5,uM,=,0.8129133566428556,1,c1ccc(CSc2nc3ccccc3s2)cc1
4240,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C=C=CCCCCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O,"4-(3'-chloro-4'-fluorophenylamino)-6-(hepta-5,6-dienyloxy)-7-methoxyquinazoline",0.0655,uM,=,-1.183758700008217,0,c1ccc(Nc2ncnc3ccccc23)cc1
4241,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccccc2N=C=S)n1,N-(2-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)isothiocyanate,20.12,uM,=,1.3036279763838898,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4242,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCCC1,(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(pyrrolidin-1-yl)but-2-enamide,0.003,uM,=,-2.5228787452803374,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
4243,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),O=[N+]([O-])CCc1c(SSc2[nH]c3ccccc3c2CC[N+](=O)[O-])[nH]c2ccccc12,di[3-(2-nitroethyl)-1H-2-indolyl] disulfide,89.0,uM,=,1.9493900066449128,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
4244,1650711,10.1016/j.bmcl.2017.02.023,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay,O=C(Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)C1CCC2(CC1)OOC1(OO2)C2CC3CC(C2)CC1C3,"N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3,3-adamantane-1,2,4,5-tetraoxaspiro[5.5]undecane-9-carboxamide",0.3797,uM,=,-0.4205594028602028,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CCC2(CC1)OOC1(OO2)C2CC3CC(C2)CC1C3
4245,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1NC(=O)/C(F)=C/CN(C)C,(Z)-N-(4-((3-Bromophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.0026,uM,=,-2.5850266520291822,0,c1ccc(Nc2ncnc3ccccc23)cc1
4246,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,COc1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"N*4*-(3-Chloro-phenyl)-N*3*-(4-methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",1.5,uM,=,0.1760912590556812,1,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
4247,1739299,10.1016/j.ejmech.2018.05.006,,,,Inhibition of wild type EGFR (unknown origin) using FAM-labeled peptide substrate after 10 mins by mobility shift assay,COc1cc2ncnc(N3CCc4ccccc43)c2cc1NC(=O)/C=C/CN1CCC(CO)CC1,(E)-4-(4-(hydroxymethyl)piperidin-1-yl)-N-(4-(indolin-1-yl)-7-methoxyquinazolin-6-yl)but-2-enamide,0.004,uM,=,-2.397940008672037,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(N3CCc4ccccc43)c2c1
4248,473572,10.1073/pnas.0708800104,,,,Inhibition of wild type EGFR,O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1,N-3-6-3-trifluoromethyl-phenylamino-pyrimidin-4-ylamino-phenyl-cyclopropanecarboxamide,0.021,uM,=,-1.6777807052660807,0,O=C(Nc1cccc(Nc2cc(Nc3ccccc3)ncn2)c1)C1CC1
4249,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CN(C)CCCC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(dimethylamino)butanamide",0.799,uM,=,-0.0974532206860085,0,c1ccc(Nc2ncnc3sccc23)cc1
4250,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,CCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1,"6-(2,6-Dichloro-phenyl)-2-ethylamino-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",4.5,uM,=,0.6532125137753437,1,O=c1[nH]c2ncncc2cc1-c1ccccc1
4251,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,COc1ccc2c(NCc3ccccc3)ncnc2c1,Benzyl-(7-methoxy-quinazolin-4-yl)-amine,0.058,uM,=,-1.2365720064370629,0,c1ccc(CNc2ncnc3ccccc23)cc1
4252,2070249,10.1021/acs.jmedchem.0c00491,,,,Inhibition of EGFR (unknown origin),O=C(CCCCCCC(=O)Nc1ccccc1)NO,Octanedioic acid hydroxyamide phenylamide,0.9,uM,=,-0.0457574905606751,0,c1ccccc1
4253,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Brc1cccc(Nc2ncnc3c2NCc2ccccc2O3)c1,"(3-Bromo-phenyl)-(10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",3.4,uM,=,0.5314789170422551,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
4254,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H]([N+](C)(C)C)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl(trimethyl)ammonium",0.019,uM,=,-1.7212463990471711,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
4255,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cnc(Nc2ccccc2)nc1,N-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-2-(phenylamino)-pyrimidine-5-carboxamide,0.006,uM,=,-2.2218487496163566,0,O=C(Nc1cccc(C(=O)Nc2ccc(CN3CCNCC3)cc2)c1)c1cnc(Nc2ccccc2)nc1
4256,1991520,10.1016/j.bmcl.2020.127327,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,BRIGATINIB,0.0482999999999999,uM,=,-1.316052869248488,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
4257,1842443,10.1016/j.ejmech.2019.03.004,,,,Inhibition of EGFR (unknown origin) assessed as reduction of phosphorylation of Crk incubated for 10 mins in ice with gamma-ATP followed by incubated for 20 mins in 30 degC by radioactive phosphorylation assay,C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,"N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododeca[2,3-g]quinazolin-4-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)cc1
4258,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,Cn1c(SSc2c(C(=O)Nc3ccccc3)c3cc(Br)ccc3n2C)c(C(=O)Nc2ccccc2)c2cc(Br)ccc21,"2,2'-Dithiobis(1-methyl-5-bromo-N-phenyl-1H-indole-3-carboxamide)",11.4,uM,=,1.0569048513364727,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
4259,2017350,10.1021/acs.jmedchem.0c00870,,,,Inhibiton of EGFR (unknown origin) expressed in human A431 cells assessed as reduction in EGFR induced cell viability after 96 hrs by CellTiter-Glo assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,2.685,uM,=,0.4289442900355744,1,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
4260,488353,10.1021/jm701575k,,,,Inhibition of EGF-tyrosine kinase,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.0053,uM,=,-2.275724130399211,0,c1ccc(Nc2ncnc3ccccc23)cc1
4261,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1cc2c(Nc3cccc(C)c3)ncnc2cc1OCCCN1CCOCC1,N-[7-(3-Morpholin-4-yl-propoxy)-4-m-tolylamino-quinazolin-6-yl]-acrylamide,0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
4262,2107115,10.1016/j.ejmech.2021.113300,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,NS(=O)(=O)c1ccc(CCNC(=S)Nc2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cc1,4-(2-(3-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)thioureido)ethyl)benzenesulfonamide,0.0283999999999999,uM,=,-1.5466816599529625,0,S=C(NCCc1ccccc1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
4263,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@H]6CNCCO6)c45)ccc32)c1,"(R)-N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((morpholin-2-ylmethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.083,uM,=,-1.080921907623926,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@H]6CNCCO6)c45)ccc32)cc1
4264,1639950,,,,,Inhibition of recombinant human N-terminal GST His6-tagged thrombin cleavage site-fused EGFR (H672 to A1210 residues) expressed in baculovirus using poly-EY as substrate after 210 mins by luciferase coupled chemiluminescence assay,COc1cc2c(Nc3ccc(Cl)c(Cl)c3)ncnc2cc1OCc1csc(-c2ccc(C(F)(F)F)cc2)n1,"N-(3,4-dichlorophenyl)-6-(methyloxy)-7-[({2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-4-yl}methyl)oxy]quinazolin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3cc(OCc4csc(-c5ccccc5)n4)ccc23)cc1
4265,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCNCCN(C)C,"N-{2-[4-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-ethyl}-N',N'-dimethyl-ethane-1,2-diamine",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
4266,2080997,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(CCCCC(=O)NO)nn1,"5-(4-(((6-Acrylamido-4-((3-chloro-4-fluorophenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypentanamide",0.00088,uM,=,-3.055517327849832,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
4267,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",S=C(NNc1nncc2ccccc12)Nc1ccccc1,N-Phenyl-2-(phthalazin-1-yl)hydrazine-1-carbothioamide,0.065,uM,=,-1.1870866433571443,0,S=C(NNc1nncc2ccccc12)Nc1ccccc1
4268,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1ncc(N2C[C@H](O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((8-((2R,3S)-3-hydroxy-2-methylazetidin-1-yl)-5-isopropyl-2,6-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",25.0,uM,=,1.3979400086720375,1,c1cc(Nc2cc3cncc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
4269,2132157,10.1021/acs.jmedchem.1c01559,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"US9447106, 27b (peak 2)",0.0212,uM,=,-1.6736641390712486,0,c1ccc(Oc2ccc(-c3cc4n(n3)[C@H](C3CCNCC3)CCN4)cc2)cc1
4270,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,Brc1cccc(Nc2ncnc3cc(NCCCCN4CCOCC4)ncc23)c1,"N*4*-(3-Bromo-phenyl)-N*7*-(4-morpholin-4-yl-butyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0054,uM,=,-2.2676062401770314,0,c1ccc(Nc2ncnc3cc(NCCCCN4CCOCC4)ncc23)cc1
4271,512722,10.1021/jm8006189,,,,Inhibition of EGFR,COc1cc2c(Oc3ccc(-c4cnc(Nc5ccc(F)cc5)n(C)c4=O)cc3F)ccnc2cc1OCCCN1CCOCC1,5-(3-Fluoro-4-(6-methoxy-7-(3-morpholino-propoxy)quinolin-4-yloxy)phenyl)-2-(4-fluorophenylamino)-3-methylpyrimidin-4(3H)-one,1.7,uM,=,0.2304489213782739,1,O=c1[nH]c(Nc2ccccc2)ncc1-c1ccc(Oc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1
4272,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CCOc1cc(/C=C2/CCNC2=O)cc(CSc2ccccc2)c1O,3-(3-ethoxy-4-hydroxy-5-(phenylthiomethyl)benzylidene)pyrrolidin-2-one,0.9,uM,=,-0.0457574905606751,0,O=C1NCC/C1=C/c1cccc(CSc2ccccc2)c1
4273,2296337,10.1039/d3md00038a,,,,Inhibition of EGFR (unknown origin),CCc1c(C(=O)NCCc2ccc(N3CCCCC3)cc2)[nH]c2ccc(C)cc12,3-ethyl-5-methyl-N-(4-(piperidin-1-yl)phenethyl)-1H-indole-2-carboxamide,0.117,uM,=,-0.9318141382538384,0,O=C(NCCc1ccc(N2CCCCC2)cc1)c1cc2ccccc2[nH]1
4274,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,COc1cc2ncnc(Nc3cc(F)cc(C(F)(F)F)c3)c2cc1OC.Cl,"4-[3'-fluoro-5'-(trifluoromethyl)anilino]-6,7-dimethoxyquinazoline hydrochloride",0.0191,uM,=,-1.7189666327522723,0,c1ccc(Nc2ncnc3ccccc23)cc1
4275,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccc(Br)cc1,"(R)-4-(4-((1-(4-Bromophenyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.062,uM,=,-1.207608310501746,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
4276,1674791,10.1016/j.ejmech.2017.03.001,,,,"Inhibition of recombinant human N-terminal GST-tagged wild-type EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(Oc4ccnc(C(=O)NC)c4)cc3)ncc2F)c1,4-(4-(4-(3-acrylamidophenylamino)-5-fluoropyrimidin-2-ylamino)phenoxy)-N-methylpicolinamide,0.737,uM,=,-0.1325325121409485,0,c1ccc(Nc2ccnc(Nc3ccc(Oc4ccncc4)cc3)n2)cc1
4277,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3cc(Cl)ccc3s2)c1O,3-[3-(5-Chloro-benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,4.5,uM,=,0.6532125137753437,1,c1ccc(CSc2nc3ccccc3s2)cc1
4278,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C=CCCCCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,4-(3'-Chloro-4'-fluorophenylamino)-6-(hex-5-enyloxy)-7-methoxyquinazoline,0.0326,uM,=,-1.4867823999320608,0,c1ccc(Nc2ncnc3ccccc23)cc1
4279,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,O=C(C#CCN1CCSCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Thiomorpholin-4-yl-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.095,uM,=,-1.0222763947111522,0,O=C(C#CCN1CCSCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4280,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C=C=CCOc1cc2c(Nc3cccc(Cl)c3)ncnc2cc1O,"6-(Buta-2,3-dienyloxy)-4-(3'-chlorophenylamino)-7-methoxyquinazoline",0.0169,uM,=,-1.7721132953863266,0,c1ccc(Nc2ncnc3ccccc23)cc1
4281,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccc(C)c(C)c4)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,"1-(2-chloro-4-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)phenyl)-3-(3,4-dimethylphenyl)urea",0.051,uM,=,-1.2924298239020635,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
4282,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCO)c(OCCOC)cc23)c1,N-(3-Ethynylphenyl)-7-(2-hydroxyethoxy)-6-methoxyethoxy-4-quinazolinamine,0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
4283,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=c1c(-c2ccc(O)c(O)c2)coc2cc(O)cc(O)c12,"3-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one",10.487759912230068,uM,=,1.020682736844965,1,O=c1c(-c2ccccc2)coc2ccccc12
4284,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Oc1ccc(CN(Cc2cccc(Br)c2O)C(=S)Nc2ccccc2)cc1,1-(5-Bromo-2-hydroxybenzyl)-1-(4-hydroxybenzyl)-3-phenylthiourea,0.12,uM,=,-0.9208187539523752,0,S=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
4285,67206,10.1021/jm010496a,,,,Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase,CCOc1cc2ncnc(Nc3cccc(-c4cc[nH]n4)c3)c2cc1OCC,"(6,7-Diethoxy-quinazolin-4-yl)-[3-(1H-pyrazol-3-yl)-phenyl]-amine",0.011,uM,=,-1.958607314841775,0,c1cc(Nc2ncnc3ccccc23)cc(-c2cc[nH]n2)c1
4286,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc(Cl)cc4)c3cc21,"Ethyl 4-(8-(4-chlorophenylamino)-2-oxooxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",1.2,uM,=,0.0791812460476248,1,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
4287,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1/C=C/c1ccc(CNCCS(C)(=O)=O)o1,N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-methyl-5-(2-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)vinyl)pyrimidin-4-amine,0.46,uM,=,-0.3372421683184259,0,C(=C/c1cncnc1Nc1ccc(OCc2ccccc2)cc1)\c1ccco1
4288,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3nc[nH]c3n2)C[C@H]1F,"N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide",0.75,uM,=,-0.1249387366082999,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1
4289,1776289,10.1016/j.bmcl.2018.06.043,,,,Inhibition of EGFR isolated from human A431 cells,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC,"(3-Chloro-4-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2ncnc3ccccc23)cc1
4290,787272,10.1016/j.bmcl.2011.09.008,,,,Inhibition of EGFR preincubated for 60 mins measured after 60 mins by TR-FRET Assay,Cc1ccc(F)cc1Nc1nc2cc(Cl)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12,"(E)-N-(7-Chloro-4-(5-fluoro-2-methylphenylamino)imidazo[1,5-a]quinoxalin-8-yl)-4-(dimethylamino)-N-methylbut-2-enamide",0.00335,uM,=,-2.474955192963155,0,c1ccc(Nc2nc3ccccc3n3cncc23)cc1
4291,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",CN(C)CCNC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(2-(dimethylamino)ethyl)urea,0.635,uM,=,-0.1972262747080243,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
4292,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,CC(=O)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccccc1Cl,"1-(5-(2-Chlorophenyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone",24.15,uM,=,1.382917135087531,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
4293,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CN[C@H]1C[C@@H]2O[C@](C)([C@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@@H]4O,"18-hydroxy-3-methoxy-2-methyl-4-methylamino-(2R,3S,4S,6S,18R)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-16-one",0.017,uM,=,-1.769551078621726,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
4294,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(=O)Nc3ccccc3C(=O)O)c3ccccc3n2C)c(C(=O)Nc2ccccc2C(=O)O)c2ccccc21,2-{2-[3-(2-carboxyphenylcarbamoyl)-1-methyl-1H-2-indolyldisulfanyl]-1-methyl-1H-3-indolylcarboxamido}benzoic acid2.0 H2O,47.0,uM,=,1.6720978579357175,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
4295,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1,"6-(3-morpholinopropyl)-4-(phenylamino)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.5186000000000001,uM,=,-0.2851674875666672,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
4296,2203131,10.1016/j.ejmech.2022.114455,,,,Inhibition of wild type EGFR (unknown origin) incubated for 10 mins by HTRF KinEASE-TK assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,0.07661,uM,=,-1.1157145376603248,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4297,321418,10.1016/j.bmcl.2005.06.068,,,,Inhibitory concentration against EGFR kinase phosphorylation using synthetic peptide as a substrate,CN1CCC(Oc2cccc3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,[3-Chloro-4-(pyridin-2-ylmethoxy)-phenyl]-[5-(1-methyl-piperidin-4-yloxy)-quinazolin-4-yl]-amine,0.14,uM,=,-0.8538719643217619,0,c1ccc(COc2ccc(Nc3ncnc4cccc(OC5CCNCC5)c34)cc2)nc1
4298,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3cnccc3c2)c2c(N)ncnc21,"1-isopropyl-3-(isoquinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",25.0,uM,=,1.3979400086720375,1,c1cc2cc(-c3n[nH]c4ncncc34)ccc2cn1
4299,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC[C@H]1C(N)=O,(S)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidine-2-carboxamide,0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
4300,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(CN1CCC(CCO)CC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-2-(4-(2-hydroxyethyl)piperidin-1-yl)acetamide",0.542,uM,=,-0.266000713461613,0,O=C(CN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
4301,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Fc1cccc(COc2ccc(Nc3cc(-c4ccccc4)ncn3)cc2Cl)c1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-phenylpyrimidin-4-amine,1.2,uM,=,0.0791812460476248,1,c1ccc(COc2ccc(Nc3cc(-c4ccccc4)ncn3)cc2)cc1
4302,982643,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis,Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine",0.02145,uM,=,-1.668572703479257,0,c1ccc(Nc2ncnc3ccccc23)cc1
4303,600206,10.1016/j.bmcl.2009.05.060,,,,Inhibition of EGFR-mediated poly(L-glutamic acid L-tyrosine) phosphorylation,CN(/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)C(=O)Oc1ccc([N+](=O)[O-])cc1,4-nitrophenyl 3-(4-(3-chlorophenylamino)quinazolin-6-yl)-1-methyltriaz-2-ene-1-carboxylate,0.77,uM,=,-0.1135092748275181,0,O=C(N/N=N/c1ccc2ncnc(Nc3ccccc3)c2c1)Oc1ccccc1
4304,436426,10.1021/jm070144p,,,,Inhibition of EGFR tyrosine kinase expressed in A431 cells,CN(CCCl)CCN/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,1-{4-[(3-chlorophenyl)amino-6-quinazolinyl}-3-{2-[N-(2-chloroethyl)-N-methylethylenamine]}triazene,0.0044,uM,=,-2.356547323513813,0,c1ccc(Nc2ncnc3ccccc23)cc1
4305,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2cc(-c3cn4c5c(cccc35)CCC4)nc(OC)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((6-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-2-methoxypyrimidin-4-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)Acrylamide",0.543,uM,=,-0.265200170411153,0,c1ccc(Nc2cc(-c3cn4c5c(cccc35)CCC4)ncn2)cc1
4306,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C)c3ncnc(N)c23)cc1O,"5-(4-amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol",100.0,uM,=,2.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
4307,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccc5ccccc5c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(naphthalen-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.015,uM,=,-1.8239087409443189,0,c1ccc2cc(COc3ccc(Nc4ccnc5ccccc45)cc3)ccc2c1
4308,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccn4)c3)ncnc2cc1OC,N-(7-Methoxy-4-{[1-(2-pyridinylmethyl)-1H-indazol-5-yl]amino}-6-quinazolinyl)propanamide,0.094,uM,=,-1.0268721464003014,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccccc45)ccc32)nc1
4309,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1ccc(N2C[C@H](O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((8-((2R,3S)-3-hydroxy-2-methylazetidin-1-yl)-5-isopropylisoquinolin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",25.0,uM,=,1.3979400086720375,1,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
4310,2270859,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) using TK as substrate incubated for 30 min in presence of ATP by TR-FRET assay,C=CC(=O)Nc1ccc2ncc(NC(=O)Nc3ccccc3)nc2c1,N-(3-(3-phenylureido)quinoxalin-6-yl)acrylamide,0.025,uM,=,-1.6020599913279625,0,O=C(Nc1ccccc1)Nc1cnc2ccccc2n1
4311,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CS(=O)(=O)CCNC/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-((2-(methylsulfonyl)ethyl)amino)but-2-enamide",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3sccc23)cc1
4312,1832355,10.1016/j.bmcl.2018.12.056,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,COC[C@H](C)Oc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,"(S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(2-methoxy-1-methylethoxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide",0.00273,uM,=,-2.563837352959244,0,c1ccc(Nc2ncnc3ccccc23)cc1
4313,82323,10.1021/jm9904295,,,,Inhibitory activity against ligand-dependent EGF cell proliferation,COc1cccc(-c2ccc3c(c2)NC(=O)/C3=C\c2[nH]cc(C)c2CCC(=O)O)c1,"3-{2-[6-(3-Methoxy-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-4-methyl-1H-pyrrol-3-yl}-propionic acid",49.2,uM,=,1.6919651027673603,1,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1ccc[nH]1
4314,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Sc3cccc(Cl)c3)c1NC2,"1-(3-chloro-phenylsulfanyl)-7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene",1.0,uM,=,0.0,0,c1ccc(Sc2ncnc3c2NCc2ccccc2O3)cc1
4315,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1OC,"3-(3-ethoxy-4-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",54.2,uM,=,1.7339992865383869,1,c1ccc(-c2n[nH]c3ncncc23)cc1
4316,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C3CCC(C)C3)c3ncnc(N)c23)cc1O,"5-(4-amino-1-(3-methylcyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol",0.27,uM,=,-0.5686362358410126,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
4317,1883874,10.1021/acsmedchemlett.8b00270,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay,C=CC(=O)N(c1cc(Cl)ccc1F)c1ncnc2cc(OC)c(OCCCN3CCOCC3)cc12,4-[N-acryloyl-(5-chloro-2-fluorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline,0.133,uM,=,-0.8761483590329142,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
4318,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCc1c(CC(=O)O)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"[4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-acetic acid",1.6,uM,=,0.2041199826559248,1,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
4319,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,C=C(C)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-{4-(3-Chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl}-2-methylacrylamide,0.067,uM,=,-1.1739251972991736,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
4320,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COC(=O)c1ccc(-c2cc3c(N[C@H](C)c4ccccc4)ncnc3s2)c(OC)c1,"Methyl (R)-3-methoxy-4-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzoate",0.02,uM,=,-1.6989700043360187,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
4321,2080588,10.1021/acs.jmedchem.0c02005,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu-Tyr) 4:1 as substrate incubated for 1 hr in presence of ATP by ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.1523,uM,=,-0.8173000966639574,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4322,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,COc1cc2ncnc(/C=C/CCc3ccccc3)c2cc1OC,"(E)-6,7-dimethoxy-4-(4-phenylbut-1-enyl)quinazoline",0.004,uM,=,-2.397940008672037,0,C(=C/c1ncnc2ccccc12)\CCc1ccccc1
4323,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,Cc1ccc2[nH]c(SSc3[nH]c4ccc(C)cc4c3CCC(=O)O)c(CCC(=O)O)c2c1,3-{2-[3-(2-Carboxy-ethyl)-5-methyl-1H-indol-2-yldisulfanyl]-5-methyl-1H-indol-3-yl}-propionic acid,8.4,uM,=,0.9242792860618816,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
4324,2229998,10.1021/acs.jmedchem.1c00876,,,,Inhibition of wild type EGFR (unknown origin),COc1cc(N2CCC(N3CCN(CCO)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1,N-(2-((5-chloro-2-((4-(4-(4-(2-hydroxyethyl)piperazin-1-yl)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide,0.26,uM,=,-0.585026652029182,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
4325,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1cnc(N2C[C@H](CS(C)(=O)=O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",0.781,uM,=,-0.1073489661226996,0,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
4326,2293062,10.1021/acs.jmedchem.6b00995,,,,Inhibition of EGFR autophosphorylation in human NCI-H292 cells harboring harboring wild type EGFR preincubated for 60 mins followed by EGF stimulation and measured after 8 mins by SULFO-TAG based electrochemiluminescent assay,CC(C)n1nc(N)c2cnc(Nc3ccnc(-c4cnn(S(=O)(=O)C5CC5)c4)n3)cc21,"N6-(2-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-yl)-1-isopropyl-1H-pyrazolo[4,3-c]pyridine-3,6-diamine",3.9,uM,=,0.5910646070264992,1,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3cc4[nH]ncc4cn3)n2)cn1
4327,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CNc1ccc2c(Nc3cccc(Br)c3)ncnc2c1,"N*4*-(3-Bromo-phenyl)-N*7*-methyl-quinazoline-4,7-diamine",0.007,uM,=,-2.154901959985743,0,c1ccc(Nc2ncnc3ccccc23)cc1
4328,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,O=C(/C=C/N1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,(2E)-N-{4-[(3-Bromophenyl)amino]-6-quinazolinyl}-3-(N-morpholinyl)-2-propenamide,0.215,uM,=,-0.6675615400843947,0,O=C(/C=C/N1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4329,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCOC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,Hexyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetate,9.12,uM,=,0.959994838328416,1,O=c1cc(-c2ccccc2)oc2ccccc12
4330,933957,10.1016/j.bmcl.2012.12.028,,,,Inhibition of EGFR (unknown origin) in presence of ATP,CN1CCC(NC(=O)c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2N[C@@H]2COC[C@H]2O)CC1,"2-(3,5-dichlorophenylamino)-4-((3R,4S)-4-hydroxytetrahydrofuran-3-ylamino)-N-(1-methylpiperidin-4-yl)pyrimidine-5-carboxamide",30.0,uM,=,1.4771212547196624,1,O=C(NC1CCNCC1)c1cnc(Nc2ccccc2)nc1N[C@H]1CCOC1
4331,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Fc1c(Nc2ncnc3cc4c(cc23)OCCO4)cccc1C(F)(F)F,"N-[2-Fluoro-3-(trifluoromethyl)phenyl]-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.055,uM,=,-1.259637310505756,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
4332,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)c(OC)c4)nc32)c1,"N-(3-(3-Isopropyl-7-((3-methoxy-4-(4-methylpiperazin-1-yl)-phenyl)amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.119,uM,=,-0.9244530386074692,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12
4333,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1ccc(Cl)cc1)NS(=O)(=O)c1ccccc1,2-(4-Chlorophenyl)-N-(phenylsulfonyl)acetamide,11.91,uM,=,1.0759117614827776,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
4334,86513,10.1021/jm00110a022,,,,Inhibition of HER14 (human EGFR overexpressing) cell proliferation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NC1CCCCC1,"2-Cyano-N-cyclohexyl-3-(3,4-dihydroxy-phenyl)-acrylamide",15.0,uM,=,1.1760912590556811,1,O=C(C=Cc1ccccc1)NC1CCCCC1
4335,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,2.32,uM,=,0.3654879848908996,1,c1ccc(Nc2ccnc3ccccc23)cc1
4336,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCCCCC(=O)NO,7-(4-(3-Chloro-4-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yloxy)-N-hydroxyheptanamide,0.0104,uM,=,-1.98296666070122,0,c1ccc(Nc2ncnc3ccccc23)cc1
4337,305007,10.1021/jm050267e,,,,Inhibition of Epidermal growth factor receptor,Cc1ccsc1C(=O)n1nc(Nc2ccc(S(N)(=O)=O)cc2)nc1N,"4-[5-Amino-1-(3-methyl-thiophene-2-carbonyl)-1H-[1,2,4]triazol-3-ylamino]-benzenesulfonamide",8.4,uM,=,0.9242792860618816,1,O=C(c1cccs1)n1cnc(Nc2ccccc2)n1
4338,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",CCN(C/C=C/C(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1)CCO,"(2E)-4-[Ethyl(2-hydroxyethyl)amino]-N-[3-(4-{[(1S)-2-hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]but-2-enamide",0.013,uM,=,-1.8860566476931635,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
4339,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)cc(-c3ccccc3)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-5-phenylpyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.097,uM,=,-1.0132282657337552,0,O=c1cc(-c2ccccc2)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
4340,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1ncnc(Sc3cccc(Br)c3)c1NC2,"1-(3-bromo-phenylsulfanyl)-7,8-dimethoxy-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cycloheptene",1.6,uM,=,0.2041199826559248,1,c1ccc(Sc2ncnc3c2NCc2ccccc2S3)cc1
4341,935919,10.1016/j.bmcl.2012.11.001,,,,Inhibition of EGFR (unknown origin) by Z-LYTE assay,CC1=CCC[C@](C)(CC/C(C)=C/CC2=C(O)C(=O)C=C(N[C@H](C(=O)O)C(C)C)C2=O)[C@@H]1C,"(S)-2-(4-hydroxy-5-((E)-3-methyl-5-((1R,2S)-1,2,3-trimethylcyclohex-3-enyl)pent-2-enyl)-3,6-dioxocyclohexa-1,4-dienylamino)-3-methylbutanoic acid",293.27684934771696,uM,=,2.467277782048547,1,O=C1C=CC(=O)C(C/C=C/CCC2CC=CCC2)=C1
4342,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C(C)C)[C@@H](C)C(N)=O,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(isopropyl)amino)propanamide,0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
4343,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Oc3cccc(Br)c3)c1N(C)C2,"7-(3-bromophenoxy)-13,14-dimethoxy-9-methyl-2-oxa-4,6,9-triazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaene",1.2,uM,=,0.0791812460476248,1,c1ccc(Oc2ncnc3c2NCc2ccccc2O3)cc1
4344,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CSC1CCN(C/C=C/C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3s2)CC1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(4-(methylthio)piperidin-1-yl)but-2-enamide",0.018,uM,=,-1.744727494896694,0,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
4345,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",CCC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)CC1,"1-(4-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)piperidin-1-yl)propan-1-one",0.26754,uM,=,-0.5726112772667491,0,c1cc2nc(Nc3ccc(N4CCNCC4)cc3)nc(OC3CCNCC3)c2s1
4346,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3ccc(C(=O)NCCN(C)C)cc3)cc12)c1ccccc1,"(R)-N-(2-(Dimethylamino)ethyl)-4-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzamide",0.002,uM,=,-2.6989700043360187,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
4347,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,COc1ccc(-n2c(=O)cnc3cnc(Nc4ccc(N)cc4)nc32)cc1,2-(4-Aminophenylamino)-8-(4-methoxyphenyl)pteridin-7(8H)-one,25.825,uM,=,1.4120403301916582,1,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
4348,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCOc1cc2ncnc(C#Cc3c[nH]nc3-c3ccc(F)cc3)c2cc1OCC,"6,7-diethoxy-4-(2-(3-(4-fluorophenyl)-1H-pyrazol-4-yl)ethynyl)quinazoline",0.0018,uM,=,-2.744727494896694,0,C(#Cc1ncnc2ccccc12)c1c[nH]nc1-c1ccccc1
4349,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Nc3cccc(Br)c3)c2c1C,"(3-Bromo-phenyl)-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1
4350,2069689,10.1016/j.bmc.2021.116039,,,,Inhibition of recombinant wild type EGFR (696 to C terminal end) (unknown origin) using poly (Glu-Tyr) as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by ELISA,COc1ccc(-c2c3c4cc(O)c(OCCCN(C)C)cc4[nH]c(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O.O=C(O)C(F)(F)F,"3-[3-(dimethylamino)propoxy]-2,11-dihydroxy-14-(3-hydroxy-4-methoxyphenyl)-12-methoxybenzo[7,8]indolizino[3,2-c]quinolin-6(5H)-one 2,2,2-trifluoroacetate",0.0247,uM,=,-1.6073030467403342,0,O=c1[nH]c2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
4351,2074183,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin),CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.0108,uM,=,-1.9665762445130504,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
4352,1650711,10.1016/j.bmcl.2017.02.023,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay,O=C(Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)C1CCC2(CC1)OCC1(OO2)C2CC3CC(C2)CC1C3,"N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3,3-adamantane-1,2,5-trioxaspiro[5.5]undecane-9-carboxamide",0.09472,uM,=,-1.0235583106211554,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CCC2(CC1)OCC1(OO2)C2CC3CC(C2)CC1C3
4353,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,CN(C)C/C=C/C(=O)NCc1cccc(-c2nc(-c3ccc(F)cc3)c(-c3ccnc4[nH]c(-c5ccccc5)cc34)[nH]2)c1,"(E)-4-(Dimethylamino)-N-(3-(4-(4-fluorophenyl)-5-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-imidazol-2-yl)benzyl)but-2-enamide",0.0062,uM,=,-2.207608310501746,0,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccccc4)ccnc3[nH]2)cc1
4354,942125,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin) using biotinylated-PTP1B (Tyr66) as substrate incubated for 5 mins prior to substrate addition measured after 1 hr by ELISA,COc1cc2ncnc(Nc3cccc(-c4ccccc4)c3)c2cc1OC,"N-[(3'-phenyl)phenyl]-6,7-dimethoxyquinazolin-4-amine",0.1267,uM,=,-0.8972233851165586,0,c1ccc(-c2cccc(Nc3ncnc4ccccc34)c2)cc1
4355,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C=CC(=O)Nc1cc2c(Nc3ccc(NC(=O)C=C)c(C(F)(F)F)c3)ncnc2cc1OCCOC,N-(4-(4-Acrylamido-3-(trifluoromethyl)phenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)acrylamide,0.1151,uM,=,-0.9389246763702084,0,c1ccc(Nc2ncnc3ccccc23)cc1
4356,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(C)c(=O)c3cnc(Nc4ccc(N5CCOCC5)cc4OC)nc32)c1,"N-(3-(7-((2-Methoxy-4-morpholinophenyl)amino)-3-methyl-2,4-dioxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)-acrylamide",0.341,uM,=,-0.4672456210075022,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCOCC4)cc3)ncc12
4357,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1cccc3[nH]ccc13)nn2C1CCCC1,"1-cyclopentyl-3-(1H-indol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",1.4,uM,=,0.1461280356782379,1,c1cc(-c2nn(C3CCCC3)c3ncncc23)c2cc[nH]c2c1
4358,2080995,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R/T790M (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCc1cn(CCCCC(=O)NO)nn1,"5-(4-(((6-Acrylamido-4-((3-chloro-4-((2-fluorobenzyl)oxy)phenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypentanamide",0.014,uM,=,-1.853871964321762,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCc5c[nH]nn5)ccc34)cc2)cc1
4359,1782454,10.1016/j.ejmech.2017.12.022,,,,Inhibition of recombinant human C-terminal His/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using biotin-labeled poly[Glu:Tyr] (4:1) as substrate after 30 mins by Kinase-Glo plus luminescence assay,Cc1oc2ncnc(Nc3cccc(Cl)c3)c2c1C(=O)O,"4-((3-Chlorophenyl)amino)-6-methylfuro[2,3-d]pyrimidine-5-carboxylic acid",0.901,uM,=,-0.045275209020937,0,c1ccc(Nc2ncnc3occc23)cc1
4360,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,COc1cc(C=C(C#N)C#N)ccc1O,2-(4-Hydroxy-3-methoxy-benzylidene)-malononitrile,200.0,uM,=,2.3010299956639813,1,c1ccccc1
4361,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=c1cc(-c2ccccc2)oc2ccccc12,2-Phenyl-chromen-4-one,225.15617777696244,uM,=,2.3524838675220807,1,O=c1cc(-c2ccccc2)oc2ccccc12
4362,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccco4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(furan-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.023,uM,=,-1.6382721639824072,0,c1coc(COc2ccc(Nc3ccnc4ccccc34)cc2)c1
4363,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CN(C)CCCNC/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-((3-(dimethylamino)propyl)amino)but-2-enamide",1.196,uM,=,0.077731179652392,1,c1ccc(Nc2ncnc3sccc23)cc1
4364,2298900,10.1016/j.bmc.2023.117241,,,,Inhibition of wild type EGFR (unknown origin) pre-incubated for 10 mins followed by substrate addition measured after 60 mins in presence of ATP by mobility shifting assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)NC3CC3)n2)c(OC)cc1N(C)CCN(C)C,N-(5-((5-chloro-4-((2-(N-cyclopropylsulfamoyl)phenyl)amino)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,0.02325,uM,=,-1.6335770427740273,0,O=S(=O)(NC1CC1)c1ccccc1Nc1ccnc(Nc2ccccc2)n1
4365,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3OC)nc3ccsc23)CC1,"1-(4-((2-((2-methoxy-4-morpholinophenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.24621,uM,=,-0.6086943118570912,0,c1cc2nc(Nc3ccc(N4CCOCC4)cc3)nc(OC3CCNCC3)c2s1
4366,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,O=C(C#CCO)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Hydroxy-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
4367,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC,"(3-Chloro-4-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.08,uM,=,-1.0969100130080565,0,c1ccc(Nc2ncnc3ccccc23)cc1
4368,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,N#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1F,"3-[(7,8-Dihydro[1,4]dioxino[2,3-g]quinazolin-4-yl)amino]-2-fluorobenzonitrile",0.0282,uM,=,-1.5497508916806388,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
4369,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cccc(C#CCO)c3)c2cc1OC,"3-(3-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)prop-2-yn-1-ol",1.6436,uM,=,0.2157961325898336,1,c1ccc(Nc2ncnc3ccccc23)cc1
4370,1553877,10.1016/j.ejmech.2016.01.045,,,,Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay,COCCOc1cc2ncnc(Nc3cccc(NC(=O)C45CC6CC(CC(C6)C4)C5)c3)c2cc1OCCOC,"N-(3-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)amino)phenyl)adamantane-1-carboxamide",0.00163,uM,=,-2.7878123955960423,0,O=C(Nc1cccc(Nc2ncnc3ccccc23)c1)C12CC3CC(CC(C3)C1)C2
4371,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CN1CCN(CCC#CC(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cn2)CC1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-5-(4-methyl-1-piperazinyl)-2-pentynamide",0.0019,uM,=,-2.721246399047171,0,O=C(C#CCCN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
4372,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",2.9e-05,uM,=,-4.537602002101044,0,c1ccc(Nc2ncnc3ccccc23)cc1
4373,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CCC(=O)Nc1cc(Nc2ncc(Br)c(Nc3ccc4cc[nH]c4c3)n2)c(OC)cc1N1CCN(C)CC1,N-(5-((4-((1H-indol-6-yl)amino)-5-bromopyrimidin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)propionamide,0.0920999999999999,uM,=,-1.035740369803151,0,c1cc(Nc2ccc3cc[nH]c3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
4374,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(2-Fluorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0176,uM,=,-1.75448733218585,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
4375,612309,10.1021/jm901453q,,,,Inhibition of EGFR,C#Cc1cc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)ccc1F,7-(4-(3-Ethynyl-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.0288,uM,=,-1.5406075122407692,0,c1ccc(Nc2ncnc3ccccc23)cc1
4376,624979,10.1016/j.bmcl.2010.03.015,,,,Inhibition of EGFR intracellular phosphorylation in human A431 cells by ELISA,CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(NC(=O)Cc6ccccc6)c5)nc5sccn45)n3)cc2)CC1,"N-(3-(5-(2-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-phenylacetamide",0.35,uM,=,-0.4559319556497244,0,O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
4377,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,Dacomitinib,0.006,uM,=,-2.2218487496163566,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4378,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(NCc3cccc([N+](=O)[O-])c3)c2cn1,"N*4*-(3-Nitro-benzyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",10.1,uM,=,1.0043213737826426,1,c1ccc(CNc2ncnc3ccncc23)cc1
4379,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,O=C(O)Cn1ncc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"[5-(3-Bromo-phenylamino)-pyrazolo[4,3-g]quinazolin-1-yl]-acetic acid",1.196,uM,=,0.077731179652392,1,c1ccc(Nc2ncnc3cc4[nH]ncc4cc23)cc1
4380,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1cnc(N2CC[C@@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-((S)-2-methylazetidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",25.0,uM,=,1.3979400086720375,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
4381,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(F)cc3)nn21,"US9447106, 151",0.0012,uM,=,-2.920818753952376,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1
4382,942125,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin) using biotinylated-PTP1B (Tyr66) as substrate incubated for 5 mins prior to substrate addition measured after 1 hr by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCNCCN,6-(2-(2-Aminoethylamino)ethoxy)-4-(3'-chloro-4'-fluoroanilino)-7-methoxy-quinazoline,0.0121,uM,=,-1.91721462968355,0,c1ccc(Nc2ncnc3ccccc23)cc1
4383,2127056,10.1016/j.bmcl.2021.128118,,,,Inhibition of recombinant wild type EGFR-TK (unknown origin) by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
4384,1799769,10.1016/j.ejmech.2018.06.011,,,,"Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay",O=C(Nc1ccc(-c2cc3c(Nc4ccc(Oc5cccc(C(F)(F)F)c5)c(Cl)c4)ncnc3s2)cc1)NC1CC1,"1-(4-(4-(3-chloro-4-(3-(trifluoromethyl)phenoxy)phenylamino)thieno[2,3-d]pyrimidin-6-yl)phenyl)-3-cyclopropylurea",0.112,uM,=,-0.9507819773298184,0,O=C(Nc1ccc(-c2cc3c(Nc4ccc(Oc5ccccc5)cc4)ncnc3s2)cc1)NC1CC1
4385,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",1.1,uM,=,0.041392685158225,1,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
4386,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",OC[C@@H](Nc1ncnc2oc(-c3ccccc3)c(-c3ccccc3)c12)c1ccccc1,"S-2-(5,6-Diphenylfuro[2,3-d]pyrimidin-4-ylamino)-2-phenylethano",0.223,uM,=,-0.6516951369518393,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
4387,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CS(=O)(=O)CCNCc1ccc(-c2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)o1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)thieno[3,2-d]pyrimidin-4-amine",0.001,uM,=,-3.0,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5ccco5)sc34)cc2)cc1
4388,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(3-pyrrolidin-1-yl-propoxy)-quinazolin-4-yl]-amine,0.071,uM,=,-1.1487416512809248,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCCC4)cc23)cc1
4389,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,C=CC(=O)Nc1ccccc1Oc1nc(Nc2ccc(N3CCN(C)CC3)cc2OC)ncc1Cl,N-(2-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,6.98,uM,=,0.8438554226231612,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4390,853584,10.1021/ml3001984,,,,Inhibition of recombinant EGFR catalytic domain in presence of 1 uM radiolabeled ATP,Cc1ccc(O)cc1-n1c(=O)c2c(c3c(N)ncnc31)CCCC2,"1-amino-5-(5-hydroxy-2-methylphenyl)-7,8,9,10-tetrahydropyrimido[4,5-c]isoquinolin-6(5H)-one",1.62,uM,=,0.2095150145426309,1,O=c1c2c(c3cncnc3n1-c1ccccc1)CCCC2
4391,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,O=c1oc2cc3ncnc(Nc4ccc(OCc5ccc(Cl)cc5)cc4)c3cc2n1CCCN1CCOCC1,"8-(4-(4-Chlorobenzyloxy)phenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.99,uM,=,-0.00436480540245,0,O=c1oc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc2n1CCCN1CCOCC1
4392,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2NC(C)=O)c1O,3-[3-(2-Acetylamino-phenylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,9.0,uM,=,0.9542425094393248,1,c1ccc(CSc2ccccc2)cc1
4393,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(F)cc3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.13,uM,=,-0.8860566476931633,0,c1ccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)cc1
4394,63772,10.1021/jm9903949,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cells,Nc1cc2sc3c(Nc4cccc(Br)c4)ncnc3c2cc1F,"N*4*-(3-Bromo-phenyl)-8-fluoro-benzo[4,5]thieno[3,2-d]pyrimidine-4,7-diamine",0.042,uM,=,-1.3767507096020994,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
4395,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C#CCCCOc1cc2c(Nc3cccc(Cl)c3)ncnc2cc1OC,4-(3'-Chloroanilino)-7-methoxy-6-(pent-4-ynyloxy)quinazoline,0.0177,uM,=,-1.7520267336381934,0,c1ccc(Nc2ncnc3ccccc23)cc1
4396,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(N[C@H](C)c3ccccn3)ncnc2s1,"(R)-6-(2-Methoxyphenyl)-N-(1-(pyridin-2-yl)ethyl)thieno[2,3-d]pyrimidin-4-amine",0.153,uM,=,-0.8153085691824012,0,c1ccc(-c2cc3c(NCc4ccccn4)ncnc3s2)cc1
4397,2291456,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR autophosphorylation at Tyr1068 residue in EGFR-amplified human A-431 cells preincubated with compound for 1 hrs followed by stimulation with human recombinant EGF and measured after 10 mins by HTRF-based analysis,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.17,uM,=,-0.7695510786217261,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
4398,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)c(OC)c3OC)ncc2Cl)c1,"US9238629, I-7",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
4399,1627833,10.1016/j.ejmech.2016.06.056,,,,Inhibition of EGFR (unknown origin) using peptide as substrate after 60 mins by HTRF assay,CC(C)S(=O)(=O)c1ccccc1Nc1nc(N/N=C/c2ccc(F)cc2)ncc1Cl,(E)-5-chloro-2-(2-(4-fluorobenzylidene)hydrazinyl)-N-(2-(isopropylsulfonyl)phenyl)pyrimidin-4-amine,0.57,uM,=,-0.2441251443275086,0,C(=N/Nc1nccc(Nc2ccccc2)n1)\c1ccccc1
4400,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,COCCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCN(C)CC1,(2E)-N-[4-[(1-Benzyl-1H-indazol-5-yl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]-4-(4-methyl-1-piperazinyl)-2-butenamide,0.016,uM,=,-1.7958800173440752,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
4401,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,(2E)-N-{4-(3-Chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)-propoxy]-6-quinazolinyl}-2-butenamide,0.075,uM,=,-1.1249387366083,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
4402,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,O=C(/C=C/CN1CCCC1)N1CCCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-8,9-dihydro-7H-pyrimido[5,4-h][1,5]benzoxazepin-6-yl]-4-pyrrolidin-1-yl-but-2-en-1-one",0.578,uM,=,-0.2380721615794709,0,O=C(/C=C/CN1CCCC1)N1CCCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
4403,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21,"1-isopropyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.38,uM,=,-0.4202164033831898,0,c1ncc2c(-c3cnc4[nH]ccc4c3)n[nH]c2n1
4404,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1,"N-[4-(3-Chloro-4-fluoro-phenylamino)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.018,uM,=,-1.744727494896694,0,c1ccc(Nc2ncnc3cccnc23)cc1
4405,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,CN1C(=S)C(C(=O)Nc2ccccc2)c2ccccc21,"1-Methyl-2-thioxo-2,3-dihydro-1H-indole-3-carboxylic acid phenylamide",1.0,uM,=,0.0,0,O=C(Nc1ccccc1)C1C(=S)Nc2ccccc21
4406,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,CCCCN(c1ccc(OC)cc1)c1nc(C)nc2oc(C)cc12,"N-Butyl-N-(4-methoxyphenyl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine",0.3401,uM,=,-0.4683933680672778,0,c1ccc(Nc2ncnc3occc23)cc1
4407,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,COc1ccc(N(C)c2nc(C)nc3oc(C)cc23)cc1.Cl,"N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d]pyrimidin-4-amine hydrochloride",0.0823,uM,=,-1.08460016478773,0,c1ccc(Nc2ncnc3occc23)cc1
4408,1991314,10.1016/j.bmcl.2020.127288,,,,Inhibition of wild type EGFR (unknown origin) in presence of radiolabelled gammaATP by radioisotope filter binding assay,N#Cc1cnc2cc(OC[C@@H](O)CO)c(NC(=O)CC3CSSC3)cc2c1Nc1ccc(OCc2cccc(F)c2)c(Cl)c1,"(S)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-3-cyano-7-(2,3-dihydroxypropoxy)quinolin-6-yl)-2-(1,2-dithiolan-4-yl)acetamide",0.0024,uM,=,-2.619788758288394,0,O=C(CC1CSSC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
4409,653005,10.1038/nchembio866,,,,Inhibition of human recombinant EGFR expressed in baculovirus-infected Sf9 cells by radioactive phosphotransfer assay,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(C(C)(C)C)cc3)c2c1,N-(4-(4-tert-butylphenylamino)quinazolin-6-yl)acrylamide,0.689,uM,=,-0.1617807780923742,0,c1ccc(Nc2ncnc3ccccc23)cc1
4410,2017353,10.1021/acs.jmedchem.0c00870,,,,Inhibition of human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using TK as substrate preincubated for 30 mins followed by substrate addition and measured after 25 mins by HTRF assay,C=CC(=O)Nc1cccc(-c2c[nH]c3ncnc(Nc4ccc(CN5C(=O)c6ccccc6C5=O)cc4)c23)c1,"N-{3-{4-{{4-[(1,3-Dioxoisoindolin-2-yl)methyl]phenyl}amino}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl}acrylamide",0.0004,uM,=,-3.397940008672037,0,O=C1c2ccccc2C(=O)N1Cc1ccc(Nc2ncnc3[nH]cc(-c4ccccc4)c23)cc1
4411,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCOC,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(2-methoxy-ethoxy)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.377,uM,=,-0.4236586497942071,0,c1ccc(Nc2ncnc3cccnc23)cc1
4412,66726,10.1021/jm970641d,,,,Inhibition of tyrosine/glutamic acid copolymer phosphorylation by epidermal growth factor receptor prepared of human A431,CCN(CC)CC(O)CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"1-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-3-diethylamino-propan-2-ol",0.0046,uM,=,-2.337242168318426,0,c1ccc(Nc2ncnc3cnccc23)cc1
4413,2076853,10.1039/d0md00436g,,,,Inhibition of human EGFR TK domain expressed in Escherichia coli BL21 (DE3) pLysS using poly-Glu-Tyr (51 to 68 residues) as substrate incubated for 1 hr by ADP-Glo assay,CNc1nc(C)c(C(=O)/C=C/c2ccsc2)s1,(E)-1-(4-methyl-2-(methylamino)thiazol-5-yl)-3-(thiophen-3-yl)prop-2-en-1-one,0.14363,uM,=,-0.8427548395248052,0,O=C(/C=C/c1ccsc1)c1cncs1
4414,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C/c1ccc(O)c(O)c1)C(=O)NCCCCc1ccccc1,"2-cyano-3-(3,4-dihydroxyphenyl)-N-(4-phenylbutyl)acrylamide",0.1,uM,=,-1.0,0,O=C(C=Cc1ccccc1)NCCCCc1ccccc1
4415,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,C#Cc1cccc(Nc2ncnc3cc(OC)c4c(c23)OCCO4)c1,"N-(3-Ethynylphenyl)-5-methoxy-2,3-dihydro[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0109,uM,=,-1.9625735020593764,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
4416,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(OCc4ccccn4)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,"(S,E)-N-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide",0.0081,uM,=,-2.0915149811213505,0,c1ccc(COc2ccc(Nc3ncnc4cc(O[C@H]5CCOC5)ccc34)cc2)nc1
4417,1769307,10.1016/j.bmc.2018.02.029,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0167,uM,=,-1.7772835288524167,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4418,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1C(C)CCCC1C,"4-(2,6-Dimethyl-piperidin-1-yl)-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide",0.247,uM,=,-0.6073030467403343,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
4419,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,COc1ccc(CC(=O)NS(=O)(=O)c2ccc(Br)cc2)cc1,N-(4-Bromophenylsulfonyl)-2-(4-methoxyphenyl)acetamide,24.15,uM,=,1.382917135087531,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
4420,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,CCN(CC)CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Diethylamino-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3ccccc23)cc1
4421,982643,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis,O=C(COc1c(F)c(F)c(F)c(F)c1F)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(perfluorophenoxy)-acetamide,0.0498,uM,=,-1.3027706572402824,0,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4422,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CN(C)CCN(C)CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-2-((2-(dimethylamino)ethyl)(methyl)amino)acetamide",4.286,uM,=,0.6320521667058099,1,c1ccc(Nc2ncnc3sccc23)cc1
4423,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1cccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1,"US9447106, 3",0.141,uM,=,-0.8507808873446201,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(c3ccccc3)CCN4)cc2)cc1
4424,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.037,uM,=,-1.431798275933005,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
4425,66567,10.1021/jm950692f,,,,Inhibition of tyrosine kinase activity of Epidermal growth factor receptor from human A431 cells,Brc1cccc(Nc2ncnc3cc4c[nH]nc4cc23)c1,"(3-Bromo-phenyl)-(1H-pyrazolo[3,4-g]quinazolin-8-yl)-amine",0.00034,uM,=,-3.468521082957745,0,c1ccc(Nc2ncnc3cc4c[nH]nc4cc23)cc1
4426,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,NS(=O)(=O)c1ccc(Nc2nc3ncnc(Nc4ccc(N5CCOCC5)c(Cl)c4)c3s2)cc1,"4-(7-(3-chloro-4-morpholinophenylamino)thiazolo[4,5-d]pyrimidin-2-ylamino)benzenesulfonamide",3.3,uM,=,0.5185139398778875,1,c1ccc(Nc2nc3ncnc(Nc4ccc(N5CCOCC5)cc4)c3s2)cc1
4427,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,COc1ccc(/C=C(\C#N)C(=O)O)cc1,2-Cyano-3-(4-methoxy-phenyl)-acrylic acid,833.0,uM,=,2.9206450014067875,1,c1ccccc1
4428,306444,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate; Range = 10-50 nM,CN(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1,"(E)-4-Dimethylamino-but-2-enoic acid [4-(4,5-dichloro-2-fluoro-phenylamino)-quinazolin-6-yl]-amide",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
4429,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,CCCCN(Cc1cccc(Cl)c1O)C(=S)Nc1ccccc1,1-Butyl-1-(5-chloro-2-hydroxybenzyl)-3-phenylthiourea,18.12,uM,=,1.2581581933407944,1,S=C(NCc1ccccc1)Nc1ccccc1
4430,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,CC#CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"US9447106, 176",2.613,uM,=,0.4171394097273256,1,c1ccc(Oc2ccc(-c3cc4n(n3)[C@H](C3CCNCC3)CCN4)cc2)cc1
4431,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,COc1ccc(-c2cc3c(N[C@H](CCO)c4ccccc4)ncnc3o2)cc1,"(R)-3-((6-(4-Methoxyphenyl)furo[2,3-d]pyrimidin-4-yl)amino)-3-phenylpropan-1-ol",0.004,uM,=,-2.397940008672037,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
4432,2201427,10.1016/j.ejmech.2021.114085,,,,Inhibition of wild-type EGFR (unknown origin),NNC(=O)/C=C1/Nc2ccc(Br)cc2NC1=O,"2-(6-bromo-3-oxo-3,4-dihydroquinoxalin-2(1H)-ylidene)acetohydrazide",1.547,uM,=,0.1894903136993675,1,C=C1Nc2ccccc2NC1=O
4433,305482,10.1021/jm0501275,,,,Inhibition of human epidermal growth factor receptor (HER-1),CONC(=O)c1cc(Nc2ncnn3cc(NC(=O)OCC4CCCO4)c(C(C)C)c23)c(F)cc1F,"[4-(2,4-Difluoro-5-methoxycarbamoyl-phenylamino)-5-isopropyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid tetrahydro-furan-2-ylmethyl ester",5.5,uM,=,0.7403626894942439,1,O=C(Nc1cc2c(Nc3ccccc3)ncnn2c1)OCC1CCCO1
4434,1869715,10.1016/j.bmc.2019.02.012,,,,Inhibition of His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometry,COc1cc(/C=C/C(=O)c2ccc(NC(=O)c3cc4cc5cc(C)ccc5nc4s3)cc2)cc(OC)c1OC,"(E)-6-Methyl-N-(4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenyl)thieno[2,3-b]quinoline-2-carboxamide",3.2,uM,=,0.505149978319906,1,O=C(/C=C/c1ccccc1)c1ccc(NC(=O)c2cc3cc4ccccc4nc3s2)cc1
4435,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,O=C(NCCCCOc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1)C(F)(F)F,"N-{4-[4-(4-Benzyloxy-phenylamino)-quinazolin-6-yloxy]-butyl}-2,2,2-trifluoro-acetamide",0.074,uM,=,-1.1307682802690238,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
4436,63763,10.1021/jm00018a008,,,,Inhibition of Epidermal growth factor receptor from A431 cells,c1ccc(CNc2ncnc3ccccc23)cc1,Benzyl-quinazolin-4-yl-amine,0.32,uM,=,-0.494850021680094,0,c1ccc(CNc2ncnc3ccccc23)cc1
4437,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,CN(CCCOc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1)CCS(C)(=O)=O,(4-Benzyloxy-phenyl)-(6-{3-[(2-methanesulfonyl-ethyl)-methyl-amino]-propoxy}-quinazolin-4-yl)-amine,0.83,uM,=,-0.0809219076239261,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
4438,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CCC(=O)ON[C@H](CS(C)(=O)=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,(S)-ethyl(1-(5-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)furan-2-yl)-2-(methylsulfonyl)ethyl)carbamate,0.0896,uM,=,-1.0476919903378747,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
4439,791584,10.1016/j.bmc.2011.11.023,,,,"Inhibition of EGFR using poly(Glu,Tyr)4:1 as substrate and [gamma33P]ATP after 60 mins by scintillation counting",O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3cccc(Cl)c3)ncnc2s1,"(4-(3-Chlorophenylamino)thieno[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanone",0.0166,uM,=,-1.779891911959945,0,O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3ccccc3)ncnc2s1
4440,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=CC(=O)N(CCCN1CCOCC1)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-N-(3-morpholin-4-yl-propyl)-acrylamide",0.0027,uM,=,-2.5686362358410126,0,c1ccc(Nc2ncnc3cnc(NCCCN4CCOCC4)cc23)cc1
4441,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCO,N-(2-((2-hydroxyethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,1.771,uM,=,0.2482185611900747,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4442,1983835,10.1016/j.bmc.2019.115281,,,,Inhibition of wild type EGFR (unknown origin),C=C1CC(CI)(c2ccc(F)cc2)OC1=O,rac-5-(4-fluorophenyl)-5-(iodomethyl)-3-methylenedihydrofuran-2(3H)-one,24.0,uM,=,1.380211241711606,1,C=C1CC(c2ccccc2)OC1=O
4443,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,CC(C)NC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,4-(2-nitrovinyl)phenyl 4-(isopropylcarbamoyl)benzenesulfonate,1.0,uM,=,0.0,0,O=S(=O)(Oc1ccccc1)c1ccccc1
4444,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/C(C)N1CCOCC1,(E)-4-Morpholin-4-yl-pent-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,10.59,uM,=,1.024895960107485,1,O=C(/C=C/CN1CCOCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
4445,2080995,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R/T790M (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCc1cn(CCCC(=O)NO)nn1,"4-(4-(((6-Acrylamido-4-((3-chloro-4-((2-fluorobenzyl)oxy)phenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutanamide",0.015,uM,=,-1.8239087409443189,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCc5c[nH]nn5)ccc34)cc2)cc1
4446,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(NCc1ccc(Cl)cc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(4-chlorobenzyl)thiourea,0.0283,uM,=,-1.5482135644757098,0,S=C(NCc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4447,445904,10.1021/jm070436q,,,,Inhibition of P-EGFR expressed in A431 cells,N#Cc1cnc2c(F)cc(NCc3c[nH]cn3)cc2c1Nc1ccc(F)c(Cl)c1,4-[(3-chloro-4-fluorophenyl)amino]-8-fluoro-6-[(1H-imidazol-5-ylmethyl)amino]quinoline-3-carbonitrile,0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ccnc3ccc(NCc4c[nH]cn4)cc23)cc1
4448,946792,10.1016/j.bmc.2013.01.040,,,,Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA,COc1cccc(Nc2nc(N)nc3[nH]c4cccc(Cl)c4c23)c1,"5-chloro-N4-(3-methoxyphenyl)-9H-pyrimido[4,5-b]indole-2,4-diamine",82.9,uM,=,1.9185545305502736,1,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
4449,5000,10.1021/jm960118j,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Cc1[nH]c2ncnc(Nc3cccc(Br)c3)c2c1C,"(3-Bromo-phenyl)-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",1.5,uM,=,0.1760912590556812,1,c1ccc(Nc2ncnc3[nH]ccc23)cc1
4450,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,Cn1c(SSc2c(CCCC(=O)O)c3ccccc3n2C)c(CCCC(=O)O)c2ccccc21,4-{2-[3-(3-Carboxy-propyl)-1-methyl-1H-indol-2-yldisulfanyl]-1-methyl-1H-indol-3-yl}-butyric acid,8.3,uM,=,0.919078092376074,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
4451,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,COCCn1c(=O)oc2cc3ncnc(Nc4ccc(OCc5nccc(OCC(F)(F)F)c5C)cc4)c3cc21,"1-(2-Methoxyethyl)-8-(4-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methoxy)phenylamino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.34,uM,=,-0.4685210829577448,0,O=c1[nH]c2cc3c(Nc4ccc(OCc5ccccn5)cc4)ncnc3cc2o1
4452,1706891,10.1016/j.bmcl.2017.07.009,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (696 to end residues) expressed in baculovirus Sf21 insect cells preincubated for 5 mins followed by substrate addition after 30 to 60 mins in presence of ATP by fluorescence assay,C=CS(=O)(=O)N1CCC[C@@H]1Cn1cc(-c2ccc3c(c2)OCO3)c2c(N)ncnc21,"(R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.6427,uM,=,-0.1919917000895999,0,c1ncc2c(-c3ccc4c(c3)OCO4)cn(C[C@H]3CCCN3)c2n1
4453,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccs4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(thiophen-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.277,uM,=,-0.5575202309355514,0,c1csc(COc2ccc(Nc3ccnc4ccccc34)cc2)c1
4454,306070,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,COCC(=O)Nc1ccc2ncnc(Nc3cccc(I)c3)c2c1,N-[4-(3-Iodo-phenylamino)-quinazolin-6-yl]-2-methoxy-acetamide,50.0,uM,=,1.6989700043360187,1,c1ccc(Nc2ncnc3ccccc23)cc1
4455,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,CS(=O)(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl methanesulfonate",0.081,uM,=,-1.0915149811213505,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
4456,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,O=c1oc2cc3ncnc(NCc4ccccc4)c3cc2n1CCCN1CCOCC1,"8-(Benzylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",65.0,uM,=,1.812913356642856,1,O=c1oc2cc3ncnc(NCc4ccccc4)c3cc2n1CCCN1CCOCC1
4457,1448250,10.1016/j.bmcl.2014.07.094,,,,Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry,N#CC1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2cc(Cl)ccc2n2nnnc12,"2-Amino-4-(7-chlorotetrazolo[1,5-a]quinolin-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile",18.3,uM,=,1.2624510897304295,1,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1
4458,1526584,10.1021/acsmedchemlett.5b00193,,,,Inhibition of wild type EGFR phosphorylation in human A431 cells after 60 mins by mesoscale multiplex assay,C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N(C)CCN(C)C)cc4OC)nc32)c1,"N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.521,uM,=,-0.2831622767004755,0,O=c1ccc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
4459,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(OCCc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid phenethyl ester",0.13,uM,=,-0.8860566476931633,0,O=C(OCCc1ccccc1)c1cccc(NCc2ccccc2)c1
4460,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,O=C(NCCN1CCCCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-Bromophenyl)amino)quinazolin-6-yl)-3-(2-(piperidin-1-yl)ethyl)urea,0.021,uM,=,-1.6777807052660807,0,O=C(NCCN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4461,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1C(=O)c1cn(-c2ccc(Cl)cc2)nc1C(=O)Nc1ccccc1,"4-(2-Methyl-4,5-diphenyl-1H-pyrrole-3-carbonyl)-N-phenyl-1-(p-tolyl)-1H-pyrazole-3-carboxamide",3.78,uM,=,0.5774917998372253,1,O=C(c1cn(-c2ccccc2)nc1C(=O)Nc1ccccc1)c1c[nH]c(-c2ccccc2)c1-c1ccccc1
4462,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CCCCC(O)CN(C)[C@H]1C[C@@H]2O[C@](C)([C@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"4-[2-hydroxyhexyl(methyl)amino]-3-methoxy-2-methyl-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-16-one",1.3,uM,=,0.1139433523068367,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
4463,2074610,10.1016/j.bmc.2020.115680,,,,Inhibition of wild type EGFR (unknown origin) in presence of ATP preincubated 5 mins measured for 30 mins by detection reagent based HTRF analysis,C=C(Cl)C(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)c(Cl)c3)ncc2Cl)c1,N-(3-((2-((4-(4-acetylpiperazin-1-yl)-3-chlorophenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)-2-chloroacrylamide,0.053,uM,=,-1.275724130399211,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4464,65107,10.1021/jm00032a020,,,,Inhibition of EGF-stimulated DNA synthesis in ER 22 (EGF-receptor expressing) cells,CCOP(=O)(Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O)OCC,"(5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-benzyl)-phosphonic acid diethyl ester",75.0,uM,=,1.8750612633917,1,C(=N/c1ccccc1)\c1ccccc1
4465,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3cnn(C)c3)nc3[nH]ccc23)CC1,"1-(4-((2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.38742,uM,=,-0.4118179632105168,0,c1cc2c(OC3CCNCC3)nc(Nc3cn[nH]c3)nc2[nH]1
4466,1829742,10.1021/acs.jmedchem.8b01612,,,,Inhibition of wild type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system after 1 hr in presence of ULight-labeled peptide substrate and ATP by LANCE ultra kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Br)c3)c2cc1OCCCN1CCNCCNCC1,"6-(3-(1,4,7-Triazonan-1-yl)propoxy)-N-(3-bromo-4-fluorophenyl)-7-methoxyquinazolin-4-amine",0.0056,uM,=,-2.2518119729938,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCNCCNCC4)cc23)cc1
4467,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)C4CCCC4)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1,"(S)-3-(2-Chlorophenyl)-1-(1-(cyclopentanecarbonyl)-pyrrolidin-3-yl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)-phenyl)amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0255,uM,=,-1.593459819566045,0,O=C(C1CCCC1)N1CC[C@H](N2C(=O)N(c3ccccc3)Cc3cnc(Nc4ccc(N5CCNCC5)cc4)nc32)C1
4468,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2CC1CCNCC1,"5-(4-amino-1-(piperidin-4-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",100.0,uM,=,2.0,1,c1ccc(-c2nn(CC3CCNCC3)c3ncncc23)cc1
4469,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1c(Br)cc(Cl)cc1Nc1ncnc2cc3c(cc12)OCCO3,"N-(3-Bromo-5-chloro-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.7827999999999999,uM,=,-0.1063491830140364,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
4470,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,O=C(C#CCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]-4-(4-morpholinyl)-2-butynamide,0.086,uM,=,-1.0655015487564323,0,O=C(C#CCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4471,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,Cn1c(SSc2c(CCC(=O)O)c3ccccc3n2C)c(CCC(=O)O)c2ccccc21,3-{2-[3-(2-Carboxy-ethyl)-1-methyl-1H-indol-2-yldisulfanyl]-1-methyl-1H-indol-3-yl}-propionic acid,3.1,uM,=,0.4913616938342727,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
4472,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CN1CCN(c2ccc(Nc3ncc(Br)c(Nc4ccc5cn[nH]c5c4)n3)cc2)CC1,"5-bromo-N4-(1H-indazol-6-yl)-N2-[4-(4-methylpiperazin-1-yl)phenyl]pyrimidine-2,4-diamine",1.1,uM,=,0.041392685158225,1,c1cc(Nc2ccc3cn[nH]c3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
4473,1986369,10.1016/j.bmc.2020.115373,,,,Inhibition of human EGFR-TK using PTK substrate after 40 mins in presence of ATP by Kinase-Glo luminescent assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,1.74,uM,=,0.2405492482825997,1,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
4474,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,CC(C)(C)OC(=O)Nc1ccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"{4-[4-(3-Chloro-phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-phenyl}-carbamic acid tert-butyl ester",0.27,uM,=,-0.5686362358410126,0,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
4475,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",Cc1cccc(Nc2ncnc3cnc(N)nc23)c1,"N*8*-m-Tolyl-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.017,uM,=,-1.769551078621726,0,c1ccc(Nc2ncnc3cncnc23)cc1
4476,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(O)cc2)c2c(N)ncnc21,"4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol",0.922,uM,=,-0.0352690789463706,0,c1ccc(-c2n[nH]c3ncncc23)cc1
4477,1516568,10.1016/j.ejmech.2015.08.031,,,,Inhibition of EGFR (unknown origin) after 40 mins by scintillation counting analysis,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.283,uM,=,-0.5482135644757098,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
4478,1566936,10.1021/acs.jmedchem.5b01633,,,,Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,1.6,uM,=,0.2041199826559248,1,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4479,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,COc1cc2ncnc(Nc3cc(F)cc(C(F)(F)F)c3)c2cc1OC.Cl,"4-[3'-fluoro-5'-(trifluoromethyl)anilino]-6,7-dimethoxyquinazoline hydrochloride",1.634,uM,=,0.2132520521963966,1,c1ccc(Nc2ncnc3ccccc23)cc1
4480,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nc[nH]c(=O)c3c2)c2c(N)ncnc21,"6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)quinazolin-4(3H)-one",7.4,uM,=,0.8692317197309762,1,O=c1[nH]cnc2ccc(-c3n[nH]c4ncncc34)cc12
4481,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(-c3ccnn3C)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-5-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2ncc(-c3ccn[nH]3)c(-c3cn4c5c(cccc35)CCC4)n2)cc1
4482,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,O=C(O)COCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"2-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methoxy)acetic acid",0.03,uM,=,-1.5228787452803376,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
4483,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,O=C(Nc1nccs1)Nc1cc(-c2cncnc2)ccc1OC(F)(F)F,1-(5-(Pyrimidin-5-yl)-2-(trifluoromethoxy)phenyl)-3-(thiazol-2-yl)urea,0.07171,uM,=,-1.144420277498282,0,O=C(Nc1cccc(-c2cncnc2)c1)Nc1nccs1
4484,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,CCOc1cc2ncnc(Nc3cccc(OC)c3)c2c2c1OCCO2,"5-Ethoxy-N-(3-methoxyphenyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0044,uM,=,-2.356547323513813,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
4485,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc(C(F)(F)F)c3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-amino-3-(3-(trifluoromethyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.37,uM,=,-0.431798275933005,0,c1ccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)cc1
4486,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=C(O)c1ccc(O)cc1,4-Hydroxy-benzoic acid,72.44712939792471,uM,=,1.8600211819212071,1,c1ccccc1
4487,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc(OC)cc3)C2)cc1,"2-(3,5-bis(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",6.92,uM,=,0.8401060944567578,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
4488,1330695,10.1039/C2MD20017A,,,,Inhibition of EGF-induced EGFR autophosphorylation in human A431 cells after 1 hr by immunoblotting method,CCC(=O)Nc1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1,N-(3-(6-(3-bromophenylamino)pyrimidin-4-ylamino)phenyl)propionamide,0.166,uM,=,-0.7798919119599449,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
4489,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,COC[C@@H]1CCCN1C/C=C\C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-(2-Methoxymethyl-pyrrolidin-1-yl)-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.194,uM,=,-0.712198270069774,0,O=C(/C=C\CN1CCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4490,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)CNC(=O)OC(C)(C)C)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Staurosporine derivative,3.5,uM,=,0.5440680443502757,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
4491,1299287,10.1039/C3MD00096F,,,,Inhibition of EGFR (unknown origin) after 1 hr by Caliper mobility shift assay,COc1cc2ncnc(Nc3ccc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)cc3)c2cc1OCCCN1CCOCC1,1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-ylamino)phenyl)urea,0.285,uM,=,-0.5451551399914898,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
4492,2052738,10.1016/j.ejmech.2019.111966,,,,Inhibition of wild type N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus infected Sf21 cells using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km concentration and further incubated for 20 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,Lazertinib,0.0346,uM,=,-1.4609239012072237,0,c1ccc(-c2ccn(-c3ccnc(Nc4ccc(N5CCOCC5)cc4)n3)n2)cc1
4493,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,OCCOc1n[nH]c2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12,"2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yloxy)ethanol",0.016,uM,=,-1.7958800173440752,0,c1ccc(COc2ccc(Nc3ncnc4[nH]ncc34)cc2)nc1
4494,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",Cc1cc(C)nc(NS(=O)(=O)c2ccc(Nc3nncc4ccccc34)cc2)n1,"N-(4,6-Dimethylpyrimidin-2-yl)-4-(phthalazin-1-ylamino)benzenesulfonamide",0.0067,uM,=,-2.1739251972991736,0,O=S(=O)(Nc1ncccn1)c1ccc(Nc2nncc3ccccc23)cc1
4495,65249,10.1021/jm960380s,,,,Inhibition of erbB-1 receptor tyrosine kinase from A431 human epidermoid carcinoma cells,Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,"2-(4-Amino-pyrazolo[3,4-d]pyrimidin-1-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol",195.0,uM,=,2.290034611362518,1,c1ncc2ncn([C@H]3CCCO3)c2n1
4496,2198131,10.1016/j.ejmech.2022.114661,,,,Inhibition of recombinant human EGFR incubated for 40 to 45 mins and measured after 15 mins by Kinase-Glo Max assay,Cc1ccc(-c2c(CN3CCCCC3)nc3scc(C(=O)O)n23)cc1,"6-(Piperidin-1-ylmethyl)-5-(p-tolyl)imidazo[2,1-b]thiazole-3-carboxylic acid",0.18,uM,=,-0.744727494896694,0,c1ccc(-c2c(CN3CCCCC3)nc3sccn23)cc1
4497,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)CC)CC4)cc3OC(F)F)ncc2SC)c1,N-(3-((2-((2-(difluoromethoxy)-4-(4-propionylpiperazin-1-yl)phenyl)amino)-5-(methylthio)pyrimidin-4-yl)oxy)phenyl)acrylamide,0.0464,uM,=,-1.3334820194451191,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4498,2270873,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin),NS(=O)(=O)c1ccc(CCn2c(SCC(=O)Nc3ccc(Cl)cc3)nc3ccccc3c2=O)cc1,"N-(4-chlorophenyl)-2-((4-oxo-3-(4-sulfamoylphenethyl)-3,4-dihydroquinazolin-2-yl)thio)acetamide",0.2,uM,=,-0.6989700043360187,0,O=C(CSc1nc2ccccc2c(=O)n1CCc1ccccc1)Nc1ccccc1
4499,1674599,10.1021/acs.jmedchem.8b00125,,,,Inhibition of EGFR (unknown origin),CNS(=O)(=O)c1cccc(N(C)c2cc(Nc3cccc(C)c3)ncn2)c1,N-Methyl-3-(methyl{6-[(3-methylphenyl)amino]-4-pyrimidinyl}-amino)benzenesulfonamide,2.0,uM,=,0.3010299956639812,1,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
4500,1472645,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) after 40 mins by scintillation proximity assay,C#Cc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2s1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-ethynylthieno[2,3-d]pyrimidin-4-amine",0.071,uM,=,-1.1487416512809248,0,c1ccc(COc2ccc(Nc3ncnc4sccc34)cc2)cc1
4501,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(OC)cc3OC)c2c1,"N-(4-(2,4-dimethoxyphenylamino)quinazolin-6-yl)acrylamide",53.6,uM,=,1.72916478969277,1,c1ccc(Nc2ncnc3ccccc23)cc1
4502,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CC2(CSC2)C1,6-(2-(2-thia-6-azaspiro[3.3]heptan-6-yl)ethoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine,0.052,uM,=,-1.2839966563652008,0,c1ccc(Nc2ncnc3ccc(OCCN4CC5(CSC5)C4)cc23)cc1
4503,506208,10.1021/np50089a001,,,,Inhibition of EGFR,N#CC(C#N)=C1C(=O)Nc2ccc(O)cc21,"2-(5-Hydroxy-2-oxo-1,2-dihydro-indol-3-ylidene)-malononitrile",10.0,uM,=,1.0,1,C=C1C(=O)Nc2ccccc21
4504,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(NCc4cccc(Oc5ccccc5)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(3-phenoxybenzylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.18,uM,=,-0.744727494896694,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(NCc4cccc(Oc5ccccc5)c4)c3s2)C1)N1CCOCC1
4505,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,CN1CCN(CCOc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NO)n3)cc2)CC1,2-((5-chloro-2-((4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)-N-hydroxybenzamide,0.0007632,uM,=,-3.117361638303961,0,c1ccc(Nc2ccnc(Nc3ccc(OCCN4CCNCC4)cc3)n2)cc1
4506,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,Fc1cccc(COc2ccc(Nc3ncnc4cc(C#C[C@H]5CCCN5)sc34)cc2Cl)c1,"(R)-N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(pyrrolidin-2-ylethynyl)thieno[3,2-d]pyrimidin-4-amine",0.007,uM,=,-2.154901959985743,0,C(#C[C@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
4507,791584,10.1016/j.bmc.2011.11.023,,,,"Inhibition of EGFR using poly(Glu,Tyr)4:1 as substrate and [gamma33P]ATP after 60 mins by scintillation counting",COc1ccc2[nH]c(C(=O)c3cc4c(Nc5ccc(F)c(Cl)c5)ncnc4s3)cc2c1,"(4-(3-Chloro-4-fluorophenylamino)thieno[2,3-d]pyrimidin-6-yl)(5-methoxy-1H-indol-2-yl)methanone",0.0059299999999999,uM,=,-2.2269453066357374,0,O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3ccccc3)ncnc2s1
4508,1801908,10.1016/j.ejmech.2018.06.061,,,,Inhibition of EGFR in human HepG2 cells,O=C1Nc2ccc(S(=O)(=O)N3CCOCC3)cc2/C1=N/c1ccc(O)cc1,3-((4-Hydroxyphenyl)imino)-5-(morpholinosulfonyl)indolin-2-one,0.751,uM,=,-0.1243600629958316,0,O=C1Nc2ccc(S(=O)(=O)N3CCOCC3)cc2/C1=N/c1ccccc1
4509,2063587,10.1016/j.ejmech.2016.08.068,,,,Inhibition of EGFR (unknown origin) using Tyr 04 peptide as substrate incubated for 1 hr by Z'-LYTE assay,COc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-2-(6-(2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-2-phenylethanol",0.0008,uM,=,-3.096910013008056,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
4510,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1,"N-Benzyl-6-phenylfuro[2,3-d]pyrimidin-4-amine",0.093,uM,=,-1.031517051446065,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
4511,1467840,10.1016/j.ejmech.2015.03.029,,,,Inhibition of EGFR intracellular domain (unknown origin) purified from a baculovirus expression system using Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2 as substrate after 10 mins by scintillation counting in presence of [gamma-33P]ATP,CN(CCO)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1,"2-((4-(1-benzyl-1H-indazol-5-ylamino)pyrido[3,4-d]pyrimidin-6-yl)(methyl)amino)ethanol",0.036,uM,=,-1.4436974992327127,0,c1ccc(Cn2ncc3cc(Nc4ncnc5cnccc45)ccc32)cc1
4512,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4ccc(F)cc4)c3cc2N1CCCN1CCOCC1,"4-((4-fluorophenyl)amino)-6-(3-morpholinopropyl)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.4341,uM,=,-0.3624102141613,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
4513,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,Cc1ccc(-n2cc(NC(=O)c3ccc(NS(=O)(=O)c4ccccc4)cc3)cn2)cc1,4-(Phenylsulfonamido)-N-(1-(p-tolyl)-1H-pyrazol-4-yl)benzamide,18.26,uM,=,1.26150077319828,1,O=C(Nc1cnn(-c2ccccc2)c1)c1ccc(NS(=O)(=O)c2ccccc2)cc1
4514,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,CC(C)(C)OC(=O)Nc1ccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"{4-[4-(3-Chloro-phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-phenyl}-carbamic acid tert-butyl ester",1.5,uM,=,0.1760912590556812,1,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
4515,1657723,10.1016/j.bmcl.2017.02.018,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells preincubated for 60 mins followed by EGF induction measured after 10 mins by ELISA,Nc1nc(N)c2c(n1)[nH]c1cccc(Sc3ccc4ccccc4c3)c12,"5-(2-Naphthylsulfanyl)-9H-pyrimido[4,5-b]indole-2,4-diamine",20.0,uM,=,1.3010299956639813,1,c1ccc2cc(Sc3cccc4[nH]c5ncncc5c34)ccc2c1
4516,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccc(N(C)C)cc3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(4-(dimethylamino)benzylidene)cyclohexanone",3.9,uM,=,0.5910646070264992,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
4517,66581,10.1016/s0960-894x(02)00598-x,,,,Inhibition of Epidermal Growth Factor Receptor (EGFR) autophosphorylation,C#Cc1cccc(Nc2c(C#N)cnc3cc(OCCOC)c(OCCOC)cc23)c1,"4-(3-Ethynyl-phenylamino)-6,7-bis-(2-methoxy-ethoxy)-quinoline-3-carbonitrile",0.85,uM,=,-0.0705810742857072,0,c1ccc(Nc2ccnc3ccccc23)cc1
4518,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,COc1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1,2-(4-methoxyphenyl)-N-(phenylsulfonyl)acetamide,26.2,uM,=,1.4183012913197457,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
4519,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N1CC(CCN(C)C)C1,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-2-(3-(2-(dimethylamino)ethyl)azetidin-1-yl)-4-methoxyphenyl)acrylamide",0.2511,uM,=,-0.6001532872870776,0,c1cc2c3c(c1)c(-c1ccnc(Nc4ccc(N5CCC5)cc4)n1)cn3CCC2
4520,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,OC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"1-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)piperidin-4-ol",0.068,uM,=,-1.1674910872937636,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
4521,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4ccc(F)c(F)c4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-N-[4-({4-[(3,4-difluorobenzyl)oxy]-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)-7-ethoxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide",0.1667,uM,=,-0.7780644001719947,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
4522,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Oc1ncnc(Nc3ccc(F)cc3)c1NC2,"(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(4-fluoro-phenyl)-amine",7.6,uM,=,0.8808135922807914,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
4523,1986369,10.1016/j.bmc.2020.115373,,,,Inhibition of human EGFR-TK using PTK substrate after 40 mins in presence of ATP by Kinase-Glo luminescent assay,N#CC1=C(N)N(c2nnc3c4ccccc4nc(Sc4ccc(Br)cc4)n23)C(=O)C1,"2-Amino-1-{5-[(4-bromophenyl)sulfanyl]-[1,2,4]triazolo[4,3-c]quinazolin-3-yl}-5-oxo-4,5-dihydro-1H-pyrrole-3-carbonitrile",1.8,uM,=,0.255272505103306,1,O=C1CC=CN1c1nnc2c3ccccc3nc(Sc3ccccc3)n12
4524,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccc(Br)cc3)CC2c2ccc(Cl)cc2)=N1,"2-(3-(4-Bromophenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",4.12,uM,=,0.6148972160331346,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
4525,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,Cc1ccc(NC(=O)/C=C/CN(C)C)cc1C(=O)Nc1ccc(OCc2cccc(F)c2)c(Cl)c1,N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-5-(4-(dimethylamino)but-2-enamido)-2-methylbenzamide,0.45,uM,=,-0.3467874862246563,0,O=C(Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
4526,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,Cc1cccc(Nc2ncnc3ccc(NC(=S)NCc4ccccc4)cc23)c1,1-benzyl-3-(4-(m-tolylamino)quinazolin-6-yl)thiourea,0.0368,uM,=,-1.4341521813264824,0,S=C(NCc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4527,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCN1CCN(CCCNC(=O)/C(C#N)=C/c2ccc(O)c(O)c2)CC1,"(E)-2-Cyano-N-[3-(4-{3-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-propyl}-piperazin-1-yl)-propyl]-3-(3,4-dihydroxy-phenyl)-acrylamide",7.0,uM,=,0.8450980400142568,1,O=C(C=Cc1ccccc1)NCCCN1CCN(CCCNC(=O)/C=C/c2ccccc2)CC1
4528,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cc(Cl)ccc3F)c2cc1OC1CCN(CC(N)=O)CC1,2-(4-(4-(5-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)acetamide,0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
4529,1541392,10.1016/j.ejmech.2015.09.031,,,,Inhibition of wild type recombinant human EGFR preincubated for 10 mins followed by FAM-labeled peptide/ATP addition measured after 1 hr by mobility shift assay,C=CC(=O)Nc1cccc(Nc2nc(N/N=C(\C)c3ccc(F)cc3F)ncc2Cl)c1,"(E)-N-(3-(5-Chloro-2-(2-(1-(2,4-difluorophenyl)ethylidene)hydrazinyl)pyrimidin-4-ylamino)phenyl)acrylamide",11.75,uM,=,1.070037866607755,1,C(=NNc1nccc(Nc2ccccc2)n1)c1ccccc1
4530,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(NCCN1CCCCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(2-(piperidin-1-yl)ethyl)urea,0.165,uM,=,-0.7825160557860937,0,O=C(NCCN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
4531,1912354,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGFR phosphorylation at Tyr1068 residues preincubated for 1 hr followed by human EGF stimulation and measured after 10 mins by HTRF assay,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"US9447106, 27b (peak 2)",0.606,uM,=,-0.2175273758337138,0,c1ccc(Oc2ccc(-c3cc4n(n3)[C@H](C3CCNCC3)CCN4)cc2)cc1
4532,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,C=CC(=O)Nc1ccc2c(c1)CNc1c(Nc3cccc(Br)c3)ncnc1O2,"N-[1-(3-Bromo-phenylamino)-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-8-yl]-acrylamide",5.4,uM,=,0.7323937598229685,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
4533,63764,10.1021/jm960689b,,,,Inhibition of epidermal growth factor receptor (EGFr),CNC(=O)c1c(SSc2c(C(=O)NC)c3ccccc3n2C)n(C)c2ccccc12,"1,3N-dimethyl-2-(1-methyl-3-methylcarbamoyl-1H-2-indolyldisulfanyl)-1H-3-indolecarboxamide",6.9,uM,=,0.8388490907372553,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
4534,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)/C(F)=C/CN1CCOCC1,(Z)-(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-4-morpholinobut-2-enamide,0.00026,uM,=,-3.585026652029182,0,O=C(/C=C/CN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
4535,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CCCS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-(5-((2-(propylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.021,uM,=,-1.6777807052660807,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
4536,2239138,10.1021/acs.jmedchem.2c01041,,,,Inhibition of wild type EGFR (unknown origin) preincubated with compound 30 mins followed ATP addition incubated for 30 mins by HTRF KinEASE TK assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0345,uM,=,-1.4621809049267258,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4537,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc(C)cc3)C2)cc1,"2-(3-(4-methoxyphenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",7.48,uM,=,0.8739015978644614,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
4538,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1ccc(Nc2ncc3ncc(=O)n(-c4ccc(OC)cc4)c3n2)cc1,"N-(4-(8-(4-Methoxyphenyl)-7-oxo-7,8-dihydropteridin-2-ylamino)phenyl)acrylamide",33.885,uM,=,1.5300074899760443,1,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
4539,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,CC1CNCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((6-methyl-1,4-diazepan-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.13,uM,=,-0.8860566476931633,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)cc1
4540,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#CC(C#N)=C(N)/C(C#N)=C/c1cc(O)c(O)c(O)c1,"3-Amino-2,4-dicyano-5-(3,4,5-trihydroxy-phenyl)-penta-2,4-dienenitrile",0.8,uM,=,-0.0969100130080563,0,c1ccccc1
4541,66595,10.1021/jm960879m,,,,Tested for ability to inhibit autophosphorylation of the Epidermal growth factor receptor in human epidermoid carcinoma cells,Brc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)nc23)c1,"N*8*-(3-Bromo-phenyl)-N*2*-(2-morpholin-4-yl-ethyl)-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.0031,uM,=,-2.508638306165728,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)nc23)cc1
4542,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,COc1cc2ncnc(Nc3ccc(F)cc3)c2cc1OC.Cl,"4-(4'-fluoroanilino)-6,7-dimethoxyquinazoline hydrochloride",0.0191,uM,=,-1.7189666327522723,0,c1ccc(Nc2ncnc3ccccc23)cc1
4543,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=[N+]([O-])/C=C/c1ccc(O)cc1,4-(2-Nitro-vinyl)-phenol,10.0,uM,=,1.0,1,c1ccccc1
4544,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,CN1CCN(C/C=C/C(=O)N2CCOc3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4cc32)CC1,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7,8-dihydropyrimido[5,4-g][1,4]benzoxazin-6-yl]-4-(4-methylpiperazin-1-yl)but-2-en-1-one",0.045,uM,=,-1.3467874862246565,0,O=C(/C=C/CN1CCNCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
4545,940299,10.1021/ml300327z,,,,Inhibition of human wild type EGFR expressed in Sf9 cells using [gamma32P]-ATP after 10 mins by scintillation counting,O=C(Nc1cccc(Oc2ccc(Nc3ncnc4ccn(CCOCCO)c34)cc2Cl)c1)NC1CCCCC1,"1-(3-(2-Chloro-4-((5-(2-(2-hydroxyethoxy)ethyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)phenoxy)phenyl)-3-cyclohexylurea",0.0069,uM,=,-2.161150909262745,0,O=C(Nc1cccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)c1)NC1CCCCC1
4546,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-5,6-dimethylpyrimidin-4-amine",0.017,uM,=,-1.769551078621726,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
4547,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,FC(F)(F)c1cccc(Nc2ncnc3ccccc23)c1,Quinazolin-4-yl-(3-trifluoromethyl-phenyl)-amine,0.577,uM,=,-0.2388241868442686,0,c1ccc(Nc2ncnc3ccccc23)cc1
4548,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3cccc(Br)c3)nc21,"2-(3-Bromo-phenylamino)-6-(2,6-dichloro-phenyl)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",0.67,uM,=,-0.1739251972991735,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
4549,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1ncc(N2CC[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-((R)-2-methylazetidin-1-yl)-2,6-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",3.42,uM,=,0.534026106056135,1,c1cc(Nc2cc3cncc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
4550,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Nc1ccc2sc3c(Nc4cccc(Br)c4)ncnc3c2c1,"N*4*-(3-Bromo-phenyl)-benzo[4,5]thieno[3,2-d]pyrimidine-4,8-diamine",0.00027,uM,=,-3.5686362358410126,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
4551,974507,10.1016/j.ejmech.2013.05.026,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(COc3no[n+]([O-])c3S(=O)(=O)c3ccccc3)cc2)n1,"4-((4-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)benzyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide",1.09,uM,=,0.0374264979406236,1,O=S(=O)(c1ccccc1)c1[nH+]onc1OCc1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4552,221782,10.1016/0960-894X(95)00157-O,,,,Inhibition of epidermal growth factor receptor (EGFR),COc1cc2c(cc1OC)Nc1ncn(C)c(=O)c1C2,"7,8-Dimethoxy-3-methyl-5,10-dihydro-3H-pyrimido[4,5-b]quinolin-4-one",160.0,uM,=,2.204119982655925,1,O=c1[nH]cnc2c1Cc1ccccc1N2
4553,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(=O)c2ccc(O)c(O)c2)cc(CSCc2ccccc2)c1O,"3-(3-Benzylsulfanylmethyl-4-hydroxy-5-methoxy-phenyl)-2-(3,4-dihydroxy-benzoyl)-acrylonitrile",4.5,uM,=,0.6532125137753437,1,O=C(C=Cc1cccc(CSCc2ccccc2)c1)c1ccccc1
4554,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",O=C1CS/C(=N/Nc2nncc3ccccc23)N1c1ccc(Cl)cc1,3-(4-Chlorophenyl)-2-(2-(phthalazin-1-yl)hydrazono)thiazolidin-4-one,0.042,uM,=,-1.3767507096020994,0,O=C1CS/C(=N/Nc2nncc3ccccc23)N1c1ccccc1
4555,1798716,10.1016/j.ejmech.2017.03.083,,,,"Inhibition of wild type N-terminal GST tagged human recombinant EGFR (695 to end amino acids) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) Peptide substrate by ADP-Glo assay",C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(NC(=O)CN3CCOCC3)cc2)ncc1Cl,N-(2-(5-chloro-2-(4-(2-morpholinoacetamido)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide,0.5921000000000001,uM,=,-0.2276049389179997,0,O=C(CN1CCOCC1)Nc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1
4556,2107115,10.1016/j.ejmech.2021.113300,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCCC(=O)Nc1ccc(S(N)(=O)=O)cc1,5-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-(4-sulfamoylphenyl)pentanamide,0.0183,uM,=,-1.7375489102695705,0,O=C(CCCCOc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1ccccc1
4557,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,O=[N+]([O-])c1cccc(Oc2cc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncn2)c1,4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-nitro phenoxy)pyrimidine,1.204,uM,=,0.0806264869218057,1,c1ccc(COc2ccc(Nc3cc(Oc4ccccc4)ncn3)cc2)cc1
4558,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)NCc1cn(Cc2cccc(Nc3cc(-c4[nH]c(SC)nc4-c4ccc(F)cc4)ccn3)c2)nn1,"N-((1-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridin-2-yl)amino)benzyl)-1H-1,2,3-triazol-4-yl)methyl)-acrylamide",0.164,uM,=,-0.7851561519523022,0,c1ccc(-c2nc[nH]c2-c2ccnc(Nc3cccc(Cn4ccnn4)c3)c2)cc1
4559,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cc(F)ccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1,"(R)-6-(4-Fluoro-2-methoxyphenyl)-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine",0.006,uM,=,-2.2218487496163566,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
4560,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((4-methylpiperazin-1-yl)methyl)furan-2-yl)thieno[3,2-d]pyrimidin-4-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5ccc(CN6CCNCC6)o5)sc34)cc2)cc1
4561,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccc(Cl)cc4)cs3)C(c3ccc(OC)cc3)C2)cc1,"2-(3,5-bis(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-chlorophenyl)thiazole",6.27,uM,=,0.7972675408307164,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
4562,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
4563,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1ccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)cc1,N-(4-(2-(2-Methoxy-4-(4-methylpiperazin-1-yl)-phenylamino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.395,uM,=,-0.4034029043735397,0,O=c1cnc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
4564,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,CCOc1cc2ncnc(Nc3ccc(OCC4CC4)c(Cl)c3)c2cc1NC(=O)/C(F)=C\CN(C)C,(E)-N-(4-((3-Chloro-4-(cyclopropylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.0112,uM,=,-1.9507819773298185,0,c1ccc2c(Nc3ccc(OCC4CC4)cc3)ncnc2c1
4565,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,C=CCn1nc(-c2ccc(OCC)c(OC)c2)c2c(N)ncnc21,"1-allyl-3-(4-ethoxy-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",5.08,uM,=,0.7058637122839193,1,c1ccc(-c2n[nH]c3ncncc23)cc1
4566,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,Cc1ncc([N+](=O)[O-])n1CC(=O)NS(=O)(=O)c1ccc(Br)cc1,N-(4-Bromophenylsulfonyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetamide,2.17,uM,=,0.3364597338485295,1,O=C(Cn1ccnc1)NS(=O)(=O)c1ccccc1
4567,1353177,10.1021/ml4003309,,,,Inhibition of recombinant EGFR (unknown origin) using poly-GT peptide as substrate by Transcreener assay,COc1cc2c(Oc3ccc(NS(=O)(=O)c4cccc(-c5ccco5)c4)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,N-[3-fluoro-4-({6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yl}oxy)phenyl]-3-(2-furyl)benzenesulfonamide,1.907,uM,=,0.2803506930460056,1,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1cccc(-c2ccco2)c1
4568,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CO)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-12",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4569,5722,10.1021/jm010888h,,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,C[C@@H](Nc1[nH]cnc2nc(-c3ccccc3)cc1-2)c1ccccc1,"(1-Phenyl-ethyl)-(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",0.01,uM,=,-2.0,0,c1ccc(CNc2[nH]cnc3nc(-c4ccccc4)cc2-3)cc1
4570,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1ccc(Br)cc1)NS(=O)(=O)c1ccc(Br)cc1,2-(4-Bromophenyl)-N-(4-bromophenylsulfonyl)acetamide,17.26,uM,=,1.2370407913791908,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
4571,1898287,10.1016/j.bmc.2019.115051,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system using Srctide as substrate incubated for 1 hr by mobility shift assay,COc1cc(NC(=O)C2CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2NC(C)=O)n1,N-(4-((4-((2-acetamidophenyl)amino)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)cyclopropanecarboxamide,0.617,uM,=,-0.2097148359667583,0,O=C(Nc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)C1CC1
4572,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCOc1cc2ncnc(/C=C/CCCc3ccccc3)c2cc1OCC,"6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline",0.14,uM,=,-0.8538719643217619,0,C(=C/c1ncnc2ccccc12)\CCCc1ccccc1
4573,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,Brc1cccc(Nc2ncnc3cc(OCCCN4CCOCC4)c4c(c23)OCCO4)c1,"N-(3-Bromophenyl)-5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.01848,uM,=,-1.733298033115912,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c4c(c23)OCCO4)cc1
4574,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3cccc(I)c3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-iodo-phenyl)-amine",0.00089,uM,=,-3.050609993355087,0,c1ccc(Nc2ncnc3ccccc23)cc1
4575,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1.Cl.Cl,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, hydrochloride (CI-1033)",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
4576,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,CN(C)C/C=C/C(=O)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1,4-(6-(4-(dimethylamino)but-2-enamido)quinolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.275,uM,=,-0.5606673061697374,0,O=C(Nc1ccccn1)c1ccc(Oc2ccnc3ccccc23)cc1
4577,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,Fc1ccc(Nc2ncnc3ccc(NC(=S)NCCN4CCOCC4)cc23)cc1Cl,1-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)thiourea,0.15,uM,=,-0.8239087409443188,0,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4578,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=C(O)c1cc(N(Cc2cc(O)ccc2O)Cc2cc(O)ccc2O)ccc1O,"5-(bis(2,5-dihydroxybenzyl)amino)-2-hydroxybenzoic acid",0.0251815494054984,uM,=,-1.5989175515293363,0,c1ccc(CN(Cc2ccccc2)c2ccccc2)cc1
4579,67206,10.1021/jm010496a,,,,Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase,CCOc1cc2ncnc(Nc3cccc(-c4nc[nH]n4)c3)c2cc1OCC,"(6,7-Diethoxy-quinazolin-4-yl)-[3-(1H-[1,2,4]triazol-3-yl)-phenyl]-amine",0.39,uM,=,-0.4089353929735008,0,c1cc(Nc2ncnc3ccccc23)cc(-c2nc[nH]n2)c1
4580,2296337,10.1039/d3md00038a,,,,Inhibition of EGFR (unknown origin),Cc1c(C(=O)NCCc2ccc(F)cc2)[nH]c2cc(F)ccc12,6-fluoro-N-(4-fluorophenethyl)-3-methyl-1H-indole-2-carboxamide,0.098,uM,=,-1.0087739243075051,0,O=C(NCCc1ccccc1)c1cc2ccccc2[nH]1
4581,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,CN(C)C(=O)CN1CCC(n2cc(-c3cccc(O)c3)c3c(N)ncnc32)CC1,"2-{4-[4-Amino-5-(3-hydroxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-piperidin-1-yl}-N,N-dimethyl-acetamide",0.5,uM,=,-0.3010299956639812,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1
4582,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,O=C(O)CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-acetic acid",0.00028,uM,=,-3.552841968657781,0,c1ccc(Nc2ncnc3cnccc23)cc1
4583,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,Cc1cc2cc(Nc3ccnc4cc(-c5ccc(CNCCO)cc5)sc34)ccc2[nH]1,"2-{4-[7-(2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-ethanol",1.0,uM,=,0.0,0,c1ccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
4584,4991,10.1016/S0960-894X(97)10117-2,,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,COc1cc2nccc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinolin-4-yl)-amine",0.37,uM,=,-0.431798275933005,0,c1ccc(Nc2ccnc3ccccc23)cc1
4585,1832278,10.1016/j.bmc.2018.12.032,,,,Inhibition of recombinant human His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in autophosphorylation preincubated for 10 mins followed by ATP-MgCl2 addition and measured after 1 hr by DELFIA/time-resolved fluorometric analysis,CCOc1cc2ncc(C#N)c(Nc3ccc(Cl)c(F)c3)c2cc1NC(=O)/C=C/CN(C)C,N-(4-(4-chloro-3-fluorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0385,uM,=,-1.4145392704914994,0,c1ccc(Nc2ccnc3ccccc23)cc1
4586,1883874,10.1021/acsmedchemlett.8b00270,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay,C=CC(=O)N(c1cccc(Cl)c1F)c1ncnc2cc(OC)c(OCCCN3CCOCC3)cc12,4-[N-acryloyl-(3-chloro-2-fluorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline,0.0526,uM,=,-1.279014255846261,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
4587,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,3.566,uM,=,0.5521813388393357,1,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
4588,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)CC(=C)C,N-(4-methoxy-2-(methyl(2-(methyl(2-methylallyl)amino)ethyl)amino)-5-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.06398,uM,=,-1.193955764251912,0,c1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1
4589,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)Cc1ccccc1,N-(2-((2-(benzyl(methyl)amino)ethyl)(methyl)amino)-4-methoxy-5-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.01123,uM,=,-1.949620243738542,0,c1ccc(CNCCNc2ccc(Nc3nccc(Nc4c[nH]c5ccccc45)n3)cc2)cc1
4590,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,CC(=O)NC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"N-(1-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)piperidin-4-yl)acetamide",0.38,uM,=,-0.4202164033831898,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
4591,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C=CC(=O)Nc1cccc(-c2c(Cl)sc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-[3-(6-Chloro-4-{[(1S)-2-hydroxy-1-phenylethyl]amino}thieno-[2,3-d]pyrimidin-5-yl)phenyl]prop-2-enamide",0.081,uM,=,-1.0915149811213505,0,c1ccc(CNc2ncnc3scc(-c4ccccc4)c23)cc1
4592,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(N=[N+]=[N-])cc2)n1,N-(4-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)azide,26.87,uM,=,1.4292676664331685,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4593,2018691,10.1016/j.bmc.2020.115674,,,,Inhibition of EGFR-TK (unknown origin) relative to control,CCN1CCN(CC(=O)Nc2cc(C)on2)CC1,2-(4-Ethylpiperazin-1-yl)-N-(5-methylisoxazol-3-yl)acetamide,0.081,uM,=,-1.0915149811213505,0,O=C(CN1CCNCC1)Nc1ccon1
4594,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1SCCCCCCC(=O)NO,7-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ylthio)-N-hydroxyheptanamide,0.00199,uM,=,-2.701146923590293,0,c1ccc(Nc2ncnc3ccccc23)cc1
4595,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C(Nc1ccccc1)N(Cc1ccc(F)cc1)Cc1cccc(Cl)c1O,1-(5-Chloro-2-hydroxybenzyl)-1-(4-fluorobenzyl)-3-phenylurea,1.98,uM,=,0.2966651902615311,1,O=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
4596,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,C=C(CNc1cc2c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c(C#N)cnc2cc1OCC)C(=O)O,2-{[4-(4-Benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-ylamino]-methyl}-acrylic acid,1.191,uM,=,0.0759117614827775,1,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
4597,2215982,10.1016/j.bmc.2022.116835,,,,Inhibition of EGFR (unknown origin) assessed as kinase activity by measuring ATP remaining for 40 mins in presence of ATP by Kinase-Glo Plus luminescence kinase assay,O=C(Cc1csc2nc3ccccc3n12)Nc1cccc2ccccc12,"2-(benzo[4,5]imidazo[2,1-b]thiazol-3-yl)-N-(naphthalen-1-yl)acetamide",55.0,uM,=,1.740362689494244,1,O=C(Cc1csc2nc3ccccc3n12)Nc1cccc2ccccc12
4598,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,CN(C)CCn1ncc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-[1-(2-dimethylamino-ethyl)-1H-pyrazolo[4,3-g]quinazolin-5-yl]-amine",0.262,uM,=,-0.5816987086802545,0,c1ccc(Nc2ncnc3cc4[nH]ncc4cc23)cc1
4599,1515019,10.1016/j.ejmech.2015.07.030,,,,Inhibition of epidermal growth factor receptor kinase (unknown origin) using [33P]-ATP after 20 to 30 mins by radiometric assay,CN(C)c1ccc(/C=C/C(=O)c2ccc3ncc(C(N)=O)c(Nc4ccc(Cl)cc4)c3c2)cc1,4-(4-Chlorophenylamino)-6-(3-(4-(dimethylamino)phenyl)acryloyl)quinoline-3-carboxamide,5.283,uM,=,0.7228806106869394,1,O=C(/C=C/c1ccccc1)c1ccc2nccc(Nc3ccccc3)c2c1
4600,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COCCN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1,N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(1-(2-methoxyethyl)piperidin-4-yloxy)quinazolin-4-amine,0.035,uM,=,-1.4559319556497243,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
4601,1717129,10.1016/j.ejmech.2017.07.028,,,,Inhibition of EGFR1 (unknown origin) after 1 hr in presence of adenosine 5'[gamma-33P]triphosphate by microbeta microplate counting method,Brc1cccc(Nc2ncnc3sc4c(c23)CCCC4)c1,"N-(3-bromophenyl)-5,6,7,8-tetrahydrobenzothiopheno[2,3-d]pyrimidin-4-amine",0.00261,uM,=,-2.583359492661719,0,c1ccc(Nc2ncnc3sc4c(c23)CCCC4)cc1
4602,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cnn4ccccc34)n2)c(OC)cc1N1CCN(C)CC1,"N-(4-methoxy-2-(4-methylpiperazin-1-yl)-5-(4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide",19.0,uM,=,1.2787536009528289,1,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c2c1
4603,1472645,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) after 40 mins by scintillation proximity assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.011,uM,=,-1.958607314841775,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
4604,974507,10.1016/j.ejmech.2013.05.026,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(COc3no[n+]([O-])c3S(=O)(=O)c3ccccc3)c2)n1,"4-((3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)benzyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide",0.13,uM,=,-0.8860566476931633,0,O=S(=O)(c1ccccc1)c1[nH+]onc1OCc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
4605,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,"[5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-phenyl]-acetic acid",6.0,uM,=,0.7781512503836436,1,c1ccc(CNc2ccccc2)cc1
4606,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,C=CC(=O)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1,"N-[4-(4,5-Dichloro-2-fluoro-phenylamino)-quinazolin-6-yl]-acrylamide",3.7e-05,uM,=,-4.431798275933005,0,c1ccc(Nc2ncnc3ccccc23)cc1
4607,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)/C(F)=C\CN(C)C,(E)-N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.0013,uM,=,-2.886056647693163,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
4608,1299287,10.1039/C3MD00096F,,,,Inhibition of EGFR (unknown origin) after 1 hr by Caliper mobility shift assay,O=C(Nc1cccc(Nc2ncnc3cc(OCCCN4CCN(CCO)CC4)ccc23)c1)Nc1ccc(Cl)c(C(F)(F)F)c1,1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(3-(7-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propoxy)quinazolin-4-ylamino)phenyl)urea,0.099,uM,=,-1.00436480540245,0,O=C(Nc1ccccc1)Nc1cccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)c1
4609,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C=CC(=O)Nc1cccc(-c2c(-c3ccccc3OC)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-{3-[4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-(2-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}prop-2-enamide",0.024,uM,=,-1.619788758288394,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
4610,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3cc(O)c(Cl)cc3F)ncnc2cc1OCC1CCN(C)CC1.Cl,2-Chloro-4-fluoro-5-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-ylamino]-phenol hydrochloride,0.07,uM,=,-1.154901959985743,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
4611,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CN(C)c1ccc2ncnc(Nc3cccc(Br)c3)c2n1,"N*4*-(3-Bromo-phenyl)-N*6*,N*6*-dimethyl-pyrido[3,2-d]pyrimidine-4,6-diamine",0.0096,uM,=,-2.017728766960432,0,c1ccc(Nc2ncnc3cccnc23)cc1
4612,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC(=O)C(C)c4ccc5cc(OC)ccc5c4)c(OCCOC(=O)C(C)c4ccc5cc(OC)ccc5c4)cc23)c1,"((4-((3-Ethynylphenyl)amino)quinazoline-6,7-diyl)bis(oxy))bis(ethane-2,1-diyl)-bis(2-(6-methoxynaphthalen-2-yl)propanoate)",0.39,uM,=,-0.4089353929735008,0,O=C(Cc1ccc2ccccc2c1)OCCOc1cc2ncnc(Nc3ccccc3)c2cc1OCCOC(=O)Cc1ccc2ccccc2c1
4613,515179,10.1016/j.bmcl.2008.12.023,,,,Inhibition of EGFR,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(C(=O)NNc4ccccc4)cc32)c(C)c1CCC(=O)O,"3-{2,4-dimethyl-5-[2-oxo-5-(N'-phenylhydrazinocarbonyl)-1,2-dihydro-indol-3-ylidenemethyl]-1H-pyrrol-3-yl}-propionic acid",3.48,uM,=,0.541579243946581,1,O=C1Nc2ccc(C(=O)NNc3ccccc3)cc2/C1=C/c1ccc[nH]1
4614,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,COC(=O)COCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"methyl 2-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methoxy)acetate",0.46,uM,=,-0.3372421683184259,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
4615,64442,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor (EGFR) in A431 cells,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,0.0043,uM,=,-2.3665315444204134,0,c1ccc(Nc2ncnc3ccccc23)cc1
4616,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),c1ccc(Nc2[nH]cnc3nc4ccccc4c2-3)cc1,"Phenyl-(9H-pyrimido[4,5-b]indol-4-yl)-amine",0.264,uM,=,-0.5783960731301689,0,c1ccc(Nc2[nH]cnc3nc4ccccc4c2-3)cc1
4617,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[S+]([O-])CCN(C)C,(+)-N-(2-((2-(dimethylamino)ethyl)sulfinyl)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,0.318,uM,=,-0.4975728800155673,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4618,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,COc1cc(Nc2ncnc3[nH]nc(OCCN4CCC(O)CC4)c23)ccc1OCc1ccccn1,"1-(2-(4-(3-methoxy-4-(pyridin-2-ylmethoxy)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yloxy)ethyl)piperidin-4-ol",0.104,uM,=,-0.9829666607012196,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCCC5)c34)cc2)nc1
4619,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COCC6CNCCOC6)c45)ccc32)c1,"5-(((1,4-oxazepan-6-yl)methoxy)methyl)-N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.21,uM,=,-0.6777807052660807,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COCC6CNCCOC6)c45)ccc32)cc1
4620,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,Cc1ccc(C2CC(c3ccc(Br)c(Br)c3)=NN2C(N)=S)cc1,"3-(3,4-Dibromophenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazole-1-carbothioamide",9.83,uM,=,0.9925535178321356,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
4621,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Brc1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1,"(3-Bromo-phenyl)-(6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]indol-4-yl)-amine",0.046,uM,=,-1.337242168318426,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1
4622,958682,10.1021/jm400463q,,,,Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC(=O)OCCCCCCOc5no[n+]([O-])c5S(=O)(=O)c5ccccc5)CC4)cc3OC)ncc2Cl)c1,"4-((6-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetoxy)hexyl)-oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide",0.292,uM,=,-0.5346171485515817,0,O=C(CN1CCN(c2ccc(Nc3nccc(Oc4ccccc4)n3)cc2)CC1)OCCCCCCOc1no[nH+]c1S(=O)(=O)c1ccccc1
4623,989154,10.1016/j.bmc.2013.09.027,,,,Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA,COc1cc(O)c2c(=O)n(-c3cccc(C(=O)N4CCCCC4)c3)ccc2c1,8-hydroxy-6-methoxy-2-(3-(piperidin-1-ylcarbonyl)phenyl)isoquinolin-1(2H)-one,1.38,uM,=,0.1398790864012364,1,O=C(c1cccc(-n2ccc3ccccc3c2=O)c1)N1CCCCC1
4624,1774290,10.1016/j.ejmech.2018.03.001,,,,Inhibition of His-6 tagged recombinant EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in Baculovirus infected Sf9 cells by dissociation-enhanced lanthanide fluorescence immunoassay/time-resolved fluorometric analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.08,uM,=,-1.0969100130080565,0,c1ccc(Nc2ncnc3ccccc23)cc1
4625,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1cccc([N+](=O)[O-])c1)c1ccccc1,(Z)-2-((E)-3-(3-nitrophenyl)-1-phenylallylidene)hydrazinecarbothioamide,3.74,uM,=,0.5728716022004802,1,N=C(/C=C/c1ccccc1)c1ccccc1
4626,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,COc1cccc(Nc2ncnc3[nH]c(C)c(C)c23)c1,"(5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(3-methoxy-phenyl)-amine",1.2,uM,=,0.0791812460476248,1,c1ccc(Nc2ncnc3[nH]ccc23)cc1
4627,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,Clc1cc(Nc2ncnc3[nH]nc(OCCCN4CCOCC4)c23)ccc1OCc1ccccn1,"N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-3-(3-morpholinopropoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.016,uM,=,-1.7958800173440752,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCCN5CCOCC5)c34)cc2)nc1
4628,2080997,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCc1cn(CCCCC(=O)NO)nn1,"5-(4-(((6-Acrylamido-4-((3-chloro-4-((2-fluorobenzyl)oxy)phenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypentanamide",0.0026,uM,=,-2.5850266520291822,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCc5c[nH]nn5)ccc34)cc2)cc1
4629,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,1.983,uM,=,0.2973227142053027,1,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4630,1649110,10.1016/j.bmc.2016.11.026,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF induced phosphorylation preincubated for 60 mins followed by EGF addition measured after 10 mins by ELISA method,COc1ccc2c(c1)CCN2c1nc(C)nc2c(Cc3ccccc3)c[nH]c12.Cl,"7-Benzyl-4-(5-methoxyindolin-1-yl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidine hydrochloride",0.1671,uM,=,-0.7770235501066087,0,c1ccc(Cc2c[nH]c3c(N4CCc5ccccc54)ncnc23)cc1
4631,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,CN1CCN(CCC(=O)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)CC1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-(4-methylpiperazin-1-yl)propanamide,0.00023,uM,=,-3.638272163982407,0,O=C(CCN1CCNCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4632,1799769,10.1016/j.ejmech.2018.06.011,,,,"Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay",CS(=O)(=O)Nc1ccc(-c2cc3c(Nc4ccc(Oc5cccc(C(F)(F)F)c5)c(Cl)c4)ncnc3s2)cc1,"N-(4-(4-(3-chloro-4-(3-(trifluoromethyl)phenoxy)phenylamino)thieno[2,3-d]pyrimidin-6-yl)phenyl)methanesulfonamide",0.0471,uM,=,-1.3269790928711038,0,c1ccc(Oc2ccc(Nc3ncnc4sc(-c5ccccc5)cc34)cc2)cc1
4633,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC(=O)C(C)c4ccc(CC(C)C)cc4)c(OCCOC)cc23)c1,2-((4-((3-Ethynylphenyl)amino)-6-(2-methoxyethoxy)quinazolin-7-yl)oxy)ethyl-2-(4-isobutylphenyl)propanoate,0.009,uM,=,-2.0457574905606752,0,O=C(Cc1ccccc1)OCCOc1ccc2c(Nc3ccccc3)ncnc2c1
4634,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CC(C)(CN1CCOCC1)NC/C=C/C(=O)N1CCc2c(sc3ncnc(Nc4ccc(F)c(Cl)c4)c23)C1,"US8524722, 12",0.001,uM,=,-3.0,0,O=C(/C=C/CNCCN1CCOCC1)N1CCc2c(sc3ncnc(Nc4ccccc4)c23)C1
4635,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,CCNC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2c1,1-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)quinazolin-6-yl)-3-ethylurea,0.227,uM,=,-0.6439741428068773,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
4636,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)Cc2ccccc2)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"4-benzyl(methyl)amino-3-methoxy-2-methyl-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-16-one",0.91,uM,=,-0.0409586076789063,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1C[C@@H](NCc2ccccc2)C[C@@H]3O1
4637,2030549,10.1016/j.ejmech.2020.112062,,,,Inhibition of EGFR in human RPMI-8226 cells incubated for 2 hrs by ELISA,COc1ccc(/C=C/C(=O)c2nnn(-c3ccc(Cl)cc3)c2C)cc1OC,"(E)-1-[1-(4-Chlorophenyl)-5-methyl-triazol-4-yl]-3-(3,4-dimethoxyphenyl)prop-2-en-1-one",0.036,uM,=,-1.4436974992327127,0,O=C(/C=C/c1ccccc1)c1cn(-c2ccccc2)nn1
4638,66724,10.1021/jm00032a020,,,,Inhibition of EGFR(epidermal growth factor receptor) autophosphorylation in ER22 cell membranes,COC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid methyl ester",1.0,uM,=,0.0,0,c1ccc(CNc2ccccc2)cc1
4639,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,CN(C)c1ccccc1Nc1ncnc2cc(N)ncc12,"N*4*-(2-Dimethylamino-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",69.0,uM,=,1.8388490907372552,1,c1ccc(Nc2ncnc3ccncc23)cc1
4640,586303,10.1016/s0006-2952(00)00405-6,,,,Inhibition of EGFR,Cc1cc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)ccc1F,"6-(2,6-dichlorophenyl)-2-((4-fluoro-3-methylphenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one",0.39,uM,=,-0.4089353929735008,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
4641,2270916,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) incubated for 10 mins in presence of ATP by mobility shift assay,CN(C)CCn1cccc1/C=N/NC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,"(S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-((1-((dimethylamino)ethyl)-1H-pyrrol-2-yl)methylene)hydrazine carboxamide",5e-05,uM,=,-4.301029995663981,0,O=C(N/N=C/c1ccc[nH]1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
4642,1556348,10.1016/j.bmc.2016.02.017,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by addition of substrate by mobility shift assay,COc1ccc(/C=C/C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2O[C@H]2CCOC2)c(OC)c1OC,"(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-3-(2,3,4-trimethoxyphenyl)acrylamide",0.0036,uM,=,-2.4436974992327127,0,O=C(/C=C/c1ccccc1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
4643,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(OC)cc4)nc32)c1,N-(3-(2-(4-Methoxyphenylamino)-7-oxopteridin-8(7H)-yl)-phenyl)acrylamide,0.0138,uM,=,-1.8601209135987635,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
4644,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC1CCN(CC(N)=O)CC1,2-(4-(4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)acetamide,0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
4645,808129,10.1016/j.bmc.2012.02.017,,,,"Inhibition of human recombinant EGF-R expressed in Sf9 cells using poly(E,Y)4:1 as substrate after 80 mins by scintillation counting",O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23,"2,3,7,8-Tetrahydroxy-chromeno[5,4,3-cde]chromene-5,10-dione",0.69,uM,=,-0.1611509092627447,0,O=c1oc2cccc3c(=O)oc4cccc1c4c23
4646,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,COc1ccc(C2CC(c3ccc(C)c(C)c3)=NN2C(N)=S)cc1,"3-(3,4-Dimethylphenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",0.07,uM,=,-1.154901959985743,0,c1ccc(C2=NNC(c3ccccc3)C2)cc1
4647,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN1CCOCC1,(Z)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-(morpholine-4-yl)but-2-enamide,0.00053,uM,=,-3.275724130399211,0,O=C(/C=C/CN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4648,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,COc1ccc2c(c1)Oc1ncnc(Nc3cccc(Br)c3)c1NC2,"(3-Bromo-phenyl)-(7-methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",1.9,uM,=,0.2787536009528289,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
4649,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,"5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide",0.1721,uM,=,-0.7642191296724398,0,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1
4650,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,C[C@@H](Nc1ncnc2oc(-c3ccc(NCCN4CCOCC4)cc3)cc12)c1ccccc1,"(R)-6-(4-((2-Morpholinoethyl)amino)phenyl)-N-(1-phenylethyl)furo[2,3-d]pyrimidin-4-amine",0.0011,uM,=,-2.958607314841775,0,c1ccc(CNc2ncnc3oc(-c4ccc(NCCN5CCOCC5)cc4)cc23)cc1
4651,787272,10.1016/j.bmcl.2011.09.008,,,,Inhibition of EGFR preincubated for 60 mins measured after 60 mins by TR-FRET Assay,Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12,"(E)-4-(Dimethylamino)-N-(7-fluoro-4-(o-tolylamino)imidazo[1,5-a]quinoxalin-8-yl)-N-methylbut-2-enamide",0.0014,uM,=,-2.853871964321762,0,c1ccc(Nc2nc3ccccc3n3cncc23)cc1
4652,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,COC(=O)c1cnc(Nc2ccc(N3CCN(C)CC3)cc2OC)nc1-c1cn(C)c2ccccc12,methyl 2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.023,uM,=,-1.6382721639824072,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c[nH]c2c1
4653,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,CN(C)C1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((4-(dimethylamino)piperidin-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.1,uM,=,-1.0,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
4654,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c(C)c(OC)c4)nn32)CC1,"rac-7-(1-acryloylpiperidin-4-yl)-2-(3,5-dimethoxy-4-methylphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",3.326,uM,=,0.5219222448835005,1,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1
4655,2241040,10.1021/acs.jmedchem.1c00848,,,,Displacement of sapitinib-BODIPY tracer from C-terminal NanoLuc-fused full length wild type EGFR (unknown origin) transfected in HEK293T cells incubated for 2 hrs by NanoBRET assay,C=CC(=O)Nc1ccc(OC)c(Nc2cc(-c3[nH]c(SC)nc3-c3cccc(NC(=O)c4c(F)ccc(O)c4CN4C(=O)c5ccccc5C4=O)c3)ccn2)c1,"N-(3-(5-(2-((5-Acrylamido-2-methoxyphenyl)amino)pyridin-4-yl)-2-(methylthio)-1H-imidazol-4-yl)phenyl)-2-((1,3-dioxoisoindolin-2-yl)methyl)-6-fluoro-3-hydroxybenzamide",6.7,uM,=,0.8260748027008264,1,O=C(Nc1cccc(-c2nc[nH]c2-c2ccnc(Nc3ccccc3)c2)c1)c1ccccc1CN1C(=O)c2ccccc2C1=O
4656,2031969,10.1016/j.ejmech.2020.112199,,,,"Inhibition of EGFR L858R/T790M (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate measured after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(CCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)NCc6ccc(-c7scnc7C)cc6)C(C)(C)C)CC5)cc4OC)nc32)c1,"(2S,4R)-1-((S)-2-(6-(4-(4-((8-(3-acrylamidophenyl)-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)hexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide",0.0193,uM,=,-1.714442690992226,0,O=C(CCCCCN1CCN(c2ccc(Nc3ncc4ccc(=O)n(-c5ccccc5)c4n3)cc2)CC1)NCC(=O)N1CCC[C@H]1C(=O)NCc1ccc(-c2cncs2)cc1
4657,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2ccc3occc(=O)c3c2)c2c(N)ncnc21,"6-(4-amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4H-chromen-4-one",10.0,uM,=,1.0,1,O=c1ccoc2ccc(-c3n[nH]c4ncncc34)cc12
4658,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),O=C(/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1)NCCCN1CCOCC1,"But-2-enedioic acid [4-(3-chloro-4-fluoro-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide (3-morpholin-4-yl-propyl)-amide",0.00061,uM,=,-3.214670164989233,0,O=C(/C=C/C(=O)Nc1cc2c(Nc3ccccc3)ncnc2cn1)NCCCN1CCOCC1
4659,82323,10.1021/jm9904295,,,,Inhibitory activity against ligand-dependent EGF cell proliferation,COc1ccc(-c2ccc3c(c2)NC(=O)/C3=C\c2[nH]cc(CCC(=O)O)c2C)cc1,"3-{5-[6-(4-Methoxy-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-4-methyl-1H-pyrrol-3-yl}-propionic acid",22.8,uM,=,1.3579348470004535,1,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1ccc[nH]1
4660,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CCl)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(Oc5cccc(C(F)(F)F)c5)c(Cl)c4)c3cc21,"1-(2-(2-chloroacetoxy)ethyl)-8-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.51,uM,=,-0.2924298239020636,0,O=c1[nH]c2cc3c(Nc4ccc(Oc5ccccc5)cc4)ncnc3cc2o1
4661,66573,10.1016/s0960-894x(00)00441-8,,,,Inhibition of Epidermal growth factor receptor,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1,"7-Cyclopentyl-5-(4-phenoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",3.2,uM,=,0.505149978319906,1,c1ccc(Oc2ccc(-c3cn(C4CCCC4)c4ncncc34)cc2)cc1
4662,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)nc1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-(pyridin-2-yl)-1,3,4-oxadiazole",73.5,uM,=,1.866287339084195,1,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)nc1
4663,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)cc3OC)ncc2C(F)(F)F)c1,"US9238629, I-9",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
4664,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CBr)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"1-(2-(2-bromoacetoxy)ethyl)-8-(3-Chloro-4-fluorophenylamino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.46,uM,=,-0.3372421683184259,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
4665,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,COc1cccc(-c2cn(C3CC(CNCCO)C3)c3ncnc(N)c23)c1,"2-({3-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-cyclobutylmethyl}-amino)-ethanol",0.49,uM,=,-0.3098039199714864,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1
4666,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,CC(C)Oc1cc2ncnc(Nc3ccc(F)c(C#N)c3)c2c2c1OCCO2,"2-Fluoro-5-((5-isopropoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-yl)amino)benzonitrile",0.3136,uM,=,-0.5036239459875991,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
4667,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC[C@H]1CCCN(C)C1,(S)-(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-3-ylmethoxy)-quinazolin-4-yl]-amine,0.15,uM,=,-0.8239087409443188,0,c1ccc(Nc2ncnc3cc(OC[C@H]4CCCNC4)ccc23)cc1
4668,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,COc1cc2ncnc(NCc3ccc(F)cc3)c2cc1OC.Cl,"4-[(4'-fluorobenzyl)amino]-6,7-dimethoxyquinazoline hydrochloride",0.0109,uM,=,-1.9625735020593764,0,c1ccc(CNc2ncnc3ccccc23)cc1
4669,2224994,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3ccc(-c4cc(-c5ccc(Br)cc5)c(C#N)c(=N)[nH]4)cc3)c2cc1OC,"4-(4-bromophenyl)-6-(4-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)-2-imino-1,2-dihydropyridine-3-carbonitrile",1.935,uM,=,0.2866809693549302,1,N=c1cc(-c2ccccc2)cc(-c2ccc(Nc3ncnc4ccccc34)cc2)[nH]1
4670,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCOCC1,(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-morpholinobut-2-enamide,0.026,uM,=,-1.585026652029182,0,O=C(/C=C/CN1CCOCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
4671,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,O=C(O)CCCC1C(S)=Nc2ccccc21,"4-(2-Thioxo-2,3-dihydro-1H-indol-3-yl)-butyric acid",6.7,uM,=,0.8260748027008264,1,C1=Nc2ccccc2C1
4672,66576,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1ccc2c(Nc3cccc(Cl)c3)ncnc2c1,N-[4-(3-Chloro-phenylamino)-quinazolin-7-yl]-acrylamide,0.00025,uM,=,-3.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
4673,974507,10.1016/j.ejmech.2013.05.026,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay,COc1cc(N2CCC(O)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(COc3no[n+]([O-])c3S(=O)(=O)c3ccccc3)c2)n1,"4-((3-((5-Chloro-2-((4-(4-hydroxypiperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)oxy)benzyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide",0.24,uM,=,-0.619788758288394,0,O=S(=O)(c1ccccc1)c1[nH+]onc1OCc1cccc(Oc2ccnc(Nc3ccc(N4CCCCC4)cc3)n2)c1
4674,571606,10.1016/j.ejmech.2008.09.051,,,,Inhibition of EGFR,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,"2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one",0.9,uM,=,-0.0457574905606751,0,O=c1cc(-c2ccccc2)oc2ccccc12
4675,608090,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 1 hr by Western blot,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-phenoxyacetamide,0.076,uM,=,-1.1191864077192086,0,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4676,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(Oc4ccc5c(c4)OCO5)cc3)ncnc2cc1OC,"N-{4-[4-(1,3-Benzodioxol-5-yloxy)anilino]-7-methoxy-6-quinazolinyl}propanamide",0.509,uM,=,-0.2932822176632412,0,c1ccc2c(Nc3ccc(Oc4ccc5c(c4)OCO5)cc3)ncnc2c1
4677,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)Nc1ccc(OC)c(Nc2cc(-c3[nH]c(SC)nc3C3CC3)ccn2)c1,N-(3-((4-(4-Cyclopropyl-2-(methylthio)-1H-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.0023,uM,=,-2.638272163982407,0,c1ccc(Nc2cc(-c3[nH]cnc3C3CC3)ccn2)cc1
4678,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,Fc1ccc(Nc2ncnc3c2NCc2cc(Cl)ccc2O3)cc1Cl,"(8-Chloro-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(3-chloro-4-fluoro-phenyl)-amine",4.3,uM,=,0.6334684555795865,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
4679,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CS(=O)(=O)CC(NC1CCCCC1)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,Rac-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(1-(cyclohexylamino)-2-(methylsulfonyl)ethyl)furan-2-yl)quinazolin-4-amine,0.0772,uM,=,-1.1123826996642638,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CNC6CCCCC6)o5)cc34)cc2)cc1
4680,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,CN(c1ccccc1)c1ncnc2cc3oc(=O)n(CCCN4CCOCC4)c3cc12,"8-(Methyl(phenyl)amino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",7.2,uM,=,0.8573324964312685,1,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
4681,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c5ccoc5c4)nn32)CC1,"7-(1-acryloylpiperidin-4-yl)-2-(4-methoxybenzofuran-6-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",0.271,uM,=,-0.5670307091255943,0,c1cc2ccc(-c3cc4n(n3)C(C3CCNCC3)CCN4)cc2o1
4682,501537,10.1016/j.bmcl.2009.03.104,,,,Inhibition of EGFR,COc1c(NC(=O)Nc2ccc(-c3ccc(CN4CCOCC4)nc3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O,N-(5-tert-butyl-2-methoxy-3-(3-(4-(6-(morpholinomethyl)pyridin-3-yl)naphthalen-1-yl)ureido)phenyl)methanesulfonamide,5.4,uM,=,0.7323937598229685,1,O=C(Nc1ccccc1)Nc1ccc(-c2ccc(CN3CCOCC3)nc2)c2ccccc12
4683,1642199,,,,,Inhibition Assay: Inhibition of various kinase enzyme.,CC(C)c1ccccc1Nc1nc(N)nc2c1Cc1ccccc1-2,"US9422297, AAG145-342",23.0,uM,=,1.3617278360175928,1,c1ccc(Nc2ncnc3c2Cc2ccccc2-3)cc1
4684,1642164,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0021,uM,=,-2.6777807052660805,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
4685,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#CC(C#N)=C(N)/C(C#N)=C/c1cc(O)c(O)c(Br)c1,"3-Amino-5-(3-bromo-4,5-dihydroxy-phenyl)-2,4-dicyano-penta-2,4-dienenitrile",0.5,uM,=,-0.3010299956639812,0,c1ccccc1
4686,1929287,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide substrate preincubated for 10 mins followed by substrate addition measured after 40 mins by caliper motility shift assay,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(piperidin-1-yl)but-2-en-1-one",0.004,uM,=,-2.397940008672037,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
4687,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,C=CC(=O)Nc1cc(Nc2ncc(Br)c(Nc3ccc4ccn(C)c4c3)n2)c(OC)cc1N1CCN(C)CC1,N-(5-((5-bromo-4-((1-methyl-1H-indol-6-yl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide,0.2804,uM,=,-0.552221990705379,0,c1cc(Nc2ccc3cc[nH]c3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
4688,1448250,10.1016/j.bmcl.2014.07.094,,,,Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry,COC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2cc(C)ccc2n2nnnc12,"Methyl 2-amino-4-(7-methyltetrazolo[1,5-a]quinolin-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",4.3,uM,=,0.6334684555795865,1,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1
4689,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,Cc1cc(Nc2ncnc3cc(O)c(NC(=O)/C=C/[C@H]4CCCN4C)cc23)ccc1Oc1ccn2ncnc2c1,"(E)-N-[7-hydroxy-4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)anilino]quinazolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide",0.0028,uM,=,-2.552841968657781,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4ccn5ncnc5c4)cc3)c2c1
4690,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cc(C=O)ccc1-c1cc2c(NCc3ccccc3)ncnc2s1,"4-(4-(Benzylamino)thieno[2,3-d]pyrimidin-6-yl)-3-methoxybenzaldehyde",0.006,uM,=,-2.2218487496163566,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
4691,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{2-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-ethyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",10.0,uM,=,1.0,1,O=C(C=Cc1ccccc1)NCCNC(=O)/C=C/c1ccccc1
4692,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CN(C)CCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-phenyl)-N*7*-(2-dimethylamino-ethyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.045,uM,=,-1.3467874862246565,0,c1ccc(Nc2ncnc3ccncc23)cc1
4693,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C=CC(=O)Nc1cccc(-c2c(C)sc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-methylthieno-[2,3-d]pyrimidin-5-yl)phenyl]prop-2-enamide",0.107,uM,=,-0.9706162223147904,0,c1ccc(CNc2ncnc3scc(-c4ccccc4)c23)cc1
4694,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,CC(=O)N1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"1-(4-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)piperazin-1-yl)ethanone",0.71,uM,=,-0.1487416512809247,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCNCC6)c45)ccc32)cc1
4695,4991,10.1016/S0960-894X(97)10117-2,,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,COc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1OC,"(3,4-Dimethoxy-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",2.8,uM,=,0.4471580313422192,1,c1ccc(Nc2ncnc3ccccc23)cc1
4696,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,OCCSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,2-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)ethan-1-ol,0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
4697,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,O=C(/C=C/c1ccc(OCCOc2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cc1)NO,3-(4-(2-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yloxy)ethoxy)phenyl)-N-hydroxyacrylamide,1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3ccc(OCCOc4ccccc4)cc23)cc1
4698,506208,10.1021/np50089a001,,,,Inhibition of EGFR,NC(=O)c1oc2cc(O)cc(O)c2c(=O)c1-c1ccc(O)cc1,"5,7-dihydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromene-2-carboxamide",31.942897642207875,uM,=,1.5043743098281868,1,O=c1c(-c2ccccc2)coc2ccccc12
4699,305378,10.1021/jm049892u,,,,In vitro inhibition of Epidermal growth factor receptor,Cc1ccc(Nc2ncnn3cccc23)cc1O,"2-Methyl-5-(pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-phenol",0.51,uM,=,-0.2924298239020636,0,c1ccc(Nc2ncnn3cccc23)cc1
4700,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(NCc3cccs3)ncnc2s1,"6-(2-Methoxyphenyl)-N-(thiophen-2-ylmethyl)thieno[2,3-d]pyrimidin-4-amine",0.17,uM,=,-0.7695510786217261,0,c1ccc(-c2cc3c(NCc4cccs4)ncnc3s2)cc1
4701,2259971,10.6019/CHEMBL5212743,,,,Selectivity interaction (Enzymatic activity assay) EUB0000596aBDA EGFR,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,AFATINIB DIMALEATE,0.0004,uM,=,-3.397940008672037,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
4702,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,CC1CCCCN1C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7,8-dihydropyrimido[5,4-g][1,4]benzoxazin-6-yl]-4-(2-methyl-1-piperidyl)but-2-en-1-one",0.179,uM,=,-0.7471469690201069,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
4703,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC1CCN(C(=O)CO)CC1,1-(4-(4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-2-hydroxyethanone,0.204,uM,=,-0.6903698325741012,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
4704,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc(Sc4nccs4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(thiazol-2-ylsulfanyl)-phenylamino]-3-cyano-7-methoxy-quinolin-6-yl}-amide,0.042,uM,=,-1.3767507096020994,0,c1ccc2c(Nc3ccc(Sc4nccs4)cc3)ccnc2c1
4705,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Cc1cc(C)c(O)c(CN(Cc2ccc(O)cc2)C(=S)Nc2ccccc2)c1,"1-(2-Hydroxy-3,5-dimethylbenzyl)-1-(4-hydroxybenzyl)-3-phenylthiourea",5.83,uM,=,0.7656685547590141,1,S=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
4706,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),CCN(CC)CCCNC(=O)/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"But-2-enedioic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide (3-diethylamino-propyl)-amide",0.00073,uM,=,-3.136677139879544,0,c1ccc(Nc2ncnc3cnccc23)cc1
4707,510417,10.1021/jm8002813,,,,Inhibition of EGFR,O=C(/C=C/c1ccc(O)c(O)c1)c1ccc(O)cc1O,"3-(3,4-Dihydroxy-phenyl)-1-(2,4-dihydroxy-phenyl)-propenone",16.0,uM,=,1.2041199826559248,1,O=C(/C=C/c1ccccc1)c1ccccc1
4708,1627833,10.1016/j.ejmech.2016.06.056,,,,Inhibition of EGFR (unknown origin) using peptide as substrate after 60 mins by HTRF assay,CC(C)S(=O)(=O)c1ccccc1Nc1nc(N/N=C/c2cccc(C(F)(F)F)c2)ncc1Cl,(E)-5-chloro-N-(2-(isopropylsulfonyl)phenyl)-2-(2-(3-(trifluoromethyl)benzylidene)hydrazinyl)pyrimidin-4-amine,0.46,uM,=,-0.3372421683184259,0,C(=N/Nc1nccc(Nc2ccccc2)n1)\c1ccccc1
4709,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",CCN(CC)CCN(C)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-3-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-1-(2-(diethylamino)ethyl)-1-methylurea,0.505,uM,=,-0.2967086218813386,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
4710,305482,10.1021/jm0501275,,,,Inhibition of human epidermal growth factor receptor (HER-1),CONC(=O)c1cc(Nc2ncnn3cc(NC(=O)OCCCS(C)(=O)=O)c(C(C)C)c23)c(F)cc1F,"[4-(2,4-Difluoro-5-methoxycarbamoyl-phenylamino)-5-isopropyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid 3-methanesulfonyl-propyl ester",4.2,uM,=,0.6232492903979004,1,c1ccc(Nc2ncnn3cccc23)cc1
4711,622914,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR by HTRF assay,CCN(CC)CCNC(=O)c1[nH]c2cnnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1C,"4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-N-(2-(diethylamino)ethyl)-3-methyl-1H-pyrrolo[3,2-d]pyridazine-2-carboxamide",1.28,uM,=,0.1072099696478683,1,c1ccc(COc2ccc(Nc3nncc4[nH]ccc34)cc2)cc1
4712,1883874,10.1021/acsmedchemlett.8b00270,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay,C=CC(=O)N(c1ccc(Cl)c(Cl)c1)c1ncnc2cc(OC)c(OCCCN3CCOCC3)cc12,"4-[N-acryloyl-(3,4-dichlorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline",0.0317,uM,=,-1.4989407377822486,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
4713,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1/C=N/OCCCN1CCOCC1,4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-methylpyrimidine-5-carbaldehyde O-3-morpholinopropyl oxime,0.065,uM,=,-1.1870866433571443,0,C(=N/OCCCN1CCOCC1)\c1cncnc1Nc1ccc(OCc2ccccc2)cc1
4714,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,FC(F)(F)c1cccc(Nc2ncnc3cc(OCCCN4CCOCC4)c4c(c23)OCCO4)c1,"5-(3-Morpholinopropoxy)-N-(3-(trifluoromethyl)-phenyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.09718,uM,=,-1.0124231052730126,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c4c(c23)OCCO4)cc1
4715,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3ccc(F)cc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(4-Fluorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0716,uM,=,-1.1450869776921444,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
4716,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid,3.2769,uM,=,0.5154631883732687,1,c1ccc(-c2nnn[nH]2)c(-c2ccc(Cn3cnc4ccccc43)cc2)c1
4717,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=C(C)C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-{4-[(3-Bromophenyl)amino]-6-quinazolinyl}-2-methylacrylamide,0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3ccccc23)cc1
4718,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,COc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,"6-(2,6-Dichloro-phenyl)-2-(4-methoxy-phenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",0.22,uM,=,-0.6575773191777937,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
4719,1847939,10.1016/j.ejmech.2019.03.038,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in Baculovirus expression system using srctide as substrate incubated for 1 hr by mobility shift assay,COc1cc(N2CCN(CC(=O)N(C)C)C2=O)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,"2-(3-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-2-oxo-imidazolidin-1-yl)-N,N-dimethylacetamide",0.598,uM,=,-0.2232988160115891,0,O=C1NCCN1c1ccc(Nc2nccc(Nc3ccccc3)n2)cc1
4720,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,COc1ccc(-c2ccc(Cn3cc(CCN)c4cc(OCCc5ccc(O)cc5)ccc43)cc2)cc1.Cl,2-[5-(4-Hydroxyphenethoxy)-1-(4-methoxyphenyl)-benzyl-1H-indole-3-yl]ethanamine hydrochloride,1.25,uM,=,0.0969100130080564,1,c1ccc(CCOc2ccc3c(ccn3Cc3ccc(-c4ccccc4)cc3)c2)cc1
4721,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",CNc1ncc2ncnc(Nc3cccc(C)c3)c2n1,"N*2*-Methyl-N*8*-m-tolyl-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.0043,uM,=,-2.3665315444204134,0,c1ccc(Nc2ncnc3cncnc23)cc1
4722,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,COc1cccc(-n2cc(NC(=O)c3cccc(NS(=O)(=O)c4ccc(Cl)cc4)c3)cn2)c1,3-((4-Chlorophenyl)sulfonamido)-N-(1-(3-methoxyphenyl)-1H-pyrazol-4-yl)benzamide,15.63,uM,=,1.193958978019187,1,O=C(Nc1cnn(-c2ccccc2)c1)c1cccc(NS(=O)(=O)c2ccccc2)c1
4723,1649110,10.1016/j.bmc.2016.11.026,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF induced phosphorylation preincubated for 60 mins followed by EGF addition measured after 10 mins by ELISA method,COc1ccc2c(c1)CCCN2c1nc(N)nc2c(Cc3ccccc3)c[nH]c12,"7-Benzyl-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5Hpyrrolo[3,2-d]pyrimidin-2-amine",0.0471,uM,=,-1.3269790928711038,0,c1ccc(Cc2c[nH]c3c(N4CCCc5ccccc54)ncnc23)cc1
4724,519199,10.1016/j.ejmech.2007.09.018,,,,Inhibition of human EGFR tyrosine kinase activity,N#C/C(=C\c1ccc(O)c(O)c1)C(N)=S,"2-Cyano-3-(3,4-dihydroxy-phenyl)-thioacrylamide",1.31,uM,=,0.1172712956557642,1,c1ccccc1
4725,66899,10.1016/s0960-894x(99)00188-2,,,,In vitro activity against Epidermal growth factor receptor (using poly(Glu4Tyr1) as a substrate),O=C(O)c1ccc(NN2C(=O)c3c(c4c5cccc(O)c5n(C5OC(CO)C(O)C(O)C5O)c4c4[nH]c5c(O)cccc5c34)C2=O)cc1,"4-[1,11-dihydroxy-5,7-dioxo-12-(3,4,5-trihydroxy-6-hydroxymethyltetrahydro-2H-2-pyranyl)-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-6-ylamino]benzoic acid",90.0,uM,=,1.954242509439325,1,O=C1c2c(c3c4ccccc4n(C4CCCCO4)c3c3[nH]c4ccccc4c23)C(=O)N1Nc1ccccc1
4726,1674791,10.1016/j.ejmech.2017.03.001,,,,"Inhibition of recombinant human N-terminal GST-tagged wild-type EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay",C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.123,uM,=,-0.910094888560602,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
4727,523777,10.1016/j.bmcl.2009.05.009,,,,Inhibition of EGFR,CCN1CCC(n2cc(CNc3cc(Cl)c4ncc(C#N)c(Nc5ccc(F)c(Cl)c5)c4c3)nn2)CC1,"8-chloro-4-(3-chloro-4-fluorophenylamino)-6-((1-(1-ethylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)methylamino)quinoline-3-carbonitrile",11.0,uM,=,1.0413926851582251,1,c1ccc(Nc2ccnc3ccc(NCc4cn(C5CCNCC5)nn4)cc23)cc1
4728,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,COc1cc2ncnc(Nc3cccc(I)c3)c2cc1OC.Cl,"4-(3'-iodoanilino)-6,7-dimethoxyquinazoline hydrochloride",0.0064,uM,=,-2.193820026016113,0,c1ccc(Nc2ncnc3ccccc23)cc1
4729,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(Oc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid phenyl ester",0.07,uM,=,-1.154901959985743,0,O=C(Oc1ccccc1)c1cccc(NCc2ccccc2)c1
4730,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(C#N)c(F)c2)c2c(N)ncnc21,"4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorobenzonitrile",8.9,uM,=,0.9493900066449128,1,c1ccc(-c2n[nH]c3ncncc23)cc1
4731,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC.Cl,"(3-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine hydrochloride",0.173,uM,=,-0.7619538968712046,0,c1ccc(Nc2ncnc3ccccc23)cc1
4732,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC,"(3-Chloro-4-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
4733,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCOc1cc2ncnc(C#C[C@](C)(Cc3ccccc3)N3CCC(C(=O)O)CC3)c2cc1OCC,"(S)-1-(4-(6,7-diethoxyquinazolin-4-yl)-2-methyl-1-phenylbut-3-yn-2-yl)piperidine-4-carboxylic acid",0.662,uM,=,-0.1791420105603,0,C(#CC(Cc1ccccc1)N1CCCCC1)c1ncnc2ccccc12
4734,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,CN(CCO)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"2-({2-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-ethyl}-methyl-amino)-ethanol",0.0017,uM,=,-2.7695510786217263,0,c1ccc(Nc2ncnc3cnccc23)cc1
4735,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@H]1CCNC1,"(S)-5-(4-amino-1-(pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",8.7,uM,=,0.9395192526186184,1,c1ccc(-c2nn([C@H]3CCNC3)c3ncncc23)cc1
4736,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(OC)c4)nc32)c1,"N-(3-(7-(3-Methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)-phenyl)acrylamide",0.00041,uM,=,-3.3872161432802645,0,O=C1NCc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
4737,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,C#Cc1cccc(Nc2ncnc3ccc(OCCCCCC(=O)NO)cc23)c1,6-(4-(3-ethynylphenylamino)quinazolin-6-yloxy)-N-hydroxyhexanamide,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
4738,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,C=C(CN(C)C)C(=O)c1ccc(OS(=O)(=O)c2ccc(C(=O)N(C)C)cc2)cc1.Cl,4-Dimethylcarbamoyl-benzenesulfonic acid 4-(2-dimethylaminomethyl-acryloyl)-phenyl ester hydrochloride,0.7,uM,=,-0.1549019599857432,0,O=S(=O)(Oc1ccccc1)c1ccccc1
4739,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",Brc1cccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)nc23)c1,"N*8*-(3-Bromo-phenyl)-N*2*-[2-(3H-imidazol-4-yl)-ethyl]-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.00025,uM,=,-3.6020599913279625,0,c1ccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)nc23)cc1
4740,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Nc1ncnc(N[C@H](C)c3ccccc3)c1NC2,"(7,8-dimethoxy-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cyclohepten-1-yl)-((R)-1-phenyl-ethyl)-amine",0.15,uM,=,-0.8239087409443188,0,c1ccc(CNc2ncnc3c2NCc2ccccc2N3)cc1
4741,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(OC)cc3OC)n2)c1,"N-(3-(3-(2-(2,4-dimethoxyphenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide",0.348,uM,=,-0.4584207560534191,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccccc2)n1
4742,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,O=c1oc2cc3ncnc(Nc4ccccc4O)c3cc2n1CCCN1CCOCC1,"8-(2-Hydroxyphenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",30.0,uM,=,1.4771212547196624,1,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
4743,2132157,10.1021/acs.jmedchem.1c01559,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,CC#CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N,(S)-1-amino-2-(1-(but-2-ynoyl)piperidin-2-yl)-4-(4-((4-(trifluoromethyl)pyridin-2-yl)carbamoyl)phenyl)-1H-imidazole-5-carboxamide,11.802,uM,=,1.0719556103029804,1,O=C(Nc1ccccn1)c1ccc(-c2c[nH]c([C@@H]3CCCCN3)n2)cc1
4744,1869715,10.1016/j.bmc.2019.02.012,,,,Inhibition of His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometry,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.06,uM,=,-1.2218487496163564,0,c1ccc(Nc2ncnc3ccccc23)cc1
4745,946792,10.1016/j.bmc.2013.01.040,,,,Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA,CC(C)c1ccc(Nc2nc(NC(=O)C(C)(C)C)nc3[nH]c4cccc(Cl)c4c23)cc1,"N-(5-chloro-4-(4-isopropylphenylamino)-9H-pyrimido[4,5-b]indol-2-yl)pivalamide",39.2,uM,=,1.5932860670204574,1,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
4746,751818,10.1016/j.bmcl.2011.04.060,,,,Inhibition of human EGFR using poly[Glu:Tyr] by Hotspot assay,CNC(=O)c1ncc(C#Cc2cc(C(=O)Nc3ccc(CN4CCN(CCO)CC4)c(C(F)(F)F)c3)ccc2C)n1C,"5-((5-(4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenylcarbamoyl)-2-methylphenyl)ethynyl)-N,1-dimethyl-1H-imidazole-2-carboxamide",0.736,uM,=,-0.1331221856625011,0,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(C#Cc2cnc[nH]2)c1
4747,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12,3N-phenyl-2-(3-phenylcarbamoyl-1H-2-indolyldisulfanyl)-1H-3-indolecarboxamide,100.0,uM,=,2.0,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
4748,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CNCC1COC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-((oxetan-3-ylmethyl)amino)but-2-enamide",0.01,uM,=,-2.0,0,O=C(/C=C/CNCC1COC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
4749,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,O=C(C#CCO)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-[(3-Chloro-4-fluorophenyl)amino]-6-quinazolinyl]-4-hydroxy-2-butynamide,0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
4750,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3ccc(C(=O)O)cc3)cc12)c1ccccc1,"(R)-4-(4-((1-Phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzoic acid",0.019,uM,=,-1.7212463990471711,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
4751,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),CN(C)c1ccc2sc3c(Nc4cccc(Br)c4)ncnc3c2c1,"N*4*-(3-Bromo-phenyl)-N*8*,N*8*-dimethyl-benzo[4,5]thieno[3,2-d]pyrimidine-4,8-diamine",0.0198,uM,=,-1.7033348097384688,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
4752,2229998,10.1021/acs.jmedchem.1c00876,,,,Inhibition of wild type EGFR (unknown origin),CCc1cc(Nc2ncc(Br)c(Nc3ccc4nccnc4c3P(C)(C)=O)n2)c(OC)cc1N1CCC(N2CCN(C)CC2)CC1,(6-((5-bromo-2-((5-ethyl-2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide,0.00512,uM,=,-2.290730039024169,0,c1cc(Nc2ccc3nccnc3c2)nc(Nc2ccc(N3CCC(N4CCNCC4)CC3)cc2)n1
4753,1829742,10.1021/acs.jmedchem.8b01612,,,,Inhibition of wild type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system after 1 hr in presence of ULight-labeled peptide substrate and ATP by LANCE ultra kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCNCCNCCNCC1,"6-(3-(1,4,7,10-Tetraazacyclododecan-1-yl)propoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine",0.0066,uM,=,-2.1804560644581312,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCNCCNCCNCC4)cc23)cc1
4754,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@@H]1CCNC1,"(R)-5-(4-amino-1-(pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",15.6,uM,=,1.1931245983544616,1,c1ccc(-c2nn([C@@H]3CCNC3)c3ncncc23)cc1
4755,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,CCCN(CCC)C(=O)c1ccc(N(CCCl)CCCl)cc1,"4-(Bis(2-chloroethyl)amino)-N,N-dipropylbenzamide",29.83,uM,=,1.4746532533620629,1,c1ccccc1
4756,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,C/C=C\C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,But-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.269,uM,=,-0.570247719997592,0,c1ccc(Nc2ncnc3ccccc23)cc1
4757,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.00019,uM,=,-3.721246399047171,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
4758,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(1H-pyrrol-2-yl)thieno[3,2-d]pyrimidin-4-amine",0.068,uM,=,-1.1674910872937636,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2)cc1
4759,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C#CCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,4-(3'-Chloro-4'-fluoroanilino)-6-(prop-2-ynyloxy)-7-methoxyquinazoline,0.0148,uM,=,-1.8297382846050425,0,c1ccc(Nc2ncnc3ccccc23)cc1
4760,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2NC(C)=O)c1O,3-[3-(2-Acetylamino-phenylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,22.0,uM,=,1.3424226808222062,1,c1ccc(CSc2ccccc2)cc1
4761,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,COc1cccc(-c2cn(C3CC(CO)C3)c3ncnc(N)c23)c1,"{3-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-cyclobutyl}-methanol",0.42,uM,=,-0.3767507096020995,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1
4762,1329770,10.1039/C2MD00317A,,,,Inhibition of recombinant EGFR (unknown origin) using poly-Glu-Tyr peptide as substrate,C#Cc1cccc(Nc2ncnc3ccc(OCc4ccc(C(=O)Nc5ccccc5N)cc4)cc23)c1,N-(2-Aminophenyl)-4-{[4-(3-ethynylphenylamino)quinazoline-6-yloxy]methyl}benzamide,0.078,uM,=,-1.1079053973095196,0,O=C(Nc1ccccc1)c1ccc(COc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
4763,445904,10.1021/jm070436q,,,,Inhibition of P-EGFR expressed in A431 cells,CC(=O)c1cc(NCc2c[nH]cn2)cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc12,8-acetyl-4-[(3-chloro-4-fluorophenyl)amino]-6-[(1H-imidazol-5-ylmethyl)amino]quinoline-3-carbonitrile,0.156,uM,=,-0.8068754016455384,0,c1ccc(Nc2ccnc3ccc(NCc4c[nH]cn4)cc23)cc1
4764,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COCCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-N-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0054,uM,=,-2.2676062401770314,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
4765,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Oc1ccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"4-[4-(3-Chloro-phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-phenol",0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
4766,63772,10.1021/jm9903949,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cells,Brc1cccc(Nc2[nH]cnc3nc4ccccc4c2-3)c1,"(3-Bromo-phenyl)-(9H-pyrimido[4,5-b]indol-4-yl)-amine",0.63,uM,=,-0.2006594505464183,0,c1ccc(Nc2[nH]cnc3nc4ccccc4c2-3)cc1
4767,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(/C=C/c1ccc(Br)cc1)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,(E)-N-(4-(3-Chlorophenylamino)quinazolin-6-yl)-3-(4-bromophenyl)acrylamide,3.49,uM,=,0.5428254269591799,1,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4768,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,N-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)acrylamide,0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccccc23)cc1
4769,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,CCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C(F)=C\CN(C)C,(E)-N-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.00089,uM,=,-3.050609993355087,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
4770,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,COc1cc(/C=C(\C#N)C(=O)NCCCCNC(=O)/C(C#N)=C/c2cc(OC)c(O)c([N+](=O)[O-])c2)cc([N+](=O)[O-])c1O,(E)-2-Cyano-N-{4-[(E)-2-cyano-3-(4-hydroxy-3-methoxy-5-nitro-phenyl)-acryloylamino]-butyl}-3-(4-hydroxy-3-methoxy-5-nitro-phenyl)-acrylamide,19.0,uM,=,1.2787536009528289,1,O=C(C=Cc1ccccc1)NCCCCNC(=O)/C=C/c1ccccc1
4771,1580794,10.1021/acs.jmedchem.6b00087,,,,Inhibition of GST-tagged human recombinant EGFR (668 to1210 residues) expressed in baculovirus using Fluorescein-Poly GT as substrate,COC(=O)c1cc2cc(NCc3cc(NC(=O)c4cc(-n5cnc(C)c5)cc(C(F)(F)F)c4)ccc3C)cnc2[nH]1,"5-{2-Methyl-5-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-benzoylamino]-benzylamino}-1H-pyrrolo[2,3-b]pyridine-2-carboxylicAcid Methyl Ester",0.015,uM,=,-1.8239087409443189,0,O=C(Nc1cccc(CNc2cnc3[nH]ccc3c2)c1)c1cccc(-n2ccnc2)c1
4772,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Fc1ccc2c(c1)CNc1c(Nc3cccc(-c4ccccc4)c3)ncnc1O2,"Biphenyl-3-yl-(8-fluoro-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",2.0,uM,=,0.3010299956639812,1,c1ccc(-c2cccc(Nc3ncnc4c3NCc3ccccc3O4)c2)cc1
4773,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N(C)CCN(C)C)cc3OC)n2)c1,N-(3-(3-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.049,uM,=,-1.3098039199714864,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccccc2)n1
4774,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3ccc(C(F)(F)F)cc3)c2cn1,"N*4*-(4-Trifluoromethyl-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",4.7,uM,=,0.6720978579357175,1,c1ccc(Nc2ncnc3ccncc23)cc1
4775,1883874,10.1021/acsmedchemlett.8b00270,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay,C=CC(=O)N(c1cccc(Cl)c1F)c1ncnc2cc(OC)c(OC(=O)N3CCN(C)C[C@H]3C)cc12,"4-[N-acryloyl-(3-chloro-2-fluorophenyl)amino]-6-[(2R)-2,4-dimethylpiperazine-1-carboxylate]-7-methoxyquinazoline",0.0087,uM,=,-2.0604807473813813,0,O=C(Oc1ccc2ncnc(Nc3ccccc3)c2c1)N1CCNCC1
4776,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN1CCCCC1,(Z)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide,0.00027,uM,=,-3.5686362358410126,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4777,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(NC3CC3c3ccccc3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-(2-phenyl-cyclopropyl)-amine",0.14,uM,=,-0.8538719643217619,0,c1ccc(C2CC2Nc2ncnc3ccccc23)cc1
4778,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3cc(Cl)c(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,"4-Dimethylamino-but-2-enoic acid [4-(4-benzyloxy-3,5-dichloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide",0.163,uM,=,-0.7878123955960422,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
4779,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc(F)cc3)C2)cc1C,"2-(3-(3,4-dimethylphenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",1.73,uM,=,0.2380461031287954,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
4780,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,C=CC(=O)Nc1cc(Nc2ncc(Br)c(Nc3ccc4ccn(C)c4c3)n2)ccc1N1CCN(C)CC1,N-(5-((5-bromo-4-((1-methyl-1H-indol-6-yl)amino)pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide,0.4141,uM,=,-0.3828947694976219,0,c1cc(Nc2ccc3cc[nH]c3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
4781,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3ccccc3Br)c2cn1,"N*4*-(2-Bromo-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.24,uM,=,-0.619788758288394,0,c1ccc(Nc2ncnc3ccncc23)cc1
4782,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,COC(=O)CN1CCC(n2cc(-c3cccc(O)c3)c3c(N)ncnc32)CC1,"{4-[4-Amino-5-(3-hydroxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-piperidin-1-yl}-acetic acid methyl ester",0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1
4783,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(Oc4cccnc4)cc3)ncnc2cc1OC,N-{7-Methoxy-4-[4-(3-pyridinyloxy)anilino]-6-quinazolinyl}-propanamide,0.531,uM,=,-0.2749054789185309,0,c1cncc(Oc2ccc(Nc3ncnc4ccccc34)cc2)c1
4784,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3c2NCc2cc(Cl)ccc2O3)cc1Cl,"(8-Chloro-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(3-chloro-4-fluoro-phenyl)-amine",1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
4785,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CN(C)[C@H](C)C(N)=O,(R)-2-(((4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)propanamide,0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
4786,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(C(=O)N2CCN(C)CC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[3-methyl-5-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.0028,uM,=,-2.552841968657781,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCNCC2)[nH]1
4787,1528598,,,,,"In Vitro Kinase Assay: In vitro kinase analysis was performed by using HTScan EGF Receptor Kinase Assay Kit (#7909) and HTScan HER2/ErbB2 Kinase Assay Kit (#7058) from Cell Signaling Technology Company. Operation steps refer to the specification of the used kits, and the method was used to measure the inhibition effects of the compound to be tested on substrate peptide phosphorylation of EGFR or Her2 receptor tyrosine kinase. At room temperature, ATP and substrate peptide as well as the compound to be tested were incubated in kinase reaction buffer, after a period of incubation, a stop buffer was added to terminate the reaction and the sample was transferred to a streptavidin-coated 96-well plate, the plate was washed and the phosphorylation level of substrate peptide was detected by using HRP-marked antibody against substrate phosphorylation, colorated with TMB, terminated the reaction with 2M sulfuric acid. Absorption at 450 nm wavelength was detected, and IC50 value (Î¼M) was calculated.",C[S+]([O-])CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,"US8916574, Compound 2",0.05267,uM,=,-1.2784366816425192,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
4788,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccccc3OC)ncc2C(F)(F)F)c1,"US9238629, I-2",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
4789,306538,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate; Range = 3-5 nM,COc1cc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2cc1OC,"(4,5-Dichloro-2-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
4790,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CS(=O)(=O)C[C@H](N)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,(R)-6-(5-(1-amino-2-(methylsulfonyl)ethyl)furan-2-yl)-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)quinazolin-4-amine,0.0135,uM,=,-1.869666231504994,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
4791,1661463,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant GST-tagged EGFR (668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system,S=C(Nc1cccc(Cl)c1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(3-chlorophenyl)thiourea,0.041,uM,=,-1.3872161432802643,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4792,1586270,10.1016/j.bmc.2016.04.046,,,,Inhibition of wild type human EGFR preincubated for 5 mins followed by ATP addition for 30 mins by HTRF assay,CCOc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)[C@H]1NC(=O)O[C@@H]1C,"(4S,5R)-N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-5-methyl-2-oxooxazolidine-4-carboxamide",0.00257,uM,=,-2.5900668766687054,0,O=C1N[C@H](C(=O)Nc2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)CO1
4793,66567,10.1021/jm950692f,,,,Inhibition of tyrosine kinase activity of Epidermal growth factor receptor from human A431 cells,CN(C)CCn1cnc2c(Cl)c3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-[9-chloro-3-(2-dimethylamino-ethyl)-3H-imidazo[4,5-g]quinazolin-8-yl]-amine",0.203,uM,=,-0.6925039620867871,0,c1ccc(Nc2ncnc3cc4[nH]cnc4cc23)cc1
4794,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,Nc1ccc2ncnc(NCc3ccccc3)c2c1,"N*4*-Benzyl-quinazoline-4,6-diamine",1.4,uM,=,0.1461280356782379,1,c1ccc(CNc2ncnc3ccccc23)cc1
4795,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-10",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4796,1283337,10.1016/j.ejmech.2013.10.058,,,,Inhibition of wild type EGFR (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,COc1cc2nc(Cl)nc(Nc3ccc(S(C)(=O)=O)cc3)c2cc1OC,"2-Chloro-6,7-dimethoxy-N-(4-(methylsulfonyl)phenyl)quinazolin-4-amine",61.5,uM,=,1.7888751157754168,1,c1ccc(Nc2ncnc3ccccc23)cc1
4797,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#CCCCN1CCOCC1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-(5-morpholinopent-1-ynyl)pyrimidin-4-amine,0.034,uM,=,-1.4685210829577449,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)CCCN1CCOCC1
4798,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3ccncc3c2)c2c(N)ncnc21,"1-isopropyl-3-(isoquinolin-7-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",100.0,uM,=,2.0,1,c1cc2ccc(-c3n[nH]c4ncncc34)cc2cn1
4799,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,N#CCC(=O)Nc1cccc(Oc2cc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncn2)c1,4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-cyanoacetamidophenoxy)pyrimidine,0.048,uM,=,-1.3187587626244128,0,c1ccc(COc2ccc(Nc3cc(Oc4ccccc4)ncn3)cc2)cc1
4800,1353177,10.1021/ml4003309,,,,Inhibition of recombinant EGFR (unknown origin) using poly-GT peptide as substrate by Transcreener assay,COc1cc2c(Oc3ccc(NC(=O)c4c(C)n(C)n(-c5ccccc5)c4=O)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,"N-[3-fluoro-4-({6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yl}oxy)phenyl]-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide",7.67,uM,=,0.884795363948981,1,O=C(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1c[nH]n(-c2ccccc2)c1=O
4801,2120336,10.1016/j.ejmech.2021.113711,,,,Inhibition of wild type EGFR (unknown origin) pretreated with substrate for 10 mins followed by ATP addition measured after 60 mins by mobility shift assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(N)c3)nc3[nH]ccc23)c1,"N-(3-(2-(3-amino-4-(4-methylpiperazin-1-yl)phenylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl)acrylamide",0.022,uM,=,-1.6575773191777938,0,c1ccc(Oc2nc(Nc3ccc(N4CCNCC4)cc3)nc3[nH]ccc23)cc1
4802,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,Cc1ccc(C(/C=C/c2ccccc2)=N\NC(N)=S)cc1,(Z)-2-((E)-3-phenyl-1-p-tolylallylidene)hydrazinecarbothioamide,0.35,uM,=,-0.4559319556497244,0,N=C(/C=C/c1ccccc1)c1ccccc1
4803,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cccc(CNc2ncnc3c2NCc2cc(OC)c(OC)cc2N3)c1,"(7,8-dimethoxy-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cyclohepten-1-yl)-(3-methoxy-benzyl)-amine",0.8,uM,=,-0.0969100130080563,0,c1ccc(CNc2ncnc3c2NCc2ccccc2N3)cc1
4804,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,CN(CC(=O)O)Cc1c[nH]c2cc3ncnc(Nc4cccc(Br)c4)c3cc12,"{[4-(3-Bromo-phenylamino)-8H-pyrrolo[3,2-g]quinazolin-6-ylmethyl]-methyl-amino}-acetic acid",0.584,uM,=,-0.2335871528876005,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
4805,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,OCC(Nc1ncnc2sc(Br)cc12)c1ccccc1,"(rac)-2-((6-Bromothieno[2,3-d]pyrimidin-4-yl)amino)-2-phenylethanol",0.083,uM,=,-1.080921907623926,0,c1ccc(CNc2ncnc3sccc23)cc1
4806,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2ncc(F)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(N,N-dimethylsulfamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide",0.172,uM,=,-0.7644715530924511,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
4807,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,CN(C)C(=O)CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,"2-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)-N,N-dimethylacetamide",0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
4808,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,CCOc1cc2ncnc(Nc3cccc(I)c3)c2cc1OCC.Cl,"4-(3'-iodoanilino)-6,7-diethoxyquinazoline hydrochloride",0.153,uM,=,-0.8153085691824012,0,c1ccc(Nc2ncnc3ccccc23)cc1
4809,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccc(OC)c4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-[7-ethoxy-4-({4-[(3-methoxybenzyl)oxy]-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)-quinazolin-6-yl]but-2-enamide",0.3469,uM,=,-0.4597957001579402,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
4810,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Cc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccnc4)c3)c12,"5-methyl-N-(1-(pyridin-3-ylmethyl)-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",1.8,uM,=,0.255272505103306,1,c1cncc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)c1
4811,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C\CN1CCOCC1,(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-(morpholine-4-yl)but-2-enamide,0.0003,uM,=,-3.522878745280338,0,O=C(/C=C\CN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4812,608090,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 1 hr by Western blot,O=C(O)[C@H]1O[C@@H]1C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"(2S,3S)-Ethyl 3-(4-(3-Bromoanilino)quinazolin-6-ylcarbamoyl)oxirane-2-carboxylate",0.034,uM,=,-1.4685210829577449,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)[C@@H]1CO1
4813,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)CC)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-5-propionylpyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)cc1
4814,1283337,10.1016/j.ejmech.2013.10.058,,,,Inhibition of wild type EGFR (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,COc1cc2nc(Cl)nc(Nc3ccc(N(C)C)cc3)c2cc1OC,"N1-(2-Chloro-6,7-dimethoxyquinazolin-4-yl)-N4,N4-dimethylbenzene-1,4-diamine",36.0,uM,=,1.5563025007672873,1,c1ccc(Nc2ncnc3ccccc23)cc1
4815,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1,"(6,7,8,9-Tetrahydro-5H-pyrimido[4,5-b]indol-4-yl)-m-tolyl-amine",0.82,uM,=,-0.0861861476162833,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1
4816,78513,10.1016/s0960-894x(02)01047-8,,,,Inhibition of EGFR overexpressing HN5 (Head and neck) tumor cell proliferation,CS(=O)(=O)CCNc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1,{6-[2-(2-Methanesulfonyl-ethylamino)-thiazol-4-yl]-quinazolin-4-yl}-[4-(3-trifluoromethyl-benzyloxy)-phenyl]-amine,18.0,uM,=,1.255272505103306,1,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5cscn5)cc34)cc2)cc1
4817,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CNC1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)but-2-enamide",0.02,uM,=,-1.6989700043360187,0,O=C(/C=C/CNC1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
4818,1774204,10.1016/j.ejmech.2018.02.080,,,,Inhibition of recombinant human EGFR using peptide as substrate by fluorimetric analysis,Clc1ccc(SCc2n[nH]c(-c3ccc(Cl)cc3)n2)cc1,"5-(4-Chlorophenyl)-3-(((4-chlorophenyl)thio)methyl)-1H-1,2,4-triazole",45.5,uM,=,1.6580113966571124,1,c1ccc(SCc2n[nH]c(-c3ccccc3)n2)cc1
4819,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,C=C(CN1CCOCC1)C(=O)Nc1cc2c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c(C#N)cnc2cc1OCC,N-[4-(4-Benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-2-morpholin-4-ylmethyl-acrylamide,0.075,uM,=,-1.1249387366083,0,C=C(CN1CCOCC1)C(=O)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
4820,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,COc1ccc(-n2c(=O)cnc3cnc(Nc4cccc(N)c4)nc32)cc1,2-(3-Aminophenylamino)-8-(4-methoxyphenyl)pteridin-7(8H)-one,18.28,uM,=,1.2619761913978127,1,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
4821,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)CCN1CCCCC1,N-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)anilino)-3-cyano-7-ethoxyquinolin-6-yl)-3-piperidin-1-ylpropanamide,0.0248,uM,=,-1.6055483191737838,0,O=C(CCN1CCCCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccn4)cc3)c2c1
4822,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(NO)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2,N-dihydroxy-benzamide",40.0,uM,=,1.6020599913279625,1,c1ccc(CNc2ccccc2)cc1
4823,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCN(CC)CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC,N-(3-chloro-4-fluorophenyl)-7-(2-(diethylamino)ethoxy)-6-methoxyquinazolin-4-amine,9.9,uM,=,0.99563519459755,1,c1ccc(Nc2ncnc3ccccc23)cc1
4824,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,CC(C)(C)c1ccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)cc1,"8-(4-tert-Butylphenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",79.0,uM,=,1.8976270912904407,1,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
4825,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,COC(=O)CN(C)Cc1c[nH]c2cc3ncnc(Nc4cccc(Br)c4)c3cc12,"{[4-(3-Bromo-phenylamino)-8H-pyrrolo[3,2-g]quinazolin-6-ylmethyl]-methyl-amino}-acetic acid methyl ester",0.0096,uM,=,-2.017728766960432,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
4826,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Brc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1,"N-(3-Bromophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0155,uM,=,-1.8096683018297088,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
4827,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1cc(O)ccc1[N+](=O)[O-],2-(5-Hydroxy-2-nitro-benzylidene)-malononitrile,96.0,uM,=,1.9822712330395684,1,c1ccccc1
4828,1472644,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) using Poly(Glu:Tyr) 4:1 as substrate after 12 to 16 hrs,OC[C@@H](Nc1ncnc2sc(-c3ccc(CN4CCNCC4)cc3)cc12)c1ccccc1,"(S)-2-phenyl-2-(6-(4-(piperazin-1-ylmethyl)phenyl)thieno[2,3-d]pyrimidin-4-ylamino)ethanol",0.6,uM,=,-0.2218487496163563,0,c1ccc(CNc2ncnc3sc(-c4ccc(CN5CCNCC5)cc4)cc23)cc1
4829,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccccc3)C2=O)cc(OC)c1,"(2E,6E)-2-Benzylidene-6-(3,5-dimethoxybenzylidene)-cyclohexanone",1.6,uM,=,0.2041199826559248,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
4830,2088168,10.1016/j.ejmech.2020.112363,,,,Inhibition of EGFR (unknown origin) by FRET assay,Cc1c(NC(=S)Nc2ccc3c(c2)OCO3)c(=O)n(-c2ccccc2)n1C,"1-(benzo[d][1,3]dioxol-5-yl)-3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)thiourea",0.358,uM,=,-0.4461169733561256,0,O=c1c(NC(=S)Nc2ccc3c(c2)OCO3)c[nH]n1-c1ccccc1
4831,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccccc1F,"3-(3,4-Dichlorophenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",6.56,uM,=,0.8169038393756602,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
4832,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC[C@H](Oc2cc3c(N[C@H](C)c4ccccc4)ncnc3cc2OC)C1,1-((3S)-3-(7-methoxy-4-((lR)-1-phenylethylamine)quinazolin-6-yloxy)pyrrolidin-1-yl)prop-2-en-1-one,0.012,uM,=,-1.9208187539523751,0,c1ccc(CNc2ncnc3ccc(O[C@H]4CCNC4)cc23)cc1
4833,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(NC3CC3c3ccccc3)c2cc1OCCN1CCOCC1,[7-Methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-(2-phenyl-cyclopropyl)-amine,0.57,uM,=,-0.2441251443275086,0,c1ccc(C2CC2Nc2ncnc3ccc(OCCN4CCOCC4)cc23)cc1
4834,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Cc1cccc(Nc2ncnc3cc(N)ncc23)c1,"N*4*-m-Tolyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3ccncc23)cc1
4835,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,"[5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-phenyl]-acetic acid",38.0,uM,=,1.57978359661681,1,c1ccc(CNc2ccccc2)cc1
4836,2059412,10.1016/j.bmc.2021.116061,,,,Inhibition of EGFR in human A431 cells preincubated for 60 mins followed by EGF stimulation and measured after 10 mins by ELISA,COc1ccc2c(c1)CCCN2c1ncnc2ccccc12,"6-Methoxy-N1-(4'-quinazolyl)-1,2,3,4-tetrahydroquinoline",0.0489,uM,=,-1.3106911408763795,0,c1ccc2c(c1)CCCN2c1ncnc2ccccc12
4837,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Cl.O=[N+]([O-])c1ccc2sc3c(Nc4cccc(Br)c4)ncnc3c2c1,"(3-Bromo-phenyl)-(8-nitro-benzo[4,5]thieno[3,2-d]pyrimidin-4-yl)-amine hydrochloride",0.0123,uM,=,-1.9100948885606024,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
4838,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(Cl)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(3-chloro-benzyloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.007,uM,=,-2.154901959985743,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
4839,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,C[C@@H](Nc1ncnc2ccc(OCCCCCCC(=O)NO)cc12)c1ccccc1,(R)-N-hydroxy-7-(4-(1-phenylethylamino)quinazolin-6-yloxy)heptanamide,0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3ccccc23)cc1
4840,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),O=C(/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1)NCCCn1ccnc1,"But-2-enedioic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide (3-imidazol-1-yl-propyl)-amide",0.00056,uM,=,-3.2518119729938,0,O=C(/C=C/C(=O)Nc1cc2c(Nc3ccccc3)ncnc2cn1)NCCCn1ccnc1
4841,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2ncnc3cc4[nH]cnc4cc23)c1,"(3-Bromo-phenyl)-(3H-imidazo[4,5-g]quinazolin-8-yl)-amine",8e-06,uM,=,-5.096910013008056,0,c1ccc(Nc2ncnc3cc4[nH]cnc4cc23)cc1
4842,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,C=C(C)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-{4-(3-Chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl}-2-methylacrylamide,0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
4843,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=C(O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1O,2-Hydroxy-4-[4-(2-nitro-vinyl)-phenoxysulfonyl]-benzoic acid,0.05,uM,=,-1.3010299956639813,0,O=S(=O)(Oc1ccccc1)c1ccccc1
4844,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CCl)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(F)c(F)c4)c3cc21,"1-(2-(2-chloroacetoxy)ethyl)-8-((3,4-difluorophenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",4.7,uM,=,0.6720978579357175,1,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
4845,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCc2ccc(Cl)cc2)c1O,3-[3-(4-Chloro-benzylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,20.0,uM,=,1.3010299956639813,1,c1ccc(CSCc2ccccc2)cc1
4846,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,COc1ccc(NC(=O)/C=C/CN(C)C)cc1Nc1ncc(Cl)c(-c2c[nH]c3ccccc23)n1,(E)-N-(3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)-4-(dimethylamino)but-2-enamide,1.55,uM,=,0.1903316981702915,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4847,2018691,10.1016/j.bmc.2020.115674,,,,Inhibition of EGFR-TK (unknown origin) relative to control,Cc1cc(NC2=NC(=O)CS2)no1,2-((5-Methylisoxazol-3-yl)amino)thiazol-4(5H)-one,0.081,uM,=,-1.0915149811213505,0,O=C1CSC(Nc2ccon2)=N1
4848,63761,10.1021/jm9906116,,,,Evaluated for inhibitory activity towards tyrosine kinase Epidermal growth factor receptor,O=C(O)CCc1c(/C=C2\C(=O)Nc3ccc(C(=O)O)cc32)[nH]c2c1CCCC2,"3-[3-(2-Carboxy-ethyl)-4,5,6,7-tetrahydro-1H-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid",56.5,uM,=,1.7520484478194385,1,O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCCC2
4849,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),CCN(CC)CCn1c2ccccc2c2c(Nc3cccc(Br)c3)ncnc21,"(3-Bromo-phenyl)-[9-(2-diethylamino-ethyl)-9H-pyrimido[4,5-b]indol-4-yl]-amine",4.1,uM,=,0.6127838567197355,1,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
4850,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,COc1cc(/C=C(\C#N)C(=O)NCCCCNC(=O)/C(C#N)=C/c2cc(Br)c(O)c(OC)c2)cc(Br)c1O,(E)-3-(3-Bromo-4-hydroxy-5-methoxy-phenyl)-N-{4-[(E)-3-(3-bromo-4-hydroxy-5-methoxy-phenyl)-2-cyano-acryloylamino]-butyl}-2-cyano-acrylamide,102.0,uM,=,2.008600171761917,1,O=C(C=Cc1ccccc1)NCCCCNC(=O)/C=C/c1ccccc1
4851,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(Nc3ccc(-c4nc5ccccc5s4)c(O)c3)ncnc2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)-3-methylphenyl]-6'-methoxy-7'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,0.11,uM,=,-0.958607314841775,0,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
4852,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CC)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-35",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4853,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CBr)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(N5CCCCC5)c(Cl)c4)c3cc21,"1-(2-(2-bromoacetoxy)ethyl)-8-((3-chloro-4-(piperidin-1-yl)phenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.184,uM,=,-0.7351821769904636,0,O=c1[nH]c2cc3c(Nc4ccc(N5CCCCC5)cc4)ncnc3cc2o1
4854,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,Cc1ccc(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)cc1,"3-(3,4-Dihydroxy-phenyl)-2-(4-methyl-benzoyl)-acrylonitrile",15.0,uM,=,1.1760912590556811,1,O=C(/C=C/c1ccccc1)c1ccccc1
4855,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,CN(N)C/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ccnc2cn1,"N-(4-(3-bromophenylamino)-1,7-naphthyridin-6-yl)-4-(1-methylhydrazinyl)but-2-enamide",0.0086,uM,=,-2.065501548756432,0,c1ccc(Nc2ccnc3cnccc23)cc1
4856,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,C#CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-[(3-bromophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-2-propynamide",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3cnccc23)cc1
4857,2268665,10.1016/j.ejmech.2021.113781,,,,Inhibition of human EGFR in presence of ATP by Kinase-Glo Plus luminescence kinase assay kit method,COc1cc(/C=N/NC(=O)COC2=NC(C)=NC3C2C(C)=NN3c2ccccc2)cc(OC)c1OC,"2-((3,6-dimethyl-1-phenyl-3a,7a-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy)-N'-(3,4,5-trimethoxybenzylidene)acetohydrazide",4.18,uM,=,0.6211762817750351,1,O=C(COC1=NC=NC2C1C=NN2c1ccccc1)N/N=C/c1ccccc1
4858,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,COc1cc2ncnc(N[C@H](C)c3ccc(F)cc3)c2cc1OCCCCCCC(=O)NO,(R)-7-(4-(1-(4-fluorophenyl)ethylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3ccccc23)cc1
4859,2268700,10.1016/j.ejmech.2021.113768,,,,Inhibition of EGFR (unknown origin),CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@]5(C(=O)OCCCC[N+](=O)[O-])CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)CO,"4-nitrobutyl(4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-10-acetoxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a(2H)-carboxylate",0.01,uM,=,-2.0,0,C1=C2C(CCC3CCCC[C@@H]23)C2CC[C@H]3CCCCC3[C@H]2C1
4860,1761038,10.1016/j.ejmech.2018.01.042,,,,Inhibition of His6-tagged EGFR (unknown origin) cytoplasmic domain expressed in baculovirus infected Sf9 insect cells after 10 mins followed by addition of ATP-MgCl2 and measured after 1 hr by time-resolved fluorometric analysis,O=c1[nH]c(Cc2ccccc2)cn2c1cc1cc(Cl)ccc12,"3-Benzyl-8-chloropyrazino[1,2-a]indol-1(2H)-one",2.4,uM,=,0.380211241711606,1,O=c1[nH]c(Cc2ccccc2)cn2c1cc1ccccc12
4861,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3ccccc3[nH]2)c1O,3-[3-(1H-Benzoimidazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,75.0,uM,=,1.8750612633917,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
4862,506208,10.1021/np50089a001,,,,Inhibition of EGFR,COC(=O)/C=C/c1cc(O)ccc1O,"(E)-3-(2,5-Dihydroxy-phenyl)-acrylic acid methyl ester",103.06201959855396,uM,=,2.013098648622958,1,c1ccccc1
4863,947940,10.1021/np300764u,,,,Inhibition of EGFR (unknown origin),O=C1N/C=C/c2ccc(c(Br)c2)Oc2cc(cc(Br)c2O)CCNC(=O)/C(=N/O)Cc2ccc(c(Br)c2)Oc2cc(cc(Br)c2O)C/C1=N\O,polybrominated diphenyl ether derivative,1.5,uM,=,0.1760912590556812,1,N=C1Cc2cccc(c2)Oc2ccc(cc2)CC(=N)C(=O)NCCc2cccc(c2)Oc2ccc(cc2)/C=C/NC1=O
4864,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,CCC(=O)Nc1cccc(-c2c[nH]c3nccc(-c4[nH]c(CCCO)nc4-c4ccc(F)cc4)c23)c1,"N-(3-(4-(4-(4-Fluorophenyl)-2-(3-hydroxypropyl)-1H-imidazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl)propionamide",0.673,uM,=,-0.1719849357760231,0,c1ccc(-c2nc[nH]c2-c2ccnc3[nH]cc(-c4ccccc4)c23)cc1
4865,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(CN(C)C)c(Br)c3)c2c1,N-[4-(3-Bromo-4-dimethylaminomethyl-phenylamino)-quinazolin-6-yl]-acrylamide,0.045,uM,=,-1.3467874862246565,0,c1ccc(Nc2ncnc3ccccc23)cc1
4866,792378,10.1016/j.ejmech.2011.11.015,,,,Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis,Fc1ccccc1-c1nnc(SCc2ccccc2)o1,"2-(Benzylthio)-5-(2-fluorophenyl)-1,3,4-oxadiazole",5.11,uM,=,0.7084209001347128,1,c1ccc(CSc2nnc(-c3ccccc3)o2)cc1
4867,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CCNC(CS(C)(=O)=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,Rac-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(1-(ethylamino)-2-(methylsulfonyl)ethyl)furan-2-yl)quinazolin-4-amine,0.0147,uM,=,-1.832682665251824,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
4868,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc(N)c(C(=O)Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1NC(=O)c1ccc(CN2CCN(C)CC2)cc1,2-amino-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-4-ethoxy-5-(4-((4-methylpiperazin-1-yl)methyl)benzamido)benzamide,5.0,uM,=,0.6989700043360189,1,O=C(Nc1cccc(C(=O)Nc2ccc(OCc3ccccc3)cc2)c1)c1ccc(CN2CCNCC2)cc1
4869,935919,10.1016/j.bmcl.2012.11.001,,,,Inhibition of EGFR (unknown origin) by Z-LYTE assay,CC1=CCC[C@](C)(CC/C(C)=C/CC2=C(O)C(=O)C=C(N[C@@H](C(=O)O)[C@@H](C)O)C2=O)[C@@H]1C,"(2R,3R)-3-hydroxy-2-(4-hydroxy-5-((E)-3-methyl-5-((1R,2S)-1,2,3-trimethylcyclohex-3-enyl)pent-2-enyl)-3,6-dioxocyclohexa-1,4-dienylamino)butanoic acid",269.51366659360497,uM,=,2.430580792438161,1,O=C1C=CC(=O)C(C/C=C/CCC2CC=CCC2)=C1
4870,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OCCOCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-{2-[2-({4-[(3,4-Dichloro-2-fluorophenyl)amino]-6-methoxyquinazolin-7-yl}oxy)ethoxy]ethyl}-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.00069,uM,=,-3.161150909262745,0,O=C(Cn1cncn1)NCCOCCOc1ccc2c(Nc3ccccc3)ncnc2c1
4871,699068,10.1016/j.bmc.2010.11.007,,,,Inhibition of EGFR by HTRF assay,CCC(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1,N-(1-(3-Bromophenylamino)-4-cyanoisoquinolin-7-yl)propionamide,20.8,uM,=,1.3180633349627615,1,c1ccc(Nc2nccc3ccccc23)cc1
4872,2101621,10.1016/j.bmcl.2021.128258,,,,Inhibition of EGFR (unknown origin),COc1cccc(-c2cc(-c3c(O)c4ccccc4oc3=O)nc(N)c2C#N)c1,2-amino-6-(4-hydroxy-2-oxo-2H-chromen-3-yl)-4-(3-methoxyphenyl)nicotinonitrile,0.033,uM,=,-1.4814860601221125,0,O=c1oc2ccccc2cc1-c1cc(-c2ccccc2)ccn1
4873,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccccc1Br)c1ccccc1,(Z)-2-((E)-3-(2-bromophenyl)-1-phenylallylidene)hydrazinecarbothioamide,26.0,uM,=,1.414973347970818,1,N=C(/C=C/c1ccccc1)c1ccccc1
4874,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(C)=O)c2)n1,N-(3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)acetamide,17.41,uM,=,1.2407987711173312,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4875,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CCCCCCCCc1ccc(O)cc1,4-Octyl-phenol,16.219,uM,=,1.2100240738042325,1,c1ccccc1
4876,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{5-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-pentyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",20.0,uM,=,1.3010299956639813,1,O=C(C=Cc1ccccc1)NCCCCCNC(=O)/C=C/c1ccccc1
4877,2259969,10.6019/CHEMBL5212743,,,,Selectivity interaction (Enzymatic activity assay) EUB0000596aBDA EGFR,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,AFATINIB DIMALEATE,0.0005,uM,=,-3.3010299956639813,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
4878,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(N=C=S)c2)n1,N-(3-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)isothiocyanate,22.33,uM,=,1.348888723071438,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
4879,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(C)c(=O)c3cnc(Nc4ccccc4)nc32)c1,"N-(3-(3-Methyl-2,4-dioxo-7-(phenylamino)-3,4-dihydropyrimido-[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.082,uM,=,-1.0861861476162833,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccccc3)ncc12
4880,1693612,10.1016/j.bmc.2017.06.004,,,,Inhibition of wild-type EGFR (unknown origin) using Tyr 4 peptide as substrate in presence of ATP by Z-LYTE kinase assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c(F)cccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-(7-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.1746,uM,=,-0.7579557606304491,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4881,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCc1c(CO)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"[4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-methanol",0.49,uM,=,-0.3098039199714864,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
4882,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2CC(c3ccc(Br)cc3)=NN2c2nc(-c3ccccc3)cs2)cc1,"2-(3-(4-bromophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",10.17,uM,=,1.0073209529227447,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
4883,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1cnc(N2C[C@H](O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((8-((2R,3S)-3-hydroxy-2-methylazetidin-1-yl)-5-isopropyl-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",4.503,uM,=,0.6535019469629328,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
4884,64443,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-yl]-acrylamide",0.00054,uM,=,-3.2676062401770314,0,c1ccc(Nc2ncnc3ccncc23)cc1
4885,2088808,10.1016/j.ejmech.2020.112388,,,,Inhibition of N-terminal GST-fused human wild type EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate incubated for 20 mins by Mobility shift assay,CN(C)CCNc1ccc(Nc2nc(Oc3ccc4ccc(=O)[nH]c4c3)c3sccc3n2)cc1F,"7-(2-(4-(2-(dimethylamino)ethylamino)-3-fluorophenylamino)thieno[3,2-d]pyrimidin-4-yloxy)quinolin-2(1H)one",13.97,uM,=,1.145196406114182,1,O=c1ccc2ccc(Oc3nc(Nc4ccccc4)nc4ccsc34)cc2[nH]1
4886,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1cccc(Nc2ncnc3[nH]c(C)c(C)c23)c1,"(5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-m-tolyl-amine",0.57,uM,=,-0.2441251443275086,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1
4887,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CN(C)C/C=C/C(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,"US9181263, 12::US9278100, 12",0.6982999999999999,uM,=,-0.1559579579589835,0,c1ccc(Oc2ccc(-c3nn(C[C@@H]4CCCN4)c4ncncc34)cc2)cc1
4888,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)COC(C)=O,2-((4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)amino)-2-oxoethyl acetate,0.034,uM,=,-1.4685210829577449,0,c1ccc(Nc2ncnc3ccccc23)cc1
4889,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,Oc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1,4-(4-Benzyloxy-phenylamino)-quinazolin-6-ol,0.098,uM,=,-1.0087739243075051,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
4890,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",C#CCNC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(prop-2-ynyl)urea,0.232,uM,=,-0.6345120151091003,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
4891,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COC(=O)CNC(=O)c1ccc(Nc2ncnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)cc1,Methyl 2-(4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)benzamido)acetate,0.611,uM,=,-0.2139587897574457,0,c1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
4892,340860,10.1016/j.bmcl.2005.12.028,,,,Inhibitory activity against EGFR,COc1cc(OC2CCOC2)c2c(Nc3ccc(F)c(Cl)c3)ncnc2c1,N-(3-chloro-4-fluorophenyl)-7-methoxy-5-(tetrahydrofuran-3-yloxy)quinazolin-4-amine,0.187,uM,=,-0.728158393463501,0,c1ccc(Nc2ncnc3cccc(OC4CCOC4)c23)cc1
4893,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Clc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"(3-Bromo-phenyl)-(6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3cnccc23)cc1
4894,791584,10.1016/j.bmc.2011.11.023,,,,"Inhibition of EGFR using poly(Glu,Tyr)4:1 as substrate and [gamma33P]ATP after 60 mins by scintillation counting",O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(4-(3-Chloro-4-fluorophenylamino)thieno[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanone",0.00554,uM,=,-2.25649023527157,0,O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3ccccc3)ncnc2s1
4895,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccc(C)c(C)c4)c(Cl)c3)ncnc2cc1OCCN1CCCCC1,"1-(2-chloro-4-((6-methoxy-7-(2-(piperidin-1-yl)ethoxy)quinazolin-4-yl)amino)phenyl)-3-(3,4-dimethylphenyl)urea",0.817,uM,=,-0.0877779434675845,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCN4CCCCC4)ccc23)cc1
4896,1462679,10.1016/j.ejmech.2014.10.084,,,,Inhibition of EGFR (unknown origin),Clc1cc(Nc2ncnc3ccc(NC4=NC[C@@H](COc5ccccc5)O4)cc23)ccc1OCc1nccs1,"(S)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(5-(phenoxymethyl)-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine",0.95,uM,=,-0.0222763947111522,0,c1ccc(OC[C@@H]2CN=C(Nc3ccc4ncnc(Nc5ccc(OCc6nccs6)cc5)c4c3)O2)cc1
4897,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,CC(C)N(CC#CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1)C(C)C,4-Diisopropylamino-but-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.25,uM,=,-0.6020599913279624,0,c1ccc(Nc2ccnc3ccccc23)cc1
4898,1448250,10.1016/j.bmcl.2014.07.094,,,,Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry,COc1ccc2c(c1)cc(C1C(C#N)=C(N)N(c3cccnc3)C3=C1C(=O)CCC3)c1nnnn12,"2-Amino-4-(7-methoxytetrazolo[1,5-a]quinolin-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile",5.4,uM,=,0.7323937598229685,1,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1
4899,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Fc1ccc2ncnc(Nc3cccc(Br)c3)c2n1,"(3-Bromo-phenyl)-(6-fluoro-pyrido[3,2-d]pyrimidin-4-yl)-amine",0.044,uM,=,-1.3565473235138126,0,c1ccc(Nc2ncnc3cccnc23)cc1
4900,1720134,10.1016/j.ejmech.2017.09.061,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus virus expression system after 1 hr by ELISA,NS(=O)(=O)c1ccc(-n2c(SCC(=O)Nc3ccc([N+](=O)[O-])cc3[N+](=O)[O-])nc3cc4ccccc4cc3c2=O)cc1,"N-(2,4-dinitrophenyl)-2-(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydrobenzo[g]quinazolin-2-ylthio)acetamide",0.06,uM,=,-1.2218487496163564,0,O=C(CSc1nc2cc3ccccc3cc2c(=O)n1-c1ccccc1)Nc1ccccc1
4901,850408,10.1016/j.bmc.2012.08.039,,,,Inhibition of EGFR phosphorylation in human PC9 cells after 24 hrs by by Western blot analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",1.36,uM,=,0.1335389083702175,1,c1ccc(Nc2ncnc3ccccc23)cc1
4902,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cccc(-c2cc3c(N[C@H](C)c4ccccc4)ncnc3s2)c1OC,"(R)-6-(2,3-Dimethoxyphenyl)-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine",0.013,uM,=,-1.8860566476931635,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
4903,2151929,10.1021/acs.jmedchem.0c01949,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(N[C@H](C)c3ccccc3)c2cc1OC,SID49672242,0.001,uM,=,-3.0,0,c1ccc(CNc2ncnc3ccccc23)cc1
4904,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,COCC1CCCN1CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-(2-Methoxymethyl-pyrrolidin-1-yl)-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.065,uM,=,-1.1870866433571443,0,O=C(C#CCN1CCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4905,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1/C=C/c1ccc(CN2CCOCC2)cc1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-(4-(morpholinomethyl)styryl)pyrimidin-4-amine,0.12,uM,=,-0.9208187539523752,0,C(=C/c1cncnc1Nc1ccc(OCc2ccccc2)cc1)\c1ccc(CN2CCOCC2)cc1
4906,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(Cl)c4)nc32)C1,"(S)-7-((3-Chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",1.2,uM,=,0.0791812460476248,1,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
4907,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,COc1cccc(-c2cn(C3CCNC3)c3ncnc(N)c23)c1,"5-(3-Methoxy-phenyl)-7-pyrrolidin-3-yl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",1.12,uM,=,0.0492180226701816,1,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1
4908,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(OC)c4)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.6,uM,=,-0.2218487496163563,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
4909,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(OCCCCc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 4-phenyl-butyl ester",0.4,uM,=,-0.3979400086720376,0,O=C(OCCCCc1ccccc1)c1cccc(NCc2ccccc2)c1
4910,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1ccc(OC)c(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)c1,N-(3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,0.55,uM,=,-0.2596373105057561,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4911,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
4912,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1N,"3-(4-amino-3-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",3.85,uM,=,0.5854607295085007,1,c1ccc(-c2n[nH]c3ncncc23)cc1
4913,1299287,10.1039/C3MD00096F,,,,Inhibition of EGFR (unknown origin) after 1 hr by Caliper mobility shift assay,COc1cc2ncnc(Nc3cccc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)c3)c2cc1OCCCN1CCOCC1,1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(3-(7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-ylamino)phenyl)urea,0.082,uM,=,-1.0861861476162833,0,O=C(Nc1ccccc1)Nc1cccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)c1
4914,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccccc1,"2-Benzoyl-3-(3,4-dihydroxy-phenyl)-acrylonitrile",14.0,uM,=,1.146128035678238,1,O=C(C=Cc1ccccc1)c1ccccc1
4915,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cnc2[nH]ccc2c1,"N-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide",0.008,uM,=,-2.096910013008056,0,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(NC(=O)c2cnc3[nH]ccc3c2)c1
4916,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CS(=O)(=O)C[C@@H](N)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,(S)-6-(5-(1-amino-2-(methylsulfonyl)ethyl)furan-2-yl)-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)quinazolin-4-amine,0.0108,uM,=,-1.9665762445130504,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
4917,78750,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCC1CCCC(CNC(=O)/C(C#N)=C/c2ccc(O)c(O)c2)C1,"(E)-2-Cyano-N-(3-{[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-methyl}-cyclohexylmethyl)-3-(3,4-dihydroxy-phenyl)-acrylamide",12.5,uM,=,1.0969100130080565,1,O=C(C=Cc1ccccc1)NCC1CCCC(CNC(=O)/C=C/c2ccccc2)C1
4918,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(OCCN(C)C)cc4OC)nc32)c1,"N-(3-(7-((4-(2-(Dimethylamino)ethoxy)-2-methoxyphenyl)-amino)-3-isopropyl-2,4-dioxo-3,4-dihydropyrimido[4,5-d]-pyrimidin-1(2H)-yl)phenyl)acrylamide",0.227,uM,=,-0.6439741428068773,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccccc3)ncc12
4919,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,Cc1cc(Nc2c(C#N)cnc3ccc(NC(=O)/C=C/CN(C)C)cc23)ccc1Oc1cc2nncn2cn1,"(E)-N-[3-cyano-4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]-6-quinolyl]-4-(dimethylamino)but-2-enamide",0.02072,uM,=,-1.6836102489268046,0,c1ccc2c(Nc3ccc(Oc4cc5nncn5cn4)cc3)ccnc2c1
4920,305059,10.1021/jm0580196,,,,Inhibition of HER1 kinase in intact DHER14 cells,CN(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1,"(E)-4-Dimethylamino-but-2-enoic acid [4-(4,5-dichloro-2-fluoro-phenylamino)-quinazolin-6-yl]-amide",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccccc23)cc1
4921,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COC(=O)c1cc(OC)c(-c2cc3c(N[C@H](C)c4ccccc4)ncnc3s2)c(OC)c1,"Methyl (R)-3,5-dimethoxy-4-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzoate",0.004,uM,=,-2.397940008672037,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
4922,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(C(N)=O)cc4)nc32)c1,"4-(8-(3-Acrylamidophenyl)-7-oxo-7,8-dihydropteridin-2-ylamino)benzamide",0.0121,uM,=,-1.91721462968355,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
4923,305912,10.1016/j.bmcl.2005.05.100,,,,Inhibitory concentration against EGFR by using [gamma-33P]-ATP as radioligand in pH 7.5,Fc1cccc(COc2ccc(Nc3ncnc4nn5ccccc5c34)cc2Cl)c1,"[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(1,3,8a,9-tetraaza-fluoren-4-yl)-amine",0.032,uM,=,-1.494850021680094,0,c1ccc(COc2ccc(Nc3ncnc4nn5ccccc5c34)cc2)cc1
4924,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(2-fluoro-benzyloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.401,uM,=,-0.3968556273798176,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
4925,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC[C@H](Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)C1,"1-((3S)-3-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1-yl)prop-2-en-1-one",0.007,uM,=,-2.154901959985743,0,c1ccc(Nc2ncnc3ccc(O[C@H]4CCNC4)cc23)cc1
4926,699068,10.1016/j.bmc.2010.11.007,,,,Inhibition of EGFR by HTRF assay,N#Cc1cnc(Nc2cccc(Br)c2)c2cc(NC(=O)c3ccco3)ccc12,N-(1-(3-Bromophenylamino)-4-cyanoisoquinolin-7-yl)furan-2-carboxamide,55.6,uM,=,1.7450747915820577,1,O=C(Nc1ccc2ccnc(Nc3ccccc3)c2c1)c1ccco1
4927,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1)c1ccccn1,(S)-2-(2-Benzoyl-phenylamino)-3-{4-[2-(methyl-pyridin-2-yl-amino)-ethoxy]-phenyl}-propionic acid,10.896,uM,=,1.03726709456871,1,O=C(c1ccccc1)c1ccccc1NCCc1ccc(OCCNc2ccccn2)cc1
4928,2296008,10.1021/acsmedchemlett.3c00006,,,,Inhibition of recombinant human EGFR del19/T790M using biotinEEPLYWSFPAKKK-NH2 as substrate incubated for 120 mins by TR-FRET assay,C=CC(=O)N1CC[C@@H](n2cc(-c3cnc4ccccc4c3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-amino-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one",0.0004,uM,=,-3.397940008672037,0,c1ccc2ncc(-c3cn([C@@H]4CCNC4)c4ncncc34)cc2c1
4929,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,COc1cc(/C(C)=C(\C#N)C(=O)O)ccc1O,2-Cyano-3-(4-hydroxy-3-methoxy-phenyl)-but-2-enoic acid,1100.0,uM,=,3.041392685158225,1,c1ccccc1
4930,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(S(=O)(=O)NC(=N)N)cc3)c2c1,N-(4-(4-(N-carbamimidoylsulfamoyl)phenylamino)quinazolin-6-yl)acrylamide,53.3,uM,=,1.7267272090265722,1,c1ccc(Nc2ncnc3ccccc23)cc1
4931,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,CC(=O)c1ccccc1-c1nnc(Cc2nc3ccccc3[nH]2)o1,"1-(2-(5-((1H-benzo[d]imidazol-2-yl)methyl)-1,3,4-oxadiazol-2-yl)phenyl)ethanone",65.4,uM,=,1.8155777483242672,1,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
4932,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCNCC6)c45)ccc32)c1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-(piperazin-1-ylmethyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.09,uM,=,-1.0457574905606752,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCNCC6)c45)ccc32)cc1
4933,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nccc(NC(=O)OC(C)(C)C)c3c2)c2c(N)ncnc21,"tert-butyl 6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)quinolin-4-ylcarbamate",100.0,uM,=,2.0,1,c1cnc2ccc(-c3n[nH]c4ncncc34)cc2c1
4934,622913,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR in human A431 cells by HTRF assay,CCN(CC)CCNC(=O)c1[nH]c2cnnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1C,"4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-N-(2-(diethylamino)ethyl)-3-methyl-1H-pyrrolo[3,2-d]pyridazine-2-carboxamide",1.16,uM,=,0.0644579892269184,1,c1ccc(COc2ccc(Nc3nncc4[nH]ccc34)cc2)cc1
4935,2153740,10.1021/acsmedchemlett.1c00555,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,CN1CCN(C2CCN(c3cc(Cl)c(Nc4ncc(Cl)c(Nc5ccccc5P(C)(C)=O)n4)cc3Cl)CC2)CC1,"(2-((5-Chloro-2-((2,5-dichloro-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide",0.0659,uM,=,-1.18111458540599,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
4936,1291542,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGFR (unknown origin) after 10 mins,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN(CC)CC)CCO4)c1,"4-(diethylamino)-1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)but-2-en-1-one",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3cc4c(cc23)NCCO4)cc1
4937,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",1.6,uM,=,0.2041199826559248,1,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
4938,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(Cc3ccccc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(3-Benzyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)-phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.00029,uM,=,-3.537602002101044,0,O=C1N(Cc2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
4939,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1ccc2nc(-c3ccc(Nc4ncnc5cc(OCCCN6CCN(C)CC6)c(OC)cc45)cc3)sc2c1,N-[4-(Benzo[d]thiazol-2''-yl)-3-chlorophenyl]-6'-methoxy-7'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,0.2,uM,=,-0.6989700043360187,0,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
4940,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)c2cc1NC(=O)/C=C/CN1CCCC1,(2E)-N-(7-Ethoxy-4-{4-[(phenylsulfonyl)amino]anilino}-6-quinazolinyl)-4-(1-pyrrolidinyl)-2-butenamide,0.021,uM,=,-1.6777807052660807,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)c2c1
4941,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)NCC1CCNc2c(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)nn21,"US9447106, 33",0.021,uM,=,-1.6777807052660807,0,c1ccc(Oc2ccc(-c3cc4n(n3)CCCN4)cc2)cc1
4942,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,CN(C)CCCCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-(4-dimethylamino-butyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0018,uM,=,-2.744727494896694,0,c1ccc(Nc2ncnc3cnccc23)cc1
4943,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN(CCO)CCO,2-[{2-[4-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-ethyl}-(2-hydroxy-ethyl)-amino]-ethanol,0.035,uM,=,-1.4559319556497243,0,c1ccc(Nc2ncnc3ccccc23)cc1
4944,627419,10.1021/jm9011142,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine cell-based ELISA,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.23,uM,=,-0.6382721639824072,0,c1ccc(Nc2ncnc3ccccc23)cc1
4945,2160722,10.1021/acs.jmedchem.1c02208,,,,Inhibition of EGFR phosphorylation in human A549 cells incubated for 4 hrs by Western blot assay,C=CC(=O)Nc1cccc(-n2c(=O)c(C3CCCCC3)nc3cnc(Nc4cccc(OCCOC)c4)nc32)c1,N-(3-(6-Cyclohexyl-2-((3-(2-methoxyethoxy)phenyl)amino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.1176,uM,=,-0.9295926782598803,0,O=c1c(C2CCCCC2)nc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
4946,661840,10.1016/j.bmc.2010.05.049,,,,Inhibition of EGFR expressed in human A431 cells,CN(c1cccc(Br)c1)c1nc(N)nc2[nH]c(Cc3ccccc3)cc12,"2-Amino-4-(N-methyl-m-bromoanilino)-6-benzyl-pyrrolo[2,3-d]pyrimidine",53.1,uM,=,1.725094521081469,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
4947,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(Br)c(OC)c3)c2c1,N-(4-(4-bromo-3-methoxyphenylamino)quinazolin-6-yl)acrylamide,2.5,uM,=,0.3979400086720376,1,c1ccc(Nc2ncnc3ccccc23)cc1
4948,1799769,10.1016/j.ejmech.2018.06.011,,,,"Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using Poly-(Glu, Tyr) as substrate measured after 45 minutes by Kinase-Glo luminescent assay",CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.047,uM,=,-1.3279021420642825,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
4949,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,COc1ccccc1NC(=O)/C=C/c1ccccc1,(E)-N-(2-methoxyphenyl)cinnamamide,5.16,uM,=,0.7126497016272114,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
4950,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,CCCCCCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,4-(3-Chloro-4-fluorophenylamino)-6-hexyloxy-7-methoxyquinazoline,0.106,uM,=,-0.9746941347352298,0,c1ccc(Nc2ncnc3ccccc23)cc1
4951,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccc[nH]5)cc34)cc2Cl)c1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(1H-pyrrol-2-yl)thieno[2,3-d]pyrimidin-4-amine",0.115,uM,=,-0.9393021596463884,0,c1ccc(COc2ccc(Nc3ncnc4sc(-c5ccc[nH]5)cc34)cc2)cc1
4952,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-1",0.065,uM,=,-1.1870866433571443,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
4953,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,COc1ccc2c(c1)CNc1c(Nc3cccc(Br)c3)ncnc1O2,"(3-Bromo-phenyl)-(8-methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
4954,1527997,,,,,"ELISA-Based Kinase Assay: Inhibition of erbB tyrosine kinase activity was assessed using an ELISA-based receptor tyrosine kinase assay. Kinase reactions (50 mM HEPES, pH 7.4, 125 mM NaCl, 10 mM MgCl2, 100 Î¼M sodium orthovanadate, 2 mM dithiothreitol, 20 uM ATP, test compound or vehicle control and 1-5 nM GST-erbB per 50 uL reaction) were run in 96-well plates coated with 0.25 mg/ml poly-Glu-Tyr (Sigma). The reactions were incubated for 6 minutes at room temperature while shaking. Kinase reactions were stopped by removal of reaction mixture, then wells were washed with wash buffer comprising 3% Bovine Serum Albumin and 0.1% Tween 20 in Phosphate Buffered Saline (PBS). Phosphorylated tyrosine residues were detected by adding 0.2 Î¼g/ml anti-phosphotyrosine antibody (Oncogene Ab-4; 50 Î¼L/well) coupled to Horse Radish Peroxidase (HRP) for 25 minutes while shaking at room temperature.",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCC(F)CC1,"US8623883, No. 9",0.01808,uM,=,-1.7428015738606557,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
4955,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1ccc(Cl)cc1)NS(=O)(=O)c1ccc(Br)cc1,N-(4-Bromophenylsulfonyl)-2-(4-chlorophenyl)acetamide,11.29,uM,=,1.052693941924968,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
4956,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)c2cc1NC(=O)/C=C/CN1CCN(C)CC1,(2E)-N-(7-Ethoxy-4-{4-[(phenylsulfonyl)amino]anilino}-6-quinazolinyl)-4-(4-methyl-1-piperazinyl)-2-butenamide,0.082,uM,=,-1.0861861476162833,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)c2c1
4957,1642166,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0067,uM,=,-2.1739251972991736,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
4958,800208,10.1016/j.bmcl.2011.12.067,,,,Inhibition of wild-type EGFR expressed using baculovirus expression system by ELISA,CC(=O)Nc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc(C(=O)O)cc2)cc1,4-(3-(4-acetamidophenylsulfonamido)quinoxalin-2-ylamino)benzoic acid,35.8,uM,=,1.5538830266438743,1,O=S(=O)(Nc1nc2ccccc2nc1Nc1ccccc1)c1ccccc1
4959,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COc1ccc(-c2coc3cc(O)cc(O)c3c2=O)cc1,"5,7-Dihydroxy-3-(4-methoxy-phenyl)-chromen-4-one",105.6083402429722,uM,=,2.023698217236347,1,O=c1c(-c2ccccc2)coc2ccccc12
4960,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OCCCN1CCOCC1,N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine,0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
4961,2260200,10.1016/j.ejmech.2020.112995,,,,Inhibition of wild type EGFR (unknown origin),Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccnc4c3CC(c3ccccc3)N4)[nH]2)cc1,"4-(4-(4-fluorophenyl)-5-(2-phenyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-imidazol-2-yl)phenol",0.0492,uM,=,-1.3080348972326397,0,c1ccc(-c2nc(-c3ccccc3)c(-c3ccnc4c3CC(c3ccccc3)N4)[nH]2)cc1
4962,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"(1H-Indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine",0.068,uM,=,-1.1674910872937636,0,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
4963,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,C=C(Cl)C(=O)Nc1cc(Nc2ncc(C#N)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,2-chloro-N-(5-((5-cyano-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,0.137,uM,=,-0.8632794328435932,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4964,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,COc1cc(C=C(C#N)C#N)cc([N+](=O)[O-])c1O,2-(4-Hydroxy-3-methoxy-5-nitro-benzylidene)-malononitrile,160.0,uM,=,2.204119982655925,1,c1ccccc1
4965,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Cc1ccc(-n2cc3c(-c4c[nH]c(-c5ccccc5)c4-c4ccccc4)nnc(O)c3n2)cc1,"2-(4-Chlorophenyl)-4-(4,5-diphenyl-1H-pyrrol-3-yl)-2H-pyrazolo[3,4-d]pyridazin-7-ol",3.45,uM,=,0.5378190950732742,1,c1ccc(-c2[nH]cc(-c3nncc4nn(-c5ccccc5)cc34)c2-c2ccccc2)cc1
4966,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,N#CCCCCn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,"5-(4-amino-3-(4-fluoro-3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pentanenitrile",11.0,uM,=,1.0413926851582251,1,c1ccc(-c2n[nH]c3ncncc23)cc1
4967,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,PYROTINIB,0.00098,uM,=,-3.0087739243075053,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2nccc(Nc3ccc(OCc4ccccn4)cc3)c2c1
4968,2153185,10.1016/j.ejmech.2021.113845,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(N3CCc4sccc4C3)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((5-chloro-4-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.0064,uM,=,-2.193820026016113,0,c1ccc(Nc2nccc(N3CCc4sccc4C3)n2)cc1
4969,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,COC[C@H]1Oc2cc3ncnc(Nc4cccc(I)c4)c3cc2O[C@@H]1COC,"(7R,8R)-N-(3-iodophenyl)-7,8-bis(methoxymethyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine",0.00166,uM,=,-2.779891911959945,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
4970,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc4c(ccn4Cc4ccccn4)c3)ncnc2cc1OC,N-(7-Methoxy-4-{[1-(2-pyridinylmethyl)-1H-indol-5-yl]amino}-6-quinazolinyl)propanamide,0.061,uM,=,-1.214670164989233,0,c1ccc(Cn2ccc3cc(Nc4ncnc5ccccc45)ccc32)nc1
4971,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,CN(C)CCC(=O)c1ccc(OCc2ccccc2)c(O)c1.Cl,1-(4-Benzyloxy-3-hydroxy-phenyl)-3-dimethylamino-propan-1-one hydrochloride,0.36,uM,=,-0.4436974992327127,0,c1ccc(COc2ccccc2)cc1
4972,5000,10.1021/jm960118j,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Cc1[nH]c2ncnc(Nc3cccc(Cl)c3)c2c1-c1ccccc1,"(3-Chloro-phenyl)-(6-methyl-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",6.0,uM,=,0.7781512503836436,1,c1ccc(Nc2ncnc3[nH]cc(-c4ccccc4)c23)cc1
4973,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc([N+](=O)[O-])c(C(=O)Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1NC(=O)c1ccc(CN2CCN(C)CC2)cc1,N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-4-ethoxy-5-(4-((4-methylpiperazin-1-yl)methyl)benzamido)-2-nitrobenzamide,5.5,uM,=,0.7403626894942439,1,O=C(Nc1cccc(C(=O)Nc2ccc(OCc3ccccc3)cc2)c1)c1ccc(CN2CCNCC2)cc1
4974,1706882,10.1016/j.bmcl.2017.07.009,,,,Inhibition of EGFR (unknown origin),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.0056,uM,=,-2.2518119729938,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
4975,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Cn1c2ccccc2c2c(Nc3cccc(Br)c3)ncnc21,"(3-Bromo-phenyl)-(9-methyl-9H-pyrimido[4,5-b]indol-4-yl)-amine",0.742,uM,=,-0.1295960947209729,0,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
4976,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(Oc4ccncc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-4-yloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.65,uM,=,-0.1870866433571444,0,c1ccc2c(Nc3ccc(Oc4ccncc4)cc3)ccnc2c1
4977,67049,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor,COc1cc(O)c2c(=O)c(-c3cccc(Cl)c3)coc2c1,3-(3-Chloro-phenyl)-5-hydroxy-7-methoxy-chromen-4-one,1.27,uM,=,0.1038037209559568,1,O=c1c(-c2ccccc2)coc2ccccc12
4978,624184,10.1021/jm901877j,,,,Inhibition of wild type EGFR by HTRF assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0002,uM,=,-3.6989700043360174,0,c1ccc(Nc2ncnc3ccccc23)cc1
4979,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,O=C(NCc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)NCc2ccccc2)[nH]c2ccccc12,3N-benzyl-2-(3-benzylcarbamoyl-1H-2-indolyldisulfanyl)-1H-3-indolecarboxamide,15.0,uM,=,1.1760912590556811,1,O=C(NCc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)NCc2ccccc2)[nH]c2ccccc12
4980,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/c1ccccc1N(C)C,N-[4-(4-Benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-3-(2-dimethylamino-phenyl)-acrylamide,1.569,uM,=,0.1956229435869366,1,O=C(/C=C/c1ccccc1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
4981,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Oc1ncnc(Oc3cccc(Br)c3)c1NC2,"1-(3-bromo-phenoxy)-7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene",1.8,uM,=,0.255272505103306,1,c1ccc(Oc2ncnc3c2NCc2ccccc2O3)cc1
4982,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1c(C=O)cccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1,"(R)-2-Methoxy-3-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzaldehyde",0.021,uM,=,-1.6777807052660807,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
4983,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCOC(=O)Nc1cc(Nc2ncnc3cc(OC)c(OC)cc23)ccc1Cl,"ethyl 2-chloro-5-(6,7-dimethoxyquinazolin-4-ylamino)phenylcarbamate",0.9,uM,=,-0.0457574905606751,0,c1ccc(Nc2ncnc3ccccc23)cc1
4984,699068,10.1016/j.bmc.2010.11.007,,,,Inhibition of EGFR by HTRF assay,CN1CCN(CCC(=O)Nc2ccc3c(C#N)cnc(Nc4cccc(Br)c4)c3c2)CC1,N-(1-(3-Bromophenylamino)-4-cyanoisoquinolin-7-yl)-3-(4-methylpiperazin-1yl)propanamide,1.3,uM,=,0.1139433523068367,1,O=C(CCN1CCNCC1)Nc1ccc2ccnc(Nc3ccccc3)c2c1
4985,557465,10.1021/jm800758s,,,,Inhibition of human EGFR,N=C(N)SCCCn1c(=O)c2c(c1=O)n1c3ccccc3cc1c1cccc3ccn2c31,"3-(1,3-Dioxo-1,3-dihydro-2H-indolo[1',7':4,5,6]pyrrolo[3',4':2,3][1,4]diazepino[1,7-a]indol-2-yl)propyl Imidothiocarbamate",4.6,uM,=,0.6627578316815741,1,O=c1[nH]c(=O)c2c1n1ccc3cccc(c31)c1cc3ccccc3n12
4986,1553877,10.1016/j.ejmech.2016.01.045,,,,Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay,COc1cc2ncnc(Nc3ccc(C(=O)NC45CC6CC(CC(C6)C4)C5)c(C#N)c3)c2cc1OCCCN1CCOCC1,N-(Adamantan-1-yl)-2-cyano-4-((7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl)amino)benzamide,0.00471,uM,=,-2.326979092871104,0,O=C(NC12CC3CC(CC(C3)C1)C2)c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
4987,67049,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor,O=c1c(-c2cccc(Cl)c2)coc2cc(O)cc(O)c12,"3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one",0.095,uM,=,-1.0222763947111522,0,O=c1c(-c2ccccc2)coc2ccccc12
4988,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CCl)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(N5CCOCC5)c(Cl)c4)c3cc21,"1-(2-(2-chloroacetoxy)ethyl)-8-((3-chloro-4-morpholinophenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.019,uM,=,-1.7212463990471711,0,O=c1[nH]c2cc3c(Nc4ccc(N5CCOCC5)cc4)ncnc3cc2o1
4989,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Bromo-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.0053,uM,=,-2.275724130399211,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
4990,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(7-(2-Methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)-phenyl)acrylamide",0.00116,uM,=,-2.9355420107730814,0,O=C1NCc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
4991,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.00095,uM,=,-3.0222763947111524,0,c1ccc(Nc2ncnc3cccnc23)cc1
4992,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),CN(C)CCCNC(=O)/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"But-2-enedioic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide (3-dimethylamino-propyl)-amide",0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2ncnc3cnccc23)cc1
4993,2268691,10.1016/j.ejmech.2021.113768,,,,Inhibition of GST-fused EGFR (unknown origin) in presence of ATP by microplate reader analysis,Fc1ccc(C2=Nc3ccc(F)cc3CN2/N=C\c2ccccc2)cc1,N-(6-fluoro-2-(4-fluorophenyl)quinazolin-3(4H)-yl)-1-phenylmethanimine,0.0752,uM,=,-1.1237821594083577,0,C(=N\N1Cc2ccccc2N=C1c1ccccc1)\c1ccccc1
4994,792073,10.1016/j.bmc.2011.10.085,,,,Inhibition of EGFR expressed in baculovirus infected Sf9 cells assessed as inhibition of autophosphorylation preincubated for 10 mins measured after 1 hr by DELFIA/Time-Resolved Fluorometry,COc1ccccc1CNc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,"N4-(3-chlorophenyl)-N6-(2-methoxybenzyl)quinazoline-4,6-diamine",13.88,uM,=,1.142389466118836,1,c1ccc(CNc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
4995,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccccc2NC(=O)COCc2ccccc2)n1,N-(2-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-2-benzyloxyacetamide,3.53,uM,=,0.5477747053878226,1,O=C(COCc1ccccc1)Nc1ccccc1Oc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1
4996,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(N)=O)c3ccccc3n2C)c(C(N)=O)c2ccccc21,2-(3-carbamoyl-1-methyl-1H-2-indolyldisulfanyl)-1-methyl-1H-3-indolecarboxamide0.5 H2O,4.7,uM,=,0.6720978579357175,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
4997,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,CCCCN(Cc1cc(Cl)cc(Cl)c1O)C(=S)Nc1ccccc1,"1-Butyl-1-(3,5-dichloro-2-hydroxybenzyl)-3-phenylthiourea",24.65,uM,=,1.3918169236132487,1,S=C(NCc1ccccc1)Nc1ccccc1
4998,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)cc3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(4-benzyloxy-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.345,uM,=,-0.4621809049267259,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
4999,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(Cn4ccnc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-imidazol-1-ylmethyl-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.519,uM,=,-0.2848326421515421,0,c1ccc2c(Nc3ccc(Cn4ccnc4)cc3)ccnc2c1
5000,2090284,10.1016/j.ejmech.2020.112522,,,,Inhibition of wild type EGFR in human A-431 cells assessed as cell growth inhibition measured after 72 hrs by Celltiter-Glo luminescent cell viability assay,C=CCSSCCC(=O)OCCCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,3-Allyldisulfanyl-propionic acid 3-[4-(3-bromo-phenylamino)-6-methoxy-quinazolin-7-yloxy]-propyl ester,6.702999999999999,uM,=,0.8262692193937262,1,c1ccc(Nc2ncnc3ccccc23)cc1
5001,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)c2cc1NC(=O)/C=C/CN1CCOCC1,(2E)-N-(7-Ethoxy-4-{4-[(phenylsulfonyl)amino]anilino}-6-quinazolinyl)-4-(4-morpholinyl)-2-butenamide,0.014,uM,=,-1.853871964321762,0,O=C(/C=C/CN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)c2c1
5002,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CCN(CC)CCC#CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]-5-(4-diethylamino)-2-pentynamide,0.0018,uM,=,-2.744727494896694,0,c1ccc(Nc2ncnc3ccccc23)cc1
5003,409130,10.1021/jm060727j,,,,Inhibition of Her1,Cc1cc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)nc(C)n1,"2-(2,6-Dimethyl-pyrimidin-4-ylamino)-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide",5.2,uM,=,0.7160033436347992,1,O=C(Nc1ccccc1)c1cnc(Nc2ccncn2)s1
5004,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)N1CCC(F)(F)CC1,"(S)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4,4-difluoropiperidine-1-carboxamide",0.859,uM,=,-0.0660068361687577,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1)N1CCCCC1
5005,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1,(3-Ethynyl-phenyl)-{6-[4-(methanesulfonylmethyl-amino)-butoxy]-quinazolin-4-yl}-amine,0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccccc23)cc1
5006,2185650,10.1016/j.ejmech.2021.113523,,,,Inhibition of EGFR (unknown origin) incubated for 30 min in presence of ATP by fluorescence based assay,Cc1nn(-c2ccc(F)cc2)c2c(Nc3ccc(F)c(Cl)c3)ncnc12,"N-(3-chloro-4-fluorophenyl)-1-(4-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine",0.18,uM,=,-0.744727494896694,0,c1ccc(Nc2ncnc3cnn(-c4ccccc4)c23)cc1
5007,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(C=O)c(F)c2)c2c(N)ncnc21,"4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorobenzaldehyde",9.0,uM,=,0.9542425094393248,1,c1ccc(-c2n[nH]c3ncncc23)cc1
5008,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-ol",0.014,uM,=,-1.853871964321762,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
5009,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,CC(C)(C)OC(=O)N1CCC(n2cc(-c3cccc(O)c3)c3c(N)ncnc32)C1,"3-[4-Amino-5-(3-hydroxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester",2.2,uM,=,0.3424226808222063,1,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1
5010,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Br)c(O)c1)nn2C1CCCC1,"5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-bromophenol",0.236,uM,=,-0.6270879970298935,0,c1ccc(-c2nn(C3CCCC3)c3ncncc23)cc1
5011,974507,10.1016/j.ejmech.2013.05.026,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay,C=CC(=O)N1CCN(c2ccc(Nc3ncc(Cl)c(Oc4cccc(COc5no[n+]([O-])c5S(=O)(=O)c5ccccc5)c4)n3)c(OC)c2)CC1,"4-((3-((2-((4-(4-Acryloylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)oxy)benzyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide",0.35,uM,=,-0.4559319556497244,0,O=S(=O)(c1ccccc1)c1[nH+]onc1OCc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
5012,566595,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by SPA assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5CCc5ccccc5)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(1-phenethyl-1H-indol-5-ylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",3.16,uM,=,0.4996870826184038,1,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5CCc5ccccc5)c4)c3s2)C1)N1CCOCC1
5013,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-(2-(3-aminophenyl)ethynyl)pyrimidin-4-amine,0.042,uM,=,-1.3767507096020994,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
5014,2121823,10.1016/j.ejmech.2021.113786,,,,Inhibition of wild type EGFR (unknown origin) using fluoresceine-labelled poly-GT peptide as substrate incubated for 1 hr by TR-FRET assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0034,uM,=,-2.468521082957745,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5015,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,C[C@@H](Nc1ncnc2oc(-c3ccc(F)cc3)cc12)c1ccccc1,"(R)-6-(4-Fluorophenyl)-N-(1-phenylethyl)furo[2,3-d]pyrimidin-4-amine",0.013,uM,=,-1.8860566476931635,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
5016,64442,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor (EGFR) in A431 cells,C=CC(=O)Nc1ccc2c(Nc3cccc(Br)c3)ncnc2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-7-yl]-acrylamide,0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3ccccc23)cc1
5017,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1nc(C)nc(Nc3ccc4[nH]cnc4c3)c1NC2,"(1H-benzoimidazol-5-yl)-(7,8-dimethoxy-3-methyl-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",14.5,uM,=,1.1613680022349748,1,c1ccc2c(c1)CNc1c(Nc3ccc4[nH]cnc4c3)ncnc1S2
5018,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(NS(=O)(=O)c1ccc(F)cc1)c1cccnc1Cl,2-Chloro-N-(4-fluorophenylsulfonyl)nicotinamide,28.66,uM,=,1.4572761860613257,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
5019,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",Nc1ncc2ncnc(Nc3cccc(Br)c3)c2n1,"N*8*-(3-Bromo-phenyl)-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2ncnc3cncnc23)cc1
5020,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2ncc3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",6.9,uM,=,0.8388490907372553,1,c1ncc2cnn([C@@H]3CCCNC3)c2n1
5021,1847939,10.1016/j.ejmech.2019.03.038,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in Baculovirus expression system using srctide as substrate incubated for 1 hr by mobility shift assay,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,"3-(2,6-dichloro-3-fluorobenzyloxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine",0.681,uM,=,-0.1668528880872148,0,c1ccc(COc2cncc(-c3cnn(C4CCNCC4)c3)c2)cc1
5022,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,CN(CCO)Cc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"2-(((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)(methyl)amino)ethanol",0.11,uM,=,-0.958607314841775,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
5023,946792,10.1016/j.bmc.2013.01.040,,,,Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA,CC(C)(C)C(=O)Nc1nc(Nc2cccc(F)c2)c2c(n1)[nH]c1cccc(Cl)c12,"N-(5-chloro-4-(3-fluorophenylamino)-9H-pyrimido[4,5-b]indol-2-yl)pivalamide",30.8,uM,=,1.4885507165004443,1,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
5024,66584,10.1016/s0960-894x(02)01047-8,,,,Inhibition of EGFR,CS(=O)(=O)CCNc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1,(3-Chloro-4-fluoro-phenyl)-{6-[2-(2-methanesulfonyl-ethylamino)-thiazol-4-yl]-quinazolin-4-yl}-amine,0.035,uM,=,-1.4559319556497243,0,c1ccc(Nc2ncnc3ccc(-c4cscn4)cc23)cc1
5025,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,COc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1C,"6-(2,6-Dichloro-phenyl)-2-(4-methoxy-3-methyl-phenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",0.25,uM,=,-0.6020599913279624,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
5026,1472645,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) after 40 mins by scintillation proximity assay,C[C@H](N)C#Cc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2s1,"(S)-6-(3-aminobut-1-ynyl)-N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)thieno[2,3-d]pyrimidin-4-amine",0.069,uM,=,-1.1611509092627446,0,c1ccc(COc2ccc(Nc3ncnc4sccc34)cc2)cc1
5027,972431,10.1021/ml400146c,,,,Inhibition of human EGFR kinase domain expressed in baculovirus/Sf21 system by ELISA,CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1,4-(3-Chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline,0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
5028,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,CC(=O)c1nn(-c2ccccc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1,"1-(4-(2-Methyl-4,5-diphenyl-1H-pyrrole-3-carbonyl)-1-phenyl-1H-pyrazol-3-yl)-ethanone",4.67,uM,=,0.6693168805661122,1,O=C(c1cnn(-c2ccccc2)c1)c1c[nH]c(-c2ccccc2)c1-c1ccccc1
5029,558980,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by scintillation proximity assay,CCN(CC)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl diethylcarbamate",0.063,uM,=,-1.2006594505464183,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
5030,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,C[C@@H](Nc1ncnc2oc(-c3cccc(O)c3)cc12)c1ccccc1,"(R)-3-(4-((1-Phenylethyl)amino)furo[2,3-d]pyrimidin-6-yl)phenol",0.0046,uM,=,-2.337242168318426,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
5031,1693612,10.1016/j.bmc.2017.06.004,,,,Inhibition of wild-type EGFR (unknown origin) using Tyr 4 peptide as substrate in presence of ATP by Z-LYTE kinase assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.2251999999999999,uM,=,-0.6474316138206915,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5032,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1Cl,"(3-Chloro-4-fluoro-phenyl)-(10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",1.1,uM,=,0.041392685158225,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
5033,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C(C)C)C(C)C,4-Diisopropylamino-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.03,uM,=,-1.5228787452803376,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
5034,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,CCOc1cc2ncnc(Nc3cccc(I)c3)c2cc1OCC.Cl,"4-(3'-iodoanilino)-6,7-diethoxyquinazoline hydrochloride",0.0046,uM,=,-2.337242168318426,0,c1ccc(Nc2ncnc3ccccc23)cc1
5035,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,O=C(/C=C/c1ccccc1)Nc1ccccc1Br,(E)-N-(2-bromophenyl)cinnamamide,15.74,uM,=,1.1970047280230458,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
5036,1832355,10.1016/j.bmcl.2018.12.056,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,CCOCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(2-ethoxyethoxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.00069,uM,=,-3.161150909262745,0,c1ccc(Nc2ncnc3ccccc23)cc1
5037,1589608,10.1016/j.ejmech.2016.04.026,,,,Inhibition of cytoplasmic GST-tagged human recombinant EGFR expressed in baculovirus system by z-lyte assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.000585,uM,=,-3.23284413391782,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
5038,2059412,10.1016/j.bmc.2021.116061,,,,Inhibition of EGFR in human A431 cells preincubated for 60 mins followed by EGF stimulation and measured after 10 mins by ELISA,CSc1ccc(N(C)c2nc(C)nc3ccccc23)cc1,"N-(4-Methylthiophenyl)-N,2-dimethylquinazolin-4-amine",0.0087,uM,=,-2.0604807473813813,0,c1ccc(Nc2ncnc3ccccc23)cc1
5039,1448250,10.1016/j.bmcl.2014.07.094,,,,Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry,CCOC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2cc(C)ccc2n2nnnc12,"Ethyl 2-amino-4-(7-methyltetrazolo[1,5-a]quinolin-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",7.0,uM,=,0.8450980400142568,1,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1
5040,384427,10.1016/j.bmcl.2006.05.010,,,,Inhibition of EGFR-mediated polyGAT phosphorylation at 10 uM,O=C1NC(=O)N(CCc2ccccc2)/C1=C/c1ccc(O)cc1,"(E)-5-(4-hydroxybenzylidene)-1-phenethylimidazolidine-2,4-dione",0.71,uM,=,-0.1487416512809247,0,O=C1NC(=O)N(CCc2ccccc2)/C1=C/c1ccccc1
5041,2281135,10.1016/j.ejmech.2021.113205,,,,Inhibition of EGFR (unknown origin) using biotin as substrate incubated for 1 hrs in the presence of ATP by HTRF assay,COc1cc2ncnc(Oc3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)c4ccccc34)c2cc1OC,"1-(4-((6,7-Dimethoxyquinazolin-4-yl)oxy)naphthalen-1-yl)-3-(3-(trifluoromethyl)phenyl)urea",0.0862,uM,=,-1.0644927341752872,0,O=C(Nc1ccccc1)Nc1ccc(Oc2ncnc3ccccc23)c2ccccc12
5042,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c3)c2cc1NC(=O)/C=C/CN(C)C,(2E)-4-(Dimethylamino)-N-(7-ethoxy-4-{[1-(phenylsulfonyl)-1Hindol-5-yl]amino}-6-quinazolinyl)-2-butenamide,0.038,uM,=,-1.42021640338319,0,O=S(=O)(c1ccccc1)n1ccc2cc(Nc3ncnc4ccccc34)ccc21
5043,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1,"7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-1H-imidazo[1,2-b]pyrazole-3-carboxamide",0.109,uM,=,-0.9625735020593764,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNCC5)c4[nH]3)cc2)cc1
5044,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Nc1ccc2ncnc(Nc3ccc4[nH]ccc4c3)c2c1,"N4-(1H-indol-5-yl)quinazoline-4,6-diamine",0.00065,uM,=,-3.1870866433571443,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1
5045,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-Bromophenyl)amino)quinazolin-6-yl)-3-(2-(piperidin-1-yl)ethyl)thiourea,0.00181,uM,=,-2.7423214251308154,0,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5046,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,Cc1cc(C(=O)N2CC(C)NC(C)C2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[5-(3,5-dimethyl-piperazine-1-carbonyl)-3-methyl-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.0059,uM,=,-2.229147988357856,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCNCC2)[nH]1
5047,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](C)C(N)=O,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)propanamide,0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3ccccc23)cc1
5048,1586270,10.1016/j.bmc.2016.04.046,,,,Inhibition of wild type human EGFR preincubated for 5 mins followed by ATP addition for 30 mins by HTRF assay,O=C1N[C@H](C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2OCCN2CCCCC2)CO1,(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(2-(piperidin-1-yl)ethoxy)quinazolin-6-yl)-2-oxooxazolidine-4-carboxamide,0.02553,uM,=,-1.5929491851957498,0,O=C1N[C@H](C(=O)Nc2cc3c(Nc4ccccc4)ncnc3cc2OCCN2CCCCC2)CO1
5049,850422,10.1016/j.bmc.2012.08.002,,,,Inhibition of human N-terminal DYKDDDD tagged EGFR cytoplasmic domain amino acid 669 to 1210 expressed in baculovirus after 5 mins by scintillation counter,CC(C)(C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21)S(C)(=O)=O,"N-{2-[4-({3-Chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-2-methyl-2-(methylsulfonyl)propanamide",0.047,uM,=,-1.3279021420642825,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
5050,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.017,uM,=,-1.769551078621726,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
5051,1986369,10.1016/j.bmc.2020.115373,,,,Inhibition of human EGFR-TK using PTK substrate after 40 mins in presence of ATP by Kinase-Glo luminescent assay,CCN1CCN(CC(=O)Nc2nnc3c4ccccc4nc(Sc4ccc(Br)cc4)n23)CC1,"N-{5-[(4-Bromophenyl)sulfanyl]-[1,2,4]triazolo[4,3-c]quinazolin-3-yl}-2-(4-ethylpiperazin-1-yl)acetamide",3.91,uM,=,0.5921767573958668,1,O=C(CN1CCNCC1)Nc1nnc2c3ccccc3nc(Sc3ccccc3)n12
5052,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",CCOc1cc2ncnc(Nc3cccc(F)c3)c2cc1OCC.Cl,"4-(3'-fluoroanilino)-6,7-diethoxyquinazoline hydrochloride",0.00817,uM,=,-2.0877779434675845,0,c1ccc(Nc2ncnc3ccccc23)cc1
5053,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Nc1nc(Nc2cccc(Br)c2)c2c(n1)[nH]c1ccccc12,"N*4*-(3-Bromo-phenyl)-9H-pyrimido[4,5-b]indole-2,4-diamine",0.147,uM,=,-0.8326826652518239,0,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
5054,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,CCCN(CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)CCC,4-Dipropylamino-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.062,uM,=,-1.207608310501746,0,c1ccc(Nc2ncnc3ccccc23)cc1
5055,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,O=C(O)C1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"1-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)piperidine-4-carboxylic acid",0.22,uM,=,-0.6575773191777937,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
5056,947940,10.1021/np300764u,,,,Inhibition of EGFR (unknown origin),O=C1NCCc2cc(Br)c(O)c(c2)Oc2c(Br)cc(cc2Br)CCNC(=O)/C(=N/O)Cc2cc(Br)c(O)c(c2)Oc2c(Br)cc(cc2Br)C/C1=N\O,Bastadin 6,2.0,uM,=,0.3010299956639812,1,N=C1Cc2ccc(cc2)Oc2cccc(c2)CC(=N)C(=O)NCCc2ccc(cc2)Oc2cccc(c2)CCNC1=O
5057,506208,10.1021/np50089a001,,,,Inhibition of EGFR,COC(=O)c1oc2cc(O)cc(O)c2c(=O)c1-c1ccc(O)cc1,"methyl 5,7-dihydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromene-2-carboxylate",6.096477313310457,uM,=,0.7850789620096563,1,O=c1c(-c2ccccc2)coc2ccccc12
5058,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,(2E)-N-{4-(3-Chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)-propoxy]-6-quinazolinyl}-2-butenamide,0.022,uM,=,-1.6575773191777938,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
5059,1738745,10.1016/j.ejmech.2018.04.052,,,,"Inhibition of recombinant human GST-tagged wild type EGFR expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.2704,uM,=,-0.5679933127304018,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5060,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CCOC(=O)Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O,"(5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-phenyl)-acetic acid ethyl ester",100.0,uM,=,2.0,1,C(=N/c1ccccc1)\c1ccccc1
5061,989154,10.1016/j.bmc.2013.09.027,,,,Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA,COc1cc(OC)c2c(=O)n(-c3ccc(F)c(Cl)c3)ccc2c1,"6,8-dimethoxy-2-(3-chloro-4-fluorophenyl)isoquinolin-1(2H)-one",5.49,uM,=,0.7395723444500919,1,O=c1c2ccccc2ccn1-c1ccccc1
5062,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),CN(C)CCCNC(=O)/C=C/C(=O)N(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"But-2-enedioic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-methyl-amide (3-dimethylamino-propyl)-amide",0.00145,uM,=,-2.838631997765025,0,c1ccc(Nc2ncnc3cnccc23)cc1
5063,2296008,10.1021/acsmedchemlett.3c00006,,,,Inhibition of recombinant human EGFR del19/T790M using biotinEEPLYWSFPAKKK-NH2 as substrate incubated for 120 mins by TR-FRET assay,C=CC(=O)N1CC[C@H](n2cc(-c3cnc4ccccc4c3)c3c(N)ncnc32)C1,"(S)-1-(3-(4-amino-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one",0.111,uM,=,-0.9546770212133424,0,c1ccc2ncc(-c3cn([C@H]4CCNC4)c4ncncc34)cc2c1
5064,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc(O)cc3)C2)cc1,"4-(3-(4-methoxyphenyl)-1-(4-phenylthiazol-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)phenol",5.35,uM,=,0.7283537820212285,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
5065,1553877,10.1016/j.ejmech.2016.01.045,,,,Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay,COc1cc2ncnc(Nc3cc(C(=O)NC45CC6CC(CC(C6)C4)C5)ccc3C)c2cc1OCCCN1CCOCC1,N-(Adamantan-1-yl)-3-((7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl)amino)-4-methylbenzamide,0.0154,uM,=,-1.812479279163537,0,O=C(NC12CC3CC(CC(C3)C1)C2)c1cccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)c1
5066,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CCOc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc(O)cc2)c1O,2-cyano-3-(3-ethoxy-4-hydroxy-5-((4-hydroxyphenylthio)methyl)phenyl)acrylamide,3.0,uM,=,0.4771212547196624,1,c1ccc(CSc2ccccc2)cc1
5067,2080997,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCc1cn(CCCC(=O)NO)nn1,"4-(4-(((6-Acrylamido-4-((3-chloro-4-((2-fluorobenzyl)oxy)phenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutanamide",0.0029,uM,=,-2.537602002101044,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCc5c[nH]nn5)ccc34)cc2)cc1
5068,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,OCCn1ccc2ncnc(Nc3ccc(Oc4cccc5sncc45)c(Cl)c3)c21,"2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]-amino}-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethanol",0.0040999999999999,uM,=,-2.3872161432802645,0,c1cc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)c2cnsc2c1
5069,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,C=C(N/N=C/c1cn[nH]c1-c1ccccc1)[C@H](C)Cc1ccccc1,(R)-4-((2-(3-methyl-4-phenylbut-1-en-2-yl)hydrazono)methyl)-5-phenyl-1H-pyrazole,26.6,uM,=,1.424881636631067,1,C=C(CCc1ccccc1)N/N=C/c1cn[nH]c1-c1ccccc1
5070,2241031,10.1021/acs.jmedchem.1c00848,,,,Inhibition of wild type human EGFR expressed in Sf9 insect cells in presence of ATP measured by HTRF assay,C=CC(=O)Nc1ccc(OC)c(Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)c1,N-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.0065,uM,=,-2.1870866433571443,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
5071,67049,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor,Oc1cc(O)c2c(O)c(-c3cccc(Cl)c3)cnc2c1,"3-(3-Chloro-phenyl)-5,7-dihydroxy-1H-quinolin-4-one",0.008,uM,=,-2.096910013008056,0,c1ccc(-c2cnc3ccccc3c2)cc1
5072,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Nc3cccc(Cl)c3F)c1NC2,"(3-chloro-2-fluoro-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
5073,2285813,10.1016/j.ejmech.2020.112652,,,,Inhibition of EGFR (unknown origin) infected in insect sf9 cells incubated for 1 hrs in presence of ATP,COc1ccc(C(=O)n2nc(-c3ccncc3)nc2N)cc1,"(5-amino-3-(pyridin-4-yl)-1H-1,2,4-triazol-1-yl)(4-methoxyphenyl)methanone",4.6,uM,=,0.6627578316815741,1,O=C(c1ccccc1)n1cnc(-c2ccncc2)n1
5074,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(C#N)cc3F)ncnc2cc1OC/C=C/CN1CCCC1,3-Fluoro-4-[6-methoxy-7-(4-pyrrolidin-1-yl-but-2-enyloxy)-quinazolin-4-ylamino]-benzonitrile,1.4,uM,=,0.1461280356782379,1,C(=C/CN1CCCC1)\COc1ccc2c(Nc3ccccc3)ncnc2c1
5075,1476964,10.1016/j.bmc.2015.04.038,,,,Inhibition of wild type N-terminal His6-tagged human EGFR kinase domain (702 to 1016 residues) expressed in Sf9 cells pre-incubated for 30 mins before ATP and substrate addition by homogeneous time-resolved FRET assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)/C(C#N)=C/C3CC3)c2)n1,N-(3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)-2-cyano-3-cyclopropylacrylamide,7.2,uM,=,0.8573324964312685,1,O=C(/C=C/C1CC1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
5076,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-26",0.02,uM,=,-1.6989700043360187,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5077,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CN(C)C1,3-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-1-methylazetidine-3-carboxamide,0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3ccc(CNC4CNC4)cc23)cc1
5078,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,COc1ccc(C(O)=C(C#N)C#N)cc1,2-[Hydroxy-(4-methoxy-phenyl)-methylene]-malononitrile,450.0,uM,=,2.6532125137753435,1,c1ccccc1
5079,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,O=C(C#CCCN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Br)c3)ncnc2cn1,"N-[4-[(3-bromo-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-5-(4-morpholinyl)-2-pentynamide",0.0045,uM,=,-2.3467874862246565,0,O=C(C#CCCN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
5080,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Nc1ccc2ncnc(Nc3ccccc3)c2c1,"N*4*-Phenyl-quinazoline-4,6-diamine",0.77,uM,=,-0.1135092748275181,0,c1ccc(Nc2ncnc3ccccc23)cc1
5081,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3cccc(C(F)(F)F)c3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-trifluoromethyl-phenyl)-amine",0.0002399999999999,uM,=,-3.619788758288394,0,c1ccc(Nc2ncnc3ccccc23)cc1
5082,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccnc1,N-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)nicotinamide,0.55,uM,=,-0.2596373105057561,0,O=C(Nc1cccc(C(=O)Nc2ccc(CN3CCNCC3)cc2)c1)c1cccnc1
5083,1589608,10.1016/j.ejmech.2016.04.026,,,,Inhibition of cytoplasmic GST-tagged human recombinant EGFR expressed in baculovirus system by z-lyte assay,Fc1ccc(Nc2ncnc3ccc(-c4cnn(C5CCNCC5)c4)cc23)cc1Cl,N-(3-chloro-4-fluorophenyl)-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinazolin-4-amine,0.0319,uM,=,-1.496209316942819,0,c1ccc(Nc2ncnc3ccc(-c4cnn(C5CCNCC5)c4)cc23)cc1
5084,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",COc1cc2ncnc(NCc3ccc(F)cc3)c2cc1OC.Cl,"4-[(4'-fluorobenzyl)amino]-6,7-dimethoxyquinazoline hydrochloride",0.0477,uM,=,-1.321481620959886,0,c1ccc(CNc2ncnc3ccccc23)cc1
5085,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,Nc1ncnc2c1c(-c1ccccc1)cn2C1CCC1,"7-Cyclobutyl-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",0.73,uM,=,-0.1366771398795441,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1
5086,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,CCCCc1cc(/C=C(\C#N)C(N)=O)cc(CCCC)c1O,"2-Cyano-3-(3,5-dibutyl-4-hydroxy-phenyl)-acrylamide",55.0,uM,=,1.740362689494244,1,c1ccccc1
5087,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,COc1cc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2cc1OC,"(4,5-Dichloro-2-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.000208,uM,=,-3.68193666503724,0,c1ccc(Nc2ncnc3ccccc23)cc1
5088,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3c(c2)OCCO3)c2c(N)ncnc21,"3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",15.0,uM,=,1.1760912590556811,1,c1ncc2c(-c3ccc4c(c3)OCCO4)n[nH]c2n1
5089,792378,10.1016/j.ejmech.2011.11.015,,,,Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis,Nc1ccccc1-c1nnc(SCc2ccccc2)o1,"2-(5-(benzylthio)-1,3,4-oxadiazol-2-yl)aniline",1.51,uM,=,0.1789769472931694,1,c1ccc(CSc2nnc(-c3ccccc3)o2)cc1
5090,66898,10.1021/jm970367n,,,,Inhibition of epidermal growth factor receptor (EGFr) tyrosine kinase,CC(C)(C)NC(=O)Nc1nc2nc(N)ncc2cc1-c1ccccc1,"1-(2-Amino-6-phenyl-pyrido[2,3-d]pyrimidin-7-yl)-3-tert-butyl-urea",5.53,uM,=,0.7427251313046983,1,c1ccc(-c2cnc3ncncc3c2)cc1
5091,1650711,10.1016/j.bmcl.2017.02.023,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay,O=C(Nc1ccc2nccc(Nc3cccc(Cl)c3)c2c1)C1CCC2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3,"N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-2,2-adamantane-1,4-dioxaspiro[4.5]decane-8-carboxamide",0.1778,uM,=,-0.750068243365805,0,O=C(Nc1ccc2nccc(Nc3ccccc3)c2c1)C1CCC2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3
5092,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COCCN1CC(C(N)=O)(N(C)Cc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)C1,3-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-1-(2-methoxyethyl)azetidine-3-carboxamide,0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccc(CNC4CNC4)cc23)cc1
5093,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,O=C(CCCCl)Nc1ccc2ncnc(Nc3ccc4c(ccn4Cc4cccc(F)c4)c3)c2c1,4-chloro-N-(4-(1-(3-fluorobenzyl)-1H-indol-5-ylamino)quinazolin-6-yl)butanamide,0.0069,uM,=,-2.161150909262745,0,c1ccc(Cn2ccc3cc(Nc4ncnc5ccccc45)ccc32)cc1
5094,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COCCOc1cc2ncnc(Nc3ccc(Cl)c(C(F)(F)F)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-N-(4-(4-Chloro-3-(trifluoromethyl)phenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.5736,uM,=,-0.2413908573402562,0,c1ccc(Nc2ncnc3ccccc23)cc1
5095,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,C[C@@H](Nc1ncnc2oc(-c3ccccc3O)cc12)c1ccccc1,"(R)-2-(4-((1-Phenylethyl)amino)furo[2,3-d]pyrimidin-6-yl)phenol",0.002,uM,=,-2.6989700043360187,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
5096,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,CCOc1cc2ncnc(Nc3ccc(C)cc3)c2c2c1OCCO2,"5-Ethoxy-N-(p-tolyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0036,uM,=,-2.4436974992327127,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
5097,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,Nc1ncnc2c1ncn2[C@@H]1O[C@H](COC(=O)c2ccc(S(=O)(=O)Oc3ccc(/C=C/[N+](=O)[O-])cc3)cc2)[C@@H](O)[C@H]1O,"4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester",0.6000000000000001,uM,=,-0.2218487496163563,0,O=C(OC[C@@H]1CC[C@H](n2cnc3cncnc32)O1)c1ccc(S(=O)(=O)Oc2ccccc2)cc1
5098,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(Cl)c(Br)c(Cl)c4)nn32)CC1,"7-(1-acryloylpiperidin-4-yl)-2-(4-bromo-3,5-dichlorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",0.603,uM,=,-0.2196826878598487,0,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1
5099,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,COc1cc2ncnc(Oc3ccc(Br)c(F)c3)c2cc1OC,"4-(4-Bromo-2-fluorophenoxy)-6,7-dimethoxyquinazoline",5.9,uM,=,0.7708520116421442,1,c1ccc(Oc2ncnc3ccccc23)cc1
5100,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccc(Cl)cc4)cs3)C(c3ccc(Br)cc3)C2)cc1,"2-(5-(4-bromophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-chlorophenyl)thiazole",6.31,uM,=,0.8000293592441343,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
5101,792073,10.1016/j.bmc.2011.10.085,,,,Inhibition of EGFR expressed in baculovirus infected Sf9 cells assessed as inhibition of autophosphorylation preincubated for 10 mins measured after 1 hr by DELFIA/Time-Resolved Fluorometry,Oc1ccc(CNc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)cc1,4-((4-(3-Bromophenylamino)quinazolin-6-ylamino)methyl)phenol,0.87,uM,=,-0.0604807473813814,0,c1ccc(CNc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
5102,506208,10.1021/np50089a001,,,,Inhibition of EGFR,N#CC(C#N)=C1C(=O)Nc2cc(O)c(O)cc21,"2-(5,6-Dihydroxy-2-oxo-1,2-dihydro-indol-3-ylidene)-malononitrile",3.0,uM,=,0.4771212547196624,1,C=C1C(=O)Nc2ccccc21
5103,1291543,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCN(C)CC2)CCO4)c1,"1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(4-methylpiperazin-1-yl)but-2-en-1-one",0.78,uM,=,-0.1079053973095195,0,O=C(/C=C/CN1CCNCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
5104,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(C)c3F)c2c1,N-(4-(2-fluoro-3-methylphenylamino)quinazolin-6-yl)acrylamide,0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2ncnc3ccccc23)cc1
5105,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CN(CC(O)CO)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"3-{[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-yl]-methyl-amino}-propane-1,2-diol",0.0032,uM,=,-2.494850021680094,0,c1ccc(Nc2ncnc3ccncc23)cc1
5106,947940,10.1021/np300764u,,,,Inhibition of EGFR (unknown origin),O=C(NCCc1ccc(O)c(Br)c1)/C(Cc1cc(Br)c(O)c(Oc2ccc(CCNC(=O)/C(Cc3cc(Br)c(O)c(-c4cc(C/C(=N\O)C(=O)NCCc5ccc(O)c(Br)c5)cc(Br)c4O)c3)=N/O)cc2Br)c1)=N/O,Sesquibastadin 1,0.6,uM,=,-0.2218487496163563,0,N=C(Cc1cccc(Oc2ccc(CCNC(=O)C(=N)Cc3cccc(-c4cccc(CC(=N)C(=O)NCCc5ccccc5)c4)c3)cc2)c1)C(=O)NCCc1ccccc1
5107,624979,10.1016/j.bmcl.2010.03.015,,,,Inhibition of EGFR intracellular phosphorylation in human A431 cells by ELISA,O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1,"N-(3-(5-(2-(3-morpholinophenylamino)pyrimidin-4-yl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-phenylacetamide",0.61,uM,=,-0.2146701649892329,0,O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1
5108,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCN(CC)[C@@](C)(C#Cc1ncnc2cc(OC)c(OC)cc12)c1ccccc1,"(R)-4-(6,7-dimethoxyquinazolin-4-yl)-N,N-diethyl-2-phenylbut-3-yn-2-amine",7.3,uM,=,0.8633228601204559,1,C(#Cc1ncnc2ccccc12)Cc1ccccc1
5109,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCCCCn1ccnc1[N+](=O)[O-],N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-methoxy-7-(4-(2-nitro-1H-imidazol-1-yl)butoxy)quinazolin-4-amine,0.0119,uM,=,-1.9244530386074687,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCCCCn5ccnc5)ccc34)cc2)cc1
5110,64451,10.1016/s0960-894x(01)00570-4,,,,Inhibition of EGFR kinase,COc1nccc(-c2c(-c3ccc(F)cc3)ncn2[C@H]2CC[C@H](O)CC2)n1,4-[4-(4-Fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-imidazol-1-yl]-cyclohexanol,0.083,uM,=,-1.080921907623926,0,c1ccc(-c2ncn(C3CCCCC3)c2-c2ccncn2)cc1
5111,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCC1,4-Azetidin-1-yl-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.026,uM,=,-1.585026652029182,0,O=C(/C=C/CN1CCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
5112,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,Cn1c(SSc2c(CC(=O)O)c3ccccc3n2C)c(CC(=O)O)c2ccccc21,[2-(3-Carboxymethyl-1-methyl-1H-indol-2-yldisulfanyl)-1-methyl-1H-indol-3-yl]-acetic acid,53.0,uM,=,1.7242758696007892,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
5113,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl dimethylcarbamate",0.028,uM,=,-1.5528419686577808,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
5114,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo-[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.01,uM,=,-2.0,0,c1ncc2c(-c3cnc4[nH]ccc4c3)nn([C@@H]3CCCNC3)c2n1
5115,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,COc1cccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)c1,"N*4*-(3-Chloro-phenyl)-N*3*-(3-methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
5116,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,COc1cc(OC)c2c(c1)Oc1ncnc(Nc3cccc(Br)c3)c1NC2,"(3-Bromo-phenyl)-(7,9-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",6.3,uM,=,0.7993405494535817,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
5117,2293062,10.1021/acs.jmedchem.6b00995,,,,Inhibition of EGFR autophosphorylation in human NCI-H292 cells harboring harboring wild type EGFR preincubated for 60 mins followed by EGF stimulation and measured after 8 mins by SULFO-TAG based electrochemiluminescent assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
5118,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3cccc([N+](=O)[O-])c3)c2cn1,"N*4*-(3-Nitro-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3ccncc23)cc1
5119,63782,10.1021/jm970366v,,,,Inhibition of epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Cc1cccc(Nc2ncnc3cc(NCCCn4ccnc4)ncc23)c1,"N*7*-(3-Imidazol-1-yl-propyl)-N*4*-m-tolyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0035,uM,=,-2.4559319556497243,0,c1ccc(Nc2ncnc3cc(NCCCn4ccnc4)ncc23)cc1
5120,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1cc(O)c(O)c([N+](=O)[O-])c1)C(=O)NCCCNC(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,"(E)-2-Cyano-N-{3-[(E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-acryloylamino]-propyl}-3-(3,4-dihydroxy-5-nitro-phenyl)-acrylamide",35.0,uM,=,1.5440680443502757,1,O=C(C=Cc1ccccc1)NCCCNC(=O)/C=C/c1ccccc1
5121,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COC[C@@H](C(N)=O)N(C)Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-3-methoxypropanamide,0.035,uM,=,-1.4559319556497243,0,c1ccc(Nc2ncnc3ccccc23)cc1
5122,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,O=C(CCl)Nc1ccc2ncnc(Nc3cccc(I)c3)c2c1,2-Chloro-N-[4-(3-iodo-phenylamino)-quinazolin-6-yl]-acetamide,0.0001199999999999,uM,=,-3.9208187539523753,0,c1ccc(Nc2ncnc3ccccc23)cc1
5123,1641517,,,,,"In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CC#CC(=O)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,"US9181263, 16::US9278100, 16",0.2894,uM,=,-0.5385014732169814,0,c1ccc(Oc2ccc(-c3nn(C[C@@H]4CCCN4)c4ncncc34)cc2)cc1
5124,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3OC(F)F)ncc2C(F)(F)F)c1,"US8975249, I-13",0.065,uM,=,-1.1870866433571443,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
5125,462537,10.1016/j.bmcl.2007.12.041,,,,Inhibition of EGFR,CCN(CC)CCOc1ccc(Nc2cc(NC(=O)Nc3c(Cl)cccc3Cl)ncn2)cc1,"1-(2,6-dichlorophenyl)-3-(6-(4-(2-(diethylamino)ethoxy)phenylamino)pyrimidin-4-yl)urea",0.38,uM,=,-0.4202164033831898,0,O=C(Nc1ccccc1)Nc1cc(Nc2ccccc2)ncn1
5126,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc(OC)cc3)C2)cc1,"2-(3,5-bis(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",8.89,uM,=,0.9489017609702136,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
5127,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1,"(3R,5R)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.05,uM,=,-1.3010299956639813,0,O=C(O[C@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3s2)C1)N1CCOCC1
5128,879290,10.1021/jm1013693,,,,Inhibition of HER1,COC(=O)c1ccc2c(c1)S(=O)(=O)N=S2c1ccc(Br)cc1,"3-(4-Bromophenyl)-6-(methoxycarbonyl)benzo[1.3.2]dithiazolium ylide 1,1-dioxide",1.0,uM,=,0.0,0,O=S1(=O)N=S(c2ccccc2)c2ccccc21
5129,1642156,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
5130,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CNC(=O)[C@H]1CCCCN1C,(R)-N-((4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)-1-methylpiperidine-2-carboxamide,0.008,uM,=,-2.096910013008056,0,O=C(NCc1ccc2ncnc(Nc3ccccc3)c2c1)[C@H]1CCCCN1
5131,2293062,10.1021/acs.jmedchem.6b00995,,,,Inhibition of EGFR autophosphorylation in human NCI-H292 cells harboring harboring wild type EGFR preincubated for 60 mins followed by EGF stimulation and measured after 8 mins by SULFO-TAG based electrochemiluminescent assay,CC(C)n1nc(N2CC(C(C)(C)O)C2)c2cnc(Nc3ccnc(-c4cnn(S(=O)(=O)C5CC5)c4)n3)cc21,"2-(1-(6-((2-(1-(Cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-yl)amino)-1-isopropyl-1H-pyrazolo[4,3-c]pyridin-3-yl)azetidin-3-yl)propan-2-ol",0.21,uM,=,-0.6777807052660807,0,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3cc4[nH]nc(N5CCC5)c4cn3)n2)cn1
5132,1769307,10.1016/j.bmc.2018.02.029,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,C=CC(=O)Nc1cc(Nc2ncc3ncn(-c4ccc(C(C)C)cc4)c3n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((9-(4-isopropylphenyl)-9H-purin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncc3ncn(-c4ccccc4)c3n2)cc1
5133,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CBr)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-(2-(2-bromoacetoxy)ethyl)-8-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.077,uM,=,-1.1135092748275182,0,O=c1[nH]c2cc3c(Nc4ccc(OCc5ccccc5)cc4)ncnc3cc2o1
5134,1650711,10.1016/j.bmcl.2017.02.023,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay,O=C(Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)C1CCCCC1,N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)cyclohexanecarboxamide,0.00613,uM,=,-2.212539525481585,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CCCCC1
5135,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,Cc1ccc(S(=O)(=O)NC(=O)c2ccc(C)nc2Cl)cc1,2-Chloro-6-methyl-N-tosylnicotinamide,15.02,uM,=,1.1766699326681496,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
5136,1668743,10.1021/acs.jmedchem.7b00076,,,,"Inhibition of recombinant EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",Cc1n[nH]c2ccc(-c3cc(N[C@@H](CO)c4ccccc4)cnc3-c3cc(F)ccc3O)cc12,(R)-4-Fluoro-2-(5-(2-hydroxy-1-phenylethylamino)-3-(3-methyl-1H-indazol-5-yl)pyridin-2-yl)phenol,0.0047,uM,=,-2.3279021420642825,0,c1ccc(CNc2cnc(-c3ccccc3)c(-c3ccc4[nH]ncc4c3)c2)cc1
5137,608091,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 8 hrs by Western blot,O=C(O)[C@@H]1O[C@H]1C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"(2R,3R)-ethyl 3-(4-(3-bromoanilino)quinazolin-6-ylcarbamoyl)oxirane-2-carboxylate",0.145,uM,=,-0.8386319977650252,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)[C@H]1CO1
5138,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,O=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,1-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)urea,0.087,uM,=,-1.0604807473813815,0,O=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5139,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OC/C=C/CN1CCCC1.Cl,(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(4-pyrrolidin-1-yl-but-2-enyloxy)-quinazolin-4-yl]-amine hydrochloride,0.08,uM,=,-1.0969100130080565,0,C(=C/CN1CCCC1)\COc1ccc2c(Nc3ccccc3)ncnc2c1
5140,63780,10.1016/j.bmcl.2004.01.034,,,,Inhibition of epidermal growth factor receptor kinase autophosphorylation,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)c(C#N)cnc2cn1,"(E)-4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-[1,7]naphthyridin-6-yl]-amide",0.0086,uM,=,-2.065501548756432,0,c1ccc(Nc2ccnc3cnccc23)cc1
5141,2220271,10.1016/j.bmcl.2022.128529,,,,Inhibition of EGFR (unknown origin),COc1cc(-c2nc3ccccc3s2)ccc1OCC(=O)NNC(=O)CN[C@@H](Cc1c[nH]cn1)C(=O)O,"(2S)-2-[(2-{2-[4-(1,3-benzothiazol-2-yl)-2-methoxyphenoxy]acetohydrazido}-2-oxoethyl)amino]-3-(1H-imidazol-4-yl)propanoic acid",0.305,uM,=,-0.5157001606532141,0,O=C(CNCCc1c[nH]cn1)NNC(=O)COc1ccc(-c2nc3ccccc3s2)cc1
5142,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,COc1cc2ncnc(NCc3ccc(F)cc3)c2cc1OCCCCCCC(=O)NO,7-(4-(4-Fluorobenzylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3ccccc23)cc1
5143,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CC(C)=CC[C@@H](OC(=O)/C=C\C(=O)c1ccc(Cl)cc1)C1=CC(=O)c2c(O)ccc(O)c2C1=O,"(R)-1-(5,8-Dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (Z)-4-(4-chlorophenyl)-4-oxobut-2-enoate",0.0325,uM,=,-1.4881166390211256,0,O=C(/C=C\C(=O)c1ccccc1)OCC1=CC(=O)c2ccccc2C1=O
5144,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,CNC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C(\C)[N+](=O)[O-])cc2OC)cc1,4-Methylcarbamoyl-benzenesulfonic acid 2-methoxy-4-(2-nitro-propenyl)-phenyl ester,4.0,uM,=,0.6020599913279624,1,O=S(=O)(Oc1ccccc1)c1ccccc1
5145,2260216,10.1016/j.ejmech.2020.113016,,,,Inhibition of EGFR (unknown origin),Cc1ccc2c(-c3ccccc3)nc(=O)n(C(C)C)c2c1,1-Isopropyl-7-methyl-4-phenyl-1H-quinazolin-2-one,0.002,uM,=,-2.6989700043360187,0,O=c1nc(-c2ccccc2)c2ccccc2[nH]1
5146,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,C#Cc1cccc(Nc2ncnc3ccc(NC(N)=O)cc23)c1,1-(4-((3-Ethynylphenyl)amino)quinazolin-6-yl)urea,0.00222,uM,=,-2.653647025549361,0,c1ccc(Nc2ncnc3ccccc23)cc1
5147,512831,10.1016/j.bmcl.2008.07.057,,,,Inhibition of EGFR,Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)NNC(=O)CCN1CCOCC1,4-amino-6-(4-(benzyloxy)-3-chlorophenylamino)-N'-(3-morpholinopropanoyl)pyrimidine-5-carbohydrazide,0.62,uM,=,-0.2076083105017461,0,O=C(CCN1CCOCC1)NNC(=O)c1cncnc1Nc1ccc(OCc2ccccc2)cc1
5148,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,Brc1cccc(Nc2ncnc3cc4[nH]ncc4cc23)c1,"(3-Bromo-phenyl)-(1H-pyrazolo[4,3-g]quinazolin-5-yl)-amine",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3cc4[nH]ncc4cc23)cc1
5149,563101,10.1016/j.bmc.2009.02.054,,,,Inhibition of EGFR,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,"N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide",2.87,uM,=,0.4578818967339924,1,O=C(Nc1ccccc1)c1cnc(Nc2cc(N3CCNCC3)ncn2)s1
5150,1353177,10.1021/ml4003309,,,,Inhibition of recombinant EGFR (unknown origin) using poly-GT peptide as substrate by Transcreener assay,COc1cc2c(Oc3ccc(NS(=O)(=O)c4ccc(-c5cnn(C)c5)cc4)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,N-[3-fluoro-4-({6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yl}oxy)phenyl]-4-(1-methyl-1H-pyrazol-4-yl)benzenesulfonamide,4.354,uM,=,0.6388884247050756,1,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1ccc(-c2cn[nH]c2)cc1
5151,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)nc3[nH]ccc23)CC1,"1-(4-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.13265,uM,=,-0.8772927456816519,0,c1cc2c(OC3CCNCC3)nc(Nc3ccc(N4CCNCC4)cc3)nc2[nH]1
5152,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,CCOc1cc2ncnc(Nc3ccc(C)c(Cl)c3)c2c2c1OCCO2,"N-(3-Chloro-4-methylphenyl)-5-ethoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0067,uM,=,-2.1739251972991736,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
5153,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3nc(Nc4ccc(CCN5CCOCC5)cc4)sc23)cc1Cl,"N7-(3-chloro-4-fluorophenyl)-N2-(4-(2-morpholinoethyl)phenyl)thiazolo[4,5-d]pyrimidine-2,7-diamine",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3nc(Nc4ccc(CCN5CCOCC5)cc4)sc23)cc1
5154,1776289,10.1016/j.bmcl.2018.06.043,,,,Inhibition of EGFR isolated from human A431 cells,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
5155,2284955,10.1016/j.ejmech.2019.112016,,,,Inhibition of EGFR (unknown origin),FC(F)(F)c1ccc(/C=N/Nc2nc(-c3ccc(Cl)cc3Cl)cs2)cc1,"(E)-4-(2,4-dichlorophenyl)-2-{2-[4-(trifluoromethyl)benzylidene]hydrazinyl}thiazole",5.48,uM,=,0.7387805584843692,1,C(=N/Nc1nc(-c2ccccc2)cs1)\c1ccccc1
5156,2121824,10.1016/j.ejmech.2021.113786,,,,Inhibition of wild type EGFR (unknown origin) using fluoresceine-labelled poly-GT peptide as substrate preincubated with enzyme for 3 hrs followed by substrate and ATP addition by TR-FRET assay,COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(Nc2ccc(NCc3ccc(S(=O)(=O)F)cc3)cc2)n1,4-(((4-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)amino)methyl)benzenesulfonyl fluoride,0.03,uM,=,-1.5228787452803376,0,c1ccc(CNc2ccc(Nc3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)cc2)cc1
5157,1657589,10.1016/j.bmcl.2017.02.027,,,,"Inhibition of wild type recombinant EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",C#Cc1cccc(Nc2ncnc3ccc(-c4ccc(CNCCS(C)(=O)=O)o4)cc23)c1,4-(3-ethynylphenylamino)-6-(5-((2-(methylsulfonyl)ethyl)aminomethyl)furan-2-yl)quinazoline,0.0341599999999999,uM,=,-1.4664821379830326,0,c1ccc(Nc2ncnc3ccc(-c4ccco4)cc23)cc1
5158,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2Cc1ocnc1-c1ccccc1,"5-(4-amino-1-((4-phenyloxazol-5-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",100.0,uM,=,2.0,1,c1ccc(-c2ncoc2Cn2nc(-c3ccccc3)c3cncnc32)cc1
5159,86512,10.1021/jm00110a022,,,,Inhibition of HER14 (human EGFR overexpressing) cell proliferation.,N#C/C(=C\c1ccc(O)c(O)c1)C(N)=O,"(E)-2-Cyano-3-(3,4-dihydroxy-phenyl)-acrylamide",15.0,uM,=,1.1760912590556811,1,c1ccccc1
5160,573684,10.1021/jm9006559,,,,Inhibition of EGFR,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,"N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]-amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide",3.069,uM,=,0.4869968884318226,1,c1cc(N2CCNCC2)ccc1Nc1ncc2c(n1)-c1[nH]ncc1CC2
5161,2270866,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) incubated for 1 hrs by ELISA assay,CN1C(=O)c2ccc(NC(=O)CSc3nc4cc5ccccc5cc4c(=O)n3-c3ccc(S(N)(=O)=O)cc3)cc2C1=O,"N-(2-methyl-1,3-dioxoisoindolin-5-yl)-2-((4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydrobenzo[g]quinazolin-2-yl)thio)acetamide",0.64,uM,=,-0.1938200260161128,0,O=C(CSc1nc2cc3ccccc3cc2c(=O)n1-c1ccccc1)Nc1ccc2c(c1)C(=O)NC2=O
5162,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",0.3702979244341203,uM,=,-0.4314487222182718,0,O=c1c(-c2ccccc2)coc2ccccc12
5163,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.1,uM,=,-1.0,0,c1ccc(/N=c2\nc[nH]c3cc(OCC4CCNCC4)ccc23)cc1
5164,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),COc1ccc2c(c1)sc1c(Nc3cccc(Br)c3)ncnc12,"(3-Bromo-phenyl)-(7-methoxy-benzo[4,5]thieno[3,2-d]pyrimidin-4-yl)-amine",0.08,uM,=,-1.0969100130080565,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
5165,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,0.35,uM,=,-0.4559319556497244,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5166,608090,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 1 hr by Western blot,O=C(Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)[C@@H]1O[C@H]1CN1CCCCC1,"(2R,3S)-N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-(piperidin-1-ylmethyl)oxirane-2-carboxamide",0.007,uM,=,-2.154901959985743,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)[C@@H]1O[C@H]1CN1CCCCC1
5167,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COCCOc1cc2ncnc(Nc3ccc(NC(=O)/C=C/CN(C)C)c(C(F)(F)F)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-(Dimethylamino)-N-(4-(4-((E)-4-(dimethylamino)but-2-enamido)-3-(trifluoromethyl)phenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)but-2-enamide,0.1023,uM,=,-0.9901243662878398,0,c1ccc(Nc2ncnc3ccccc23)cc1
5168,1778842,10.1016/j.bmcl.2018.07.039,,,,Inhibition of EGF-induced EGFR activation in human A431 cells pretreated for 60 mins followed by EGF addition and measured after 10 mins by ELISA,CCCN(c1ccc(OC)cc1)c1ncnc2occ(C)c12,"N-(4-methoxyphenyl)-5-methyl-N-propylfuro[2,3-d]pyrimidin-4-amine",0.0070999999999999,uM,=,-2.148741651280925,0,c1ccc(Nc2ncnc3occc23)cc1
5169,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCc2ccccc2Cl)c1O,3-[3-(2-Chloro-benzylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,1.0,uM,=,0.0,0,c1ccc(CSCc2ccccc2)cc1
5170,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CN(C)c1ccc2c(Nc3cccc(Br)c3)ncnc2n1,"N*4*-(3-Bromo-phenyl)-N*7*,N*7*-dimethyl-pyrido[2,3-d]pyrimidine-4,7-diamine",0.324,uM,=,-0.4894549897933878,0,c1ccc(Nc2ncnc3ncccc23)cc1
5171,2229998,10.1021/acs.jmedchem.1c00876,,,,Inhibition of wild type EGFR (unknown origin),CSc1nc(-c2ccc(F)cc2)c(-c2ccnc3[nH]c(-c4ccccc4)cc23)[nH]1,"4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-2-phenyl-1H-pyrrolo[2,3-b]pyridine",0.287,uM,=,-0.5421181032660077,0,c1ccc(-c2cc3c(-c4[nH]cnc4-c4ccccc4)ccnc3[nH]2)cc1
5172,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,O=C(O)CCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"3-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-ylamino]-propionic acid",0.00061,uM,=,-3.214670164989233,0,c1ccc(Nc2ncnc3ccncc23)cc1
5173,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,COc1cc2ncnc(Nc3ccc(Br)cc3F)c2cc1OC,"4-(4-Bromo-2-fluoroanilino)-6,7-dimethoxyquinazoline",5.7,uM,=,0.7558748556724915,1,c1ccc(Nc2ncnc3ccccc23)cc1
5174,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CN(C(C)C)C1,3-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-1-isopropylazetidine-3-carboxamide,0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccc(CNC4CNC4)cc23)cc1
5175,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,Cc1cccc(Nc2ncnc3ccccc23)c1,Quinazolin-4-yl-m-tolyl-amine,0.91,uM,=,-0.0409586076789063,0,c1ccc(Nc2ncnc3ccccc23)cc1
5176,933476,10.1016/j.bmcl.2012.12.013,,,,Inhibition of EGFR (unknown origin),O=C(NCCCN1CCCC1=O)c1cnc(NCc2cc(Cl)ccc2Cl)nc1NC1CCCC1,"4-(cyclopentylamino)-2-(2,5-dichlorobenzylamino)-N-(3-(2-oxopyrrolidin-1-yl)propyl)pyrimidine-5-carboxamide",4.29,uM,=,0.6324572921847242,1,O=C(NCCCN1CCCC1=O)c1cnc(NCc2ccccc2)nc1NC1CCCC1
5177,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-morpholinophenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.02,uM,=,-1.6989700043360187,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
5178,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,FC(F)(F)c1nnc(NC(=S)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)s1,"1-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)thiourea",0.13,uM,=,-0.8860566476931633,0,S=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)Nc1nncs1
5179,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,COc1nc(Nc2ccc(-c3nc4ccccc4s3)cc2)c2cc[nH]c2n1,"N-(4-(benzo[d]thiazol-2-yl)phenyl)-2-methoxy-7H-pyrrolo[2,3-d]pyrimidin-4-amine",7.7,uM,=,0.8864907251724818,1,c1ccc2sc(-c3ccc(Nc4ncnc5[nH]ccc45)cc3)nc2c1
5180,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,Cc1cccc(Nc2ncnc3cc(NCCCN4CCOCC4)ncc23)c1,"N*7*-(3-Morpholin-4-yl-propyl)-N*4*-m-tolyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0093,uM,=,-2.0315170514460648,0,c1ccc(Nc2ncnc3cc(NCCCN4CCOCC4)ncc23)cc1
5181,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CS(=O)(=O)CC(N)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,rac-6-(5-(1-Amino-2-(methylsulfonyl)ethyl)furan-2-yl)-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)quinazolin-4-amine,0.0176,uM,=,-1.75448733218585,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
5182,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,Cc1ccc(S(=O)(=O)NC(=O)c2cccnc2)cc1,N-Tosylnicotinamide,24.83,uM,=,1.3949767195545644,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
5183,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,CCN(CC)C(C)/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OC,(E)-4-Diethylamino-pent-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,4.84,uM,=,0.6848453616444125,1,c1ccc(Nc2ccnc3ccccc23)cc1
5184,506208,10.1021/np50089a001,,,,Inhibition of EGFR,O=CN/C=C/c1cc(O)ccc1O,"N-[(E)-2-(2,5-Dihydroxy-phenyl)-vinyl]-formamide",3.071626250378204,uM,=,0.4873683704502314,1,c1ccccc1
5185,67049,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,"(3-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccccc23)cc1
5186,67056,10.1016/j.bmcl.2003.08.054,,,,Inhibitory activity against HER1 kinase,Cc1cccc(Cl)c1NC(=O)c1cnc(NC(=O)C2CC2)s1,2-(Cyclopropanecarbonyl-amino)-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide,10.0,uM,=,1.0,1,O=C(Nc1ccccc1)c1cnc(NC(=O)C2CC2)s1
5187,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CCc1cccnc1,N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-3-(pyridin-3-yl)propanamide,0.014,uM,=,-1.853871964321762,0,O=C(CCc1cccnc1)Oc1ccc2ncnc(Nc3ccccc3)c2c1
5188,2215982,10.1016/j.bmc.2022.116835,,,,Inhibition of EGFR (unknown origin) assessed as kinase activity by measuring ATP remaining for 40 mins in presence of ATP by Kinase-Glo Plus luminescence kinase assay,O=C(Cc1csc2nc3ccccc3n12)Nc1cccc(O)c1,"2-(benzo[4,5]imidazo[2,1-b]thiazol-3-yl)-N-(3-hydroxyphenyl)acetamide",55.0,uM,=,1.740362689494244,1,O=C(Cc1csc2nc3ccccc3n12)Nc1ccccc1
5189,82323,10.1021/jm9904295,,,,Inhibitory activity against ligand-dependent EGF cell proliferation,Cc1c[nH]c(/C=C2\C(=O)Nc3cccc(C)c32)c1CCC(=O)O,"3-{4-Methyl-2-[4-methyl-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrrol-3-yl}-propionic acid",28.8,uM,=,1.4593924877592308,1,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1
5190,2145645,10.1016/j.bmcl.2021.128406,,,,Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence of ATP by IMAP-FP assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
5191,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1.O,Tykerb,0.005,uM,=,-2.3010299956639813,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1.c1ccccc1.c1ccccc1
5192,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,O=C(O)CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)O)[nH]c2ccccc12,3-{2-[3-(2-Carboxy-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-propionic acid,4.2,uM,=,0.6232492903979004,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
5193,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,CCOC(=O)N[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"ethyl (3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-ylcarbamate",0.06,uM,=,-1.2218487496163564,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
5194,1883986,10.1021/acsmedchemlett.8b00461,,,,Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay,NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)/C=C/C(F)F)C2)c1N,"(R)-5-Amino-1-(1-((2E)-4,4-difluorobut-2-enoyl)piperidin-3-yl)-3-(4-(2,4-difluorophenoxy)phenyl)-1H-pyrazole-4-carboxamide",0.274,uM,=,-0.5622494371796121,0,c1ccc(Oc2ccc(-c3ccn([C@@H]4CCCNC4)n3)cc2)cc1
5195,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Nc3ccccc3Cl)c2c1C,"(2-Chloro-phenyl)-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",75.1,uM,=,1.8756399370041683,1,c1ccc(Nc2ncnc3[nH]ccc23)cc1
5196,2153740,10.1021/acsmedchemlett.1c00555,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,CN1CCN(C2CCN(c3ccc(Nc4ncc(Br)c(Nc5ccccc5P(C)(C)=O)n4)cc3Cl)CC2)CC1,(2-((5-Bromo-2-((3-chloro-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide,0.1130999999999999,uM,=,-0.9465373950745448,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
5197,1761038,10.1016/j.ejmech.2018.01.042,,,,Inhibition of His6-tagged EGFR (unknown origin) cytoplasmic domain expressed in baculovirus infected Sf9 insect cells after 10 mins followed by addition of ATP-MgCl2 and measured after 1 hr by time-resolved fluorometric analysis,Cc1c2cc(Cl)ccc2n2cc(Cc3ccccc3)[nH]c(=O)c12,"3-Benzyl-8-chloro-10-methylpyrazino[1,2-a]indol-1(2H)-one",1.7,uM,=,0.2304489213782739,1,O=c1[nH]c(Cc2ccccc2)cn2c1cc1ccccc12
5198,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,CCOc1cc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(Cl)c3)c2cc1NC(=O)/C(F)=C\CN(C)C,(E)-N-(4-((3-Chloro-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.0095,uM,=,-2.0222763947111524,0,c1cncc(Oc2ccc(Nc3ncnc4ccccc34)cc2)c1
5199,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-Bromophenyl)amino)quinazolin-6-yl)-3-(2-(piperidin-1-yl)ethyl)thiourea,0.076,uM,=,-1.1191864077192086,0,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5200,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,O=C(Nc1cnn(-c2ccccc2)c1)c1cccc(NS(=O)(=O)c2ccccc2)c1,N-(1-Phenyl-1H-pyrazol-4-yl)-3-(phenylsulfonamido)benzamide,15.36,uM,=,1.1863912156954932,1,O=C(Nc1cnn(-c2ccccc2)c1)c1cccc(NS(=O)(=O)c2ccccc2)c1
5201,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccccc4C)cc3)ncnc2cc1OCCCN1CCN(C)CC1,1-(4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)phenyl)-3-(o-tolyl)urea,0.502,uM,=,-0.2992962828549806,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
5202,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/c1cccc2cccnc12,N-[4-(4-Benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-3-quinolin-8-yl-acrylamide,0.99,uM,=,-0.00436480540245,0,O=C(/C=C/c1cccc2cccnc12)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
5203,305378,10.1021/jm049892u,,,,In vitro inhibition of Epidermal growth factor receptor,Cc1ccc(Nc2ncnn3ccc(C)c23)cc1O,"2-Methyl-5-(5-methyl-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-phenol",0.34,uM,=,-0.4685210829577448,0,c1ccc(Nc2ncnn3cccc23)cc1
5204,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C[C@@H]1CCCN1C(=O)/C=C/CN1CCOCC1,"US9181263, 21::US9278100, 21",6.238,uM,=,0.795045370421125,1,O=C(/C=C/CN1CCOCC1)N1CCC[C@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2cncnc21
5205,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,COCCOc1cc2ncnc(Nc3ccc(F)c([N+](=O)[O-])c3)c2c2c1OCCO2,"N-(4-Fluoro-3-nitrophenyl)-5-(2-methoxyethoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0438,uM,=,-1.3585258894959005,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
5206,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC1CCN(C)CC1,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(1-methylpiperidin-4-yloxy)quinazolin-4-amine,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
5207,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccc([N+](=O)[O-])cc1,"3-(3,4-Dichlorophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",7.78,uM,=,0.890979596989689,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
5208,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCC(N(C)C)CC5)c(C)c4)nc32)C1,"(S)-7-((4-(4-(Dimethylamino)piperidin-1-yl)-3-methylphenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]-pyrimidin-2(1H)-one",0.286,uM,=,-0.543633966870957,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCCCC4)cc3)nc2N1[C@H]1CCNC1
5209,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CCCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-pyrrolidin-1-yl-ethoxy)-quinazolin-4-yl]-amine,0.087,uM,=,-1.0604807473813815,0,c1ccc(Nc2ncnc3ccc(OCCN4CCCC4)cc23)cc1
5210,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,C=C(CN(C)C)C(=O)c1ccc(OCc2ccccc2)c(O)c1.Cl,1-(4-Benzyloxy-3-hydroxy-phenyl)-2-dimethylaminomethyl-propenone hydrochloride,0.67,uM,=,-0.1739251972991735,0,c1ccc(COc2ccccc2)cc1
5211,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COC[C@@H](Nc1ncnc2sc(-c3ccccc3OC)cc12)c1ccccc1,"(S)-N-(2-Methoxy-1-phenylethyl)-6-(2-methoxyphenyl)thieno[2,3-d]pyrimidin-4-amine",0.023,uM,=,-1.6382721639824072,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
5212,1720864,10.1016/j.ejmech.2017.10.030,,,,Inhibition of EGFR (unknown origin),C=CC(=O)Nc1ccc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2)cn1,N-(5-(4-(3-(3-chlorophenyl)ureido)phenyl)pyridin-2-yl)acrylamide,0.0087,uM,=,-2.0604807473813813,0,O=C(Nc1ccccc1)Nc1ccc(-c2cccnc2)cc1
5213,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)CN(C)C)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1,"(S)-3-(2-Chlorophenyl)-1-(1-(2-(dimethylamino)acetyl)-pyrrolidin-3-yl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)-phenyl)amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0266,uM,=,-1.575118363368933,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
5214,803381,10.1016/j.bmc.2005.05.012,,,,Inhibition of human recombinant His-tagged intracellular domain of EGFR using biotin-EEEEYFELV as substrate by HTRF assay,COc1ccc(N2Cc3cnc(Nc4ccccc4)nc3N([C@H]3CC[C@H](O)C3)C2=O)cc1,"(-)-1-((1S,3S)-3-hydroxycyclopentyl)-3-(4-methoxyphenyl)-7-(phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.365,uM,=,-0.4377071355435253,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccccc3)nc2N1C1CCCC1
5215,340860,10.1016/j.bmcl.2005.12.028,,,,Inhibitory activity against EGFR,COc1cc(OC2CCN(S(C)(=O)=O)CC2)c2c(Nc3ccc(F)c(Cl)c3)ncnc2c1,N-(3-chloro-4-fluorophenyl)-7-methoxy-5-(1-(methylsulfonyl)piperidin-4-yloxy)quinazolin-4-amine,9.601,uM,=,0.9823164696920652,1,c1ccc(Nc2ncnc3cccc(OC4CCNCC4)c23)cc1
5216,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,COCCn1c(=O)oc2cc3ncnc(Nc4ccc(OC)c(OC)c4)c3cc21,"8-(3, 4-Dimethoxyphenylamino)-1-(2-methoxyethyl)oxazolo[4,5-g]quinazolin-2(1H)-one",5.5,uM,=,0.7403626894942439,1,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
5217,506208,10.1021/np50089a001,,,,Inhibition of EGFR,N#C/C(=C\c1cc(CSc2ccccc2)c(O)c(OCc2ccccc2)c1)C(N)=O,3-(3-(benzyloxy)-4-hydroxy-5-(phenylthiomethyl)phenyl)-2-cyanoacrylamide,0.8,uM,=,-0.0969100130080563,0,c1ccc(COc2cccc(CSc3ccccc3)c2)cc1
5218,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCSC,N-(4-methoxy-2-(methyl(2-(methylthio)ethyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,1.433,uM,=,0.1562461903973445,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5219,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)cc3C)c2cc1OC,"N-(4-(benzo[d]thiazol-2-yl)-2-methylphenyl)-6,7-dimethoxyquinazolin-4-amine",0.24,uM,=,-0.619788758288394,0,c1ccc2sc(-c3ccc(Nc4ncnc5ccccc45)cc3)nc2c1
5220,876582,10.1021/jm301365e,,,,Inhibition of human recombinant EGFR by radiometric kinase assay,CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccccc5)n(C5CCCC5)c4n3)cc2)CC1,"9-Cyclopentyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc3n2C2CCCC2)cc1
5221,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",Cc1cc(C)cc(COC(=O)c2cc(NCc3cc(O)ccc3O)ccc2O)c1,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3,5-dimethyl-benzyl ester",1.6,uM,=,0.2041199826559248,1,O=C(OCc1ccccc1)c1cccc(NCc2ccccc2)c1
5222,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCCN(C(=O)OC(C)(C)C)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-43",0.65,uM,=,-0.1870866433571444,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCCNCC4)cc3)n2)cc1
5223,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)CO)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-11",0.02,uM,=,-1.6989700043360187,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5224,322238,10.1016/j.bmcl.2005.07.061,,,,Inhibitory activity against EGFR,COc1cc(Nc2c(C#N)cnc3cc(-c4ccc(CN5CCN(C)CC5)cn4)sc23)c(Cl)cc1Cl,"7-(2,4-Dichloro-5-methoxy-phenylamino)-2-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-thieno[3,2-b]pyridine-6-carbonitrile",2.0,uM,=,0.3010299956639812,1,c1ccc(Nc2ccnc3cc(-c4ccc(CN5CCNCC5)cn4)sc23)cc1
5225,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,Cn1ncc2c(Oc3ccc(Nc4ncnc5ccn(CCO)c45)cc3Cl)cccc21,"2-[4-({3-chloro-4-[(1-methyl-1H-indazol-4-yl)oxy]phenyl}-amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethanol",0.036,uM,=,-1.4436974992327127,0,c1cc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)c2cn[nH]c2c1
5226,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1cccc(Br)c1)NS(=O)(=O)c1ccc(F)cc1,2-(3-Bromophenyl)-N-(4-fluorophenylsulfonyl)acetamide,18.72,uM,=,1.2723058444020865,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
5227,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,CCC/C=C\C(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,(Z)-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)hex-2-enamide,1.502,uM,=,0.1766699326681496,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5228,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,O=C(Cc1cc(F)c(F)cc1F)Nc1cccc(Oc2cc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncn2)c1,"4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-6-[3-(2,4,5-trifluorophenylacetamido)phenoxy]pyrimidine",0.627,uM,=,-0.2027324591692835,0,O=C(Cc1ccccc1)Nc1cccc(Oc2cc(Nc3ccc(OCc4ccccc4)cc3)ncn2)c1
5229,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CBr)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(OCc5ccc(Cl)cc5)cc4)c3cc21,"1-(2-(2-bromoacetoxy)ethyl)-8-((4-((4-chlorobenzyl)oxy)phenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",6.4,uM,=,0.8061799739838872,1,O=c1[nH]c2cc3c(Nc4ccc(OCc5ccccc5)cc4)ncnc3cc2o1
5230,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,C#Cc1cccc(Nc2ncnc3sc(-c4ccccc4OC)cc23)c1,"N-(3-Ethynylphenyl)-6-(2-methoxyphenyl)thieno[2,3-d]pyrimidin-4-amine",0.018,uM,=,-1.744727494896694,0,c1ccc(Nc2ncnc3sc(-c4ccccc4)cc23)cc1
5231,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCCCCCCCCCCCCOC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,Icosyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetate,1.589,uM,=,0.2011238972073795,1,O=c1cc(-c2ccccc2)oc2ccccc12
5232,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)N1CCc2c(sc3ncnc(Nc4ccc(Br)cc4F)c23)C1,"1-(4-((4-bromo-2-fluorophenyl)amino)-5,6-dihydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(8H)-yl)prop-2-en-1-one",3.71,uM,=,0.5693739096150459,1,c1ccc(Nc2ncnc3sc4c(c23)CCNC4)cc1
5233,384428,10.1016/j.bmcl.2006.05.010,,,,Antiproliferative activity against human A431 cell line overexpressing EGFR at 20 uM,O=C1NC(=O)N(CCc2ccccc2)/C1=C/c1ccc(O)cc1,"(E)-5-(4-hydroxybenzylidene)-1-phenethylimidazolidine-2,4-dione",27.0,uM,=,1.4313637641589874,1,O=C1NC(=O)N(CCc2ccccc2)/C1=C/c1ccccc1
5234,1515019,10.1016/j.ejmech.2015.07.030,,,,Inhibition of epidermal growth factor receptor kinase (unknown origin) using [33P]-ATP after 20 to 30 mins by radiometric assay,CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,But-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.00025,uM,=,-3.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
5235,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,CCOC(=O)c1nn(-c2ccccc2)cc1C(=O)c1c(C)[nH]c(-c2ccccc2)c1-c1ccccc1,"4-(2-methyl-4,5-diphenyl-1H-pyrrole-3-carbonyl)-1-phenyl-1H-pyrazole-3-carboxylate",3.22,uM,=,0.5078558716958309,1,O=C(c1cnn(-c2ccccc2)c1)c1c[nH]c(-c2ccccc2)c1-c1ccccc1
5236,66907,10.1016/S0960-894X(00)80473-4,,,,Inhibition of epidermal growth factor receptor (EGFR),O=C(Nc1ccccc1)c1cc2ccc(O)c(O)c2cn1,"7,8-Dihydroxy-isoquinoline-3-carboxylic acid phenylamide",7.7,uM,=,0.8864907251724818,1,O=C(Nc1ccccc1)c1cc2ccccc2cn1
5237,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1cc(Br)c(F)c(Nc2ncnc3cc4c(cc23)OCCO4)c1,"N-(3-Bromo-2,5-difluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.00616,uM,=,-2.2104192878355744,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
5238,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,O=C(O)Cc1c(SSc2[nH]c3ccccc3c2CC(=O)O)[nH]c2ccccc12,[2-(3-Carboxymethyl-1H-indol-2-yldisulfanyl)-1H-indol-3-yl]-acetic acid,10.2,uM,=,1.0086001717619175,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
5239,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccccc2N=[N+]=[N-])n1,N-(2-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)azido,6.34,uM,=,0.8020892578817327,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5240,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C(=O)C=C,N-(2-((2-acrylamido-5-methoxy-4-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)-N-methylacrylamide,0.7235,uM,=,-0.1405614645449437,0,c1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1
5241,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)c1ccc(O)c(Nc2ncnc3cc4oc(=O)n(CCOC)c4cc23)c1,"Ethyl 4-hydroxy-3-(1-(2-methoxyethyl)-2-oxo-1, 2-dihydrooxazolo[4,5-g]quinazolin-8-ylamino)benzoate",0.44,uM,=,-0.3565473235138126,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
5242,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc4c(c3)CCN4Cc3ccccc3)ncnc2cc1OC,"N-{4-[(1-Benzyl-2,3-dihydro-1H-indol-5-yl)amino]-7-methoxy-6-quinazolinyl}propanamide",0.175,uM,=,-0.7569619513137056,0,c1ccc(CN2CCc3cc(Nc4ncnc5ccccc45)ccc32)cc1
5243,2076846,10.1039/d0md00436g,,,,Inhibition of EGFR (unknown origin),O=C(Cc1csc2nc3ccccc3n12)Nc1ccccc1O,"2-(benzo[4,5]imidazo[2,1-b]thiazol-3-yl)-N-(2-hydroxyphenyl)acetamide",55000.0,uM,=,4.740362689494244,1,O=C(Cc1csc2nc3ccccc3n12)Nc1ccccc1
5244,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,CCNC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,1-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)-3-ethylurea,0.035,uM,=,-1.4559319556497243,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
5245,791584,10.1016/j.bmc.2011.11.023,,,,"Inhibition of EGFR using poly(Glu,Tyr)4:1 as substrate and [gamma33P]ATP after 60 mins by scintillation counting",C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0031,uM,=,-2.508638306165728,0,c1ccc(Nc2ncnc3ccccc23)cc1
5246,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccc(Cl)cc4)cs3)C(c3ccc(F)cc3)C2)cc1,"4-(4-chlorophenyl)-2-(5-(4-fluorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazole",5.07,uM,=,0.705007959333336,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
5247,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,CCn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3ccncc3)nc21,"6-(2,6-Dichloro-phenyl)-8-ethyl-2-(pyridin-4-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one",0.49,uM,=,-0.3098039199714864,0,O=c1[nH]c2nc(Nc3ccncc3)ncc2cc1-c1ccccc1
5248,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-7",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCCNCC4)cc3)n2)cc1
5249,787273,10.1016/j.bmcl.2011.09.008,,,,Inhibition of EGFR after 60 mins by TR-FRET Assay,Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12,"(E)-4-(Dimethylamino)-N-(7-fluoro-4-(o-tolylamino)imidazo[1,5-a]quinoxalin-8-yl)-N-methylbut-2-enamide",0.0172,uM,=,-1.764471553092451,0,c1ccc(Nc2nc3ccccc3n3cncc23)cc1
5250,82323,10.1021/jm9904295,,,,Inhibitory activity against ligand-dependent EGF cell proliferation,COc1ccccc1-c1ccc2c(c1)NC(=O)/C2=C\c1[nH]cc(CCC(=O)O)c1C,"3-{5-[6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-4-methyl-1H-pyrrol-3-yl}-propionic acid",19.2,uM,=,1.2833012287035497,1,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1ccc[nH]1
5251,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,COCCNC/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-((2-methoxyethyl)amino)but-2-enamide",1.04,uM,=,0.0170333392987803,1,c1ccc(Nc2ncnc3sccc23)cc1
5252,791584,10.1016/j.bmc.2011.11.023,,,,"Inhibition of EGFR using poly(Glu,Tyr)4:1 as substrate and [gamma33P]ATP after 60 mins by scintillation counting",O=C(c1cc2ccccc2s1)c1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"benzo[b]thiophen-2-yl(4-(3-chloro-4-fluorophenylamino)thieno[2,3-d]pyrimidin-6-yl)methanone",0.0108,uM,=,-1.9665762445130504,0,O=C(c1cc2ccccc2s1)c1cc2c(Nc3ccccc3)ncnc2s1
5253,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)ncnc2cc1OCCCN1CCN(C)CC1,1-(3-chlorophenyl)-3-(4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)phenyl)urea,0.5,uM,=,-0.3010299956639812,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
5254,1914433,10.1021/acs.jnatprod.9b00659,,,,Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay,CC(=O)OC[C@@]1(C)[C@@H]2CC[C@]3(C)[C@H](CC=C4[C@@H]5CC(C)(C)CC[C@]5(C(=O)OCCCCO[N+](=O)[O-])CC[C@]43C)[C@@]2(C)CC[C@@H]1OC(C)=O,"4'-Nitroxybutyl-3beta,23-diacetyloxyolean-12-en-28-oic acid",0.06,uM,=,-1.2218487496163564,0,C1=C2C(CCC3CCCC[C@@H]23)C2CC[C@H]3CCCCC3[C@H]2C1
5255,942122,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3ccc(C(C)(F)F)cc3)c2cc1OC,"N-(4-(1,1-difluoroethyl)phenyl)-6,7-dimethoxyquinazolin-4-amine",4.7,uM,=,0.6720978579357175,1,c1ccc(Nc2ncnc3ccccc23)cc1
5256,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCCC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-1-(1-Butyrylpyrrolidin-3-yl)-3-(2-chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0289,uM,=,-1.5391021572434522,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
5257,2185639,10.1016/j.ejmech.2021.113523,,,,Inhibition of EGFR (unknown origin),CCC/C=C/C(=O)Nc1cc(Nc2ncc(-c3cc4ccccc4n3C)c(C)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-methyl-5-(1-methyl-1H-indol-2-yl)pyrimidin-2-ylamino)phenyl)hex-2-enamide,191.3,uM,=,2.281714970027296,1,c1ccc(Nc2ncc(-c3cc4ccccc4[nH]3)cn2)cc1
5258,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1O,"4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol",0.908,uM,=,-0.0419141514789148,0,c1ccc(-c2n[nH]c3ncncc23)cc1
5259,1882261,10.1016/j.bmc.2018.10.018,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (696-end residues) expressed in baculovirus expression system using Srctide as substrate by fluorescence assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4cccnc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide",63.0,uM,=,1.7993405494535817,1,c1ccc(Nc2nccc(-c3c[nH]c4cccnc34)n2)cc1
5260,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Nc1ccc2c(Nc3ccccc3)ncnc2c1,"N*4*-Phenyl-quinazoline-4,7-diamine",0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
5261,512831,10.1016/j.bmcl.2008.07.057,,,,Inhibition of EGFR,Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1-c1nnc(CCN2CCOCC2)o1,"N-(4-Benzyloxy-3-chloro-phenyl)-5-[5-(2-morpholin-4-yl-ethyl)-[1,3,4]oxadiazol-2-yl]-pyrimidine-4,6-diamine",0.03,uM,=,-1.5228787452803376,0,c1ccc(COc2ccc(Nc3ncncc3-c3nnc(CCN4CCOCC4)o3)cc2)cc1
5262,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),c1ccc(CNc2[nH]cnc3c4ccccc4nc2-3)cc1,"Benzyl-(5H-pyrimido[5,4-b]indol-4-yl)-amine",0.46,uM,=,-0.3372421683184259,0,c1ccc(CNc2[nH]cnc3c4ccccc4nc2-3)cc1
5263,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Br)c(Br)c2)CC1c1ccc(Cl)cc1,"5-(4-Chlorophenyl)-3-(3,4-dibromophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",8.15,uM,=,0.9111576087399766,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
5264,887632,10.1021/jm3003203,,,,Inhibition of GST-tagged EGFR expressed in sf9 cells by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1.O,DACOMITINIB,0.006,uM,=,-2.2218487496163566,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5265,835647,10.1016/j.bmcl.2012.07.079,,,,Inhibition of EGFR in human A431 cell lysate using tyrosine/glutamic acid polymer as substrate by ELISA,Brc1cccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCO5)cc23)c1,"N6-(benzo[d][1,3]dioxol-5-ylmethyl)-N4-(3-bromophenyl)quinazoline-4,6-diamine",0.63,uM,=,-0.2006594505464183,0,c1ccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCO5)cc23)cc1
5266,665191,10.1016/j.bmcl.2010.08.052,,,,Inhibition of EGFR phosphorylation in human MIAPaCa cells by ELISA,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.433,uM,=,-0.3635121036466345,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
5267,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3cccc(Cl)c3)c2cn1,"N*4*-(3-Chloro-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.12,uM,=,-0.9208187539523752,0,c1ccc(Nc2ncnc3ccncc23)cc1
5268,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,COc1ccc(-n2cc(NC(=O)c3cccc(NS(=O)(=O)c4ccc(Cl)cc4)c3)cn2)cc1,3-((4-Chlorophenyl)sulfonamido)-N-(1-(4-methoxyphenyl)-1H-pyrazol-4-yl)benzamide,15.33,uM,=,1.1855421548543752,1,O=C(Nc1cnn(-c2ccccc2)c1)c1cccc(NS(=O)(=O)c2ccccc2)c1
5269,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNC1,"3-(4-Amino-7-pyrrolidin-3-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-phenol",1.53,uM,=,0.1846914308175988,1,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1
5270,63773,10.1021/jm9508651,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 human epidermoid carcinoma cells,CN(C)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-phenyl)-N*7*,N*7*-dimethyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3ccncc23)cc1
5271,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)nc3ccsc23)CC1,"1-(4-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.06074,uM,=,-1.2165252124177537,0,c1cc2nc(Nc3ccc(N4CCNCC4)cc3)nc(OC3CCNCC3)c2s1
5272,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,OCCCc1nc(-c2ccc(F)cc2)c(-c2ccnc3[nH]ccc23)[nH]1,"3-(4-(4-Fluorophenyl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1Himidazol-2-yl)propan-1-ol",0.044,uM,=,-1.3565473235138126,0,c1ccc(-c2nc[nH]c2-c2ccnc3[nH]ccc23)cc1
5273,2198131,10.1016/j.ejmech.2022.114661,,,,Inhibition of recombinant human EGFR incubated for 40 to 45 mins and measured after 15 mins by Kinase-Glo Max assay,Cc1ccc(-c2c(CN3CCOCC3)nc3scc(C(=O)NN)n23)cc1,"6-(Morpholinomethyl)-5-(p-tolyl)imidazo[2,1-b]thiazole-3-carbohydrazide",0.246,uM,=,-0.6090648928966208,0,c1ccc(-c2c(CN3CCOCC3)nc3sccn23)cc1
5274,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccc(C)c(C)c4)c(Cl)c3)ncnc2cc1OCCCN1CCN(C)CC1,"1-(2-chloro-4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)phenyl)-3-(3,4-dimethylphenyl)urea",0.001,uM,=,-3.0,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
5275,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,CC[C@@H](Nc1ncnc2oc(-c3ccc(OC)cc3)cc12)c1ccccc1,"(R)-6-(4-Methoxyphenyl)-N-(1-phenylpropyl)furo[2,3-d]pyrimidin-4-amine",0.022,uM,=,-1.6575773191777938,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
5276,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OCC)nc32)c1,"N-(3-(7-(2-Ethoxy-4-(4-methylpiperazin-1-yl)phenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)-phenyl)acrylamide",0.00441,uM,=,-2.3555614105321614,0,O=C1NCc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
5277,63772,10.1021/jm9903949,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cells,Brc1cccc(Nc2[nH]cnc3c4ccccc4nc2-3)c1.Cl,"(3-Bromo-phenyl)-(5H-pyrimido[5,4-b]indol-4-yl)-amine hydrochloride",0.093,uM,=,-1.031517051446065,0,c1ccc(Nc2[nH]cnc3c4ccccc4nc2-3)cc1
5278,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,Cc1ccc(SCC(CN(C)C)C(=O)c2ccc(OCc3ccccc3)cc2)cc1C.Cl,"1-(4-Benzyloxy-phenyl)-3-dimethylamino-2-(3,4-dimethyl-phenylsulfanylmethyl)-propan-1-one hydrochloride",2.1,uM,=,0.3222192947339193,1,O=C(CCSc1ccccc1)c1ccc(OCc2ccccc2)cc1
5279,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Clc1ccc2ncnc(Nc3cccc(Br)c3)c2n1,"(3-Bromo-phenyl)-(6-chloro-pyrido[3,2-d]pyrimidin-4-yl)-amine",0.018,uM,=,-1.744727494896694,0,c1ccc(Nc2ncnc3cccnc23)cc1
5280,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(NS(=O)(=O)c1ccc(Cl)cc1)c1cccnc1,N-(4-Chlorophenylsulfonyl)nicotinamide,25.36,uM,=,1.404149249209695,1,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
5281,1330695,10.1039/C2MD20017A,,,,Inhibition of EGF-induced EGFR autophosphorylation in human A431 cells after 1 hr by immunoblotting method,C=CC(=O)Nc1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1,N-(3-(6-(3-bromophenylamino)pyrimidin-4-ylamino)phenyl)acrylamide,0.049,uM,=,-1.3098039199714864,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
5282,2134749,10.1016/j.ejmech.2021.113766,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,"(3-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2ncnc3ccccc23)cc1
5283,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(R)-3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0233999999999999,uM,=,-1.6307841425898573,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@@H]1CCNC1
5284,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)c2ccc(Cl)cc2)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"4-[4-chlorophenyl(methyl)carboxamido]-3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaene",7.0,uM,=,0.8450980400142568,1,O=C(N[C@@H]1CC2O[C@@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O)c1ccccc1
5285,66581,10.1016/s0960-894x(02)00598-x,,,,Inhibition of Epidermal Growth Factor Receptor (EGFR) autophosphorylation,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.074,uM,=,-1.1307682802690238,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
5286,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(Cl)c(Cl)c(Cl)c4)nn32)CC1,"7-(1-acryloylpiperidin-4-yl)-2-(3,4,5-trichlorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",0.713,uM,=,-0.1469104701481344,0,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1
5287,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccccc4)nc32)c1,N-(3-(7-Oxo-2-(phenylamino)pteridin-8(7H)-yl)phenyl)-acrylamide,0.0128,uM,=,-1.892790030352132,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
5288,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1O,"5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methylphenol",0.663,uM,=,-0.1784864715952268,0,c1ccc(-c2n[nH]c3ncncc23)cc1
5289,66906,10.1016/s0960-894x(01)00776-4,,,,Inhibition of epidermal growth factor receptor (EGFR),COc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1OC,"4-(3-Chloro-4-fluoro-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile",5.17,uM,=,0.7134905430939426,1,c1ccc(Nc2ccnc3ccccc23)cc1
5290,1869715,10.1016/j.bmc.2019.02.012,,,,Inhibition of His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometry,COc1ccc2nc3sc(C(=O)Nc4ccc(C(=O)/C=C/c5cc(OC)c(OC)c(OC)c5)cc4)cc3cc2c1,"(E)-6-Methoxy-N-(4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenyl)thieno[2,3-b]quinoline-2-carboxamide",1.4,uM,=,0.1461280356782379,1,O=C(/C=C/c1ccccc1)c1ccc(NC(=O)c2cc3cc4ccccc4nc3s2)cc1
5291,63591,10.1016/s0960-894x(01)00219-0,,,,Inhibition of EGF receptor,CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1,"N*4*-(1-Benzyl-1H-indazol-5-yl)-N*6*,N*6*-dimethyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.001,uM,=,-3.0,0,c1ccc(Cn2ncc3cc(Nc4ncnc5cnccc45)ccc32)cc1
5292,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,CC(=O)c1c(SSc2c(C(C)=O)c3ccccc3n2C)n(C)c2ccccc12,1-[2-(3-Acetyl-1-methyl-1H-indol-2-yldisulfanyl)-1-methyl-1H-indol-3-yl]-ethanone,5.6,uM,=,0.7481880270062004,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
5293,1798716,10.1016/j.ejmech.2017.03.083,,,,"Inhibition of wild type N-terminal GST tagged human recombinant EGFR (695 to end amino acids) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) Peptide substrate by ADP-Glo assay",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(CC(=O)N4CCOCC4)cc3)ncc2Cl)c1,N-[3-[[5-Chloro-2-[4-((2-morpholino)acetyl)phenylamino]-4-pyrimidinyl]oxygen]phenyl]acrylamide,0.996,uM,=,-0.0017406615763012,0,O=C(Cc1ccc(Nc2nccc(Oc3ccccc3)n2)cc1)N1CCOCC1
5294,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,NCc1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"[6-(4-Aminomethyl-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine",0.004,uM,=,-2.397940008672037,0,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
5295,331141,10.1016/j.bmcl.2005.08.115,,,,Inhibitory activity against EGFR kinase,COC(=O)c1c(OCCCN(C)C)c2ccccc2c2oc3c(c12)C(=O)c1ccccc1C3=O,"5-(3-dimethylamino-propoxy)-7,12-dioxo-7,12-dihydro-dinaphtho[1,2-b;2',3'-d]furan-6-carboxylic acid methyl ester",13.6,uM,=,1.1335389083702174,1,O=C1c2ccccc2C(=O)c2c1oc1c2ccc2ccccc21
5296,63769,10.1016/S0960-894X(97)00014-0,,,,Displacement of [gamma-32P]-ATP from Epidermal growth factor receptor in A431 cell-free extracts,CCCCCCNC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-N-hexyl-2-hydroxy-benzamide",0.9,uM,=,-0.0457574905606751,0,c1ccc(CNc2ccccc2)cc1
5297,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NC1CCCC[C@@H]1NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{(S)-2-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-cyclohexyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",13.5,uM,=,1.130333768495006,1,O=C(C=Cc1ccccc1)NC1CCCC[C@@H]1NC(=O)/C=C/c1ccccc1
5298,1897499,10.1016/j.bmc.2019.07.042,,,,Inhibition of EGFR-TK in human MCF7 cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",1.88,uM,=,0.2741578492636798,1,c1ccc(Nc2ncnc3ccccc23)cc1
5299,2227151,10.1016/j.ejmech.2022.114492,,,,Inhibition of wild type EGFR (unknown origin) by mobility shift assay,COc1cc(N(C)CCN(C)C)c(NC(=O)c2cnccn2)cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)pyrazine-2-carboxamide,0.224,uM,=,-0.6497519816658371,0,O=C(Nc1cccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c1)c1cnccn1
5300,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CCN(C(=O)[C@H](C)O)CC1,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-2-(4-((S)-2-hydroxypropanoyl)piperazin-1-yl)-4-methoxyphenyl)acrylamide",11000.0,uM,=,4.041392685158225,1,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c2c1
5301,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,COc1ccc2c(c1)CNc1c(Nc3ccc(Cl)cc3)ncnc1O2,"(4-Chloro-phenyl)-(8-methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",5.8,uM,=,0.7634279935629373,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
5302,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C/c1ccc(O)c(O)c1)C(=O)Nc1ccccc1Cl,"N-(2-chlorophenyl)-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide",10.0,uM,=,1.0,1,O=C(C=Cc1ccccc1)Nc1ccccc1
5303,455061,10.1016/j.bmcl.2007.02.067,,,,Inhibition of EGFR by radioactive filtration assay,CNc1ncnc(-c2cccnc2Oc2cc(NC(=O)c3cccc(OC(F)(F)C(F)F)c3)ccc2C)n1,"N-(4-methyl-3-(3-(4-(methylamino)-1,3,5-triazin-2-yl)pyridin-2-yloxy)phenyl)-3-(1,1,2,2-tetrafluoroethoxy)benzamide",25.0,uM,=,1.3979400086720375,1,O=C(Nc1cccc(Oc2ncccc2-c2ncncn2)c1)c1ccccc1
5304,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(-c3cnn(C(C)C)c3)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-5-(1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncc(-c3cn[nH]c3)c(-c3cn4c5c(cccc35)CCC4)n2)cc1
5305,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2SC)c1,N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(methylthio)pyrimidin-4-yl)oxy)phenyl)acrylamide,0.0875,uM,=,-1.0579919469776868,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5306,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)N1CCC[C@@H]1CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,(R)-1-(2-(((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)methyl)pyrrolidin-1-yl)prop-2-en-1-one,0.028,uM,=,-1.5528419686577808,0,c1ccc(Nc2cc(-c3[nH]c(SC[C@H]4CCCN4)nc3-c3ccccc3)ccn2)cc1
5307,2132157,10.1021/acs.jmedchem.1c01559,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(-c4ccc(F)cc4)ccn3)cc2)c(C(N)=O)n1N,(S)-2-(1-Acryloylpiperidin-2-yl)-1-amino-4-(4-((4-(4-fluorophenyl)pyridin-2-yl)carbamoyl)phenyl)-1H-imidazole-5-carboxamide,0.113,uM,=,-0.9469215565165804,0,O=C(Nc1cc(-c2ccccc2)ccn1)c1ccc(-c2c[nH]c([C@@H]3CCCCN3)n2)cc1
5308,622914,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR by HTRF assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,Erlotinib hydrochloride,0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3ccccc23)cc1
5309,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,COc1cc(N2CCC(N)CC2)ccc1Nc1ncc(C(=O)OC(C)C)c(-c2cn(C)c3ccccc23)n1,isopropyl-2-((4-(4-aminopiperidin-1-yl)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidin-5-carboxylate,0.00035,uM,=,-3.4559319556497243,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCCCC5)cc4)n3)c[nH]c2c1
5310,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(NC(=O)CCOCc3ccccc3)cc2)n1,N-(4-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-3-benzyloxypropanamide,16.97,uM,=,1.229681842317676,1,O=C(CCOCc1ccccc1)Nc1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5311,1739299,10.1016/j.ejmech.2018.05.006,,,,Inhibition of wild type EGFR (unknown origin) using FAM-labeled peptide substrate after 10 mins by mobility shift assay,CC/C=C/C(=O)Nc1cc2c(N3CCc4ccccc43)ncnc2cc1OC,(E)-N-(4-(indolin-1-yl)-7-methoxyquinazolin-6-yl)pent-2-enamide,0.017,uM,=,-1.769551078621726,0,c1ccc2c(c1)CCN2c1ncnc2ccccc12
5312,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(Nc1cc(Cl)cc(Cl)c1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(3,5-dichlorophenyl)thiourea",0.1463,uM,=,-0.8347556738746891,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5313,1291543,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCCCC2C)CCO4)c1,"1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(2-methylpiperidin-1-yl)but-2-en-1-one",0.067,uM,=,-1.1739251972991736,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
5314,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,CS(=O)(=O)Nc1ccc2c(c1)CNc1c(Nc3cccc(Br)c3)ncnc1O2,"N-[1-(3-Bromo-phenylamino)-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-8-yl]-methanesulfonamide",4.1,uM,=,0.6127838567197355,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
5315,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CC#CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,"US9181263, 17::US9278100, 17",0.4353,uM,=,-0.3612113328426016,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
5316,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(Sc4nc(-c5ccccc5)cs4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(4-phenyl-thiazol-2-ylsulfanyl)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.125,uM,=,-0.9030899869919436,0,c1ccc(-c2csc(Sc3ccc(Nc4ccnc5ccccc45)cc3)n2)cc1
5317,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,Cc1cc(C=C(C#N)C#N)cc(O)c1O,"2-(3,4-Dihydroxy-5-methyl-benzylidene)-malononitrile",5.6,uM,=,0.7481880270062004,1,c1ccccc1
5318,2112388,10.1016/j.bmcl.2021.127987,,,,Inhibition of EGFR (unknown origin),COc1ccc(-c2coc3cc(OCC(=O)N/C=C\c4ccc(O)cc4)ccc3c2=O)cc1,N-(4-hydroxystyryl)-2-(3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yloxy)acetamide,0.0331,uM,=,-1.4801720062242811,0,O=C(COc1ccc2c(=O)c(-c3ccccc3)coc2c1)N/C=C\c1ccccc1
5319,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1.O,Tykerb,0.011,uM,=,-1.958607314841775,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1.c1ccccc1.c1ccccc1
5320,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCOCC5)c(C)c4)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-morpholinophenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.626,uM,=,-0.2034256667895703,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCOCC4)cc3)nc2N1[C@H]1CCNC1
5321,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CN1CCN(C/C=C/C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cn2)CC1,"(2E)-N-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(4-methyl-1-piperazinyl)-2-butenamide",0.009,uM,=,-2.0457574905606752,0,O=C(/C=C/CN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
5322,1472645,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) after 40 mins by scintillation proximity assay,Fc1cccc(COc2ccc(Nc3ncnc4sc(C#CC5CCCN5)cc34)cc2Cl)c1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(pyrrolidin-2-ylethynyl)thieno[2,3-d]pyrimidin-4-amine",0.109,uM,=,-0.9625735020593764,0,C(#CC1CCCN1)c1cc2c(Nc3ccc(OCc4ccccc4)cc3)ncnc2s1
5323,2272590,10.1016/j.ejmech.2021.113865,,,,Inhibition of human EGFR,COc1ccc2nc(Cl)c(C3CC(c4ccc(C)cc4)=NN3c3nc(C)c(C(=O)Nc4ccccc4)s3)cc2c1,"2-(5-(2-chloro-6-methoxyquinolin-3-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-methyl-N-phenylthiazole-5-carboxamide",0.04252,uM,=,-1.3714067441487408,0,O=C(Nc1ccccc1)c1cnc(N2N=C(c3ccccc3)CC2c2cnc3ccccc3c2)s1
5324,86514,10.1021/jm00110a022,,,,Inhibition of HER14 (human EGFR overexpressing) cell proliferation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccccc1,"2-Benzoyl-3-(3,4-dihydroxy-phenyl)-acrylonitrile",15.0,uM,=,1.1760912590556811,1,O=C(C=Cc1ccccc1)c1ccccc1
5325,2017350,10.1021/acs.jmedchem.0c00870,,,,Inhibiton of EGFR (unknown origin) expressed in human A431 cells assessed as reduction in EGFR induced cell viability after 96 hrs by CellTiter-Glo assay,C=CC(=O)Nc1cc(-c2c[nH]c3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c23)ccc1OCCO,"N-{5-{4-[(1-Benzyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]-pyrimidin-5-yl}-2-(2-hydroxyethoxy)phenyl}acrylamide",2.236,uM,=,0.3494717992143857,1,c1ccc(Cn2ncc3cc(Nc4ncnc5[nH]cc(-c6ccccc6)c45)ccc32)cc1
5326,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,O=C(NCCN1CCCCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-Bromophenyl)amino)quinazolin-6-yl)-3-(2-(piperidin-1-yl)ethyl)urea,0.000772,uM,=,-3.112382699664264,0,O=C(NCCN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5327,2224501,10.1016/j.bmc.2021.116534,,,,Inhibition of EGFR in human A-431 cell membrane vesicles using phospholipase C-gamma-1 as substrate incubated for 10 mins by scintillation counter method,Brc1cccc(Nc2ncnc3c2[nH]c2ccccc23)c1,"N-(3-bromophenyl)-5H-pyrimido[5,4-b]indol-4-amine",0.072,uM,=,-1.1426675035687317,0,c1ccc(Nc2ncnc3c2[nH]c2ccccc23)cc1
5328,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0138,uM,=,-1.8601209135987635,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5329,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1cccc(CNC(=O)/C(C#N)=C/c2ccc(O)c(O)c2)c1,"(E)-2-Cyano-N-(3-{[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-methyl}-benzyl)-3-(3,4-dihydroxy-phenyl)-acrylamide",6.0,uM,=,0.7781512503836436,1,O=C(C=Cc1ccccc1)NCc1cccc(CNC(=O)/C=C/c2ccccc2)c1
5330,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccnc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-3-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.341,uM,=,-0.4672456210075022,0,c1cncc(COc2ccc(Nc3ccnc4ccccc34)cc2)c1
5331,1628132,10.1016/j.bmc.2016.10.006,,,,Inhibition of EGFR (unknown origin),C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,VARLITINIB,0.007,uM,=,-2.154901959985743,0,c1csc(COc2ccc(Nc3ncnc4ccc(NC5=NCCO5)cc34)cc2)n1
5332,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,COc1ccc(Nc2nc(C)nc3oc(C)cc23)cc1,"N-(4-Methoxyphenyl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine",0.0422,uM,=,-1.374687549038326,0,c1ccc(Nc2ncnc3occc23)cc1
5333,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccn3ccnc3c2)c2c(N)ncnc21,"3-(imidazo[1,2-a]pyridin-7-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",45.0,uM,=,1.6532125137753435,1,c1ncc2c(-c3ccn4ccnc4c3)n[nH]c2n1
5334,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(5-(5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,58.0,uM,=,1.7634279935629371,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5335,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine,28.868,uM,=,1.4604166966257357,1,c1ccc2c(c1)Nc1ccccc1S2
5336,1769307,10.1016/j.bmc.2018.02.029,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,C=CC(=O)Nc1cc(Nc2ncc3nc(Nc4ccccc4)n(C)c3n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((9-methyl-8-(phenylamino)-9H-purin-2-yl)amino)phenyl)acrylamide,0.0224,uM,=,-1.6497519816658373,0,c1ccc(Nc2ncc3nc(Nc4ccccc4)[nH]c3n2)cc1
5337,1840426,10.1016/j.ejmech.2019.01.066,,,,Inhibition of recombinant human wild-type N-terminal GST-His6-fused EGFR C-terminal domain (H672 to A1210) expressed in Sf9 insect cells using Poly(Glu:Tyr)4:1 as substrate measured after 60 mins in presence of [gamma-33P]-ATP by scintillation counting method,CN(CCc1ccc(-c2ccccc2)cc1)Cc1cn(C)c2ccc(C(=O)Nc3ccc(F)cc3)cc12,"3-(((2-([1,1'-biphenyl]-4-yl)ethyl)(methyl)amino)methyl)-N-(4-fluorophenyl)-1-methyl-1H-indole-5-carboxamide",10.0,uM,=,1.0,1,O=C(Nc1ccccc1)c1ccc2[nH]cc(CNCCc3ccc(-c4ccccc4)cc3)c2c1
5338,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0035,uM,=,-2.4559319556497243,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
5339,2278677,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced wild type EGFR phosphorylation in human A-431 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,MOBOCERTINIB,0.0345,uM,=,-1.4621809049267258,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5340,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.291,uM,=,-0.5361070110140927,0,c1ccc(Nc2ncnc3cccnc23)cc1
5341,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-Bromophenyl)amino)quinazolin-6-yl)-3-(2-(piperidin-1-yl)ethyl)thiourea,0.0107,uM,=,-1.9706162223147905,0,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5342,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3ccccc3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-phenyl-amine",0.029,uM,=,-1.537602002101044,0,c1ccc(Nc2ncnc3ccccc23)cc1
5343,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=CC(=O)N(CCN(C)C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-N-(2-dimethylamino-ethyl)-acrylamide",0.0042,uM,=,-2.3767507096021,0,c1ccc(Nc2ncnc3cnccc23)cc1
5344,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCCN(C)C,N-[4-(3-Bromo-phenylamino)-7-(4-dimethylamino-butoxy)-quinazolin-6-yl]-acrylamide,0.0039,uM,=,-2.408935392973501,0,c1ccc(Nc2ncnc3ccccc23)cc1
5345,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(Br)cc3)cc12)c1ccc(F)cc1,"(R)-6-(4-Bromophenyl)-N-(1-(4-fluorophenyl)ethyl)-7Hpyrrolo[2,3-d]pyrimidin-4-amine",0.029,uM,=,-1.537602002101044,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
5346,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(N[C@@H](CO)c3ccccc3)ncnc2s1,"(R)-2-((6-(2-Methoxyphenyl)thieno[2,3-d]pyrimidin-4-yl)amino)-2-phenylethanol",0.629,uM,=,-0.201349354554731,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
5347,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Cc1ccn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"N-(1-benzyl-1H-indazol-5-yl)-5-methylpyrrolo[1,2-f][1,2,4]triazin-4-amine",0.086,uM,=,-1.0655015487564323,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
5348,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1cccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)c1,"US9447106, 3",0.334,uM,=,-0.4762535331884355,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(c3ccccc3)CCN4)cc2)cc1
5349,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,NC1CCN(Cc2ccn3ncnc(Nc4ccc(OCc5cccnc5)c(Cl)c4)c23)CC1,"5-((4-aminopiperidin-1-yl)methyl)-N-(3-chloro-4-(pyridin-3-ylmethoxy)phenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.15,uM,=,-0.8239087409443188,0,c1cncc(COc2ccc(Nc3ncnn4ccc(CN5CCCCC5)c34)cc2)c1
5350,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,O=C(Nc1cnn(-c2ccccc2)c1)c1cccc(NS(=O)(=O)c2ccc(Cl)cc2)c1,3-((4-Chlorophenyl)sulfonamido)-N-(1-phenyl-1H-pyrazol-4-yl)benzamide,10.58,uM,=,1.024485667699167,1,O=C(Nc1cnn(-c2ccccc2)c1)c1cccc(NS(=O)(=O)c2ccccc2)c1
5351,1782454,10.1016/j.ejmech.2017.12.022,,,,Inhibition of recombinant human C-terminal His/N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using biotin-labeled poly[Glu:Tyr] (4:1) as substrate after 30 mins by Kinase-Glo plus luminescence assay,Cc1oc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1C(=O)O,"4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-methylfuro[2,3-d]pyrimidine-5-carboxylic acid",0.951,uM,=,-0.021819483062586,0,c1ccc(COc2ccc(Nc3ncnc4occc34)cc2)cc1
5352,1553877,10.1016/j.ejmech.2016.01.045,,,,Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay,COCCOc1cc2ncnc(Nc3ccc(C(=O)NC45CC6CC(CC(C6)C4)C5)cc3)c2cc1OCCOC,"N-(Adamantan-1-yl)-4-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)amino)benzamide",0.0096099999999999,uM,=,-2.0172766123314547,0,O=C(NC12CC3CC(CC(C3)C1)C2)c1ccc(Nc2ncnc3ccccc23)cc1
5353,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,Fc1ccc2c(c1)CNc1c(Nc3cccc(-c4ccccc4)c3)ncnc1O2,"Biphenyl-3-yl-(8-fluoro-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",9.9,uM,=,0.99563519459755,1,c1ccc(-c2cccc(Nc3ncnc4c3NCc3ccccc3O4)c2)cc1
5354,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N(C)C)cc3)n2)c1,N-(3-(3-(2-(4-(dimethylamino)phenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.462,uM,=,-0.3353580244438744,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccccc2)n1
5355,2224994,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin),O=C(CCCCn1cc(-c2ccc3ncnc(Nc4ccccc4F)c3c2)nn1)NO,5-[4-[4-(2-fluoroanilino)quinazolin-6-yl]triazol-1-yl]pentanehydroxamic acid,0.0103,uM,=,-1.987162775294828,0,c1ccc(Nc2ncnc3ccc(-c4c[nH]nn4)cc23)cc1
5356,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1,N-(4-(benzyloxy)-3-chlorophenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.018,uM,=,-1.744727494896694,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
5357,801719,10.1016/j.bmc.2012.01.004,,,,Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(NS(=O)(=O)c1ccc(Cl)cc1)c1cncc(Br)c1,5-bromo-N-(4-chlorophenylsulfonyl)nicotinamide,0.09,uM,=,-1.0457574905606752,0,O=C(NS(=O)(=O)c1ccccc1)c1cccnc1
5358,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",CN(C)CCCNC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(3-(dimethylamino)propyl)urea,0.024,uM,=,-1.619788758288394,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
5359,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)c2cc1NC(=O)/C=C/CN1CCN(C)CC1,(2E)-N-(7-Ethoxy-4-{4-[(phenylsulfonyl)amino]anilino}-6-quinazolinyl)-4-(4-methyl-1-piperazinyl)-2-butenamide,0.39,uM,=,-0.4089353929735008,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)c2c1
5360,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,Cc1ccc(C2=NN(C(N)=S)C(c3ccccc3Cl)C2)cc1C,"5-(2-Chlorophenyl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",3.87,uM,=,0.5877109650189114,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
5361,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CN(C)C(=O)N1CCN(C/C=C/C(=O)N2CCc3c(sc4ncnc(Nc5ccc(F)c(Cl)c5)c34)C2)CC1,"US8524722, 70",0.001,uM,=,-3.0,0,O=C(/C=C/CN1CCNCC1)N1CCc2c(sc3ncnc(Nc4ccccc4)c23)C1
5362,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"methyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidine-5-carboxylate",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)cc1
5363,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)C1=CCCC1,N-{4-(3-Chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl}-1-cyclopentene-1-carboxamide,0.026,uM,=,-1.585026652029182,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)C1=CCCC1
5364,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,CCOc1cc2ncnc(NCc3ccc(F)cc3)c2cc1OCC.Cl,"4-[(4'-fluorobenzyl)amino]-6,7-diethoxyquinazoline hydrochloride",0.0066,uM,=,-2.1804560644581312,0,c1ccc(CNc2ncnc3ccccc23)cc1
5365,1739299,10.1016/j.ejmech.2018.05.006,,,,Inhibition of wild type EGFR (unknown origin) using FAM-labeled peptide substrate after 10 mins by mobility shift assay,COc1cc2ncnc(N3CCc4ccccc43)c2cc1NC(=O)/C=C/CN1CCCCC1,(E)-N-(4-(indolin-1-yl)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide,0.0453999999999999,uM,=,-1.3429441471428962,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(N3CCc4ccccc43)c2c1
5366,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),c1ccc(CNc2ncnc3c2sc2ccccc23)cc1,"Benzo[4,5]thieno[3,2-d]pyrimidin-4-yl-benzyl-amine",0.191,uM,=,-0.7189666327522725,0,c1ccc(CNc2ncnc3c2sc2ccccc23)cc1
5367,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,C/C=C(\C)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-2-methylbut-2-enamide",6.414,uM,=,0.8071289555924216,1,c1ccc(Nc2ncnc3sccc23)cc1
5368,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1SCCCN(CC)CC,N-[4-(3-Bromo-phenylamino)-7-(3-diethylamino-propylsulfanyl)-quinazolin-6-yl]-acrylamide,0.196,uM,=,-0.707743928643524,0,c1ccc(Nc2ncnc3ccccc23)cc1
5369,1914926,10.1016/j.ejmech.2019.111943,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669-1210 AA) expressed in baculovirus using FAM-labelled peptide as substrate pre-incubated for 10 mins followed by substrate addition by mobility shift assay,Cc1cc(F)cc(Nc2cc(NC(=O)Nc3c(Cl)cccc3Cl)ncn2)c1,"1-(2,6-dichlorophenyl)-3-(6-((3-fluoro-5-methylphenyl)amino)pyrimidin-4-yl)urea",0.528,uM,=,-0.2773660774661877,0,O=C(Nc1ccccc1)Nc1cc(Nc2ccccc2)ncn1
5370,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(/C=C/c1cccc([N+](=O)[O-])c1)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,(E)-N-(4-(3-Chlorophenylamino)quinazolin-6-yl)-3-(3-nitrophenyl)acrylamide,0.19,uM,=,-0.721246399047171,0,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5371,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CCOc1cc(/C=C(\C#N)C(N)=O)cc(CSc2cccc(OC)c2)c1O,2-cyano-3-(3-ethoxy-4-hydroxy-5-((3-methoxyphenylthio)methyl)phenyl)acrylamide,4.0,uM,=,0.6020599913279624,1,c1ccc(CSc2ccccc2)cc1
5372,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(OCCCc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3-phenyl-propyl ester",1.5,uM,=,0.1760912590556812,1,O=C(OCCCc1ccccc1)c1cccc(NCc2ccccc2)c1
5373,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,CC/C=C\C(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccc(F)cc34)n2)c(OC)cc1N(C)CCN(C)C,(Z)-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(5-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)pent-2-enamide,0.684,uM,=,-0.1649438982798837,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5374,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,OCC#Cc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,3-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)prop-2-yn-1-ol,0.0141,uM,=,-1.85078088734462,0,c1ccc(Nc2ncnc3ccccc23)cc1
5375,63780,10.1016/j.bmcl.2004.01.034,,,,Inhibition of epidermal growth factor receptor kinase autophosphorylation,CC#CC(=O)Nc1cnc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2c1,"But-2-ynoic acid [5-(3-chloro-4-fluoro-phenylamino)-6-cyano-[1,8]naphthyridin-3-yl]-amide",6.7948,uM,=,0.8321766781141817,1,c1ccc(Nc2ccnc3ncccc23)cc1
5376,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCn4ccnc4[N+](=O)[O-])cc23)c1,N-(3-ethynylphenyl)-7-methoxy-6-((6-(2-nitro-1H-imidazol-1-yl)hexyl)oxy)quinazolin-4-amine,0.0005,uM,=,-3.3010299956639813,0,c1ccc(Nc2ncnc3ccc(OCCCCCCn4ccnc4)cc23)cc1
5377,5008,10.1016/s0960-894x(01)00776-4,,,,Inhibition of EGFR overexpressing A431 cell proliferation,COc1cc2cc3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3cc2cc1OC,"4-(3-Chloro-4-fluoro-phenylamino)-7,8-dimethoxy-benzo[g]quinoline-3-carbonitrile",0.68,uM,=,-0.1674910872937636,0,c1ccc(Nc2ccnc3cc4ccccc4cc23)cc1
5378,1642158,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
5379,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,O=C(Nc1ccncc1)Nc1cc(-c2cccnc2)ccc1OC(F)(F)F,1-(5-(Pyridin-3-yl)-2-(trifluoromethoxy)phenyl)-3-(pyridin-4-yl)urea,0.09722,uM,=,-1.0122443832614767,0,O=C(Nc1ccncc1)Nc1cccc(-c2cccnc2)c1
5380,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)C4CC4)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1,"(S)-3-(2-Chlorophenyl)-1-(1-(cyclopropanecarbonyl)-pyrrolidin-3-yl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)-phenyl)amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0287,uM,=,-1.5421181032660076,0,O=C(C1CC1)N1CC[C@H](N2C(=O)N(c3ccccc3)Cc3cnc(Nc4ccc(N5CCNCC5)cc4)nc32)C1
5381,63764,10.1021/jm960689b,,,,Inhibition of epidermal growth factor receptor (EGFr),CNC(=O)c1c([Se][Se]c2c(C(=O)NC)c3ccccc3n2C)n(C)c2ccccc12,"2,2'-Diselenobis[N,1-dimethyl-1H-indole-3-carboxamide]",6.1,uM,=,0.785329835010767,1,c1ccc2[nH]c([Se][Se]c3cc4ccccc4[nH]3)cc2c1
5382,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC.Cl,"4-(3'-bromoanilino)-6,7-diethoxyquinazoline hydrochloride",0.0032,uM,=,-2.494850021680094,0,c1ccc(Nc2ncnc3ccccc23)cc1
5383,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,Cn1ccnc1S(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1,N-(4-(3-fluorobenzyloxy)-3-(trifluoromethyl)phenyl)-6-(5-((2-(1-methyl-1H-imidazol-2-ylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.017,uM,=,-1.769551078621726,0,O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1)c1ncc[nH]1
5384,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,CC(=O)CCCSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,5-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)pentan-2-one,0.185,uM,=,-0.7328282715969863,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
5385,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Fc1ccc(Br)cc1Nc1ncnc2cc3c(cc12)OCCO3,"N-(5-Bromo-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0111,uM,=,-1.9546770212133424,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
5386,2123527,10.1016/j.ejmech.2021.113778,,,,Inhibition of EGFR (unknown origin),COCCOc1cc2ncnc(Sc3nc[nH]n3)c2cc1OCCOC,"4-((1H-1,2,4-triazol-3-yl)thio)-6,7-bis(2-methoxyethoxy)quinazoline",5.21,uM,=,0.7168377232995244,1,c1ccc2c(Sc3nc[nH]n3)ncnc2c1
5387,67049,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor,COc1cc(O)c2c(=O)c(-c3cccc(Cl)c3)cn(C)c2c1,3-(3-Chloro-phenyl)-5-hydroxy-7-methoxy-1-methyl-1H-quinolin-4-one,0.17,uM,=,-0.7695510786217261,0,O=c1c(-c2ccccc2)c[nH]c2ccccc12
5388,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CN1CC[C@@H](C(N)=O)C1,(R)-1-((4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidine-3-carboxamide,0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
5389,1541392,10.1016/j.ejmech.2015.09.031,,,,Inhibition of wild type recombinant human EGFR preincubated for 10 mins followed by FAM-labeled peptide/ATP addition measured after 1 hr by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cccc(Nc2nc(N/N=C/c3ccc(F)cc3)ncc2Cl)c1,(E)-N-(3-(5-Chloro-2-((E)-2-(2-fluorobenzylidene)hydrazinyl)pyrimidin-4-ylamino)phenyl)-4-(dimethylamino)but-2-enamide,10.65,uM,=,1.0273496077747566,1,C(=N/Nc1nccc(Nc2ccccc2)n1)\c1ccccc1
5390,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(N2C(=O)C(C)N(C)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6,7-dimethyl-5,8-dioxo-7,8-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-9(6H)-yl)phenyl)acrylamide",0.02212,uM,=,-1.6552148773673394,0,O=C1NCC(=O)N(c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc21
5391,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),CC(=O)OC(Cc1c(SSc2[nH]c3ccccc3c2CC(OC(C)=O)C(=O)NCc2ccccc2)[nH]c2ccccc12)C(=O)NCc1ccccc1,Acetic acid 2-{2-[3-(2-acetoxy-2-benzylcarbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-1-benzylcarbamoyl-ethyl ester,28.0,uM,=,1.4471580313422192,1,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
5392,2076853,10.1039/d0md00436g,,,,Inhibition of human EGFR TK domain expressed in Escherichia coli BL21 (DE3) pLysS using poly-Glu-Tyr (51 to 68 residues) as substrate incubated for 1 hr by ADP-Glo assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.02846,uM,=,-1.5457651042517344,0,c1ccc(Nc2ncnc3ccccc23)cc1
5393,935919,10.1016/j.bmcl.2012.11.001,,,,Inhibition of EGFR (unknown origin) by Z-LYTE assay,CC1=CCC[C@H]2[C@](C)(CC3=C(O)C(=O)C=C(N[C@@H](CO)C(=O)O)C3=O)[C@@H](C)CC[C@]12C,Nakijiquinone C,289.86798610708297,uM,=,2.46220025321364,1,O=C1C=CC(=O)C(CC2CCCC3C=CCC[C@H]32)=C1
5394,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccc(Br)cc3)CC2c2ccc(Br)cc2)=N1,"2-(3,5-Bis(4-bromophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",2.03,uM,=,0.3074960379132129,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
5395,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(C3CC3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.7,uM,=,-0.1549019599857432,0,c1ncc2c(C3CC3)nn([C@@H]3CCCNC3)c2n1
5396,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Nc1ccc2ncnc(Nc3cccc(C(F)(F)F)c3)c2c1,"N*4*-(3-Trifluoromethyl-phenyl)-quinazoline-4,6-diamine",0.574,uM,=,-0.2410881076020265,0,c1ccc(Nc2ncnc3ccccc23)cc1
5397,946709,10.1016/j.bmc.2012.12.045,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,Nc1nc(Nc2cccc(Br)c2)c2cc(CCc3ccccn3)[nH]c2n1,"N4-(3-Bromophenyl)-6-(2-pyridin-2-yl-ethyl)-7Hpyrrolo[2,3-d]pyrimidine-2,4-diamine",0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3[nH]c(CCc4ccccn4)cc23)cc1
5398,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,(4-Chloro-phenyl)-(4-pyridin-4-ylmethyl-phthalazin-1-yl)-amine,0.4577,uM,=,-0.3394190875727004,0,c1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
5399,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,O=C(C#CCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]-5-(4-morpholinyl)-2-pentynamide,0.012,uM,=,-1.9208187539523751,0,O=C(C#CCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5400,942125,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin) using biotinylated-PTP1B (Tyr66) as substrate incubated for 5 mins prior to substrate addition measured after 1 hr by ELISA,COc1cc2ncnc(Nc3cccc(C#N)c3)c2cc1OC,"3-(6,7-Dimethoxyquinazolin-4-ylamino)benzonitrile",0.4128,uM,=,-0.384260311380845,0,c1ccc(Nc2ncnc3ccccc23)cc1
5401,1641793,,,,,"Cell Proliferation Inhibition Assay: The following in vitro assay is to determine the activity of the tested compounds for inhibiting the proliferation of cancer cells, which has high expression of EGFR. The activity is represented by the IC50 value. The general procedures of the assay are given as follows: The cancer cells A431 that highly expressing EGFR (Institute of biochemistry and cell biology) were chosen and seeded to 96-well cell culture plate at a suitable concentration (e.g., 5000 cells/mL medium). The cells then were incubated in carbon dioxide (CO2) incubator until they reached 85% confluency. Then, the cell culture medium was replaced by fresh one with tested compounds added in it at serial concentrations (general 6 to 7 concentrations). Then the cells were put back to the incubator and cultured continuously. 72 hours later, the activity of the tested compounds for inhibiting the cell proliferation was determined by using Sulforhodamine B (SRB) method.",CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@@H]1CCCN1C,"US8901140, 1::US9358227, 1",0.022,uM,=,-1.6575773191777938,0,O=C(/C=C/[C@@H]1CCCN1)Nc1ccc2nccc(Nc3ccc(OCc4ccccn4)cc3)c2c1
5402,2225014,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin) by microplate reader,NS(=O)(=O)c1ccc(NC(=O)c2ccccc2NC(=O)c2ccco2)cc1,N-{2-[(4-sulfamoylphenyl)carbamoyl]phenyl}furan-2-carboxamide,0.0312,uM,=,-1.5058454059815571,0,O=C(Nc1ccccc1C(=O)Nc1ccccc1)c1ccco1
5403,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1,7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.0024,uM,=,-2.619788758288394,0,c1ccc(Nc2ncnc3ccccc23)cc1
5404,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(CC)c3n2)C[C@H]1F,"N-((3R,4R)-1-(9-Ethyl-6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9H-purin-2-yl)-4-fluoropyrrolidin-3-yl)acrylamide",0.083,uM,=,-1.080921907623926,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1
5405,2207742,10.1021/acs.jmedchem.2c00893,,,,Inhibition of wild type EGFR expressed in human A-431 cells,O=C(Nc1nccs1)C(c1cc(F)ccc1O)N1Cc2ccc(-c3ccc(N4CCNCC4)cc3)cc2C1=O,2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-6-(4-(piperazin-1-yl)phenyl)isoindolin-2-yl)-N-(thiazol-2-yl)acetamide,4.213,uM,=,0.6245914591268478,1,O=C(Nc1nccs1)C(c1ccccc1)N1Cc2ccc(-c3ccc(N4CCNCC4)cc3)cc2C1=O
5406,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",O=C(Nc1ccc(Br)cc1)c1cc(Br)cc(Br)c1O,"3,5-Dibromo-N-(4-bromo-phenyl)-2-hydroxy-benzamide",2.987,uM,=,0.4752352226041283,1,O=C(Nc1ccccc1)c1ccccc1
5407,933957,10.1016/j.bmcl.2012.12.028,,,,Inhibition of EGFR (unknown origin) in presence of ATP,CN1CCC(NC(=O)c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2NC2CCC(N(C)C)CC2)CC1,"2-(3,5-dichlorophenylamino)-4-(4-(dimethylamino)cyclohexylamino)-N-(1-methylpiperidin-4-yl)pyrimidine-5-carboxamide",30.0,uM,=,1.4771212547196624,1,O=C(NC1CCNCC1)c1cnc(Nc2ccccc2)nc1NC1CCCCC1
5408,2112388,10.1016/j.bmcl.2021.127987,,,,Inhibition of EGFR (unknown origin),CN(C(=O)NCCCl)c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,3-(2-chloroethyl)-1-(4-(3-chlorophenylamino)quinazolin-6-yl)-1-methylurea,0.081,uM,=,-1.0915149811213505,0,c1ccc(Nc2ncnc3ccccc23)cc1
5409,1299287,10.1039/C3MD00096F,,,,Inhibition of EGFR (unknown origin) after 1 hr by Caliper mobility shift assay,CCN(CCO)CCCOc1ccc2c(Nc3cccc(NC(=O)Nc4ccc(F)c(Cl)c4)c3)ncnc2c1,1-(3-Chloro-4-fluorophenyl)-3-(3-(7-(3-(ethyl(2-hydroxyethyl)-amino)propoxy)quinazolin-4-ylamino)phenyl)urea,0.165,uM,=,-0.7825160557860937,0,O=C(Nc1ccccc1)Nc1cccc(Nc2ncnc3ccccc23)c1
5410,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(NCc3ccc(Br)cc3)c2cn1,"N*4*-(4-Bromo-benzyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",2.46,uM,=,0.3909351071033791,1,c1ccc(CNc2ncnc3ccncc23)cc1
5411,2107115,10.1016/j.ejmech.2021.113300,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,NS(=O)(=O)c1ccc(NC(=S)Nc2ccc3ncnc(Nc4cccc(C(F)(F)F)c4)c3c2)cc1,4-(3-(4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-yl)thioureido)benzenesulfonamide,0.0512,uM,=,-1.2907300390241692,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5412,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(NCc3ccccc3N)c2cn1,"N*4*-(2-Amino-benzyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.23,uM,=,-0.6382721639824072,0,c1ccc(CNc2ncnc3ccncc23)cc1
5413,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C1CC1,(E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-4-(cyclopropyl(methyl)amino)but-2-enamide,0.0269,uM,=,-1.570247719997592,0,O=C(/C=C/CNC1CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5414,1291543,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCCCC2)CCO4)c1,"1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(piperidin-1-yl)but-2-en-1-one",0.042,uM,=,-1.3767507096020994,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
5415,67049,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor,COC(=O)Cn1cc(-c2cccc(Cl)c2)c(=O)c2c(O)cc(OC)cc21,[3-(3-Chloro-phenyl)-5-hydroxy-7-methoxy-4-oxo-4H-quinolin-1-yl]-acetic acid methyl ester,0.064,uM,=,-1.193820026016113,0,O=c1c(-c2ccccc2)c[nH]c2ccccc12
5416,835647,10.1016/j.bmcl.2012.07.079,,,,Inhibition of EGFR in human A431 cell lysate using tyrosine/glutamic acid polymer as substrate by ELISA,Brc1cccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCCCO5)cc23)c1,"N4-(3-bromophenyl)-N6-((3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)methyl)quinazoline-4,6-diamine",0.098,uM,=,-1.0087739243075051,0,c1ccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCCCO5)cc23)cc1
5417,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,N#Cc1cnc2ccc(NC(=O)C#CCN3CCSCC3)cc2c1Nc1cccc(Br)c1,4-Thiomorpholin-4-yl-but-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.55,uM,=,-0.2596373105057561,0,O=C(C#CCN1CCSCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
5418,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cc(C(N)=O)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2s1,"(S)-4-(4-((2-Hydroxy-1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)-3-methoxybenzamide",0.0015,uM,=,-2.8239087409443187,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
5419,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,COc1cc2nccc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/C(C)N(C)C,N-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinolin-6-yl)-4-(dimethylamino)pent-2-enamide,5.22,uM,=,0.7176705030022621,1,c1ccc(Nc2ccnc3ccccc23)cc1
5420,523777,10.1016/j.bmcl.2009.05.009,,,,Inhibition of EGFR,CCCN1CCC(n2cc(CNc3cc(Cl)c4ncc(C#N)c(Nc5ccc(F)c(Cl)c5)c4c3)nn2)CC1,"8-chloro-4-(3-chloro-4-fluorophenylamino)-6-((1-(1-propylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)methylamino)quinoline-3-carbonitrile",30.0,uM,=,1.4771212547196624,1,c1ccc(Nc2ccnc3ccc(NCc4cn(C5CCNCC5)nn4)cc23)cc1
5421,1348544,10.1016/j.bmcl.2014.03.072,,,,Inhibition of autophosphorylation of recombinant his-tagged EGFR (amino acid 645-1186) (unknown origin) expressed in Sf-9 cells after 10 mins by time-resolved fluorometry,Cc1ccc(C2=NN(C3=NC(=O)CS3)C(c3cccc4ccccc34)C2)cc1C,"2-(3-(3,4-dimethylphenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",1.32,uM,=,0.1205739312058498,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2cccc3ccccc23)=N1
5422,840627,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR-mediated intracellular tyrosine phosphorylation in EGF-stimulated human A431 cells after 2.5 hrs by SDS-PAGE analysis,Fc1ccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)cc1Cl,"N-(3-chloro-4-fluorophenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododeca[2,3-g]quinazolin-4-amine",0.045,uM,=,-1.3467874862246565,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)cc1
5423,409715,10.1021/jm060434q,,,,Inhibition of recombinant EGFR by ELISA,Clc1ccc2c(c1Nc1ncnc3cc(OCCCN4CCCC4)cc(OC4CCOCC4)c13)OCO2,"N-(5-chlorobenzo[d][1,3]dioxol-4-yl)-7-(3-(pyrrolidin-1-yl)propoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine",0.9,uM,=,-0.0457574905606751,0,c1cc(Nc2ncnc3cc(OCCCN4CCCC4)cc(OC4CCOCC4)c23)c2c(c1)OCO2
5424,793571,10.1016/j.bmc.2011.11.058,,,,Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA,COc1ccc(OC)c(Cc2cc3c(Nc4cccc(Br)c4)nc(N)nc3[nH]2)c1,"N4-(3-bromophenyl)-6-(2,5-dimethoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",0.24,uM,=,-0.619788758288394,0,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
5425,741313,10.1016/j.bmcl.2011.02.075,,,,Inhibition of EGFR,COc1cc(Nc2nccc(Nc3cnc4ccccc4c3)n2)cc(OC)c1OC,"N4-(quinolin-3-yl)-N2-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine",0.853,uM,=,-0.0690509688324769,0,c1ccc(Nc2nccc(Nc3cnc4ccccc4c3)n2)cc1
5426,67049,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor,O=c1c(-c2cccc(Cl)c2)coc2cc(O)ccc12,3-(3-Chloro-phenyl)-7-hydroxy-chromen-4-one,58.8,uM,=,1.7693773260761383,1,O=c1c(-c2ccccc2)coc2ccccc12
5427,2059412,10.1016/j.bmc.2021.116061,,,,Inhibition of EGFR in human A431 cells preincubated for 60 mins followed by EGF stimulation and measured after 10 mins by ELISA,COc1ccc2c(c1)CCCN2c1nc(Cl)nc2ccccc12,"N-(2'-Chloroquinazol-4'-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline",0.0054,uM,=,-2.2676062401770314,0,c1ccc2c(c1)CCCN2c1ncnc2ccccc12
5428,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCc2ccccc2)c1O,3-(3-Benzylsulfanylmethyl-4-hydroxy-5-methoxy-phenyl)-2-cyano-acrylamide,12.5,uM,=,1.0969100130080565,1,c1ccc(CSCc2ccccc2)cc1
5429,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(5-(4-(1H-indol-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,33.0,uM,=,1.5185139398778875,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5430,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CN(C)c1cc2ncnc(Nc3cccc(Br)c3)c2cc1[N+](=O)[O-],"N*4*-(3-Bromo-phenyl)-N*7*,N*7*-dimethyl-6-nitro-quinazoline-4,7-diamine",2.0,uM,=,0.3010299956639812,1,c1ccc(Nc2ncnc3ccccc23)cc1
5431,519199,10.1016/j.ejmech.2007.09.018,,,,Inhibition of human EGFR tyrosine kinase activity,COc1cc2ncnc(-c3c[nH]c4cc(F)c(Cl)cc34)c2cc1OCCCN1CCOCC1,4-(5-Chloro-6-fluoroindole-3-yl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazoline,0.333,uM,=,-0.4775557664936801,0,c1ccc2c(-c3ncnc4ccc(OCCCN5CCOCC5)cc34)c[nH]c2c1
5432,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccccc3OC)ncc2F)c1,"US9238629, I-19",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
5433,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccc(F)cc3)CC2c2ccc(F)cc2)=N1,"2-(3,5-Bis(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",16.92,uM,=,1.2284003587030048,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
5434,1695880,10.1016/j.bmcl.2017.08.035,,,,Inhibition of wild type recombinant EGFR (unknown origin) by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCCN4C[C@H](O)[C@@H](O)[C@H](O)[C@H]4CO)c(OC)cc23)c1,"4-(3-ethynylphenylamino)-6-methoxy-7-(3-((2R,3R,4R,5S)-2-hydroxymethyl-3,4,5-trihydroxy-1-piperidyl)propoxy)quinazoline",0.00487,uM,=,-2.312471038785365,0,c1ccc(Nc2ncnc3cc(OCCCN4CCCCC4)ccc23)cc1
5435,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1,"propyl 4-(6,7-dimethoxyquinazolin-4-ylamino)phenylcarbamate",7.05,uM,=,0.8481891169913987,1,c1ccc(Nc2ncnc3ccccc23)cc1
5436,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Clc1cccc(Nc2[nH]nc3ncnc(Nc4ccccc4)c23)c1,"N*3*-(3-Chloro-phenyl)-N*4*-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.084,uM,=,-1.0757207139381184,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
5437,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N1CC(N(C)C)C1,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-2-(3-(dimethylamino)azetidin-1-yl)-4-methoxyphenyl)acrylamide",0.0639,uM,=,-1.1944991418415998,0,c1cc2c3c(c1)c(-c1ccnc(Nc4ccc(N5CCC5)cc4)n1)cn3CCC2
5438,942125,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin) using biotinylated-PTP1B (Tyr66) as substrate incubated for 5 mins prior to substrate addition measured after 1 hr by ELISA,COc1cc2ncnc(Nc3ccccc3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-phenyl-amine",0.201,uM,=,-0.6968039425795112,0,c1ccc(Nc2ncnc3ccccc23)cc1
5439,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC)cc3)nn21,"US9447106, 94",0.099,uM,=,-1.00436480540245,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1
5440,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCCCC5)cc4)nc32)c1,N-(3-(7-Oxo-2-(4-(piperidin-1-yl)phenylamino)pteridin-8(7H)-yl)phenyl)acrylamide,0.0157,uM,=,-1.8041003475907664,0,O=c1cnc2cnc(Nc3ccc(N4CCCCC4)cc3)nc2n1-c1ccccc1
5441,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C(=O)/C=C/C,(E)-N-(2-((2-acrylamido-5-methoxy-4-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)-N-methylbut-2-enamide,0.9024,uM,=,-0.0446009133607329,0,c1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1
5442,1338035,10.1016/j.ejmech.2014.02.032,,,,Inhibition of EGFR (unknown origin) after 1.5 hr by FRET-based Z-lyte assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)CCN3CCCC3)c2)n1,N-(3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)-3-(pyrrolidin-1-yl)propanamide,0.525,uM,=,-0.2798406965940431,0,O=C(CCN1CCCC1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
5443,2080997,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(CCCC(=O)NO)nn1,"4-(4-(((6-Acrylamido-4-((3-chloro-4-fluorophenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutanamide",0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
5444,2088168,10.1016/j.ejmech.2020.112363,,,,Inhibition of EGFR (unknown origin) by FRET assay,O=S(=O)(Nc1nccs1)c1ccc(NC(=S)Nc2ccc3c(c2)OCO3)cc1,"4-(3-Benzo[d][1,3]dioxol-5-ylthioureido)-N-(thiazol-2-yl)benzenesulfonamide",1.6230000000000002,uM,=,0.2103185198262319,1,O=S(=O)(Nc1nccs1)c1ccc(NC(=S)Nc2ccc3c(c2)OCO3)cc1
5445,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=S)NCCN5CCOCC5)cc34)cc2Cl)c1,1-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)thiourea,0.00226,uM,=,-2.6458915608525992,0,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
5446,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2=NN(c3nc(-c4ccc(Cl)cc4)cs3)C(c3ccc(F)cc3)C2)cc1C,"4-(4-chlorophenyl)-2-(3-(3,4-dimethylphenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazole",0.06,uM,=,-1.2218487496163564,0,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
5447,850422,10.1016/j.bmc.2012.08.002,,,,Inhibition of human N-terminal DYKDDDD tagged EGFR cytoplasmic domain amino acid 669 to 1210 expressed in baculovirus after 5 mins by scintillation counter,CC(C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(Cl)c4)c(Cl)c3)c21)S(C)(=O)=O,"N-[2-(4-{[3-Chloro-4-(3-chlorophenoxy)phenyl]amino}-5Hpyrrolo[3,2-d]pyrimidin-5-yl)ethyl]-2-(methylsulfonyl)propanamide",0.0098,uM,=,-2.008773924307505,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
5448,946709,10.1016/j.bmc.2012.12.045,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,CC(C)(C)C(=O)Nc1nc(Nc2ccc(F)c(Cl)c2)c2cc(CCc3ccccn3)[nH]c2n1,"N-{4-[(3-Chloro,4-fluorophenyl)amino]-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl}-2,2-dimethylpropanamide",16.3,uM,=,1.212187604403958,1,c1ccc(Nc2ncnc3[nH]c(CCc4ccccn4)cc23)cc1
5449,1770089,10.1016/j.bmcl.2017.12.009,,,,Inhibition of wild-type EGFR phosphorylation in human A431 cells preincubated for 1 hr followed by EGF stimulation measured after 45 mins by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-10",1.034,uM,=,0.0145205387579237,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5450,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1,"1-isopropyl-3-(3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2n[nH]c3ncncc23)cc1
5451,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,Brc1cccc(Nc2ncnc3cnc(NCCCN4CCOCC4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-(3-morpholin-4-yl-propyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3cnc(NCCCN4CCOCC4)cc23)cc1
5452,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CCN(C(=O)CNC)CC1,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-(2-(methylamino)acetyl)piperazin-1-yl)phenyl)acrylamide",7500.0,uM,=,3.8750612633917,1,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c2c1
5453,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)nc3[nH]ccc23)CC1,"1-(4-((2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.0368,uM,=,-1.4341521813264824,0,c1cc2c(OC3CCNCC3)nc(Nc3ccc(N4CCNCC4)cc3)nc2[nH]1
5454,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,CCN1CCN(CC#CC(=O)Nc2ccc3nccc(Oc4ccc(C(=O)Nc5ccccn5)cc4)c3c2)CC1,4-(6-(4-(4-ethylpiperazin-1-yl)but-2-ynamido)quinolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.055,uM,=,-1.259637310505756,0,O=C(C#CCN1CCNCC1)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1
5455,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccc(O)cc2)c1O,2-Cyano-3-[4-hydroxy-3-(4-hydroxy-phenylsulfanylmethyl)-5-methoxy-phenyl]-acrylamide,2.0,uM,=,0.3010299956639812,1,c1ccc(CSc2ccccc2)cc1
5456,1897498,10.1016/j.bmc.2019.07.042,,,,Inhibition of EGFR-TK in human HeLa cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",2.72,uM,=,0.4345689040341987,1,c1ccc(Nc2ncnc3ccccc23)cc1
5457,2272590,10.1016/j.ejmech.2021.113865,,,,Inhibition of human EGFR,COc1ccc2nc(Cl)c(C3CC(c4ccc(C)cc4)=NN3c3nc(-c4ccc(F)cc4)cs3)cc2c1,"2-(5-(2-chloro-6-methoxyquinolin-3-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-fluorophenyl)thiazole",0.0318,uM,=,-1.4975728800155672,0,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3cnc4ccccc4c3)C2)cc1
5458,933957,10.1016/j.bmcl.2012.12.028,,,,Inhibition of EGFR (unknown origin) in presence of ATP,Cc1cc(-c2cnc(Nc3cc(Cl)cc(Cl)c3)nc2NC2CCC(N(C)C)CC2)on1,"N2-(3,5-dichlorophenyl)-N4-(4-(dimethylamino)cyclohexyl)-5-(3-methylisoxazol-5-yl)pyrimidine-2,4-diamine",0.59,uM,=,-0.2291479883578558,0,c1ccc(Nc2ncc(-c3ccno3)c(NC3CCCCC3)n2)cc1
5459,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,CC(C)NC/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,"(S,E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(isopropylamino)but-2-enamide",0.007,uM,=,-2.154901959985743,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
5460,4991,10.1016/S0960-894X(97)10117-2,,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,COc1cc2nccc(Oc3cccc(Br)c3)c2cc1OC,"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline",2.5,uM,=,0.3979400086720376,1,c1ccc(Oc2ccnc3ccccc23)cc1
5461,792073,10.1016/j.bmc.2011.10.085,,,,Inhibition of EGFR expressed in baculovirus infected Sf9 cells assessed as inhibition of autophosphorylation preincubated for 10 mins measured after 1 hr by DELFIA/Time-Resolved Fluorometry,Brc1ccc(CNc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)cc1,"N6-(4-Bromobenzyl)-N4-(3-bromophenyl)quinazoline-4,6-diamine",3.13,uM,=,0.4955443375464484,1,c1ccc(CNc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
5462,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1C[C@@H](C)N[C@@H](C)C1,"(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-((3S,5R)-3,5-dimethylpiperazin-1-yl)but-2-enamide",0.017,uM,=,-1.769551078621726,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
5463,2017353,10.1021/acs.jmedchem.0c00870,,,,Inhibition of human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using TK as substrate preincubated for 30 mins followed by substrate addition and measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(-c2c[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)ccc1OCCN(C)C,"N-{5-{4-{[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-[2-(dimethylamino)ethoxy]phenyl}-acrylamide",8.999999999999999e-05,uM,=,-4.045757490560675,0,c1ccc(-c2c[nH]c3ncnc(Nc4ccc(OCc5ccccn5)cc4)c23)cc1
5464,1566936,10.1021/acs.jmedchem.5b01633,,,,Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA,C#CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(prop-2-yn-1-yloxy)quinazolin-6-yl)acrylamide,0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3ccccc23)cc1
5465,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,NC(=O)COCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"2-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methoxy)acetamide",0.14,uM,=,-0.8538719643217619,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
5466,2225014,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin) by microplate reader,O=C(Nc1ccccc1C(=O)N/N=C/c1ccc(O)cc1O)c1ccco1,"N-[2-[[(E)-(2,4-dihydroxyphenyl)methyleneamino]carbamoyl]phenyl]furan-2-carboxamide",0.0854,uM,=,-1.068542129310995,0,O=C(Nc1ccccc1C(=O)N/N=C/c1ccccc1)c1ccco1
5467,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,Cl.NC1CCc2c(c3cc(OCCc4ccc(O)cc4)ccc3n2CCCCCc2ccc(C(F)(F)F)cc2)C1,"4-(2-(3-Amino-9-(5-(4-(trifluoromethyl)phenyl)pentyl)-2,3,4,9-tetrahydro-1H-tetrahydrocarbazole-6-yloxy)ethyl)-phenol hydrochloride",2.75,uM,=,0.4393326938302626,1,c1ccc(CCCCCn2c3c(c4cc(OCCc5ccccc5)ccc42)CCCC3)cc1
5468,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Oc1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"4-[4-(3-Chloro-phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-ylamino]-phenol",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
5469,66907,10.1016/S0960-894X(00)80473-4,,,,Inhibition of epidermal growth factor receptor (EGFR),O=C(NCCc1ccccc1)c1cc2ccc(O)c(O)c2cn1,"7,8-Dihydroxy-isoquinoline-3-carboxylic acid phenethyl-amide",1.4,uM,=,0.1461280356782379,1,O=C(NCCc1ccccc1)c1cc2ccccc2cn1
5470,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3ccc(Br)c(Br)c3)c2cc1OC,"(3,4-Dibromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",7.199999999999999e-05,uM,=,-4.142667503568732,0,c1ccc(Nc2ncnc3ccccc23)cc1
5471,2261295,10.1016/j.ejmech.2022.114502,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr in presence of ATP by Kinase-Glo Plus luminescence kinase assay,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide,0.00011,uM,=,-3.958607314841775,0,O=C(Nc1cccc(Nc2nccc(-c3cccnc3)n2)c1)c1ccc(CN2CCNCC2)cc1
5472,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)cc(N(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(5-(dimethylamino)-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.21,uM,=,-0.6777807052660807,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
5473,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,O=C(/C=C/c1ccccc1[N+](=O)[O-])Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,(E)-N-(4-(3-Bromophenylamino)quinazolin-6-yl)-3-(2-nitrophenyl)acrylamide,1.02,uM,=,0.0086001717619175,1,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5474,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,O=C1NCc2cccc(Oc3ccc(Nc4ncnc5ccn(CCO)c45)cc3Cl)c21,"7-(2-Chloro-4-{[5-(2-hydroxyethyl)-5H-pyrrolo[3,2-d]-pyrimidin-4-yl]amino}phenoxy)-2,3-dihydro-1H-isoindol-1-one",0.021,uM,=,-1.6777807052660807,0,O=C1NCc2cccc(Oc3ccc(Nc4ncnc5cc[nH]c45)cc3)c21
5475,1986369,10.1016/j.bmc.2020.115373,,,,Inhibition of human EGFR-TK using PTK substrate after 40 mins in presence of ATP by Kinase-Glo luminescent assay,Nc1nc(Nc2nnc3c4ccccc4nc(Sc4ccc(Br)cc4)n23)cs1,"N4-[5-(4-bromophenyl)sulfanyl-[1,2,4]triazolo[4,3-c]quinazolin-3-yl]thiazole-2,4-diamine",0.69,uM,=,-0.1611509092627447,0,c1ccc(Sc2nc3ccccc3c3nnc(Nc4cscn4)n23)cc1
5476,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,Cc1ccc(C2=NN(C(N)=S)C(c3ccc([N+](=O)[O-])cc3)C2)cc1C,"3-(3,4-Dimethylphenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",3.06,uM,=,0.48572142648158,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
5477,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,O=[N+]([O-])c1ccc2c(Nc3cccc(Cl)c3)ncnc2c1,(3-Chloro-phenyl)-(7-nitro-quinazolin-4-yl)-amine,0.81,uM,=,-0.0915149811213502,0,c1ccc(Nc2ncnc3ccccc23)cc1
5478,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)C(C)C5)cc4OC)nc32)c1,"N-(3-(2-((4-(3,4-Dimethylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-methyl-7-oxopyrido-[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.1692,uM,=,-0.7715996412969953,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
5479,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC[C@H](Oc2cc3c(Nc4ccc(F)c(Cl)c4F)ncnc3cc2OC)C[C@H]1C(N)=O,"(2S,4S)-1-acryloyl-4-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-2-carboxamide",0.0014,uM,=,-2.853871964321762,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
5480,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CC(OC)C1,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-(3-methoxyazetidin-1-yl)ethoxy)quinazolin-4-amine,0.094,uM,=,-1.0268721464003014,0,c1ccc(Nc2ncnc3ccc(OCCN4CCC4)cc23)cc1
5481,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3ccc(C=O)cc3F)cc12)c1ccccc1,"(R)-3-Fluoro-4-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzaldehyde",0.059,uM,=,-1.2291479883578558,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
5482,1770089,10.1016/j.bmcl.2017.12.009,,,,Inhibition of wild-type EGFR phosphorylation in human A431 cells preincubated for 1 hr followed by EGF stimulation measured after 45 mins by ELISA,C=CC(=O)Nc1cccc(NC(=O)Nc2nc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cc3OC)ncc2Cl)c1,N-(3-(3-(5-chloro-2-(2-methoxy-4-(4-morpholinopiperidin-1-yl)phenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,2.21,uM,=,0.3443922736851107,1,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCC(N4CCOCC4)CC3)cc2)n1
5483,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1nnc(N2CC[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((1-isopropyl-4-((R)-2-methylazetidin-1-yl)pyrido[3,4-d]pyridazin-7-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",8.171,uM,=,0.9122752104988124,1,c1cc(Nc2cc3cnnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
5484,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,O=C(/C=C/Cn1cccn1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Pyrazol-1-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,1.124,uM,=,0.0507663112330423,1,O=C(/C=C/Cn1cccn1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5485,982643,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis,CN(C)CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-(dimethylamino)-propanamide,0.00859,uM,=,-2.0660068361687576,0,c1ccc(Nc2ncnc3ccccc23)cc1
5486,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cnc3ccccc3c2)c2c(N)ncnc21,"1-isopropyl-3-(quinolin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",1.0,uM,=,0.0,0,c1ccc2ncc(-c3n[nH]c4ncncc34)cc2c1
5487,1684241,10.1016/j.bmc.2017.04.001,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate measured after 10 mins by mobility shift assay,O=C(N/N=C/c1ccc(O)cc1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,"(S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-(4-hydroxybenzylidene)hydrazine carboxamide",0.056,uM,=,-1.2518119729937995,0,O=C(N/N=C/c1ccccc1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
5488,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,CN1CCC=C(C(=O)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)C1,"1-Methyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide",0.115,uM,=,-0.9393021596463884,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1=CCCNC1
5489,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1ncc(N2C[C@H](O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((8-((2R,3S)-3-hydroxy-2-methylazetidin-1-yl)-5-isopropyl-2,6-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",4.194,uM,=,0.622628426129325,1,c1cc(Nc2cc3cncc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
5490,990874,10.1021/ml4002437,,,,Inhibition of wild type EGFR in human A431 cells assessed as growth inhibition after 48 hrs by MTT assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,4.0,uM,=,0.6020599913279624,1,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
5491,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(C#CC3CCCC3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(cyclopentylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.75,uM,=,-0.1249387366082999,0,C(#CC1CCCC1)c1nn([C@@H]2CCCNC2)c2ncncc12
5492,792073,10.1016/j.bmc.2011.10.085,,,,Inhibition of EGFR expressed in baculovirus infected Sf9 cells assessed as inhibition of autophosphorylation preincubated for 10 mins measured after 1 hr by DELFIA/Time-Resolved Fluorometry,Clc1ccc(CNc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)cc1,"N6-(4-Chlorobenzyl)-N4-(3-bromophenyl)quinazoline-4,6-diamine",1.64,uM,=,0.2148438480476978,1,c1ccc(CNc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
5493,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,COc1ccc(CCCCCn2c3c(c4cc(OCCc5ccc(O)cc5)ccc42)CC(N)CC3)cc1.Cl,"4-(2-(3-Amino-9-(5-(4-methoxyphenyl)pentyl)-2,3,4,9-tetrahydro-1H-tetrahydrocarbazole-6-yloxy)ethyl)phenol hydrochloride",1.37,uM,=,0.1367205671564068,1,c1ccc(CCCCCn2c3c(c4cc(OCCc5ccccc5)ccc42)CCCC3)cc1
5494,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(F)cc3)cc12)c1ccccc1,"(R)-6-(4-Fluorophenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.0066,uM,=,-2.1804560644581312,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
5495,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CCN(C)[C@H]1C[C@@H]2O[C@](C)([C@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"4-ethyl(methyl)amino-3-methoxy-2-methyl-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-16-one",0.33,uM,=,-0.4814860601221125,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
5496,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc(-n4ccnc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-imidazol-1-yl-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,0.77,uM,=,-0.1135092748275181,0,c1ccc2c(Nc3ccc(-n4ccnc4)cc3)ccnc2c1
5497,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-phenyl-acrylamide",0.7000000000000001,uM,=,-0.1549019599857431,0,O=C(C=Cc1ccccc1)Nc1ccccc1
5498,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCCCn1ccnc1[N+](=O)[O-],N-(3-Chloro-4-fluorophenyl)-6-methoxy-7-((5-(2-nitro-1H-imidazol-1-yl)pentyl)oxy)quinazolin-4-amine,0.00052,uM,=,-3.283996656365201,0,c1ccc(Nc2ncnc3cc(OCCCCCn4ccnc4)ccc23)cc1
5499,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,O=C(C#CCO)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1,4-(6-(4-hydroxybut-2-ynamido)quinolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.0063,uM,=,-2.2006594505464183,0,O=C(Nc1ccccn1)c1ccc(Oc2ccnc3ccccc23)cc1
5500,340860,10.1016/j.bmcl.2005.12.028,,,,Inhibitory activity against EGFR,COc1cc(OC2CCNCC2)c2c(Nc3ccc(F)c(Cl)c3)ncnc2c1,N-(3-chloro-4-fluorophenyl)-7-methoxy-5-(piperidin-4-yloxy)quinazolin-4-amine,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3cccc(OC4CCNCC4)c23)cc1
5501,465,10.1016/s0960-894x(02)00364-5,,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Cc1cc(C)c(/C=C2\C(=O)Nc3ncnc(Nc4ccc(F)c(Cl)c4)c32)[nH]1,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-(3,5-dimethyl-1H-pyrrol-2-yl)-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",7.82,uM,=,0.893206753059848,1,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
5502,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",Cc1cccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)nc23)c1,"N*2*-[2-(3H-Imidazol-4-yl)-ethyl]-N*8*-m-tolyl-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)nc23)cc1
5503,1338416,10.1016/j.ejmech.2014.01.018,,,,Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1nn(-c2ccccc2)c(Cl)c1C1C(C#N)=C(N)N(c2cccnc2)C2=C1C(=O)CCC2,"2-Amino-4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile",18.02,uM,=,1.255754786643044,1,O=C1CCCC2=C1C(c1cnn(-c3ccccc3)c1)C=CN2c1cccnc1
5504,1500854,10.1016/j.bmc.2015.04.065,,,,Inhibition of recombinant EGFR (unknown origin) assessed as inhibition of autophosphorylation after 1 hr by DELFIA/Time-resolved fluorometry,Cc1cccc(/C=C2/SC(N3CCC[C@H]3C(=O)Nc3ccc4ncnc(Nc5cccc(Cl)c5)c4c3)=NC2=O)n1,"(S,E)-N-(4-((3-Chlorophenyl)amino)quinazolin-6-yl)-1-(5-((6-methylpyridin-2-yl)methylene)-4-oxo-4,5-dihydrothiazol-2-yl)pyrrolidine-2-carboxamide",6.5,uM,=,0.8129133566428556,1,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)S/C1=C/c1ccccn1
5505,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCN1CCN(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)CC1,"(E)-2-Cyano-N-{4-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloyl]-piperazin-1-ylmethyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",5.8,uM,=,0.7634279935629373,1,O=C(C=Cc1ccccc1)NCN1CCN(C(=O)/C=C/c2ccccc2)CC1
5506,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",Fc1ccc(Nc2nncc3ccccc23)cc1,N-(4-Fluorophenyl)phthalazin-1-amine,0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2nncc3ccccc23)cc1
5507,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,CC(c1cccc(F)c1)n1ncc2cc(Nc3ncnc4cc(C#C[C@@H]5C[C@@H](OC(=O)N6CCOCC6)CN5)sc34)ccc21,"(3R,5S)-5-((4-(1-(1-(3-fluorophenyl)ethyl)-1H-indazol-5-ylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.12,uM,=,-0.9208187539523752,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1
5508,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1,"(R)-4-(4-((1-Phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.0037,uM,=,-2.431798275933005,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
5509,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3cc(O)ccc3c2)c2c(N)ncnc21,"6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)naphthalen-2-ol",0.088,uM,=,-1.055517327849831,0,c1ccc2cc(-c3n[nH]c4ncncc34)ccc2c1
5510,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3ccc(CC(=O)O)cc3)nc21,"{4-[6-(2,6-Dichloro-phenyl)-8-methyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-phenyl}-acetic acid",0.22,uM,=,-0.6575773191777937,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
5511,1674599,10.1021/acs.jmedchem.8b00125,,,,Inhibition of EGFR (unknown origin),CNS(=O)(=O)c1cccc(Nc2cc(Nc3cccc([N+](=O)[O-])c3)ncn2)c1,N-Methyl-3-({6-[(3-nitrophenyl)amino]-4-pyrimidinyl}amino)-benzenesulfonamide,0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
5512,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,COCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-(methoxymethyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.34,uM,=,-0.4685210829577448,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
5513,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3ncccc3c1)nn2C1CCCC1,"1-cyclopentyl-3-(quinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",2.1,uM,=,0.3222192947339193,1,c1cnc2ccc(-c3nn(C4CCCC4)c4ncncc34)cc2c1
5514,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,CCOC(=O)c1cnc(Nc2ccc(N3CCN(C)CC3)cc2OC)nc1-c1cn(C)c2ccccc12,Ethyl 2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.0052,uM,=,-2.283996656365201,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c[nH]c2c1
5515,1869715,10.1016/j.bmc.2019.02.012,,,,Inhibition of His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometry,COc1ccc(/C=C/C(=O)c2ccc(NC(=O)c3cc4cc5cc(C)ccc5nc4s3)cc2)cc1OC,"(E)-N-(4-(3-(3,4-Dimethoxyphenyl)acryloyl)phenyl)-6-methylthieno[2,3-b]quinoline-2-carboxamide",0.5,uM,=,-0.3010299956639812,0,O=C(/C=C/c1ccccc1)c1ccc(NC(=O)c2cc3cc4ccccc4nc3s2)cc1
5516,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ccnc2cc1CC,N-(4-(3-chloro-4-fluorophenylamino)-7-ethylquinolin-6-yl)but-2-enamide,7.5,uM,=,0.8750612633917001,1,c1ccc(Nc2ccnc3ccccc23)cc1
5517,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,NC(=O)CN1CCC(n2cc(-c3cccc(O)c3)c3c(N)ncnc32)CC1,"2-{4-[4-Amino-5-(3-hydroxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-piperidin-1-yl}-acetamide",0.17,uM,=,-0.7695510786217261,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1
5518,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,CN(C)CCC(=O)c1ccc(OCc2ccccc2)cc1.Cl,1-(4-Benzyloxy-phenyl)-3-dimethylamino-propan-1-one hydrochloride,1.5,uM,=,0.1760912590556812,1,c1ccc(COc2ccccc2)cc1
5519,609779,10.1016/j.bmc.2009.12.004,,,,Inhibition of EGFR after 80 mins by radiometric protein kinase assay,COc1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)cc(OC)c1OC,"3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione",10.133,uM,=,1.0057380426514249,1,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1ccccc1
5520,1330698,10.1039/C2MD20017A,,,,Inhibition of EGF-induced EGFR-mediated pS6 phosphorylation in human A431 cells after 1 hr by immunoblotting method,CCC(=O)Nc1cccc(Nc2cc(Nc3cccc(Br)c3)ncn2)c1,N-(3-(6-(3-bromophenylamino)pyrimidin-4-ylamino)phenyl)propionamide,0.243,uM,=,-0.6143937264016879,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
5521,2296008,10.1021/acsmedchemlett.3c00006,,,,Inhibition of recombinant human EGFR del19/T790M using biotinEEPLYWSFPAKKK-NH2 as substrate incubated for 120 mins by TR-FRET assay,C=CC(=O)N1CCC(n2cc(-c3cnc4ccccc4c3)c3c(N)ncnc32)C1,"rac-1-(3-(4-amino-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one",0.0012,uM,=,-2.920818753952376,0,c1ccc2ncc(-c3cn(C4CCNC4)c4ncncc34)cc2c1
5522,2153740,10.1021/acsmedchemlett.1c00555,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.2075,uM,=,-0.6829818989518885,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5523,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Nc1ncnc(NCc3ccccc3)c1NC2,"benzyl-(7,8-dimethoxy-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cyclohepten-1-yl)-amine",0.9,uM,=,-0.0457574905606751,0,c1ccc(CNc2ncnc3c2NCc2ccccc2N3)cc1
5524,622913,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR in human A431 cells by HTRF assay,Cc1c(C(=O)NCCCN2CCN(C)CC2)[nH]c2cnnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c12,"4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-3-methyl-N-(3-(4-methylpiperazin-1-yl)propyl)-1H-pyrrolo[3,2-d]pyridazine-2-carboxamide",0.98,uM,=,-0.0087739243075051,0,O=C(NCCCN1CCNCC1)c1cc2c(Nc3ccc(OCc4ccccc4)cc3)nncc2[nH]1
5525,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,2-{4-[3-(2-Trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol (Fluphenazine),40.107,uM,=,1.6032201780082669,1,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1
5526,1738745,10.1016/j.ejmech.2018.04.052,,,,"Inhibition of recombinant human GST-tagged wild type EGFR expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(Nc2nccc(Nc3ccccc3-n3nccn3)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-((2-(2H-1,2,3-triazol-2-yl)phenyl)amino)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.2806,uM,=,-0.5519123333076589,0,c1ccc(Nc2nccc(Nc3ccccc3-n3nccn3)n2)cc1
5527,1589608,10.1016/j.ejmech.2016.04.026,,,,Inhibition of cytoplasmic GST-tagged human recombinant EGFR expressed in baculovirus system by z-lyte assay,Cn1cc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cn1,N-(3-chloro-4-fluorophenyl)-6-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-amine,0.00297,uM,=,-2.527243550682788,0,c1ccc(Nc2ncnc3ccc(-c4cn[nH]c4)cc23)cc1
5528,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)cc4)c3c2)o1,N-(4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.024,uM,=,-1.619788758288394,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
5529,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1,"N-(3-(7-(4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.00352,uM,=,-2.453457336521869,0,O=C1NCc2cnc(Nc3ccc(N4CCCCC4)cc3)nc2N1c1ccccc1
5530,1368552,10.1021/jm500034j,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of [32P] gamma-ATP in to myelin basic protein after 30 mins by autoradiographic analysis,c1ccc(-c2cccc(Nc3ncnc4cc5c(cc34)OCCCO5)c2)cc1,"N-(biphenyl-3-yl)-8,9-dihydro-7H-[1,4]dioxepino[2,3-g]quinazolin-4-amine",0.027,uM,=,-1.5686362358410126,0,c1ccc(-c2cccc(Nc3ncnc4cc5c(cc34)OCCCO5)c2)cc1
5531,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",COc1cc2ncnc(Nc3cc(F)cc(C(F)(F)F)c3)c2cc1OC.Cl,"4-[3'-fluoro-5'-(trifluoromethyl)anilino]-6,7-dimethoxyquinazoline hydrochloride",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
5532,2052738,10.1016/j.ejmech.2019.111966,,,,Inhibition of wild type N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus infected Sf21 cells using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km concentration and further incubated for 20 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0337,uM,=,-1.4723700991286617,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5533,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Fc1c(Nc2ncnc3cc4c(cc23)OCCO4)ccc(Br)c1Br,"N-(3,4-Dibromo-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0326,uM,=,-1.4867823999320608,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
5534,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=C(C)C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-2-methyl-acrylamide",0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2ncnc3cnccc23)cc1
5535,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,Cc1ncc([N+](=O)[O-])n1CC(=O)NS(=O)(=O)c1ccc(F)cc1,N-(4-Fluorophenylsulfonyl)-2-(2-methyl-5-nitro-1Himidazol-1-yl)acetamide,0.39,uM,=,-0.4089353929735008,0,O=C(Cn1ccnc1)NS(=O)(=O)c1ccccc1
5536,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1ncnc(Nc3cccc(Br)c3)c1NC2,"(3-bromo-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",5.9,uM,=,0.7708520116421442,1,c1ccc(Nc2ncnc3c2NCc2ccccc2S3)cc1
5537,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(C(=O)NC3=NCCS3)c2)c2c(N)ncnc21,"3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4,5-dihydrothiazol-2-yl)benzamide",0.579,uM,=,-0.2373214362725638,0,O=C(NC1=NCCS1)c1cccc(-c2n[nH]c3ncncc23)c1
5538,2298648,10.1016/j.bmcl.2023.129285,,,,Inhibition of EGFR (unknown origin) by fluorimetric assay,CC(=O)Nc1nc(C(=O)NNC(=O)CCN2CCOCC2)cs1,N-(4-(2-(3-morpholinopropanoyl)hydrazine-1-carbonyl)thiazol-2-yl)acetamide,0.143,uM,=,-0.8446639625349383,0,O=C(CCN1CCOCC1)NNC(=O)c1cscn1
5539,676221,10.1021/jm100607r,,,,Inhibition of EGFR,OC[C@@H](Nc1ncnc2sc3c(c12)CCC3)c1ccccc1,"(2S)-2-(6,7-Dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-ylamino)-2-phenylethan-1-ol",1.09,uM,=,0.0374264979406236,1,c1ccc(CNc2ncnc3sc4c(c23)CCC4)cc1
5540,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,COc1ccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"(3-Chloro-phenyl)-[3-(4-methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine",1.5,uM,=,0.1760912590556812,1,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
5541,5000,10.1021/jm960118j,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Clc1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1,"(3-Chloro-phenyl)-(6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]indol-4-yl)-amine",0.12,uM,=,-0.9208187539523752,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1
5542,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1nn(-c2ccccc2)nc1Cn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,"5-(4-amino-1-((5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",100.0,uM,=,2.0,1,c1ccc(-c2nn(Cc3cnn(-c4ccccc4)n3)c3ncncc23)cc1
5543,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CN(C)C/C=C/C(=O)N[C@H]1CC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1,"US9181263, 18",0.02253,uM,=,-1.647238808276169,0,c1ccc(Oc2ccc(-c3nn(C4CCCCC4)c4ncncc34)cc2)cc1
5544,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,CC(C)N(C)CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-(Isopropyl-methyl-amino)-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.085,uM,=,-1.0705810742857071,0,c1ccc(Nc2ncnc3ccccc23)cc1
5545,4991,10.1016/S0960-894X(97)10117-2,,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,COc1cc2ncnc(Oc3cccc(Br)c3)c2cc1OC,"4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline",0.07,uM,=,-1.154901959985743,0,c1ccc(Oc2ncnc3ccccc23)cc1
5546,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1)c1ccccn1,N-(4-(3-fluorobenzyloxy)-3-(trifluoromethyl)phenyl)-6-(5-((2-(pyridin-2-ylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.019,uM,=,-1.7212463990471711,0,O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1)c1ccccn1
5547,66579,10.1016/j.bmcl.2004.03.106,,,,Inhibition of human epidermal growth factor receptor,CN1CCN(c2ccc3c(n2)nc(-c2ccc(F)cc2)n3-c2ccnc(NC3CCCC3)n2)CC1,"Cyclopentyl-{4-[2-(4-fluoro-phenyl)-5-(4-methyl-piperazin-1-yl)-imidazo[4,5-b]pyridin-1-yl]-pyrimidin-2-yl}-amine",8.7,uM,=,0.9395192526186184,1,c1ccc(-c2nc3nc(N4CCNCC4)ccc3n2-c2ccnc(NC3CCCC3)n2)cc1
5548,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cnc(NC2CCCCC2)nc1,2-(Cyclohexylamino)-N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-pyrimidine-5-carboxamide,0.047,uM,=,-1.3279021420642825,0,O=C(Nc1cccc(C(=O)Nc2ccc(CN3CCNCC3)cc2)c1)c1cnc(NC2CCCCC2)nc1
5549,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CC(C)=CC[C@@H](OC(=O)/C=C\C(=O)c1ccc(Br)cc1)C1=CC(=O)c2c(O)ccc(O)c2C1=O,"(R)-1-(5,8-Dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (Z)-4-(4-bromophenyl)-4-oxobut-2-enoate",0.1197,uM,=,-0.9219058495935892,0,O=C(/C=C\C(=O)c1ccccc1)OCC1=CC(=O)c2ccccc2C1=O
5550,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CNC1CC1,(E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-ethoxyquinazolin-6-yl)-4-(cyclopropylamino)but-2-enamide,0.0009,uM,=,-3.0457574905606752,0,O=C(/C=C/CNC1CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5551,734983,10.1021/jm101479y,,,,Inhibition of EGFR,CC(C)(N)c1cc(C(=O)N[C@@H]2CCc3ccc(Oc4ccnc5c4CCC(=O)N5)cc3C2)cc(C(F)(F)F)c1,"3-(1-Amino-1-methylethyl)-N-{(2R)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalen-2-yl}-5-(trifluoromethyl)benzamide",0.19,uM,=,-0.721246399047171,0,O=C1CCc2c(Oc3ccc4c(c3)C[C@H](NC(=O)c3ccccc3)CC4)ccnc2N1
5552,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,COc1cc(OC)cc(C2CC(c3ccc(Cl)c(Cl)c3)=NN2C(C)=O)c1,"1-(3-(3,4-Dichlorophenyl)-5-(3,5-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone",25.47,uM,=,1.4060289449636152,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
5553,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1O[C@H]1CCOC1,"(S)-N-(4-Methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((tetrahydrofuran-3-yl)oxy)phenyl)buta-2,3-dienamide",0.0291,uM,=,-1.5361070110140926,0,c1ccc2c(-c3ccnc(Nc4ccc(O[C@H]5CCOC5)cc4)n3)c[nH]c2c1
5554,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,c1ccc(Nc2ncnc3ccccc23)cc1,Phenyl-quinazolin-4-yl-amine,0.344,uM,=,-0.4634415574284699,0,c1ccc(Nc2ncnc3ccccc23)cc1
5555,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CCNC(=O)O[C@@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3S,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl ethylcarbamate",0.125,uM,=,-0.9030899869919436,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
5556,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(OC/C=C/c1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid (E)-3-phenyl-allyl ester",2.0,uM,=,0.3010299956639812,1,O=C(OC/C=C/c1ccccc1)c1cccc(NCc2ccccc2)c1
5557,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCCN(C(=O)OC(C)(C)C)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-39::US8975249, I-44",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCCNCC4)cc3)n2)cc1
5558,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3nc(Nc4ccc(CN5CCOCC5)cc4)sc23)cc1Cl,"N7-(3-chloro-4-fluorophenyl)-N2-(4-(morpholinomethyl)phenyl)thiazolo[4,5-d]pyrimidine-2,7-diamine",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3nc(Nc4ccc(CN5CCOCC5)cc4)sc23)cc1
5559,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#CC(C#N)=C(C#N)c1ccc(O)c(O)c1,"2-(3,4-dihydroxyphenyl)ethene-1,1,2-tricarbonitrile",10.0,uM,=,1.0,1,c1ccccc1
5560,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccn(C)n3)n2)c(OC)cc1N(C)CCN(C)CC(=C)C,N-(4-methoxy-2-(methyl(2-(methyl(2-methylallyl)amino)ethyl)amino)-5-((4-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.6254,uM,=,-0.2038421230930855,0,c1ccc(Nc2nccc(Nc3cc[nH]n3)n2)cc1
5561,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3c(F)cc(Cl)cc3F)ncnc2cc1OCC1CCN(C)CC1,"(4-Chloro-2,6-difluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine",0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
5562,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)CO)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-3",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5563,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(NCc4ccccc4)cc3)ncnc2cc1OC,N-{4-[4-(Benzylamino)anilino]-7-methoxy-6-quinazolinyl}-propanamide,0.383,uM,=,-0.4168012260313772,0,c1ccc(CNc2ccc(Nc3ncnc4ccccc34)cc2)cc1
5564,1824355,10.1021/acs.jmedchem.9b01169,,,,Inhibition of human recombinant GST-tagged wild type EGFR expressed in baculovirus expression system assessed as decrease in phosphorylation of ULight-poly-GT using ULight-poly-GT as substrate incubated for 90 mins in presence of ATP by TR-FRET LANCE assay,COc1ccncc1-c1cc(C(=O)/N=c2\[nH]c3ccccc3n2CC(C)(C)O)ccn1,"4'-Methoxy-[2,3']bipyridinyl-4-carboxylic Acid [1-(2-Hydroxy-2-methyl-propyl)-1H-benzoimidazol-2-yl]-amide",10.0,uM,=,1.0,1,O=C(N=c1[nH]c2ccccc2[nH]1)c1ccnc(-c2cccnc2)c1
5565,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Clc1cccc(Nc2[nH]nc3ncnc(Oc4cccc(Cl)c4)c23)c1,"[4-(3-Chloro-phenoxy)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-(3-chloro-phenyl)-amine",24.2,uM,=,1.383815365980431,1,c1ccc(Nc2[nH]nc3ncnc(Oc4ccccc4)c23)cc1
5566,1714364,10.1016/j.bmc.2018.05.039,,,,"Inhibition of wild type EGFR (unknown origin) using Poly(Glu,Tyr) as substrate after 40 mins by Kinase-Glo luminescence assay",C=CC(=O)N[C@@H]1CCCN(c2nc(Nc3ccccc3)nc3cnc(Nc4ccc(N5CCN(C)CC5)cn4)cc23)C1,"(R)-N-(1-(6-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-2-(phenylamino)pyrido[3,4-d]pyrimidin-4-yl)piperidin-3-yl)acrylamide",0.0054,uM,=,-2.2676062401770314,0,c1ccc(Nc2nc(N3CCCCC3)c3cc(Nc4ccc(N5CCNCC5)cn4)ncc3n2)cc1
5567,1674677,10.1021/acs.jmedchem.6b00788,,,,Inhibition of EGF-stimulated wild type EGFR phosphorylation in human LoVo cells incubated for 2 hrs followed by EGF stimulation for 10 mins by ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.48,uM,=,-0.3187587626244128,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5568,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCS(=O)(=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-49",0.0055,uM,=,-2.2596373105057563,0,O=S1(=O)CCN(c2ccc(Nc3nccc(Nc4ccccc4)n3)cc2)CC1
5569,1741055,10.1016/j.ejmech.2018.06.024,,,,Inhibition of EGFR in human MCF7 cell lysates after 24 to 48 hrs by ELISA,CN1CCN(CC(=O)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)CC1,N-(4-((3-bromophenyl)amino)quinazolin-6-yl)-2-(4-methylpiperazin-1-yl)acetamide,0.032,uM,=,-1.494850021680094,0,O=C(CN1CCNCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5570,1650711,10.1016/j.bmcl.2017.02.023,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay,Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,"N*4*-(3-Chloro-phenyl)-quinazoline-4,6-diamine",0.0033799999999999,uM,=,-2.4710832997223453,0,c1ccc(Nc2ncnc3ccccc23)cc1
5571,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=c1c(-c2ccc(O)c(O)c2)coc2cc(O)cc(O)c12,"3-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one",0.3495919970743356,uM,=,-0.4564385178746974,0,O=c1c(-c2ccccc2)coc2ccccc12
5572,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,c1ccc(CCCN(c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)n2ccnc2)cc1,"N*6*-Imidazol-1-yl-N*4*-(1H-indol-5-yl)-N*6*-(3-phenyl-propyl)-thieno[3,2-d]pyrimidine-4,6-diamine",0.005,uM,=,-2.3010299956639813,0,c1ccc(CCCN(c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)n2ccnc2)cc1
5573,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Cc1ccn2ncnc(Nc3ccc4c(cnn4Cc4ccccn4)c3)c12,"5-methyl-N-(1-(pyridin-2-ylmethyl)-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.2,uM,=,-0.6989700043360187,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)nc1
5574,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,COc1ccc(CC(=O)NS(=O)(=O)c2ccc(Cl)cc2)cc1,N-(4-chlorophenylsulfonyl)-2-(4-methoxyphenyl)acetamide,32.85,uM,=,1.5165353738957996,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
5575,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1ccc2c(Nc3ccccc3)ncnc2c1,(7-Methoxy-quinazolin-4-yl)-phenyl-amine,0.12,uM,=,-0.9208187539523752,0,c1ccc(Nc2ncnc3ccccc23)cc1
5576,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc(OCc5nccc(OCC(F)(F)F)c5C)cc4)c3cc21,"Ethyl 4-(8-(4-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methoxy)phenylamino)-2-oxooxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",0.78,uM,=,-0.1079053973095195,0,O=c1[nH]c2cc3c(Nc4ccc(OCc5ccccn5)cc4)ncnc3cc2o1
5577,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Cl.O=[N+]([O-])c1ccc2sc3c(Nc4ccccc4)ncnc3c2c1,"(8-Nitro-benzo[4,5]thieno[3,2-d]pyrimidin-4-yl)-phenyl-amine hydrochloride",0.058,uM,=,-1.2365720064370629,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
5578,1476964,10.1016/j.bmc.2015.04.038,,,,Inhibition of wild type N-terminal His6-tagged human EGFR kinase domain (702 to 1016 residues) expressed in Sf9 cells pre-incubated for 30 mins before ATP and substrate addition by homogeneous time-resolved FRET assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)/C(C#N)=C/c3ccc(F)cc3)c2)n1,N-(3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)-phenyl)-2-cyano-3-(4-fluorophenyl)acrylamide,7.0,uM,=,0.8450980400142568,1,O=C(/C=C/c1ccccc1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
5579,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c(OC)cc1N1CCN(C)CC1,N-(5-(4-(1H-indol-3-yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide,1.2,uM,=,0.0791812460476248,1,c1ccc2c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c[nH]c2c1
5580,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(C)c(C)c(C)c4)nn32)CC1,"7-(1-acryloylpiperidin-4-yl)-2-(3,4,5-trimethylphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",2.458,uM,=,0.3905818785504353,1,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1
5581,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CC(C)CCCC(C)CCOC(=O)c1cc(/N=C/c2cc(O)ccc2O)ccc1O,"5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-benzoic acid 3,7-dimethyl-octyl ester",5.0,uM,=,0.6989700043360189,1,C(=N/c1ccccc1)\c1ccccc1
5582,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid",0.03,uM,=,-1.5228787452803376,0,c1ccc(CNc2ccccc2)cc1
5583,2080995,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R/T790M (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(CCCCC(=O)NO)nn1,"5-(4-(((6-Acrylamido-4-((3-chloro-4-fluorophenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypentanamide",0.0018,uM,=,-2.744727494896694,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
5584,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCn1c([N+](=O)[O-])cnc1C,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(2-methyl-5-nitro-1H-imidazol-1-yl)propoxy)-quinazolin-4-amine,0.00343,uM,=,-2.4647058799572297,0,c1ccc(Nc2ncnc3ccc(OCCCn4ccnc4)cc23)cc1
5585,506208,10.1021/np50089a001,,,,Inhibition of EGFR,O=c1c(-c2ccc(O)cc2)c(CNC2=NCCS2)oc2cc(O)cc(O)c12,"2-((4,5-dihydrothiazol-2-ylamino)methyl)-5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one",52.0727570564144,uM,=,1.7166105725419931,1,O=c1c(-c2ccccc2)c(CNC2=NCCS2)oc2ccccc12
5586,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.001065,uM,=,-2.972650392225244,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5587,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,c1ccc(CCCN(c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)n2ccnc2)cc1,"N*6*-Imidazol-1-yl-N*4*-(1H-indol-5-yl)-N*6*-(3-phenyl-propyl)-thieno[3,2-d]pyrimidine-4,6-diamine",0.001,uM,=,-3.0,0,c1ccc(CCCN(c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)n2ccnc2)cc1
5588,331141,10.1016/j.bmcl.2005.08.115,,,,Inhibitory activity against EGFR kinase,COC(=O)c1c(OCCN2CCCCC2)c2ccccc2c2oc3c(c12)C(=O)c1ccccc1C3=O,"7,12-dioxo-5-(2-piperidin-1-yl-ethoxy)-7,12-dihydro-dinaphtho[1,2-b;2',3'-d]furan-6-carboxylic acid methyl ester",2.8,uM,=,0.4471580313422192,1,O=C1c2ccccc2C(=O)c2c1oc1c2cc(OCCN2CCCCC2)c2ccccc21
5589,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)N(C)c1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-pyrido[3,2-d]pyrimidin-6-yl]-N-methyl-acrylamide",0.088,uM,=,-1.055517327849831,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)cnc23)cc1
5590,1873904,10.1021/acs.jmedchem.9b00794,,,,Inhibition of N-terminal GST-tagged human EGFR (696 to end aminoacids) expressed in baculovirus infected Sf21 cells,C=CC(=O)Nc1cccc(Oc2ccnc(N)c2-c2ccc(Oc3ccccc3)cc2)c1,N-(3-((2-amino-3-(4-phenoxyphenyl)pyridin-4-yl)oxy)phenyl)acrylamide,0.14,uM,=,-0.8538719643217619,0,c1ccc(Oc2ccc(-c3cnccc3Oc3ccccc3)cc2)cc1
5591,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,Cl.O=C(CCN1CCOCC1)c1ccc(OCc2ccccc2)cc1,1-(4-Benzyloxy-phenyl)-3-morpholin-4-yl-propan-1-one hydrochloride,1.5,uM,=,0.1760912590556812,1,O=C(CCN1CCOCC1)c1ccc(OCc2ccccc2)cc1
5592,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,CNC(=O)[C@H]1CCCN1Cc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,(R)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)-N-methylpyrrolidine-2-carboxamide,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
5593,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C=CS(=O)(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro-[2,3-d]pyrimidin-5-yl)phenyl]ethenesulfonamide",3.675,uM,=,0.5652573434202137,1,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
5594,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,OC1CCN(CCCOc2n[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,"1-(3-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yloxy)propyl)piperidin-4-ol",0.009,uM,=,-2.0457574905606752,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCCN5CCCCC5)c34)cc2)nc1
5595,952256,10.1016/j.bmc.2013.02.014,,,,Inhibition of human N-terminal DYKDDDD-tagged EGFR cytoplasmic domain (669 to 1210) expressed in baculovirus expression system incubated for 5 mins prior to [gamma-32P]ATP addition measured after 10 mins by scintillation counting analysis,COC(=O)C1=Cc2c(ncnc2Nc2ccc(Oc3cccc(C(F)(F)F)c3)c(Cl)c2)NCC1,"Methyl 4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-8,9-dihydro-7Hpyrimido[4,5-b]azepine-6-carboxylate",0.11,uM,=,-0.958607314841775,0,C1=Cc2c(ncnc2Nc2ccc(Oc3ccccc3)cc2)NCC1
5596,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3cccc(S(C)(=O)=O)c3)cc12)c1ccccc1,"(R)-6-(3-(Methylsulfonyl)phenyl)-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine",0.026,uM,=,-1.585026652029182,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
5597,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccc([N+](=O)[O-])cc1,"3-(3,4-Dihydroxy-phenyl)-2-(4-nitro-benzoyl)-acrylonitrile",11.0,uM,=,1.0413926851582251,1,O=C(C=Cc1ccccc1)c1ccccc1
5598,1662113,10.1016/j.ejmech.2017.02.061,,,,Inhibition of EGFR (unknown origin) measured after 40 mins by Kinase Glo luminescence assay,CC(C)C[C@@H](NC(=O)OC(C)(C)C)C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,(R)-tert-butyl (1-((4-((3-bromophenyl)amino)quinazolin-6-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate,0.145,uM,=,-0.8386319977650252,0,c1ccc(Nc2ncnc3ccccc23)cc1
5599,2127056,10.1016/j.bmcl.2021.128118,,,,Inhibition of recombinant wild type EGFR-TK (unknown origin) by ELISA,COc1ccc(C(Nc2ccccc2)n2c(=O)ccc3cc(O)ccc32)cc1,6-hydroxy-1-((4-methoxyphenyl)(phenylamino)methyl)quinolin-2(1H)-one,14.26,uM,=,1.1541195255158467,1,O=c1ccc2ccccc2n1C(Nc1ccccc1)c1ccccc1
5600,879290,10.1021/jm1013693,,,,Inhibition of HER1,O=[N+]([O-])c1ccc2c(c1)S(=O)(=O)N=S2c1ccc(Br)cc1,"3-(4-bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium-ylide 1,1-dioxide",22.0,uM,=,1.3424226808222062,1,O=S1(=O)N=S(c2ccccc2)c2ccccc21
5601,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3[nH]ncc3c2)c2c(N)ncnc21,"3-(1H-indazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",1.1,uM,=,0.041392685158225,1,c1ncc2c(-c3ccc4[nH]ncc4c3)n[nH]c2n1
5602,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,O=C(CCCl)Nc1ccc2ncnc(Nc3ccc4[nH]cc(Br)c4c3)c2c1,N-(4-(3-bromo-1H-indol-5-ylamino)quinazolin-6-yl)-3-chloropropanamide,0.0007199999999999,uM,=,-3.1426675035687315,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1
5603,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@H](C)C(=O)N(C)C,"(R)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-N,N-dimethylpropanamide",0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
5604,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,Brc1cccc(Oc2ncnc3ccccc23)c1,4-(3-Bromo-phenoxy)-quinazoline,0.756,uM,=,-0.1214782044987934,0,c1ccc(Oc2ncnc3ccccc23)cc1
5605,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Br)c(O)c1)nn2C1CCC1,"5-(4-amino-1-cyclobutyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-bromophenol",0.324,uM,=,-0.4894549897933878,0,c1ccc(-c2nn(C3CCC3)c3ncncc23)cc1
5606,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(N2C(=O)C(Cc3ccccc3)N(C)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(7-benzyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6-methyl-5,8-dioxo-7,8-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-9(6H)-yl)phenyl)acrylamide",0.00468,uM,=,-2.329754146925876,0,O=C1NC(Cc2ccccc2)C(=O)N(c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc21
5607,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,Cc1ccc(Oc2ccc(Nc3ncnc4[nH]nc(OCCN5CCC(O)CC5)c34)cc2F)cn1,"1-(2-(4-(3-fluoro-4-(6-methylpyridin-3-yloxy)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yloxy)ethyl)piperidin-4-ol",1.43,uM,=,0.1553360374650617,1,c1cncc(Oc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCCC5)c34)cc2)c1
5608,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(Nc3ccc(-c4nc5ccccc5s4)c(C)c3)ncnc2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)-2-fluorophenyl]-6'-methoxy-7'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,0.032,uM,=,-1.494850021680094,0,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
5609,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,CCN(CC)C/C=C/C(=O)N1CCCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-8,9-dihydro-7H-pyrimido[5,4-h][1,5]benzoxazepin-6-yl]-4-(diethylamino)but-2-en-1-one",0.08,uM,=,-1.0969100130080565,0,c1ccc(COc2ccc(Nc3ncnc4cc5c(cc34)NCCCO5)cc2)cc1
5610,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3cccc(I)c3)c2cn1,"N*4*-(3-Iodo-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.26,uM,=,-0.585026652029182,0,c1ccc(Nc2ncnc3ccncc23)cc1
5611,454469,10.1016/j.bmcl.2007.01.057,,,,Inhibition of EGFR,c1ccc(-c2c(-c3ccc(OCCN4CCCC4)cc3)oc3ncnc(NCCN4CCNCC4)c23)cc1,"5-phenyl-N-(2-(piperazin-1-yl)ethyl)-6-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)furo[2,3-d]pyrimidin-4-amine",0.397,uM,=,-0.4012094932368849,0,c1ccc(-c2c(-c3ccc(OCCN4CCCC4)cc3)oc3ncnc(NCCN4CCNCC4)c23)cc1
5612,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methylamide,0.00296,uM,=,-2.5287082889410613,0,O=C(Nc1ccccc1)Nc1ccc(Oc2ccncc2)cc1
5613,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.Cc1ccccc1C(C)Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12,"rac-(4-((1-(o-Tolyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.017,uM,=,-1.769551078621726,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
5614,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,CCOc1cc2ncnc(Nc3ccc(Oc4cc5nncn5cn4)c(C)c3)c2cc1NC(=O)/C(F)=C\[C@H]1CCCN1C,"(E)-N-[7-ethoxy-4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]-2-fluoro-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide",0.08633,uM,=,-1.0638382590888424,0,O=C(/C=C\[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccc(Oc4cc5nncn5cn4)cc3)c2c1
5615,2120336,10.1016/j.ejmech.2021.113711,,,,Inhibition of wild type EGFR (unknown origin) pretreated with substrate for 10 mins followed by ATP addition measured after 60 mins by mobility shift assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1,ABIVERTINIB,0.021,uM,=,-1.6777807052660807,0,c1ccc(Oc2nc(Nc3ccc(N4CCNCC4)cc3)nc3[nH]ccc23)cc1
5616,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccc4c(ccn4C)c3)n2)c(OC)cc1N1CCN(C)CC1,N-(4-methoxy-5-((4-((1-methyl-1H-indol-5-yl)amino)pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide,0.0269,uM,=,-1.570247719997592,0,c1cc(Nc2ccc3[nH]ccc3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
5617,67206,10.1021/jm010496a,,,,Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase,CCOc1cc2ncnc(Nc3cccc(-c4cocn4)c3)c2cc1OCC,"(6,7-Diethoxy-quinazolin-4-yl)-(3-oxazol-4-yl-phenyl)-amine",0.72,uM,=,-0.1426675035687315,0,c1cc(Nc2ncnc3ccccc23)cc(-c2cocn2)c1
5618,1739299,10.1016/j.ejmech.2018.05.006,,,,Inhibition of wild type EGFR (unknown origin) using FAM-labeled peptide substrate after 10 mins by mobility shift assay,CCC/C=C/C(=O)Nc1cc2c(N3CCCc4ccccc43)ncnc2cc1OC,"(E)-N-(4-(3,4-dihydroquinolin-1(2H)-yl)-7-methoxyquinazolin-6-yl)hex-2-enamide",0.033,uM,=,-1.4814860601221125,0,c1ccc2c(c1)CCCN2c1ncnc2ccccc12
5619,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CCN(C(=O)[C@H]2CCCCN2)CC1,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-((R)-piperidine-2-carbonyl)piperazin-1-yl)phenyl)acrylamide",5600.0,uM,=,3.7481880270062,1,O=C([C@H]1CCCCN1)N1CCN(c2ccc(Nc3nccc(-c4cnn5ccccc45)n3)cc2)CC1
5620,2069689,10.1016/j.bmc.2021.116039,,,,Inhibition of recombinant wild type EGFR (696 to C terminal end) (unknown origin) using poly (Glu-Tyr) as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by ELISA,COc1ccc(-c2c3c4cc(OCCCN(C)C)c(O)cc4[nH]c(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O.O=C(O)C(F)(F)F,"2-[3-(dimethylamino)propoxy]-3,11-dihydroxy-14-(3-hydroxy-4-methoxyphenyl)-12-methoxybenzo[7,8]indolizino[3,2-c]quinolin-6(5H)-one 2,2,2-trifluoroacetate",0.0236,uM,=,-1.6270879970298933,0,O=c1[nH]c2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
5621,63780,10.1016/j.bmcl.2004.01.034,,,,Inhibition of epidermal growth factor receptor kinase autophosphorylation,C=CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-3-cyano-quinolin-6-yl]-acrylamide,0.0869,uM,=,-1.0609802235513337,0,c1ccc(Nc2ccnc3ccccc23)cc1
5622,63782,10.1021/jm970366v,,,,Inhibition of epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3cc(NCCCn4ccnc4)ncc23)c1,"N*4*-(3-Bromo-phenyl)-N*7*-(3-imidazol-1-yl-propyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.00051,uM,=,-3.292429823902064,0,c1ccc(Nc2ncnc3cc(NCCCn4ccnc4)ncc23)cc1
5623,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,COc1cc(/C=C(\C#N)S(=O)(=O)/C(C#N)=C/c2cc(O)c(O)c(OC)c2)cc(O)c1O,"(E)-2-[(E)-2-Cyano-1-(3,4-dihydroxy-5-methoxy-phenyl)-ethenesulfonyl]-3-(3,4-dihydroxy-5-methoxy-phenyl)-acrylonitrile",4.0,uM,=,0.6020599913279624,1,O=S(=O)(C=Cc1ccccc1)/C=C/c1ccccc1
5624,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CO)CC4)cc3OC(F)(F)F)ncc2C(F)(F)F)c1,"US8975249, I-30",0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5625,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,Cc1nc(Nc2cccc3[nH]ccc23)c2cc(C)oc2n1,"N-(1H-Indol-4-yl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine",0.0902,uM,=,-1.0447934624580584,0,c1cc(Nc2ncnc3occc23)c2cc[nH]c2c1
5626,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@H]1CCOC1,"(S)-5-(4-amino-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",4.8,uM,=,0.6812412373755872,1,c1ccc(-c2nn([C@H]3CCOC3)c3ncncc23)cc1
5627,1883986,10.1021/acsmedchemlett.8b00461,,,,Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay,N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c(C(N)=O)c2N)C1,(R)-5-Amino-1-(1-cyanopiperidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide,1.71,uM,=,0.2329961103921538,1,c1ccc(Oc2ccc(-c3ccn([C@@H]4CCCNC4)n3)cc2)cc1
5628,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(O)cc3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(4-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.02,uM,=,-1.6989700043360187,0,c1ccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)cc1
5629,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(N2C(=O)CN(c3ccccc3)C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5,8-dioxo-6-phenyl-7,8-dihydro-5H-pyrimido[4,5-e][1,4]diazepin-9(6H)-yl)phenyl)acrylamide",0.00699,uM,=,-2.1555228242543185,0,O=C1c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N(c2ccccc2)C(=O)CN1c1ccccc1
5630,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,CC(C)c1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cnc2[nH]ccc2c1,"N-(2-Isopropyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide",0.16,uM,=,-0.7958800173440752,0,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(NC(=O)c2cnc3[nH]ccc3c2)c1
5631,63764,10.1021/jm960689b,,,,Inhibition of epidermal growth factor receptor (EGFr),N[C@H](Cc1c([Se][Se]c2[nH]c3ccccc3c2C[C@H](N)C(=O)NCc2ccccc2)[nH]c2ccccc12)C(=O)NCc1ccccc1,"[S-(R*,R*)]-2,2'-Diselenobis [alpha-amino-N-(phenylmethyl)-1H-indole-3-propanamide]",1.3,uM,=,0.1139433523068367,1,O=C(CCc1c([Se][Se]c2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
5632,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(C(F)(F)F)cc3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-amino-3-(4-(trifluoromethyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.06,uM,=,-1.2218487496163564,0,c1ccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)cc1
5633,1778842,10.1016/j.bmcl.2018.07.039,,,,Inhibition of EGF-induced EGFR activation in human A431 cells pretreated for 60 mins followed by EGF addition and measured after 10 mins by ELISA,COc1ccc(N(C)c2ncnc3occ(C)c23)cc1,"N-(4-methoxyphenyl)-N,5-dimethylfuro[2,3-d]pyrimidin-4-amine",0.0155,uM,=,-1.8096683018297088,0,c1ccc(Nc2ncnc3occc23)cc1
5634,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5cccs5)sc34)cc2Cl)c1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(thiophen-2-yl)thieno[3,2-d]pyrimidin-4-amine",0.008,uM,=,-2.096910013008056,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5cccs5)sc34)cc2)cc1
5635,2184321,10.1016/j.bmc.2020.115897,,,,Inhibition of EGFR (unknown origin) incubated for 40 mins by intrinsic ATPase activity luminescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0019,uM,=,-2.721246399047171,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
5636,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidine-5-carboxylate",0.039,uM,=,-1.408935392973501,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)cc1
5637,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)c(OC)c3)c2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)-3-methoxyphenyl]-7'-methoxy-6'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,0.015,uM,=,-1.8239087409443189,0,c1ccc2sc(-c3ccc(Nc4ncnc5ccc(OCCCN6CCNCC6)cc45)cc3)nc2c1
5638,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccc(F)c4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-[7-ethoxy-4-({4-[(3-fluorobenzyl)oxy]-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)quinazolin-6-yl]but-2-enamide",0.0431,uM,=,-1.3655227298392685,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
5639,453859,10.1016/j.bmcl.2006.11.077,,,,Inhibition of EGFR,COc1cc(Nc2c(C#N)cnc3cc(C#CCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,"4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[4-(4-methylpiperazin-1-yl)but-1-ynyl]-3-quinolinecarbonitrile",0.72,uM,=,-0.1426675035687315,0,C(#Cc1ccc2c(Nc3ccccc3)ccnc2c1)CCN1CCNCC1
5640,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,COc1ccc(C2CC(c3ccc(Cl)c(Cl)c3)=NN2C(C)=O)cc1,"1-(3-(3,4-Dichlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone",17.19,uM,=,1.2352758766870524,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
5641,331141,10.1016/j.bmcl.2005.08.115,,,,Inhibitory activity against EGFR kinase,N#CC(C#N)=C(N)/C(C#N)=C/c1cc(O)c(O)c(O)c1,"3-Amino-2,4-dicyano-5-(3,4,5-trihydroxy-phenyl)-penta-2,4-dienenitrile",4.1,uM,=,0.6127838567197355,1,c1ccccc1
5642,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.018,uM,=,-1.744727494896694,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5643,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@@H]1CCNC1,"(R)-5-(4-amino-1-(pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",12.4,uM,=,1.0934216851622351,1,c1ccc(-c2nn([C@@H]3CCNC3)c3ncncc23)cc1
5644,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1cccc(O)c1,2-(3-Hydroxy-benzylidene)-malononitrile,375.0,uM,=,2.574031267727719,1,c1ccccc1
5645,63773,10.1021/jm9508651,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 human epidermoid carcinoma cells,CN(C)c1ccc2ncnc(Nc3cccc(Br)c3)c2n1,"N*4*-(3-Bromo-phenyl)-N*6*,N*6*-dimethyl-pyrido[3,2-d]pyrimidine-4,6-diamine",0.032,uM,=,-1.494850021680094,0,c1ccc(Nc2ncnc3cccnc23)cc1
5646,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,"5,7-Dihydroxy-2-(4-hydroxy-phenyl)-chromen-4-one",111.08937733023608,uM,=,2.0456725325013907,1,O=c1cc(-c2ccccc2)oc2ccccc12
5647,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,C=CC(=O)Nc1cc(Nc2ncc(Br)c(Nc3ccc4cc[nH]c4c3)n2)ccc1N(C)CCN(C)C,N-(5-((4-((1H-indol-6-yl)amino)-5-bromopyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide,0.0087,uM,=,-2.0604807473813813,0,c1ccc(Nc2nccc(Nc3ccc4cc[nH]c4c3)n2)cc1
5648,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Oc1ncnc(Nc3cc(Cl)ccc3F)c1NC2,"(5-chloro-2-fluoro-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",3.9,uM,=,0.5910646070264992,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
5649,1994718,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 40 mins in presence of ATP by caliper mobility shift assay,O=C(/C=C/CN1CCCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7,8-dihydropyrimido[5,4-g][1,4]benzoxazin-6-yl]-4-pyrrolidin-1-yl-but-2-en-1-one",0.007,uM,=,-2.154901959985743,0,O=C(/C=C/CN1CCCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
5650,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2ncc(OC)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((5-methoxy-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)buta-2,3-dienamide",0.0063,uM,=,-2.2006594505464183,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5651,1714364,10.1016/j.bmc.2018.05.039,,,,"Inhibition of wild type EGFR (unknown origin) using Poly(Glu,Tyr) as substrate after 40 mins by Kinase-Glo luminescence assay",C=CC(=O)N1CC[C@@H](Nc2nc(Nc3ccccc3)nc3cnc(Nc4ccc(N5CCN(C)CC5)cn4)cc23)C1,"(R)-1-(3-((6-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-2-(phenylamino)pyrido[3,4-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)prop-2-en-1-one",0.0033,uM,=,-2.4814860601221125,0,c1ccc(Nc2nc(N[C@@H]3CCNC3)c3cc(Nc4ccc(N5CCNCC5)cn4)ncc3n2)cc1
5652,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1nnc(N2CC[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((1-isopropyl-4-((R)-2-methylazetidin-1-yl)pyrido[3,4-d]pyridazin-7-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",25.0,uM,=,1.3979400086720375,1,c1cc(Nc2cc3cnnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
5653,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CC(C)N(C)C/C=C/C(=O)N1CCc2c(oc3ncnc(Nc4ccc(F)c(Cl)c4)c23)C1,"US8524722, 90",0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3oc4c(c23)CCNC4)cc1
5654,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)OCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-6-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.21,uM,=,-0.6777807052660807,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)OCC4)n2)cc1
5655,2270899,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR L858R/T790M (unknown origin) incubated for 60 mins in presence of ATP by ADP-Glo kinase assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5656,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)ncnc2cc1OCc1ccccc1,1-(4-((7-(benzyloxy)-6-methoxyquinazolin-4-yl)amino)phenyl)-3-(3-chlorophenyl)urea,4.649,uM,=,0.6673595461830871,1,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1
5657,1291543,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN(C)C)CCO4)c1,"4-(dimethylamino)-1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)but-2-en-1-one",0.046,uM,=,-1.337242168318426,0,c1ccc(Nc2ncnc3cc4c(cc23)NCCO4)cc1
5658,5002,10.1021/jm00033a019,,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,Cc1ccc(Nc2cc3c(cc2Nc2ccc(C)cc2)C(=O)NC3=O)cc1,"5,6-Bis-p-tolylamino-isoindole-1,3-dione",4.5,uM,=,0.6532125137753437,1,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21
5659,2110442,10.1016/j.ejmech.2020.112831,,,,Inhibition of EGFR (unknown origin) incubated for 40 mins by kinase-glo plus luminescence assay,COc1cc(NC(=O)CCCCCCCCCCC(=O)NO)ccc1Nc1nccc(-c2cn(C)c3ccccc23)n1,N1-hydroxy-N12-(3-methoxy-4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)dodecanediamide,5.7,uM,=,0.7558748556724915,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5660,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,NCCOCc1ccn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((2-aminoethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.09,uM,=,-1.0457574905606752,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
5661,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)c(OC)c4)nn32)CC1,"US9447106, 172",0.011,uM,=,-1.958607314841775,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(C3CCNCC3)CCN4)cc2)cc1
5662,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1.Cl,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine hydrochloride(ZD6474),0.17,uM,=,-0.7695510786217261,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
5663,695077,10.1021/jm100665z,,,,Inhibition of EGFR by flash plate based radioactive enzyme assay,Nc1ccccc1NC(=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,N-(2-aminophenyl)-5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carboxamide,0.0029,uM,=,-2.537602002101044,0,O=C(Nc1ccccc1)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1
5664,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4nc5ccccc5s4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[4-(benzothiazol-2-ylmethoxy)-3-chloro-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.188,uM,=,-0.7258421507363202,0,c1ccc2sc(COc3ccc(Nc4ccnc5ccccc45)cc3)nc2c1
5665,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,COc1ccc2ncncc2c1,6-Methoxy-quinazoline,0.03,uM,=,-1.5228787452803376,0,c1ccc2ncncc2c1
5666,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,CC(O)C#Cc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,4-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)but-3-yn-2-ol,0.0945,uM,=,-1.024568191490737,0,c1ccc(Nc2ncnc3ccccc23)cc1
5667,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(NCCN1CCCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(2-(pyrrolidin-1-yl)ethyl)urea,0.068,uM,=,-1.1674910872937636,0,O=C(NCCN1CCCC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
5668,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(C#N)c3)ncnc2cc1OCCOC,N-(4-(3-Cyano-4-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)acrylamide,0.1958,uM,=,-0.708187312532881,0,c1ccc(Nc2ncnc3ccccc23)cc1
5669,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CN(C)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-phenyl)-N*7*,N*7*-dimethyl-pyrido[4,3-d]pyrimidine-4,7-diamine",9.1e-05,uM,=,-4.040958607678906,0,c1ccc(Nc2ncnc3ccncc23)cc1
5670,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCn4ccnc4[N+](=O)[O-])cc23)c1,N-(3-ethynylphenyl)-7-methoxy-6-(4-(2-nitro-1H-imidazol-1-yl)butoxy)quinazolin-4-amine,0.00056,uM,=,-3.2518119729938,0,c1ccc(Nc2ncnc3ccc(OCCCCn4ccnc4)cc23)cc1
5671,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)CC(N)=O,2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)acetamide,0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
5672,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)CCN1CCOCC1,N-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)anilino)-3-cyano-7-ethoxyquinolin-6-yl)-3-morpholinopropanamide,0.0375,uM,=,-1.4259687322722812,0,O=C(CCN1CCOCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccn4)cc3)c2c1
5673,621332,10.1016/j.bmcl.2009.10.037,,,,Inhibition of EGFR after 1 hr,O=C(Nc1cccc(-c2cn3ccnc3c(NCc3ccncc3)n2)c1)Nc1cccc(C(F)(F)F)c1,"1-(3-(8-(pyridin-4-ylmethylamino)imidazo[1,2-a]pyrazin-6-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea",50.0,uM,=,1.6989700043360187,1,O=C(Nc1ccccc1)Nc1cccc(-c2cn3ccnc3c(NCc3ccncc3)n2)c1
5674,989154,10.1016/j.bmc.2013.09.027,,,,Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA,C#Cc1cccc(-n2ccc3cc(OC)cc(O)c3c2=O)c1,8-hydroxy-6-methoxy-2-(3-ethynylphenyl)isoquinolin-1(2H)-one,3.06,uM,=,0.48572142648158,1,O=c1c2ccccc2ccn1-c1ccccc1
5675,1642199,,,,,Inhibition Assay: Inhibition of various kinase enzyme.,Nc1nc(Nc2ccccc2)c2c(n1)-c1ccccc1C2,"US9422297, AAG145-344",232.7,uM,=,2.36679638328673,1,c1ccc(Nc2ncnc3c2Cc2ccccc2-3)cc1
5676,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CC[S+]([O-])CC1,(E)-4-(1-Oxo-1lambda(4)-thiomorpholin-4-yl)-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-7-(2-methoxy-ethoxy)-quinazolin-6-yl]-amide,0.3566,uM,=,-0.4478186611606641,0,O=C(/C=C/CN1CC[SH+]CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5677,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",C(=C/c1ccccc1)\C(=N\Nc1nncc2ccccc12)c1ccccc1,"1-(2-(1,3-Diphenylallylidene)hydrazinyl)phthalazine",0.0056,uM,=,-2.2518119729938,0,C(=C/c1ccccc1)\C(=N\Nc1nncc2ccccc12)c1ccccc1
5678,1338416,10.1016/j.ejmech.2014.01.018,,,,Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1ccc(-n2nc(C)c(C3C(C#N)=C(N)N(c4cccnc4)C4=C3C(=O)CCC4)c2Cl)cc1,"2-Amino-4-(5-chloro-3-methyl-1-p-tolyl-1H-pyrazol-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile",10.12,uM,=,1.0051805125037805,1,O=C1CCCC2=C1C(c1cnn(-c3ccccc3)c1)C=CN2c1cccnc1
5679,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1ccc(C(=O)Nc2nccc(-c3cccnc3)n2)cc1NC(=O)/C=C/CN(C)C,3-(4-(Dimethylamino)but-2-enamido)-4-ethoxy-N-(4-(pyridin-3-yl)pyrimidin-2-yl)benzamide,6.0,uM,=,0.7781512503836436,1,O=C(Nc1nccc(-c2cccnc2)n1)c1ccccc1
5680,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)NC)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-21",0.02,uM,=,-1.6989700043360187,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5681,1882933,10.1016/j.ejmech.2018.11.029,,,,Inhibition of recombinant human wild type GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system after 1 hr by kinase tracer 199 based TR-FRET assay,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CSc1ncc[nH]1,2-((1H-imidazol-2-yl)thio)eN-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)acetamide,0.00062,uM,=,-3.207608310501746,0,O=C(CSc1ncc[nH]1)Oc1ccc2ncnc(Nc3ccccc3)c2c1
5682,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(CCc3ccccc3)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1,"N-(3-(7-((4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-2,4-dioxo-3-phenethyl-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.0007,uM,=,-3.154901959985743,0,O=c1c2cnc(Nc3ccc(N4CCCCC4)cc3)nc2n(-c2ccccc2)c(=O)n1CCc1ccccc1
5683,66715,10.1021/jm00046a020,,,,Inhibition of in vitro activity of EGFr enzyme from A431 cells in presence of 5 uM ATP,Nc1ccc(-c2cc(=O)c3cc(N)c(O)cc3o2)cc1,6-Amino-2-(4-amino-phenyl)-7-hydroxy-chromen-4-one,14.1,uM,=,1.14921911265538,1,O=c1cc(-c2ccccc2)oc2ccccc12
5684,1693612,10.1016/j.bmc.2017.06.004,,,,Inhibition of wild-type EGFR (unknown origin) using Tyr 4 peptide as substrate in presence of ATP by Z-LYTE kinase assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccc(F)cc34)n2)c(OC)cc1N(C)CC[N+](C)(C)[O-],"2-((2-Acrylamido-4-((4-(5-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-methoxyphenyl)(methyl)amino)-N,Ndimethylethan-1-amine oxide",0.3573,uM,=,-0.44696698379756,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5685,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(C=C(C#N)C#N)cc(CSc2ccccc2C(=O)O)c1O,"2-[5-(2,2-Dicyano-vinyl)-2-hydroxy-3-methoxy-benzylsulfanyl]-benzoic acid",8.0,uM,=,0.9030899869919436,1,c1ccc(CSc2ccccc2)cc1
5686,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(C2CC(c3ccc(F)cc3)=NN2C2=NC(=O)CS2)cc1,"2-(3-(4-Fluorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",10.69,uM,=,1.028977705208778,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
5687,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,CN(C)C/C=C/C(=O)Nc1ccc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2c1,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.65,uM,=,-0.1870866433571444,0,c1ccc(Nc2ccnc3ccccc23)cc1
5688,952256,10.1016/j.bmc.2013.02.014,,,,Inhibition of human N-terminal DYKDDDD-tagged EGFR cytoplasmic domain (669 to 1210) expressed in baculovirus expression system incubated for 5 mins prior to [gamma-32P]ATP addition measured after 10 mins by scintillation counting analysis,COC(=O)C1=Cc2c(ncnc2Nc2ccc(Oc3cccc4sccc34)c(Cl)c2)NCC1,"Methyl 4-((4-(benzo[b]thiophen-4-yloxy)-3-chlorophenyl)amino)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylate",0.044,uM,=,-1.3565473235138126,0,C1=Cc2c(ncnc2Nc2ccc(Oc3cccc4sccc34)cc2)NCC1
5689,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,O=C1Cc2ccc(Oc3ccc(Nc4ncnc5ccn(CCO)c45)cc3Cl)cc2N1,"6-(2-Chloro-4-{[5-(2-hydroxyethyl)-5H-pyrrolo[3,2-d]-pyrimidin-4-yl]amino}phenoxy)-1,3-dihydro-2H-indol-2-one",2.3,uM,=,0.3617278360175928,1,O=C1Cc2ccc(Oc3ccc(Nc4ncnc5cc[nH]c45)cc3)cc2N1
5690,850915,10.1021/jm300403a,,,,Inhibition of EGFR,CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N,"3-Amino-6-(4-chloro-3-(N-(2,3-difluorophenyl)sulfamoyl)-phenyl)-N-methylpyrazine-2-carboxamide",0.739,uM,=,-0.1313555616051742,0,O=S(=O)(Nc1ccccc1)c1cccc(-c2cnccn2)c1
5691,82323,10.1021/jm9904295,,,,Inhibitory activity against ligand-dependent EGF cell proliferation,COc1cccc(-c2ccc3c(c2)NC(=O)/C3=C\c2[nH]cc(CCC(=O)O)c2C)c1,"3-{5-[6-(3-Methoxy-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-4-methyl-1H-pyrrol-3-yl}-propionic acid",30.5,uM,=,1.484299839346786,1,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1ccc[nH]1
5692,763210,10.1021/np200196j,,,,Inhibition of EGFR-induced AP1 activation in human HeLa cells preincubated for 1 hr prior to EGF stimulation by luciferase reporter gene assay,C/C=C(\C)C(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)/C=C(C)/C=C/CC(C)/C=C/c1oc(OC)c(C)c(=O)c1C,"2-methoxy-3,5-dimethyl-6-((1E,5E,7E,11E)-3,7,9,11-tetramethyl-10-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)trideca-1,5,7,11-tetraenyl)-4H-pyran-4-one",0.16,uM,=,-0.7958800173440752,0,O=c1ccoc(/C=C/CC/C=C/C=C/CCO[C@H]2CCCCO2)c1
5693,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,CCOc1cc2ncc(C#N)c(Nc3cccc(Br)c3)c2cc1NC(=O)/C=C/CN1CCOCC1,(E)-4-Morpholin-4-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,10.32,uM,=,1.0136796972911926,1,O=C(/C=C/CN1CCOCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
5694,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Brc1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccc(Br)cc3)C2)cc1,"2-(3,5-bis(4-bromophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",8.95,uM,=,0.951823035315912,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
5695,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)NC)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-28",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5696,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CC(C)=CC[C@@H](O)C1=CC(=O)c2c(O)ccc(O)c2C1=O,"5,8-Dihydroxy-2-((R)-1-hydroxy-4-methyl-pent-3-enyl)-[1,4]naphthoquinone",0.1392,uM,=,-0.8563607647254567,0,O=C1C=CC(=O)c2ccccc21
5697,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,COc1cccc(-n2cc(NC(=O)c3cccc(NS(=O)(=O)c4ccccc4)c3)cn2)c1,N-(1-(3-Methoxyphenyl)-1H-pyrazol-4-yl)-3-(phenylsulfonamido)benzamide,22.85,uM,=,1.3588862044058692,1,O=C(Nc1cnn(-c2ccccc2)c1)c1cccc(NS(=O)(=O)c2ccccc2)c1
5698,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COCC#CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,4-Methoxy-but-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.96,uM,=,-0.0177287669604316,0,c1ccc(Nc2ccnc3ccccc23)cc1
5699,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,COc1ccc2c(Nc3cccc(Br)c3)ncnc2n1,"(3-Bromo-phenyl)-(7-methoxy-pyrido[2,3-d]pyrimidin-4-yl)-amine",0.263,uM,=,-0.5800442515102421,0,c1ccc(Nc2ncnc3ncccc23)cc1
5700,1577194,10.1016/j.bmc.2016.05.012,,,,Inhibition of recombinant His6-tagged EGFR (unknown origin) cytoplasmic domain (645 to 1186 residues) autophosphorylation expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometric analysis,Clc1ccc(C2CC(c3ccc4c(c3)OCCO4)=NN2c2ccccc2)cc1Cl,"5-(3,4-Dichlorophenyl)-3-(2,3-dihydrobenzo[b][1,4]-dioxin-6-yl)-1-phenyl-4,5-dihydro-1H-pyrazol",192.0,uM,=,2.2833012287035497,1,c1ccc(C2CC(c3ccc4c(c3)OCCO4)=NN2c2ccccc2)cc1
5701,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,C#Cc1cccc(Nc2ncnc3ccc(NC(C)=O)cc23)c1,N-(4-((3-Ethynylphenyl)amino)quinazolin-6-yl)acetamide,0.00204,uM,=,-2.690369832574101,0,c1ccc(Nc2ncnc3ccccc23)cc1
5702,2017350,10.1021/acs.jmedchem.0c00870,,,,Inhibiton of EGFR (unknown origin) expressed in human A431 cells assessed as reduction in EGFR induced cell viability after 96 hrs by CellTiter-Glo assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,1.401,uM,=,0.1464381352857746,1,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
5703,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC(=O)C(C)c4ccc5cc(OC)ccc5c4)c(OCCOC)cc23)c1,2-((4-((3-Ethynylphenyl)amino)-6-(2-methoxyethoxy)quinazolin-7-yl)oxy)ethyl-2-(6-methoxynaphthalen-2-yl)propanoate,0.072,uM,=,-1.1426675035687317,0,O=C(Cc1ccc2ccccc2c1)OCCOc1ccc2c(Nc3ccccc3)ncnc2c1
5704,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.3297,uM,=,-0.481881052856847,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
5705,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.CC(Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccc(C(F)(F)F)cc1,"rac-4-(4-((1-(4-(Trifluoromethyl)phenyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",4.608,uM,=,0.6635124704151556,1,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
5706,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cc(C=O)ccc1-c1cc2c(Nc3ccccc3)ncnc2s1,"3-Methoxy-4-(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)benzaldehyde",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3sc(-c4ccccc4)cc23)cc1
5707,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cnccn1,N-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrazine-2-carboxamide,3.9,uM,=,0.5910646070264992,1,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(NC(=O)c2cnccn2)c1
5708,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(C=C(C#N)C#N)cc(CS(=O)(=O)c2ccc(C)cc2)c1O,2-[4-Hydroxy-3-methoxy-5-(toluene-4-sulfonylmethyl)-benzylidene]-malononitrile,85.0,uM,=,1.9294189257142929,1,O=S(=O)(Cc1ccccc1)c1ccccc1
5709,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,O=C(COc1ccc(Nc2ncc(Cl)c(Nc3ccccc3C(=O)NO)n2)cc1)NO,2-(5-chloro-2-(4-(2-(hydroxyamino)-2-oxoethoxy)phenylamino)pyrimidin-4-ylamino)-N-hydroxybenzamide,0.05022,uM,=,-1.2991232916230964,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
5710,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1CCNC1=O,3-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)pyrrolidin-2-one,0.07,uM,=,-1.154901959985743,0,O=C1NCCC1NCc1ccc2ncnc(Nc3ccccc3)c2c1
5711,2227151,10.1016/j.ejmech.2022.114492,,,,Inhibition of wild type EGFR (unknown origin) by mobility shift assay,COc1cc(N(C)CCN(C)C)c(NC(=O)c2ccncn2)cc1Nc1nccc(-c2cn(C)c3ccccc23)n1,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)pyrimidine-4-carboxamide,0.029,uM,=,-1.537602002101044,0,O=C(Nc1cccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c1)c1ccncn1
5712,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cc(C=O)ccc1-c1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"4-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-3-methoxybenzaldehyde",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3sc(-c4ccccc4)cc23)cc1
5713,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2=NN(c3nc(-c4ccc(Cl)cc4)cs3)C(c3ccc([N+](=O)[O-])cc3)C2)cc1C,"4-(4-chlorophenyl)-2-(3-(3,4-dimethylphenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazole",0.63,uM,=,-0.2006594505464183,0,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
5714,531091,10.1073/pnas.0707498104,,,,Inhibition of EGFR,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0004,uM,=,-3.397940008672037,0,c1ccc(Nc2ncnc3ccccc23)cc1
5715,1441971,10.1016/j.ejmech.2014.10.044,,,,Inhibition of recombinant EGFR (unknown origin) after 60 mins by z'-lyte kinase assay,O=C1/C(=C\c2ccc(O)c(O)c2)Oc2ccccc21,"2-(3,4-dihydroxybenzylidene)benzofuran-3(2H)-one",100.0,uM,=,2.0,1,O=C1/C(=C\c2ccccc2)Oc2ccccc21
5716,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#C/C=C/c1ccc(O)cc1,3-(4-Hydroxy-phenyl)-acrylonitrile,2400.0,uM,=,3.380211241711606,1,c1ccccc1
5717,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,N#C/C(=C\c1cc(O)c(O)c(CSCc2ccccc2)c1)C(N)=O,"3-(3-Benzylsulfanylmethyl-4,5-dihydroxy-phenyl)-2-cyano-acrylamide",3.0,uM,=,0.4771212547196624,1,c1ccc(CSCc2ccccc2)cc1
5718,305912,10.1016/j.bmcl.2005.05.100,,,,Inhibitory concentration against EGFR by using [gamma-33P]-ATP as radioligand in pH 7.5,c1ccc(Cc2nc3cc(Nc4ncnc5nn6ccccc6c45)ccc3[nH]2)cc1,"(2-Benzyl-1H-benzoimidazol-5-yl)-(1,3,8a,9-tetraaza-fluoren-4-yl)-amine",5.01,uM,=,0.6998377258672457,1,c1ccc(Cc2nc3cc(Nc4ncnc5nn6ccccc6c45)ccc3[nH]2)cc1
5719,952256,10.1016/j.bmc.2013.02.014,,,,Inhibition of human N-terminal DYKDDDD-tagged EGFR cytoplasmic domain (669 to 1210) expressed in baculovirus expression system incubated for 5 mins prior to [gamma-32P]ATP addition measured after 10 mins by scintillation counting analysis,O=C(NCCO)C1=Cc2c(ncnc2Nc2ccc(Oc3cccc4sccc34)c(Cl)c2)NCC1,"4-(4-(benzo[b]thiophen-4-yloxy)-3-chlorophenylamino)-N-(2-hydroxyethyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxamide",0.036,uM,=,-1.4436974992327127,0,C1=Cc2c(ncnc2Nc2ccc(Oc3cccc4sccc34)cc2)NCC1
5720,792378,10.1016/j.ejmech.2011.11.015,,,,Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis,O=[N+]([O-])c1ccccc1-c1nnc(SCc2ccccc2)o1,"2-(Benzylthio)-5-(2-nitrophenyl)-1,3,4-oxadiazole",38.32,uM,=,1.5834255004065068,1,c1ccc(CSc2nnc(-c3ccccc3)o2)cc1
5721,66904,10.1016/S0960-894X(96)00601-4,,,,Inhibition of the epidermal growth factor receptor.,O=[N+]([O-])c1cccc(Nc2nccc(-c3cccnc3)n2)c1,(3-Nitro-phenyl)-(4-pyridin-3-yl-pyrimidin-2-yl)-amine,100.0,uM,=,2.0,1,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1
5722,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,COc1ccc(C2CC(c3ccc(C)c(C)c3)=NN2C(C)=O)cc1,"1-(3-(3,4-Dimethylphenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone",15.24,uM,=,1.1829849670035817,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
5723,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1,"2-(3,5-Diphenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",3.38,uM,=,0.5289167002776547,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
5724,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,(3-Bromo-phenyl)-(6-methoxy-quinazolin-4-yl)-amine,0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccccc23)cc1
5725,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,Nc1ccccc1C#Cc1cncnc1Nc1ccc(OCc2cccc(F)c2)c(Cl)c1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-(2-(2-aminophenyl)ethynyl)pyrimidin-4-amine,0.063,uM,=,-1.2006594505464183,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
5726,529998,10.1016/j.bmc.2008.02.053,,,,Inhibition of EGFR,CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-propionamide,0.00043,uM,=,-3.3665315444204134,0,c1ccc(Nc2ncnc3ccccc23)cc1
5727,2102324,10.1016/j.bmcl.2021.128308,,,,Inhibition of EGFR (unknown origin),C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0965999999999999,uM,=,-1.0150228735845066,0,c1ccc(Nc2ncnc3ccccc23)cc1
5728,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C6COC6)CC5)c(C)c4)nc32)C1,"(S)-3-(2-Chloro-5-methoxyphenyl)-7-((3-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.36,uM,=,-0.4436974992327127,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCN(C5COC5)CC4)cc3)nc2N1[C@H]1CCNC1
5729,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2ncc(F)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((5-fluoro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.046,uM,=,-1.337242168318426,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
5730,1842434,10.1016/j.ejmech.2019.03.004,,,,Inhibition of EGFR in human DIFI cells assessed as reduction in cell proliferation incubated for 72 hrs by Coulter counter method,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3ccccc23)cc1
5731,1778842,10.1016/j.bmcl.2018.07.039,,,,Inhibition of EGF-induced EGFR activation in human A431 cells pretreated for 60 mins followed by EGF addition and measured after 10 mins by ELISA,COc1ccc(Nc2ncnc3occ(C)c23)cc1,"N-(4-methoxyphenyl)-5-methylfuro[2,3-d]pyrimidin-4-amine",0.2831,uM,=,-0.548060130634897,0,c1ccc(Nc2ncnc3occc23)cc1
5732,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC,"(3-Bromo-phenyl)-(6,7-diethoxy-quinazolin-4-yl)-amine",6e-06,uM,=,-5.221848749616356,0,c1ccc(Nc2ncnc3ccccc23)cc1
5733,1883986,10.1021/acsmedchemlett.8b00461,,,,Inhibition of human EGFR cytoplasmic domain expressed in baculovirus expression system using FITC-C6-KKAEEEEYFELVAKK-NH2 as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET Lanthascreen assay,N#CN1CCC[C@@H](n2nc(-c3ccc(Oc4ccc(F)cc4F)cc3)c(C(N)=O)c2N)C1,"(R)-5-Amino-1-(1-cyanopiperidin-3-yl)-3-(4-(2,4-difluorophenoxy)phenyl)-1H-pyrazole-4-carboxamide",16.8,uM,=,1.2253092817258628,1,c1ccc(Oc2ccc(-c3ccn([C@@H]4CCCNC4)n3)cc2)cc1
5734,1662113,10.1016/j.ejmech.2017.02.061,,,,Inhibition of EGFR (unknown origin) measured after 40 mins by Kinase Glo luminescence assay,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1,N-(4-(6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-ylamino)phenyl)benzamide,0.11,uM,=,-0.958607314841775,0,O=C(Nc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1)c1ccccc1
5735,5004,10.1016/s0960-894x(02)00364-5,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Cc1cc(C(=O)NCCN2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"5-[4-(3-Chloro-4-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide",0.04,uM,=,-1.3979400086720375,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1
5736,1641793,,,,,"Cell Proliferation Inhibition Assay: The following in vitro assay is to determine the activity of the tested compounds for inhibiting the proliferation of cancer cells, which has high expression of EGFR. The activity is represented by the IC50 value. The general procedures of the assay are given as follows: The cancer cells A431 that highly expressing EGFR (Institute of biochemistry and cell biology) were chosen and seeded to 96-well cell culture plate at a suitable concentration (e.g., 5000 cells/mL medium). The cells then were incubated in carbon dioxide (CO2) incubator until they reached 85% confluency. Then, the cell culture medium was replaced by fresh one with tested compounds added in it at serial concentrations (general 6 to 7 concentrations). Then the cells were put back to the incubator and cultured continuously. 72 hours later, the activity of the tested compounds for inhibiting the cell proliferation was determined by using Sulforhodamine B (SRB) method.",CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@@H]1CCCN1,"US8901140, 2::US9358227, 2",0.003,uM,=,-2.5228787452803374,0,O=C(/C=C/[C@@H]1CCCN1)Nc1ccc2nccc(Nc3ccc(OCc4ccccn4)cc3)c2c1
5737,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,Cc1cc2cc(Nc3ccnc4cc(-c5ccc(CNCCN6CCNCC6)cc5)sc34)ccc2[nH]1,"(2-Methyl-1H-indol-5-yl)-(2-{4-[(2-pyridin-1-yl-ethylamino)-methyl]-phenyl}-thieno[3,2-b]pyridin-7-yl)-amine",0.25,uM,=,-0.6020599913279624,0,c1cc(Nc2ccc3[nH]ccc3c2)c2sc(-c3ccc(CNCCN4CCNCC4)cc3)cc2n1
5738,506208,10.1021/np50089a001,,,,Inhibition of EGFR,Cc1oc2cc(O)cc(O)c2c(=O)c1-c1ccc(O)cc1,"5,7-dihydroxy-3-(4-hydroxyphenyl)-2-methyl-4H-chromen-4-one",7.040556016198146,uM,=,0.847606958180666,1,O=c1c(-c2ccccc2)coc2ccccc12
5739,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3ccc(Br)cc3)c2cn1,"N*4*-(4-Bromo-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ncnc3ccncc23)cc1
5740,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCC(O)(O)CC1,"4-(4,4-Dihydroxy-piperidin-1-yl)-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide",0.282,uM,=,-0.549750891680639,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
5741,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCOC(=O)c1cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1C,"4-(1-Benzyl-1H-indazol-5-ylamino)-5-methyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester",0.2,uM,=,-0.6989700043360187,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
5742,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5F)cc4)[nH]c23)CC1,"2-(4-(2,4-difluorophenoxy)phenyl)-7-(1-propioloylpiperidin-4-yl)-1H-imidazo[1,2-b]pyrazole-3-carboxamide",0.0327999999999999,uM,=,-1.484126156288321,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNCC5)c4[nH]3)cc2)cc1
5743,2017350,10.1021/acs.jmedchem.0c00870,,,,Inhibiton of EGFR (unknown origin) expressed in human A431 cells assessed as reduction in EGFR induced cell viability after 96 hrs by CellTiter-Glo assay,C=CC(=O)Nc1cccc(-c2c[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)c1,"N-{3-{4-{[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl}acrylamide",1.675,uM,=,0.224014811372864,1,c1ccc(-c2c[nH]c3ncnc(Nc4ccc(OCc5ccccn5)cc4)c23)cc1
5744,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CNC1,"5-(4-amino-1-(azetidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",2.9,uM,=,0.4623979978989561,1,c1ccc(-c2nn(C3CNC3)c3ncncc23)cc1
5745,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(OCCCc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3-phenyl-propyl ester",0.03,uM,=,-1.5228787452803376,0,O=C(OCCCc1ccccc1)c1cccc(NCc2ccccc2)c1
5746,2119947,10.1021/acsmedchemlett.1c00156,,,,Inhibition of EGFR (unknown origin),c1ccc(-c2ccc3c(Nc4ccc5scnc5c4)ccnc3c2)cc1,N-(7-phenylquinolin-4-yl)benzo[d]thiazol-5-amine,2.5,uM,=,0.3979400086720376,1,c1ccc(-c2ccc3c(Nc4ccc5scnc5c4)ccnc3c2)cc1
5747,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(Oc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid phenyl ester",10.0,uM,=,1.0,1,O=C(Oc1ccccc1)c1cccc(NCc2ccccc2)c1
5748,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Nc1ccc2ncnc(Nc3ccc4c(c3)CCC4)c2c1,"N4-(2,3-dihydro-1H-inden-5-yl)quinazoline-4,6-diamine",0.2513,uM,=,-0.5998075114074239,0,c1ccc2c(Nc3ccc4c(c3)CCC4)ncnc2c1
5749,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=CNc1ccc(O)cc1,2-[(4-Hydroxy-phenylamino)-methylene]-malononitrile,350.0,uM,=,2.544068044350276,1,c1ccccc1
5750,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(NCc3ccc(F)cc3)c2cc1OCCCCCCC(=O)NO,7-(4-(4-Fluorobenzylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.268,uM,=,-0.5718652059712112,0,c1ccc(CNc2ncnc3ccccc23)cc1
5751,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,C=CC(=O)Nc1cc(Nc2ncc(Br)c(Nc3ccc4c(c3)CCC4)n2)c(OC)cc1N1CCN(C)CC1,"N-(5-((5-bromo-4-((2,3-dihydro-1H-inden-5-yl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide",0.2025,uM,=,-0.6935749724493127,0,c1cc(Nc2ccc3c(c2)CCC3)nc(Nc2ccc(N3CCNCC3)cc2)n1
5752,2268691,10.1016/j.ejmech.2021.113768,,,,Inhibition of GST-fused EGFR (unknown origin) in presence of ATP by microplate reader analysis,O=C(Nc1ccccc1C(=O)N/N=C/c1ccc(O)cc1O)c1ccco1,"N-[2-[[(E)-(2,4-dihydroxyphenyl)methyleneamino]carbamoyl]phenyl]furan-2-carboxamide",0.0312,uM,=,-1.5058454059815571,0,O=C(Nc1ccccc1C(=O)N/N=C/c1ccccc1)c1ccco1
5753,591074,10.1021/jm9010065,,,,Inhibition of human recombinant HER1 expressed in Sf9 cells by liquid scintillation counting,CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)OCC1CCCCN1,"{4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl}-carbamic acid piperidin-2-ylmethyl ester",0.045,uM,=,-1.3467874862246565,0,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OCC1CCCCN1
5754,63616,10.1016/S0960-894X(97)00034-6,,,,Inhibition of Epidermal growth factor receptor autophosphorylation.,COc1cc2ncnc(NCc3ccccc3)c2cc1OC.Cl,"Benzyl-(6,7-dimethoxy-quinazolin-4-yl)-amine hydrochloride, 0.2 M H2O",0.004,uM,=,-2.397940008672037,0,c1ccc(CNc2ncnc3ccccc23)cc1
5755,1882933,10.1016/j.ejmech.2018.11.029,,,,Inhibition of recombinant human wild type GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system after 1 hr by kinase tracer 199 based TR-FRET assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.00047,uM,=,-3.3279021420642825,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
5756,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)COC(=O)c1c(C)cccc1C,"2-((4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)amino)-2-oxoethyl 2,6-dimethylbenzoate",0.044,uM,=,-1.3565473235138126,0,O=C(COC(=O)c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5757,5004,10.1016/s0960-894x(02)00364-5,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Cc1cc(C(=O)N2CCN(C)CC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc(F)c(Cl)c3)c21,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[3-methyl-5-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.1,uM,=,-1.0,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCNCC2)[nH]1
5758,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,CS(=O)(=O)CCNCCCCOc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,(3-Chloro-4-fluoro-phenyl)-{6-[4-(methanesulfonylmethyl-amino)-butoxy]-quinazolin-4-yl}-amine,0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
5759,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,C=CC(=O)Nc1cccc(-c2c[nH]c3nccc(-c4[nH]c(CCCO)nc4C(F)(F)F)c23)c1,"N-(3-(4-(2-(3-Hydroxypropyl)-4-(trifluoromethyl)-1H-imidazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl)acrylamide",0.68,uM,=,-0.1674910872937636,0,c1ccc(-c2c[nH]c3nccc(-c4cnc[nH]4)c23)cc1
5760,2127056,10.1016/j.bmcl.2021.128118,,,,Inhibition of recombinant wild type EGFR-TK (unknown origin) by ELISA,COc1ccc(C(Nc2ccc(Br)cc2)n2c(=O)ccc3cc(O)ccc32)cc1,1-((4-bromophenylamino)(4-methoxyphenyl)methyl)-6-hydroxyquinolin-2(1H)-one,0.96,uM,=,-0.0177287669604316,0,O=c1ccc2ccccc2n1C(Nc1ccccc1)c1ccccc1
5761,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,C#CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-[(3-bromophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-2-propynamide",0.0006,uM,=,-3.2218487496163566,0,c1ccc(Nc2ncnc3cnccc23)cc1
5762,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc(N)c(C(=O)Nc2ccc(F)c(Cl)c2)cc1NC(=O)c1ccc(CN2CCN(C)CC2)cc1,2-amino-N-(3-chloro-4-fluorophenyl)-4-ethoxy-5-(4-((4-methylpiperazin-1-yl)methyl)benzamido)benzamide,0.8,uM,=,-0.0969100130080563,0,O=C(Nc1cccc(C(=O)Nc2ccccc2)c1)c1ccc(CN2CCNCC2)cc1
5763,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCOC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,Heptyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetate,7.23,uM,=,0.8591382972945308,1,O=c1cc(-c2ccccc2)oc2ccccc12
5764,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,C#Cc1cccc(Nc2ncnc3cc4oc(=O)n(CCOC(=O)CBr)c4cc23)c1,"1-(2-(2-bromoacetoxy)ethyl)-8-((3-ethynylphenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",5.2,uM,=,0.7160033436347992,1,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
5765,2224994,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin),Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"[4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid,(3S)-3-morpholinylmethyl ester",0.02,uM,=,-1.6989700043360187,0,O=C(Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnn2c1)OC[C@@H]1COCCN1
5766,2248093,10.1021/acs.jmedchem.1c00710,,,,Inhibition of wild type human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells incubated for 30 mins in presence of ATP by HTRF analysis,C=CC(=O)Nc1cc2c(Nc3ccc(Oc4cc5nncn5cn4)c(C)c3)ncnc2cc1OCC,"N-[7-ethoxy-4-[3-methyl-4-([1,2,4]triazolo[4,3-c]pyrimidin-7-yloxy)anilino]quinazolin-6-yl]prop-2-enamide",0.00147,uM,=,-2.832682665251824,0,c1ccc2c(Nc3ccc(Oc4cc5nncn5cn4)cc3)ncnc2c1
5767,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c(Br)c(OC)c4)nn32)CC1,"rac-7-(1-acryloylpiperidin-4-yl)-2-(4-bromo-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",1.999,uM,=,0.3008127941181169,1,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1
5768,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)nc4)nc32)c1,"N-(3-(5-methyl-2-((6-(4-methylpiperazin-1-yl)pyridin-3-yl)amino)-7-oxo-pyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.0467999999999999,uM,=,-1.329754146925876,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)nc3)nc2n1-c1ccccc1
5769,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Br)c(Br)c2)CC1c1ccc(O)cc1,"3-(3,4-Dibromophenyl)-5-(4-hydroxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",11.27,uM,=,1.0519239160461065,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
5770,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,c1ccc2c(Cc3nnc(Cc4nc5ccccc5[nH]4)o3)cccc2c1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-(naphthalen-1-ylmethyl)-1,3,4-oxadiazole",5.7,uM,=,0.7558748556724915,1,c1ccc2c(Cc3nnc(Cc4nc5ccccc5[nH]4)o3)cccc2c1
5771,612309,10.1021/jm901453q,,,,Inhibition of EGFR,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.0112,uM,=,-1.9507819773298185,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
5772,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc(C(=O)OCc5ccc(Cl)cc5)cc4)c3cc21,"4-Chlorobenzyl 4-(1-(4-ethoxy-4-oxobutyl)-2-oxo-1,2-dihydrooxazolo[4,5-g]quinazolin-8-ylamino)benzoate",0.66,uM,=,-0.1804560644581313,0,O=C(OCc1ccccc1)c1ccc(Nc2ncnc3cc4oc(=O)[nH]c4cc23)cc1
5773,1462679,10.1016/j.ejmech.2014.10.084,,,,Inhibition of EGFR (unknown origin),Clc1cc(Nc2ncnc3ccc(NC4=NC[C@H](COc5ccccc5)O4)cc23)ccc1OCc1nccs1,"(R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(5-(phenoxymethyl)-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine",1.21,uM,=,0.08278537031645,1,c1ccc(OC[C@H]2CN=C(Nc3ccc4ncnc(Nc5ccc(OCc6nccs6)cc5)c4c3)O2)cc1
5774,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc2N1CCCN1CCOCC1,"4-((3-chloro-4-fluorophenyl)amino)-6-(3-morpholinopropyl)-6H-[1,4]oxazino[3,2-g]quinazoline-7(8H)-one",0.0531,uM,=,-1.274905478918531,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
5775,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,Brc1cccc(Nc2ncnc3cc4c(cnn4CCN4CCOCC4)cc23)c1,"(3-Bromo-phenyl)-[1-(2-morpholin-4-yl-ethyl)-1H-pyrazolo[4,3-g]quinazolin-5-yl]-amine",0.192,uM,=,-0.7166987712964504,0,c1ccc(Nc2ncnc3cc4c(cnn4CCN4CCOCC4)cc23)cc1
5776,982646,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type human EGFR tyrosine kinase assessed as Ulight-CAGAGAIETDKEYYTVKD phosphorylation after 15 mins by time-resolved fluorometry,O=C(CCCN1CCCCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-bromoanilino)quinazolin-6-yl)-4-(piperidin-1-yl)butanamide,0.00063,uM,=,-3.2006594505464183,0,O=C(CCCN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5777,622913,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR in human A431 cells by HTRF assay,CCN(CC)CCNC(=O)c1cc2cnnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2[nH]1,"7-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-N-(2-(diethylamino)ethyl)-1H-pyrrolo[2,3-d]pyridazine-2-carboxamide",77.22,uM,=,1.8877297972880305,1,c1ccc(COc2ccc(Nc3nncc4cc[nH]c34)cc2)cc1
5778,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.Oc1ccc(-c2cc3c(NCc4ccc(F)cc4)ncnc3[nH]2)cc1,"4-(4-((4-Fluorobenzyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.026,uM,=,-1.585026652029182,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
5779,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,O=C(CCN1CCCCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-piperidin-1-ylpropanamide,0.00027,uM,=,-3.5686362358410126,0,O=C(CCN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5780,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.026,uM,=,-1.585026652029182,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
5781,66897,10.1021/jm970367n,,,,Inhibition of Epidermal growth factor receptor (EGFr) tyrosine kinase,Cc1cc(C)c(C)c(-c2cc3cnc(N)nc3nc2NC(=O)NC(C)(C)C)c1C,"1-[2-Amino-6-(2,3,5,6-tetramethyl-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl-urea",6.68,uM,=,0.8247764624755457,1,c1ccc(-c2cnc3ncncc3c2)cc1
5782,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1ncc(N2CC[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-((R)-2-methylazetidin-1-yl)-2,6-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",25.0,uM,=,1.3979400086720375,1,c1cc(Nc2cc3cncc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
5783,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
5784,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),CCO.Nc1ccc2sc3c(Nc4ccccc4)ncnc3c2c1,"N*4*-Phenyl-benzo[4,5]thieno[3,2-d]pyrimidine-4,8-diamine; compound with ethanol",0.0094,uM,=,-2.026872146400301,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
5785,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,Cc1nc(Nc2ccccc2)c2cc(C)oc2n1,"2,6-Dimethyl-N-phenylfuro[2,3-d]pyrimidin-4-amine",0.1132,uM,=,-0.9461535731477474,0,c1ccc(Nc2ncnc3occc23)cc1
5786,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CC#CC(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,"US9181263, 15::US9278100, 15",0.2894,uM,=,-0.5385014732169814,0,c1ccc(Oc2ccc(-c3nn(C[C@H]4CCCN4)c4ncncc34)cc2)cc1
5787,940299,10.1021/ml300327z,,,,Inhibition of human wild type EGFR expressed in Sf9 cells using [gamma32P]-ATP after 10 mins by scintillation counting,CN(C)C/C=C/C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,"(E)-N-(2-(4-((3-Chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-4-(dimethylamino)but-2-enamide",0.0046,uM,=,-2.337242168318426,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
5788,1770089,10.1016/j.bmcl.2017.12.009,,,,Inhibition of wild-type EGFR phosphorylation in human A431 cells preincubated for 1 hr followed by EGF stimulation measured after 45 mins by ELISA,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCC(N(CC)CC)CC4)cc3OC)n2)c1,N-(3-(3-(2-(4-(4-(diethylamino)piperidin-1-yl)-2-methoxyphenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,1.013,uM,=,0.0056094453602803,1,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCCCC3)cc2)n1
5789,792073,10.1016/j.bmc.2011.10.085,,,,Inhibition of EGFR expressed in baculovirus infected Sf9 cells assessed as inhibition of autophosphorylation preincubated for 10 mins measured after 1 hr by DELFIA/Time-Resolved Fluorometry,Clc1cccc(Nc2ncnc3ccc(NCc4ccc(Br)cc4)cc23)c1,"N6-(4-Bromobenzyl)-N4-(3-chlorophenyl)quinazoline-4,6-diamine",5.67,uM,=,0.7535830588929066,1,c1ccc(CNc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
5790,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCN1CCN(C)CC1.Cl,(4-Bromo-2-fluoro-phenyl)-{6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinazolin-4-yl}-amine hydrochloride,0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
5791,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1F,"(R)-4-(4-((1-(2-Fluorophenyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.008,uM,=,-2.096910013008056,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
5792,565660,10.1016/j.bmcl.2009.02.094,,,,Inhibition of EGFR,NC[C@H](Cc1cccc(F)c1)NC(=O)c1cc(Br)c(-c2ccnc3[nH]ccc23)s1,"N-((S)-1-amino-3-(3-fluorophenyl)propan-2-yl)-4-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide",10.0,uM,=,1.0,1,O=C(NCCc1ccccc1)c1ccc(-c2ccnc3[nH]ccc23)s1
5793,346246,10.1016/j.bmcl.2005.12.092,,,,Inhibitory activity against recombinant human EGFR,COc1ccc(N2Cc3cnc(Nc4ccc(F)cc4)nc3N([C@@H]3CC[C@@H](O)C3)C2=O)cc1,"7-(4-fluorophenylamino)-1-((1S,3R)-3-hydroxycyclopentyl)-3-(4-methoxyphenyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.545,uM,=,-0.2636034977233575,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccccc3)nc2N1C1CCCC1
5794,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(N3CCc4ccccc43)c2cc1OC,"4-(2,3-Dihydro-indol-1-yl)-6,7-dimethoxy-quinazoline",0.82,uM,=,-0.0861861476162833,0,c1ccc2c(c1)CCN2c1ncnc2ccccc12
5795,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl methylcarbamate",0.05,uM,=,-1.3010299956639813,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
5796,66599,10.1021/jm960879m,,,,Tested for inhibition of PLC gamma-derived substrate in Epidermal growth factor receptor stimulated A431 cells,CN(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*,N*6*-dimethyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0026,uM,=,-2.5850266520291822,0,c1ccc(Nc2ncnc3cnccc23)cc1
5797,2067577,10.1016/j.ejmech.2019.111888,,,,"Inhibition of EGFR L858R/T790M/C797S (unknown origin) using Poly (Glu, Tyr) as substrate measured after 40 mins by kinase-glo assay",CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccc(F)cc5)n([C@H]5CCCN(C(=O)CO)C5)c4n3)cc2)CC1,"(S)-9-(1-hydroxyacetylpiperidine-3-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-4-fluorophenyl-9H-purine-2,8-diamine",0.041,uM,=,-1.3872161432802643,0,c1ccc(Nc2nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc3n2[C@H]2CCCNC2)cc1
5798,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CCN(CC)CCN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-((2-(diethylamino)ethyl)(methyl)amino)but-2-enamide",0.139,uM,=,-0.8569851997459049,0,c1ccc(Nc2ncnc3sccc23)cc1
5799,321418,10.1016/j.bmcl.2005.06.068,,,,Inhibitory concentration against EGFR kinase phosphorylation using synthetic peptide as a substrate,Clc1cc(Nc2ncnc3cccc(OC4CCOCC4)c23)ccc1OCc1ccccn1,[3-Chloro-4-(pyridin-2-ylmethoxy)-phenyl]-[5-(tetrahydro-pyran-4-yloxy)-quinazolin-4-yl]-amine,2.4,uM,=,0.380211241711606,1,c1ccc(COc2ccc(Nc3ncnc4cccc(OC5CCOCC5)c34)cc2)nc1
5800,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN(C)C,(3-Chloro-4-fluoro-phenyl)-[6-(2-dimethylamino-ethoxy)-7-methoxy-quinazolin-4-yl]-amine,0.007,uM,=,-2.154901959985743,0,c1ccc(Nc2ncnc3ccccc23)cc1
5801,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3[nH]ccc3c1)nn2C1CCCC1,"1-cyclopentyl-3-(1H-indol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.734,uM,=,-0.1343039400839294,0,c1ncc2c(-c3ccc4[nH]ccc4c3)nn(C3CCCC3)c2n1
5802,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,Brc1cccc(Nc2ncnc3cc(NCCCN4CCOCC4)ncc23)c1,"N*4*-(3-Bromo-phenyl)-N*7*-(3-morpholin-4-yl-propyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0019,uM,=,-2.721246399047171,0,c1ccc(Nc2ncnc3cc(NCCCN4CCOCC4)ncc23)cc1
5803,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1nc(C)nc(Nc3ccc4ccccc4c3)c1NC2,"(7,8-dimethoxy-3-methyl-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-naphthalen-2-yl-amine",17.0,uM,=,1.230448921378274,1,c1ccc2c(c1)CNc1c(Nc3ccc4ccccc4c3)ncnc1S2
5804,2089816,10.1016/j.ejmech.2020.112470,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr)4:1 as substrate in presence of ATP measured after 30 mins by HTRF assay",COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,EXEL-2880/GSK-1363089,3.18,uM,=,0.5024271199844327,1,O=C(Nc1ccccc1)C1(C(=O)Nc2ccc(Oc3ccnc4cc(OCCCN5CCOCC5)ccc34)cc2)CC1
5805,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,Cn1cnc(-c2ccc(OC(F)(F)F)c(NC(=O)Nc3ccncc3)c2)c1,1-(5-(1-methyl-1H-imidazol-4-yl)-2-(trifluoromethoxy)phenyl)-3-(pyridin-4-yl)urea,0.0948199999999999,uM,=,-1.0231000490170623,0,O=C(Nc1ccncc1)Nc1cccc(-c2c[nH]cn2)c1
5806,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,CCc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-ethyl-5-methylpyrimidin-4-amine,0.64,uM,=,-0.1938200260161128,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
5807,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCN(C)CC1,"N-{4-(3-Chloro-4-fluoro-phenylamino)-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-pyrido[3,2-d]pyrimidin-6-yl}-acrylamide",0.264,uM,=,-0.5783960731301689,0,c1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)cnc23)cc1
5808,2294501,10.1016/j.bmc.2023.117202,,,,Inhibition of wild type EGFR (unknown origin),C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2O[C@H]2CCOC2)CC1,"(S)-1-(4-((4-((3,4-diChloro-2-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.00034,uM,=,-3.468521082957745,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(OC4CCNCC4)cc23)cc1
5809,1870312,10.1021/acs.jmedchem.8b00672,,,,Inhibition of wild type EGFR (unknown origin),COc1cc2c(Oc3ccc(NS(=O)(=O)c4ccccc4OC(F)(F)F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,N-(3-fluoro-4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinolin-4-yloxy)phenyl)-2-(trifluoromethoxy)benzenesulfonamide,3.081,uM,=,0.4886916983169406,1,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1ccccc1
5810,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccc(-c2ccccc2)cc1)c1ccccc1,(Z)-2-((E)-3-(biphenyl-4-yl)-1-phenylallylidene)hydrazinecarbothioamide,5.11,uM,=,0.7084209001347128,1,N=C(/C=C/c1ccc(-c2ccccc2)cc1)c1ccccc1
5811,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CCN(C(C)C)CC1,4-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-1-isopropylpiperidine-4-carboxamide,0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccc(CNC4CCNCC4)cc23)cc1
5812,632810,10.1016/j.bmc.2010.04.001,,,,Noncompetitive inhibition of EGFR after 30 mins by chemiluminescence ELISA in presence of 250 uM ATP,Cl.NCCc1cn(Cc2ccc(-c3cccc(C(F)(F)F)c3)cc2)c2ccc(OCCc3ccc(O)cc3)cc12,2-{5-(4-Hydroxyphenethoxy)-1-[4-(3-trifluoromethylphenyl)]benzyl-1H-indole-3-yl}ethanamine hydrochloride,1.06,uM,=,0.0253058652647702,1,c1ccc(CCOc2ccc3c(ccn3Cc3ccc(-c4ccccc4)cc3)c2)cc1
5813,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3ccc(C#Cc4cccs4)cc23)cc1Cl,N-(3-chloro-4-fluorophenyl)-6-(2-(thiophen-2-yl)ethynyl)quinazolin-4-amine,1.6405999999999998,uM,=,0.2150027072149522,1,C(#Cc1cccs1)c1ccc2ncnc(Nc3ccccc3)c2c1
5814,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCN(CCO)CC1,"3-{4-Amino-7-[1-(2-hydroxy-ethyl)-piperidin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-phenol",2.54,uM,=,0.404833716619938,1,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1
5815,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,COCCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN(C)C,(2E)-N-[4-[(1-Benzyl-1H-indazol-5-yl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]-4-(dimethylamino)-2-butenamide,0.007,uM,=,-2.154901959985743,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccccc45)ccc32)cc1
5816,1348544,10.1016/j.bmcl.2014.03.072,,,,Inhibition of autophosphorylation of recombinant his-tagged EGFR (amino acid 645-1186) (unknown origin) expressed in Sf-9 cells after 10 mins by time-resolved fluorometry,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccc3ccccc3c2)=N1,"2-(5-(naphthalen-2-yl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",6.31,uM,=,0.8000293592441343,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccc3ccccc3c2)=N1
5817,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),CN(C)CCCNC(=O)/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,But-2-enedioic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide (3-dimethylamino-propyl)-amide,0.00044,uM,=,-3.356547323513813,0,c1ccc(Nc2ncnc3ccccc23)cc1
5818,66897,10.1021/jm970367n,,,,Inhibition of Epidermal growth factor receptor (EGFr) tyrosine kinase,CN1CCN(CCCNc2ncc3cc(-c4c(Cl)cccc4Cl)c(NC(=O)NC(C)(C)C)nc3n2)CC1,"1-tert-Butyl-3-{6-(2,6-dichloro-phenyl)-2-[3-(4-methyl-piperazin-1-yl)-propylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea",0.15,uM,=,-0.8239087409443188,0,c1ccc(-c2cnc3nc(NCCCN4CCNCC4)ncc3c2)cc1
5819,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Nc1ccc2ncnc(Nc3cccc4ccccc34)c2c1,"N4-(naphthalen-1-yl)quinazoline-4,6-diamine",0.0016,uM,=,-2.7958800173440754,0,c1ccc2c(Nc3ncnc4ccccc34)cccc2c1
5820,665430,10.1016/j.bmcl.2010.08.079,,,,Inhibition of EGFR,N#Cc1ccc2c(c1)C(c1ccccc1F)=Nc1c[nH]nc1N2,"5-(2-fluorophenyl)-2,10-dihydrobenzo[e]pyrazolo[4,3-b][1,4]diazepine-7-carbonitrile",10.9,uM,=,1.0374264979406236,1,c1ccc(C2=Nc3c[nH]nc3Nc3ccccc32)cc1
5821,2229998,10.1021/acs.jmedchem.1c00876,,,,Inhibition of wild type EGFR (unknown origin),Cn1cc(-c2cc(C(=O)/N=c3\[nH]c4ccccc4n3[C@H]3CC[C@H](O)CC3)ccn2)cn1,"N-(1-((1r,4r)-4-hydroxycyclohexyl)-1H-benzo[d]imidazol-2(3H)-ylidene)-2-(1-methyl-1H-pyrazol-4-yl)isonicotinamide",0.54,uM,=,-0.2676062401770315,0,O=C(/N=c1\[nH]c2ccccc2n1C1CCCCC1)c1ccnc(-c2cn[nH]c2)c1
5822,982646,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type human EGFR tyrosine kinase assessed as Ulight-CAGAGAIETDKEYYTVKD phosphorylation after 15 mins by time-resolved fluorometry,O=C(CCOc1ccccc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-bromoanilino)quinazolin-6-yl)-3-phenoxypropanamide,0.019,uM,=,-1.7212463990471711,0,O=C(CCOc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5823,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC[C@H](Oc2cc3c(Nc4ccc(Br)c(Cl)c4F)ncnc3cc2OC)C1,1-((3S)-3-(4-(4-bromo-3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1-yl)prop-2-en-1-one,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccc(O[C@H]4CCNC4)cc23)cc1
5824,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5C[C@H]6CN(C)C[C@H]6C5)c(C)c4)nc32)C1,"3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-((3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)phenyl)amino)-1-((S)-1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]-pyrimidin-2(1H)-one",0.216,uM,=,-0.6655462488490691,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4C[C@H]5CNC[C@H]5C4)cc3)nc2N1[C@H]1CCNC1
5825,1861191,10.1016/j.ejmech.2019.07.064,,,,Inhibition of EGFR (unknown origin),COc1ccc(/C=C/C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2O[C@@H]2CCOC2)cc1,(R)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(4-methoxyphenyl)acrylamide,0.009,uM,=,-2.0457574905606752,0,O=C(/C=C/c1ccccc1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@@H]1CCOC1
5826,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCCCC(=O)NO,7-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyhexanamide,0.0034,uM,=,-2.468521082957745,0,c1ccc(Nc2ncnc3ccccc23)cc1
5827,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.011,uM,=,-1.958607314841775,0,c1ccc(/N=c2\nc[nH]c3cc(OCC4CCNCC4)ccc23)cc1
5828,1650711,10.1016/j.bmcl.2017.02.023,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay,O=C(Nc1ccc2nccc(Nc3cccc(Cl)c3)c2c1)C1CCC2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3,"N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-2,2-adamantane-1,4-dioxaspiro[4.5]decane-8-carboxamide",0.1278,uM,=,-0.8934691461776186,0,O=C(Nc1ccc2nccc(Nc3ccccc3)c2c1)C1CCC2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3
5829,1970998,10.1016/j.ejmech.2019.111918,,,,Inhibition of EGFR (unknown origin) using TK as substrate incubated for 30 mins by HTRF assay,C=CC(=O)NCCOc1cc(Cc2ccccc2)cc2[nH]c(-c3n[nH]c4cc(-c5cn[nH]c5)ccc34)cc12,N-(2-((2-(6-(1H-pyrazol-4-yl)-1H-indazol-3-yl)-6-benzyl-1H-indol-4-yl)oxy)ethyl)acrylamide,4.5,uM,=,0.6532125137753437,1,c1ccc(Cc2ccc3cc(-c4n[nH]c5cc(-c6cn[nH]c6)ccc45)[nH]c3c2)cc1
5830,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN(C)C,(3-Chloro-4-fluoro-phenyl)-[6-(3-dimethylamino-propoxy)-7-methoxy-quinazolin-4-yl]-amine,0.049,uM,=,-1.3098039199714864,0,c1ccc(Nc2ncnc3ccccc23)cc1
5831,1337213,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ccc2nc(Oc3ccc(F)cc3)c(/C=N/NC(=O)Cn3c([N+](=O)[O-])cnc3C)cc2c1,(E)-N'-((2-(4-fluorophenoxy)-6-methylquinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,0.43,uM,=,-0.3665315444204134,0,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
5832,699068,10.1016/j.bmc.2010.11.007,,,,Inhibition of EGFR by HTRF assay,CCOC(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1,Ethyl 1-(3-Bromopheylamino)-4-cyanoisoquinolin-7-ylcarbamate,12.8,uM,=,1.1072099696478683,1,c1ccc(Nc2nccc3ccccc23)cc1
5833,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3c[nH]c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(1H-Indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)buta2,3-dienamide",0.0032,uM,=,-2.494850021680094,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5834,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=C(O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid,1.0,uM,=,0.0,0,O=S(=O)(Oc1ccccc1)c1ccccc1
5835,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccn2)c1O,2-Cyano-3-[4-hydroxy-3-methoxy-5-(pyridin-2-ylsulfanylmethyl)-phenyl]-acrylamide,16.0,uM,=,1.2041199826559248,1,c1ccc(CSc2ccccn2)cc1
5836,1738745,10.1016/j.ejmech.2018.04.052,,,,"Inhibition of recombinant human GST-tagged wild type EGFR expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(Nc2nccc(Nc3ccccc3-c3ncn(C)n3)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-((2-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide",0.66,uM,=,-0.1804560644581313,0,c1ccc(Nc2nccc(Nc3ccccc3-c3nc[nH]n3)n2)cc1
5837,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,NC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,1-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)urea,0.186,uM,=,-0.7304870557820837,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
5838,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CSc1ccccn1,N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-2-(pyridin-2-ylthio)acetamide,0.07,uM,=,-1.154901959985743,0,O=C(CSc1ccccn1)Oc1ccc2ncnc(Nc3ccccc3)c2c1
5839,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccc(OCc2ccccc2)cc1)c1ccccc1,(Z)-2-((E)-3-(4-(benzyloxy)phenyl)-1-phenylallylidene)hydrazinecarbothioamide,0.7,uM,=,-0.1549019599857432,0,N=C(/C=C/c1ccc(OCc2ccccc2)cc1)c1ccccc1
5840,1882933,10.1016/j.ejmech.2018.11.029,,,,Inhibition of recombinant human wild type GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system after 1 hr by kinase tracer 199 based TR-FRET assay,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CCl,2-chloro-N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)acetamide,0.00087,uM,=,-3.0604807473813813,0,c1ccc(Nc2ncnc3ccccc23)cc1
5841,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CCCCN(CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1)CCCC,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-4-(dibutylamino)-2-butynamide",0.049,uM,=,-1.3098039199714864,0,c1ccc(Nc2ncnc3cnccc23)cc1
5842,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)NCCSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,N-(2-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)ethyl)acrylamide,0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
5843,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,Cl.O=C(NCCn1ccc2ncnc(Nc3ccc(Oc4cccc5sncc45)c(Cl)c3)c21)[C@@H]1CCCN1,"N-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]-amino}-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl]prolinamide hydrochloride",0.003,uM,=,-2.5228787452803374,0,O=C(NCCn1ccc2ncnc(Nc3ccc(Oc4cccc5sncc45)cc3)c21)[C@@H]1CCCN1
5844,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(OCCC12C[C@H]3C[C@@H](C1)C[C@@H](C2)C3)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 2-adamantan-1-yl-ethyl ester",1.25,uM,=,0.0969100130080564,1,O=C(OCCC12C[C@H]3C[C@@H](C1)C[C@@H](C2)C3)c1cccc(NCc2ccccc2)c1
5845,1586270,10.1016/j.bmc.2016.04.046,,,,Inhibition of wild type human EGFR preincubated for 5 mins followed by ATP addition for 30 mins by HTRF assay,CCOc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)[C@@H]1COC(=O)N1,(S)-N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-2-oxooxazolidine-4-carboxamide,0.00134,uM,=,-2.8728952016351923,0,O=C1N[C@H](C(=O)Nc2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)CO1
5846,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,CN(CC(O)CO)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"3-{[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-methyl-amino}-propane-1,2-diol",0.00056,uM,=,-3.2518119729938,0,c1ccc(Nc2ncnc3cnccc23)cc1
5847,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Cc1cccc(CN(Cc2ccc(F)cc2)C(=O)Nc2ccccc2)c1O,1-(4-Fluorobenzyl)-1-(2-hydroxy-5-methylbenzyl)-3-phenylurea,21.71,uM,=,1.33665982345442,1,O=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
5848,1448250,10.1016/j.bmcl.2014.07.094,,,,Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry,Cc1ccc2c(c1)cc(C1C(C#N)=C(N)N(c3cccnc3)C3=C1C(=O)CCC3)c1nnnn12,"2-Amino-4-(7-methyltetrazolo[1,5-a]quinolin-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile",10.4,uM,=,1.0170333392987805,1,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1
5849,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,NC(=O)C1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc6[nH]ccc6c5)c4s3)cc2)CC1,"1-{4-[4-(1H-Indol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl}-isonicotinamide",0.007,uM,=,-2.154901959985743,0,c1nc(Nc2ccc3[nH]ccc3c2)c2sc(-c3ccc(CN4CCCCC4)cc3)cc2n1
5850,1348544,10.1016/j.bmcl.2014.03.072,,,,Inhibition of autophosphorylation of recombinant his-tagged EGFR (amino acid 645-1186) (unknown origin) expressed in Sf-9 cells after 10 mins by time-resolved fluorometry,Cc1ccc(C2=NN(C3=NC(=O)CS3)C(c3ccc4ccccc4c3)C2)cc1,"2-(5-(naphthalen-2-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",3.25,uM,=,0.5118833609788744,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccc3ccccc3c2)=N1
5851,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCC(N6CCN(C)CC6)CC5)cc4OC)nc32)c1,"N-(3-(3-Isopropyl-7-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)-piperidin-1-yl)phenyl)amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.24,uM,=,-0.619788758288394,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)ncc12
5852,989154,10.1016/j.bmc.2013.09.027,,,,Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA,C#Cc1cccc(-n2ccc3cc(OC)cc(OC)c3c2=O)c1,"6,8-dimethoxy-2-(3-ethynylphenyl)isoquinolin-1(2H)-one",3.51,uM,=,0.5453071164658241,1,O=c1c2ccccc2ccn1-c1ccccc1
5853,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N[C@H]1CCN(c2nc(Nc3cnn(C)c3)c3ncn(C(C)C)c3n2)C1,(S)-N-(1-(9-isopropyl-6-((1-methyl-1H-pyrazol-4-yl)amino)-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide,0.652,uM,=,-0.1857524042680797,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1
5854,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-10",0.067,uM,=,-1.1739251972991736,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5855,1363799,10.1021/ml400527n,,,,Inhibition of EGF receptor (unknown origin),CCc1ccccc1NC(=O)N1C[C@@H](C)Oc2cc(-c3ccc([C@H]4CC[C@H](CC(=O)O)CC4)cc3)ccc21,"(R)-2-((trans)-4-(4-(4-(2-ethylphenylcarbamoyl)-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)cyclohexyl)aceticacid",7.5,uM,=,0.8750612633917001,1,O=C(Nc1ccccc1)N1CCOc2cc(-c3ccc(C4CCCCC4)cc3)ccc21
5856,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,c1ccc(CNc2ncnc3cccnc23)cc1,"Benzyl-pyrido[3,2-d]pyrimidin-4-yl-amine",0.603,uM,=,-0.2196826878598487,0,c1ccc(CNc2ncnc3cccnc23)cc1
5857,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,COc1ccc2c(c1)Oc1ncnc(Nc3ccc(F)c(Cl)c3)c1NC2,"(3-Chloro-4-fluoro-phenyl)-(7-methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",8.9,uM,=,0.9493900066449128,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
5858,1675840,10.1016/j.bmc.2017.03.032,,,,"Inhibition of recombinant wild type human EGFR (695 to end residues) using Poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(/C=C/c4cc(C)cc(C)c4)cc3)ncc2Cl)c1,". N-[3-[[5-Chloro-2-[(E)-4-(3,5-dimethylstyryl)phenylamino]-4-pyrimidinyl]amino]phenyl]-2-acrylamide",0.6065,uM,=,-0.2171691947974082,0,C(=C/c1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)\c1ccccc1
5859,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",CCN1C(=O)CS/C1=N/Nc1nncc2ccccc12,3-Ethyl-2-(2-(phthalazin-1-yl)hydrazono)thiazolidin-4-one,0.047,uM,=,-1.3279021420642825,0,O=C1CS/C(=N/Nc2nncc3ccccc23)N1
5860,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,Cc1ncc(C#N)c(Nc2ccc(OCc3ccccn3)c(Cl)c2)c1C#Cc1ccc(CNCCS(C)(=O)=O)o1,4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-6-methyl-5-((5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)ethynyl)nicotinonitrile,1.5,uM,=,0.1760912590556812,1,C(#Cc1cnccc1Nc1ccc(OCc2ccccn2)cc1)c1ccco1
5861,1353177,10.1021/ml4003309,,,,Inhibition of recombinant EGFR (unknown origin) using poly-GT peptide as substrate by Transcreener assay,COc1cc2c(Oc3ccc(NS(=O)(=O)c4cccc(-c5cccs5)c4)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,N-[3-fluoro-4-({6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yl}oxy)phenyl]-3-(2-thienyl)benzenesulfonamide,1.052,uM,=,0.0220157398177202,1,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1cccc(-c2cccs2)c1
5862,1283337,10.1016/j.ejmech.2013.10.058,,,,Inhibition of wild type EGFR (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,COc1cc2nc(Cl)nc(Nc3ccc(NC(C)=O)cc3)c2cc1OC,"N-(4-((2-Chloro-6,7-dimethoxyquinazolin-4-yl)amino)phenyl)acetamide",37.6,uM,=,1.575187844927661,1,c1ccc(Nc2ncnc3ccccc23)cc1
5863,947883,10.1021/np300535c,,,,Inhibition of EGFR (unknown origin) after 20 mins by scintillation counting,NC(=O)C1=C(N)C(=O)C=C(Nc2ccccc2O)C1=O,Vegfrecine,2.6,uM,=,0.414973347970818,1,O=C1C=CC(=O)C(Nc2ccccc2)=C1
5864,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)Cc1ccc(O)cc1,2-(4-Hydroxy-benzyl)-malononitrile,6500.0,uM,=,3.812913356642856,1,c1ccccc1
5865,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.Cc1ccc([C@@H](C)Nc2ncnc3[nH]c(-c4ccc(O)cc4)cc23)cc1,"(R)-4-(4-((1-(p-Tolyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.45,uM,=,-0.3467874862246563,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
5866,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(C)cc3F)ncnc2cc1OCC1CCNCC1,(2-Fluoro-4-methyl-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.45,uM,=,-0.3467874862246563,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
5867,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CCNC(=O)/C(C#N)=C/c1ccc(O)cc1,2-Cyano-N-cyanomethyl-3-(4-hydroxy-phenyl)-acrylamide,625.0,uM,=,2.7958800173440754,1,c1ccccc1
5868,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(C)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1,"N-(3-(7-((4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-3-methyl-2,4-dioxo-3,4-dihydropyrimido-[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.137,uM,=,-0.8632794328435932,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCCCC4)cc3)ncc12
5869,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)cc3)nn21,"US9447106, 134",1.059,uM,=,0.0248959601074849,1,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1
5870,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,CCCN(CC#CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1)CCC,4-Dipropylamino-but-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.13,uM,=,-0.8860566476931633,0,c1ccc(Nc2ccnc3ccccc23)cc1
5871,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)OC)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-20",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5872,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1-c1nnc(C)c2nn(-c3ccccc3)cc12,"7-Methyl-4-(2-methyl-4,5-diphenyl-1H-pyrrol-3-yl)-2-phenyl-2H-pyrazolo[3,4-d]-pyridazine",3.89,uM,=,0.5899496013257077,1,c1ccc(-c2[nH]cc(-c3nncc4nn(-c5ccccc5)cc34)c2-c2ccccc2)cc1
5873,66907,10.1016/S0960-894X(00)80473-4,,,,Inhibition of epidermal growth factor receptor (EGFR),O=C(Nc1ccccc1)c1cc2cc(O)c(O)cc2cn1,"6,7-Dihydroxy-isoquinoline-3-carboxylic acid phenylamide",5.6,uM,=,0.7481880270062004,1,O=C(Nc1ccccc1)c1cc2ccccc2cn1
5874,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,Cc1ccc(Oc2ccc(Nc3ncnc4ccc(-c5cn(CCCCCCC(=O)NO)nn5)cc34)cc2C)cn1,"N-Hydroxy-7-(4-(4-((3-methyl-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)heptanamide",0.01,uM,=,-2.0,0,c1cncc(Oc2ccc(Nc3ncnc4ccc(-c5c[nH]nn5)cc34)cc2)c1
5875,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(/N=N/c3ccc(F)c(Cl)c3)c2cc1OC,"(3-Chloro-4-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-diazene",3.93,uM,=,0.5943925503754267,1,c1ccc(/N=N/c2ncnc3ccccc23)cc1
5876,2112388,10.1016/j.bmcl.2021.127987,,,,Inhibition of EGFR (unknown origin),CN(/N=N\c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)C(=O)OCCl,chloromethyl 3-(4-(3-chlorophenylamino)quinazolin-6-yl)-1-methyltriaz-2-ene-1-carboxylate,0.00039,uM,=,-3.408935392973501,0,c1ccc(Nc2ncnc3ccccc23)cc1
5877,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CN(C)c1ccc2cncnc2c1,Dimethyl-quinazolin-7-yl-amine,0.011,uM,=,-1.958607314841775,0,c1ccc2ncncc2c1
5878,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,CCOC(=O)C(=CNc1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c2c1)C(=O)OCC,Diethyl 2-(((4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)quinazolin-6-yl)amino)methylene)malonate,0.023,uM,=,-1.6382721639824072,0,c1ccc(Oc2ccc(Nc3ncnc4ccccc34)cc2)cc1
5879,1832355,10.1016/j.bmcl.2018.12.056,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0009599999999999,uM,=,-3.017728766960432,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
5880,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C(C)C)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(3-Isopropyl-7-(2-methoxy-4-(4-methylpiperazin-1-yl)-phenylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.00038,uM,=,-3.42021640338319,0,O=C1NCc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
5881,1983835,10.1016/j.bmc.2019.115281,,,,Inhibition of wild type EGFR (unknown origin),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5882,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21,"1-methyl-3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.388,uM,=,-0.4111682744057927,0,c1ccc2cc(-c3n[nH]c4ncncc34)ccc2c1
5883,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(Cl)c(Cl)c3)c2c1,"1-(4-((3,4-Dichlorophenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)thiourea",0.772,uM,=,-0.1123826996642638,0,S=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5884,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3cnccc23)c1,"(3-Bromo-phenyl)-pyrido[3,4-d]pyrimidin-4-yl-amine",0.051,uM,=,-1.2924298239020635,0,c1ccc(Nc2ncnc3cnccc23)cc1
5885,64443,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1ccc2ncnc(N3CCc4ccc(Br)cc43)c2c1,"N-[4-(6-Bromo-2,3-dihydro-indol-1-yl)-quinazolin-6-yl]-acrylamide",0.0004,uM,=,-3.397940008672037,0,c1ccc2c(c1)CCN2c1ncnc2ccccc12
5886,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCC1CCN(C)CC1,(4-Chloro-2-fluoro-phenyl)-{6-methoxy-7-[2-(1-methyl-piperidin-4-yl)-ethoxy]-quinazolin-4-yl}-amine,0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3cc(OCCC4CCNCC4)ccc23)cc1
5887,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,NC(=O)c1c(-c2ccc(Oc3ccccc3)cc2)nn2c1[nH]c1ccc(N)cc12,"US9447106, 66",0.0059,uM,=,-2.229147988357856,0,c1ccc(Oc2ccc(-c3cc4[nH]c5ccccc5n4n3)cc2)cc1
5888,2059412,10.1016/j.bmc.2021.116061,,,,Inhibition of EGFR in human A431 cells preincubated for 60 mins followed by EGF stimulation and measured after 10 mins by ELISA,COc1ccc(N(C)c2nc(Cl)nc3ccccc23)cc1,2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine,0.0036,uM,=,-2.4436974992327127,0,c1ccc(Nc2ncnc3ccccc23)cc1
5889,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccs4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-(4-{[3,6-dioxo-4-(2-thienylmethoxy)cyclohexa-1,4-dien-1-yl]amino}-7-ethoxyquinazolin-6-yl)but-2-enamide",0.2951999999999999,uM,=,-0.5298836468489961,0,O=C1C=C(OCc2cccs2)C(=O)C=C1Nc1ncnc2ccccc12
5890,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1ccc(C=O)cc1,2-(4-Formyl-benzylidene)-malononitrile,60.0,uM,=,1.7781512503836436,1,c1ccccc1
5891,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Nc1ncnc2c1c(-c1ccccc1)nn2-c1ccccc1,"1,3-Diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine",0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2nn(-c3ccccc3)c3ncncc23)cc1
5892,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1F,"3-(4-fluoro-3-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",3.86,uM,=,0.5865873046717549,1,c1ccc(-c2n[nH]c3ncncc23)cc1
5893,2237044,10.1016/j.ejmech.2021.113329,,,,Inhibition EGFR (unknown origin) expressed in baculovirus expression system by ELISA,C=CC(=O)Nc1cccc(N2C(=O)OC(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(7-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-4-methyl-2-oxo-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazin-1-yl)phenyl)acrylamide",0.0474,uM,=,-1.324221658325915,0,O=C1OCc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
5894,1914927,10.1016/j.ejmech.2019.111943,,,,Inhibition of N-terminal GST-tagged human EGFR (d746-750AA) expressed in baculovirus using FAM-labelled peptide as substrate pre-incubated for 10 mins followed by substrate addition by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.00075,uM,=,-3.1249387366083,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
5895,67206,10.1021/jm010496a,,,,Inhibition of (EGFR) epidermal growth factor receptor tyrosine kinase,CCOc1cc2ncnc(Nc3cccc(-c4nccs4)c3)c2cc1OCC,"(6,7-Diethoxy-quinazolin-4-yl)-(3-thiazol-2-yl-phenyl)-amine",0.002,uM,=,-2.6989700043360187,0,c1cc(Nc2ncnc3ccccc23)cc(-c2nccs2)c1
5896,67068,10.1016/s0960-894x(99)00615-0,,,,Inhibition of Epidermal growth factor receptor (EGFr),COc1cc(Nc2nccc(-c3ccc(N4CCNCC4)nc3)n2)cc(OC)c1OC,"[4-(6-Piperazin-1-yl-pyridin-3-yl)-pyrimidin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine",1.704,uM,=,0.2314695904306813,1,c1ccc(Nc2nccc(-c3ccc(N4CCNCC4)nc3)n2)cc1
5897,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c3)ncnc2cc1OC,N-(7-Methoxy-4-{[1-(phenylsulfonyl)-1H-indol-5-yl]amino}-6-quinazolinyl)propanamide,0.127,uM,=,-0.8961962790440431,0,O=S(=O)(c1ccccc1)n1ccc2cc(Nc3ncnc4ccccc34)ccc21
5898,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,CN(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.00041,uM,=,-3.3872161432802645,0,c1ccc(Nc2ncnc3ccccc23)cc1
5899,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,(E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide,0.0021,uM,=,-2.6777807052660805,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5900,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,N#CC(C#N)=CNc1ccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2c1,2-(((4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)quinazolin-6-yl)amino)methylene)malononitrile,3.05,uM,=,0.4842998393467858,1,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
5901,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1c(Nc2ncnc3cc4c(cc23)OCCO4)ccc(Cl)c1Cl,"N-(3,4-Dichloro-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
5902,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,CN1CCN(c2ccc(Nc3ncnc4cc5oc(=O)n(CCOC(=O)CBr)c5cc34)cc2Cl)CC1,"1-(2-(2-bromoacetoxy)ethyl)-8-((3-chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.008,uM,=,-2.096910013008056,0,O=c1[nH]c2cc3c(Nc4ccc(N5CCNCC5)cc4)ncnc3cc2o1
5903,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COc1cc2ncc(C#N)c(Nc3cccc(Br)c3)c2cc1NC(=O)/C=C/CN1CCOCC1,(E)-4-Morpholin-4-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,3.83,uM,=,0.5831987739686227,1,O=C(/C=C/CN1CCOCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
5904,622914,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR by HTRF assay,Cc1c(C(=O)NCCN2CCOCC2)[nH]c2cnnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c12,"4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-3-methyl-N-(2-morpholinoethyl)-1H-pyrrolo[3,2-d]pyridazine-2-carboxamide",5.0,uM,=,0.6989700043360189,1,O=C(NCCN1CCOCC1)c1cc2c(Nc3ccc(OCc4ccccc4)cc3)nncc2[nH]1
5905,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCCCCCCOC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,Tetradecyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetate,1.01,uM,=,0.0043213737826425,1,O=c1cc(-c2ccccc2)oc2ccccc12
5906,676221,10.1021/jm100607r,,,,Inhibition of EGFR,CC[C@@H](Nc1ncnc2sc3c(c12)CCN(C(=O)/C=C/CN(C)C)C3)c1ccccc1,"(E)-4-(Dimethylamino)-1-(4-[(1S)-1-phenylpropyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-buten-1-one",0.012,uM,=,-1.9208187539523751,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1
5907,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,C#Cc1cccc(Nc2ncnc3cc(OC(C)C)c4c(c23)OCCO4)c1,"N-(3-Ethynylphenyl)-5-isopropoxy-2,3-dihydro-[1,4]-dioxino[2,3-f]quinazolin-10-amine",0.0237,uM,=,-1.6252516539898962,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
5908,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2ncnc3ccccc23)cc1
5909,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCc1c(C(=O)N(C)C)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid dimethylamide",0.2,uM,=,-0.6989700043360187,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
5910,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cnc(N)nc1,2-Amino-N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)-methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-pyrimidine-5-carboxamide,0.043,uM,=,-1.3665315444204136,0,O=C(Nc1cccc(C(=O)Nc2ccc(CN3CCNCC3)cc2)c1)c1cncnc1
5911,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3cccc(CO)c3)nc21,"6-(2,6-Dichloro-phenyl)-2-(3-hydroxymethyl-phenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",0.09,uM,=,-1.0457574905606752,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
5912,1448250,10.1016/j.bmcl.2014.07.094,,,,Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry,COC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1cc2cc(Cl)ccc2n2nnnc12,"Methyl 2-amino-4-(7-chlorotetrazolo[1,5-a]quinolin-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",8.1,uM,=,0.9084850188786496,1,O=C1CCCC2=C1C(c1cc3ccccc3n3nnnc13)C=CN2c1cccnc1
5913,946709,10.1016/j.bmc.2012.12.045,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,CC(C)(C)C(=O)Nc1nc(Nc2cccc(C(F)(F)F)c2)c2cc(CCc3ccccn3)[nH]c2n1,"N-{4-[(3-Trifluoromethylphenyl)amino]-6-(2-pyridin-2-yl-ethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl}-2,2-dimethylpropanamide",12.8,uM,=,1.1072099696478683,1,c1ccc(Nc2ncnc3[nH]c(CCc4ccccn4)cc23)cc1
5914,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)N1CC(F)C1,(S)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-fluoroazetidine-1-carboxamide,0.967,uM,=,-0.0145735259169983,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1)N1CCC1
5915,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CSc1ncccn1,N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-2-(pyrimidin-2-ylthio)acetamide,0.027,uM,=,-1.5686362358410126,0,O=C(CSc1ncccn1)Oc1ccc2ncnc(Nc3ccccc3)c2c1
5916,431038,10.1021/jm050607w,,,,Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation,CCOc1cc2ncnc(Nc3ccc(F)cc3)c2cc1OCC.Cl,"4-(4'-fluoroanilino)-6,7-diethoxyquinazoline hydrochloride",0.622,uM,=,-0.2062096153091813,0,c1ccc(Nc2ncnc3ccccc23)cc1
5917,65120,10.1021/jm00023a009,,,,In vitro inhibition of EGF-stimulated DNA synthesis of ER 22 cells by following the incorporation of methyl-[3H]thymidine.,CC(C)(C)c1cc(O)cc(-c2ccc(C(=O)NCc3ccccc3)cc2)c1,3'-tert-Butyl-5'-hydroxy-biphenyl-4-carboxylic acid benzylamide,5.4,uM,=,0.7323937598229685,1,O=C(NCc1ccccc1)c1ccc(-c2ccccc2)cc1
5918,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Nc3cccc(Cl)c3)c2c1-c1ccccc1,"(3-Chloro-phenyl)-(6-methyl-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",0.23,uM,=,-0.6382721639824072,0,c1ccc(Nc2ncnc3[nH]cc(-c4ccccc4)c23)cc1
5919,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,COc1cc(NC(=O)Nc2ccccn2)cc(-c2cccnc2)c1OC,"1-(3,4-Dimethoxy-5-(pyridin-3-yl)phenyl)-3-(pyridin-2-yl)urea",0.04881,uM,=,-1.3114911923434789,0,O=C(Nc1cccc(-c2cccnc2)c1)Nc1ccccn1
5920,63769,10.1016/S0960-894X(97)00014-0,,,,Displacement of [gamma-32P]-ATP from Epidermal growth factor receptor in A431 cell-free extracts,O=[N+]([O-])c1cc(NCc2cc(O)ccc2O)ccc1O,"2-[(4-Hydroxy-3-nitro-phenylamino)-methyl]-benzene-1,4-diol",5.4,uM,=,0.7323937598229685,1,c1ccc(CNc2ccccc2)cc1
5921,2132157,10.1021/acs.jmedchem.1c01559,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(Br)ccn3)cc2)c(C(N)=O)n1N,(S)-2-(1-acryloylpiperidin-2-yl)-1-amino-4-(4-((4-bromopyridin-2-yl)carbamoyl)phenyl)-1H-imidazole-5-carboxamide,0.578,uM,=,-0.2380721615794709,0,O=C(Nc1ccccn1)c1ccc(-c2c[nH]c([C@@H]3CCCCN3)n2)cc1
5922,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C(C)C)C(C)C,(2E)-N-[4-(3-Chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(diisopropylamino)-2-butenamide,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
5923,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCNC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,N-Nonyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetamide,3.58,uM,=,0.5538830266438743,1,O=c1cc(-c2ccccc2)oc2ccccc12
5924,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5925,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCc2ccc(Cl)cc2)c1O,3-[3-(4-Chloro-benzylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,16.0,uM,=,1.2041199826559248,1,c1ccc(CSCc2ccccc2)cc1
5926,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,CCN(CC)CCCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,(3-Chloro-4-fluoro-phenyl)-[6-(3-diethylamino-propoxy)-7-methoxy-quinazolin-4-yl]-amine,0.057,uM,=,-1.2441251443275083,0,c1ccc(Nc2ncnc3ccccc23)cc1
5927,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,Oc1ccc2c(Nc3cccc(Br)c3)ncnc2c1,4-(3-Bromo-phenylamino)-quinazolin-7-ol,0.0047,uM,=,-2.3279021420642825,0,c1ccc(Nc2ncnc3ccccc23)cc1
5928,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Nc3ccc(Br)cc3)c1NC2,"(4-bromo-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",8.7,uM,=,0.9395192526186184,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
5929,557465,10.1021/jm800758s,,,,Inhibition of human EGFR,CNC(=N)SCCCn1c(=O)c2c(c1=O)n1c3ccccc3cc1c1cccc3ccn2c31,"3-(1,3-Dioxo-1,3-dihydro-2H-indolo[1',7':4,5,6]pyrrolo[3',4':2,3][1,4]diazepino[1,7-a]indol-2-yl)propyl N-Methylimidothiocarbamate",9.9,uM,=,0.99563519459755,1,O=c1[nH]c(=O)c2c1n1ccc3cccc(c31)c1cc3ccccc3n12
5930,553933,10.1021/np070447m,,,,Inhibition of recombinant EGFR,COc1cc(O)c(C(=O)O)c(-c2cc(O)c(O)cc2C)c1,altenusin,0.0337838958026477,uM,=,-1.4712902710457607,0,c1ccc(-c2ccccc2)cc1
5931,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),COc1cc2sc3c(Nc4cccc(Br)c4)ncnc3c2cc1OC.Cl,"(3-Bromo-phenyl)-(7,8-dimethoxy-benzo[4,5]thieno[3,2-d]pyrimidin-4-yl)-amine hydrochloride",0.444,uM,=,-0.3526170298853802,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
5932,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccc(C(=O)O)c(O)c2)[nH]c2ccccc12)NCc1ccc(C(=O)O)c(O)c1,4-[2-(2-{3-[2-(4-carboxy-3-hydroxybenzylcarbamoyl)ethyl]-1H-2-indolyldisulfanyl}-1H-3-indolyl)ethylcarboxamidomethyl]-2-hydroxybenzoic acid,8.5,uM,=,0.9294189257142929,1,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
5933,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,COCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2c2c1OCCO2,"N-(3-Chloro-4-fluorophenyl)-5-(2-methoxyethoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0130999999999999,uM,=,-1.882728704344236,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
5934,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CCOC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid ethyl ester",0.4,uM,=,-0.3979400086720376,0,c1ccc(CNc2ccccc2)cc1
5935,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,Cc1ccc(C2CC(c3ccc(C)c(C)c3)=NN2C(N)=S)cc1,"3-(3,4-Dimethylphenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazole-1-carbothioamide",0.34,uM,=,-0.4685210829577448,0,c1ccc(C2=NNC(c3ccccc3)C2)cc1
5936,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,COc1cc2ncnc(Nc3cccc(F)c3)c2cc1OC.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-fluoro-phenyl)-amine hydrochloride",0.0063,uM,=,-2.2006594505464183,0,c1ccc(Nc2ncnc3ccccc23)cc1
5937,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-(2-(4-aminophenyl)ethynyl)pyrimidin-4-amine,0.03,uM,=,-1.5228787452803376,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
5938,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(Oc4cccc(F)c4)cc3)ncnc2cc1OC,N-{4-[4-(3-Fluorophenoxy)anilino]-7-methoxy-6-quinazolinyl}-propanamide,0.881,uM,=,-0.055024091587952,0,c1ccc(Oc2ccc(Nc3ncnc4ccccc34)cc2)cc1
5939,78511,10.1016/j.bmcl.2003.10.010,,,,Inhibition of EGFR overexpressing HN5 (head/neck carcinoma) cell line proliferation,CS(=O)(=O)CCNCCCCOc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,(3-Chloro-4-fluoro-phenyl)-{6-[4-(methanesulfonylmethyl-amino)-butoxy]-quinazolin-4-yl}-amine,0.071,uM,=,-1.1487416512809248,0,c1ccc(Nc2ncnc3ccccc23)cc1
5940,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccccc23)cc1
5941,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,OCC(O)Cn1ncc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"3-[5-(3-Bromo-phenylamino)-pyrazolo[4,3-g]quinazolin-1-yl]-propane-1,2-diol",0.318,uM,=,-0.4975728800155673,0,c1ccc(Nc2ncnc3cc4[nH]ncc4cc23)cc1
5942,1832355,10.1016/j.bmcl.2018.12.056,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,CC(C)OCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(2-isopropoxyethoxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,0.00154,uM,=,-2.812479279163537,0,c1ccc(Nc2ncnc3ccccc23)cc1
5943,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,CCOc1cc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN1CCCCC1,(Z)-N-(4-((3-Chloro-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide,0.0129,uM,=,-1.889410289700751,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccc(Oc4cccnc4)cc3)c2c1
5944,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",CNc1ncc2ncnc(Nc3cccc(Br)c3)c2n1,"N*8*-(3-Bromo-phenyl)-N*2*-methyl-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.00076,uM,=,-3.1191864077192086,0,c1ccc(Nc2ncnc3cncnc23)cc1
5945,2102324,10.1016/j.bmcl.2021.128308,,,,Inhibition of EGFR (unknown origin),O=C(CSc1nc2ccccc2c(=O)n1Cc1ccc2c(c1)OCO2)Nc1ccc(Br)cc1Br,"2-(3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-oxo-3,4-dihydroquinazolin-2-ylthio)-N-(2,4-dibromophenyl)acetamide",1.0327,uM,=,0.013974177020916,1,O=C(CSc1nc2ccccc2c(=O)n1Cc1ccc2c(c1)OCO2)Nc1ccccc1
5946,86514,10.1021/jm00110a022,,,,Inhibition of HER14 (human EGFR overexpressing) cell proliferation.,CC(NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1)c1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-(1-phenyl-ethyl)-acrylamide",3.5,uM,=,0.5440680443502757,1,O=C(/C=C/c1ccccc1)NCc1ccccc1
5947,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(Br)cc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-Bromo-5-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.057,uM,=,-1.2441251443275083,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
5948,66567,10.1021/jm950692f,,,,Inhibition of tyrosine kinase activity of Epidermal growth factor receptor from human A431 cells,Brc1cccc(Nc2ncnc3cc4[nH]nnc4cc23)c1,"(3-Bromo-phenyl)-(1H-1,2,3,5,7-pentaaza-cyclopenta[b]naphthalen-8-yl)-amine",0.0040999999999999,uM,=,-2.3872161432802645,0,c1ccc(Nc2ncnc3cc4[nH]nnc4cc23)cc1
5949,982643,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis,O=C(CCOc1ccccc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-bromoanilino)quinazolin-6-yl)-3-phenoxypropanamide,0.0217,uM,=,-1.6635402661514704,0,O=C(CCOc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5950,1912354,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGFR phosphorylation at Tyr1068 residues preincubated for 1 hr followed by human EGF stimulation and measured after 10 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.101,uM,=,-0.9956786262173574,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
5951,67208,10.1021/jm010496a,,,,Inhibition of Epidermal growth factor receptor,CCOc1cc2ncnc(Nc3cccc(-c4csc(C)n4)c3)c2cc1OCC,"(6,7-Diethoxy-quinazolin-4-yl)-[3-(2-methyl-thiazol-4-yl)-phenyl]-amine",4.8,uM,=,0.6812412373755872,1,c1cc(Nc2ncnc3ccccc23)cc(-c2cscn2)c1
5952,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CCNc1ccc2c(Nc3cccc(Br)c3)ncnc2c1,"N*4*-(3-Bromo-phenyl)-N*7*-ethyl-quinazoline-4,7-diamine",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3ccccc23)cc1
5953,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CN(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*,N*6*-dimethyl-pyrido[3,4-d]pyrimidine-4,6-diamine",6e-06,uM,=,-5.221848749616356,0,c1ccc(Nc2ncnc3cnccc23)cc1
5954,67057,10.1016/j.bmcl.2003.10.010,,,,Inhibitory activity against epidermal growth factor receptor,COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1,(4-Benzyloxy-phenyl)-(6-methoxy-quinazolin-4-yl)-amine,0.068,uM,=,-1.1674910872937636,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
5955,1715285,10.1021/acs.jmedchem.8b00346,,,,"Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Poly(Glu,Tyr)4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)n(CCC)c(=O)c3cnc(Nc4ccc(N5CCC(N(C)C)CC5)cc4OC)nc32)c1,"N-(3-(7-((4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-2,4-dioxo-3-propyl-3,4-dihydropyrimido-[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.013,uM,=,-1.8860566476931635,0,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCCCC4)cc3)ncc12
5956,952256,10.1016/j.bmc.2013.02.014,,,,Inhibition of human N-terminal DYKDDDD-tagged EGFR cytoplasmic domain (669 to 1210) expressed in baculovirus expression system incubated for 5 mins prior to [gamma-32P]ATP addition measured after 10 mins by scintillation counting analysis,O=C(NCCO)C1=Cc2c(ncnc2Nc2ccc(Oc3cccc(C(F)(F)F)c3)c(Cl)c2)NCC1,"4-((3-Chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-N-(2-hydroxyethyl)-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxamide",0.038,uM,=,-1.42021640338319,0,C1=Cc2c(ncnc2Nc2ccc(Oc3ccccc3)cc2)NCC1
5957,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C(=O)C#CC,N-(2-((2-acrylamido-5-methoxy-4-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)-N-methylbut-2-ynamide,0.9488,uM,=,-0.0228253239798126,0,c1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1
5958,2017353,10.1021/acs.jmedchem.0c00870,,,,Inhibition of human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using TK as substrate preincubated for 30 mins followed by substrate addition and measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0002,uM,=,-3.6989700043360174,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5959,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1/C=N/OCCN1CCOCC1,4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-methylpyrimidine-5-carbaldehyde O-2-morpholinoethyl oxime,0.068,uM,=,-1.1674910872937636,0,C(=N/OCCN1CCOCC1)\c1cncnc1Nc1ccc(OCc2ccccc2)cc1
5960,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc(Oc4ccccc4)cc3)ncnc2cn1,"(2E)-N-[4-(4-Phenoxybenzyl)pyrido[3,4-d]pyrimidin-6-yl]-4-(1-pyrrolidinyl)-2-butenamide",0.008,uM,=,-2.096910013008056,0,O=C(/C=C/CN1CCCC1)Nc1cc2c(Nc3ccc(Oc4ccccc4)cc3)ncnc2cn1
5961,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COCCN(CCOC)CCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,(6-{2-[Bis-(2-methoxy-ethyl)-amino]-ethoxy}-7-methoxy-quinazolin-4-yl)-(3-chloro-4-fluoro-phenyl)-amine,0.061,uM,=,-1.214670164989233,0,c1ccc(Nc2ncnc3ccccc23)cc1
5962,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CC(CCOC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O)c1ccccc1,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3-phenyl-butyl ester",2.7,uM,=,0.4313637641589873,1,O=C(OCCCc1ccccc1)c1cccc(NCc2ccccc2)c1
5963,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,Cn1cc(NC(=O)c2cccc(NS(=O)(=O)c3ccc(Cl)cc3)c2)cn1,3-((4-Chlorophenyl)sulfonamido)-N-(1-methyl-1H-pyrazol-4-yl)benzamide,30.45,uM,=,1.483587296968894,1,O=C(Nc1cn[nH]c1)c1cccc(NS(=O)(=O)c2ccccc2)c1
5964,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C(C)(C)C)c3n2)C[C@H]1F,"N-((3R,4R)-1-(9-(tert-Butyl)-6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9H-purin-2-yl)-4-fluoropyrrolidin-3-yl)acrylamide",0.673,uM,=,-0.1719849357760231,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1
5965,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,COc1cc(N(C)CCN(C)C)c(NC(=O)/C=C\C(C)C)cc1Nc1nccc(-c2cn(C)c3ccc(F)cc23)n1,(Z)-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(5-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)-4-methylpent-2-enamide,0.977,uM,=,-0.0101054362812269,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5966,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccccc2NC(C)=O)n1,N-(2-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acetamide,33.21,uM,=,1.5212688755983852,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5967,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,OCCN(CCO)CCCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"2-[{3-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-propyl}-(2-hydroxy-ethyl)-amino]-ethanol",0.00035,uM,=,-3.4559319556497243,0,c1ccc(Nc2ncnc3cnccc23)cc1
5968,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2c2c1OCCO2,"N-(3-Chloro-4-fluorophenyl)-5-ethoxy-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
5969,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1ccc(O)c(O)c1,"2-(3,4-Dihydroxy-benzylidene)-malononitrile",35.0,uM,=,1.5440680443502757,1,c1ccccc1
5970,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,CC(C)(CO)C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc5sncc45)c(Cl)c3)c21,"N-[2-(4-{[4-(1,2-Benzisothiazol-4-yloxy)-3-chlorophenyl]-amino}-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl]-3-hydroxy-2,2-dimethylpropanamide",0.007,uM,=,-2.154901959985743,0,c1cc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)c2cnsc2c1
5971,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCOC(=O)c1cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1CC,"4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester",0.12,uM,=,-0.9208187539523752,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
5972,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,O=c1oc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc2n1CCCN1CCOCC1,"8-(4-(Benzyloxy)phenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.14,uM,=,-0.8538719643217619,0,O=c1oc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc2n1CCCN1CCOCC1
5973,2268700,10.1016/j.ejmech.2021.113768,,,,Inhibition of EGFR (unknown origin),Cc1cc(NC2=NC(=O)/C(=C/c3c4ccccc4cc4ccccc34)S2)no1,5-(anthracen-9-ylmethylene)-2-((5-methylisoxazol-3-yl)amino)thiazol-4(5H)-one,0.045,uM,=,-1.3467874862246565,0,O=C1N=C(Nc2ccon2)S/C1=C\c1c2ccccc2cc2ccccc12
5974,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,methyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
5975,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cn1,"(2E)-N-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}pyrido[3,4-d]-pyrimidin-6-yl)-4-(dimethylamino)-2-butenamide",0.011,uM,=,-1.958607314841775,0,c1ccc(COc2ccc(Nc3ncnc4cnccc34)cc2)cc1
5976,78513,10.1016/s0960-894x(02)01047-8,,,,Inhibition of EGFR overexpressing HN5 (Head and neck) tumor cell proliferation,CS(=O)(=O)CCNc1nc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)cs1,(4-Benzyloxy-phenyl)-{6-[2-(2-methanesulfonyl-ethylamino)-thiazol-4-yl]-quinazolin-4-yl}-amine,1.6,uM,=,0.2041199826559248,1,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5cscn5)cc34)cc2)cc1
5977,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccccc2NC(=O)CO)n1,N-(2-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-2-hydroxyacetamide,2.01,uM,=,0.3031960574204888,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5978,1883874,10.1021/acsmedchemlett.8b00270,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay,C=CC(=O)N(c1cccc(C(F)(F)F)c1)c1ncnc2cc(OC)c(OCCCN3CCOCC3)cc12,4-[N-acryloyl-(3-(trifluoromethyl)phenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline,0.844,uM,=,-0.0736575533743449,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
5979,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-10",0.2,uM,=,-0.6989700043360187,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
5980,1873759,10.1021/acs.jmedchem.9b00576,,,,"Inhibition of wild-type EGFR (unknown origin) using Poly(Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,BRIGATINIB,0.0765999999999999,uM,=,-1.115771230367396,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
5981,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Clc1cccc(Nc2[nH]nc3ncnc(NCc4ccccc4)c23)c1,"N*4*-Benzyl-N*3*-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.87,uM,=,-0.0604807473813814,0,c1ccc(CNc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
5982,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1-c1ccc(NC(=O)c2ccccc2)c(=O)o1,"N-(6-(2-methyl-4,5-diphenyl-1H-pyrrol-3-yl)-2-oxo-2H-pyran-3-yl)benzamide",2.89,uM,=,0.4608978427565479,1,O=C(Nc1ccc(-c2c[nH]c(-c3ccccc3)c2-c2ccccc2)oc1=O)c1ccccc1
5983,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,CC(=O)N1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1.Cc1ccc(S(=O)(=O)O)cc1,1-(4-((5-(4-(3-Chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-yl)methyl)piperazin-1-yl)ethanone tosylate,0.0114,uM,=,-1.9430951486635275,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccc(CN6CCNCC6)o5)cc34)cc2)cc1.c1ccccc1
5984,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSC2=NCCS2)c1O,"2-Cyano-3-[3-(4,5-dihydro-thiazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-acrylamide",16.3,uM,=,1.212187604403958,1,c1ccc(CSC2=NCCS2)cc1
5985,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,c1csc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)c1,"(1H-Indol-5-yl)-(6-thiophen-2-yl-thieno[3,2-d]pyrimidin-4-yl)-amine",0.001,uM,=,-3.0,0,c1csc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)c1
5986,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccc(Cl)cc1)c1ccccc1,(Z)-2-((E)-3-(4-chlorophenyl)-1-phenylallylidene)hydrazinecarbothioamide,20.48,uM,=,1.3113299523037931,1,N=C(/C=C/c1ccccc1)c1ccccc1
5987,1561423,10.1016/j.bmcl.2016.02.059,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",O=C(Nc1ccc(Oc2ccnc3[nH]ccc23)c(F)c1)c1nnn(-c2ccc(F)cc2)c1C(F)(F)F,"N-(4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-3-fluorophenyl)-1-(4-fluorophenyl)-5-(trifluoromethyl)-1H-1,2,3-triazole-4-carboxamide",0.58217,uM,=,-0.23495017809705,0,O=C(Nc1ccc(Oc2ccnc3[nH]ccc23)cc1)c1cn(-c2ccccc2)nn1
5988,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,NCC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((4-(aminomethyl)piperidin-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.035,uM,=,-1.4559319556497243,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
5989,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)CCC(=O)O)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"3-[3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl(methyl)carbamoyl]propanoic acid",0.16,uM,=,-0.7958800173440752,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
5990,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Fc1c(Nc2ncnc3cc4c(cc23)OCCO4)cccc1C(F)(F)F,"N-[2-Fluoro-3-(trifluoromethyl)phenyl]-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0414,uM,=,-1.3829996588791011,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
5991,2070646,10.1016/j.bmcl.2020.127261,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 peptide as substrate preincubated for 1 hr by Z'-LYTE assay,COc1cc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2cc1NC(=O)C#CCCN1CCOCC1,4-(7-methoxy-6-(5-morpholinopent-2-ynamido)quinolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.138,uM,=,-0.8601209135987634,0,O=C(C#CCCN1CCOCC1)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1
5992,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc(N)c(C(=O)Nc2ccc(OCc3ccccn3)c(Cl)c2)cc1NC(=O)c1ccc(CN2CCN(C)CC2)cc1,2-amino-N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-4-ethoxy-5-(4-((4-methylpiperazin-1-yl)methyl)benzamido)benzamide,1.0,uM,=,0.0,0,O=C(Nc1cccc(C(=O)Nc2ccc(OCc3ccccn3)cc2)c1)c1ccc(CN2CCNCC2)cc1
5993,2282820,10.1039/d1md00280e,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr in presence of ATP by ADP-Glo kinase assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3ccccc23)cc1
5994,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,Nc1ccc2ncnc(Nc3cccc(Br)c3)c2n1,"N*4*-(3-Bromo-phenyl)-pyrido[3,2-d]pyrimidine-4,6-diamine",0.0076,uM,=,-2.1191864077192086,0,c1ccc(Nc2ncnc3cccnc23)cc1
5995,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,O=C(NC(=S)Nc1ccc(O)c(-c2nc3ccccc3s2)c1)c1ccc([N+](=O)[O-])cc1,N-(3-(benzo[d]thiazol-2-yl)-4-hydroxyphenylcarbamothioyl)-4-nitrobenzamide,0.28,uM,=,-0.5528419686577808,0,O=C(NC(=S)Nc1cccc(-c2nc3ccccc3s2)c1)c1ccccc1
5996,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,O=C(C#CCN1CCCCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Piperidin-1-yl-but-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.057,uM,=,-1.2441251443275083,0,O=C(C#CCN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
5997,520709,10.1016/j.ejmech.2008.04.012,,,,Inhibition of EGFR,Nc1ncnc2c1ncn2CC(=O)c1c[nH]c2ccccc12,2-(6-Amino-9H-purine-9-yl)-1-(1H-indole-3-yl)ethanone,35.0,uM,=,1.5440680443502757,1,O=C(Cn1cnc2cncnc21)c1c[nH]c2ccccc12
5998,523777,10.1016/j.bmcl.2009.05.009,,,,Inhibition of EGFR,N#Cc1cnc2c(Br)cc(NCc3c[nH]nn3)cc2c1Nc1ccc(F)c(Cl)c1,"8-bromo-4-[(3-chloro-4-fluorophenyl)amino]-6-[(2H-1,2,3-triazol-4-ylmethyl)amino]quinoline-3-carbonitrile",1.0,uM,=,0.0,0,c1ccc(Nc2ccnc3ccc(NCc4c[nH]nn4)cc23)cc1
5999,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CC(O)C1,1-(2-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)ethyl)azetidin-3-ol,0.026,uM,=,-1.585026652029182,0,c1ccc(Nc2ncnc3ccc(OCCN4CCC4)cc23)cc1
6000,1639950,,,,,Inhibition of recombinant human N-terminal GST His6-tagged thrombin cleavage site-fused EGFR (H672 to A1210 residues) expressed in baculovirus using poly-EY as substrate after 210 mins by luciferase coupled chemiluminescence assay,COc1cc2c(Nc3ccc(Cl)c(Cl)c3)ncnc2cc1OCc1ccc2nc(C(F)(F)F)cc(Cl)c2c1,"7-({[4-chloro-2-(trifluoromethyl)quinolin-6-yl]methyl}oxy)-N-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3cc(OCc4ccc5ncccc5c4)ccc23)cc1
6001,1650711,10.1016/j.bmcl.2017.02.023,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay,O=C(Nc1ccc2nccc(Nc3cccc(Cl)c3)c2c1)C1CCC2(CC1)OCC1(OO2)C2CC3CC(C2)CC1C3,"N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3,3-adamantane-1,5-dioxaspiro[5.5]undecane-9-carboxamide",0.1694,uM,=,-0.771086594005312,0,O=C(Nc1ccc2nccc(Nc3ccccc3)c2c1)C1CCC2(CC1)OCC1(OO2)C2CC3CC(C2)CC1C3
6002,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccc(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)cc1,"US9447106, 99",0.169,uM,=,-0.7721132953863264,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(c3ccccc3)CCN4)cc2)cc1
6003,807903,10.1016/j.bmc.2012.01.029,,,,Inhibition of EGF-induced EGFR autophosphorylation in human A431 cells incubated for 60 mins prior to EGF-induction measured after 10 mins by phosphotyrosine ELISA,Nc1nc(Nc2cccc(Br)c2)c2ccn(Cc3ccc(Cl)cc3)c2n1,"N4-(3-bromophenyl)-7-(4-chlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",99.9,uM,=,1.9995654882259823,1,c1ccc(Cn2ccc3c(Nc4ccccc4)ncnc32)cc1
6004,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(1-benzenesulfonyl-1H-indol-5-ylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.082,uM,=,-1.0861861476162833,0,O=S(=O)(c1ccccc1)n1ccc2cc(Nc3ccnc4ccccc34)ccc21
6005,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc(N)c(C(=O)Nc2ccc(OCc3ccccn3)c(Cl)c2)cc1NC(=O)/C=C/CN(C)C,2-amino-N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-5-(4-(dimethylamino)but-2-enamido)-4-ethoxybenzamide,0.8,uM,=,-0.0969100130080563,0,O=C(Nc1ccc(OCc2ccccn2)cc1)c1ccccc1
6006,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1,"Phenyl-(6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]indol-4-yl)-amine",0.31,uM,=,-0.5086383061657274,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1
6007,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2Br)c1,"US8975249, I-40",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6008,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)C1,1-(3-(4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1-yl)prop-2-en-1-one,0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccc(OC4CNC4)cc23)cc1
6009,63787,10.1021/jm00039a016,,,,Inhibition of tyrosine phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase from human A-431 carcinoma cell-shed membrane vesicles,CC(=O)Oc1cccc2c(C(=O)Nc3ccccc3)c(SSc3c(C(=O)Nc4ccccc4)c4cccc(OC(C)=O)c4n3C)n(C)c12,Acetic acid 2-(7-acetoxy-1-methyl-3-phenylcarbamoyl-1H-indol-2-yldisulfanyl)-1-methyl-3-phenylcarbamoyl-1H-indol-7-yl ester,9.9,uM,=,0.99563519459755,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
6010,2296008,10.1021/acsmedchemlett.3c00006,,,,Inhibition of recombinant human EGFR del19/T790M using biotinEEPLYWSFPAKKK-NH2 as substrate incubated for 120 mins by TR-FRET assay,C=CC(=O)N1CC[C@@H](n2nc(-c3cnc4ccccc4c3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-amino-3-(quinolin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one",0.0054,uM,=,-2.2676062401770314,0,c1ccc2ncc(-c3nn([C@@H]4CCNC4)c4ncncc34)cc2c1
6011,792378,10.1016/j.ejmech.2011.11.015,,,,Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis,COc1cc(OC)cc(-c2nnc(SCc3ccccc3)o2)c1,"2-(Benzylthio)-5-(3,5-dimethoxyphenyl)-1,3,4-oxadiazole",26.06,uM,=,1.415974411376566,1,c1ccc(CSc2nnc(-c3ccccc3)o2)cc1
6012,2090284,10.1016/j.ejmech.2020.112522,,,,Inhibition of wild type EGFR in human A-431 cells assessed as cell growth inhibition measured after 72 hrs by Celltiter-Glo luminescent cell viability assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,2.823,uM,=,0.4507108781469193,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6013,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CC(C)(C)C)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-45",0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6014,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,COc1cc(Nc2ncnc3ccc(-c4cn(CCCCCCC(=O)NO)nn4)cc23)ccc1Oc1ccccc1,"N-Hydroxy-7-(4-(4-((3-methoxy-4-phenoxyphenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)heptanamide",0.0116,uM,=,-1.9355420107730816,0,c1ccc(Oc2ccc(Nc3ncnc4ccc(-c5c[nH]nn5)cc34)cc2)cc1
6015,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Nc3cccc(Br)c3)c1NC2,"(3-Bromo-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6016,1770089,10.1016/j.bmcl.2017.12.009,,,,Inhibition of wild-type EGFR phosphorylation in human A431 cells preincubated for 1 hr followed by EGF stimulation measured after 45 mins by ELISA,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCC(N(C)C)CC4)cc3OC)n2)c1,N-(3-(3-(2-(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,1.535,uM,=,0.1861083798132052,1,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCCCC3)cc2)n1
6017,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc(F)c(C=O)c(F)c2)c2c(N)ncnc21,"4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2,6-difluorobenzaldehyde",10.0,uM,=,1.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
6018,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3ccccc3[nH]2)c1O,3-[3-(1H-Benzoimidazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,35.0,uM,=,1.5440680443502757,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
6019,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,COC(=O)N1CCC[C@@H]1C#Cc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2s1,"(R)-methyl 2-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidine-1-carboxylate",0.14,uM,=,-0.8538719643217619,0,C(#C[C@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
6020,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,C1=CC2=C(Cc3nnc(Cc4nc5ccccc5[nH]4)o3)CNC2C=C1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-((2,7a-dihydro-1H-indol-3-yl)methyl)-1,3,4-oxadiazole",86.2,uM,=,1.9355072658247128,1,C1=CC2=C(Cc3nnc(Cc4nc5ccccc5[nH]4)o3)CNC2C=C1
6021,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,COCC(=O)Nc1ccc2ncnc(Nc3cccc(I)c3)c2c1,N-[4-(3-Iodo-phenylamino)-quinazolin-6-yl]-2-methoxy-acetamide,0.15,uM,=,-0.8239087409443188,0,c1ccc(Nc2ncnc3ccccc23)cc1
6022,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,COC(CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1)OC,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-((2,2-dimethoxyethyl)(methyl)amino)but-2-enamide",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3sccc23)cc1
6023,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",O=C(OCCc1ccccc1)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid phenethyl ester",3.0,uM,=,0.4771212547196624,1,O=C(OCCc1ccccc1)c1cccc(NCc2ccccc2)c1
6024,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,C=C(CN1CCOCC1)C(=O)Nc1ccc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2c1,N-[4-(3-Chloro-4-fluoro-phenylamino)-3-cyano-quinolin-6-yl]-2-morpholin-4-ylmethyl-acrylamide,2.7,uM,=,0.4313637641589873,1,C=C(CN1CCOCC1)C(=O)Nc1ccc2nccc(Nc3ccccc3)c2c1
6025,1891469,10.1016/j.bmc.2019.03.049,,,,Inhibition of EGFR (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins by mobility shift assay,COc1cc2c(Oc3ccc(C4SCC(=O)N4NC(=O)Nc4ccc(F)cc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,"N1-(2,4-difluorophenyl)-N3-(2-(3-fluoro-4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-4-oxothiazolidin-3-yl)urea",0.4,uM,=,-0.3979400086720376,0,O=C(Nc1ccccc1)NN1C(=O)CSC1c1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1
6026,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Nc3cccc(C(F)(F)F)c3)c2c1C,"(5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(3-trifluoromethyl-phenyl)-amine",1.9,uM,=,0.2787536009528289,1,c1ccc(Nc2ncnc3[nH]ccc23)cc1
6027,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,Cn1cnc(-c2cc(NC(=O)Nc3nccs3)cc(C(F)(F)F)c2)c1,1-(3-(1-methyl-1H-imidazol-4-yl)-5-(trifluoromethyl)phenyl)-3-(thiazol-2-yl)urea,0.31076,uM,=,-0.5075748872239135,0,O=C(Nc1cccc(-c2c[nH]cn2)c1)Nc1nccs1
6028,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,Cc1c(OCC(F)(F)F)ccnc1COc1ccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)cc1,"8-(4-((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methoxy)phenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",7.8,uM,=,0.8920946026904804,1,O=c1oc2cc3ncnc(Nc4ccc(OCc5ccccn5)cc4)c3cc2n1CCCN1CCOCC1
6029,5000,10.1021/jm960118j,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Clc1cccc(Nc2ncnc3[nH]c(-c4ccccc4)c(-c4ccccc4)c23)c1,"(3-Chloro-phenyl)-(5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",3.0,uM,=,0.4771212547196624,1,c1ccc(Nc2ncnc3[nH]c(-c4ccccc4)c(-c4ccccc4)c23)cc1
6030,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",COC(CCNC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)OC,"(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(3,3-dimethoxypropyl)urea",0.544,uM,=,-0.26440110030182,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
6031,787273,10.1016/j.bmcl.2011.09.008,,,,Inhibition of EGFR after 60 mins by TR-FRET Assay,Cc1ccc(F)cc1Nc1nc2cc(Cl)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12,"(E)-N-(7-Chloro-4-(5-fluoro-2-methylphenylamino)imidazo[1,5-a]quinoxalin-8-yl)-4-(dimethylamino)-N-methylbut-2-enamide",0.068,uM,=,-1.1674910872937636,0,c1ccc(Nc2nc3ccccc3n3cncc23)cc1
6032,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCC(O)Cn1ccnc1,1-[4-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-3-imidazol-1-yl-propan-2-ol,0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3ccc(OCCCn4ccnc4)cc23)cc1
6033,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,Fc1ccc(Nc2ncnc3cc(OC4CCOCC4)c4c(c23)OCCO4)cc1Cl,"N-(3-Chloro-4-fluorophenyl)-5-((1-methoxypropan-2-yl)oxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0588,uM,=,-1.2306226739238617,0,c1ccc(Nc2ncnc3cc(OC4CCOCC4)c4c(c23)OCCO4)cc1
6034,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((5-Chloro-4-((2-(N,N-dimethylsulfamoyl)phenyl)amino)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.204,uM,=,-0.6903698325741012,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
6035,1924071,10.1021/acs.jmedchem.6b00403,,,,"Inhibition of wild type EGFR kinase domain (unknown origin) expressed using baculovirus expression system incubated for 1 hr using Poly(Glu,Tyr) 4:1 by ELISA method",C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)c(OC)c4)nc32)c1,"N-(3-(5-isopropyl-2-(3-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6,7-dioxo-6,7-dihydropteridin-8(5H)-yl)phenyl)acrylamide",0.0086,uM,=,-2.065501548756432,0,O=c1[nH]c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n(-c2ccccc2)c1=O
6036,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(Br)cc(-c2nn(C(C)C)c3ncnc(N)c23)c1,"3-(3-bromo-5-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",11.0,uM,=,1.0413926851582251,1,c1ccc(-c2n[nH]c3ncncc23)cc1
6037,661840,10.1016/j.bmc.2010.05.049,,,,Inhibition of EGFR expressed in human A431 cells,Cc1ccccc1Cc1cc2c(N(C)c3cccc(Br)c3)nc(N)nc2n1C,"2-Amino-4-(N-methyl-m-bromoanilino)-6-(2-methylbenzyl)-7-methyl-pyrrolo[2,3-d]pyrimidine",1.2,uM,=,0.0791812460476248,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
6038,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,COc1cc2ncnc(C#Cc3ccccc3)c2cc1OC,"6,7-dimethoxy-4-(2-phenylethynyl)quinazoline",5.6,uM,=,0.7481880270062004,1,C(#Cc1ncnc2ccccc12)c1ccccc1
6039,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2s1,"N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(2-methoxyphenyl)thieno[2,3-d]pyrimidin-4-amine",0.22,uM,=,-0.6575773191777937,0,c1ccc(COc2ccc(Nc3ncnc4sc(-c5ccccc5)cc34)cc2)cc1
6040,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(Nc3ccc(-c4nc5ccccc5s4)c(Cl)c3)ncnc2cc1OCCCN1CCN(C)CC1,N-(4-(benzo[d]thiazol-2-yl)-3-chlorophenyl)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-amine,0.016,uM,=,-1.7958800173440752,0,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
6041,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3cc(Cl)ccc3s2)c1O,3-[3-(5-Chloro-benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,4.4,uM,=,0.6434526764861874,1,c1ccc(CSc2nc3ccccc3s2)cc1
6042,665191,10.1016/j.bmcl.2010.08.052,,,,Inhibition of EGFR phosphorylation in human MIAPaCa cells by ELISA,CN1CCN([C@H]2CC[C@H](n3nc(-c4ccc(Nc5nc6cccc(Cl)c6o5)cc4)c4c(N)ncnc43)CC2)CC1,"trans-N-(4-(4-amino-1-(4-(4-methylpiperazin-1-yl)cyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)-7-chlorobenzo[d]oxazol-2-amine",2.3,uM,=,0.3617278360175928,1,c1ccc2oc(Nc3ccc(-c4nn([C@H]5CC[C@H](N6CCNCC6)CC5)c5ncncc45)cc3)nc2c1
6043,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(NC(C)=O)cc2)n1,N-(4-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acetamide,8.55,uM,=,0.9319661147281728,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6044,1991520,10.1016/j.bmcl.2020.127327,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(CCCO)c4ccccc34)n2)c(OC)cc1F,N-(2-fluoro-5-(4-(1-(3-hydroxypropyl)-1H-indol-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,0.2825,uM,=,-0.5489815478445427,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6045,1769307,10.1016/j.bmc.2018.02.029,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,C=CC(=O)Nc1cc(Nc2ncc3ncn(-c4ccc(F)c(Br)c4)c3n2)c(OC)cc1N(C)CCN(C)C,N-(5-((9-(3-bromo-4-fluorophenyl)-9H-purin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,0.01,uM,=,-2.0,0,c1ccc(Nc2ncc3ncn(-c4ccccc4)c3n2)cc1
6046,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCCCCCCCCCCOC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,Octadecyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetate,0.692,uM,=,-0.1598939055432422,0,O=c1cc(-c2ccccc2)oc2ccccc12
6047,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.1421,uM,=,-0.8474059220725303,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6048,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,OC1CCN(CCOc2n[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,"1-(2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yloxy)ethyl)piperidin-4-ol",0.013,uM,=,-1.8860566476931635,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCCC5)c34)cc2)nc1
6049,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,CN(C)Cc1ccc(-c2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)o1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((dimethylamino)methyl)furan-2-yl)thieno[3,2-d]pyrimidin-4-amine",0.002,uM,=,-2.6989700043360187,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5ccco5)sc34)cc2)cc1
6050,624184,10.1021/jm901877j,,,,Inhibition of wild type EGFR by HTRF assay,C#Cc1cccc(Nc2ccnc3cc(OC)c(OC)cc23)c1,"N-(3-Ethynylphenyl)-6,7-dimethoxyquinolin-4-amine",0.019,uM,=,-1.7212463990471711,0,c1ccc(Nc2ccnc3ccccc23)cc1
6051,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,C[C@H](NC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1)C(=O)N[C@@H](C)C(=O)NCCN.Cl,4-(2-nitrovinyl)phenyl 4-((S)-1-((S)-1-(2-aminoethylamino)-1-oxopropan-2-ylamino)-1-oxopropan-2-ylcarbamoyl)benzenesulfonate hydrochloride,20.0,uM,=,1.3010299956639813,1,O=S(=O)(Oc1ccccc1)c1ccccc1
6052,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ccncn3)cc2Cl)c1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)pyrimidin-4-amine,0.32,uM,=,-0.494850021680094,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
6053,2059412,10.1016/j.bmc.2021.116061,,,,Inhibition of EGFR in human A431 cells preincubated for 60 mins followed by EGF stimulation and measured after 10 mins by ELISA,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1,"N-(4-Methoxyphenyl)-N,2-dimethylquinazolin-4-amine",0.0028,uM,=,-2.552841968657781,0,c1ccc(Nc2ncnc3ccccc23)cc1
6054,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCCCOc1cc2c(Nc3ccc(NC(=O)OCC)c(Cl)c3)ncnc2cc1OCCN(CC)CC,ethyl 4-(6-butoxy-7-(2-(diethylamino)ethoxy)quinazolin-4-ylamino)-2-chlorophenylcarbamate,9.15,uM,=,0.9614210940664484,1,c1ccc(Nc2ncnc3ccccc23)cc1
6055,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",CCOc1cc2ncnc(Nc3cccc(I)c3)c2cc1OCC.Cl,"4-(3'-iodoanilino)-6,7-diethoxyquinazoline hydrochloride",0.00064,uM,=,-3.193820026016113,0,c1ccc(Nc2ncnc3ccccc23)cc1
6056,1778842,10.1016/j.bmcl.2018.07.039,,,,Inhibition of EGF-induced EGFR activation in human A431 cells pretreated for 60 mins followed by EGF addition and measured after 10 mins by ELISA,CCc1ccc(N(C)c2ncnc3occ(C)c23)cc1,"N-(4-ethylphenyl)-N,5-dimethylfuro[2,3-d]pyrimidin-4-amine",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3occc23)cc1
6057,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",C=CC(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,"US9181263, 13::US9278100, 13",0.01875,uM,=,-1.7269987279362624,0,c1ccc(Oc2ccc(-c3nn(C[C@H]4CCCN4)c4ncncc34)cc2)cc1
6058,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)S(C)(=O)=O)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"N-[3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl]-N-methylmethanesulfonamide",1.1,uM,=,0.041392685158225,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
6059,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3ccc([N+](=O)[O-])cc3)c2cn1,"N*4*-(4-Nitro-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",65.0,uM,=,1.812913356642856,1,c1ccc(Nc2ncnc3ccncc23)cc1
6060,1935778,10.1021/acs.jmedchem.9b00102,,,,Inhibition of wild type EGFR (unknown origin) by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3cn(-c4cc(C(F)(F)F)cnc4C#N)nn3)c3c(N)ncnc32)C1,"(R)-3-(4-(1-(1-acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)picolinonitrile",0.006,uM,=,-2.2218487496163566,0,c1cncc(-n2cc(-c3nn([C@@H]4CCCNC4)c4ncncc34)nn2)c1
6061,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4ccccc4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-N-(4-{[4-(benzyloxy)-3,6-dioxocyclohexa-1,4-dien-1-yl]amino}-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)but-2-enamide",0.2161999999999999,uM,=,-0.6651443103827085,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
6062,2153740,10.1021/acsmedchemlett.1c00555,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3P(C)(C)=O)n2)ccc1N1CCC(N2CCN(C)CC2)CC1,(2-((5-Chloro-2-((3-methyl-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide,0.0622999999999999,uM,=,-1.2055119533408305,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
6063,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3cccc(C(=O)O)c3)nc21,"3-[6-(2,6-Dichloro-phenyl)-8-methyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-benzoic acid",0.19,uM,=,-0.721246399047171,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
6064,1642199,,,,,Inhibition Assay: Inhibition of various kinase enzyme.,Nc1nc(Nc2cccc(Cl)c2)c2c(n1)-c1ccccc1C2,"US9422297, AAG145-335",45.1,uM,=,1.6541765418779606,1,c1ccc(Nc2ncnc3c2Cc2ccccc2-3)cc1
6065,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cccc(OC)c1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1,"(R)-6-(2,6-Dimethoxyphenyl)-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine",0.002,uM,=,-2.6989700043360187,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
6066,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,O=C(CCCCCn1cc(-c2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)nn1)NO,"6-(4-(4-((3-Chloro-4-(thiazol-2-ylmethoxy)phenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)-N-hydroxyhexanamide",0.0069,uM,=,-2.161150909262745,0,c1csc(COc2ccc(Nc3ncnc4ccc(-c5c[nH]nn5)cc34)cc2)n1
6067,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(OC)c(NC(=O)/C=C/CN(C)C4CC4)cc23)c1,(E)-4-(Cyclopropyl(methyl)amino)-N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)but-2-enamide,0.0033,uM,=,-2.4814860601221125,0,O=C(/C=C/CNC1CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6068,1649110,10.1016/j.bmc.2016.11.026,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF induced phosphorylation preincubated for 60 mins followed by EGF addition measured after 10 mins by ELISA method,COc1ccc2c(c1)CCCN2c1nc(C)nc2c(Cc3ccccc3)c[nH]c12.Cl,"1-(7-Benzyl-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline hydrochloride",0.0336,uM,=,-1.473660722610156,0,c1ccc(Cc2c[nH]c3c(N4CCCc5ccccc54)ncnc23)cc1
6069,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3cccc(O)c3)c2cn1,"3-(7-Amino-pyrido[4,3-d]pyrimidin-4-ylamino)-phenol",0.07,uM,=,-1.154901959985743,0,c1ccc(Nc2ncnc3ccncc23)cc1
6070,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)C1,"2-(4-phenoxyphenyl)-7-(1-propioloylpyrrolidin-3-yl)-1Himidazo[1,2-b]pyrazole-3-carboxamide",0.0297,uM,=,-1.5272435506827875,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNC5)c4[nH]3)cc2)cc1
6071,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OC(CF)CF)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-[7-ethoxy-4-({4-[2-fluoro-1-(fluoromethyl)ethoxy]-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)quinazolin-6-yl]but-2-enamide",2.089,uM,=,0.3199384399803086,1,O=C1C=CC(=O)C(Nc2ncnc3ccccc23)=C1
6072,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Oc1ncnc(Oc3cccc(Br)c3)c1N(C)C2,"7-(3-bromophenoxy)-13,14-dimethoxy-9-methyl-2-oxa-4,6,9-triazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaene",6.1,uM,=,0.785329835010767,1,c1ccc(Oc2ncnc3c2NCc2ccccc2O3)cc1
6073,2260086,10.1016/j.ejmech.2020.112904,,,,Inhibition of EGFR wildtype (unknown origin) incubated for 40 mins in presence of ATP,Cn1cc(-c2ccnc(Nc3ccc(NC(=O)CCCCCCC(=O)NO)cc3)n2)c2ccccc21,,3.2,uM,=,0.505149978319906,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6074,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,O=C(Nc1ccccn1)Nc1cc(-c2cncnc2)ccc1OC(F)(F)F,1-(Pyridin-2-yl)-3-(5-(pyrimidin-5-yl)-2-(trifluoromethoxy)phenyl)urea,0.02656,uM,=,-1.5757719293040202,0,O=C(Nc1cccc(-c2cncnc2)c1)Nc1ccccn1
6075,66719,10.1021/jm00050a005,,,,Inhibition of EGF-R Tyrosine kinase (TK),O=C(O)c1cc(N(Cc2ccccc2O)Cc2cc(O)ccc2O)ccc1O,"5-[(2,5-Dihydroxy-benzyl)-(2-hydroxy-benzyl)-amino]-2-hydroxy-benzoic acid",4.1,uM,=,0.6127838567197355,1,c1ccc(CN(Cc2ccccc2)c2ccccc2)cc1
6076,1523969,10.1016/j.ejmech.2015.08.027,,,,Inhibition of EGFR (unknown origin) using omnia tyr peptide 7 substrate by fluorescence assay,Clc1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2SC3)cc1,"8-Chloro-2-(p-chloroanilino)-5H-benzothiopyrane[4,3-d]pyrimidine",45.7,uM,=,1.6599162000698502,1,c1ccc(Nc2ncc3c(n2)-c2ccccc2SC3)cc1
6077,946709,10.1016/j.bmc.2012.12.045,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,Nc1nc(Nc2ccc(F)c(Cl)c2)c2cc(CCc3ccccn3)[nH]c2n1,"N4-(3-Chloro,4-fluorophenyl)-6-(2-pyridin-2-yl-ethyl)-7Hpyrrolo[2,3-d]pyrimidine-2,4-diamine",110.6,uM,=,2.04375512696868,1,c1ccc(Nc2ncnc3[nH]c(CCc4ccccn4)cc23)cc1
6078,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1ccc(F)cc1)NS(=O)(=O)c1ccc(Br)cc1,N-(4-Bromophenylsulfonyl)-2-(4-fluorophenyl)acetamide,6.41,uM,=,0.8068580295188175,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
6079,86514,10.1021/jm00110a022,,,,Inhibition of HER14 (human EGFR overexpressing) cell proliferation.,N#CC(C#N)=C1C(=O)Nc2ccc([N+](=O)[O-])cc21,"2-(5-Nitro-2-oxo-1,2-dihydro-indol-3-ylidene)-malononitrile",20.0,uM,=,1.3010299956639813,1,C=C1C(=O)Nc2ccccc21
6080,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,CC(C)(C)OC(=O)NCCNC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,4-(2-tert-Butoxycarbonylamino-ethylcarbamoyl)-benzenesulfonic acid 4-(2-nitro-vinyl)-phenyl ester,1.0,uM,=,0.0,0,O=S(=O)(Oc1ccccc1)c1ccccc1
6081,1639950,,,,,Inhibition of recombinant human N-terminal GST His6-tagged thrombin cleavage site-fused EGFR (H672 to A1210 residues) expressed in baculovirus using poly-EY as substrate after 210 mins by luciferase coupled chemiluminescence assay,COc1cc2c(Nc3ccc(Cl)c(Cl)c3)ncnc2cc1OCc1csc(-c2ccc(Cl)cc2)n1,"7-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}oxy)-N-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3cc(OCc4csc(-c5ccccc5)n4)ccc23)cc1
6082,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3cccc(F)c3)ncnc2cc1OCCOCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-{2-[2-({4-[(3-Fluorophenyl)amino]-6-methoxyquinazolin-7-yl}oxy)ethoxy]ethyl}-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.00311,uM,=,-2.5072396109731625,0,O=C(Cn1cncn1)NCCOCCOc1ccc2c(Nc3ccccc3)ncnc2c1
6083,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCCCCC(=O)NO,7-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide,0.0031,uM,=,-2.508638306165728,0,c1ccc(Nc2ncnc3ccccc23)cc1
6084,2279927,10.1021/acs.jmedchem.2c01352,,,,Inhibition of EGFR (unknown origin),Cc1nnc2n1N=C(c1ccccc1OCCNCCCNCCOc1ccccc1C1=Nn3c(C)nnc3SC1)CS2,"N1,N3-bis(2-(2-(3-methyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-6-yl)phenoxy)ethyl)propane-1,3-diamine",0.06465,uM,=,-1.1894314707835871,0,c1ccc(C2=Nn3cnnc3SC2)c(OCCNCCCNCCOc2ccccc2C2=Nn3cnnc3SC2)c1
6085,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CN(C)C/C=C/C(=O)N1Cc2sc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2C1,"US8524722, 86",0.005,uM,=,-2.3010299956639813,0,c1ccc(COc2ccc(Nc3ncnc4sc5c(c34)CNC5)cc2)cc1
6086,5004,10.1016/s0960-894x(02)00364-5,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,CCN(CC)CCNC(=O)c1cc(C)c(/C=C2\C(=O)Nc3ncnc(Nc4ccc(F)c(Cl)c4)c32)[nH]1,"5-[4-(3-Chloro-4-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)-amide",0.2,uM,=,-0.6989700043360187,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
6087,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CN(C)CCCN(C)CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-2-((3-(dimethylamino)propyl(methyl)amino)acetamide",5.222,uM,=,0.7178368674869257,1,c1ccc(Nc2ncnc3sccc23)cc1
6088,1832355,10.1016/j.bmcl.2018.12.056,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,COC[C@@H](C)Oc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,"(R,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(2-methoxy-1-methylethoxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide",0.00094,uM,=,-3.026872146400301,0,c1ccc(Nc2ncnc3ccccc23)cc1
6089,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(NCc3ccccc3Br)c2cn1,"N*4*-(2-Bromo-benzyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",1.67,uM,=,0.2227164711475832,1,c1ccc(CNc2ncnc3ccncc23)cc1
6090,1641517,,,,,"In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.0005,uM,=,-3.3010299956639813,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
6091,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,COc1ccc(C(=O)Nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2)cc1,N-(4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-ylamino)phenyl)-4-methoxylbenzamide,1.11,uM,=,0.0453229787866574,1,O=C(Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1ccccc1
6092,1986369,10.1016/j.bmc.2020.115373,,,,Inhibition of human EGFR-TK using PTK substrate after 40 mins in presence of ATP by Kinase-Glo luminescent assay,Clc1nc2ccccc2c2nnc(/N=C/C=C/c3ccccc3)n12,"5-Chloro-N-(E)-(3-phenylprop-2-ene-1-ylidene)-[1,2,4]triazolo[4,3-c]quinazolin-3-amine",7.56,uM,=,0.8785217955012066,1,C(=C/c1ccccc1)\C=N\c1nnc2c3ccccc3ncn12
6093,1642162,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",0.17,uM,=,-0.7695510786217261,0,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
6094,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,CCCCN(Cc1cccc(Br)c1O)C(=S)Nc1ccccc1,1-(5-Bromo-2-hydroxybenzyl)-1-butyl-3-phenylthiourea,22.04,uM,=,1.3432115901797474,1,S=C(NCc1ccccc1)Nc1ccccc1
6095,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3ccccc3o2)c1O,3-[3-(Benzooxazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,5.3,uM,=,0.724275869600789,1,c1ccc(CSc2nc3ccccc3o2)cc1
6096,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CCN(C(=O)[C@@H](C)N)CC1,"N-(2-(4-((R)-2-aminopropanoyl)piperazin-1-yl)-5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide",9000.0,uM,=,3.9542425094393248,1,c1ccn2ncc(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)c2c1
6097,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccn(C)n3)n2)c(OC)cc1N(C)CCN(C)CC(=O)OC,methyl 2-((2-((2-acrylamido-5-methoxy-4-((4-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)(methyl)amino)acetate,0.1062,uM,=,-0.9738754832545498,0,c1ccc(Nc2nccc(Nc3cc[nH]n3)n2)cc1
6098,529998,10.1016/j.bmc.2008.02.053,,,,Inhibition of EGFR,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,8e-05,uM,=,-4.096910013008056,0,c1ccc(Nc2ncnc3ccccc23)cc1
6099,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2n[nH]c3ncnc(N)c23)cc1O,"5-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol",100.0,uM,=,2.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
6100,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2c(Nc3ccc(-c4nc5ccccc5s4)cc3C)ncnc2cc1OCCCN1CCN(C)CC1,N-(4-(benzo[d]thiazol-2-yl)-2-methylphenyl)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-amine,0.25,uM,=,-0.6020599913279624,0,c1ccc2sc(-c3ccc(Nc4ncnc5cc(OCCCN6CCNCC6)ccc45)cc3)nc2c1
6101,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N1CCC(CN(C)C)C1,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-2-(3-((dimethylamino)methyl)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamide",0.0088,uM,=,-2.055517327849832,0,c1cc2c3c(c1)c(-c1ccnc(Nc4ccc(N5CCCC5)cc4)n1)cn3CCC2
6102,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@H](C)C(=O)N(C)C,"(R)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-N,N-dimethylpropanamide",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3ccccc23)cc1
6103,1618202,10.1021/acs.jmedchem.5b01985,,,,Inhibition of wild type EGFR phosphorylation in human HaCaT cells incubated for 3 hrs by ELISA method,Cc1cccc2nc(NC(=O)c3ccnc(C(F)(F)F)c3)n([C@@H]3CCCCN(C(=O)/C=C/CN(C)C)C3)c12,"(R,E)-N-(1-(1-(4-(Dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-1H-benzo[d]imidazol-2-yl)-2-(trifluoromethyl)-isonicotinamide",0.072,uM,=,-1.1426675035687317,0,O=C(Nc1nc2ccccc2n1[C@@H]1CCCCNC1)c1ccncc1
6104,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,Nc1cc(Nc2cccc(Oc3cc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncn3)c2)ncn1,"N4-(3-(6-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)pyrimidin-4-yloxy)phenyl)pyrimidine-4,6-diamine",0.061,uM,=,-1.214670164989233,0,c1ccc(COc2ccc(Nc3cc(Oc4cccc(Nc5ccncn5)c4)ncn3)cc2)cc1
6105,1641865,,,,,"Enzyme Assay: BT474 Cell Line: 1. 5Ã103 cells per well in 100 Î¼l of medium were seeded in 96-well plate, here the medium contained 5% FBS2. 24 hours later, 100 Î¼l fresh medium was added with various concentrations of compounds into each well, while the medium here was free of FBS.3. After the cells were treated with compounds for 72 hours, 20 Î¼l MTT (5 mg/ml) was added into each well, and then the assay plate was incubated at 37Â° C. for 4 more hours.4. The assay plate was centrifuged at 800 g for 10 min. The medium was aspirated, 150 Î¼l DMSO was added into each well. The plate was gently shaken for 10 min.5. The absorbance at 570 nm was measured on the plate reader.6. IR %=(WCâWT)/WCÃ100%.",C#Cc1cccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(NC(=O)/C=C/CN(CC)CC)cc23)c1,"US9388170, 20",0.0068,uM,=,-2.167491087293764,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
6106,5004,10.1016/s0960-894x(02)00364-5,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,CCN1CCN(C(=O)c2cc(C)c(/C=C3\C(=O)Nc4ncnc(Nc5ccc(F)c(Cl)c5)c43)[nH]2)CC1,"4-(3-Chloro-4-fluoro-phenylamino)-5-[1-[5-(4-ethyl-piperazine-1-carbonyl)-3-methyl-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one",0.2,uM,=,-0.6989700043360187,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)N2CCNCC2)[nH]1
6107,1869715,10.1016/j.bmc.2019.02.012,,,,Inhibition of His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometry,COc1cccc(/C=C/C(=O)c2ccc(NC(=O)c3cc4cc5cc(C)ccc5nc4s3)cc2)c1,"(E)-N-(4-(3-(3-Methoxyphenyl)acryloyl)phenyl)-6-methylthieno[2,3-b]quinoline-2-carboxamide",2.9,uM,=,0.4623979978989561,1,O=C(/C=C/c1ccccc1)c1ccc(NC(=O)c2cc3cc4ccccc4nc3s2)cc1
6108,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CC(C)CCCC(C)CCOC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 3,7-dimethyl-octyl ester",0.8,uM,=,-0.0969100130080563,0,c1ccc(CNc2ccccc2)cc1
6109,65120,10.1021/jm00023a009,,,,In vitro inhibition of EGF-stimulated DNA synthesis of ER 22 cells by following the incorporation of methyl-[3H]thymidine.,O=C(NCc1ccccc1)c1ccc(-c2cc(O)cc(-c3ccccc3)c2)cc1,"5'-Hydroxy-[1,1',3',1'']terphenyl-4-carboxylic acid benzylamide",8.0,uM,=,0.9030899869919436,1,O=C(NCc1ccccc1)c1ccc(-c2cccc(-c3ccccc3)c2)cc1
6110,331141,10.1016/j.bmcl.2005.08.115,,,,Inhibitory activity against EGFR kinase,COC(=O)c1c(OCCN2CCCC2)c2ccccc2c2oc3c(c12)C(=O)c1ccccc1C3=O,"7,12-dioxo-5-(2-pyrrolidin-1-yl-ethoxy)-7,12-dihydro-dinaphtho[1,2-b;2',3'-d]furan-6-carboxylic acid methyl ester",9.0,uM,=,0.9542425094393248,1,O=C1c2ccccc2C(=O)c2c1oc1c2cc(OCCN2CCCC2)c2ccccc21
6111,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,COc1ccc(NC(=O)/C=C/c2ccccc2)cc1,(E)-N-(4-methoxyphenyl)cinnamamide,9.05,uM,=,0.9566485792052032,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
6112,520709,10.1016/j.ejmech.2008.04.012,,,,Inhibition of EGFR,Nc1ncnc2c1ncn2CC(=O)c1ccccc1,2-(6-Amino-9H-purine-9-yl)-1-phenylethanone,75.0,uM,=,1.8750612633917,1,O=C(Cn1cnc2cncnc21)c1ccccc1
6113,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CC(C)(C)c1cc(/C=C(\C#N)C(N)=O)cc(C(C)(C)C)c1O,"2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)acrylamide",50.0,uM,=,1.6989700043360187,1,c1ccccc1
6114,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccc(F)cc1,"(R)-4-(4-((1-(4-Fluorophenyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",0.0038,uM,=,-2.42021640338319,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
6115,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,COc1ccccc1Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1,"6-(2,6-Dichloro-phenyl)-2-(2-methoxy-phenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",0.066,uM,=,-1.1804560644581312,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
6116,734983,10.1021/jm101479y,,,,Inhibition of EGFR,CN(C)Cc1cc(C(=O)N[C@@H]2CCc3ccc(Oc4ccnc5c4CCC(=O)N5)cc3C2)cc(C(F)(F)F)c1,"3-[(Dimethylamino)methyl]-N-{(2R)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalen-2-yl}-5-(trifluoromethyl)benzamide",4.9,uM,=,0.6901960800285137,1,O=C1CCc2c(Oc3ccc4c(c3)C[C@H](NC(=O)c3ccccc3)CC4)ccnc2N1
6117,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,O=C(/C=C/c1ccc(F)cc1)Nc1cccc(Oc2cc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncn2)c1,(E)-4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-p-fluorocinnamamidophenoxy)pyrimidine,0.821,uM,=,-0.0856568428805592,0,O=C(/C=C/c1ccccc1)Nc1cccc(Oc2cc(Nc3ccc(OCc4ccccc4)cc3)ncn2)c1
6118,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,CCNc1ncc(C(=O)Nc2cc(C(=O)Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)ccc2C)cn1,2-(Ethylamino)-N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)-methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-pyrimidine-5-carboxamide,0.13,uM,=,-0.8860566476931633,0,O=C(Nc1cccc(C(=O)Nc2ccc(CN3CCNCC3)cc2)c1)c1cncnc1
6119,627419,10.1021/jm9011142,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine cell-based ELISA,Cc1ccc(Sc2cccc3[nH]c4nc(N)nc(N)c4c23)cc1,"5-(p-tolylthio)-9H-pyrimido[4,5-b]indole-2,4-diamine",10.41,uM,=,1.0174507295105362,1,c1ccc(Sc2cccc3[nH]c4ncncc4c23)cc1
6120,1984105,10.1021/acs.jmedchem.9b01617,,,,Inhibition of EGFR1 (unknown origin),C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0006,uM,=,-3.2218487496163566,0,c1ccc(Nc2ncnc3ccccc23)cc1
6121,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,CN1CCN(Cc2ccc(NC(=O)c3cccc(NC(=O)c4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1,"N-(3-((4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-pyrrolo[2,3-b]-pyridine-5-carboxamide",0.68,uM,=,-0.1674910872937636,0,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(NC(=O)c2cnc3[nH]ccc3c2)c1
6122,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",Brc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1,"N-(3-Bromophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0136,uM,=,-1.8664610916297824,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
6123,340860,10.1016/j.bmcl.2005.12.028,,,,Inhibitory activity against EGFR,COc1cc(OC(C)C)c2c(Nc3ccc(F)c(Cl)c3)ncnc2c1,N-(3-chloro-4-fluorophenyl)-5-isopropoxy-7-methoxyquinazolin-4-amine,8.068,uM,=,0.9067658895407278,1,c1ccc(Nc2ncnc3ccccc23)cc1
6124,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#CCCNCc1ccccc1,5-(4-(benzylamino)but-1-ynyl)-N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methylpyrimidin-4-amine,0.27,uM,=,-0.5686362358410126,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)CCNCc1ccccc1
6125,2067577,10.1016/j.ejmech.2019.111888,,,,"Inhibition of EGFR L858R/T790M/C797S (unknown origin) using Poly (Glu, Tyr) as substrate measured after 40 mins by kinase-glo assay",CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccccc5)n([C@@H]5CCN(S(=O)(=O)C6CC6)C5)c4n3)cc2)CC1,"(R)-9-(1-cyclopropylsulfonylpyrrolidine-3-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-4-phenyl-9H-purine-2,8-diamine",0.018,uM,=,-1.744727494896694,0,O=S(=O)(C1CC1)N1CC[C@@H](n2c(Nc3ccccc3)nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc32)C1
6126,2069689,10.1016/j.bmc.2021.116039,,,,Inhibition of recombinant wild type EGFR (696 to C terminal end) (unknown origin) using poly (Glu-Tyr) as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by ELISA,COc1ccc(-c2c3c4cc(OCCCN(C)C)c(OCCCN(C)C)cc4[nH]c(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,"2,3-bis[3-(dimethylamino)propoxy]-11-hydroxy-14-(3-hydroxy-4-methoxyphenyl)-12-methoxybenzo[7,8]indolizino[3,2-c]quinolin-6(5H)-one 2,2,2-trifluoroacetate",0.0046,uM,=,-2.337242168318426,0,O=c1[nH]c2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
6127,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CC(C)c1ccc(COC(=O)c2cc(NCc3cc(O)ccc3O)ccc2O)cc1,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 4-isopropyl-benzyl ester",1.4,uM,=,0.1461280356782379,1,O=C(OCc1ccccc1)c1cccc(NCc2ccccc2)c1
6128,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC(Oc2cc3c(N[C@H](C)c4ccccc4)ncnc3cc2OC)C1,1-(3-(7-methoxy-4-((1R)-1-phenylethylamino)quinazolin-6-yloxy)azetidin-1-yl)prop-2-en-1-one,0.006,uM,=,-2.2218487496163566,0,c1ccc(CNc2ncnc3ccc(OC4CNC4)cc23)cc1
6129,958682,10.1021/jm400463q,,,,Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC(=O)NCCCOc5no[n+]([O-])c5S(=O)(=O)c5ccccc5)CC4)cc3OC)ncc2Cl)c1,"4-(3-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetamido)-propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide",0.059,uM,=,-1.2291479883578558,0,O=C(CN1CCN(c2ccc(Nc3nccc(Oc4ccccc4)n3)cc2)CC1)NCCCOc1no[nH+]c1S(=O)(=O)c1ccccc1
6130,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC(=O)CC4=C(C)/C(=C\c5ccc([S+](C)[O-])cc5)c5ccc(F)cc54)c(OCCOC)cc23)c1,(E)-2-((4-((3-Ethynylphenyl)amino)-6-(2-methoxyethoxy)quinazolin-7-yl)oxy)ethyl-2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetate,0.031,uM,=,-1.5086383061657274,0,O=C(CC1=C/C(=C\c2ccccc2)c2ccccc21)OCCOc1ccc2c(Nc3ccccc3)ncnc2c1
6131,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(N4CCOCC4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-morpholin-4-yl-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,12.7,uM,=,1.1038037209559568,1,c1ccc2c(Nc3ccc(N4CCOCC4)cc3)ccnc2c1
6132,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,C=CC(=O)Nc1ccc2c(c1)CNc1c(Nc3ccc(F)c(Cl)c3)ncnc1O2,"N-[1-(3-Chloro-4-fluoro-phenylamino)-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-8-yl]-acrylamide",8.9,uM,=,0.9493900066449128,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6133,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CC(C)N(C)C/C=C/C(=O)N1CCc2c(sc3ncc(C#N)c(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)C1,"US8524722, 151",0.0064,uM,=,-2.193820026016113,0,c1ccc(Cn2ncc3cc(Nc4ccnc5sc6c(c45)CCNC6)ccc32)cc1
6134,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,Cc1cc(Oc2ccc(Nc3ncnc4cc(C#C[C@@H]5C[C@@H](OC(=O)N6CCOCC6)CN5)sc34)cc2Cl)no1,"(3R,5S)-5-((4-(3-chloro-4-(5-methylisoxazol-3-yloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.4,uM,=,-0.3979400086720376,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Oc5ccon5)cc4)c3s2)C1)N1CCOCC1
6135,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,COc1cccc(Nc2ncnc3cc(N)ncc23)c1,"N*4*-(3-Methoxy-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.13,uM,=,-0.8860566476931633,0,c1ccc(Nc2ncnc3ccncc23)cc1
6136,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Fc1c(I)cccc1Nc1ncnc2cc3c(cc12)OCCO3,"N-(2-Fluoro-3-iodophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0130999999999999,uM,=,-1.882728704344236,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
6137,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCCCC(=O)O)c1O,4-[5-(2-Carbamoyl-2-cyano-vinyl)-2-hydroxy-3-methoxy-benzylsulfanyl]-butyric acid,60.0,uM,=,1.7781512503836436,1,c1ccccc1
6138,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3ccccc3C(N)=O)cc12)c1ccccc1,"(R)-2-(4-((1-Phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzamide",0.276,uM,=,-0.5590909179347823,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
6139,553933,10.1021/np070447m,,,,Inhibition of recombinant EGFR,Cc1cc(O)cc2oc(=O)c3c(O)cc(OS(=O)(=O)O)cc3c12,Alternariol 5-O-sulfate,0.0124256811769397,uM,=,-1.9056797938801653,0,O=c1oc2ccccc2c2ccccc12
6140,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)Cc1ccc(Br)cc1,N-(2-((2-((4-bromobenzyl)(methyl)amino)ethyl)(methyl)amino)-4-methoxy-5-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.1428,uM,=,-0.8452717925598444,0,c1ccc(CNCCNc2ccc(Nc3nccc(Nc4c[nH]c5ccccc45)n3)cc2)cc1
6141,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2Br)c1,"US8975249, I-40",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6142,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2[nH]cnc3c4ccccc4nc2-3)c1.Cl,"(3-Bromo-phenyl)-(5H-pyrimido[5,4-b]indol-4-yl)-amine hydrochloride",0.072,uM,=,-1.1426675035687317,0,c1ccc(Nc2[nH]cnc3c4ccccc4nc2-3)cc1
6143,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,Brc1cccc(Nc2ncnc3cc4c(ccn4CCN4CCOCC4)cc23)c1,"(3-Bromo-phenyl)-[8-(2-morpholin-4-yl-ethyl)-8H-pyrrolo[3,2-g]quinazolin-4-yl]-amine",0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ncnc3cc4c(ccn4CCN4CCOCC4)cc23)cc1
6144,2259970,10.6019/CHEMBL5212743,,,,Selectivity interaction (Enzymatic activity assay) EUB0000596aBDA EGFR,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,AFATINIB DIMALEATE,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
6145,614501,10.1021/jm901132v,,,,Inhibition of EGFR,COCCCN1CCC([C@H]2CC[C@H](n3nc(-c4ccc5nc(Cc6ccccc6Cl)[nH]c5c4)c4c(N)ncnc43)CC2)CC1,"3-(2-(2-chlorobenzyl)-1H-benzo[d]imidazol-6-yl)-1-((1r,4r)-4-(1-(3-methoxypropyl)piperidin-4-yl)cyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.058,uM,=,-1.2365720064370629,0,c1ccc(Cc2nc3ccc(-c4nn([C@H]5CC[C@H](C6CCNCC6)CC5)c5ncncc45)cc3[nH]2)cc1
6146,78741,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O,3-[3-(Benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,35.0,uM,=,1.5440680443502757,1,c1ccc(CSc2nc3ccccc3s2)cc1
6147,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,C#Cc1cccc(Nc2ncnc3cc(OC4CCOC4)c4c(c23)OCCO4)c1,"N-(3-ethynylphenyl)-5-(tetrahydrofuran-3-yloxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0167,uM,=,-1.7772835288524167,0,c1ccc(Nc2ncnc3cc(OC4CCOC4)c4c(c23)OCCO4)cc1
6148,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC1CCN(C)CC1,N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(1-methylpiperidin-4-yloxy)quinazolin-4-amine,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
6149,5004,10.1016/s0960-894x(02)00364-5,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,CCN(CC)CCNC(=O)c1cc(C)c(/C=C2\C(=O)Nc3ncnc(Nc4ccc(Cl)cc4F)c32)[nH]1,"5-[4-(4-Chloro-2-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)-amide",0.5,uM,=,-0.3010299956639812,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
6150,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",COc1ccc(NC(=S)NNc2nncc3ccccc23)cc1,N-(4-Methoxyphenyl)-2-(phthalazin-1-yl)hydrazine-1-carbothioamide,0.053,uM,=,-1.275724130399211,0,S=C(NNc1nncc2ccccc12)Nc1ccccc1
6151,1662113,10.1016/j.ejmech.2017.02.061,,,,Inhibition of EGFR (unknown origin) measured after 40 mins by Kinase Glo luminescence assay,CC[C@H](C)[C@@H](NC(=O)OC(C)(C)C)C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"(2R,3S)-tert-butyl (1-((4-((3-bromophenyl)amino)quinazolin-6-yl)amino)-3-methyl-1-oxopentan-2-yl)carbamate",0.0555,uM,=,-1.2557070168773237,0,c1ccc(Nc2ncnc3ccccc23)cc1
6152,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CN[C@H]1C[C@@H]2O[C@](C)([C@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)[C@H](O)NC4=O,"18-hydroxy-5-methoxy-6-methyl-4-methylamino-(2S,4S,5S,6R,18S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-16-one",0.26,uM,=,-0.585026652029182,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1[C@@H]1CCCC3O1
6153,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,Cc1cccc(Nc2ncnc3cc(NCCCCN(C)C)ncc23)c1,"N*7*-(4-Dimethylamino-butyl)-N*4*-m-tolyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0054,uM,=,-2.2676062401770314,0,c1ccc(Nc2ncnc3ccncc23)cc1
6154,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,O=C(Nc1cc(-c2cccnc2)cc(C(F)(F)F)c1)Nc1nccs1,1-(3-(Pyridin-3-yl)-5-(trifluoromethyl)phenyl)-3-(thiazol-2-yl)urea,0.07817,uM,=,-1.106959888042882,0,O=C(Nc1cccc(-c2cccnc2)c1)Nc1nccs1
6155,1842432,10.1016/j.ejmech.2019.03.004,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.026,uM,=,-1.585026652029182,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6156,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,COc1cc(Nc2ncnc3[nH]cnc23)ccc1-c1nc2ccccc2s1,N-(4-(benzo[d]thiazol-2-yl)-3-methoxyphenyl)-9H-purin-6-amine,2.6,uM,=,0.414973347970818,1,c1ccc2sc(-c3ccc(Nc4ncnc5[nH]cnc45)cc3)nc2c1
6157,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cc(CO)ccc1-c1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(4-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-3-methoxyphenyl)methanol",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3sc(-c4ccccc4)cc23)cc1
6158,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(NC(=O)CCO)cc2)n1,N-(4-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-3-hydroxypropanamide,23.31,uM,=,1.367542273520577,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6159,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OCCC)nc32)c1,"N-(3-(5-Methyl-2-((4-(4-methylpiperazin-1-yl)-2-propoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.27,uM,=,-0.5686362358410126,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
6160,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(3-fluoro-benzyloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.034,uM,=,-1.4685210829577449,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
6161,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(N[C@@H](C)c3ccccc3)c2cc1OCCCCCCC(=O)NO,(S)-N-hydroxy-7-(7-methoxy-4-(1-phenylethylamino)quinazolin-6-yloxy)heptanamide,5.077,uM,=,0.705607163404605,1,c1ccc(CNc2ncnc3ccccc23)cc1
6162,1566936,10.1021/acs.jmedchem.5b01633,,,,Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
6163,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.4085,uM,=,-0.3888079391315657,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6164,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1Cl,"propyl 2-chloro-4-(6,7-dimethoxyquinazolin-4-ylamino)phenylcarbamate",1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
6165,2108351,10.1016/j.ejmech.2021.113327,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 60 mins in presence of ATP by caliper mobility shift assay,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.078,uM,=,-1.1079053973095196,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
6166,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(NC(=O)C=C)cc23)c1,N-(4-(3-Ethynylphenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)acrylamide,0.0018,uM,=,-2.744727494896694,0,c1ccc(Nc2ncnc3ccccc23)cc1
6167,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,CNC(=O)c1cc(Nc2ccc(-c3nc4ccccc4s3)cc2)ccn1,4-(4-(benzo[d]thiazol-2-yl)phenylamino)-N-methylpicolinamide,2.0,uM,=,0.3010299956639812,1,c1ccc2sc(-c3ccc(Nc4ccncc4)cc3)nc2c1
6168,1553877,10.1016/j.ejmech.2016.01.045,,,,Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay,COc1cc2ncnc(Nc3ccc(C(=O)NC45CC6CC(CC(C6)C4)C5)c(Cl)c3)c2cc1OCCCN1CCOCC1,N-(Adamantan-1-yl)-2-chloro-4-((7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl)amino)benzamide,0.00642,uM,=,-2.192464971931147,0,O=C(NC12CC3CC(CC(C3)C1)C2)c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6169,2293062,10.1021/acs.jmedchem.6b00995,,,,Inhibition of EGFR autophosphorylation in human NCI-H292 cells harboring harboring wild type EGFR preincubated for 60 mins followed by EGF stimulation and measured after 8 mins by SULFO-TAG based electrochemiluminescent assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccccc23)cc1
6170,1861191,10.1016/j.ejmech.2019.07.064,,,,Inhibition of EGFR (unknown origin),COc1cc(/C=C/C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2O[C@@H]2CCOC2)cc(OC)c1OC,"(R)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(3,4,5-trimethoxyphenyl)acrylamide",0.009,uM,=,-2.0457574905606752,0,O=C(/C=C/c1ccccc1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@@H]1CCOC1
6171,1650711,10.1016/j.bmcl.2017.02.023,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay,O=C(Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)C1CCC2(CC1)OOC1(CCCCC1)OO2,"N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3,3-cyclohexane-1,2,4,5-tetraoxaspiro[5.5]undecane-9-carboxamide",0.0838199999999999,uM,=,-1.0766523435021744,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CCC2(CC1)OOC1(CCCCC1)OO2
6172,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Oc1ccccc1O,"Benzene-1,2-diol",26.043,uM,=,1.4156910109407237,1,c1ccccc1
6173,1935778,10.1021/acs.jmedchem.9b00102,,,,Inhibition of wild type EGFR (unknown origin) by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3cn(Cc4nc5ccc(Cl)cn5c4Br)nn3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-amino-3-(1-((3-bromo-6-chloroimidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.085,uM,=,-1.0705810742857071,0,c1ccn2cc(Cn3cc(-c4nn([C@@H]5CCCNC5)c5ncncc45)nn3)nc2c1
6174,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,Fc1ccc(Nc2ncnc3c2NCc2cc(Br)ccc2O3)cc1Cl,"(8-Bromo-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(3-chloro-4-fluoro-phenyl)-amine",8.4,uM,=,0.9242792860618816,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6175,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Clc1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1,"(3-Chloro-phenyl)-(6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]indol-4-yl)-amine",0.029,uM,=,-1.537602002101044,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1
6176,1994718,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 40 mins in presence of ATP by caliper mobility shift assay,CCN(CC)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7,8-dihydropyrimido[5,4-g][1,4]benzoxazin-6-yl]-4-(diethylamino)but-2-en-1-one",0.008,uM,=,-2.096910013008056,0,c1ccc(COc2ccc(Nc3ncnc4cc5c(cc34)NCCO5)cc2)cc1
6177,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCOC(=O)c1cn2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2c1CC,"5-Ethyl-4-(4-phenoxy-phenylamino)-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester",0.61,uM,=,-0.2146701649892329,0,c1ccc(Oc2ccc(Nc3ncnn4cccc34)cc2)cc1
6178,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,CS(=O)(=O)Nc1ccc2c(c1)CNc1c(Nc3cccc(Br)c3)ncnc1O2,"N-[1-(3-Bromo-phenylamino)-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-8-yl]-methanesulfonamide",7.0,uM,=,0.8450980400142568,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6179,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2cc(-c3cn(C)c4ccccc34)nc(C)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((2-methyl-6-(1-methyl-1H-indol-3-yl)pyrimidin-4-yl)amino)phenyl)acrylamide,0.192,uM,=,-0.7166987712964504,0,c1ccc(Nc2cc(-c3c[nH]c4ccccc34)ncn2)cc1
6180,1883874,10.1021/acsmedchemlett.8b00270,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 20 mins in presence of [gamma33P]ATP by filter-binding assay,C=CC(=O)N(c1ccc(F)c(Cl)c1)c1ncnc2cc(OC)c(OCCCN3CCOCC3)cc12,4-[N-acryloyl-(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline,0.0652,uM,=,-1.1857524042680798,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6181,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CCCCN(CC#CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1)CCCC,N-[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]-4-(dibutylamino)-2-butynamide,0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccccc23)cc1
6182,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,FC(F)(F)c1cccc(Nc2ncnc3[nH]c4c(c23)CCCC4)c1,"(6,7,8,9-Tetrahydro-5H-pyrimido[4,5-b]indol-4-yl)-(3-trifluoromethyl-phenyl)-amine",0.36,uM,=,-0.4436974992327127,0,c1ccc(Nc2ncnc3[nH]c4c(c23)CCCC4)cc1
6183,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,COc1ccc(CCOc2ccc3c(c2)c(CCN)cn3CCCCCc2ccc(SC)cc2)cc1.Cl,2-{5-(4-Methoxyphenethoxy)-1-{5-[4-(methylthio)-phenyl]pentyl}-1H-indole-3-yl}ethanamine hydrochloride,2.45,uM,=,0.3891660843645325,1,c1ccc(CCCCCn2ccc3cc(OCCc4ccccc4)ccc32)cc1
6184,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2nc(N)nc(Nc3cccc(Br)c3)c2cc1OC,"N*4*-(3-Bromo-phenyl)-6,7-dimethoxy-quinazoline-2,4-diamine",0.463,uM,=,-0.3344190089820468,0,c1ccc(Nc2ncnc3ccccc23)cc1
6185,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.054,uM,=,-1.2676062401770316,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6186,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,COC[C@H]1CCCN1C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-(2-Methoxymethyl-pyrrolidin-1-yl)-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.085,uM,=,-1.0705810742857071,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6187,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2ncnc3cc4[nH]ccc4cc23)c1,"(3-Bromo-phenyl)-(8H-pyrrolo[3,2-g]quinazolin-4-yl)-amine",0.00039,uM,=,-3.408935392973501,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
6188,1801908,10.1016/j.ejmech.2018.06.061,,,,Inhibition of EGFR in human HepG2 cells,COc1ccc(-c2c(C#N)c(N)n(/N=C3\C(=O)Nc4ccc(S(=O)(=O)N5CCOCC5)cc43)c(=O)c2C#N)cc1,"6-Amino-4-(4-methoxyphenyl)-1-((5-(morpholinosulfonyl)-2-oxoindolin-3-ylidene)amino)-2-oxo-1,2-dihydropyridine-3,5-dicarbonitrile",1.931,uM,=,0.2857822737793947,1,O=C1Nc2ccc(S(=O)(=O)N3CCOCC3)cc2/C1=N/n1ccc(-c2ccccc2)cc1=O
6189,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)c2ccccc2Cl)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"4-[2-chlorophenyl(methyl)carboxamido]-3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaene",4.7,uM,=,0.6720978579357175,1,O=C(N[C@@H]1CC2O[C@@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O)c1ccccc1
6190,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCNCC1,"5-(4-amino-1-(piperidin-4-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",100.0,uM,=,2.0,1,c1ccc(-c2nn(CC3CCNCC3)c3ncncc23)cc1
6191,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,Nc1ncnc2c1c(-c1ccc(O)cc1)cn2C1CCC1,"4-(4-Amino-7-cyclobutyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-phenol",0.6,uM,=,-0.2218487496163563,0,c1ccc(-c2cn(C3CCC3)c3ncncc23)cc1
6192,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CC2(CCO2)C1,6-(2-(1-oxa-6-azaspiro[3.3]heptan-6-yl)ethoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine,0.19,uM,=,-0.721246399047171,0,c1ccc(Nc2ncnc3ccc(OCCN4CC5(CCO5)C4)cc23)cc1
6193,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,COC(=O)CCCC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1,methyl 5-(3-(2-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)pyrimidin-5-yl)ethynyl)phenylamino)-5-oxopentanoate,0.031,uM,=,-1.5086383061657274,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
6194,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,COC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1O,2-Hydroxy-4-[4-(2-nitro-vinyl)-phenoxysulfonyl]-benzoic acid methyl ester,2.0,uM,=,0.3010299956639812,1,O=S(=O)(Oc1ccccc1)c1ccccc1
6195,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6196,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1cc2ncnc(Nc3ccccc3[N+](=O)[O-])c2cn1,"N*4*-(2-Nitro-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",1.25,uM,=,0.0969100130080564,1,c1ccc(Nc2ncnc3ccncc23)cc1
6197,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CCOc1cc(-c2nn(CCO)c3ncnc(N)c23)ccc1OC,"2-(4-amino-3-(3-ethoxy-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethanol",8.01,uM,=,0.9036325160842376,1,c1ccc(-c2n[nH]c3ncncc23)cc1
6198,1353177,10.1021/ml4003309,,,,Inhibition of recombinant EGFR (unknown origin) using poly-GT peptide as substrate by Transcreener assay,COc1cc2c(Oc3ccc(NS(=O)(=O)c4cc(-c5ccsc5)ccc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,2-fluoro-N-[3-fluoro-4-({6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yl}oxy)phenyl]-5-(3-thienyl)benzenesulfonamide,0.572,uM,=,-0.2426039712069758,0,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1cccc(-c2ccsc2)c1
6199,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.001,uM,=,-3.0,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
6200,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,Cc1nc(Nc2cccc3ccccc23)c2cc(C)oc2n1,"2,6-Dimethyl-N-(naphthalen-1-yl)furo[2,3-d]pyrimidin-4-amine",0.1452,uM,=,-0.838033383635925,0,c1ccc2c(Nc3ncnc4occc34)cccc2c1
6201,1668743,10.1021/acs.jmedchem.7b00076,,,,"Inhibition of recombinant EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",OC[C@H](Nc1cnc(-c2cc(Cl)ccc2O)c(-c2ccc3cnccc3c2)c1)c1ccccc1,(R)-4-Chloro-2-(5-(2-hydroxy-1-phenylethylamino)-3-(isoquinolin-6-yl)pyridin-2-yl)phenol,0.0042,uM,=,-2.3767507096021,0,c1ccc(CNc2cnc(-c3ccccc3)c(-c3ccc4cnccc4c3)c2)cc1
6202,990874,10.1021/ml4002437,,,,Inhibition of wild type EGFR in human A431 cells assessed as growth inhibition after 48 hrs by MTT assay,CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"(E)-1-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7, 8-dihydro-6H-[1, 4]oxazino[3,2-g]quinazolin-6-yl)-4-(dimethylamino)but-2-en-1-one",0.9,uM,=,-0.0457574905606751,0,c1ccc(COc2ccc(Nc3ncnc4cc5c(cc34)NCCO5)cc2)cc1
6203,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,O=C(Cc1ccc(Br)cc1)NS(=O)(=O)c1ccc(Cl)cc1,2-(4-Bromophenyl)-N-(4-chlorophenylsulfonyl)acetamide,15.92,uM,=,1.20194306340165,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
6204,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(-c3ncco3)c(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-5-(oxazol-2-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.045,uM,=,-1.3467874862246565,0,c1ccc(Nc2ncc(-c3ncco3)c(-c3cn4c5c(cccc35)CCC4)n2)cc1
6205,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1/C=C(\F)C(=O)NCCN1CCCC1,3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-methylpyrimidin-5-yl)-2-fluoro-N-(2-(pyrrolidin-1-yl)ethyl)acrylamide,0.003,uM,=,-2.5228787452803374,0,O=C(C=Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)NCCN1CCCC1
6206,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,COc1ccc(-c2cc3c(N[C@H](C)c4ccc(F)cc4)ncnc3o2)cc1,"(R)-N-(1-(4-Fluorophenyl)ethyl)-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-4-amine",0.027,uM,=,-1.5686362358410126,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
6207,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",C=CC(=O)N(C)CCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,"US9181263, 19::US9278100, 19",0.02822,uM,=,-1.549442990581671,0,c1ccc(Oc2ccc(-c3n[nH]c4ncncc34)cc2)cc1
6208,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCN1CCN(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)CC1,"(E)-2-Cyano-N-(2-{4-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloyl]-piperazin-1-yl}-ethyl)-3-(3,4-dihydroxy-phenyl)-acrylamide",6.2,uM,=,0.7923916894982539,1,O=C(C=Cc1ccccc1)NCCN1CCN(C(=O)/C=C/c2ccccc2)CC1
6209,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Brc1cccc(Nc2ncnc3c2NCc2cc(Br)ccc2O3)c1,"(8-Bromo-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(3-bromo-phenyl)-amine",1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6210,982642,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.498,uM,=,-0.3027706572402824,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6211,2052738,10.1016/j.ejmech.2019.111966,,,,Inhibition of wild type N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus infected Sf21 cells using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km concentration and further incubated for 20 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2cc(-n3c(SC)nnc3-c3ccc(F)cc3)ccn2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-(3-(4-fluorophenyl)-5-(methylthio)-4H-1,2,4-triazol-4-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide",0.0892999999999999,uM,=,-1.0491485411114536,0,c1ccc(Nc2cc(-n3cnnc3-c3ccccc3)ccn2)cc1
6212,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,COc1cc(NC(=O)Nc2ccncc2)cc(-c2cncnc2)c1OC,"1-(3,4-Dimethoxy-5-(pyrimidin-5-yl)phenyl)-3-(pyridin-4-yl)urea",0.29046,uM,=,-0.5369136669754667,0,O=C(Nc1ccncc1)Nc1cccc(-c2cncnc2)c1
6213,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCCOCC4)cc3OC)ncc2Cl)c1,"US8975249, I-37",0.065,uM,=,-1.1870866433571443,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCCOCC4)cc3)n2)cc1
6214,982646,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type human EGFR tyrosine kinase assessed as Ulight-CAGAGAIETDKEYYTVKD phosphorylation after 15 mins by time-resolved fluorometry,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0006,uM,=,-3.2218487496163566,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6215,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)Nc1ccccc1Cl,1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(2-chlorophenyl)thiourea,0.0158,uM,=,-1.8013429130455774,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6216,591074,10.1021/jm9010065,,,,Inhibition of human recombinant HER1 expressed in Sf9 cells by liquid scintillation counting,CCC1=C2C(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)=NC=NC2N=C1NC(=O)OC[C@@H]1COCCN1,"[4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid,(3S)-3-morpholinylmethyl ester",0.023,uM,=,-1.6382721639824072,0,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OC[C@@H]1COCCN1
6217,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,C=CC(=O)Nc1cc(Nc2ncc(I)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((5-iodo-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.865,uM,=,-0.0629838925351857,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
6218,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Cc1[nH]c(-c2ccccc2)c(-c2ccccc2)c1C(=O)c1cn(-c2ccccc2)nc1C(=O)Nc1ccccc1,"4-(2-Methyl-4,5-diphenyl-1H-pyrrole-3-carbonyl)-N,1-diphenyl-1H-pyrazole-3-carboxamide",3.56,uM,=,0.5514499979728752,1,O=C(c1cn(-c2ccccc2)nc1C(=O)Nc1ccccc1)c1c[nH]c(-c2ccccc2)c1-c1ccccc1
6219,1436963,10.1021/jm500973a,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cnn4ccccc34)n2)c(OC)cc1N1CCN(C(=O)[C@@H]2CCCCN2)CC1,"N-(5-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxy-2-(4-((S)-piperidine-2-carbonyl)piperazin-1-yl)phenyl)acrylamide",6060.0,uM,=,3.782472624166286,1,O=C([C@@H]1CCCCN1)N1CCN(c2ccc(Nc3nccc(-c4cnn5ccccc45)n3)cc2)CC1
6220,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Nc3cc(Cl)cc(Cl)c3)c2c1C,"(3,5-Dichloro-phenyl)-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",0.17,uM,=,-0.7695510786217261,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1
6221,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,CCCCN(Cc1cccc(Br)c1O)C(=O)Nc1ccccc1,1-(5-Bromo-2-hydroxybenzyl)-1-butyl-3-phenylurea,36.88,uM,=,1.5667909123815915,1,O=C(NCc1ccccc1)Nc1ccccc1
6222,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1cnc3ccccc3c1)nn2C1CCCC1,"1-cyclopentyl-3-(quinolin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.54,uM,=,-0.2676062401770315,0,c1ccc2ncc(-c3nn(C4CCCC4)c4ncncc34)cc2c1
6223,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,COc1ccc2c(c1)CNc1c(Nc3cccc(-c4ccccc4)c3)ncnc1O2,"Biphenyl-3-yl-(8-methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",9.8,uM,=,0.9912260756924948,1,c1ccc(-c2cccc(Nc3ncnc4c3NCc3ccccc3O4)c2)cc1
6224,63616,10.1016/S0960-894X(97)00034-6,,,,Inhibition of Epidermal growth factor receptor autophosphorylation.,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC.Cl,"(3-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine hydrochloride",0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccccc23)cc1
6225,1541552,10.1039/C4MD00560K,,,,Inhibition of EGFR (unknown origin) by microfluidic assay relative to control,Oc1nnc(-c2c[nH]c(-c3ccccc3)c2-c2ccccc2)c2cn(-c3ccc(Cl)cc3)nc12,"4-(4,5-Diphenyl-1H-pyrrol-3-yl)-2-(p-tolyl)-2H-pyrazolo[3,4-d]pyridazin-7-ol",4.39,uM,=,0.6424645202421213,1,c1ccc(-c2[nH]cc(-c3nncc4nn(-c5ccccc5)cc34)c2-c2ccccc2)cc1
6226,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,COc1ccc2c(c1)CNc1c(Nc3cccc(Br)c3)ncnc1O2,"(3-Bromo-phenyl)-(8-methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",3.1,uM,=,0.4913616938342727,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6227,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCCN(C(=O)OC(C)(C)C)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-43",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCCNCC4)cc3)n2)cc1
6228,607646,10.1016/j.bmc.2009.11.035,,,,Inhibition of recombinant EGFR by ELISA,C#CCCCOc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC,4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(pent-4-ynyloxy)quinazoline,0.0025299999999999,uM,=,-2.596879478824182,0,c1ccc(Nc2ncnc3ccccc23)cc1
6229,443222,10.1016/j.bmcl.2007.02.050,,,,Inhibition of human EGFR,CS(=O)(=O)N1CCCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((4-(methylsulfonyl)-1,4-diazepan-1-yl)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.21,uM,=,-0.6777807052660807,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCNCC6)c45)ccc32)cc1
6230,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCN(C)CC1,N-(4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-ylamino)phenyl)benzamide,0.13,uM,=,-0.8860566476931633,0,O=C(Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1ccccc1
6231,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,"4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol",5.551,uM,=,0.7443712273318607,1,c1ccc(CCCNCCc2ccccc2)cc1
6232,64450,10.1016/s0960-894x(00)00200-6,,,,Inhibition of EGFR kinase,CN1CCC(O)(c2nc(-c3ccc(F)cc3)c(-c3ccncc3)o2)CC1,4-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-oxazol-2-yl]-1-methyl-piperidin-4-ol,0.797,uM,=,-0.0985416786038876,0,c1ccc(-c2nc(C3CCNCC3)oc2-c2ccncc2)cc1
6233,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21,"3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol",0.954,uM,=,-0.0204516252959049,0,c1ccc(-c2n[nH]c3ncncc23)cc1
6234,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2ncnc3cc4[nH]ncc4cc23)c1,"(3-Bromo-phenyl)-(1H-pyrazolo[4,3-g]quinazolin-5-yl)-amine",0.00044,uM,=,-3.356547323513813,0,c1ccc(Nc2ncnc3cc4[nH]ncc4cc23)cc1
6235,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#CC(C#N)=C(C#N)c1cc(O)c(O)c(O)c1,"2-(3,4,5-trihydroxyphenyl)ethene-1,1,2-tricarbonitrile",3.0,uM,=,0.4771212547196624,1,c1ccccc1
6236,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,COC[C@@H]1CCCN1C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-(2-Methoxymethyl-pyrrolidin-1-yl)-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.131,uM,=,-0.8827287043442358,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6237,66899,10.1016/s0960-894x(99)00188-2,,,,In vitro activity against Epidermal growth factor receptor (using poly(Glu4Tyr1) as a substrate),O=C(Nc1ccccc1)NN1C(=O)c2c(c3c4cccc(O)c4n(C4OC(CO)C(O)C(O)C4O)c3c3[nH]c4c(O)cccc4c23)C1=O,"6-phenylamino-1,11-dihydroxy-12-(3,4,5-trihydroxy-6-hydroxymethyltetrahydro-2H-2-pyranyl)-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione",95.0,uM,=,1.977723605288848,1,O=C(Nc1ccccc1)NN1C(=O)c2c(c3c4ccccc4n(C4CCCCO4)c3c3[nH]c4ccccc4c23)C1=O
6238,531091,10.1073/pnas.0707498104,,,,Inhibition of EGFR,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,"N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine",2.59,uM,=,0.4132997640812518,1,c1cc(Nc2ncnc3cc(OCCN4CCNCC4)cc(OC4CCOCC4)c23)c2c(c1)OCO2
6239,835647,10.1016/j.bmcl.2012.07.079,,,,Inhibition of EGFR in human A431 cell lysate using tyrosine/glutamic acid polymer as substrate by ELISA,Brc1cccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCCCCO5)cc23)c1,"N4-(3-bromophenyl)-N6-((2,3,4,5-tetrahydrobenzo[b][1,4]dioxocin-8-yl)methyl)quinazoline-4,6-diamine",1.14,uM,=,0.0569048513364725,1,c1ccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCCCCO5)cc23)cc1
6240,840626,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR using GST-Crk as substrate assessed as phosphorylated Crk level after 20 mins by SDS-PAGE analysis,Brc1cccc(Nc2ncnc3cc4c(cc23)OCCCO4)c1,"N-(3-bromophenyl)-8,9-dihydro-7H-[1,4]dioxepino[2,3-g]quinazolin-4-amine",0.085,uM,=,-1.0705810742857071,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCCO4)cc1
6241,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,CNCCOc1n[nH]c2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12,"N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-3-(2-(methylamino)ethoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.017,uM,=,-1.769551078621726,0,c1ccc(COc2ccc(Nc3ncnc4[nH]ncc34)cc2)nc1
6242,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1ccc(-n2c(=O)cnc3cnc(Nc4ccc(Cl)cc4)nc32)cc1,N-(4-(2-(4-Chlorophenylamino)-7-oxopteridin-8(7H)-yl)-phenyl)acrylamide,0.3735,uM,=,-0.4277093938485824,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
6243,1642199,,,,,Inhibition Assay: Inhibition of various kinase enzyme.,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,0.521,uM,=,-0.2831622767004755,0,c1ccc(Nc2ncnc3ccccc23)cc1
6244,66588,10.1021/jm9802259,,,,Inhibitory concentration was evaluated against epidermal growth factor receptor (EGFr) tyrosine kinase,COc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1,"6-(2,6-Dichloro-phenyl)-2-(3-methoxy-phenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",0.03,uM,=,-1.5228787452803376,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
6245,791584,10.1016/j.bmc.2011.11.023,,,,"Inhibition of EGFR using poly(Glu,Tyr)4:1 as substrate and [gamma33P]ATP after 60 mins by scintillation counting",C#Cc1cccc(Nc2ncnc3sc(C(=O)c4cc5ccccc5[nH]4)cc23)c1,"(4-(3-Ethynylphenylamino)thieno[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanone",0.0186999999999999,uM,=,-1.728158393463501,0,O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3ccccc3)ncnc2s1
6246,632804,10.1016/j.bmc.2010.04.001,,,,Inhibition of EGFR after 30 mins by chemiluminescence ELISA,Cl.NC1CCc2c(c3cc(OCCc4ccc(O)cc4)ccc3n2CCCCCc2ccccc2)C1,"4-(2-(3-amino-9-(5-phenylpentyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazol-6-yloxy)ethyl)phenol hydrochloride",1.01,uM,=,0.0043213737826425,1,c1ccc(CCCCCn2c3c(c4cc(OCCc5ccccc5)ccc42)CCCC3)cc1
6247,1761038,10.1016/j.ejmech.2018.01.042,,,,Inhibition of His6-tagged EGFR (unknown origin) cytoplasmic domain expressed in baculovirus infected Sf9 insect cells after 10 mins followed by addition of ATP-MgCl2 and measured after 1 hr by time-resolved fluorometric analysis,CCc1c(C(=O)NC(CO)Cc2ccccc2)[nH]c2ccc(C(F)(F)F)cc12,3-Ethyl-N-(1-hydroxy-3-phenylpropan-2-yl)-5-(trifluoromethyl)-1H-indole-2-carboxamide,0.9,uM,=,-0.0457574905606751,0,O=C(NCCc1ccccc1)c1cc2ccccc2[nH]1
6248,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4ccccn4)cc3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(4-(Pyridin-2-ylmethoxy)phenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)acrylamide,0.1001,uM,=,-0.9995659225206814,0,c1ccc(COc2ccc(Nc3ncnc4cc(O[C@H]5CCOC5)ccc34)cc2)nc1
6249,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Fc1ccc(C2CC(c3ccc(Br)cc3)=NN2c2nc(-c3ccccc3)cs2)cc1,"2-(3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole",11.24,uM,=,1.0507663112330423,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
6250,792378,10.1016/j.ejmech.2011.11.015,,,,Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis,c1ccc(CSc2nnc(-c3ccccc3)o2)cc1,"2-(Benzylthio)-5-phenyl-1,3,4-oxadiazole",16.63,uM,=,1.220892249219519,1,c1ccc(CSc2nnc(-c3ccccc3)o2)cc1
6251,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCN(C)CC1,(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(4-methylpiperazin-1-yl)but-2-enamide,0.008,uM,=,-2.096910013008056,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
6252,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide,0.008,uM,=,-2.096910013008056,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
6253,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCOc1cc2ncnc(/C=C/CCc3ccccc3)c2cc1OCC,"6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline",0.005,uM,=,-2.3010299956639813,0,C(=C/c1ncnc2ccccc12)\CCc1ccccc1
6254,1337213,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ccc(Oc2nc3ccccc3cc2/C=N/NC(=O)Cn2c([N+](=O)[O-])cnc2C)cc1,(E)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)-N'-((2-(p-tolyloxy)quinolin-3-yl)methylene)acetohydrazide,7.67,uM,=,0.884795363948981,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
6255,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(OC)c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(3-Methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.417,uM,=,-0.3798639450262425,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
6256,1986369,10.1016/j.bmc.2020.115373,,,,Inhibition of human EGFR-TK using PTK substrate after 40 mins in presence of ATP by Kinase-Glo luminescent assay,Clc1nc2ccccc2c2nnc(/N=C/c3ccco3)n12,"5-Chloro-N-[(furan-2-yl)methylene][1,2,4]triazolo[4,3-c]quinazolin-3-amine",0.74,uM,=,-0.1307682802690238,0,C(=N/c1nnc2c3ccccc3ncn12)\c1ccco1
6257,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,CCOc1ccc(Nc2ncnc3cc4oc(=O)n(CCCN5CCOCC5)c4cc23)cc1,"8-(4-Ethoxyphenylamino)-1-(3-morpholinopropyl)oxazolo[4,5-g]quinazolin-2(1H)-one",1.4,uM,=,0.1461280356782379,1,O=c1oc2cc3ncnc(Nc4ccccc4)c3cc2n1CCCN1CCOCC1
6258,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,O=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-Bromophenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)urea,0.269,uM,=,-0.570247719997592,0,O=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6259,1641135,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OC)cc3OC)ncc2Br)c1,"US9238629, I-20",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
6260,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,O=C(CCCCCCn1cc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)nn1)NO,"7-(4-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)-N-hydroxyheptanamide",0.00069,uM,=,-3.161150909262745,0,c1ccc(Nc2ncnc3ccc(-c4c[nH]nn4)cc23)cc1
6261,676221,10.1021/jm100607r,,,,Inhibition of EGFR,O=C(/C=C/c1ccccc1)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,"(E)-1-(4-[(1S)-2-Hydroxy-1-phenylethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-3-phenyl-2-propen-1-one",3.503,uM,=,0.5444401373176924,1,O=C(/C=C/c1ccccc1)N1CCc2c(sc3ncnc(NCc4ccccc4)c23)C1
6262,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,COC(=O)Cc1c(SSc2[nH]c3ccccc3c2CC(=O)OC)[nH]c2ccccc12,[2-(3-Methoxycarbonylmethyl-1H-indol-2-yldisulfanyl)-1H-indol-3-yl]-acetic acid methyl ester,18.0,uM,=,1.255272505103306,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
6263,1751807,10.1016/j.bmc.2017.11.039,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide substrate after 10 mins by mobility shift assay,Cc1cc(=O)n(-c2ccc(F)cc2)nc1C(=O)Nc1ccc(Oc2ncnc3ccsc23)c(F)c1,"N-(3-Fluoro-4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl)-1-(4-fluorophenyl)-4-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide",6.9,uM,=,0.8388490907372553,1,O=C(Nc1ccc(Oc2ncnc3ccsc23)cc1)c1ccc(=O)n(-c2ccccc2)n1
6264,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4ccc(OCc5ccccn5)cc4)c3cc21,"Ethyl 4-(2-oxo-8-(4-(pyridin-2-ylmethoxy)phenylamino)oxazolo[4,5-g]quinazolin-1(2H)-yl)butanoate",2.3,uM,=,0.3617278360175928,1,O=c1[nH]c2cc3c(Nc4ccc(OCc5ccccn5)cc4)ncnc3cc2o1
6265,2153740,10.1021/acsmedchemlett.1c00555,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,CN1CCN(C2CCN(c3c(Cl)cc(Nc4ncc(Cl)c(Nc5ccccc5P(C)(C)=O)n4)cc3Cl)CC2)CC1,"(2-((5-Chloro-2-((3,5-dichloro-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide",0.2998,uM,=,-0.5231683714877393,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
6266,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#CCCN1CCOCC1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-(4-morpholinobut-1-ynyl)pyrimidin-4-amine,0.013,uM,=,-1.8860566476931635,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)CCN1CCOCC1
6267,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl ethylcarbamate",0.032,uM,=,-1.494850021680094,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
6268,1924071,10.1021/acs.jmedchem.6b00403,,,,"Inhibition of wild type EGFR kinase domain (unknown origin) expressed using baculovirus expression system incubated for 1 hr using Poly(Glu,Tyr) 4:1 by ELISA method",C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)c1,"N-(3-(5-isopropyl-2-(3-methyl-4-(4-methylpiperazin-1-yl)phenylamino)-6,7-dioxo-6,7-dihydropteridin-8(5H)-yl)phenyl)acrylamide",0.0014,uM,=,-2.853871964321762,0,O=c1[nH]c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n(-c2ccccc2)c1=O
6269,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(C#N)cc3)cc12)c1ccc(F)cc1,"(R)-4-(4-((1-(4-Fluorophenyl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzonitrile",0.014,uM,=,-1.853871964321762,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
6270,1390771,10.1039/C0MD00119H,,,,Inhibition of EGFR kinase (unknown origin) using poly(Glu:Tyr) as substrate,CC1(C)[C@H]2CC3OB(COc4ccc5ncnc(Nc6cccc(Cl)c6)c5c4)O[C@@]3(C)[C@@H]1C2,,0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3ccc(OCB4OC5C[C@H]6C[C@H](C6)C5O4)cc23)cc1
6271,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,c1csc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)c1,"(1H-Indol-5-yl)-(2-thiophen-2-yl-thieno[3,2-b]pyridin-7-yl)-amine",0.001,uM,=,-3.0,0,c1csc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4)c3s2)c1
6272,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1,N-(4-(3-fluorobenzyloxy)-3-(trifluoromethyl)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.08,uM,=,-1.0969100130080565,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
6273,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,NC(=S)N1N=C(c2ccc(Br)c(Br)c2)CC1c1ccccc1Cl,"5-(2-Chlorophenyl)-3-(3,4-dibromophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",12.26,uM,=,1.0884904701823963,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
6274,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Cl.O=[N+]([O-])c1ccc2sc3c(Nc4cccc(C(F)(F)F)c4)ncnc3c2c1,"(8-Nitro-benzo[4,5]thieno[3,2-d]pyrimidin-4-yl)-(3-trifluoromethyl-phenyl)-amine hydrochloride",0.46,uM,=,-0.3372421683184259,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
6275,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6276,729712,10.1021/ml100146z,,,,Inhibition of EGFR after 60 mins by radiometric assay,O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,"2,5-Dichloro-N-(2-chloro-4-nitro-phenyl)-benzamide",10.5,uM,=,1.021189299069938,1,O=C(Nc1ccccc1)c1ccccc1
6277,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCCCCn1ccnc1[N+](=O)[O-],N-(3-Bromophenyl)-6-methoxy-7-((6-(2-nitro-1H-imidazol-1-yl)hexyl)oxy)quinazolin-4-amine,0.00078,uM,=,-3.10790539730952,0,c1ccc(Nc2ncnc3cc(OCCCCCCn4ccnc4)ccc23)cc1
6278,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,"N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide",0.02,uM,=,-1.6989700043360187,0,O=C(Nc1ccccc1)c1cnc(Nc2cc(N3CCNCC3)ncn2)s1
6279,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,CCC(=O)NCCSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,N-(2-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)ethyl)propionamide,0.033,uM,=,-1.4814860601221125,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
6280,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)/C(F)=C\CN1CCCCC1,(E)-(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide,0.0025499999999999,uM,=,-2.593459819566045,0,O=C(/C=C\CN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
6281,1994718,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 40 mins in presence of ATP by caliper mobility shift assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.022,uM,=,-1.6575773191777938,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
6282,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccc(S(C)(=O)=O)cc3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(4-(methylsulfonyl)benzylidene)cyclohexanone",1.9,uM,=,0.2787536009528289,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
6283,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)N(C)c1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-pyrido[3,2-d]pyrimidin-6-yl]-N-methyl-acrylamide",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)cnc23)cc1
6284,2049843,10.1021/acs.jmedchem.0c01059,,,,Inhibition of GST-tagged recombinant HER1 (unknown origin) expressed in baculovirus expression system incubated for 15-45 mins in presence of [gamma32P]-ATP by radiometric assay,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,2-[5-chloro-2-[2-methoxy-4-(4-morpholinyl)phenylamino]pyrimidin-4-ylamino]-N-methylbenzamide,0.55,uM,=,-0.2596373105057561,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
6285,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(2-Chloro-5-methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.373,uM,=,-0.4282911681913124,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
6286,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)C(C)(C)C)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-34",0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6287,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,COc1ccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"(3-Chloro-phenyl)-[3-(4-methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine",0.096,uM,=,-1.0177287669604316,0,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
6288,553933,10.1021/np070447m,,,,Inhibition of recombinant EGFR,Cc1cc(O)cc2oc(=O)c3c(O)cc(O)cc3c12,alternariol,0.0213134656970923,uM,=,-1.6713459256614576,0,O=c1oc2ccccc2c2ccccc12
6289,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Oc1ncnc(Nc3cccc(C)c3)c1NC2,"(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-m-tolyl-amine",7.4,uM,=,0.8692317197309762,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6290,5004,10.1016/s0960-894x(02)00364-5,,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Cc1cc(C(=O)NCCN2CCOCC2)[nH]c1/C=C1\C(=O)Nc2ncnc(Nc3ccc4c(ccn4Cc4ccccc4)c3)c21,"5-[4-(1-Benzyl-1H-indol-5-ylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide",0.2,uM,=,-0.6989700043360187,0,O=C1Nc2ncnc(Nc3ccc4c(ccn4Cc4ccccc4)c3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1
6291,1869224,10.1021/acs.jmedchem.8b01391,,,,Inhibition of wild type EGFR (unknown origin) by bioluminescent ADP-glo kinase assay,COc1cc(Nc2ncnc3cc(-c4ccccc4)sc23)cc(OC)c1OC,"6-Phenyl-N-(3,4,5-trimethoxyphenyl)thieno[3,2-d]pyrimidin-4-amine",0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2ncnc3cc(-c4ccccc4)sc23)cc1
6292,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(C)c3F)c2c1,N-(4-(2-fluoro-3-methylphenylamino)quinazolin-6-yl)acrylamide,1.5,uM,=,0.1760912590556812,1,c1ccc(Nc2ncnc3ccccc23)cc1
6293,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCOCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-{2-[2-({4-[(4-Bromo-2-fluorophenyl)amino]-6-methoxyquinazolin-7-yl}oxy)ethoxy]ethyl}-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.0059,uM,=,-2.229147988357856,0,O=C(Cn1cncn1)NCCOCCOc1ccc2c(Nc3ccccc3)ncnc2c1
6294,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CC(C)=CC[C@@H](OC(=O)/C=C\C(=O)c1ccc(C)c(F)c1)C1=CC(=O)c2c(O)ccc(O)c2C1=O,"(R)-1-(5,8-Dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (Z)-4-(3-fluoro-4-methylphenyl)-4-oxobut-2-enoate",0.1072,uM,=,-0.9698052146432488,0,O=C(/C=C\C(=O)c1ccccc1)OCC1=CC(=O)c2ccccc2C1=O
6295,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)N1CCC(Sc2nc(-c3ccc(F)cc3)c(-c3ccnc(Nc4ccccc4)c3)[nH]2)C1,1-(3-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)pyrrolidin-1-yl)prop-2-en-1-one,0.217,uM,=,-0.6635402661514705,0,c1ccc(Nc2cc(-c3[nH]c(SC4CCNC4)nc3-c3ccccc3)ccn2)cc1
6296,1523969,10.1016/j.ejmech.2015.08.027,,,,Inhibition of EGFR (unknown origin) using omnia tyr peptide 7 substrate by fluorescence assay,COc1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2SC3)cc1,"8-Chloro-2-(p-methoxyanilino)-5H-benzothiopyrane[4,3-d]pyrimidine",21.56,uM,=,1.333648756514701,1,c1ccc(Nc2ncc3c(n2)-c2ccccc2SC3)cc1
6297,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",C=CC(=O)Nc1cccc(-c2noc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}[1,2]oxazolo[5,4-d]pyrimidin-3-yl)phenyl]prop-2-enamide",0.416,uM,=,-0.3809066693732573,0,c1ccc(CNc2ncnc3onc(-c4ccccc4)c23)cc1
6298,350362,10.1016/j.bmcl.2006.01.111,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-(2-phenylethynyl)pyrimidin-4-amine,0.079,uM,=,-1.1023729087095586,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
6299,506208,10.1021/np50089a001,,,,Inhibition of EGFR,O=c1c(-c2ccc(O)cc2)c(CN2CCCCC2)oc2cc(O)cc(O)c12,"5,7-dihydroxy-3-(4-hydroxyphenyl)-2-(piperidin-1-ylmethyl)-4H-chromen-4-one",27.23741969488772,uM,=,1.435165962809391,1,O=c1c(-c2ccccc2)c(CN2CCCCC2)oc2ccccc12
6300,512831,10.1016/j.bmcl.2008.07.057,,,,Inhibition of EGFR,COC(=O)c1c(N)ncnc1Nc1ccc(OCc2ccccc2)c(Cl)c1,methyl 4-amino-6-(4-(benzyloxy)-3-chlorophenylamino)pyrimidine-5-carboxylate,0.054,uM,=,-1.2676062401770316,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
6301,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(c3ccc(Oc4ccccc4)cc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(7-(2-Methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-2-oxo-3-(4-phenoxyphenyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",0.00152,uM,=,-2.818156412055228,0,O=C1N(c2ccc(Oc3ccccc3)cc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
6302,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccccc1)c1ccc(Cl)c(Cl)c1,"(Z)-2-((E)-1-(3,4-dichlorophenyl)-3-phenylallylidene)hydrazinecarbothioamide",9.78,uM,=,0.9903388547876014,1,N=C(/C=C/c1ccccc1)c1ccccc1
6303,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CNc1ccc2ncnc(Nc3cccc(Br)c3)c2n1,"N*4*-(3-Bromo-phenyl)-N*6*-methyl-pyrido[3,2-d]pyrimidine-4,6-diamine",0.0031,uM,=,-2.508638306165728,0,c1ccc(Nc2ncnc3cccnc23)cc1
6304,67051,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor-dependent phosphorylation,COc1cc(O)c2c(=O)c(-c3cccc(Cl)c3)cn(CCc3ccccc3)c2c1,3-(3-Chloro-phenyl)-5-hydroxy-7-methoxy-1-phenethyl-1H-quinolin-4-one,1.5,uM,=,0.1760912590556812,1,O=c1c(-c2ccccc2)cn(CCc2ccccc2)c2ccccc12
6305,321418,10.1016/j.bmcl.2005.06.068,,,,Inhibitory concentration against EGFR kinase phosphorylation using synthetic peptide as a substrate,COc1cc(ON2CCC(C)CC2)c2c(Nc3ccc(OCc4ccccn4)c(Cl)c3)ncnc2c1,[3-Chloro-4-(pyridin-2-ylmethoxy)-phenyl]-[7-methoxy-5-(4-methyl-piperidin-1-yloxy)-quinazolin-4-yl]-amine,0.005,uM,=,-2.3010299956639813,0,c1ccc(COc2ccc(Nc3ncnc4cccc(ON5CCCCC5)c34)cc2)nc1
6306,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C=CC(=O)N1CCC[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,"US8476284, 13",0.0012,uM,=,-2.920818753952376,0,c1ccc(Oc2ccc(-c3nn([C@H]4CCCNC4)c4ncncc34)cc2)cc1
6307,831926,10.1016/j.ejmech.2012.06.055,,,,Inhibition of EGFR,O=c1oc2cc3ncnc(Nc4ccc(OCc5ccccn5)cc4)c3cc2n1CCCN1CCOCC1,"1-(3-Morpholinopropyl)-8-(4-(pyridin-2-ylmethoxy)phenylamino)oxazolo[4,5-g]quinazolin-2(1H)-one",1.7,uM,=,0.2304489213782739,1,O=c1oc2cc3ncnc(Nc4ccc(OCc5ccccn5)cc4)c3cc2n1CCCN1CCOCC1
6308,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,O=C(CCl)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-2-chloro-acetamide,0.032,uM,=,-1.494850021680094,0,c1ccc(Nc2ncnc3ccccc23)cc1
6309,699068,10.1016/j.bmc.2010.11.007,,,,Inhibition of EGFR by HTRF assay,N#Cc1cnc(Nc2cccc(Br)c2)c2cc(NC(=O)CCN3CCOCC3)ccc12,N-(1-(3-Bromophenylamino)-4-cyanoisoquinolin-7-yl)-3-morpholinopropanamide,6.9,uM,=,0.8388490907372553,1,O=C(CCN1CCOCC1)Nc1ccc2ccnc(Nc3ccccc3)c2c1
6310,946709,10.1016/j.bmc.2012.12.045,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,CC(C)(C)C(=O)Nc1nc(Nc2ccc(F)c(Br)c2)c2cc(CCc3ccccn3)[nH]c2n1,"N-{4-[(3-Bromo,4-fluorophenyl)amino]-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl}2,2-dimethylpropanamide",5.4,uM,=,0.7323937598229685,1,c1ccc(Nc2ncnc3[nH]c(CCc4ccccn4)cc23)cc1
6311,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),O=C(/C=C/C(F)(F)F)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"4,4,4-Trifluoro-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide",0.00175,uM,=,-2.7569619513137056,0,c1ccc(Nc2ncnc3ccccc23)cc1
6312,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=P(O)(O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,"[5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzyl]-phosphonic acid",3.0,uM,=,0.4771212547196624,1,c1ccc(CNc2ccccc2)cc1
6313,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1ccc(N2C[C@H](CS(C)(=O)=O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@](C)(O)[C@@H](F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(5-((5-isopropyl-8-((2R)-2-methyl-3-(methylsulfonyl)azetidin-1-yl)isoquinolin-3-yl)amino)pyrimidin-2-yl)-4-methylpiperidin-4-ol",1.089,uM,=,0.0370278797557749,1,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
6314,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N1CC(CN(C)C)C1,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-2-(3-((dimethylamino)methyl)azetidin-1-yl)-4-methoxyphenyl)acrylamide",0.2021,uM,=,-0.6944336864846961,0,c1cc2c3c(c1)c(-c1ccnc(Nc4ccc(N5CCC5)cc4)n1)cn3CCC2
6315,78742,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,COc1cc(C=C(C#N)C#N)cc(CS(=O)(=O)c2ccc(C)cc2)c1O,2-[4-Hydroxy-3-methoxy-5-(toluene-4-sulfonylmethyl)-benzylidene]-malononitrile,15.0,uM,=,1.1760912590556811,1,O=S(=O)(Cc1ccccc1)c1ccccc1
6316,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,O=C(CCN1CCOCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-morpholinopropanamide,0.00051,uM,=,-3.292429823902064,0,O=C(CCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6317,1528501,,,,,"Time-Resolved Fluorescence Assay: The following assay may be used to determine the activity of the compounds of the invention for inhibiting EGFR kinase activity. The half maximal inhibitory concentration IC50 (the concentration of the tested compound showing 50% inhibition of the enzyme activity) of each compound was determined by incubating several different concentrations of the tested compounds with a specific enzyme and substrate. EGFR kinase used in this assay is a human-derived recombinant protein (Cell signaling technology, #7908), which was reacted with peptide substrate and different concentrations of tested compounds in a buffer solution containing 60 mM HEPES (pH7.5), 5 mM MgCl2, 5 mM MnCl2, 3 Î¼M Na3VO4, 1.25 M DTT (1000Ã) and 20 Î¼M ATP at 25Â° C., for 45 minutes.",CCOc1cc2[nH]cc(C#N)c(=Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1C[C@H](O)CN1C,"US8901140, 3::US9358227, 3",0.059,uM,=,-1.2291479883578558,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2[nH]ccc(=Nc3ccc(OCc4ccccn4)cc3)c2c1
6318,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,O=C(C#CCCN1CCOCC1)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1,4-(6-(5-morpholinopent-2-ynamido)quinolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.081,uM,=,-1.0915149811213505,0,O=C(C#CCCN1CCOCC1)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1
6319,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCO4)c1F,"N-(3-Ethynyl-2-fluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0197,uM,=,-1.705533773838407,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
6320,1619030,10.1016/j.bmc.2016.09.001,,,,Inhibition of human recombinant N-terminal GST-tagged wild type EGFR cytoplasmic domain (695 end residues) autophosphorylation expressed in baculovirus infected Sf9 insect cells by ADP-Glo luminescence assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(Cn4ccnc4)cc3OC)ncc2Cl)c1,N-[3-[[5-Chloro-2-[2-methoxyl-4-(1H-imidazol-1-ylmethyl)phenylamino]-4-pyrimidinyl]amino]phenyl]-2-propenamide,0.506,uM,=,-0.2958494831602009,0,c1ccc(Nc2ccnc(Nc3ccc(Cn4ccnc4)cc3)n2)cc1
6321,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5)cc4)[nH]c23)C1,"2-(4-(4-fluorophenoxy)phenyl)-7-(1-propioloylpyrrolidin-3-yl)-1H-imidazo[1,2-b]pyrazole-3-carboxamide",0.0386,uM,=,-1.413412695328245,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNC5)c4[nH]3)cc2)cc1
6322,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccc(F)cc5F)cc4)nn32)CC1,"US9447106, 183",0.018,uM,=,-1.744727494896694,0,c1ccc(Oc2ccc(-c3cc4n(n3)C(C3CCNCC3)CCN4)cc2)cc1
6323,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Fc1cccc(COc2ccc(Nc3cc(Oc4ccccc4)ncn3)cc2Cl)c1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-phenoxypyrimidin-4-amine,10.0,uM,=,1.0,1,c1ccc(COc2ccc(Nc3cc(Oc4ccccc4)ncn3)cc2)cc1
6324,2017350,10.1021/acs.jmedchem.0c00870,,,,Inhibiton of EGFR (unknown origin) expressed in human A431 cells assessed as reduction in EGFR induced cell viability after 96 hrs by CellTiter-Glo assay,C=CC(=O)Nc1cc(-c2c[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)ccc1OCCN(C)C,"N-{5-{4-{[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2-[2-(dimethylamino)ethoxy]phenyl}-acrylamide",0.862,uM,=,-0.0644927341752872,0,c1ccc(-c2c[nH]c3ncnc(Nc4ccc(OCc5ccccn5)cc4)c23)cc1
6325,1291542,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGFR (unknown origin) after 10 mins,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCCCC2)CCO4)c1,"1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(piperidin-1-yl)but-2-en-1-one",0.004,uM,=,-2.397940008672037,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
6326,983491,10.1016/j.bmcl.2013.07.049,,,,Inhibition of wild type EGFR (unknown origin) after 24 hrs by fluorescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CC2(CSC2)C1,6-(3-(2-thia-6-azaspiro[3.3]heptan-6-yl)propoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine,0.048,uM,=,-1.3187587626244128,0,c1ccc(Nc2ncnc3ccc(OCCCN4CC5(CSC5)C4)cc23)cc1
6327,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,O=C1CSC(N2N=C(c3ccc(F)cc3)CC2c2ccccc2)=N1,"2-(3-(4-Fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",8.14,uM,=,0.9106244048892012,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
6328,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0096,uM,=,-2.017728766960432,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6329,66907,10.1016/S0960-894X(00)80473-4,,,,Inhibition of epidermal growth factor receptor (EGFR),O=C(NCc1ccccc1)c1cc2ccc(O)c(O)c2cn1,"7,8-Dihydroxy-isoquinoline-3-carboxylic acid benzylamide",1.4,uM,=,0.1461280356782379,1,O=C(NCc1ccccc1)c1cc2ccccc2cn1
6330,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(NCc3cccc(C)c3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-methyl-benzyl)-amine",1.6,uM,=,0.2041199826559248,1,c1ccc(CNc2ncnc3ccccc23)cc1
6331,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),NC(Cc1c(SSc2[nH]c3ccccc3c2CC(N)C(=O)NCc2ccccc2)[nH]c2ccccc12)C(=O)NCc1ccccc1,2-Amino-3-{2-[3-(2-amino-2-benzylcarbamoyl-ethyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-N-benzyl-propionamide,7.6,uM,=,0.8808135922807914,1,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
6332,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,O=C(Nc1ccncc1)Nc1cc(-c2cccnc2)cc(C(F)(F)F)c1,1-(3-(Pyridin-3-yl)-5-(trifluoromethyl)phenyl)-3-(pyridin-4-yl)urea,0.18949,uM,=,-0.7224137042152368,0,O=C(Nc1ccncc1)Nc1cccc(-c2cccnc2)c1
6333,1830445,10.1016/j.ejmech.2018.11.057,,,,Inhibition of EGFR (unknown origin) using FAM-labelled peptide and ATP incubated for 10 mins by mobility shift assay,CCN1CCN(CCCOc2cc3nccc(Oc4c(F)cc(NC(=O)NN5C(=O)CSC5c5c(F)cccc5F)cc4F)c3cc2OC)CC1,"N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea",0.52,uM,=,-0.2839966563652008,0,O=C(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)NN1C(=O)CSC1c1ccccc1
6334,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,3.5,uM,=,0.5440680443502757,1,c1ccc(Nc2ncnc3ccccc23)cc1
6335,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccccc1)c1ccccc1,"(Z)-2-((E)-1,3-diphenylallylidene)hydrazinecarbothioamide",2.38,uM,=,0.3765769570565119,1,N=C(/C=C/c1ccccc1)c1ccccc1
6336,506208,10.1021/np50089a001,,,,Inhibition of EGFR,N#C/C(=C/c1cc(Cc2ccccc2)c(O)c(Cc2ccccc2)c1)C(N)=O,"2-cyano-3-(3,5-dibenzyl-4-hydroxyphenyl)acrylamide",0.6000000000000001,uM,=,-0.2218487496163563,0,c1ccc(Cc2cccc(Cc3ccccc3)c2)cc1
6337,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,Brc1cc2c(NCc3ccccn3)ncnc2s1,"6-Bromo-N-(pyridin-2-ylmethyl)thieno[2,3-d]pyrimidin-4-amine",7.904,uM,=,0.8978469315795717,1,c1ccc(CNc2ncnc3sccc23)nc1
6338,63595,10.1016/s0960-894x(98)00691-x,,,,Inhibit of epidermal growth factor receptor (EGFR),CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CCC[C@@H](N)C3)nc21,"N*2*-((1S,3R)-3-Amino-cyclohexyl)-N*6*-(3-chloro-phenyl)-9-ethyl-9H-purine-2,6-diamine",5.3,uM,=,0.724275869600789,1,c1ccc(Nc2nc(NC3CCCCC3)nc3[nH]cnc23)cc1
6339,1771292,10.1016/j.bmc.2018.03.039,,,,Inhibition of EGFR (unknown origin),CNC(=O)c1ccc(Sc2cccc(NC(=S)Nc3ccc(Cl)c(C(F)(F)F)c3)c2)nc1,6-{3-[3-(4-Chloro-3-trifluoromethylphenyl)thioureido]-phenyl sulfanyl}-N-methylnicotinamide,0.596,uM,=,-0.2247537402597635,0,S=C(Nc1ccccc1)Nc1cccc(Sc2ccccn2)c1
6340,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,C=CC(=O)Nc1ccccc1Oc1nc(Nc2cc(C)[nH]n2)cc(N2CCN(C)CC2)n1,N-(2-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-yloxy)phenyl)acrylamide,0.9,uM,=,-0.0457574905606751,0,c1ccc(Oc2nc(Nc3cc[nH]n3)cc(N3CCNCC3)n2)cc1
6341,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc4c(ccn4Cc4ccco4)c3)ncnc2cc1OC,N-(4-{[1-(2-Furylmethyl)-1H-indol-5-yl]amino}-7-methoxy-6-quinazolinyl)propanamide,0.086,uM,=,-1.0655015487564323,0,c1coc(Cn2ccc3cc(Nc4ncnc5ccccc45)ccc32)c1
6342,1798716,10.1016/j.ejmech.2017.03.083,,,,"Inhibition of wild type N-terminal GST tagged human recombinant EGFR (695 to end amino acids) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) Peptide substrate by ADP-Glo assay",C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(OCCN3CCOCC3)cc2)ncc1Cl,N-[2-[[5-Chloro-2-[4-((2-morpholino)ethoxy)phenylamino]-4-pyrimidinyl]amino]phenyl]acrylamide,0.491,uM,=,-0.3089185078770315,0,c1ccc(Nc2ccnc(Nc3ccc(OCCN4CCOCC4)cc3)n2)cc1
6343,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCC4CCCCC4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-cyclohexylmethoxy-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.285,uM,=,-0.5451551399914898,0,c1ccc2c(Nc3ccc(OCC4CCCCC4)cc3)ccnc2c1
6344,2222492,10.1021/acs.jmedchem.1c02134,,,,Inhibition of EGFR phosphorylation (unknown origin),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.184,uM,=,-0.7351821769904636,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6345,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3c(F)cc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,"(4-Bromo-2,6-difluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine",0.4,uM,=,-0.3979400086720376,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
6346,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(Br)cc3F)c2c1,N-(4-(4-bromo-2-fluorophenylamino)quinazolin-6-yl)acrylamide,2.1,uM,=,0.3222192947339193,1,c1ccc(Nc2ncnc3ccccc23)cc1
6347,436426,10.1021/jm070144p,,,,Inhibition of EGFR tyrosine kinase expressed in A431 cells,COc1ccc(N(CCCl)CCN/N=N/c2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)cc1,1-{4-[(3-chlorophenyl)amino-6-quinazolinyl}-3-{2-[N-(2-chloroethyl)-N-4-methoxyphenylethylenamine]} triazene,3.96,uM,=,0.5976951859255123,1,c1ccc(NCCN/N=N/c2ccc3ncnc(Nc4ccccc4)c3c2)cc1
6348,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCN(CC)[C@@](C)(CCc1ncnc2cc(OC)c(OC)cc12)Cc1ccccc1,"(S)-4-(6,7-dimethoxyquinazolin-4-yl)-N,N-diethyl-2-methyl-1-phenylbutan-2-amine",0.13,uM,=,-0.8860566476931633,0,c1ccc(CCCCc2ncnc3ccccc23)cc1
6349,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3[nH]ccc23)CC1,"1-(4-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.03608,uM,=,-1.442733471130096,0,c1cc2c(OC3CCNCC3)nc(Nc3ccc(N4CCNCC4)cc3)nc2[nH]1
6350,408552,10.1021/jm0608762,,,,Inhibition of EGFR tyrosine kinase activity,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.028,uM,=,-1.5528419686577808,0,c1ccc(Nc2ncnc3ccccc23)cc1
6351,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Cc1cccc(Nc2[nH]cnc3nnc(Nc4cccc(Cl)c4)c2-3)c1,"N*3*-(3-Chloro-phenyl)-N*4*-m-tolyl-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.15,uM,=,-0.8239087409443188,0,c1ccc(Nc2nnc3nc[nH]c(Nc4ccccc4)c2-3)cc1
6352,1627921,10.1016/j.ejmech.2016.07.049,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",Oc1cc(O)c2cc(O)c(-c3cc(O)c(O)c(O)c3)[o+]c2c1.[Cl-],Delphinidin chloride,0.0062699999999999,uM,=,-2.202732459169284,0,c1ccc(-c2ccc3ccccc3[o+]2)cc1
6353,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,CCC(=O)Nc1cccc(-c2nc(Nc3cc[nH]n3)c3ccccc3n2)c1,N-(3-(4-(1H-pyrazol-3-ylamino)quinazolin-2-yl)phenyl)propionamide,3.7,uM,=,0.568201724066995,1,c1ccc(-c2nc(Nc3cc[nH]n3)c3ccccc3n2)cc1
6354,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#C/C(=C\c1ccc(F)cc1)C(=O)O,2-Cyano-3-(4-fluoro-phenyl)-acrylic acid,833.0,uM,=,2.9206450014067875,1,c1ccccc1
6355,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,Cc1cccc(NC(=O)/C=C/c2ccccc2)c1,N-m-tolylcinnamamide,19.69,uM,=,1.2942457161381182,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
6356,2067577,10.1016/j.ejmech.2019.111888,,,,"Inhibition of EGFR L858R/T790M/C797S (unknown origin) using Poly (Glu, Tyr) as substrate measured after 40 mins by kinase-glo assay",CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccc(F)cc5)n([C@H]5CCN(C(=O)OC(C)(C)C)C5)c4n3)cc2)CC1,"(S)-9-(1-Bocpyrrolidine-3-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-4-fluorophenyl-9H-purine-2,8-diamine",0.122,uM,=,-0.9136401693252518,0,c1ccc(Nc2nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc3n2[C@H]2CCNC2)cc1
6357,1618196,10.1021/acs.jmedchem.5b01985,,,,Inhibition of N-terminal 6x-HIS-tagged wild type human recombinant EGFR (696 to 1022 residues) expressed in Sf9 cells pre-incubated for 90 mins followed by 10 uM ATP addition by HTRF assay,Cc1cccc2nc(NC(=O)c3cccc(C(F)(F)F)c3)n([C@H]3CC[C@H](O)CC3)c12,N-(1-(trans-4-Hydroxycyclohexyl)-7-methyl-1H-benzo[d]-imidazol-2-yl)-3-(trifluoromethyl)benzamide,5.27,uM,=,0.7218106152125465,1,O=C(Nc1nc2ccccc2n1C1CCCCC1)c1ccccc1
6358,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",COc1cc2ncnc(Nc3ccc(F)cc3)c2cc1OC.Cl,"4-(4'-fluoroanilino)-6,7-dimethoxyquinazoline hydrochloride",0.051,uM,=,-1.2924298239020635,0,c1ccc(Nc2ncnc3ccccc23)cc1
6359,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCNCc1cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1CC,"(1-Benzyl-1H-indazol-5-yl)-(5-ethyl-6-ethylaminomethyl-pyrrolo[2,1-f][1,2,4]triazin-4-yl)-amine",7.4,uM,=,0.8692317197309762,1,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
6360,1690842,10.1021/acs.jmedchem.7b00515,,,,Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccccc3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.14,uM,=,-0.8538719643217619,0,c1ccc(-c2nn([C@@H]3CCCNC3)c3ncncc23)cc1
6361,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(Nc1cccnc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(pyridin-3-yl)thiourea,0.0101999999999999,uM,=,-1.9913998282380825,0,S=C(Nc1cccnc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6362,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(=O)NCc3ccc(C(=O)O)cc3)c3ccccc3n2C)c(C(=O)NCc2ccc(C(=O)O)cc2)c2ccccc21,4-{2-[3-(4-carboxybenzylcarbamoyl)-1-methyl-1H-2-indolyldisulfanyl]-1-methyl-1H-3-indolylcarboxamidomethyl}benzoic acid1.5 H2O,5.3,uM,=,0.724275869600789,1,O=C(NCc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)NCc2ccccc2)[nH]c2ccccc12
6363,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCC(N(CC)CC)CC4)cc3OC)n2)c1,N-(3-(3-(2-(4-(4-(diethylamino)piperidin-1-yl)-2-methoxyphenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.036,uM,=,-1.4436974992327127,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCCCC3)cc2)n1
6364,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,OCc1ccc(-c2cc3c(NCc4ccccc4)ncnc3s2)cc1,"(4-(4-(Benzylamino)thieno[2,3-d]pyrimidin-6-yl)phenyl)methanol",0.048,uM,=,-1.3187587626244128,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
6365,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC[C@]1(F)CN(c2nccc(Nc3cc4c(C(C)C)ccc(N5C[C@H](CS(C)(=O)=O)[C@H]5C)c4cn3)n2)CC[C@H]1O,(3S)-3-ethyl-3-fluoro-1-(5-((5-isopropyl-8-((2R)-2-methyl-3-(methylsulfonyl)azetidin-1-yl)isoquinolin-3-yl)amino)pyrimidin-2-yl)piperidin-4-ol,0.709,uM,=,-0.1493537648169335,0,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
6366,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1ncnc(Sc3cccc(Cl)c3)c1NC2,"1-(3-chloro-phenylsulfanyl)-7,8-dimethoxy-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cycloheptene",2.9,uM,=,0.4623979978989561,1,c1ccc(Sc2ncnc3c2NCc2ccccc2S3)cc1
6367,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccco5)sc34)cc2Cl)c1,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(furan-2-yl)thieno[3,2-d]pyrimidin-4-amine",0.01,uM,=,-2.0,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5ccco5)sc34)cc2)cc1
6368,1720134,10.1016/j.ejmech.2017.09.061,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus virus expression system after 1 hr by ELISA,NS(=O)(=O)c1ccc(-n2c(SCC(=O)Nc3cc(Cl)c(Cl)cc3Cl)nc3cc4ccccc4cc3c2=O)cc1,"2-(4-Oxo-3-(4-sulfamoylphenyl)-3,4-dihydrobenzo[g]quinazolin-2-ylthio)-N-(2,4,5-trichlorophenyl)acetamide",0.24,uM,=,-0.619788758288394,0,O=C(CSc1nc2cc3ccccc3cc2c(=O)n1-c1ccccc1)Nc1ccccc1
6369,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3ccc(F)c(C=O)c3)cc12)c1ccccc1,"(R)-2-Fluoro-5-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzaldehyde",0.008,uM,=,-2.096910013008056,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
6370,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,Fc1ccc(Nc2ncnc3ccc(NC(=S)NCCN4CCCCC4)cc23)cc1Cl,1-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)-3-(2-(piperidin-1-yl)ethyl)thiourea,0.0037,uM,=,-2.431798275933005,0,S=C(NCCN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6371,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc3ccccc3nc2Cl)c2c(N)ncnc21,"3-(2-chloroquinolin-3-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",100.0,uM,=,2.0,1,c1ccc2ncc(-c3n[nH]c4ncncc34)cc2c1
6372,2121824,10.1016/j.ejmech.2021.113786,,,,Inhibition of wild type EGFR (unknown origin) using fluoresceine-labelled poly-GT peptide as substrate preincubated with enzyme for 3 hrs followed by substrate and ATP addition by TR-FRET assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0001,uM,=,-4.0,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6373,622913,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR in human A431 cells by HTRF assay,Cc1c(C(=O)NCCN2CCOCC2)[nH]c2cnnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c12,"4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-3-methyl-N-(2-morpholinoethyl)-1H-pyrrolo[3,2-d]pyridazine-2-carboxamide",12.65,uM,=,1.1020905255118367,1,O=C(NCCN1CCOCC1)c1cc2c(Nc3ccc(OCc4ccccc4)cc3)nncc2[nH]1
6374,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",CNc1ncc2ncnc(Nc3ccccc3)c2n1,"N*2*-Methyl-N*8*-phenyl-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2ncnc3cncnc23)cc1
6375,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,CCOC(=O)C(=CNc1ccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2c1)C(=O)OCC,diethyl 2-(((4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)quinazolin-6-yl)amino)methylene)malonate,1.02,uM,=,0.0086001717619175,1,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
6376,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,CCC(=O)Nc1ccc(OC)c(Nc2cc(-c3cnc(SC)[nH]3)ccn2)c1,N-(4-Methoxy-3-((4-(2-(methylthio)-1H-imidazol-5-yl)pyridin-2-yl)amino)phenyl)propionamide,1.767,uM,=,0.247236549506764,1,c1ccc(Nc2cc(-c3cnc[nH]3)ccn2)cc1
6377,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,CCc1nccn1Cc1ccc(Nc2nc3ncnc(Nc4ccc(F)c(Cl)c4)c3s2)cc1,"N7-(3-chloro-4-fluorophenyl)-N2-(4-((2-ethyl-1H-imidazol-1-yl)methyl)phenyl)thiazolo[4,5-d]pyrimidine-2,7-diamine",0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3nc(Nc4ccc(Cn5ccnc5)cc4)sc23)cc1
6378,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,O=C(/C=C/CN1CCSCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Thiomorpholin-4-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.203,uM,=,-0.6925039620867871,0,O=C(/C=C/CN1CCSCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6379,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Oc1c(Cl)cc(Cl)cc1CN(Cc1ccc(F)cc1)C(=S)Nc1ccccc1,"1-(3,5-Dichloro-2-hydroxybenzyl)-1-(4-fluorobenzyl)-3-phenylthiourea",1.34,uM,=,0.1271047983648076,1,S=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
6380,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,CN1CCN(NCCCNc2cc3c(Nc4cccc(Br)c4)ncnc3cn2)CC1,"N*4*-(3-Bromo-phenyl)-N*6*-[3-(4-methyl-piperazin-1-ylamino)-propyl]-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0039,uM,=,-2.408935392973501,0,c1ccc(Nc2ncnc3cnc(NCCCNN4CCNCC4)cc23)cc1
6381,1583975,10.1016/j.bmc.2016.05.063,,,,Inhibition of wild type EGFR (unknown origin) expressed in mouse BaF/3 cells assessed as cell growth inhibition after 72 hrs by MTS assay,O=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,1-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)-3-(2-morpholinoethyl)urea,0.259,uM,=,-0.5867002359187482,0,O=C(NCCN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
6382,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2CC(c3ccc(Br)cc3)=NN2c2nc(-c3ccc(Cl)cc3)cs2)cc1,"2-(3-(4-bromophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-chlorophenyl)thiazole",19.83,uM,=,1.2973227142053028,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
6383,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1ncnc(Oc3cccc(Br)c3)c1NC2,"1-(3-bromo-phenoxy)-7,8-dimethoxy-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cycloheptene",21.7,uM,=,1.3364597338485296,1,c1ccc(Oc2ncnc3c2NCc2ccccc2S3)cc1
6384,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)CCC#N)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"2-[3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl(methyl)amino]ethyl cyanide",1.1,uM,=,0.041392685158225,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
6385,540158,10.1016/j.bmcl.2008.07.062,,,,Inhibition of EGFR,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.0023,uM,=,-2.638272163982407,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
6386,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,Cc1ccc(C2=NN(C(N)=S)C(c3ccccc3Br)C2)cc1C,"5-(2-Bromophenyl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",4.21,uM,=,0.6242820958356683,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
6387,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,CN(C)c1ccc(Nc2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"N*4*-(3-Chloro-phenyl)-N*3*-(4-dimethylamino-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",1.5,uM,=,0.1760912590556812,1,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
6388,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,O=C(O)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"3-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-propionic acid",0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ncnc3cnccc23)cc1
6389,66582,10.1021/jm970634p,,,,Inhibition of human epidermal growth factor receptor,CN1CCN(CCCNc2ncc3cc(-c4c(Cl)cccc4Cl)c(NC(=O)NCc4ccccc4)nc3n2)CC1,"1-Benzyl-3-{6-(2,6-dichloro-phenyl)-2-[3-(4-methyl-piperazin-1-yl)-propylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea",0.98,uM,=,-0.0087739243075051,0,O=C(NCc1ccccc1)Nc1nc2nc(NCCCN3CCNCC3)ncc2cc1-c1ccccc1
6390,221782,10.1016/0960-894X(95)00157-O,,,,Inhibition of epidermal growth factor receptor (EGFR),COc1cc2c(cc1OC)Nc1ncnc(O)c1C2,"7,8-Dimethoxy-5,10-dihydro-3H-pyrimido[4,5-b]quinolin-4-one",75.0,uM,=,1.8750612633917,1,c1ccc2c(c1)Cc1cncnc1N2
6391,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,O=C(/C=C/c1ccccc1)Nc1ccccc1,N-phenylcinnamamide,23.16,uM,=,1.3647385550553983,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
6392,2268691,10.1016/j.ejmech.2021.113768,,,,Inhibition of GST-fused EGFR (unknown origin) in presence of ATP by microplate reader analysis,CCc1nnc2c(Nc3ccc(C(=O)/C=C/c4cc(OC)c(OC)c(OC)c4)cc3)nc3ccccc3n12,"(E)-1-[4-[(1-ethyl-[1,2,4]triazolo[4,3-a]quinoxalin-4-yl)amino]phenyl]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",0.093,uM,=,-1.031517051446065,0,O=C(/C=C/c1ccccc1)c1ccc(Nc2nc3ccccc3n3cnnc23)cc1
6393,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=C(O)c1ccc(O)cc1,2-[Hydroxy-(4-hydroxy-phenyl)-methylene]-malononitrile,230.0,uM,=,2.361727836017593,1,c1ccccc1
6394,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/c1cn(C)cn1,N-[4-(4-Benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-3-(1H-imidazol-4-yl)-acrylamide,0.255,uM,=,-0.5934598195660449,0,O=C(/C=C/c1c[nH]cn1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
6395,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N1C[C@@H]2CN(c3nc(Nc4cnn(C)c4)c4ncn(C(C)C)c4n3)C[C@@H]2C1,"1-((cis)-5-(9-Isopropyl-6-((1-methyl-1H-pyrazol-4-yl)amino)-9H-purin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)prop-2-en-1-one",0.805,uM,=,-0.0942041196321314,0,c1nc2c(Nc3cn[nH]c3)nc(N3C[C@H]4CNC[C@H]4C3)nc2[nH]1
6396,1337213,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ncc([N+](=O)[O-])n1CC(=O)N/N=C/c1cc2ccccc2nc1Oc1ccc(Cl)cc1,(E)-N'-((2-(4-chlorophenoxy)quinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,4.1,uM,=,0.6127838567197355,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
6397,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(NC(=O)/C=C/CN(C)C)cc23)c1,"(S,E)-4-(Dimethylamino)-N-(4-(3-ethynylphenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)but-2-enamide",0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
6398,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,CNC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,4-Methylcarbamoyl-benzenesulfonic acid 4-(2-nitro-vinyl)-phenyl ester,0.4,uM,=,-0.3979400086720376,0,O=S(=O)(Oc1ccccc1)c1ccccc1
6399,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(CCN(C)C)[C@@H](C)C(N)=O,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(2-(dimethylamino)ethyl)amino)propanamide,0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
6400,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1,1-(4-(4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one,0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
6401,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,COC1CN(c2ncc(C(C)C)c3cc(Nc4ccnc(N5CC[C@@H](O)[C@@](C)(F)C5)n4)ncc23)C1,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-(3-methoxyazetidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",25.0,uM,=,1.3979400086720375,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
6402,523777,10.1016/j.bmcl.2009.05.009,,,,Inhibition of EGFR,N#Cc1cnc2c(Cl)cc(NCc3cn(C4CCN(C5CCC5)CC4)nn3)cc2c1Nc1ccc(F)c(Cl)c1,"8-chloro-4-(3-chloro-4-fluorophenylamino)-6-((1-(1-cyclobutylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)methylamino)quinoline-3-carbonitrile",22.0,uM,=,1.3424226808222062,1,c1ccc(Nc2ccnc3ccc(NCc4cn(C5CCN(C6CCC6)CC5)nn4)cc23)cc1
6403,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CN(C(C)C)C1,3-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-1-isopropylazetidine-3-carboxamide,0.035,uM,=,-1.4559319556497243,0,c1ccc(Nc2ncnc3ccc(CNC4CNC4)cc23)cc1
6404,1299434,10.1039/C3MD00118K,,,,Inhibition of recombinant wild type EGFR kinase(unknown origin) after 30 mins in presence of [gamma32P]ATP,C=CC(=O)N1CCc2c(sc3ncnc(Nc4ccc(CC)cc4)c23)C1,"1-(4-((4-ethylphenyl)amino)-5,6-dihydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7(8H)-yl)prop-2-en-1-one",7.38,uM,=,0.8680563618230416,1,c1ccc(Nc2ncnc3sc4c(c23)CCNC4)cc1
6405,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(F)cc3Cl)ncnc2cc1OCCOCCOCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-(2-{2-[2-({4-[(2-Chloro-4-fluorophenyl)amino]-6-methoxy-quinazolin-7-yl}oxy)ethoxy]ethoxy}ethyl)-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.01293,uM,=,-1.8884014751196057,0,O=C(Cn1cncn1)NCCOCCOCCOc1ccc2c(Nc3ccccc3)ncnc2c1
6406,506208,10.1021/np50089a001,,,,Inhibition of EGFR,O=CN/C=C/c1ccc(O)c(O)c1,"N-[(E)-2-(3,4-Dihydroxy-phenyl)-vinyl]-formamide",5.584775000687644,uM,=,0.7470056809559875,1,c1ccccc1
6407,1476964,10.1016/j.bmc.2015.04.038,,,,Inhibition of wild type N-terminal His6-tagged human EGFR kinase domain (702 to 1016 residues) expressed in Sf9 cells pre-incubated for 30 mins before ATP and substrate addition by homogeneous time-resolved FRET assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)/C(C#N)=C/c3ccc(SC)cc3)c2)n1,N-(3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)-phenyl)-2-cyano-3-(4-(methylthio)phenyl)acrylamide,4.8,uM,=,0.6812412373755872,1,O=C(/C=C/c1ccccc1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
6408,1882261,10.1016/j.bmc.2018.10.018,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (696-end residues) expressed in baculovirus expression system using Srctide as substrate by fluorescence assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4cccnc34)n2)c(OC)cc1NCCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)amino)-4-methoxy-5-((4(1-methyl-(1H-pyrrolo[3,2-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide",77.0,uM,=,1.8864907251724816,1,c1ccc(Nc2nccc(-c3c[nH]c4cccnc34)n2)cc1
6409,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(C(=O)OC(C)C)c(-c2c[nH]c3ccccc23)n1,Isopropyl-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-4-(1H-indol-3-yl)pyrimidin-5-carboxylate,0.00016,uM,=,-3.795880017344075,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCCCC5)cc4)n3)c[nH]c2c1
6410,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)Nc1ccc(Cl)cc1Cl,"1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(2,4-dichlorophenyl)thiourea",0.0489,uM,=,-1.3106911408763795,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6411,1548912,10.1039/C5MD00208G,,,,Inhibiton of wild type EGFR (unknown origin) using Poly (Glu4Tyr1) as substrate incubated for 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.035,uM,=,-1.4559319556497243,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6412,1880799,10.1016/j.ejmech.2017.04.079,,,,Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,"5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine",2.156,uM,=,0.3336487565147011,1,c1ccc(Nc2ccnc(Nc3ccc(C4CCNCC4)cc3)n2)cc1
6413,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,OCCN(CCO)CCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"2-[{2-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-ylamino]-ethyl}-(2-hydroxy-ethyl)-amino]-ethanol",0.0092,uM,=,-2.036212172654445,0,c1ccc(Nc2ncnc3ccncc23)cc1
6414,1353177,10.1021/ml4003309,,,,Inhibition of recombinant EGFR (unknown origin) using poly-GT peptide as substrate by Transcreener assay,COc1cc2c(Oc3ccc(NS(=O)(=O)c4cccc(-c5ccsc5)c4)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,N-[3-fluoro-4-({6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yl}oxy)phenyl]-3-(3-thienyl)benzenesulfonamide,0.094,uM,=,-1.0268721464003014,0,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1cccc(-c2ccsc2)c1
6415,1929287,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide substrate preincubated for 10 mins followed by substrate addition measured after 40 mins by caliper motility shift assay,CC1CCN(C/C=C/C(=O)N2CCOc3cc4ncnc(Nc5ccc(F)c(Cl)c5)c4cc32)CC1,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(4-methylpiperidin-1-yl)but-2-en-1-one",0.005,uM,=,-2.3010299956639813,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
6416,1650711,10.1016/j.bmcl.2017.02.023,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-Lyte assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.00015,uM,=,-3.823908740944319,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6417,99801,10.1021/jm990947f,,,,Inhibition of EGF-stimulated MCF-7 human breast tumor cell proliferation,N#C/C(=C\c1ccc(O)cc1)c1ccccn1,3-(4-Hydroxy-phenyl)-2-pyridin-2-yl-acrylonitrile,71.7,uM,=,1.8555191556678,1,C(=Cc1ccccn1)c1ccccc1
6418,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",COc1cc2ncnc(Nc3ccccc3F)c2cc1OC.Cl,"4-(2'-fluoroanilino)-6,7-dimethoxyquinazoline hydrochloride",0.0322,uM,=,-1.4921441283041692,0,c1ccc(Nc2ncnc3ccccc23)cc1
6419,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C1CC1,(E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)-4-(cyclopropyl(methyl)amino)but-2-enamide,0.0089,uM,=,-2.050609993355087,0,O=C(/C=C/CNC1CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6420,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
6421,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)CC(C)(C)C)CC4)cc3OC)ncc2Cl)c1,"US8975249, I-23",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6422,622913,10.1016/j.bmcl.2009.09.038,,,,Inhibition of EGFR in human A431 cells by HTRF assay,O=C(NCCN1CCCC1)c1cc2cnnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2[nH]1,"7-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-N-(2-(pyrrolidin-1-yl)ethyl)-1H-pyrrolo[2,3-d]pyridazine-2-carboxamide",15.14,uM,=,1.180125875164054,1,O=C(NCCN1CCCC1)c1cc2cnnc(Nc3ccc(OCc4ccccc4)cc3)c2[nH]1
6423,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)N1CCC(CCO)CC1,(S)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(2-hydroxyethyl)piperidine-1-carboxamide,0.304,uM,=,-0.5171264163912462,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1)N1CCCCC1
6424,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(NC(C)c3ccccc3)ncnc2s1,"(rac)-6-(2-Methoxyphenyl)-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine",0.019,uM,=,-1.7212463990471711,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
6425,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)N1CC(O)C1,(S)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-hydroxyazetidine-1-carboxamide,0.543,uM,=,-0.265200170411153,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1)N1CCC1
6426,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(OCCN(C)C)c(Br)c3)c2c1,N-{4-[3-Bromo-4-(2-dimethylamino-ethoxy)-phenylamino]-quinazolin-6-yl}-acrylamide,7.693,uM,=,0.8860957324377474,1,c1ccc(Nc2ncnc3ccccc23)cc1
6427,553933,10.1021/np070447m,,,,Inhibition of recombinant EGFR,Cc1cc(O)c(O)cc1-c1cc(O)cc(O)c1C(=O)O,desmethylaltenusin,0.0152138971735641,uM,=,-1.8177595233448736,0,c1ccc(-c2ccccc2)cc1
6428,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.0055,uM,=,-2.2596373105057563,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
6429,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(OC(F)F)c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(3-(Difluoromethoxy)phenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.257,uM,=,-0.5900668766687055,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
6430,1553877,10.1016/j.ejmech.2016.01.045,,,,Inhibition of wild type recombinant human EGFR assessed as reduction in autophosphorylation of cytoplasmic domain by Z'-Lyte assay,COc1cc2ncnc(Nc3cccc(NC(=O)C45CC6CC(CC(C6)C4)C5)c3)c2cc1OCCCN1CCOCC1,N-(3-((7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl)amino)phenyl)adamantane-1-carboxamide,0.00311,uM,=,-2.5072396109731625,0,O=C(Nc1cccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)c1)C12CC3CC(CC(C3)C1)C2
6431,1885922,10.1016/j.bmc.2019.07.007,,,,Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay,Cc1ccc(-n2cc(NC(=O)c3ccc(NS(=O)(=O)c4ccc(Cl)cc4)cc3)cn2)cc1,4-((4-Chlorophenyl)sulfonamido)-N-(1-(p-tolyl)-1H-pyrazol-4-yl)benzamide,12.45,uM,=,1.095169351431755,1,O=C(Nc1cnn(-c2ccccc2)c1)c1ccc(NS(=O)(=O)c2ccccc2)cc1
6432,946709,10.1016/j.bmc.2012.12.045,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,Nc1nc(Nc2ccc(F)c(Br)c2)c2cc(CCc3ccccn3)[nH]c2n1,"N4-(3-Bromo,4-fluorophenyl)-6-(2-pyridin-2-yl-ethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",85.9,uM,=,1.9339931638312424,1,c1ccc(Nc2ncnc3[nH]c(CCc4ccccn4)cc23)cc1
6433,479562,10.1016/j.bmcl.2008.03.057,,,,Inhibition of EGFR,Cc1nnc(-c2cn3ncnc(Nc4cnc5[nH]ccc5c4)c3c2C(C)C)o1,"5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.15,uM,=,-0.8239087409443188,0,c1nc(Nc2cnc3[nH]ccc3c2)c2cc(-c3nnco3)cn2n1
6434,879277,10.1021/jm1013693,,,,Inhibition of human EGFR kinase activity,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.07,uM,=,-1.154901959985743,0,c1ccc(Nc2ncnc3ccccc23)cc1
6435,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CC(C)N(CC#CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1)C(C)C,N-[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]-4-(bis-(1-methylethyl)amino)-2-butynamide,0.0042,uM,=,-2.3767507096021,0,c1ccc(Nc2ncnc3ccccc23)cc1
6436,1337213,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ccc(Oc2nc3ccc(C)cc3cc2/C=N/NC(=O)Cn2c([N+](=O)[O-])cnc2C)cc1,(E)-N'-((6-methyl-2-(p-tolyloxy)quinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,17.0,uM,=,1.230448921378274,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
6437,63616,10.1016/S0960-894X(97)00034-6,,,,Inhibition of Epidermal growth factor receptor autophosphorylation.,COc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-p-tolyl-amine hydrochloride",0.25,uM,=,-0.6020599913279624,0,c1ccc(Nc2ncnc3ccccc23)cc1
6438,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3ccc(C#CCN4CCCCC4)cc23)cc1Cl,N-(3-chloro-4-fluorophenyl)-6-(3-(piperidin-1-yl)prop-1-ynyl)quinazolin-4-amine,0.0887,uM,=,-1.0520763801682735,0,C(#Cc1ccc2ncnc(Nc3ccccc3)c2c1)CN1CCCCC1
6439,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Nc1ccc2ncnc(Nc3cccc4c3CCCC4)c2c1,"N4-(5,6,7,8-tetrahydronaphthalen-1-yl)quinazoline-4,6-diamine",0.1648,uM,=,-0.783042792638903,0,c1cc2c(c(Nc3ncnc4ccccc34)c1)CCCC2
6440,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(-c3cn4c5c(cccc35)OCC4)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((5-chloro-4-(2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-6-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.036,uM,=,-1.4436974992327127,0,c1ccc(Nc2nccc(-c3cn4c5c(cccc35)OCC4)n2)cc1
6441,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1ccc(-c2nn(C[C@H](C)CO)c3ncnc(N)c23)cc1OC,"(S)-3-(4-amino-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methylpropan-1-ol",12.0,uM,=,1.0791812460476249,1,c1ccc(-c2n[nH]c3ncncc23)cc1
6442,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCNC1,"5-(4-amino-1-(pyrrolidin-3-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",2.01,uM,=,0.3031960574204888,1,c1ccc(-c2nn(CC3CCNC3)c3ncncc23)cc1
6443,819567,10.1021/jm201591k,,,,Inhibition of EGFR after 1.5 hr by FRET assay,C=CC(=O)Nc1cccc(N2C(=O)N(C)Cc3cnc(Nc4ccc(N5CCOCC5)cc4OC)nc32)c1,"N-(3-(7-(2-Methoxy-4-morpholinophenylamino)-3-methyl-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)-acrylamide",0.0163999999999999,uM,=,-1.7851561519523025,0,O=C1NCc2cnc(Nc3ccc(N4CCOCC4)cc3)nc2N1c1ccccc1
6444,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4ccccc4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-N-(4-{[4-(benzyloxy)-3,6-dioxocyclohexa-1,4-dien-1-yl]amino}-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)but-2-enamide",0.0186999999999999,uM,=,-1.728158393463501,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
6445,2075028,10.1021/acsmedchemlett.9b00599,,,,Inhibition of wild type EGFR in human U87 cells assessed as heparin/human EGF stimulated phosphorylation after 1 hr by immunoblotting analysis,Fc1ccc(Br)c(F)c1Nc1ncnc2cc3c(cc12)OCCO3,"N-(3-Bromo-2,6-difluorophenyl)-7,8-dihydro[1,4]dioxino[2,3-g]quinazolin-4-amine",0.0158,uM,=,-1.8013429130455774,0,c1ccc(Nc2ncnc3cc4c(cc23)OCCO4)cc1
6446,1870312,10.1021/acs.jmedchem.8b00672,,,,Inhibition of wild type EGFR (unknown origin),COc1cc2c(Oc3ccc(NS(=O)(=O)c4ccccc4C(F)(F)F)cc3F)ccnc2cc1OCCCN1CCOCC1,N-(3-fluoro-4-(6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yloxy)phenyl)-2-(trifluoromethyl)benzenesulfonamide,0.65,uM,=,-0.1870866433571444,0,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1)c1ccccc1
6447,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,Cc1ccc(C2=NN(C(N)=S)C(c3ccc(O)cc3)C2)cc1C,"3-(3,4-Dimethylphenyl)-5-(4-hydroxyphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",0.13,uM,=,-0.8860566476931633,0,c1ccc(C2=NNC(c3ccccc3)C2)cc1
6448,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,COc1cc2nccc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/C(C)N1CCOCC1,N-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinolin-6-yl)-4-morpholinopent-2-enamide,10.59,uM,=,1.024895960107485,1,O=C(/C=C/CN1CCOCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
6449,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,C#Cc1cccc(Nc2ncnc3c2/C(=C/c2[nH]c(C(=O)NCCN4CCOCC4)cc2C)C(=O)N3)c1,"5-[4-(3-Ethynyl-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide",0.018,uM,=,-1.744727494896694,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc(C(=O)NCCN2CCOCC2)[nH]1
6450,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CSc1nccn1C,N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-2-((1-methyl-1H-imidazol-2-yl)thio)acetamide,0.011,uM,=,-1.958607314841775,0,O=C(CSc1ncc[nH]1)Oc1ccc2ncnc(Nc3ccccc3)c2c1
6451,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,Fc1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1Cl,"(3-Chloro-4-fluoro-phenyl)-(10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",2.7,uM,=,0.4313637641589873,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6452,2017350,10.1021/acs.jmedchem.0c00870,,,,Inhibiton of EGFR (unknown origin) expressed in human A431 cells assessed as reduction in EGFR induced cell viability after 96 hrs by CellTiter-Glo assay,C=CC(=O)Nc1cccc(-c2c[nH]c3ncnc(Nc4ccc(CN5C(=O)c6ccccc6C5=O)cc4)c23)c1,"N-{3-{4-{{4-[(1,3-Dioxoisoindolin-2-yl)methyl]phenyl}amino}-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl}acrylamide",1.57,uM,=,0.1958996524092337,1,O=C1c2ccccc2C(=O)N1Cc1ccc(Nc2ncnc3[nH]cc(-c4ccccc4)c23)cc1
6453,64443,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1ccc2c(Nc3cccc(Br)c3)ncnc2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-7-yl]-acrylamide,0.00045,uM,=,-3.3467874862246565,0,c1ccc(Nc2ncnc3ccccc23)cc1
6454,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,But-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.0025,uM,=,-2.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
6455,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,N#CCCCn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21,"4-(4-amino-3-(4-fluoro-3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butanenitrile",18.0,uM,=,1.255272505103306,1,c1ccc(-c2n[nH]c3ncncc23)cc1
6456,591074,10.1021/jm9010065,,,,Inhibition of human recombinant HER1 expressed in Sf9 cells by liquid scintillation counting,CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)OCC1CCCNC1,"{4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl}-carbamic acid piperidin-3-ylmethyl ester",0.038,uM,=,-1.42021640338319,0,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OCC1CCCNC1
6457,2069689,10.1016/j.bmc.2021.116039,,,,Inhibition of recombinant wild type EGFR (696 to C terminal end) (unknown origin) using poly (Glu-Tyr) as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6458,1445067,10.1016/j.ejmech.2014.11.010,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCCn1ccnc1[N+](=O)[O-],N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(4-(2-nitro-1Himidazol-1-yl)butoxy)quinazolin-4-amine,0.00047,uM,=,-3.3279021420642825,0,c1ccc(Nc2ncnc3ccc(OCCCCn4ccnc4)cc23)cc1
6459,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1)/C(F)=C/CN1CCCCC1,(Z)-(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-4-(piperidin-1-yl)but-2-enamide,0.0026,uM,=,-2.5850266520291822,0,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
6460,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(Nc3cc4ccccc4cn3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-isoquinolin-3-yl-amine",0.81,uM,=,-0.0915149811213502,0,c1ccc2cc(Nc3ncnc4ccccc34)ncc2c1
6461,2205223,10.1016/j.bmc.2022.116907,,,,Inhibition of wild type EGFR (unknown origin) using TK as substrate incubated for 120 mins in the presence of ATP by HTRF assay,CCc1cc(Nc2ncc(Br)c(Nc3ccc4nccnc4c3P(C)(C)=O)n2)c(OC)cc1N1CCC(N2CCCN(C)CC2)CC1,"(6-((5-Bromo-2-((5-ethyl-2-methoxy-4-(4-(4-methyl-1,4-diazepan-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide",3.003,uM,=,0.4775553321989811,1,c1cc(Nc2ccc3nccnc3c2)nc(Nc2ccc(N3CCC(N4CCCNCC4)CC3)cc2)n1
6462,63772,10.1021/jm9903949,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cells,COc1ccc2[nH]c3ncnc(Nc4cccc(Br)c4)c3c2c1,"(3-Bromo-phenyl)-(6-methoxy-9H-pyrimido[4,5-b]indol-4-yl)-amine",0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
6463,831566,10.1016/j.bmcl.2012.05.125,,,,Inhibition of EGFR in presence of 10 uM ATP,Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,SID103904451,2.09,uM,=,0.320146286111054,1,O=C(Nc1ccccc1)Nc1ccc(NC(=O)c2ccn3ncncc23)cc1
6464,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,O=C(O)CNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-ylamino]-acetic acid",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2ncnc3ccncc23)cc1
6465,64442,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor (EGFR) in A431 cells,C=CC(=O)Nc1cc2c(Nc3cccc(C)c3)ncnc2cn1,"N-(4-m-Tolylamino-pyrido[3,4-d]pyrimidin-6-yl)-acrylamide",0.0083,uM,=,-2.0809219076239263,0,c1ccc(Nc2ncnc3cnccc23)cc1
6466,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)c([N+](=O)[O-])c1,"3-Amino-2,4-dicyano-5-(4-hydroxy-3-nitro-phenyl)-penta-2,4-dienenitrile",60.0,uM,=,1.7781512503836436,1,c1ccccc1
6467,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCCN(C(C)=O)CC4)cc3OC)ncc2SC)c1,"N-(3-((2-((4-(4-Acetyl-1,4-diazepan-1-yl)-2-methoxyphenyl)amino)-5-(methylthio)pyrimidin-4-yl)oxy)phenyl)acrylamide",0.3893999999999999,uM,=,-0.4096040528159871,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCCNCC4)cc3)n2)cc1
6468,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,CN(C)c1cccc(CNc2ncnc3cc(N)ncc23)c1,"N*4*-(3-Dimethylamino-benzyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",10.0,uM,=,1.0,1,c1ccc(CNc2ncnc3ccncc23)cc1
6469,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1c(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)ncnc1-c1ccccc1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-5-methyl-6-phenylpyrimidin-4-amine,20.0,uM,=,1.3010299956639813,1,c1ccc(COc2ccc(Nc3cc(-c4ccccc4)ncn3)cc2)cc1
6470,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,OCCN(CCO)CCCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"2-[{3-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-ylamino]-propyl}-(2-hydroxy-ethyl)-amino]-ethanol",0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3ccncc23)cc1
6471,791584,10.1016/j.bmc.2011.11.023,,,,"Inhibition of EGFR using poly(Glu,Tyr)4:1 as substrate and [gamma33P]ATP after 60 mins by scintillation counting",O=C(c1cc2cc(O)ccc2[nH]1)c1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(4-(3-Chloro-4-fluorophenylamino)thieno[2,3-d]pyrimidin-6-yl)(5-hydroxy-1H-indol-2-yl)methanone",0.024,uM,=,-1.619788758288394,0,O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3ccccc3)ncnc2s1
6472,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,COc1ccc2cncnc2c1,7-Methoxy-quinazoline,0.01,uM,=,-2.0,0,c1ccc2ncncc2c1
6473,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1NC(C)CO,3-(3-ethyl-4-(2-methylbutyl)phenyl)-1-isopropyl-4-methyl-1H-indene,5.32,uM,=,0.7259116322950482,1,c1ccc(-c2n[nH]c3ncncc23)cc1
6474,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(Nc3nnc4ccccc4n3)c2cc1OC,"Benzo[1,2,4]triazin-3-yl-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.82,uM,=,-0.0861861476162833,0,c1ccc2nc(Nc3ncnc4ccccc34)nnc2c1
6475,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CN1CCS(=O)(=O)CC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(1,1-dioxidothiomorpholino)but-2-enamide",0.029,uM,=,-1.537602002101044,0,O=C(/C=C/CN1CCS(=O)(=O)CC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
6476,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)C1,"1-(3-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)azetidin-1-yl)prop-2-en-1-one",0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccc(OC4CNC4)cc23)cc1
6477,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",CCOc1cc2ncnc(Nc3cc(F)cc(C(F)(F)F)c3)c2cc1OCC.Cl,"4-[3'fluoro-5'-(trifluoromethyl)anilino)]-6,7-diethoxyquinazoline hydrochloride",0.00895,uM,=,-2.048176964684088,0,c1ccc(Nc2ncnc3ccccc23)cc1
6478,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc(Cc4nc(-c5ccccc5)cs4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(4-phenyl-thiazol-2-ylmethyl)-phenylamino]-3-cyano-7-methoxy-quinolin-6-yl}-amide,0.214,uM,=,-0.6695862266508091,0,c1ccc(-c2csc(Cc3ccc(Nc4ccnc5ccccc45)cc3)n2)cc1
6479,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,O=C(O)c1ccc2c(c1)CNc1c(Nc3cccc(Br)c3)ncnc1O2,"1-(3-Bromo-phenylamino)-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cycloheptene-8-carboxylic acid",1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6480,63773,10.1021/jm9508651,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 human epidermoid carcinoma cells,CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3cnccc23)cc1
6481,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",O=C(O)/C=C/C(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"(2E)-4-{[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]amino}-4-oxobut-2-enoic Acid",3.059,uM,=,0.4855794769846787,1,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
6482,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)cc(C(F)(F)F)c1,"N-(3-(2-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)-5-(trifluoromethyl)phenyl)acrylamide",0.1819,uM,=,-0.7401673009365164,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
6483,66582,10.1021/jm970634p,,,,Inhibition of human epidermal growth factor receptor,CCN(CC)CCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1,"6-(2,6-Dichloro-phenyl)-2-(3-diethylamino-propylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",1.35,uM,=,0.1303337684950061,1,O=c1[nH]c2ncncc2cc1-c1ccccc1
6484,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,C#Cc1cccc(Nc2ncnc3ccc(OCCCCCCC(=O)NO)cc23)c1,7-(4-(3-ethynylphenylamino)quinazolin-6-yloxy)-N-hydroxyheptanamide,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
6485,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,CC#CC(=O)Nc1cc2c(Nc3cccc(Br)c3)c(C#N)cnc2cc1OC,But-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,0.91,uM,=,-0.0409586076789063,0,c1ccc(Nc2ccnc3ccccc23)cc1
6486,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Cc1cccc(CN(Cc2ccc(F)cc2)C(=S)Nc2ccccc2)c1O,1-(4-Fluorobenzyl)-1-(2-hydroxy-5-methylbenzyl)-3-phenylthiourea,8.54,uM,=,0.931457870689005,1,S=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
6487,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,Cc1cccc(Nc2ncnc3cnc(N)cc23)c1,"N*4*-m-Tolyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0031,uM,=,-2.508638306165728,0,c1ccc(Nc2ncnc3cnccc23)cc1
6488,66885,10.1021/jm00037a020,,,,Cytotoxic effect on EGF-receptor overexpressing HN5 squamous carcinoma cells,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,"2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one",190.0,uM,=,2.278753600952829,1,O=c1cc(-c2ccccc2)oc2ccccc12
6489,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccc(F)cc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-(5-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.0087,uM,=,-2.0604807473813813,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6490,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCC1CCNCC1.Cl,(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine hydrochloride,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
6491,1541392,10.1016/j.ejmech.2015.09.031,,,,Inhibition of wild type recombinant human EGFR preincubated for 10 mins followed by FAM-labeled peptide/ATP addition measured after 1 hr by mobility shift assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.079,uM,=,-1.1023729087095586,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6492,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cnn(C)c3)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.05435,uM,=,-1.2648004515776867,0,c1ccc(Nc2nccc(Nc3cn[nH]c3)n2)cc1
6493,66570,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor in A431 cells,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1,N-[4-(4-Benzyloxy-phenylamino)-quinazolin-6-yl]-acrylamide,0.0042,uM,=,-2.3767507096021,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
6494,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CC(C)=CC[C@@H](OC(=O)/C=C\C(=O)c1ccc(C)c(C)c1)C1=CC(=O)c2c(O)ccc(O)c2C1=O,"(R)-1-(5,8-Dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (Z)-4-(3,4-dimethylphenyl)-4-oxobut-2-enoate",0.1186,uM,=,-0.9259153109717562,0,O=C(/C=C\C(=O)c1ccccc1)OCC1=CC(=O)c2ccccc2C1=O
6495,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc(Oc4ccccc4)cc3)ncnc2cc1OC,N-[7-Methoxy-4-(4-phenoxyanilino)-6-quinazolinyl]-propanamide,0.065,uM,=,-1.1870866433571443,0,c1ccc(Oc2ccc(Nc3ncnc4ccccc34)cc2)cc1
6496,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CC(=O)Nc1ccc2c(Nc3cccc(Br)c3)ncnc2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-7-yl]-acetamide,0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3ccccc23)cc1
6497,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1cnc(N2CC(C#N)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"1-(6-((2-((3S,4R)-3-fluoro-4-hydroxy-3-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-4-isopropyl-2,7-naphthyridin-1-yl)azetidine-3-carbonitrile",3.401,uM,=,0.5316066319327222,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
6498,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Fc1cccc(COc2ccc(Nc3cc(-c4ccsc4)ncn3)cc2Cl)c1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(thiophen-3-yl)pyrimidin-4-amine,22.0,uM,=,1.3424226808222062,1,c1ccc(COc2ccc(Nc3cc(-c4ccsc4)ncn3)cc2)cc1
6499,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4cccc(Cl)c4)cc3)ncnc2cc1OCCCN1CCN(C)CC1,N-(4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-ylamino)phenyl)-3-chlorobenzamide,0.15,uM,=,-0.8239087409443188,0,O=C(Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1ccccc1
6500,606933,10.1016/j.bmcl.2009.10.103,,,,Inhibition of EGFR,NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21,"5-(2-aminoethyl)-7-(7-(benzo[b]thiophen-2-yl)-1H-indazol-5-yl)-5H-pyrrolo[3,2-d]pyrimidin-2-amine",0.94,uM,=,-0.0268721464003013,0,c1ccc2sc(-c3cc(-c4c[nH]c5cncnc45)cc4cn[nH]c34)cc2c1
6501,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC1CCN(S(C)(=O)=O)CC1,N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(1-(methylsulfonyl)piperidin-4-yloxy)quinazolin-4-amine,0.007,uM,=,-2.154901959985743,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
6502,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(CC(C)O)CC(C)O,4-[Bis-(2-hydroxy-propyl)-amino]-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.098,uM,=,-1.0087739243075051,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
6503,2261295,10.1016/j.ejmech.2022.114502,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr in presence of ATP by Kinase-Glo Plus luminescence kinase assay,N#Cc1c(NC(=O)CNc2n[nH]c3ncccc23)sc2c1CCCC2,"2-((1H-pyrazolo[3,4-b]pyridin-3-yl)amino)-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)acetamide",0.00047,uM,=,-3.3279021420642825,0,O=C(CNc1n[nH]c2ncccc12)Nc1cc2c(s1)CCCC2
6504,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=C(O)/C=C/c1ccc(O)c(O)c1,"(E)-3-(3,4-Dihydroxy-phenyl)-acrylic acid",1000.0,uM,=,3.0,1,c1ccccc1
6505,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)cc3)c2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)phenyl]-7'-methoxy-6'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,0.67,uM,=,-0.1739251972991735,0,c1ccc2sc(-c3ccc(Nc4ncnc5ccc(OCCCN6CCNCC6)cc45)cc3)nc2c1
6506,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,C[C@@H](Nc1ncnc2oc(-c3ccc(Br)cc3)cc12)c1ccccc1,"(R)-6-(4-Bromophenyl)-N-(1-phenylethyl)furo[2,3-d]pyrimidin-4-amine",0.056,uM,=,-1.2518119729937995,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
6507,2220271,10.1016/j.bmcl.2022.128529,,,,Inhibition of EGFR (unknown origin),COc1cc(-c2nc3ccccc3s2)ccc1OCC(=O)NNC(=O)CN1CCC[C@H]1C(=O)O,"(2S)-1-(2-{2-[4-(1,3-benzothiazol-2-yl)-2-methoxyphenoxy]acetohydrazido}-2-oxoethyl)pyrrolidine-2-carboxylic acid",0.342,uM,=,-0.4659738939438649,0,O=C(COc1ccc(-c2nc3ccccc3s2)cc1)NNC(=O)CN1CCCC1
6508,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,CNC(=O)c1c(SSc2c(C(=O)NC)c3ccccc3n2C)n(C)c2ccccc12,"1,3N-dimethyl-2-(1-methyl-3-methylcarbamoyl-1H-2-indolyldisulfanyl)-1H-3-indolecarboxamide",1.8,uM,=,0.255272505103306,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
6509,1527409,10.1016/j.bmcl.2015.10.003,,,,Inhibition of EGFR (unknown origin) after 120 mins by HotSpot assay,NC(=O)Nc1ccc2ncnc(Nc3ccc(Oc4ccc(Cl)c(Cl)c4)c(Cl)c3)c2c1,"1-(4-((3-chloro-4-(3,4-dichlorophenoxy)phenyl)amino)quinazolin-6-yl)urea",0.543,uM,=,-0.265200170411153,0,c1ccc(Oc2ccc(Nc3ncnc4ccccc34)cc2)cc1
6510,2101621,10.1016/j.bmcl.2021.128258,,,,Inhibition of EGFR (unknown origin),CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.015,uM,=,-1.8239087409443189,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
6511,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,CC(C)(C)NC(=O)c1cccc(Oc2ccc(Nc3ncnc4ccn(CCO)c34)cc2Cl)c1,"N-tert-butyl-3-(2-chloro-4-(5-(2-hydroxyethyl)-5H-pyrrolo[3,2-d]pyrimidin-4-ylamino)phenoxy)benzamide",0.033,uM,=,-1.4814860601221125,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1
6512,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,COc1ccc2c(c1)Oc1ncnc(Nc3cccc(Br)c3)c1NC2,"(3-Bromo-phenyl)-(7-methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",3.0,uM,=,0.4771212547196624,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6513,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",COCCCNC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-1-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-3-(3-methoxypropyl)urea,0.197,uM,=,-0.7055337738384071,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
6514,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,N-(4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)acetamide,0.000662,uM,=,-3.1791420105603,0,c1ccc(Nc2ncnc3ccccc23)cc1
6515,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,CN(C)c1cccc(Nc2ncnc3cc(N)ncc23)c1,"N*4*-(3-Dimethylamino-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",1.79,uM,=,0.2528530309798932,1,c1ccc(Nc2ncnc3ccncc23)cc1
6516,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,Cn1c(SSc2c(C(=O)Nc3ccccc3)c3ccccc3n2C)c(C(=O)Nc2ccccc2)c2ccccc21,"2,2'-Dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide)",10.9,uM,=,1.0374264979406236,1,O=C(Nc1ccccc1)c1c(SSc2[nH]c3ccccc3c2C(=O)Nc2ccccc2)[nH]c2ccccc12
6517,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC[C@@H]1C(=O)N(C)C,"(R)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)-N,N-dimethylpyrrolidine-2-carboxamide",0.95,uM,=,-0.0222763947111522,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
6518,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,CCN1CCN(CCCC#Cc2c(C)ncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)CC1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-5-(5-(4-ethylpiperazin-1-yl)pent-1-ynyl)-6-methylpyrimidin-4-amine,0.009,uM,=,-2.0457574905606752,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)CCCN1CCNCC1
6519,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,COC(=O)Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O,"(5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-phenyl)-acetic acid methyl ester",100.0,uM,=,2.0,1,C(=N/c1ccccc1)\c1ccccc1
6520,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,COc1cc(Nc2ncnc3[nH]nc(OCCN4CCC(O)CC4)c23)ccc1OCc1cccc(F)c1,"1-(2-(4-(4-(3-fluorobenzyloxy)-3-methoxyphenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yloxy)ethyl)piperidin-4-ol",0.013,uM,=,-1.8860566476931635,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCCCC5)c34)cc2)cc1
6521,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccc(F)c(Cl)c4)c(Cl)c3)ncnc2cc1OCCCN1CCN(C)CC1,1-(2-chloro-4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)phenyl)-3-(3-chloro-4-fluorophenyl)urea,0.078,uM,=,-1.1079053973095196,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
6522,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCOCC1,(E)-4-Morpholin-4-yl-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,13.57,uM,=,1.132579847659737,1,O=C(/C=C/CN1CCOCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
6523,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1,"(1H-Indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine",0.003,uM,=,-2.5228787452803374,0,c1ccc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)cc1
6524,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCOCC1,4-Morpholin-4-yl-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.02,uM,=,-1.6989700043360187,0,O=C(/C=C/CN1CCOCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
6525,1390771,10.1039/C0MD00119H,,,,Inhibition of EGFR kinase (unknown origin) using poly(Glu:Tyr) as substrate,OB(O)c1ccc(COc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)cc1,4-((4-(3-chlorophenylamino)quinazolin-6-yloxy)methyl)phenylboronic acid,0.85,uM,=,-0.0705810742857072,0,c1ccc(COc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
6526,67058,10.1016/j.bmcl.2003.10.030,,,,Inhibitory activity against epidermal growth factor receptor,c1csc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)c1,"(1H-Indol-5-yl)-(6-thiophen-2-yl-thieno[3,2-d]pyrimidin-4-yl)-amine",0.039,uM,=,-1.408935392973501,0,c1csc(-c2cc3ncnc(Nc4ccc5[nH]ccc5c4)c3s2)c1
6527,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CCl)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(N5CCCCC5)c(Cl)c4)c3cc21,"1-(2-(2-chloroacetoxy)ethyl)-8-((3-chloro-4-(piperidin-1-yl)phenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.24,uM,=,-0.619788758288394,0,O=c1[nH]c2cc3c(Nc4ccc(N5CCCCC5)cc4)ncnc3cc2o1
6528,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(C(=O)Oc2ccc(F)cc2)c(-c2cn(C)c3ccccc23)n1,4-Fluorophenyl 2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.00028,uM,=,-3.552841968657781,0,O=C(Oc1ccccc1)c1cnc(Nc2ccc(N3CCNCC3)cc2)nc1-c1c[nH]c2ccccc12
6529,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,CN1CCN(CCOc2n[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,"N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-3-(2-(4-methylpiperazin-1-yl)ethoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.005,uM,=,-2.3010299956639813,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCN5CCNCC5)c34)cc2)nc1
6530,93565,10.1016/S0960-894X(97)10059-2,,,,Inhibition of EGF-stimulated proliferation of KB cells in culture,COc1cc2ncnc(Nc3nccc4ccccc34)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-isoquinolin-1-yl-amine",1.8,uM,=,0.255272505103306,1,c1ccc2c(Nc3ncnc4ccccc34)nccc2c1
6531,1586270,10.1016/j.bmc.2016.04.046,,,,Inhibition of wild type human EGFR preincubated for 5 mins followed by ATP addition for 30 mins by HTRF assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)[C@@H]1COC(=O)N1,(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-oxooxazolidine-4-carboxamide,0.00106,uM,=,-2.9746941347352296,0,O=C1N[C@H](C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)CO1
6532,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,O=C(/C=C/CN1CCCOCC1)N1CCCc2c(sc3ncnc(Nc4ccc(Cl)c(Cl)c4)c23)C1,"US8524722, 143",0.001,uM,=,-3.0,0,O=C(/C=C/CN1CCCOCC1)N1CCCc2c(sc3ncnc(Nc4ccccc4)c23)C1
6533,346436,10.1016/j.bmcl.2005.12.067,,,,Inhibition of EGFR kinase activity,Cc1cccc(-n2ncc3c(NCc4ccc5c(c4)OCO5)ncnc32)c1,"N-(1,3-benzodioxol-5-ylmethyl)-1-(3-methylphenyl)-1Hpyrazolo[3,4-d]pyrimidin-4-amine",15.0,uM,=,1.1760912590556811,1,c1ccc(-n2ncc3c(NCc4ccc5c(c4)OCO5)ncnc32)cc1
6534,66584,10.1016/s0960-894x(02)01047-8,,,,Inhibition of EGFR,CS(=O)(=O)CCNc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1,{6-[2-(2-Methanesulfonyl-ethylamino)-thiazol-4-yl]-quinazolin-4-yl}-[4-(3-trifluoromethyl-benzyloxy)-phenyl]-amine,0.54,uM,=,-0.2676062401770315,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5cscn5)cc34)cc2)cc1
6535,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(C#N)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(3-cyano-benzyloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.195,uM,=,-0.7099653886374819,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
6536,305999,10.1016/j.bmcl.2004.08.007,,,,Inhibitory concentration against Epidermal growth factor receptor tyrosine kinase activity,COc1cc2ncnc(Nc3cc(NC(=O)c4ccccc4)ccc3Cl)c2cc1OC,"N-[4-Chloro-3-(6,7-dimethoxy-quinazolin-4-ylamino)-phenyl]-benzamide",11.0,uM,=,1.0413926851582251,1,O=C(Nc1cccc(Nc2ncnc3ccccc23)c1)c1ccccc1
6537,2260188,10.1016/j.ejmech.2020.112995,,,,Inhibition of human wild type GST-tagged EGFR expressed in Sf9 cells assessed as substrate phosphorylation using TK-peptide as substrate incubated for 25 mins by HTRF assay,CCC(=O)Nc1cccc(-c2c(-c3ccc(N4CCN(C)CC4)cc3)[nH]c3ncnc(OC(C)C)c23)c1,"N-(3-(4-isopropoxy-6-(4-(4-methylpiperazin-1-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl)propionamide",0.0001,uM,=,-4.0,0,c1ccc(-c2c(-c3ccc(N4CCNCC4)cc3)[nH]c3ncncc23)cc1
6538,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CN[C@H]1C[C@@H]2O[C@](C)([C@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4=O,"3-methoxy-2-methyl-4-methylamino-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaene-16,18-dione",0.2,uM,=,-0.6989700043360187,0,O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1[C@@H]1CCCC3O1
6539,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(NC3CCCCC3)c2c1C,"Cyclohexyl-(2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine",6.92,uM,=,0.8401060944567578,1,c1nc(NC2CCCCC2)c2cc[nH]c2n1
6540,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,C=C(CN1CCNCC1)C(=O)c1ccc(OCc2ccccc2)cc1.Cl,1-(4-Benzyloxy-phenyl)-2-piperazin-1-ylmethyl-propenone hydrochloride,1.5,uM,=,0.1760912590556812,1,C=C(CN1CCNCC1)C(=O)c1ccc(OCc2ccccc2)cc1
6541,1639950,,,,,Inhibition of recombinant human N-terminal GST His6-tagged thrombin cleavage site-fused EGFR (H672 to A1210 residues) expressed in baculovirus using poly-EY as substrate after 210 mins by luciferase coupled chemiluminescence assay,COc1cc2c(Nc3ccc(Cl)c(Cl)c3)ncnc2cc1OCc1cc(Br)cc(Br)c1,"7-{[(3,5-dibromophenyl)methyl]oxy}-N-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(COc2ccc3c(Nc4ccccc4)ncnc3c2)cc1
6542,2296337,10.1039/d3md00038a,,,,Inhibition of EGFR (unknown origin),CCc1c(C(=O)NCCc2ccc(N3CCOCC3)cc2)[nH]c2ccc(C)cc12,3-ethyl-5-methyl-N-(4-morpholinophenethyl)-1H-indole-2-carboxamide,0.085,uM,=,-1.0705810742857071,0,O=C(NCCc1ccc(N2CCOCC2)cc1)c1cc2ccccc2[nH]1
6543,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,OC[C@@H](Nc1ncnc2sc(-c3ccccc3)cc12)c1ccccc1,"(S)-2-Phenyl-2-((6-phenylthieno[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol",0.009,uM,=,-2.0457574905606752,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
6544,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CS(=O)(=O)CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl 2-(methylsulfonyl)ethylcarbamate",0.04,uM,=,-1.3979400086720375,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
6545,2268700,10.1016/j.ejmech.2021.113768,,,,Inhibition of EGFR (unknown origin),O=C(CCCCCn1cc(-c2ccc3ncnc(Nc4ccc(Br)cc4F)c3c2)nn1)NO,"6-(4-(4-((4-bromo-2-fluorophenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)-N-hydroxyhexanamide",0.0103,uM,=,-1.987162775294828,0,c1ccc(Nc2ncnc3ccc(-c4c[nH]nn4)cc23)cc1
6546,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(NC(=O)CCNCC(=O)NO)cc3)cc12)c1ccccc1,"(R)-3-(2-(hydroxyamino)-2-oxoethylamino)-N-(4-(4-(1-phenylethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)propanamide",0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
6547,501564,10.1016/j.bmcl.2009.02.067,,,,Inhibition of EGFR,NS(=O)(=O)c1ccc(Nc2nc3ncnc(Nc4cccc(Cl)c4)c3s2)cc1,"4-(7-(3-chlorophenylamino)thiazolo[4,5-d]pyrimidin-2-ylamino)benzenesulfonamide",0.007,uM,=,-2.154901959985743,0,c1ccc(Nc2nc3ncnc(Nc4ccccc4)c3s2)cc1
6548,658253,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR autophosphorylation in human A431 cells,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.00802,uM,=,-2.0958256317158366,0,c1ccc(Nc2ccnc3ccccc23)cc1
6549,305378,10.1021/jm049892u,,,,In vitro inhibition of Epidermal growth factor receptor,Fc1ccc(Nc2ncnn3cccc23)cc1Cl,"(3-Chloro-4-fluoro-phenyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl-amine",0.11,uM,=,-0.958607314841775,0,c1ccc(Nc2ncnn3cccc23)cc1
6550,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,CN(C)c1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-N*6*,N*6*-dimethyl-quinazoline-4,6-diamine",0.084,uM,=,-1.0757207139381184,0,c1ccc(Nc2ncnc3ccccc23)cc1
6551,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4cccc(Br)c4)c3cc2N1CCCN1CCCCC1,"4-((3-bromophenyl)amino)-6-(3-(piperidin-1-yl)propyl)-6H-[1,4]oxazino[3,2-g]quinazoline-7(8H)-one",0.099,uM,=,-1.00436480540245,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCCCC1
6552,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccc(F)cc1,"(R)-N-(1-(4-Fluorophenyl)ethyl)-6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.033,uM,=,-1.4814860601221125,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
6553,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,CCC/C=C\C(=O)Nc1cc(Nc2ncc(C#N)c(-c3cn(C)c4ccc(F)cc34)n2)c(OC)cc1N(C)CCN(C)C,(Z)-N-(5-((5-cyano-4-(5-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)hex-2-enamide,1.064,uM,=,0.0269416279590294,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6554,64454,10.1021/jm00069a003,,,,Inhibition of EGF-stimulated EGFR tyrosine kinase activity using plasma membrane vesicles shed from cultured human A431 carcinoma cells,O=C(O)CCCc1c(SSc2[nH]c3ccccc3c2CCCC(=O)O)[nH]c2ccccc12,4-{2-[3-(3-Carboxy-propyl)-1H-indol-2-yldisulfanyl]-1H-indol-3-yl}-butyric acid,18.0,uM,=,1.255272505103306,1,c1ccc2[nH]c(SSc3cc4ccccc4[nH]3)cc2c1
6555,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CO[C@@H]1[C@H](O)CN(c2nccc(Nc3cc4c(C(C)C)ccc(N5C[C@H](CS(C)(=O)=O)[C@H]5C)c4cn3)n2)CC1(F)F,"N-(2-((4R,5R)-3,3-difluoro-4-methoxy-5-methylpiperidin-1-yl)pyrimidin-5-yl)-5-isopropyl-8-((2R)-2-methyl-3-(methylsulfonyl)azetidin-1-yl)isoquinolin-3-amine",0.191,uM,=,-0.7189666327522725,0,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
6556,67040,10.1016/s0960-894x(01)00080-4,,,,Concentration required for inhibition of epidermal growth factor receptor (EGF-R) by tyrosine kinase enzyme activity,COc1cccc(-c2cn(C3CCN(C(=O)OC(C)(C)C)C3)c3ncnc(N)c23)c1,"3-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester",2.1,uM,=,0.3222192947339193,1,c1ccc(-c2cn(C3CCNC3)c3ncncc23)cc1
6557,1328444,10.1039/C2MD20078C,,,,Inhibition of wild type EGFR kinase (unknown origin) after 1.5 hrs by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cccc(N2C(=O)C3CCCCN3C(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-5,11-dioxo-7,8,9,10,10a,11-hexahydropyrido[1,2-a]pyrimido[4,5-e][1,4]diazepin-12(5H)-yl)phenyl)acrylamide",0.00245,uM,=,-2.6108339156354674,0,O=C1C2CCCCN2C(=O)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1c1ccccc1
6558,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(C(=O)N4CCN(C)CC4)cc3OC)n2)c1,N-(3-(3-(2-(2-methoxy-4-(4-methylpiperazine-1-carbonyl)phenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.972,uM,=,-0.0123337350737254,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(C(=O)N3CCNCC3)cc2)n1
6559,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,Brc1cccc(Nc2ncnc3cc4[nH]ccc4cc23)c1,"(3-Bromo-phenyl)-(8H-pyrrolo[3,2-g]quinazolin-4-yl)-amine",0.022,uM,=,-1.6575773191777938,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
6560,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3nonc3c2)c2c(N)ncnc21,"3-(benzo[c][1,2,5]oxadiazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",8.3,uM,=,0.919078092376074,1,c1ncc2c(-c3ccc4nonc4c3)n[nH]c2n1
6561,519199,10.1016/j.ejmech.2007.09.018,,,,Inhibition of human EGFR tyrosine kinase activity,COc1cc2ncnc(-c3c[nH]c4cc(F)c(C)cc34)c2cc1OC,"4-(6-Fluoro-5-methylindole-3-yl)-6,7-dimethoxyquinazoline",0.533,uM,=,-0.2732727909734277,0,c1ccc2c(-c3c[nH]c4ccccc34)ncnc2c1
6562,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cccc(OC)c1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2s1,"(S)-2-((6-(2,6-Dimethoxyphenyl)thieno[2,3-d]pyrimidin-4-yl)amino)-2-phenylethanol",0.0009,uM,=,-3.0457574905606752,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
6563,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,CCOC(=O)C1CCN(CCC(=O)c2ccc(OCc3ccccc3)cc2)CC1.Cl,1-[3-(4-Benzyloxy-phenyl)-3-oxo-propyl]-piperidine-4-carboxylic acid ethyl ester hydrochloride,0.3,uM,=,-0.5228787452803376,0,O=C(CCN1CCCCC1)c1ccc(OCc2ccccc2)cc1
6564,306537,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate; Range = 10000-50000 nM,COCC(=O)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1,"N-[4-(4,5-Dichloro-2-fluoro-phenylamino)-quinazolin-6-yl]-2-methoxy-acetamide",50.0,uM,=,1.6989700043360187,1,c1ccc(Nc2ncnc3ccccc23)cc1
6565,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1cccc(-n2c(=O)cnc3cnc(Nc4ccc(NC(C)=O)cc4)nc32)c1,N-(3-(2-(4-Acetamidophenylamino)-7-oxopteridin-8(7H)-yl)-phenyl)acrylamide,0.0125,uM,=,-1.9030899869919435,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
6566,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)CC(N)=O,2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)acetamide,0.045,uM,=,-1.3467874862246565,0,c1ccc(Nc2ncnc3ccccc23)cc1
6567,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3OC)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1,"(S)-3-(2-Methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0273999999999999,uM,=,-1.562249437179612,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
6568,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,COc1cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c2c1CN1CCC(N)CC1,"N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((4-aminopiperidin-1-yl)methyl)-6-methoxypyrrolo[1,2-f][1,2,4]triazin-4-amine",0.04,uM,=,-1.3979400086720375,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
6569,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,O=C(/C=C/c1ccccc1)Nc1cc(F)cc(F)c1,"(E)-N-(3,5-difluorophenyl)cinnamamide",13.23,uM,=,1.121559844187501,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
6570,2017353,10.1021/acs.jmedchem.0c00870,,,,Inhibition of human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using TK as substrate preincubated for 30 mins followed by substrate addition and measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(-c2c[nH]c3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c23)ccc1OCCO,"N-{5-{4-[(1-Benzyl-1H-indazol-5-yl)amino]-7H-pyrrolo[2,3-d]-pyrimidin-5-yl}-2-(2-hydroxyethoxy)phenyl}acrylamide",7.000000000000001e-05,uM,=,-4.154901959985743,0,c1ccc(Cn2ncc3cc(Nc4ncnc5[nH]cc(-c6ccccc6)c45)ccc32)cc1
6571,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Clc1cccc(Nc2ncnc3[nH]c4ccccc4c23)c1,"(3-Chloro-phenyl)-(9H-pyrimido[4,5-b]indol-4-yl)-amine",0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3[nH]c4ccccc4c23)cc1
6572,63616,10.1016/S0960-894X(97)00034-6,,,,Inhibition of Epidermal growth factor receptor autophosphorylation.,COc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1OC.Cl,"(3,4-Dimethoxy-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine hydrochloride",0.35,uM,=,-0.4559319556497244,0,c1ccc(Nc2ncnc3ccccc23)cc1
6573,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,CCOc1cc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C,(Z)-N-(4-((3-Chloro-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.0045,uM,=,-2.3467874862246565,0,c1cncc(Oc2ccc(Nc3ncnc4ccccc34)cc2)c1
6574,67042,10.1021/jm960118j,,,,In vitro inhibitory activity against epidermal growth factor receptor,Cc1[nH]c2ncnc(Nc3cccc(O)c3)c2c1C,"3-(5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-phenol",1.25,uM,=,0.0969100130080564,1,c1ccc(Nc2ncnc3[nH]ccc23)cc1
6575,792073,10.1016/j.bmc.2011.10.085,,,,Inhibition of EGFR expressed in baculovirus infected Sf9 cells assessed as inhibition of autophosphorylation preincubated for 10 mins measured after 1 hr by DELFIA/Time-Resolved Fluorometry,Clc1ccc(CNc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)cc1,"N6-(4-Chlorobenzyl)-N4-(3-chlorophenyl)quinazoline-4,6-diamine",4.41,uM,=,0.6444385894678386,1,c1ccc(CNc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
6576,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Clc1cccc(Nc2nc[nH]c3nnc(Nc4cccc(Cl)c4)c2-3)c1,"N*3*,N*4*-Bis-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.33,uM,=,-0.4814860601221125,0,c1ccc(Nc2nc[nH]c3nnc(Nc4ccccc4)c2-3)cc1
6577,1541778,10.1016/j.bmc.2015.12.001,,,,Inhibition of wild-type EGFR tyrosine kinase (unknown origin) assessed as ATP level by luminescence analysis,O=C(Nc1ccc(CN2CCCC2)cc1)Nc1ccc2ncnc(Nc3cccc(C(F)(F)F)c3)c2c1,1-(4-(Pyrrolidin-1-yl-methyl)phenyl)-3-(4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-yl)urea,0.0040999999999999,uM,=,-2.3872161432802645,0,O=C(Nc1ccc(CN2CCCC2)cc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6578,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cccc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CC(C)N(C)C(C)C5)cc4OC)nc32)c1,"N-(3-(2-((2-Methoxy-4-(3,4,5-trimethylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.097,uM,=,-1.0132282657337552,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
6579,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-morpholinophenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.065,uM,=,-1.1870866433571443,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
6580,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,COc1cc(C(=O)NCCN(C)C)ccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1,"(R)-N-(2-(Dimethylamino)ethyl)-3-methoxy-4-(4-((1-phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzamide",0.0005,uM,=,-3.3010299956639813,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
6581,1914927,10.1016/j.ejmech.2019.111943,,,,Inhibition of N-terminal GST-tagged human EGFR (d746-750AA) expressed in baculovirus using FAM-labelled peptide as substrate pre-incubated for 10 mins followed by substrate addition by mobility shift assay,COc1cc(Nc2cc(NC(=O)Nc3c(Cl)cccc3Cl)ncn2)cc(OC)c1,"1-(2,6-dichlorophenyl)-3-(6-((3,5-dimethoxyphenyl)amino)pyrimidin-4-yl)urea",0.332,uM,=,-0.4788619162959637,0,O=C(Nc1ccccc1)Nc1cc(Nc2ccccc2)ncn1
6582,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,C=C(CN(C)C)C(=O)c1ccccc1.Cl,2-Dimethylaminomethyl-1-phenyl-propenone hydrochloride,5.6,uM,=,0.7481880270062004,1,c1ccccc1
6583,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",CC#CC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro-[2,3-d]pyrimidin-5-yl)phenyl]but-2-ynamide",0.064,uM,=,-1.193820026016113,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
6584,63769,10.1016/S0960-894X(97)00014-0,,,,Displacement of [gamma-32P]-ATP from Epidermal growth factor receptor in A431 cell-free extracts,Oc1ccc(NCc2cc(O)ccc2O)cc1,"2-[(4-Hydroxy-phenylamino)-methyl]-benzene-1,4-diol",41.9,uM,=,1.6222140229662954,1,c1ccc(CNc2ccccc2)cc1
6585,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,C=Cc1ccc(-c2cc3c(N[C@H](C)c4ccccc4)ncnc3o2)cc1,"(R)-N-(1-Phenylethyl)-6-(4-vinylphenyl)furo[2,3-d]pyrimidin-4-amine",0.029,uM,=,-1.537602002101044,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
6586,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)cc3F)c2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)-2-fluorophenyl]-7'-methoxy-6'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,4.5,uM,=,0.6532125137753437,1,c1ccc2sc(-c3ccc(Nc4ncnc5ccc(OCCCN6CCNCC6)cc45)cc3)nc2c1
6587,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N1CCC(N2CCN(C)CC2)CC1,"N-(4-Methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)buta-2,3-dienamide",0.0058,uM,=,-2.2365720064370627,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCC(N6CCNCC6)CC5)cc4)n3)c[nH]c2c1
6588,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,O=C(/C=C/CNC1CC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC(F)F,(E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(difluoromethoxy)quinazolin-6-yl)-4-(cyclopropylamino)but-2-enamide,0.0096,uM,=,-2.017728766960432,0,O=C(/C=C/CNC1CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6589,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CO[C@@H]1CCN(c2nccc(Nc3cc4c(C(C)C)ccc(N5C[C@H](CS(C)(=O)=O)[C@H]5C)c4cn3)n2)C[C@@H]1F,BLU-945,0.683,uM,=,-0.1655792963184674,0,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
6590,1774290,10.1016/j.ejmech.2018.03.001,,,,Inhibition of His-6 tagged recombinant EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in Baculovirus infected Sf9 cells by dissociation-enhanced lanthanide fluorescence immunoassay/time-resolved fluorometric analysis,O=C(N/N=C1\CC2(CCCCC2)Oc2c1ccc1ccccc21)C1C2CC3CC(C2)CC1C3,"N'-(spiro[benzo[h]chromene-2,1'-cyclohexan]-4(3H)-ylidene)adamantane-1-carbohydrazide",1.2,uM,=,0.0791812460476248,1,O=C(N/N=C1\CC2(CCCCC2)Oc2c1ccc1ccccc21)C1C2CC3CC(C2)CC1C3
6591,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,N#CC(C#N)=Cc1ccc(O)cc1,2-(4-Hydroxy-benzylidene)-malononitrile,560.0,uM,=,2.7481880270062,1,c1ccccc1
6592,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,COc1cc2c(cc1OC)Oc1ncnc(Nc3ccc(F)c(Cl)c3)c1NC2,"(3-Chloro-4-fluoro-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",0.69,uM,=,-0.1611509092627447,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6593,676221,10.1021/jm100607r,,,,Inhibition of EGFR,C=CC(=O)N1CCc2c(sc3ncnc(N[C@H](CO)c4ccccc4)c23)C1,"1-(4-(((1S)-2-Hydroxy-1-phenylethyl)amino)-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-2-propen-1-one",0.008,uM,=,-2.096910013008056,0,c1ccc(CNc2ncnc3sc4c(c23)CCNC4)cc1
6594,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,CC/C=C\C(=O)Nc1cc(Nc2ncc(C#N)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,(Z)-N-(5-((5-cyano-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)pent-2-enamide,0.387,uM,=,-0.4122890349810886,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6595,958682,10.1021/jm400463q,,,,Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC(=O)N5CCN(CCOc6no[n+]([O-])c6S(=O)(=O)c6ccccc6)CC5)CC4)cc3OC)ncc2Cl)c1,"4-(2-(4-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetyl)-piperazin-1-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide",0.039,uM,=,-1.408935392973501,0,O=C(CN1CCN(c2ccc(Nc3nccc(Oc4ccccc4)n3)cc2)CC1)N1CCN(CCOc2no[nH+]c2S(=O)(=O)c2ccccc2)CC1
6596,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,C[C@@H](CN)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21,"(S)-5-(4-amino-1-(1-aminopropan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol",9.14,uM,=,0.9609461957338314,1,c1ccc(-c2n[nH]c3ncncc23)cc1
6597,2074610,10.1016/j.bmc.2020.115680,,,,Inhibition of wild type EGFR (unknown origin) in presence of ATP preincubated 5 mins measured for 30 mins by detection reagent based HTRF analysis,C=C(Cl)C(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)c(C)c3)ncc2Cl)c1,N-(3-((2-((4-(4-acetylpiperazin-1-yl)-3-methylphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)-2-chloroacrylamide,0.051,uM,=,-1.2924298239020635,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6598,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,Cc1cncc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCC(N)CC6)c45)ccc32)c1,"5-((4-aminopiperidin-1-yl)methyl)-N-(1-((5-methylpyridin-3-yl)methyl)-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.019,uM,=,-1.7212463990471711,0,c1cncc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)c1
6599,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccccc2[N+](=O)[O-])n1,5-Chloro-N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)-4-(2-nitrophenoxy)pyrimidin-2-amine,19.63,uM,=,1.2929202996000062,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6600,66582,10.1021/jm970634p,,,,Inhibition of human epidermal growth factor receptor,CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,"6-(2,6-Dichloro-phenyl)-2-[4-(2-diethylamino-ethoxy)-phenylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",0.35,uM,=,-0.4559319556497244,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
6601,1877090,10.1016/j.ejmech.2019.111709,,,,Inhibition of recombinant human GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system using Tyr 04 as substrate incubated for 1 hr by Z'-LYTE assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1S(=O)(=O)CCN(C)C,N-(2-(2-(dimethylamino)ethylsulfonyl)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,1.006,uM,=,0.0025979807199085,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6602,608091,10.1021/jm901558p,,,,Inhibition of EGFR autophosphorylation in human A431 cells after 8 hrs by Western blot,O=C(O)[C@H]1O[C@@H]1C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"(2S,3S)-Ethyl 3-(4-(3-Bromoanilino)quinazolin-6-ylcarbamoyl)oxirane-2-carboxylate",0.068,uM,=,-1.1674910872937636,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)[C@@H]1CO1
6603,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,CN(C(=O)c1ccc(N(CCCl)CCCl)cc1)c1ccccc1,4-(Bis(2-chloroethyl)amino)-N-methyl-N-phenylbenzamide,14.72,uM,=,1.16790781000148,1,O=C(Nc1ccccc1)c1ccccc1
6604,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1[N+](=O)[O-],(3-Bromo-phenyl)-(7-methoxy-6-nitro-quinazolin-4-yl)-amine,0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3ccccc23)cc1
6605,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,Dacomitinib,0.0018,uM,=,-2.744727494896694,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6606,1641794,,,,,"Time-Resolved Fluorescence Assay: The following assay may be used to determine the activity of the compounds of the invention for inhibiting EGFR kinase activity. The half maximal inhibitory concentration IC50 (the concentration of the tested compound showing 50% inhibition of the enzyme activity) of each compound was determined by incubating several different concentrations of the tested compounds with a specific enzyme and substrate. EGFR kinase used in this assay is a human-derived recombinant protein (Cell signaling technology, #7908), which was reacted with peptide substrate and different concentrations of tested compounds in a buffer solution containing 60 mM HEPES (pH7.5), 5 mM MgCl2, 5 mM MnCl2, 3 Î¼M Na3VO4, 1.25 M DTT (1000Ã) and 20 Î¼M ATP at 25Â° C., for 45 minutes. The EGFR kinase activity was determined by using a Time-Resolved fluorescence method.",CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,"US8901140, 9::US9358227, 9",0.002,uM,=,-2.6989700043360187,0,O=C(/C=C/[C@H]1CCCN1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6607,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCC1CCN(C)CC1.Cl,(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine hydrochloride,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
6608,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,C[C@@H](Nc1ncnc2sc(Br)cc12)c1ccccn1,"(R)-6-Bromo-N-(1-(pyridin-2-yl)ethyl)thieno[2,3-d]pyrimidin-4-amine",2.079,uM,=,0.3178544893314692,1,c1ccc(CNc2ncnc3sccc23)nc1
6609,1994717,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA,CN1CCN(C/C=C/C(=O)N2CCCOc3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4cc32)CC1,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-8,9-dihydro-7H-pyrimido[5,4-h][1,5]benzoxazepin-6-yl]-4-(4-methylpiperazin-1-yl)but-2-en-1-one",4.87,uM,=,0.6875289612146344,1,O=C(/C=C/CN1CCNCC1)N1CCCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
6610,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,COc1cc(Nc2ncnc3[nH]ccc23)ccc1-c1nc2ccccc2s1,"N-(4-(benzo[d]thiazol-2-yl)-3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.72,uM,=,-0.1426675035687315,0,c1ccc2sc(-c3ccc(Nc4ncnc5[nH]ccc45)cc3)nc2c1
6611,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3cccc(OCc4ccccc4)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid [4-(3-benzyloxy-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,13.0,uM,=,1.1139433523068367,1,c1ccc(COc2cccc(Nc3ccnc4ccccc34)c2)cc1
6612,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Clc1cccc(Nc2[nH]nc3ncnc(NCc4ccccc4)c23)c1,"N*4*-Benzyl-N*3*-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",1.5,uM,=,0.1760912590556812,1,c1ccc(CNc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
6613,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,"(S,E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide",0.0053,uM,=,-2.275724130399211,0,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1O[C@H]1CCOC1
6614,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,O=[N+]([O-])c1ccc(C2CC(c3ccc(Br)cc3)=NN2c2nc(-c3ccc(Cl)cc3)cs2)cc1,"2-(3-(4-bromophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-chlorophenyl)thiazole",24.37,uM,=,1.3868555291847244,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
6615,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,COc1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole",0.098,uM,=,-1.0087739243075051,0,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
6616,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,c1ccc(Nc2nc[nH]c3nnc(Nc4ccccc4)c2-3)cc1,"N*3*,N*4*-Diphenyl-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",12.0,uM,=,1.0791812460476249,1,c1ccc(Nc2nc[nH]c3nnc(Nc4ccccc4)c2-3)cc1
6617,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)c2cc1NC(=O)/C=C/CN1CCOCC1,(2E)-N-(7-Ethoxy-4-{4-[(phenylsulfonyl)amino]anilino}-6-quinazolinyl)-4-(4-morpholinyl)-2-butenamide,0.069,uM,=,-1.1611509092627446,0,O=C(/C=C/CN1CCOCC1)Nc1ccc2ncnc(Nc3ccc(NS(=O)(=O)c4ccccc4)cc3)c2c1
6618,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,O=[N+]([O-])c1ccc2c(Nc3cccc(I)c3)ncnc2c1,(3-Iodo-phenyl)-(7-nitro-quinazolin-4-yl)-amine,0.54,uM,=,-0.2676062401770315,0,c1ccc(Nc2ncnc3ccccc23)cc1
6619,1870312,10.1021/acs.jmedchem.8b00672,,,,Inhibition of wild type EGFR (unknown origin),COc1cc2c(Oc3ccc(NS(=O)(=O)c4c(F)cccc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,"2,6-difluoro-N-(3-fluoro-4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinolin-4-yloxy)phenyl)benzenesulfonamide",0.178,uM,=,-0.7495799976911061,0,O=S(=O)(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1ccccc1
6620,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3[nH]ccc3c2)c2c(N)ncnc21,"3-(1H-indol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.176,uM,=,-0.7544873321858502,0,c1ncc2c(-c3ccc4[nH]ccc4c3)n[nH]c2n1
6621,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,COc1ccc2ncnc(Nc3ccccc3)c2c1,(6-Methoxy-quinazolin-4-yl)-phenyl-amine,0.055,uM,=,-1.259637310505756,0,c1ccc(Nc2ncnc3ccccc23)cc1
6622,1882261,10.1016/j.bmc.2018.10.018,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (696-end residues) expressed in baculovirus expression system using Srctide as substrate by fluorescence assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,15.0,uM,=,1.1760912590556811,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6623,728730,10.1016/j.bmcl.2011.01.119,,,,Inhibition of EGFR by homogeneous time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1/C=C(\F)C(=O)NCCS(C)(=O)=O,3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-methylpyrimidin-5-yl)-2-fluoro-N-(2-(methylsulfonyl)ethyl)acrylamide,0.019,uM,=,-1.7212463990471711,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
6624,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Nc1ncnc2c1ncn2-c1ccccc1,9-Phenyl-9H-purin-6-ylamine,15.0,uM,=,1.1760912590556811,1,c1ccc(-n2cnc3cncnc32)cc1
6625,1291543,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCCC2)CCO4)c1,"1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(pyrrolidin-1-yl)but-2-en-1-one",0.06,uM,=,-1.2218487496163564,0,O=C(/C=C/CN1CCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
6626,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,Cc1ccc(Nc2ncnc3cc4c(cc23)N(CCCN2CCOCC2)C(=O)CO4)cc1,"6-(3-morpholinopropyl)-4-(p-tolylamino)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.5945,uM,=,-0.2258481410452896,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
6627,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,c1ccc(C(c2ccccc2)c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-benzhydryl-1,3,4-oxadiazole",45.0,uM,=,1.6532125137753435,1,c1ccc(C(c2ccccc2)c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
6628,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCCOCC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-38",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCCOCC4)cc3)n2)cc1
6629,2052738,10.1016/j.ejmech.2019.111966,,,,Inhibition of wild type N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus infected Sf21 cells using biotin-labeled TK substrate preincubated for 30 mins followed by substrate and ATP addition at Km concentration and further incubated for 20 mins by HTRF assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0064,uM,=,-2.193820026016113,0,c1ccc(Nc2ncnc3ccccc23)cc1
6630,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,C=CC(=O)Nc1ccc2ncnc(Nc3ccc4[nH]ccc4c3)c2c1,N-(4-((1H-indol-5-yl)amino)quinazolin-6-yl)acrylamide,0.0136999999999999,uM,=,-1.863279432843593,0,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1
6631,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CC6(CCN(C)CC6)C5)c(C)c4)nc32)C1,"(S)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.218,uM,=,-0.6615435063953952,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CC5(CCNCC5)C4)cc3)nc2N1[C@H]1CCNC1
6632,2067577,10.1016/j.ejmech.2019.111888,,,,"Inhibition of EGFR L858R/T790M/C797S (unknown origin) using Poly (Glu, Tyr) as substrate measured after 40 mins by kinase-glo assay",CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccc(F)cc5)n([C@@H]5CCN(S(=O)(=O)C6CC6)C5)c4n3)cc2)CC1,"(R)-9-(1-cyclopropylsulfonylpyrrolidine-3-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-4-fluorophenyl-9H-purine-2,8-diamine",0.022,uM,=,-1.6575773191777938,0,O=S(=O)(C1CC1)N1CC[C@@H](n2c(Nc3ccccc3)nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc32)C1
6633,2161992,10.1016/j.ejmech.2021.113984,,,,Inhibition of EGFR del19 (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccn(C)n3)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.01259,uM,=,-1.8999742698921367,0,c1ccc(Nc2nccc(Nc3cc[nH]n3)n2)cc1
6634,591074,10.1021/jm9010065,,,,Inhibition of human recombinant HER1 expressed in Sf9 cells by liquid scintillation counting,CCC1=C2C(Nc3ccc4c(cnn4Cc4ccccc4)c3)=NC=NC2N=C1NC(=O)OCCN1CCNCC1,"{4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl}-carbamic acid 2-(piperazin-1-yl)ethyl ester",0.021,uM,=,-1.6777807052660807,0,O=C(NC1=NC2N=CN=C(Nc3ccc4c(cnn4Cc4ccccc4)c3)C2=C1)OCCN1CCNCC1
6635,66904,10.1016/S0960-894X(96)00601-4,,,,Inhibition of the epidermal growth factor receptor.,Cc1ccc(NC(=O)c2ccccc2)cc1Nc1nccc(-c2cccnc2)n1,N-[4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide,65.0,uM,=,1.812913356642856,1,O=C(Nc1cccc(Nc2nccc(-c3cccnc3)n2)c1)c1ccccc1
6636,498291,10.1021/jm800861c,,,,Inhibition of EGFR,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.132,uM,=,-0.8794260687941501,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
6637,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,C=CC(=O)Nc1cccc(Oc2cc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncn2)c1,4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-acrylamidophenoxy)pyrimidine,0.037,uM,=,-1.431798275933005,0,c1ccc(COc2ccc(Nc3cc(Oc4ccccc4)ncn3)cc2)cc1
6638,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.011,uM,=,-1.958607314841775,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6639,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1ccc(/C=C2\CCC/C(=C\c3cc(OC)cc(OC)c3)C2=O)cc1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(4-methoxybenzylidene)cyclohexanone",18.6,uM,=,1.2695129442179165,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
6640,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"(2E)-N-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]-4-(dimethylamino)-2-butenamide",0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3cnccc23)cc1
6641,67067,10.1016/S0960-894X(01)80792-7,,,,Inhibition of Epidermal growth factor receptor,N#C/C(=C\c1ccc(O)c(O)c1)C(N)=O,"(E)-2-Cyano-3-(3,4-dihydroxy-phenyl)-acrylamide",4.0,uM,=,0.6020599913279624,1,c1ccccc1
6642,65107,10.1021/jm00032a020,,,,Inhibition of EGF-stimulated DNA synthesis in ER 22 (EGF-receptor expressing) cells,CCOC(=O)c1cc(/N=C/c2cc(O)ccc2O)ccc1O,"5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-benzoic acid ethyl ester",40.0,uM,=,1.6020599913279625,1,C(=N/c1ccccc1)\c1ccccc1
6643,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cc3OC)n2)c1,N-(3-(3-(2-(2-methoxy-4-(4-morpholinopiperidin-1-yl)phenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.086,uM,=,-1.0655015487564323,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCC(N4CCOCC4)CC3)cc2)n1
6644,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,COc1cc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2cc1NC(=O)C#CCN1CCOCC1,4-(7-methoxy-6-(4-morpholinobut-2-ynamido)quinolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.024,uM,=,-1.619788758288394,0,O=C(C#CCN1CCOCC1)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1
6645,64443,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2n1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2ncnc3cccnc23)cc1
6646,2088168,10.1016/j.ejmech.2020.112363,,,,Inhibition of EGFR (unknown origin) by FRET assay,S=C(NNc1ccccc1)Nc1ccc2c(c1)OCO2,"N-(benzo[d][1,3]dioxol-5-yl)-2-phenylhydrazinecarbothioamide",8.264,uM,=,0.917190308511564,1,S=C(NNc1ccccc1)Nc1ccc2c(c1)OCO2
6647,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,CS(=O)(=O)CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-(5-((2-(methylsulfonyl)ethoxy)methyl)furan-2-yl)quinazolin-4-amine,0.026,uM,=,-1.585026652029182,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
6648,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,CCOC(=O)CCCn1c(=O)oc2cc3ncnc(Nc4cc(C(=O)OCC)ccc4O)c3cc21,"Ethyl 3-(1-(4-ethoxy-4-oxobutyl)-2-oxo-1,2-dihydrooxazolo[4,5-g]quinazolin-8-ylamino)-4-hydroxybenzoate",0.0073,uM,=,-2.136677139879544,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
6649,67041,10.1016/s0960-894x(01)00080-4,,,,Inhibition of epidermal growth factor receptor (EGF-R),COCCN(C)CCN1CCC(n2cc(-c3cccc(OC)c3)c3c(N)ncnc32)CC1,"7-(1-{2-[(2-Methoxy-ethyl)-methyl-amino]-ethyl}-piperidin-4-yl)-5-(3-methoxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",0.93,uM,=,-0.0315170514460648,0,c1ccc(-c2cn(C3CCNCC3)c3ncncc23)cc1
6650,64442,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor (EGFR) in A431 cells,C=CC(=O)Nc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-yl]-acrylamide",0.108,uM,=,-0.9665762445130504,0,c1ccc(Nc2ncnc3ccncc23)cc1
6651,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#CC(C#N)=C(C#N)c1ccc(O)cc1,"2-(4-hydroxyphenyl)ethene-1,1,2-tricarbonitrile",600.0,uM,=,2.778151250383644,1,c1ccccc1
6652,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(piperidin-1-yl)but-2-enamide",0.009,uM,=,-2.0457574905606752,0,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
6653,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)CN)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"1N-[3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl]-1N-methyl-2-aminoacetamide",0.22,uM,=,-0.6575773191777937,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@@H]3O1
6654,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,Clc1ccccc1-c1nnc(Cc2nc3ccccc3[nH]2)o1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-(2-chlorophenyl)-1,3,4-oxadiazole",4.5,uM,=,0.6532125137753437,1,c1ccc(-c2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
6655,5008,10.1016/s0960-894x(01)00776-4,,,,Inhibition of EGFR overexpressing A431 cell proliferation,COc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1OC,"4-(3-Chloro-4-fluoro-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile",1.03,uM,=,0.0128372247051722,1,c1ccc(Nc2ccnc3ccccc23)cc1
6656,1842436,10.1016/j.ejmech.2019.03.004,,,,Inhibition of EGFR in human MDA-MB-468 cells assessed as reduction in cell proliferation incubated for 72 hrs by Coulter counter method,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.68,uM,=,-0.1674910872937636,0,c1ccc(Nc2ncnc3ccccc23)cc1
6657,78749,10.1021/jm960225d,,,,Antiproliferative activity determined by measuring the ability to block [3H]- thymidine uptake in HER-14 cells stimulated by EGF,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{4-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-butyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",5.0,uM,=,0.6989700043360189,1,O=C(C=Cc1ccccc1)NCCCCNC(=O)/C=C/c1ccccc1
6658,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Cc1cccc(CN(Cc2ccc(O)cc2)C(=O)Nc2ccccc2)c1O,1-(2-Hydroxy-5-methylbenzyl)-1-(4-hydroxybenzyl)-3-phenylurea,7.51,uM,=,0.8756399370041684,1,O=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
6659,1633275,10.1016/j.bmcl.2016.08.068,,,,Inhibition of human recombinant GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system,CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21,"(S)-7-(4-hydroxy-2,3-dihydro-1H-inden-1-yl)-5,5-dimethyl-2-(phenylamino)-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one",10.0,uM,=,1.0,1,O=C1Cc2cnc(Nc3ccccc3)nc2N1[C@H]1CCc2ccccc21
6660,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(C2CC(c3ccc(C)cc3)=NN2C2=NC(=O)CS2)cc1,"2-(5-(4-Methoxyphenyl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",4.24,uM,=,0.6273658565927327,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
6661,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Oc1ccc(-n2c(=O)cnc3cnc(Nc4ccc(OC)cc4)nc32)cc1,4-(2-(4-Methoxyphenylamino)-7-oxopteridin-8(7H)-yl)-phenylacrylate,0.0603999999999999,uM,=,-1.2189630613788682,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
6662,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC.Cl,"4-(3'-bromoanilino)-6,7-dimethoxyquinazoline hydrochloride",0.00066,uM,=,-3.1804560644581312,0,c1ccc(Nc2ncnc3ccccc23)cc1
6663,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,Cc1ccc(S(=O)(=O)NC(=O)Cn2c([N+](=O)[O-])cnc2C)cc1,2-(2-Methyl-5-nitro-1H-imidazol-1-yl)-N-tosylacetamide,3.43,uM,=,0.5352941200427705,1,O=C(Cn1ccnc1)NS(=O)(=O)c1ccccc1
6664,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0026,uM,=,-2.5850266520291822,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6665,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,COc1ccc(C2=NN(c3nc(-c4ccc(Cl)cc4)cs3)C(c3ccc([N+](=O)[O-])cc3)C2)cc1,"4-(4-chlorophenyl)-2-(3-(4-methoxyphenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazole",8.43,uM,=,0.9258275746247424,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
6666,536843,10.1016/j.bmc.2008.09.009,,,,Inhibition of EGFR in presence of 100 uM ATP,CCN1CCN(CC/C=C/c2ccc3c(Nc4ccc(Sc5nccn5C)c(Cl)c4)c(C#N)cnc3c2)CC1,4-({3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl}-amino)-7-[(1E)-4-(4-ethylpiperazin-1-yl)but-1-enyl]quinoline-3-carbonitrile,0.01,uM,=,-2.0,0,C(=C/c1ccc2c(Nc3ccc(Sc4ncc[nH]4)cc3)ccnc2c1)\CCN1CCNCC1
6667,67051,10.1021/jm980551o,,,,Inhibition of Epidermal growth factor receptor-dependent phosphorylation,Oc1cc(O)c2c(O)c(-c3cccc(Cl)c3)cnc2c1,"3-(3-Chloro-phenyl)-5,7-dihydroxy-1H-quinolin-4-one",2.0,uM,=,0.3010299956639812,1,c1ccc(-c2cnc3ccccc3c2)cc1
6668,2063587,10.1016/j.ejmech.2016.08.068,,,,Inhibition of EGFR (unknown origin) using Tyr 04 peptide as substrate incubated for 1 hr by Z'-LYTE assay,COc1cc(CO)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-2-(6-(4-(hydroxymethyl)-2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-2-phenylethanol",0.0002,uM,=,-3.6989700043360174,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
6669,813068,10.1021/jm2013453,,,,Inhibition of human EGFR expressed in human A431 cells using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,CCCCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1,"butyl 4-(6,7-dimethoxyquinazolin-4-ylamino)phenylcarbamate",0.8,uM,=,-0.0969100130080563,0,c1ccc(Nc2ncnc3ccccc23)cc1
6670,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,NC(=S)N/N=C(/C=C/c1ccc([N+](=O)[O-])cc1)c1ccccc1,(Z)-2-((E)-3-(4-nitrophenyl)-1-phenylallylidene)hydrazinecarbothioamide,1.57,uM,=,0.1958996524092337,1,N=C(/C=C/c1ccccc1)c1ccccc1
6671,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-phenyl)-N*7*-methyl-pyrido[4,3-d]pyrimidine-4,7-diamine",0.00013,uM,=,-3.886056647693163,0,c1ccc(Nc2ncnc3ccncc23)cc1
6672,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC[C@H]1C(N)=O,(S)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidine-2-carboxamide,0.055,uM,=,-1.259637310505756,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
6673,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCCCCC1,"5-(4-amino-1-cycloheptyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol",0.775,uM,=,-0.1106982974936897,0,c1ccc(-c2nn(C3CCCCCC3)c3ncncc23)cc1
6674,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Clc1cccc(Nc2[nH]cnc3nnc(NCc4ccccc4)c2-3)c1,"N*3*-Benzyl-N*4*-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.003,uM,=,-2.5228787452803374,0,c1ccc(CNc2nnc3nc[nH]c(Nc4ccccc4)c2-3)cc1
6675,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,Fc1cccc(Nc2ncnc3cc(OCCCN4CCOCC4)c4c(c23)OCCO4)c1,"N-(3-Fluorophenyl)-5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.08388,uM,=,-1.0763415782066938,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c4c(c23)OCCO4)cc1
6676,305171,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate,C=CC(=O)Nc1cc2c(Nc3cc(Cl)c(Cl)cc3F)ncnc2cc1N1CCN(C)CC1,"N-[4-(4,5-Dichloro-2-fluoro-phenylamino)-7-(4-methyl-piperazin-1-yl)-quinazolin-6-yl]-acrylamide",6.0,uM,=,0.7781512503836436,1,c1ccc(Nc2ncnc3cc(N4CCNCC4)ccc23)cc1
6677,63767,10.1021/jm00013a020,,,,In vitro inhibition of the Epidermal growth factor receptor activity in A431 membranes,C=C(CN(C)C)C(=O)c1ccc(OS(=O)(=O)c2ccc(C(=O)O)c(O)c2)cc1,4-[4-(2-Dimethylaminomethyl-acryloyl)-phenoxysulfonyl]-2-hydroxy-benzoic acid,0.47,uM,=,-0.3279021420642826,0,O=S(=O)(Oc1ccccc1)c1ccccc1
6678,1994718,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 40 mins in presence of ATP by caliper mobility shift assay,CN1CCN(C/C=C/C(=O)N2CCOc3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4cc32)CC1,"1-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-7,8-dihydropyrimido[5,4-g][1,4]benzoxazin-6-yl]-4-(4-methylpiperazin-1-yl)but-2-en-1-one",0.006,uM,=,-2.2218487496163566,0,O=C(/C=C/CN1CCNCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
6679,431034,10.1021/jm050607w,,,,"Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes",CCOc1cc2ncnc(NCc3ccc(F)cc3)c2cc1OCC.Cl,"4-[(4'-fluorobenzyl)amino]-6,7-diethoxyquinazoline hydrochloride",0.017,uM,=,-1.769551078621726,0,c1ccc(CNc2ncnc3ccccc23)cc1
6680,1527997,,,,,"ELISA-Based Kinase Assay: Inhibition of erbB tyrosine kinase activity was assessed using an ELISA-based receptor tyrosine kinase assay. Kinase reactions (50 mM HEPES, pH 7.4, 125 mM NaCl, 10 mM MgCl2, 100 Î¼M sodium orthovanadate, 2 mM dithiothreitol, 20 uM ATP, test compound or vehicle control and 1-5 nM GST-erbB per 50 uL reaction) were run in 96-well plates coated with 0.25 mg/ml poly-Glu-Tyr (Sigma). The reactions were incubated for 6 minutes at room temperature while shaking. Kinase reactions were stopped by removal of reaction mixture, then wells were washed with wash buffer comprising 3% Bovine Serum Albumin and 0.1% Tween 20 in Phosphate Buffered Saline (PBS). Phosphorylated tyrosine residues were detected by adding 0.2 Î¼g/ml anti-phosphotyrosine antibody (Oncogene Ab-4; 50 Î¼L/well) coupled to Horse Radish Peroxidase (HRP) for 25 minutes while shaking at room temperature.",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCCC1,"US8623883, No. 10",0.01213,uM,=,-1.9161391991334271,0,O=C(/C=C/CN1CCCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6681,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc([N+](=O)[O-])c(C(=O)Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1NC(=O)/C=C/CN(C)C,N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-5-(4-(dimethylamino)but-2-enamido)-4-ethoxy-2-nitrobenzamide,2.0,uM,=,0.3010299956639812,1,O=C(Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
6682,2018691,10.1016/j.bmc.2020.115674,,,,Inhibition of EGFR-TK (unknown origin) relative to control,CC(C)(C)c1cc(NC(=O)CN2CCN(c3ccccc3)CC2)no1,N-(5-(t-Butyl)isoxazol-3-yl)-2-(4-phenylpiperazin-1-yl)acetamide,0.066,uM,=,-1.1804560644581312,0,O=C(CN1CCN(c2ccccc2)CC1)Nc1ccon1
6683,1550368,10.1016/j.ejmech.2015.11.012,,,,Inhibition of EGFR (unknown origin) by Z -LYTE assay,C[C@@H](Nc1ncnc2sc(-c3cccc(C(=O)O)c3)cc12)c1ccccc1,"(R)-3-(4-((1-Phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzoic acid",0.008,uM,=,-2.096910013008056,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
6684,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,C[C@@H](c1ccccc1)n1ncc2cc(Nc3ncnn4ccc(COC[C@@H]5CNCCO5)c34)ccc21,"5-(((S)-morpholin-2-ylmethoxy)methyl)-N-(1-((S)-1-phenylethyl)-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.69,uM,=,-0.1611509092627447,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)cc1
6685,762782,10.1016/j.bmc.2011.06.044,,,,Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay,COc1cccc(/C=C/C(=O)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)c1,(E)-N-(4-(3-Chlorophenylamino)quinazolin-6-yl)-3-(3-methoxyphenyl)acrylamide,6.63,uM,=,0.8215135284047731,1,O=C(/C=C/c1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6686,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CC(C)(C)OC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid tert-butyl ester",8.0,uM,=,0.9030899869919436,1,c1ccc(CNc2ccccc2)cc1
6687,1649110,10.1016/j.bmc.2016.11.026,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF induced phosphorylation preincubated for 60 mins followed by EGF addition measured after 10 mins by ELISA method,COc1ccc(N(C)c2nc(C)nc3c(Cc4ccccc4)cn(C)c23)cc1.Cl,"7-Benzyl-N-(4-methoxyphenyl)-N,2,5-trimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine hydrochloride",0.0023,uM,=,-2.638272163982407,0,c1ccc(Cc2c[nH]c3c(Nc4ccccc4)ncnc23)cc1
6688,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",Clc1ncc2ncnc(Nc3ccccc3)c2n1,"(6-Chloro-pyrimido[5,4-d]pyrimidin-4-yl)-phenyl-amine",2.55,uM,=,0.4065401804339551,1,c1ccc(Nc2ncnc3cncnc23)cc1
6689,2224994,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin),COc1ccc(/C=C\C(=O)c2ccc(Br)c3cc(-c4ccc(F)cc4)oc23)cc1,(Z)-1-[4-bromo-2-(4-fluorophenyl)benzofuran-7-yl]-3-(4-methoxyphenyl)prop-2-en-1-one,0.09,uM,=,-1.0457574905606752,0,O=C(/C=C\c1ccccc1)c1cccc2cc(-c3ccccc3)oc12
6690,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,CCS(=O)(=O)N[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"N-((3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl)ethanesulfonamide",0.05,uM,=,-1.3010299956639813,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
6691,515202,10.1016/j.bmcl.2008.12.011,,,,Inhibition of EGFR,OCc1ccc(-c2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)o1,"(5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)furan-2-yl)methanol",0.003,uM,=,-2.5228787452803374,0,c1ccc(COc2ccc(Nc3ncnc4cc(-c5ccco5)sc34)cc2)cc1
6692,1652512,10.1016/j.ejmech.2016.12.006,,,,"Inhibition of N-terminal 6His/TEV protease cleavage site-tagged wild type human EGFR using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)Nc1cc(CC)cc(-n2c(=O)cc(C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-Ethyl-5-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide",0.4721,uM,=,-0.325965999568745,0,O=c1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1-c1ccccc1
6693,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"Buta-2,3-dienoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide",0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2ncnc3ccccc23)cc1
6694,840626,10.1016/j.bmcl.2012.06.067,,,,Inhibition of EGFR using GST-Crk as substrate assessed as phosphorylated Crk level after 20 mins by SDS-PAGE analysis,Cc1ccc(S(=O)(=O)N2CCOc3cc4ncnc(Nc5cccc(Br)c5)c4cc3OCC2)cc1,"N-(3-bromophenyl)-9-tosyl-8,9,10,11-tetrahydro-7H-[1,4,7]dioxazonino[2,3-g]quinazolin-4-amine",0.15,uM,=,-0.8239087409443188,0,O=S(=O)(c1ccccc1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc2OCC1
6695,66584,10.1016/s0960-894x(02)01047-8,,,,Inhibition of EGFR,CS(=O)(=O)CCNc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)cs1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-{6-[2-(2-methanesulfonyl-ethylamino)-thiazol-4-yl]-quinazolin-4-yl}-amine,0.01,uM,=,-2.0,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5cscn5)cc34)cc2)cc1
6696,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",O=C(/C=C/CN1CCOCC1)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"(2E)-N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]-4-(morpholin-4-yl)but-2-enamide",0.019,uM,=,-1.7212463990471711,0,O=C(/C=C/CN1CCOCC1)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(NCc4ccccc4)c23)c1
6697,612309,10.1021/jm901453q,,,,Inhibition of EGFR,COc1cc2ncnc(N[C@H](C)c3ccccc3)c2cc1OCCCCCCC(=O)NO,(R)-N-Hydroxy-7-(7-methoxy-4-(1-phenylethylamino)quinazolin-6-yloxy)heptanamide,0.0128,uM,=,-1.892790030352132,0,c1ccc(CNc2ncnc3ccccc23)cc1
6698,1675840,10.1016/j.bmc.2017.03.032,,,,"Inhibition of recombinant wild type human EGFR (695 to end residues) using Poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo assay",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(/C=C/c4cc(C)cc(C)c4)cc3)ncc2Cl)c1,"N-[3-[[5-Chloro-2-[(E)-4-(3,5-dimethylstyryl)phenylamino]-4-pyrimidinyl]yloxy]phenyl]-2-acrylamide",0.087,uM,=,-1.0604807473813815,0,C(=C/c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1)\c1ccccc1
6699,66586,10.1021/jm9503613,,,,Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles,O=[N+]([O-])c1ccc2ncnc(Nc3ccccc3)c2c1,(6-Nitro-quinazolin-4-yl)-phenyl-amine,5.0,uM,=,0.6989700043360189,1,c1ccc(Nc2ncnc3ccccc23)cc1
6700,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)cc3OC(F)(F)F)ncc2Cl)c1,"US8975249, I-47",0.02,uM,=,-1.6989700043360187,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6701,791584,10.1016/j.bmc.2011.11.023,,,,"Inhibition of EGFR using poly(Glu,Tyr)4:1 as substrate and [gamma33P]ATP after 60 mins by scintillation counting",CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.0089,uM,=,-2.050609993355087,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
6702,1770086,10.1016/j.bmcl.2017.12.009,,,,Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay,C=CC(=O)Nc1cccc(NC(=O)Nc2nc(Nc3ccc(N4CCC(N5CCOCC5)CC4)cc3OC)ncc2Cl)c1,N-(3-(3-(5-chloro-2-(2-methoxy-4-(4-morpholinopiperidin-1-yl)phenylamino)pyrimidin-4-yl)ureido)phenyl)acrylamide,0.641,uM,=,-0.1931419704811825,0,O=C(Nc1ccccc1)Nc1ccnc(Nc2ccc(N3CCC(N4CCOCC4)CC3)cc2)n1
6703,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)N1CCC[C@H]1CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,(S)-1-(2-(((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1H-imidazol-2-yl)thio)methyl)pyrrolidin-1-yl)prop-2-en-1-one,0.019,uM,=,-1.7212463990471711,0,c1ccc(Nc2cc(-c3[nH]c(SC[C@@H]4CCCN4)nc3-c3ccccc3)ccn2)cc1
6704,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,Cc1ccc(N2NC(=O)/C(=C/c3ccc(OCc4ccccc4)cc3)C2=O)cc1Cl,"4-(4-(benzyloxy)benzylidene)-1-(3-chloro-4-methylphenyl)pyrazolidine-3,5-dione",8.6,uM,=,0.9344984512435676,1,O=C1NN(c2ccccc2)C(=O)/C1=C\c1ccc(OCc2ccccc2)cc1
6705,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4cc(F)ccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-(6-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)buta-2,3-dienamide",0.0105,uM,=,-1.978810700930062,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6706,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)C(C)C)CC4)cc3OC)ncc2SC)c1,N-(3-((2-((4-(4-isobutyrylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(methylthio)pyrimidin-4-yl)oxy)phenyl)acrylamide,0.1736,uM,=,-0.7604502791595269,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6707,63619,10.1021/jm00031a009,,,,Inhibition of the tyrosine kinase activity of the human epidermal growth factor receptor (EGFR),O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccc(C(=O)O)cc2)[nH]c2ccccc12)NCc1ccc(C(=O)O)cc1,4-[2-(2-{3-[2-(4-carboxybenzylcarbamoyl)ethyl]-1H-2-indolyldisulfanyl}-1H-3-indolyl)ethylcarboxamidomethyl]benzoic acid,7.4,uM,=,0.8692317197309762,1,O=C(CCc1c(SSc2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
6708,2222500,10.1021/acs.jmedchem.1c02134,,,,Inhibition of EGFR (unknown origin),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.0053,uM,=,-2.275724130399211,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
6709,1914433,10.1021/acs.jnatprod.9b00659,,,,Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.39,uM,=,-0.4089353929735008,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6710,66720,10.1021/jm00130a020,,,,Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase,O=CN/C=C/c1cc(O)ccc1O,"N-[(E)-2-(2,5-Dihydroxy-phenyl)-vinyl]-formamide",14.0,uM,=,1.146128035678238,1,c1ccccc1
6711,2246841,10.1016/j.ejmech.2022.114249,,,,Inhibition of wild-type EGFR (14 to 721 residues) (unknown origin) by western blot analysis,Cn1ccc2cc(Nc3ncnc4ccc(N)cc34)ccc21,"N4-(1-methyl-1H-indol-5-yl)quinazoline-4,6-diamine",4.02,uM,=,0.60422605308447,1,c1ccc2c(Nc3ccc4[nH]ccc4c3)ncnc2c1
6712,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C#CC(=O)N1CC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccc(OC)cc5)cc4)[nH]c23)C1,"2-(4-(4-methoxyphenoxy)phenyl)-7-(1-propioloylazetidin-3-yl)-1H-imidazo[1,2-b]pyrazole-3-carboxamide",0.0883,uM,=,-1.0540392964224314,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CNC5)c4[nH]3)cc2)cc1
6713,63764,10.1021/jm960689b,,,,Inhibition of epidermal growth factor receptor (EGFr),O=C(NCc1ccccc1)[C@H](Cc1c([Se][Se]c2[nH]c3ccccc3c2C[C@@H](NC(=O)C(F)(F)F)C(=O)NCc2ccccc2)[nH]c2ccccc12)NC(=O)C(F)(F)F,"[R-(R*,R*)]-2,2'-Diselenobis [N-(phenyl-methyl)-alpha-[(trifluoroacetyl)amino]-1H-indole-3-propanamide]",7.0,uM,=,0.8450980400142568,1,O=C(CCc1c([Se][Se]c2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
6714,1291542,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGFR (unknown origin) after 10 mins,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCN(C)CC2)CCO4)c1,"1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(4-methylpiperazin-1-yl)but-2-en-1-one",0.016,uM,=,-1.7958800173440752,0,O=C(/C=C/CN1CCNCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
6715,78513,10.1016/s0960-894x(02)01047-8,,,,Inhibition of EGFR overexpressing HN5 (Head and neck) tumor cell proliferation,CS(=O)(=O)CCNc1nc(-c2ccc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3c2)cs1,(1-Benzyl-1H-indazol-5-yl)-{6-[2-(2-methanesulfonyl-ethylamino)-thiazol-4-yl]-quinazolin-4-yl}-amine,0.11,uM,=,-0.958607314841775,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccc(-c6cscn6)cc45)ccc32)cc1
6716,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,O=C(O)CCCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"4-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-ylamino]-butyric acid",0.00028,uM,=,-3.552841968657781,0,c1ccc(Nc2ncnc3ccncc23)cc1
6717,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,CN(C)CCn1ccc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-[8-(2-dimethylamino-ethyl)-8H-pyrrolo[3,2-g]quinazolin-4-yl]-amine",0.145,uM,=,-0.8386319977650252,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
6718,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)nc4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(6-(3-fluorobenzyloxy)pyridin-3-ylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",2.6,uM,=,0.414973347970818,1,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5ccccc5)nc4)c3s2)C1)N1CCOCC1
6719,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3ccc(C#CCN4CCOCC4)cc23)cc1Cl,N-(3-chloro-4-fluorophenyl)-6-(3-morpholinoprop-1-ynyl)quinazolin-4-amine,0.0503,uM,=,-1.298432014944073,0,C(#Cc1ccc2ncnc(Nc3ccccc3)c2c1)CN1CCOCC1
6720,512722,10.1021/jm8006189,,,,Inhibition of EGFR,COc1cc2c(Oc3ccc(-c4cnc(Cc5ccccc5)n(C)c4=O)cc3F)ccnc2cc1OCCCN1CCOCC1,2-Benzyl-5-(3-fluoro-4-(6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yloxy)phenyl)-3-methylpyrimidin-4(3H)-one,1.7,uM,=,0.2304489213782739,1,O=c1[nH]c(Cc2ccccc2)ncc1-c1ccc(Oc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1
6721,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCC(=O)Nc1cc2c(Nc3ccc4c(ccn4Cc4cccnc4)c3)ncnc2cc1OC,N-(7-Methoxy-4-{[1-(3-pyridinylmethyl)-1H-indol-5-yl]amino}-6-quinazolinyl)propanamide,0.714,uM,=,-0.1463017882238256,0,c1cncc(Cn2ccc3cc(Nc4ncnc5ccccc45)ccc32)c1
6722,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccs4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-(4-{[3,6-dioxo-4-(2-thienylmethoxy)cyclohexa-1,4-dien-1-yl]amino}-7-ethoxyquinazolin-6-yl)but-2-enamide",0.0475,uM,=,-1.3233063903751334,0,O=C1C=C(OCc2cccs2)C(=O)C=C1Nc1ncnc2ccccc12
6723,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccccc4)c(Cl)c3)ncnc2cc1OCCCN1CCN(C)CC1,1-(2-chloro-4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)phenyl)-3-phenylurea,0.014,uM,=,-1.853871964321762,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
6724,78742,10.1021/jm00075a010,,,,Inhibition of HER-14 (human EGFR overexpressing NIH3T3) cell proliferation,Cc1cc(C=C(C#N)C#N)cc(O)c1O,"2-(3,4-Dihydroxy-5-methyl-benzylidene)-malononitrile",13.0,uM,=,1.1139433523068367,1,c1ccccc1
6725,305912,10.1016/j.bmcl.2005.05.100,,,,Inhibitory concentration against EGFR by using [gamma-33P]-ATP as radioligand in pH 7.5,Fc1ccc(Nc2ncnc3nn4ccccc4c23)cc1Cl,"(3-Chloro-4-fluoro-phenyl)-(1,3,8a,9-tetraaza-fluoren-4-yl)-amine",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3nn4ccccc4c23)cc1
6726,850422,10.1016/j.bmc.2012.08.002,,,,Inhibition of human N-terminal DYKDDDD tagged EGFR cytoplasmic domain amino acid 669 to 1210 expressed in baculovirus after 5 mins by scintillation counter,CC(C)(C(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(Cl)c4)c(Cl)c3)c21)S(C)(=O)=O.Cc1ccc(S(=O)(=O)O)cc1,"N-[2-(4-{[3-Chloro-4-(3-chlorophenoxy)phenyl]amino}-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl]-2-methyl-2-(methylsulfonyl)propanamide p-toluenesulfonate",0.011,uM,=,-1.958607314841775,0,c1ccc(Oc2ccc(Nc3ncnc4cc[nH]c34)cc2)cc1.c1ccccc1
6727,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CNc1ccc2cncnc2c1,Methyl-quinazolin-7-yl-amine,0.004,uM,=,-2.397940008672037,0,c1ccc2ncncc2c1
6728,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCN(CC)[C@@](C)(C#Cc1ncnc2cc(OC)c(OC)cc12)Cc1ccccc1,"(R)-4-(6,7-dimethoxyquinazolin-4-yl)-N,N-diethyl-2-methyl-1-phenylbut-3-yn-2-amine",0.003,uM,=,-2.5228787452803374,0,C(#Cc1ncnc2ccccc12)CCc1ccccc1
6729,1994718,10.1016/j.bmcl.2020.127045,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 40 mins in presence of ATP by caliper mobility shift assay,O=C(/C=C/CN1CCOCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21,"(E)-1-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7, 8-dihydro-6H-[1, 4]oxazino[3,2-g]quinazolin-6-yl)-4-morpholinobut-2-en-1-one",0.007,uM,=,-2.154901959985743,0,O=C(/C=C/CN1CCOCC1)N1CCOc2cc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3cc21
6730,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CCC(C)n1nc(-c2ccc(C)c(O)c2)c2c(N)ncnc21,"5-(4-amino-1-sec-butyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methylphenol",1.67,uM,=,0.2227164711475832,1,c1ccc(-c2n[nH]c3ncncc23)cc1
6731,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2cc(F)c(O)cc2F)c2c(N)ncnc21,"4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2,5-difluorophenol",6.9,uM,=,0.8388490907372553,1,c1ccc(-c2n[nH]c3ncncc23)cc1
6732,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,CN(C)CCCn1ccc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-[8-(3-dimethylamino-propyl)-8H-pyrrolo[3,2-g]quinazolin-4-yl]-amine",0.23,uM,=,-0.6382721639824072,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
6733,2302351,10.1016/j.ejmech.2017.08.061,,,,Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system by ELISA,CN1CCN(c2ccc(Nc3ncc(Br)c(Nc4ccc5ccn(C)c5c4)n3)cc2)CC1,"5-bromo-N4-(1-methyl-1H-indol-6-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,4-diamine",1.3,uM,=,0.1139433523068367,1,c1cc(Nc2ccc3cc[nH]c3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
6734,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2ncnc(-c3cn(C)c4ccccc34)c2F)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((5-fluoro-6-(1-methyl-1H-indol-3-yl)pyrimidin-4-yl)amino)-4-methoxyphenyl)acrylamide,0.0321,uM,=,-1.493494967595128,0,c1ccc(Nc2cc(-c3c[nH]c4ccccc34)ncn2)cc1
6735,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CN(CC(O)C(O)C(O)C(O)CO)c1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"6-{[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-yl]-methyl-amino}-hexane-1,2,3,4,5-pentaol",0.0032,uM,=,-2.494850021680094,0,c1ccc(Nc2ncnc3ccncc23)cc1
6736,786919,10.1016/j.ejmech.2011.10.012,,,,Inhibition of EGFR by Z-LYTE assay,Br.CC(Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1cccc2ccccc12,"rac-4-(4-((1-(Naphthalen-1-yl)ethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol hydrobromide",1.008,uM,=,0.0034605321095064,1,c1ccc(-c2cc3c(NCc4cccc5ccccc45)ncnc3[nH]2)cc1
6737,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)nc1,"(S)-5-((morpholin-2-ylmethoxy)methyl)-N-(1-(pyridin-2-ylmethyl)-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.5,uM,=,-0.3010299956639812,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)nc1
6738,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(Nc3cc4ccccc4cn3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-isoquinolin-3-yl-amine",0.66,uM,=,-0.1804560644581313,0,c1ccc2cc(Nc3ncnc4ccccc34)ncc2c1
6739,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CN(C)C/C=C/C(=O)N1CCCC1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21,"US9181263, 11",0.01885,uM,=,-1.7246886454581882,0,c1ccc(Oc2ccc(-c3nn(CC4CCCN4)c4ncncc34)cc2)cc1
6740,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,COCCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN(C)C,(2E)-N-[4-[(1-Benzyl-1H-indazol-5-yl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]-4-(dimethylamino)-2-butenamide,0.005,uM,=,-2.3010299956639813,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccccc45)ccc32)cc1
6741,1782455,10.1016/j.ejmech.2017.12.022,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6742,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CCOc1cc(N)c(C(=O)Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1NC(=O)/C=C/CN(C)C,2-amino-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-5-(4-(dimethylamino)but-2-enamido)-4-ethoxybenzamide,1.5,uM,=,0.1760912590556812,1,O=C(Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
6743,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(Nc3cnc4ccccc4n3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-quinoxalin-2-yl-amine",0.78,uM,=,-0.1079053973095195,0,c1ccc2nc(Nc3ncnc4ccccc34)cnc2c1
6744,67068,10.1016/s0960-894x(99)00615-0,,,,Inhibition of Epidermal growth factor receptor (EGFr),COc1cc(Nc2nccc(-c3ccc(NCCN)nc3)n2)cc(OC)c1OC,"N*1*-{5-[2-(3,4,5-Trimethoxy-phenylamino)-pyrimidin-4-yl]-pyridin-2-yl}-ethane-1,2-diamine",5.1,uM,=,0.7075701760979364,1,c1ccc(Nc2nccc(-c3cccnc3)n2)cc1
6745,1674791,10.1016/j.ejmech.2017.03.001,,,,"Inhibition of recombinant human N-terminal GST-tagged wild-type EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay",C=CC(=O)Nc1cccc(Nc2ncc(NC(=O)c3cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc3C)cn2)c1,N-(2-(3-Acrylamidophenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide,0.072,uM,=,-1.1426675035687317,0,O=C(Nc1cccc(C(=O)Nc2cnc(Nc3ccccc3)nc2)c1)c1ccccc1
6746,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)COCc3ccccc3)c2)n1,N-(3-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-2-benzyloxyacetamide,9.5,uM,=,0.9777236052888478,1,O=C(COCc1ccccc1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
6747,1774204,10.1016/j.ejmech.2018.02.080,,,,Inhibition of recombinant human EGFR using peptide as substrate by fluorimetric analysis,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,"2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one",14.9,uM,=,1.173186268412274,1,O=c1cc(-c2ccccc2)oc2ccccc12
6748,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CN1CCOCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-morpholinobut-2-enamide",0.003,uM,=,-2.5228787452803374,0,O=C(/C=C/CN1CCOCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
6749,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,Brc1cccc(Nc2ncnc3cnc(NCCc4ccccn4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-(2-pyridin-2-yl-ethyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3cnc(NCCc4ccccn4)cc23)cc1
6750,506208,10.1021/np50089a001,,,,Inhibition of EGFR,CSCc1cc(/C=C2\C(=O)Nc3ccccc32)cc(CSC)c1O,"3-(4-hydroxy-3,5-bis(methylthiomethyl)benzylidene)indolin-2-one",0.4,uM,=,-0.3979400086720376,0,O=C1Nc2ccccc2/C1=C/c1ccccc1
6751,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)cc3OCC)ncc2Cl)c1,"US8975249, I-18",0.02,uM,=,-1.6989700043360187,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6752,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,O=C(/C=C/CN1CCC(F)(F)CC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(4,4-difluoropiperidin-1-yl)but-2-enamide",0.007,uM,=,-2.154901959985743,0,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
6753,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(C#N)c(O)c2)c2c(N)ncnc21,"4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-hydroxybenzonitrile",2.6,uM,=,0.414973347970818,1,c1ccc(-c2n[nH]c3ncncc23)cc1
6754,63763,10.1021/jm00018a008,,,,Inhibition of Epidermal growth factor receptor from A431 cells,COc1cccc2c(Nc3cccc(Br)c3)ncnc12,(3-Bromo-phenyl)-(8-methoxy-quinazolin-4-yl)-amine,0.974,uM,=,-0.0114410431213844,0,c1ccc(Nc2ncnc3ccccc23)cc1
6755,1291542,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGFR (unknown origin) after 10 mins,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCCCC2C)CCO4)c1,"1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(2-methylpiperidin-1-yl)but-2-en-1-one",0.005,uM,=,-2.3010299956639813,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
6756,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Clc1cccc(Nc2[nH]nc3ncnc(Nc4ccccc4)c23)c1,"N*3*-(3-Chloro-phenyl)-N*4*-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3n[nH]c(Nc4ccccc4)c23)cc1
6757,1674791,10.1016/j.ejmech.2017.03.001,,,,"Inhibition of recombinant human N-terminal GST-tagged wild-type EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay",C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4cc5c(s4)CCCC5)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1,"N-(3-(5-(3-acrylamido-4-(morpholine-4-carbonyl)phenylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide",6.863,uM,=,0.8365139988906715,1,O=C(Nc1cccc(-c2c[nH]c(=O)c(Nc3ccc(C(=O)N4CCOCC4)cc3)c2)c1)c1cc2c(s1)CCCC2
6758,1432458,10.1016/j.ejmech.2014.10.006,,,,Inhibition of HER1 (unknown origin) assessed as reduction in autophosphorylation by ELISA method,CS(=O)(=O)CCNC(CS(C)(=O)=O)c1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,Rac-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(2-(methylsulfonyl)-1-((2-(methylsulfonyl)ethyl)amino)ethyl)furan-2-yl)quinazolin-4-amine,0.0287,uM,=,-1.5421181032660076,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
6759,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccc2[nH]c3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn3c2c1,"US9447106, 67",0.0022,uM,=,-2.657577319177794,0,c1ccc(Oc2ccc(-c3cc4[nH]c5ccccc5n4n3)cc2)cc1
6760,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1C[C@H](OC)C[C@@H]1C(N)=O,"(2R,4R)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)-4-methoxypyrrolidine-2-carboxamide",0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
6761,676221,10.1021/jm100607r,,,,Inhibition of EGFR,CN(C)C/C=C/C(=O)N1CCc2c(sc3ncnc(N[C@H](CO)Cc4ccccc4)c23)C1,"(E)-1-(4-[(1R)-1-Benzyl-2-hydroxyethyl]amino-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-7-yl)-4-(dimethylamino)-2-buten-1-one",0.149,uM,=,-0.826813731587726,0,c1ccc(CCNc2ncnc3sc4c(c23)CCNC4)cc1
6762,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,CN(C)CCN(C)Cc1c[nH]c2cc3ncnc(Nc4cccc(Br)c4)c3cc12,"N-[4-(3-Bromo-phenylamino)-8H-pyrrolo[3,2-g]quinazolin-6-ylmethyl]-N,N',N'-trimethyl-ethane-1,2-diamine",0.081,uM,=,-1.0915149811213505,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
6763,2122893,10.1016/j.ejmech.2021.113626,,,,Inhibition of wild type EGFR (unknown origin) measured after 60 mins by ADP-Glo kinase based luminescence assay,O=C(NO)c1ccccc1Nc1nc(Nc2ccc(OCCCN3CCOCC3)cc2)ncc1Cl,2-(5-chloro-2-(4-(3-morpholinopropoxy)phenylamino)pyrimidin-4-ylamino)-N-hydroxybenzamide,0.001246,uM,=,-2.904481957676849,0,c1ccc(Nc2ccnc(Nc3ccc(OCCCN4CCOCC4)cc3)n2)cc1
6764,462993,10.1016/j.bmcl.2008.02.035,,,,Inhibition of EGF-stimulated human EGFR autophosphorylation in KB cells,C[C@@H](Oc1cccc2ncnc(Nc3ccc4c(cnn4Cc4nccs4)c3)c12)C(=O)N1CCOCC1,(R)-1-morpholino-2-(4-(1-(thiazol-2-ylmethyl)-1H-indazol-5-ylamino)quinazolin-5-yloxy)propan-1-one,0.366,uM,=,-0.4365189146055893,0,O=C(COc1cccc2ncnc(Nc3ccc4c(cnn4Cc4nccs4)c3)c12)N1CCOCC1
6765,563101,10.1016/j.bmc.2009.02.054,,,,Inhibition of EGFR,COCCOc1cc2ncnc(Nc3c(Cl)ccc4c3OCO4)c2cc1NC(=O)[C@@H]1CCCN1,"(S)-N-(4-(5-chlorobenzo[d][1,3]dioxol-4-ylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)pyrrolidine-2-carboxamide",7.13,uM,=,0.8530895298518656,1,O=C(Nc1ccc2ncnc(Nc3cccc4c3OCO4)c2c1)[C@@H]1CCCN1
6766,1914433,10.1021/acs.jnatprod.9b00659,,,,Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@]5(C(=O)OCCCCO[N+](=O)[O-])CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C,4'-Nitroxybutyl-3beta-acetyloxyolean-12-en-28-oic acid,0.1,uM,=,-1.0,0,C1=C2C(CCC3CCCC[C@@H]23)C2CC[C@H]3CCCCC3[C@H]2C1
6767,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,CC(COC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O)Cc1ccccc1,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid 2-methyl-3-phenyl-propyl ester",0.36,uM,=,-0.4436974992327127,0,O=C(OCCCc1ccccc1)c1cccc(NCc2ccccc2)c1
6768,586303,10.1016/s0006-2952(00)00405-6,,,,Inhibition of EGFR,Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3cccc(CO)c3)nc21,"6-(2,6-Dichloro-phenyl)-2-(3-hydroxymethyl-phenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one",0.082,uM,=,-1.0861861476162833,0,O=c1[nH]c2nc(Nc3ccccc3)ncc2cc1-c1ccccc1
6769,468599,10.1016/j.bmcl.2007.12.035,,,,Inhibition of EGFR,CN1CCN(CCCOc2n[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,"N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-3-(3-(4-methylpiperazin-1-yl)propoxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.014,uM,=,-1.853871964321762,0,c1ccc(COc2ccc(Nc3ncnc4[nH]nc(OCCCN5CCNCC5)c34)cc2)nc1
6770,2284955,10.1016/j.ejmech.2019.112016,,,,Inhibition of EGFR (unknown origin),CCOC(=O)c1csc(NC(=S)Nc2ccc(Cl)cc2)n1,Ethyl 2-(3-(4-chlorophenyl)thioureido)thiazole-4-carboxylate,10.1,uM,=,1.0043213737826426,1,S=C(Nc1ccccc1)Nc1nccs1
6771,497284,10.1016/j.bmcl.2008.09.090,,,,Inhibition of EGFR kinase,CCC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3R,5S)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl propionate",0.063,uM,=,-1.2006594505464183,0,C(#C[C@@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
6772,1907864,10.1016/j.bmc.2019.115153,,,,Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0154,uM,=,-1.812479279163537,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
6773,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,S=C(Nc1ccc(Cl)cc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(4-((3-bromophenyl)amino)quinazolin-6-yl)-3-(4-chlorophenyl)thiourea,0.0195,uM,=,-1.709965388637482,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6774,608076,10.1021/jm9016043,,,,Inhibition of EGFR,CN(CCN/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)CCNS(=O)(=O)c1cccc2c(N(C)C)cccc12,N-(2-((2-(3-(4-(3-chlorophenylamino)quinazolin-6-yl)triaz-2-enyl)ethyl)(methyl)amino)ethyl)-5-(dimethylamino)naphthalene-1-sulfonamide,0.6,uM,=,-0.2218487496163563,0,O=S(=O)(NCCNCCN/N=N/c1ccc2ncnc(Nc3ccccc3)c2c1)c1cccc2ccccc12
6775,557465,10.1021/jm800758s,,,,Inhibition of human EGFR,N=C(Nc1ccccc1)SCCCN1C(=O)C2=C(C1=O)n1ccc3cccc(c31)C1Cc3ccccc3N21,"3-(1,3-Dioxo-1,3,9b,10-tetrahydro-2H-indolo[1',7':4,5,6]pyrrolo[3',4':2,3][1,4] diazepino[1,7-a]indol-2-yl)propyl N-phenylimidothiocarbamate",9.5,uM,=,0.9777236052888478,1,N=C(Nc1ccccc1)SCCCN1C(=O)C2=C(C1=O)n1ccc3cccc(c31)C1Cc3ccccc3N21
6776,2147415,10.1021/acs.jmedchem.1c01055,,,,Inhibition of Wild type EGFR (unknown origin),COc1cc(N2CCC(N(C)C)CC2)c(-c2cnn(C)c2)cc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,(2-((5-Chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide,0.0017,uM,=,-2.7695510786217263,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCCCC4)c(-c4cn[nH]c4)c3)n2)cc1
6777,1774290,10.1016/j.ejmech.2018.03.001,,,,Inhibition of His-6 tagged recombinant EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in Baculovirus infected Sf9 cells by dissociation-enhanced lanthanide fluorescence immunoassay/time-resolved fluorometric analysis,O=C(N/N=C1\CC2(CCCC2)Oc2ccccc21)Nc1ccc(Cl)cc1,"N-(4-chlorophenyl)-2-(spiro[chroman-2,1'-cyclohexan]-4-ylidene)hydrazinecarboxamide",1.9,uM,=,0.2787536009528289,1,O=C(N/N=C1\CC2(CCCC2)Oc2ccccc21)Nc1ccccc1
6778,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccnc5ccccc45)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(quinolin-4-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.238,uM,=,-0.623423042943488,0,c1ccc2c(COc3ccc(Nc4ccnc5ccccc45)cc3)ccnc2c1
6779,65120,10.1021/jm00023a009,,,,In vitro inhibition of EGF-stimulated DNA synthesis of ER 22 cells by following the incorporation of methyl-[3H]thymidine.,COCOc1cc(-c2ccccc2)ccc1-c1ccc(C(=O)NCc2ccccc2)cc1,"2'-Methoxymethoxy-[1,1';4',1'']terphenyl-4-carboxylic acid benzylamide",1.1,uM,=,0.041392685158225,1,O=C(NCc1ccccc1)c1ccc(-c2ccc(-c3ccccc3)cc2)cc1
6780,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,CC(Nc1ncnc2sc(Br)cc12)c1ccccc1,"(rac)-6-Bromo-N-(1-phenylethyl)thieno[2,3-d]pyrimidin-4-amine",0.156,uM,=,-0.8068754016455384,0,c1ccc(CNc2ncnc3sccc23)cc1
6781,321418,10.1016/j.bmcl.2005.06.068,,,,Inhibitory concentration against EGFR kinase phosphorylation using synthetic peptide as a substrate,CN1CCC(Oc2cccc3ncnc(Nc4ccc(OCc5cscn5)c(Cl)c4)c23)CC1,[3-Chloro-4-(thiazol-4-ylmethoxy)-phenyl]-[5-(1-methyl-piperidin-4-yloxy)-quinazolin-4-yl]-amine,0.698,uM,=,-0.1561445773768389,0,c1cc(OC2CCNCC2)c2c(Nc3ccc(OCc4cscn4)cc3)ncnc2c1
6782,1438922,10.1016/j.bmcl.2014.08.036,,,,Inhibition of EGFR (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay,CCOc1cc(Br)c(Br)c(/C=N/c2ccc3[nH]c(=O)[nH]c3c2)c1O,"(E)-5-((2,3-dibromo-5-ethoxy-6-hydroxybenzylidene)amino)-1H-benzo[d]imidazol-2(3H)-one",76.7,uM,=,1.884795363948981,1,O=c1[nH]c2ccc(/N=C/c3ccccc3)cc2[nH]1
6783,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3cc(F)cc([N+](=O)[O-])c3)c2)[nH]1,N-(3-Fluoro-5-nitrophenyl)-4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridin-2-amine,0.265,uM,=,-0.5767541260631921,0,c1ccc(Nc2cc(-c3[nH]cnc3-c3ccccc3)ccn2)cc1
6784,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c5c(C)csc5c4)nn32)CC1,"7-(1-acryloylpiperidin-4-yl)-2-(4-methoxy-3-methylbenzo[b]thiophen-6-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",0.023,uM,=,-1.6382721639824072,0,c1cc2ccc(-c3cc4n(n3)C(C3CCNCC3)CCN4)cc2s1
6785,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.035,uM,=,-1.4559319556497243,0,c1ccc(Nc2ncnc3ccccc23)cc1
6786,66581,10.1016/s0960-894x(02)00598-x,,,,Inhibition of Epidermal Growth Factor Receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,4-(3-Chloro-4-fluoro-phenylamino)-7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile,1.04,uM,=,0.0170333392987803,1,c1ccc(Nc2ccnc3ccc(OCCCN4CCOCC4)cc23)cc1
6787,1556348,10.1016/j.bmc.2016.02.017,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by addition of substrate by mobility shift assay,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.048,uM,=,-1.3187587626244128,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
6788,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,C=C(CN1CCOCC1)C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-{4-[(3-Bromophenyl)amino]-6-quinazolinyl}-2-(4-morpholinylmethyl)acrylamide,0.107,uM,=,-0.9706162223147904,0,C=C(CN1CCOCC1)C(=O)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6789,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCOCC1,(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-morpholinobut-2-enamide,0.004,uM,=,-2.397940008672037,0,O=C(/C=C/CN1CCOCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
6790,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccccc23)cc1
6791,800208,10.1016/j.bmcl.2011.12.067,,,,Inhibition of wild-type EGFR expressed using baculovirus expression system by ELISA,COc1cccc2c1C(=O)c1c(O)ccc(O)c1C2=O,"1,4-dihydroxy-5-methoxyanthracene-9,10-dione",4.3,uM,=,0.6334684555795865,1,O=C1c2ccccc2C(=O)c2ccccc21
6792,987016,10.1021/jm401045n,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay,C=CC(=O)Nc1ccc(-n2c(=O)cnc3cnc(Nc4ccc(N5CCOCC5)cc4)nc32)cc1,N-(4-(2-(4-Morpholinophenylamino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,5.585,uM,=,0.7470231774516278,1,O=c1cnc2cnc(Nc3ccc(N4CCOCC4)cc3)nc2n1-c1ccccc1
6793,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,O=C1COc2cc3ncnc(Nc4ccc(Cl)cc4)c3cc2N1CCCN1CCOCC1,"4-((4-chlorophenyl)amino)-6-(3-morpholinopropyl)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.3537,uM,=,-0.4513649401852484,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCOCC1
6794,2225014,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin) by microplate reader,CCOCCSc1nc(-c2ccccc2Cl)nn1CCOCC,"3-(2-chlorophenyl)-1-(2-ethoxyethyl)-5-(2-ethoxyethylsulfanyl)-1,2,4-triazole",0.0867,uM,=,-1.0619809025237896,0,c1ccc(-c2nc[nH]n2)cc1
6795,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(Oc6ccccn6)cccc5c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(5-(pyridin-2-yloxy)naphthalen-2-ylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",1.05,uM,=,0.021189299069938,1,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(Oc6ccccn6)cccc5c4)c3s2)C1)N1CCOCC1
6796,1338035,10.1016/j.ejmech.2014.02.032,,,,Inhibition of EGFR (unknown origin) after 1.5 hr by FRET-based Z-lyte assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)CCN3CCCCC3)c2)n1,N-(3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)-3-(piperidin-1-yl)propanamide,10.0,uM,=,1.0,1,O=C(CCN1CCCCC1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
6797,558972,10.1016/j.bmcl.2008.11.023,,,,Inhibition of EGFR by HTRF assay,CCNC(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1,"(3S,5R)-5-((4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl ethylcarbamate",0.05,uM,=,-1.3010299956639813,0,C(#C[C@H]1CCCN1)c1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2s1
6798,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,COCCn1c(=O)oc2cc3ncnc(Nc4ccc(OC)cc4)c3cc21,"1-(2-Methoxyethyl)-8-(4-methoxyphenylamino)oxazolo[4,5-g]quinazolin-2(1H)-one",5.1,uM,=,0.7075701760979364,1,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
6799,2059412,10.1016/j.bmc.2021.116061,,,,Inhibition of EGFR in human A431 cells preincubated for 60 mins followed by EGF stimulation and measured after 10 mins by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0012,uM,=,-2.920818753952376,0,c1ccc(Nc2ncnc3ccccc23)cc1
6800,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,Brc1cccc(Nc2ncnc3c2NCc2cc(Br)ccc2O3)c1,"(8-Bromo-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(3-bromo-phenyl)-amine",7.2,uM,=,0.8573324964312685,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6801,4989,10.1021/jm970124v,,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Clc1cccc(Nc2nc[nH]c3nnc(Nc4cccc(Cl)c4)c2-3)c1,"N*3*,N*4*-Bis-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine",0.25,uM,=,-0.6020599913279624,0,c1ccc(Nc2nc[nH]c3nnc(Nc4ccccc4)c2-3)cc1
6802,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,O=C(O)c1cc(N(Cc2ccccc2O)Cc2ccccc2O)ccc1O,lavendustin B,1.3693890823638637,uM,=,0.1365268610747274,1,c1ccc(CN(Cc2ccccc2)c2ccccc2)cc1
6803,1754932,10.1021/acs.jmedchem.8b00441,,,,"Inhibition of recombinant human EGFR using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C,"(-)-(S)-N-(4-Amino-6-methylene-5-(4-phenoxyphenyl)-7,8-dihydro-6H-pyrimido[5,4-b]pyrrolizin-7-yl)acrylamide",0.0013,uM,=,-2.886056647693163,0,C=C1CCn2c1c(-c1ccc(Oc3ccccc3)cc1)c1cncnc12
6804,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC(C)c1ccc(N2C[C@H](CS(C)(=O)=O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinolin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",0.505,uM,=,-0.2967086218813386,0,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
6805,321418,10.1016/j.bmcl.2005.06.068,,,,Inhibitory concentration against EGFR kinase phosphorylation using synthetic peptide as a substrate,COc1ccc(Nc2ncnc3cccc(OC4CCN(C)CC4)c23)cc1Cl,(3-Chloro-4-methoxy-phenyl)-[5-(1-methyl-piperidin-4-yloxy)-quinazolin-4-yl]-amine,1.8,uM,=,0.255272505103306,1,c1ccc(Nc2ncnc3cccc(OC4CCNCC4)c23)cc1
6806,1587871,10.1016/j.ejmech.2016.04.035,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 30 mins by HTRF assay",COc1cc2c(Oc3ccc(NC(=O)c4cn(-c5ccccc5Cl)nn4)cc3F)ccnc2cc1OCCCN1CCCCC1,"1-(2-chlorophenyl)-N-(3-fluoro-4-((6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-1H-1,2,3-triazole-4-carboxamide",0.5294,uM,=,-0.2762160630346706,0,O=C(Nc1ccc(Oc2ccnc3cc(OCCCN4CCCCC4)ccc23)cc1)c1cn(-c2ccccc2)nn1
6807,1649110,10.1016/j.bmc.2016.11.026,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF induced phosphorylation preincubated for 60 mins followed by EGF addition measured after 10 mins by ELISA method,COc1ccc(Nc2nc(C)nc3c(Cc4ccccc4)cn(C)c23)cc1.Cl,"7-Benzyl-N-(4-methoxyphenyl)-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine hydrochloride",0.0026,uM,=,-2.5850266520291822,0,c1ccc(Cc2c[nH]c3c(Nc4ccccc4)ncnc23)cc1
6808,82007,10.1021/jm011022e,,,,Inhibition of human endothelial cell growth stimulate by endothelial growth factor,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC/C=C/CN1CCCC1.Cl,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(4-pyrrolidin-1-yl-but-2-enyloxy)-quinazolin-4-yl]-amine hydrochloride,0.09,uM,=,-1.0457574905606752,0,C(=C/CN1CCCC1)\COc1ccc2c(Nc3ccccc3)ncnc2c1
6809,2299669,10.1021/acsmedchemlett.2c00514,,,,Inhibition of wild type EGFR (unknown origin) using TK-substrate preincubated with enzyme for 30 mins followed by substrate and ATP addition for 25 mins by HTRF assay,COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(C(=O)OC(C)C)c(-c2cn(C)c3ccccc23)n1,isopropyl 2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate,0.0004,uM,=,-3.397940008672037,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCCCC5)cc4)n3)c[nH]c2c1
6810,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COc1cc(NC(=O)/C=C/CN2CCOCC2)cc2c(Nc3cccc(Br)c3)c(C#N)cnc12,(E)-4-Morpholin-4-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-8-methoxy-quinolin-6-yl]-amide,5.39,uM,=,0.7315887651867387,1,O=C(/C=C/CN1CCOCC1)Nc1ccc2nccc(Nc3ccccc3)c2c1
6811,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Bromo-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.0036,uM,=,-2.4436974992327127,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
6812,642516,10.1021/jm1000198,,,,Inhibition of GST-tagged EGFR expressed in Escherichia coli,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6813,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1cnc(N2CC[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-((R)-2-methylazetidin-1-yl)-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",9.965,uM,=,0.9984773030365064,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
6814,401654,10.1016/j.bmcl.2006.06.054,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cc(Cl)ccc3F)c2cc1OCC1CCN(C)CC1,N-(5-chloro-2-fluorophenyl)-7-methoxy-6-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine,0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccc(OCC4CCNCC4)cc23)cc1
6815,63608,10.1021/jm00110a022,,,,In vitro inhibition of HER1 autophosphorylation.,CC(NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1)c1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-(1-phenyl-ethyl)-acrylamide",2.5,uM,=,0.3979400086720376,1,O=C(/C=C/c1ccccc1)NCc1ccccc1
6816,67213,10.1021/jm020113o,,,,Inhibition of Epidermal growth factor receptor,Cc1nc(O)c2c(ccc3[nH]c(Nc4c(Cl)cccc4Cl)nc32)c1C,"2-(2,6-Dichloro-phenylamino)-6,7-dimethyl-1,8-dihydro-imidazo[4,5-h]isoquinolin-9-one",100.0,uM,=,2.0,1,c1ccc(Nc2nc3c(ccc4ccncc43)[nH]2)cc1
6817,64445,10.1021/jm990482t,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography,C=CC(=O)Nc1cc2c(Nc3cccc(C)c3)ncnc2cc1OCCCN1CCOCC1,N-[7-(3-Morpholin-4-yl-propoxy)-4-m-tolylamino-quinazolin-6-yl]-acrylamide,0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
6818,1278553,10.1016/j.bmc.2013.09.049,,,,"Inhibition of wild type EGFR (unknown origin) expressed in baculovirus expression system using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",CN(C)CCCN(C)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-3-(4-(3-Chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-1-(3-(dimethylamino)propyl)-1-methylurea,0.464,uM,=,-0.3334820194451191,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
6819,2134266,10.1016/j.ejmech.2021.113724,,,,Inhibition of N-terminal DYKDDDD-tagged EGFR (669 to 1210 residues) (unknown origin) expressed in Sf21 insect cells using NH2-ETVYSEVRK-biotin as substrate preincubated for 1 hr followed by ATP addition and measured after 2 hrs by ELISA,C#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5F)cc4)[nH]c23)CC1,"2-(4-(2-fluorophenoxy)phenyl)-7-(1-propioloylpiperidin-4-yl)-1H-imidazo[1,2-b]pyrazole-3-carboxamide",0.0163,uM,=,-1.787812395596042,0,c1ccc(Oc2ccc(-c3cn4ncc(C5CCNCC5)c4[nH]3)cc2)cc1
6820,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",CN(C)c1ncc2ncnc(Nc3cccc(Br)c3)c2n1,"N*8*-(3-Bromo-phenyl)-N*2*,N*2*-dimethyl-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.00095,uM,=,-3.0222763947111524,0,c1ccc(Nc2ncnc3cncnc23)cc1
6821,1524114,10.1016/j.bmc.2015.10.035,,,,Inhibition of human EGFR after 1 hr using [gamma-32P]ATP,Fc1ccc(Nc2ncnc3sc4c(c23)CCCC4)cc1Cl,"4-(3-Chloro-4-fluoroanilino)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine",1.33,uM,=,0.1238516409670858,1,c1ccc(Nc2ncnc3sc4c(c23)CCCC4)cc1
6822,553933,10.1021/np070447m,,,,Inhibition of recombinant EGFR,COc1cc(O)c2c(=O)oc3c(O)c(O)cc(C)c3c2c1,3-Hydroxyalternariol 5-O-methyl ether,0.0038186039789369,uM,=,-2.418095379249219,0,O=c1oc2ccccc2c2ccccc12
6823,807903,10.1016/j.bmc.2012.01.029,,,,Inhibition of EGF-induced EGFR autophosphorylation in human A431 cells incubated for 60 mins prior to EGF-induction measured after 10 mins by phosphotyrosine ELISA,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
6824,2153740,10.1021/acsmedchemlett.1c00555,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,BRIGATINIB,0.2613,uM,=,-0.5828605902726743,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
6825,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,N#C/C(=C\c1cc(O)c(O)c(CSCc2ccccc2)c1)C(N)=O,"3-(3-Benzylsulfanylmethyl-4,5-dihydroxy-phenyl)-2-cyano-acrylamide",0.94,uM,=,-0.0268721464003013,0,c1ccc(CSCc2ccccc2)cc1
6826,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCC1CCN(C)CC1,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine,0.018,uM,=,-1.744727494896694,0,c1ccc(Nc2ncnc3ccc(OCC4CCNCC4)cc23)cc1
6827,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Nc1nc(N)c2c(Nc3cccc(Cl)c3)[nH]nc2n1,"N*3*-(3-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3,4,6-triamine",0.22,uM,=,-0.6575773191777937,0,c1ccc(Nc2[nH]nc3ncncc23)cc1
6828,1510113,10.1021/acs.jmedchem.5b01082,,,,Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3n[nH]c4ccc(Br)cc34)cc(N3CCN(C)CC3)n2)c1,N-(3-(4-(5-bromo-1H-indazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-yloxy)phenyl)acrylamide,2.9,uM,=,0.4623979978989561,1,c1ccc(Oc2nc(Nc3n[nH]c4ccccc34)cc(N3CCNCC3)n2)cc1
6829,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CCCCN(CC#CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1)CCCC,N-[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]-4-(dibutylamino)-2-butynamide,0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3ccccc23)cc1
6830,2147415,10.1021/acs.jmedchem.1c01055,,,,Inhibition of Wild type EGFR (unknown origin),COc1cc(N2CCN(C)CC2)c(-c2cnn(C)c2)cc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,(2-((5-Chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide,0.0033,uM,=,-2.4814860601221125,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)c(-c4cn[nH]c4)c3)n2)cc1
6831,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.08,uM,=,-1.0969100130080565,0,c1ccc(Nc2ccnc3ccccc23)cc1
6832,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,18.21,uM,=,1.26030994579492,1,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
6833,401655,10.1016/j.bmcl.2006.06.054,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc2ncnc(Nc3cc(Cl)ccc3F)c2cc1OCCCN1CCOCC1,N-(5-chloro-2-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine,0.11,uM,=,-0.958607314841775,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6834,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccccc3Cl)C2=O)cc(OC)c1,"(2E,6E)-2-(2-Chlorobenzylidene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",1.5,uM,=,0.1760912590556812,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
6835,619932,10.1016/j.bmcl.2009.10.024,,,,Inhibition of EGFR autophosphorylation in human A431 cells,Clc1cccc(Nc2ncnc3ccc(Cl)cc23)c1,6-chloro-N-(3-chlorophenyl)quinazolin-4-amine,2.7,uM,=,0.4313637641589873,1,c1ccc(Nc2ncnc3ccccc23)cc1
6836,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,CCOc1cc2ncnc(C#C[C@@](C)(Cc3ccccc3)N3CCC(C(=O)O)CC3)c2cc1OCC,"(R)-1-(4-(6,7-diethoxyquinazolin-4-yl)-2-methyl-1-phenylbut-3-yn-2-yl)piperidine-4-carboxylic acid",0.0042,uM,=,-2.3767507096021,0,C(#CC(Cc1ccccc1)N1CCCCC1)c1ncnc2ccccc12
6837,1743840,10.1021/acs.jmedchem.6b01894,,,,Inhibition of EGF-stimulated wild-type EGFR phosphorylation in human A549 cells preincubated for 2 hrs followed by EGF stimulation for 10 mins by sandwich ELISA,C=CC(=O)N1CC[C@@H](Nc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c3ncn(C(C)C)c3n2)C1,(R)-1-(3-((9-Isopropyl-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-9H-purin-2-yl)amino)pyrrolidin-1-yl)prop-2-en-1-one,0.387,uM,=,-0.4122890349810886,0,c1nc2c(Nc3ccc(N4CCNCC4)cc3)nc(N[C@@H]3CCNC3)nc2[nH]1
6838,2153185,10.1016/j.ejmech.2021.113845,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0296,uM,=,-1.5287082889410617,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6839,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCCC[C@@H]1C(N)=O,(R)-1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)piperidine-2-carboxamide,0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3ccc(CN4CCCCC4)cc23)cc1
6840,2284955,10.1016/j.ejmech.2019.112016,,,,Inhibition of EGFR (unknown origin),COc1cc(C(=NC#N)c2csc(-c3ccccc3)n2)cc(OC)c1OC,"N-((2-phenylthiazol-4-yl)(3,4,5-trimethoxyphenyl)methylene)cyanamide",0.02,uM,=,-1.6989700043360187,0,N=C(c1ccccc1)c1csc(-c2ccccc2)n1
6841,63615,10.1021/jm980123i,,,,Concentration required to achieve 50% inhibition of tyrosine phosphorylation on human Epidermal growth factor receptor (EGF RTK).,CC(C)c1ccc(/C=C2/C(=O)Nc3ccccc32)cc1,"3-(4-Isopropyl-benzylidene)-1,3-dihydro-indol-2-one",18.5,uM,=,1.2671717284030135,1,O=C1Nc2ccccc2/C1=C\c1ccccc1
6842,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(C)c3)c2c1,N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide,0.0047,uM,=,-2.3279021420642825,0,c1ccc(Nc2ncnc3ccccc23)cc1
6843,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCC1C(N)=O,1-((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)azetidine-2-carboxamide,0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ncnc3ccc(CN4CCC4)cc23)cc1
6844,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,O=C(Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)c1ccco1,N-(4-(3-bromophenylamino)quinazolin-6-yl)furan-2-carboxamide,0.0084,uM,=,-2.0757207139381184,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccco1
6845,339196,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR autophosphorylation in DiFi cells,COc1cc2c(cc1OC)Oc1ncnc(Nc3cccc(Br)c3)c1NC2,"(3-Bromo-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",0.47,uM,=,-0.3279021420642826,0,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6846,1551515,10.1016/j.ejmech.2015.12.032,,,,Inhibition of human EGFR preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,COc1cc2c(Nc3ccc(NC(=O)c4cccc(Cl)c4)cc3)ncnc2cc1OCCCN1CCOCC1,N-(4-(6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-ylamino)phenyl)-3-chlorobenzamide,0.23,uM,=,-0.6382721639824072,0,O=C(Nc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1)c1ccccc1
6847,493905,10.1021/jm800829v,,,,Inhibition of human recombinant EGFR,COc1cc2ncnc(Nc3cccc(C)c3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine",0.0046,uM,=,-2.337242168318426,0,c1ccc(Nc2ncnc3ccccc23)cc1
6848,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCCn1ccnc1[N+](=O)[O-],N-(3-Bromophenyl)-6-methoxy-7-(4-(2-nitro-1H-imidazol-1-yl)butoxy)quinazolin-4-amine,0.00037,uM,=,-3.431798275933005,0,c1ccc(Nc2ncnc3cc(OCCCCn4ccnc4)ccc23)cc1
6849,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Br)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Bromo-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.0047,uM,=,-2.3279021420642825,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
6850,793571,10.1016/j.bmc.2011.11.058,,,,Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA,Nc1nc(Nc2ccc(Cl)cc2)c2cc(Cc3cccc4ccccc34)[nH]c2n1,"N4-(4-Chlorophenyl)-6-(1-naphthylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",12.62,uM,=,1.1010593549081156,1,c1ccc(Nc2ncnc3[nH]c(Cc4cccc5ccccc45)cc23)cc1
6851,1335368,10.1016/j.bmc.2014.01.035,,,,Inhibition of wild type EGFR domain (unknown origin) expressed in baculovirus expression system using Poly(Glu:Tyr)4:1 substrate after 60 mins by ELISA,CCN1CCN(C/C=C/C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3s2)CC1,"(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)thieno[2,3-d]pyrimidin-6-yl)-4-(4-ethylpiperazin-1-yl)but-2-enamide",0.035,uM,=,-1.4559319556497243,0,O=C(/C=C/CN1CCNCC1)Nc1cc2c(Nc3ccccc3)ncnc2s1
6852,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,Cn1c(NCc2cccc(C(F)(F)F)c2)cc(=O)n(C)c1=O,"1,3-dimethyl-6-(3-(trifluoromethyl)benzylamino)pyrimidine-2,4(1H,3H)-dione",83.9,uM,=,1.9237619608287,1,O=c1cc(NCc2ccccc2)[nH]c(=O)[nH]1
6853,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,COc1cc(NC(=O)Nc2ccncc2)cc(-c2cccnc2)c1OC,"1-(3,4-Dimethoxy-5-(pyridin-3-yl)phenyl)-3-(pyridin-4-yl)urea",0.13109,uM,=,-0.8824304365361725,0,O=C(Nc1ccncc1)Nc1cccc(-c2cccnc2)c1
6854,2198131,10.1016/j.ejmech.2022.114661,,,,Inhibition of recombinant human EGFR incubated for 40 to 45 mins and measured after 15 mins by Kinase-Glo Max assay,CC(=O)NNC(=O)c1csc2ncc(-c3ccc(Br)cc3)n12,"N'-Acetyl-5-(4-bromophenyl)imidazo[2,1-b]thiazole-3-carbohydrazide",0.153,uM,=,-0.8153085691824012,0,c1ccc(-c2cnc3sccn23)cc1
6855,2129802,10.1021/acs.jmedchem.1c00678,,,,Inhibition of EGFR (unknown origin),COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.5,uM,=,-0.3010299956639812,0,c1ccc(/N=c2\nc[nH]c3cc(OCC4CCNCC4)ccc23)cc1
6856,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc4c(c3)CCN4Cc3ccccc3)c2cc1NC(=O)/C=C/CN(C)C,"4-Dimethylamino-but-2-enoic acid [4-(1-benzyl-2,3-dihydro-1H-indol-5-ylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide",0.34,uM,=,-0.4685210829577448,0,c1ccc(CN2CCc3cc(Nc4ccnc5ccccc45)ccc32)cc1
6857,1675840,10.1016/j.bmc.2017.03.032,,,,"Inhibition of recombinant wild type human EGFR (695 to end residues) using Poly (4:1 Glu, Tyr) as substrate after 1 hr by ADP-Glo assay",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(/C=C/c4ccc(C)cc4C)cc3)ncc2F)c1,"N-[3-[[5-Fluoro-2-[(E)-4-(2,4-dimethylstyryl)phenylamino]-4-pyrimidinyl]amino]phenyl]-2-acrylamide",0.3867,uM,=,-0.4126258279269346,0,C(=C/c1ccc(Nc2nccc(Nc3ccccc3)n2)cc1)\c1ccccc1
6858,2187466,10.1016/j.bmc.2022.117052,,,,"Inhibition of N-terminal GST-tagged human recombinant wild type EGFR (695 to end residues) expressed in baculovirus-infected Sf9 cells using poly (4:1 Glu,Tyr) peptide as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay",C=CC(=O)N1CCC(Oc2nc(Nc3ccc(CN4CCC(CO)CC4)cc3)ncc2Cl)CC1,1-(4-((5-chloro-2-((4-((4-(hydroxymethyl)piperidin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one,0.17952,uM,=,-0.7458871604239325,0,c1cc(OC2CCNCC2)nc(Nc2ccc(CN3CCCCC3)cc2)n1
6859,1744966,10.1016/j.bmcl.2017.09.048,,,,Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)CCOCc3ccccc3)c2)n1,N-(3-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)-3-benzyloxypropanamide,17.93,uM,=,1.2535802895621828,1,O=C(CCOCc1ccccc1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
6860,1914433,10.1021/acs.jnatprod.9b00659,,,,Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay,CC1(C)CC[C@]2(C(=O)OCCCCO[N+](=O)[O-])CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@]43C)[C@@H]2C1,"4'-Nitroxybutyl-3beta,23-dihydroxyolean-12-en-28-oic acid",0.19,uM,=,-0.721246399047171,0,C1=C2C(CCC3CCCC[C@@H]23)C2CC[C@H]3CCCCC3[C@H]2C1
6861,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1ccc(N2CC(CS(C)(=O)=O)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((5-isopropyl-8-(3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinolin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",1.362,uM,=,0.1341771075767663,1,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
6862,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,CC(C)(C)c1ccc(Nc2ncnc3cc4oc(=O)n(CCOC(=O)CBr)c4cc23)cc1,"1-(2-(2-bromoacetoxy)ethyl)-8-((3-chloro-4-(tert-butyl)phenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.87,uM,=,-0.0604807473813814,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
6863,63789,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by autophosphorylation,COc1cc(C=C(C#N)C#N)cc(CSCC(=O)O)c1O,"[5-(2,2-Dicyano-vinyl)-2-hydroxy-3-methoxy-benzylsulfanyl]-acetic acid",54.0,uM,=,1.7323937598229686,1,c1ccccc1
6864,402645,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR autophosphorylation in DiFi cells by ELISA,COc1cc2c(cc1OC)Oc1ncnc(Nc3cccc(C)c3)c1NC2,"(7,8-dimethoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-m-tolyl-amine",4.4,uM,=,0.6434526764861874,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6865,1642156,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
6866,1515283,10.1016/j.ejmech.2015.07.008,,,,Inhibition of EGFR (unknown origin) assessed as incorporation of 33Pi after 1 hr by ELISA,C#Cc1cccc(Nc2ncnc3cc4oc(=O)n(CCOC)c4cc23)c1,"8-(3-Ethynylphenylamino)-1-(2-methoxyethyl)oxazolo[4,5-g]quinazolin-2(1H)-one",0.19,uM,=,-0.721246399047171,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
6867,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)CCN1CCOCC1,N-(4-((3-Chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-3-morpholinopropanamide,0.00029,uM,=,-3.537602002101044,0,O=C(CCN1CCOCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6868,1714364,10.1016/j.bmc.2018.05.039,,,,"Inhibition of wild type EGFR (unknown origin) using Poly(Glu,Tyr) as substrate after 40 mins by Kinase-Glo luminescence assay",C=CC(=O)N1CC[C@H](Nc2nc(Nc3ccccc3)nc3cnc(Nc4ccc(N5CCN(C)CC5)cn4)cc23)C1,"(S)-1-(3-((6-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-2-(phenyl amino)pyrido[3,4-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)prop-2-en-1-one",0.0099,uM,=,-2.00436480540245,0,c1ccc(Nc2nc(N[C@H]3CCNC3)c3cc(Nc4ccc(N5CCNCC5)cn4)ncc3n2)cc1
6869,793832,10.1016/j.bmc.2011.11.056,,,,Inhibition of human EGFR preincubated 2 hrs prior addition of ATP by HTRF assay,O=C(COc1ccccc1)Nc1cccc(Oc2cc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncn2)c1,4-[3-Chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-phenoxyacetamidophenoxy)pyrimidine,0.065,uM,=,-1.1870866433571443,0,O=C(COc1ccccc1)Nc1cccc(Oc2cc(Nc3ccc(OCc4ccccc4)cc3)ncn2)c1
6870,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C#Cc1cccc(Nc2ncnc3cc(OCC)c(NC(=O)/C=C/CN4CCCCC4)cc23)c1,(E)-N-(7-Ethoxy-4-(3-ethynylphenylamino)quinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide,0.0060999999999999,uM,=,-2.214670164989233,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6871,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-2-butynamide",0.0003,uM,=,-3.522878745280338,0,c1ccc(Nc2ncnc3cnccc23)cc1
6872,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CBr)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(N5CCOCC5)c(Cl)c4)c3cc21,"1-(2-(2-bromoacetyl)ethyl)-8-((3-chloro-4-morpholinophenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.01,uM,=,-2.0,0,O=c1[nH]c2cc3c(Nc4ccc(N5CCOCC5)cc4)ncnc3cc2o1
6873,774682,,,,,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1,Tirilazad,20.397,uM,=,1.3095662958937735,1,O=C1C=CC2C(=C1)CC[C@@H]1C2=CCC2[C@@H](C(=O)CN3CCN(c4cc(N5CCCC5)nc(N5CCCC5)n4)CC3)CC[C@H]21
6874,63616,10.1016/S0960-894X(97)00034-6,,,,Inhibition of Epidermal growth factor receptor autophosphorylation.,COc1cc2ncnc(Oc3cccc(Cl)c3)c2cc1OC,"4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazoline",0.02,uM,=,-1.6989700043360187,0,c1ccc(Oc2ncnc3ccccc23)cc1
6875,1560433,10.1016/j.bmcl.2016.02.009,,,,Inhibition of wildtype EGFR (unknown origin) preincubated for 30 mins followed by addition of 2x ATP-substrate mixture measured after 1 hr by Kinase Glo luminescent kinase assay,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(CCCN2CCCCC2)C(=O)CO4)c1,"4-((3-ethynylphenyl)amino)-6-(3-(piperidin-1-yl)propyl)-6H-[1,4]oxazino[3,2-g]quinazolin-7(8H)-one",0.2114,uM,=,-0.6748950170285926,0,O=C1COc2cc3ncnc(Nc4ccccc4)c3cc2N1CCCN1CCCCC1
6876,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3[nH]c(=O)ccc3c2)c2c(N)ncnc21,"6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)quinolin-2(1H)-one",6.7,uM,=,0.8260748027008264,1,O=c1ccc2cc(-c3n[nH]c4ncncc34)ccc2[nH]1
6877,642443,10.1016/j.bmc.2010.05.034,,,,Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA,CC(=O)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccccc1,"1-(3-(3,4-Dichlorophenyl)-5-phenyl-4,5-dihydro-1Hpyrazol-1-yl)ethanone",28.69,uM,=,1.4577305482459983,1,c1ccc(C2=NNC(c3ccccc3)C2)cc1
6878,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1nc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1CCCCN1CCOCC1,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(4-morpholin-4-yl-butyl)-pyrido[3,2-d]pyrimidin-6-yl]-acrylamide",5.1,uM,=,0.7075701760979364,1,c1ccc(Nc2ncnc3cc(CCCCN4CCOCC4)cnc23)cc1
6879,2080995,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR L858R/T790M (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCc1cn(CCCC(=O)NO)nn1,"4-(4-(((6-Acrylamido-4-((3-chloro-2-fluorophenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutanamide",0.0054,uM,=,-2.2676062401770314,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
6880,1642165,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl,"4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2cn(-c3ccccc3)nc2-c2ccncc2)cc1
6881,65135,10.1021/jm00001a011,,,,Inhibitory concentration compound against EFGR tyrosine kinase obtained from plasma membrane vesicles from cultured A431 cells,c1ccc(-c2c(SSc3[nH]c4ccccc4c3-c3ccccc3)[nH]c3ccccc23)cc1,di(3-phenyl-1H-2-indolyl) disulfide,100.0,uM,=,2.0,1,c1ccc(-c2c(SSc3[nH]c4ccccc4c3-c3ccccc3)[nH]c3ccccc23)cc1
6882,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C2\CCC/C(=C\c3ccc(F)cc3)C2=O)cc(OC)c1,"(2E,6E)-2-(3,5-Dimethoxybenzylidene)-6-(4-fluorobenzylidene)cyclohexanone",5.6,uM,=,0.7481880270062004,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
6883,1642157,,,,,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 Î¼l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 Î¼l of ATP solution (in H2O), 20 Î¼l of assay buffer (see below), 5 Î¼l of test sample in 10% DMSO, 10 Î¼l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 Î¼M Na-orthovanadate, 1.2 mM DTT, 50 Î¼g/ml PEG20000, 1 Î¼M [Î³-33P]-ATP (approx. 8Ã10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 Î¼g/ml Phosphatidylserine and 1 Î¼g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 Î¼g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 Î¼M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30Â° C. for 80 minutes. The reaction was stopped with 50 Î¼l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 Î¼l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.28,uM,=,-0.5528419686577808,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6884,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Fc1cccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)c1,"(S)-N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((morpholin-2-ylmethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.061,uM,=,-1.214670164989233,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(COC[C@@H]6CNCCO6)c45)ccc32)cc1
6885,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Cl.O=[N+]([O-])c1ccc2c(c1)sc1c(Nc3cccc(Br)c3)ncnc12,"(3-Bromo-phenyl)-(7-nitro-benzo[4,5]thieno[3,2-d]pyrimidin-4-yl)-amine hydrochloride",0.048,uM,=,-1.3187587626244128,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
6886,431035,10.1021/jm050607w,,,,Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells,CCOc1cc2ncnc(Nc3ccccc3F)c2cc1OCC.Cl,"4-(2'-fluoroanilino)-6,7-diethoxyquinazoline hydrochloride",0.0158,uM,=,-1.8013429130455774,0,c1ccc(Nc2ncnc3ccccc23)cc1
6887,600206,10.1016/j.bmcl.2009.05.060,,,,Inhibition of EGFR-mediated poly(L-glutamic acid L-tyrosine) phosphorylation,C=COC(=O)N(CCN(C)C)/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,vinyl 3-(4-(3-chlorophenylamino)quinazolin-6-yl)-1-(2-(dimethylamino)ethyl)triaz-2-ene-1-carboxylate,0.18,uM,=,-0.744727494896694,0,c1ccc(Nc2ncnc3ccccc23)cc1
6888,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1nc(-c2ccc3cc[nH]c3c2)c2c(N)ncnc21,"3-(1H-indol-6-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",2.9,uM,=,0.4623979978989561,1,c1ncc2c(-c3ccc4cc[nH]c4c3)n[nH]c2n1
6889,1642092,,,,,"Time-Resolved Fluorescence Assay: The kinase activity of EGFR was detected according to time-resolved fluorescence detection technology to evaluate automatic phosphorylation levels. The test compound was dissolved in 100% DMSO, diluted with 25 mM HEPES (pH=7.4) to the desired concentration, added into each well with 10 Î¼L of the test compounds and 10 Î¼L solution containing 5 ng EGFR, then cultured for 10 min at room temperature using the recombinase diluted by 100 mM HEPES with a dilution ratio of 1:80, subsequently added with 10 Î¼L solution containing 20 mM HEPES, 2 mM MnCl2, 100 Î¼M Na3VO4, 1 mM DTT buffer, and 20 Î¼L of 0.1 mM ATP and 50 mM MgCl2 and cultured for 1 h. The positive group in each plate was added with ATP-MgCl2 enzyme, the negative control group without adding with ATP-MgCl2 enzyme, the liquid was sucked out completely after cultured for 1 h, and each well was washed with buffer for three times. The wells were added with 75 Î¼L anti-phosphorylated tyrosine antibody containing 400 ng europium labeling and cultured 1 h, washed, then added with enhancing solution. At the excitation wavelength 340 nm and the emission wavelength 615 nm, the fluorescence intensities were detected by using Victor type 2 time-resolved luminoscope, wherein the inhibitory rate of the compound on automatic phosphorylation: the inhibitory rate of autophosphorylation=100%â[(negative control)/(positive controlânegative control)].",COc1cc(/C=C2\CCC/C(=C\c3ccccc3Cl)C2=O)cc(OC)c1,"(2E,6E)-2-(2-Chlorobenzylidene)-6-(3,5-dimethoxybenzylidene)cyclohexanone",1.54,uM,=,0.1875207208364631,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
6890,2233412,10.1016/j.bmcl.2022.128703,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells using kinase substrate 22 incubated for 30 mins in presence of ATP,C=CC(=O)Oc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC,"4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl acrylate",0.00054,uM,=,-3.2676062401770314,0,c1ccc(Nc2ncnc3ccccc23)cc1
6891,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC[C@H](Oc2cc3c(Nc4ccc(F)c(Cl)c4F)ncnc3cc2OC)C1,"1-((3S)-3-(4-(3-chloro-2,4-difluorophenylamino)-7-methoxyquinazolin-6-yloxy)pyrrolidin-1-yl)prop-2-en-1-one",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3ccc(O[C@H]4CCNC4)cc23)cc1
6892,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)C4CCCCC4)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1,"(S)-3-(2-Chlorophenyl)-1-(1-(cyclohexanecarbonyl)-pyrrolidin-3-yl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)-phenyl)amino)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.0249,uM,=,-1.6038006529042637,0,O=C(C1CCCCC1)N1CC[C@H](N2C(=O)N(c3ccccc3)Cc3cnc(Nc4ccc(N5CCNCC5)cc4)nc32)C1
6893,64442,10.1021/jm9806603,,,,Inhibition of EGF-stimulated autophosphorylation of epidermal growth factor receptor (EGFR) in A431 cells,C=CC(=O)Nc1ccc2ncnc(N3CCc4ccc(Br)cc43)c2c1,"N-[4-(6-Bromo-2,3-dihydro-indol-1-yl)-quinazolin-6-yl]-acrylamide",0.0099,uM,=,-2.00436480540245,0,c1ccc2c(c1)CCN2c1ncnc2ccccc12
6894,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,C#Cc1cccc(Nc2ncnc3cc(OCC)c4c(c23)OCCO4)c1,"5-Ethoxy-N-(3-ethynylphenyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0092,uM,=,-2.036212172654445,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
6895,1639055,,,,,"Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus infected Sf21 cells using poly (Glu,Tyr)4:1 as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence polarization assay",C=CC(=O)N1CC[C@H](Oc2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)C1,1-((3S)-3-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yloxy)pyrrolidin-1-yl)prop-2-en-1-one,0.008,uM,=,-2.096910013008056,0,c1ccc(COc2ccc(Nc3ncnc4ccc(O[C@H]5CCNC5)cc34)cc2)cc1
6896,1772659,10.1016/j.ejmech.2017.06.003,,,,Inhibition of EGFR (unknown origin),Oc1ccc(Nc2nnnc3sc4c(c23)CCC4)cc1,"4-(2,3-Dihydro-1H-8-thia-5,6,7-triaza-cyclopenta[a]inden-4-ylamino)-phenol",38.73,uM,=,1.5880474969860827,1,c1ccc(Nc2nnnc3sc4c(c23)CCC4)cc1
6897,457867,10.1016/j.bmcl.2007.08.020,,,,Inhibition of partially purified EGFR tyrosine kinase from human A431 cells,COc1cc2ncnc(C#CC(C)(C)Cc3ccccc3)c2cc1OC,"4-(3,3-dimethyl-4-phenylbut-1-ynyl)-6,7-dimethoxyquinazoline",0.013,uM,=,-1.8860566476931635,0,C(#Cc1ncnc2ccccc12)CCc1ccccc1
6898,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Oc1ccc(C2CC(c3ccc(Br)cc3)=NN2c2nc(-c3ccccc3)cs2)cc1,"4-(3-(4-bromophenyl)-1-(4-phenylthiazol-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)phenol",22.36,uM,=,1.3494717992143856,1,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
6899,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1cnc(N2CC(O)C2)c2cnc(Nc3ccnc(N4CC[C@@H](O)[C@@](C)(F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(4-((8-(3-hydroxyazetidin-1-yl)-5-isopropyl-2,7-naphthyridin-3-yl)amino)pyrimidin-2-yl)-3-methylpiperidin-4-ol",25.0,uM,=,1.3979400086720375,1,c1cc(Nc2cc3ccnc(N4CCC4)c3cn2)nc(N2CCCCC2)n1
6900,2293062,10.1021/acs.jmedchem.6b00995,,,,Inhibition of EGFR autophosphorylation in human NCI-H292 cells harboring harboring wild type EGFR preincubated for 60 mins followed by EGF stimulation and measured after 8 mins by SULFO-TAG based electrochemiluminescent assay,CC[C@H](C)n1nc(N2CC(C(C)(C)O)C2)c2cnc(Nc3ccnc(-c4cnn(S(=O)(=O)C5CC5)c4)n3)cc21,"(S)-2-(1-(1-(sec-Butyl)-6-((2-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-yl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)azetidin-3-yl)propan-2-ol",0.218,uM,=,-0.6615435063953952,0,O=S(=O)(C1CC1)n1cc(-c2nccc(Nc3cc4[nH]nc(N5CCC5)c4cn3)n2)cn1
6901,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N1CCC(N2CCOCC2)CC1,"N-(4-Methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(4-morpholinopiperidin-1-yl)phenyl)buta-2,3-dienamide",0.0086,uM,=,-2.065501548756432,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCC(N6CCOCC6)CC5)cc4)n3)c[nH]c2c1
6902,339195,10.1016/j.bmcl.2005.12.018,,,,Inhibition of EGFR,Fc1ccc(Nc2ncnc3c2NCc2cc(Br)ccc2O3)cc1Cl,"(8-Bromo-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-(3-chloro-4-fluoro-phenyl)-amine",2.0,uM,=,0.3010299956639812,1,c1ccc(Nc2ncnc3c2NCc2ccccc2O3)cc1
6903,2192552,10.1021/acs.jmedchem.1c01170,,,,Inhibition of EGFR (unknown origin) using peptide substrate in presence of ATP by caliper electrophoresis method,CC(C)(/C=C(/C#N)C(=O)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc21)N1CCOCC1,"(R)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methyl-4-morpholinopent-2-enenitrile",3.0,uM,=,0.4771212547196624,1,O=C(C=CCN1CCOCC1)N1CCC[C@@H]1Cn1nc(-c2ccc(Oc3ccccc3)cc2)c2cncnc21
6904,1586270,10.1016/j.bmc.2016.04.046,,,,Inhibition of wild type human EGFR preincubated for 5 mins followed by ATP addition for 30 mins by HTRF assay,O=C1N[C@H](C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2OCCCN2CCOCC2)CO1,(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-oxooxazolidine-4-carboxamide,0.00454,uM,=,-2.342944147142896,0,O=C1N[C@H](C(=O)Nc2cc3c(Nc4ccccc4)ncnc3cc2OCCCN2CCOCC2)CO1
6905,2278659,10.1016/j.bmcl.2022.129084,,,,Inhibition of EGR-induced EGFR phosphorylation in human A549 cells pretreated for 2 hrs followed by EGF stimulation by immune assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6906,1661441,10.1021/acs.jmedchem.6b01774,,,,Inhibition of human recombinant N-terminal GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 insect cells using KHKKLAEGSAYEEV as substrate after 30 mins in presence of gamma-[32P]ATP by densitometry,Fc1cc(F)cc(NC(=S)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)c1,"1-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3-(3,5-difluorophenyl)thiourea",0.0601,uM,=,-1.2211255279972606,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6907,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,COc1cc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2cc1NC(=O)C#CCCN1CCOCC1,4-(7-methoxy-6-(5-morpholinopent-2-ynamido)quinolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.033,uM,=,-1.4814860601221125,0,O=C(C#CCCN1CCOCC1)Nc1ccc2nccc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1
6908,66725,10.1021/jm970641d,,,,Inhibit of phosphorylation of a tyrosine/glutamic acid copolymer by epidermal growth factor receptor prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography.,OCCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"2-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-ethanol",0.00019,uM,=,-3.721246399047171,0,c1ccc(Nc2ncnc3cnccc23)cc1
6909,2229998,10.1021/acs.jmedchem.1c00876,,,,Inhibition of wild type EGFR (unknown origin),Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccnc4[nH]c(-c5ccccc5)cc34)[nH]2)cc1,"4-[4-(4-Fluorophenyl)-5-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-imidazol-2-yl]phenol",1.0,uM,=,0.0,0,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccccc4)ccnc3[nH]2)cc1
6910,64444,10.1021/jm990482t,,,,Inhibition of EGF-stimulated autophosphorylation of EGFR enzyme in A431 cells detected by immunoblotting,C=CC(=O)Nc1cc2c(Nc3cccc(C)c3)ncnc2cc1OCCCN1CCN(C)CC1,N-{7-[3-(4-Methyl-piperazin-1-yl)-propoxy]-4-m-tolylamino-quinazolin-6-yl}-acrylamide,0.018,uM,=,-1.744727494896694,0,c1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
6911,2233412,10.1016/j.bmcl.2022.128703,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in Sf21 insect cells using kinase substrate 22 incubated for 30 mins in presence of ATP,C=CC(=O)N1CCN(C(=O)Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)[C@H](C)C1,4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl(R)-4-acryloyl-2-methylpiperazine-1-carboxylate,0.00034,uM,=,-3.468521082957745,0,O=C(Oc1ccc2ncnc(Nc3ccccc3)c2c1)N1CCNCC1
6912,987605,10.1016/j.ejmech.2013.09.032,,,,Inhibition of EGFR (unknown origin) using poly-(Glu4-Tyr) as substrate after 1 hr by ELISA-based spectrophotometry,CS(=O)(=O)NCCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1,6-(5-((2-(Methylsulfonamido)ethylamino)methyl)furan-2-yl)-N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)quinazolin-4-amine tosylate,0.0186999999999999,uM,=,-1.728158393463501,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1.c1ccccc1
6913,5170,10.1021/jm970641d,,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine",13.0,uM,=,1.1139433523068367,1,c1ccc(Nc2ncnc3cnccc23)cc1
6914,66904,10.1016/S0960-894X(96)00601-4,,,,Inhibition of the epidermal growth factor receptor.,NCCCn1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)C(F)F)c4)n3)cccc21,"{4-[1-(3-Amino-propyl)-1H-indol-4-yl]-pyrimidin-2-yl}-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-amine",0.53,uM,=,-0.2757241303992109,0,c1ccc(Nc2nccc(-c3cccc4[nH]ccc34)n2)cc1
6915,1761187,10.1016/j.ejmech.2018.01.081,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr by mobility shift assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0023,uM,=,-2.638272163982407,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6916,1329770,10.1039/C2MD00317A,,,,Inhibition of recombinant EGFR (unknown origin) using poly-Glu-Tyr peptide as substrate,C#Cc1cccc(Nc2ncnc3ccc(S(=O)(=O)n4ccc(/C=C/C(=O)Nc5ccccc5N)c4)cc23)c1,(E)-N-(2-aminophenyl)-3-{1-[4-(3-ethynylphenylamino)quinazoline-6-ylsulfonyl]-1H-pyrrol-3-yl}acrylamide,1.3,uM,=,0.1139433523068367,1,O=C(/C=C/c1ccn(S(=O)(=O)c2ccc3ncnc(Nc4ccccc4)c3c2)c1)Nc1ccccc1
6917,566594,10.1016/j.bmcl.2009.01.080,,,,Inhibition of EGFR by HTRF assay,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1,"(3R,5S)-5-((4-(1-benzyl-1H-indol-5-ylamino)thieno[3,2-d]pyrimidin-6-yl)ethynyl)pyrrolidin-3-yl morpholine-4-carboxylate",0.09,uM,=,-1.0457574905606752,0,O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1
6918,63759,10.1021/jm960879m,,,,"Inhibition of phosphorylation of phospholipase C gamma1 by Epidermal growth factor receptor, from human A431 carcinoma cell vesicles",CN(C)CCNc1ncc2ncnc(Nc3cccc(Br)c3)c2n1,"N*8*-(3-Bromo-phenyl)-N*2*-(2-dimethylamino-ethyl)-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.035,uM,=,-1.4559319556497243,0,c1ccc(Nc2ncnc3cncnc23)cc1
6919,980992,10.1021/jm400822z,,,,Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay,COc1ccc(NC(=O)/C=C/CN(C)C)cc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"(E)-N-(3-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)-4-(dimethylamino)but-2-enamide",23.0,uM,=,1.3617278360175928,1,c1ccc(Nc2nccc(-c3cnn4ccccc34)n2)cc1
6920,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1CN1CCC[C@H]1C(N)=O,(S)-1-((4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)pyrrolidine-2-carboxamide,0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ncnc3ccc(CN4CCCC4)cc23)cc1
6921,1527997,,,,,"ELISA-Based Kinase Assay: Inhibition of erbB tyrosine kinase activity was assessed using an ELISA-based receptor tyrosine kinase assay. Kinase reactions (50 mM HEPES, pH 7.4, 125 mM NaCl, 10 mM MgCl2, 100 Î¼M sodium orthovanadate, 2 mM dithiothreitol, 20 uM ATP, test compound or vehicle control and 1-5 nM GST-erbB per 50 uL reaction) were run in 96-well plates coated with 0.25 mg/ml poly-Glu-Tyr (Sigma). The reactions were incubated for 6 minutes at room temperature while shaking. Kinase reactions were stopped by removal of reaction mixture, then wells were washed with wash buffer comprising 3% Bovine Serum Albumin and 0.1% Tween 20 in Phosphate Buffered Saline (PBS). Phosphorylated tyrosine residues were detected by adding 0.2 Î¼g/ml anti-phosphotyrosine antibody (Oncogene Ab-4; 50 Î¼L/well) coupled to Horse Radish Peroxidase (HRP) for 25 minutes while shaking at room temperature.",O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,"US8623883, No. 7",0.0113499999999999,uM,=,-1.9450041384708583,0,O=C(/C=C/CN1CCCCC1)Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1
6922,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,O=[N+]([O-])c1cccc2ncnc(NCc3ccccc3)c12,Benzyl-(5-nitro-quinazolin-4-yl)-amine,8.0,uM,=,0.9030899869919436,1,c1ccc(CNc2ncnc3ccccc23)cc1
6923,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(C)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(3-methyl-benzyloxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide,0.111,uM,=,-0.9546770212133424,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
6924,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1NC(=O)/C=C/CN1[C@H](C)CNC[C@@H]1C,"(E)-N-(4-(1-Benzyl-1H-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-((2R,6S)-2,6-dimethylpiperazin-1-yl)but-2-enamide",0.072,uM,=,-1.1426675035687317,0,O=C(/C=C/CN1CCNCC1)Nc1ccc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2c1
6925,1646279,10.1016/j.ejmech.2016.12.014,,,,Inhibition of EGF induced EGFR phosphorylation in human KB cells preincubated for 90 mins followed by EGF addition for 5 mins by sandwich ELISA method,Cc1ccccc1Cc1nnc(Cc2nc3ccccc3[nH]2)o1,"2-((1H-benzo[d]imidazol-2-yl)methyl)-5-(2-methylbenzyl)-1,3,4-oxadiazole",50.0,uM,=,1.6989700043360187,1,c1ccc(Cc2nnc(Cc3nc4ccccc4[nH]3)o2)cc1
6926,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,COc1cc2ncc(C#N)c(Nc3ccc(Sc4ncccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyrimidin-2-ylsulfanyl)-phenylamino]-3-cyano-7-methoxy-quinolin-6-yl}-amide,0.403,uM,=,-0.3946949538588905,0,c1cnc(Sc2ccc(Nc3ccnc4ccccc34)cc2)nc1
6927,766557,10.1016/j.bmcl.2011.07.010,,,,Inhibition of recombinant (His)6-tagged EGFR cytoplasmic domain (645-1186) autophosphorylation pre-incubated for 10 mins measured after 1 hrs by DELFIA based time-resolved fluorimetry assay,Cc1ccc(C2=NN(c3nc(-c4ccc(Cl)cc4)cs3)C(c3ccc(O)cc3)C2)cc1C,"4-(1-(4-(4-chlorophenyl)thiazol-2-yl)-3-(3,4-dimethylphenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol",0.97,uM,=,-0.0132282657337551,0,c1ccc(C2=NN(c3nc(-c4ccccc4)cs3)C(c3ccccc3)C2)cc1
6928,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COc1cc(NC(=O)/C=C/CN(C)C)cc2c(Nc3cccc(Br)c3)c(C#N)cnc12,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-8-methoxy-quinolin-6-yl]-amide,2.88,uM,=,0.4593924877592308,1,c1ccc(Nc2ccnc3ccccc23)cc1
6929,1547891,10.1016/j.bmc.2015.12.038,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,COc1ccc(-c2cc(NC(=O)Nc3nccs3)cc(C(F)(F)F)c2)cn1,1-(3-(6-Methoxypyridin-3-yl)-5-(trifluoromethyl)phenyl)-3-(thiazol-2-yl)urea,0.47666,uM,=,-0.3217912913457748,0,O=C(Nc1cccc(-c2cccnc2)c1)Nc1nccs1
6930,2153185,10.1016/j.ejmech.2021.113845,,,,Inhibition of wild type EGFR (unknown origin) measured by ELISA,C=C(Cl)C(=O)Nc1cc(Nc2ncc(Cl)c(N3CCc4sccc4C3)n2)c(OC)cc1N(C)CCN(C)C,"2-Chloro-N-(5-((5-chloro-4-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.0963,uM,=,-1.0163737128754655,0,c1ccc(Nc2nccc(N3CCc4sccc4C3)n2)cc1
6931,65106,10.1021/jm00032a020,,,,Inhibition of EGF-stimulated DNA synthesis in ER 22 (EGF-receptor expressing) cells,CCOC(=O)Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O,"(5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-phenyl)-acetic acid ethyl ester",20.0,uM,=,1.3010299956639813,1,C(=N/c1ccccc1)\c1ccccc1
6932,1914433,10.1021/acs.jnatprod.9b00659,,,,Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay,CC1(C)CC[C@]2(C(=O)OCCO[N+](=O)[O-])CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1,2'-Nitroxyethyl-3beta-hydroxyolean-12-en-28-oic acid,0.11,uM,=,-0.958607314841775,0,C1=C2C(CCC3CCCC[C@@H]23)C2CC[C@H]3CCCCC3[C@H]2C1
6933,806753,10.1016/j.bmc.2012.01.051,,,,Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1ccc(C2CC(c3ccc(F)cc3)=NN2C2=NC(=O)CS2)cc1,"2-(3-(4-Fluorophenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4(5H)-one",8.36,uM,=,0.9222062774390164,1,O=C1CSC(N2N=C(c3ccccc3)CC2c2ccccc2)=N1
6934,1861352,10.1016/j.ejmech.2019.07.055,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,COc1cc2c(Nc3ccc(F)c(F)c3)ncnc2cc1OCCOCCNC(=O)Cn1cnc([N+](=O)[O-])n1,"N-{2-[2-({4-[(3,4-Difluorophenyl)amino]-6-methoxyquinazolin-7-yl}oxy)ethoxy]ethyl}-2-(3-nitro-[1,2,4]triazol-1-yl)acetamide",0.0037,uM,=,-2.431798275933005,0,O=C(Cn1cncn1)NCCOCCOc1ccc2c(Nc3ccccc3)ncnc2c1
6935,82323,10.1021/jm9904295,,,,Inhibitory activity against ligand-dependent EGF cell proliferation,COc1cccc(-c2ccc3c(c2)NC(=O)/C3=C\c2[nH]c(C)c(CCC(=O)O)c2C)c1,"3-{5-[6-(3-Methoxy-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propionic acid",24.1,uM,=,1.3820170425748683,1,O=C1Nc2cc(-c3ccccc3)ccc2/C1=C/c1ccc[nH]1
6936,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3occc(=O)c3c1)nn2C1CCCC1,"6-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4H-chromen-4-one",100.0,uM,=,2.0,1,O=c1ccoc2ccc(-c3nn(C4CCCC4)c4ncncc34)cc12
6937,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2cc(-c3cn4c5c(cccc35)CCC4)ncn2)c(OC)cc1N(C)CCN(C)C,"N-(5-((6-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-4-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.0031,uM,=,-2.508638306165728,0,c1ccc(Nc2cc(-c3cn4c5c(cccc35)CCC4)ncn2)cc1
6938,2018691,10.1016/j.bmc.2020.115674,,,,Inhibition of EGFR-TK (unknown origin) relative to control,Cc1cc(NC(=O)CN2CCN(c3ccccc3)CC2)no1,N-(5-Methylisoxazol-3-yl)-2-(4-phenylpiperazin-1-yl)acetamide,0.064,uM,=,-1.193820026016113,0,O=C(CN1CCN(c2ccccc2)CC1)Nc1ccon1
6939,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,C[C@H](NC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1)C(=O)N[C@@H](C)C(=O)OC(C)(C)C,(S)-tert-butyl 2-((S)-2-(4-(4-(2-nitrovinyl)phenoxysulfonyl)benzamido)propanamido)propanoate,40.0,uM,=,1.6020599913279625,1,O=S(=O)(Oc1ccccc1)c1ccccc1
6940,1663475,10.1021/acs.jmedchem.7b00316,,,,Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6941,982642,10.1016/j.bmcl.2013.08.008,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,0.0179,uM,=,-1.747146969020107,0,c1ccc(Nc2ncnc3ccccc23)cc1
6942,958682,10.1021/jm400463q,,,,Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC(=O)OCCOc5no[n+]([O-])c5S(=O)(=O)c5ccccc5)CC4)cc3OC)ncc2Cl)c1,"4-(2-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide",0.059,uM,=,-1.2291479883578558,0,O=C(CN1CCN(c2ccc(Nc3nccc(Oc4ccccc4)n3)cc2)CC1)OCCOc1no[nH+]c1S(=O)(=O)c1ccccc1
6943,1829742,10.1021/acs.jmedchem.8b01612,,,,Inhibition of wild type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system after 1 hr in presence of ULight-labeled peptide substrate and ATP by LANCE ultra kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0058,uM,=,-2.2365720064370627,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6944,396273,10.1016/j.bmcl.2006.05.090,,,,Inhibition of ErbB1,O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1,N-(4-(3-fluorobenzyloxy)-3-(trifluoromethyl)phenyl)-6-(5-((2-(phenylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,0.019,uM,=,-1.7212463990471711,0,O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1)c1ccccc1
6945,1291542,10.1016/j.bmcl.2013.12.079,,,,Inhibition of EGFR (unknown origin) after 10 mins,C#Cc1cccc(Nc2ncnc3cc4c(cc23)N(C(=O)/C=C/CN2CCOCC2)CCO4)c1,"1-(4-(3-ethynylphenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-morpholinobut-2-en-1-one",0.012,uM,=,-1.9208187539523751,0,O=C(/C=C/CN1CCOCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
6946,1528326,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-morpholinophenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.0055,uM,=,-2.2596373105057563,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
6947,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C(C)C)C(C)C,(2E)-N-[4-(3-Chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(diisopropylamino)-2-butenamide,0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
6948,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,O=C(/C=C/CNC1CC1)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCC(F)(F)F,"(E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-(2,2,2-trifluoroethoxy)quinazolin-6-yl)-4-(cyclopropylamino)but-2-enamide",0.0069,uM,=,-2.161150909262745,0,O=C(/C=C/CNC1CC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
6949,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,C[C@@H](Nc1ncnc2oc(-c3ccc(C#N)cc3)cc12)c1ccccc1,"(R)-4-(4-((1-phenylethyl)amino)furo[2,3-d]pyrimidin-6-yl)benzonitrile",0.044,uM,=,-1.3565473235138126,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
6950,2227703,10.1021/acs.jmedchem.2c00704,,,,Inhibition of N-terminal GST tagged recombinant wild type human EGFR expressed in baculovirus infected Sf9 insect cells expression system using 5-FAM-EEPLYINSFPAKKK-CONH peptide as substrate preincubated for 10 mins followed by peptide substrate addition in presence of ATP,CC[C@]1(F)CN(c2nccc(Nc3cc4c(C(C)C)ccc(N5C[C@H](CS(C)(=O)=O)[C@H]5C)c4cn3)n2)CC[C@H]1O,(3S)-3-ethyl-3-fluoro-1-(5-((5-isopropyl-8-((2R)-2-methyl-3-(methylsulfonyl)azetidin-1-yl)isoquinolin-3-yl)amino)pyrimidin-2-yl)piperidin-4-ol,0.761,uM,=,-0.1186153432294271,0,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
6951,611747,10.1016/j.bmc.2009.11.037,,,,Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA,O=C(Nc1cccc2ccccc12)c1ccc(N(CCCl)CCCl)cc1,4-(Bis(2-chloroethyl)amino)-N-(1-naphthyl)benzamide,0.09,uM,=,-1.0457574905606752,0,O=C(Nc1cccc2ccccc12)c1ccccc1
6952,66565,10.1021/jm970124v,,,,Inhibitory activity against epidermal growth factor receptor tyrosine kinase.,Nc1ccc(-c2[nH]nc3ncnc(Nc4cccc(Cl)c4)c23)cc1,"[3-(4-Amino-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-chloro-phenyl)-amine",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3n[nH]c(-c4ccccc4)c23)cc1
6953,2147415,10.1021/acs.jmedchem.1c01055,,,,Inhibition of Wild type EGFR (unknown origin),COc1cc(N2CCC(N(C)C)CC2)c(-c2cn[nH]c2)cc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,(2-((5-Chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxy-5-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide,0.0009,uM,=,-3.0457574905606752,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCCCC4)c(-c4cn[nH]c4)c3)n2)cc1
6954,1701496,10.1021/acs.jmedchem.7b00178,,,,Inhibition of recombinant human GST-tagged wild type EGFR ( 668 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method,C=CC(=O)Nc1cccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccc(F)cc4)ccnc3[nH]2)c1,"N-(3-(4-(4-(4-Fluorophenyl)-2-phenyl-1H-imidazol-5-yl)-1Hpyrrolo[2,3-b]pyridin-2-yl)phenyl)acrylamide",0.0432,uM,=,-1.3645162531850878,0,c1ccc(-c2cc3c(-c4[nH]c(-c5ccccc5)nc4-c4ccccc4)ccnc3[nH]2)cc1
6955,934773,10.1016/j.bmc.2012.11.031,,,,Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry,COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,"1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione",8.6,uM,=,0.9344984512435676,1,O=C(/C=C/C=C/c1ccccc1)/C=C/c1ccccc1
6956,1586270,10.1016/j.bmc.2016.04.046,,,,Inhibition of wild type human EGFR preincubated for 5 mins followed by ATP addition for 30 mins by HTRF assay,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1NC(=O)[C@@H]1COC(=O)N1,(S)-N-(4-((3-Bromophenyl)amino)-7-methoxyquinazolin-6-yl)-2-oxooxazolidine-4-carboxamide,0.00047,uM,=,-3.3279021420642825,0,O=C1N[C@H](C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)CO1
6957,1913522,10.1021/acs.jmedchem.9b00722,,,,"Inhibition of GST-tagged human EGFR kinase domain (696 to 1022 residues) using poly(Glu, Tyr) 4:1 substrate incubated for 60 mins by kinase-Glo plus luminescent kinase assay",CCN(CC)C/C=C/C(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"(2E)-4-(Diethylamino)-N-[3-(4-{[(1S)-2-hydroxy-1-phenylethyl]-amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]but-2-enamide",0.014,uM,=,-1.853871964321762,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
6958,1914926,10.1016/j.ejmech.2019.111943,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669-1210 AA) expressed in baculovirus using FAM-labelled peptide as substrate pre-incubated for 10 mins followed by substrate addition by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.00028,uM,=,-3.552841968657781,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
6959,63610,10.1021/jm00043a002,,,,Inhibition of Epidermal growth factor receptor tyrosine kinase,Oc1cc2cc(-c3ccncc3)cnc2cc1O,"3-Pyridin-4-yl-quinoline-6,7-diol",5.0,uM,=,0.6989700043360189,1,c1ccc2ncc(-c3ccncc3)cc2c1
6960,1632252,10.1016/j.bmc.2016.12.002,,,,Inhibition of EGFR (unknown origin),COc1cc2c(Oc3ccc(NC(=O)c4cn(-c5ccccc5OC)cn4)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,N-(3-Fluoro-4-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-1-(2-methoxyphenyl)-1H-imidazole-4-carboxamide,0.69,uM,=,-0.1611509092627447,0,O=C(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1cn(-c2ccccc2)cn1
6961,67061,10.1016/s0960-894x(01)00079-8,,,,Inhibition of Epidermal growth factor receptor (EGF-R) tyrosine kinase activity ,Nc1ncnc2c1c(-c1ccccc1)cn2C(CO)Cc1ccccc1,"2-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-3-phenyl-propan-1-ol",0.44,uM,=,-0.3565473235138126,0,c1ccc(CCn2cc(-c3ccccc3)c3cncnc32)cc1
6962,1566936,10.1021/acs.jmedchem.5b01633,,,,Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.15,uM,=,-0.8239087409443188,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6963,961867,10.1016/j.bmc.2013.03.053,,,,Inhibition of recombinant EGFR (unknown origin) after 10 mins by DELFIA/time-resolved fluorometry,CN1CCN(Cc2ccc(C(=O)Nc3ccc(-c4cncc(C#N)c4Nc4ccc(F)c(Cl)c4)cc3)cc2)CC1,N-(4-(4-((3-Chloro-4-fluorophenyl)amino)-5-cyanopyridin-3-yl)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide,3.0,uM,=,0.4771212547196624,1,O=C(Nc1ccc(-c2cnccc2Nc2ccccc2)cc1)c1ccc(CN2CCNCC2)cc1
6964,942125,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin) using biotinylated-PTP1B (Tyr66) as substrate incubated for 5 mins prior to substrate addition measured after 1 hr by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC,"(3-Chloro-4-fluoro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",0.0038,uM,=,-2.42021640338319,0,c1ccc(Nc2ncnc3ccccc23)cc1
6965,2102324,10.1016/j.bmcl.2021.128308,,,,Inhibition of EGFR (unknown origin),O=C(CSc1nc2ccccc2c(=O)n1Cc1ccc2c(c1)OCO2)Nc1ccccc1F,"2-(3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-oxo-3,4-dihydroquinazolin-2-ylthio)-N-(2-fluorophenyl)acetamide",0.2071,uM,=,-0.6838199011065473,0,O=C(CSc1nc2ccccc2c(=O)n1Cc1ccc2c(c1)OCO2)Nc1ccccc1
6966,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CCl)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"1-(2-(2-chloroacetoxy)ethyl)-8-(3-Chloro-4-fluorophenylamino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.33,uM,=,-0.4814860601221125,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
6967,1668446,10.1016/j.bmcl.2017.04.014,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,178.0,uM,=,2.250420002308894,1,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
6968,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-{4-(3-Chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl}propanamide,0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
6969,66590,10.1021/jm9508651,,,,Inhibitory potency against isolated epidermal growth factor receptor (EGFR) from human A431 carcinoma cells,CNc1cc2c(Nc3ccccc3)ncnc2cn1,"N*6*-Methyl-N*4*-phenyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3cnccc23)cc1
6970,66591,10.1021/jm00032a020,,,,Inhibitory potency against protein tyrosine kinase activity associated with EGFR was evaluated using ER 22 cell membrane,O=C(O)Cc1cc(/N=C/c2cc(O)ccc2O)ccc1O,"(5-{[1-(2,5-Dihydroxy-phenyl)-meth-(E)-ylidene]-amino}-2-hydroxy-phenyl)-acetic acid",35.0,uM,=,1.5440680443502757,1,C(=N/c1ccccc1)\c1ccccc1
6971,512831,10.1016/j.bmcl.2008.07.057,,,,Inhibition of EGFR,Nc1ncnc(Nc2ccc(OCc3ccccc3)c(Cl)c2)c1C(=O)OCCN1CCOCC1,2-morpholinoethyl 4-amino-6-(4-(benzyloxy)-3-chlorophenylamino)pyrimidine-5-carboxylate,0.15,uM,=,-0.8239087409443188,0,O=C(OCCN1CCOCC1)c1cncnc1Nc1ccc(OCc2ccccc2)cc1
6972,354894,10.1016/j.bmcl.2006.02.025,,,,Inhibition of EGFR in presence of 2 uM ATP,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](CN(C)C)C(N)=O,(S)-2-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-3-(dimethylamino)propanamide,0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
6973,770250,10.1016/j.bmc.2011.08.038,,,,Inhibition of human recombinant (His)6-tagged EGFR autophosphorylation pre-incubated for 10 mins by DELFIA/Time-resolved fluorimetry,COc1ccc(CC(=O)NS(=O)(=O)c2ccc(F)cc2)cc1,N-(4-Fluorophenylsulfonyl)-2-(4-methoxy phenyl)acetamide,21.84,uM,=,1.3392526340326996,1,O=C(Cc1ccccc1)NS(=O)(=O)c1ccccc1
6974,1909512,10.1016/j.ejmech.2018.11.069,,,,Inhibition of wild-type EGFR (unknown origin) using substrate-biotin by ELISA-based mobility shift assay,C=CC(=O)Nc1cc(Nc2ncc(C#N)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(5-(5-cyano-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,0.311,uM,=,-0.5072396109731625,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6975,2121824,10.1016/j.ejmech.2021.113786,,,,Inhibition of wild type EGFR (unknown origin) using fluoresceine-labelled poly-GT peptide as substrate preincubated with enzyme for 3 hrs followed by substrate and ATP addition by TR-FRET assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.00062,uM,=,-3.207608310501746,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6976,66571,10.1021/jm960225d,,,,Inhibitory activity of compound against Epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{2-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-ethyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",113.0,uM,=,2.05307844348342,1,O=C(C=Cc1ccccc1)NCCNC(=O)/C=C/c1ccccc1
6977,1769307,10.1016/j.bmc.2018.02.029,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,C=CC(=O)Nc1cc(Nc2ncc3ncn(-c4ccc(Cl)cc4)c3n2)c(OC)cc1N(C)CCN(C)C,N-(5-((9-(4-chlorophenyl)-9H-purin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,0.0156,uM,=,-1.8068754016455384,0,c1ccc(Nc2ncc3ncn(-c4ccccc4)c3n2)cc1
6978,1500854,10.1016/j.bmc.2015.04.065,,,,Inhibition of recombinant EGFR (unknown origin) assessed as inhibition of autophosphorylation after 1 hr by DELFIA/Time-resolved fluorometry,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)S/C1=C/c1cccs1,"(S,E)-N-(4-((3-Chlorophenyl)amino)quinazolin-6-yl)-1-(4-oxo-5-(thiophen-2-ylmethylene)-4,5-dihydrothiazol-2-yl)-pyrrolidine-2-carboxamide",8.1,uM,=,0.9084850188786496,1,O=C1N=C(N2CCC[C@H]2C(=O)Nc2ccc3ncnc(Nc4ccccc4)c3c2)S/C1=C/c1cccs1
6979,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=C[S+]([O-])c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"(3-Bromo-phenyl)-(6-ethenesulfinyl-pyrido[3,4-d]pyrimidin-4-yl)-amine",0.0046,uM,=,-2.337242168318426,0,c1ccc(Nc2ncnc3cnccc23)cc1
6980,1693612,10.1016/j.bmc.2017.06.004,,,,Inhibition of wild-type EGFR (unknown origin) using Tyr 4 peptide as substrate in presence of ATP by Z-LYTE kinase assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4c(F)cccc34)n2)c(OC)cc1N(C)CC[N+](C)(C)[O-],"2-((2-Acrylamido-4-((4-(7-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-methoxyphenyl)(methyl)amino)-N,Ndimethylethan-1-amine oxide",0.5952000000000001,uM,=,-0.2253370774621776,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
6981,63768,10.1016/s0960-894x(01)00344-4,,,,In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCNC(C)C,(3-Chloro-4-fluoro-phenyl)-[6-(2-isopropylamino-ethoxy)-7-methoxy-quinazolin-4-yl]-amine,0.31,uM,=,-0.5086383061657274,0,c1ccc(Nc2ncnc3ccccc23)cc1
6982,1527789,,,,,Inhibition Assay: EGFR inhibitory activity of compounds of the present invention is quantified employing the EGFR HTRF assay.,CN1CCC[C@H]1/C=C/C(=O)N1CCc2c(sc3ncnc(Nc4ccc(F)c(Cl)c4)c23)C1,"US8524722, 14",0.001,uM,=,-3.0,0,O=C(/C=C/[C@@H]1CCCN1)N1CCc2c(sc3ncnc(Nc4ccccc4)c23)C1
6983,1583973,10.1016/j.bmc.2016.05.063,,,,Inhibition of recombinant human EGFR expressed in baculovirus by fluorescence based assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.000509,uM,=,-3.2932822176632413,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
6984,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc(F)c(C#N)c2)c2c(N)ncnc21,"5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorobenzonitrile",100.0,uM,=,2.0,1,c1ccc(-c2n[nH]c3ncncc23)cc1
6985,1577081,10.1016/j.bmc.2016.01.003,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation preincubated for 30 mins followed by ATP addition measured after 1 hr by kinase-glo luminescence assay,Clc1cccc(Nc2ncnc3cc(OCCCN4CCOCC4)c4c(c23)OCCO4)c1,"N-(3-Chlorophenyl)-5-(3-morpholinopropoxy)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.02195,uM,=,-1.65856547542186,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c4c(c23)OCCO4)cc1
6986,1924071,10.1021/acs.jmedchem.6b00403,,,,"Inhibition of wild type EGFR kinase domain (unknown origin) expressed using baculovirus expression system incubated for 1 hr using Poly(Glu,Tyr) 4:1 by ELISA method",C=CC(=O)Nc1cccc(-n2c(=O)c(=O)n(C(C)C)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(5-isopropyl-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)-6,7-dioxo-6,7-dihydropteridin-8(5H)-yl)phenyl)acrylamide",0.002,uM,=,-2.6989700043360187,0,O=c1[nH]c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n(-c2ccccc2)c1=O
6987,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",CCOC(=O)Cc1cc(NCc2cc(O)ccc2O)ccc1O,"[5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-phenyl]-acetic acid ethyl ester",11.0,uM,=,1.0413926851582251,1,c1ccc(CNc2ccccc2)cc1
6988,807903,10.1016/j.bmc.2012.01.029,,,,Inhibition of EGF-induced EGFR autophosphorylation in human A431 cells incubated for 60 mins prior to EGF-induction measured after 10 mins by phosphotyrosine ELISA,Cc1ccccc1Cn1ccc2c(Nc3cccc(Br)c3)nc(N)nc21,"N4-(3-bromophenyl)-7-(2-methylbenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",113.3,uM,=,2.0542299098633974,1,c1ccc(Cn2ccc3c(Nc4ccccc4)ncnc32)cc1
6989,86512,10.1021/jm00110a022,,,,Inhibition of HER14 (human EGFR overexpressing) cell proliferation.,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1,"N-Benzyl-2-cyano-3-(3,4-dihydroxy-phenyl)-acrylamide",3.5,uM,=,0.5440680443502757,1,O=C(C=Cc1ccccc1)NCc1ccccc1
6990,2291428,10.1021/acs.jmedchem.2c01938,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hrs followed by substrate addition and measured after 1 hrs in the presence of ATP at Km concentration by TR-FRET assay,C=CC(=O)N1CCC(C2CCNc3c(C(N)=O)c(-c4cc(OC)c(Cl)c(OC)c4)nn32)CC1,"7-(1-acryloylpiperidin-4-yl)-2-(4-chloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",1.76,uM,=,0.2455126678141498,1,c1ccc(-c2cc3n(n2)C(C2CCNCC2)CCN3)cc1
6991,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Nc1ncnc2c1c(-c1ccc3[nH]ncc3c1)nn2C1CCCC1,"1-cyclopentyl-3-(1H-indazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.571,uM,=,-0.243363891754152,0,c1ncc2c(-c3ccc4[nH]ncc4c3)nn(C3CCCC3)c2n1
6992,1368204,10.1016/j.bmc.2014.04.049,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay,COc1ccc(N(C)c2nc(C)nc3oc(C)cc23)cc1,"N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d]pyrimidin-4-amine",0.0682,uM,=,-1.1662156253435212,0,c1ccc(Nc2ncnc3occc23)cc1
6993,312997,10.1021/jm040159c,,,,Inhibition of human epidermal growth factor receptor (EGFR) autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccc4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCC1,4-Pyrrolidin-1-yl-but-2-enoic acid [4-(4-benzyloxy-3-chloro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.078,uM,=,-1.1079053973095196,0,O=C(/C=C/CN1CCCC1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
6994,1702577,10.1016/j.ejmech.2017.04.036,,,,Inhibition of human recombinant cytoplasmic GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 15 mins followed by substrate addition measured after 60 mins by FRET-based Z'-Lyte assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N1CCN(C)CC1,"N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl)acrylamide",0.8774,uM,=,-0.0568023699310736,0,c1cc2c3c(c1)c(-c1ccnc(Nc4ccc(N5CCNCC5)cc4)n1)cn3CCC2
6995,1528598,,,,,"In Vitro Kinase Assay: In vitro kinase analysis was performed by using HTScan EGF Receptor Kinase Assay Kit (#7909) and HTScan HER2/ErbB2 Kinase Assay Kit (#7058) from Cell Signaling Technology Company. Operation steps refer to the specification of the used kits, and the method was used to measure the inhibition effects of the compound to be tested on substrate peptide phosphorylation of EGFR or Her2 receptor tyrosine kinase. At room temperature, ATP and substrate peptide as well as the compound to be tested were incubated in kinase reaction buffer, after a period of incubation, a stop buffer was added to terminate the reaction and the sample was transferred to a streptavidin-coated 96-well plate, the plate was washed and the phosphorylation level of substrate peptide was detected by using HRP-marked antibody against substrate phosphorylation, colorated with TMB, terminated the reaction with 2M sulfuric acid. Absorption at 450 nm wavelength was detected, and IC50 value (Î¼M) was calculated.",CS(=O)(=O)NCCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,"US8916574, Compound 4",0.01554,uM,=,-1.8085489855351045,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
6996,67052,10.1016/0960-894X(94)80004-9,,,,Inhibitory activity against protein tyrosine kinase of Epidermal growth factor receptor was determined,CO[C@H]1[C@@H](N(C)C(=O)c2cccnc2)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,"3-methoxy-2-methyl-4-methyl(3-pyridyl)carboxamido-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaene",8.18,uM,=,0.912753303671323,1,O=C(N[C@@H]1CC2O[C@@H](C1)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O)c1cccnc1
6997,66714,10.1016/s0960-894x(02)00364-5,,,,Inhibitory activity towards tyrosine phosphorylation for the epidermal growth factor-receptor kinase,CCN(CC)CCNC(=O)c1cc(C)c(/C=C2\C(=O)Nc3ncnc(Nc4ccc(Cl)cc4F)c32)[nH]1,"5-[4-(4-Chloro-2-fluoro-phenylamino)-6-oxo-6,7-dihydro-pyrrolo[2,3-d]pyrimidin-(5Z)-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)-amide",0.45,uM,=,-0.3467874862246563,0,O=C1Nc2ncnc(Nc3ccccc3)c2/C1=C/c1ccc[nH]1
6998,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,CC(C)n1nc(-c2ccc3c(N)n[nH]c3c2)c2c(N)ncnc21,"3-(3-amino-1H-indazol-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.207,uM,=,-0.6840296545430823,0,c1ncc2c(-c3ccc4cn[nH]c4c3)n[nH]c2n1
6999,607157,10.1016/j.bmc.2009.10.054,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C(Nc1ccccc1)N(Cc1ccc(O)cc1)Cc1cc(Br)cc(Br)c1O,"1-(3,5-Dibromo-2-hydroxybenzyl)-1-(4-hydroxybenzyl)-3-phenylurea",1.12,uM,=,0.0492180226701816,1,O=C(Nc1ccccc1)N(Cc1ccccc1)Cc1ccccc1
7000,2272590,10.1016/j.ejmech.2021.113865,,,,Inhibition of human EGFR,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.02916,uM,=,-1.535212480354063,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
7001,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,COc1cc2nc(Nc3cc(C)[nH]n3)nc(Nc3cccc(-c4nc5ccccc5s4)c3)c2cc1OC,"N4-(3-(benzo[d]thiazol-2-yl)phenyl)-6,7-dimethoxy-N2-(5-methyl-1H-pyrazol-3-yl)quinazoline-2,4-diamine",3.3,uM,=,0.5185139398778875,1,c1cc(Nc2nc(Nc3cc[nH]n3)nc3ccccc23)cc(-c2nc3ccccc3s2)c1
7002,63780,10.1016/j.bmcl.2004.01.034,,,,Inhibition of epidermal growth factor receptor kinase autophosphorylation,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.0975999999999999,uM,=,-1.0105501823333085,0,c1ccc(Nc2ccnc3ccccc23)cc1
7003,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",CN(C)C/C=C/C(=O)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CC1,"US9181263, 8::US9278100, 8",0.0834,uM,=,-1.0788339493622612,0,c1ccc(Oc2ccc(-c3nn(C4CCCCC4)c4ncncc34)cc2)cc1
7004,1520607,10.1016/j.ejmech.2015.08.026,,,,Inhibition of EGFR (unknown origin) by ELISA method,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-Chloro-4-(3-fluorobenzyloxy)phenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)acrylamide,0.5604,uM,=,-0.251501873386263,0,c1ccc(COc2ccc(Nc3ncnc4cc(O[C@H]5CCOC5)ccc34)cc2)cc1
7005,436426,10.1021/jm070144p,,,,Inhibition of EGFR tyrosine kinase expressed in A431 cells,CN(C)CCN/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,"1-{4-[(3-chlorophenyl)amino-6-quinazolinyl}-3-(2-N,N-dimethylaminoethyl)triazene",0.037,uM,=,-1.431798275933005,0,c1ccc(Nc2ncnc3ccccc23)cc1
7006,1829742,10.1021/acs.jmedchem.8b01612,,,,Inhibition of wild type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system after 1 hr in presence of ULight-labeled peptide substrate and ATP by LANCE ultra kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCNCCNCC1,"6-(3-(1,4,7-Triazonan-1-yl)propoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine",0.0083,uM,=,-2.0809219076239263,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCNCCNCC4)cc23)cc1
7007,1614965,10.1016/j.ejmech.2016.04.054,,,,Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus by Z'-LYTE assay,C[C@@H](Nc1ncnc2oc(-c3ccc(NCCN(C)C)cc3)cc12)c1ccccc1,"(R)-N1, N1-Dimethyl-N2-(4-(4-((1-phenylethyl)amino)furo[2,3-d]pyrimidin-6-yl)phenyl)ethane-1,2-diamine",0.0004,uM,=,-3.397940008672037,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
7008,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Nc1cc2sc3c(Nc4cccc(Br)c4)ncnc3c2cc1F,"N*4*-(3-Bromo-phenyl)-8-fluoro-benzo[4,5]thieno[3,2-d]pyrimidine-4,7-diamine",0.001,uM,=,-3.0,0,c1ccc(Nc2ncnc3c2sc2ccccc23)cc1
7009,1869224,10.1021/acs.jmedchem.8b01391,,,,Inhibition of wild type EGFR (unknown origin) by bioluminescent ADP-glo kinase assay,COc1ccc(-c2cc3ncnc(Nc4cc(OC)c(OC)c(OC)c4)c3s2)cc1,"6-(4-Methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)thieno[3,2-d]-pyrimidin-4-amine",0.052,uM,=,-1.2839966563652008,0,c1ccc(Nc2ncnc3cc(-c4ccccc4)sc23)cc1
7010,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCCC1,(2E)-N-(7-Ethoxy-4-{[1-(phenylsulfonyl)-1H-indol-5-yl]amino}-6-quinazolinyl)-4-(1-pyrrolidinyl)-2-butenamide,0.053,uM,=,-1.275724130399211,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c3)c2c1
7011,1338416,10.1016/j.ejmech.2014.01.018,,,,Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1nn(-c2ccc(Cl)cc2)c(Cl)c1C1C(C#N)=C(N)N(c2cccnc2)C2=C1C(=O)CC(C)(C)C2,"2-Amino-4-(5-chloro-1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl)-7,7-dimethyl-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile",24.05,uM,=,1.381115080709851,1,O=C1CCCC2=C1C(c1cnn(-c3ccccc3)c1)C=CN2c1cccnc1
7012,566606,10.1016/j.bmcl.2009.01.054,,,,Inhibition of EGFR by virtual HTS assay,Clc1ccc2c(Nc3ccc(-c4nc5ccccc5s4)cc3)ccnc2c1,N-(4-(benzo[d]thiazol-2-yl)phenyl)-7-chloroquinolin-4-amine,5.3,uM,=,0.724275869600789,1,c1ccc2sc(-c3ccc(Nc4ccnc5ccccc45)cc3)nc2c1
7013,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CSc1nc2ccccc2s1,2-(benzo[d]thiazol-2-ylthio)eN-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)acetamide,0.083,uM,=,-1.080921907623926,0,O=C(CSc1nc2ccccc2s1)Oc1ccc2ncnc(Nc3ccccc3)c2c1
7014,321412,10.1016/j.bmcl.2005.07.027,,,,In vitro inhibitory concentration against EGFR cytoplasmic sequence expressed in Sf9 cells,CCc1c(C(=O)O)cn2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c12,"4-(1-Benzyl-1H-indazol-5-ylamino)-5-ethyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid",0.02,uM,=,-1.6989700043360187,0,c1ccc(Cn2ncc3cc(Nc4ncnn5cccc45)ccc32)cc1
7015,1476964,10.1016/j.bmc.2015.04.038,,,,Inhibition of wild type N-terminal His6-tagged human EGFR kinase domain (702 to 1016 residues) expressed in Sf9 cells pre-incubated for 30 mins before ATP and substrate addition by homogeneous time-resolved FRET assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)/C=C/C3CC3)c2)n1,(E)-N-(3-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)-phenyl)-3-cyclopropylacrylamide,5.6,uM,=,0.7481880270062004,1,O=C(/C=C/C1CC1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
7016,334483,10.1021/jm050936o,,,,Inhibition of erbB1 fusion protein expressed in baculovirus by ELISA,CCN(CC)CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-4-(diethylamino)-2-butynamide",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3cnccc23)cc1
7017,456855,10.1016/j.bmcl.2007.06.019,,,,Inhibition of human recombinant EGFR expressed in insect Sf9 cells,O=C(CO)NC1CCN(Cc2ccn3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c23)CC1,"N-(1-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)pyrrolo[1,2-f][1,2,4]triazin-5-yl)methyl)piperidin-4-yl)-2-hydroxyacetamide",0.11,uM,=,-0.958607314841775,0,c1ccc(Cn2ncc3cc(Nc4ncnn5ccc(CN6CCCCC6)c45)ccc32)cc1
7018,818652,10.1021/jm201507x,,,,Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 mins by time-resolved fluorimetric analysis,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c(C#N)cnc2cc1OCC,N-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)anilino)-3-cyano-7-ethoxyquinolin-6-yl)acrylamide,0.0507,uM,=,-1.294992040666664,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
7019,1338035,10.1016/j.ejmech.2014.02.032,,,,Inhibition of EGFR (unknown origin) after 1.5 hr by FRET-based Z-lyte assay,CCOC(=O)N1CCN(CCC(=O)Nc2cccc(Oc3nc(Nc4ccc(N5CCN(C)CC5)cc4OC)ncc3Cl)c2)CC1,Ethyl-4-(3-((3-((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)amino)-3-oxopropyl)piperazine-1-carboxylate,0.698,uM,=,-0.1561445773768389,0,O=C(CCN1CCNCC1)Nc1cccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)c1
7020,443788,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 uM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4cccc(C)c4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-4-(dimethylamino)-N-[7-ethoxy-4-({4-[(3-methylbenzyl)oxy]-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)quinazolin-6-yl]but-2-enamide",0.0249,uM,=,-1.6038006529042637,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
7021,835647,10.1016/j.bmcl.2012.07.079,,,,Inhibition of EGFR in human A431 cell lysate using tyrosine/glutamic acid polymer as substrate by ELISA,Clc1cccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCO5)cc23)c1,"N6-(benzo[d][1,3]dioxol-5-ylmethyl)-N4-(3-chlorophenyl)quinazoline-4,6-diamine",0.57,uM,=,-0.2441251443275086,0,c1ccc(Nc2ncnc3ccc(NCc4ccc5c(c4)OCO5)cc23)cc1
7022,66718,10.1021/jm00019a007,,,,Inhibition of tyrosine phosphorylation by full length Epidermal growth factor receptor from human A431 carcinoma cells.,Nc1ccc(Nc2ncnc3cc(N)ncc23)cc1,"N*4*-(4-Amino-phenyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",5.9,uM,=,0.7708520116421442,1,c1ccc(Nc2ncnc3ccncc23)cc1
7023,768754,10.1016/j.ejmech.2011.07.016,,,,Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis,COc1ccccc1/C=C/C(=N/NC(N)=S)c1ccccc1,(Z)-2-((E)-3-(2-methoxyphenyl)-1-phenylallylidene)hydrazinecarbothioamide,33.0,uM,=,1.5185139398778875,1,N=C(/C=C/c1ccccc1)c1ccccc1
7024,1612509,10.1016/j.ejmech.2016.04.072,,,,Inhibition of GST-tagged wild type recombinant human EGFR (668 to 1210 residues) expressed in baculovirus after 1 hr by Z-lyte assay,O=C(CBr)OCCn1c(=O)oc2cc3ncnc(Nc4ccc(F)c(F)c4)c3cc21,"1-(2-(2-bromoacetoxy)ethyl)-8-((3,4-difluorophenyl)amino)oxazolo[4,5-g]quinazolin-2(1H)-one",0.3,uM,=,-0.5228787452803376,0,O=c1[nH]c2cc3c(Nc4ccccc4)ncnc3cc2o1
7025,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O,3-[3-(Benzothiazol-2-ylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,18.6,uM,=,1.2695129442179165,1,c1ccc(CSc2nc3ccccc3s2)cc1
7026,1657723,10.1016/j.bmcl.2017.02.018,,,,Inhibition of EGF-induced EGFR phosphorylation in human A431 cells preincubated for 60 mins followed by EGF induction measured after 10 mins by ELISA,Nc1nc(N)c2c(n1)[nH]c1cccc(Sc3ccc(Cl)cc3)c12,"5-[(4-chlorophenyl)sulfanyl]-9H-pyrimido[4,5-b]indole-2,4-diamine",8.3,uM,=,0.919078092376074,1,c1ccc(Sc2cccc3[nH]c4ncncc4c23)cc1
7027,1524114,10.1016/j.bmc.2015.10.035,,,,Inhibition of human EGFR after 1 hr using [gamma-32P]ATP,Fc1ccc(Nc2ncnc3sccc23)cc1Cl,"4-(3-Chloro-4-fluoroanilino)thieno[2,3-d]pyrimidine",2.98,uM,=,0.4742162640762553,1,c1ccc(Nc2ncnc3sccc23)cc1
7028,1640810,,,,,"HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 Î¼M ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate.",Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@H]1CC[C@@H](NC(=O)/C=C/CN2CCOCC2)CC1,"US9181263, 25::US9278100, 25",0.2729,uM,=,-0.5639964643301035,0,O=C(/C=C/CN1CCOCC1)N[C@H]1CC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3cncnc32)CC1
7029,63764,10.1021/jm960689b,,,,Inhibition of epidermal growth factor receptor (EGFr),N[C@H](Cc1c([Se][Se]c2[nH]c3ccccc3c2C[C@H](N)C(=O)NCc2ccccc2)[nH]c2ccccc12)C(=O)NCc1ccccc1,"[S-(R*,R*)]-2,2'-Diselenobis [alpha-amino-N-(phenylmethyl)-1H-indole-3-propanamide]",0.9,uM,=,-0.0457574905606751,0,O=C(CCc1c([Se][Se]c2[nH]c3ccccc3c2CCC(=O)NCc2ccccc2)[nH]c2ccccc12)NCc1ccccc1
7030,66595,10.1021/jm960879m,,,,Tested for ability to inhibit autophosphorylation of the Epidermal growth factor receptor in human epidermoid carcinoma cells,CN(C)c1ncc2ncnc(Nc3cccc(Br)c3)c2n1,"N*8*-(3-Bromo-phenyl)-N*2*,N*2*-dimethyl-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.022,uM,=,-1.6575773191777938,0,c1ccc(Nc2ncnc3cncnc23)cc1
7031,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(OC(F)(F)F)cc3)nn21,"US9447106, 149",0.00046,uM,=,-3.337242168318426,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1
7032,1869224,10.1021/acs.jmedchem.8b01391,,,,Inhibition of wild type EGFR (unknown origin) by bioluminescent ADP-glo kinase assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2ncnc3ccccc23)cc1
7033,454316,10.1016/j.bmcl.2007.01.002,,,,Inhibition of EGFR,Fc1cccc(COc2ccc(Nc3ncnn4ccc(COC[C@@H]5CNCCO5)c34)cc2Cl)c1,"(S)-N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-5-((morpholin-2-ylmethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.57,uM,=,-0.2441251443275086,0,c1ccc(COc2ccc(Nc3ncnn4ccc(COC[C@@H]5CNCCO5)c34)cc2)cc1
7034,614501,10.1021/jm901132v,,,,Inhibition of EGFR,COc1ccccc1Cc1nc2ccc(-c3nn([C@H]4CC[C@H](C5CCN(C)CC5)CC4)c4ncnc(N)c34)cc2[nH]1,"trans-3-(2-(2-methoxybenzyl)-1H-benzo[d]imidazol-6-yl)-1-(4-(1-methylpiperidin-4-yl)cyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.058,uM,=,-1.2365720064370629,0,c1ccc(Cc2nc3ccc(-c4nn([C@H]5CC[C@H](C6CCNCC6)CC5)c5ncncc45)cc3[nH]2)cc1
7035,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,CN(C)CCCCCNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"N*4*-(3-Bromo-phenyl)-N*7*-(5-dimethylamino-pentyl)-pyrido[4,3-d]pyrimidine-4,7-diamine",0.0084,uM,=,-2.0757207139381184,0,c1ccc(Nc2ncnc3ccncc23)cc1
7036,609779,10.1016/j.bmc.2009.12.004,,,,Inhibition of EGFR after 80 mins by radiometric protein kinase assay,COc1cc(C2=C(c3c[nH]c4ccc(Br)cc34)C(=O)NC2=O)cc(OC)c1OC,"3-(5-Bromo-1H-indol-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione",5.797,uM,=,0.7632033003707717,1,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1ccccc1
7037,506200,10.1021/np50089a001,,,,Inhibition of EGFR in human A431 cells,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccc([N+](=O)[O-])cc1,"3-(3,4-Dihydroxy-phenyl)-2-(4-nitro-benzoyl)-acrylonitrile",2.0,uM,=,0.3010299956639812,1,O=C(C=Cc1ccccc1)c1ccccc1
7038,64435,10.1021/jm9805236,,,,Inhibition of EGF receptor kinase,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-phenyl)-3H-imidazol-4-yl]-pyridine,96.0,uM,=,1.9822712330395684,1,c1ccc(-c2nc(-c3ccccc3)c(-c3ccncc3)[nH]2)cc1
7039,605384,10.1016/j.bmc.2009.07.047,,,,Inhibition of wild type EGF-R by microplate scintillation counting,COc1cc2ncnc(Nc3ccc(-c4nc5ccccc5s4)c(O)c3)c2cc1OCCCN1CCN(C)CC1,N-[4-(Benzo[d]thiazol-2''-yl)-3-hydroxyphenyl]-7'-methoxy-6'-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4'-amine,3.3,uM,=,0.5185139398778875,1,c1ccc2sc(-c3ccc(Nc4ncnc5ccc(OCCCN6CCNCC6)cc45)cc3)nc2c1
7040,974507,10.1016/j.ejmech.2013.05.026,,,,Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Oc2ccc(CCOc3no[n+]([O-])c3S(=O)(=O)c3ccccc3)cc2)n1,"4-(4-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide",2.94,uM,=,0.4683473304121572,1,O=S(=O)(c1ccccc1)c1[nH+]onc1OCCc1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7041,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1nc(C)nc(Nc3ccc(F)c(Cl)c3)c1NC2,"(3-chloro-4-fluoro-phenyl)-(7,8-dimethoxy-3-methyl-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",45.9,uM,=,1.6618126855372612,1,c1ccc(Nc2ncnc3c2NCc2ccccc2S3)cc1
7042,334486,10.1021/jm050936o,,,,Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells,CC(C)N(CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1)C(C)C,"N-[4-[(3-chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]-4-(bis(1-methylethyl)amino)-2-butynamide",0.073,uM,=,-1.136677139879544,0,c1ccc(Nc2ncnc3cnccc23)cc1
7043,1433615,10.1021/jm5014659,,,,Inhibition of wild type EGFR (unknown origin) incubated for 5 mins by HTRF assay,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1NC(=O)/C(F)=C\CN(C)C,(E)-N-(4-((3-Bromophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)-2-fluorobut-2-enamide,0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
7044,763211,10.1021/np200196j,,,,Inhibition of EGFR-induced HIF1alpha activation in human HeLa cells preincubated for 1 hr prior to EGF stimulation by luciferase reporter gene assay,C/C=C(\C)C(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)/C=C(C)/C=C/CC(C)/C=C/c1oc(OC)c(C)c(=O)c1C,"2-methoxy-3,5-dimethyl-6-((1E,5E,7E,11E)-3,7,9,11-tetramethyl-10-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)trideca-1,5,7,11-tetraenyl)-4H-pyran-4-one",0.06,uM,=,-1.2218487496163564,0,O=c1ccoc(/C=C/CC/C=C/C=C/CCO[C@H]2CCCCO2)c1
7045,63609,10.1021/jm00110a022,,,,Inhibition of epidermal growth factor receptor autophosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccc(F)cc1,"3-(3,4-Dihydroxy-phenyl)-2-(4-fluoro-benzoyl)-acrylonitrile",5.1,uM,=,0.7075701760979364,1,O=C(C=Cc1ccccc1)c1ccccc1
7046,1542269,10.1021/acsmedchemlett.5b00286,,,,Inhibition of EGFR (unknown origin) using tyrosine 4 as substrate by fluorescence analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0005,uM,=,-3.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
7047,443791,10.1016/j.bmc.2007.03.055,,,,Inhibition of human EGFR in presence of 1 mM ATP,CCOc1cc2ncnc(NC3=CC(=O)C(OCc4ccc(F)c(F)c4)=CC3=O)c2cc1NC(=O)/C=C/CN(C)C,"(2E)-N-[4-({4-[(3,4-difluorobenzyl)oxy]-3,6-dioxocyclohexa-1,4-dien-1-yl}amino)-7-ethoxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide",0.8943,uM,=,-0.0485167692477068,0,O=C1C=C(OCc2ccccc2)C(=O)C=C1Nc1ncnc2ccccc12
7048,63756,10.1021/jm9903949,,,,Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography),Brc1cccc(Nc2[nH]cnc3nc4ccccc4c2-3)c1,"(3-Bromo-phenyl)-(9H-pyrimido[4,5-b]indol-4-yl)-amine",0.031,uM,=,-1.5086383061657274,0,c1ccc(Nc2[nH]cnc3nc4ccccc4c2-3)cc1
7049,63788,10.1021/jm00075a010,,,,Inhibitory concentration against EGF receptor by polyGAT phosphorylation,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCc2ccccc2Cl)c1O,3-[3-(2-Chloro-benzylsulfanylmethyl)-4-hydroxy-5-methoxy-phenyl]-2-cyano-acrylamide,2.5,uM,=,0.3979400086720376,1,c1ccc(CSCc2ccccc2)cc1
7050,1873904,10.1021/acs.jmedchem.9b00794,,,,Inhibition of N-terminal GST-tagged human EGFR (696 to end aminoacids) expressed in baculovirus infected Sf21 cells,C=CC(=O)Nc1cccc(Nc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)c1,N-{3-[6-Amino-5-(4-phenoxyphenyl)pyrimidin-4-ylamino]phenyl}acrylamide,0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncncc2-c2ccc(Oc3ccccc3)cc2)cc1
7051,1338377,10.1021/jm500007h,,,,Inhibition of EGFR (unknown origin) after 1 to 1.5 hrs by FRET-based Z'-Lyte assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cnc(NC2CCCC2)nc1,2-(Cyclopentylamino)-N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)-phenyl)pyrimidine-5-carboxamide,0.033,uM,=,-1.4814860601221125,0,O=C(Nc1cccc(C(=O)Nc2ccc(CN3CCNCC3)cc2)c1)c1cnc(NC2CCCC2)nc1
7052,1912312,10.1021/acs.jmedchem.9b00687,,,,Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured after 1 hr by TR-FRET assay,C=CC(=O)Nc1ccccc1C1CCNc2c(C(N)=O)c(-c3ccc(Cl)cc3)nn21,"US9447106, 134",0.0001799999999999,uM,=,-3.744727494896694,0,c1ccc(-c2cc3n(n2)C(c2ccccc2)CCN3)cc1
7053,607962,10.1016/j.bmc.2009.12.048,,,,Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry,CCCCCCCCCCCCCCCCCCNC(=O)COc1cc(O)c2c(=O)cc(-c3ccccc3)oc2c1,N-Octadecyl 2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetamide,0.464,uM,=,-0.3334820194451191,0,O=c1cc(-c2ccccc2)oc2ccccc12
7054,1613067,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of full length human ERBB1 autophosphorylation transfected in EGF-stimulated mouse NIH/3T3 cells incubated for 2 hrs followed by stimulation with EGF for 10 mins,CCOc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCC1,(2E)-N-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}-7-ethoxy-6-quinazolinyl)-4-(1-pyrrolidinyl)-2-butenamide,0.023,uM,=,-1.6382721639824072,0,O=C(/C=C/CN1CCCC1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
7055,2070644,10.1016/j.bmcl.2020.127261,,,,Inhibition of EGFR (unknown origin) expressed in baculovirus system using fluorescein labeled PDGFR-tide substrate peptide preincubated for 60 mins followed by ATP addition and measured after 60 mins by IMAP assay,C=CC(=O)Nc1ccc2ncnc(Oc3ccc(C(=O)Nc4ccccn4)cc3)c2c1,4-(6-acrylamidoquinazolin-4-yloxy)-N-(pyridin-2-yl)benzamide,0.011,uM,=,-1.958607314841775,0,O=C(Nc1ccccn1)c1ccc(Oc2ncnc3ccccc23)cc1
7056,1882927,10.1016/j.ejmech.2018.11.029,,,,Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(=O)CSc1ncc[nH]1,2-((1H-imidazol-2-yl)thio)eN-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)acetamide,0.027,uM,=,-1.5686362358410126,0,O=C(CSc1ncc[nH]1)Oc1ccc2ncnc(Nc3ccccc3)c2c1
7057,2205223,10.1016/j.bmc.2022.116907,,,,Inhibition of wild type EGFR (unknown origin) using TK as substrate incubated for 120 mins in the presence of ATP by HTRF assay,CCc1cc(Nc2ncc(Br)c(Nc3ccc4c(c3P(C)(C)=O)OCCO4)n2)c(OC)cc1N1CCC(N2CC(CC#N)C2)CC1,"2-(1-(1-(4-((5-Bromo-4-((5-(dimethylphosphoryl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)pyrimidin-2-yl)amino)-2-ethyl-5-methoxyphenyl)piperidin-4-yl)azetidin-3-yl)acetonitrile",0.416,uM,=,-0.3809066693732573,0,c1cc(Nc2ccc3c(c2)OCCO3)nc(Nc2ccc(N3CCC(N4CCC4)CC3)cc2)n1
7058,835647,10.1016/j.bmcl.2012.07.079,,,,Inhibition of EGFR in human A431 cell lysate using tyrosine/glutamic acid polymer as substrate by ELISA,O=C(Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1)C1COc2ccccc2O1,"N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamide",2.75,uM,=,0.4393326938302626,1,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1COc2ccccc2O1
7059,458089,10.1016/j.bmcl.2007.08.061,,,,Inhibition of EGFR,COc1cc2ncnc(Nc3cccc(C#CC(C)(C)O)c3)c2cc1OC,"4-(3-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)-2-methylbut-3-yn-2-ol",0.2058,uM,=,-0.6865546295735858,0,c1ccc(Nc2ncnc3ccccc23)cc1
7060,1882933,10.1016/j.ejmech.2018.11.029,,,,Inhibition of recombinant human wild type GST-tagged EGFR (668 to 1210 residues) expressed in baculovirus expression system after 1 hr by kinase tracer 199 based TR-FRET assay,CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)CO,N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-2-hydroxyacetamide,0.00034,uM,=,-3.468521082957745,0,c1ccc(Nc2ncnc3ccccc23)cc1
7061,65110,10.1021/jm00032a020,,,,"Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells",COC(=O)c1cc(NCc2cc(O)ccc2O)ccc1O,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid methyl ester",9.0,uM,=,0.9542425094393248,1,c1ccc(CNc2ccccc2)cc1
7062,1761038,10.1016/j.ejmech.2018.01.042,,,,Inhibition of His6-tagged EGFR (unknown origin) cytoplasmic domain expressed in baculovirus infected Sf9 insect cells after 10 mins followed by addition of ATP-MgCl2 and measured after 1 hr by time-resolved fluorometric analysis,O=C(NC(CO)Cc1ccccc1)c1cc2cc(Cl)ccc2[nH]1,5-Chloro-N-(1-hydroxy-3-phenylpropan-2-yl)-1H-indole-2-carboxamide,0.8,uM,=,-0.0969100130080563,0,O=C(NCCc1ccccc1)c1cc2ccccc2[nH]1
7063,66727,10.1021/jm000372i,,,,Inhibition of phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (from human A431 carcinoma cell vesicles),C=C/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"Penta-2,4-dienoic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide",0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2ncnc3cnccc23)cc1
7064,1472642,10.1016/j.ejmech.2015.03.004,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE assay,COc1ccccc1-c1cc2c(NCc3ccccc3)ncnc2s1,"N-Benzyl-6-(2-methoxyphenyl)thieno[2,3-d]pyrimidin-4-amine",0.017,uM,=,-1.769551078621726,0,c1ccc(CNc2ncnc3sc(-c4ccccc4)cc23)cc1
7065,1638894,,,,,Inhibition of N-terminal GST-fused human EGFR (His672 to Ala1210 residues) expressed in baculovirus expression system using biotinylated PTP1B at Tyr66 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA,COc1cc2ncnc(NCc3ccc(F)c(F)c3)c2cc1OCCCCCCC(=O)NO,"7-(4-(3,4-difluorobenzylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide",0.1,uM,=,-1.0,0,c1ccc(CNc2ncnc3ccccc23)cc1
7066,1535006,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13xATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM beta-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25C. with a 0.5 ÃÂ¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at lamda ex360/lamda em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics (R2, 95% confidence interval, absolute sum of squares). Initial velocity (0 minutes to 30 minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log [Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, Calif.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCCN(C(=O)C(F)(F)F)CC4)cc3OC)ncc2C(F)(F)F)c1,"US8975249, I-19",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCCNCC4)cc3)n2)cc1
7067,66597,10.1021/jm020241c,,,,Inhibition of autophosphorylation of cytoplasmic domain of epidermal growth factor receptor,COCC#CC(=O)Nc1cc2c(Nc3cccc(Br)c3)c(C#N)cnc2cc1OC,4-Methoxy-but-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-7-methoxy-quinolin-6-yl]-amide,0.79,uM,=,-0.1023729087095585,0,c1ccc(Nc2ccnc3ccccc23)cc1
7068,63612,10.1021/jm960789h,,,,Inhibition of autophosphorylation of epidermal growth factor receptor prepared from human A431 carcinoma cells.,Cn1ccc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-(8-methyl-8H-pyrrolo[3,2-g]quinazolin-4-yl)-amine",0.022,uM,=,-1.6575773191777938,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
7069,827250,10.1021/jm300185p,,,,Inhibition of N-terminus peptide-tagged human recombinant EGFR expressed using baculovirus infection system using [gamma-33P]-ATP preincubated with compound for 5 mins measured after 10 mins by scintillation counting,O=C1Cc2cccc(Oc3ccc(Nc4ncnc5ccn(CCO)c45)cc3Cl)c2N1,"7-(2-Chloro-4-{[5-(2-hydroxyethyl)-5H-pyrrolo[3,2-d]-pyrimidin-4-yl]amino}phenoxy)-1,3-dihydro-2H-indol-2-one",0.0028,uM,=,-2.552841968657781,0,O=C1Cc2cccc(Oc3ccc(Nc4ncnc5cc[nH]c45)cc3)c2N1
7070,1338416,10.1016/j.ejmech.2014.01.018,,,,Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,CCOC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CC(C)(C)C2)C1c1c(C)nn(-c2ccc(Cl)cc2)c1Cl,"Ethyl 2-amino-4-(5-chloro-1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl)-7,7-dimethyl-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",1.03,uM,=,0.0128372247051722,1,O=C1CCCC2=C1C(c1cnn(-c3ccccc3)c1)C=CN2c1cccnc1
7071,1786815,10.1039/C7MD00571G,,,,"Inhibition of Wild type human EGFR using poly(Glu, Tyr) 4 : 1 as substrate after 1 hr by ELISA",C=C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4cc(Cl)ccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-(6-Chloro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)buta-2,3-dienamide",0.0306,uM,=,-1.51427857351842,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
7072,1338416,10.1016/j.ejmech.2014.01.018,,,,Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,Cc1ccc(-n2nc(C)c(C3C(C#N)=C(N)N(c4cccnc4)C4=C3C(=O)CC(C)(C)C4)c2Cl)cc1,"2-Amino-4-(5-chloro-3-methyl-1-p-tolyl-1H-pyrazol-4-yl)-7,7-dimethyl-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile",14.7,uM,=,1.167317334748176,1,O=C1CCCC2=C1C(c1cnn(-c3ccccc3)c1)C=CN2c1cccnc1
7073,66587,10.1021/jm0005555,,,,Inhibition of epidermal growth factor receptor using enzyme assay,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Piperidin-1-yl-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.106,uM,=,-0.9746941347352298,0,O=C(/C=C/CN1CCCCC1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
7074,1613063,10.1021/acs.jmedchem.6b00883,,,,Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA,CCOc1cc2ncnc(Nc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c3)c2cc1NC(=O)/C=C/CN1CCOCC1,(2E)-N-(7-Ethoxy-4-{[1-(phenylsulfonyl)-1H-indol-5-yl]amino}-6-quinazolinyl)-4-(4-morpholinyl)-2-butenamide,0.122,uM,=,-0.9136401693252518,0,O=C(/C=C/CN1CCOCC1)Nc1ccc2ncnc(Nc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c3)c2c1
7075,2227705,10.1021/acs.jmedchem.2c00704,,,,Inhibition of wild type EGFR in human A-431 cells preincubated for 4 to 5 hrs followed by EGF stimulation for 10 mins by AlphaLISA method,CC(C)c1ccc(N2C[C@H](CS(C)(=O)=O)[C@H]2C)c2cnc(Nc3ccnc(N4CC[C@@](C)(O)[C@@H](F)C4)n3)cc12,"(3S,4R)-3-fluoro-1-(5-((5-isopropyl-8-((2R)-2-methyl-3-(methylsulfonyl)azetidin-1-yl)isoquinolin-3-yl)amino)pyrimidin-2-yl)-4-methylpiperidin-4-ol",1.206,uM,=,0.0813473078041324,1,c1cc(N2CCC2)c2cnc(Nc3ccnc(N4CCCCC4)n3)cc2c1
7076,1634977,10.1016/j.ejmech.2016.09.039,,,,Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,COc1cc2c(Nc3ccc(NC(=O)Nc4ccc(Cl)cc4)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,1-(2-chloro-4-((6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl)amino)phenyl)-3-(4-chlorophenyl)urea,0.017,uM,=,-1.769551078621726,0,O=C(Nc1ccccc1)Nc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
7077,1873904,10.1021/acs.jmedchem.9b00794,,,,Inhibition of N-terminal GST-tagged human EGFR (696 to end aminoacids) expressed in baculovirus infected Sf21 cells,C=CC(=O)Nc1cccc(Oc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)c1,N-(3-{[6-Amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]oxy}phenyl)acrylamide,0.078,uM,=,-1.1079053973095196,0,c1ccc(Oc2ccc(-c3cncnc3Oc3ccccc3)cc2)cc1
7078,402644,10.1016/j.bmcl.2006.07.031,,,,Inhibition of EGFR measured as pGAT-biotin peptide phosphorylation in presence of 2.0 uM ATP by HTRF assay,COc1cc2c(cc1OC)Sc1ncnc(Nc3cccc(Cl)c3F)c1NC2,"(3-chloro-2-fluoro-phenyl)-(7,8-dimethoxy-10,11-dihydro-5-thia-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-amine",62.9,uM,=,1.7986506454452689,1,c1ccc(Nc2ncnc3c2NCc2ccccc2S3)cc1
7079,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(NC3CC3c3ccccc3)c2cc1OCCN1CCOCC1,[7-Methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-(2-phenyl-cyclopropyl)-amine,0.3,uM,=,-0.5228787452803376,0,c1ccc(C2CC2Nc2ncnc3ccc(OCCN4CCOCC4)cc23)cc1
7080,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,C#Cc1cccc(Nc2ncnc3cc(OCCCCCCn4ccnc4[N+](=O)[O-])c(OC)cc23)c1,N-(3-Ethynylphenyl)-6-methoxy-7-((6-(2-nitro-1H-imidazol-1-yl)hexyl)oxy)quinazolin-4-amine,0.00057,uM,=,-3.2441251443275085,0,c1ccc(Nc2ncnc3cc(OCCCCCCn4ccnc4)ccc23)cc1
7081,354895,10.1016/j.bmcl.2006.02.025,,,,Antiproliferative activity against EGF-stimulated human KB cell line,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C1(C(N)=O)CN(C)C1,3-(((4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)methyl)(methyl)amino)-1-methylazetidine-3-carboxamide,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccc(CNC4CNC4)cc23)cc1
7082,1338416,10.1016/j.ejmech.2014.01.018,,,,Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis,CCOC(=O)C1=C(N)N(c2cccnc2)C2=C(C(=O)CCC2)C1c1c(C)nn(-c2ccc(Cl)cc2)c1Cl,"Ethyl 2-amino-4-(5-chloro-1-(4-chlorophenyl)-3-methyl-1Hpyrazol-4-yl)-5-oxo-1-(pyridin-3-yl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate",6.15,uM,=,0.7888751157754168,1,O=C1CCCC2=C1C(c1cnn(-c3ccccc3)c1)C=CN2c1cccnc1
7083,819893,10.1016/j.bmcl.2012.04.092,,,,Inhibition of EGFR after 50 mins by HTRF assay,O=C(Cc1ccc(F)cc1)Nc1cc(SC[C@@H](O)CO)cc([N+](=O)[O-])c1,"(S)-N-(3-(2,3-dihydroxypropylthio)-5-nitrophenyl)-2-(4-fluorophenyl)acetamide",48.6,uM,=,1.6866362692622934,1,O=C(Cc1ccccc1)Nc1ccccc1
7084,63783,10.1021/jm970366v,,,,Inhibition of phosphorylation of polyglutamic acid/tyrosine random copolymer by epidermal growth factor receptor.,OCC(O)CNc1cc2ncnc(Nc3cccc(Br)c3)c2cn1,"3-[4-(3-Bromo-phenylamino)-pyrido[4,3-d]pyrimidin-7-ylamino]-propane-1,2-diol",0.00092,uM,=,-3.036212172654445,0,c1ccc(Nc2ncnc3ccncc23)cc1
7085,63762,10.1021/jm00018a008,,,,Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.,Nc1cccc2c(Nc3cccc(Br)c3)ncnc12,"N*4*-(3-Bromo-phenyl)-quinazoline-4,8-diamine",0.105,uM,=,-0.978810700930062,0,c1ccc(Nc2ncnc3ccccc23)cc1
7086,2246488,10.1016/j.ejmech.2022.114231,,,,Inhibition of EGFR (unknown origin),CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.0101999999999999,uM,=,-1.9913998282380825,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
7087,2270920,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
7088,922237,10.1007/s00044-012-0093-z,,,,Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry,O=C(/C=C/c1ccccc1)Nc1ccccc1Cl,SID448898,9.86,uM,=,0.9938769149412112,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
7089,1573292,10.1016/j.bmc.2016.04.032,,,,Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.0311,uM,=,-1.5072396109731625,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7090,305378,10.1021/jm049892u,,,,In vitro inhibition of Epidermal growth factor receptor,Cc1ccc(Nc2ncnn3cc(C)c(C)c23)cc1O,"5-(5,6-Dimethyl-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-2-methyl-phenol",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnn3cccc23)cc1
7091,66598,10.1016/S0960-894X(97)10059-2,,,,Tested for inhibition of Epidermal growth factor receptor from A431 vulval squamous carcinoma cells,COc1cc2ncnc(NNc3ccc(F)c(Cl)c3)c2cc1OC,"N-(3-Chloro-4-fluoro-phenyl)-N'-(6,7-dimethoxy-quinazolin-4-yl)-hydrazine",0.43,uM,=,-0.3665315444204134,0,c1ccc(NNc2ncnc3ccccc23)cc1
7092,942125,10.1016/j.ejmech.2012.07.036,,,,Inhibition of EGFR (unknown origin) using biotinylated-PTP1B (Tyr66) as substrate incubated for 5 mins prior to substrate addition measured after 1 hr by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCn1ccnc1,(3-Chloro-4-fluoro-phenyl)-[6-(2-imidazol-1-yl-ethoxy)-7-methoxy-quinazolin-4-yl]-amine,0.0602,uM,=,-1.2204035087421754,0,c1ccc(Nc2ncnc3ccc(OCCn4ccnc4)cc23)cc1
7093,1443957,10.1016/j.bmc.2014.10.038,,,,Inhibition of wild type EGFR (unknown origin) by Z'-Lyte kinase assay,COc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCCCCn1ccnc1[N+](=O)[O-],N-(3-Chloro-4-fluorophenyl)-6-methoxy-7-((6-(2-nitro-1H-imidazol-1-yl)hexyl)oxy)quinazolin-4-amine,0.0014399999999999,uM,=,-2.8416375079047502,0,c1ccc(Nc2ncnc3cc(OCCCCCCn4ccnc4)ccc23)cc1
7094,654933,10.1038/nchembio.117,,,,Inhibition of recombinant EGFR by radioactive phosphotransfer assay in presence of 10 uM ATP,Cn1ccc2cc(-c3nn(C4CCCC4)c4ncnc(N)c34)ccc21,"1-cyclopentyl-3-(1-methyl-1H-indol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",0.539,uM,=,-0.2684112348132613,0,c1ncc2c(-c3ccc4[nH]ccc4c3)nn(C3CCCC3)c2n1
7095,1687538,10.1021/acs.jmedchem.7b01612,,,,Inhibition of recombinant human wild type GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay,CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(CC)c4)nc32)C1,"(S)-7-((3-Ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one",0.518,uM,=,-0.2856702402547669,0,O=C1N(c2ccccc2)Cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2N1[C@H]1CCNC1
7096,2075027,10.1021/acsmedchemlett.9b00599,,,,"Inhibition of human recombinant EGFR expressed in baculovirus infected Sf9 insect cells using poly (Glu, Tyr) 4:1 peptide as substrate incubated for 40 mins in presence of 10 uM ATP by ADP-Glo luminescence assay",C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.00217,uM,=,-2.6635402661514704,0,c1ccc(Nc2ncnc3ccccc23)cc1
7097,1628119,10.1016/j.bmc.2016.10.006,,,,Inhibition of wild-type EGFR (unknown origin) assessed as remaining ATP level measured after 15 mins by luminescence analysis,O=C(CCCCCCn1cc(-c2ccc3ncnc(Nc4cccc(Cl)c4F)c3c2)nn1)NO,"7-(4-(4-((3-chloro-2-fluorophenyl)amino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)-N-hydroxyheptanamide",0.0001199999999999,uM,=,-3.9208187539523753,0,c1ccc(Nc2ncnc3ccc(-c4c[nH]nn4)cc23)cc1
7098,1640870,,,,,"Time-Resolved Fret (TR-FRET) Assay: 1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dilutions of 10 fold from 100 micoM are used. Kinase activity was determined with time-resolved Fret (TR-FRET) assay (LanthaScreenÂ® kinase activity assay, from InVitrogen).2) The assay is performed in a Black 384-well plate (from Corning). The kinase and the compound was incubated for 30 mM at room temperature. ATP (1 mM) and fluorescein-poly GT were added, and the reaction was incubated for 15 mM. Detection agent SA-XL665 (from Cisbio Assay) and TK Ab-Cryptate detection antibody (from InVitrogen) were added to stop the reaction.3) The 384-well plate was sealed and incubated for 1 hour. The fluorescence was then measured at 620 nM (Cryptate) and 665 nM (XL655) wavelength.4) Each concentration of compound was done in triplicate, and vehicle (without compound) and a positive control were used.",CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCC12COCC1C2,"US9187459, 5",0.00037,uM,=,-3.431798275933005,0,c1ccc(Nc2ncnc3cc(OCC45COCC4C5)ccc23)cc1
7099,603361,10.1016/j.bmc.2009.08.044,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA,COc1ccccc1C(=Cc1coc2nc(=N)[nH]c(N)c12)C(C)C,"5-[(Z/E)-2-(20-Methoxyphenyl)-3-methylbut-1-en-1-yl]-furo[2,3-d]pyrimidine-2,4-diamine",111.4,uM,=,2.04688519083771,1,N=c1nc2occ(C=Cc3ccccc3)c2c[nH]1
7100,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(Cl)c(Cl)cc3F)ncnc2cc1OCCNC(=O)CS(C)(=O)=O,"US8846699, 139",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3ccccc23)cc1
7101,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cccc([N+](=O)[O-])c1F,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-3-nitrobenzamide,0.013,uM,=,-1.8860566476931635,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7102,1640870,,,,,"Time-Resolved Fret (TR-FRET) Assay: 1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dilutions of 10 fold from 100 micoM are used. Kinase activity was determined with time-resolved Fret (TR-FRET) assay (LanthaScreenÂ® kinase activity assay, from InVitrogen).2) The assay is performed in a Black 384-well plate (from Corning). The kinase and the compound was incubated for 30 mM at room temperature. ATP (1 mM) and fluorescein-poly GT were added, and the reaction was incubated for 15 mM. Detection agent SA-XL665 (from Cisbio Assay) and TK Ab-Cryptate detection antibody (from InVitrogen) were added to stop the reaction.3) The 384-well plate was sealed and incubated for 1 hour. The fluorescence was then measured at 620 nM (Cryptate) and 665 nM (XL655) wavelength.4) Each concentration of compound was done in triplicate, and vehicle (without compound) and a positive control were used.",CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCC1C2COCC21,"US9187459, 2",0.00013,uM,=,-3.886056647693163,0,c1ccc(Nc2ncnc3cc(OCC4C5COCC54)ccc23)cc1
7103,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccc(O)c(O)c1,"2-(3,4-Dihydroxy-benzoyl)-3-(3,4-dihydroxy-phenyl)-acrylonitrile",0.37,uM,=,-0.431798275933005,0,O=C(C=Cc1ccccc1)c1ccccc1
7104,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCc1ccncc1,"US8846699, 6",0.056,uM,=,-1.2518119729937995,0,c1ccc(Nc2ncnc3cc(OCc4ccncc4)ccc23)cc1
7105,2213922,10.1016/j.ejmech.2021.113963,,,,Inhibition of N-terminal GST-tagged recombinant wild type human EGFR (669 to 1210 residues) expressed in baculovirus infected Sf21 cells incubated for 1 hr in presence of ATP by caliper mobility shift assay,CN1CCN(c2ccc(Nc3ncc(Br)c(Nc4ccc5cn[nH]c5c4)n3)cc2)CC1,"5-bromo-N4-(1H-indazol-6-yl)-N2-[4-(4-methylpiperazin-1-yl)phenyl]pyrimidine-2,4-diamine",1.1387,uM,=,0.0564093206499179,1,c1cc(Nc2ccc3cn[nH]c3c2)nc(Nc2ccc(N3CCNCC3)cc2)n1
7106,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(C(C)C)nc3cnc(Nc4ccc(OCCOC)cc4)nc32)c1,N-(3-(6-Isopropyl-2-((4-(2-methoxyethoxy)phenyl)amino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.379,uM,=,-0.4213607900319276,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
7107,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C(=O)C(F)(F)F)CC1,"US8846699, 2",0.047,uM,=,-1.3279021420642825,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7108,1512952,10.1021/acsmedchemlett.5b00231,,,,Inhibition of wild type EGFR in human A549 cells assessed as inhibition of phosphorylation at Y1068 after 2 hrs by sandwich ELISA method,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C4CCN(C)C4)nc3OC)c3ncn(C(C)C)c3n2)C[C@H]1F,"N-((3R,4R)-4-fluoro-1-(9-isopropyl-6-(3-methoxy-1-(1-methylpyrrolidin-3-yl)-1H-pyrazol-4-ylamino)-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide",0.142,uM,=,-0.8477116556169436,0,c1nc2c(Nc3cnn(C4CCNC4)c3)nc(N3CCCC3)nc2[nH]1
7109,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(C)nc3cnc(Nc4ccc(OCCOC)cc4)nc32)c1,N-(3-(2-((4-(2-Methoxyethoxy)phenyl)amino)-6-methyl-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.3355,uM,=,-0.4743074754949891,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
7110,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3ccccc23)c(OC)cc1N(C)CCN(C)C,N-(5-((1H-indazol-3-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,9.272,uM,=,0.9671734229555397,1,c1ccc(Nc2n[nH]c3ccccc23)cc1
7111,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(C(=O)O)cc3)cc12)c1ccccc1,"(R)-4-(4-((1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzoic acid",0.0011,uM,=,-2.958607314841775,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7112,1329559,10.1039/C0MD00115E,,,,Inhibition of EGFR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1B1OC(C)(C)C(C)(C)O1,"N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-4-amine",0.52,uM,=,-0.2839966563652008,0,c1ccc(Nc2ncnc3ccc(B4OCCO4)cc23)cc1
7113,202292,10.1021/jm00037a020,,,,Cytotoxic effect on EGF-receptor overexpressing HN5 squamous carcinoma cells,Oc1ccc(-c2nc3ccc(O)cc3s2)cc1,2-(4-Hydroxy-phenyl)-benzothiazol-6-ol,130.0,uM,=,2.113943352306837,1,c1ccc(-c2nc3ccccc3s2)cc1
7114,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,CS(=O)(=O)c1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1,"(S)-2-((6-(4-(Methylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0008,uM,=,-3.096910013008056,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7115,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Cl)nc3)ncnc2cc1OCCNC(C)=O,"US8846699, 128",0.065,uM,=,-1.1870866433571443,0,c1cncc(Nc2ncnc3ccccc23)c1
7116,2045678,10.1039/d0md00146e,,,,Inhibition of EGFR (unknown origin) using Tyrosine 4 peptide and ATP as substrate incubated for 1 hr by Z'-lyte kinase assay based UV-VIS spectrophotometric method,CC(C)c1ccc(C2N=C(C(N)=O)c3ncn(-c4ccc(F)cc4)c3N2)cc1,9-(4-Fluorophenyl)-2-(4-isopropylphenyl)-9H-purine-6-carboxamide,0.71,uM,=,-0.1487416512809247,0,C1=NC(c2ccccc2)Nc2c1ncn2-c1ccccc1
7117,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CCN(CC)CC,"US8846699, 59",0.044,uM,=,-1.3565473235138126,0,c1ccc(Nc2ncnc3ccccc23)cc1
7118,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(C(N)=O)cc3)cc12)c1ccccc1,"(R)-4-(4-((1-Phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzamide",0.0008,uM,=,-3.096910013008056,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7119,1983834,10.1016/j.bmc.2019.115281,,,,Inhibition of EGFR L858R/T790M (unknown origin),C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
7120,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CCCOc1cc2ncnc(Nc3ccc(Br)cc3F)c2cc1NC(=O)C=C,"US8846699, 31",0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
7121,202292,10.1021/jm00037a020,,,,Cytotoxic effect on EGF-receptor overexpressing HN5 squamous carcinoma cells,Oc1cc(O)c2nc(-c3ccc(O)c(O)c3)sc2c1,"2-(3,4-Dihydroxy-phenyl)-benzothiazole-4,6-diol",130.0,uM,=,2.113943352306837,1,c1ccc(-c2nc3ccccc3s2)cc1
7122,982464,10.1016/j.bmc.2013.06.070,,,,Inhibition of recombinant EGFR kinase cytoplasmic domain (unknown origin) expressed in baculovirus expression vector-infected insect sf9 cells assessed as level of autophosphorylation after 10 mins by DELFIA/time-resolved fluorometry,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2ncnc3ccccc23)cc1
7123,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccccc2)CC1c1ccc(C(=O)OCCn2c([N+](=O)[O-])cnc2C)cc1,"2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-(1-acetyl-3-phenyl-4,5-dihydro-1H-pyrazol-5-yl)benzoate",9.58,uM,=,0.9813655090785444,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7124,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,CN(c1ccccc1)c1ncnc2ccc(N)cc12,"N*4*-Methyl-N*4*-phenyl-quinazoline-4,6-diamine",8.4,uM,=,0.9242792860618816,1,c1ccc(Nc2ncnc3ccccc23)cc1
7125,1684313,10.1016/j.ejmech.2017.04.025,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (unknown origin) (645 to 1186 residues) expressed in baculovirus infected Sf-9 cells preincubated for 10 mins followed by ATP addition measured after 1 hr by DELFIA/Time-Resolved fluorometry,COc1cc(Br)c(/C=C2\CN(C(C)C)CC(=C\c3nc(C)c(C)nc3C)/C2=N/O)cc1OC,"3-(2-Bromo-4,5-dimethoxy-benzylidene)-1-isopropyl-5-(3,5,6-trimethyl-pyrazin-2-ylmethylene)-piperidin-4-one oxime",4.9,uM,=,0.6901960800285137,1,N=C1/C(=C/c2ccccc2)CNC/C1=C\c1cnccn1
7126,66568,10.1021/jm00033a019,,,,Inhibitory activity against recombinant tyrosine kinase EGF-R (EGF-R ICD),O=C1NC(=O)c2cc(Nc3ccc(O)cc3)c(Nc3ccc(O)cc3)cc21,"5,6-Bis-(4-hydroxy-phenylamino)-isoindole-1,3-dione",2.5,uM,=,0.3979400086720376,1,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21
7127,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,COc1cc(O)c(C(=O)Nc2ccc(F)c(Cl)c2)cc1NC(=O)CCCCCC(=O)NO,N-(3-Chloro-4-fluorophenyl)-2-hydroxy-5-(7-hydroxyamino-7-oxoheptanamido)-4-methoxybenzamide,1.56,uM,=,0.1931245983544616,1,O=C(Nc1ccccc1)c1ccccc1
7128,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccc(F)cc1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl3-(4-fluorophenyl)acrylate,4.12,uM,=,0.6148972160331346,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
7129,473565,10.1073/pnas.0708800104,,,,Inhibition of EGFR,CC(C)(C)c1cc(C=C2C(=O)C=CC2=O)cc(C(C)(C)C)c1O,"2-((3,5-di-tert-butyl-4-hydroxyphenyl)-methylene)-4-cyclopentene-1,3-dione",320.0,uM,=,2.505149978319906,1,O=C1C=CC(=O)C1=Cc1ccccc1
7130,2031601,10.1016/j.ejmech.2020.112185,,,,"Inhibition of EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate incubated for 8 mins in presence of ATP by colorimetric analysis",CN(CCCl)c1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N4-(3-bromophenyl)-N6-(2-chloroethyl)-N6-methylquinazoline-4,6-diamine",0.504,uM,=,-0.2975694635544747,0,c1ccc(Nc2ncnc3ccccc23)cc1
7131,2059437,10.1016/j.bmc.2021.116094,,,,Inhibition of wild-type EGFR (unknown origin) using biotinylated TK peptide as substrate measured after 30 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(S(=O)(=O)N(C)C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-(4-(1-(N,N-dimethylsulfamoyl)-1H-indol-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide",0.0014,uM,=,-2.853871964321762,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
7132,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCC1CCN(C)CC1,(4-Chloro-2-fluoro-phenyl)-{6-methoxy-7-[2-(1-methyl-piperidin-4-yl)-ethoxy]-quinazolin-4-yl}-amine,0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3cc(OCCC4CCNCC4)ccc23)cc1
7133,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C(=O)OC,methyl (2-((2-acrylamido-5-methoxy-4-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)(methyl)carbamate,2.909,uM,=,0.4637437212470591,1,c1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1
7134,1512952,10.1021/acsmedchemlett.5b00231,,,,Inhibition of wild type EGFR in human A549 cells assessed as inhibition of phosphorylation at Y1068 after 2 hrs by sandwich ELISA method,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3C)c3ncn(C(C)C)c3n2)C[C@H]1F,"N-((3R,4R)-1-(6-(1,3-dimethyl-1H-pyrazol-4-ylamino)-9-isopropyl-9H-purin-2-yl)-4-fluoropyrrolidin-3-yl)acrylamide",10.0,uM,=,1.0,1,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1
7135,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,N#Cc1cnc2ccc(-c3cccc(CN4CCOCC4)c3)cc2c1N[C@@H]1C[C@H]1c1ccccc1,"6-(3-(morpholinomethyl)phenyl)-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",5.26,uM,=,0.7209857441537391,1,c1ccc([C@@H]2C[C@H]2Nc2ccnc3ccc(-c4cccc(CN5CCOCC5)c4)cc23)cc1
7136,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-methyl oxime,0.008,uM,=,-2.096910013008056,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
7137,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,COc1cc2ncc(C#N)c(Nc3cc(OC)c(OC)c(OC)c3)c2cc1OC,"6,7-Dimethoxy-4-(3,4,5-trimethoxy-phenylamino)-quinoline-3-carbonitrile",7.1,uM,=,0.8512583487190752,1,c1ccc(Nc2ccnc3ccccc23)cc1
7138,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3C(F)(F)F)ncnc2cc1OCCNC(C)=O,"US8846699, 114",0.456,uM,=,-0.341035157335565,0,c1ccc(Nc2ncnc3ccccc23)cc1
7139,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,CN1CCN(CCC(=O)N2CCOc3c2ccc2ncnc(Nc4ccc(F)c(Cl)c4)c32)CC1,"1-(10-((3-chloro-4-fluorophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-3-(4-methylpiperazin-1-yl)propan-1-one",0.02569,uM,=,-1.5902358957336538,0,O=C(CCN1CCNCC1)N1CCOc2c1ccc1ncnc(Nc3ccccc3)c21
7140,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-((3-chloro-4-fluorophenyl)amino)-7,8-dihydro-6H-[1,4]oxazino[3,2 g]quinazolin-6-yl)-4-(dimethylamino)but-2-en-1-one",0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3cc4c(cc23)NCCO4)cc1
7141,1801470,10.1016/j.ejmech.2018.07.024,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP-MgCl2 addition and measured after 1 hr by DELFIA/time-resolved fluorometric analysis,c1ccc(-c2nc3sc(-c4ccccc4)cn3n2)cc1,"2,5-Diphenylthiazolo[3,2-b][1,2,4]triazole",9.8,uM,=,0.9912260756924948,1,c1ccc(-c2nc3sc(-c4ccccc4)cn3n2)cc1
7142,2251609,10.1021/acs.jmedchem.2c00168,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,CCS(=O)(=O)n1cc2c3ccc(cc31)OCCCCCCOc1cc(c(F)cc1N1CCOCC1)Nc1ncc(Cl)c-2n1,"2(5)-chloro-1(1)-(ethylsulfonyl)-4(6)-fluoro-4(4)-morpholino-1(1)H-5,12-dioxa-3-aza-1(3,6)-indola-2(4,2)-pyrimidina-4(1,3)-benzenacyclododecaphane",0.8852000000000001,uM,=,-0.0529585947447796,0,c1cc2nc(n1)Nc1ccc(N3CCOCC3)c(c1)OCCCCCCOc1ccc3c-2c[nH]c3c1
7143,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3cc(-c4cccc(F)c4)ccc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((6-(3-fluorophenyl)-1H-indazol-3-yl)amino)-4-methoxyphenyl)acrylamide,0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2n[nH]c3cc(-c4ccccc4)ccc23)cc1
7144,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cc(CNCCN2CCOCC2)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-2-((6-(2-Methoxy-4-(((2-morpholinoethyl)amino)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0001,uM,=,-4.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccc(CNCCN5CCOCC5)cc4)cc23)cc1
7145,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Brc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-(2-morpholin-4-yl-ethyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0079,uM,=,-2.1023729087095586,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)cc1
7146,1337212,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ccc(Oc2nc3ccc(C)cc3cc2/C=N/NC(=O)Cn2c([N+](=O)[O-])cnc2C)cc1,(E)-N'-((6-methyl-2-(p-tolyloxy)quinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,0.18,uM,=,-0.744727494896694,0,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
7147,876534,10.1021/jm301365e,,,,Inhibition of EGFR in human NCI-H1975 cells assessed as reduction in ERK phosphorylation incubated for 8 hrs by Western blotting method,CN1CCN(c2ccc(Nc3ncc4nc(Nc5ccccc5)n(C5CCCC5)c4n3)cc2)CC1,"9-Cyclopentyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine",0.4,uM,=,-0.3979400086720376,0,c1ccc(Nc2nc3cnc(Nc4ccc(N5CCNCC5)cc4)nc3n2C2CCCC2)cc1
7148,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCCCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1Cl.Cl,"{2-Chloro-4-[6,7-dimethoxyquinazolin-4-ylamino]phenyl}carbamic acid butyl ester hydrochloride",6.4,uM,=,0.8061799739838872,1,c1ccc(Nc2ncnc3ccccc23)cc1
7149,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3ccc(-c4ccc5ccccc5c4)cc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((5-(naphthalen-2-yl)-1H-indazol-3-yl)amino)phenyl)acrylamide,0.0081,uM,=,-2.0915149811213505,0,c1ccc(Nc2n[nH]c3ccc(-c4ccc5ccccc5c4)cc23)cc1
7150,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OC)cc3OC)ncc2Cl)c1,"US9238629, I-21",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
7151,775025,10.1016/j.ejmech.2011.09.041,,,,Inhibition of human EGFR,Cc1c(C#N)c(NCCO)nc2nc(NCCO)nc(N)c12,"4-amino-2,7-bis((2-hydroxyethyl)amino)-5-methylpyrido[2,3-d]pyrimidine-6-carbonitrile",47.9,uM,=,1.6803355134145632,1,c1cnc2ncncc2c1
7152,1848601,10.1016/j.ejmech.2019.03.055,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected Sf21 insect cells using STK as substrate by HTRF assay,C=CC(=O)N1CCC[C@@H](Oc2nc(Nc3ccc(N4CCN(CC)CC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)C1,"(R)-1-(3-((2-((4-(4-ethylpiperazin-1-yl)phenyl)amino)-5-(6-(methylamino)pyrazin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl-oxy)piperidin-1-yl)prop-2-en-1-one",0.0087,uM,=,-2.0604807473813813,0,c1cnc(-c2c[nH]c3nc(Nc4ccc(N5CCNCC5)cc4)nc(O[C@@H]4CCCNC4)c23)cn1
7153,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cccc([N+](=O)[O-])c1Cl,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-chloro-3-nitrobenzamide,0.014,uM,=,-1.853871964321762,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7154,528400,10.1021/np9905259,,,,Inhibition of human recombinant EGFR kinase expressed in Sf9 insect cells,CO[C@H](C)c1c(O)cc2c(c1O)C(=O)c1c(cc(O)c(O)c1O)C2=O,"(R)-1,2,3,6,8-pentahydroxy-7-(1-methoxyethyl)anthracene-9,10-dione",41.0,uM,=,1.6127838567197357,1,O=C1c2ccccc2C(=O)c2ccccc21
7155,63602,10.1021/jm00077a014,,,,Inhibition of EGF-dependent DNA synthesis in ER 22 cells incubated with [3H]TdR,COC(=O)c1cc(NCc2cccc(O)c2)ccc1O,2-Hydroxy-5-(3-hydroxy-benzylamino)-benzoic acid methyl ester,21.0,uM,=,1.3222192947339193,1,c1ccc(CNc2ccccc2)cc1
7156,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,CCN(CC)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(diethylamino)but-2-en-1-one",0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ncnc3cc4c(cc23)NCCO4)cc1
7157,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1C.Cl,"{4-[6,7-Dimethoxyquinazolin-4-ylamino]-2-methylphenyl}carbamic acid propyl ester hydrochloride",0.9,uM,=,-0.0457574905606751,0,c1ccc(Nc2ncnc3ccccc23)cc1
7158,63790,10.1016/S0960-894X(97)00035-8,,,,Antagonism towards Epidermal growth factor receptor,Cc1cccc(N(C)c2ncnc3cc(C)c(C)cc23)c1.Cl,"(6,7-Dimethyl-quinazolin-4-yl)-methyl-m-tolyl-amine hydrochloride",6.5,uM,=,0.8129133566428556,1,c1ccc(Nc2ncnc3ccccc23)cc1
7159,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(-c3ccccc3Cl)nc3cnc(Nc4ccc(OCCOC)cc4)nc32)c1,N-(3-(6-(2-Chlorophenyl)-2((4-(2-methoxyethoxy)phenyl)-amino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.011,uM,=,-1.958607314841775,0,O=c1c(-c2ccccc2)nc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
7160,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,"N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine",0.066,uM,=,-1.1804560644581312,0,c1cc(Nc2ncnc3cc(OCCN4CCNCC4)cc(OC4CCOCC4)c23)c2c(c1)OCO2
7161,761853,10.1016/j.bmc.2011.06.022,,,,Inhibition of EGFR after 1 hrs by luminescence assay,Cn1cccc1-c1nc2cc(NC(=O)CCl)ccc2[nH]1,2-chloro-N-(2-(1-methyl-1H-pyrrol-2-yl)-1H-benzo[d]imidazol-5-yl)acetamide,12.07,uM,=,1.0817072700973491,1,c1c[nH]c(-c2nc3ccccc3[nH]2)c1
7162,556139,10.1016/j.bmc.2008.04.019,,,,Inhibition of EGFR expressed in human tumor cells,Nc1nc(Nc2ccc(F)c(C(F)(F)F)c2)c2cc(CCc3ccccc3)[nH]c2n1,"N4-[4-Fluoro-3-(trifluoromethyl)phenyl]-6-(2-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",122.0,uM,=,2.0863598306747484,1,c1ccc(CCc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7163,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3c(F)cc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,"(4-Bromo-2,6-difluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine",0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7164,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,0.0017,uM,=,-2.7695510786217263,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7165,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,CC(NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1)c1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-(1-phenyl-ethyl)-acrylamide",0.86,uM,=,-0.0655015487564322,0,O=C(/C=C/c1ccccc1)NCc1ccccc1
7166,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CC(C)N(C)C,"US8846699, 75",0.325,uM,=,-0.4881166390211256,0,c1ccc(Nc2ncnc3ccccc23)cc1
7167,1466619,10.1016/j.bmc.2015.03.061,,,,Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,COc1ccc2c(c1)CCN2c1nc(C)nc2oc(C)cc12,"4-(5-Methoxyindolin-1-yl)-2,6-dimethylfuro[2,3-d]-pyrimidine",0.1032,uM,=,-0.9863203027088074,0,c1ccc2c(c1)CCN2c1ncnc2occc12
7168,1675765,10.1016/j.bmc.2017.03.039,,,,Inhibition of human EGFR preincubated for 5 mins with substrate followed by ATP addition measured after 30 mins by HTRF method,O=c1c2ccccc2nc(-c2ccccc2)n1-c1nnc(-c2ccccc2Cl)s1,"3-(5-(2-Chlorophenyl)-1,3,4-thiadiazol-2-yl)-2-phenylquinazolin-4(3H)-one",78.23,uM,=,1.893373330246025,1,O=c1c2ccccc2nc(-c2ccccc2)n1-c1nnc(-c2ccccc2)s1
7169,1675765,10.1016/j.bmc.2017.03.039,,,,Inhibition of human EGFR preincubated for 5 mins with substrate followed by ATP addition measured after 30 mins by HTRF method,CC(=O)c1ccccc1-n1c(-c2ccccc2)nc2cc(Cl)ccc2c1=O,3-(2-Acetylphenyl)-7-chloro-2-phenylquinazolin-4(3H)-one,34.32,uM,=,1.5355472791766678,1,O=c1c2ccccc2nc(-c2ccccc2)n1-c1ccccc1
7170,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#CC(C#N)=C(N)/C(C#N)=C/c1ccc2[nH]ccc2c1,"3-Amino-2,4-dicyano-5-(1H-indol-5-yl)-penta-2,4-dienenitrile",820.0,uM,=,2.9138138523837167,1,c1ccc2[nH]ccc2c1
7171,1747423,10.1016/j.bmc.2017.10.030,,,,Inhibition of recombinant wild type EGFR (696 to C-terminal residues) (unknown origin) preincubated for 30 mins followed by poly (Glu-Tyr) biotinylated peptide substrate addition measured after 30 mins in presence of ATP by ELISA,COc1ccc(-c2c3c4cc(O)c(OCCCN(C)C)cc4oc(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O.O=C(O)C(F)(F)F,"3-[3-(dimethylamino)propoxy]-2,11-dihydroxy-14-(3-hydroxy-4-methoxyphenyl)-12-methoxy-6H-[1]benzopyrano[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one Trifluoroacetic acid salt",0.0477999999999999,uM,=,-1.3205721033878812,0,O=c1oc2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
7172,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc(F)cc2)CC1c1ccc(C(=O)OC(C)Cn2c([N+](=O)[O-])cnc2C)cc1,"1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-yl 4-(1-acetyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",6.58,uM,=,0.8182258936139555,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7173,556139,10.1016/j.bmc.2008.04.019,,,,Inhibition of EGFR expressed in human tumor cells,COc1ccc(CCc2cc3c(Nc4cccc(Br)c4)nc(N)nc3[nH]2)cc1,"N4-(3-Bromophenyl)-6-[2-(4-methoxyphenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",2.2,uM,=,0.3424226808222063,1,c1ccc(CCc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7174,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(F)c3F)ncnc2cc1OCCNC(=O)CCN1CCCCC1,"US8846699, 126",0.894,uM,=,-0.0486624812040823,0,O=C(CCN1CCCCC1)NCCOc1ccc2c(Nc3ccccc3)ncnc2c1
7175,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0005,uM,=,-3.3010299956639813,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
7176,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1Cl.Cl,"{2-Chloro-4-[6,7-Dimethoxyquinazolin-4-ylamino]phenyl}carbamic acid ethyl ester hydrochloride",1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
7177,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccccc1,"2-Benzoyl-3-(3,4-dihydroxy-phenyl)-acrylonitrile",1.3,uM,=,0.1139433523068367,1,O=C(C=Cc1ccccc1)c1ccccc1
7178,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,OCC(O)Cn1ncc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"3-[5-(3-Bromo-phenylamino)-pyrazolo[4,3-g]quinazolin-1-yl]-propane-1,2-diol",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3cc4[nH]ncc4cc23)cc1
7179,2251609,10.1021/acs.jmedchem.2c00168,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,BRIGATINIB,0.1397,uM,=,-0.8548035938858182,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)cc1
7180,321282,10.1021/jm050512u,,,,Inhibitory concentration of EGFr,COc1cc(Nc2c(C#N)cnc3cc4cc(OCCN5CCOCC5)c(OC)cc4cc23)c(Cl)cc1Cl,"4-(2,4-Dichloro-5-methoxy-phenylamino)-7-methoxy-8-(2-morpholin-4-yl-ethoxy)-benzo[g]quinoline-3-carbonitrile",2.7,uM,=,0.4313637641589873,1,c1ccc(Nc2ccnc3cc4cc(OCCN5CCOCC5)ccc4cc23)cc1
7181,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C(C)N,"US8846699, 173",0.018,uM,=,-1.744727494896694,0,c1ccc(Nc2ncnc3ccccc23)cc1
7182,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,C#Cc1cccc(Nc2ncnc3cc(OC)c(OC)cc23)c1,"(6,7-Dimethoxy-quinazolin-4-yl)-(3-ethynyl-phenyl)-amine",0.019,uM,=,-1.7212463990471711,0,c1ccc(Nc2ncnc3ccccc23)cc1
7183,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)CN(CC)CC,"US8846699, 151",0.058,uM,=,-1.2365720064370629,0,c1ccc(Nc2ncnc3ccccc23)cc1
7184,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1.Cl,"{4-[6,7-Dimethoxyquinazolin-4-ylamino]phenyl}carbamic acid propyl ester hydrochloride",7.05,uM,=,0.8481891169913987,1,c1ccc(Nc2ncnc3ccccc23)cc1
7185,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCN,"US8846699, 29",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccccc23)cc1
7186,1466619,10.1016/j.bmc.2015.03.061,,,,Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,COc1ccc(N(C)c2nc(C)nc3oc(C)cc23)c(OC)c1,"N-(2,4-Dimethoxyphenyl)-N,2,6-trimethylfuro[2,3-d]-pyrimidin-4-amine",0.1623,uM,=,-0.7896814801737682,0,c1ccc(Nc2ncnc3occc23)cc1
7187,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,Cc1cccc(Nc2ncnc3ccc(N(C)C(=O)N(CCCl)N=O)cc23)c1,1-(2-chloroethyl)-1-nitroso-3-methyl-3-{[4-(3-methylphenyl)amino]quinazolin-6-yl}urea,1.139,uM,=,0.0565237240791003,1,c1ccc(Nc2ncnc3ccccc23)cc1
7188,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,Clc1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1Cl,"3-(3,4-Dichlorophenyl)-5-(naphthalen-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",0.05,uM,=,-1.3010299956639813,0,c1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1
7189,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,CN(C)CCOc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)c4cc([N+](=O)[O-])ccc4F)cc23)cc1Cl,N-(4-((3-chloro-4-(2-(dimethylamino)ethoxy)phenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.374,uM,=,-0.4271283977995198,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7190,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1Cl,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-chloro-5-nitrobenzamide,0.0083,uM,=,-2.0809219076239263,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7191,462992,10.1016/j.bmcl.2008.02.035,,,,Inhibition of EGFR,C[C@@H](Oc1cccc2ncnc(Nc3ccc4c(cnn4Cc4ccccn4)c3)c12)C(=O)N(C)C,"(R)-N,N-dimethyl-2-(4-(1-(pyridin-2-ylmethyl)-1H-indazol-5-ylamino)quinazolin-5-yloxy)propanamide",0.18,uM,=,-0.744727494896694,0,c1ccc(Cn2ncc3cc(Nc4ncnc5ccccc45)ccc32)nc1
7192,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccc(Br)cc1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl3-(4-bromophenyl)acrylate,3.24,uM,=,0.5105450102066121,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
7193,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,Cc1cccc(Nc2ncnc3ccc(N)cc23)c1,"N*4*-m-Tolyl-quinazoline-4,6-diamine",1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
7194,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",CCc1nc(C(N)=O)c(Nc2ccc(N3CCN(C)CC3)cc2)nc1Oc1cccc(NC(=O)/C=C/CN(C)C)c1,"US9085540, 3",0.017,uM,=,-1.769551078621726,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7195,2270900,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) incubated for 60 mins in presence of ATP by ADP-Glo kinase assay,C=CC(=O)Nc1ccccc1Nc1ncnc2cc(OC)c(OCCN3CCOCC3)cc12,N-(2-Propenamide)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine,0.0243999999999999,uM,=,-1.6126101736612706,0,c1ccc(Nc2ncnc3ccc(OCCN4CCOCC4)cc23)cc1
7196,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cn1c(-c2csc(N/N=C\c3ccc(F)cc3)n2)nc2ccccc21,2-(2-(4-Fluorobenzylidene)hydrazinyl)-4-(1-methyl-1H-benzo[d]imdazol-2-yl)thiazole,0.25374,uM,=,-0.595611064469456,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccccc1
7197,1684313,10.1016/j.ejmech.2017.04.025,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (unknown origin) (645 to 1186 residues) expressed in baculovirus infected Sf-9 cells preincubated for 10 mins followed by ATP addition measured after 1 hr by DELFIA/Time-Resolved fluorometry,COc1cc(Br)c(/C=C2\CC(C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)cc1OC,"2-(2-Bromo-4,5-dimethoxy-benzylidene)-4-methyl-6-(3,5,6-trimethyl-pyrazin-2-ylmethylene)-cyclohexanone",1.9,uM,=,0.2787536009528289,1,O=C1/C(=C/c2ccccc2)CCC/C1=C\c1cnccn1
7198,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,NC(=S)N1N=C(c2ccc(F)cc2)CC1c1cccc2ccccc12,"3-(4-Fluorophenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1Hpyrazole-1-carbothioamide",8.25,uM,=,0.9164539485499252,1,c1ccc(C2=NNC(c3cccc4ccccc34)C2)cc1
7199,987829,10.1016/j.ejmech.2013.08.019,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) (4:1) as substrate after 30 mins by spectrophotometric analysis",COc1cc2c(Oc3ccc(NC(=O)c4cc(-c5ccc(C)cc5)ccn4)cc3F)ccnc2cc1OCCCN1CCN(C)CC1,N-(3-Fluoro-4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinolin-4-yloxy)phenyl)-4-p-tolylpicolinamide,0.0900499999999999,uM,=,-1.045516282844448,0,O=C(Nc1ccc(Oc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1)c1cc(-c2ccccc2)ccn1
7200,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccccc3)n2)c(OC)cc1N(C)CCN(C)C,N-(2-(2-Dimethylaminoethylmethylamino)-4-methoxy-5-((4-benzamidopyrimidin-2-yl)amino)-phenyl)acrylamide,0.3176,uM,=,-0.4981195062449413,0,O=C(Nc1ccnc(Nc2ccccc2)n1)c1ccccc1
7201,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(Cl)c(Br)cc3F)ncnc2cc1OCCNCC(C)=O,"US8846699, 134",0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2ncnc3ccccc23)cc1
7202,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)benzamide,0.027,uM,=,-1.5686362358410126,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7203,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,FC(F)(F)c1cccc(Nc2ncnc3ccc4c(c23)OCCN4)c1,"N-(3-(trifluoromethyl)phenyl)-3,4-dihydro-2H-[1,4]oxazino[2,3-f]quinazolin-10-amine",0.9377,uM,=,-0.0279360839919777,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCN4)cc1
7204,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OC)c(OC)c3OC)ncc2Br)c1,"US9238629, I-5",0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
7205,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,O=NN(CCCl)C(=O)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,1-(2-Chloroethyl)-1-nitroso-3-{[4-(3-chlorophenyl)amino]quinazolin-6-yl}urea,0.067,uM,=,-1.1739251972991736,0,c1ccc(Nc2ncnc3ccccc23)cc1
7206,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.019,uM,=,-1.7212463990471711,0,c1ccc(Nc2ncnc3ccccc23)cc1
7207,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CCCN(C)CCN(C)c1cc(OC)c(Nc2nccc(Nc3ccn(C)n3)n2)cc1NC(=O)C=C,N-(2-((2-(but-3-en-1-yl(methyl)amino)ethyl)(methyl)amino)-4-methoxy-5-((4-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,7.513,uM,=,0.8758133888397576,1,c1ccc(Nc2nccc(Nc3cc[nH]n3)n2)cc1
7208,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,NC(=S)N1N=C(c2ccc(Cl)cc2)CC1c1ccc2ccccc2c1,"3-(4-Chlorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",0.53,uM,=,-0.2757241303992109,0,c1ccc(C2=NNC(c3ccc4ccccc4c3)C2)cc1
7209,608087,10.1021/jm901558p,,,,Inhibition of human recombinant EGFR expressed in insect cells by time-resolved fluorimetry,O=C(CNC(=O)Oc1ccccc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[2-[(4-(3-Bromoanilino)quinazolin-6-yl)amino]-2-oxoethyl]Phenylcarbamate,0.00037,uM,=,-3.431798275933005,0,O=C(CNC(=O)Oc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
7210,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(-c3ccccc3)nc3cnc(Nc4ccc(OCCOC)cc4)nc32)c1,N-(3-(2-((4-(2-Methoxyethoxy)phenyl)amino)-7-oxo-6-phenylpteridin-8(7H-)yl)phenyl)acrylamide,0.0050999999999999,uM,=,-2.292429823902064,0,O=c1c(-c2ccccc2)nc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
7211,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,COc1ccc(C2=NN(C(N)=S)C(c3ccc4ccccc4c3)C2)cc1,"3-(4-Methoxyphenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",1.04,uM,=,0.0170333392987803,1,c1ccc(C2=NNC(c3ccc4ccccc4c3)C2)cc1
7212,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)OC,"US8846699, 165",0.098,uM,=,-1.0087739243075051,0,c1ccc(Nc2ncnc3ccccc23)cc1
7213,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,Cc1ccc(C2=NN(C(N)=S)C(c3ccc4ccccc4c3)C2)cc1,"5-(Naphthalen-2-yl)-3-(p-tolyl)-4,5-dihydro-1Hpyrazole-1-carbothioamide",0.52,uM,=,-0.2839966563652008,0,c1ccc(C2=NNC(c3ccc4ccccc4c3)C2)cc1
7214,2107166,10.1016/j.ejmech.2021.113265,,,,Inhibition of EGFR (unknown origin),Cn1cc(-c2cc3ncnc(Nc4ccc(CC(=O)Nc5cc(C(C)(C)C)nn5C)cc4)c3s2)cn1,"N-(3-(tert-butyl)-1-methyl-1H-pyrazol-5-yl)-2-(4-((6-(1-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4-yl)amino)phenyl)acetamide",176.09,uM,=,2.2457346934565856,1,O=C(Cc1ccc(Nc2ncnc3cc(-c4cn[nH]c4)sc23)cc1)Nc1ccn[nH]1
7215,982464,10.1016/j.bmc.2013.06.070,,,,Inhibition of recombinant EGFR kinase cytoplasmic domain (unknown origin) expressed in baculovirus expression vector-infected insect sf9 cells assessed as level of autophosphorylation after 10 mins by DELFIA/time-resolved fluorometry,CSCCCNc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,N4-(3-Chlorophenyl)-N6-(3-(methylthio)propyl)quinazoline,5.1,uM,=,0.7075701760979364,1,c1ccc(Nc2ncnc3ccccc23)cc1
7216,608087,10.1021/jm901558p,,,,Inhibition of human recombinant EGFR expressed in insect cells by time-resolved fluorimetry,N#CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-cyanoacetamide,0.00017,uM,=,-3.769551078621726,0,c1ccc(Nc2ncnc3ccccc23)cc1
7217,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,COCCOc1cc2ncnc(Nc3cccc(Cl)c3)c2c2c1OC(COC)CO2,"N-(3-chlorophenyl)-5-(2-methoxyethoxy)-3-(methoxymethyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinazolin-10-amine",0.0102899999999999,uM,=,-1.987584625237567,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCO4)cc1
7218,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CCN,"US8846699, 62",0.258,uM,=,-0.5883802940367698,0,c1ccc(Nc2ncnc3ccccc23)cc1
7219,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(NS(C)(=O)=O)cc3)cc12)c1ccccc1,"(R)-N-(4-(4-((1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methanesulfonamide",0.0003,uM,=,-3.522878745280338,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7220,556139,10.1016/j.bmc.2008.04.019,,,,Inhibition of EGFR expressed in human tumor cells,Nc1nc(Nc2ccc(F)c(Cl)c2)c2cc(CCc3ccccc3)[nH]c2n1,"N4-(3-Chloro-4-fluorophenyl)-6-(2-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",22.8,uM,=,1.3579348470004535,1,c1ccc(CCc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7221,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Cc1cccc(/C=N/NC2=NC(=O)CS2)c1,2-(2-(3-Methylbenzylidene)hydrazinyl)thiazol-4(5H)-one,23.49,uM,=,1.3708830167776058,1,O=C1CSC(N/N=C/c2ccccc2)=N1
7222,473565,10.1073/pnas.0708800104,,,,Inhibition of EGFR,CN(c1cccnc1)c1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cn1,"4-(3-chloro-4-fluorophenylamino)-6-(pyridin-3-yl-methylamino)-3-cyano-[1,7]-naphthyridine",5000.0,uM,=,3.6989700043360174,1,c1ccc(Nc2ccnc3cnc(Nc4cccnc4)cc23)cc1
7223,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CC(C)CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-isobutyl oxime,0.032,uM,=,-1.494850021680094,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
7224,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,COc1cc2nccc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinolin-4-yl)-amine",0.17,uM,=,-0.7695510786217261,0,c1ccc(Nc2ccnc3ccccc23)cc1
7225,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3c(F)cc(Cl)cc3F)ncnc2cc1OCC1CCN(C)CC1,"(4-Chloro-2,6-difluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine",0.45,uM,=,-0.3467874862246563,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7226,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)NCCC,"US8846699, 169",0.026,uM,=,-1.585026652029182,0,c1ccc(Nc2ncnc3ccccc23)cc1
7227,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,CN(CCCl)C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,3-(2-chloroethyl)-1-methyl-1-{[4-(3-bromophenyl)amino]quinazolin-6-yl}urea,0.156,uM,=,-0.8068754016455384,0,c1ccc(Nc2ncnc3ccccc23)cc1
7228,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C1CCCN1C,"US8846699, 100::US8846699, 98",0.024,uM,=,-1.619788758288394,0,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)C1CCCN1
7229,1684313,10.1016/j.ejmech.2017.04.025,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (unknown origin) (645 to 1186 residues) expressed in baculovirus infected Sf-9 cells preincubated for 10 mins followed by ATP addition measured after 1 hr by DELFIA/Time-Resolved fluorometry,Cc1nc(C)c(/C=C2\CN(C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)nc1C,"3,5-Bis-(3,5,6-trimethyl-pyrazin-2-ylmethylene)-1-methylpiperidin-4-one",0.04,uM,=,-1.3979400086720375,0,O=C1/C(=C/c2cnccn2)CNC/C1=C\c1cnccn1
7230,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(F)c3F)ncnc2cc1OCCNC(=O)CCN(CC)CC,"US8846699, 125",0.019,uM,=,-1.7212463990471711,0,c1ccc(Nc2ncnc3ccccc23)cc1
7231,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CO,"US8846699, 45",0.032,uM,=,-1.494850021680094,0,c1ccc(Nc2ncnc3ccccc23)cc1
7232,2207741,10.1021/acs.jmedchem.2c00893,,,,Inhibition of wild type EGFR expressed in human NCI-H2073 cells,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.24,uM,=,-0.619788758288394,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
7233,610616,10.1021/jm901386e,,,,Inhibition of EGFR,COc1cc(/C=C2\SC(=N)NC2=O)ccc1OCCCOc1cc(C)cc(C)c1,"(Z)-5-(4-(3-(3,5-dimethylphenoxy)propoxy)-3-methoxybenzylidene)-2-iminothiazolidin-4-one",56.0,uM,=,1.7481880270062005,1,N=C1NC(=O)/C(=C/c2ccc(OCCCOc3ccccc3)cc2)S1
7234,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)CC(=C)C,N-(4-methoxy-2-(methyl(2-(methyl(2-methylallyl)amino)ethyl)amino)-5-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.1808,uM,=,-0.7428015738606555,0,c1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1
7235,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,Nc1ncnc(Nc2ccc3c(cnn3Cc3cccc(F)c3)c2)c1/C=N/OCc1ccccc1,4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-benzyl oxime,0.023,uM,=,-1.6382721639824072,0,C(=N/OCc1ccccc1)\c1cncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1
7236,2225007,10.1021/acs.jmedchem.1c01714,,,,Inhibition of wildtype EGFR (unknown origin) incubated for 40 mins by luminescence based assay,COc1cc(NC(=O)CCCCCCC(=O)NO)ccc1Nc1nccc(-c2cn(C)c3ccccc23)n1,8-(hydroxyamino)-N-[3-methoxy-4-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]-8-oxo-octanamide,5.7,uM,=,0.7558748556724915,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
7237,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)N1CCN(c2ccccc2)CC1,"3-(3,4-Dihydroxy-phenyl)-2-(4-phenyl-piperazine-1-carbonyl)-acrylonitrile",4.3,uM,=,0.6334684555795865,1,O=C(C=Cc1ccccc1)N1CCN(c2ccccc2)CC1
7238,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,Clc1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1,"3-(4-Chlorophenyl)-5-(naphthalen-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",0.11,uM,=,-0.958607314841775,0,c1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1
7239,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,Brc1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1,"3-(4-Bromophenyl)-5-(naphthalen-1-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",0.49,uM,=,-0.3098039199714864,0,c1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1
7240,2302058,10.1016/j.ejmech.2017.08.009,,,,Inhibition of EGFR (unknown origin),Cc1cc2c(Nc3ccc(C)c(O)c3)ncnn2c1,"2-Methyl-5-(6-methyl-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-phenol",0.405,uM,=,-0.3925449767853314,0,c1ccc(Nc2ncnn3cccc23)cc1
7241,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,COc1ccc(C2=NN(C(C)=O)C(c3ccc(C(=O)OC(C)Cn4c([N+](=O)[O-])cnc4C)cc3)C2)cc1,"1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-yl 4-(1-acetyl-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",21.31,uM,=,1.328583449714202,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7242,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(Cc2ccccc2F)nn1,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-((1-(2-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.065,uM,=,-1.1870866433571443,0,c1ccc(Cn2cc(COc3ccc4c(Nc5ccccc5)ncnc4c3)nn2)cc1
7243,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,C[C@@H](Nc1ncnc2[nH]c(-c3cccc(C(N)=O)c3)cc12)c1ccccc1,"(R)-3-(4-((1-Phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzamide",0.0014,uM,=,-2.853871964321762,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7244,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,CCOC(=O)/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,3-[4-(3-Bromo-phenylamino)-quinazolin-6-ylcarbamoyl]-acrylic acid ethyl ester,0.064,uM,=,-1.193820026016113,0,c1ccc(Nc2ncnc3ccccc23)cc1
7245,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCOP(N)(=O)N(CCCl)CCCl,"3-((4-((3-Chloro-4-fluorophenyl)amino))-7-methoxyquinazolin-6-yl)oxy)propyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.0005,uM,=,-3.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
7246,1983834,10.1016/j.bmc.2019.115281,,,,Inhibition of EGFR L858R/T790M (unknown origin),C=C1CC(c2ccccc2)(C(Br)c2ccccc2)OC1=O,rac-5-(bromo(phenyl)methyl)-3-methylene-5-phenyldihydrofuran-2(3H)-one,14.0,uM,=,1.146128035678238,1,C=C1CC(Cc2ccccc2)(c2ccccc2)OC1=O
7247,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=CC(=O)N(CCCN1CCOCC1)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-N-(3-morpholin-4-yl-propyl)-acrylamide",0.156,uM,=,-0.8068754016455384,0,c1ccc(Nc2ncnc3cnc(NCCCN4CCOCC4)cc23)cc1
7248,63790,10.1016/S0960-894X(97)00035-8,,,,Antagonism towards Epidermal growth factor receptor,COc1cc2ncnc(N(C)c3ccc(C)cc3)c2cc1OC.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-methyl-p-tolyl-amine hydrochloride",4.0,uM,=,0.6020599913279624,1,c1ccc(Nc2ncnc3ccccc23)cc1
7249,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,COc1cc2c(N[C@@H]3C[C@H]3c3ccccc3)c(C#N)cnc2cc1OC1CCN(C)CC1,"6-methoxy-7-(1-methylpiperidin-4-yloxy)-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",0.36,uM,=,-0.4436974992327127,0,c1ccc([C@@H]2C[C@H]2Nc2ccnc3cc(OC4CCNCC4)ccc23)cc1
7250,78740,10.1021/jm00075a010,,,,Inhibition of polyGAT phosphorylation by EGF receptor,COc1cc(/C=C(\C#N)C(N)=O)cc(CSCCC(=O)O)c1O,3-[5-(2-Carbamoyl-2-cyano-vinyl)-2-hydroxy-3-methoxy-benzylsulfanyl]-propionic acid,125.0,uM,=,2.096910013008056,1,c1ccccc1
7251,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CNC(=O)O1,"US8846699, 91",0.017,uM,=,-1.769551078621726,0,O=C1NCC(COc2ccc3c(Nc4ccccc4)ncnc3c2)O1
7252,1886849,10.1016/j.bmcl.2019.04.029,,,,Inhibition of probe binding to wild type EGFR (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay,COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)C1CSSC1,"N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-1,2-dithiolane-4-carboxamide",0.076,uM,=,-1.1191864077192086,0,O=C(Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1)C1CSSC1
7253,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCCCOc1cc2c(Nc3ccc(NC(=O)OCC)c(Cl)c3)ncnc2cc1OCCN(CC)CC.Cl,{4-[6-Butoxy-7-(2-diethylaminoethoxy)quinazolin-4-ylamino]-2-chlorophenyl}carbamic acid ethyl ester hydrochloride,9.8,uM,=,0.9912260756924948,1,c1ccc(Nc2ncnc3ccccc23)cc1
7254,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,CNc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-N*6*-methyl-quinazoline-4,6-diamine",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
7255,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OC[C@H](C)NC(=O)CN(C)C,"US8846699, 158::US8846699, 163",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3ccccc23)cc1
7256,603361,10.1016/j.bmc.2009.08.044,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA,COc1ccccc1C(Cc1coc2nc(N)nc(N)c12)C(C)C,"5-[(R/S)-2-(2-Methoxyphenyl)-3-methylbutyl]furo[2,3-d]-pyrimidine-2,4-diamine",18.2,uM,=,1.260071387985075,1,c1ccc(CCc2coc3ncncc23)cc1
7257,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.021,uM,=,-1.6777807052660807,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
7258,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,Cc1cccc(Nc2ncnc3ccc(/N=N/N(C)C)cc23)c1,"6-[(1E)-3,3-dimethyltriaz-1-enyl]-N-(3-methylphenyl)quinazolin-4-amine",0.024,uM,=,-1.619788758288394,0,c1ccc(Nc2ncnc3ccccc23)cc1
7259,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cnn(CC)c3)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,0.1006,uM,=,-0.9974020192800914,0,c1ccc(Nc2nccc(Nc3cn[nH]c3)n2)cc1
7260,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,CNc1ccc2ncnc(Nc3cccc(C)c3)c2c1,4-[(3-methylphenyl)amino]-6-(methylamino)quinazoline,0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccccc23)cc1
7261,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2cnc(C(N)=O)c(Nc3ccc(N4CCN(C)CC4)cc3)n2)c1,"US9085540, 26",0.00092,uM,=,-3.036212172654445,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7262,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)NC(C)(C)C,"US8846699, 54",0.045,uM,=,-1.3467874862246565,0,c1ccc(Nc2ncnc3ccccc23)cc1
7263,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",CCC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(C)=O,"US8846699, 77",0.866,uM,=,-0.0624821079826533,0,c1ccc(Nc2ncnc3ccccc23)cc1
7264,1337212,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ccc2nc(Oc3ccccc3)c(/C=N/NC(=O)Cn3c([N+](=O)[O-])cnc3C)cc2c1,(E)-N'-((6-methyl-2-phenoxyquinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,3.17,uM,=,0.5010592622177514,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
7265,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CCO,"US8846699, 67",0.089,uM,=,-1.0506099933550872,0,c1ccc(Nc2ncnc3ccccc23)cc1
7266,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,NC(=S)N1N=C(c2ccccc2)CC1c1ccc2ccccc2c1,"5-(Naphthalen-2-yl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide",3.01,uM,=,0.4785664955938433,1,c1ccc(C2=NNC(c3ccc4ccccc4c3)C2)cc1
7267,63790,10.1016/S0960-894X(97)00035-8,,,,Antagonism towards Epidermal growth factor receptor,COc1cc2ncnc(N(C)c3ccc(Cl)cc3)c2cc1OC.Cl,"(4-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-methyl-amine hydrochloride",3.0,uM,=,0.4771212547196624,1,c1ccc(Nc2ncnc3ccccc23)cc1
7268,1538409,10.1021/acs.jmedchem.5b01412,,,,Inhibition of EGFR phosphorylation in human NCI-H1975 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay,CC(C)n1c(CO)nc2cnc(Nc3ccnc(N4CC[C@H](O)[C@H](F)C4)n3)cc21,"(+/-)-3-Fluoro-1-(4-((2-(hydroxymethyl)-1-isopropyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)pyrimidin-2-yl)piperidin-4-ol",2.53,uM,=,0.4031205211758178,1,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1
7269,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CNc1cc2c(Nc3cccc(C)c3)ncnc2cn1,"N*6*-Methyl-N*4*-m-tolyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2ncnc3cnccc23)cc1
7270,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,OC[C@@H](Nc1ncnc2oc(-c3ccccc3)c(-c3ccco3)c12)c1ccccc1,"(2S)-2-{[5-(Furan-2-yl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]-amino}-2-phenylethanol",0.434,uM,=,-0.3625102704874893,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccco4)c23)cc1
7271,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,CCC(=O)N1CCOc2c1ccc1ncnc(Nc3cccc(Br)c3)c21,"1-(10-((3-bromophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)propan-1-one",0.07028,uM,=,-1.1531682471767426,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCN4)cc1
7272,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OC)cc3OC)ncc2Br)c1,"US9238629, I-20",0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
7273,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CCC,"US8846699, 51",0.032,uM,=,-1.494850021680094,0,c1ccc(Nc2ncnc3ccccc23)cc1
7274,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccc(OC)c(OC)c3)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-(2-Dimethylaminoethylmethylamino)-4-methoxy-5-((4-(3,4dimethoxybenzamido)pyri-midin-2-yl)amino)phenyl)acrylamide",0.1871999999999999,uM,=,-0.7276941555979136,0,O=C(Nc1ccnc(Nc2ccccc2)n1)c1ccccc1
7275,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CN(C)CCN(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-(2-dimethylamino-ethyl)-N*6*-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.046,uM,=,-1.337242168318426,0,c1ccc(Nc2ncnc3cnccc23)cc1
7276,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)Cc1ccccc1,N-(2-((2-(benzyl(methyl)amino)ethyl)(methyl)amino)-4-methoxy-5-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.4064,uM,=,-0.3910463007241371,0,c1ccc(CNCCNc2ccc(Nc3nccc(Nc4c[nH]c5ccccc45)n3)cc2)cc1
7277,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,COc1ccc(CCNC(=O)/C(C#N)=C/c2ccc(O)c(O)c2)cc1OC,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-[2-(3,4-dimethoxy-phenyl)-ethyl]-acrylamide",1.7,uM,=,0.2304489213782739,1,O=C(/C=C/c1ccccc1)NCCc1ccccc1
7278,793611,10.1016/j.bmc.2011.11.023,,,,Inhibition of EGFR autophosphorylation in EGF-stimulated human A431 cells after 1 hr by immunoblotting,O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3cccc(Cl)c3)ncnc2s1,"(4-(3-Chlorophenylamino)thieno[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanone",0.3,uM,=,-0.5228787452803376,0,O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3ccccc3)ncnc2s1
7279,887628,10.1021/jm3003203,,,,Inhibition of EGFR,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide,0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
7280,655538,10.1038/leu.2008.334,,,,Inhibition of EGFR,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,"4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile",0.053,uM,=,-1.275724130399211,0,c1ccc(Nc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1
7281,63781,10.1016/j.bmcl.2004.01.034,,,,Inhibition of peptide substrate phosphorylation by epidermal growth factor receptor,CC#CC(=O)Nc1ccc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2c1,But-2-ynoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.3302,uM,=,-0.4812229310732252,0,c1ccc(Nc2ccnc3ccccc23)cc1
7282,509296,10.1074/jbc.m609721200,,,,Inhibition of EGFR,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C,"5-(5-Chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide",3.0,uM,=,0.4771212547196624,1,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1
7283,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Brc1cccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-[2-(3H-imidazol-4-yl)-ethyl]-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0063,uM,=,-2.2006594505464183,0,c1ccc(Nc2ncnc3cnc(NCCc4c[nH]cn4)cc23)cc1
7284,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,OCC(O)Cn1ccc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"3-[4-(3-Bromo-phenylamino)-pyrrolo[3,2-g]quinazolin-8-yl]-propane-1,2-diol",0.0016,uM,=,-2.7958800173440754,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
7285,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,OCC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccccc1,"(R)-3-Phenyl-3-((6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)propan-1-ol",0.0005,uM,=,-3.3010299956639813,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7286,1801470,10.1016/j.ejmech.2018.07.024,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP-MgCl2 addition and measured after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(-c2nc3sc(-c4ccccc4)cn3n2)cc1,"2-(4-Methoxyphenyl)-5-phenylthiazolo[3,2-b][1,2,4]triazole",5.6,uM,=,0.7481880270062004,1,c1ccc(-c2nc3sc(-c4ccccc4)cn3n2)cc1
7287,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,CC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]acetamide",0.218,uM,=,-0.6615435063953952,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
7288,1538409,10.1021/acs.jmedchem.5b01412,,,,Inhibition of EGFR phosphorylation in human NCI-H1975 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay,CO[C@H]1CCN(c2nccc(Nc3cc4c(cn3)nc(CO)n4C(C)C)n2)C[C@H]1F,"(+/-)-{6-[2-((cis)-3-Fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-ylamino]-1-isopropyl-1H-imidazo[4,5-c]pyridin-2-yl}methanol",0.29,uM,=,-0.5376020021010439,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1
7289,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CCOc1ccc(C2=NN(C(C)=O)C(c3ccc(C(=O)OC(C)Cn4c([N+](=O)[O-])cnc4C)cc3)C2)cc1,"1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-yl 4-(1-acetyl-3-p-tolyl-4,5-dihydro-1H-pyrazol-5-yl)benzoate",26.92,uM,=,1.4300750555519393,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7290,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",NP(=O)(OCCCOc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1)N(CCCl)CCCl,"3-((4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)oxy)propyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.075,uM,=,-1.1249387366083,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
7291,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)/C=C/CN(C)C,"US8846699, 53",0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ncnc3ccccc23)cc1
7292,2059437,10.1016/j.bmc.2021.116094,,,,Inhibition of wild-type EGFR (unknown origin) using biotinylated TK peptide as substrate measured after 30 mins by HTRF assay,C#CCn1cc(-c2ccnc(Nc3cc(NC(=O)C=C)c(N(C)CCN(C)C)cc3OC)n2)c2ccccc21,N-(2-((2-(Dimethylamino)ethyl)(methypamino)-4-methoxy-5-((4-(1-(prop-2-yn-1-yl)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide,0.01372,uM,=,-1.8626458886292672,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
7293,1828521,10.1016/j.ejmech.2018.10.052,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.155,uM,=,-0.8096683018297085,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
7294,2045678,10.1039/d0md00146e,,,,Inhibition of EGFR (unknown origin) using Tyrosine 4 peptide and ATP as substrate incubated for 1 hr by Z'-lyte kinase assay based UV-VIS spectrophotometric method,COc1ccc(C2N=C(C(N)=O)c3ncn(-c4ccc(F)cc4)c3N2)cc1OC,"2-(3,4-Dimethoxyphenyl)-9-(4-fluorophenyl)-3,9-dihydro-2H-purine-6-carboxamide",0.61733,uM,=,-0.2094826173826799,0,C1=NC(c2ccccc2)Nc2c1ncn2-c1ccccc1
7295,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc2c(c1)CCN2Cc1cccc(F)c1,4-(1-(3-fluorobenzyl)indolin-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-methyl oxime,0.057,uM,=,-1.2441251443275083,0,c1ccc(CN2CCc3cc(Nc4ccncn4)ccc32)cc1
7296,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,Cc1ccc(Nc2ncnn3ccc(CN4CCC(N)CC4)c23)cc1,"5-((4-aminopiperidin-1-yl)methyl)-N-p-tolylpyrrolo[1,2-f][1,2,4]triazin-4-amine",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1
7297,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C(=O)OCC,"US8846699, 71",0.098,uM,=,-1.0087739243075051,0,c1ccc(Nc2ncnc3ccccc23)cc1
7298,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cc(CNCCN(C)C)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-2-((6-(4-(((2-(Dimethylamino)ethyl)amino)methyl)-2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0003,uM,=,-3.522878745280338,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7299,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c(C(N)=O)nc2CC)c1,"US9085540, 1",0.0013,uM,=,-2.886056647693163,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7300,2270900,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) incubated for 60 mins in presence of ATP by ADP-Glo kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0155,uM,=,-1.8096683018297088,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
7301,63781,10.1016/j.bmcl.2004.01.034,,,,Inhibition of peptide substrate phosphorylation by epidermal growth factor receptor,CN(C)C/C=C/C(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.0372,uM,=,-1.4294570601181025,0,c1ccc(Nc2ccnc3ccccc23)cc1
7302,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,CN(C)CCn1ccc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-[8-(2-dimethylamino-ethyl)-8H-pyrrolo[3,2-g]quinazolin-4-yl]-amine",0.041,uM,=,-1.3872161432802643,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
7303,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,CN(C)C/C=C/C(=O)N1CCCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-8,9-dihydro-[1,4]oxazepino[3,2-g]quinazolin-6(7H)-yl)-4-(dimethylamino)but-2-en-1-one",0.36,uM,=,-0.4436974992327127,0,c1ccc(Nc2ncnc3cc4c(cc23)NCCCO4)cc1
7304,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,COc1ccc2c(N[C@@H]3C[C@H]3c3ccccc3)c(C#N)cnc2c1,"7-methoxy-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",2.58,uM,=,0.4116197059632301,1,c1ccc([C@@H]2C[C@H]2Nc2ccnc3ccccc23)cc1
7305,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,O=C(O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)c(O)c1,3-Hydroxy-4-[4-(2-nitro-vinyl)-phenoxysulfonyl]-benzoic acid,0.31,uM,=,-0.5086383061657274,0,O=S(=O)(Oc1ccccc1)c1ccccc1
7306,1886849,10.1016/j.bmcl.2019.04.029,,,,Inhibition of probe binding to wild type EGFR (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay,COc1cc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2cc1NC(=O)CC1CCSS1,"2-(1,2-Dithiolan-3-yl)-N-(7-methoxy-4-((3-methyl-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)quinazolin-6-yl)acetamide",0.253,uM,=,-0.5968794788241821,0,O=C(CC1CCSS1)Nc1ccc2ncnc(Nc3ccc(Oc4cccnc4)cc3)c2c1
7307,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C(COC)N(C)C,"US8846699, 161",0.057,uM,=,-1.2441251443275083,0,c1ccc(Nc2ncnc3ccccc23)cc1
7308,1848601,10.1016/j.ejmech.2019.03.055,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected Sf21 insect cells using STK as substrate by HTRF assay,CNc1cncc(-c2c[nH]c3nc(Nc4ccc(N5CCN(C(C)=O)CC5)cc4)nc(Oc4ccccc4)c23)n1,"1-(4-(4-((5-(6-(methylamino)pyrazin-2-yl)-4-phenoxy-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)ethan-1-one",1.048,uM,=,0.0203612826477078,1,c1ccc(Oc2nc(Nc3ccc(N4CCNCC4)cc3)nc3[nH]cc(-c4cnccn4)c23)cc1
7309,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,Clc1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1Cl,"3-(3,4-Dichlorophenyl)-5-(naphthalen-1-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",0.14,uM,=,-0.8538719643217619,0,c1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1
7310,528400,10.1021/np9905259,,,,Inhibition of human recombinant EGFR kinase expressed in Sf9 insect cells,C[C@@H](O)c1c(O)cc2c(c1O)C(=O)c1c(O)cc(O)cc1C2=O,"(R)-1,3,6,8-tetrahydroxy-2-(1-hydroxyethyl)anthracene-9,10-dione",37.5,uM,=,1.5740312677277188,1,O=C1c2ccccc2C(=O)c2ccccc21
7311,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",NP(=O)(OCCCCOc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1)N(CCCl)CCCl,"4-((4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)oxy)butyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3ccccc23)cc1
7312,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,COc1cccc(/C=C/C(=O)OCCn2c([N+](=O)[O-])cnc2C)c1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl 3-(3-methoxyphenyl)acrylate,13.87,uM,=,1.1420764610732848,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
7313,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCNCC1)c1cc([N+](=O)[O-])ccc1F,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(piperazin-1-yl)propoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.0026,uM,=,-2.5850266520291822,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCNCC1)c1ccccc1
7314,2065502,10.1016/j.bmc.2018.02.022,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.0267,uM,=,-1.5734887386354248,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
7315,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C(=O)NCC)CC1,"US8846699, 171",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7316,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)/C=N/OC,"US8846699, 73",0.256,uM,=,-0.5917600346881504,0,c1ccc(Nc2ncnc3ccccc23)cc1
7317,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,COCCOc1cc2ncc(C#N)c(N[C@@H]3C[C@H]3c3ccccc3)c2cc1OC,"6-methoxy-7-(2-methoxyethoxy)-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",0.0528,uM,=,-1.2773660774661877,0,c1ccc([C@@H]2C[C@H]2Nc2ccnc3ccccc23)cc1
7318,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CN(C)CC,"US8846699, 56",0.198,uM,=,-0.7033348097384688,0,c1ccc(Nc2ncnc3ccccc23)cc1
7319,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,Cc1cccc(Nc2ncnn3ccc(CN4CCC(N)CC4)c23)c1,"5-((4-aminopiperidin-1-yl)methyl)-N-m-tolylpyrrolo[1,2-f][1,2,4]triazin-4-amine",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1
7320,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCN(C)c1ccncc1,(4-Chloro-2-fluoro-phenyl)-{6-methoxy-7-[2-(methyl-pyridin-4-yl-amino)-ethoxy]-quinazolin-4-yl}-amine,0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3cc(OCCNc4ccncc4)ccc23)cc1
7321,2059437,10.1016/j.bmc.2021.116094,,,,Inhibition of wild-type EGFR (unknown origin) using biotinylated TK peptide as substrate measured after 30 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2ncc(C(F)(F)F)c(-c3cn(C4CC4)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(5-(4-(1-cyclopropyl-1H-indol-3-yl)-5-(trifluoromethyl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,0.05058,uM,=,-1.296021174991614,0,c1ccc(Nc2nccc(-c3cn(C4CC4)c4ccccc34)n2)cc1
7322,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC(NC(=O)CN(C)C)C(C)C,"US8846699, 156",0.149,uM,=,-0.826813731587726,0,c1ccc(Nc2ncnc3ccccc23)cc1
7323,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(Cc2ccc(F)cc2)nn1,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.045,uM,=,-1.3467874862246565,0,c1ccc(Cn2cc(COc3ccc4c(Nc5ccccc5)ncnc4c3)nn2)cc1
7324,1329559,10.1039/C0MD00115E,,,,Inhibition of EGFR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,CC1(C)OB(c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)OC1(C)C,"N-(3-chloro-4-fluorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-4-amine",0.57,uM,=,-0.2441251443275086,0,c1ccc(Nc2ncnc3ccc(B4OCCO4)cc23)cc1
7325,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)N(C)c1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(C)=O,"US8846699, 78",0.389,uM,=,-0.4100503986742922,0,c1ccc(Nc2ncnc3ccccc23)cc1
7326,63781,10.1016/j.bmcl.2004.01.034,,,,Inhibition of peptide substrate phosphorylation by epidermal growth factor receptor,CC#CC(=O)Nc1cnc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2c1,"But-2-ynoic acid [5-(3-chloro-4-fluoro-phenylamino)-6-cyano-[1,8]naphthyridin-3-yl]-amide",3.7624,uM,=,0.5754649657380231,1,c1ccc(Nc2ccnc3ncccc23)cc1
7327,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,CS(=O)(=O)c1ccc(F)c(C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2OCCCN2CCOCC2)c1,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-5-(methylsulfonyl)benzamide,0.057,uM,=,-1.2441251443275083,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7328,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#Cc1ccc(CNCCS(C)(=O)=O)cc1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-((4-((2-(methylsulfonyl)ethylamino)methyl)phenyl)ethynyl)pyrimidin-4-amine,0.022,uM,=,-1.6575773191777938,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
7329,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,C#Cc1cccc(Nc2ccnc3cc(OC)c(OC)cc23)c1,"N-(3-Ethynylphenyl)-6,7-dimethoxyquinolin-4-amine",0.042,uM,=,-1.3767507096020994,0,c1ccc(Nc2ccnc3ccccc23)cc1
7330,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc(OCc2cc(F)cc(F)c2)c(Cl)c1,"4-(4-(3,5-difluorobenzyloxy)-3-chlorophenylamino)-6-aminopyrimidine-5-carbaldehyde O-methyl oxime",0.033,uM,=,-1.4814860601221125,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
7331,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccccc1Br,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl3-(2-bromophenyl)acrylate,24.32,uM,=,1.3859635706006974,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
7332,2283190,10.1039/d2md00139j,,,,Inhibition of wild type EGFR (unknown origin),C=CC(=O)N1CCC[C@@H](n2nc(-c3cn(C)c4ccccc34)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(1-methyl-1H-indol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.058,uM,=,-1.2365720064370629,0,c1ccc2c(-c3nn([C@@H]4CCCNC4)c4ncncc34)c[nH]c2c1
7333,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,CN(C)/N=N/c1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N-(3-bromophenyl)-6-[(1E)-3,3-dimethyltriaz-1-enyl]quinazolin-4-amine",0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccccc23)cc1
7334,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine",0.044,uM,=,-1.3565473235138126,0,c1ccc(Nc2ncnc3ccccc23)cc1
7335,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,CN(C)CCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)c1cc([N+](=O)[O-])ccc1F,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(dimethylamino)propoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.0092,uM,=,-2.036212172654445,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccccc1
7336,2272129,10.1016/j.ejmech.2020.113070,,,,Inhibition of wild type human EGFR measured by ELISA analysis,COc1ccc(-c2nnc(-n3c(-c4ccccc4)nc4cc(Cl)ccc4c3=O)o2)cc1,"7-chloro-3-(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)-2-phenylquinazolin-4(3H)-one",0.021,uM,=,-1.6777807052660807,0,O=c1c2ccccc2nc(-c2ccccc2)n1-c1nnc(-c2ccccc2)o1
7337,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,COc1cc(/C=C/[N+](=O)[O-])ccc1O,2-Methoxy-4-(2-nitro-vinyl)-phenol,7.9,uM,=,0.8976270912904415,1,c1ccccc1
7338,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,CC1CCCCN1C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(2-methylpiperidin-1-yl)but-2-en-1-one",0.043,uM,=,-1.3665315444204136,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
7339,2061598,10.1016/j.bmcl.2015.11.049,,,,Inhibition of HER1 (unknown origin),Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3c(C)[nH]nc3n2)c(OC(C)C)cc1C1CCN(C)CC1,"US8592432, 34",0.96,uM,=,-0.0177287669604316,0,c1ccc(Nc2nc(Nc3ccc(C4CCNCC4)cc3)nc3n[nH]cc23)cc1
7340,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc(OCc2cccc(F)c2)c(Cl)c1,4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-6-aminopyrimidine-5-carbaldehyde O-methyl oxime,0.012,uM,=,-1.9208187539523751,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
7341,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cc(CNCCN2CCNCC2)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-2-((6-(2-Methoxy-4-(((2-(piperazin-1-yl)ethyl)amino)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0001,uM,=,-4.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccc(CNCCN5CCNCC5)cc4)cc23)cc1
7342,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cn1c(-c2csc(N/N=C\c3cccs3)n2)nc2ccccc21,4-(1-Methyl-1H-benzo[d]imidazol-2-yl)-2-(2-(thiophen-2-ylmethylene)hydrazinyl)thiazole,0.77324,uM,=,-0.1116856878432466,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1cccs1
7343,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cc(NS(C)(=O)=O)ccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2[nH]1,"(R)-N-(3-methoxy-4-(4-((1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methanesulfonamide",0.0007,uM,=,-3.154901959985743,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7344,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3cc(-c4cccc5ccccc45)ccc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((6-(naphthalen-1-yl)-1H-indazol-3-yl)amino)phenyl)acrylamide,0.0014,uM,=,-2.853871964321762,0,c1ccc(Nc2n[nH]c3cc(-c4cccc5ccccc45)ccc23)cc1
7345,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC(C)NC(=O)CCN(CC)CC,"US8846699, 155",0.024,uM,=,-1.619788758288394,0,c1ccc(Nc2ncnc3ccccc23)cc1
7346,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cn1c(-c2csc(N/N=C\c3ccccc3)n2)nc2ccccc21,2-(2-Benzylidenehydrazinyl)-4-(1-methyl-1H-benzo[d]imidazol2-yl)thiazole,1.23534,uM,=,0.0917865039939774,1,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccccc1
7347,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2cnc(C(N)=O)c(Nc3ccc(N4CCN(C)CC4)cc3)n2)c1,"US9085540, 26",0.0011,uM,=,-2.958607314841775,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7348,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C#CCN(C)CCN(C)c1cc(OC)c(Nc2nccc(Nc3ccn(C)n3)n2)cc1NC(=O)C=C,N-(4-methoxy-2-(methyl(2-(methyl(prop-2-yn-1-yl)amino)ethyl)amino)-5-((4-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.05076,uM,=,-1.2944783865773328,0,c1ccc(Nc2nccc(Nc3cc[nH]n3)n2)cc1
7349,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CCCN(C)CCN(C)c1cc(OC)c(Nc2nccc(Nc3cn(C)c4ccccc34)n2)cc1NC(=O)C=C,N-(2-((2-(but-3-en-1-yl(methyl)amino)ethyl)(methyl)amino)-4-methoxy-5-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.04272,uM,=,-1.3693687559795,0,c1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1
7350,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,Cc1cc(C)c(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)c(C)c1,"3-(3,4-Dihydroxy-phenyl)-2-(2,4,6-trimethyl-benzoyl)-acrylonitrile",10.7,uM,=,1.0293837776852095,1,O=C(/C=C/c1ccccc1)c1ccccc1
7351,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,c1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1,"5-(Naphthalen-1-yl)-1,3-diphenyl-4,5-dihydro-1Hpyrazole",2.52,uM,=,0.4014005407815441,1,c1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1
7352,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COC[C@@H](Nc1ncnc2[nH]c(-c3ccc(CO)cc3OC)cc12)c1ccccc1,"(S)-(3-Methoxy-4-(4-((2-methoxy-1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methanol",0.0005,uM,=,-3.3010299956639813,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7353,1337212,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ncc([N+](=O)[O-])n1CC(=O)N/N=C/c1cc2ccccc2nc1Oc1ccc(Cl)cc1,(E)-N'-((2-(4-chlorophenoxy)quinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,5.12,uM,=,0.7092699609758308,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
7354,1801470,10.1016/j.ejmech.2018.07.024,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP-MgCl2 addition and measured after 1 hr by DELFIA/time-resolved fluorometric analysis,Clc1ccc(-c2cn3nc(-c4ccccc4)nc3s2)cc1,"5-(4-Chlorophenyl)-2-phenylthiazolo[3,2-b][1,2,4]triazole",7.2,uM,=,0.8573324964312685,1,c1ccc(-c2nc3sc(-c4ccccc4)cn3n2)cc1
7355,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",NP(=O)(OCCCCOc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1)N(CCCl)CCCl,"4-((4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)oxy)butyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.027,uM,=,-1.5686362358410126,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
7356,556139,10.1016/j.bmc.2008.04.019,,,,Inhibition of EGFR expressed in human tumor cells,Nc1nc(Nc2ccc(Cl)cc2)c2cc(CCc3ccccc3)[nH]c2n1,"N4-(4-Chlorophenyl)-6-(2-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",3.18,uM,=,0.5024271199844327,1,c1ccc(CCc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7357,1986907,10.1016/j.bmc.2020.115481,,,,Inhibition of human recombinant EGFR in presence of substrate Ulight-CAGAGAIETDKEYYTVKD and Km ATP,C[C@@H]1[C@@H]2CN(c3nc(Nc4cnn(C)c4)ncc3F)C[C@]12NC(=O)[C@@H]1CC1(F)F,"(1S)-2,2-difluoro-N-[(1S,5R,6R)-3-[5-fluoro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-6-methyl-3-azabicyclo[3.1.0]hexan-1-yl]cyclopropanecarboxamide",4.11,uM,=,0.6138418218760693,1,O=C(N[C@@]12C[C@@H]1CN(c1ccnc(Nc3cn[nH]c3)n1)C2)C1CC1
7358,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C(=O)O,"US8846699, 72",0.102,uM,=,-0.9913998282380824,0,c1ccc(Nc2ncnc3ccccc23)cc1
7359,608087,10.1021/jm901558p,,,,Inhibition of human recombinant EGFR expressed in insect cells by time-resolved fluorimetry,O=C(COc1ccc(F)cc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(4-fluorophenoxy)-acetamide,0.00843,uM,=,-2.0741724253752576,0,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
7360,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3cc(-c4cccc(C(F)(F)F)c4)ccc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((6-(3-(trifluoromethyl)phenyl)-1Hindazol-3-yl)amino)phenyl)acrylamide,0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2n[nH]c3cc(-c4ccccc4)ccc23)cc1
7361,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.0009,uM,=,-3.0457574905606752,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
7362,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OC)cc3OC)ncc2C(F)(F)F)c1,"US9238629, I-3",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
7363,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1cccc([N+](=O)[O-])c1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl 3-(3-nitrophenyl)acrylate,14.53,uM,=,1.1622656142980214,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
7364,306573,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate; Range = 50-250 nM,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1N1CCN(C)CC1,N-[4-(3-Bromo-phenylamino)-7-(4-methyl-piperazin-1-yl)-quinazolin-6-yl]-acrylamide,0.25,uM,=,-0.6020599913279624,0,c1ccc(Nc2ncnc3cc(N4CCNCC4)ccc23)cc1
7365,1567373,10.1016/j.bmcl.2016.02.067,,,,Inhibition of wild type EGFR in human NCI-H1666 cells assessed as suppression of cell proliferation,C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1,"US9085540, 54",0.23,uM,=,-0.6382721639824072,0,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(O[C@@H]2CCNC2)n1
7366,1521039,10.1021/acs.jmedchem.5b01073,,,,Inhibition of EGFR phosphorylation in human H838 cells,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C,"4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2R)-2,4-Dimethylpiperazine-1-carboxylate",0.0645,uM,=,-1.1904402853647322,0,O=C(Oc1ccc2ncnc(Nc3ccccc3)c2c1)N1CCNCC1
7367,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CC(C)O/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-isopropyl oxime,0.014,uM,=,-1.853871964321762,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
7368,2251609,10.1021/acs.jmedchem.2c00168,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,CCOc1cc(N2CCC(N3CCN(C)CC3)CC2)c(Cl)cc1Nc1ncc(Cl)c(-c2cn(S(=O)(=O)CC)c3ccccc23)n1,5-chloro-N-(5-chloro-2-ethoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-4-(1-(ethylsulfonyl)-1H-indol-3-yl)pyrimidin-2-amine,0.3437,uM,=,-0.4638204678627747,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCC(N6CCNCC6)CC5)cc4)n3)c[nH]c2c1
7369,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,COc1cc2ncc(C(=O)O)c(Nc3cccc(Br)c3)c2cc1OC,"4-(3-Bromo-phenylamino)-6,7-dimethoxy-quinoline-3-carboxylic acid",8.719,uM,=,0.9404666776635288,1,c1ccc(Nc2ccnc3ccccc23)cc1
7370,1886849,10.1016/j.bmcl.2019.04.029,,,,Inhibition of probe binding to wild type EGFR (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)CC1CCSS1,"N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1,2-dithiolan-3-yl)acetamide",0.12,uM,=,-0.9208187539523752,0,O=C(CC1CCSS1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
7371,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,CN1CCN(CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc2NC(=O)c2cc([N+](=O)[O-])ccc2F)CC1,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(2-(4-methylpiperazin-1-yl)ethoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.013,uM,=,-1.8860566476931635,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCN1CCNCC1)c1ccccc1
7372,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CCOc1ccc(C2=NN(C(C)=O)C(c3ccc(C(=O)OCCn4c([N+](=O)[O-])cnc4C)cc3)C2)cc1,"2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-(1-acetyl-3-p-tolyl-4,5-dihydro-1H-pyrazol-5-yl)benzoate",15.16,uM,=,1.180699201296035,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7373,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(F)c3F)ncnc2cc1OCC1CCN(C(C)=O)CC1,"US8846699, 7",0.026,uM,=,-1.585026652029182,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7374,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C(=O)CN(C)C)CC1,"US8846699, 10",0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7375,63790,10.1016/S0960-894X(97)00035-8,,,,Antagonism towards Epidermal growth factor receptor,COc1cc2ncnc(N(C)c3cccc(Cl)c3)c2cc1OC.Cl,"(3-Chloro-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-methyl-amine hydrochloride",0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
7376,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,CN1C(=O)C(=C(C#N)C#N)c2cc(O)ccc21,"2-(5-Hydroxy-1-methyl-2-oxo-1,2-dihydro-indol-3-ylidene)-malononitrile",26.0,uM,=,1.414973347970818,1,C=C1C(=O)Nc2ccccc21
7377,615344,10.1016/j.ejmech.2009.12.026,,,,Inhibition of EGFR,CC1=C(C(=O)Nc2ccc(C)cc2)C(c2ccc(O)cc2O)NC(NCc2ccccc2)=N1,"2-(Benzylamino)-6-(2,4-dihydroxyphenyl)-4-methyl-N-(4-methylphenyl)-l,6-dihydropyrimi-dine-5-carboxamide",23.5,uM,=,1.3710678622717365,1,O=C(Nc1ccccc1)C1=CN=C(NCc2ccccc2)NC1c1ccccc1
7378,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccc(C(F)(F)F)cc3)n2)c(OC)cc1N1CCN(C)CC1,N-(2-(4-Methylpiperazin-1-yl)-4-methoxy-5-((4-(4-trifluoromethylbenzamido)pyrimidin-2-yl)-amino)phenyl)acrylamide,0.1522,uM,=,-0.817585347565446,0,O=C(Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1)c1ccccc1
7379,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(C#N)c2)c1,3-((5-(6-amino-5-((methoxyimino)methyl)pyrimidin-4-ylamino)-1H-indazol-1-yl)methyl)benzonitrile,0.02,uM,=,-1.6989700043360187,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
7380,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccc2ccccc2c1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl 3-(naphthalen-2-yl)acrylate,5.76,uM,=,0.7604224834232121,1,O=C(/C=C/c1ccc2ccccc2c1)OCCn1ccnc1
7381,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,NC1CCN(Cc2ccn3ncnc(Nc4cc(Cl)cc(Cl)c4)c23)CC1,"5-((4-aminopiperidin-1-yl)methyl)-N-(3,5-dichlorophenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.13,uM,=,-0.8860566476931633,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1
7382,2080996,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCc1cn(CCCCC(=O)NO)nn1,"5-(4-(((6-Acrylamido-4-((3-chloro-4-((2-fluorobenzyl)oxy)phenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypentanamide",0.0015,uM,=,-2.8239087409443187,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCc5c[nH]nn5)ccc34)cc2)cc1
7383,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,6-amino-4-[(3-chloro-4-fluorophenyl)amino]quinazoline,0.029,uM,=,-1.537602002101044,0,c1ccc(Nc2ncnc3ccccc23)cc1
7384,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,CCN(CC)C/C=C/C(=O)N1CCCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-8,9-dihydro-[1,4]oxazepino[3,2-g]quinazolin-6(7H)-yl)-4-(diethylamino)but-2-en-1-one",1.01,uM,=,0.0043213737826425,1,c1ccc(Nc2ncnc3cc4c(cc23)NCCCO4)cc1
7385,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,CC(=O)N1CCOc2c1ccc1ncnc(Nc3ccc(F)c(Cl)c3)c21,"1-(10-((3-chloro-4-fluorophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)ethan-1-one",0.04722,uM,=,-1.3258740172572918,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCN4)cc1
7386,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3cc4c(cnn4CCCN4CCOCC4)cc23)c1,"(3-Bromo-phenyl)-[1-(3-morpholin-4-yl-propyl)-1H-pyrazolo[4,3-g]quinazolin-5-yl]-amine",0.0088,uM,=,-2.055517327849832,0,c1ccc(Nc2ncnc3cc4c(cnn4CCCN4CCOCC4)cc23)cc1
7387,556139,10.1016/j.bmc.2008.04.019,,,,Inhibition of EGFR expressed in human tumor cells,Nc1nc(Nc2cccc(Br)c2)c2cc(Cc3ccccc3Cl)[nH]c2n1,"2-(2-chlorobenzyl)-N4-(3-bromophenyl)-1H-indole-4,6-diamine",4.31,uM,=,0.6344772701607315,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7388,1512952,10.1021/acsmedchemlett.5b00231,,,,Inhibition of wild type EGFR in human A549 cells assessed as inhibition of phosphorylation at Y1068 after 2 hrs by sandwich ELISA method,C=CC(=O)N1C[C@@H]2CN(c3nc(Nc4ccc(N5CCN(C)CC5)cc4)c4ncn(C(C)C)c4n3)C[C@@H]2C1,"1-((3aR,6aS)-5-(9-isopropyl-6-(4-(4-methylpiperazin-1-yl)phenylamino)-9H-purin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)prop-2-en-1-one",0.181,uM,=,-0.7423214251308154,0,c1nc2c(Nc3ccc(N4CCNCC4)cc3)nc(N3C[C@H]4CNC[C@H]4C3)nc2[nH]1
7389,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3cc(-c4cn(C)c5ccccc45)ccc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((6-(1-methyl-1H-indol-3-yl)-1H-indazol-3-yl)amino)phenyl)acrylamide,0.0093,uM,=,-2.0315170514460648,0,c1ccc(Nc2n[nH]c3cc(-c4c[nH]c5ccccc45)ccc23)cc1
7390,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(Cc3ccccc3)nc3cnc(Nc4ccc(OC)cc4)nc32)c1,N-(3-(6-Benzyl-2((4-methoxyphenyl)amino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.1303,uM,=,-0.8850555842874153,0,O=c1c(Cc2ccccc2)nc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
7391,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc(C)cc2)CC1c1ccc(C(=O)OC(C)Cn2c([N+](=O)[O-])cnc2C)cc1,"1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-yl 4-(1-acetyl-3-(4-ethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",25.58,uM,=,1.4079005401426352,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7392,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1cc(O)c(O)c(Br)c1)S(=O)(=O)/C(C#N)=C/c1cc(O)c(O)c(Br)c1,"(E)-3-(3-Bromo-4,5-dihydroxy-phenyl)-2-[(E)-1-(3-bromo-4,5-dihydroxy-phenyl)-2-cyano-ethenesulfonyl]-acrylonitrile",0.85,uM,=,-0.0705810742857072,0,O=S(=O)(C=Cc1ccccc1)/C=C/c1ccccc1
7393,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C(CO)N(C)C,"US8846699, 162",0.126,uM,=,-0.8996294548824371,0,c1ccc(Nc2ncnc3ccccc23)cc1
7394,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,O=C(CCCCCC(=O)Nc1ccc(O)c(C(=O)Nc2cccc(F)c2)c1)NO,N-(3-Fluorophenyl)-2-hydroxy-5-(7-hydroxyamino-7-oxohep-tanamido)benzamide,1.41,uM,=,0.1492191126553798,1,O=C(Nc1ccccc1)c1ccccc1
7395,558078,10.1016/j.bmcl.2008.10.039,,,,Inhibition of HER1,CN(C)CCOc1ccc(/C=C/c2cc(-c3cc4c(=O)[nH]cnc4[nH]3)ccn2)cc1,"6-(2-(4-(2-(dimethylamino)ethoxy)styryl)pyridin-4-yl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one",3.3,uM,=,0.5185139398778875,1,O=c1[nH]cnc2[nH]c(-c3ccnc(/C=C/c4ccccc4)c3)cc12
7396,2059437,10.1016/j.bmc.2021.116094,,,,Inhibition of wild-type EGFR (unknown origin) using biotinylated TK peptide as substrate measured after 30 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2ncc(C(F)(F)F)c(-c3cn(C4COC4)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-(oxetan-3-yl)-1H-indol-3-yl)-5-(trifluoromethyl)pyrimidin-2-ylamino)phenyl)acrylamide,0.0026,uM,=,-2.5850266520291822,0,c1ccc(Nc2nccc(-c3cn(C4COC4)c4ccccc34)n2)cc1
7397,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,CCC(=O)N1CCOc2c1ccc1ncnc(Nc3ccc(F)c(Cl)c3)c21,"1-(10-((3-chloro-4-fluorophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)propan-1-one",0.07061,uM,=,-1.1511337885052206,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCN4)cc1
7398,2080996,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCc1cn(CCCC(=O)NO)nn1,"4-(4-(((6-Acrylamido-4-((3-chloro-2-fluorophenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutanamide",0.0003599999999999,uM,=,-3.4436974992327127,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
7399,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,Cc1cccc(Nc2ncnc3ccc(NC(=O)N(CCCl)N=O)cc23)c1,1-(2-Chloroethyl)-1-nitroso-3-{[4-(3-methylphenyl)amino]quinazolin-6-yl}urea,1.061,uM,=,0.0257153839013406,1,c1ccc(Nc2ncnc3ccccc23)cc1
7400,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,NC(=S)N1N=C(c2ccc(Cl)cc2)CC1c1cccc2ccccc12,"3-(4-Chlorophenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1Hpyrazole-1-carbothioamide",0.94,uM,=,-0.0268721464003013,0,c1ccc(C2=NNC(c3cccc4ccccc34)C2)cc1
7401,1684313,10.1016/j.ejmech.2017.04.025,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (unknown origin) (645 to 1186 residues) expressed in baculovirus infected Sf-9 cells preincubated for 10 mins followed by ATP addition measured after 1 hr by DELFIA/Time-Resolved fluorometry,Cc1nc(C)c(/C=C2\CN(C)C/C(=C\c3nc(C)c(C)nc3C)C2=NO)nc1C,"3,5-Bis-(3,5,6-trimethyl-pyrazin-2-ylmethylene)-1-methylpiperidin-4-one oxime",0.02,uM,=,-1.6989700043360187,0,N=C1/C(=C/c2cnccn2)CNC/C1=C\c1cnccn1
7402,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc(F)cc(F)c1F,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2,3,5-trifluorobenzamide",0.365,uM,=,-0.4377071355435253,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7403,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,O=C(CCCCCC(=O)Nc1ccc(O)c(C(=O)Nc2ccc(F)c(F)c2)c1)NO,"N-(3,4-Difluorophenyl)-2-hydroxy-5-(7-hydroxyamino-7-oxoheptanamido)benzamide",2.22,uM,=,0.3463529744506387,1,O=C(Nc1ccccc1)c1ccccc1
7404,63781,10.1016/j.bmcl.2004.01.034,,,,Inhibition of peptide substrate phosphorylation by epidermal growth factor receptor,C=CC(=O)Nc1cnc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,"N-[5-(3-Bromo-phenylamino)-6-cyano-[1,8]naphthyridin-3-yl]-acrylamide",0.3748,uM,=,-0.4262004177842593,0,c1ccc(Nc2ccnc3ncccc23)cc1
7405,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccc(Cl)cc1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl3-(4-chlorophenyl)acrylate,3.62,uM,=,0.5587085705331657,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
7406,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.068,uM,=,-1.1674910872937636,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
7407,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C1CC1,"US8846699, 21",0.008,uM,=,-2.096910013008056,0,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)C1CC1
7408,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(C3CCCCC3)nc3cnc(Nc4cccc(N5CCN(C)CC5)c4)nc32)c1,N-(3-(6-Cyclohexyl-2((3-(4-methylpiperazin-1-yl)phenyl)-amino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.3416,uM,=,-0.4664821379830325,0,O=c1c(C2CCCCC2)nc2cnc(Nc3cccc(N4CCNCC4)c3)nc2n1-c1ccccc1
7409,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,COc1ccc(OC)c(Nc2cc(NCCc3cccs3)ncn2)c1,"N4-(2,5-Dimethoxyphenyl)-N6-(2-(thiophen-2-yl)ethyl)pyrimidine-4,6-diamine",0.125,uM,=,-0.9030899869919436,0,c1ccc(Nc2cc(NCCc3cccs3)ncn2)cc1
7410,2220184,10.1016/j.bmcl.2021.128524,,,,Inhibition of EGFR tyrosine kinase (unknown origin),COc1cccc2c1C(=O)C1=C(C2=O)c2c(O)cc(CO)cc2[C@@H](O)[C@@H]1O,"(5R,6R)-1,5,6-trihydroxy-3-(hydroxymethyl)-8-methoxy-5,6-dihydrotetraphene-7,12-dione",0.00654,uM,=,-2.184422251675733,0,O=C1C2=C(C(=O)c3ccccc31)c1ccccc1CC2
7411,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(F)cc3F)ncnc2cc1OCCNC(=O)CN(C)C,"US8846699, 68",0.156,uM,=,-0.8068754016455384,0,c1ccc(Nc2ncnc3ccccc23)cc1
7412,1538409,10.1021/acs.jmedchem.5b01412,,,,Inhibition of EGFR phosphorylation in human NCI-H1975 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay,Cc1nc2cnc(Nc3ccnc(N4CC[C@H](O)[C@H](F)C4)n3)cc2n1C(C)C,"(+/-)-3-Fluoro-1-(4-((1-isopropyl-2-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)pyrimidin-2-yl)piperidin-4-ol",1.0,uM,=,0.0,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1
7413,615344,10.1016/j.ejmech.2009.12.026,,,,Inhibition of EGFR,CC1=C(C(=O)Nc2ccc(C)cc2)C(c2ccc(O)cc2O)NC(SCc2ccccc2)=N1,"2-(Benzylthio)-6-(2,4-dihydroxyphenyl)-4-methyl-N-(4-methylphenyl)-l,6-dihydro-pyrimidine-5-carboxamide",93.5,uM,=,1.970811610872517,1,O=C(Nc1ccccc1)C1=CN=C(SCc2ccccc2)NC1c1ccccc1
7414,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)N1CCOCC1,"US8846699, 41",0.035,uM,=,-1.4559319556497243,0,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)N1CCOCC1
7415,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,NC(=S)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccc2ccccc2c1,"3-(3,4-Dichlorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",0.66,uM,=,-0.1804560644581313,0,c1ccc(C2=NNC(c3ccc4ccccc4c3)C2)cc1
7416,1848601,10.1016/j.ejmech.2019.03.055,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected Sf21 insect cells using STK as substrate by HTRF assay,C=CC(=O)N1CCC[C@@H](Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)C1,"(R)-1-(3-((5-(6-(methylamino)pyrazin-2-yl)-2-((4-morpholinophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.138,uM,=,-0.8601209135987634,0,c1cnc(-c2c[nH]c3nc(Nc4ccc(N5CCOCC5)cc4)nc(O[C@@H]4CCCNC4)c23)cn1
7417,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,COc1ccc(/C=N\Nc2nc(-c3nc4ccccc4n3C)cs2)cc1,2-(2-(4-Methoxybenzylidene)hydrazinyl)-4-(1-methyl-1H-benzo[d]imidazol-2-yl)thiazole,0.31175,uM,=,-0.5061935378494198,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccccc1
7418,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,O=C(/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1)NCCCN1CCOCC1,"But-2-enedioic acid [4-(3-chloro-4-fluoro-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide (3-morpholin-4-yl-propyl)-amide",0.014,uM,=,-1.853871964321762,0,O=C(/C=C/C(=O)Nc1cc2c(Nc3ccccc3)ncnc2cn1)NCCCN1CCOCC1
7419,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C(N)=O)nc2CC)c1,"US9085540, 64",0.00056,uM,=,-3.2518119729938,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7420,1653587,10.1016/j.ejmech.2016.11.037,,,,"Inhibition of recombinant EGFR (unknown origin) using poly (Glu4, Tyr) as substrate after 60 mins by ADP-glo kinase assay",CCCCOC(=O)c1c(-c2ccccc2)nn2ccccc12,"Butyl 2-phenylpyrazolo[1,5-a]pyridine-3-carboxylate",23.7,uM,=,1.374748346010104,1,c1ccc(-c2cc3ccccn3n2)cc1
7421,1801470,10.1016/j.ejmech.2018.07.024,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP-MgCl2 addition and measured after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1cc(-c2nc3sc(-c4ccc(Cl)cc4)cn3n2)cc(OC)c1OC,"5-(4-Chlorophenyl)-2-(3,4,5-trimethoxyphenyl)thiazolo[3,2-b][1,2,4]triazole",1.7,uM,=,0.2304489213782739,1,c1ccc(-c2nc3sc(-c4ccccc4)cn3n2)cc1
7422,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc(I)cc2)CC1c1ccc(C(=O)OCCn2c([N+](=O)[O-])cnc2C)cc1,"2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-(1-acetyl-3-(4-iodophenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",1.26,uM,=,0.1003705451175629,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7423,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C(N)=O)nc2CC)c1,"US9085540, 63",0.0018,uM,=,-2.744727494896694,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7424,2218523,10.1021/acs.jmedchem.0c01467,,,,Inhibition of EGFR (unknown origin),CCN(CC)CC1CCN(c2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1,SID29215540,0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3cnc(N4CCCCC4)nc23)cc1
7425,1930229,10.1016/j.ejmech.2019.02.050,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end) expressed in baculovirus infected Sf9 cells using ATP as substrate after 40 mins by Kinase-Glo MAX luminescence assay,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methylamide,0.057,uM,=,-1.2441251443275083,0,O=C(Nc1ccccc1)Nc1ccc(Oc2ccncc2)cc1
7426,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCCCOP(N)(=O)N(CCCl)CCCl,"3-((4-((3-Bromophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.0003,uM,=,-3.522878745280338,0,c1ccc(Nc2ncnc3ccccc23)cc1
7427,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc(F)cc2)CC1c1ccc(C(=O)OCCn2c([N+](=O)[O-])cnc2C)cc1,"2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-(1-acetyl-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",5.02,uM,=,0.7007037171450193,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7428,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NC1CCCCC1,"2-Cyano-N-cyclohexyl-3-(3,4-dihydroxy-phenyl)-acrylamide",1.6,uM,=,0.2041199826559248,1,O=C(C=Cc1ccccc1)NC1CCCCC1
7429,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cn1c(-c2csc(N/N=C\c3ccc([N+](=O)[O-])cc3)n2)nc2ccccc21,4-(1-Methyl-1H-benzo[d]imidazol-2-yl)-2-(2-(4-nitrobenzylidene)hydrazinyl)thiazole,0.08503,uM,=,-1.07042782092345,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccccc1
7430,1732106,10.1016/j.ejmech.2018.01.061,,,,"Inhibition of EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,CABOZANTINIB,3.11,uM,=,0.4927603890268375,1,O=C(Nc1ccccc1)C1(C(=O)Nc2ccc(Oc3ccnc4ccccc34)cc2)CC1
7431,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CCN(C)C,"US8846699, 61",0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
7432,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cc(C(N)=O)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-4-(4-((2-Hydroxy-1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methoxybenzamide",0.0005,uM,=,-3.3010299956639813,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7433,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,Nc1ncnc2c1c(-c1cccc(Cl)c1)cn2-c1ccccc1,"5-(3-Chloro-phenyl)-7-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",0.7,uM,=,-0.1549019599857432,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
7434,66580,10.1021/jm950692f,,,,Inhibition of tyrosine kinase activity of Epidermal growth factor receptor from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3cc4ncsc4cc23)c1,"(3-Bromo-phenyl)-(1-thia-3,5,7-triaza-cyclopenta[b]naphthalen-8-yl)-amine",0.044,uM,=,-1.3565473235138126,0,c1ccc(Nc2ncnc3cc4ncsc4cc23)cc1
7435,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=CC(=O)N(CCCN1CCOCC1)c1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-N-(3-morpholin-4-yl-propyl)-acrylamide,0.194,uM,=,-0.712198270069774,0,c1ccc(Nc2ncnc3ccc(NCCCN4CCOCC4)cc23)cc1
7436,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,COc1cc2ncc(C#N)c(N[C@@H]3C[C@H]3c3ccccc3)c2cc1OC,"6,7-dimethoxy-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",0.09,uM,=,-1.0457574905606752,0,c1ccc([C@@H]2C[C@H]2Nc2ccnc3ccccc23)cc1
7437,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,Clc1ccc(Nc2cc(Nc3cccc(Cl)n3)ncn2)cc1,"N4-(4-Chlorophenyl)-N6-(6-chloropyridin-2-yl)pyrimidine-4,6-diamine",0.324,uM,=,-0.4894549897933878,0,c1ccc(Nc2cc(Nc3ccccn3)ncn2)cc1
7438,1894188,10.1016/j.ejmech.2019.05.015,,,,Inhibition of human EGFR measured after 3 hrs by ELISA,COc1ccc(/C(CSc2nc3[nH]c(=O)n(C)c(=O)c3[nH]2)=N\O)cc1,"8-((2-(Hydroxyimino)-2-(4-methoxyphenyl)ethyl)thio)-1-methyl-3,7-dihydro-1H-purine-2,6-dione",0.71,uM,=,-0.1487416512809247,0,N=C(CSc1nc2[nH]c(=O)[nH]c(=O)c2[nH]1)c1ccccc1
7439,509684,10.1016/j.bmcl.2008.07.020,,,,Inhibition of human EGFR expressed in SF9 cells,CN/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,"N-[1-(3-Fluoro-benzyl)-1H-indazol-5-yl]-5-(methyl-hydrazonomethyl)-pyrimidine-4,6-diamine",0.012,uM,=,-1.9208187539523751,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
7440,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC[C@@H](C)NC(C)=O,"US8846699, 82",0.029,uM,=,-1.537602002101044,0,c1ccc(Nc2ncnc3ccccc23)cc1
7441,1329559,10.1039/C0MD00115E,,,,Inhibition of EGFR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1B1OC(C)(C)C(C)(C)O1,"N-(3-chlorophenyl)-7-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-4-amine",0.49,uM,=,-0.3098039199714864,0,c1ccc(Nc2ncnc3ccc(B4OCCO4)cc23)cc1
7442,658103,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/c1cn(CCF)nn1,"(E)-N-[4-(3-Chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl]-3-[1-(2-fluoroethyl)-1H-[1,2,3]triazol-4-yl]-acrylamide",0.00405,uM,=,-2.392544976785332,0,O=C(/C=C/c1c[nH]nn1)Nc1ccc2nccc(Nc3ccccc3)c2c1
7443,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(-c3ccccc3)nc3cnc(Nc4ccc(OC)cc4)nc32)c1,N-(3-(2-((4-Methoxyphenyl)amino)-7-oxo-6-phenylpteridin-8(7H)-yl)phenyl)acrylamide,0.0181,uM,=,-1.7423214251308154,0,O=c1c(-c2ccccc2)nc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
7444,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{4-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-butyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",0.6,uM,=,-0.2218487496163563,0,O=C(C=Cc1ccccc1)NCCCCNC(=O)/C=C/c1ccccc1
7445,1675765,10.1016/j.bmc.2017.03.039,,,,Inhibition of human EGFR preincubated for 5 mins with substrate followed by ATP addition measured after 30 mins by HTRF method,Cc1nnc(-n2c(-c3ccccc3)nc3cc(Cl)ccc3c2=O)s1,"7-Chloro-3-(5-methyl-1,3,4-thiadiazol-2-yl)-2-phenylquinazolin-4(3H)-one",3.21,uM,=,0.5065050324048721,1,O=c1c2ccccc2nc(-c2ccccc2)n1-c1nncs1
7446,2283190,10.1039/d2md00139j,,,,Inhibition of wild type EGFR (unknown origin),C=CC(=O)N[C@H]1C=C(C)c2c(-c3cnc4ccccc4c3)c3c(N)ncnc3n2C1,CLN-081,0.0011,uM,=,-2.958607314841775,0,C1=Cc2c(-c3cnc4ccccc4c3)c3cncnc3n2CC1
7447,608087,10.1021/jm901558p,,,,Inhibition of human recombinant EGFR expressed in insect cells by time-resolved fluorimetry,O=C(O)[C@H]1O[C@@H]1C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"(2S,3S)-Ethyl 3-(4-(3-Bromoanilino)quinazolin-6-ylcarbamoyl)oxirane-2-carboxylate",0.00049,uM,=,-3.3098039199714866,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)[C@@H]1CO1
7448,1747423,10.1016/j.bmc.2017.10.030,,,,Inhibition of recombinant wild type EGFR (696 to C-terminal residues) (unknown origin) preincubated for 30 mins followed by poly (Glu-Tyr) biotinylated peptide substrate addition measured after 30 mins in presence of ATP by ELISA,COc1ccc(-c2c3c4cc(OC)c(OCCN(C)C)cc4oc(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O.O=C(O)C(F)(F)F,"3-[2-(dimethylamino)ethoxy]-11-hydroxy-14-(3-hydroxy-4-methoxyphenyl)-2,12-dimethoxy-6H-[1]benzopyrano[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one Trifluoroacetic acid salt",0.5953999999999999,uM,=,-0.2251911696892941,0,O=c1oc2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
7449,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(Cc2ccc(OC)cc2)nn1,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.041,uM,=,-1.3872161432802643,0,c1ccc(Cn2cc(COc3ccc4c(Nc5ccccc5)ncnc4c3)nn2)cc1
7450,1761975,10.1016/j.ejmech.2018.02.051,,,,"Inhibition of wild type EGFR (unknown origin) using Poly (Glu, Tyr) as substrate after 40 mins by kinase-Glo luminescence assay",CN(C)C1CCN(c2ccc(Nc3cc4c(N5CCC(CO)CC5)nc(Nc5ccccc5)nc4cn3)nc2)CC1,"(1-(6-((5-(4-(Dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-2-(phenylamino)pyrido[3,4-d]pyrimidin-4-yl)piperidin-4-yl)methanol",0.0021,uM,=,-2.6777807052660805,0,c1ccc(Nc2nc(N3CCCCC3)c3cc(Nc4ccc(N5CCCCC5)cn4)ncc3n2)cc1
7451,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,COc1cc2ncc(C(=O)NC3CC(C)(C)N([O])C(C)(C)C3)c(Nc3ccc(F)c(Cl)c3)c2cc1OC,"4-(3-Chloro-4-fluorophenylamino)-6,7-dimethoxy-N-[(2,2,6,6-tetramethyl-1-oxyl)piperidin-4-yl]quinoline-3-carboxamide",0.422,uM,=,-0.3746875490383261,0,O=C(NC1CCNCC1)c1cnc2ccccc2c1Nc1ccccc1
7452,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2cccc(Br)c2)=N1,2-(2-(3-Bromobenzylidene)hydrazinyl)thiazol-4(5H)-one,7.46,uM,=,0.8727388274726688,1,O=C1CSC(N/N=C/c2ccccc2)=N1
7453,1801470,10.1016/j.ejmech.2018.07.024,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP-MgCl2 addition and measured after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1cc(-c2nc3sc(-c4ccccc4)cn3n2)cc(OC)c1OC,"2-(3,4,5-Trimethoxyphenyl)-5-phenylthiazolo[3,2-b][1,2,4]triazole",2.8,uM,=,0.4471580313422192,1,c1ccc(-c2nc3sc(-c4ccccc4)cn3n2)cc1
7454,1848601,10.1016/j.ejmech.2019.03.055,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected Sf21 insect cells using STK as substrate by HTRF assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4ccncc4)c23)c1,"N-(3-((2-((4-morpholinophenyl)amino)-5-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide",0.0023,uM,=,-2.638272163982407,0,c1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4ccncc4)c23)cc1
7455,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cc(CNCCN(C)C)ccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2[nH]1,"(R)-N1-(3-methoxy-4-(4-((1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzyl)-N2,N2-dimethylethane-1,2-diamine",0.0001,uM,=,-4.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7456,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,C/N=N/Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,N-(3-chlorophenyl)-6-[(1E)-3-methyltriaz-1-enyl]quinazolin-4-amine,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
7457,1671226,10.1016/j.bmc.2017.04.003,,,,Inhibition of EGFR (unknown origin) by HTRF method,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.044,uM,=,-1.3565473235138126,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
7458,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,CN(C)/N=N/c1ccc2ncnc(NCc3ccccc3)c2c1,"N-benzyl-6-[(1E)-3,3-dimethyltriaz-1-enyl]quinazolin-4-amine",0.482,uM,=,-0.3169529617611504,0,c1ccc(CNc2ncnc3ccccc23)cc1
7459,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(F)c3F)ncnc2cc1OCCNC(=O)CCCN(C)C,"US8846699, 127",0.568,uM,=,-0.2456516642889811,0,c1ccc(Nc2ncnc3ccccc23)cc1
7460,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCCCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1.Cl,"{4-[6,7-Dimethoxyquinazolin-4-ylamino]phenyl}carbamic acid butyl ester hydrochloride",0.8,uM,=,-0.0969100130080563,0,c1ccc(Nc2ncnc3ccccc23)cc1
7461,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,Cc1ccc(Oc2ccc(Nc3ncnc4cc(OCCCN5CCOCC5)c(NC(=O)c5cc([N+](=O)[O-])ccc5F)cc34)cc2Cl)cn1,2-fluoro-N-(4-((3-chloro-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-5-nitrobenzamide,0.39,uM,=,-0.4089353929735008,0,O=C(Nc1cc2c(Nc3ccc(Oc4cccnc4)cc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7462,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCCOc1cc2ncnc(Nc3ccc(NC(=O)OCC)c(C)c3)c2cc1OC.Cl,{4-[6-methoxy-7-propyloxyquinazolin-4-ylamino]-2-methylphenyl}carbamic acid ethyl ester hydrochloride,3.9,uM,=,0.5910646070264992,1,c1ccc(Nc2ncnc3ccccc23)cc1
7463,632680,10.1016/j.bmc.2010.03.052,,,,Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA,Nc1nc(Nc2cccc(F)c2)c2cc(Cc3ccc(Cl)cc3Cl)[nH]c2n1,"N4-(3-Fluorophenyl)-6-(2,4-dichlorobenzyl)-7H-pyrrolo-[2,3-d]pyrimidine-2,4-diamine",161.6,uM,=,2.208441356438567,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7464,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,O=C(/C=C/CN1CCCC1)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(pyrrolidin-1-yl)but-2-en-1-one",0.018,uM,=,-1.744727494896694,0,O=C(/C=C/CN1CCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
7465,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,Cc1ccc(/C=N/NC2=NC(=O)CS2)cc1,2-(2-(4-Methylbenzylidene)hydrazinyl)thiazol-4(5H)-one,3.26,uM,=,0.5132176000679389,1,O=C1CSC(N/N=C/c2ccccc2)=N1
7466,1538409,10.1021/acs.jmedchem.5b01412,,,,Inhibition of EGFR phosphorylation in human NCI-H1975 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay,COC1CCN(c2nccc(Nc3cc4c(cn3)nc(C)n4C(C)C)n2)CC1,"(1-Isopropyl-2-methyl-1H-imidazo[4,5-c]pyridin-6-yl)-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]amine",0.882,uM,=,-0.0545314148681802,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1
7467,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#CC(C#N)=Cc1ncc[nH]1,2-(1H-Imidazol-2-ylmethylene)-malononitrile,532.0,uM,=,2.7259116322950483,1,c1c[nH]cn1
7468,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(Cl)c2)c1,4-(1-(3-chlorobenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-methyl oxime,0.023,uM,=,-1.6382721639824072,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
7469,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CNC,"US8846699, 60",0.136,uM,=,-0.8664610916297825,0,c1ccc(Nc2ncnc3ccccc23)cc1
7470,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,Cc1cccc(Nc2ncnc3ccc(NC(=O)N(C)CCCl)cc23)c1,3-(2-chloroethyl)-1-methyl-1-{[4-(3-methylphenyl)amino]quinazolin-6-yl}urea,1.693,uM,=,0.2286569581089352,1,c1ccc(Nc2ncnc3ccccc23)cc1
7471,1801470,10.1016/j.ejmech.2018.07.024,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP-MgCl2 addition and measured after 1 hr by DELFIA/time-resolved fluorometric analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,Erlotinib hydrochloride,0.07,uM,=,-1.154901959985743,0,c1ccc(Nc2ncnc3ccccc23)cc1
7472,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,CC(C)Oc1ccccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2[nH]1,"(R)-6-(2-Isopropoxyphenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.0006,uM,=,-3.2218487496163566,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7473,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),COC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1C.Cl,"{4-[6,7-Dimethoxyquinazolin-4-ylamino]-2-methylphenyl}carbamic acid methyl ester hydrochloride",4.0,uM,=,0.6020599913279624,1,c1ccc(Nc2ncnc3ccccc23)cc1
7474,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,C/C(=C\c1ccc(O)c(O)c1)[N+](=O)[O-],"4-(2-Nitro-propenyl)-benzene-1,2-diol",9.4,uM,=,0.9731278535996988,1,c1ccccc1
7475,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cccc(C(F)(F)F)c1F,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-3-(trifluoromethyl)benzamide,0.03,uM,=,-1.5228787452803376,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7476,1337212,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ncc([N+](=O)[O-])n1CC(=O)N/N=C/c1cc2ccccc2nc1Oc1ccccc1,(E)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)-N'-((2-phenoxyquinolin-3-yl)methylene)acetohydrazide,10.35,uM,=,1.0149403497929366,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
7477,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,C#Cc1cccc(NC(=O)c2cc(NC(=O)CCCCCC(=O)NO)ccc2O)c1,N-(3-Ethynylphenyl)-2-hydroxy-5-(7-hydroxyamino-7-oxoheptanamido)benzamide,3.31,uM,=,0.5198279937757188,1,O=C(Nc1ccccc1)c1ccccc1
7478,1671226,10.1016/j.bmc.2017.04.003,,,,Inhibition of EGFR (unknown origin) by HTRF method,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,CABOZANTINIB,0.225,uM,=,-0.6478174818886375,0,O=C(Nc1ccccc1)C1(C(=O)Nc2ccc(Oc3ccnc4ccccc34)cc2)CC1
7479,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F,N-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.028,uM,=,-1.5528419686577808,0,O=C(Nc1cc2c(Nc3ccc(OCc4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7480,1274575,10.1016/j.bmcl.2013.09.086,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation expressed in baculovirus infected insect Sf9 cells preincubated for 10 mins followed by ATP-MgCl2 addition measured after 1 hr by fluorometric analysis,Cc1ncc([N+](=O)[O-])n1C/C(=N/NC(=O)c1ccncc1)c1ccc(Br)cc1,(E)-N'-(1-(4-bromophenyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylidene)isonicotinohydrazide,8.19,uM,=,0.9132839017604184,1,O=C(N/N=C(/Cn1ccnc1)c1ccccc1)c1ccncc1
7481,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cn1c(-c2csc(N/N=C\C3CCCN3)n2)nc2ccccc21,2-(2-(1-(1H-pyrrol-2-yl)ethylidene)hydrazinyl)-4-(1-methyl-1H-benzo[d]imidazol-2-yl)thiazole,0.34206,uM,=,-0.4658977086122244,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\C1CCCN1
7482,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)c(OC)c3OC)ncc2Br)c1,"US9238629, I-8",0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
7483,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3cccc(OC)c3)n2)c(OC)cc1N1CCC(C(N)=O)CC1,N-(2-(4-Carbamoylpiperidin-1-yl)-4-methoxy-5-((4-(3-methoxybenzamido)pyrimidin-2-yl)-amino)phenyl)acrylamide,0.0505,uM,=,-1.2967086218813386,0,O=C(Nc1ccnc(Nc2ccc(N3CCCCC3)cc2)n1)c1ccccc1
7484,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,O=C(O)CCCC(=O)Nc1cc(N2CCOCC2)ncn1,5-((6-Morpholinopyrimidin-4-yl)amino)-5-oxopentanoic acid,0.053,uM,=,-1.275724130399211,0,c1cc(N2CCOCC2)ncn1
7485,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,O=[N+]([O-])c1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"(2S)-2-{[5-(3-Nitrophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol",0.82,uM,=,-0.0861861476162833,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
7486,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"Buta-2,3-dienoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide",0.12,uM,=,-0.9208187539523752,0,c1ccc(Nc2ncnc3ccccc23)cc1
7487,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3cc(O)c(Cl)cc3F)ncnc2cc1OCC1CCN(C)CC1.Cl,2-Chloro-4-fluoro-5-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-ylamino]-phenol hydrochloride,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7488,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cc(NC(C)=O)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-N-(4-(4-(2-hydroxy-1-phenylethylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methoxyphenyl)acetamide",0.0008,uM,=,-3.096910013008056,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7489,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(F)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F,"N-(4-((3,4-difluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide",0.053,uM,=,-1.275724130399211,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7490,1274575,10.1016/j.bmcl.2013.09.086,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation expressed in baculovirus infected insect Sf9 cells preincubated for 10 mins followed by ATP-MgCl2 addition measured after 1 hr by fluorometric analysis,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.032,uM,=,-1.494850021680094,0,c1ccc(Nc2ncnc3ccccc23)cc1
7491,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,CN1CCN(CCC(=O)N2CCOc3c2ccc2ncnc(Nc4cccc(C(F)(F)F)c4)c32)CC1,"3-(4-methylpiperazin-1-yl)-1-(10-((3-(trifluoromethyl)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)propan-1-one",0.1484,uM,=,-0.8285660990569917,0,O=C(CCN1CCNCC1)N1CCOc2c1ccc1ncnc(Nc3ccccc3)c21
7492,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,COc1ccc(OC)c(Nc2cc(NC(=O)CCCC(=O)O)ncn2)c1,"5-((6-((2,5-Dimethoxyphenyl)amino)pyrimidin-4-yl)amino)-5-oxopentanoic acid",0.068,uM,=,-1.1674910872937636,0,c1ccc(Nc2ccncn2)cc1
7493,66580,10.1021/jm950692f,,,,Inhibition of tyrosine kinase activity of Epidermal growth factor receptor from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3cc4ccccc4cc23)c1,Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine,3e-06,uM,=,-5.522878745280337,0,c1ccc(Nc2ncnc3cc4ccccc4cc23)cc1
7494,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,C[C@@H](NC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1)C(=O)N[C@H](C)C(=O)NCCN,1-{4-[1-[1-(2-aminoethylcarbamoyl)-(1R)-ethylcarbamoyl]-(1R)-ethylcarbamoyl]phenylsulfonyloxy}-4-[2-nitro-(E)-1-ethenyl]benzene HCl,17.0,uM,=,1.230448921378274,1,O=S(=O)(Oc1ccccc1)c1ccccc1
7495,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3c(F)cc(Br)cc3F)ncnc2cc1OCC1CCNCC1,"(4-Bromo-2,6-difluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine",0.45,uM,=,-0.3467874862246563,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7496,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",NP(=O)(OCCCC(=O)Oc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1)N(CCCl)CCCl,"4-Oxo-4-((4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)amino)butyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.0087,uM,=,-2.0604807473813813,0,c1ccc(Nc2ncnc3ccccc23)cc1
7497,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC(C)NC(=O)CN(C)C,"US8846699, 153",0.172,uM,=,-0.7644715530924511,0,c1ccc(Nc2ncnc3ccccc23)cc1
7498,856711,10.1016/j.bmcl.2012.09.004,,,,Inhibition of EGFR,COc1ccc(C2=NN(C(=O)c3ccc(Cl)cc3O)C(c3ccc(Cl)cc3)C2)cc1,"(4-Chloro-2-hydroxyphenyl)(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone",10.49,uM,=,1.0207754881935578,1,O=C(c1ccccc1)N1N=C(c2ccccc2)CC1c1ccccc1
7499,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,CN(C)CCCn1ccc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-[8-(3-dimethylamino-propyl)-8H-pyrrolo[3,2-g]quinazolin-4-yl]-amine",0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
7500,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3cc(-c4ccc5ccccc5c4)ccc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((6-(naphthalen-2-yl)-1H-indazol-3-yl)amino)phenyl)acrylamide,0.312,uM,=,-0.5058454059815573,0,c1ccc(Nc2n[nH]c3cc(-c4ccc5ccccc5c4)ccc23)cc1
7501,463277,10.1016/j.bmcl.2007.11.052,,,,Inhibition of EGFR,C[C@@H](Oc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12)C(=O)N(C)C,"(R)-2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-5-yloxy)-N,N-dimethylpropanamide",0.022,uM,=,-1.6575773191777938,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)nc1
7502,1817056,10.1021/acs.jmedchem.8b00147,,,,Inhibition of erbB1 (unknown origin) using FRET-capable peptide substrate by FRET assay,Cn1c(C[N+](C)(C)C/C=C/C(=O)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)ccc1[N+](=O)[O-].[Br-],"4-(4-(3-bromophenylamino)quinazolin-6-ylamino)-N,N-dimethyl-N-((1-methyl-5-nitro-1H-pyrrol-2-yl)methyl)-4-oxobut-2-en-1-aminium bromide",0.00022,uM,=,-3.657577319177794,0,O=C(/C=C/C[NH2+]Cc1ccc[nH]1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
7503,424214,10.1016/j.bmcl.2006.08.035,,,,Inhibition of EGFR,Cc1cccc(C)c1-c1cc(C)c2nc(Nc3ccc(OCCN4CCCC4)cc3)nnc2c1,"7-(2,6-dimethylphenyl)-5-methyl-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)benzo[e][1,2,4]triazin-3-amine",0.965,uM,=,-0.0154726866562074,0,c1ccc(-c2ccc3nc(Nc4ccc(OCCN5CCCC5)cc4)nnc3c2)cc1
7504,63790,10.1016/S0960-894X(97)00035-8,,,,Antagonism towards Epidermal growth factor receptor,CN(c1ccccc1)c1[nH]cnc2ncnc1-2,Methyl-phenyl-(9H-purin-6-yl)-amine,2.0,uM,=,0.3010299956639812,1,c1ccc(Nc2[nH]cnc3ncnc2-3)cc1
7505,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,O=NN(CCCl)C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(2-chloroethyl)-1-nitroso-3-{[4-(3-bromophenyl)amino]quinazolin-6-yl}urea,0.047,uM,=,-1.3279021420642825,0,c1ccc(Nc2ncnc3ccccc23)cc1
7506,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,OCc1cc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)ccc1F,"(S)-2-((6-(4-Fluoro-3-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0016,uM,=,-2.7958800173440754,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7507,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,Brc1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1,"3-(4-Bromophenyl)-5-(naphthalen-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",0.71,uM,=,-0.1487416512809247,0,c1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1
7508,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)c(N4CCN(C)CC4)c3)c(C(N)=O)nc2CC)c1,"US9085540, 42",0.0014,uM,=,-2.853871964321762,0,c1ccc(Oc2cncc(Nc3cccc(N4CCNCC4)c3)n2)cc1
7509,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,OC[C@@H](Nc1ncnc2oc(-c3ccccc3)c(Br)c12)c1ccccc1,"(2S)-2-[(5-Bromo-6-phenylfuro[2,3-d]pyrimidin-4-yl)amino]-2-phenylethanol",0.452,uM,=,-0.3448615651886179,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
7510,603361,10.1016/j.bmc.2009.08.044,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA,CCCCC(Cc1coc2nc(N)nc(N)c12)c1ccccc1OC,"5-[(R/S)-2-(20-Methoxyphenyl)hexyl]furo[2,3-d]pyrimidine-2,4-diamine",13.4,uM,=,1.1271047983648077,1,c1ccc(CCc2coc3ncncc23)cc1
7511,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3cc(-c4cccc(N(C)C)c4)ccc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((6-(3-(dimethylamino)phenyl)-1H-indazol-3-yl)amino)-4-methoxyphenyl)acrylamide,0.048,uM,=,-1.3187587626244128,0,c1ccc(Nc2n[nH]c3cc(-c4ccccc4)ccc23)cc1
7512,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#Cc1ccc(CNC(C)C)cc1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-5-((4-((isopropylamino)methyl)phenyl)ethynyl)-6-methylpyrimidin-4-amine,0.003,uM,=,-2.5228787452803374,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
7513,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccn(C)n3)n2)c(OC)cc1N(C)CCN(C)C(=O)OC,methyl (2-((2-acrylamido-5-methoxy-4-((4-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)(methyl)carbamate,4.934,uM,=,0.6931991451537173,1,c1ccc(Nc2nccc(Nc3cc[nH]n3)n2)cc1
7514,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,C/N=N/Nc1ccc2ncnc(NCc3ccccc3)c2c1,N-benzyl-6-[(1E)-3-methyltriaz-1-enyl]quinazolin-4-amine,0.335,uM,=,-0.4749551929631547,0,c1ccc(CNc2ncnc3ccccc23)cc1
7515,556139,10.1016/j.bmc.2008.04.019,,,,Inhibition of EGFR expressed in human tumor cells,Nc1nc(Nc2cccc(Br)c2)c2cc(Cc3ccc4ccccc4c3)[nH]c2n1,"N4-(3-bromophenyl)-2-(naphthalen-2-ylmethyl)-1H-indole-4,6-diamine",1.24,uM,=,0.093421685162235,1,c1ccc(Nc2ncnc3[nH]c(Cc4ccc5ccccc5c4)cc23)cc1
7516,1761975,10.1016/j.ejmech.2018.02.051,,,,"Inhibition of wild type EGFR (unknown origin) using Poly (Glu, Tyr) as substrate after 40 mins by kinase-Glo luminescence assay",CN(C)C1CCN(c2ccc(Nc3cc4c(N5CCOCC5)nc(Nc5ccc(F)cc5F)nc4cn3)nc2)CC1,"N2-(3,4-difluorophenyl)-N6-(5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)-4-morpholinopyrido[3,4-d]pyrimidine-2,6-diamine",0.0009,uM,=,-3.0457574905606752,0,c1ccc(Nc2nc(N3CCOCC3)c3cc(Nc4ccc(N5CCCCC5)cn4)ncc3n2)cc1
7517,1274575,10.1016/j.bmcl.2013.09.086,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation expressed in baculovirus infected insect Sf9 cells preincubated for 10 mins followed by ATP-MgCl2 addition measured after 1 hr by fluorometric analysis,Cc1ncc([N+](=O)[O-])n1C/C(=N/NC(=O)c1ccccc1O)c1ccc(Br)cc1,(E)-N'-(1-(4-bromophenyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylidene)-2-hydroxybenzohydrazide,2.58,uM,=,0.4116197059632301,1,O=C(N/N=C(/Cn1ccnc1)c1ccccc1)c1ccccc1
7518,1466619,10.1016/j.bmc.2015.03.061,,,,Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,Cc1nc(N(C)c2ccc3occc3c2)c2cc(C)oc2n1,"N-1-Benzofuran-5-yl-N,2,6-trimethylfuro[2,3-d]-pyrimidin-4-amine",0.3066,uM,=,-0.5134278494816436,0,c1nc(Nc2ccc3occc3c2)c2ccoc2n1
7519,1675765,10.1016/j.bmc.2017.03.039,,,,Inhibition of human EGFR preincubated for 5 mins with substrate followed by ATP addition measured after 30 mins by HTRF method,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.076,uM,=,-1.1191864077192086,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
7520,2059437,10.1016/j.bmc.2021.116094,,,,Inhibition of wild-type EGFR (unknown origin) using biotinylated TK peptide as substrate measured after 30 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.00115,uM,=,-2.939302159646388,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
7521,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)N1CCC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1,"US9085540, 79",0.0013,uM,=,-2.886056647693163,0,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(O[C@@H]2CCCNC2)n1
7522,2270673,10.1016/j.ejmech.2020.112506,,,,Inhibition of EGFR (unknown origin),CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.028,uM,=,-1.5528419686577808,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
7523,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,COc1cc2ncc(C(=O)O)c(Nc3ccc(F)c(Cl)c3)c2cc1OC,"4-(3-chloro-4-fluorophenylamino)-6,7-dimethoxyquinoline-3-carboxylic acid",9.284,uM,=,0.9677351317838802,1,c1ccc(Nc2ccnc3ccccc23)cc1
7524,2080996,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCc1cn(CCCC(=O)NO)nn1,"4-(4-(((6-Acrylamido-4-((3-chloro-4-((2-fluorobenzyl)oxy)phenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutanamide",0.0018,uM,=,-2.744727494896694,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCc5c[nH]nn5)ccc34)cc2)cc1
7525,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=[N+]([O-])c1ccc(F)c(CNc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2OCCCN2CCOCC2)c1,"N4-(3-chloro-4-fluorophenyl)-N6-(2-fluoro-5-nitrobenzyl)-7-(3-morpholinopropoxy)quinazoline-4,6-diamine",0.2424,uM,=,-0.6154673845057514,0,c1ccc(CNc2cc3c(Nc4ccccc4)ncnc3cc2OCCCN2CCOCC2)cc1
7526,1747423,10.1016/j.bmc.2017.10.030,,,,Inhibition of recombinant wild type EGFR (696 to C-terminal residues) (unknown origin) preincubated for 30 mins followed by poly (Glu-Tyr) biotinylated peptide substrate addition measured after 30 mins in presence of ATP by ELISA,COc1ccc(-c2c3c4cc(O)c(OC)cc4oc(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O,"2,11-Dihydroxy-14-(3-hydroxy-4-methoxyphenyl)-3,12-dimethoxy-6H-[1]benzopyrano[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one",0.2491,uM,=,-0.6036262724634935,0,O=c1oc2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
7527,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=S)NCC,"US8846699, 36",0.091,uM,=,-1.0409586076789064,0,c1ccc(Nc2ncnc3ccccc23)cc1
7528,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCNC(=O)CN(C)C,"US8846699, 12",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
7529,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCN(C)C,"US8846699, 19",0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
7530,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CN(CCO)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"2-({2-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-ethyl}-methyl-amino)-ethanol",0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ncnc3cnccc23)cc1
7531,1684313,10.1016/j.ejmech.2017.04.025,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (unknown origin) (645 to 1186 residues) expressed in baculovirus infected Sf-9 cells preincubated for 10 mins followed by ATP addition measured after 1 hr by DELFIA/Time-Resolved fluorometry,Cc1nc(C)c(/C=C2\CN(C(C)C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)nc1C,"3,5-Bis-(3,5,6-trimethyl-pyrazin-2-ylmethylene)-1-isopropyl-piperidin-4-one",2.5,uM,=,0.3979400086720376,1,O=C1/C(=C/c2cnccn2)CNC/C1=C\c1cnccn1
7532,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.008807,uM,=,-2.0551720036567835,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
7533,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,CN(C)CC/N=N/Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(3-bromophenyl)-6-{(1E)-3-[2-(dimethylamino)ethyl]triaz-1-enyl}quinazolin-4-amine,0.038,uM,=,-1.42021640338319,0,c1ccc(Nc2ncnc3ccccc23)cc1
7534,321388,10.1021/jm050392q,,,,In vitro inhibitory concentration EGF receptor with ATP concentration at 1/2Km,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one,1.6,uM,=,0.2041199826559248,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCOCC3)cc2[nH]1
7535,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#CCOc1ccc(CNC(C)C)cc1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-5-(3-(4-((isopropylamino)methyl)phenoxy)prop-1-ynyl)-6-methylpyrimidin-4-amine,0.086,uM,=,-1.0655015487564323,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)COc1ccccc1
7536,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{2-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-ethyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",0.5,uM,=,-0.3010299956639812,0,O=C(C=Cc1ccccc1)NCCNC(=O)/C=C/c1ccccc1
7537,608087,10.1021/jm901558p,,,,Inhibition of human recombinant EGFR expressed in insect cells by time-resolved fluorimetry,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-phenoxyacetamide,0.00925,uM,=,-2.0338582672609675,0,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
7538,1538409,10.1021/acs.jmedchem.5b01412,,,,Inhibition of EGFR phosphorylation in human NCI-H1975 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay,CO[C@H]1CCN(c2nccc(Nc3cc4c(cn3)nc(CO)n4C(C)C)n2)CC1(F)F,"(+/-)-{6-[2-(3,3-Difluoro-4-methoxypiperidin-1-yl)pyrimidin-4-ylamino]-1-isopropyl-1H-imidazo[4,5-c]pyridin-2-yl}methanol",1.0,uM,=,0.0,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1
7539,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNS(C)(=O)=O,"US8846699, 33",0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
7540,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,CN(C)CCN(C)Cc1c[nH]c2cc3ncnc(Nc4cccc(Br)c4)c3cc12,"N-[4-(3-Bromo-phenylamino)-8H-pyrrolo[3,2-g]quinazolin-6-ylmethyl]-N,N',N'-trimethyl-ethane-1,2-diamine",0.0075,uM,=,-2.1249387366083,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
7541,2080996,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCc1cn(CCC(=O)NO)nn1,"N-(4-((3-chloro-2-fluorophenyl)amino)-7-((1-(3-(hydroxyamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.00034,uM,=,-3.468521082957745,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
7542,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,NC1CCN(Cc2ccn3ncnc(Nc4ccc(F)c(Cl)c4)c23)CC1,"5-((4-aminopiperidin-1-yl)methyl)-N-(3-chloro-4-fluorophenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.01,uM,=,-2.0,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1
7543,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)CN(C)C,"US8846699, 143",0.019,uM,=,-1.7212463990471711,0,c1ccc(Nc2ncnc3ccccc23)cc1
7544,1848601,10.1016/j.ejmech.2019.03.055,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected Sf21 insect cells using STK as substrate by HTRF assay,C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)CC1,"1-(4-((2-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-5-(6-(methylamino)pyrazin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.903,uM,=,-0.0443122496864941,0,c1cnc(-c2c[nH]c3nc(Nc4ccc(N5CCNCC5)cc4)nc(OC4CCNCC4)c23)cn1
7545,1848601,10.1016/j.ejmech.2019.03.055,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected Sf21 insect cells using STK as substrate by HTRF assay,C=CC(=O)N1CCC[C@@H]1COc1nc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2)nc2[nH]cc(-c3cncc(NC)n3)c12,"(R)-1-(2-(((2-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-5-(6-(methylamino)pyrazin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)pyrrolidin-1-yl)prop-2-en-1-one",0.15,uM,=,-0.8239087409443188,0,c1cnc(-c2c[nH]c3nc(Nc4ccc(N5CCNCC5)cc4)nc(OC[C@H]4CCCN4)c23)cn1
7546,2296723,10.1021/acs.jmedchem.6b00276,,,,Inhibition of recombinant 6His-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) autophosphorylation expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP and MgCl2 addition measured after 60 mins by DELFIA/time-resolved fluorometric analysis,COc1cc(/C=C2\CCc3c(O)cccc3\C2=N\O)c(Br)c(OC)c1OC,"6-[(2-bromo-3,4,5-trimethoxyphenyl)methylidene]-5-(hydroxyimino)-5,6,7,8-tetrahydronaphthalen-1-ol",4.6,uM,=,0.6627578316815741,1,N=C1/C(=C/c2ccccc2)CCc2ccccc21
7547,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"US9447106, 27b (peak 2)",0.0382999999999999,uM,=,-1.4168012260313774,0,c1ccc(Oc2ccc(-c3cc4n(n3)[C@H](C3CCNCC3)CCN4)cc2)cc1
7548,1574498,10.1016/j.bmcl.2016.04.011,,,,Inhibition of EGFR in human MDA231 cells assessed as growth inhibition after 24 hrs by MTT assay,O=C(c1ccccc1)c1cccc(NC(=O)c2cc3ccccc3[nH]2)c1,N-(3-benzoylphenyl)-1H-indole-2-carboxamide,45.0,uM,=,1.6532125137753435,1,O=C(c1ccccc1)c1cccc(NC(=O)c2cc3ccccc3[nH]2)c1
7549,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccc(OCc2ccccc2)cc1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl3-(4-(benzyloxy)phenyl)acrylate,1.27,uM,=,0.1038037209559568,1,O=C(/C=C/c1ccc(OCc2ccccc2)cc1)OCCn1ccnc1
7550,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,O=C(NCCCl)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(2-chloroethyl)-3-{[4-(3-bromophenyl)amino]quinazolin-6-yl}urea,0.018,uM,=,-1.744727494896694,0,c1ccc(Nc2ncnc3ccccc23)cc1
7551,1983834,10.1016/j.bmc.2019.115281,,,,Inhibition of EGFR L858R/T790M (unknown origin),C=C1CC(CI)(c2ccc(F)cc2)OC1=O,rac-5-(4-fluorophenyl)-5-(iodomethyl)-3-methylenedihydrofuran-2(3H)-one,15.0,uM,=,1.1760912590556811,1,C=C1CC(c2ccccc2)OC1=O
7552,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc(OCc2ccccc2)c(Cl)c1,4-amino-6-(4-(benzyloxy)-3-chlorophenylamino)pyrimidine-5-carbaldehyde O-methyl oxime,0.016,uM,=,-1.7958800173440752,0,c1ccc(COc2ccc(Nc3ccncn3)cc2)cc1
7553,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#Cc1ccc(CN2CCCC2)cc1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-((4-(pyrrolidin-1-ylmethyl)phenyl)ethynyl)pyrimidin-4-amine,0.009,uM,=,-2.0457574905606752,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccc(CN2CCCC2)cc1
7554,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,O=C(O)Cn1ccc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"[4-(3-Bromo-phenylamino)-pyrrolo[3,2-g]quinazolin-8-yl]-acetic acid",0.0050999999999999,uM,=,-2.292429823902064,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
7555,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1,4-(3-Chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline,0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccc(OC4CCNCC4)cc23)cc1
7556,1817056,10.1021/acs.jmedchem.8b00147,,,,Inhibition of erbB1 (unknown origin) using FRET-capable peptide substrate by FRET assay,Cn1cnc([N+](=O)[O-])c1C[N+](C)(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1.[Br-],"4-(4-(3-bromophenylamino)quinazolin-6-ylamino)-N,N-dimethyl-N-((1-methyl-4-nitro-1H-imidazol-5-yl)methyl)-4-oxobut-2-en-1-aminium bromide",0.00022,uM,=,-3.657577319177794,0,O=C(/C=C/C[NH2+]Cc1cnc[nH]1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
7557,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCCN1CCN(C)CC1.Cl,(4-Chloro-2-fluoro-phenyl)-{6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinazolin-4-yl}-amine hydrochloride,0.075,uM,=,-1.1249387366083,0,c1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
7558,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CN(C)C,"US8846699, 25",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
7559,1640870,,,,,"Time-Resolved Fret (TR-FRET) Assay: 1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dilutions of 10 fold from 100 micoM are used. Kinase activity was determined with time-resolved Fret (TR-FRET) assay (LanthaScreenÂ® kinase activity assay, from InVitrogen).2) The assay is performed in a Black 384-well plate (from Corning). The kinase and the compound was incubated for 30 mM at room temperature. ATP (1 mM) and fluorescein-poly GT were added, and the reaction was incubated for 15 mM. Detection agent SA-XL665 (from Cisbio Assay) and TK Ab-Cryptate detection antibody (from InVitrogen) were added to stop the reaction.3) The 384-well plate was sealed and incubated for 1 hour. The fluorescence was then measured at 620 nM (Cryptate) and 665 nM (XL655) wavelength.4) Each concentration of compound was done in triplicate, and vehicle (without compound) and a positive control were used.",CO[C@@H]1COC2C1OC[C@H]2Oc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,"US9187459, 1",0.0004,uM,=,-3.397940008672037,0,c1ccc(Nc2ncnc3cc(O[C@@H]4COC5CCOC54)ccc23)cc1
7560,2213950,10.1016/j.ejmech.2021.113963,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins in presence of ATP by caliper mobility shift assay,COc1cc2c(cc1OC)C(Oc1cccc(NC(=S)Nc3ccc(Cl)c(C(F)(F)F)c3)c1)=NCN2,"1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-[(6,7-dimethoxy-1,2-dihydroquinazolin-4-yl)oxy]phenyl]thiourea",0.02,uM,=,-1.6989700043360187,0,S=C(Nc1ccccc1)Nc1cccc(OC2=NCNc3ccccc32)c1
7561,1837344,10.1016/j.ejmech.2019.111664,,,,Inhibition of EGFR (unknown origin),N=C1N=C(NCCS(=O)(=O)O)/C(=C/C(O)CNC(=O)c2cc(Br)c(Br)[nH]2)N1,tauroacidin A,38.02809404002601,uM,=,1.5801045592101004,1,N=C1N=C/C(=C/CCNC(=O)c2ccc[nH]2)N1
7562,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1/C=C/c1ccc(CNC(C)C)cc1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-5-(4-((isopropylamino)methyl)styryl)-6-methylpyrimidin-4-amine,0.024,uM,=,-1.619788758288394,0,C(=C/c1cncnc1Nc1ccc(OCc2ccccc2)cc1)\c1ccccc1
7563,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=C(C)C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-{4-[(3-Bromophenyl)amino]-6-quinazolinyl}-2-methylacrylamide,0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ncnc3ccccc23)cc1
7564,775025,10.1016/j.ejmech.2011.09.041,,,,Inhibition of human EGFR,N#Cc1cc2c(N)ncnc2nc1NCCO,"4-amino-7-((2-hydroxyethyl)amino)pyrido[2,3-d]pyrimidine-6-carbonitrile",93.3,uM,=,1.9698816437465,1,c1cnc2ncncc2c1
7565,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,COc1cc2ncnc(Nc3cc(OC)c(OC)c(OC)c3)c2cc1OC,"(6,7-Dimethoxy-quinazolin-4-yl)-(3,4,5-trimethoxy-phenyl)-amine",5.4,uM,=,0.7323937598229685,1,c1ccc(Nc2ncnc3ccccc23)cc1
7566,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3cc(O)c(C)cc3F)ncnc2cc1OCC1CCN(C)CC1.Cl,4-Fluoro-5-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-ylamino]-2-methyl-phenol hydrochloride,0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7567,63781,10.1016/j.bmcl.2004.01.034,,,,Inhibition of peptide substrate phosphorylation by epidermal growth factor receptor,CN(C)C/C=C/C(=O)Nc1cnc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,"(E)-4-Dimethylamino-but-2-enoic acid [5-(3-bromo-phenylamino)-6-cyano-[1,8]naphthyridin-3-yl]-amide",2.0436,uM,=,0.3103958940102259,1,c1ccc(Nc2ccnc3ncccc23)cc1
7568,1732820,10.1016/j.ejmech.2018.01.090,,,,Inhibition of recombinant human N-terminal His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells by ELISA,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.0271,uM,=,-1.5670307091255942,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
7569,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cc(CN(C)CCN(C)C)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-2-((6-(4-(((2-(Dimethylamino)ethyl)(methyl)amino)methyl)-2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0001,uM,=,-4.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7570,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,O=C(O)Cn1ncc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"[5-(3-Bromo-phenylamino)-pyrazolo[4,3-g]quinazolin-1-yl]-acetic acid",0.053,uM,=,-1.275724130399211,0,c1ccc(Nc2ncnc3cc4[nH]ncc4cc23)cc1
7571,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccc(OC)c(OC)c3)n2)c(OC)cc1N1CCN(C)CC1,"N-(2-(4-Methylpiperazin-1-yl)-4-methoxy-5-((4-(3,4-dimethoxybenzamido)pyrimidin-2-yl)-amino)phenyl)acrylamide",0.1575,uM,=,-0.8027194418743807,0,O=C(Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1)c1ccccc1
7572,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#CC(C#N)=C1CCc2c1ccc(O)c2O,"2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile",7.0,uM,=,0.8450980400142568,1,C=C1CCc2ccccc21
7573,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)c(N4CCN(C)CC4)c3)c(C(N)=O)nc2CC)c1,"US9085540, 42",0.0012,uM,=,-2.920818753952376,0,c1ccc(Oc2cncc(Nc3cccc(N4CCNCC4)c3)n2)cc1
7574,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cc(CNCCS(C)(=O)=O)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-2-((6-(2-Methoxy-4-(((2-(methylsulfonyl)ethyl)amino)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0004,uM,=,-3.397940008672037,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7575,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNCC(C)=O,"US8846699, 27::US8846699, 55",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3ccccc23)cc1
7576,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,CN(C)CCn1ncc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-[1-(2-dimethylamino-ethyl)-1H-pyrazolo[4,3-g]quinazolin-5-yl]-amine",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3cc4[nH]ncc4cc23)cc1
7577,615344,10.1016/j.ejmech.2009.12.026,,,,Inhibition of EGFR,CC1=C(C(=O)Nc2cccc([N+](=O)[O-])c2)C(c2ccc(O)cc2O)NC(NN2C(=O)/C(=C\c3ccco3)SC2=S)=N1,"4-(2,4-Dihydroxyphenyl)-2-(5-(furan-2-ylmethylene)-4-oxo-2-thioxothiazolidin-3-ylamino)-6-methyl-N-(3-nitrophenyl)-1,4-dihydropyrimidine-5-carboxamide",99.3,uM,=,1.9969492484953808,1,O=C(Nc1ccccc1)C1=CN=C(NN2C(=O)/C(=C\c3ccco3)SC2=S)NC1c1ccccc1
7578,2296723,10.1021/acs.jmedchem.6b00276,,,,Inhibition of recombinant 6His-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) autophosphorylation expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP and MgCl2 addition measured after 60 mins by DELFIA/time-resolved fluorometric analysis,COc1ccc(/C=C2\CCc3ccc([N+](=O)[O-])cc3\C2=N\O)c(Cl)c1OC,"2-(2-chloro-3,4-dimethoxybenzylidene)-7-nitro-3,4-dihydronaphthalen-1(2H)-one oxime",2.0,uM,=,0.3010299956639812,1,N=C1/C(=C/c2ccccc2)CCc2ccccc21
7579,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c(C(N)=O)nc2CC)c1C,"US9085540, 15",0.0011,uM,=,-2.958607314841775,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7580,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,COc1cc2ncc(C(=O)NC3CC(C)(C)N([O])C(C)(C)C3)c(Nc3cccc(Br)c3)c2cc1OC,"4-(3-Bromophenylamino)-6,7-dimethoxy-N-[(2,2,6,6-tetramethyl-1-oxyl)piperidin-4-yl]quinoline-3-carboxamide",0.342,uM,=,-0.4659738939438649,0,O=C(NC1CCNCC1)c1cnc2ccccc2c1Nc1ccccc1
7581,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,Cn1c(-c2ccccc2)cc2c(N[C@H](CO)c3ccccc3)ncnc21,"(S)-2-((7-Methyl-6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.9,uM,=,-0.0457574905606751,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7582,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,O=C(CCCCCC(=O)Nc1ccc(O)c(C(=O)Nc2cccc(C(F)(F)F)c2)c1)NO,N-(3-Trifluoromethylphenyl)-2-hydroxy-5-(7-hydroxyamino-7-oxoheptanamido)benzamide,4.2,uM,=,0.6232492903979004,1,O=C(Nc1ccccc1)c1ccccc1
7583,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,NC(=S)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1cccc2ccccc12,"3-(3,4-Dichlorophenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",0.21,uM,=,-0.6777807052660807,0,c1ccc(C2=NNC(c3cccc4ccccc34)C2)cc1
7584,66580,10.1021/jm950692f,,,,Inhibition of tyrosine kinase activity of Epidermal growth factor receptor from human A431 carcinoma cells,Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-(3-methyl-3H-imidazo[4,5-g]quinazolin-8-yl)-amine",2.5e-05,uM,=,-4.6020599913279625,0,c1ccc(Nc2ncnc3cc4[nH]cnc4cc23)cc1
7585,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,OC[C@@H](Nc1ncnc2oc(-c3ccccc3)c(-c3ccc4c(c3)OCO4)c12)c1ccccc1,"(2S)-2-{[5-(1,3-Benzodioxol-5-yl)-6-phenylfuro[2,3-d]-pyrimidin-4-yl]amino}-2-phenylethanol",0.258,uM,=,-0.5883802940367698,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccc5c(c4)OCO5)c23)cc1
7586,2296723,10.1021/acs.jmedchem.6b00276,,,,Inhibition of recombinant 6His-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) autophosphorylation expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP and MgCl2 addition measured after 60 mins by DELFIA/time-resolved fluorometric analysis,COc1cc(/C=C2\CCc3ccc([N+](=O)[O-])cc3\C2=N\O)c(Br)c(OC)c1OC,"2-(2-bromo-3,4,5-trimethoxybenzylidene)-7-nitro-3,4-dihydronaphthalen-1(2H)-one oxime",1.9,uM,=,0.2787536009528289,1,N=C1/C(=C/c2ccccc2)CCc2ccccc21
7587,509684,10.1016/j.bmcl.2008.07.020,,,,Inhibition of human EGFR expressed in SF9 cells,CN(C)/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,"5-(Dimethyl-hydrazonomethyl)-N-[1-(3-fluoro-benzyl)-1H-indazol-5-yl]-pyrimidine-4,6-diamine",0.008,uM,=,-2.096910013008056,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
7588,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C1CCCN1C(=O)CC,"US8846699, 106",0.196,uM,=,-0.707743928643524,0,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)C1CCCN1
7589,2090281,10.1016/j.ejmech.2020.112522,,,,Inhibition of wild type EGFR in human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by Celltiter-Glo luminescent cell viability assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,2.239,uM,=,0.3500540935790302,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
7590,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)cc3OC)ncc2C(F)(F)F)c1,"US9238629, I-9",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
7591,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,COc1ccc(OC)c(Nc2cc(Nc3ccc(F)cc3)ncn2)c1,"N4-(2,5-Dimethoxyphenyl)-N6-(4-fluorophenyl)pyrimidine-4,6-diamine",0.336,uM,=,-0.4736607226101559,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
7592,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(OC)c(Cl)cc3OC)ncnc2cc1OCCNC(C)=O,"US8846699, 172",0.087,uM,=,-1.0604807473813815,0,c1ccc(Nc2ncnc3ccccc23)cc1
7593,66580,10.1021/jm950692f,,,,Inhibition of tyrosine kinase activity of Epidermal growth factor receptor from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3cc4nccnc4cc23)c1,"(3-Bromo-phenyl)-(1,3,5,8-tetraaza-anthracen-4-yl)-amine",0.0017,uM,=,-2.7695510786217263,0,c1ccc(Nc2ncnc3cc4nccnc4cc23)cc1
7594,1675765,10.1016/j.bmc.2017.03.039,,,,Inhibition of human EGFR preincubated for 5 mins with substrate followed by ATP addition measured after 30 mins by HTRF method,O=c1c2ccc(Cl)cc2nc(-c2ccccc2)n1-c1nnc(C2CC2)s1,"7-Chloro-3-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2-phenylquinazolin-4(3H)-one",0.53,uM,=,-0.2757241303992109,0,O=c1c2ccccc2nc(-c2ccccc2)n1-c1nnc(C2CC2)s1
7595,1848601,10.1016/j.ejmech.2019.03.055,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected Sf21 insect cells using STK as substrate by HTRF assay,C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4ccnc(NC)c4)c23)CC1,"1-(4-((5-(2-(methylamino)pyridin-4-yl)-2-((4-morpholinophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.038,uM,=,-1.42021640338319,0,c1cc(-c2c[nH]c3nc(Nc4ccc(N5CCOCC5)cc4)nc(OC4CCNCC4)c23)ccn1
7596,632680,10.1016/j.bmc.2010.03.052,,,,Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA,CC(C)c1ccccc1Nc1nc(N)nc2[nH]c(Cc3ccc(Cl)cc3Cl)cc12,"N4-(2-Isopropylphenyl)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",96.4,uM,=,1.9840770339028309,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7597,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1cccc2ccccc12,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl 3-(naphthalen-1-yl)acrylate,3.88,uM,=,0.5888317255942073,1,O=C(/C=C/c1cccc2ccccc12)OCCn1ccnc1
7598,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)OC,"US8846699, 63",0.158,uM,=,-0.8013429130455774,0,c1ccc(Nc2ncnc3ccccc23)cc1
7599,306556,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate; Range = 4-10 nM,CN(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1,"(E)-4-Dimethylamino-but-2-enoic acid [4-(4,5-dichloro-2-fluoro-phenylamino)-quinazolin-6-yl]-amide",0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
7600,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#CC(C#N)=C1CCc2cc(O)c(O)cc21,"2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile",0.5,uM,=,-0.3010299956639812,0,C=C1CCc2ccccc21
7601,615344,10.1016/j.ejmech.2009.12.026,,,,Inhibition of EGFR,CC1=C(C(=O)Nc2ccc(C)cc2)C(c2ccc(O)cc2O)NC(Nc2ccc([N+](=O)[O-])cc2Cl)=N1,"2-(2-Chloro-4-nitrophenylamino)-6-(2,4-dihydroxyphenyl)-4-methyl-N-(4-methylphenyl)-l,6-dihydropyrimidine-5-carboxamide",60.9,uM,=,1.7846172926328754,1,O=C(Nc1ccccc1)C1=CN=C(Nc2ccccc2)NC1c1ccccc1
7602,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,COc1ccc(/C=N\Nc2nc(-c3nc4ccccc4n3C)cs2)cc1OC,"2-(2-(3,4-Dimethoxybenzylidene)hydrazinyl)-4-(1-methyl-1H-benzo[d]imidazol-2-yl)thiazole",0.20809,uM,=,-0.6817487897988004,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccccc1
7603,2251609,10.1021/acs.jmedchem.2c00168,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,CCS(=O)(=O)n1cc(-c2nc(Nc3cc(Cl)c(N4CCC(N5CCN(C)CC5)CC4)cc3OC)ncc2Cl)c2ccccc21,5-chloro-N-(5-chloro-2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-4-(1-(ethylsulfonyl)-1H-indol-3-yl)pyrimidin-2-amine,0.816,uM,=,-0.0883098412461388,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCC(N6CCNCC6)CC5)cc4)n3)c[nH]c2c1
7604,2270900,10.1016/j.ejmech.2020.112640,,,,Inhibition of EGFR (unknown origin) incubated for 60 mins in presence of ATP by ADP-Glo kinase assay,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,ROCILETINIB,0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7605,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-{6-methoxy-7-[2-(1-methyl-piperidin-4-yl)-ethoxy]-quinazolin-4-yl}-amine,0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3cc(OCCC4CCNCC4)ccc23)cc1
7606,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,CN(C)CCC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N3,N3-dimethyl-beta-alaninamide",0.008,uM,=,-2.096910013008056,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
7607,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC(C)NC(C)=O,"US8846699, 81",0.154,uM,=,-0.8124792791635369,0,c1ccc(Nc2ncnc3ccccc23)cc1
7608,2220184,10.1016/j.bmcl.2021.128524,,,,Inhibition of EGFR tyrosine kinase (unknown origin),CCc1ccc(C2=C(O)C(=O)C(c3ccc(CC)cc3)=C(O)C2=O)cc1,"4,4''-diethyl-3',6'-dihydroxy-[1,1':4',1''-terphenyl]-2',5'-dione",0.03018,uM,=,-1.520280764560429,0,O=C1C=C(c2ccccc2)C(=O)C=C1c1ccccc1
7609,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(F)c(Br)cc3F)ncnc2cc1OCCNC(C)=O,"US8846699, 119",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3ccccc23)cc1
7610,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,NCCNC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,4-(2-Amino-ethylcarbamoyl)-benzenesulfonic acid 4-(2-nitro-vinyl)-phenyl ester HCl,5.4,uM,=,0.7323937598229685,1,O=S(=O)(Oc1ccccc1)c1ccccc1
7611,1747423,10.1016/j.bmc.2017.10.030,,,,Inhibition of recombinant wild type EGFR (696 to C-terminal residues) (unknown origin) preincubated for 30 mins followed by poly (Glu-Tyr) biotinylated peptide substrate addition measured after 30 mins in presence of ATP by ELISA,COc1ccc(-c2c3c4cc(OCCCN(C)C)c(OCCCN(C)C)cc4oc(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,"2,3-bis[3-(dimethylamino)propoxy]-11-hydroxy-14-(3-hydroxy-4-methoxyphenyl)-12-methoxy-6H-[1]benzopyrano[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one ditrifluoroacetic acid salt",0.0318,uM,=,-1.4975728800155672,0,O=c1oc2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
7612,1761975,10.1016/j.ejmech.2018.02.051,,,,"Inhibition of wild type EGFR (unknown origin) using Poly (Glu, Tyr) as substrate after 40 mins by kinase-Glo luminescence assay",CN1CCN(c2ccc(Nc3cc4c(N5CCCCC5)nc(Nc5ccccc5)nc4cn3)nc2)CC1,"N6-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)-N2-phenyl-4-(piperidin-1-yl)pyrido[3,4-d]pyrimidine-2,6-diamine",0.0011,uM,=,-2.958607314841775,0,c1ccc(Nc2nc(N3CCCCC3)c3cc(Nc4ccc(N5CCNCC5)cn4)ncc3n2)cc1
7613,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3cc4c(cnn4CCN4CCOCC4)cc23)c1,"(3-Bromo-phenyl)-[1-(2-morpholin-4-yl-ethyl)-1H-pyrazolo[4,3-g]quinazolin-5-yl]-amine",0.0037,uM,=,-2.431798275933005,0,c1ccc(Nc2ncnc3cc4c(cnn4CCN4CCOCC4)cc23)cc1
7614,1983834,10.1016/j.bmc.2019.115281,,,,Inhibition of EGFR L858R/T790M (unknown origin),C=C1CC(CI)(c2ccccc2)OC1=O,rac-5-(iodomethyl)-3-methylene-5-phenyldihydrofuran-2(3H)-one,26.0,uM,=,1.414973347970818,1,C=C1CC(c2ccccc2)OC1=O
7615,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CCCN(C)C,"US8846699, 66",0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3ccccc23)cc1
7616,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
7617,1983376,10.1021/acs.jmedchem.9b00167,,,,Inhibition of HER1 (unknown origin),CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1,BRANEBRUTINIB,2.0,uM,=,0.3010299956639812,1,c1cc(N2CCCCC2)c2cc[nH]c2c1
7618,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(C3CC3)nc3cnc(Nc4ccc(OCCOC)cc4)nc32)c1,N-(3-(6-Cyclopropyl-2-((4-(2-methoxyethoxy)phenyl)-amino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.4629,uM,=,-0.3345128192171893,0,O=c1c(C2CC2)nc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
7619,2080996,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(CCCCC(=O)NO)nn1,"5-(4-(((6-Acrylamido-4-((3-chloro-4-fluorophenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypentanamide",0.00035,uM,=,-3.4559319556497243,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
7620,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)S(=O)(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-[(E)-2-Cyano-1-(3,4-dihydroxy-phenyl)-ethenesulfonyl]-3-(3,4-dihydroxy-phenyl)-acrylonitrile",0.38,uM,=,-0.4202164033831898,0,O=S(=O)(C=Cc1ccccc1)/C=C/c1ccccc1
7621,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CN1CCOCC1,"US8846699, 103",0.032,uM,=,-1.494850021680094,0,O=C(CN1CCOCC1)NCCOc1ccc2c(Nc3ccccc3)ncnc2c1
7622,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,CN(C)/N=N/c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,"N-(3-chlorophenyl)-6-[(1E)-3,3-dimethyltriaz-1-enyl]quinazolin-4-amine",0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3ccccc23)cc1
7623,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccccc3)n2)c(OC)cc1N(C)C,N-(2-Dimethylamino-4-methoxy-5-((4-benzamidopyrimidin-2-yl)amino)phenyl)acrylamide,0.1251,uM,=,-0.90274269030658,0,O=C(Nc1ccnc(Nc2ccccc2)n1)c1ccccc1
7624,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C(C)N(C)C,"US8846699, 58",0.125,uM,=,-0.9030899869919436,0,c1ccc(Nc2ncnc3ccccc23)cc1
7625,1574498,10.1016/j.bmcl.2016.04.011,,,,Inhibition of EGFR in human MDA231 cells assessed as growth inhibition after 24 hrs by MTT assay,CC(O)c1cccc(NC(=O)c2cc3ccccc3[nH]2)c1,N-(3-(1-hydroxyethyl)phenyl)-1H-indole-2-carboxamide,34.0,uM,=,1.5314789170422551,1,O=C(Nc1ccccc1)c1cc2ccccc2[nH]1
7626,1675765,10.1016/j.bmc.2017.03.039,,,,Inhibition of human EGFR preincubated for 5 mins with substrate followed by ATP addition measured after 30 mins by HTRF method,NCCn1c(-c2ccccc2)nc2cc(Cl)ccc2c1=O,3-(2-Aminoethyl)-7-chloro-2-phenylquinazolin-4(3H)-one,2.11,uM,=,0.3242824552976926,1,O=c1[nH]c(-c2ccccc2)nc2ccccc12
7627,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccccc1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethylcinnamate,7.83,uM,=,0.8937617620579434,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
7628,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,CN(C)CCCNC(=O)/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"But-2-enedioic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide (3-dimethylamino-propyl)-amide",0.057,uM,=,-1.2441251443275083,0,c1ccc(Nc2ncnc3cnccc23)cc1
7629,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,Cc1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1,"5-(Naphthalen-1-yl)-1-phenyl-3-(p-tolyl)-4,5-dihydro-1H-pyrazole",0.2,uM,=,-0.6989700043360187,0,c1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1
7630,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-acrylamide",0.0034,uM,=,-2.468521082957745,0,c1ccc(Nc2ncnc3cnccc23)cc1
7631,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccc(C(C)C)cc1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl3-(4-isopropylphenyl)acrylate,6.82,uM,=,0.8337843746564789,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
7632,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCCCCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{10-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-decyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",1.3,uM,=,0.1139433523068367,1,O=C(C=Cc1ccccc1)NCCCCCCCCCCNC(=O)/C=C/c1ccccc1
7633,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,COc1ccccc1/C=C/C(=O)OCCn1c([N+](=O)[O-])cnc1C,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl 3-(2-methoxyphenyl)acrylate,32.0,uM,=,1.505149978319906,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
7634,66568,10.1021/jm00033a019,,,,Inhibitory activity against recombinant tyrosine kinase EGF-R (EGF-R ICD),CN(c1ccccc1)c1cc2c(cc1Nc1ccccc1)C(=O)NC2=O,"5-(Methyl-phenyl-amino)-6-phenylamino-isoindole-1,3-dione",8.7,uM,=,0.9395192526186184,1,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21
7635,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,Brc1cccc(Nc2ncnc3ccc4c(c23)OCCN4)c1,"N-(3-bromophenyl)-3,4-dihydro-2H-[1,4]oxazino[2,3-f]quinazolin-10-amine",0.1205,uM,=,-0.9190129530891128,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCN4)cc1
7636,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CCN1CCCCC1,"US8846699, 104",0.014,uM,=,-1.853871964321762,0,O=C(CCN1CCCCC1)NCCOc1ccc2c(Nc3ccccc3)ncnc2c1
7637,658103,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR,Nc1cc2ncnc(Nc3cccc(Br)c3)c2cc1N,"N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine",0.00081,uM,=,-3.09151498112135,0,c1ccc(Nc2ncnc3ccccc23)cc1
7638,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)N1CCN(C(C)=O)CC1,"US8846699, 95",0.076,uM,=,-1.1191864077192086,0,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)N1CCNCC1
7639,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{6-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-hexyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",0.7,uM,=,-0.1549019599857432,0,O=C(C=Cc1ccccc1)NCCCCCCNC(=O)/C=C/c1ccccc1
7640,1761975,10.1016/j.ejmech.2018.02.051,,,,"Inhibition of wild type EGFR (unknown origin) using Poly (Glu, Tyr) as substrate after 40 mins by kinase-Glo luminescence assay",CN1CCN(c2ccc(Nc3cc4c(N5CCCC5)nc(Nc5ccccc5)nc4cn3)nc2)CC1,"N6-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)-N2-phenyl-4-(pyrrolidin-1-yl)pyrido[3,4-d]pyrimidine-2,6-diamine",0.0044,uM,=,-2.356547323513813,0,c1ccc(Nc2nc(N3CCCC3)c3cc(Nc4ccc(N5CCNCC5)cn4)ncc3n2)cc1
7641,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC/C=C/CN1CCCC1.Cl,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(4-pyrrolidin-1-yl-but-2-enyloxy)-quinazolin-4-yl]-amine hydrochloride,0.1,uM,=,-1.0,0,C(=C/CN1CCCC1)\COc1ccc2c(Nc3ccccc3)ncnc2c1
7642,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=C(C)C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-2-methyl-acrylamide",0.044,uM,=,-1.3565473235138126,0,c1ccc(Nc2ncnc3cnccc23)cc1
7643,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,CCOc1ccccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2[nH]1,"(R)-6-(2-Ethoxyphenyl)-N-(1-phenylethyl)-7H-pyrrolo-[2,3-d]pyrimidin-4-amine",0.0003,uM,=,-3.522878745280338,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7644,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)N1CCOCC1,"US8846699, 93",0.036,uM,=,-1.4436974992327127,0,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)N1CCOCC1
7645,1814080,10.1016/j.ejmech.2019.111693,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,O=[N+]([O-])c1ccc(/C=N/Nc2nnc(-c3ccncc3)o2)cc1,"2-(2-(4-Nitrobenzylidene)hydrazinyl)-5-(pyridin-4-yl)-1,3,4-oxadiazole",0.4123,uM,=,-0.3847866651986415,0,C(=N/Nc1nnc(-c2ccncc2)o1)\c1ccccc1
7646,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,CN(C)CCCNC(=O)/C=C/C(=O)N(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"But-2-enedioic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-methyl-amide (3-dimethylamino-propyl)-amide",0.193,uM,=,-0.7144426909922262,0,c1ccc(Nc2ncnc3cnccc23)cc1
7647,63790,10.1016/S0960-894X(97)00035-8,,,,Antagonism towards Epidermal growth factor receptor,COc1cc2ncnc(N(C)c3ccccc3)c2cc1OC.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-methyl-phenyl-amine hydrochloride, 0.8 M EtOH",4.0,uM,=,0.6020599913279624,1,c1ccc(Nc2ncnc3ccccc23)cc1
7648,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCNC(=O)CS(C)(=O)=O,"US8846699, 15",0.068,uM,=,-1.1674910872937636,0,c1ccc(Nc2ncnc3ccccc23)cc1
7649,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,Cc1ccc(C2=NN(C(N)=S)C(c3cccc4ccccc34)C2)cc1,"5-(Naphthalen-1-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",2.06,uM,=,0.3138672203691534,1,c1ccc(C2=NNC(c3cccc4ccccc34)C2)cc1
7650,2185718,10.1016/j.ejmech.2021.113495,,,,"Inhibition of EGFR (unknown origin) using Poly(Gly,Tyr) as substrate incubated for 45 mins in the presence of ATP by ADP-Glo reagent based luminescence assay",CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.43057,uM,=,-0.3659562329619954,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
7651,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,O=C(Nc1cc(N2CCOCC2)ncn1)c1ccc(F)cc1,SID24795904,0.131,uM,=,-0.8827287043442358,0,O=C(Nc1cc(N2CCOCC2)ncn1)c1ccccc1
7652,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,COCCOc1cc2ncnc(Nc3cc(OC)c(OC)c(OC)c3)c2cc1OCCOC,"6,7-bis(2-methoxyethoxy)-N-(3,4,5-trimethoxyphenyl)quinazolin-4-amine",2.4,uM,=,0.380211241711606,1,c1ccc(Nc2ncnc3ccccc23)cc1
7653,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(Cl)c(Br)cc3F)ncnc2cc1OCCNC(C)=O,"US8846699, 133",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3ccccc23)cc1
7654,1640870,,,,,"Time-Resolved Fret (TR-FRET) Assay: 1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dilutions of 10 fold from 100 micoM are used. Kinase activity was determined with time-resolved Fret (TR-FRET) assay (LanthaScreenÂ® kinase activity assay, from InVitrogen).2) The assay is performed in a Black 384-well plate (from Corning). The kinase and the compound was incubated for 30 mM at room temperature. ATP (1 mM) and fluorescein-poly GT were added, and the reaction was incubated for 15 mM. Detection agent SA-XL665 (from Cisbio Assay) and TK Ab-Cryptate detection antibody (from InVitrogen) were added to stop the reaction.3) The 384-well plate was sealed and incubated for 1 hour. The fluorescence was then measured at 620 nM (Cryptate) and 665 nM (XL655) wavelength.4) Each concentration of compound was done in triplicate, and vehicle (without compound) and a positive control were used.",CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC[C@@]12COC[C@@H]1C2,"US9187459, 4",0.00051,uM,=,-3.292429823902064,0,c1ccc(Nc2ncnc3cc(OC[C@@]45COC[C@@H]4C5)ccc23)cc1
7655,463277,10.1016/j.bmcl.2007.11.052,,,,Inhibition of EGFR,Cc1ccc(Oc2ccc(Nc3ncnc4cccc(O[C@H](C)C(=O)N(C)C)c34)cc2C)cn1,"(R)-N,N-dimethyl-2-(4-(3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino)quinazolin-5-yloxy)propanamide",1.1,uM,=,0.041392685158225,1,c1cncc(Oc2ccc(Nc3ncnc4ccccc34)cc2)c1
7656,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3cccc4ccccc34)n2)c(OC)cc1N1CCN(C)CC1,N-(2-(4-Methylpiperazin-1-yl)-4-methoxy-5-((4-(1-naphthoamido)pyrimidin-2-yl)amino)-phenyl)acrylamide,0.1339,uM,=,-0.8732194229879909,0,O=C(Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1)c1cccc2ccccc12
7657,2207741,10.1021/acs.jmedchem.2c00893,,,,Inhibition of wild type EGFR expressed in human NCI-H2073 cells,Cc1c(C#Cc2ccc(CN3CCC(CO)CC3)cc2)cc(C(F)F)c2cn(C(C(=O)Nc3nccs3)c3ncn4c3CCC43CC3)nc12,"2-[4-(Difluoromethyl)-6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-7-methyl-indazol-2-yl)-2-spiro[6,7-dihydropyrrolo[1,2-c]imidazole-5,1'-cyclopropane)-1-yl-N-thiazol-2-yl-acetamide",0.545,uM,=,-0.2636034977233575,0,O=C(Nc1nccs1)C(c1ncn2c1CCC21CC1)n1cc2ccc(C#Cc3ccc(CN4CCCCC4)cc3)cc2n1
7658,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,OC[C@@H](Nc1ncnc2oc(-c3ccccc3)c(Cl)c12)c1ccccc1,"(2S)-2-[(5-Chloro-6-phenylfuro[2,3-d]pyrimidin-4-yl)amino]-2-phenylethanol",0.589,uM,=,-0.2298847052128984,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)cc23)cc1
7659,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C(=C)C,"US8846699, 49",0.069,uM,=,-1.1611509092627446,0,c1ccc(Nc2ncnc3ccccc23)cc1
7660,63790,10.1016/S0960-894X(97)00035-8,,,,Antagonism towards Epidermal growth factor receptor,COc1cc2ncnc(N(C)c3cccc(C(F)(F)F)c3)c2cc1OC.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-methyl-(3-trifluoromethyl-phenyl)-amine hydrochloride",30.0,uM,=,1.4771212547196624,1,c1ccc(Nc2ncnc3ccccc23)cc1
7661,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)[C@H](C)C4)cc3)c(C(N)=O)nc2CC)c1,"US9085540, 64",0.0017,uM,=,-2.7695510786217263,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7662,2251609,10.1021/acs.jmedchem.2c00168,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,CCc1cc(Nc2ncc(Cl)c(-c3cn(S(=O)(=O)CC)c4ccccc34)n2)c(OC)cc1N1CCC(N2CCN(C)CC2)CC1,5-chloro-N-(5-ethyl-2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-4-(1-(ethylsulfonyl)-1H-indol-3-yl)pyrimidin-2-amine,0.2618,uM,=,-0.5820303577852629,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCC(N6CCNCC6)CC5)cc4)n3)c[nH]c2c1
7663,1675765,10.1016/j.bmc.2017.03.039,,,,Inhibition of human EGFR preincubated for 5 mins with substrate followed by ATP addition measured after 30 mins by HTRF method,O=c1c2ccc(Cl)cc2nc(-c2ccccc2)n1-c1nnc(-c2ccccc2)s1,"7-Chloro-2-phenyl-3-(5-phenyl-1,3,4-thiadiazol-2-yl)quinazolin-4(3H)-one",1.68,uM,=,0.2253092817258628,1,O=c1c2ccccc2nc(-c2ccccc2)n1-c1nnc(-c2ccccc2)s1
7664,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3cc4c(ccn4CCN4CCOCC4)cc23)c1,"(3-Bromo-phenyl)-[8-(2-morpholin-4-yl-ethyl)-8H-pyrrolo[3,2-g]quinazolin-4-yl]-amine",0.0037,uM,=,-2.431798275933005,0,c1ccc(Nc2ncnc3cc4c(ccn4CCN4CCOCC4)cc23)cc1
7665,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccccc3OC)ncc2Cl)c1,"US9238629, I-18",0.65,uM,=,-0.1870866433571444,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
7666,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,C/N=N/Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(3-bromophenyl)-6-[(1E)-3-methyltriaz-1-enyl]quinazolin-4-amine,0.039,uM,=,-1.408935392973501,0,c1ccc(Nc2ncnc3ccccc23)cc1
7667,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,COc1cccc(-c2cn(-c3ccc(CC(=O)NCCO)cc3)c3ncnc(N)c23)c1,"2-{4-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-phenyl}-N-(2-hydroxy-ethyl)-acetamide",0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
7668,1337212,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,COc1ccc(Oc2nc3ccc(C)cc3cc2/C=N/NC(=O)Cn2c([N+](=O)[O-])cnc2C)cc1,(E)-N'-((2-(4-methoxyphenoxy)-6-methylquinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,0.12,uM,=,-0.9208187539523752,0,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
7669,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)NCCC,"US8846699, 34",0.026,uM,=,-1.585026652029182,0,c1ccc(Nc2ncnc3ccccc23)cc1
7670,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cn1c(-c2csc(N/N=C\c3ccc([N+](=O)[O-])o3)n2)nc2ccccc21,4-(1-Methyl-1H-benzo[d]imidazol-2-yl)-2-(2-((5-nitrofuran-2-yl)methylene)hydrazinyl)thiazole,0.07167,uM,=,-1.1446625955304597,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccco1
7671,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cc(NS(C)(=O)=O)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-N-(4-(4-((2-Hydroxy-1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methoxyphenyl)methanesulfonamide",0.0003,uM,=,-3.522878745280338,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7672,1894188,10.1016/j.ejmech.2019.05.015,,,,Inhibition of human EGFR measured after 3 hrs by ELISA,Cn1c(=O)c2[nH]c(SC/C(=N/O)c3ccc(Cl)cc3)nc2n(C)c1=O,"8-((2-(4-Chlorophenyl)-2-(hydroxyimino)ethyl)thio)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione",0.4,uM,=,-0.3979400086720376,0,N=C(CSc1nc2[nH]c(=O)[nH]c(=O)c2[nH]1)c1ccccc1
7673,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCC1CCNCC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(2-piperidin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3cc(OCCC4CCNCC4)ccc23)cc1
7674,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C(=O)C=C)CC1,"US8846699, 5",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7675,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",NP(=O)(OCCCC(=O)Oc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)N(CCCl)CCCl,"4-Oxo-4-((4-((3-bromophenyl)amino)quinazolin-6-yl)amino)butyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.0033,uM,=,-2.4814860601221125,0,c1ccc(Nc2ncnc3ccccc23)cc1
7676,632680,10.1016/j.bmc.2010.03.052,,,,Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA,Nc1nc(Nc2cccc(C(F)(F)F)c2)c2cc(Cc3ccc(Cl)cc3Cl)[nH]c2n1,"N4-(3-Trifluoromethylphenyl)-6-(2,4-dichlorobenzyl)-7Hpyrrolo[2,3-d]pyrimidine-2,4-diamine",27.2,uM,=,1.434568904034199,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7677,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2ccc(F)cc2)=N1,2-(2-(4-Fluorobenzylidene)hydrazinyl)thiazol-4(5H)-one,2.18,uM,=,0.3384564936046048,1,O=C1CSC(N/N=C/c2ccccc2)=N1
7678,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3cc4[nH]ccc4cc23)c1,"(3-Bromo-phenyl)-(8H-pyrrolo[3,2-g]quinazolin-4-yl)-amine",0.00044,uM,=,-3.356547323513813,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
7679,1896478,10.1021/acs.jmedchem.9b00631,,,,Inhibition of EGFR (unknown origin) using biotin-labelled peptide as substrate preincubated for 2 hrs followed by substrate addition and measured after 30 mins by HTRF FRET assay,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide,0.0017,uM,=,-2.7695510786217263,0,c1ccc(Oc2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7680,1930229,10.1016/j.ejmech.2019.02.050,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end) expressed in baculovirus infected Sf9 cells using ATP as substrate after 40 mins by Kinase-Glo MAX luminescence assay,O=C(Nc1cccc(NC(=O)c2ccccn2)c1)NC1CCCCC1,N-(3-(3-Cyclohexylureido)phenyl)picolinamide,0.147,uM,=,-0.8326826652518239,0,O=C(Nc1cccc(NC(=O)c2ccccn2)c1)NC1CCCCC1
7681,2296723,10.1021/acs.jmedchem.6b00276,,,,Inhibition of recombinant 6His-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) autophosphorylation expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP and MgCl2 addition measured after 60 mins by DELFIA/time-resolved fluorometric analysis,COc1cc(/C=C2\CC(C)C/C(=C\c3cc(OC)c(OC)c(OC)c3Br)C2=NO)c(Br)c(OC)c1OC,"2,6-bis(2-bromo-3,4,5-trimethoxybenzylidene)-4-methylcyclohexan-1-one oxime",0.5,uM,=,-0.3010299956639812,0,N=C1/C(=C/c2ccccc2)CCC/C1=C\c1ccccc1
7682,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",CCC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c(C(N)=O)nc2CC)C1,"US9085540, 73",0.0012,uM,=,-2.920818753952376,0,c1cc(N2CCNCC2)ccc1Nc1cncc(O[C@@H]2CCNC2)n1
7683,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccc(-c2ccccc2)cc1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl3-(4-phenyl)acrylate,0.62,uM,=,-0.2076083105017461,0,O=C(/C=C/c1ccc(-c2ccccc2)cc1)OCCn1ccnc1
7684,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-2-(6-(2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-2-phenylethanol",0.0004,uM,=,-3.397940008672037,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7685,761853,10.1016/j.bmc.2011.06.022,,,,Inhibition of EGFR after 1 hrs by luminescence assay,Cc1ccc(-c2nc3cc(NC(=O)CCl)ccc3[nH]2)cc1,2-chloro-N-(2-p-tolyl-1H-benzo[d]imidazol-5-yl)acetamide,1.929,uM,=,0.2853322276438845,1,c1ccc(-c2nc3ccccc3[nH]2)cc1
7686,603361,10.1016/j.bmc.2009.08.044,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA,COc1ccccc1C(Cc1coc2nc(N)nc(N)c12)C1CC1,"5-[(R/S)-2-Cyclopropyl-2-(20-methoxyphenyl)ethyl]furo-[2,3-d]pyrimidine-2,4-diamine",56.5,uM,=,1.7520484478194385,1,c1ccc(C(Cc2coc3ncncc23)C2CC2)cc1
7687,2185652,10.1016/j.ejmech.2021.113523,,,,"Inhibition of recombinant EGFR (unknown origin) using Poly-(Glu,Tyr 4:1) peptide as a substrate in presence of ATP by luminescence based assay",CC1=NNC2=NC(=O)NC(c3ccccc3Br)C12,"4-(2-bromophenyl)-3-methyl-1,3a,4,5-tetrahydro-6H-pyrazolo[3,4-d]pyrimidin-6-one",0.09,uM,=,-1.0457574905606752,0,O=C1N=C2NN=CC2C(c2ccccc2)N1
7688,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,CC(C)(C)OC(=O)NCCNC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,4-(2-tert-Butoxycarbonylamino-ethylcarbamoyl)-benzenesulfonic acid 4-(2-nitro-vinyl)-phenyl ester,1.4,uM,=,0.1461280356782379,1,O=S(=O)(Oc1ccccc1)c1ccccc1
7689,2251609,10.1021/acs.jmedchem.2c00168,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.1206,uM,=,-0.9186526921958676,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
7690,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,CN(C)CCCCCC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"6-(Dimethylamino)-N-[3-(4-{[(1S)-2-hydroxy-1-phenylethyl]-amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]hexanamide",4.327,uM,=,0.6361868951987243,1,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
7691,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,O=C(/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1)NCCCn1ccnc1,"But-2-enedioic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide (3-imidazol-1-yl-propyl)-amide",0.014,uM,=,-1.853871964321762,0,O=C(/C=C/C(=O)Nc1cc2c(Nc3ccccc3)ncnc2cn1)NCCCn1ccnc1
7692,1761975,10.1016/j.ejmech.2018.02.051,,,,"Inhibition of wild type EGFR (unknown origin) using Poly (Glu, Tyr) as substrate after 40 mins by kinase-Glo luminescence assay",CN(C)C1CCN(c2ccc(Nc3cc4c(N5CCOCC5)nc(Nc5ccccc5)nc4cn3)nc2)CC1,"N6-(5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)-4-morpholino-N2-phenylpyrido[3,4-d]pyrimidine-2,6-diamine",0.0046,uM,=,-2.337242168318426,0,c1ccc(Nc2nc(N3CCOCC3)c3cc(Nc4ccc(N5CCCCC5)cn4)ncc3n2)cc1
7693,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,CCOC(=O)c1ccc(Nc2cc(NC(=O)CCCC(=O)O)ncn2)cc1,5-((6-((4-(Ethoxycarbonyl)phenyl)amino)pyrimidin-4-yl)amino)-5-oxopentanoic acid,0.048,uM,=,-1.3187587626244128,0,c1ccc(Nc2ccncn2)cc1
7694,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,OCCN(CCO)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"2-[{2-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-ethyl}-(2-hydroxy-ethyl)-amino]-ethanol",0.071,uM,=,-1.1487416512809248,0,c1ccc(Nc2ncnc3cnccc23)cc1
7695,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CC,"US8846699, 55",0.589,uM,=,-0.2298847052128984,0,c1ccc(Nc2ncnc3ccccc23)cc1
7696,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,C[C@@H](NC(=O)[C@@H](C)NC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1)C(=O)O,2-[1-(4-{4-[2-nitro-(E)-1-ethenyl]phenyloxysulfonyl}phenylcarboxamido)-(1R)-ethylcarboxamido]-(2R)-propanoic acid,7.0,uM,=,0.8450980400142568,1,O=S(=O)(Oc1ccccc1)c1ccccc1
7697,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,CN(C)CCCC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"4-(Dimethylamino)-N-[3-(4-{[(1S)-2-hydroxy-1-phenylethyl]-amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]butanamide",0.029,uM,=,-1.537602002101044,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
7698,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3)ncnc2cc1OCCNC(=O)CN(C)C,"US8846699, 152",0.075,uM,=,-1.1249387366083,0,c1ccc(Nc2ncnc3ccccc23)cc1
7699,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C1CCCN1C(C)=O,"US8846699, 105",0.025,uM,=,-1.6020599913279625,0,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)C1CCCN1
7700,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=C[S+]([O-])c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"(3-Bromo-phenyl)-(6-ethenesulfinyl-pyrido[3,4-d]pyrimidin-4-yl)-amine",0.34,uM,=,-0.4685210829577448,0,c1ccc(Nc2ncnc3cnccc23)cc1
7701,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,COc1cccc(Nc2cc(Nc3cc(OC)ccc3OC)ncn2)c1,"N4-(2,5-Dimethoxyphenyl)-N6-(3-methoxyphenyl)pyrimidine-4,6-diamine",0.026,uM,=,-1.585026652029182,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
7702,1888594,10.1016/j.bmc.2019.06.023,,,,Inhibition of EGFR (unknown origin),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.012,uM,=,-1.9208187539523751,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
7703,485268,10.1021/np50066a009,,,,Inhibition of EGFR,O=CN/C=C/c1cc(O)ccc1O,"N-[(E)-2-(2,5-Dihydroxy-phenyl)-vinyl]-formamide",1.1169550001375288,uM,=,0.0480356766199687,1,c1ccccc1
7704,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCc1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-(4-phenyl-butyl)-acrylamide",1.1,uM,=,0.041392685158225,1,O=C(C=Cc1ccccc1)NCCCCc1ccccc1
7705,755598,10.1016/j.bmcl.2010.07.008,,,,Inhibition of EGFR,CSc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C)ns2)n1,"3-methyl-N-(6-(methylthio)-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl)isothiazol-5-amine",5.048,uM,=,0.7031193462360779,1,c1cc(Nc2nccn3c(-c4cn[nH]c4)cnc23)sn1
7706,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(S(N)(=O)=O)cc3)cc12)c1ccccc1,"(R)-4-(4-((1-Phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzenesulfonamide",0.0007,uM,=,-3.154901959985743,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7707,1774161,10.1016/j.ejmech.2018.03.013,,,,Inhibition of recombinant human EGFR using Ulight-CAGAGAIETDKEYYTVKD as substrate measured after 15 mins by LANCE assay,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,"(3-Bromo-phenyl)-(6,7-dimethoxy-quinazolin-4-yl)-amine",9.5e-05,uM,=,-4.022276394711152,0,c1ccc(Nc2ncnc3ccccc23)cc1
7708,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cc(CNCCN2CCCCC2)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-2-((6-(2-Methoxy-4-(((2-(piperidin-1-yl)ethyl)amino)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0001,uM,=,-4.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccc(CNCCN5CCCCC5)cc4)cc23)cc1
7709,775025,10.1016/j.ejmech.2011.09.041,,,,Inhibition of human EGFR,Nc1scc2c1c(NCCO)nc1nc(NCCO)nc(N)c12,"2,2'-((1,7-diaminothieno[3',4':4,5]pyrido[2,3-d]pyrimidine-3,6-diyl)bis(azanediyl))diethanol",66.1,uM,=,1.82020145948564,1,c1ncc2c(n1)ncc1cscc12
7710,2296723,10.1021/acs.jmedchem.6b00276,,,,Inhibition of recombinant 6His-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) autophosphorylation expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP and MgCl2 addition measured after 60 mins by DELFIA/time-resolved fluorometric analysis,COc1ccc2c(c1)CCC(=C\c1cc(OC)c(OC)c(OC)c1Br)/C2=N\O,"2-(2-bromo-3,4,5-trimethoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one oxime",2.1,uM,=,0.3222192947339193,1,N=C1/C(=C/c2ccccc2)CCc2ccccc21
7711,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,CN(c1ccccc1)c1ncnc2ccc(N/N=N/Cc3ccccn3)cc12,N-methyl-N-phenyl-6-[(1E)-3-(pyridin-2-ylmethyl)triaz-1-enyl]quinazolin-4-amine,9.3,uM,=,0.9684829485539352,1,c1ccc(Nc2ncnc3ccc(N/N=N/Cc4ccccn4)cc23)cc1
7712,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccccc2)CC1c1ccc(C(=O)OC(C)Cn2c([N+](=O)[O-])cnc2C)cc1,"1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-yl 4-(1-acetyl-3-phenyl-4,5-dihydro-1H-pyrazol-5-yl)benzoate",12.24,uM,=,1.0877814178095424,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7713,2220184,10.1016/j.bmcl.2021.128524,,,,Inhibition of EGFR tyrosine kinase (unknown origin),C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.00352,uM,=,-2.453457336521869,0,c1ccc(Nc2ncnc3ccccc23)cc1
7714,473565,10.1073/pnas.0708800104,,,,Inhibition of EGFR,Cc1cc(C=C2C(=O)C=CC2=O)cc(C)c1O,"2-((3,5-dimethyl-4-hydroxyphenyl)-methylene)-4-cyclopentene-1,3-dione",440.0,uM,=,2.6434526764861874,1,O=C1C=CC(=O)C1=Cc1ccccc1
7715,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2cc(Br)cc(Br)c2O)=N1,"2-(2-(3,5-Dibromo-2-hydroxybenzylidene)hydrazinyl)thiazol-4(5H)-one",1.24,uM,=,0.093421685162235,1,O=C1CSC(N/N=C/c2ccccc2)=N1
7716,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"But-2-enoic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide",0.0077,uM,=,-2.113509274827518,0,c1ccc(Nc2ncnc3cnccc23)cc1
7717,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNCC(C)=O,"US8846699, 142",0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3ccccc23)cc1
7718,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(Oc3ccccc3)nc3cnc(Nc4ccc(OC)cc4)nc32)c1,N-(3-(2-((4-Methoxyphenyl)amino)-7-oxo-6-phenoxypteridin-8(7H)-yl)phenyl)acrylamide,0.0091,uM,=,-2.0409586076789066,0,O=c1c(Oc2ccccc2)nc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
7719,615344,10.1016/j.ejmech.2009.12.026,,,,Inhibition of EGFR,CC1=C(C(=O)Nc2cccc([N+](=O)[O-])c2)C(c2ccc(O)cc2O)NC(NN)=N1,"6-(2,4-Dihydroxyphenyl)-2-hydrazinyl-4-methyl-N-(3-nitrophenyl)-l,6-dihydro-pyrimidine-5-carboxamide",47.9,uM,=,1.6803355134145632,1,O=C(Nc1ccccc1)C1=CN=CNC1c1ccccc1
7720,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,Cn1ncc2cc(Nc3ncnn4ccc(CN5CCC(N)CC5)c34)ccc21,"5-((4-aminopiperidin-1-yl)methyl)-N-(1-methyl-1H-indazol-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.95,uM,=,-0.0222763947111522,0,c1nc(Nc2ccc3[nH]ncc3c2)c2c(CN3CCCCC3)ccn2n1
7721,2283190,10.1039/d2md00139j,,,,Inhibition of wild type EGFR (unknown origin),N#C/C(=C/C(=O)N1CCC[C@@H](n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)C1)C1CC1,"(R)-4-(3-(4-Amino-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-cyclopropyl-4-oxobut-2-enenitrile",0.013,uM,=,-1.8860566476931635,0,O=C(C=CC1CC1)N1CCC[C@@H](n2nc(-c3cnc4[nH]ccc4c3)c3cncnc32)C1
7722,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,Fc1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1,"3-(4-Fluorophenyl)-5-(naphthalen-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",0.3,uM,=,-0.5228787452803376,0,c1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1
7723,1466619,10.1016/j.bmc.2015.03.061,,,,Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,Cc1nc(N(C)c2ccc3c(c2)OCO3)c2cc(C)oc2n1,"N-1,3-Benzodioxol-5-yl-N,2,6-trimethylfuro[2,3-d]pyrimidin-4-amine",0.2981999999999999,uM,=,-0.5254923608830243,0,c1nc(Nc2ccc3c(c2)OCO3)c2ccoc2n1
7724,66568,10.1021/jm00033a019,,,,Inhibitory activity against recombinant tyrosine kinase EGF-R (EGF-R ICD),CCN(CC)c1ccc(Nc2cc3c(cc2Nc2ccc(N(CC)CC)cc2)C(=O)NC3=O)cc1,"5,6-Bis-(4-diethylamino-phenylamino)-isoindole-1,3-dione",50.0,uM,=,1.6989700043360187,1,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21
7725,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Cc1cccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)c1,"N*6*-(2-Morpholin-4-yl-ethyl)-N*4*-m-tolyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3cnc(NCCN4CCOCC4)cc23)cc1
7726,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCNCCC=O,"US8846699, 87",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnc3ccccc23)cc1
7727,1894188,10.1016/j.ejmech.2019.05.015,,,,Inhibition of human EGFR measured after 3 hrs by ELISA,COc1ccc(/C(CSc2nc3c([nH]2)c(=O)n(C)c(=O)n3C)=N\O)cc1,"8-((2-(Hydroxyimino)-2-(4-methoxyphenyl)ethyl)thio)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione",0.32,uM,=,-0.494850021680094,0,N=C(CSc1nc2[nH]c(=O)[nH]c(=O)c2[nH]1)c1ccccc1
7728,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(OCc4ccccn4)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F,N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.039,uM,=,-1.408935392973501,0,O=C(Nc1cc2c(Nc3ccc(OCc4ccccn4)cc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7729,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCOC(=O)Nc1ccc(Nc2ncnc3cc(OCCN4CCOCC4)c(OC)cc23)cc1Cl.Cl,{2-Chloro-4-[6-methoxy-7-(2-morpholinoethoxy)quinazolin-4-ylamino]phenyl}carbamic acid ethyl ester hydrochloride,8.5,uM,=,0.9294189257142929,1,c1ccc(Nc2ncnc3cc(OCCN4CCOCC4)ccc23)cc1
7730,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OC/C=C/CN1CCCC1.Cl,(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(4-pyrrolidin-1-yl-but-2-enyloxy)-quinazolin-4-yl]-amine hydrochloride,0.09,uM,=,-1.0457574905606752,0,C(=C/CN1CCCC1)\COc1ccc2c(Nc3ccccc3)ncnc2c1
7731,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,COc1ccc2ncc(C#N)c(N[C@@H]3C[C@H]3c3ccccc3)c2c1,"6-methoxy-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",8.27,uM,=,0.9175055095525466,1,c1ccc([C@@H]2C[C@H]2Nc2ccnc3ccccc23)cc1
7732,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,C#Cc1cccc(NC(=O)c2cc(NC(=O)CCCCCCC(=O)NO)ccc2O)c1,N-(3-Ethynylphenyl)-2-hydroxy-5-(8-hydroxyamino-8-oxooctanamido)benzamide,2.25,uM,=,0.3521825181113625,1,O=C(Nc1ccccc1)c1ccccc1
7733,1274575,10.1016/j.bmcl.2013.09.086,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation expressed in baculovirus infected insect Sf9 cells preincubated for 10 mins followed by ATP-MgCl2 addition measured after 1 hr by fluorometric analysis,Cc1ncc([N+](=O)[O-])n1C/C(=N/NC(=O)c1ccc(N)cc1)c1ccc(Br)cc1,(E)-N'-(1-(4-bromophenyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylidene)-4-amino-benzohydrazide,0.43,uM,=,-0.3665315444204134,0,O=C(N/N=C(/Cn1ccnc1)c1ccccc1)c1ccccc1
7734,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{8-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-octyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",2.2,uM,=,0.3424226808222063,1,O=C(C=Cc1ccccc1)NCCCCCCCCNC(=O)/C=C/c1ccccc1
7735,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,OCCN(CCO)Cc1c[nH]c2cc3ncnc(Nc4cccc(Br)c4)c3cc12,"2-[[4-(3-Bromo-phenylamino)-8H-pyrrolo[3,2-g]quinazolin-6-ylmethyl]-(2-hydroxy-ethyl)-amino]-ethanol",0.0035,uM,=,-2.4559319556497243,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
7736,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,OC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccccc1,"(S)-2-phenyl-2-((6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol",0.0008,uM,=,-3.096910013008056,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7737,1732106,10.1016/j.ejmech.2018.01.061,,,,"Inhibition of EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",COc1cc2c(Oc3ccc(NC(=O)NN4C(=O)CSC4c4c(F)cccc4F)c(F)c3)ccnc2cc1OCCCN1CCCC1,"1-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(2-fluoro-4-((6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)urea",0.812,uM,=,-0.0904439707588246,0,O=C(Nc1ccc(Oc2ccnc3cc(OCCCN4CCCC4)ccc23)cc1)NN1C(=O)CSC1c1ccccc1
7738,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#Cc1ncc(CN2CCCC2)s1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-((5-(pyrrolidin-1-ylmethyl)thiazol-2-yl)ethynyl)pyrimidin-4-amine,0.074,uM,=,-1.1307682802690238,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ncc(CN2CCCC2)s1
7739,1574498,10.1016/j.bmcl.2016.04.011,,,,Inhibition of EGFR in human MDA231 cells assessed as growth inhibition after 24 hrs by MTT assay,O=C(Nc1ccc(C(O)c2ccccc2)cc1)c1cc2ccccc2[nH]1,N-(4-(hydroxy(phenyl)methyl)phenyl)-1H-indole-2-carboxamide,38.0,uM,=,1.57978359661681,1,O=C(Nc1ccc(Cc2ccccc2)cc1)c1cc2ccccc2[nH]1
7740,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,COc1cc(/C=C(\C)[N+](=O)[O-])ccc1OS(=O)(=O)c1ccc(C(=O)O)cc1,4-[2-Methoxy-4-(2-nitro-propenyl)-phenoxysulfonyl]-benzoic acid,2.5,uM,=,0.3979400086720376,1,O=S(=O)(Oc1ccccc1)c1ccccc1
7741,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,CC(=O)Nc1ccc(-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)cc1,"(R)-N-(4-(4-((1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)acetamide",0.0007,uM,=,-3.154901959985743,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7742,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3ccc(-c4ccc(F)cc4)cc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((5-(4-fluorophenyl)-1H-indazol-3-yl)amino)-4-methoxyphenyl)acrylamide,0.0068,uM,=,-2.167491087293764,0,c1ccc(Nc2n[nH]c3ccc(-c4ccccc4)cc23)cc1
7743,1274575,10.1016/j.bmcl.2013.09.086,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation expressed in baculovirus infected insect Sf9 cells preincubated for 10 mins followed by ATP-MgCl2 addition measured after 1 hr by fluorometric analysis,Cc1ncc([N+](=O)[O-])n1C/C(=N/NC(=O)c1ccc(O)cc1)c1ccc(Br)cc1,(E)-N'-(1-(4-bromophenyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylidene)-4-hydroxybenzohydrazide,0.21,uM,=,-0.6777807052660807,0,O=C(N/N=C(/Cn1ccnc1)c1ccccc1)c1ccccc1
7744,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=C/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"Penta-2,4-dienoic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide",0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ncnc3cnccc23)cc1
7745,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1,"US9085540, 54",0.0017,uM,=,-2.7695510786217263,0,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(O[C@@H]2CCNC2)n1
7746,473565,10.1073/pnas.0708800104,,,,Inhibition of EGFR,O=c1ccc2ccc(O)c(O)c2o1,"7,8-dihydroxy-2H-chromen-2-one",7.67,uM,=,0.884795363948981,1,O=c1ccc2ccccc2o1
7747,2296723,10.1021/acs.jmedchem.6b00276,,,,Inhibition of recombinant 6His-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) autophosphorylation expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP and MgCl2 addition measured after 60 mins by DELFIA/time-resolved fluorometric analysis,COc1ccc(OC)c2c1CCC(=C\c1cc(OC)c(OC)c(OC)c1Br)/C2=N\O,"2-(2-Bromo-3,4,5-trimethoxy-benzylidene)-5,8-dimethoxy-tetralone oxime",4.2,uM,=,0.6232492903979004,1,N=C1/C(=C/c2ccccc2)CCc2ccccc21
7748,63790,10.1016/S0960-894X(97)00035-8,,,,Antagonism towards Epidermal growth factor receptor,COc1cc2ncnc(Nc3ccccc3)c2cc1OC.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-phenyl-amine hydrochloride",0.05,uM,=,-1.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
7749,2080996,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCc1cn(CCCCC(=O)NO)nn1,"5-(4-(((6-Acrylamido-4-((3-chloro-2-fluorophenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxypentanamide",0.00044,uM,=,-3.356547323513813,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
7750,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccc(F)cc1,"3-(3,4-Dihydroxy-phenyl)-2-(4-fluoro-benzoyl)-acrylonitrile",0.56,uM,=,-0.2518119729937995,0,O=C(C=Cc1ccccc1)c1ccccc1
7751,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)nc3C)n2)c(OC)cc1N(C)CCN(C)C,"N-(5-((4-((1,3-dimethyl-1H-pyrazol-4-yl)amino)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",0.07128,uM,=,-1.1470323089711816,0,c1ccc(Nc2nccc(Nc3cn[nH]c3)n2)cc1
7752,2224999,10.1021/acs.jmedchem.1c01714,,,,Inhibition of EGFR (unknown origin) using biotin as substrate incubated for 2 hrs by HTRF assay,COc1cc2ncnc(Oc3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)c4ccccc34)c2cc1OC,"1-(4-((6,7-Dimethoxyquinazolin-4-yl)oxy)naphthalen-1-yl)-3-(3-(trifluoromethyl)phenyl)urea",83.9,uM,=,1.9237619608287,1,O=C(Nc1ccccc1)Nc1ccc(Oc2ncnc3ccccc23)c2ccccc12
7753,887628,10.1021/jm3003203,,,,Inhibition of EGFR,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0005,uM,=,-3.3010299956639813,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
7754,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1F)c1cc([N+](=O)[O-])ccc1F,N-(4-((3-chloro-4-fluorophenyl)amino)-7-fluoroquinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.044,uM,=,-1.3565473235138126,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccccc1
7755,526697,10.1021/np050229y,,,,Inhibition of EGFR,O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O,"(phloretin)3-(4-Hydroxy-phenyl)-1-(2,4,6-trihydroxy-phenyl)-propan-1-one",25000.0,uM,=,4.3979400086720375,1,O=C(CCc1ccccc1)c1ccccc1
7756,2251609,10.1021/acs.jmedchem.2c00168,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,CCS(=O)(=O)n1cc(-c2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)c(Cl)c3)ncc2Cl)c2ccccc21,5-chloro-N-(3-chloro-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-4-(1-(ethylsulfonyl)-1H-indol-3-yl)pyrimidin-2-amine,0.4661,uM,=,-0.3315208970674144,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCC(N6CCNCC6)CC5)cc4)n3)c[nH]c2c1
7757,1761975,10.1016/j.ejmech.2018.02.051,,,,"Inhibition of wild type EGFR (unknown origin) using Poly (Glu, Tyr) as substrate after 40 mins by kinase-Glo luminescence assay",CN(C)C1CCN(c2ccc(Nc3cc4c(N5CCOCC5)nc(Nc5ccc(F)cc5)nc4cn3)nc2)CC1,"N6-(5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)-N2-(4-fluorophenyl)-4-morpholinopyrido[3,4-d]pyrimidine-2,6-diamine",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Nc2nc(N3CCOCC3)c3cc(Nc4ccc(N5CCCCC5)cn4)ncc3n2)cc1
7758,526697,10.1021/np050229y,,,,Inhibition of EGFR,O=C(/C=C/c1ccc(O)c(O)c1)c1ccc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(O)c1O,Marein,19000.0,uM,=,4.278753600952829,1,O=C(/C=C/c1ccccc1)c1ccc(O[C@H]2CCCCO2)cc1
7759,632680,10.1016/j.bmc.2010.03.052,,,,Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA,Nc1nc(Nc2cccc(Br)c2)c2cc(Cc3ccc(Cl)cc3Cl)[nH]c2n1,"N4-(3-bromophenyl)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",0.2,uM,=,-0.6989700043360187,0,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7760,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",NP(=O)(OCCOc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)N(CCCl)CCCl,"2-(6-(4-((3-Bromophenyl)amino)quinazolin-6-yl)oxy)ethyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.0043,uM,=,-2.3665315444204134,0,c1ccc(Nc2ncnc3ccccc23)cc1
7761,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,O=C(/C=C/Cn1ccnc1)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(1H-imidazol-1-yl)but-2-en-1-one",0.55,uM,=,-0.2596373105057561,0,O=C(/C=C/Cn1ccnc1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
7762,793611,10.1016/j.bmc.2011.11.023,,,,Inhibition of EGFR autophosphorylation in EGF-stimulated human A431 cells after 1 hr by immunoblotting,O=C(c1cc2cc(O)ccc2[nH]1)c1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1,"(4-(3-Chloro-4-fluorophenylamino)thieno[2,3-d]pyrimidin-6-yl)(5-hydroxy-1H-indol-2-yl)methanone",0.1,uM,=,-1.0,0,O=C(c1cc2ccccc2[nH]1)c1cc2c(Nc3ccccc3)ncnc2s1
7763,1837344,10.1016/j.ejmech.2019.111664,,,,Inhibition of EGFR (unknown origin),N=C1NC(=O)/C(=C2/CCNC(=O)c3[nH]cc(Br)c32)N1,Spongiacidin B,18.575748642269136,uM,=,1.2689463257787543,1,N=C1NC(=O)/C(=C2/CCNC(=O)c3[nH]ccc32)N1
7764,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C(F)(F)F,"US8846699, 28",0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2ncnc3ccccc23)cc1
7765,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,COc1ccccc1CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-2-methoxybenzyl oxime,0.047,uM,=,-1.3279021420642825,0,C(=N/OCc1ccccc1)\c1cncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1
7766,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCNC(C)=O,"US8846699, 112",0.018,uM,=,-1.744727494896694,0,c1ccc(Nc2ncnc3ccccc23)cc1
7767,528400,10.1021/np9905259,,,,Inhibition of human recombinant EGFR kinase expressed in Sf9 insect cells,CO[C@H](C)c1c(O)cc2c(c1O)C(=O)c1c(O)cc(O)cc1C2=O,"(R)-1,3,6,8-tetrahydroxy-2-(1-methoxyethyl)anthracene-9,10-dione",27.5,uM,=,1.4393326938302626,1,O=C1c2ccccc2C(=O)c2ccccc21
7768,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1cccc(F)c1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl 3-(3-fluorophenyl)acrylate,12.42,uM,=,1.0941215958405617,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
7769,2296723,10.1021/acs.jmedchem.6b00276,,,,Inhibition of recombinant 6His-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) autophosphorylation expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP and MgCl2 addition measured after 60 mins by DELFIA/time-resolved fluorometric analysis,COc1cc2c(cc1OC)C(=N/O)/C(=C/c1cc(OC)c(OC)c(OC)c1Br)CC2,"2-(2-bromo-3,4,5-trimethoxybenzylidene)-6,7-dimethoxy-3,4-dihydronaphthalen-1(2H)-one oxime",8.4,uM,=,0.9242792860618816,1,N=C1/C(=C/c2ccccc2)CCc2ccccc21
7770,1574498,10.1016/j.bmcl.2016.04.011,,,,Inhibition of EGFR in human MDA231 cells assessed as growth inhibition after 24 hrs by MTT assay,CC(=O)c1ccc(NC(=O)c2cc3ccccc3[nH]2)cc1,N-(4-acetylphenyl)-1H-indole-2-carboxamide,50.0,uM,=,1.6989700043360187,1,O=C(Nc1ccccc1)c1cc2ccccc2[nH]1
7771,1329559,10.1039/C0MD00115E,,,,Inhibition of EGFR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,CC1(C)OB(c2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)OC1(C)C,"N-(3-chlorophenyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-4-amine",0.59,uM,=,-0.2291479883578558,0,c1ccc(Nc2ncnc3ccc(B4OCCO4)cc23)cc1
7772,1983834,10.1016/j.bmc.2019.115281,,,,Inhibition of EGFR L858R/T790M (unknown origin),C=C1CC(CBr)(c2ccc(F)cc2)OC1=O,rac-5-(bromomethyl)-5-(4-fluorophenyl)-3-methylenedihydrofuran-2(3H)-one,30.0,uM,=,1.4771212547196624,1,C=C1CC(c2ccccc2)OC1=O
7773,608087,10.1021/jm901558p,,,,Inhibition of human recombinant EGFR expressed in insect cells by time-resolved fluorimetry,CC(C)c1nsc(C(=O)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)n1,"N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-isopropyl-1,2,4-thiadiazole-5-carboxamide",0.129,uM,=,-0.889410289700751,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ncns1
7774,509684,10.1016/j.bmcl.2008.07.020,,,,Inhibition of human EGFR expressed in SF9 cells,Nc1ncnc(Nc2ccc3c(cnn3Cc3cccc(F)c3)c2)c1/C=N/NCC(F)(F)F,"N-[1-(3-Fluoro-benzyl)-1H-indazol-5-yl]-5-[(2,2,2-trifluoro-ethyl)-hydrazonomethyl]-pyrimidine-4,6-diamine",0.052,uM,=,-1.2839966563652008,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
7775,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCOC(=O)Nc1cc(Nc2ncnc3cc(OC)c(OC)cc23)ccc1C.Cl,"{5-[6,7-Dimethoxyquinazolin-4-ylamino]-2-methylphenyl}carbamic acid ethyl ester hydrochloride",5.0,uM,=,0.6989700043360189,1,c1ccc(Nc2ncnc3ccccc23)cc1
7776,67060,10.1021/jm0108348,,,,Inhibition of Epidermal growth factor receptor,CN1CCC(c2c(O)cc(O)c3c2O/C(=C\c2ccccc2Cl)C3=O)CC1,"2-(2-Chloro-benzylidene)-4,6-dihydroxy-7-(1-methyl-piperidin-4-yl)-benzofuran-3-one",1.68,uM,=,0.2253092817258628,1,O=C1/C(=C/c2ccccc2)Oc2c1cccc2C1CCNCC1
7777,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{5-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-pentyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",0.7,uM,=,-0.1549019599857432,0,O=C(C=Cc1ccccc1)NCCCCCNC(=O)/C=C/c1ccccc1
7778,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cn1c(-c2csc(NN=C3CCCC3)n2)nc2ccccc21,2-(2-Cyclopentylidenehydrazinyl)-4-(1-methyl-1H-benzo[d]imidazol-2-yl)thiazole,0.1097099999999999,uM,=,-0.9597537849422932,0,c1ccc2[nH]c(-c3csc(NN=C4CCCC4)n3)nc2c1
7779,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2ccc(F)cc2)c1,4-(1-(4-fluorobenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-methyl oxime,0.104,uM,=,-0.9829666607012196,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
7780,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccc(OC)c(OC)c3)n2)c(OC)cc1N1CCC(C(N)=O)CC1,"N-(2-(4-Carbamoylpiperidin-1-yl)-4-methoxy-5-((4-(3,4-dimethoxybenzamido)pyrimidin-2-yl)amino)phenyl)acrylamide",0.128,uM,=,-0.8927900303521317,0,O=C(Nc1ccnc(Nc2ccc(N3CCCCC3)cc2)n1)c1ccccc1
7781,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCNC(=O)CN(C)C,"US8846699, 116",0.419,uM,=,-0.3777859770337047,0,c1ccc(Nc2ncnc3ccccc23)cc1
7782,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)COC,"US8846699, 146",0.213,uM,=,-0.6716203965612623,0,c1ccc(Nc2ncnc3ccccc23)cc1
7783,63790,10.1016/S0960-894X(97)00035-8,,,,Antagonism towards Epidermal growth factor receptor,COc1cc2ncnc(Nc3cc(OC)c(OC)c(OC)c3)c2cc1OC.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-(3,4,5-trimethoxy-phenyl)-amine hydrochloride",0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ncnc3ccccc23)cc1
7784,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2cccc(Cl)c2)=N1,2-(2-(3-Chlorobenzylidene)hydrazinyl)thiazol-4(5H)-one,10.78,uM,=,1.0326187608507198,1,O=C1CSC(N/N=C/c2ccccc2)=N1
7785,658103,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)CCF,(E)-4-[(2-Fluoroethyl)methylamino]-but-2-enoic acid[4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinoline-6-yl]amide,0.0008,uM,=,-3.096910013008056,0,c1ccc(Nc2ccnc3ccccc23)cc1
7786,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)COC,"US8846699, 44",0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3ccccc23)cc1
7787,1683690,10.1016/j.ejmech.2017.03.045,,,,"Inhibition of EGFR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",Cc1cc(=O)n(-c2ccc(F)cc2)nc1C(=O)Nc1ccc(Oc2ccnc3[nH]ccc23)c(F)c1,"N-(4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-3-fluorophenyl)-1-(4-fluorophenyl)-4-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide",0.7253,uM,=,-0.1394823225382537,0,O=C(Nc1ccc(Oc2ccnc3[nH]ccc23)cc1)c1ccc(=O)n(-c2ccccc2)n1
7788,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc(F)ccc1[N+](=O)[O-],N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-5-fluoro-2-nitrobenzamide,0.043,uM,=,-1.3665315444204136,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7789,1869615,10.1016/j.bmc.2019.01.027,,,,Inhibition of EGFR (unknown origin),CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,"2-(2-Chloro-phenyl)-5,7-dihydroxy-8-((3R,4S)-3-hydroxy-1-methyl-piperidin-4-yl)-chromen-4-one",21.0,uM,=,1.3222192947339193,1,O=c1cc(-c2ccccc2)oc2c(C3CCNCC3)cccc12
7790,1641866,,,,,"Enzyme Assay: A431 Cell Line: 1. 5Ã103 cells per well in 100 Î¼l of medium were seeded in 96-well plate, here the medium contained 5% FBS2. 24 hours later, 100 Î¼l fresh medium was added with various concentrations of compounds into each well, while the medium here was free of FBS.3. After the cells were treated with compounds for 72 hours, 20 Î¼l MTT (5 mg/ml) was added into each well, and then the assay plate was incubated at 37Â° C. for 4 more hours.4. The assay plate was centrifuged at 800 g for 10 min. The medium was aspirated, 150 Î¼l DMSO was added into each well. The plate was gently shaken for 10 min.5. The absorbance at 570 nm was measured on the plate reader.6. IR %=(WCâWT)/WCÃ100%.",C#Cc1cccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(NC(=O)/C=C/CN(CC)CC)cc23)c1,"US9388170, 20",1.791,uM,=,0.2530955858490315,1,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
7791,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC1CCCN(C(C)=O)C1,"US8846699, 89",0.128,uM,=,-0.8927900303521317,0,c1ccc(Nc2ncnc3cc(OC4CCCNC4)ccc23)cc1
7792,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)N1CCN(C)CC1,"US8846699, 96",0.013,uM,=,-1.8860566476931635,0,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)N1CCNCC1
7793,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1ccc(F)c(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c(C(N)=O)nc2CC)c1,"US9085540, 82",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7794,655538,10.1038/leu.2008.334,,,,Inhibition of EGFR,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,"N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide",0.322,uM,=,-0.4921441283041691,0,O=C(Nc1ccccc1)c1cnc(Nc2cc(N3CCNCC3)ncn2)s1
7795,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,CC1(C)CC(C(=O)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)CC(C)(C)N1[O],"2,2,6,6-Tetramethyl-1-oxyl-N-[4-(3-bromophenylamino)quinazolin-6-yl]piperidine-4-carboxamide",0.031,uM,=,-1.5086383061657274,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CCNCC1
7796,1837344,10.1016/j.ejmech.2019.111664,,,,Inhibition of EGFR (unknown origin),COc1ccc(Cc2nc(-c3cc(Br)c(OCCCN(C)C)c(Br)c3)c[nH]c2=O)cc1Br,Ma'edamine A,10.686883009389271,uM,=,1.0288510551418453,1,O=c1[nH]cc(-c2ccccc2)nc1Cc1ccccc1
7797,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCNCC(C)=O,"US8846699, 84",0.026,uM,=,-1.585026652029182,0,c1ccc(Nc2ncnc3ccccc23)cc1
7798,509684,10.1016/j.bmcl.2008.07.020,,,,Inhibition of human EGFR expressed in SF9 cells,COC[C@H]1CCCN1/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,"(R,E)-N4-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((2-(methoxymethyl)pyrrolidin-1-ylimino)methyl)pyrimidine-4,6-diamine",0.031,uM,=,-1.5086383061657274,0,C(=N/N1CCCC1)\c1cncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1
7799,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1SCCNC(C)=O,"US8846699, 43",0.109,uM,=,-0.9625735020593764,0,c1ccc(Nc2ncnc3ccccc23)cc1
7800,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)NCCOc1cc2ncnc(Nc3ccc(Br)cc3F)c2cc1NC(=O)C=C,"US8846699, 26",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
7801,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C(=O)NCCC)CC1,"US8846699, 9",0.036,uM,=,-1.4436974992327127,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7802,1574498,10.1016/j.bmcl.2016.04.011,,,,Inhibition of EGFR in human MDA231 cells assessed as growth inhibition after 24 hrs by MTT assay,O=C(Nc1cccc(C(O)c2ccccc2)c1)c1cc2ccccc2[nH]1,N-(3-(hydroxy(phenyl)methyl)phenyl)-1H-indole-2-carboxamide,15.0,uM,=,1.1760912590556811,1,O=C(Nc1cccc(Cc2ccccc2)c1)c1cc2ccccc2[nH]1
7803,1816244,10.1016/j.ejmech.2019.111809,,,,Inhibition of wildtype EGFR (unknown origin) using biotin as substrate in presence of ATP by mobility shift assay based ELISA,C=CC(=O)Nc1cc(Nc2nc3c(c(-c4cn(C)c5ccccc45)n2)CSCC3)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide",0.511,uM,=,-0.2915790998652872,0,c1ccc(Nc2nc3c(c(-c4c[nH]c5ccccc45)n2)CSCC3)cc1
7804,615344,10.1016/j.ejmech.2009.12.026,,,,Inhibition of EGFR,CC1=C(C(=O)Nc2cccc([N+](=O)[O-])c2)C(c2ccc(O)cc2O)NC(NN2C(=O)/C(=C\c3cccs3)SC2=S)=N1,"6-(2,4-Dihydroxyphenyl)-4-methyl-N-(3-nitrophenyl)-2-(4-oxo-5-(thiophen-2-ylmethylene)-2-thioxothiazolidin-3-ylamino)-1,6-dihydropyrimidine-5-carboxamide",80.6,uM,=,1.9063350418050904,1,O=C(Nc1ccccc1)C1=CN=C(NN2C(=O)/C(=C\c3cccs3)SC2=S)NC1c1ccccc1
7805,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OC[C@@H](C)NC(=O)CN(C)C,"US8846699, 159::US8846699, 164",0.286,uM,=,-0.543633966870957,0,c1ccc(Nc2ncnc3ccccc23)cc1
7806,632680,10.1016/j.bmc.2010.03.052,,,,Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA,Nc1nc(Nc2ccc(C(F)(F)F)c(F)c2)c2cc(Cc3ccc(Cl)cc3Cl)[nH]c2n1,"N4-(3-Fluoro-4-trifluoromethylphenyl)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",91.7,uM,=,1.9623693356700207,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7807,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CN,"US8846699, 57",0.089,uM,=,-1.0506099933550872,0,c1ccc(Nc2ncnc3ccccc23)cc1
7808,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(Cc2cccc(F)c2)nn1,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-((1-(3-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.068,uM,=,-1.1674910872937636,0,c1ccc(Cn2cc(COc3ccc4c(Nc5ccccc5)ncnc4c3)nn2)cc1
7809,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Brc1cccc(Nc2ncnc3cnc(NCCCn4ccnc4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-(3-imidazol-1-yl-propyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0091,uM,=,-2.0409586076789066,0,c1ccc(Nc2ncnc3cnc(NCCCn4ccnc4)cc23)cc1
7810,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccccc3OC)ncc2C(F)(F)F)c1,"US9238629, I-2",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
7811,1747423,10.1016/j.bmc.2017.10.030,,,,Inhibition of recombinant wild type EGFR (696 to C-terminal residues) (unknown origin) preincubated for 30 mins followed by poly (Glu-Tyr) biotinylated peptide substrate addition measured after 30 mins in presence of ATP by ELISA,COc1ccc(-c2c3c4cc(OC)c(OCCCNC(=N)N)cc4oc(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O.O=C(O)C(F)(F)F,"N-{3-[10-Hydroxy-13-(3-hydroxy-4-methoxy-phenyl)-2,11-dimethoxy-6-oxo-6H-5-oxa-6b-aza-dibenzo[a,i]fluoren-3-yloxy]-propyl}-guanidine Trifluoroacetic acid salt",0.047,uM,=,-1.3279021420642825,0,O=c1oc2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
7812,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccccc3)n2)c(OC)cc1N1CCC(C(N)=O)CC1,N-(2-(4-Carbamoylpiperidin-1-yl)-4-methoxy-5-((4-benzamidopyrimidin-2-yl)amino)phenyl)-acrylamide,0.1805999999999999,uM,=,-0.743282254022513,0,O=C(Nc1ccnc(Nc2ccc(N3CCCCC3)cc2)n1)c1ccccc1
7813,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc(Br)cc2)CC1c1ccc(C(=O)OC(C)Cn2c([N+](=O)[O-])cnc2C)cc1,"1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-yl 4-(1-acetyl-3-(4-bromophenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",5.96,uM,=,0.7752462597402364,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7814,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"(2S)-2-{[5-(3-Aminophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol",0.203,uM,=,-0.6925039620867871,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
7815,67054,10.1021/jm0307943,,,,Inhibition of Epidermal growth factor receptor,CC(O)C(/N=C1/C=C(O)/C(=N\C(C(=O)O)C(C)O)C=C1O)C(=O)O,"2-[4-(1-Carboxy-2-hydroxy-propylamino)-3,6-dioxo-cyclohexa-1,4-dienylamino]-3-hydroxy-butyric acid",44.0,uM,=,1.6434526764861874,1,N=C1C=CC(=N)C=C1
7816,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC[C@H](C)NC(C)=O,"US8846699, 83",0.098,uM,=,-1.0087739243075051,0,c1ccc(Nc2ncnc3ccccc23)cc1
7817,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,O=C(O)CCCC(=O)Nc1cc(Nc2cccc(Cl)c2)ncn1,5-((6-((3-Chlorophenyl)amino)pyrimidin-4-yl)amino)-5-oxopentanoic acid,0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ccncn2)cc1
7818,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,COc1ccc(C=C(C#N)C#N)cc1F,2-(3-Fluoro-4-methoxy-benzylidene)-malononitrile,800.0,uM,=,2.903089986991944,1,c1ccccc1
7819,2302058,10.1016/j.ejmech.2017.08.009,,,,Inhibition of EGFR (unknown origin),Cc1ccc(Nc2ncnn3ccc(C)c23)cc1O,"2-Methyl-5-(5-methyl-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-phenol",0.066,uM,=,-1.1804560644581312,0,c1ccc(Nc2ncnn3cccc23)cc1
7820,761853,10.1016/j.bmc.2011.06.022,,,,Inhibition of EGFR after 1 hrs by luminescence assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0042,uM,=,-2.3767507096021,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
7821,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,CC(C)(C)NC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,4-tert-Butylcarbamoyl-benzenesulfonic acid 4-(2-nitro-vinyl)-phenyl ester,1.3,uM,=,0.1139433523068367,1,O=S(=O)(Oc1ccccc1)c1ccccc1
7822,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(C3CCCCC3)nc3cnc(Nc4cccc(OCC(C)=O)c4)nc32)c1,N-(3-(6-Cyclohexyl-7-oxo-2((3-(2-oxopropoxy)phenyl)-amino)pteridin-8(7H)-yl)phenyl)acrylamide,0.0338,uM,=,-1.4710832997223453,0,O=c1c(C2CCCCC2)nc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
7823,1894188,10.1016/j.ejmech.2019.05.015,,,,Inhibition of human EGFR measured after 3 hrs by ELISA,Cn1c(=O)c2[nH]c(SC/C(=N/O)c3ccc(Br)cc3)nc2n(C)c1=O,"8-((2-(4-Bromophenyl)-2-(hydroxyimino)ethyl)thio)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione",0.45,uM,=,-0.3467874862246563,0,N=C(CSc1nc2[nH]c(=O)[nH]c(=O)c2[nH]1)c1ccccc1
7824,1816244,10.1016/j.ejmech.2019.111809,,,,Inhibition of wildtype EGFR (unknown origin) using biotin as substrate in presence of ATP by mobility shift assay based ELISA,C=C(Cl)C(=O)Nc1cc(Nc2nc3c(c(-c4cn(C)c5ccccc45)n2)CSCC3)c(OC)cc1N(C)CCN(C)C,"2-chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide",0.57,uM,=,-0.2441251443275086,0,c1ccc(Nc2nc3c(c(-c4c[nH]c5ccccc45)n2)CSCC3)cc1
7825,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1cccs1,"3-(3,4-Dihydroxy-phenyl)-2-(thiophene-2-carbonyl)-acrylonitrile",3.1,uM,=,0.4913616938342727,1,O=C(C=Cc1ccccc1)c1cccs1
7826,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,CN(C)CCCOC(=O)/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,3-[4-(3-Bromo-phenylamino)-quinazolin-6-ylcarbamoyl]-acrylic acid 3-dimethylamino-propyl ester,0.108,uM,=,-0.9665762445130504,0,c1ccc(Nc2ncnc3ccccc23)cc1
7827,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)c(OC)c3OC)ncc2C(F)(F)F)c1,"US9238629, I-10",0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
7828,2296723,10.1021/acs.jmedchem.6b00276,,,,Inhibition of recombinant 6His-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) autophosphorylation expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP and MgCl2 addition measured after 60 mins by DELFIA/time-resolved fluorometric analysis,COc1cc(/C=C2\CN(C)C/C(=C\c3cc(OC)c(OC)c(OC)c3Br)C2=NO)c(Br)c(OC)c1OC,"3,5-bis(2-bromo-3,4,5-trimethoxybenzylidene)-1-methylpiperidin-4-one oxime",0.07,uM,=,-1.154901959985743,0,N=C1/C(=C/c2ccccc2)CNC/C1=C\c1ccccc1
7829,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cnn(C)c3)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.4953999999999999,uM,=,-0.3050439977501818,0,c1ccc(Nc2nccc(Nc3cn[nH]c3)n2)cc1
7830,2218523,10.1021/acs.jmedchem.0c01467,,,,Inhibition of EGFR (unknown origin),O=C(Cc1cccs1)Nc1cccc(-c2ccc3nnc(-c4cccnc4)n3n2)c1,TDR81591,0.079,uM,=,-1.1023729087095586,0,O=C(Cc1cccs1)Nc1cccc(-c2ccc3nnc(-c4cccnc4)n3n2)c1
7831,615344,10.1016/j.ejmech.2009.12.026,,,,Inhibition of EGFR,CC1=C(C(=O)Nc2cccc([N+](=O)[O-])c2)C(c2ccc(O)cc2O)NC(Nc2ccc(S(=O)(=O)Nc3nc(C)cc(C)n3)cc2)=N1,"6-(2,4-dihydroxyphenyl)-2-(4-(N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl)phenylamino)-4-methyl-N-(3-nitrophenyl)-1,6-dihydropyrimidine-5-carboxamide",79.8,uM,=,1.9020028913507288,1,O=C(Nc1ccccc1)C1=CN=C(Nc2ccc(S(=O)(=O)Nc3ncccn3)cc2)NC1c1ccccc1
7832,2080996,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(CCC(=O)NO)nn1,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-((1-(3-(hydroxyamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.00033,uM,=,-3.4814860601221125,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
7833,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,N#Cc1cnc2ccc(-c3ccc(CN4CCOCC4)cc3)cc2c1N[C@@H]1C[C@H]1c1ccccc1,"6-(4-(morpholinomethyl)phenyl)-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",2.53,uM,=,0.4031205211758178,1,c1ccc([C@@H]2C[C@H]2Nc2ccnc3ccc(-c4ccc(CN5CCOCC5)cc4)cc23)cc1
7834,1747423,10.1016/j.bmc.2017.10.030,,,,Inhibition of recombinant wild type EGFR (696 to C-terminal residues) (unknown origin) preincubated for 30 mins followed by poly (Glu-Tyr) biotinylated peptide substrate addition measured after 30 mins in presence of ATP by ELISA,COc1ccc(-c2c3c4cc(OCCN(C)C)c(OC)cc4oc(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O.O=C(O)C(F)(F)F,"2-[2-(dimethylamino)ethoxy]-11-hydroxy-14-(3-hydroxy-4-methoxyphenyl)-3,12-dimethoxy-6H-[1]benzopyrano[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one Trifluoroacetic acid salt",0.8422999999999999,uM,=,-0.0745331993084621,0,O=c1oc2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
7835,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,COc1ccc(/C=C/C(=O)OCCn2c([N+](=O)[O-])cnc2C)cc1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl3-(4-methoxyphenyl)acrylate,10.85,uM,=,1.0354297381845483,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
7836,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NC1CCCC[C@@H]1NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"(E)-2-Cyano-N-{(S)-2-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-cyclohexyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",2.1,uM,=,0.3222192947339193,1,O=C(C=Cc1ccccc1)NC1CCCC[C@@H]1NC(=O)/C=C/c1ccccc1
7837,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC[C@H]1CCCN(C)C1,(S)-(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-3-ylmethoxy)-quinazolin-4-yl]-amine,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3cc(OC[C@H]4CCCNC4)ccc23)cc1
7838,1684313,10.1016/j.ejmech.2017.04.025,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (unknown origin) (645 to 1186 residues) expressed in baculovirus infected Sf-9 cells preincubated for 10 mins followed by ATP addition measured after 1 hr by DELFIA/Time-Resolved fluorometry,Cc1nc(C)c(/C=C2\CC(C)C/C(=C\c3nc(C)c(C)nc3C)C2=NO)nc1C,"4-Methyl-2,6-bis-(3,5,6-trimethyl-pyrazin-2-ylmethylene)-cyclohexanone oxime",2.4,uM,=,0.380211241711606,1,N=C1/C(=C/c2cnccn2)CCC/C1=C\c1cnccn1
7839,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,O=C(/C=C/CN1CCCC1)N1CCCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-8,9-dihydro-[1,4]oxazepino[3,2-g]quinazolin-6(7H)-yl)-4-(pyrrolidin-1-yl)but-2-en-1-one",0.89,uM,=,-0.0506099933550872,0,O=C(/C=C/CN1CCCC1)N1CCCOc2cc3ncnc(Nc4ccccc4)c3cc21
7840,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,O=[N+]([O-])/C=C/c1ccc(O)c(O)c1,"4-(2-Nitro-vinyl)-benzene-1,2-diol",8.8,uM,=,0.9444826721501688,1,c1ccccc1
7841,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,Cc1cccc(Nc2ncnc3ccc(NC(=O)NCCCl)cc23)c1,1-(2-chloroethyl)-3-{[4-(3-methylphenyl)amino]quinazolin-6-yl}urea,0.676,uM,=,-0.170053304058364,0,c1ccc(Nc2ncnc3ccccc23)cc1
7842,2213950,10.1016/j.ejmech.2021.113963,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins in presence of ATP by caliper mobility shift assay,COc1cc2c(cc1OC)C(Sc1cccc(NC(=S)Nc3ccc(Br)c(C(F)(F)F)c3)c1)=NCN2,"1-[4-bromo-3-(trifluoromethyl)phenyl]-3-[3-[(6,7-dimethoxy-1,2-dihydroquinazolin-4-yl)sulfanyl]phenyl]thiourea",0.01,uM,=,-2.0,0,S=C(Nc1ccccc1)Nc1cccc(SC2=NCNc3ccccc32)c1
7843,1512952,10.1021/acsmedchemlett.5b00231,,,,Inhibition of wild type EGFR in human A549 cells assessed as inhibition of phosphorylation at Y1068 after 2 hrs by sandwich ELISA method,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(CC)nc3OC)c3ncn(C)c3n2)C[C@H]1F,"N-((3R,4R)-1-(6-(1-ethyl-3-methoxy-1H-pyrazol-4-ylamino)-9-methyl-9H-purin-2-yl)-4-fluoropyrrolidin-3-yl)acrylamide",0.194,uM,=,-0.712198270069774,0,c1nc2c(Nc3cn[nH]c3)nc(N3CCCC3)nc2[nH]1
7844,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,Cn1ccc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-(8-methyl-8H-pyrrolo[3,2-g]quinazolin-4-yl)-amine",0.0008,uM,=,-3.096910013008056,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
7845,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",NP(=O)(Oc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)N(CCCl)CCCl,"4-((3-Bromophenyl)amino)quinazolin-6-yl N,N-bis(2-chloroethyl)phosphorodiamidate",0.0092,uM,=,-2.036212172654445,0,c1ccc(Nc2ncnc3ccccc23)cc1
7846,2080996,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(CCCC(=O)NO)nn1,"4-(4-(((6-Acrylamido-4-((3-chloro-4-fluorophenyl)amino)quinazolin-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)-N-hydroxybutanamide",0.00035,uM,=,-3.4559319556497243,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
7847,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1ccccc1Cl,"N-(2-Chloro-phenyl)-2-cyano-3-(3,4-dihydroxy-phenyl)-acrylamide",1.1,uM,=,0.041392685158225,1,O=C(C=Cc1ccccc1)Nc1ccccc1
7848,1337212,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ccc2nc(Oc3ccc(Cl)cc3)c(/C=N/NC(=O)Cn3c([N+](=O)[O-])cnc3C)cc2c1,(E)-N'-((2-(4-chlorophenoxy)-6-methylquinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,8.66,uM,=,0.9375178920173468,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
7849,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3cccc(OC)c3)n2)c(OC)cc1N(C)CCN(C)C,N-(2-(2-Dimethylaminoethylmethylamino)-4-methoxy-5-((4-(3-methoxybenzamido)pyrimidin-2-yl)amino)phenyl)acrylamide,0.1535,uM,=,-0.8138916201867947,0,O=C(Nc1ccnc(Nc2ccccc2)n1)c1ccccc1
7850,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,COC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1O,2-Hydroxy-4-[4-(2-nitro-vinyl)-phenoxysulfonyl]-benzoic acid methyl ester,1.8,uM,=,0.255272505103306,1,O=S(=O)(Oc1ccccc1)c1ccccc1
7851,1848601,10.1016/j.ejmech.2019.03.055,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected Sf21 insect cells using STK as substrate by HTRF assay,CNc1cncc(-c2c[nH]c3nc(Nc4ccc(N5CCN(C(C)=O)CC5)cc4)nc(OC4CCOCC4)c23)n1,"1-(4-(4-((5-(6-(methylamino)pyrazin-2-yl)-4-((tetrahydro-2H-pyran-4-yl)oxy)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)ethan-1-one",0.937,uM,=,-0.0282604091122217,0,c1cnc(-c2c[nH]c3nc(Nc4ccc(N5CCNCC5)cc4)nc(OC4CCOCC4)c23)cn1
7852,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c(C(N)=O)nc2CC)c1,"US9085540, 1",0.0022,uM,=,-2.657577319177794,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7853,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)N1CCc2ccccc21,"2-(2,3-Dihydro-indole-1-carbonyl)-3-(3,4-dihydroxy-phenyl)-acrylonitrile",2.1,uM,=,0.3222192947339193,1,O=C(C=Cc1ccccc1)N1CCc2ccccc21
7854,1814080,10.1016/j.ejmech.2019.111693,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,Clc1ccc(/C=N/c2nnc(-c3cccnc3)o2)cc1,"N-(4-Chlorobenzylidene)-5-(pyridin-3-yl)-1,3,4-oxadiazol-2-amine",1.1289,uM,=,0.0526554730395267,1,C(=N/c1nnc(-c2cccnc2)o1)\c1ccccc1
7855,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,O=C(CCCCCC(=O)Nc1ccc(O)c(C(=O)Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1)NO,N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-2-hydroxy-5-(7-hydroxyamino-7-oxoheptanamido)benzamide,1.1,uM,=,0.041392685158225,1,O=C(Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
7856,556139,10.1016/j.bmc.2008.04.019,,,,Inhibition of EGFR expressed in human tumor cells,Nc1nc(Nc2ccc(Cl)cc2F)c2cc(CCc3ccccc3)[nH]c2n1,"N4-(4-chloro-2-fluorophenyl)-6-(2-phenylethyl)-7Hpyrrolo[2,3-d]pyrimidine-2,4-diamine",1.32,uM,=,0.1205739312058498,1,c1ccc(CCc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7857,658103,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.0002399999999999,uM,=,-3.619788758288394,0,c1ccc(Nc2ccnc3ccccc23)cc1
7858,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",NP(=O)(OCCCC(=O)Oc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1)N(CCCl)CCCl,"4-Oxo-4-((4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)amino)butyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.026,uM,=,-1.585026652029182,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
7859,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C(C)=O)CC1,"US8846699, 1",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7860,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)CCCN(C)C,"US8846699, 148",0.028,uM,=,-1.5528419686577808,0,c1ccc(Nc2ncnc3ccccc23)cc1
7861,1642049,,,,,"Omnia Assay: Briefly, 10Ã stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13ÃATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1Ã kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10Ã stock, KB002A) and 0.2 mM DTT (DS001A). 5 Î¼L of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â°ree; C. with a 0.5 Î¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 Î¼L of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NC(C)C)cc3OC)ncc2Cl)c1,"US9409887, I-4",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
7862,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0073,uM,=,-2.136677139879544,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
7863,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
7864,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,CCCCNC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,4-Butylcarbamoyl-benzenesulfonic acid 4-(2-nitro-vinyl)-phenyl ester,4.8,uM,=,0.6812412373755872,1,O=S(=O)(Oc1ccccc1)c1ccccc1
7865,2302058,10.1016/j.ejmech.2017.08.009,,,,Inhibition of EGFR (unknown origin),Cc1ccc(Nc2ncnn3cc(C)c(C)c23)cc1O,"5-(5,6-Dimethyl-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-2-methyl-phenol",0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2ncnn3cccc23)cc1
7866,63790,10.1016/S0960-894X(97)00035-8,,,,Antagonism towards Epidermal growth factor receptor,CCN(c1ccccc1)c1ncnc2cc(OC)c(OC)cc12.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-ethyl-phenyl-amine hydrochloride",5.5,uM,=,0.7403626894942439,1,c1ccc(Nc2ncnc3ccccc23)cc1
7867,2272586,10.1016/j.ejmech.2021.113865,,,,Inhibition of EGFR (unknown origin),CN(C)c1ccc(/C=C/c2cc(C(=O)O)c3cc(Br)ccc3n2)cc1,6-bromo-2-(4-(dimethylamino)styryl)quinoline-4-carboxylic acid,2.23,uM,=,0.3483048630481606,1,C(=C/c1ccc2ccccc2n1)\c1ccccc1
7868,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,CN1CCN(CCCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc2NC(=O)c2cc([N+](=O)[O-])ccc2F)CC1,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.0066,uM,=,-2.1804560644581312,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCNCC1)c1ccccc1
7869,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,CC1(C)CC(C(=O)Nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)CC(C)(C)N1[O],"2,2,6,6-Tetramethyl-1-oxyl-N-[4-(3-chlorophenylamino)quinazolin-6-yl]piperidine-4-carboxamide",0.065,uM,=,-1.1870866433571443,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CCNCC1
7870,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,CN(C)CCNCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1,"(S)-2-((6-(4-(((2-(Dimethylamino)ethyl)amino)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0003,uM,=,-3.522878745280338,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7871,1329559,10.1039/C0MD00115E,,,,Inhibition of EGFR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,OB(O)c1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,4-(3-chloro-4-fluorophenylamino)quinazolin-6-ylboronic acid,0.8,uM,=,-0.0969100130080563,0,c1ccc(Nc2ncnc3ccccc23)cc1
7872,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,NC1CCN(Cc2ccn3ncnc(Nc4cccc(Cl)c4)c23)CC1,"5-((4-aminopiperidin-1-yl)methyl)-N-(3-chlorophenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1
7873,775025,10.1016/j.ejmech.2011.09.041,,,,Inhibition of human EGFR,Nc1scc2c1c(Nc1ccc(S(N)(=O)=O)cc1)nc1ncnc(N)c12,"4-((1,7-diaminothieno[3',4':4,5]pyrido[2,3-d]pyrimidin-6-yl)amino)benzenesulfonamide",29.5,uM,=,1.469822015978163,1,c1ccc(Nc2nc3ncncc3c3cscc23)cc1
7874,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1,4-amino-6-(1-benzyl-1H-indazol-5-ylamino)pyrimidine-5-carbaldehyde O-methyl oxime,0.044,uM,=,-1.3565473235138126,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
7875,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCCN1CCOCC1,(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
7876,1930229,10.1016/j.ejmech.2019.02.050,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end) expressed in baculovirus infected Sf9 cells using ATP as substrate after 40 mins by Kinase-Glo MAX luminescence assay,O=C(CSC(=S)N1CCCCC1)Nc1cccc(NC(=O)c2ccccn2)c1,2-Oxo-2-((3-(picolinamido)phenyl)amino)ethyl piperidine-1-carbodithioate,0.084,uM,=,-1.0757207139381184,0,O=C(CSC(=S)N1CCCCC1)Nc1cccc(NC(=O)c2ccccn2)c1
7877,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,OC[C@@H](Nc1ncnc2[nH]c(-c3ccncc3)cc12)c1ccccc1,"(S)-2-Phenyl-2-((6-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol",0.002,uM,=,-2.6989700043360187,0,c1ccc(CNc2ncnc3[nH]c(-c4ccncc4)cc23)cc1
7878,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3cc(-c4ccc(N(C)C)cc4)ccc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((6-(4-(dimethylamino)phenyl)-1H-indazol-3-yl)amino)-4-methoxyphenyl)acrylamide,0.387,uM,=,-0.4122890349810886,0,c1ccc(Nc2n[nH]c3cc(-c4ccccc4)ccc23)cc1
7879,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,NC(=S)N1N=C(c2ccc(Br)cc2)CC1c1ccc2ccccc2c1,"3-(4-Bromophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",0.35,uM,=,-0.4559319556497244,0,c1ccc(C2=NNC(c3ccc4ccccc4c3)C2)cc1
7880,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#Cc1ccc(CN(C)C)cc1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-5-((4-((dimethylamino)methyl)phenyl)ethynyl)-6-methylpyrimidin-4-amine,0.007,uM,=,-2.154901959985743,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
7881,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,N#Cc1cnc2cc(-c3ccc(CN4CCOCC4)cc3)ccc2c1N[C@@H]1C[C@H]1c1ccccc1,"7-(4-(morpholinomethyl)phenyl)-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",0.234,uM,=,-0.6307841425898572,0,c1ccc([C@@H]2C[C@H]2Nc2ccnc3cc(-c4ccc(CN5CCOCC5)cc4)ccc23)cc1
7882,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CN(C)CCCCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-(4-dimethylamino-butyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.019,uM,=,-1.7212463990471711,0,c1ccc(Nc2ncnc3cnccc23)cc1
7883,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3cccc(OC)c3OC)ncc2C(F)(F)F)c1,"US9238629, I-16",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
7884,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(NN=C2CCCCC2)=N1,2-(2-Cyclohexylidenehydrazinyl)thiazol-4(5H)-one,41.0,uM,=,1.6127838567197357,1,O=C1CSC(NN=C2CCCCC2)=N1
7885,66575,10.1021/jm9806603,,,,Inhibition of phosphorylation of glutamic acid/tyrosine random copolymer by isolated epidermal growth factor receptor (EGFR),C=CC(=O)Nc1ccc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2c1,N-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-acrylamide,0.0058,uM,=,-2.2365720064370627,0,c1ccc(Oc2ccc(Nc3ncnc4ccccc34)cc2)cc1
7886,982464,10.1016/j.bmc.2013.06.070,,,,Inhibition of recombinant EGFR kinase cytoplasmic domain (unknown origin) expressed in baculovirus expression vector-infected insect sf9 cells assessed as level of autophosphorylation after 10 mins by DELFIA/time-resolved fluorometry,O=C(/C=C/c1ccc(Br)s1)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,(E)-3-(5-Bromothiophen-2-yl)-N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)acrylamide,2.4,uM,=,0.380211241711606,1,O=C(/C=C/c1cccs1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
7887,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccccc1CNCCO,"2-[2-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-benzylamino]-ethanol",6.4,uM,=,0.8061799739838872,1,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
7888,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cccc(OC)c1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2[nH]1,"(R)-6-(2,6-dimethoxyphenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.0006,uM,=,-3.2218487496163566,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
7889,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,O=C(O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1O,2-Hydroxy-4-[4-(2-nitro-vinyl)-phenoxysulfonyl]-benzoic acid,0.054,uM,=,-1.2676062401770316,0,O=S(=O)(Oc1ccccc1)c1ccccc1
7890,1761975,10.1016/j.ejmech.2018.02.051,,,,"Inhibition of wild type EGFR (unknown origin) using Poly (Glu, Tyr) as substrate after 40 mins by kinase-Glo luminescence assay",CN(C)C1CCN(c2ccc(Nc3cc4c(N5CCC(CO)CC5)nc(Nc5ccc(F)cc5)nc4cn3)nc2)CC1,"(1-(6-((5-(4-(Dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-2-((4-fluorophenyl)amino)pyrido[3,4-d]pyrimidin-4-yl)piperidin-4-yl)methanol",0.0104,uM,=,-1.98296666070122,0,c1ccc(Nc2nc(N3CCCCC3)c3cc(Nc4ccc(N5CCCCC5)cn4)ncc3n2)cc1
7891,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CCO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-ethyl oxime,0.005,uM,=,-2.3010299956639813,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
7892,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2ccc(Br)cc2)=N1,2-(2-(4-Bromobenzylidene)hydrazinyl)thiazol-4(5H)-one,1.72,uM,=,0.2355284469075489,1,O=C1CSC(N/N=C/c2ccccc2)=N1
7893,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc2c(ccn2Cc2cccc(F)c2)c1,4-(1-(3-fluorobenzyl)-1H-indol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-methyl oxime,0.013,uM,=,-1.8860566476931635,0,c1ccc(Cn2ccc3cc(Nc4ccncn4)ccc32)cc1
7894,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,COC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1,4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid methyl ester,1.5,uM,=,0.1760912590556812,1,O=S(=O)(Oc1ccccc1)c1ccccc1
7895,2266398,10.1021/acsmedchemlett.2c00476,,,,Inhibition of human EGFR,COc1cc2ncnc(Nc3ccc(O[C@H]4CO[C@H]5[C@@H]4OC[C@@H]5O)c(Cl)c3)c2cc1OC,"(3S,3aR,6S,6aR)-6-[2-Chloro-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenoxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-ol",0.0053,uM,=,-2.275724130399211,0,c1ccc2c(Nc3ccc(O[C@H]4CO[C@@H]5CCO[C@H]45)cc3)ncnc2c1
7896,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Brc1cccc(Nc2ncnc3cnc(NCc4cccnc4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-pyridin-3-ylmethyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2ncnc3cnc(NCc4cccnc4)cc23)cc1
7897,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,O=C(O)CCCC(=O)Nc1cc(Nc2cccc(Br)c2)ncn1,5-((6-((3-Bromophenyl)amino)pyrimidin-4-yl)amino)-5-oxopentanoic acid,0.07,uM,=,-1.154901959985743,0,c1ccc(Nc2ccncn2)cc1
7898,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CCNC(=O)NCCOc1cc2ncnc(Nc3ccc(Br)cc3F)c2cc1NC(=O)C=C,"US8846699, 40",0.019,uM,=,-1.7212463990471711,0,c1ccc(Nc2ncnc3ccccc23)cc1
7899,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,C#Cc1cccc(NC(=O)c2cc(NC(=O)CCCCCC(=O)NO)ccc2OC)c1,N-(3-Ethynylphenyl)-5-(7-hydroxyamino-7-oxoheptanamido)-2-methoxy benzamide,5.16,uM,=,0.7126497016272114,1,O=C(Nc1ccccc1)c1ccccc1
7900,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OCCNC(=O)CN(C)C,"US8846699, 117",0.924,uM,=,-0.0343280287798932,0,c1ccc(Nc2ncnc3ccccc23)cc1
7901,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,COc1cc(/C=C/[N+](=O)[O-])ccc1OS(=O)(=O)c1ccc(C(=O)O)cc1,4-[2-Methoxy-4-(2-nitro-vinyl)-phenoxysulfonyl]-benzoic acid,2.8,uM,=,0.4471580313422192,1,O=S(=O)(Oc1ccccc1)c1ccccc1
7902,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,COc1cccc(-c2cn(-c3cccc(CO)c3)c3ncnc(N)c23)c1,"{3-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-phenyl}-methanol",0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
7903,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccc(C(F)(F)F)cc3)n2)c(OC)cc1N(C)CCN(C)C,N-(2-(2-Dimethylaminoethylmethylamino)-4-methoxy-5-((4-(4-trifluoromethylbenzamido)py-rimidin-2-yl)amino)phenyl)acrylamide,0.1087,uM,=,-0.9637704559137056,0,O=C(Nc1ccnc(Nc2ccccc2)n1)c1ccccc1
7904,1837344,10.1016/j.ejmech.2019.111664,,,,Inhibition of EGFR (unknown origin),N=C1N=C(NCCS(=O)(=O)O)/C(=C/C(O)CNC(=O)c2cc(Br)c[nH]2)N1,Tauroacidin B,44.6412178990011,uM,=,1.6497360344868823,1,N=C1N=C/C(=C/CCNC(=O)c2ccc[nH]2)N1
7905,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2cccc(O)c2)=N1,2-(2-(3-Hydroxybenzylidene)hydrazinyl)thiazol-4(5H)-one,19.32,uM,=,1.2860071220794749,1,O=C1CSC(N/N=C/c2ccccc2)=N1
7906,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,c1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1,"5-(Naphthalen-2-yl)-1,3-diphenyl-4,5-dihydro-1Hpyrazole",0.24,uM,=,-0.619788758288394,0,c1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1
7907,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1.Cl.Cl,"N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, hydrochloride (CI-1033)",0.0074,uM,=,-2.130768280269024,0,c1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1
7908,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cnccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-2-((6-(3-Methoxypyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0006,uM,=,-3.2218487496163566,0,c1ccc(CNc2ncnc3[nH]c(-c4ccncc4)cc23)cc1
7909,519643,10.1016/j.bmcl.2008.11.058,,,,Inhibition of EGFR,CCc1cc(Nc2nccc(-c3c(-c4cccc(C(=O)Nc5c(F)cccc5F)c4)nc4ccccn34)n2)c(OC)cc1N1CCC(N2CCN(S(C)(=O)=O)CC2)CC1,"N-(2,6-difluorophenyl)-3-(3-(2-(5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)imidazo[1,2-a]pyridin-2-yl)benzamide",0.022,uM,=,-1.6575773191777938,0,O=C(Nc1ccccc1)c1cccc(-c2nc3ccccn3c2-c2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)c1
7910,1301095,10.1039/C4MD00028E,,,,"Inhibition of EGFR (unknown origin) using poly(Glu,Tyr) as substrate after 60 mins by scintillation counting",Oc1cccc(Nc2ccnc3[nH]c4ccccc4c23)c1,"3-(9H-Pyrido[2,3-b]indol-4-ylamino)phenol",0.27,uM,=,-0.5686362358410126,0,c1ccc(Nc2ccnc3[nH]c4ccccc4c23)cc1
7911,1816244,10.1016/j.ejmech.2019.111809,,,,Inhibition of wildtype EGFR (unknown origin) using biotin as substrate in presence of ATP by mobility shift assay based ELISA,C=C(Cl)C(=O)Nc1cc(Nc2nc3c(c(-c4cn(C)c5ccccc45)n2)CS(=O)(=O)CC3)c(OC)cc1N(C)CCN(C)C,"2-chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-6,6-dioxido-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-yl)amino)phenyl)acrylamide",0.104,uM,=,-0.9829666607012196,0,O=S1(=O)CCc2nc(Nc3ccccc3)nc(-c3c[nH]c4ccccc34)c2C1
7912,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccc(C(F)(F)F)cc3)n2)c(OC)cc1N1CCC(C(N)=O)CC1,N-(2-(4-Carbamoylpiperidin-1-yl)-4-methoxy-5-((4-(4-trifluoromethylbenzamido)pyrimidin-2-yl)amino)phenyl)acrylamide,0.1272,uM,=,-0.8955128886876049,0,O=C(Nc1ccnc(Nc2ccc(N3CCCCC3)cc2)n1)c1ccccc1
7913,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(C)cc3F)ncnc2cc1OCC1CCNCC1,(2-Fluoro-4-methyl-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7914,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#CC(C#N)=C1C(=O)Nc2ccc([N+](=O)[O-])cc21,"2-(5-Nitro-2-oxo-1,2-dihydro-indol-3-ylidene)-malononitrile",40.0,uM,=,1.6020599913279625,1,C=C1C(=O)Nc2ccccc21
7915,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNc1nccs1,"US8846699, 90",0.295,uM,=,-0.530177984021837,0,c1ccc(Nc2ncnc3cc(OCCNc4nccs4)ccc23)cc1
7916,644442,10.1016/j.ejmech.2010.04.026,,,,Inhibition of EGFR,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.1024,uM,=,-0.989700043360188,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
7917,1894188,10.1016/j.ejmech.2019.05.015,,,,Inhibition of human EGFR measured after 3 hrs by ELISA,Cn1c(=O)[nH]c2nc(SC/C(=N/O)c3ccc(Br)cc3)[nH]c2c1=O,"8-((2-(4-Bromophenyl)-2-(hydroxyimino)ethyl)thio)-1-methyl-3,7-dihydro-1H-purine-2,6-dione",2.88,uM,=,0.4593924877592308,1,N=C(CSc1nc2[nH]c(=O)[nH]c(=O)c2[nH]1)c1ccccc1
7918,66580,10.1021/jm950692f,,,,Inhibition of tyrosine kinase activity of Epidermal growth factor receptor from human A431 carcinoma cells,Cn1cnc2cc3ncnc(Nc4cccc(Br)c4)c3cc21,"(3-Bromo-phenyl)-(1-methyl-1H-imidazo[4,5-g]quinazolin-8-yl)-amine",1e-05,uM,=,-5.0,0,c1ccc(Nc2ncnc3cc4nc[nH]c4cc23)cc1
7919,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)N1CCC(c2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)c(C)c3)c(C(N)=O)nc2CC)CC1,"US9085540, 24",0.0011,uM,=,-2.958607314841775,0,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(C2CCNCC2)n1
7920,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCN1CCOCC1,(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.4,uM,=,-0.3979400086720376,0,c1ccc(Nc2ncnc3cc(OCCN4CCOCC4)ccc23)cc1
7921,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,CNc1ncnc2c1c(-c1ccccc1)cn2-c1ccccc1,"(5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-methyl-amine",31.0,uM,=,1.4913616938342726,1,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
7922,526697,10.1021/np050229y,,,,Inhibition of EGFR,O=C(/C=C/c1ccc(O)c(O)c1)c1ccc(O)cc1O,"3-(3,4-Dihydroxy-phenyl)-1-(2,4-dihydroxy-phenyl)-propenone",8.0,uM,=,0.9030899869919436,1,O=C(/C=C/c1ccccc1)c1ccccc1
7923,1808197,10.1016/j.bmc.2019.06.001,,,,Inhibition of EGFR (unknown origin) using TK substrate incubated for 60 mins by FRET assay,FC(F)(F)c1ccc(COc2ccc(Nc3ncnc4cc5c(cc34)OCCOCCOCCOCCO5)cc2)cc1,"N-(4-(4-trifluoromethylphenyl)methoxyphenyl)-6,7-(benzo-15-coronal-5)-4-quinazolinamide",0.3848,uM,=,-0.4147649366342246,0,c1ccc(COc2ccc(Nc3ncnc4cc5c(cc34)OCCOCCOCCOCCO5)cc2)cc1
7924,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccccc1Cl,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl3-(2-chlorophenyl)acrylate,20.81,uM,=,1.318272080211627,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
7925,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C1CCCN1C,"US8846699, 100::US8846699, 98",0.069,uM,=,-1.1611509092627446,0,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)C1CCCN1
7926,1466619,10.1016/j.bmc.2015.03.061,,,,Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,COc1ccc2c(c1)CCCN2c1nc(C)nc2oc(C)cc12,"4-(6-Methoxy-3,4-dihydroquinolin-1(2H)-yl)-2,6-dimethylfuro[2,3-d]pyrimidine",0.0034,uM,=,-2.468521082957745,0,c1ccc2c(c1)CCCN2c1ncnc2occc12
7927,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(Cl)c(Cl)cc3F)ncnc2cc1OCCN(C)C,"US8846699, 136",0.321,uM,=,-0.4934949675951279,0,c1ccc(Nc2ncnc3ccccc23)cc1
7928,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1NCc1ccc(F)c(Cl)c1,4-(3-chloro-4-fluorobenzylamino)-6-aminopyrimidine-5-carbaldehyde O-methyl oxime,1.123,uM,=,0.0503797562614577,1,c1ccc(CNc2ccncn2)cc1
7929,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"[4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid,(3S)-3-morpholinylmethyl ester",0.032,uM,=,-1.494850021680094,0,O=C(Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnn2c1)OC[C@@H]1COCCN1
7930,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,CN(C)CCCCC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"5-(Dimethylamino)-N-[3-(4-{[(1S)-2-hydroxy-1-phenylethyl]-amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]-pentanamide",0.034,uM,=,-1.4685210829577449,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
7931,1886849,10.1016/j.bmcl.2019.04.029,,,,Inhibition of probe binding to wild type EGFR (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay,N#Cc1cnc2cc(OC[C@@H](O)CO)c(NC(=O)C3CSSC3)cc2c1Nc1ccc(OCc2cccc(F)c2)c(Cl)c1,"(S)-N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-3-cyano-7-(2,3-dihydroxypropoxy)quinolin-6-yl)-1,2-dithiolane-4-carboxamide",0.125,uM,=,-0.9030899869919436,0,O=C(Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1)C1CSSC1
7932,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1cc(O)c(O)c(Br)c1)C(=O)NCCCNC(=O)/C(C#N)=C/c1cc(O)c(O)c(Br)c1,"(E)-3-(3-Bromo-4,5-dihydroxy-phenyl)-N-{3-[(E)-3-(3-bromo-4,5-dihydroxy-phenyl)-2-cyano-acryloylamino]-propyl}-2-cyano-acrylamide",0.34,uM,=,-0.4685210829577448,0,O=C(C=Cc1ccccc1)NCCCNC(=O)/C=C/c1ccccc1
7933,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C(=O)NC(C)(C)C)CC1,"US8846699, 11",0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7934,1848601,10.1016/j.ejmech.2019.03.055,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected Sf21 insect cells using STK as substrate by HTRF assay,C=CC(=O)N1CCC[C@@H](Oc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)C1,"(R)-1-(3-((2-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-5-(6-(methylamino)pyrazin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",0.499,uM,=,-0.3018994543766101,0,c1cnc(-c2c[nH]c3nc(Nc4ccc(N5CCNCC5)cc4)nc(O[C@@H]4CCCNC4)c23)cn1
7935,2059437,10.1016/j.bmc.2021.116094,,,,Inhibition of wild-type EGFR (unknown origin) using biotinylated TK peptide as substrate measured after 30 mins by HTRF assay,C=CCn1cc(-c2ccnc(Nc3cc(NC(=O)C=C)c(N(C)CCN(C)C)cc3OC)n2)c2ccccc21,N-(5-(4-(1-allyl-1H-indol-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,0.0153599999999999,uM,=,-1.8136087843045068,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
7936,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,CN(C(=O)N(CCCl)N=O)c1ccc2ncnc(Nc3cccc(Br)c3)c2c1,1-(2-chloroethyl)-1-nitroso-3-methyl-3-{[4-(3-bromophenyl)amino]quinazolin-6-yl}urea,0.294,uM,=,-0.5316526695878427,0,c1ccc(Nc2ncnc3ccccc23)cc1
7937,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)Cc1ccc(Br)cc1,N-(2-((2-((4-bromobenzyl)(methyl)amino)ethyl)(methyl)amino)-4-methoxy-5-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,2.468,uM,=,0.392345155361204,1,c1ccc(CNCCNc2ccc(Nc3nccc(Nc4c[nH]c5ccccc45)n3)cc2)cc1
7938,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,CC(=O)/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,4-Oxo-pent-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,1.039,uM,=,0.0166155475571773,1,c1ccc(Nc2ncnc3ccccc23)cc1
7939,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",NP(=O)(OCCCCOc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)N(CCCl)CCCl,"4-((4-((3-Bromophenyl)amino)quinazolin-6-yl)oxy)butyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.0074,uM,=,-2.130768280269024,0,c1ccc(Nc2ncnc3ccccc23)cc1
7940,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,COC(=O)CN(C)Cc1c[nH]c2cc3ncnc(Nc4cccc(Br)c4)c3cc12,"{[4-(3-Bromo-phenylamino)-8H-pyrrolo[3,2-g]quinazolin-6-ylmethyl]-methyl-amino}-acetic acid methyl ester",0.0034,uM,=,-2.468521082957745,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
7941,2272586,10.1016/j.ejmech.2021.113865,,,,Inhibition of EGFR (unknown origin),Cc1ccc2nc(/C=C/c3ccc(N(C)C)cc3)cc(-c3nnc(N)s3)c2c1,"5-(2-(4-(dimethylamino)styryl)-6-methylquinolin-4-yl)-1,3,4-thiadiazol-2-amine",1.11,uM,=,0.0453229787866574,1,C(=C/c1cc(-c2nncs2)c2ccccc2n1)\c1ccccc1
7942,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,Nc1ccc2ncnc(NCc3ccccc3)c2c1,"N*4*-Benzyl-quinazoline-4,6-diamine",0.508,uM,=,-0.2941362877160807,0,c1ccc(CNc2ncnc3ccccc23)cc1
7943,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCNC(C)=O,"US8846699, 111",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3ccccc23)cc1
7944,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,CN(CC(=O)O)Cc1c[nH]c2cc3ncnc(Nc4cccc(Br)c4)c3cc12,"{[4-(3-Bromo-phenylamino)-8H-pyrrolo[3,2-g]quinazolin-6-ylmethyl]-methyl-amino}-acetic acid",0.0007199999999999,uM,=,-3.1426675035687315,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
7945,982464,10.1016/j.bmc.2013.06.070,,,,Inhibition of recombinant EGFR kinase cytoplasmic domain (unknown origin) expressed in baculovirus expression vector-infected insect sf9 cells assessed as level of autophosphorylation after 10 mins by DELFIA/time-resolved fluorometry,Clc1cccc(Nc2ncnc3ccc(NCc4cccs4)cc23)c1,"N4-(3-Chlorophenyl)-N6-(thiophen-2-ylmethyl)quinazoline-4,6-diamine",3.4,uM,=,0.5314789170422551,1,c1ccc(Nc2ncnc3ccc(NCc4cccs4)cc23)cc1
7946,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC(C)NC(=O)NCCC,"US8846699, 85",0.029,uM,=,-1.537602002101044,0,c1ccc(Nc2ncnc3ccccc23)cc1
7947,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Brc1cccc(Nc2ncnc3cnc(NCCCN4CCOCC4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-(3-morpholin-4-yl-propyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0059,uM,=,-2.229147988357856,0,c1ccc(Nc2ncnc3cnc(NCCCN4CCOCC4)cc23)cc1
7948,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,CCOC(=O)C(Cc1ccccc1)NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"2-[2-Cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-3-phenyl-propionic acid ethyl ester",1.53,uM,=,0.1846914308175988,1,O=C(/C=C/c1ccccc1)NCCc1ccccc1
7949,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3cc(-c4ccncc4)ccc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((6-(pyridin-4-yl)-1H-indazol-3-yl)amino)phenyl)acrylamide,0.03,uM,=,-1.5228787452803376,0,c1ccc(Nc2n[nH]c3cc(-c4ccncc4)ccc23)cc1
7950,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(CCCN2CCOCC2)nn1,"N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((1-(3-morpholinopropyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3cc(OCc4cn(CCCN5CCOCC5)nn4)ccc23)cc1
7951,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)N1CCC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)c(C)c3)c(C(N)=O)nc2CC)C1,"US9085540, 80",0.0012,uM,=,-2.920818753952376,0,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(O[C@@H]2CCCNC2)n1
7952,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CN1CCN(c2cc3c(Nc4cccc(Br)c4)ncnc3cn2)CC1,"(3-Bromo-phenyl)-[6-(4-methyl-piperazin-1-yl)-pyrido[3,4-d]pyrimidin-4-yl]-amine",0.102,uM,=,-0.9913998282380824,0,c1ccc(Nc2ncnc3cnc(N4CCNCC4)cc23)cc1
7953,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CN1CCN(NCCCNc2cc3c(Nc4cccc(Br)c4)ncnc3cn2)CC1,"N*4*-(3-Bromo-phenyl)-N*6*-[3-(4-methyl-piperazin-1-ylamino)-propyl]-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0089,uM,=,-2.050609993355087,0,c1ccc(Nc2ncnc3cnc(NCCCNN4CCNCC4)cc23)cc1
7954,63775,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=CC(=O)N(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-N-methyl-acrylamide",0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2ncnc3cnccc23)cc1
7955,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,Cn1ncc2cc3c(Nc4cccc(Br)c4)ncnc3cc21,"(3-Bromo-phenyl)-(1-methyl-1H-pyrazolo[4,3-g]quinazolin-5-yl)-amine",0.00037,uM,=,-3.431798275933005,0,c1ccc(Nc2ncnc3cc4[nH]ncc4cc23)cc1
7956,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=S)NCC,"US8846699, 170",0.068,uM,=,-1.1674910872937636,0,c1ccc(Nc2ncnc3ccccc23)cc1
7957,603361,10.1016/j.bmc.2009.08.044,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA,CCCC(Cc1coc2nc(N)nc(N)c12)c1ccccc1OC,"5-[(R/S)-2-(20-Methoxyphenyl)pentyl]furo[2,3-d]pyrimidine-2,4-diamine",2.2,uM,=,0.3424226808222063,1,c1ccc(CCc2coc3ncncc23)cc1
7958,63602,10.1021/jm00077a014,,,,Inhibition of EGF-dependent DNA synthesis in ER 22 cells incubated with [3H]TdR,COC(=O)c1cc(NCc2cc(O)ccc2O)ccc1OC,"5-(2,5-Dihydroxy-benzylamino)-2-methoxy-benzoic acid methyl ester",9.5,uM,=,0.9777236052888478,1,c1ccc(CNc2ccccc2)cc1
7959,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccccc3OC)ncc2Br)c1,"US9238629, I-22",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
7960,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCCNC(C)=O,"US8846699, 20",0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
7961,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,OC[C@@H](Nc1ncnc2oc(-c3ccccc3)c(-c3ccoc3)c12)c1ccccc1,"(2S)-2-{[5-(Furan-3-yl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]-amino}-2-phenylethanol",0.352,uM,=,-0.453457336521869,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccoc4)c23)cc1
7962,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCC1CCNCC1.Cl,(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine hydrochloride,0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
7963,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c(C(N)=O)nc2C(C)C)c1,"US9085540, 22",0.0019,uM,=,-2.721246399047171,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7964,2118271,10.1016/j.bmcl.2021.128238,,,,Inhibition of EGFR (unknown origin) by ADP-Glo kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CC[Se]CC1,Selenogefitinib,25.3,uM,=,1.403120521175818,1,c1ccc(Nc2ncnc3ccc(OCCCN4CC[Se]CC4)cc23)cc1
7965,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,O=C(CCCCCC(=O)Nc1ccc(O)c(C(=O)Nc2ccc(Cl)c(C(F)(F)F)c2)c1)NO,N-(4-Chloro-3-trifluoromethylphenyl)-2-hydroxy-5-(7-hydroxyamino-7-oxoheptanamido)benzamide,1.41,uM,=,0.1492191126553798,1,O=C(Nc1ccccc1)c1ccccc1
7966,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)CCO,"US8846699, 145",0.041,uM,=,-1.3872161432802643,0,c1ccc(Nc2ncnc3ccccc23)cc1
7967,1684313,10.1016/j.ejmech.2017.04.025,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (unknown origin) (645 to 1186 residues) expressed in baculovirus infected Sf-9 cells preincubated for 10 mins followed by ATP addition measured after 1 hr by DELFIA/Time-Resolved fluorometry,Cc1nc(C)c(/C=C2\CC(C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)nc1C,"2,6-Bis-(3,5,6-trimethyl-pyrazin-2-ylmethylene)-4-methylcyclohexanone",1.1,uM,=,0.041392685158225,1,O=C1/C(=C/c2cnccn2)CCC/C1=C\c1cnccn1
7968,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,COCCOc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)c4cc([N+](=O)[O-])ccc4F)cc23)cc1Cl,N-(4-((3-chloro-4-(2-methoxyethoxy)phenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.503,uM,=,-0.2984320149440726,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
7969,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc(C)cc2)CC1c1ccc(C(=O)OCCn2c([N+](=O)[O-])cnc2C)cc1,"2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-(1-acetyl-3-(4-ethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",10.92,uM,=,1.0382226383687183,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7970,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",NP(=O)(OCCCOc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)N(CCCl)CCCl,"3-(6-(4-((3-Bromophenyl)amino)quinazolin-6-yl)oxy)propyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3ccccc23)cc1
7971,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c(C(N)=O)nc2CC)c1C,"US9085540, 15",0.0012,uM,=,-2.920818753952376,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
7972,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC1CCN(C(C)=O)C1,"US8846699, 88",0.094,uM,=,-1.0268721464003014,0,c1ccc(Nc2ncnc3cc(OC4CCNC4)ccc23)cc1
7973,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1cccc(CNC(=O)/C(C#N)=C/c2ccc(O)c(O)c2)c1,"(E)-2-Cyano-N-(3-{[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-methyl}-benzyl)-3-(3,4-dihydroxy-phenyl)-acrylamide",1.6,uM,=,0.2041199826559248,1,O=C(C=Cc1ccccc1)NCc1cccc(CNC(=O)/C=C/c2ccccc2)c1
7974,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2ncnc3cnccc23)cc1
7975,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,COc1ccc(-c2cn(-c3ccccc3)c3ncnc(N)c23)cc1,"5-(4-Methoxy-phenyl)-7-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",0.35,uM,=,-0.4559319556497244,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
7976,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccnc4)c(Cl)c3)ncnc2cc1OCCNC(C)=O,"US8846699, 130",0.796,uM,=,-0.0990869322623309,0,c1cncc(COc2ccc(Nc3ncnc4ccccc34)cc2)c1
7977,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(F)c3)ncnc2cc1OCCNC(=O)CN(C)C,"US8846699, 79",0.078,uM,=,-1.1079053973095196,0,c1ccc(Nc2ncnc3ccccc23)cc1
7978,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccccc1,"5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",0.5,uM,=,-0.3010299956639812,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
7979,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#Cc1ccc(CN2CCCC2)c(F)c1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-5-((3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl)ethynyl)-6-methylpyrimidin-4-amine,0.19,uM,=,-0.721246399047171,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccc(CN2CCCC2)cc1
7980,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,COc1ccc(C2=NN(C(C)=O)C(c3ccc(C(=O)OCCn4c([N+](=O)[O-])cnc4C)cc3)C2)cc1,"2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-(1-acetyl-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",8.54,uM,=,0.931457870689005,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7981,1817056,10.1021/acs.jmedchem.8b00147,,,,Inhibition of erbB1 (unknown origin) using FRET-capable peptide substrate by FRET assay,C[N+](C)(C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)Cc1ccccc1[N+](=O)[O-].[Br-],"4-(4-(3-bromophenylamino)quinazolin-6-ylamino)-N,N-dimethyl-N-(2-nitrobenzyl)-4-oxobut-2-en-1-aminium bromide",0.00022,uM,=,-3.657577319177794,0,O=C(/C=C/C[NH2+]Cc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
7982,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc(I)cc2)CC1c1ccc(C(=O)OC(C)Cn2c([N+](=O)[O-])cnc2C)cc1,"1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-yl 4-(1-acetyl-3-(4-iodophenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",10.69,uM,=,1.028977705208778,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
7983,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CN(C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*,N*6*-dimethyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3cnccc23)cc1
7984,1761975,10.1016/j.ejmech.2018.02.051,,,,"Inhibition of wild type EGFR (unknown origin) using Poly (Glu, Tyr) as substrate after 40 mins by kinase-Glo luminescence assay",CN(C)C1CCN(c2ccc(Nc3cc4c(N5CCCCC5)nc(Nc5ccccc5)nc4cn3)nc2)CC1,"N6-(5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)-N2-phenyl-4-(piperidin-1-yl)pyrido[3,4-d]pyrimidine-2,6-diamine",0.0009,uM,=,-3.0457574905606752,0,c1ccc(Nc2nc(N3CCCCC3)c3cc(Nc4ccc(N5CCCCC5)cn4)ncc3n2)cc1
7985,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,CCOC(=O)c1ccc(-c2cn(-c3ccccc3)c3ncnc(N)c23)cc1,"4-(4-Amino-7-phenyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-benzoic acid ethyl ester",1.3,uM,=,0.1139433523068367,1,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
7986,556139,10.1016/j.bmc.2008.04.019,,,,Inhibition of EGFR expressed in human tumor cells,Nc1nc(Nc2cccc(Br)c2)c2cc(CCc3ccc4ccccc4c3)[nH]c2n1,"N4-(3-Bromophenyl)-6-[2-(2-naphthyl)ethyl]-7Hpyrrolo[2,3-d]pyrimidine-2,4-diamine",4.7,uM,=,0.6720978579357175,1,c1ccc(Nc2ncnc3[nH]c(CCc4ccc5ccccc5c4)cc23)cc1
7987,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(OC)c(Cl)cc3Cl)ncnc2cc1OCCNC(C)=O,"US8846699, 132",0.042,uM,=,-1.3767507096020994,0,c1ccc(Nc2ncnc3ccccc23)cc1
7988,1832293,10.1016/j.bmc.2018.12.032,,,,Inhibition of EGFR (unknown origin),CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(F)c3)c2cc1NC(=O)/C=C/CN(C)C,N-(3-cyano-7-ethoxy-4-(3-fluoro-4-(pyridin-2-ylmethoxy)phenylamino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.092,uM,=,-1.0362121726544449,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)nc1
7989,63781,10.1016/j.bmcl.2004.01.034,,,,Inhibition of peptide substrate phosphorylation by epidermal growth factor receptor,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)c(C#N)cnc2cn1,"(E)-4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-[1,7]naphthyridin-6-yl]-amide",0.0019,uM,=,-2.721246399047171,0,c1ccc(Nc2ccnc3cnccc23)cc1
7990,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccccc3OC)ncc2Cl)c1,"US9238629, I-12",0.65,uM,=,-0.1870866433571444,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
7991,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Brc1cccc(Nc2ncnc3cnc(NCCc4ccccn4)cc23)c1,"N*4*-(3-Bromo-phenyl)-N*6*-(2-pyridin-2-yl-ethyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.0081,uM,=,-2.0915149811213505,0,c1ccc(Nc2ncnc3cnc(NCCc4ccccn4)cc23)cc1
7992,202292,10.1021/jm00037a020,,,,Cytotoxic effect on EGF-receptor overexpressing HN5 squamous carcinoma cells,Oc1ccc(-c2nc3c(O)cc(O)cc3s2)cc1,"2-(4-Hydroxy-phenyl)-benzothiazole-4,6-diol",300.0,uM,=,2.4771212547196626,1,c1ccc(-c2nc3ccccc3s2)cc1
7993,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(F)c3F)ncnc2cc1OCCNC(C)=O,"US8846699, 118",0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3ccccc23)cc1
7994,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CCOC,"US8846699, 64",0.07,uM,=,-1.154901959985743,0,c1ccc(Nc2ncnc3ccccc23)cc1
7995,556139,10.1016/j.bmc.2008.04.019,,,,Inhibition of EGFR expressed in human tumor cells,Nc1nc(Nc2cccc(Br)c2)c2cc(CCc3ccccc3)[nH]c2n1,"N4-(3-Bromophenyl)-6-(2-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",0.3,uM,=,-0.5228787452803376,0,c1ccc(CCc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7996,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccccc1CO,"[2-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-phenyl]-methanol",1.1,uM,=,0.041392685158225,1,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
7997,556139,10.1016/j.bmc.2008.04.019,,,,Inhibition of EGFR expressed in human tumor cells,Nc1nc(Nc2cccc(Br)c2)c2cc(Cc3ccccc3)[nH]c2n1,"2-benzyl-N4-(3-bromophenyl)-1H-indole-4,6-diamine",1.67,uM,=,0.2227164711475832,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
7998,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc2[nH]c(Cc3cccc(F)c3)nc2c1,4-(2-(3-fluorobenzyl)-1H-benzo[d]imidazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-methyl oxime,0.048,uM,=,-1.3187587626244128,0,c1ccc(Cc2nc3cc(Nc4ccncn4)ccc3[nH]2)cc1
7999,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(N)=O,"US8846699, 24",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccccc23)cc1
8000,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)cc3OC)ncc2Cl)c1,"US9238629, I-15",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
8001,1466619,10.1016/j.bmc.2015.03.061,,,,Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,Cc1nc(N(C)c2ccc(OC(C)C)cc2)c2cc(C)oc2n1,"N-2,6-Trimethyl-N-(4-isopropoxyphenyl)furo[2,3-d]-pyrimidin-4-amine",0.1022,uM,=,-0.9905491042013062,0,c1ccc(Nc2ncnc3occc23)cc1
8002,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCNC(C)=O,"US8846699, 13",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccccc23)cc1
8003,763212,10.1021/np200196j,,,,Inhibition of EGFR-induced Beta-casein activation in human HeLa cells preincubated for 1 hr prior to EGF stimulation by luciferase reporter gene assay,C/C=C(\C)C(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)/C=C(C)/C=C/CC(C)/C=C/c1oc(OC)c(C)c(=O)c1C,"2-methoxy-3,5-dimethyl-6-((1E,5E,7E,11E)-3,7,9,11-tetramethyl-10-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)trideca-1,5,7,11-tetraenyl)-4H-pyran-4-one",0.17,uM,=,-0.7695510786217261,0,O=c1ccoc(/C=C/CC/C=C/C=C/CCO[C@H]2CCCCO2)c1
8004,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,Fc1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1,"3-(4-Fluorophenyl)-5-(naphthalen-1-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",1.07,uM,=,0.0293837776852096,1,c1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1
8005,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(C3CCCC3)nc3cnc(Nc4ccc(OCCOC)cc4)nc32)c1,N-(3-(6-Cyclopentyl-2-((4-(2-methoxyethoxy)phenyl)-amino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.1369,uM,=,-0.86359655186601,0,O=c1c(C2CCCC2)nc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
8006,2118271,10.1016/j.bmcl.2021.128238,,,,Inhibition of EGFR (unknown origin) by ADP-Glo kinase assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,15.5,uM,=,1.1903316981702914,1,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
8007,2282389,10.1016/j.bmc.2021.116358,,,,Inhibition of EGFR (unknown origin),C=CC(=O)N1CCc2ccc(N3C(=O)CCc4cnc5ccc(-c6cnn(C)c6)cc5c43)cc21,"1-(1-acryloylindolin-6-yl)-9-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydrobenzo[h][1,6]naphthyridin-2(1H)-one",4.31,uM,=,0.6344772701607315,1,O=C1CCc2cnc3ccc(-c4cn[nH]c4)cc3c2N1c1ccc2c(c1)NCC2
8008,658103,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CNCc1cn(CCF)nn1,"(E)-4-{[1-(2-Fluoroethyl)-1H-[1,2,3]triazol-4-ylmethyl]-amino}-but-2-enoic acid[4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide",0.00181,uM,=,-2.7423214251308154,0,O=C(/C=C/CNCc1c[nH]nn1)Nc1ccc2nccc(Nc3ccccc3)c2c1
8009,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2cccc([N+](=O)[O-])c2)=N1,2-(2-(3-Nitrobenzylidene)hydrazinyl)thiazol-4(5H)-one,26.61,uM,=,1.4250448745513888,1,O=C1CSC(N/N=C/c2ccccc2)=N1
8010,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)/C=C/CC,"US8846699, 52",0.036,uM,=,-1.4436974992327127,0,c1ccc(Nc2ncnc3ccccc23)cc1
8011,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,Nc1ncnc(Nc2ccc3c(cnn3Cc3cccc(F)c3)c2)c1/C=N/O,4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde oxime,0.012,uM,=,-1.9208187539523751,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
8012,1337212,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,COc1ccc(Oc2nc3ccccc3cc2/C=N/NC(=O)Cn2c([N+](=O)[O-])cnc2C)cc1,(E)-N'-((2-(4-methoxyphenoxy)quinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,0.27,uM,=,-0.5686362358410126,0,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
8013,1886849,10.1016/j.bmcl.2019.04.029,,,,Inhibition of probe binding to wild type EGFR (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)C(CSC(C)=O)CSC(C)=O,"S,S'-(2-((4-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)carbomoyl)propane-1,3-diyl)diethanethioate",0.34,uM,=,-0.4685210829577448,0,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
8014,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(Cc2ccccc2)nn1,"N-(7-((1-benzyl-1H-1,2,3-triazol-4-yl)methoxy)-4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)acrylamide",0.039,uM,=,-1.408935392973501,0,c1ccc(Cn2cc(COc3ccc4c(Nc5ccccc5)ncnc4c3)nn2)cc1
8015,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#CC(C#N)=C1CCCc2c(O)cccc21,"2-(5-Hydroxy-3,4-dihydro-2H-naphthalen-1-ylidene)-malononitrile",1200.0,uM,=,3.0791812460476247,1,C=C1CCCc2ccccc21
8016,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,COc1cc2c(N[C@@H]3C[C@H]3c3ccccc3)c(C#N)cnc2cc1OCCCc1cccnc1,"6-methoxy-4-((1R,2S)-2-phenylcyclopropylamino)-7-(3-(pyridin-3-yl)propoxy)quinoline-3-carbonitrile",0.173,uM,=,-0.7619538968712046,0,c1ccc([C@@H]2C[C@H]2Nc2ccnc3cc(OCCCc4cccnc4)ccc23)cc1
8017,1894188,10.1016/j.ejmech.2019.05.015,,,,Inhibition of human EGFR measured after 3 hrs by ELISA,Cn1c(=O)[nH]c2nc(SC/C(=N/O)c3ccc(Cl)cc3)[nH]c2c1=O,"8-((2-(4-Chlorophenyl)-2-(hydroxyimino)ethyl)thio)-1-methyl-3,7-dihydro-1H-purine-2,6-dione",0.82,uM,=,-0.0861861476162833,0,N=C(CSc1nc2[nH]c(=O)[nH]c(=O)c2[nH]1)c1ccccc1
8018,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,O=C(CCCCCC(=O)Nc1ccc(O)c(C(=O)Nc2ccc(Cl)c(Cl)c2)c1)NO,"N-(3,4-Dichlorophenyl)-2-hydroxy-5-(7-hydroxyamino-7-oxoheptanamido)benzamide",1.8,uM,=,0.255272505103306,1,O=C(Nc1ccccc1)c1ccccc1
8019,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,Brc1cccc(Nc2ncnc3ccc(N/N=N/Cc4ccccn4)cc23)c1,N-(3-bromophenyl)-6-[(1E)-3-(pyridin-2-ylmethyl)triaz-1-enyl]quinazolin-4-amine,0.238,uM,=,-0.623423042943488,0,c1ccc(Nc2ncnc3ccc(N/N=N/Cc4ccccn4)cc23)cc1
8020,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.15259,uM,=,-0.8164739269782784,0,c1ccc(Nc2ncnc3ccccc23)cc1
8021,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccccc3)n2)c(OC)cc1N1CCN(C)CC1,N-(2-(4-Methylpiperazin-1-yl)-4-methoxy-5-((4-benzamidopyrimidin-2-yl)amino)phenyl)acryl-amide,0.1565,uM,=,-0.8054856581175327,0,O=C(Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1)c1ccccc1
8022,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1OCCCOP(N)(=O)N(CCCl)CCCl,"3-((4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.022,uM,=,-1.6575773191777938,0,c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1
8023,632680,10.1016/j.bmc.2010.03.052,,,,Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA,C#Cc1cccc(Nc2nc(N)nc3[nH]c(Cc4ccc(Cl)cc4Cl)cc23)c1,"N4-(3-Ethynylphenyl)-6-(2,4-dichlorobenzyl)-7Hpyrrolo[2,3-d]pyrimidine-2,4-diamine",55.2,uM,=,1.741939077729199,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
8024,1466619,10.1016/j.bmc.2015.03.061,,,,Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,Cc1nc(N(C)c2ccc3c(c2)CCO3)c2cc(C)oc2n1,"N-(2,3-Dihydro-1-benzofuran-5-yl)-N,2,6-trimethylfuro-[2,3-d]pyrimidin-4-amine",0.2264,uM,=,-0.6451235774837661,0,c1nc(Nc2ccc3c(c2)CCO3)c2ccoc2n1
8025,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CNC(=O)NCCOc1cc2ncnc(Nc3ccc(Br)cc3F)c2cc1NC(=O)C=C,"US8846699, 39",0.029,uM,=,-1.537602002101044,0,c1ccc(Nc2ncnc3ccccc23)cc1
8026,2031601,10.1016/j.ejmech.2020.112185,,,,"Inhibition of EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate incubated for 8 mins in presence of ATP by colorimetric analysis",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.031,uM,=,-1.5086383061657274,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
8027,509684,10.1016/j.bmcl.2008.07.020,,,,Inhibition of human EGFR expressed in SF9 cells,COc1ccc(/N=C/c2c(N)ncnc2Nc2ccc3c(cnn3Cc3cccc(F)c3)c2)cc1,"N-[1-(3-Fluoro-benzyl)-1H-indazol-5-yl]-5-{[4-methoxy-phenylimino]-methyl}-pyrimidine-4,6-diamine",0.049,uM,=,-1.3098039199714864,0,C(=N/c1ccccc1)\c1cncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1
8028,1684313,10.1016/j.ejmech.2017.04.025,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (unknown origin) (645 to 1186 residues) expressed in baculovirus infected Sf-9 cells preincubated for 10 mins followed by ATP addition measured after 1 hr by DELFIA/Time-Resolved fluorometry,COc1cc(Br)c(/C=C2\CN(C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)cc1OC,"3-(2-Bromo-4,5-dimethoxy-benzylidene)-1-methyl-5-(3,5,6-trimethyl-pyrazin-2-ylmethylene)-piperidin-4-one",0.06,uM,=,-1.2218487496163564,0,O=C1/C(=C/c2ccccc2)CNC/C1=C\c1cnccn1
8029,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccccc3OC)ncc2F)c1,"US9238629, I-19",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
8030,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1=NCCO1,"US8846699, 109",0.125,uM,=,-0.9030899869919436,0,c1ccc(Nc2ncnc3cc(OCC4=NCCO4)ccc23)cc1
8031,66896,10.1021/jm00109a008,,,,Inhibition of Epidermal growth factor receptor autophosphorylation in A431 cell membranes,O=P(O)(O)C(O)c1ccc2ccccc2c1,(Hydroxy-naphthalen-2-yl-methyl)-phosphonic acid,250.0,uM,=,2.397940008672037,1,c1ccc2ccccc2c1
8032,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,Brc1cccc(Nc2ncnc3ccc(N/N=N/Cc4ccccc4)cc23)c1,6-[(1E)-3-benzyltriaz-1-enyl]-N-(3-bromophenyl)quinazolin-4-amine,0.025,uM,=,-1.6020599913279625,0,c1ccc(C/N=N/Nc2ccc3ncnc(Nc4ccccc4)c3c2)cc1
8033,473565,10.1073/pnas.0708800104,,,,Inhibition of EGFR,CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21,"1-tert-Butyl-3-(4-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine",0.48,uM,=,-0.3187587626244128,0,c1ccc(-c2n[nH]c3ncncc23)cc1
8034,1814080,10.1016/j.ejmech.2019.111693,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,O=C(Nc1ccccc1)Nc1nnc(-c2cccnc2)o1,"1-Phenyl-3-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)urea",0.2757,uM,=,-0.5595632338942264,0,O=C(Nc1ccccc1)Nc1nnc(-c2cccnc2)o1
8035,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCN1CCN(C)CC1.Cl,(4-Bromo-2-fluoro-phenyl)-{6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinazolin-4-yl}-amine hydrochloride,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3cc(OCCCN4CCNCC4)ccc23)cc1
8036,887628,10.1021/jm3003203,,,,Inhibition of EGFR,CC#CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,But-2-ynoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.00037,uM,=,-3.431798275933005,0,c1ccc(Nc2ncnc3ccccc23)cc1
8037,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",COc1cc(/C=C(\C#N)S(=O)(=O)/C(C#N)=C/c2cc(O)c(O)c(OC)c2)cc(O)c1O,"(E)-2-[(E)-2-Cyano-1-(3,4-dihydroxy-5-methoxy-phenyl)-ethenesulfonyl]-3-(3,4-dihydroxy-5-methoxy-phenyl)-acrylonitrile",0.94,uM,=,-0.0268721464003013,0,O=S(=O)(C=Cc1ccccc1)/C=C/c1ccccc1
8038,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc(C(F)(F)F)cc2)CC1c1ccc(C(=O)OCCn2c([N+](=O)[O-])cnc2C)cc1,"2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-(1-acetyl-3-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",0.26,uM,=,-0.585026652029182,0,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
8039,1586014,10.1016/j.bmc.2016.05.057,,,,Inhibition of EGFR (unknown origin) incubated for 1 hr by spectrophotometric analysis,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,Indolocarbazole nitrogen derivative,0.0742,uM,=,-1.1295960947209729,0,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC[C@H]3O1
8040,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,COc1cc2ncc(C(=O)NC3CC(C)(C)N([O])C(C)(C)C3)c(Nc3cccc(Cl)c3)c2cc1OC,"4-(3-Chlorophenylamino)-6,7-dimethoxy-N-[(2,2,6,6-tetramethyl-1-oxyl)piperidin-4-yl]quinoline-3-carboxamide",0.623,uM,=,-0.2055119533408304,0,O=C(NC1CCNCC1)c1cnc2ccccc2c1Nc1ccccc1
8041,978663,10.1016/j.ejmech.2013.06.057,,,,Inhibition of EGFR (unknown origin),Cl.c1ccc(-c2cccc(Nc3ncnc4cc5c(cc34)OCCCO5)c2)cc1,"(8,9-Dihydro-7H-[1,4]dioxepino[2,3-g]quinazolin-4-yl)-(biphenyl-3'-yl)amine hydrochloride",0.027,uM,=,-1.5686362358410126,0,c1ccc(-c2cccc(Nc3ncnc4cc5c(cc34)OCCCO5)c2)cc1
8042,615344,10.1016/j.ejmech.2009.12.026,,,,Inhibition of EGFR,CC1=C(C(=O)Nc2cccc([N+](=O)[O-])c2)C(c2ccc(O)cc2O)NC(Nc2ccc(S(=O)(=O)Nc3ncccn3)cc2)=N1,"6-(2,4-dihydroxyphenyl)-4-methyl-N-(3-nitrophenyl)-2-(4-(N-pyrimidin-2-ylsulfamoyl)phenylamino)-1,6-dihydropyrimidine-5-carboxamide",88.3,uM,=,1.9459607035775688,1,O=C(Nc1ccccc1)C1=CN=C(Nc2ccc(S(=O)(=O)Nc3ncccn3)cc2)NC1c1ccccc1
8043,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,C#Cc1cccc(NC(=O)c2cccc(NC(=O)CCCCCC(=O)NO)c2)c1,N-(3-Ethynylphenyl)-3-(7-hydroxyamino-7-oxoheptanamido)benzamide,6.17,uM,=,0.7902851640332417,1,O=C(Nc1ccccc1)c1ccccc1
8044,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3cccc(OC)c3)n2)c(OC)cc1N1CCN(C)CC1,N-(2-(4-Methylpiperazin-1-yl)-4-methoxy-5-((4-(3-methoxybenzamido)pyrimidin-2-yl)amino)-phenyl)acrylamide,0.1474,uM,=,-0.8315025164769674,0,O=C(Nc1ccnc(Nc2ccc(N3CCNCC3)cc2)n1)c1ccccc1
8045,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(CC)nc3cnc(Nc4ccc(OCCOC)cc4)nc32)c1,N-(3-(6-Ethyl-2-((4-(2-methoxyethoxy)phenyl)amino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.2792,uM,=,-0.5540845860488766,0,O=c1cnc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
8046,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,CCNc1cc(Nc2cccc(Cl)c2)ncn1,"N4-(3-Chlorophenyl)-N6-ethylpyrimidine-4,6-diamine",0.17,uM,=,-0.7695510786217261,0,c1ccc(Nc2ccncn2)cc1
8047,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(C(=O)NOC)c(Br)cc3F)ncnc2cc1OCCNC(C)=O,"US8846699, 131",10.0,uM,=,1.0,1,c1ccc(Nc2ncnc3ccccc23)cc1
8048,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3c(F)cc(Br)cc3F)ncnc2cc1OCC1CCN(C(C)=O)CC1,"US8846699, 8",0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
8049,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3cc(-c4cccnc4)ccc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((6-(pyridin-3-yl)-1H-indazol-3-yl)amino)phenyl)acrylamide,0.097,uM,=,-1.0132282657337552,0,c1ccc(Nc2n[nH]c3cc(-c4cccnc4)ccc23)cc1
8050,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C(C)C,"US8846699, 48",0.128,uM,=,-0.8927900303521317,0,c1ccc(Nc2ncnc3ccccc23)cc1
8051,1565887,10.1016/j.bmcl.2016.02.075,,,,Inhibition of HER1 (unknown origin) in presence of [gamma33P]ATP,Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CN2CCC2)C1,"3-(4-amino-7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenol",2.3,uM,=,0.3617278360175928,1,c1ccc(-c2cn([C@H]3C[C@@H](CN4CCC4)C3)c3ncncc23)cc1
8052,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CN(C)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-(2-dimethylamino-ethyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.043,uM,=,-1.3665315444204136,0,c1ccc(Nc2ncnc3cnccc23)cc1
8053,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,CN(C)CCNCc1cc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)ccc1F,"(S)-2-((6-(3-(((2-(Dimethylamino)ethyl)amino)methyl)-4-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0012,uM,=,-2.920818753952376,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8054,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,Brc1cccc(Nc2ncnc3ccc(N/N=N/CCN4CCOCC4)cc23)c1,6-[(1E)-3-[(2-morpholin-4-yl)-ethyl]triaz-1-enyl]-N-(3-bromo-phenyl)-quinazolin-4-amine,0.064,uM,=,-1.193820026016113,0,c1ccc(Nc2ncnc3ccc(N/N=N/CCN4CCOCC4)cc23)cc1
8055,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)CCN(CC)CC,"US8846699, 144",0.007,uM,=,-2.154901959985743,0,c1ccc(Nc2ncnc3ccccc23)cc1
8056,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,COCCO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-2-methoxyethyl oxime,0.014,uM,=,-1.853871964321762,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
8057,1684313,10.1016/j.ejmech.2017.04.025,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (unknown origin) (645 to 1186 residues) expressed in baculovirus infected Sf-9 cells preincubated for 10 mins followed by ATP addition measured after 1 hr by DELFIA/Time-Resolved fluorometry,COc1cc(Cl)c(/C=C2\CN(C(C)C)C/C(=C\c3nc(C)c(C)nc3C)C2=O)cc1OC,"3-(2-Bromo-4,5-dimethoxy-benzylidene)-1-isopropyl-5-(3,5,6-trimethyl-pyrazin-2-ylmethylene)-piperidin-4-one",3.1,uM,=,0.4913616938342727,1,O=C1/C(=C/c2ccccc2)CNC/C1=C\c1cnccn1
8058,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCC1CCN(C)CC1.Cl,(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine hydrochloride,0.3,uM,=,-0.5228787452803376,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
8059,556139,10.1016/j.bmc.2008.04.019,,,,Inhibition of EGFR expressed in human tumor cells,Nc1nc(Nc2cccc(Br)c2)c2cc(CCc3ccccc3Cl)[nH]c2n1,"N4-(3-Bromophenyl)-6-[2-(2-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",3.4,uM,=,0.5314789170422551,1,c1ccc(CCc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
8060,2260230,10.1016/j.ejmech.2020.113016,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins in presence of ATP by caliper mobility shift assay,COc1cc2ncnc(Sc3cccc(NC(=S)Nc4ccc(Br)c(C(F)(F)F)c4)c3)c2cc1OC,"1-(4-bromo-3-(trifluoromethyl)phenyl)-3-(3-((6,7-dimethoxyquinazolin-4-yl)thio)phenyl)thiourea",0.01,uM,=,-2.0,0,S=C(Nc1ccccc1)Nc1cccc(Sc2ncnc3ccccc23)c1
8061,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=C(C)C(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(C)=O,"US8846699, 76",1.02,uM,=,0.0086001717619175,1,c1ccc(Nc2ncnc3ccccc23)cc1
8062,2045678,10.1039/d0md00146e,,,,Inhibition of EGFR (unknown origin) using Tyrosine 4 peptide and ATP as substrate incubated for 1 hr by Z'-lyte kinase assay based UV-VIS spectrophotometric method,COc1ccc(C2N=C(C(N)=O)c3ncn(-c4ccc(N5CCN(C)CC5)c([N+](=O)[O-])c4)c3N2)cc1OC,"2-(3,4-dimethoxyphenyl)-9-(4-(4-methylpiperazin-1-yl)-3-nitrophenyl)-9H-purine-6-carboxamide",0.23638,uM,=,-0.626389271687069,0,C1=NC(c2ccccc2)Nc2c1ncn2-c1ccc(N2CCNCC2)cc1
8063,608087,10.1021/jm901558p,,,,Inhibition of human recombinant EGFR expressed in insect cells by time-resolved fluorimetry,O=C(COc1c(F)c(F)c(F)c(F)c1F)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(perfluorophenoxy)-acetamide,0.0236,uM,=,-1.6270879970298933,0,O=C(COc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
8064,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,CN(C)CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)c1cc([N+](=O)[O-])ccc1F,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(2-(dimethylamino)ethoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.05,uM,=,-1.3010299956639813,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccccc1
8065,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,COc1cc2c(N[C@@H]3C[C@H]3c3ccccc3)c(C#N)cnc2cc1OCCCN1CCN(C)CC1,"6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",0.0057,uM,=,-2.2441251443275085,0,c1ccc([C@@H]2C[C@H]2Nc2ccnc3cc(OCCCN4CCNCC4)ccc23)cc1
8066,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CN(C)CCCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-N*6*-(3-dimethylamino-propyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ncnc3cnccc23)cc1
8067,2218523,10.1021/acs.jmedchem.0c01467,,,,Inhibition of EGFR (unknown origin),COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.033,uM,=,-1.4814860601221125,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
8068,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,O=C(/C=C/C(F)(F)F)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"4,4,4-Trifluoro-but-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide",0.035,uM,=,-1.4559319556497243,0,c1ccc(Nc2ncnc3ccccc23)cc1
8069,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,CS(=O)(=O)Nc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1,"(S)-N-(4-(4-((2-Hydroxy-1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methanesulfonamide",0.0005,uM,=,-3.3010299956639813,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8070,2207741,10.1021/acs.jmedchem.2c00893,,,,Inhibition of wild type EGFR expressed in human NCI-H2073 cells,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.017,uM,=,-1.769551078621726,0,c1ccc(Nc2ncnc3ccccc23)cc1
8071,632680,10.1016/j.bmc.2010.03.052,,,,Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA,COc1ccc(OC)c(Cc2cc3c(Nc4cccc(Br)c4)nc(N)nc3[nH]2)c1,"N4-(3-bromophenyl)-6-(2,5-dimethoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",12.6,uM,=,1.100370545117563,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
8072,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,N#Cc1ccc(F)c(C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2OCCCN2CCOCC2)c1,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-5-cyanobenzamide,0.0013,uM,=,-2.886056647693163,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
8073,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#CC(C#N)=C1C(=O)Nc2ccc(O)cc21,"2-(5-Hydroxy-2-oxo-1,2-dihydro-indol-3-ylidene)-malononitrile",12.5,uM,=,1.0969100130080565,1,C=C1C(=O)Nc2ccccc21
8074,1886849,10.1016/j.bmcl.2019.04.029,,,,Inhibition of probe binding to wild type EGFR (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)CCCCC1CCSS1,"N-(4-(3-Chloro-4-((3-fluorobenzyl)oxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-5-(1,2-dithiolan-3-yl)pentanamide",0.73,uM,=,-0.1366771398795441,0,O=C(CCCCC1CCSS1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
8075,63781,10.1016/j.bmcl.2004.01.034,,,,Inhibition of peptide substrate phosphorylation by epidermal growth factor receptor,CC#CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,But-2-ynoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide,0.2588999999999999,uM,=,-0.586867949565128,0,c1ccc(Nc2ccnc3ccccc23)cc1
8076,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,COc1cc2c(N[C@@H]3C[C@H]3c3ccccc3)c(C#N)cnc2cc1OCCCN1CCOCC1,"6-methoxy-7-(3-morpholinopropoxy)-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",0.005,uM,=,-2.3010299956639813,0,c1ccc([C@@H]2C[C@H]2Nc2ccnc3cc(OCCCN4CCOCC4)ccc23)cc1
8077,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1C.Cl,"{4-[6,7-Dimethoxyquinazolin-4-ylamino]-2-methylphenyl}carbamic acid ethyl ester hydrochloride",0.9,uM,=,-0.0457574905606751,0,c1ccc(Nc2ncnc3ccccc23)cc1
8078,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#Cc1ccc(CN2CCCC2)o1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-((5-(pyrrolidin-1-ylmethyl)furan-2-yl)ethynyl)pyrimidin-4-amine,0.079,uM,=,-1.1023729087095586,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccc(CN2CCCC2)o1
8079,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccn(C)n3)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,0.0964899999999999,uM,=,-1.0155176935977372,0,c1ccc(Nc2nccc(Nc3cc[nH]n3)n2)cc1
8080,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,O=C(CCCCCC(=O)Nc1ccc(O)c(C(=O)Nc2ccc(F)c(Cl)c2)c1)NO,N-(3-Chloro-4-fluorophenyl)-2-hydroxy-5-(7-hydroxyamino-7-oxoheptanamido)benzamide,3.53,uM,=,0.5477747053878226,1,O=C(Nc1ccccc1)c1ccccc1
8081,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",NP(=O)(OCCCCCOc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)N(CCCl)CCCl,"5-((4-((3-Bromophenyl)amino)quinazolin-6-yl)oxy)pentyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.0023,uM,=,-2.638272163982407,0,c1ccc(Nc2ncnc3ccccc23)cc1
8082,2090282,10.1016/j.ejmech.2020.112522,,,,Inhibition of wild type EGFR in human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by Celltiter-Glo luminescent cell viability assay,C=CCSSCCC(=O)OCCCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,3-Allyldisulfanyl-propionic acid 3-[4-(3-bromo-phenylamino)-6-methoxy-quinazolin-7-yloxy]-propyl ester,7.309,uM,=,0.863857961883973,1,c1ccc(Nc2ncnc3ccccc23)cc1
8083,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,CN1CCN(CCC(=O)N2CCOc3c2ccc2ncnc(Nc4cccc(Br)c4)c32)CC1,"1-(10-((3-bromophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)-3-(4-methylpiperazin-1-yl)propan-1-one",0.0407,uM,=,-1.39040559077478,0,O=C(CCN1CCNCC1)N1CCOc2c1ccc1ncnc(Nc3ccccc3)c21
8084,63790,10.1016/S0960-894X(97)00035-8,,,,Antagonism towards Epidermal growth factor receptor,COc1cc2ncnc(N(C)c3cccc(C)c3)c2cc1OC.Cl,"(6,7-Dimethoxy-quinazolin-4-yl)-methyl-m-tolyl-amine hydrochloride",12.0,uM,=,1.0791812460476249,1,c1ccc(Nc2ncnc3ccccc23)cc1
8085,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,C#Cc1cccc(NC(=O)c2cc(OCCCCCCC(=O)NO)ccc2O)c1,N-(3-Ethynylphenyl)-2-hydroxy-5-(7-hydroxyamino-7-oxoheptyloxy)benzamide,0.9,uM,=,-0.0457574905606751,0,O=C(Nc1ccccc1)c1ccccc1
8086,631519,10.1016/j.bmcl.2010.03.025,,,,Inhibition of EGFR,COc1cc(Nc2c(C#N)cnc3cc(/C=C/CCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,"(E)-4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(4-(4-methylpiperazin-1-yl)but-1-enyl)quinoline-3-carbonitrile",3.3,uM,=,0.5185139398778875,1,C(=C/c1ccc2c(Nc3ccccc3)ccnc2c1)\CCN1CCNCC1
8087,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,COc1cc2nccc(Nc3cc(OC)c(OC)c(OC)c3)c2cc1OC,"(6,7-Dimethoxy-quinolin-4-yl)-(3,4,5-trimethoxy-phenyl)-amine",27.0,uM,=,1.4313637641589874,1,c1ccc(Nc2ccnc3ccccc23)cc1
8088,66568,10.1021/jm00033a019,,,,Inhibitory activity against recombinant tyrosine kinase EGF-R (EGF-R ICD),COc1ccc(Nc2cc3c(cc2Nc2ccccc2)C(=O)NC3=O)cc1,"5-(4-Methoxy-phenylamino)-6-phenylamino-isoindole-1,3-dione",2.0,uM,=,0.3010299956639812,1,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21
8089,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3cnn(C4CCN(C)CC4)c3)c(C(N)=O)nc2C(C)C)c1,"US9085540, 56",0.0013,uM,=,-2.886056647693163,0,c1ccc(Oc2cncc(Nc3cnn(C4CCNCC4)c3)n2)cc1
8090,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=CS(=O)(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"Ethenesulfonic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide",0.0024,uM,=,-2.619788758288394,0,c1ccc(Nc2ncnc3cnccc23)cc1
8091,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,COc1cc(N(C)c2ccnc3ccc(C(F)(F)F)cc23)cc(OC)c1OC,"N-methyl-6-(trifluoromethyl)-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine",2.2,uM,=,0.3424226808222063,1,c1ccc(Nc2ccnc3ccccc23)cc1
8092,1817056,10.1021/acs.jmedchem.8b00147,,,,Inhibition of erbB1 (unknown origin) using FRET-capable peptide substrate by FRET assay,C[N+](C)(C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)Cc1ccc([N+](=O)[O-])cc1.[Br-],"4-(4-(3-bromophenylamino)quinazolin-6-ylamino)-N,N-dimethyl-N-(4-nitrobenzyl)-4-oxobut-2-en-1-aminium bromide",0.00022,uM,=,-3.657577319177794,0,O=C(/C=C/C[NH2+]Cc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
8093,2127168,10.1016/j.bmc.2021.116266,,,,Inhibition of EGFR (unknown origin),Oc1ccc(/C=N/Nc2nc3ccccc3c3nncn23)cc1,"(E)-4-((2-([1,2,4]triazolo[4,3-c]quinazolin-5-yl)hydrazono)methyl)phenol",0.69,uM,=,-0.1611509092627447,0,C(=N/Nc1nc2ccccc2c2nncn12)\c1ccccc1
8094,632680,10.1016/j.bmc.2010.03.052,,,,Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,"5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide",172.1,uM,=,2.2357808703275603,1,O=C1Nc2ccccc2/C1=C/c1ccc[nH]1
8095,2272129,10.1016/j.ejmech.2020.113070,,,,Inhibition of wild type human EGFR measured by ELISA analysis,O=c1c2ccc(Cl)cc2nc(-c2ccccc2)n1-c1nnc(-c2ccccc2C2CC2)o1,"7-chloro-3-(5-(2-cyclopropylphenyl)-1,3,4-oxadiazol-2-yl)-2-phenylquinazolin-4(3H)-one",0.102,uM,=,-0.9913998282380824,0,O=c1c2ccccc2nc(-c2ccccc2)n1-c1nnc(-c2ccccc2C2CC2)o1
8096,473874,10.1073/pnas.0708800104,,,,Inhibition of wild type EGFR,O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCC(Br)C2,"(Z)-5-bromo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-1,3-dihydroindol-2-one",13.3,uM,=,1.1238516409670858,1,O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCCC2
8097,2296723,10.1021/acs.jmedchem.6b00276,,,,Inhibition of recombinant 6His-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) autophosphorylation expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP and MgCl2 addition measured after 60 mins by DELFIA/time-resolved fluorometric analysis,COc1cc(/C=C2\CC(C)c3ccccc3\C2=N\O)c(Br)c(OC)c1OC,"2-(2-bromo-3,4,5-trimethoxybenzylidene)-4-methyl-3,4-dihydronaphthalen-1(2H)-one oxime",3.2,uM,=,0.505149978319906,1,N=C1/C(=C/c2ccccc2)CCc2ccccc21
8098,2090282,10.1016/j.ejmech.2020.112522,,,,Inhibition of wild type EGFR in human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by Celltiter-Glo luminescent cell viability assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,2.54,uM,=,0.404833716619938,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
8099,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C(=O)CS(C)(=O)=O)CC1,"US8846699, 3",0.026,uM,=,-1.585026652029182,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
8100,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC[C@@H]1CCCN(C)C1,(R)-(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-3-ylmethoxy)-quinazolin-4-yl]-amine,0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3cc(OC[C@@H]4CCCNC4)ccc23)cc1
8101,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccccc3OC)ncc2C(F)(F)F)c1,"US9238629, I-1",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
8102,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=CS(=O)(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,Ethenesulfonic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.0027,uM,=,-2.5686362358410126,0,c1ccc(Nc2ncnc3ccccc23)cc1
8103,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=S)NC,"US8846699, 35",0.098,uM,=,-1.0087739243075051,0,c1ccc(Nc2ncnc3ccccc23)cc1
8104,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.005,uM,=,-2.3010299956639813,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
8105,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc2[nH]ncc2c1,4-(1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-methyl oxime,0.306,uM,=,-0.51427857351842,0,c1cc(Nc2ccc3[nH]ncc3c2)ncn1
8106,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#CC(C#N)=Cc1ccc(C#N)cc1,2-(4-Cyano-benzylidene)-malononitrile,1400.0,uM,=,3.146128035678238,1,c1ccccc1
8107,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC(C)CNC(C)=O,"US8846699, 80",0.036,uM,=,-1.4436974992327127,0,c1ccc(Nc2ncnc3ccccc23)cc1
8108,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),COC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1Cl.Cl,"{2-Chloro-4-[6,7-dimethoxyquinazolin-4-ylamino]phenyl}carbamic acid methyl ester hydrochloride",6.15,uM,=,0.7888751157754168,1,c1ccc(Nc2ncnc3ccccc23)cc1
8109,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(Cl)c(Cl)cc3F)ncnc2cc1OCCNC(=O)COC,"US8846699, 138",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
8110,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCNC(=O)NCC,"US8846699, 16",0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccccc23)cc1
8111,78512,10.1016/s0960-894x(01)00219-0,,,,Inhibition of EGF receptor overexpressing HN5 cell proliferation,CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1,"N*4*-(1-Benzyl-1H-indazol-5-yl)-N*6*,N*6*-dimethyl-pyrido[3,4-d]pyrimidine-4,6-diamine",0.21,uM,=,-0.6777807052660807,0,c1ccc(Cn2ncc3cc(Nc4ncnc5cnccc45)ccc32)cc1
8112,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCOCCOC(=O)CC(=O)O,"US8846699, 70",0.956,uM,=,-0.0195421077238999,0,c1ccc(Nc2ncnc3ccccc23)cc1
8113,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC)CC4)cc3)c(C(N)=O)nc2CC)c1,"US9085540, 43",0.00066,uM,=,-3.1804560644581312,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
8114,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)c(OC)c3OC)ncc2Cl)c1,"US9238629, I-7",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
8115,658103,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CNC,(E)-4-(Methylamino)-but-2-enoic acid [4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxy-quinoline-6-yl]amide,0.00025,uM,=,-3.6020599913279625,0,c1ccc(Nc2ccnc3ccccc23)cc1
8116,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
8117,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,COc1cccc(Nc2cc(NC(=O)CCCC(=O)O)ncn2)c1,5-((6-((3-Methoxyphenyl)amino)pyrimidin-4-yl)amino)-5-oxopentanoic acid,0.037,uM,=,-1.431798275933005,0,c1ccc(Nc2ccncn2)cc1
8118,1466619,10.1016/j.bmc.2015.03.061,,,,Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,COc1ccc(N(C)c2nc(C)nc3oc(C)cc23)cc1OC,"N-(3,4-Dimethoxyphenyl)-N,2,6-trimethylfuro[2,3-d]-pyrimidin-4-amine",0.0902999999999999,uM,=,-1.0443122496864945,0,c1ccc(Nc2ncnc3occc23)cc1
8119,1814080,10.1016/j.ejmech.2019.111693,,,,Inhibition of recombinant human GST-tagged EGFR catalytic domain (668 to 1210 residues) expressed in baculovirus expression system using TK-biotin peptide as substrate measured after 10 mins by HTRF assay,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.4178,uM,=,-0.3790315643557102,0,c1ccc(Nc2ncnc3ccccc23)cc1
8120,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C=CC(=O)N(CCN(C)C)c1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-N-(2-dimethylamino-ethyl)-acrylamide",2.282,uM,=,0.3583156400821958,1,c1ccc(Nc2ncnc3cnccc23)cc1
8121,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2cc(F)ccc2O)=N1,2-(2-(5-Fluoro-2-hydroxybenzylidene)hydrazinyl)thiazol-4(5H)-one,0.97,uM,=,-0.0132282657337551,0,O=C1CSC(N/N=C/c2ccccc2)=N1
8122,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1cc(O)c(O)c(O)c1)C(=O)NCCCCNC(=O)/C(C#N)=C/c1cc(O)c(O)c(O)c1,"(E)-2-Cyano-N-{4-[(E)-2-cyano-3-(3,4,5-trihydroxy-phenyl)-acryloylamino]-butyl}-3-(3,4,5-trihydroxy-phenyl)-acrylamide",0.6,uM,=,-0.2218487496163563,0,O=C(C=Cc1ccccc1)NCCCCNC(=O)/C=C/c1ccccc1
8123,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,NC1CCN(Cc2ccn3ncnc(Nc4ccccc4)c23)CC1,"5-((4-aminopiperidin-1-yl)methyl)-N-phenylpyrrolo[1,2-f][1,2,4]triazin-4-amine",0.04,uM,=,-1.3979400086720375,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1
8124,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,O=C(/C=C/CN1CCOCC1)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-((3-chloro-4-fluorophenyl)amino)-7,8-dihydro-6H-[1, 4]oxazino[3, 2-g]quinazolin-6-yl)-4-morpholinobut-2-en-1-one",0.146,uM,=,-0.835647144215563,0,O=C(/C=C/CN1CCOCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
8125,1754225,10.1021/acs.jmedchem.7b01605,,,,"Inhibition of wild-type human partial length EGFR (R669 to V1011 residues) expressed in bacterial expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",Nc1nc(Nc2ccc3c(c2)CC[C@@H](N2CCCC2)CC3)nn1-c1cc2c(nn1)-c1ccccc1CCC2,BEMCENTINIB,3.9,uM,=,0.5910646070264992,1,c1ccc2c(c1)CCCc1cc(-n3cnc(Nc4ccc5c(c4)CC[C@@H](N4CCCC4)CC5)n3)nnc1-2
8126,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCOC,"US8846699, 32",0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
8127,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(C)=O,"US8846699, 141",0.013,uM,=,-1.8860566476931635,0,c1ccc(Nc2ncnc3ccccc23)cc1
8128,1640870,,,,,"Time-Resolved Fret (TR-FRET) Assay: 1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dilutions of 10 fold from 100 micoM are used. Kinase activity was determined with time-resolved Fret (TR-FRET) assay (LanthaScreenÂ® kinase activity assay, from InVitrogen).2) The assay is performed in a Black 384-well plate (from Corning). The kinase and the compound was incubated for 30 mM at room temperature. ATP (1 mM) and fluorescein-poly GT were added, and the reaction was incubated for 15 mM. Detection agent SA-XL665 (from Cisbio Assay) and TK Ab-Cryptate detection antibody (from InVitrogen) were added to stop the reaction.3) The 384-well plate was sealed and incubated for 1 hour. The fluorescence was then measured at 620 nM (Cryptate) and 665 nM (XL655) wavelength.4) Each concentration of compound was done in triplicate, and vehicle (without compound) and a positive control were used.",CN(C)CC/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OC[C@]12COC[C@H]1C2,"US9187459, 3",0.00054,uM,=,-3.2676062401770314,0,c1ccc(Nc2ncnc3cc(OC[C@]45COC[C@H]4C5)ccc23)cc1
8129,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,COc1cc2nccc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1OC,"N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6,7-dimethoxyquinolin-4-amine",1.7,uM,=,0.2304489213782739,1,c1ccc(COc2ccc(Nc3ccnc4ccccc34)cc2)cc1
8130,603361,10.1016/j.bmc.2009.08.044,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA,CCCCC(=Cc1coc2nc(=N)[nH]c(N)c12)c1ccccc1OC,"5-[(Z/E)-2-(20-Methoxyphenyl)hex-1-en-1-yl]furo[2,3-d]-pyrimidine-2,4-diamine",529.3,uM,=,2.723701893991268,1,N=c1nc2occ(C=Cc3ccccc3)c2c[nH]1
8131,1574498,10.1016/j.bmcl.2016.04.011,,,,Inhibition of EGFR in human MDA231 cells assessed as growth inhibition after 24 hrs by MTT assay,O=C(c1ccccc1)c1ccc(NC(=O)c2cc3ccccc3[nH]2)cc1,N-(4-benzoylphenyl)-1H-indole-2-carboxamide,49.0,uM,=,1.6901960800285136,1,O=C(c1ccccc1)c1ccc(NC(=O)c2cc3ccccc3[nH]2)cc1
8132,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3cccc(OC)c3OC)ncc2Br)c1,"US9238629, I-14::US9238629, I-6",0.65,uM,=,-0.1870866433571444,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
8133,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",CCc1nc(C(N)=O)c(Nc2ccc(N3CCN(C)CC3)cc2)nc1Oc1cccc(NC(=O)/C=C/CN(C)C)c1,"US9085540, 3",0.0014,uM,=,-2.853871964321762,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
8134,608087,10.1021/jm901558p,,,,Inhibition of human recombinant EGFR expressed in insect cells by time-resolved fluorimetry,O=C(O)[C@@H]1O[C@H]1C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"(2R,3R)-ethyl 3-(4-(3-bromoanilino)quinazolin-6-ylcarbamoyl)oxirane-2-carboxylate",0.0005,uM,=,-3.3010299956639813,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)[C@H]1CO1
8135,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,1.08,uM,=,0.0334237554869497,1,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
8136,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccccc3OC(F)F)cc12)c1ccccc1,"(R)-6-(2-(Difluoromethoxy)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.0008,uM,=,-3.096910013008056,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8137,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(NN=C2CCCCCCC2)=N1,2-(2-Cyclooctylidenehydrazinyl)thiazol-4(5H)-one,27.0,uM,=,1.4313637641589874,1,O=C1CSC(NN=C2CCCCCCC2)=N1
8138,982464,10.1016/j.bmc.2013.06.070,,,,Inhibition of recombinant EGFR kinase cytoplasmic domain (unknown origin) expressed in baculovirus expression vector-infected insect sf9 cells assessed as level of autophosphorylation after 10 mins by DELFIA/time-resolved fluorometry,O=C(/C=C/c1cccs1)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,(E)-N-(4-(3-Chlorophenylamino)quinazolin-6-yl)-3-(thiophen-2-yl)acrylamide,8.8,uM,=,0.9444826721501688,1,O=C(/C=C/c1cccs1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
8139,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)CO,"US8846699, 149",0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ncnc3ccccc23)cc1
8140,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cn1c(-c2csc(N/N=C\c3ccc(Br)cc3)n2)nc2ccccc21,2-(2-(4-Bromobenzylidene)hydrazinyl)-4-(1-methyl-1H-benzo[d]imidazol-2-yl)thiazole,0.4060899999999999,uM,=,-0.3913777049159992,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccccc1
8141,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2cccc(F)c2)=N1,2-(2-(3-Fluorobenzylidene)hydrazinyl)thiazol-4(5H)-one,13.53,uM,=,1.131297796597623,1,O=C1CSC(N/N=C/c2ccccc2)=N1
8142,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(CC)CC4)cc3)c(C(N)=O)nc2CC)c1,"US9085540, 43",0.0014,uM,=,-2.853871964321762,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
8143,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,COc1cc2ncc(C#N)c(N[C@@H]3C[C@H]3c3ccccc3)c2cc1OCCCc1cccnc1,"7-methoxy-4-((1R,2S)-2-phenylcyclopropylamino)-6-(3-(pyridin-3-yl)propoxy)quinoline-3-carbonitrile",0.068,uM,=,-1.1674910872937636,0,c1ccc([C@@H]2C[C@H]2Nc2ccnc3ccc(OCCCc4cccnc4)cc23)cc1
8144,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(OC)c2)c1,4-(1-(3-methoxybenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidine-5-carbaldehyde O-methyl oxime,0.267,uM,=,-0.5734887386354247,0,c1ccc(Cn2ncc3cc(Nc4ccncn4)ccc32)cc1
8145,2059437,10.1016/j.bmc.2021.116094,,,,Inhibition of wild-type EGFR (unknown origin) using biotinylated TK peptide as substrate measured after 30 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C4COC4)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-(oxetan-3-yl)-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.01132,uM,=,-1.9461535731477475,0,c1ccc(Nc2nccc(-c3cn(C4COC4)c4ccccc34)n2)cc1
8146,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,O=C(/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1)NCCCN1CCOCC1,"But-2-enedioic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide (3-morpholin-4-yl-propyl)-amide",0.0088,uM,=,-2.055517327849832,0,O=C(/C=C/C(=O)Nc1cc2c(Nc3ccccc3)ncnc2cn1)NCCCN1CCOCC1
8147,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,N#Cc1cccc(Oc2ccc(Nc3ncnc4cc(OCCCN5CCOCC5)c(NC(=O)c5cc([N+](=O)[O-])ccc5F)cc34)cc2Cl)c1,N-(4-((3-chloro-4-(3-cyanophenoxy)phenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.169,uM,=,-0.7721132953863264,0,O=C(Nc1cc2c(Nc3ccc(Oc4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
8148,1801470,10.1016/j.ejmech.2018.07.024,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP-MgCl2 addition and measured after 1 hr by DELFIA/time-resolved fluorometric analysis,COc1ccc(-c2nc3sc(-c4ccc(Cl)cc4)cn3n2)cc1,"5-(4-Chlorophenyl)-2-(4-methoxyphenyl)thiazolo[3,2-b][1,2,4]triazole",1.5,uM,=,0.1760912590556812,1,c1ccc(-c2nc3sc(-c4ccccc4)cn3n2)cc1
8149,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N*4*-(3-Bromo-phenyl)-pyrido[3,4-d]pyrimidine-4,6-diamine",0.016,uM,=,-1.7958800173440752,0,c1ccc(Nc2ncnc3cnccc23)cc1
8150,1886849,10.1016/j.bmcl.2019.04.029,,,,Inhibition of probe binding to wild type EGFR (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay,COc1cc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)CC1CCSS1,"N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-(1,2-dithiolan-3-yl)acetamide",0.025,uM,=,-1.6020599913279625,0,O=C(CC1CCSS1)Nc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1
8151,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(OC)cc3OC)ncc2Br)c1,"US9238629, I-13",0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2nccc(Oc3ccccc3)n2)cc1
8152,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCN1CCN(C)CC1,(4-Chloro-2-fluoro-phenyl)-{6-methoxy-7-[2-(4-methyl-piperazin-1-yl)-ethoxy]-quinazolin-4-yl}-amine,0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3cc(OCCN4CCNCC4)ccc23)cc1
8153,2200997,10.1016/j.ejmech.2020.112844,,,,Inhibition of EGFR (unknown origin),O=C(CCCCCCN1CC(c2ccc3ncnc(Nc4ccc(Br)cc4F)c3c2)N=N1)NO,"7-[4-[4-(4-bromo-2-fluoro-anilino)quinazolin-6-yl]-4,5-dihydrotriazol-1-yl]heptanehydroxamic acid",0.0103,uM,=,-1.987162775294828,0,c1ccc(Nc2ncnc3ccc(C4CNN=N4)cc23)cc1
8154,1274575,10.1016/j.bmcl.2013.09.086,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation expressed in baculovirus infected insect Sf9 cells preincubated for 10 mins followed by ATP-MgCl2 addition measured after 1 hr by fluorometric analysis,Cc1ccc(C(=O)N/N=C(/Cn2c([N+](=O)[O-])cnc2C)c2ccc(Br)cc2)cc1,(E)-N'-(1-(4-bromophenyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylidene)-4-methylbenzohydrazide,6.13,uM,=,0.787460474518415,1,O=C(N/N=C(/Cn1ccnc1)c1ccccc1)c1ccccc1
8155,1886849,10.1016/j.bmcl.2019.04.029,,,,Inhibition of probe binding to wild type EGFR (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay,Cc1ccc(Oc2ccc(Nc3c(C#N)cnc4ccc(NC(=O)CC5CCSS5)cc34)cc2C)cn1,"N-(3-Cyano-4-((3-methyl-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)quinolin-6-yl)-2-(1,2-dithiolan-3-yl)acetamide",8.63,uM,=,0.9360107957152096,1,O=C(CC1CCSS1)Nc1ccc2nccc(Nc3ccc(Oc4cccnc4)cc3)c2c1
8156,66717,10.1021/jm00112a003,,,,Inhibition of the epidermal growth factor receptor expressed in A431 cell line,C[C@@H](NC(=O)c1ccc(S(=O)(=O)Oc2ccc(/C=C/[N+](=O)[O-])cc2)cc1)C(=O)N[C@H](C)C(=O)OC(C)(C)C,tert-butyl 2-[1-(4-{4-[2-nitro-(E)-1-ethenyl]phenyloxysulfonyl}phenylcarboxamido)-(1R)-ethylcarboxamido]-(2R)-propanoate,40.0,uM,=,1.6020599913279625,1,O=S(=O)(Oc1ccccc1)c1ccccc1
8157,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,COc1cccc(-c2cn(-c3ccc(CCN(C)CCO)cc3)c3ncnc(N)c23)c1,"2-[(2-{4-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-phenyl}-ethyl)-methyl-amino]-ethanol",0.3,uM,=,-0.5228787452803376,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
8158,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1cccc(Br)c1,4-amino-6-(3-bromophenylamino)pyrimidine-5-carbaldehyde O-methyl oxime,0.024,uM,=,-1.619788758288394,0,c1ccc(Nc2ccncn2)cc1
8159,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2ccc([N+](=O)[O-])cc2)=N1,2-(2-(4-Nitrobenzylidene)hydrazinyl)thiazol-4(5H)-one,6.82,uM,=,0.8337843746564789,1,O=C1CSC(N/N=C/c2ccccc2)=N1
8160,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,"N*4*-(3-Chloro-phenyl)-quinazoline-4,6-diamine",0.189,uM,=,-0.7235381958267558,0,c1ccc(Nc2ncnc3ccccc23)cc1
8161,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1,"(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(2-[1,2,3]triazol-1-yl-ethoxy)-quinazolin-4-yl]-amine",0.4,uM,=,-0.3979400086720376,0,c1ccc(Nc2ncnc3cc(OCCn4ccnn4)ccc23)cc1
8162,608087,10.1021/jm901558p,,,,Inhibition of human recombinant EGFR expressed in insect cells by time-resolved fluorimetry,C=CC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide,0.0016899999999999,uM,=,-2.7721132953863266,0,c1ccc(Nc2ncnc3ccccc23)cc1
8163,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(-c3ccccc3F)nc3cnc(Nc4ccc(OCCOC)cc4)nc32)c1,N-(3-(6-(2-Fluorophenyl)-2((4-(2-methoxyethoxy)phenyl)-amino)-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.0011,uM,=,-2.958607314841775,0,O=c1c(-c2ccccc2)nc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
8164,610616,10.1021/jm901386e,,,,Inhibition of EGFR,COc1cc(-c2nc(=O)c3c([nH]2)sc2ccc(C)cc23)ccc1OCC(=O)O,"2-[4-(1,4-dihydro-6-methyl-4-oxo[1]benzothieno[2,3-d]pyrimidin-2-yl)-2-methoxyphenoxy]-acetic acid",2.4,uM,=,0.380211241711606,1,O=c1nc(-c2ccccc2)[nH]c2sc3ccccc3c12
8165,982464,10.1016/j.bmc.2013.06.070,,,,Inhibition of recombinant EGFR kinase cytoplasmic domain (unknown origin) expressed in baculovirus expression vector-infected insect sf9 cells assessed as level of autophosphorylation after 10 mins by DELFIA/time-resolved fluorometry,O=C(/C=C/c1cccnc1)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,(E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(pyridin-3-yl)acrylamide,4.7,uM,=,0.6720978579357175,1,O=C(/C=C/c1cccnc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
8166,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,NC(=S)N1N=C(c2ccc(Br)cc2)CC1c1cccc2ccccc12,"3-(4-Bromophenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1Hpyrazole-1-carbothioamide",5.68,uM,=,0.7543483357110189,1,c1ccc(C2=NNC(c3cccc4ccccc34)C2)cc1
8167,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(NC(=O)c3ccc(OC)c(OC)c3)n2)c(OC)cc1N(C)C,"N-(2-Dimethylamino-4-methoxy-5-((4-(3,4-dimethoxybenzamido)pyrimidin-2-yl)amino)-phenyl)acrylamide",0.1488,uM,=,-0.8273970687901401,0,O=C(Nc1ccnc(Nc2ccccc2)n1)c1ccccc1
8168,1675765,10.1016/j.bmc.2017.03.039,,,,Inhibition of human EGFR preincubated for 5 mins with substrate followed by ATP addition measured after 30 mins by HTRF method,COc1ccc(-c2nnc(-n3c(-c4ccccc4)nc4cc(Cl)ccc4c3=O)s2)cc1,"7-Chloro-3-(5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylquinazolin-4(3H)-one",0.32,uM,=,-0.494850021680094,0,O=c1c2ccccc2nc(-c2ccccc2)n1-c1nnc(-c2ccccc2)s1
8169,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,CC(=O)Nc1ccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)cc1,"N-[4-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]acetamide",0.179,uM,=,-0.7471469690201069,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
8170,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OC)c(OC)c3OC)ncc2C(F)(F)F)c1,"US9238629, I-11",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
8171,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCCN1CCCC1.Cl,(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(3-pyrrolidin-1-yl-propoxy)-quinazolin-4-yl]-amine hydrochloride,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3cc(OCCCN4CCCC4)ccc23)cc1
8172,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,CC(=O)N1CCOc2c1ccc1ncnc(Nc3cccc(C(F)(F)F)c3)c21,"1-(10-((3-(trifluoromethyl)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)ethan-1-one",0.534,uM,=,-0.2724587429714435,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCN4)cc1
8173,1574498,10.1016/j.bmcl.2016.04.011,,,,Inhibition of EGFR in human MDA231 cells assessed as growth inhibition after 24 hrs by MTT assay,CC(=O)c1cccc(NC(=O)c2cc3ccccc3[nH]2)c1,N-(3-acetylphenyl)-1H-indole-2-carboxamide,57.0,uM,=,1.7558748556724917,1,O=C(Nc1ccccc1)c1cc2ccccc2[nH]1
8174,1747423,10.1016/j.bmc.2017.10.030,,,,Inhibition of recombinant wild type EGFR (696 to C-terminal residues) (unknown origin) preincubated for 30 mins followed by poly (Glu-Tyr) biotinylated peptide substrate addition measured after 30 mins in presence of ATP by ELISA,COc1ccc(-c2c3c4cc(OCCN(C)C)c(OCCN(C)C)cc4oc(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F,"2,3-bis[2-(dimethylamino)ethoxy]-11-hydroxy-14-(3-hydroxy-4-methoxyphenyl)-12-methoxy-6H-[1]benzopyrano[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one ditrifluoroacetic acid salt",0.1906,uM,=,-0.7198771036976924,0,O=c1oc2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
8175,2281134,10.1016/j.ejmech.2021.113205,,,,Inhibition of EGFR (unknown origin) by Z'-LYTE Kinase assay,C=CC(=O)Nc1ccc(CN(C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)c2cc(Nc3ccc(N4CCN(C)CC4)cc3)ncn2)cc1,"N-(4-((3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)ureido)methyl)phenyl)acrylamide",0.043,uM,=,-1.3665315444204136,0,O=C(Nc1ccccc1)N(Cc1ccccc1)c1cc(Nc2ccc(N3CCNCC3)cc2)ncn1
8176,1886849,10.1016/j.bmcl.2019.04.029,,,,Inhibition of probe binding to wild type EGFR (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay,N#Cc1cnc2cc(OC[C@H](O)CO)c(NC(=O)C3CSSC3)cc2c1Nc1ccc(OCc2cccc(F)c2)c(Cl)c1,"(R)-N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-3-cyano-7-(2,3-dihydroxypropoxy)quinolin-6-yl)-1,2-dithiolane-4-carboxamide",0.256,uM,=,-0.5917600346881504,0,O=C(Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1)C1CSSC1
8177,2260230,10.1016/j.ejmech.2020.113016,,,,Inhibition of EGFR (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins in presence of ATP by caliper mobility shift assay,COc1cc2ncnc(Oc3cccc(NC(=S)Nc4ccc(Cl)c(C(F)(F)F)c4)c3)c2cc1OC,"1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)thiourea",0.02,uM,=,-1.6989700043360187,0,S=C(Nc1ccccc1)Nc1cccc(Oc2ncnc3ccccc23)c1
8178,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(NN=C2CCCCCC2)=N1,2-(2-Cycloheptylidenehydrazinyl)thiazol-4(5H)-one,36.0,uM,=,1.5563025007672873,1,O=C1CSC(NN=C2CCCCCC2)=N1
8179,1329559,10.1039/C0MD00115E,,,,Inhibition of EGFR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1B(O)O,4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ylboronic acid,0.51,uM,=,-0.2924298239020636,0,c1ccc(Nc2ncnc3ccccc23)cc1
8180,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cn1c(-c2csc(NN=C3CCCCC3)n2)nc2ccccc21,2-(2-Cyclohexylidenehydrazinyl)-4-(1-methyl-1H-benzo[d]imidazol-2-yl)thiazole,0.27888,uM,=,-0.554582630234082,0,c1ccc2[nH]c(-c3csc(NN=C4CCCCC4)n3)nc2c1
8181,1337212,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ccc2nc(Oc3ccc(F)cc3)c(/C=N/NC(=O)Cn3c([N+](=O)[O-])cnc3C)cc2c1,(E)-N'-((2-(4-fluorophenoxy)-6-methylquinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,0.42,uM,=,-0.3767507096020995,0,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
8182,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2cc(Br)ccc2O)=N1,2-(2-(5-Bromo-2-hydroxybenzylidene)hydrazinyl)thiazol-4(5H)-one,0.09,uM,=,-1.0457574905606752,0,O=C1CSC(N/N=C/c2ccccc2)=N1
8183,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)NCC,"US8846699, 23",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
8184,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccn(C)n3)n2)c(OC)cc1N(C)CCN(C)CC(=O)OC,methyl 2-((2-((2-acrylamido-5-methoxy-4-((4-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)(methyl)amino)acetate,0.9524,uM,=,-0.0211806132671577,0,c1ccc(Nc2nccc(Nc3cc[nH]n3)n2)cc1
8185,1781455,10.1016/j.ejmech.2017.11.049,,,,Inhibition of C-terminal His-tagged and N-terminal GST tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells using KHKKLAEGSAYEEV substrate peptide and gamma-[32P]ATP,Fc1cc(F)cc(NC(=S)Nc2ccc3ncnc(Nc4cccc(Br)c4)c3c2)c1,"1-(4-(3-bromophenylamino)quinazolin-6-yl)-3-(3,5-difluorophenyl)thiourea",0.06,uM,=,-1.2218487496163564,0,S=C(Nc1ccccc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
8186,526697,10.1021/np050229y,,,,Inhibition of EGFR,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",0.7405958488682406,uM,=,-0.1304187265542905,0,O=c1c(-c2ccccc2)coc2ccccc12
8187,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c(C(N)=O)nc2C(C)C)c1,"US9085540, 22",0.0015,uM,=,-2.8239087409443187,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
8188,463277,10.1016/j.bmcl.2007.11.052,,,,Inhibition of EGFR,Cc1ccc(Oc2ccc(Nc3ncnc4cccc(O[C@H](C)C(=O)N(C)CCO)c34)cc2C)cn1,(R)-N-(2-hydroxyethyl)-N-methyl-2-(4-(3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino)quinazolin-5-yloxy)propanamide,2.0,uM,=,0.3010299956639812,1,c1cncc(Oc2ccc(Nc3ncnc4ccccc34)cc2)c1
8189,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,CCN(CC)CC(O)CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"1-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-3-diethylamino-propan-2-ol",0.028,uM,=,-1.5528419686577808,0,c1ccc(Nc2ncnc3cnccc23)cc1
8190,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,0.2,uM,=,-0.6989700043360187,0,c1ccc(/N=c2\nc[nH]c3cc(OCC4CCNCC4)ccc23)cc1
8191,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,COc1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1,"3-(4-Methoxyphenyl)-5-(naphthalen-2-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",0.12,uM,=,-0.9208187539523752,0,c1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1
8192,1641866,,,,,"Enzyme Assay: A431 Cell Line: 1. 5Ã103 cells per well in 100 Î¼l of medium were seeded in 96-well plate, here the medium contained 5% FBS2. 24 hours later, 100 Î¼l fresh medium was added with various concentrations of compounds into each well, while the medium here was free of FBS.3. After the cells were treated with compounds for 72 hours, 20 Î¼l MTT (5 mg/ml) was added into each well, and then the assay plate was incubated at 37Â° C. for 4 more hours.4. The assay plate was centrifuged at 800 g for 10 min. The medium was aspirated, 150 Î¼l DMSO was added into each well. The plate was gently shaken for 10 min.5. The absorbance at 570 nm was measured on the plate reader.6. IR %=(WCâWT)/WCÃ100%.",C#Cc1cccc(Nc2ncnc3cc(O[C@H]4CCOC4)c(NC(=O)/C=C/CN(C)C)cc23)c1,"(S,E)-4-(Dimethylamino)-N-(4-(3-ethynylphenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)but-2-enamide",3.099,uM,=,0.4912215762392831,1,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
8193,63781,10.1016/j.bmcl.2004.01.034,,,,Inhibition of peptide substrate phosphorylation by epidermal growth factor receptor,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.0145,uM,=,-1.8386319977650247,0,c1ccc(Nc2ccnc3ccccc23)cc1
8194,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,CC(NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1)c1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-(1-phenyl-ethyl)-acrylamide",0.4,uM,=,-0.3979400086720376,0,O=C(/C=C/c1ccccc1)NCc1ccccc1
8195,1886849,10.1016/j.bmcl.2019.04.029,,,,Inhibition of probe binding to wild type EGFR (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay,COc1cc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2cc1NC(=O)C1CSSC1,"N-(7-Methoxy-4-((3-methyl-4-((6-methylpyridin-3-yl)oxy)phenyl)amino)quinazolin-6-yl)-1,2-dithiolane-4-carboxamide",0.658,uM,=,-0.1817741063860445,0,O=C(Nc1ccc2ncnc(Nc3ccc(Oc4cccnc4)cc3)c2c1)C1CSSC1
8196,67063,10.1016/s0960-894x(03)00626-7,,,,Inhibition of Epidermal growth factor receptor,O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1,N-(4-Chloro-phenyl)-2-[(pyridin-4-ylmethyl)-amino]-benzamide,7.3,uM,=,0.8633228601204559,1,O=C(Nc1ccccc1)c1ccccc1NCc1ccncc1
8197,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,COc1cccc(/C=N/NC2=NC(=O)CS2)c1,2-(2-(3-Methoxybenzylidene)hydrazinyl)thiazol-4(5H)-one,31.25,uM,=,1.494850021680094,1,O=C1CSC(N/N=C/c2ccccc2)=N1
8198,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,CS(=O)(=O)c1cccc(C(=O)Nc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2OCCCN2CCOCC2)c1F,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-3-(methylsulfonyl)benzamide,0.024,uM,=,-1.619788758288394,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
8199,2059437,10.1016/j.bmc.2021.116094,,,,Inhibition of wild-type EGFR (unknown origin) using biotinylated TK peptide as substrate measured after 30 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(CCO)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-(4-(1-(2-hydroxyethyl)-1H-indol-3-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide,0.00154,uM,=,-2.812479279163537,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
8200,1930229,10.1016/j.ejmech.2019.02.050,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end) expressed in baculovirus infected Sf9 cells using ATP as substrate after 40 mins by Kinase-Glo MAX luminescence assay,O=C(CCSC(=S)N1CCN(c2ccccc2)CC1)Nc1cccc(NC(=O)c2ccccn2)c1,3-Oxo-3-((3-(picolinamido)phenyl)amino)propyl-4-phenylpiperazine-1-carbodithioate,0.07,uM,=,-1.154901959985743,0,O=C(CCSC(=S)N1CCN(c2ccccc2)CC1)Nc1cccc(NC(=O)c2ccccn2)c1
8201,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,COc1cc2c(cc1O)NC(=O)C2=C(C#N)C#N,"2-(6-Hydroxy-5-methoxy-2-oxo-1,2-dihydro-indol-3-ylidene)-malononitrile",60.0,uM,=,1.7781512503836436,1,C=C1C(=O)Nc2ccccc21
8202,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc(Cl)cc2)CC1c1ccc(C(=O)OC(C)Cn2c([N+](=O)[O-])cnc2C)cc1,"1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-yl 4-(1-acetyl-3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",9.26,uM,=,0.9666109866819343,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
8203,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C(C)CN(C)C,"US8846699, 74",0.251,uM,=,-0.6003262785189619,0,c1ccc(Nc2ncnc3ccccc23)cc1
8204,1538409,10.1021/acs.jmedchem.5b01412,,,,Inhibition of EGFR phosphorylation in human NCI-H1975 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay,CO[C@H]1CCN(c2nccc(Nc3cc4c(cn3)nc([C@@H](C)O)n4[C@H](C)C(F)(F)F)n2)C[C@H]1F,"(R)-1-(6-(2-((3R,4S)-3-fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-ylamino)-1-((R)-1,1,1-trifluoropropan-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl)ethanol",21.0,uM,=,1.3222192947339193,1,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1
8205,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)N1CCC(c2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)c(C)c3)c(C(N)=O)nc2CC)CC1,"US9085540, 24",0.0021,uM,=,-2.6777807052660805,0,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(C2CCNCC2)n1
8206,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC(C)(C)NC(=O)CN(C)C,"US8846699, 154",0.222,uM,=,-0.6536470255493614,0,c1ccc(Nc2ncnc3ccccc23)cc1
8207,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)/C=C/C,"US8846699, 50",0.019,uM,=,-1.7212463990471711,0,c1ccc(Nc2ncnc3ccccc23)cc1
8208,1732820,10.1016/j.ejmech.2018.01.090,,,,Inhibition of recombinant human N-terminal His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells by ELISA,Fc1cccc(COc2ccc(Nc3ncnc4cc(OCCCN5CCOCC5)c(OCCCN5CCOCC5)cc34)cc2Cl)c1,"4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6,7-bis(3-morpholinopropoxy)quinazoline",0.007,uM,=,-2.154901959985743,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCCCN5CCOCC5)c(OCCCN5CCOCC5)cc34)cc2)cc1
8209,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3c(F)cc(Br)cc3F)ncnc2cc1OCCNC(=O)CN(C)C,"US8846699, 123",0.175,uM,=,-0.7569619513137056,0,c1ccc(Nc2ncnc3ccccc23)cc1
8210,2076845,10.1039/d0md00436g,,,,Inhibition of recombinant human DYKDDDD-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 5 mins followed by ATP addition and measured after 10 mins by [gamma-32P]-ATP based scintillation counting method,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.0026,uM,=,-2.5850266520291822,0,c1ccc(Nc2ncnc3ccccc23)cc1
8211,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,CCOc1ccccc1-c1cc2c(N[C@H](CCO)c3ccccc3)ncnc2[nH]1,"(R)-3-((6-(2-Ethoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-3-phenylpropan-1-ol",0.0001,uM,=,-4.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8212,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#CC(C#N)=C1C(=O)Nc2cc(O)c(O)cc21,"2-(5,6-Dihydroxy-2-oxo-1,2-dihydro-indol-3-ylidene)-malononitrile",2.5,uM,=,0.3979400086720376,1,C=C1C(=O)Nc2ccccc21
8213,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,CN(C)CCCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)c1cc([N+](=O)[O-])ccc1F,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(4-(dimethylamino)butoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.0063,uM,=,-2.2006594505464183,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccccc1
8214,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCOC(=O)Nc1ccc(Nc2ncnc3cc(OCCN4CCOCC4)c(OC)cc23)cc1C.Cl,{4-[6-Methoxy-7-(2-morpholinoethoxy)quinazolin-4-ylamino]-2-methylphenyl}carbamic acid ethyl ester dihydrochloride,8.0,uM,=,0.9030899869919436,1,c1ccc(Nc2ncnc3cc(OCCN4CCOCC4)ccc23)cc1
8215,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccn(C)n3)n2)c(OC)cc1N(C)CCN(C)CC(=C)C,N-(4-methoxy-2-(methyl(2-(methyl(2-methylallyl)amino)ethyl)amino)-5-((4-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)acrylamide,3.184,uM,=,0.5029730590656315,1,c1ccc(Nc2nccc(Nc3cc[nH]n3)n2)cc1
8216,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCNC,"US8846699, 17",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3ccccc23)cc1
8217,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(CCc2ccccc2)nn1,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-((1-phenethyl-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.041,uM,=,-1.3872161432802643,0,c1ccc(CCn2cc(COc3ccc4c(Nc5ccccc5)ncnc4c3)nn2)cc1
8218,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3c(F)cc(Br)cc3F)ncnc2cc1OCCNC(C)=O,"US8846699, 120",0.022,uM,=,-1.6575773191777938,0,c1ccc(Nc2ncnc3ccccc23)cc1
8219,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(-c2ccccc2)nn1,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.074,uM,=,-1.1307682802690238,0,c1ccc(Nc2ncnc3cc(OCc4cn(-c5ccccc5)nn4)ccc23)cc1
8220,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CS(C)(=O)=O,"US8846699, 47",0.024,uM,=,-1.619788758288394,0,c1ccc(Nc2ncnc3ccccc23)cc1
8221,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CN1CCN(C)CC1,"US8846699, 102",0.012,uM,=,-1.9208187539523751,0,O=C(CN1CCNCC1)NCCOc1ccc2c(Nc3ccccc3)ncnc2c1
8222,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(Cc2ccc(Cl)cc2)nn1,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.062,uM,=,-1.207608310501746,0,c1ccc(Cn2cc(COc3ccc4c(Nc5ccccc5)ncnc4c3)nn2)cc1
8223,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,Cc1cccc(C)c1NC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-(2,6-dimethyl-phenyl)-acrylamide",5.1,uM,=,0.7075701760979364,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
8224,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)N1CCC(c2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)CC1,"US9085540, 69",0.0013,uM,=,-2.886056647693163,0,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(C2CCNCC2)n1
8225,603361,10.1016/j.bmc.2009.08.044,,,,Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA,CCCC(=Cc1coc2nc(=N)[nH]c(N)c12)c1ccccc1OC,"5-[(Z/E)-2-(20-Methoxyphenyl)pent-1-en-1-yl]furo[2,3-d]-pyrimidine-2,4-diamine",160.3,uM,=,2.204933522354145,1,N=c1nc2occ(C=Cc3ccccc3)c2c[nH]1
8226,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccncc3)cc12)c1ccccc1,"(R)-N-(1-phenylethyl)-6-(pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.0006,uM,=,-3.2218487496163566,0,c1ccc(CNc2ncnc3[nH]c(-c4ccncc4)cc23)cc1
8227,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",CCC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)c(C(N)=O)nc2CC)C1,"US9085540, 73",0.0056,uM,=,-2.2518119729938,0,c1cc(N2CCNCC2)ccc1Nc1cncc(O[C@@H]2CCNC2)n1
8228,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,Clc1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1,"3-(4-Chlorophenyl)-5-(naphthalen-1-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",0.68,uM,=,-0.1674910872937636,0,c1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1
8229,509684,10.1016/j.bmcl.2008.07.020,,,,Inhibition of human EGFR expressed in SF9 cells,CN1CCN(/N=C/c2c(N)ncnc2Nc2ccc3c(cnn3Cc3cccc(F)c3)c2)CC1,"N4-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((4-methylpiperazin-1-ylimino)methyl)pyrimidine-4,6-diamine",0.016,uM,=,-1.7958800173440752,0,C(=N/N1CCNCC1)\c1cncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1
8230,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,CN(C(=O)N(CCCl)N=O)c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,1-(2-chloroethyl)-1-nitroso-3-methyl-3-{[4-(3-chloro-phenyl)amino]quinazolin-6-yl}urea,0.204,uM,=,-0.6903698325741012,0,c1ccc(Nc2ncnc3ccccc23)cc1
8231,1716304,10.1016/j.ejmech.2017.07.005,,,,Inhibition of recombinant human His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells using Tyr66-biotinylated PTP1B peptide as substrate preincubated for 5 mins followed by substrate addition measured after 1 hr by ELISA,COc1cc2c(Nc3ccc(C#N)cc3)ncnc2cc1OCCCN1CCC(c2ccccc2)CC1,4-((6-Methoxy-7-(3-(4-phenylpiperidin-1-yl)propoxy)quinazolin-4-yl)amino)benzonitrile,0.00362,uM,=,-2.441291429466834,0,c1ccc(Nc2ncnc3cc(OCCCN4CCC(c5ccccc5)CC4)ccc23)cc1
8232,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,Nc1ncnc2c1c(-c1ccccc1)cn2-c1cccc(CNCCO)c1,"2-[3-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-benzylamino]-ethanol",3.4,uM,=,0.5314789170422551,1,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
8233,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)C(=O)N1CCN(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)CC1,"(E)-2-{4-[(E)-2-Cyano-3-(3,4-dihydroxy-phenyl)-acryloyl]-piperazine-1-carbonyl}-3-(3,4-dihydroxy-phenyl)-acrylonitrile",4.0,uM,=,0.6020599913279624,1,O=C(C=Cc1ccccc1)N1CCN(C(=O)/C=C/c2ccccc2)CC1
8234,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC(=O)NCCN(CC)CC,"US8846699, 65",0.652,uM,=,-0.1857524042680797,0,c1ccc(Nc2ncnc3ccccc23)cc1
8235,2185718,10.1016/j.ejmech.2021.113495,,,,"Inhibition of EGFR (unknown origin) using Poly(Gly,Tyr) as substrate incubated for 45 mins in the presence of ATP by ADP-Glo reagent based luminescence assay",Brc1cccc(Nc2ncnc3[nH]ccc23)c1,"N-(3-bromophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",3.76,uM,=,0.5751878449276611,1,c1ccc(Nc2ncnc3[nH]ccc23)cc1
8236,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,COCC/N=N/Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(3-bromophenyl)-6-[(1E)-3-(2-methoxyethyl)triaz-1-enyl]quinazolin-4-amine,0.071,uM,=,-1.1487416512809248,0,c1ccc(Nc2ncnc3ccccc23)cc1
8237,1983376,10.1021/acs.jmedchem.9b00167,,,,Inhibition of HER1 (unknown origin),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,0.03,uM,=,-1.5228787452803376,0,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
8238,2080996,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR (unknown origin) by mobility shift assay,CN(C)C/C=C/C(=O)Nc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1O[C@@H]1CCOC1,Afatinib,0.00032,uM,=,-3.494850021680094,0,c1ccc(Nc2ncnc3ccc(O[C@@H]4CCOC4)cc23)cc1
8239,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCCCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1C.Cl,"{4-[6,7-Dimethoxyquinazolin-4-ylamino]-2-methylphenyl}carbamic acid butyl ester hydrochloride",7.6,uM,=,0.8808135922807914,1,c1ccc(Nc2ncnc3ccccc23)cc1
8240,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc([N+](=O)[O-])cc2)CC1c1ccc(C(=O)OCCn2c([N+](=O)[O-])cnc2C)cc1,"2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-(1-acetyl-3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",0.6,uM,=,-0.2218487496163563,0,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
8241,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3cc(-c4ccc(F)cc4)ccc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((6-(4-fluorophenyl)-1H-indazol-3-yl)amino)-4-methoxyphenyl)acrylamide,0.026,uM,=,-1.585026652029182,0,c1ccc(Nc2n[nH]c3cc(-c4ccccc4)ccc23)cc1
8242,1761975,10.1016/j.ejmech.2018.02.051,,,,"Inhibition of wild type EGFR (unknown origin) using Poly (Glu, Tyr) as substrate after 40 mins by kinase-Glo luminescence assay",CN1CCN(c2ccc(Nc3cc4c(N5CCOCC5)nc(Nc5ccccc5)nc4cn3)nc2)CC1,"N6-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)-4-morpholino-N2-phenylpyrido[3,4-d]pyrimidine-2,6-diamine",0.0054,uM,=,-2.2676062401770314,0,c1ccc(Nc2nc(N3CCOCC3)c3cc(Nc4ccc(N5CCNCC5)cn4)ncc3n2)cc1
8243,509684,10.1016/j.bmcl.2008.07.020,,,,Inhibition of human EGFR expressed in SF9 cells,Nc1ncnc(Nc2ccc3c(cnn3Cc3cccc(F)c3)c2)c1/C=N/N1CCOCC1,"N-[1-(3-Fluoro-benzyl)-1H-indazol-5-yl]-5-[morpholin-4-yliminomethyl]-pyrimidine-4,6-diamine",0.016,uM,=,-1.7958800173440752,0,C(=N/N1CCOCC1)\c1cncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1
8244,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3cc(-c4cncc5ccccc45)ccc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((6-(isoquinolin-4-yl)-1H-indazol-3-yl)amino)-4-methoxyphenyl)acrylamide,0.0028,uM,=,-2.552841968657781,0,c1ccc(Nc2n[nH]c3cc(-c4cncc5ccccc45)ccc23)cc1
8245,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCN1CCN(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)CC1,"(E)-2-Cyano-N-(2-{4-[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloyl]-piperazin-1-yl}-ethyl)-3-(3,4-dihydroxy-phenyl)-acrylamide",2.2,uM,=,0.3424226808222063,1,O=C(C=Cc1ccccc1)NCCN1CCN(C(=O)/C=C/c2ccccc2)CC1
8246,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccccc1F,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl3-(2-fluorophenyl)acrylate,26.74,uM,=,1.4271614029259656,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
8247,497146,10.1016/j.bmcl.2008.09.040,,,,Inhibition of EGFR,Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1,"2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo-[1,5-a]pyridine",6.3,uM,=,0.7993405494535817,1,c1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1
8248,2059437,10.1016/j.bmc.2021.116094,,,,Inhibition of wild-type EGFR (unknown origin) using biotinylated TK peptide as substrate measured after 30 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C(C)=O)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(5-(4-(1-acetyl-1H-indol-3-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,0.01549,uM,=,-1.809948582240794,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
8249,2185767,10.1016/j.ejmech.2021.113493,,,,Inhibition of recombinant EGFR (unknown origin) expressed in baculovirus incubated for 10 mins by europium-labeled antiphosphotyrosine/enhancement solution based assay,Cc1ccc(/C=N/NC(=O)CNc2nc(-c3ccccc3)c(-c3ccccc3)s2)cc1,"2-[(4,5-diphenylthiazol-2-yl)amino]-N-[(E)-p-tolylmethyleneamino]acetamide",0.2,uM,=,-0.6989700043360187,0,O=C(CNc1nc(-c2ccccc2)c(-c2ccccc2)s1)N/N=C/c1ccccc1
8250,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cc1ccc(/C=N\Nc2nc(-c3nc4ccccc4n3C)cs2)o1,4-(1-Methyl-1H-benzo[d]imidazol-2-yl)-2-(2-((5-methylfuran-2-yl)methylene)hydrazinyl)thiazole,0.2128199999999999,uM,=,-0.6719875611444137,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccco1
8251,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,COc1cc(Nc2cc(Nc3ccc(Cl)cc3)ncn2)cc(OC)c1OC,"N4-(4-Chlorophenyl)-N6-(3,4,5-trimethoxyphenyl)pyrimidine-4,6-diamine",0.901,uM,=,-0.045275209020937,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
8252,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,COc1cc(/C=N\Nc2nc(-c3nc4ccccc4n3C)cs2)cc(OC)c1OC,"4-(1-Methyl-1H-benzo[d]imidazol-2-yl)-2-(2-(3,4,5-trimethoxybenzylidene)hydrazinyl)thiazole",0.62264,uM,=,-0.2057629825592853,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccccc1
8253,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,But-2-enoic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide,0.0087,uM,=,-2.0604807473813813,0,c1ccc(Nc2ncnc3ccccc23)cc1
8254,63781,10.1016/j.bmcl.2004.01.034,,,,Inhibition of peptide substrate phosphorylation by epidermal growth factor receptor,CC#CC(=O)Nc1cnc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,"But-2-ynoic acid [5-(3-bromo-phenylamino)-6-cyano-[1,8]naphthyridin-3-yl]-amide",6.2662,uM,=,0.7970042522613289,1,c1ccc(Nc2ccnc3ncccc23)cc1
8255,1816244,10.1016/j.ejmech.2019.111809,,,,Inhibition of wildtype EGFR (unknown origin) using biotin as substrate in presence of ATP by mobility shift assay based ELISA,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C(C)C)cc1Nc1nc2c(c(-c3cn(C)c4ccc(F)cc34)n1)CS(=O)(=O)CC2,"N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(5-fluoro-1-methyl-1H-indol-3-yl)-6,6-dioxido-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-yl)amino)-4-methoxyphenyl)-3-methylbut-2-enamide",0.201,uM,=,-0.6968039425795112,0,O=S1(=O)CCc2nc(Nc3ccccc3)nc(-c3c[nH]c4ccccc34)c2C1
8256,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)NC(C)CC,"US8846699, 38",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
8257,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,NC(=S)N1N=C(c2ccc(F)cc2)CC1c1ccc2ccccc2c1,"3-(4-Fluorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1Hpyrazole-1-carbothioamide",3.28,uM,=,0.5158738437116791,1,c1ccc(C2=NNC(c3ccc4ccccc4c3)C2)cc1
8258,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)c1cccs1,"US8846699, 92",0.047,uM,=,-1.3279021420642825,0,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)c1cccs1
8259,982464,10.1016/j.bmc.2013.06.070,,,,Inhibition of recombinant EGFR kinase cytoplasmic domain (unknown origin) expressed in baculovirus expression vector-infected insect sf9 cells assessed as level of autophosphorylation after 10 mins by DELFIA/time-resolved fluorometry,Clc1cccc(Nc2ncnc3ccc(NCc4cccc(Br)n4)cc23)c1,"N6-((6-Bromopyridin-2-yl)methyl)-N4-(3-chlorophenyl)quinazoline-4,6-diamine",4.1,uM,=,0.6127838567197355,1,c1ccc(Nc2ncnc3ccc(NCc4ccccn4)cc23)cc1
8260,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)[C@@H](C)C4)cc3)c(C(N)=O)nc2CC)c1,"US9085540, 63",0.0012,uM,=,-2.920818753952376,0,c1ccc(Oc2cncc(Nc3ccc(N4CCNCC4)cc3)n2)cc1
8261,1837344,10.1016/j.ejmech.2019.111664,,,,Inhibition of EGFR (unknown origin),N=C1NC(=O)/C(=C2/CCNC(=O)c3[nH]c(Br)c(Br)c32)N1,Spongiacidin A,21.201644416917343,uM,=,1.3263695464710614,1,N=C1NC(=O)/C(=C2/CCNC(=O)c3[nH]ccc32)N1
8262,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cc1ccc(/C=N\Nc2nc(-c3nc4ccccc4n3C)cs2)cc1,4-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-(2-(4-methylbenzylidene)hydrazinyl)thiazole,0.15036,uM,=,-0.8228676829582251,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccccc1
8263,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,NC1CCN(Cc2ccn3ncnc(Nc4cccc(Br)c4)c23)CC1,"5-((4-aminopiperidin-1-yl)methyl)-N-(3-bromophenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.006,uM,=,-2.2218487496163566,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1
8264,2161994,10.1016/j.ejmech.2021.113984,,,,Inhibition of wild type EGFR (unknown origin) using flurogenic substrate in presence of ATP by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(Nc3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)CC(=O)OC,methyl 2-((2-((2-acrylamido-5-methoxy-4-((4-((1-methyl-1H-indol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)(methyl)amino)acetate,0.4531,uM,=,-0.3438059378208142,0,c1ccc(Nc2nccc(Nc3c[nH]c4ccccc34)n2)cc1
8265,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,CN(CCCl)C(=O)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,3-(2-chloroethyl)-1-methyl-1-{[4-(3-chlorophenyl)amino]quinazolin-6-yl}urea,0.081,uM,=,-1.0915149811213505,0,c1ccc(Nc2ncnc3ccccc23)cc1
8266,66568,10.1021/jm00033a019,,,,Inhibitory activity against recombinant tyrosine kinase EGF-R (EGF-R ICD),Cc1ccc(Nc2cc3c(cc2Nc2ccc(C)cc2)C(=O)NC3=O)cc1,"5,6-Bis-p-tolylamino-isoindole-1,3-dione",2.5,uM,=,0.3979400086720376,1,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21
8267,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc(C(F)(F)F)cc2)CC1c1ccc(C(=O)OC(C)Cn2c([N+](=O)[O-])cnc2C)cc1,"1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-yl 4-(1-acetyl-3-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",6.67,uM,=,0.8241258339165489,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
8268,1574498,10.1016/j.bmcl.2016.04.011,,,,Inhibition of EGFR in human MDA231 cells assessed as growth inhibition after 24 hrs by MTT assay,CC(O)c1ccc(NC(=O)c2cc3ccccc3[nH]2)cc1,N-(4-(1-hydroxyethyl)phenyl)-1H-indole-2-carboxamide,35.0,uM,=,1.5440680443502757,1,O=C(Nc1ccccc1)c1cc2ccccc2[nH]1
8269,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OC[C@@H](C)NC(=O)CN(C)C,"US8846699, 159::US8846699, 164",0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3ccccc23)cc1
8270,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(CCCO)nn1,"N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.012,uM,=,-1.9208187539523751,0,c1ccc(Nc2ncnc3cc(OCc4c[nH]nn4)ccc23)cc1
8271,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCCNC(=O)/C(C#N)=C/c1ccc(O)c(O)c1,"2-Cyano-N-{3-[2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-propyl}-3-(3,4-dihydroxy-phenyl)-acrylamide",0.4,uM,=,-0.3979400086720376,0,O=C(C=Cc1ccccc1)NCCCNC(=O)/C=C/c1ccccc1
8272,632680,10.1016/j.bmc.2010.03.052,,,,Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA,Nc1nc(Nc2ccc(Cl)cc2F)c2cc(Cc3ccc(Cl)cc3Cl)[nH]c2n1,"N4-(2-Fluoro-4-chlorophenyl)-6-(2,4-dichlorobenzyl)-7Hpyrrolo[2,3-d]pyrimidine-2,4-diamine",2.5,uM,=,0.3979400086720376,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
8273,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCN(C)C(C)=O,"US8846699, 42",0.059,uM,=,-1.2291479883578558,0,c1ccc(Nc2ncnc3ccccc23)cc1
8274,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCCNC(=O)C(F)(F)F,"US8846699, 14",0.059,uM,=,-1.2291479883578558,0,c1ccc(Nc2ncnc3ccccc23)cc1
8275,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CN1CCC1,"US8846699, 110",0.987,uM,=,-0.0056828473303632,0,O=C(CN1CCC1)NCCOc1ccc2c(Nc3ccccc3)ncnc2c1
8276,1274575,10.1016/j.bmcl.2013.09.086,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation expressed in baculovirus infected insect Sf9 cells preincubated for 10 mins followed by ATP-MgCl2 addition measured after 1 hr by fluorometric analysis,Cc1ncc([N+](=O)[O-])n1C/C(=N/NC(=O)c1ccc(Cl)cc1)c1ccc(Br)cc1,(E)-N'-(1-(4-bromophenyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylidene)-4-chlorobenzohydrazide,12.45,uM,=,1.095169351431755,1,O=C(N/N=C(/Cn1ccnc1)c1ccccc1)c1ccccc1
8277,513268,10.1021/jm800832q,,,,Inhibition of GST-tagged HER1,Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12,4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-bendo[d]imidazol-2-yl)pyridine-1-(1H)-one,21.0,uM,=,1.3222192947339193,1,O=c1[nH]ccc(NCCn2cccn2)c1-c1nc2ccc(C3CCNCC3)cc2[nH]1
8278,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1,"US9085540, 54",0.0045,uM,=,-2.3467874862246565,0,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(O[C@@H]2CCNC2)n1
8279,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,COc1ccc(/C=N/NC2=NC(=O)CS2)cc1,2-(2-(4-Methoxybenzylidene)hydrazinyl)thiazol-4(5H)-one,5.78,uM,=,0.761927838420529,1,O=C1CSC(N/N=C/c2ccccc2)=N1
8280,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cn1c(-c2csc(N/N=C\c3ccncc3)n2)nc2ccccc21,4-(1-Methyl-1H-benzo[d]imidazol-2-yl)-2-(2-(pyridin-4-ylmethylene)hydrazinyl)thiazole,0.56941,uM,=,-0.2445749100259388,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccncc1
8281,1274575,10.1016/j.bmcl.2013.09.086,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation expressed in baculovirus infected insect Sf9 cells preincubated for 10 mins followed by ATP-MgCl2 addition measured after 1 hr by fluorometric analysis,Cc1ncc([N+](=O)[O-])n1C/C(=N/NC(=O)c1ccccc1)c1ccc(Br)cc1,(E)-N'-(1-(4-bromophenyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylidene)benzohydrazide,10.02,uM,=,1.000867721531227,1,O=C(N/N=C(/Cn1ccnc1)c1ccccc1)c1ccccc1
8282,1337212,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ncc([N+](=O)[O-])n1CC(=O)N/N=C/c1cc2ccccc2nc1Oc1ccc(F)cc1,(E)-N'-((2-(4-fluorophenoxy)quinolin-3-yl)methylene)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetohydrazide,21.02,uM,=,1.3226327116922234,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
8283,1846242,10.1021/acs.jmedchem.8b01469,,,,Inhibition of human EGFR C-terminal domain,OCCNc1nc(Nc2cccc(F)c2)c2cn[nH]c2n1,"2-(4-(3-fluorophenylamino)-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino)ethanol",66.1,uM,=,1.82020145948564,1,c1ccc(Nc2ncnc3[nH]ncc23)cc1
8284,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,NC1CCN(Cc2ccn3ncnc(Nc4cccc(F)c4)c23)CC1,"5-((4-aminopiperidin-1-yl)methyl)-N-(3-fluorophenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.032,uM,=,-1.494850021680094,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1
8285,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,COC(=O)[C@@H](Nc1ncnc2oc(-c3ccccc3)c(-c3ccccc3)c12)c1ccccc1,"Methyl(2S)-[(5,6-Diphenylfuro[2,3-d]pyrimidin-4-yl)amino]-(phenyl)ethanoate",7.893,uM,=,0.8972421028053654,1,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
8286,432592,10.1016/j.bmc.2006.10.041,,,,Inhibition of EGFR,Cc1cccc(C)c1Nc1ncc(-c2ccc(OCC3CCCN(C)C3)cc2)n2cncc12.Cl,"N-(2,6-dimethylphenyl)-5-[4-(1-methylpiperidin-3-ylmethoxy)phenyl]imidazo[1,5-a]pyrazin-8-amine hydrochloride",2.73,uM,=,0.436162647040756,1,c1ccc(Nc2ncc(-c3ccc(OCC4CCCNC4)cc3)n3cncc23)cc1
8287,658103,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR,CNC/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OCCF,(E)-4-Methylamino-but-2-enoic acid[4-(3-chloro-4-fluorophenylamino)-3-cyano-7-(2-fluoroethoxy)-quinolin-6-yl]-amide,0.00029,uM,=,-3.537602002101044,0,c1ccc(Nc2ccnc3ccccc23)cc1
8288,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(piperidin-1-yl)but-2-en-1-one",0.023,uM,=,-1.6382721639824072,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
8289,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,CC(=O)N1CCN(CCCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc2NC(=O)c2cc([N+](=O)[O-])ccc2F)CC1,N-(7-(3-(4-acetylpiperazin-1-yl)propoxy)-4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.021,uM,=,-1.6777807052660807,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCNCC1)c1ccccc1
8290,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,TESEVATINIB,0.0003,uM,=,-3.522878745280338,0,c1ccc(Nc2ncnc3cc(OC[C@H]4C[C@H]5CNC[C@H]5C4)ccc23)cc1
8291,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC(CC)NC(C)=O,"US8846699, 86",0.069,uM,=,-1.1611509092627446,0,c1ccc(Nc2ncnc3ccccc23)cc1
8292,2283190,10.1039/d2md00139j,,,,Inhibition of wild type EGFR (unknown origin),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc4ccccc4c3)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.016,uM,=,-1.7958800173440752,0,c1ccc2cc(-c3nn([C@@H]4CCCNC4)c4ncncc34)ccc2c1
8293,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccc([N+](=O)[O-])cc1,"3-(3,4-Dihydroxy-phenyl)-2-(4-nitro-benzoyl)-acrylonitrile",2.3,uM,=,0.3617278360175928,1,O=C(C=Cc1ccccc1)c1ccccc1
8294,63781,10.1016/j.bmcl.2004.01.034,,,,Inhibition of peptide substrate phosphorylation by epidermal growth factor receptor,C=CC(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,N-[4-(3-Bromo-phenylamino)-3-cyano-quinolin-6-yl]-acrylamide,0.0096999999999999,uM,=,-2.0132282657337552,0,c1ccc(Nc2ccnc3ccccc23)cc1
8295,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",C#CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(prop-2-yn-1-yloxy)quinazolin-6-yl)acrylamide,0.031,uM,=,-1.5086383061657274,0,c1ccc(Nc2ncnc3ccccc23)cc1
8296,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)Nc1cccc(Oc2nc(Nc3cnn(C4CCN(C)CC4)c3)c(C(N)=O)nc2C(C)C)c1,"US9085540, 56",0.002,uM,=,-2.6989700043360187,0,c1ccc(Oc2cncc(Nc3cnn(C4CCNCC4)c3)n2)cc1
8297,1642049,,,,,"Omnia Assay: Briefly, 10Ã stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13ÃATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1Ã kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10Ã stock, KB002A) and 0.2 mM DTT (DS001A). 5 Î¼L of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â°ree; C. with a 0.5 Î¼L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 Î¼L of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(NC4CN(C(=O)OC(C)(C)C)C4)cc3OC)ncc2C(F)(F)F)c1,"US9409887, I-3",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ccnc(Nc3ccc(NC4CNC4)cc3)n2)cc1
8298,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCCc1ccccc1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-phenethyl-acrylamide",0.93,uM,=,-0.0315170514460648,0,O=C(C=Cc1ccccc1)NCCc1ccccc1
8299,1761975,10.1016/j.ejmech.2018.02.051,,,,"Inhibition of wild type EGFR (unknown origin) using Poly (Glu, Tyr) as substrate after 40 mins by kinase-Glo luminescence assay",CN(C)C1CCN(c2ccc(Nc3cc4c(N5CCCC5)nc(Nc5ccccc5)nc4cn3)nc2)CC1,"N6-(5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)-N2-phenyl-4-(pyrrolidin-1-yl)pyrido[3,4-d]pyrimidine-2,6-diamine",0.0055,uM,=,-2.2596373105057563,0,c1ccc(Nc2nc(N3CCCC3)c3cc(Nc4ccc(N5CCCCC5)cn4)ncc3n2)cc1
8300,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,NC(=O)Cc1cccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)c1,"(S)-2-(3-(4-((2-Hydroxy-1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)acetamide",0.0007,uM,=,-3.154901959985743,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8301,632680,10.1016/j.bmc.2010.03.052,,,,Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA,CC(C)c1ccc(Nc2nc(N)nc3[nH]c(Cc4ccc(Cl)cc4Cl)cc23)cc1,"N4-(4-Isopropylphenyl)-6-(2,4-dichlorobenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",45.6,uM,=,1.658964842664435,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
8302,982464,10.1016/j.bmc.2013.06.070,,,,Inhibition of recombinant EGFR kinase cytoplasmic domain (unknown origin) expressed in baculovirus expression vector-infected insect sf9 cells assessed as level of autophosphorylation after 10 mins by DELFIA/time-resolved fluorometry,O=C(/C=C/c1cccnc1Cl)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,(E)-N-(4-((3-Chlorophenyl)amino)quinazolin-6-yl)-3-(2-chloropyridin-3-yl)acrylamide,3.6,uM,=,0.5563025007672873,1,O=C(/C=C/c1cccnc1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
8303,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,OC[C@@H](Nc1ncnc2oc(-c3ccccc3)c(-c3ccccc3)c12)c1ccccc1,"S-2-(5,6-Diphenylfuro[2,3-d]pyrimidin-4-ylamino)-2-phenylethano",0.393,uM,=,-0.4056074496245733,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
8304,1538409,10.1021/acs.jmedchem.5b01412,,,,Inhibition of EGFR phosphorylation in human NCI-H1975 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay,Cc1nc2cnc(Nc3ccnc(N4CC[C@H](O)C(F)(F)C4)n3)cc2n1C(C)C,"(+/-)-3,3-Difluoro-1-(4-((1-isopropyl-2-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)pyrimidin-2-yl)piperidin-4-ol",1.04,uM,=,0.0170333392987803,1,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1
8305,1848601,10.1016/j.ejmech.2019.03.055,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected Sf21 insect cells using STK as substrate by HTRF assay,C=CC(=O)N1CCC[C@H]1COc1nc(Nc2ccc(N3CCN(C(C)=O)CC3)cc2)nc2[nH]cc(-c3cncc(NC)n3)c12,"(S)-1-(2-(((2-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-5-(6-(methylamino)pyrazin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)pyrrolidin-1-yl)prop-2-en-1-one",1.975,uM,=,0.295567099962479,1,c1cnc(-c2c[nH]c3nc(Nc4ccc(N5CCNCC5)cc4)nc(OC[C@@H]4CCCN4)c23)cn1
8306,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(OC)c(Cl)cc3F)ncnc2cc1OCCNC(C)=O,"US8846699, 129",0.08,uM,=,-1.0969100130080565,0,c1ccc(Nc2ncnc3ccccc23)cc1
8307,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC,"US8846699, 30",0.096,uM,=,-1.0177287669604316,0,c1ccc(Nc2ncnc3ccccc23)cc1
8308,1848601,10.1016/j.ejmech.2019.03.055,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected Sf21 insect cells using STK as substrate by HTRF assay,CNc1cncc(-c2c[nH]c3nc(Nc4ccc(N5CCN(C(C)=O)CC5)cc4)nc(OC4CCCCC4)c23)n1,"1-(4-(4-((4-(cyclohexyloxy)-5-(6-(methylamino)pyrazin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)piperazin-1-yl)ethan-1-one",0.654,uM,=,-0.1844222516757327,0,c1cnc(-c2c[nH]c3nc(Nc4ccc(N5CCNCC5)cc4)nc(OC4CCCCC4)c23)cn1
8309,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccc(CO)cc1,"[4-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-phenyl]-methanol",0.7,uM,=,-0.1549019599857432,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
8310,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3OC(F)F)cc12)c1ccccc1,"(S)-6-(2-(Difluoromethoxy)phenyl)-N-(2-methoxy-1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.0013,uM,=,-2.886056647693163,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8311,1538409,10.1021/acs.jmedchem.5b01412,,,,Inhibition of EGFR phosphorylation in human NCI-H1975 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay,COC1CCN(c2nccc(Nc3cc4c(cn3)nc(CO)n4C(C)C)n2)CC1,"{1-Isopropyl-6-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-ylamino]-1H-imidazo[4,5-c]pyridin-2-yl}methanol",2.36,uM,=,0.3729120029701065,1,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1
8312,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,OCCN(CCO)CCCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"2-[{3-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-propyl}-(2-hydroxy-ethyl)-amino]-ethanol",0.23,uM,=,-0.6382721639824072,0,c1ccc(Nc2ncnc3cnccc23)cc1
8313,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCCOC(=O)Nc1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1Cl.Cl,"{2-Chloro-4-[6,7-dimethoxyquinazolin-4-ylamino]phenyl}carbamic acid propyl ester hydrochloride",1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
8314,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,OC[C@@H](Nc1ncnc2[nH]c(-c3cccnc3)cc12)c1ccccc1,"(S)-2-Phenyl-2-((6-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol",0.0022,uM,=,-2.657577319177794,0,c1ccc(CNc2ncnc3[nH]c(-c4cccnc4)cc23)cc1
8315,479448,10.1016/j.bmcl.2008.05.024,,,,Inhibition of EGFR,CO/N=C/c1c(N)ncnc1Nc1ccc(F)c(Cl)c1,4-amino-6-(3-chloro-4-fluorophenylamino)pyrimidine-5-carbaldehyde O-methyl oxime,0.07,uM,=,-1.154901959985743,0,c1ccc(Nc2ccncn2)cc1
8316,632680,10.1016/j.bmc.2010.03.052,,,,Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA,FC(F)(F)c1cccc(Nc2ncnc3[nH]c(Cc4ccc(Cl)cc4Cl)cc23)c1,"6-(2,4-dichlorobenzyl)-N-(3-(trifluoromethyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",33.1,uM,=,1.5198279937757189,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
8317,556139,10.1016/j.bmc.2008.04.019,,,,Inhibition of EGFR expressed in human tumor cells,Nc1nc(Nc2cccc(Br)c2)c2cc(CCc3cccc4ccccc34)[nH]c2n1,"N4-(3-Bromophenyl)-6-[2-(1-naphthyl)ethyl]-7Hpyrrolo[2,3-d]pyrimidine-2,4-diamine",4.8,uM,=,0.6812412373755872,1,c1ccc(Nc2ncnc3[nH]c(CCc4cccc5ccccc45)cc23)cc1
8318,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ccc(/C=C/C(=O)OCCn2c([N+](=O)[O-])cnc2C)cc1,(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl3-p-tolylacrylate,8.11,uM,=,0.909020854211156,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
8319,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CN1CCCC1,"US8846699, 107",0.045,uM,=,-1.3467874862246565,0,O=C(CN1CCCC1)NCCOc1ccc2c(Nc3ccccc3)ncnc2c1
8320,1659894,10.1021/acs.jmedchem.6b01626,,,,Inhibition of wild-type human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 end amino acid residues) expressed in baculovirus expression system using TK peptide substrate preincubated with enzyme for 30 mins followed by substrate addition measured after 25 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2n[nH]c3ccc(-c4cccc5ccccc45)cc23)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((5-(naphthalen-1-yl)-1H-indazol-3-yl)amino)phenyl)acrylamide,0.033,uM,=,-1.4814860601221125,0,c1ccc(Nc2n[nH]c3ccc(-c4cccc5ccccc45)cc23)cc1
8321,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1F,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluorobenzamide,0.003,uM,=,-2.5228787452803374,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
8322,1538409,10.1021/acs.jmedchem.5b01412,,,,Inhibition of EGFR phosphorylation in human NCI-H1975 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay,C[C@@H](O)c1nc2cnc(Nc3ccnc(N4CC[C@H](O)[C@H](F)C4)n3)cc2n1[C@H](C)C(F)(F)F,"(3R,4S)-3-fluoro-1-(4-(2-((R)-1-hydroxyethyl)-1-((R)-1,1,1-trifluoropropan-2-yl)-1H-imidazo[4,5-c]pyridin-6-ylamino)pyrimidin-2-yl)piperidin-4-ol",261.0,uM,=,2.416640507338281,1,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1
8323,1337212,10.1016/j.bmcl.2014.02.041,,,,Inhibition of autophosphorylation of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry,Cc1ccc(Oc2nc3ccccc3cc2/C=N/NC(=O)Cn2c([N+](=O)[O-])cnc2C)cc1,(E)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)-N'-((2-(p-tolyloxy)quinolin-3-yl)methylene)acetohydrazide,23.13,uM,=,1.3641756327706194,1,O=C(Cn1ccnc1)N/N=C/c1cc2ccccc2nc1Oc1ccccc1
8324,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1/C=C/c1ccc(CNC2CC2)cc1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-5-(4-((cyclopropylamino)methyl)styryl)-6-methylpyrimidin-4-amine,0.098,uM,=,-1.0087739243075051,0,C(=C/c1cncnc1Nc1ccc(OCc2ccccc2)cc1)\c1ccc(CNC2CC2)cc1
8325,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,CC1CCN(C/C=C/C(=O)N2CCOc3cc4ncnc(Nc5ccc(F)c(Cl)c5)c4cc32)CC1,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(4-methylpiperidin-1-yl)but-2-en-1-one",0.04,uM,=,-1.3979400086720375,0,O=C(/C=C/CN1CCCCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
8326,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,CCOc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(R)-6-(2-Ethoxyphenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.0002,uM,=,-3.6989700043360174,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8327,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(OC)c(Cl)cc3OC)ncnc2cc1OCCNC(=O)CN(C)C,"US8846699, 166",0.014,uM,=,-1.853871964321762,0,c1ccc(Nc2ncnc3ccccc23)cc1
8328,2251609,10.1021/acs.jmedchem.2c00168,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,CCS(=O)(=O)n1cc(-c2nc(Nc3cc(Cl)c(N4CCC(N5CCN(C)CC5)CC4)cc3C)ncc2Cl)c2ccccc21,5-chloro-N-(5-chloro-2-methyl-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-4-(1-(ethylsulfonyl)-1H-indol-3-yl)pyrimidin-2-amine,0.5466,uM,=,-0.2623303726433581,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCC(N6CCNCC6)CC5)cc4)n3)c[nH]c2c1
8329,1329559,10.1039/C0MD00115E,,,,Inhibition of EGFR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,OB(O)c1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,4-(3-chlorophenylamino)quinazolin-6-ylboronic acid,0.65,uM,=,-0.1870866433571444,0,c1ccc(Nc2ncnc3ccccc23)cc1
8330,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(S(C)(=O)=O)cc3)cc12)c1ccccc1,"(R)-6-(4-(Methylsulfonyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.0004,uM,=,-3.397940008672037,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8331,1929276,10.1016/j.bmcl.2016.08.007,,,,Inhibition of EGFR phosphorylation in EGF-stimulated human KB cells preincubated for 1 hr followed by EGF stimulation measured after 6 mins by ELISA,CN1CCN(C/C=C/C(=O)N2CCOc3cc4ncnc(Nc5ccc(F)c(Cl)c5)c4cc32)CC1,"(E)-1-(4-(3-chloro-4-fluorophenylamino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)-4-(4-methylpiperazin-1-yl)but-2-en-1-one",0.083,uM,=,-1.080921907623926,0,O=C(/C=C/CN1CCNCC1)N1CCOc2cc3ncnc(Nc4ccccc4)c3cc21
8332,509684,10.1016/j.bmcl.2008.07.020,,,,Inhibition of human EGFR expressed in SF9 cells,Nc1ncnc(Nc2ccc3c(cnn3Cc3cccc(F)c3)c2)c1/C=N/N1CCCCC1,"N-[1-(3-Fluoro-benzyl)-1H-indazol-5-yl]-5-[piperidin-1-yliminomethyl]-pyrimidine-4,6-diamine",0.03,uM,=,-1.5228787452803376,0,C(=N/N1CCCCC1)\c1cncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1
8333,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,O=C(/C=C/Cl)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-3-chloro-acrylamide",0.02,uM,=,-1.6989700043360187,0,c1ccc(Nc2ncnc3cnccc23)cc1
8334,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,Nc1ncnc2c1c(-c1ccccc1)cn2-c1cccc(CO)c1,"[3-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-phenyl]-methanol",0.6,uM,=,-0.2218487496163563,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
8335,1528834,,,,,"Inhibition Assay: The phosphorylation activity on the peptide substrate of EGFR was investigated using LabChip (trademark) Systems (Caliper Life Sciences, Inc.). For the enzyme, EGFR [T790M/L858R] (Carna Biosciences, Inc.) was used. The test compound was added to a reaction liquid containing the enzyme protein to give 8 stages of final concentrations ranging from 300 nM to 0.1 nM, followed by incubation for 2 hours. Then, the substrate and the ATP solution were added thereto, followed by reaction for 1 hour. An ATP concentration of 1000 uM was used. A reaction liquid containing the enzyme protein but no test compound (in which the DMSO alone was added as a solvent at 0.4% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.",C=CC(=O)N1CCC(c2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)CC1,"US9085540, 69",0.004,uM,=,-2.397940008672037,0,c1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1cncc(C2CCNCC2)n1
8336,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)c1ccc[nH]1,"US8846699, 99",0.368,uM,=,-0.4341521813264823,0,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)c1ccc[nH]1
8337,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1/C=C/c1ccc(CNCCS(C)(=O)=O)cc1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-(4-((2-(methylsulfonyl)ethylamino)methyl)styryl)pyrimidin-4-amine,0.094,uM,=,-1.0268721464003014,0,C(=C/c1cncnc1Nc1ccc(OCc2ccccc2)cc1)\c1ccccc1
8338,1886849,10.1016/j.bmcl.2019.04.029,,,,Inhibition of probe binding to wild type EGFR (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)C1CSSC1,"N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-1,2-dithiolane-4-carboxamide",0.21,uM,=,-0.6777807052660807,0,O=C(Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1)C1CSSC1
8339,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,COc1ccc(NC(=O)/C(C#N)=C/c2ccc(O)c(O)c2)c(OC)c1,"2-Cyano-3-(3,4-dihydroxy-phenyl)-N-(2,4-dimethoxy-phenyl)-acrylamide",1.7,uM,=,0.2304489213782739,1,O=C(/C=C/c1ccccc1)Nc1ccccc1
8340,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc(Cl)cc2)CC1c1ccc(C(=O)OCCn2c([N+](=O)[O-])cnc2C)cc1,"2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-(1-acetyl-3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",7.37,uM,=,0.8674674878590515,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
8341,1684313,10.1016/j.ejmech.2017.04.025,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (unknown origin) (645 to 1186 residues) expressed in baculovirus infected Sf-9 cells preincubated for 10 mins followed by ATP addition measured after 1 hr by DELFIA/Time-Resolved fluorometry,COc1cc(Br)c(/C=C2\CC(C)CC(=C\c3nc(C)c(C)nc3C)/C2=N/O)cc1OC,"2-(2-Bromo-4,5-dimethoxy-benzylidene)-4-methyl-6-(3,5,6-trimethyl-pyrazin-2-ylmethylene)-cyclohexanone oxime",2.9,uM,=,0.4623979978989561,1,N=C1/C(=C/c2ccccc2)CCC/C1=C\c1cnccn1
8342,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,COc1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1,"3-(4-Methoxyphenyl)-5-(naphthalen-1-yl)-1-phenyl-4,5-dihydro-1H-pyrazole",0.1,uM,=,-1.0,0,c1ccc(C2=NN(c3ccccc3)C(c3cccc4ccccc34)C2)cc1
8343,1329559,10.1039/C0MD00115E,,,,Inhibition of EGFR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1B(O)O,4-(3-chlorophenylamino)-7-methoxyquinazolin-6-ylboronic acid,0.46,uM,=,-0.3372421683184259,0,c1ccc(Nc2ncnc3ccccc23)cc1
8344,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,Cc1ccccc1-c1cn(-c2ccccc2)c2ncnc(N)c12,"7-Phenyl-5-o-tolyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",2.65,uM,=,0.4232458739368078,1,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
8345,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,O=C(/C=C/c1ccccc1)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"N-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-3-phenyl-acrylamide",0.077,uM,=,-1.1135092748275182,0,O=C(/C=C/c1ccccc1)Nc1cc2c(Nc3ccccc3)ncnc2cn1
8346,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)CCOC,"US8846699, 150",0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3ccccc23)cc1
8347,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OC[C@H](C)NC(=O)CN(C)C,"US8846699, 158::US8846699, 163",0.0231,uM,=,-1.6363880201078556,0,c1ccc(Nc2ncnc3ccccc23)cc1
8348,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#C/C(=C\c1ccc(O)c(O)c1)C(=O)c1ccccc1Cl,"2-(2-Chloro-benzoyl)-3-(3,4-dihydroxy-phenyl)-acrylonitrile",1.54,uM,=,0.1875207208364631,1,O=C(C=Cc1ccccc1)c1ccccc1
8349,5171,10.1021/jm970641d,,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,O=C(O)CCNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"3-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylamino]-propionic acid",0.449,uM,=,-0.3477536589966768,0,c1ccc(Nc2ncnc3cnccc23)cc1
8350,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(Cl)c(Cl)cc3F)ncnc2cc1OCCNC(C)=O,"US8846699, 121",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
8351,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc(Br)cc2)CC1c1ccc(C(=O)OCCn2c([N+](=O)[O-])cnc2C)cc1,"2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-(1-acetyl-3-(4-bromophenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",4.13,uM,=,0.615950051656401,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
8352,2296723,10.1021/acs.jmedchem.6b00276,,,,Inhibition of recombinant 6His-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) autophosphorylation expressed in baculovirus infected Sf9 insect cells preincubated for 10 mins followed by ATP and MgCl2 addition measured after 60 mins by DELFIA/time-resolved fluorometric analysis,CCN(CC)CCON=C1/C(=C/c2cc(OC)c(OC)c(OC)c2Br)CN(C)C/C1=C\c1cc(OC)c(OC)c(OC)c1Br,"3,5-Bis(2-bromo-3,4,5-trimethoxy-benzylidene)-1-methyl-piperidin-4-one-O-(2-diethylamino)ethyl oxime",0.05,uM,=,-1.3010299956639813,0,N=C1/C(=C/c2ccccc2)CNC/C1=C\c1ccccc1
8353,1817056,10.1021/acs.jmedchem.8b00147,,,,Inhibition of erbB1 (unknown origin) using FRET-capable peptide substrate by FRET assay,Cn1ncc([N+](=O)[O-])c1C[N+](C)(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1.[Br-],"4-(4-(3-bromophenylamino)quinazolin-6-ylamino)-N,N-dimethyl-N-((1-methyl-4-nitro-1H-pyrazol-5-yl)methyl)-4-oxobut-2-en-1-aminium bromide",0.00022,uM,=,-3.657577319177794,0,O=C(/C=C/C[NH2+]Cc1ccn[nH]1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
8354,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-(6-{5-[(2-methanesulfonyl-ethylamino)-methyl]-furan-2-yl}-quinazolin-4-yl)-amine,0.28,uM,=,-0.5528419686577808,0,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1
8355,2185644,10.1016/j.ejmech.2021.113523,,,,Inhibition of EGFR (unknown origin) by ADP-Glo kinase assay,Clc1ccc(Nc2ncnc3[nH]ccc23)cc1Br,"N-(3-bromo-4-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.00363,uM,=,-2.440093374963888,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1
8356,2207741,10.1021/acs.jmedchem.2c00893,,,,Inhibition of wild type EGFR expressed in human NCI-H2073 cells,O=C(Nc1nccs1)C(c1cc(F)ccc1O)N1Cc2ccc(-c3ccc(N4CCNCC4)cc3)cc2C1=O,2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-6-(4-(piperazin-1-yl)phenyl)isoindolin-2-yl)-N-(thiazol-2-yl)acetamide,3.91,uM,=,0.5921767573958668,1,O=C(Nc1nccs1)C(c1ccccc1)N1Cc2ccc(-c3ccc(N4CCNCC4)cc3)cc2C1=O
8357,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,CC1(C)CC(C(=O)Nc2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)CC(C)(C)N1[O],"2,2,6,6-Tetramethyl-1-oxyl-N-[4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl]piperidine-4-carboxamide",0.015,uM,=,-1.8239087409443189,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)C1CCNCC1
8358,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(C#N)cc3F)ncnc2cc1OC/C=C/CN1CCCC1,3-Fluoro-4-[6-methoxy-7-(4-pyrrolidin-1-yl-but-2-enyloxy)-quinazolin-4-ylamino]-benzonitrile,0.8,uM,=,-0.0969100130080563,0,C(=C/CN1CCCC1)\COc1ccc2c(Nc3ccccc3)ncnc2c1
8359,2059437,10.1016/j.bmc.2021.116094,,,,Inhibition of wild-type EGFR (unknown origin) using biotinylated TK peptide as substrate measured after 30 mins by HTRF assay,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C4CC4)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,AUMOLERTINIB,0.00289,uM,=,-2.539102157243452,0,c1ccc(Nc2nccc(-c3cn(C4CC4)c4ccccc34)n2)cc1
8360,1871892,10.1016/j.bmcl.2018.12.020,,,,"Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate",C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCc1cn(Cc2ccc(C)cc2)nn1,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.105,uM,=,-0.978810700930062,0,c1ccc(Cn2cc(COc3ccc4c(Nc5ccccc5)ncnc4c3)nn2)cc1
8361,2251609,10.1021/acs.jmedchem.2c00168,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,CCS(=O)(=O)n1cc(-c2nc(Nc3cc(C)c(N4CCC(N5CCN(C)CC5)CC4)cc3OC)ncc2Cl)c2ccccc21,5-chloro-4-(1-(ethylsulfonyl)-1H-indol-3-yl)-N-(2-methoxy-5-methyl-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidin-2-amine,0.0559,uM,=,-1.2525881921135766,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCC(N6CCNCC6)CC5)cc4)n3)c[nH]c2c1
8362,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,C#Cc1cccc(Nc2c(C#N)cnc3cc(OC)c(OC)cc23)c1,"4-(3-ethynylphenylamino)-6,7-dimethoxyquinoline-3-carbonitrile",0.061,uM,=,-1.214670164989233,0,c1ccc(Nc2ccnc3ccccc23)cc1
8363,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2cc(Cl)ccc2O)=N1,2-(2-(5-Chloro-2-hydroxybenzylidene)hydrazinyl)thiazol-4(5H)-one,0.56,uM,=,-0.2518119729937995,0,O=C1CSC(N/N=C/c2ccccc2)=N1
8364,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,C[C@@H](Nc1ncnc2oc(-c3ccccc3)c(-c3ccccc3)c12)c1ccccc1,"5,6-Diphenyl-N-[(1R)-1-phenylethyl]furo[2,3-d]pyrimidin-4-amine",2.991,uM,=,0.4758164130313181,1,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
8365,340861,10.1016/j.bmcl.2005.12.028,,,,Antiproliferative activity against EGF-stimulated KB cells,COc1cc(OC2CCN(C)CC2)c2c(Nc3ccc(F)c(Cl)c3)ncnc2c1,N-(3-chloro-4-fluorophenyl)-7-methoxy-5-(1-methylpiperidin-4-yloxy)quinazolin-4-amine,0.087,uM,=,-1.0604807473813815,0,c1ccc(Nc2ncnc3cccc(OC4CCNCC4)c23)cc1
8366,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,COc1ccc(Nc2ncnn3ccc(CN4CCC(N)CC4)c23)cc1Cl,"5-((4-aminopiperidin-1-yl)methyl)-N-(3-chloro-4-methoxyphenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.21,uM,=,-0.6777807052660807,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1
8367,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",COc1cc(/C=C(\C#N)C(=O)NCCCCNC(=O)/C(C#N)=C/c2cc(OC)c(O)c([N+](=O)[O-])c2)cc([N+](=O)[O-])c1O,(E)-2-Cyano-N-{4-[(E)-2-cyano-3-(4-hydroxy-3-methoxy-5-nitro-phenyl)-acryloylamino]-butyl}-3-(4-hydroxy-3-methoxy-5-nitro-phenyl)-acrylamide,112.0,uM,=,2.049218022670181,1,O=C(C=Cc1ccccc1)NCCCCNC(=O)/C=C/c1ccccc1
8368,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,COc1cccc(-c2cn(-c3ccc(CNCCO)cc3)c3ncnc(N)c23)c1,"2-{4-[4-Amino-5-(3-methoxy-phenyl)-pyrrolo[2,3-d]pyrimidin-7-yl]-benzylamino}-ethanol",0.3,uM,=,-0.5228787452803376,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
8369,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",C#Cc1cccc(Nc2ncnc3ccc(OCCCOP(N)(=O)N(CCCl)CCCl)cc23)c1,"3-((4-((3-Ethynylphenyl)amino)quinazolin-6-yl)oxy)propyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.0072,uM,=,-2.1426675035687315,0,c1ccc(Nc2ncnc3ccccc23)cc1
8370,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,CN(C)/N=N/c1ccc2ncnc(N(C)c3ccccc3)c2c1,"6-[(1E)-3,3-dimethyltriaz-1-enyl]-N-methyl-N-phenylquinazolin-4-amine",13.35,uM,=,1.125481265700594,1,c1ccc(Nc2ncnc3ccccc23)cc1
8371,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,[2H]C([2H])([2H])Oc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1,"(S)-2-((6-(2-(Methoxy-d3)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0004,uM,=,-3.397940008672037,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8372,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCC(C)NC(=O)CN(C)C,"US8846699, 157",0.088,uM,=,-1.055517327849831,0,c1ccc(Nc2ncnc3ccccc23)cc1
8373,2084904,10.1021/acs.jmedchem.6b00943,,,,"Inhibition of human recombinant EGFR (696 to end residues) using poly(Glu,Tyr)4:1 as substrate incubated for 40 mins in presence of [gamma33P-ATP] by radiometric scintillation counting analysis",Cc1ccc(NC(=O)c2ccc(C)c(C(F)(F)F)c2)cc1C#Cc1nn([C@H]2CC[C@H](O)CC2)c2ncnc(N)c12,"N-(3-((4-Amino-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide",0.6509999999999999,uM,=,-0.1864190114318081,0,O=C(Nc1cccc(C#Cc2nn(C3CCCCC3)c3ncncc23)c1)c1ccccc1
8374,63790,10.1016/S0960-894X(97)00035-8,,,,Antagonism towards Epidermal growth factor receptor,COc1cc2ncnc(N3CCc4ccccc43)c2cc1OC.Cl,"(2,3-Dihydro-1H-indol-2-yl)-(6,7-dimethoxy-quinazolin-4-yl)-amine hydrochloride",3.0,uM,=,0.4771212547196624,1,c1ccc2c(c1)CCN2c1ncnc2ccccc12
8375,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CN1CCCCC1,"US8846699, 101",0.007,uM,=,-2.154901959985743,0,O=C(CN1CCCCC1)NCCOc1ccc2c(Nc3ccccc3)ncnc2c1
8376,2080996,10.1016/j.ejmech.2021.113173,,,,Inhibition of EGFR (unknown origin) by mobility shift assay,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)ncnc2cc1OCc1cn(CCC(=O)NO)nn1,"N-(4-((3-chloro-4-((2-fluorobenzyl)oxy)phenyl)amino)-7-((1-(3-(hydroxyamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazolin-6-yl)acrylamide",0.0011,uM,=,-2.958607314841775,0,c1ccc(COc2ccc(Nc3ncnc4cc(OCc5c[nH]nn5)ccc34)cc2)cc1
8377,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,CC(=O)N1CCOc2c1ccc1ncnc(Nc3cccc(Br)c3)c21,"1-(10-((3-bromophenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)ethan-1-one",0.0456,uM,=,-1.341035157335565,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCN4)cc1
8378,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,O=C(CCCCCC(=O)Nc1ccc(O)c(C(=O)Nc2ccccc2)c1)NO,N-Phenyl-2-hydroxy-5-(7-hydroxyamino-7-oxoheptanamido)benzamide,2.34,uM,=,0.3692158574101428,1,O=C(Nc1ccccc1)c1ccccc1
8379,2031601,10.1016/j.ejmech.2020.112185,,,,"Inhibition of EGFR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate incubated for 8 mins in presence of ATP by colorimetric analysis",ClCCN(CCCl)c1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N4-(3-bromophenyl)-N6,N6-bis(2-chloroethyl)quinazoline-4,6-diamine",1.257,uM,=,0.0993352776859577,1,c1ccc(Nc2ncnc3ccccc23)cc1
8380,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(Cl)c(Cl)cc3Cl)ncnc2cc1OCCNC(C)=O,"US8846699, 122",0.876,uM,=,-0.0574958938319192,0,c1ccc(Nc2ncnc3ccccc23)cc1
8381,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinolin-6-yl)-4-(dimethylamino)but-2-enamide,0.0007,uM,=,-3.154901959985743,0,c1ccc(Nc2ncnc3cc(O[C@H]4CCOC4)ccc23)cc1
8382,1684313,10.1016/j.ejmech.2017.04.025,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (unknown origin) (645 to 1186 residues) expressed in baculovirus infected Sf-9 cells preincubated for 10 mins followed by ATP addition measured after 1 hr by DELFIA/Time-Resolved fluorometry,COc1cc(Br)c(/C=C2\CN(C)CC(=C\c3nc(C)c(C)nc3C)/C2=N\O)cc1OC,"3-(2-Bromo-4,5-dimethoxy-benzylidene)-1-methyl-5-(3,5,6-trimethyl-pyrazin-2-ylmethylene)-piperidin-4-one oxime",0.02,uM,=,-1.6989700043360187,0,N=C1/C(=C/c2ccccc2)CNC/C1=C\c1cnccn1
8383,1886849,10.1016/j.bmcl.2019.04.029,,,,Inhibition of probe binding to wild type EGFR (unknown origin) using rabbit reticulate lysate system after 1 hr by luminescence assay,N#Cc1cnc2ccc(NC(=O)CC3CCSS3)cc2c1Nc1ccc(OCc2cccc(F)c2)c(Cl)c1,"N-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-3-cyanoquinolin-6-yl)-2-(1,2-dithiolan-3-yl)acetamide",0.164,uM,=,-0.7851561519523022,0,O=C(CC1CCSS1)Nc1ccc2nccc(Nc3ccc(OCc4ccccc4)cc3)c2c1
8384,330893,10.1021/jm050786h,,,,Inhibitory activity against EGFR,COc1cc2c(Nc3ncc(CC(=O)Nc4cccc(F)c4)s3)ncnc2cc1OCCCN1CCC(CO)CC1,"N-(3-fluorophenyl)-2-{2-[(7-{3-[4-(hydroxymethyl)piperidin-1-yl]propoxy}-6-methoxyquinazolin-4-yl)amino]-1,3-thiazol-5-yl}acetamide",0.8,uM,=,-0.0969100130080563,0,O=C(Cc1cnc(Nc2ncnc3cc(OCCCN4CCCCC4)ccc23)s1)Nc1ccccc1
8385,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C1CCCN1,"US8846699, 97",1.954,uM,=,0.2909245593827542,1,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)C1CCCN1
8386,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,Nc1ncnc2c1c(-c1ccccc1)cn2-c1ccc(CNCCO)cc1,"2-[4-(4-Amino-5-phenyl-pyrrolo[2,3-d]pyrimidin-7-yl)-benzylamino]-ethanol",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
8387,2302058,10.1016/j.ejmech.2017.08.009,,,,Inhibition of EGFR (unknown origin),Cc1ccc(Nc2ncnn3cccc23)cc1O,"2-Methyl-5-(pyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-phenol",1.44,uM,=,0.1583624920952496,1,c1ccc(Nc2ncnn3cccc23)cc1
8388,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#Cc1cccc(CN(C)C)c1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-5-((3-((dimethylamino)methyl)phenyl)ethynyl)-6-methylpyrimidin-4-amine,0.055,uM,=,-1.259637310505756,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
8389,202293,10.1021/jm00037a020,,,,Cytotoxic effect on EGF-receptor overexpressing HN5 squamous carcinoma cells,Oc1ccc(/N=N/c2ccc(O)cc2O)cc1,"4-(4-Hydroxy-phenylazo)-benzene-1,3-diol",58.0,uM,=,1.7634279935629371,1,c1ccc(/N=N/c2ccccc2)cc1
8390,1543611,10.1016/j.bmcl.2015.11.040,,,,Inhibition of His-tagged EGFR cytoplasmic domain (645-1186 aa) (unknown origin) assessed as inhibition of autophosphorylation by TR-fluorometry,CC(=O)N1N=C(c2ccc([N+](=O)[O-])cc2)CC1c1ccc(C(=O)OC(C)Cn2c([N+](=O)[O-])cnc2C)cc1,"1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-yl 4-(1-acetyl-3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzoate",1.45,uM,=,0.1613680022349748,1,O=C(OCCn1ccnc1)c1ccc(C2CC(c3ccccc3)=NN2)cc1
8391,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),COC(=O)Nc1cc(Nc2ncnc3cc(OC)c(OC)cc23)ccc1C.Cl,"{5-[6,7-Dimethoxyquinazolin-4-ylamino]-2-methylphenyl}carbamic acid methyl ester hydrochloride",7.2,uM,=,0.8573324964312685,1,c1ccc(Nc2ncnc3ccccc23)cc1
8392,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,NC(=S)N1N=C(c2ccccc2)CC1c1cccc2ccccc12,"5-(Naphthalen-1-yl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioamide",2.23,uM,=,0.3483048630481606,1,c1ccc(C2=NNC(c3cccc4ccccc34)C2)cc1
8393,2283190,10.1039/d2md00139j,,,,Inhibition of wild type EGFR (unknown origin),C=CC(=O)N1CCC[C@@H](n2nc(-c3cccc4ccccc34)c3c(N)ncnc32)C1,"(R)-1-(3-(4-Amino-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one",0.058,uM,=,-1.2365720064370629,0,c1ccc2c(-c3nn([C@@H]4CCCNC4)c4ncncc34)cccc2c1
8394,1512952,10.1021/acsmedchemlett.5b00231,,,,Inhibition of wild type EGFR in human A549 cells assessed as inhibition of phosphorylation at Y1068 after 2 hrs by sandwich ELISA method,C=CC(=O)N[C@H]1CCN(c2nc(Nc3ccc(N4CCN(C)CC4)cc3)c3ncn(CCO)c3n2)C1,(S)-N-(1-(9-(2-hydroxyethyl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide,4.192,uM,=,0.6224212739756703,1,c1nc2c(Nc3ccc(N4CCNCC4)cc3)nc(N3CCCC3)nc2[nH]1
8395,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,"N*4*-(3-Chloro-phenyl)-quinazoline-4,6-diamine",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
8396,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cccc([N+](=O)[O-])c1,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-3-nitrobenzamide,0.0509,uM,=,-1.2932822176632413,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
8397,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COCCOc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC,(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(2-methoxy-ethoxy)-quinazolin-4-yl]-amine,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
8398,763212,10.1021/np200196j,,,,Inhibition of EGFR-induced Beta-casein activation in human HeLa cells preincubated for 1 hr prior to EGF stimulation by luciferase reporter gene assay,C/C=C(\C)[C@H](O)[C@H](C)/C=C(C)/C=C/CC(C)/C=C/c1oc(OC)c(C)c(=O)c1C,"2-((1E,5E,7E,9R,10R,11E)-10-hydroxy-3,7,9,11-tetramethyltrideca-1,5,7,11-tetraenyl)-6-methoxy-3,5-dimethyl-4H-pyran-4-one",0.66,uM,=,-0.1804560644581313,0,O=c1ccocc1
8399,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)NCC,"US8846699, 168",0.008,uM,=,-2.096910013008056,0,c1ccc(Nc2ncnc3ccccc23)cc1
8400,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)NC(C)C,"US8846699, 37",0.036,uM,=,-1.4436974992327127,0,c1ccc(Nc2ncnc3ccccc23)cc1
8401,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,COc1cc2ncc(C#N)c(Nc3cccc(Br)c3)c2cc1OC,"4-(3-Bromo-phenylamino)-6,7-dimethoxy-quinoline-3-carbonitrile",0.09,uM,=,-1.0457574905606752,0,c1ccc(Nc2ccnc3ccccc23)cc1
8402,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC(CC)NC(=O)CN(C)C,"US8846699, 160",0.023,uM,=,-1.6382721639824072,0,c1ccc(Nc2ncnc3ccccc23)cc1
8403,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(Cl)c(Cl)cc3F)ncnc2cc1OCCNCC(C)=O,"US8846699, 137",0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccccc23)cc1
8404,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,COc1ccc(OC)c(Nc2cc(Nc3ccc(N4CCN(C)CC4)cc3)ncn2)c1,"N4-(2,5-Dimethoxyphenyl)-N6-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-4,6-diamine",0.288,uM,=,-0.5406075122407692,0,c1ccc(Nc2cc(Nc3ccc(N4CCNCC4)cc3)ncn2)cc1
8405,2225007,10.1021/acs.jmedchem.1c01714,,,,Inhibition of wildtype EGFR (unknown origin) incubated for 40 mins by luminescence based assay,Cn1cc(-c2ccnc(Nc3ccc(C(=O)NCCCCCCC(=O)NO)cc3)n2)c2ccccc21,N-(7-(hydroxyamino)-7-oxoheptyl)-4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)benzamide,3.2,uM,=,0.505149978319906,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
8406,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#CC(C#N)=Cc1cccnc1,2-Pyridin-3-ylmethylene-malononitrile,225.0,uM,=,2.3521825181113627,1,c1ccncc1
8407,658103,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR,C#CCNC/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OCC,(E)-N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(prop-2-ynylamino)but-2-enamide,3e-05,uM,=,-4.522878745280337,0,c1ccc(Nc2ccnc3ccccc23)cc1
8408,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CSC,"US8846699, 46",0.039,uM,=,-1.408935392973501,0,c1ccc(Nc2ncnc3ccccc23)cc1
8409,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,COc1cc2ncc(C#N)c(N[C@@H]3C[C@H]3c3ccccc3)c2cc1OCc1ccccc1,"6-(benzyloxy)-7-methoxy-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",1.61,uM,=,0.2068258760318497,1,c1ccc(COc2ccc3nccc(N[C@@H]4C[C@H]4c4ccccc4)c3c2)cc1
8410,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,Brc1cccc(Nc2ncnc3cc4[nH]cc(CN5CCOCC5)c4cc23)c1,"(3-Bromo-phenyl)-(6-morpholin-4-ylmethyl-8H-pyrrolo[3,2-g]quinazolin-4-yl)-amine",0.0048,uM,=,-2.318758762624413,0,c1ccc(Nc2ncnc3cc4[nH]cc(CN5CCOCC5)c4cc23)cc1
8411,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(F)c3F)ncnc2cc1OCCNC(=O)CN(C)C,"US8846699, 124",0.018,uM,=,-1.744727494896694,0,c1ccc(Nc2ncnc3ccccc23)cc1
8412,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",NP(=O)(OCCCOc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1)N(CCCl)CCCl,"3-((4-((3-Chloro-4-fluorophenyl)amino)quinazolin-6-yl)oxy)propyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.0057,uM,=,-2.2441251443275085,0,c1ccc(Nc2ncnc3ccccc23)cc1
8413,2045678,10.1039/d0md00146e,,,,Inhibition of EGFR (unknown origin) using Tyrosine 4 peptide and ATP as substrate incubated for 1 hr by Z'-lyte kinase assay based UV-VIS spectrophotometric method,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",0.2399099999999999,uM,=,-0.6199516492630748,0,c1ccc(Nc2ncnc3ccccc23)cc1
8414,1732820,10.1016/j.ejmech.2018.01.090,,,,Inhibition of recombinant human N-terminal His-tagged EGFR (1 to 645 residues) expressed in HEK293 cells by ELISA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.0032,uM,=,-2.494850021680094,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
8415,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)N1CCNCC1,"US8846699, 94",0.698,uM,=,-0.1561445773768389,0,O=C(NCCOc1ccc2c(Nc3ccccc3)ncnc2c1)N1CCNCC1
8416,2110439,10.1016/j.ejmech.2020.112831,,,,Inhibition of EGFR (unknown origin),O=C(CCCCCCn1cc(-c2ccc3ncnc(Nc4ccc(Br)cc4F)c3c2)nn1)NO,"7-(4-(4-(4-bromo-2-fluorophenylamino)quinazolin-6-yl)-1H-1,2,3-triazol-1-yl)-N-hydroxyheptanamide",0.0103,uM,=,-1.987162775294828,0,c1ccc(Nc2ncnc3ccc(-c4c[nH]nn4)cc23)cc1
8417,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,C#Cc1cccc(Nc2ncnn3ccc(COC[C@@H]4CNCCO4)c23)c1,"(S)-N-(3-ethynylphenyl)-5-((morpholin-2-ylmethoxy)methyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.67,uM,=,-0.1739251972991735,0,c1ccc(Nc2ncnn3ccc(COC[C@@H]4CNCCO4)c23)cc1
8418,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,COc1ccc(Nc2cc(NC(=O)c3ccccc3)ncn2)cc1,N-(6-((4-methoxyphenyl)amino)pyrimidin-4-yl)benzamide,0.081,uM,=,-1.0915149811213505,0,O=C(Nc1cc(Nc2ccccc2)ncn1)c1ccccc1
8419,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2cc(Cl)cc(Cl)c2O)=N1,"2-(2-(3,5-Dichloro-2-hydroxybenzylidene)hydrazinyl)thiazol-4(5H)-one",1.46,uM,=,0.1643528557844371,1,O=C1CSC(N/N=C/c2ccccc2)=N1
8420,2220184,10.1016/j.bmcl.2021.128524,,,,Inhibition of EGFR tyrosine kinase (unknown origin),COc1ccc(-c2cc(=O)cc(-c3ccc(OC)cc3)o2)cc1,"2,6-bis(4-methoxyphenyl)-4H-pyran-4-one",0.00015,uM,=,-3.823908740944319,0,O=c1cc(-c2ccccc2)oc(-c2ccccc2)c1
8421,632680,10.1016/j.bmc.2010.03.052,,,,Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA,Cc1ccccc1Cc1cc2c(Nc3cccc(Br)c3)nc(N)nc2[nH]1,"N4-(3-bromophenyl)-6-(2-methylbenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",9.1,uM,=,0.9590413923210936,1,c1ccc(Cc2cc3c(Nc4ccccc4)ncnc3[nH]2)cc1
8422,66564,10.1021/jm960225d,,,,"Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)",N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCC1CCCC(CNC(=O)/C(C#N)=C/c2ccc(O)c(O)c2)C1,"(E)-2-Cyano-N-(3-{[(E)-2-cyano-3-(3,4-dihydroxy-phenyl)-acryloylamino]-methyl}-cyclohexylmethyl)-3-(3,4-dihydroxy-phenyl)-acrylamide",1.8,uM,=,0.255272505103306,1,O=C(C=Cc1ccccc1)NCC1CCCC(CNC(=O)/C=C/c2ccccc2)C1
8423,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CN(CC)CC,"US8846699, 167",0.026,uM,=,-1.585026652029182,0,c1ccc(Nc2ncnc3ccccc23)cc1
8424,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide,0.039,uM,=,-1.408935392973501,0,c1ccc(Nc2ccnc3ccccc23)cc1
8425,642727,10.1016/j.bmc.2010.06.003,,,,Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA,Cc1ncc([N+](=O)[O-])n1CCOC(=O)/C=C/c1ccccc1[N+](=O)[O-],(E)-2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl 3-(2-nitrophenyl)acrylate,25.0,uM,=,1.3979400086720375,1,O=C(/C=C/c1ccccc1)OCCn1ccnc1
8426,2218523,10.1021/acs.jmedchem.0c01467,,,,Inhibition of EGFR (unknown origin),CN1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1,"N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)-pyrimido[5,4-d]pyrimidine-2,8-diamine",0.003,uM,=,-2.5228787452803374,0,c1ccc(Nc2ncnc3cnc(NC4CCNCC4)nc23)cc1
8427,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#CC(C#N)=Cc1ccc2[nH]ccc2c1,2-(1H-Indol-5-ylmethylene)-malononitrile,2200.0,uM,=,3.342422680822206,1,c1ccc2[nH]ccc2c1
8428,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(C)=O,"US8846699, 18",0.002,uM,=,-2.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
8429,306445,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate; Range = 25-50 nM,O=C(CCl)Nc1ccc2ncnc(Nc3cc(Cl)c(Cl)cc3F)c2c1,"2-Chloro-N-[4-(4,5-dichloro-2-fluoro-phenylamino)-quinazolin-6-yl]-acetamide",0.025,uM,=,-1.6020599913279625,0,c1ccc(Nc2ncnc3ccccc23)cc1
8430,1747423,10.1016/j.bmc.2017.10.030,,,,Inhibition of recombinant wild type EGFR (696 to C-terminal residues) (unknown origin) preincubated for 30 mins followed by poly (Glu-Tyr) biotinylated peptide substrate addition measured after 30 mins in presence of ATP by ELISA,COc1ccc(-c2c3c4cc(OC)c(OCCCN(C)C)cc4oc(=O)c3n3ccc4cc(O)c(OC)cc4c23)cc1O.O=C(O)C(F)(F)F,"3-[3-(dimethylamino)propoxy]-11-hydroxy-14-(3-hydroxy-4-methoxyphenyl)-2,12-dimethoxy-6H-[1]benzopyrano[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one Trifluoroacetic acid salt",0.2154,uM,=,-0.6667543010380372,0,O=c1oc2ccccc2c2c(-c3ccccc3)c3c4ccccc4ccn3c12
8431,2185652,10.1016/j.ejmech.2021.113523,,,,"Inhibition of recombinant EGFR (unknown origin) using Poly-(Glu,Tyr 4:1) peptide as a substrate in presence of ATP by luminescence based assay",Cc1n[nH]c2c1C(c1ccccc1Br)c1c(ncn(N)c1=N)O2,"4-(2-bromophenyl)-5-imino-3-methyl-1,4-dihydropyrazolo[4',3':5,6]pyrano[2,3-d]pyrimidin-6(5H)-amine",0.06,uM,=,-1.2218487496163564,0,N=c1[nH]cnc2c1C(c1ccccc1)c1cn[nH]c1O2
8432,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,N#Cc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)c4cc([N+](=O)[O-])ccc4F)cc23)cc1Cl,N-(4-((3-chloro-4-cyanophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,2.426,uM,=,0.3848907965305542,1,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
8433,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(Cl)c(Cl)cc3F)ncnc2cc1OCCNC(=O)CN(C)C,"US8846699, 140",0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
8434,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,CNc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,4-[(3-chlorophenyl)amino]-6-(methylamino)quinazoline,0.004,uM,=,-2.397940008672037,0,c1ccc(Nc2ncnc3ccccc23)cc1
8435,2251609,10.1021/acs.jmedchem.2c00168,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,CCS(=O)(=O)n1cc2c3ccc(cc31)OCCCCCCOc1cc(ccc1N1CCOCC1)Nc1ncc(Cl)c-2n1,"2(5)-chloro-1(1)-(ethylsulfonyl)-4(4)-morpholino-1(1)H-5,12-dioxa-3-aza-1(3,6)-indola-2(4,2)-pyrimidina-4(1,3)-benzenacyclododecaphane",0.2364,uM,=,-0.6263525277907822,0,c1cc2nc(n1)Nc1ccc(N3CCOCC3)c(c1)OCCCCCCOc1ccc3c-2c[nH]c3c1
8436,528400,10.1021/np9905259,,,,Inhibition of human recombinant EGFR kinase expressed in Sf9 insect cells,CCC(C)[C@@H]1[C@@](C)(C(=O)/C=C/OC)[C@H]2[C@H](C)C[C@@](C)(O)C[C@]2(O)C(=O)[C@@]1(C)O,10-hydroxy-18-methoxybetaenone,10.5,uM,=,1.021189299069938,1,O=C1CCC[C@H]2CCCCC12
8437,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1F,"(S)-2-((6-(3-Fluoro-4-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0006,uM,=,-3.2218487496163566,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8438,1274575,10.1016/j.bmcl.2013.09.086,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation expressed in baculovirus infected insect Sf9 cells preincubated for 10 mins followed by ATP-MgCl2 addition measured after 1 hr by fluorometric analysis,Cc1ncc([N+](=O)[O-])n1C/C(=N/NC(=O)c1ccccc1N)c1ccc(Br)cc1,(E)-N'-(1-(4-bromophenyl)-2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylidene)-2-aminobenzohydrazide,1.89,uM,=,0.2764618041732441,1,O=C(N/N=C(/Cn1ccnc1)c1ccccc1)c1ccccc1
8439,608087,10.1021/jm901558p,,,,Inhibition of human recombinant EGFR expressed in insect cells by time-resolved fluorimetry,O=C(Cn1sc2ccccc2c1=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(3-oxobenzo[d]isothiazolin-2-yl)acetamide,0.00085,uM,=,-3.070581074285707,0,O=C(Cn1sc2ccccc2c1=O)Nc1ccc2ncnc(Nc3ccccc3)c2c1
8440,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C(N)=O)CC1,"US8846699, 4",0.015,uM,=,-1.8239087409443189,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
8441,1848601,10.1016/j.ejmech.2019.03.055,,,,Inhibition of recombinant human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected Sf21 insect cells using STK as substrate by HTRF assay,C=CC(=O)N1CCC(Oc2nc(Nc3ccc(N4CCOCC4)cc3)nc3[nH]cc(-c4cncc(NC)n4)c23)CC1,"1-(4-((5-(6-(methylamino)pyrazin-2-yl)-2-((4-morpholinophenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)piperidin-1-yl)prop-2-en-1-one",1.257,uM,=,0.0993352776859577,1,c1cnc(-c2c[nH]c3nc(Nc4ccc(N5CCOCC5)cc4)nc(OC4CCNCC4)c23)cn1
8442,2019872,10.1039/d0md00227e,,,,Inhibition of EGFR (unknown origin) by Kinase-Glo luminescence assay,COc1cc(/C=N/NC(=O)COc2nc(C)nc3c2c(C)nn3-c2ccccc2)cc(OC)c1OC,"2-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)-N'-(3,4,5-trimethoxybenzylidene)acetohydrazide",4.18,uM,=,0.6211762817750351,1,O=C(COc1ncnc2c1cnn2-c1ccccc1)N/N=C/c1ccccc1
8443,1817056,10.1021/acs.jmedchem.8b00147,,,,Inhibition of erbB1 (unknown origin) using FRET-capable peptide substrate by FRET assay,Cn1cc([N+](=O)[O-])nc1C[N+](C)(C)C/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1.[Br-],"4-(4-(3-bromophenylamino)quinazolin-6-ylamino)-N,N-dimethyl-N-((1-methyl-4-nitro-1H-imidazol-2-yl)methyl)-4-oxobut-2-en-1-aminium bromide",0.00022,uM,=,-3.657577319177794,0,O=C(/C=C/C[NH2+]Cc1ncc[nH]1)Nc1ccc2ncnc(Nc3ccccc3)c2c1
8444,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,C#Cc1cccc(Nc2ncnn3ccc(CN4CCC(N)CC4)c23)c1,"5-((4-aminopiperidin-1-yl)methyl)-N-(3-ethynylphenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",0.01,uM,=,-2.0,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1
8445,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,CN(C)CC(=O)Nc1cccc(-c2c(-c3ccccc3)oc3ncnc(N[C@H](CO)c4ccccc4)c23)c1,"N-[3-(4-{[(1S)-2-Hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N2,N2-dimethylglycinamide",0.048,uM,=,-1.3187587626244128,0,c1ccc(CNc2ncnc3oc(-c4ccccc4)c(-c4ccccc4)c23)cc1
8446,1538409,10.1021/acs.jmedchem.5b01412,,,,Inhibition of EGFR phosphorylation in human NCI-H1975 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay,COC1CCN(c2nccc(Nc3cc4[nH]cnc4cn3)n2)CC1,"N-(2-(4-Methoxypiperidin-1-yl)pyrimidin-4-yl)-3H-imidazo[4,5-c]pyridin-6-amine",0.88,uM,=,-0.0555173278498313,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1
8447,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,"N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine",0.053,uM,=,-1.275724130399211,0,c1ccc(Nc2ncnc3ccccc23)cc1
8448,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,CN(C)c1ccc(/C=N\Nc2nc(-c3nc4ccccc4n3C)cs2)cc1,2-(2-(4-Dimethylaminobenzylidene)hydrazinyl)-4-(1-methyl-1H-benzo[d]imidazol-2-yl)thiazole,0.10371,uM,=,-0.9841793657379307,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccccc1
8449,1882883,10.1016/j.bmc.2018.11.009,,,,"Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay",C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide,0.5675,uM,=,-0.2460341341348396,0,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
8450,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1.Cl,(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine hydrochloride(ZD6474),0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
8451,509684,10.1016/j.bmcl.2008.07.020,,,,Inhibition of human EGFR expressed in SF9 cells,COC[C@@H]1CCCN1/N=C/c1c(N)ncnc1Nc1ccc2c(cnn2Cc2cccc(F)c2)c1,"(S)-N4-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-5-((2-(methoxymethyl)pyrrolidin-1-ylimino)methyl)pyrimidine-4,6-diamine",0.026,uM,=,-1.585026652029182,0,C(=N/N1CCCC1)\c1cncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1
8452,1644874,10.1016/j.ejmech.2016.12.055,,,,"Inhibition of recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly (Glu, Tyr) as substrate after 40 mins in presence of ATP by luminescence assay",C#Cc1cccc(Nc2ncnc3ccc(OCCCCOP(N)(=O)N(CCCl)CCCl)cc23)c1,"4-((4-((3-Ethynylphenyl)amino)quinazolin-6-yl)oxy)butyl N,N-bis(2-chloroethyl)phosphorodiamidate",0.011,uM,=,-1.958607314841775,0,c1ccc(Nc2ncnc3ccccc23)cc1
8453,698459,10.1016/j.bmcl.2010.11.100,,,,Inhibition of EGFR,Cc1ccccc1Nc1ncnn2ccc(CN3CCC(N)CC3)c12,"5-((4-aminopiperidin-1-yl)methyl)-N-o-tolylpyrrolo[1,2-f][1,2,4]triazin-4-amine",0.66,uM,=,-0.1804560644581313,0,c1ccc(Nc2ncnn3ccc(CN4CCCCC4)c23)cc1
8454,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OC)c(OC)c3OC)ncc2Cl)c1,"US9238629, I-4",0.065,uM,=,-1.1870866433571443,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
8455,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,C/N=N/Nc1ccc2ncnc(N(C)c3ccccc3)c2c1,N-methyl-6-[(1E)-3-methyltriaz-1-enyl]-N-phenylquinazolin-4-amine,8.0,uM,=,0.9030899869919436,1,c1ccc(Nc2ncnc3ccccc23)cc1
8456,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OC[C@@H]1CCCN(C)C1,(R)-(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-3-ylmethoxy)-quinazolin-4-yl]-amine,0.1,uM,=,-1.0,0,c1ccc(Nc2ncnc3cc(OC[C@@H]4CCCNC4)ccc23)cc1
8457,2074176,10.1016/j.bmc.2020.115657,,,,Inhibition of EGFR (unknown origin) using ATF-2 as substrate after 1 hr by radiometric based ELISA,Cn1c(-c2csc(N/N=C\c3ccc(Cl)cc3Cl)n2)nc2ccccc21,"2-(2-(2,4-Dichlorobenzylidene)hydrazinyl)-4-(1-methyl-1H-benzo[d]imidazol-2-yl)thiazole",0.51363,uM,=,-0.2893496180117169,0,C(=N\Nc1nc(-c2nc3ccccc3[nH]2)cs1)\c1ccccc1
8458,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3c(F)cc(Cl)cc3F)ncnc2cc1OCC1CCNCC1,"(4-Chloro-2,6-difluoro-phenyl)-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine",0.5,uM,=,-0.3010299956639812,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
8459,978663,10.1016/j.ejmech.2013.06.057,,,,Inhibition of EGFR (unknown origin),Cl.c1ccc(-c2cccc(Nc3ncnc4cc5c(cc34)OCO5)c2)cc1,"([1,3]Dioxolo[4,5-g]quinazolin-8-yl)-(biphenyl-3'-yl)amine hydrochloride",0.002,uM,=,-2.6989700043360187,0,c1ccc(-c2cccc(Nc3ncnc4cc5c(cc34)OCO5)c2)cc1
8460,608087,10.1021/jm901558p,,,,Inhibition of human recombinant EGFR expressed in insect cells by time-resolved fluorimetry,O=C(Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1)[C@@H]1O[C@H]1CN1CCCCC1,"(2R,3S)-N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-(piperidin-1-ylmethyl)oxirane-2-carboxamide",0.00124,uM,=,-2.906578314837765,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)[C@@H]1O[C@H]1CN1CCCCC1
8461,66580,10.1021/jm950692f,,,,Inhibition of tyrosine kinase activity of Epidermal growth factor receptor from human A431 carcinoma cells,Cc1nc2cc3c(Nc4cccc(Br)c4)ncnc3cc2[nH]1,"(3-Bromo-phenyl)-(2-methyl-1H-imidazo[4,5-g]quinazolin-8-yl)-amine",0.00029,uM,=,-3.537602002101044,0,c1ccc(Nc2ncnc3cc4[nH]cnc4cc23)cc1
8462,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,CCN(CC)CCCNC(=O)/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"But-2-enedioic acid [4-(3-bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide (3-diethylamino-propyl)-amide",0.021,uM,=,-1.6777807052660807,0,c1ccc(Nc2ncnc3cnccc23)cc1
8463,66566,10.1021/jm030142e,,,,In vitro inhibition of Epidermal growth factor receptor tyrosine kinase isolated from A431 (human carcinoma).,C/N=N/Nc1ccc2ncnc(Nc3cccc(C)c3)c2c1,N-(3-methylphenyl)-6-[(1E)-3-methyltriaz-1-enyl]quinazolin-4-amine,0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ncnc3ccccc23)cc1
8464,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,N#CC(C#N)=Cc1cc[nH]n1,2-(2H-Pyrazol-3-ylmethylene)-malononitrile,1480.0,uM,=,3.170261715394957,1,c1cn[nH]c1
8465,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,CCOC(=O)CCCC(=O)Nc1cc(Nc2cccc(Cl)c2)ncn1,Ethyl-5-((6-((3-chlorophenyl)amino)pyrimidin-4-yl)amino)-5-oxopentanoate,0.027,uM,=,-1.5686362358410126,0,c1ccc(Nc2ccncn2)cc1
8466,2251609,10.1021/acs.jmedchem.2c00168,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,CCS(=O)(=O)n1cc(-c2nc(Nc3cc(Cl)c(N4CCC(N5CCN(C)CC5)CC4)cc3OC(C)C)ncc2Cl)c2ccccc21,5-chloro-N-(5-chloro-2-isopropoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-4-(1-(ethylsulfonyl)-1H-indol-3-yl)pyrimidin-2-amine,0.4135,uM,=,-0.3835244861114345,0,c1ccc2c(-c3ccnc(Nc4ccc(N5CCC(N6CCNCC6)CC5)cc4)n3)c[nH]c2c1
8467,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,CCOC(=O)/C=C/C(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,"3-[4-(3-Bromo-phenylamino)-pyrido[3,4-d]pyrimidin-6-ylcarbamoyl]-acrylic acid ethyl ester",0.051,uM,=,-1.2924298239020635,0,c1ccc(Nc2ncnc3cnccc23)cc1
8468,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2ccc(Cl)cc2)=N1,2-(2-(4-Chlorobenzylidene)hydrazinyl)thiazol-4(5H)-one,1.94,uM,=,0.287801729930226,1,O=C1CSC(N/N=C/c2ccccc2)=N1
8469,63602,10.1021/jm00077a014,,,,Inhibition of EGF-dependent DNA synthesis in ER 22 cells incubated with [3H]TdR,COC(=O)c1ccc(NCc2cc(O)ccc2O)cc1O,"4-(2,5-Dihydroxy-benzylamino)-2-hydroxy-benzoic acid methyl ester",10.0,uM,=,1.0,1,c1ccc(CNc2ccccc2)cc1
8470,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,CCC(=O)N1CCOc2c1ccc1ncnc(Nc3cccc(C(F)(F)F)c3)c21,"1-(10-((3-(trifluoromethyl)phenyl)amino)-2,3-dihydro-4H-[1,4]oxazino[2,3-f]quinazolin-4-yl)propan-1-one",0.8378,uM,=,-0.0768596439747993,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCN4)cc1
8471,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,Cc1ccc(C(=O)/C(C#N)=C/c2ccc(O)c(O)c2)cc1,"3-(3,4-Dihydroxy-phenyl)-2-(4-methyl-benzoyl)-acrylonitrile",0.88,uM,=,-0.0555173278498313,0,O=C(/C=C/c1ccccc1)c1ccccc1
8472,67060,10.1021/jm0108348,,,,Inhibition of Epidermal growth factor receptor,CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H](O)C1,"2-(2-Chloro-phenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-piperidin-4-yl)-chromen-4-one ((+/-)Flavopiridol)",4.6,uM,=,0.6627578316815741,1,O=c1cc(-c2ccccc2)oc2c(C3CCNCC3)cccc12
8473,1795138,10.1016/j.ejmech.2018.08.031,,,,Inhibition of N-terminal GST-tagged wild type human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-labeled peptide as substrate after 10 mins by mobility shift assay,COc1ccc(OC)c(Nc2cc(Nc3ccc(S(N)(=O)=O)cc3)ncn2)c1,"4-((6-((2,5-Dimethoxyphenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide",0.779,uM,=,-0.1084625423274355,0,c1ccc(Nc2cc(Nc3ccccc3)ncn2)cc1
8474,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,COc1ccc(C2=NN(C(N)=S)C(c3cccc4ccccc34)C2)cc1,"3-(4-Methoxyphenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazole-1-carbothioamide",0.16,uM,=,-0.7958800173440752,0,c1ccc(C2=NNC(c3cccc4ccccc34)C2)cc1
8475,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)c(Cl)c3F)ncnc2cc1OCCNC(=O)CCN1CCCCC1,"US8846699, 147",0.012,uM,=,-1.9208187539523751,0,O=C(CCN1CCCCC1)NCCOc1ccc2c(Nc3ccccc3)ncnc2c1
8476,802194,10.1016/j.ejmech.2012.01.021,,,,Inhibition of EGFR after 50 mins by HTRF assay,COc1cc2ncc(C(=O)O)c(Nc3cccc(Cl)c3)c2cc1OC,"4-(3-chlorophenylamino)-6,7-dimethoxyquinoline-3-carboxylic acid",9.021,uM,=,0.95525468282018,1,c1ccc(Nc2ccnc3ccccc23)cc1
8477,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)cc3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F,2-fluoro-N-(4-((4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-5-nitrobenzamide,0.722,uM,=,-0.1414628024303609,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
8478,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,CN(C)CCNCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1F,"(S)-2-((6-(4-(((2-(Dimethylamino)ethyl)amino)methyl)-3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-phenylethan-1-ol",0.0001,uM,=,-4.0,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8479,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3cc(Cl)c(Br)cc3F)ncnc2cc1OCCNC(=O)CN(C)C,"US8846699, 135",0.009,uM,=,-2.0457574905606752,0,c1ccc(Nc2ncnc3ccccc23)cc1
8480,63602,10.1021/jm00077a014,,,,Inhibition of EGF-dependent DNA synthesis in ER 22 cells incubated with [3H]TdR,COC(=O)c1cccc(NCc2cc(O)ccc2O)c1,"3-(2,5-Dihydroxy-benzylamino)-benzoic acid methyl ester",9.0,uM,=,0.9542425094393248,1,c1ccc(CNc2ccccc2)cc1
8481,1538409,10.1021/acs.jmedchem.5b01412,,,,Inhibition of EGFR phosphorylation in human NCI-H1975 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay,CO[C@H]1CCN(c2nccc(Nc3cc4c(cn3)nc(C)n4C(C)C)n2)C[C@H]1F,"(+/-)-[2-((cis)-3-Fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-yl](1-isopropyl-2-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amine",0.25,uM,=,-0.6020599913279624,0,c1cc(Nc2cc3[nH]cnc3cn2)nc(N2CCCCC2)n1
8482,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)c1cc([N+](=O)[O-])ccc1F,N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.068,uM,=,-1.1674910872937636,0,O=C(Nc1ccc2ncnc(Nc3ccccc3)c2c1)c1ccccc1
8483,64440,10.1016/s0960-894x(00)00131-1,,,,Tested in vitro for inhibition of EGF-receptor tyrosine kinase,COc1cccc(-c2cn(-c3ccccc3)c3ncnc(N)c23)c1,"5-(3-Methoxy-phenyl)-7-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine",0.5,uM,=,-0.3010299956639812,0,c1ccc(-c2cn(-c3ccccc3)c3ncncc23)cc1
8484,63774,10.1021/jm000372i,,,,Inhibition of autophosphorylation of EGFR in A431 cells,CN(C)CCCNC(=O)/C=C/C(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1,But-2-enedioic acid [4-(3-bromo-phenylamino)-quinazolin-6-yl]-amide (3-dimethylamino-propyl)-amide,0.059,uM,=,-1.2291479883578558,0,c1ccc(Nc2ncnc3ccccc23)cc1
8485,2279826,10.1016/j.bmcl.2022.129104,,,,Inhibition of wild type EGFR (unknown origin) autophosphorylation by Kinase-Glo luminescent assay,Fc1ccc(Nc2ncnc3ccc4c(c23)OCCN4)cc1Cl,"N-(3-chloro-4-fluorophenyl)-3,4-dihydro-2H-[1,4]oxazino[2,3-f]quinazolin-10-amine",0.08727,uM,=,-1.0591350240332784,0,c1ccc(Nc2ncnc3ccc4c(c23)OCCN4)cc1
8486,509684,10.1016/j.bmcl.2008.07.020,,,,Inhibition of human EGFR expressed in SF9 cells,Nc1ncnc(Nc2ccc3c(cnn3Cc3cccc(F)c3)c2)c1/C=N/N1CCN(CCO)CC1,2-(4-((4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-6-aminopyrimidin-5-yl)methyleneamino)piperazin-1-yl)ethanol,0.009,uM,=,-2.0457574905606752,0,C(=N/N1CCNCC1)\c1cncnc1Nc1ccc2c(cnn2Cc2ccccc2)c1
8487,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCCOc1cc2ncnc(Nc3ccc(NC(=O)OCC)c(Cl)c3)c2cc1OC.Cl,{2-Chloro-4-[6-methoxy-7-propyloxyquinazolin-4-ylamino]phenyl}carbamic acid ethyl ester hydrochloride,5.5,uM,=,0.7403626894942439,1,c1ccc(Nc2ncnc3ccccc23)cc1
8488,827636,10.1016/j.bmc.2012.05.034,,,,Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay,C#Cc1cccc(NC(=O)c2cc(NC(=O)CCCCCC(=O)NO)c(OC)cc2O)c1,N-(3-Ethynylphenyl)-2-hydroxy-5-(7-hydroxyamino-7-oxoheptanamido)-4-methoxybenzamide,1.12,uM,=,0.0492180226701816,1,O=C(Nc1ccccc1)c1ccccc1
8489,159832,10.1021/jm00110a022,,,,Inhibition of polyGAT phosphorylation,C[S+]([O-])c1ccc(C=C(C#N)C#N)cc1,2-(4-Methanesulfinyl-benzylidene)-malononitrile,1800.0,uM,=,3.255272505103306,1,c1ccccc1
8490,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,COc1cc(C(N)=O)ccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2[nH]1,"(R)-3-Methoxy-4-(4-((1-phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzamide",0.0004,uM,=,-3.397940008672037,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8491,519643,10.1016/j.bmcl.2008.11.058,,,,Inhibition of EGFR,COc1cc(N2CCC(N3CCN(S(C)(=O)=O)CC3)CC2)ccc1Nc1nccc(-c2c(-c3cccc(C(=O)Nc4c(F)cccc4F)c3)nc3ccccn23)n1,"N-(2,6-difluorophenyl)-3-(3-(2-(2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)imidazo[1,2-a]pyridin-2-yl)benzamide",0.057,uM,=,-1.2441251443275083,0,O=C(Nc1ccccc1)c1cccc(-c2nc3ccccn3c2-c2ccnc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)n2)c1
8492,66568,10.1021/jm00033a019,,,,Inhibitory activity against recombinant tyrosine kinase EGF-R (EGF-R ICD),O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21,"5,6-Bis-(4-fluoro-phenylamino)-isoindole-1,3-dione",0.7,uM,=,-0.1549019599857432,0,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21
8493,982464,10.1016/j.bmc.2013.06.070,,,,Inhibition of recombinant EGFR kinase cytoplasmic domain (unknown origin) expressed in baculovirus expression vector-infected insect sf9 cells assessed as level of autophosphorylation after 10 mins by DELFIA/time-resolved fluorometry,Clc1cccc(Nc2ncnc3ccc(NCc4ccc(Br)s4)cc23)c1,"N6-((5-Bromothiophen-2-yl)methyl)-N4-(3-chlorophenyl)quinazoline-4,6-diamine",1.5,uM,=,0.1760912590556812,1,c1ccc(Nc2ncnc3ccc(NCc4cccs4)cc23)cc1
8494,938532,10.1016/j.bmc.2013.01.013,,,,Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation after 1 hr,Cc1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1,"5-(Naphthalen-2-yl)-1-phenyl-3-(p-tolyl)-4,5-dihydro-1H-pyrazole",0.06,uM,=,-1.2218487496163564,0,c1ccc(C2=NN(c3ccccc3)C(c3ccc4ccccc4c3)C2)cc1
8495,1808197,10.1016/j.bmc.2019.06.001,,,,Inhibition of EGFR (unknown origin) using TK substrate incubated for 60 mins by FRET assay,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,(3-Chloro-4-fluoro-phenyl)-[7-methoxy-6-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine,0.000769,uM,=,-3.114073660198569,0,c1ccc(Nc2ncnc3ccc(OCCCN4CCOCC4)cc23)cc1
8496,607148,10.1016/j.bmc.2009.10.051,,,,Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA,O=C1CSC(N/N=C/c2ccc(O)cc2)=N1,2-(2-(4-Hydroxybenzylidene)hydrazinyl)thiazol-4(5H)-one,4.71,uM,=,0.6730209071288962,1,O=C1CSC(N/N=C/c2ccccc2)=N1
8497,658103,10.1016/j.bmc.2010.08.004,,,,Inhibition of EGFR,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)Cc1ccc(F)cc1,(E)-4-[(4-Fluorobenzyl)methylamino]-but-2-enoic acid[4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinoline-6-yl]amide,0.00057,uM,=,-3.2441251443275085,0,O=C(/C=C/CNCc1ccccc1)Nc1ccc2nccc(Nc3ccccc3)c2c1
8498,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,COc1cc2ncc(C#N)c(N[C@@H]3C[C@H]3c3ccccc3)c2cc1OCCN1CCOCC1,"7-methoxy-6-(2-morpholinoethoxy)-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",0.405,uM,=,-0.3925449767853314,0,c1ccc([C@@H]2C[C@H]2Nc2ccnc3ccc(OCCN4CCOCC4)cc23)cc1
8499,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#Cc1ccc(CN2CCCC2)s1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-((5-(pyrrolidin-1-ylmethyl)thiophen-2-yl)ethynyl)pyrimidin-4-amine,0.03,uM,=,-1.5228787452803376,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccc(CN2CCCC2)s1
8500,1331050,10.1039/C0MD00183J,,,,Inhibition of EGFR (unknown origin),CCOC(=O)Nc1cc(Nc2ncnc3cc(OC)c(OC)cc23)ccc1Cl.Cl,"{2-Chloro-5-[6,7-dimethoxyquinazolin-4-ylamino]phenyl}carbamic acid ethyl ester hydrochloride",0.9,uM,=,-0.0457574905606751,0,c1ccc(Nc2ncnc3ccccc23)cc1
8501,795515,10.1016/j.bmcl.2011.10.103,,,,Inhibition of EGFR by time-resolved fluorescence assay,Cc1ncnc(Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1C#Cc1ccccc1,N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-methyl-5-(phenylethynyl)pyrimidin-4-amine,0.65,uM,=,-0.1870866433571444,0,C(#Cc1cncnc1Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
8502,2251609,10.1021/acs.jmedchem.2c00168,,,,Inhibition of wild type EGFR (unknown origin) by ELISA,CCS(=O)(=O)n1cc2c3ccc(cc31)OCCCCCCOc1cc(c(C)cc1N1CCOCC1)Nc1ncc(Cl)c-2n1,"2(5)-chloro-1(1)-(ethylsulfonyl)-4(6)-methyl-4(4)-morpholino-1(1)H-5,12-dioxa-3-aza-1(3,6)-indola-2(4,2)-pyrimidina-4(1,3)-benzenacyclododecaphane",0.3075,uM,=,-0.5121548798885645,0,c1cc2nc(n1)Nc1ccc(N3CCOCC3)c(c1)OCCCCCCOc1ccc3c-2c[nH]c3c1
8503,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Cl)cc3Cl)ncnc2cc1OCCNC(C)=O,"US8846699, 113",0.049,uM,=,-1.3098039199714864,0,c1ccc(Nc2ncnc3ccccc23)cc1
8504,1641134,,,,,"Omnia Assay: Briefly, 10x stocks of EGFR-WT (PV3872) from Invitrogen and EGFR-T790M/L858R (40350) from BPS Bioscience, San Diego, Calif., 1.13x ATP (AS001A) and appropriate Tyr-Sox conjugated peptide substrates (KCZ1001) were prepared in 1x kinase reaction buffer consisting of 20 mM Tris, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 5 mM Î²-glycerophosphate, 5% glycerol (10x stock, KB002A) and 0.2 mM DTT (DS001A). 5 uL of each enzyme were pre-incubated in a Corning (#3574) 384-well, white, non-binding surface microtiter plate (Corning, N.Y.) for 30 min. at 25Â° C. with a 0.5 uL volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Kinase reactions were started with the addition of 45 uL of the ATP/Tyr-Sox peptide substrate mix and monitored every 71 seconds for 60 minutes at Î»ex360/Î»em485 in a Synergy4 plate reader from BioTek (Winooski, Vt.). At the conclusion of each assay, progress curves from each well were examined for linear reaction kinetics and fit statistics.",C=CC(=O)Nc1cccc(Nc2nc(Nc3cccc(OC)c3OC)ncc2Cl)c1,"US9238629, I-17",0.65,uM,=,-0.1870866433571444,0,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
8505,1892587,10.1021/acs.jmedchem.9b00350,,,,Inhibition of EGFR in human A431 cells assessed as reduction in EGF-stimulated EGFR autophosphorylation preincuabted for 90 mins followed by EGF-stimulation by sandwich-ELISA,C#Cc1cccc(Nc2ccnc3cc(OCCOC)c(OCCOC)cc23)c1,"N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinolin-4-amine",0.34,uM,=,-0.4685210829577448,0,c1ccc(Nc2ccnc3ccccc23)cc1
8506,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(OCC4CC4)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F,N-(4-((3-chloro-4-(cyclopropylmethoxy)phenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoro-5-nitrobenzamide,0.172,uM,=,-0.7644715530924511,0,O=C(Nc1cc2c(Nc3ccc(OCC4CC4)cc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
8507,63785,10.1021/jm960789h,,,,Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells,CN(C)Cc1c[nH]c2cc3ncnc(Nc4cccc(Br)c4)c3cc12,"(3-Bromo-phenyl)-(6-dimethylaminomethyl-8H-pyrrolo[3,2-g]quinazolin-4-yl)-amine",0.0026,uM,=,-2.5850266520291822,0,c1ccc(Nc2ncnc3cc4[nH]ccc4cc23)cc1
8508,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cccnc1F,N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-fluoronicotinamide,0.0043,uM,=,-2.3665315444204134,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1cccnc1
8509,1675765,10.1016/j.bmc.2017.03.039,,,,Inhibition of human EGFR preincubated for 5 mins with substrate followed by ATP addition measured after 30 mins by HTRF method,O=C(Nn1c(-c2ccccc2)nc2ccccc2c1=O)c1ccc(Br)cc1,4-Bromo-N-(4-oxo-2-phenylquinazolin-3(4H)-yl)benzamide,0.42,uM,=,-0.3767507096020995,0,O=C(Nn1c(-c2ccccc2)nc2ccccc2c1=O)c1ccccc1
8510,2065927,10.1016/j.bmc.2018.02.022,,,,Inhibition of recombinant human N-terminal GST tagged EGFR (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay,O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cccc(F)c1F,"N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2,3-difluorobenzamide",0.029,uM,=,-1.537602002101044,0,O=C(Nc1cc2c(Nc3ccccc3)ncnc2cc1OCCCN1CCOCC1)c1ccccc1
8511,457645,10.1016/j.bmcl.2007.07.071,,,,Inhibition of human EGFR autophosphorylation in A431 cells,N#Cc1cnc2ccc(-c3ccc(CN)cc3)cc2c1N[C@@H]1C[C@H]1c1ccccc1,"6-(4-(aminomethyl)phenyl)-4-((1R,2S)-2-phenylcyclopropylamino)quinoline-3-carbonitrile",2.1,uM,=,0.3222192947339193,1,c1ccc(-c2ccc3nccc(N[C@@H]4C[C@H]4c4ccccc4)c3c2)cc1
8512,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)C(F)F,"US8846699, 22",0.005,uM,=,-2.3010299956639813,0,c1ccc(Nc2ncnc3ccccc23)cc1
8513,615344,10.1016/j.ejmech.2009.12.026,,,,Inhibition of EGFR,CC1=C(C(=O)Nc2cccc([N+](=O)[O-])c2)C(c2ccc(O)cc2O)NC(SCc2ccccc2)=N1,"2-(Benzylthio)-6-(2,4-dihydroxyphenyl)-4-methyl-N-(3-nitrophenyl)-l,6-dihydro-pyrimidine-5-carboxamide",55.6,uM,=,1.7450747915820577,1,O=C(Nc1ccccc1)C1=CN=C(SCc2ccccc2)NC1c1ccccc1
8514,306556,10.1021/jm0580196,,,,Inhibition of EGF Receptor autophosphorylation in A431 cell lysate; Range = 4-10 nM,O=C(CCl)Nc1ccc2ncnc(Nc3cccc(I)c3)c2c1,2-Chloro-N-[4-(3-iodo-phenylamino)-quinazolin-6-yl]-acetamide,0.01,uM,=,-2.0,0,c1ccc(Nc2ncnc3ccccc23)cc1
8515,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3Cl)ncnc2cc1OCCNC(C)=O,"US8846699, 115",0.042,uM,=,-1.3767507096020994,0,c1ccc(Nc2ncnc3ccccc23)cc1
8516,2160717,10.1021/acs.jmedchem.1c02208,,,,Inhibition of GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate incubated for 1 hrs by ELISA,C=CC(=O)Nc1cccc(-n2c(=O)c(C3CCCCC3)nc3cnc(Nc4cccc(OCC(N)=O)c4)nc32)c1,N-(3-(2-((3-(2-Amino-2-oxoethoxy)phenyl)amino)-6-cyclohexyl-7-oxopteridin-8(7H)-yl)phenyl)acrylamide,0.0832,uM,=,-1.079876673709276,0,O=c1c(C2CCCCC2)nc2cnc(Nc3ccccc3)nc2n1-c1ccccc1
8517,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCOCCOC(=O)CC(=O)OCC,"US8846699, 69",0.246,uM,=,-0.6090648928966209,0,c1ccc(Nc2ncnc3ccccc23)cc1
8518,952261,10.1021/jm400072p,,,,Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay,CCN1CCN(Cc2ccc(-c3cc4c(N[C@@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1,"(S)-6-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.04,uM,=,-1.3979400086720375,0,c1ccc(CNc2ncnc3[nH]c(-c4ccc(CN5CCNCC5)cc4)cc23)cc1
8519,2185644,10.1016/j.ejmech.2021.113523,,,,Inhibition of EGFR (unknown origin) by ADP-Glo kinase assay,Brc1cccc(Nc2ncnc3[nH]ccc23)c1,"N-(3-bromophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.00376,uM,=,-2.424812155072339,0,c1ccc(Nc2ncnc3[nH]ccc23)cc1
8520,363124,10.1021/jm0600390,,,,Inhibition of EGFR tyrosine kinase,O=C(NCCCl)Nc1ccc2ncnc(Nc3cccc(Cl)c3)c2c1,1-(2-chloroethyl)-3-{[4-(3-chlorophenyl)amino]quinazolin-6-yl}urea,0.022,uM,=,-1.6575773191777938,0,c1ccc(Nc2ncnc3ccccc23)cc1
8521,1528897,,,,,"Tyrosine Kinase Assay: EGFR1 (HER-1) enzyme assay was carried out by using Tyrosine Kinase Assay Kit Green. The entire assay was conducted in accordance with EGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present EGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 50 ng/10 ul EGFR (Proquinase); 100 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of EGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",C=CC(=O)Nc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCNC(=O)CN1CC=CC1,"US8846699, 108",0.032,uM,=,-1.494850021680094,0,O=C(CN1CC=CC1)NCCOc1ccc2c(Nc3ccccc3)ncnc2c1
8522,63784,10.1021/jm011022e,,,,Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP,COc1cc2c(Nc3ccc(C)cc3F)ncnc2cc1OCC1CCN(C)CC1,(2-Fluoro-4-methyl-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine,1.0,uM,=,0.0,0,c1ccc(Nc2ncnc3cc(OCC4CCNCC4)ccc23)cc1
8523,1684313,10.1016/j.ejmech.2017.04.025,,,,Inhibition of His6-tagged recombinant EGFR cytoplasmic domain (unknown origin) (645 to 1186 residues) expressed in baculovirus infected Sf-9 cells preincubated for 10 mins followed by ATP addition measured after 1 hr by DELFIA/Time-Resolved fluorometry,Cc1nc(C)c(/C=C2\CN(C(C)C)C/C(=C\c3nc(C)c(C)nc3C)C2=NO)nc1C,"3,5-Bis-(3,5,6-trimethyl-pyrazin-2-ylmethylene)-1-isopropyl-piperidin-4-one oxime",3.9,uM,=,0.5910646070264992,1,N=C1/C(=C/c2cnccn2)CNC/C1=C\c1cnccn1
8524,63602,10.1021/jm00077a014,,,,Inhibition of EGF-dependent DNA synthesis in ER 22 cells incubated with [3H]TdR,COC(=O)c1cc(NCc2ccccc2O)ccc1O,2-Hydroxy-5-(2-hydroxy-benzylamino)-benzoic acid methyl ester,20.0,uM,=,1.3010299956639813,1,c1ccc(CNc2ccccc2)cc1
8525,2063567,10.1016/j.ejmech.2016.08.068,,,,Inhibition of human EGFR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma33P]ATP by radiometric HotSpot assay,C[C@@H](Nc1ncnc2[nH]c(-c3ccccc3OC(F)(F)F)cc12)c1ccccc1,"(R)-N-(1-phenylethyl)-6-(2-(trifluoromethoxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",0.0043,uM,=,-2.3665315444204134,0,c1ccc(CNc2ncnc3[nH]c(-c4ccccc4)cc23)cc1
8526,526697,10.1021/np050229y,,,,Inhibition of EGFR,COc1c(O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O,Tectorigenin,3.3,uM,=,0.5185139398778875,1,O=c1c(-c2ccccc2)coc2ccccc12
